<SEC-DOCUMENT>0001628280-22-013661.txt : 20220510
<SEC-HEADER>0001628280-22-013661.hdr.sgml : 20220510
<ACCEPTANCE-DATETIME>20220510171428
ACCESSION NUMBER:		0001628280-22-013661
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		92
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220510
DATE AS OF CHANGE:		20220510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apollo Medical Holdings, Inc.
		CENTRAL INDEX KEY:			0001083446
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT CONSULTING SERVICES [8742]
		IRS NUMBER:				870042699
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37392
		FILM NUMBER:		22910996

	BUSINESS ADDRESS:	
		STREET 1:		1668 S. GARFIELD AVENUE
		STREET 2:		2ND FLOOR
		CITY:			ALHAMBRA
		STATE:			CA
		ZIP:			91801
		BUSINESS PHONE:		(626) 282-0288

	MAIL ADDRESS:	
		STREET 1:		1668 S. GARFIELD AVENUE
		STREET 2:		2ND FLOOR
		CITY:			ALHAMBRA
		STATE:			CA
		ZIP:			91801

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SICLONE INDUSTRIES INC
		DATE OF NAME CHANGE:	19990413
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ameh-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:5baec51e-b1b5-44e5-a5ac-49c0e6499a3f,g:d2f55b59-0a61-4e65-b745-a66f96888c42,d:3cbe033f261a4f1ea6a0c939c6847530--><html xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ameh="http://www.apollomed.net/20220331" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ameh-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80L2ZyYWc6NjFjM2Y5ZDUwNzQzNGQ3ZGI0YTgyYWZhYTI2OTk5NjMvdGFibGU6ZGU1ZjFlZjFhNzM4NDhlZTg3OGEyNGIwNzgxYzQ5NGIvdGFibGVyYW5nZTpkZTVmMWVmMWE3Mzg0OGVlODc4YTI0YjA3ODFjNDk0Yl8zLTEtMS0xLTcwMDQy_24bdc420-2589-40ad-adb4-183280aaa9e7">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80L2ZyYWc6NjFjM2Y5ZDUwNzQzNGQ3ZGI0YTgyYWZhYTI2OTk5NjMvdGFibGU6ZGU1ZjFlZjFhNzM4NDhlZTg3OGEyNGIwNzgxYzQ5NGIvdGFibGVyYW5nZTpkZTVmMWVmMWE3Mzg0OGVlODc4YTI0YjA3ODFjNDk0Yl80LTEtMS0xLTcwMDQy_6ba248d8-e727-4e56-bb63-e209c5e28b16">2022</ix:nonNumeric><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80L2ZyYWc6NjFjM2Y5ZDUwNzQzNGQ3ZGI0YTgyYWZhYTI2OTk5NjMvdGFibGU6ZGU1ZjFlZjFhNzM4NDhlZTg3OGEyNGIwNzgxYzQ5NGIvdGFibGVyYW5nZTpkZTVmMWVmMWE3Mzg0OGVlODc4YTI0YjA3ODFjNDk0Yl81LTEtMS0xLTcwMDQy_8cda3dff-5c4e-4c16-8197-41380dcc7e65">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80L2ZyYWc6NjFjM2Y5ZDUwNzQzNGQ3ZGI0YTgyYWZhYTI2OTk5NjMvdGFibGU6ZGU1ZjFlZjFhNzM4NDhlZTg3OGEyNGIwNzgxYzQ5NGIvdGFibGVyYW5nZTpkZTVmMWVmMWE3Mzg0OGVlODc4YTI0YjA3ODFjNDk0Yl82LTEtMS0xLTcwMDQy_a2e23a05-0455-482b-ba96-fd9648dd123a">0001083446</ix:nonNumeric><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80L2ZyYWc6NjFjM2Y5ZDUwNzQzNGQ3ZGI0YTgyYWZhYTI2OTk5NjMvdGFibGU6ZGU1ZjFlZjFhNzM4NDhlZTg3OGEyNGIwNzgxYzQ5NGIvdGFibGVyYW5nZTpkZTVmMWVmMWE3Mzg0OGVlODc4YTI0YjA3ODFjNDk0Yl83LTEtMS0xLTcwMDQy_b97825c6-0e98-4dea-80c8-38dcfec4af48">--12-31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ameh-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if80c5db3cf224b5d92f4efbc74830e91_I20220428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="icdb7399a6abd460491239b97b7522507_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i082ebdd9e5cf4b14937116ed41c6d210_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="id2b4439fa02d406d9c63972d386e09c1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b27218f21ed45fc8fe5af87b6180da5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1968744464b94c44b565a81c2bf9632e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id271ccfbc8e049649cd2b13460a8e718_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45babd110e5c45fe951fced5efef52c3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b8093adf4ca4e659bfd5cc3d0bf5b91_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fe7d345269d429594a7165974ccdcb7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17d738adb8bf4c52a41f5eb43d954b81_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81200d008433465fa399ae7b4f619096_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4efb856004934021887d5c4fcd6a352c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dce717fa9914fab879521d726f8cdd8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7675a417e574dd7bfb341601fa58abc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd48abaf892342879b0c004889f6395b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0edd9918dcb74ab7b7be0bfe975e98a6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cc1737bb2ac452c8108152c0b78582e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie565cc08147249b5871999e0d1765ed2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01c06a901fad47e3a2666a70fe1188df_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9910c7555ace4c2bb115be314dd355b1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3795672568804fb39265965ff8ee0616_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i934f486ebd2244c69aedfbc72f32d753_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30aca1425f44492ca189ea4600ae924d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ab27752b93f42388e90627d8c8ba555_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb4c95ef672647aca0d3f58bdfd3fd09_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cce845b4bcb47d4937d16c1ce6294b4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i891990513de04b79b3fbaedbe290deb4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95ae6859a8584e7eb08ef41e08f26b99_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e20c02c36c543ab98bbfa086f702db6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b7e2b312b964191b6e5a99bfa3fad1c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3da6bad4ba14fb884f02c88f6ad7610_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48596fff82734547a44b9e4ec2fc95ef_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f6053bba0574b7c8d8bc3d35aedd364_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaedbc96dc4de4eab8aed3c10bf0e0fb9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9015851c456402f83746f4b6976dfbb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b1648f5a7c74820b4705fadeec2d2c1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd3ffca58ef641c493f6d69c9456f642_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib537036edf0744c69646e8a9929a0638_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7907a63ed1d0470a879fdec321fba0f4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ea6fe0d59b441beb7ba9b153d330fae_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i109c5e7bd1a14ea599c3a7723e99ade4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e0d03cf0c84427db63e13d4e462e4e8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b20ee5e4cb845b183e38f28737aef7a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5879b7991869438bb805be20df7ad0b2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia98bbfcdcddb4e23b97bfb35198297b4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24aeb633ec154645a1fed86ccb4c65cd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13156f57748c4cfea02dbb45bd3312df_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe9ce7d0bb51473c9da95e7918990fd8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5144afd8082f4f17afadb8908f6b4051_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia01bac51df004e83a5b940703fb94049_D19990701-19990731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1999-07-01</xbrli:startDate><xbrli:endDate>1999-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i080d2011774f4a4f8a04e8046723b130_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bec4a71e3844c82b36a7dcc2f0a553b_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i42aa94e36eca45219242d025187b81a7_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic951a78e8e8641ca82615311f26c6e86_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad63aacc748841208955dbad50055a32_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic413e1b24cbb43588d69ee94b270c426_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9401c9559d0a4784bee72fa3bb729bdb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i433e9e4dc783427e8e6da7ae18299e15_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ConcourseDiagnosticSurgeryCenterLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a637dbd41eb4403a231966d0c1d8747_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MaverickMedicalGroupIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea7256f5bdac481c9e419242402ecfad_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="plan"><xbrli:measure>ameh:plan</xbrli:measure></xbrli:unit><xbrli:context id="i6791450b303a4baaa9c950aac4835c7a_I20190830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6618dfdd38574ddd8411e3675f60590e_D20190830-20190830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:Dr.JayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-30</xbrli:startDate><xbrli:endDate>2019-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbbf646a84b242da86cd62eac12d7711_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AmgIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="clinic"><xbrli:measure>ameh:clinic</xbrli:measure></xbrli:unit><xbrli:context id="i4258726bec994a1db1b081a69de757a8_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c160ab74e9f4f3f897f16bcf956f33b_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4452193fa6da4189b503a5f1f57ad4be_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5456a038b204408f8d123aa76b5524e2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib943b580b1c64fc1a7579f4ac67aa99d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iade67c79de8c433297cb64b0aa007e48_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27d0462359864892b029d29f2dbae1fa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:MPPAMGPropertiesAndZLLAssetAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e3006cf844c4dcfb98b8464dfdfecaf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae649481fa4d4190a0f5b74bc999a510_I20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccessPrimaryCareMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4078597aaf8463a99cbfd3e8f573353_I20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied48cf0dd52b4ecbacf11485317313d5_D20210801-20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47183d9ce9704d30b6eb68894c2e74b3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>ameh:segment</xbrli:measure></xbrli:unit><xbrli:context id="i5067812e23e84e4689a191e85614e031_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8bb14e9746c41a5b4dc59dfc7318107_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b1b466c96f147349e71fb4f01795a7f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06add27710ea4d7785d87fe89373d1fc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib71613c16b2142f097495def3277d766_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4057678e762644689f10e4ee0607dbed_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:ClinigenceHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1368e96397d4afb8a5b06c97f9a0e75_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3540b9617bba46ec9221f435473df8d4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97b7e4411cac4f46bd0609f16888cd7b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41c5d4e729a642c3a0808ffe69396270_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c16654928bd4eaca5078b4d6cf0e50d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5b721f38495479baa1888225f569bae_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic00f4d20ec264fa5b0dec1e5c289db51_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44447a5bff9d47778021966b6c04440e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23c400c680394251b215b33cfde92dbc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib41161b4c97242dbb50361fe75def7b4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab747f9347d841d7bed8d71175fd16b2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9221a81959848e0875b822a89e77723_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4a11153cacb478db352c47209bdd22f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b9b5a97cba2458e80bbc32a7003a7b5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide74daf0c2af45c6b4e6486c2b5f07af_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i062a900e196f43a8ad8c043ed3e37741_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7344d9ece6c54bb7a3445b3b4305a208_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorFMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8004dd5aaab243ceaebebdd9dfbe5dea_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorFMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6526cb352ff14142ad0267923f9b8458_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cf7e945065b4cbb9be75f83ecca429e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e0b992a4a41411caa3cf99acedc7773_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i812e1314b74e4b39965703038178723e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i317853952d064c0aae4c8f6086f08c69_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i395def431eb24cc797be851df63b772d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f97d77f9a334dfaa7f626c14651831b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idedee00e5b814c9ab93ebe0cdd4eefcd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe65b799ceec4dd4b60d0ed19b877f0c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f4a833b59b64e6fa2beeccb4539ee17_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee4f95d0daa5491a9f9b7cf6f20f14f0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b31a7f7ad9f4eeba82e05b893d8837b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf6c453b31384c85a91a6dac3bd293f9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i344120b3c93044e5a4e890535a20389f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7191ac8fddae474f98a72365faf35498_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48154c88054d4bfca4aae23d986f326d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icef23c4f80af41b4a7678b0043957020_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id889a0adfcca4b0483674775e3b7017d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i670c182c37f64d7c81e6e512f5a85911_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c9680a3ecd2478e8c69cac5c0ca57bc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i626fc76fa8044b489370befcecb36ff4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54a2dd1d9f194b41bd57c7a175d4260e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb648af0ac4046e19f5473b63dcc3dac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64f9c2d2092e49e2a51aeaedde7588ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf96d2529f4847d2820cfaff15062529_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9227a3f5dcdb4fe389f9629762b21c04_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="unit"><xbrli:measure>ameh:unit</xbrli:measure></xbrli:unit><xbrli:context id="i06ded7d511214a6b934ce38ddf56629e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaeae6dd376a4544a532f6990d6ef02b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice1126416af04bd8bb625efbc5740cee_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f76f479c78d4715a3a1756814601111_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:PerMemberPerMonthManagedCareContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i129c72bde37445abbf565db10f855c61_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:CMSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37c332bfa67d49cea1f207293667f549_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ameh:AccountsPayableAndAccruedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4043dc9bcd1c428faf9de8df64df4c4c_I20220124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:OrmaHealthIncAndProviderGrowthSolutionsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic90a69d35de04dc89bd59af6b50c84d2_D20220124-20220124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:OrmaHealthIncAndProviderGrowthSolutionsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-24</xbrli:startDate><xbrli:endDate>2022-01-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25fa08dfbba0471ab1f73eb7a33ab853_D20210701-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccessPrimaryCareMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4326870dc64f4f2f89fd5df3a7f241eb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccessPrimaryCareMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i963385d3851043318a55cac8d1d8e584_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72e8469da6fd456bb61b083d9a9a2852_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9449f60b9fc845af955a5c89466e5184_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i505d1f1aced648e2ac90c9458f190dd7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib92cc8812a2d47588d05bc790009d105_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f4cf5ddfa684bd38d0791137d1d848f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81cd72537a24472dad3429c1494fb9d6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8569af65a8b4eb9b5df3177f8dd7840_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b86c52f7f00483faef56f69b319a5ee_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01b454e0ae7d40d0aa1b524fc4c468b6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i120f957d1af8440481f28a0c928f55b4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3c1ae4a3ee14160b77a83df27148f53_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d30ca934a1c4d25a5117a64b30e1ec6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c57be7d1d9b4186b0c62d58ed16439b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d873576e5c74d678a79c2181b0def05_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f881cf7eb4448d49160c4fbe26a606f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic42c656984834bbe802a92fc9c2db0ec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb3e802a663f4a6b942e4d29cad772ac_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i181ceb45ba734f1e941c3bc5aff82a91_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fe5dca6b3c94505aeb4f1b8542dce43_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6f7ecc2ad814ce19177b1caaed8db74_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82294d54cab940218597a90c5e4ee4f7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7f4421b21eb4d46abaed6eca504bfe6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iece03f9e8f8a4d22966891f53113f721_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64402309fd5e4e24ad7105d9ff70a80c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f11ce9c14364c19887f12faf318e05b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i336efd7ddd3a421f8e5bba9c0816384d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43360692494245daa938bbb454eea503_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36852b2625274d7c94f009efe3625131_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefb065d83e134399924dcb98a8810645_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20b270836e8e4edfad0aac1201a837a4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i905a801d6f9b4c9ebe17dff9567e4e65_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief0c35819b504b239cc32ffedc16b209_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4103b5415884a2cb86152b06ab31f87_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98dd8ff17e4643278bde170255559ba3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia36eb2cd63f7429d942e17270c0144bf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b3e371af52a4f9ab3b9ef33b8762eb8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75681772568f4aed9e00dafa27af9156_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79f112c0b31c40119270d0df81451392_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe110e391f1347168555105f65ea038b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id638b192e4b34caeb8ee0fc5e44f48b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i418e308a689d48d4b3de11c2556a4e0f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f6b860f41b44b04be3fcc1cfe3c2c04_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6f6ea60415248a6a49fa2d020393b3d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e7eadc502bc40c6afc071e235c3a98c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83299a5c90454ecb81deb339e22e4f52_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bb2d59135f449d3b0e13fa8b28b3809_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a35e5e78f804b03bb635d5e8df0b4c1_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ef6f6f7c71f41d68d3add3e70068bc2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1e3f77f67924bf1b0442138b0c59dba_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic99a2a30fd9144b38c44bd4c90924f6a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33512e53ca8042e592da50359233581e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id918b0f4941f497f8df9f3953fdf4349_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i224451997ac146958e193c349e0fb137_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66228b4952d348d9bb6a6f5bd4664a45_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a5eaf12f18d437286bc9774e4ff6a25_I20150731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb7c2acfad5f4d90804dbceb6ca499a1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia67e2b3c33844eafa88eaa05867d7330_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if29bacb1956147fd920ad140828ddf9f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3512656649a4da789290c7c1a39c58e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie338e6a85a00449c8cb3d0ff9d028af5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4e2dedbf7694c72b5426585e1f6319e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf6b4576ffe04e9896a15272126c5839_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6178c9a34de84a89865b60e90b6cf17e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if344fb7586ce4a30a4cbc6d36795b630_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77422bd33cbc45a1aa372bb8875076a8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8ed7dfc5ec64dbf909fb3b011b41b8e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48cf45716cee43579c307972d6f19091_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i168c9d857e684999a379e78e91b03f10_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i127fc1bd4bad4c958f81e1514ab97618_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5916967379848d7af484250dae5a588_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea22839056f1415e802909f3740eb6f7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3691558e51545d9b1a33f630ec3101d_I20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9fc9a6b261b43fa800eedc49ae6e150_I20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf10dc5a3be94d50a589bf004e41c88f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief73fee5943140169a860306e97c01dd_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MediPortalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a260d4203424cdc969b85797dd116c6_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MediPortalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d2082812210428bb7329995875a8388_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i519cba15a31640d3bead178989c651a5_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f1f415161e146c9982274d3873b0801_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23ad757dae0649c281c2c43b079538ea_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Pacific6EnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83913ad0855f49819cfa7c93494153e4_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26c2e65389c446feb05b2d425a1f08c3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie53154e5f8e44ab2b5b3bc67ed958b95_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia038bf044a5d4b0888c9404c8ef66dce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ead42b914f74b3a87c5e08a25135c1b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9875be1595584e8793d5a44cabe73104_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5ff5967c0ad489ca405c9a26138a568_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04ec29552d16406bb563e4f777751d86_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93bf4ca5dbf74632b9bcabe542799cf2_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6759c2e740754692ab17fe6126840652_I20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i121db6aa4f234342a066091bbc811f6d_I20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ae5de1ac50140b281d6c8428a5ba873_I20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i958aafc9bd314ec7a793b41fdf0cc64e_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3c3078e4a3a4a97a896b1bc5d0087ef_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id506af9420ac471bab63d3cba404a645_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i411a85b04db242d0933b3b997de7b7be_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18d5ab7831f740cfbce7f376753f0fba_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73d5e3fe56914cf8b95c7c29e9501364_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79fd9f0ba878471db847749cc1aa145b_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac76cdf5c1e24249bd2cc8b73cea2d4d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddc202a2a74a429aa384ca0e94f1385f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="financial_ratio"><xbrli:measure>ameh:financial_ratio</xbrli:measure></xbrli:unit><xbrli:context id="iab25699159ef422387acd33b3b0c73ae_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia35d32a022eb4f8296d246475815c7be_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ceb4bf299aa4fbbb15c38ae65b24964_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6af45110227947abb0e1effa0224037f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29d27efd274e4640b991eab78aed11b9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8159b237bb57472289fa8745bfaf2c2a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id327c3f30f5442849d60a0720899b6b3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59ee99254c40475f9b21b9cd872385a5_D20200703-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-03</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb454af8f35b4571bbc0568a6ef8fabc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c1305632b254a819190bb04db42d4b9_D20200703-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-03</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if79f0e1f750c4d29acae8c2424f6b5a8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c965773654f4f76b80d01904268a252_D20200805-20200805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-05</xbrli:startDate><xbrli:endDate>2020-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9463aae35c1447dbc10b94c90792330_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9e05712a8f3404c91c7767902090d7c_D20200805-20200805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-05</xbrli:startDate><xbrli:endDate>2020-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28e98c01e378431d9b395cc096cd64f1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i906733a30f24439e91bed1e3615ea7da_D20200727-20200727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-27</xbrli:startDate><xbrli:endDate>2020-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3860353465b34dcf83559f00d6e7e4c0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifff506fed9ef409ab5281dde682b04df_D20200727-20200727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-27</xbrli:startDate><xbrli:endDate>2020-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i039bfa2066b9445ba0c127c9a6b7d4e6_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifeba7e1f896c47b0bb477b27fd52fe58_D20230101-20231201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e730da764a64b29b490afda93124c70_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcefe512b59843c5a4b809aa58d86dbf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8011f60b0322450ba7087bebdbf48e81_I20190910"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a5028538cf949dc976825957bdc20fc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id77595136aad43ce85c81570c5c6ccfd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa89643a73ac4d02b199b59ae1e04e17_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6ec9c984e0f4663b1287c8a1e6f562c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if917b814792a44f39620641ac0df4997_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba53eb44c7b14a578bb900cac19accbc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fc704f23ee3440f959bc11b81e7d01f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59a87528beae42e5905d598caee23304_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c4a21ba18bf43e2baa22838c457ebc6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib33aa0fdefb44c68985101f13840b075_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ameh:StockAwardsAndUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia57bf156054149e8aed82c44fb4a2e72_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ameh:StockAwardsAndUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id93dea0ce70b4ff2b46f7a49428856fd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ed7fee6f6304a0998e815c8e5445108_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ameh:EmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d75852709414d64af680d539dcb36be_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8fe9de9677f4084b60ffc90c8a538eb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1274ac1b93074e91b7b5207ef70ffa3f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i742b25817ce54efbb408cfa331c5fe5f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52ed974f00584c72870ff83e96c517c6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c33bc11247c47b3bf81a50827becf69_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bc146c68b944c84b6e8aad1dc0a79e5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17b21603feaa4b6eac83277e537457e2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i481003839719417595b8ccd16571b1b2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cfeff39834e4f6c84395e2d7dabac69_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22448a574a694a83ad45e720a7b0491c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i789d3da0a72b4fb89b415c17b6bd2710_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia90b2ff413524e3b90acbbb605243bbb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i297879f201e2401b809e877bc5ca8f1a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf372c04e8fd4b7fb0fe8f937ab557bd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i706233a8610b47c986b542c84fc02826_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id61632e270d643278e5a45ab9d986834_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1501307448a04213aad7bd6a8043ca3c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bee43ded60043dbad50b78762e0cfef_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie54e1b2ff59741a89b0243c59b6ef686_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib152b2b747a74eaeb8147b82a52c9e8c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa7033a548444263ac0237b0218a1adb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5bf970dcad14a8ba4515f1f82038323_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc43c382a55f4e86bce82fa55ccdec8b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa663b2f13a34f278cc8242cfbd66f60_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cb30ce0828947b2b67749be5fbf6bfb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9fd61dc32854b5794c5219cd64b9c91_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i149029e085754aa781bb4c12925033e9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PmiocMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a32ef7fa5834e35b4d3446fb2b911d7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PmiocMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i585cd6801b0a4b76917339116f149737_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e581b13ba1943ada689751040932d87_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c6d4670d2704e46854a6d362d7ff8dc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a544d6c34914e8180df76ac79f9061c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia407282c4d7c40f69b845a1980e98f90_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a710728186e429c9f56a34cae4c7cd8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i119ac7d8ea0849dbb246ad71c51fe403_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4788b32e9914d0ca0604092d88f6375_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaAcoIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7c1281284034e199a945b4fa25a565f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaAcoIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81646c8d09a94a9aaeadb368f60bd221_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FulgentGeneticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6a40ab43ad94c908617b8e12ab58ed0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FulgentGeneticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e92ca4dba96429ca6f565c4a96fae69_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ef6c81ae0d149dcb8f839d22ecdbf4f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69208e7b66d34e81be1ece056152eb3d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7a4db8db1a74901a4e3415b998623f7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffe651efb930429a8995404b0dc53e6b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie54eef2ca9b5495ea95cad9493906234_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie96af2c696c5435d811fd5623d3302c5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i725a2a08b1e34d65984bdfc031ea6bdb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c049a48265c4b71906a6728352ec4d1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4608970f45fe4db1a3f4e42e64795259_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifde0ed94454e448ba35d1211452c3daf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ArroyoVistaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41d101f6c0b44f5aad791956bdabaa9d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ArroyoVistaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88100c9376d541219eea1723b76e0ce5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e4fd86eeb0b4ab68d020185faa91a8f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3339dc21c97b4534b86a86264b8aff7b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac761ad94565453fb1630b4de5935fbb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66d10132ebde4c69977f0b31055a0271_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73c05785e9ff4c7cbf5b3cfde9945e78_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if14f6b3f9f9143678ca31fa46792180a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e487ca262164803a2471112a5aa3b86_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ac40763eff9488da386a8f3f515dcd2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2437426902314907bb93c3e3a054e882_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbab252c85d54d69abb776900de44d5a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib88b8cbaf9c044f48d97f4585c10e9b1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dc8e8d5b2d3450c82e20483d0b1d396_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cfa814cabb748ff9a56f20f22646f52_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad0d67abd1ee4eb5a0b58ae347cb78d5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f93afb80fb24f97b3aa96bd0066452e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6687248226604b5aa14b27933ac85631_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if57d38b69b26462fbe9ef33ebe278bce_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d3e933fec544494a455857f02039dc6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib066bd91431342b3ac8d11e80261834a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a6d0c95500f4e4bae253dfa35567e77_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMzAtMS0xLTEtNzAwNDI_27af7b16-5ca8-4fb0-85e6-327746e1b9d3 id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMzAtMy0xLTEtNzAwNDI_9aa87413-0e81-44b1-a6c9-46b296611732 id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNTYtMS0xLTEtNzAwNDI_8a508be7-60bb-4369-8ecb-378f3b1c0cb9 id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNTYtMy0xLTEtNzAwNDI_c2c1852f-3a60-4cec-a086-28febf1444cc" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RleHRyZWdpb246NGYzMDBhN2I4OGE3NDUyODk0MGQ5YmRiZTMwYTlkN2RfMTA2MQ_1ec7d3a3-c3b2-4fba-9229-2cf9b363a837" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGV4dHJlZ2lvbjpmNDkyMmYxMTNlYjQ0YmM5OTg1OGZmZjQ4MjA0YzQ0YV8yMDkz_16fe3c9a-3cef-4260-b47a-11783162e7c0">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.021%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGFibGU6NTVhNzk5M2Y0NmNlNGRiYmI0NjllZDM1MDVmZjI2NTQvdGFibGVyYW5nZTo1NWE3OTkzZjQ2Y2U0ZGJiYjQ2OWVkMzUwNWZmMjY1NF8wLTAtMS0xLTcwMDQy_7fd2e898-e4f2-4e79-9b14-a31cc79da5b6">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGV4dHJlZ2lvbjpmNDkyMmYxMTNlYjQ0YmM5OTg1OGZmZjQ4MjA0YzQ0YV8yNzQ4Nzc5MDcxNjA2_aed78149-4c11-4fd5-ba7c-c574fc67e4f9">March 31, 2022</ix:nonNumeric> </span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.021%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGFibGU6MWIzNTc3ZWJlZGVlNGQ0ZDgwM2YyNzcwMGFjZWEyNzEvdGFibGVyYW5nZToxYjM1NzdlYmVkZWU0ZDRkODAzZjI3NzAwYWNlYTI3MV8wLTAtMS0xLTcwMDQy_3731a58e-6830-4393-8236-81d84ad45da5">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from &#160;___&#160;to ___.</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File No. <ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGV4dHJlZ2lvbjpmNDkyMmYxMTNlYjQ0YmM5OTg1OGZmZjQ4MjA0YzQ0YV8yMDk0_19273c80-614b-417f-afba-1ad6ad81cd27">001-37392</ix:nonNumeric> </span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGV4dHJlZ2lvbjpmNDkyMmYxMTNlYjQ0YmM5OTg1OGZmZjQ4MjA0YzQ0YV8yMDk1_81c01298-3692-4b94-a504-6f0f761004ae">Apollo Medical Holdings, Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGFibGU6ZTBlYzk5NmZkMjg4NGFlMzg0Yjk3ZWM2YTZlYWMwNDEvdGFibGVyYW5nZTplMGVjOTk2ZmQyODg0YWUzODRiOTdlYzZhNmVhYzA0MV8wLTAtMS0xLTcwMDQy_33514c8f-c449-44bd-845c-03118d55bf93">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGFibGU6ZTBlYzk5NmZkMjg4NGFlMzg0Yjk3ZWM2YTZlYWMwNDEvdGFibGVyYW5nZTplMGVjOTk2ZmQyODg0YWUzODRiOTdlYzZhNmVhYzA0MV8wLTEtMS0xLTcwMDQy_3630b290-f47f-4257-865a-c6ddc4e2f8a0">95-4472349</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or Other Jurisdiction</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identification Number)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGV4dHJlZ2lvbjpmNDkyMmYxMTNlYjQ0YmM5OTg1OGZmZjQ4MjA0YzQ0YV8yMTAw_bd749aa2-d2da-4b41-8655-be390c1271ee">1668 S. Garfield Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGV4dHJlZ2lvbjpmNDkyMmYxMTNlYjQ0YmM5OTg1OGZmZjQ4MjA0YzQ0YV8yMDk2_23c388a9-6f58-4a97-be5a-251afb637592" continuedAt="i55614534e3c54697822edcd262e2bc43">2</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="i55614534e3c54697822edcd262e2bc43" continuedAt="iec35715543ae4c8fa1762b4257c613bd">nd</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="iec35715543ae4c8fa1762b4257c613bd"> Floor</ix:continuation>, <ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGV4dHJlZ2lvbjpmNDkyMmYxMTNlYjQ0YmM5OTg1OGZmZjQ4MjA0YzQ0YV8yMDk3_d826bdd1-8f79-4b41-8cff-683411356fe7">Alhambra</ix:nonNumeric>, <ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGV4dHJlZ2lvbjpmNDkyMmYxMTNlYjQ0YmM5OTg1OGZmZjQ4MjA0YzQ0YV8yMTAx_4fabff80-2b31-42b0-8347-27f5f4d29aa7">California</ix:nonNumeric> <ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGV4dHJlZ2lvbjpmNDkyMmYxMTNlYjQ0YmM5OTg1OGZmZjQ4MjA0YzQ0YV8yMDg2_14986ce6-c5f0-4714-a7e5-bcfd8c5e8818">91801</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices and zip code)</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGV4dHJlZ2lvbjpmNDkyMmYxMTNlYjQ0YmM5OTg1OGZmZjQ4MjA0YzQ0YV8yMDkw_cd32e825-3fcf-49a6-b4fd-8680f3b5daec">626</ix:nonNumeric>) <ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGV4dHJlZ2lvbjpmNDkyMmYxMTNlYjQ0YmM5OTg1OGZmZjQ4MjA0YzQ0YV8yMTAy_b8c4c69b-8061-4878-92dd-7cc53336e239">282-0288</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)&#160;</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.997%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.890%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title of Each Class</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trading Symbol</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of Each Exchange on Which Registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGFibGU6NDI4YWFjNmVmNWEwNDdiMzllNDM0M2ExODJiNjdmYzIvdGFibGVyYW5nZTo0MjhhYWM2ZWY1YTA0N2IzOWU0MzQzYTE4MmI2N2ZjMl8xLTAtMS0xLTcwMDQy_841aac52-39dd-40a2-a16b-2cd892489094">Common Stock, $0.001 par value per share</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGFibGU6NDI4YWFjNmVmNWEwNDdiMzllNDM0M2ExODJiNjdmYzIvdGFibGVyYW5nZTo0MjhhYWM2ZWY1YTA0N2IzOWU0MzQzYTE4MmI2N2ZjMl8xLTItMS0xLTcwMDQy_15043a9a-1c75-4da5-8c64-10c11fb82e02">AMEH</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nasdaq Capital Market</span></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days:&#160;&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   <ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGV4dHJlZ2lvbjpmNDkyMmYxMTNlYjQ0YmM5OTg1OGZmZjQ4MjA0YzQ0YV8yMDg3_877e5877-20c1-4070-803f-61c63c18e6dc">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;<ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGV4dHJlZ2lvbjpmNDkyMmYxMTNlYjQ0YmM5OTg1OGZmZjQ4MjA0YzQ0YV8yMDkx_1ffcb813-7c2c-49af-8e29-dad642f46fa6">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.675%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGFibGU6ZWRkN2JkOWY3MjliNDI3YmI5MTA3YzAzYzdjODhiMDYvdGFibGVyYW5nZTplZGQ3YmQ5ZjcyOWI0MjdiYjkxMDdjMDNjN2M4OGIwNl8wLTAtMS0xLTgyNDY3_117b5921-415c-42b5-98af-4ccd0a14eb35">Large accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGFibGU6ZWRkN2JkOWY3MjliNDI3YmI5MTA3YzAzYzdjODhiMDYvdGFibGVyYW5nZTplZGQ3YmQ5ZjcyOWI0MjdiYjkxMDdjMDNjN2M4OGIwNl8xLTMtMS0xLTcwMDQy_ae00dbc9-c8b7-45b4-904a-203d0754603b">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGFibGU6ZWRkN2JkOWY3MjliNDI3YmI5MTA3YzAzYzdjODhiMDYvdGFibGVyYW5nZTplZGQ3YmQ5ZjcyOWI0MjdiYjkxMDdjMDNjN2M4OGIwNl8yLTMtMS0xLTcwMDQy_4cfd7f34-c0d1-4973-899a-5e1402c090a8">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGV4dHJlZ2lvbjpmNDkyMmYxMTNlYjQ0YmM5OTg1OGZmZjQ4MjA0YzQ0YV8yMDky_2ede70f9-c065-4c7e-83d1-1ec35bd4f665">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160; No</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April&#160;28, 2022, there were <ix:nonFraction unitRef="shares" contextRef="if80c5db3cf224b5d92f4efbc74830e91_I20220428" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGV4dHJlZ2lvbjpmNDkyMmYxMTNlYjQ0YmM5OTg1OGZmZjQ4MjA0YzQ0YV8xOTg5_b0433f76-ebb0-4e29-b6a3-8eaac91787f3">56,048,564</ix:nonFraction> shares of common stock of the registrant, $0.001 par value per share, issued and outstanding.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO FORM 10-Q FILING</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.258%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PAGE</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_13">Introductory Note</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_13">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_13">Note About Forward-Looking Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_13">4</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_16">PART I</a></span></div><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_16">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_19">Item 1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_19">Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_19">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_22">Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_22">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_25">Consolidated Statements of Income for the Three Months Ended March 31, 2022 and 2021</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_25">8</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_31">Consolidated Statements of Mezzanine and Stockholders</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_127">&#8217;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_31"> Equity for the Three Months Ended March 31, 2022 and 2021</a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_31">9</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_34">Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2022 and 2021</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_34">10</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_37">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_37">12</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_127">Item 2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_127">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_127">49</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_175">Item 3.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_175">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_175">61</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_178">Item 4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_178">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_178">62</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_181">PART II</a></span></div><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_181">OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_184">Item 1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_184">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_184">63</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_187">Item 1A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_187">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_187">63</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_190">Item 2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_190">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_190">63</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_193">Item 3.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_193">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_193">63</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_196">Item 4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_196">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_196">63</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_199">Item 5.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_199">Other Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_199">63</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_202">Item 6.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_202">Exhibits</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3cbe033f261a4f1ea6a0c939c6847530_202">64</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Glossary</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following abbreviations or acronyms that may be used in this document shall have the adjacent meanings set forth below:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.964%"><tr><td style="width:1.0%"></td><td style="width:28.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accountable Health Care</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accountable Health Care IPA, a Professional Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AHMC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AHMC Healthcare Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AIPBP</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All-Inclusive Population-Based Payments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AKM</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AKM Medical Group, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alpha Care</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alpha Care Medical Group, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG, a Professional Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG Properties</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG Properties, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ApolloMed Hospitalists, a Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMM</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apollo Medical Management, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AP-AMH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AP-AMH Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AP-AMH 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AP-AMH 2 Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APAACO</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APA ACO, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allied Physicians of California, a Professional Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APCMG</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Access Primary Care Medical Group</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APC-LSMA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APC-LSMA Designated Shareholder Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BAHA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bay Area Hospitalist Associates</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAIPA MSO</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAIPA MSO, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CDSC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Concourse Diagnostic Surgery Center, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CMS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centers for Medicare &amp; Medicaid Services</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CQMC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Critical Quality Management Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DMHC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California Department of Managed Healthcare</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DMG</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostic Medical Group of Southern California</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GPDC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global and Professional Direct Contracting </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HSMSO</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health Source MSO Inc., a California corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ICC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AHMC International Cancer Center, a Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">independent practice association</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LMA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LaSalle Medical Associates</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MMG</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maverick Medical Group, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MPP</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Property Partners, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NGACO</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Next Generation Accountable Care Organization</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NMM</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Network Medical Management, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PMIOC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pacific Medical Imaging and Oncology Center, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SCHC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Southern California Heart Centers</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sun Labs</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sun Clinical Laboratories </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tag 6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tag-6 Medical Investments Group, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tag 8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tag-8 Medical Investments Group, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UCAP</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Universal Care Acquisition Partners, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UCI</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Universal Care, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VIE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">variable interest entity</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZLL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZLL Partners, LLC</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_13"></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTRODUCTORY NOTE</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context dictates otherwise, references in this Quarterly Report on Form 10-Q to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and similar words are references to Apollo Medical Holdings, Inc., a Delaware corporation, and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (&#8220;VIEs&#8221;) and &#8220;ApolloMed&#8221; refers to Apollo Medical Holdings, Inc.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) have not reviewed any statements contained in this Report, including statements describing the participation of APA ACO, Inc. (&#8220;APAACO&#8221;) in the Next Generation Accountable Care Organization (&#8220;NGACO&#8221;) model, or the Global and Professional Direct Contracting (&#8220;GPDC&#8221;) model. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade names and trademarks of the Company and its subsidiaries referred to herein, and their respective logos, are our property. This Quarterly Report on Form 10-Q may contain additional trade names and/or trademarks of other companies, which are the property of their respective owners. We do not intend our use or display of other companies&#8217; trade names and/or trademarks, if any, to imply an endorsement or sponsorship of us by such companies, or any relationship with any of these companies.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">NOTE ABOUT FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This Quarterly Report on Form 10-Q contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). All statements other than statements of historical fact are &#8220;forward-looking statements&#8221; for purposes of federal and state securities laws, including, but not limited to, any statements about our business, financial condition, operating results, plans, objectives, expectations, and intentions, any projections of earnings, revenue, or other financial items, such as projected payments from CMS and our future liquidity; any statements of any plans, strategies, and objectives of management for future operations, such as the material opportunities that we believe exist for our company; any statements concerning proposed services, developments, mergers, or acquisitions; any statements regarding the outlook on our NGACO, GPDC model, or strategic transactions; any statements regarding management&#8217;s view of future expectations and prospects for us; any statements about prospective adoption of new accounting standards or effects of changes in accounting standards; any statements regarding future economic conditions or performance; any statements of belief; any statements of assumptions underlying any of the foregoing; and other statements that are not historical facts. Forward-looking statements may be identified by the use of forward-looking terms, such as &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;can,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;should,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;project,&#8221; &#8220;believe,&#8221; &#8220;think,&#8221; &#8220;plan,&#8221; &#8220;envision,&#8221; &#8220;intend,&#8221; &#8220;continue,&#8221; &#8220;target,&#8221; &#8220;seek,&#8221; &#8220;contemplate,&#8221; &#8220;budgeted,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and the negative of such terms, other variations on such terms or other similar or comparable words, phrases, or terminology. These forward-looking statements present our estimates and assumptions only as of the date of this Quarterly Report on Form 10-Q and are subject to change.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Forward-looking statements involve risks and uncertainties and are based on the current beliefs, expectations, and certain assumptions of management. Some or all of such beliefs, expectations, and assumptions may not materialize or may vary significantly from actual results. Such statements are qualified by important economic, competitive, governmental, and technological factors that could cause our business, strategy, or actual results or events to differ materially from those in our forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in our Annual Report on Form 10-K, for the year ended&#160;December&#160;31, 2021, filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on February&#160;28, 2022, including the risk factors discussed under the heading &#8220;Risk Factors&#8221; in Part I, Item IA thereof. Although we believe that the expectations reflected in our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change, and significant risks and uncertainties that could cause actual conditions, outcomes, and results to differ materially from those indicated by such statements.</span></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_16"></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I FINANCIAL INFORMATION</span></div><div><span><br/></span></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_19"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_22"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNS0xLTEtMS03MDA0Mg_d5fd204c-c1af-4689-9d11-79578ade4cae">237,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNS0zLTEtMS03MDA0Mg_68b30608-22bf-4134-bee2-1dc4775a17bb">233,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNy0xLTEtMS03MDA0Mg_d86457c2-0520-428a-99e8-0d79f90551eb">42,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNy0zLTEtMS03MDA0Mg_5a3d7af3-3171-4abe-b9ba-90b45f2f2a5a">53,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfOC0xLTEtMS03MDA0Mg_eeeedadc-a18d-4186-b78c-b5c490910eab">55,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfOC0zLTEtMS03MDA0Mg_95dddbe4-c42c-4863-8445-3afe7524d486">10,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net &#8211; related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfOS0xLTEtMS03MDA0Mg_3adfdf5e-2285-4371-9690-c41e4e56267e">76,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfOS0zLTEtMS03MDA0Mg_393c2af1-60a6-47a6-b870-c0b07e2d5b1e">69,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMTAtMS0xLTEtNzAwNDI_beab151e-2e99-4012-9705-374c406f9c91">13,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMTAtMy0xLTEtNzAwNDI_b2885ae1-f00c-462a-8437-fb3abe710d44">9,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMTEtMS0xLTEtNzAwNDI_a8733a30-4561-4d71-b1e9-ddbc7357d054">14,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMTEtMy0xLTEtNzAwNDI_3c5d98dc-4cd9-4279-892c-db44e141a843">18,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMTItMS0xLTEtNzAwNDI_f7feb749-34f8-4a7a-b09d-525f423b6b6d">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMTItMy0xLTEtNzAwNDI_994718aa-da0f-40e0-af7b-9be1d0504f3b">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMTQtMS0xLTEtNzAwNDI_ac71b2e7-8c92-43a8-ae0d-0046abe586cc">444,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMTQtMy0xLTEtNzAwNDI_80604bb3-ed36-4aa7-ae15-c8075059c854">398,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property, and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMTctMS0xLTEtNzAwNDI_ef3778ab-55e3-4c5b-886c-75a1a4f01b64">70,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMTctMy0xLTEtNzAwNDI_190b9250-6445-45fb-aa2d-bf695dd41f69">53,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMTgtMS0xLTEtNzAwNDI_a2545590-3c31-4098-b392-1c21b8810af4">80,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMTgtMy0xLTEtNzAwNDI_54f9bbf4-ad74-471a-bfde-7b01f73d5ff4">82,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMTktMS0xLTEtNzAwNDI_ef5b3901-5e12-4700-a2a1-aed3d46dea78">252,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMTktMy0xLTEtNzAwNDI_80c214fc-f0fb-4ec3-add8-0e2eac0ca6a3">253,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMjAtMS0xLTEtNzAwNDI_59b8ed9e-a819-47de-af6e-9032afa6444e">549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMjAtMy0xLTEtNzAwNDI_78862984-e9f0-4dee-b745-7a145bb250ac">569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in other entities &#8211; equity method</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMjItMS0xLTEtNzAwNDI_e0e24c4b-d28c-42cf-93d8-7046c914b865">44,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMjItMy0xLTEtNzAwNDI_246c3ed7-04a8-4324-92de-db47a464ea23">41,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in privately held entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMjMtMS0xLTEtNzAwNDI_23c8443c-3c95-4ba7-a59d-ebe39351b572">896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMjMtMy0xLTEtNzAwNDI_c707cbd2-e306-4715-bb83-297e7a3cd45f">896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMjUtMS0xLTEtNzAwNDI_285004e8-8a5a-4607-983e-037e8a78e459">14,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMjUtMy0xLTEtNzAwNDI_47283b62-8015-4f36-a178-7c03a8464bdd">15,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMjYtMS0xLTEtNzAwNDI_f3bfcdfc-31ee-47d3-a3ad-65bf2299dca5">4,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMjYtMy0xLTEtNzAwNDI_3ad8f6b8-ffe8-4995-aff0-96481e3d10b5">5,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMjgtMS0xLTEtNzAwNDI_ee8181ba-3f2e-42e8-8995-795089e9cca2">467,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMjgtMy0xLTEtNzAwNDI_221b712f-7c57-4ba2-a14a-84832bf79844">453,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMzAtMS0xLTEtNzAwNDI_27af7b16-5ca8-4fb0-85e6-327746e1b9d3">912,331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMzAtMy0xLTEtNzAwNDI_9aa87413-0e81-44b1-a6c9-46b296611732">852,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities, mezzanine equity, and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMzYtMS0xLTEtNzAwNDI_204bea25-1e66-4c8e-a02d-c0b02036ef69">48,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMzYtMy0xLTEtNzAwNDI_bc6a2f04-9d8a-4f4f-af2b-720e4382f1a6">43,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiduciary accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="ameh:FiduciaryAccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMzctMS0xLTEtNzAwNDI_d1f27251-d9bb-49c0-acd9-c24e6f74c7f6">6,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="ameh:FiduciaryAccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMzctMy0xLTEtNzAwNDI_6b90ca90-3284-46e1-8910-5e16a6a631ee">10,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMzgtMS0xLTEtNzAwNDI_7b93beaf-4ec4-4ae8-9a30-35209003a63b">95,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMzgtMy0xLTEtNzAwNDI_7729eb9a-18c8-43d1-8735-7e5339184e6b">55,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMzktMS0xLTEtNzAwNDI_752d43de-0370-44e5-a9a4-eb3b20f5c2a6">4,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMzktMy0xLTEtNzAwNDI_8a2fddf9-1fe6-4c46-b617-0900caeb9f66">652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:DividendsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNDAtMS0xLTEtNzAwNDI_0dcfa439-62c1-47a2-92e6-c319e94074d4">556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:DividendsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNDAtMy0xLTEtNzAwNDI_568ba4a0-7772-4002-ab8d-873ef1ecdee0">556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNDEtMS0xLTEtNzAwNDI_f4a528dc-4039-40f3-95cb-895ad09aa8fe">543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNDEtMy0xLTEtNzAwNDI_246307fa-a8f4-4173-8c5c-11a4c1559e51">486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNDItMS0xLTEtNzAwNDI_19f7e593-b7e1-4a6b-9954-4ba20f789d94">2,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNDItMy0xLTEtNzAwNDI_495a37d4-5c4a-4cc4-af1a-d28bfa4e5a70">2,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNDMtMS0xLTEtNzAwNDI_bced1947-30d4-4ffe-8867-f0da2fe64976">1,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNDMtMy0xLTEtNzAwNDI_e8f83085-b6d5-4a16-bf91-79dcb0a53a6d">780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNDUtMS0xLTEtNzAwNDI_1392eef8-7f7b-4270-959a-c14316f0262e">160,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNDUtMy0xLTEtNzAwNDI_4d27bd27-ee84-4e56-b8aa-03b3690c9a97">115,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNDgtMS0xLTEtNzAwNDI_e9c27e7d-1a29-48bf-8622-bd70015d3257">9,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNDgtMy0xLTEtNzAwNDI_d3f2728c-8f03-4e4b-bfdd-870a37363ec1">9,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNDktMS0xLTEtNzAwNDI_3cce7ae8-1d6f-4523-9c8f-2e749f54ab12">1,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNDktMy0xLTEtNzAwNDI_407a96ad-1e4a-4f64-b5c0-9015ec2b8b96">973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNTAtMS0xLTEtNzAwNDI_6a6e244a-d98a-493b-bcef-17140e29f9a7">12,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNTAtMy0xLTEtNzAwNDI_3eb2b47b-c964-4681-a32f-5cf5dd3e4369">13,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion and deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNTEtMS0xLTEtNzAwNDI_96cc37fc-2781-4afd-b31e-bf0f4de87e2c">183,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNTEtMy0xLTEtNzAwNDI_cd6dfd1e-560e-46a2-8d99-1535524dbf2b">182,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNTItMS0xLTEtNzAwNDI_8e2a286f-9cd9-42cf-b4df-5aa7290e0ab6">13,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNTItMy0xLTEtNzAwNDI_e3700775-6193-435f-b277-114e5ba54f04">14,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNTQtMS0xLTEtNzAwNDI_a4625c1d-eb77-4b35-8d90-82326ec055b2">220,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNTQtMy0xLTEtNzAwNDI_bba39928-08ad-4899-8d97-21f4a92e7ccc">220,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNTYtMS0xLTEtNzAwNDI_8a508be7-60bb-4369-8ecb-378f3b1c0cb9">380,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNTYtMy0xLTEtNzAwNDI_c2c1852f-3a60-4cec-a086-28febf1444cc">336,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments and contingencies (Note 12)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNTgtMS0xLTEtNzAwNDI_a76608ba-134f-4d41-b5f7-c190084d3601"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNTgtMy0xLTEtNzAwNDI_a685e654-109e-4d77-b8a7-0dde8f2f238c"></ix:nonFraction>Mezzanine equity</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interest in Allied Physicians of California, a Professional Medical Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjEtMS0xLTEtNzAwNDI_6b0f9323-c9a4-4d37-baa5-2c087b5beee0">52,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjEtMy0xLTEtNzAwNDI_1ca081b0-9329-4741-b3f0-cfc03e6c3c21">55,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stockholders&#8217; equity</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i082ebdd9e5cf4b14937116ed41c6d210_I20220331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjQtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjowZDYzMDQ0ZTVjYTc0MzY2YjNmYzYxZmM0YTkzZjQ2Nl8zMA_042d5748-b399-4310-a4b6-38bec05f53f6"><ix:nonFraction unitRef="usdPerShare" contextRef="id2b4439fa02d406d9c63972d386e09c1_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjQtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjowZDYzMDQ0ZTVjYTc0MzY2YjNmYzYxZmM0YTkzZjQ2Nl8zMA_ada56805-1057-47fd-a694-ef1fc93ecb56">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i082ebdd9e5cf4b14937116ed41c6d210_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjQtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjowZDYzMDQ0ZTVjYTc0MzY2YjNmYzYxZmM0YTkzZjQ2Nl81NA_5b3d7a6f-af8a-46b5-9901-eb215aa1c7ee"><ix:nonFraction unitRef="shares" contextRef="id2b4439fa02d406d9c63972d386e09c1_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjQtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjowZDYzMDQ0ZTVjYTc0MzY2YjNmYzYxZmM0YTkzZjQ2Nl81NA_632bd2f9-2a47-4077-825c-e381a3e2e3ff">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized (inclusive of all preferred stock, including Series B Preferred stock); <ix:nonFraction unitRef="shares" contextRef="id2b4439fa02d406d9c63972d386e09c1_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjQtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjowZDYzMDQ0ZTVjYTc0MzY2YjNmYzYxZmM0YTkzZjQ2Nl8xNDc_58b35ea6-9d57-4563-8937-8f827b5fd5a6"><ix:nonFraction unitRef="shares" contextRef="i082ebdd9e5cf4b14937116ed41c6d210_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjQtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjowZDYzMDQ0ZTVjYTc0MzY2YjNmYzYxZmM0YTkzZjQ2Nl8xNDc_b803e43f-5e9e-4e6f-bf28-4de331799c23">1,111,111</ix:nonFraction></ix:nonFraction> issued and <ix:nonFraction unitRef="shares" contextRef="i082ebdd9e5cf4b14937116ed41c6d210_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjQtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjowZDYzMDQ0ZTVjYTc0MzY2YjNmYzYxZmM0YTkzZjQ2Nl8xNjE_7d53ee6a-66ff-4334-a026-ad1a224da0ed"><ix:nonFraction unitRef="shares" contextRef="id2b4439fa02d406d9c63972d386e09c1_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjQtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjowZDYzMDQ0ZTVjYTc0MzY2YjNmYzYxZmM0YTkzZjQ2Nl8xNjE_8b35a121-d69b-44d0-90a0-dcd95783049c">zero</ix:nonFraction></ix:nonFraction> outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i082ebdd9e5cf4b14937116ed41c6d210_I20220331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjQtMS0xLTEtNzAwNDI_1654f59b-0564-4473-9aba-8936d6c2ede3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2b4439fa02d406d9c63972d386e09c1_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjQtMy0xLTEtNzAwNDI_177a936c-b579-4cbe-8bc5-50b610333a03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i1b27218f21ed45fc8fe5af87b6180da5_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjUtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjo3YmI4MDJiZmFmY2U0NjFmOWMxMzVhZDFhMzE5MjQ5Yl8zMA_53b757f4-1042-4f99-8a27-e9b426e1de6c"><ix:nonFraction unitRef="usdPerShare" contextRef="i1968744464b94c44b565a81c2bf9632e_I20220331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjUtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjo3YmI4MDJiZmFmY2U0NjFmOWMxMzVhZDFhMzE5MjQ5Yl8zMA_9ab7c11f-51fe-43ba-b4b4-402f2c0709b3">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i1968744464b94c44b565a81c2bf9632e_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjUtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjo3YmI4MDJiZmFmY2U0NjFmOWMxMzVhZDFhMzE5MjQ5Yl81NA_a96e605c-806a-4818-a041-b8361dbd0792"><ix:nonFraction unitRef="shares" contextRef="i1b27218f21ed45fc8fe5af87b6180da5_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjUtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjo3YmI4MDJiZmFmY2U0NjFmOWMxMzVhZDFhMzE5MjQ5Yl81NA_cf7580c6-0c51-4f22-a081-e9368fba66af">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized (inclusive of all preferred stock, including Series A Preferred stock); <ix:nonFraction unitRef="shares" contextRef="i1968744464b94c44b565a81c2bf9632e_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjUtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjo3YmI4MDJiZmFmY2U0NjFmOWMxMzVhZDFhMzE5MjQ5Yl8xNDc_76c1eb9c-09d6-4a52-ae42-e6a08e705c6b"><ix:nonFraction unitRef="shares" contextRef="i1b27218f21ed45fc8fe5af87b6180da5_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjUtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjo3YmI4MDJiZmFmY2U0NjFmOWMxMzVhZDFhMzE5MjQ5Yl8xNDc_f21efd85-c0e6-4614-9d49-b4dd4794a147">555,555</ix:nonFraction></ix:nonFraction> issued and <ix:nonFraction unitRef="shares" contextRef="i1968744464b94c44b565a81c2bf9632e_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjUtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjo3YmI4MDJiZmFmY2U0NjFmOWMxMzVhZDFhMzE5MjQ5Yl8xNjE_5642bac7-9932-4520-9a82-aa7f53e58a91"><ix:nonFraction unitRef="shares" contextRef="i1b27218f21ed45fc8fe5af87b6180da5_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjUtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjo3YmI4MDJiZmFmY2U0NjFmOWMxMzVhZDFhMzE5MjQ5Yl8xNjE_74e8cc97-9a91-4ef4-96d5-06b97e262e4d">zero</ix:nonFraction></ix:nonFraction> outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1968744464b94c44b565a81c2bf9632e_I20220331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjUtMS0xLTEtNzAwNDI_ba157e11-b575-41f7-afe6-b4ac2c37a212">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b27218f21ed45fc8fe5af87b6180da5_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjUtMy0xLTEtNzAwNDI_4cb6a6bc-67e1-47a9-9c2a-e36f4d4175ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjYtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjpmYjFlODBiN2VmOTI0NTBlYjM2YzM0ZmYxYThlYjlhMF8xOA_280ec978-7813-474d-8b38-c39a923f256c"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjYtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjpmYjFlODBiN2VmOTI0NTBlYjM2YzM0ZmYxYThlYjlhMF8xOA_57c786f8-b93a-4df1-8250-170d213f087d">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjYtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjpmYjFlODBiN2VmOTI0NTBlYjM2YzM0ZmYxYThlYjlhMF80Mg_a6df9872-b98b-4374-a0a9-6513ca73b909"><ix:nonFraction unitRef="shares" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjYtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjpmYjFlODBiN2VmOTI0NTBlYjM2YzM0ZmYxYThlYjlhMF80Mg_e54d90f4-e309-4e07-b6f8-c9bc422b2517">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjYtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjpmYjFlODBiN2VmOTI0NTBlYjM2YzM0ZmYxYThlYjlhMF82NA_192fad18-3f17-4bcc-84d9-ff03f5c27829"><ix:nonFraction unitRef="shares" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjYtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjpmYjFlODBiN2VmOTI0NTBlYjM2YzM0ZmYxYThlYjlhMF82NA_62a70567-a191-4664-b7b0-72ef9d579d10">44,845,059</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjYtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjpmYjFlODBiN2VmOTI0NTBlYjM2YzM0ZmYxYThlYjlhMF83MQ_507bba01-b83e-4049-afa2-451edd2dff3b"><ix:nonFraction unitRef="shares" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjYtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjpmYjFlODBiN2VmOTI0NTBlYjM2YzM0ZmYxYThlYjlhMF83MQ_6dc0e33b-35fd-4de4-a27a-f61a640c72e8">44,630,873</ix:nonFraction></ix:nonFraction> shares issued and outstanding, excluding <ix:nonFraction unitRef="shares" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjYtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjpmYjFlODBiN2VmOTI0NTBlYjM2YzM0ZmYxYThlYjlhMF8xMTU_19721132-93c5-402b-a86a-5dfc43d262a3">10,925,702</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjYtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjpmYjFlODBiN2VmOTI0NTBlYjM2YzM0ZmYxYThlYjlhMF8xMjI_b17585e6-d8a8-4c56-a289-71a6855a3851">10,925,702</ix:nonFraction> treasury shares, as of March&#160;31, 2022 and December&#160;31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjYtMS0xLTEtNzAwNDI_d567eb4e-8264-4aae-8ec2-620ea218d2da">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjYtMy0xLTEtNzAwNDI_52420ca3-5bc5-49a2-b9c3-0c83ea0156c0">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjctMS0xLTEtNzAwNDI_d3c838ad-5a0c-434d-87dc-8aedf96c2b01">316,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjctMy0xLTEtNzAwNDI_de4072b5-254f-48c1-bf90-50f65bddca74">310,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Retained earnings</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjgtMS0xLTEtNzAwNDI_d04528bf-eb1a-44bc-961b-9089dc2730cc">157,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjgtMy0xLTEtNzAwNDI_967fa890-6300-4172-bb44-1fe82ec46639">143,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjktMS0xLTEtNzAwNDI_32a98e36-01e0-457c-a8f3-77d189abe755">473,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjktMy0xLTEtNzAwNDI_78555036-a09b-4f88-a0ec-cecd66bf6b4c">454,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNzEtMS0xLTEtNzAwNDI_2fd8d766-6c75-420d-b2a5-f056ad33717f">5,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNzEtMy0xLTEtNzAwNDI_6a01499a-84f1-4b37-b2c3-9feb77b87ed3">5,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNzMtMS0xLTEtNzAwNDI_020531fb-c16f-4dbd-a459-e928e3449025">479,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNzMtMy0xLTEtNzAwNDI_a35693b7-3cf3-4c60-8f52-636f4538a6c7">460,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities, mezzanine equity, and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNzUtMS0xLTEtNzAwNDI_3d53c672-a442-4227-b548-905a5fc6ca57">912,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNzUtMy0xLTEtNzAwNDI_591009d3-eb13-4916-b332-c7adb604d39b">852,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RleHRyZWdpb246NGYzMDBhN2I4OGE3NDUyODk0MGQ5YmRiZTMwYTlkN2RfMTA2MQ_1ec7d3a3-c3b2-4fba-9229-2cf9b363a837" footnoteRole="http://www.xbrl.org/2003/role/footnote">The Company&#8217;s consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#8217;s consolidated VIEs totaling $<ix:nonFraction unitRef="usd" contextRef="id271ccfbc8e049649cd2b13460a8e718_I20220331" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RleHRyZWdpb246NGYzMDBhN2I4OGE3NDUyODk0MGQ5YmRiZTMwYTlkN2RfNDcx_2847496b-6664-4817-9e27-b30871370b09">585.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i45babd110e5c45fe951fced5efef52c3_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RleHRyZWdpb246NGYzMDBhN2I4OGE3NDUyODk0MGQ5YmRiZTMwYTlkN2RfNDc4_43be6491-9ae9-4468-bec5-dca89efee2b4">567.0</ix:nonFraction>&#160;million as of March&#160;31, 2022 and December&#160;31, 2021, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $<ix:nonFraction unitRef="usd" contextRef="id271ccfbc8e049649cd2b13460a8e718_I20220331" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RleHRyZWdpb246NGYzMDBhN2I4OGE3NDUyODk0MGQ5YmRiZTMwYTlkN2RfNjYy_f2b62901-bbc6-4378-b175-48fddf573035">111.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i45babd110e5c45fe951fced5efef52c3_I20211231" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RleHRyZWdpb246NGYzMDBhN2I4OGE3NDUyODk0MGQ5YmRiZTMwYTlkN2RfNjY5_026a3442-463e-4251-9e6d-43e28e59c2ca">91.7</ix:nonFraction>&#160;million as of March&#160;31, 2022 and December&#160;31, 2021, respectively. The VIE balances do not include $<ix:nonFraction unitRef="usd" contextRef="id271ccfbc8e049649cd2b13460a8e718_I20220331" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RleHRyZWdpb246NGYzMDBhN2I4OGE3NDUyODk0MGQ5YmRiZTMwYTlkN2RfNzM1_11eee145-b062-43b6-a87d-47130fbfb264">529.6</ix:nonFraction>&#160;million of investment in affiliates and $<ix:nonFraction unitRef="usd" contextRef="id271ccfbc8e049649cd2b13460a8e718_I20220331" decimals="-5" name="us-gaap:DueFromAffiliates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RleHRyZWdpb246NGYzMDBhN2I4OGE3NDUyODk0MGQ5YmRiZTMwYTlkN2RfNzcw_82be83c7-cf2c-403a-8205-3dcde59c0f62">25.2</ix:nonFraction>&#160;million of amounts due from affiliates as of March&#160;31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i45babd110e5c45fe951fced5efef52c3_I20211231" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RleHRyZWdpb246NGYzMDBhN2I4OGE3NDUyODk0MGQ5YmRiZTMwYTlkN2RfODE3_16b47868-11ba-4948-b649-00c0c135a73d">802.8</ix:nonFraction>&#160;million of investment in affiliates and $<ix:nonFraction unitRef="usd" contextRef="i45babd110e5c45fe951fced5efef52c3_I20211231" decimals="-5" name="us-gaap:DueToAffiliateCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RleHRyZWdpb246NGYzMDBhN2I4OGE3NDUyODk0MGQ5YmRiZTMwYTlkN2RfODUy_eeb7f78e-8edd-4896-a252-1147488c6079">6.6</ix:nonFraction>&#160;million of amounts due to affiliates as of December&#160;31, 2021 as these are eliminated upon consolidation and not presented within the consolidated balance sheets. See Note 16 &#8211; Variable Interest Entities (VIEs) for further detail.</ix:footnote></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.329%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitation, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8093adf4ca4e659bfd5cc3d0bf5b91_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMy0xLTEtMS03MDA0Mg_a25d4e33-b57f-4e6a-86d7-7cfdce14ff16">222,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe7d345269d429594a7165974ccdcb7_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMy0zLTEtMS03MDA0Mg_4cfa1af7-81af-45c5-9274-4d3cf2ce32d5">144,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk pool settlements and incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d738adb8bf4c52a41f5eb43d954b81_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfNC0xLTEtMS03MDA0Mg_6f1f292f-17d7-4e97-9a1b-3cf95229ceef">18,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81200d008433465fa399ae7b4f619096_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfNC0zLTEtMS03MDA0Mg_d768b041-2489-4f46-b7a6-bb0f1a035f3d">18,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management fee income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4efb856004934021887d5c4fcd6a352c_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfNS0xLTEtMS03MDA0Mg_5eda2888-5ba9-4fc6-adc0-34cd21293466">10,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dce717fa9914fab879521d726f8cdd8_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfNS0zLTEtMS03MDA0Mg_5d392982-d4e9-4c18-810d-40e761bdec15">8,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fee-for-service, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7675a417e574dd7bfb341601fa58abc_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfNi0xLTEtMS03MDA0Mg_c19e9449-377d-4e23-b513-c8f5d7023baf">11,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd48abaf892342879b0c004889f6395b_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfNi0zLTEtMS03MDA0Mg_ede140ed-ecef-494c-b002-c92ac7c608aa">3,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0edd9918dcb74ab7b7be0bfe975e98a6_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfNy0xLTEtMS03MDA0Mg_8c13b6ee-3c25-4b86-a60b-b6748dafdf27">1,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cc1737bb2ac452c8108152c0b78582e_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfNy0zLTEtMS03MDA0Mg_a50d22f4-c226-4a1e-a6c7-661a39710e91">1,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfOS0xLTEtMS03MDA0Mg_1ab7e37f-dea4-4b74-947b-5277240e2376">263,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfOS0zLTEtMS03MDA0Mg_053be6fd-4712-4c03-b6d1-1fa4749cd998">176,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of services, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMTItMS0xLTEtNzAwNDI_a989a618-aebb-4fe6-89be-c7c749bb374b">220,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMTItMy0xLTEtNzAwNDI_a83effc6-635d-49a8-a889-f7816f2a81fb">140,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMTMtMS0xLTEtNzAwNDI_68b88f67-1496-41b5-adf5-2e09a61024d6">11,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMTMtMy0xLTEtNzAwNDI_b320de5d-242d-4ffe-b3a2-f62aeae6057c">9,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMTQtMS0xLTEtNzAwNDI_a625bad1-c103-404e-b7ab-151c606fda35">4,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMTQtMy0xLTEtNzAwNDI_c2af3905-e08b-4c64-84de-91c9af6f925c">4,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMTgtMS0xLTEtNzAwNDI_4be932e9-4abb-4881-8762-eb363e574efe">237,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMTgtMy0xLTEtNzAwNDI_8597707a-bb72-4110-881f-31f80f7d390a">154,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMjAtMS0xLTEtNzAwNDI_ef200dfb-f117-4d82-9e5f-7d65496d3a3f">26,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMjAtMy0xLTEtNzAwNDI_ce97edc9-c190-4bda-a8dd-1e8316932096">21,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMjMtMS0xLTEtNzAwNDI_4ce79814-2213-498b-8d0c-9aae984c0afa">1,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMjMtMy0xLTEtNzAwNDI_e76fce9d-8168-443a-a49b-47f95c927934">677</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMjUtMS0xLTEtNzAwNDI_4bfa5ba8-da6d-4554-b1a1-546732333201">1,073</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMjUtMy0xLTEtNzAwNDI_776b741d-b2ef-4a61-b2d4-3c79721e9fb4">1,523</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMjYtMS0xLTEtNzAwNDI_130b6f2f-d89a-4a45-91de-d322bb1eae63">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMjYtMy0xLTEtNzAwNDI_4ea9c1a3-1c16-4c4f-9e73-c5770c57c915">349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMjctMS0xLTEtNzAwNDI_b89afde0-c0db-488b-983d-f1cfe928430d">8,962</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMjctMy0xLTEtNzAwNDI_895f31ac-0452-480a-8813-0b4332f60afc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMjgtMS0xLTEtNzAwNDI_79f1f2e3-bbb9-4a03-b06d-6269b040f968">613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMjgtMy0xLTEtNzAwNDI_ba1b5845-b72e-49f8-974a-d71c91dd1295">1,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMzAtMS0xLTEtNzAwNDI_3770bb1d-5639-4935-a0ea-c2b3e182ab34">7,943</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMzAtMy0xLTEtNzAwNDI_9ae90d02-a1b3-4cf3-be9a-3f67e6db5d78">547</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMzItMS0xLTEtNzAwNDI_5ba958a4-a848-4064-bc8a-bc149cdd8999">18,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMzItMy0xLTEtNzAwNDI_69da2266-a909-43d7-bc31-5e2c6acde580">21,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMzQtMS0xLTEtNzAwNDI_f2acb82b-e8bb-4b81-bffb-48fa20e41661">6,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMzQtMy0xLTEtNzAwNDI_44a4e9e2-f134-488f-a50b-1603d0c8d619">6,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMzYtMS0xLTEtNzAwNDI_89739722-70d8-4f33-94d2-b07e93d7da04">12,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMzYtMy0xLTEtNzAwNDI_941d69fa-8138-43ce-8dbf-56a619b5ab4c">14,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss) income attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMzgtMS0xLTEtNzAwNDI_d8f115a8-ff7e-46a8-9caf-40346600252f">2,191</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMzgtMy0xLTEtNzAwNDI_75dd10dc-6d40-4047-8733-bb5ea40a2951">1,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to Apollo Medical Holdings, Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfNDAtMS0xLTEtNzAwNDI_bd7bb209-13d5-4925-8419-1560c58e2b40">14,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfNDAtMy0xLTEtNzAwNDI_9e4ce707-1baa-4097-bc62-be12ef71ab00">13,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per share &#8211; basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfNDItMS0xLTEtNzAwNDI_42b9f7ba-bd39-42d6-97c4-6f8dfac7caef">0.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfNDItMy0xLTEtNzAwNDI_266e5c9d-a4be-422f-bfcc-4ff568febae2">0.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per share &#8211; diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfNDQtMS0xLTEtNzAwNDI_159d3e2a-3d1b-4051-91f9-d40ee297d0c0">0.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfNDQtMy0xLTEtNzAwNDI_c8f45aeb-422a-49d0-b2af-7cfa176ab05d">0.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(IN THOUSANDS, EXCEPT SHARE DATA)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.701%"><tr><td style="width:1.0%"></td><td style="width:29.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.097%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.220%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.097%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.555%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine<br/>Equity&#160;&#8211;<br/>Non-controlling<br/>Interest&#160;in&#160;APC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common&#160;Stock&#160;Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional<br/>Paid-in&#160;Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie565cc08147249b5871999e0d1765ed2_I20211231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjMtMS0xLTEtNzAwNDI_98f9f37a-7655-45e7-8e57-38dec9bf2d70">55,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01c06a901fad47e3a2666a70fe1188df_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjMtMy0xLTEtNzAwNDI_bdb204dd-19a6-4375-be2f-6f7e1121ceef">44,630,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01c06a901fad47e3a2666a70fe1188df_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjMtNS0xLTEtNzAwNDI_c53218f0-4719-4862-8b71-a97d5d218cb9">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9910c7555ace4c2bb115be314dd355b1_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjMtNy0xLTEtNzAwNDI_e1edd93b-2862-4dd7-b6d0-c30cca0b5283">310,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3795672568804fb39265965ff8ee0616_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjMtOS0xLTEtNzAwNDI_4366a8b0-ea8e-4787-81f6-95282754e124">143,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934f486ebd2244c69aedfbc72f32d753_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjMtMTEtMS0xLTcwMDQy_2776ed39-b6f4-4377-a613-91f8ccd1bfe8">5,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjMtMTMtMS0xLTcwMDQy_338941ff-7302-4eac-a0ce-c2222a4816d0">460,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30aca1425f44492ca189ea4600ae924d_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:TemporaryEquityNetIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjQtMS0xLTEtNzAwNDI_ed29e0cf-cf7e-4a3c-936c-81e0530eaf06">3,129</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab27752b93f42388e90627d8c8ba555_D20220101-20220331" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjQtOS0xLTEtNzAwNDI_e2f3b633-cd46-4100-bf43-a0de9441da51">14,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb4c95ef672647aca0d3f58bdfd3fd09_D20220101-20220331" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjQtMTEtMS0xLTcwMDQy_65b1e40c-8f93-4fbb-bba1-cf3de7db6c93">938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjQtMTMtMS0xLTcwMDQy_198e4d91-efae-4e21-98e5-17af0c8bc2a9">15,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30aca1425f44492ca189ea4600ae924d_D20220101-20220331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjUtMS0xLTEtNzAwNDI_474074d3-f1e4-48e0-95a6-f760de2ba1d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb4c95ef672647aca0d3f58bdfd3fd09_D20220101-20220331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjUtMTEtMS0xLTcwMDQy_6ee4669e-97e1-4f79-bfc3-7dc0490aa6ce">200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjUtMTMtMS0xLTcwMDQy_86160e9b-487a-4cb5-b41a-d3ec8c9f538a">200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb4c95ef672647aca0d3f58bdfd3fd09_D20220101-20220331" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfNi0xMS0xLTEtMTAxNjY5_4ae6dfb6-673f-4287-b038-3af3ee271c36">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfNi0xMy0xLTEtMTAxNjY5_6553e76a-c6f1-4a2c-8b9a-79163d1ee92f">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share buy back</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30aca1425f44492ca189ea4600ae924d_D20220101-20220331" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfNi0xLTEtMS0xMDE0OTQ_1101a293-21b6-4b59-9203-d1bbb340186c">230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued for vesting of restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0cce845b4bcb47d4937d16c1ce6294b4_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjYtMy0xLTEtNzAwNDI_1488d490-7061-4d4d-8a7c-043f19381201">81,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i891990513de04b79b3fbaedbe290deb4_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjYtNy0xLTEtNzAwNDI_43f2cf5c-e9a2-4b5b-86ff-dc6edb4f25b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjYtMTMtMS0xLTcwMDQy_8526b648-48d0-4bb2-8162-419355326e43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued for exercise of options and warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0cce845b4bcb47d4937d16c1ce6294b4_D20220101-20220331" decimals="INF" name="ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjctMy0xLTEtNzAwNDI_b8ca6519-4d27-473a-ab19-b2de15a7153e">124,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i891990513de04b79b3fbaedbe290deb4_D20220101-20220331" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjctNy0xLTEtNzAwNDI_58ea53ee-8d05-4e20-869d-0d15dc404ede">1,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjctMTMtMS0xLTcwMDQy_ef398bac-0125-4148-9d3c-6fe4f5dee983">1,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i891990513de04b79b3fbaedbe290deb4_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjgtNy0xLTEtNzAwNDI_a47d7e9a-a7e8-4990-b4f9-091afc52ed2b">3,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjgtMTMtMS0xLTcwMDQy_546d22d3-af2c-466b-8f2b-d503f60eb7dc">3,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of shares for business acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0cce845b4bcb47d4937d16c1ce6294b4_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjktMy0xLTEtNzAwNDI_7e800caf-daa3-45f8-a864-a42da4f2e03e">18,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i891990513de04b79b3fbaedbe290deb4_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjktNy0xLTEtNzAwNDI_3b424891-0579-4876-8196-342e965ba585">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjktMTMtMS0xLTcwMDQy_35a8d526-ed71-4f17-87e5-e934bbcc4888">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancellation of restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0cce845b4bcb47d4937d16c1ce6294b4_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMTEtMy0xLTEtMTAxNTA4_afd510bc-3b89-49e7-b481-bf56b0a79414">11,084</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i891990513de04b79b3fbaedbe290deb4_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMTEtNy0xLTEtMTAxNTMw_51a0b90b-8390-4c05-ac92-6de2bf0dc335">457</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMTItMTMtMS0xLTEwMTcxNg_2ff90a51-bc3e-4169-b456-8d7e3370faf3">457</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30aca1425f44492ca189ea4600ae924d_D20220101-20220331" decimals="-3" name="us-gaap:TemporaryEquityAccretionOfDividends" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMzAtMS0xLTEtNzAwNDI_e648a069-c4b9-49e2-8003-d3144eec73a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb4c95ef672647aca0d3f58bdfd3fd09_D20220101-20220331" decimals="-3" sign="-" name="ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMzAtMTEtMS0xLTcwMDQy_636f3b8d-e877-450c-aad2-8253f22bbefc">1,178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" sign="-" name="ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMzAtMTMtMS0xLTcwMDQy_7c9e6c09-82e1-4dd2-966f-ba1c82ef5bdf">1,178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95ae6859a8584e7eb08ef41e08f26b99_I20220331" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMzEtMS0xLTEtNzAwNDI_0af3a66f-d0de-41d3-8681-1a169adc534f">52,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e20c02c36c543ab98bbfa086f702db6_I20220331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMzEtMy0xLTEtNzAwNDI_1a747325-4959-4a47-86b1-d9299c58ff0a">44,845,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e20c02c36c543ab98bbfa086f702db6_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMzEtNS0xLTEtNzAwNDI_c7fa45da-4349-4c74-b63a-5ee2103a54f8">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b7e2b312b964191b6e5a99bfa3fad1c_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMzEtNy0xLTEtNzAwNDI_0571df75-ed70-490d-8b29-72e8f6cb2a2d">316,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3da6bad4ba14fb884f02c88f6ad7610_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMzEtOS0xLTEtNzAwNDI_d75c3f5f-d268-4458-9dfa-96dfcd440040">157,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48596fff82734547a44b9e4ec2fc95ef_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMzEtMTEtMS0xLTcwMDQy_ed77f267-c086-4dac-9275-dda855534871">5,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMzEtMTMtMS0xLTcwMDQy_11a4a447-eea4-48fd-9e33-dd075da78289">479,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.051%"><tr><td style="width:1.0%"></td><td style="width:30.136%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.730%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.730%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.730%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.730%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.620%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine<br/>Equity&#160;&#8211;<br/>Non-controlling<br/>Interest&#160;in&#160;APC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common&#160;Stock&#160;Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional<br/>Paid-in&#160;Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6053bba0574b7c8d8bc3d35aedd364_I20201231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMTgtMS0xLTEtNzAwNDI_42343936-0da7-4ad9-b64e-d8df27cbbf7b">114,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaedbc96dc4de4eab8aed3c10bf0e0fb9_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMTgtMy0xLTEtNzAwNDI_ecbdaa7d-6a79-4d08-a739-ceedf6a55fbb">42,249,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaedbc96dc4de4eab8aed3c10bf0e0fb9_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMTgtNS0xLTEtNzAwNDI_d6af2bdb-5172-4acc-bf0e-22b8bf45f815">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9015851c456402f83746f4b6976dfbb_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMTgtNy0xLTEtNzAwNDI_b24f103b-5402-4652-ba5b-b793632fcfe4">261,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b1648f5a7c74820b4705fadeec2d2c1_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMTgtOS0xLTEtNzAwNDI_9676d7d4-668a-4261-99e1-66e3d0e878e7">69,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd3ffca58ef641c493f6d69c9456f642_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMTgtMTEtMS0xLTcwMDQy_eb35d672-f488-4ed3-a3ea-4efa9d936952">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib537036edf0744c69646e8a9929a0638_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMTgtMTMtMS0xLTcwMDQy_dea02b47-829e-4c9c-861f-52ff3ed2a244">330,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7907a63ed1d0470a879fdec321fba0f4_D20210101-20210331" decimals="-3" name="us-gaap:TemporaryEquityNetIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMTktMS0xLTEtNzAwNDI_667d95a9-b078-4ce5-a15a-ed9ea6a6f788">760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ea6fe0d59b441beb7ba9b153d330fae_D20210101-20210331" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMTktOS0xLTEtNzAwNDI_1d83b8b8-7262-433f-adc1-d21e8f8a7f5b">13,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i109c5e7bd1a14ea599c3a7723e99ade4_D20210101-20210331" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMTktMTEtMS0xLTcwMDQy_f6d89894-311d-4d85-9cbe-481e469ea39f">547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMTktMTMtMS0xLTcwMDQy_1a36683a-ff55-4319-9767-1d894c7718cb">13,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7907a63ed1d0470a879fdec321fba0f4_D20210101-20210331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjAtMS0xLTEtNzAwNDI_88fcaf93-4ce8-4582-9c99-1a253fe68e94">150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i109c5e7bd1a14ea599c3a7723e99ade4_D20210101-20210331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjAtMTEtMS0xLTcwMDQy_12b6e19f-67d9-4e65-a66d-5a0cb001399b">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjAtMTMtMS0xLTcwMDQy_a0d04efa-a528-4773-90c5-1b82ace82df3">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i109c5e7bd1a14ea599c3a7723e99ade4_D20210101-20210331" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjEtMTEtMS0xLTcwMDQy_87035743-352a-410d-8734-3744dfeb863a">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjEtMTMtMS0xLTcwMDQy_1443f899-c1d4-4019-adca-812d522fd2b8">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued for vesting of restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e0d03cf0c84427db63e13d4e462e4e8_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfNy0zLTEtMS03NjkyNQ_82d8a718-f3ae-4320-8887-b1dffbc184e6">7,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfNy0xMy0xLTEtNzY5ODA_9fa0c3eb-9276-434e-beda-f4685eeb555a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued for exercise of options and warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e0d03cf0c84427db63e13d4e462e4e8_D20210101-20210331" decimals="INF" name="ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjItMy0xLTEtNzAwNDI_a37eb6d6-6bb4-49fa-bf25-dad7f5c378b7">421,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e0d03cf0c84427db63e13d4e462e4e8_D20210101-20210331" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjItNS0xLTEtNzAwNDI_2bb72caa-05e8-4649-b704-398ddebf8e6d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b20ee5e4cb845b183e38f28737aef7a_D20210101-20210331" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjItNy0xLTEtNzAwNDI_f0eaaa50-be68-45a9-aab9-1d5880a19034">4,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjItMTMtMS0xLTcwMDQy_bd5c3e4b-0eef-4025-bebb-c2a30f458083">4,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0e0d03cf0c84427db63e13d4e462e4e8_D20210101-20210331" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjMtMy0xLTEtNzAwNDI_6261adab-8b86-4933-be08-16fca032c9a5">34,158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b20ee5e4cb845b183e38f28737aef7a_D20210101-20210331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjMtNy0xLTEtNzAwNDI_437d8da3-7a29-4da8-a97b-d9b491d94d56">342</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjMtMTMtMS0xLTcwMDQy_9425c4f0-06c5-4813-9d3c-555ea099dece">342</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b20ee5e4cb845b183e38f28737aef7a_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjQtNy0xLTEtNzAwNDI_84c4fa73-4d2a-4520-bf8b-7d0b9e9cdd7a">1,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjQtMTMtMS0xLTcwMDQy_0b4fe3da-3461-43ae-be8b-ea96473cf5f1">1,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancellation of restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0e0d03cf0c84427db63e13d4e462e4e8_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjUtMy0xLTEtNzAwNDI_26d32c63-9ceb-4071-a58e-afff3a95df79">5,281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b20ee5e4cb845b183e38f28737aef7a_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjUtNy0xLTEtNzAwNDI_da2a33f3-ee8b-4712-92b9-14acbd09def1">144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjUtMTMtMS0xLTcwMDQy_fbe169c5-5f50-405b-8158-c7c068b0fd75">144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5879b7991869438bb805be20df7ad0b2_I20210331" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjYtMS0xLTEtNzAwNDI_8a8dab64-a830-4d7d-a681-473ac18fb4af">114,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia98bbfcdcddb4e23b97bfb35198297b4_I20210331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjYtMy0xLTEtNzAwNDI_c5483f6f-8152-466c-89f9-3b4a561fbc94">42,638,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia98bbfcdcddb4e23b97bfb35198297b4_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjYtNS0xLTEtNzAwNDI_1bf7ce19-3633-45bb-ab04-b8fcd7cf1cab">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24aeb633ec154645a1fed86ccb4c65cd_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjYtNy0xLTEtNzAwNDI_8e667829-171b-4f84-8180-6faeb625260f">266,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13156f57748c4cfea02dbb45bd3312df_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjYtOS0xLTEtNzAwNDI_dd4acb02-a089-4234-9a7c-df497437cab9">82,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe9ce7d0bb51473c9da95e7918990fd8_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjYtMTEtMS0xLTcwMDQy_7d955053-6639-40ee-8cb7-c02e271c7828">596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5144afd8082f4f17afadb8908f6b4051_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjYtMTMtMS0xLTcwMDQy_75444c0b-5ac9-4334-a736-5ea3c1d1e9fb">349,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(IN THOUSANDS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMy0xLTEtMS03MDA0Mg_e221c770-6a81-4d81-b1a5-51bd1d8fdf19">12,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMy0zLTEtMS03MDA0Mg_630a6760-814d-4003-9fe7-46016a62e2e8">14,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNS0xLTEtMS03MDA0Mg_99cdf237-cc26-4c98-95fa-4b04b944f248">4,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNS0zLTEtMS03MDA0Mg_77d860a8-1122-4169-958f-0824168e3d04">4,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNy0xLTEtMS03MDA0Mg_47e37e30-9006-4c6e-bd8f-b8afbb9bebe3">237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNy0zLTEtMS03MDA0Mg_045f5f17-a7a2-430b-9fd1-6f53b67713a7">351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfOC0xLTEtMS03MDA0Mg_20eff41e-66f3-4d14-b724-27137b727b92">3,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfOC0zLTEtMS03MDA0Mg_37cd1cce-e9a9-4087-a04a-2efa0ccd451d">1,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized loss (gain) from investment in equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" sign="-" name="ameh:UnrealizedGainLossFromInvestmentInEquitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfOS0xLTEtMS03MDA0Mg_78ee37aa-67ab-4613-8b19-ff7ee181bcfa">10,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="ameh:UnrealizedGainLossFromInvestmentInEquitySecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfOS0zLTEtMS03MDA0Mg_7cd868c6-81c3-4a2a-9111-439926aa318e">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Income) loss from equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMTAtMS0xLTEtNzAwNDI_97de6064-913f-4692-912c-05c1fdcdddd6">1,433</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMTAtMy0xLTEtNzAwNDI_a577063f-4de7-4801-be9d-e686d1204ef3">677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMTMtMS0xLTEtNzAwNDI_56b14f0e-913b-4775-8c2f-5f8a6f7469be">1,593</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMTMtMy0xLTEtNzAwNDI_b6fda55f-57f0-4461-8c6a-608d35bb2298">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMTQtMS0xLTEtNzAwNDI_78ac2cd4-3497-4e06-b886-b69315036049">1,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMTQtMy0xLTEtNzAwNDI_9e011d10-8dfd-4522-8644-24442c2005eb">921</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of business combinations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMTctMS0xLTEtNzAwNDI_4972a89d-5d09-4a3a-829c-cb75098ba515">44,673</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMTctMy0xLTEtNzAwNDI_ea33fd5e-e9ce-4244-bfab-c024253913a2">9,390</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, net &#8211; related parties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMTgtMS0xLTEtNzAwNDI_7dc84ba9-fbae-4ea0-b7d9-699646c08d1e">6,865</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMTgtMy0xLTEtNzAwNDI_d8c78967-8d9e-4d03-8a9a-6e42af778cc4">17,612</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMTktMS0xLTEtNzAwNDI_3f923942-c553-4e3d-a040-2fbed8401c96">3,613</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMTktMy0xLTEtNzAwNDI_3682ee6c-16f0-4fd2-a97b-bdb192ce1fbb">223</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" sign="-" name="ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjAtMS0xLTEtNzAwNDI_125398bb-a4b6-4ea2-8583-0c185987df20">4,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" sign="-" name="ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjAtMy0xLTEtNzAwNDI_18182098-d30e-41cf-9a01-5bf998b20d90">7,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="ameh:IncreaseDecreaseInOperatingLeaseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjEtMS0xLTEtNzAwNDI_27f3637d-5033-43f2-9357-201aa3daf8f4">672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="ameh:IncreaseDecreaseInOperatingLeaseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjEtMy0xLTEtNzAwNDI_a3ddcbee-2df7-40e0-aa67-5d7520009111">836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjItMS0xLTEtNzAwNDI_075c1722-034e-40b2-afef-fdba3853df74">2,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjItMy0xLTEtNzAwNDI_a215f480-e613-4ff0-a700-c66ee4fff278">192</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjMtMS0xLTEtNzAwNDI_277aaa79-92c1-446e-b33c-48563a70205e">3,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjMtMy0xLTEtNzAwNDI_d5bd89ae-7e93-4b81-858d-2c647705a939">3,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiduciary accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjQtMS0xLTEtNzAwNDI_9af6ab85-ef63-4995-a947-66f371661be0">4,229</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjQtMy0xLTEtNzAwNDI_bd32af6d-ba24-473f-9e12-cdc5cd317f7a">2,771</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="ameh:IncreaseDecreaseInMedicalLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjUtMS0xLTEtNzAwNDI_b037f0ac-c22a-46f1-b752-432cae8ea9d8">39,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="ameh:IncreaseDecreaseInMedicalLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjUtMy0xLTEtNzAwNDI_0c9035be-4a53-449d-a86d-943e6cb4e037">1,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjYtMS0xLTEtNzAwNDI_73fabb02-c952-4860-9b07-830181297244">4,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjYtMy0xLTEtNzAwNDI_9830956f-d28f-4cbb-a252-2d3a462c9309">7,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjctMS0xLTEtNzAwNDI_552785cb-64be-4071-8f23-cfd57c80527b">645</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjctMy0xLTEtNzAwNDI_a96b3567-96de-4942-b6b9-ca0e84102415">859</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjktMS0xLTEtNzAwNDI_2a5868b7-1972-4c6b-bcd9-f5f5c5273236">24,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjktMy0xLTEtNzAwNDI_9d13fb71-30a0-47cb-bb62-c6715862cf69">9,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for business acquisition, net of cash acquired and shares issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMzItMS0xLTEtNzAwNDI_b5d8daa0-cacb-4a33-884b-ea3c8a4f6dea">999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMzItMy0xLTEtNzAwNDI_d9a78c26-996b-4466-a62e-eab2ef4f9a65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from repayment of loans receivable &#8211; related parties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMzMtMS0xLTEtNzAwNDI_4f4dce98-2e60-46ec-8e02-c949f9e96331">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMzMtMy0xLTEtNzAwNDI_7089dcdd-be46-4dc9-9806-82e348dce5a4">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMzQtMS0xLTEtNzAwNDI_6a8f124a-cc22-48cd-b593-3ebf251ae230">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMzQtMy0xLTEtNzAwNDI_ca587368-d74a-4805-8c4d-1c3044ace4a8">332</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMzctMS0xLTEtNzAwNDI_caba925f-4665-4f66-969c-ff2fa68663fd">17,489</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMzctMy0xLTEtNzAwNDI_2342e0c6-24e9-4a47-a7ae-249cb9a66286">98</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMzgtMS0xLTEtNzAwNDI_9faaa3f0-3434-4710-934b-11f79c5fc2a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMzgtMy0xLTEtNzAwNDI_fe1f10b6-5a42-49df-a691-0c1dcdfe1d99">1,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution from investment - equity method</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMzgtMS0xLTEtOTk0NTA_f119ff7b-abfc-47a7-a2f7-ab9710e4b9ec">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMzgtMy0xLTEtOTk0NTA_1c48879d-4bf5-4026-b87c-c476d9af49be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contribution to investment - equity method</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMzktMS0xLTEtNzAwNDI_ce7bba4c-8c79-435d-a676-c2ab0ed50bbc">1,435</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMzktMy0xLTEtNzAwNDI_c11e262a-4069-4c9a-bea2-6a414007fa51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNDAtMS0xLTEtNzAwNDI_688e3e82-8c19-4739-a6ad-46c5215acdd4">19,725</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNDAtMy0xLTEtNzAwNDI_a133a996-b8c3-4e51-abfe-e40bceb8f11e">692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNDMtMS0xLTEtNzAwNDI_d830080f-66d7-4d6c-ad3b-373b7b1d5f85">1,178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsOfDividends" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNDMtMy0xLTEtNzAwNDI_c5258a20-401e-4f23-8f30-448030b42356">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNDQtMS0xLTEtNzAwNDI_2af353cc-71e1-457c-8222-e6219b4e9479">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNDQtMy0xLTEtNzAwNDI_c57737d1-0ebf-4ae7-a815-a6e417e80d2b">2,434</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of finance lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNDUtMS0xLTEtNzAwNDI_2017e82c-72df-494d-b0c2-a628a4127804">141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNDUtMy0xLTEtNzAwNDI_54577f12-a104-464d-916f-04a9cfa32a77">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the exercise of stock options and warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNDYtMS0xLTEtNzAwNDI_3b9ba0af-1698-42cb-a365-685d532163a4">1,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNDYtMy0xLTEtNzAwNDI_7597e8d4-0473-4b67-b95d-ee0b2bf2e8e9">4,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNDctMS0xLTEtNzAwNDI_1bd858ef-6ef5-42ee-aaf1-ae241a1040b8">230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNDctMy0xLTEtNzAwNDI_36e5ee1f-6169-4c3e-8d49-bce19e1f5735">342</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution to non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNDgtMS0xLTEtNzAwNDI_91f540aa-f3a3-4376-b0b2-9e469c839f78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNDgtMy0xLTEtNzAwNDI_b926b244-e83b-49ab-9707-cab9f623bc1e">225</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="ameh:ProceedsFromSaleOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNDktMS0xLTEtNzAwNDI_4a3dcaf1-4adc-4fac-b36c-da2a9535c41f">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="ameh:ProceedsFromSaleOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNDktMy0xLTEtNzAwNDI_be6bfdf6-036d-48b7-b843-04648897eb60">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="ameh:PaymentsToAcquireNonControllingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNTAtMS0xLTEtMTAyMzM3_fb1e89c0-df0d-440e-88fe-99eefc942941">200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="ameh:PaymentsToAcquireNonControllingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNTAtMy0xLTEtMTAyMzM3_0aa98813-60ce-424e-aaf0-4d3bc44e49e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings on loans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNTAtMS0xLTEtNzAwNDI_71916b82-efd7-47e1-8b55-9f6d2fa0be1c">722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNTAtMy0xLTEtNzAwNDI_1671660e-6e01-4116-8358-341d825984e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNTMtMS0xLTEtNzAwNDI_10d8c15b-254f-4d93-bb7f-1ad75dc68997">532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNTMtMy0xLTEtNzAwNDI_bd18089a-3030-463d-9969-35668c0258cb">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net increase in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNTUtMS0xLTEtNzAwNDI_f661510e-9ebf-4e27-a651-ca7661cb9787">4,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNTUtMy0xLTEtNzAwNDI_aa56c456-7c16-46fc-a6df-562ecd7158f2">11,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, cash equivalents, and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNTctMS0xLTEtNzAwNDI_462cceef-913a-47fa-8a2f-12f23fc09f22">233,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib537036edf0744c69646e8a9929a0638_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNTctMy0xLTEtNzAwNDI_04194f90-a169-48cf-b395-f49bbd72a2f0">193,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, cash equivalents, and restricted cash, end of period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNTktMS0xLTEtNzAwNDI_28acc1a6-a560-40ea-8e9d-39e34f3da808">237,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5144afd8082f4f17afadb8908f6b4051_I20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNTktMy0xLTEtNzAwNDI_a9205a5a-52e8-4446-af43-11f292161f25">205,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplementary disclosures of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNjItMS0xLTEtNzAwNDI_d45cb75a-f740-446e-9a6f-c1035871fd24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNjItMy0xLTEtNzAwNDI_f0ad76a1-0410-423d-9bb5-401317249ba6">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNjMtMS0xLTEtNzAwNDI_97935688-2c12-4ecc-8c2a-04ddccd72543">845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNjMtMy0xLTEtNzAwNDI_5afdcdb1-f246-4f63-80eb-830cc237ed7d">1,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosures of non-cash investing and financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed asset obtained in exchange for finance lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNjYtMS0xLTEtNzAwNDI_1227251a-b397-4327-8f71-95bdc1f1b5ab">398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNjYtMy0xLTEtNzAwNDI_49fecd73-c006-405c-80d4-a031ee984e49">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued in business combination</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNjgtMS0xLTEtMTA0NzY0_abf1e489-1fad-49fc-801c-f4cb7f1a6497">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNjgtMy0xLTEtMTA0NzY0_1735cdd1-0474-4e1b-952d-d800c3410cff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total amounts of cash, cash equivalents, and restricted cash shown in the consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjdhZTg2ZGEwYTg3YjQ2YTBhZjIwMjk4YjA4NTM1ZjQ0L3RhYmxlcmFuZ2U6N2FlODZkYTBhODdiNDZhMGFmMjAyOThiMDg1MzVmNDRfNS0xLTEtMS03MDA0Mg_8577032a-c1d8-4ae0-8c41-046b7cd36615">237,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5144afd8082f4f17afadb8908f6b4051_I20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjdhZTg2ZGEwYTg3YjQ2YTBhZjIwMjk4YjA4NTM1ZjQ0L3RhYmxlcmFuZ2U6N2FlODZkYTBhODdiNDZhMGFmMjAyOThiMDg1MzVmNDRfNS0zLTEtMS03MDA0Mg_ff71e255-916f-4f1f-be3b-a2aec2c3d1a6">205,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjg5M2E5ODM3NTBmMTQxNTliOTNlYzQ2OGFlOWY5NzZjL3RhYmxlcmFuZ2U6ODkzYTk4Mzc1MGYxNDE1OWI5M2VjNDY4YWU5Zjk3NmNfMi0xLTEtMS03MDA0Mg_0ca5442f-c8e8-42db-bfb2-8212d4ba2f91">233,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib537036edf0744c69646e8a9929a0638_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjg5M2E5ODM3NTBmMTQxNTliOTNlYzQ2OGFlOWY5NzZjL3RhYmxlcmFuZ2U6ODkzYTk4Mzc1MGYxNDE1OWI5M2VjNDY4YWU5Zjk3NmNfMi0zLTEtMS03MDA0Mg_5adf61a7-b427-4fa6-9475-32a2d7930d04">193,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash &#8211; current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:RestrictedCashEquivalentsCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjg5M2E5ODM3NTBmMTQxNTliOTNlYzQ2OGFlOWY5NzZjL3RhYmxlcmFuZ2U6ODkzYTk4Mzc1MGYxNDE1OWI5M2VjNDY4YWU5Zjk3NmNfMy0xLTEtMS03MDA0Mg_fe60bc25-d9b2-4b58-b248-d3d5dfe64d2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib537036edf0744c69646e8a9929a0638_I20201231" decimals="-3" name="us-gaap:RestrictedCashEquivalentsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjg5M2E5ODM3NTBmMTQxNTliOTNlYzQ2OGFlOWY5NzZjL3RhYmxlcmFuZ2U6ODkzYTk4Mzc1MGYxNDE1OWI5M2VjNDY4YWU5Zjk3NmNfMy0zLTEtMS03MDA0Mg_f23feedc-696f-43d6-9c73-e6641dcf3d31">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjg5M2E5ODM3NTBmMTQxNTliOTNlYzQ2OGFlOWY5NzZjL3RhYmxlcmFuZ2U6ODkzYTk4Mzc1MGYxNDE1OWI5M2VjNDY4YWU5Zjk3NmNfNS0xLTEtMS03MDA0Mg_a59391a5-0e38-4ecc-9e6d-299335ff71de">233,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib537036edf0744c69646e8a9929a0638_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjg5M2E5ODM3NTBmMTQxNTliOTNlYzQ2OGFlOWY5NzZjL3RhYmxlcmFuZ2U6ODkzYTk4Mzc1MGYxNDE1OWI5M2VjNDY4YWU5Zjk3NmNfNS0zLTEtMS03MDA0Mg_9212058a-3582-4e16-836f-51c1e0e33772">193,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_40"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMTU4NDU_ef9cdd93-76be-48b3-99bf-581ac52f69d9" continuedAt="i24771c1e669740f2b56914486459e142" escape="true">Description of Business</ix:nonNumeric></span></div><ix:continuation id="i24771c1e669740f2b56914486459e142" continuedAt="ia1f8785205614968bc42a8b22071fb05"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Apollo Medical Holdings, Inc. (&#8220;ApolloMed&#8221;) is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high-quality care to patients in a cost-effective manner. ApolloMed was merged with Network Medical Management (&#8220;NMM&#8221;) in December 2017 (the &#8220;2017 Merger&#8221;). As a result of the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed, and the former NMM shareholders own a majority of the issued and outstanding common stock of ApolloMed and maintain control of the board of directors of ApolloMed. Unless the context dictates otherwise, references in these notes to the financial statements, the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and similar words are references to ApolloMed and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (&#8220;VIEs&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Headquartered in Alhambra, California, ApolloMed&#8217;s subsidiaries and VIEs include management services organizations (&#8220;MSOs&#8221;), affiliated independent practice associations (&#8220;IPAs&#8221;), and an accountable care organization (&#8220;ACO&#8221;) participating in the GPDC model. NMM and Apollo Medical Management, Inc. (&#8220;AMM&#8221;) are the administrative and managerial services companies for the affiliated physician-owned professional corporations that contract with independent physicians to deliver medical services in-office and virtually under the following brands: (i) Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA (&#8220;APC&#8221;), (ii) Alpha Care Medical Group, Inc. (&#8220;Alpha Care&#8221;), and (iii) Accountable Health Care IPA, a Professional Medical Corporation (&#8220;Accountable Health Care&#8221;). These affiliates are supported by ApolloMed Hospitalists, a Medical Corporation (&#8220;AMH&#8221;) and Southern California Heart Centers, a Medical Corporation (&#8220;SCHC&#8221;). The Company&#8217;s ACO operates under the APA ACO, Inc. (&#8220;APAACO&#8221;) brand and participates in the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participation in the program&#8217;s attribution-based risk-sharing model.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company&#8217;s physician network consists of primary care physicians, specialist physicians, and hospitalists. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSOs and Affiliates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMM, a wholly owned subsidiary of ApolloMed, manages affiliated medical groups, ApolloMed Hospitalists, a Medical Corporation (&#8220;AMH&#8221;) and Southern California Heart Centers, a Medical Corporation (&#8220;SCHC&#8221;). AMH provides hospitalist, intensivist, and physician advisory services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NMM was formed in 1994 as an MSO for the purposes of providing management services to medical companies and IPAs. The management services primarily include billing, collection, accounting, administration, quality assurance, marketing, compliance, and education. Following the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPAs and Affiliates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">APC was incorporated in 1992 for the purpose of arranging healthcare services as an IPA. APC is owned by California-licensed physicians and professional medical corporations, and contracts with various health maintenance organizations (&#8220;HMOs&#8221;) and other licensed healthcare service plans, as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (&#8220;PMPM&#8221;) that is to be paid to APC. In return, APC arranges for the delivery of healthcare services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering healthcare services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is subject to stop-loss provisions in contracts with HMOs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 1999, APC entered into an amended and restated management and administrative services agreement with NMM (the initial management services agreement was entered into in 1997) for an initial fixed term of <ix:nonNumeric contextRef="ia01bac51df004e83a5b940703fb94049_D19990701-19990731" name="ameh:InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfNDY3OQ_0d4de04d-2eac-4071-8b1a-003a23fac774">30</ix:nonNumeric> years. Under this management arrangement, NMM performs only non-medical administrative services, does not represent that it offers medical services, and does not exercise influence or control over the practice of medicine by APC or its physicians. In accordance with relevant accounting guidance, APC is determined to be a VIE of the Company and is consolidated by NMM.  </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="ia1f8785205614968bc42a8b22071fb05" continuedAt="ic4ac53657aff4298967a698c9c83d076"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AP-AMH Medical Corporation (&#8220;AP-AMH&#8221;) and AP-AMH 2 Medical Corporation (&#8220;AP-AMH 2&#8221;) was formed in May 2019 and July 2021, respectively, as a designated shareholder professional corporation. Dr. Thomas Lam, a shareholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is the sole shareholder of AP-AMH and AP-AMH 2. In accordance with relevant accounting guidance, AP-AMH and AP-AMH 2 is determined to be a VIE of ApolloMed and is consolidated by ApolloMed.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, ApolloMed completed the following series of transactions with its affiliates, AP-AMH and APC:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">A $<ix:nonFraction unitRef="usd" contextRef="i080d2011774f4a4f8a04e8046723b130_I20190930" decimals="-5" name="us-gaap:NotesReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfNDk0NzgwMjM0MjU1OA_b29533d9-d438-4495-a1c1-c1885a790600">545.0</ix:nonFraction>&#160;million loan to AP-AMH, pursuant to a <ix:nonNumeric contextRef="i3bec4a71e3844c82b36a7dcc2f0a553b_D20190901-20190930" name="ameh:FinanceReceivableTermOfReceivable" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMjc0ODc3OTA5NjY1NQ_34b50e6e-e8eb-4e9c-963f-ab5c0faf1d5b">10-year</ix:nonNumeric> secured loan agreement (the &#8220;AP-AMH Loan&#8221;). The loan bears interest at a rate of <ix:nonFraction unitRef="number" contextRef="i080d2011774f4a4f8a04e8046723b130_I20190930" decimals="INF" name="ameh:FinanceReceivableStatedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfNDk0NzgwMjM0MjU4NQ_6bd84e6e-d71c-40e2-9d3a-86c970397a18">10</ix:nonFraction>% per annum simple interest, is not prepayable, (except in certain limited circumstances), requires quarterly payments of interest only in arrears, and is secured by a first priority security interest in all of AP-AMH&#8217;s assets. To the extent that AP-AMH is unable to make any interest payment when due because it has received dividends on the APC Series A Preferred Stock insufficient to pay in full such interest payment, then the outstanding principal amount of the loan will be increased by the amount of any such accrued but unpaid interest, and any such increased principal amounts will bear interest at the rate of <ix:nonFraction unitRef="number" contextRef="i080d2011774f4a4f8a04e8046723b130_I20190930" decimals="INF" name="ameh:FinanceReceivableModificationsSubsequentDefaultInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfNDk0NzgwMjM0MjU5Nw_5262eaf2-98ec-4d2d-8065-3ada8924fca8">10.75</ix:nonFraction>% per annum simple interest.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">A $<ix:nonFraction unitRef="usd" contextRef="i080d2011774f4a4f8a04e8046723b130_I20190930" decimals="-5" name="us-gaap:NotesReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfNDk0NzgwMjM0MzU1NQ_b29533d9-d438-4495-a1c1-c1885a790600">545.0</ix:nonFraction>&#160;million private placement, where AP-AMH purchased <ix:nonFraction unitRef="shares" contextRef="i42aa94e36eca45219242d025187b81a7_D20190901-20190930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfNDk0NzgwMjM0MzU2OA_092b6d0f-4e1a-44b4-8917-0e5eacb3ddb1">1,000,000</ix:nonFraction> shares of APC Series A Preferred Stock which entitle AP-AMH to receive preferential, cumulative dividends that accrue on a daily basis. </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">A $<ix:nonFraction unitRef="usd" contextRef="ic951a78e8e8641ca82615311f26c6e86_I20190930" decimals="-5" name="us-gaap:NotesReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfNDk0NzgwMjM0NDQ5NQ_8189b798-902f-4a00-9fc7-6f184fe94b8d">300.0</ix:nonFraction>&#160;million private placement, where APC purchased <ix:nonFraction unitRef="shares" contextRef="iad63aacc748841208955dbad50055a32_D20190901-20190930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfNDk0NzgwMjM0NDUyMg_5c7b22f5-b35c-4922-afb7-9c8f21f2e1fa">15,015,015</ix:nonFraction> shares of the Company&#8217;s common stock and in  connection therewith, the Company granted APC certain registration rights with respect to the purchased shares.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">ApolloMed licensed to AP-AMH the right to use certain tradenames for specified purposes for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The license fee is payable out of any Series A Preferred Stock dividends received by AP-AMH from APC.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Through its subsidiary, NMM, the Company agreed to provide certain administrative services to AP-AMH for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The administrative fee is also payable out of any APC Series A Preferred Stock dividends received by AP-AMH from APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of the series of transactions, in September 2019, APC and AP-AMH entered into a Second Amendment to the Series A Preferred Stock Purchase Agreement clarifying the term excluded assets (&#8220;Excluded Assets&#8221;). Excluded Assets means (i) assets received from the sale of shares of the Series A Preferred equal to the Series A Purchase Price, (ii) the assets of the Company that are not Healthcare Services Assets, including the Company&#8217;s equity interests in Apollo Medical Holdings, Inc., and any entity that is primarily engaged in the business of owning, leasing, developing, or otherwise operating real estate, (iii) any assets acquired with the proceeds of the sale, assignment, or other disposition of any of the assets described in clauses (i) or (ii), and (iv) any proceeds of the assets described in clauses (i), (ii), and (iii). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC&#8217;s ownership in ApolloMed was <ix:nonFraction unitRef="number" contextRef="ic413e1b24cbb43588d69ee94b270c426_I20220331" decimals="4" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfOTI2Nw_80329551-746e-4405-83e2-788c286a5173">19.61</ix:nonFraction>% as of March&#160;31, 2022 and <ix:nonFraction unitRef="number" contextRef="i9401c9559d0a4784bee72fa3bb729bdb_I20211231" decimals="4" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfOTI4Mw_8620c907-8b01-47cb-a93a-170f9e8f6a96">19.68</ix:nonFraction>% as of December&#160;31, 2021. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concourse Diagnostic Surgery Center, LLC (&#8220;CDSC&#8221;) was formed in March&#160;2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California organized by a group of highly qualified physicians, which utilizes some of the most advanced equipment in the eastern part of Los Angeles County and the San Gabriel Valley. The facility is Medicare-certified and accredited by the Accreditation Association for Ambulatory Healthcare. As of March&#160;31, 2022, APC owned <ix:nonFraction unitRef="number" contextRef="i433e9e4dc783427e8e6da7ae18299e15_I20220331" decimals="4" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfOTc3Mw_5e22f8e4-e57a-4d8f-9588-d9e911475423">44.50</ix:nonFraction>% of CDSC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s capital stock. In accordance with relevant accounting guidance, CDSC is determined to be a VIE of APC and is consolidated by APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC-LSMA Designated Shareholder Medical Corporation (&#8220;APC-LSMA&#8221;) was formed in October&#160;2012 as a designated shareholder professional corporation. Dr. Thomas Lam, a stockholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is a nominee shareholder of APC-LSMA. APC makes all investment decisions on behalf of APC-LSMA, funds all investments and receives all distributions from the investments. APC has the obligation to absorb losses and right to receive benefits from all investments made by APC-LSMA. APC-LSMA&#8217;s sole function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC as the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, including the IPA lines of business of LaSalle Medical Associates (&#8220;LMA&#8221;), Pacific Medical Imaging and Oncology Center, Inc. (&#8220;PMIOC&#8221;), Diagnostic Medical Group of Southern California (&#8220;DMG&#8221;), and AHMC International Cancer Center, a Medical Corporation (&#8220;ICC&#8221;). APC-LSMA also holds a <ix:nonFraction unitRef="number" contextRef="i1a637dbd41eb4403a231966d0c1d8747_I20220331" decimals="INF" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMTEwNzM_fd905d08-1e75-4cbe-a056-1553923bd3ef">100</ix:nonFraction>% ownership interest in Maverick Medical Group, Inc. (&#8220;MMG&#8221;), Alpha Care, Accountable Health Care, and AMG, a Professional Medical Corporation (&#8220;AMG&#8221;). </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="ic4ac53657aff4298967a698c9c83d076" continuedAt="icdf9c9ecff044ece862e4bf8a7172c48"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alpha Care, an IPA acquired by the Company in May 2019, has been operating in California since 1993 as a risk-bearing organization engaged in providing professional services under capitation arrangements with its contracted health plans through a provider network consisting of primary care and specialty care physicians. Alpha Care specializes in delivering high-quality healthcare to its enrollees and focuses on Medi-Cal/Medicaid, Commercial, and Medicare and Dual Eligible members in the Riverside and San Bernardino counties of Southern California.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accountable Health Care is a California-based IPA that has served the local community in the greater Los Angeles County area through a network of physicians and healthcare providers for more than 20 years. Accountable Health Care provides quality healthcare services to its members through <ix:nonFraction unitRef="plan" contextRef="iea7256f5bdac481c9e419242402ecfad_I20220331" decimals="INF" name="ameh:NumberOfFederallyQualifiedHealthPlans" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMTIwNzE_3bb11bc8-70ff-45af-94d3-3444adcd165e">three</ix:nonFraction> federally qualified health plans and multiple product lines, including Medi-Cal, Commercial, and Medicare. In August 2019, APC and APC-LSMA acquired the remaining outstanding shares of Accountable Health Care&#8217;s capital stock that they did not already own (comprising <ix:nonFraction unitRef="number" contextRef="i6791450b303a4baaa9c950aac4835c7a_I20190830" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMTIzNDE_2350e3e4-d234-4a66-96e7-91b177ceab0d">75</ix:nonFraction>%) for&#160;$<ix:nonFraction unitRef="usd" contextRef="i6618dfdd38574ddd8411e3675f60590e_D20190830-20190830" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMTIzNDk_1f281389-a241-495e-9249-e4e50111feee">7.3</ix:nonFraction> million&#160;in cash.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMG is a network of family practice clinics operating out of <ix:nonFraction unitRef="clinic" contextRef="ibbbf646a84b242da86cd62eac12d7711_I20220331" decimals="INF" name="ameh:NumberOfFamilyPracticeClinics" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMTI0MjI_3a1e3119-ffd3-4833-9d55-4d1fa5f6711f">three</ix:nonFraction> main locations in Southern California. AMG provides professional and post-acute care services to Medicare, Medi-Cal/Medicaid, and Commercial patients through its network of doctors and nurse practitioners. In September 2019, APC-LSMA purchased <ix:nonFraction unitRef="number" contextRef="i4258726bec994a1db1b081a69de757a8_I20190930" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMTI2Njk_a8daff77-20a9-4332-8f77-2728327caa37">100</ix:nonFraction>% of the shares of capital stock of AMG for $<ix:nonFraction unitRef="usd" contextRef="i5c160ab74e9f4f3f897f16bcf956f33b_D20190901-20190930" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMTI3MTQ_fac62f3a-2cda-4e7e-ae6f-21a841e90ff0">1.2</ix:nonFraction> million in cash and $<ix:nonFraction unitRef="usd" contextRef="i4452193fa6da4189b503a5f1f57ad4be_D20190901-20190930" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMTI3Mjk_fbb36a7e-72a9-4580-a507-5b0a1f1a0185">0.4</ix:nonFraction> million of APC common stock.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DMG is a professional medical California corporation and a complete outpatient imaging center. APC accounted for its <ix:nonFraction unitRef="number" contextRef="i5456a038b204408f8d123aa76b5524e2_I20220331" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfNDk0NzgwMjM1MjExOQ_ff481869-4849-42c1-a084-2338a35f8eba">40</ix:nonFraction>% investment in DMG, under the equity method of accounting. In October 2021, DMG entered into an administrative services agreement with a subsidiary of the Company, causing the Company to reevaluate the accounting for the Company&#8217;s investment in DMG. Based on the reevaluation and in accordance with relevant accounting guidance, DMG is determined to be a VIE of the Company and is consolidated by the Company. In addition, APC-LSMA is obligated to purchase the remaining equity interest within <ix:nonNumeric contextRef="ib943b580b1c64fc1a7579f4ac67aa99d_D20220101-20220331" name="ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMjc0ODc3OTA5NjY3Mg_8c9e214c-6afb-4d2e-b107-f84c577e68a6">three years</ix:nonNumeric> from the effective date. The purchase of the remaining equity value is considered a financing obligation with a carrying value of $<ix:nonFraction unitRef="usd" contextRef="iade67c79de8c433297cb64b0aa007e48_I20220331" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfNDk0NzgwMjM1MjE2OA_a3e630a4-bde7-4bba-a53d-f9b5ccbf7a0d">8.5</ix:nonFraction>&#160;million as of March&#160;31, 2022. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, using cash comprised solely of Excluded Assets, APC purchased a <ix:nonFraction unitRef="number" contextRef="i27d0462359864892b029d29f2dbae1fa_I20201231" decimals="INF" name="ameh:AssetAcquisitionPercentageOfSharesAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMTI4MzU_f2c0637e-6989-477f-a16f-a3b4f1eb9310">100</ix:nonFraction>% interest in each of Medical Property Partners, LLC (&#8220;MPP&#8221;), AMG Properties, LLC (&#8220;AMG Properties&#8221;), and ZLL Partners, LLC (&#8220;ZLL&#8221;) and a <ix:nonFraction unitRef="number" contextRef="i9e3006cf844c4dcfb98b8464dfdfecaf_I20211231" decimals="INF" name="ameh:AssetAcquisitionPercentageOfSharesAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMjc0ODc3OTEwNTE3NQ_0b01cfee-3f7a-4900-b691-f72999619ce9">50</ix:nonFraction>% interest in each of One MSO, LLC (&#8220;One MSO&#8221;), Tag-6 Medical Investment Group, LLC (&#8220;Tag 6&#8221;), and Tag-8 Medical Investment Group, LLC (&#8220;Tag 8&#8221;). These entities own buildings that are currently leased to tenants, as well as vacant land that is being developed. MPP, AMG Properties, and ZLL are <ix:nonFraction unitRef="number" contextRef="i27d0462359864892b029d29f2dbae1fa_I20201231" decimals="INF" name="ameh:AssetAcquisitionPercentageOfSharesAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMTMyODU_f2c0637e-6989-477f-a16f-a3b4f1eb9310">100</ix:nonFraction>% owned subsidiaries of APC and are included in the consolidated financial statements. In April 2021, Tag 8 entered into a loan agreement with MUFG Union Bank N.A. with APC as their guarantor, causing the Company to reevaluate their consolidation of Tag 8. Based on the reevaluation and in accordance with relevant accounting guidance, it was concluded that Tag 8 is a VIE and is consolidated by APC. One MSO and Tag 6 are accounted for as equity method investments, as APC has the ability to exercise significant influence, but not control over the operations of the entity. These purchases are deemed Excluded Assets that are solely for the benefit of APC and its shareholders. As such, any income pertaining to APC&#8217;s interests in these properties has no impact on the Series A Dividend payable by APC to AP-AMH Medical Corporation, and consequently will not affect net income attributable to ApolloMed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, AP-AMH 2, a VIE of the Company, purchased an <ix:nonFraction unitRef="number" contextRef="iae649481fa4d4190a0f5b74bc999a510_I20210731" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMTQyODQ_0411f803-dad6-4b54-90da-1a656df854ee">80</ix:nonFraction>% equity interest (on a fully diluted basis) in Access Primary Care Medical Group (&#8220;APCMG&#8221;), a primary care physicians&#8217; group focused on providing high-quality care to senior patients in the northern California cities of Daly City and San Francisco. As a result, APCMG is consolidated by the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, Apollo Medical Holdings, Inc. acquired <ix:nonFraction unitRef="number" contextRef="ic4078597aaf8463a99cbfd3e8f573353_I20210831" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMTQ2NTY_e2d15bb5-f846-41fb-b378-79118792df1c">49</ix:nonFraction>% of the aggregate issued and outstanding shares of capital stock of Sun Clinical Laboratories (&#8220;Sun Labs&#8221;) for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="ied48cf0dd52b4ecbacf11485317313d5_D20210801-20210831" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMTQ4MDA_5afcdaf8-ebe2-4287-a604-3e4be73addf2">4.0</ix:nonFraction> million. Sun Labs is a Clinical Laboratory Improvement Amendments certified full-service lab that operates across the San Gabriel Valley in Southern California. In accordance with relevant accounting guidance, Sun Labs is determined to be a VIE of the Company and is consolidated by the Company (see Note 3). The Company is obligated to purchase the remaining equity interest within <ix:nonNumeric contextRef="ied48cf0dd52b4ecbacf11485317313d5_D20210801-20210831" name="ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfNzE0NjgyNTYxMDM1Mg_b0d46bda-8a6e-4568-94aa-a86c68b7751b">three years</ix:nonNumeric> from the effective date. The purchase of the remaining equity value is considered a financing obligation with a carrying value of at $<ix:nonFraction unitRef="usd" contextRef="i47183d9ce9704d30b6eb68894c2e74b3_I20220331" decimals="-5" name="ameh:BusinessCombinationEquityInterestPurchaseObligationNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMTUzMjM_c0a4b26f-1ad4-4ecc-bf18-da7718ff8bbd">4.2</ix:nonFraction> million at March&#160;31, 2022. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets.</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="icdf9c9ecff044ece862e4bf8a7172c48"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NGACO, GPDC / ACO REACH<br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APAACO began participating in the NGACO Model of CMS in January 2017. The NGACO Model was a CMS program that allowed provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk-sharing model. With the ending of the NGACO Model on December 31, 2021, APAACO applied, and has been selected by CMS, to participate as a Direct Contracting Entity (&#8220;DCE&#8221;) in the standard track of CMS&#8217;s GPDC Model for Performance Year 2022 (&#8220;PY22&#8221;), beginning January 1, 2022. CMS has since redesigned the GPDC Model in response to Administration priorities, including their commitment to advancing health equity, stakeholder feedback, and participant experience, and renamed the GPDC Model to ACO Realizing Equity, Access, and Community Health (&#8220;ACO REACH&#8221;) Model. The ACO REACH Model will begin participation on January 1, 2023.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyMzI_14351d27-e74f-408d-90e7-9fadee2b595b" continuedAt="i4cb9e75056ec4dfea34e557eb7ed148d" escape="true">Basis of Presentation and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i4cb9e75056ec4dfea34e557eb7ed148d" continuedAt="i7f0fd49b5972488582dbf5a10b3bf195"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyMzM_ea8b505d-36cc-444c-85d9-bca56e9c09ec" continuedAt="ie002003b7f33471686765edbbb837883" escape="true">Basis of Presentation</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie002003b7f33471686765edbbb837883">The accompanying consolidated balance sheets at December&#160;31, 2021, have been derived from the Company&#8217;s audited consolidated financial statements, but do not include all annual disclosures required by generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). The accompanying unaudited consolidated financial statements as of March&#160;31, 2022, and for the three months ended March&#160;31, 2022 and 2021, have been prepared in accordance with U.S. GAAP for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, these unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC on February&#160;28, 2022. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made to make the consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01.</ix:continuation> Operating results for the three months ended March&#160;31, 2022, are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022, or any future periods.</span></div><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyMTk_e71b58c3-27c5-4947-a661-d024afa8275e" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated balance sheets as of March&#160;31, 2022 and December&#160;31, 2021, and the consolidated statements of income for the three months ended March&#160;31, 2022 and 2021, include the accounts of (1) ApolloMed, ApolloMed&#8217;s consolidated subsidiaries, NMM, AMM, and APAACO, and its VIEs, AP-AMH, AP-AMH 2, Sun Labs, and DMG; (2) AP-AMH 2&#8217;s consolidated subsidiary, APCMG; (3) AMM&#8217;s consolidated VIEs, SCHC and AMH; (4) NMM&#8217;s VIE, APC; (5) APC&#8217;s consolidated subsidiaries, Universal Care Acquisition Partners, LLC (&#8220;UCAP&#8221;), MPP, AMG Properties, ZLL, and its VIEs, CDSC, APC-LSMA, ICC, and Tag 8; and (6) APC-LSMA&#8217;s consolidated subsidiaries, Alpha Care, Accountable Health Care, and AMG.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyNDI_02035098-9107-4db3-bfee-98fc80609115" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred but not reported (&#8220;IBNR&#8221;) claims), determination of full-risk and shared-risk revenue and receivables (including constraints, completion factors and historical margins), income tax-valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyMjk_a9fa7384-c028-437f-a9a7-b3b80a71ce91" continuedAt="i89ca585ecfba43dfb951ac1be53fa8a3" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Interest Entities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly owned by the Company in accordance with the consolidation guidance. The evaluation considers all of the Company&#8217;s variable interests, including equity ownership, as well as management services agreements. To fall within the scope of the consolidation guidance, an entity must meet both of the following criteria:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity can be in the form of a partnership, limited liability company, or corporation, among others; and</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company has a variable interest in the legal entity &#8211; i.e., variable interests that are contractual, such as equity ownership, or other financial interests that change with changes in the fair value of the entity&#8217;s net assets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting. If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i7f0fd49b5972488582dbf5a10b3bf195" continuedAt="i7212c3b0194144f8973330689566e070"><ix:continuation id="i89ca585ecfba43dfb951ac1be53fa8a3" continuedAt="i42f9fd208d174dfa9b90bb844c341875"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A legal entity is determined to be a VIE if it has any of the following three characteristics:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The entity does not have sufficient equity to finance its activities without additional subordinated financial support;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s) of voting rights); or</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they lack any of the following:</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entity&#8217;s economic performance, as evidenced by:</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">Substantive participating rights in day-to-day management of the entity&#8217;s activities; or</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Substantive kick-out rights over the party responsible for significant decisions;</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt">The obligation to absorb the entity&#8217;s expected losses; or</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt">The right to receive the entity&#8217;s expected residual returns.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company determines that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and evaluate it for consolidation under the variable interest model.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable interest model</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i42f9fd208d174dfa9b90bb844c341875">If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company &#8211; that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE&#8217;s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (economics). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer to Note 16 &#8211; &#8220;Variable Interest Entities (VIEs)&#8221; to the consolidated financial statements for information on the Company&#8217;s consolidated VIEs. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting.</ix:continuation><br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyMjU_35f85a53-2a0d-47c3-855a-07df70b8650b" continuedAt="i912b35dc3fd441f299ca8de031595063" escape="true">Business Combinations</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i912b35dc3fd441f299ca8de031595063">The Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition-related costs separately from the business combination.</ix:continuation></span></div><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyODQ_9d83f82c-6354-42a4-b35b-b5dea0340706" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/>Reportable Segments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as <ix:nonFraction unitRef="segment" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNzUxOQ_64bc587f-ae98-4fc0-b0d2-f3051a72982e"><ix:nonFraction unitRef="segment" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNzUxOQ_ef847346-c50a-44b0-9269-b5a8a6a476e0">one</ix:nonFraction></ix:nonFraction> reportable segment, the healthcare delivery segment, and implements and operates innovative healthcare models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in <ix:nonFraction unitRef="segment" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNzc5Ng_64bc587f-ae98-4fc0-b0d2-f3051a72982e"><ix:nonFraction unitRef="segment" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNzc5Ng_ef847346-c50a-44b0-9269-b5a8a6a476e0">one</ix:nonFraction></ix:nonFraction> reportable segment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyMjE_eb791265-d9d1-4ac7-9669-c85ef0f4302a" continuedAt="iaf1b054518824b8b8556557a34bdfe8d" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iaf1b054518824b8b8556557a34bdfe8d">The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents, and restricted cash.</ix:continuation> As of March&#160;31, 2022 and December&#160;31, 2021, the Company&#8217;s deposit accounts with banks exceeded the FDIC&#8217;s insured limit by approximately $<ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-5" name="us-gaap:CashUninsuredAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfODU2MQ_b0564e13-9f04-4829-aedb-7b06244af60b">282.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-5" name="us-gaap:CashUninsuredAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfODU2OA_15b99fbb-7500-4183-9a8d-034f13d24a76">285.9</ix:nonFraction> million, respectively. The Company has not experienced any losses to date and performs ongoing evaluations of these financial institutions to limit the Company&#8217;s concentration of risk exposure.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><ix:continuation id="i7212c3b0194144f8973330689566e070" continuedAt="i8801edda6432443fb8566bc4807f46b5"><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyODU_a3717d42-23d9-4c2f-9f92-34c62b1e2c39" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Marketable Securities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in marketable securities consist of equity securities and certificates of deposit with various financial institutions. The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit are reported at par value, plus accrued interest, with maturity dates from <ix:nonNumeric contextRef="i5067812e23e84e4689a191e85614e031_D20220101-20220331" name="ameh:MarketableSecuritiesCurrentMaturityPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTczMDA_79c380bd-b385-4927-9ea5-84067528041c">four months</ix:nonNumeric> to <ix:nonNumeric contextRef="ic8bb14e9746c41a5b4dc59dfc7318107_D20220101-20220331" name="ameh:MarketableSecuritiesCurrentMaturityPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfOTMyNg_aa678297-2fa3-4d6c-bada-dbfa685f85d6">24</ix:nonNumeric> months. As of March&#160;31, 2022 and December&#160;31, 2021, certificates of deposit amounted to approximately $<ix:nonFraction unitRef="usd" contextRef="i8b1b466c96f147349e71fb4f01795a7f_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfOTQwNA_0197f11f-95d1-4536-8173-789bb374d3c9"><ix:nonFraction unitRef="usd" contextRef="i06add27710ea4d7785d87fe89373d1fc_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfOTQwNA_2cf2d43b-517e-4e19-ac90-f8e12db23c50">25.0</ix:nonFraction></ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8b1b466c96f147349e71fb4f01795a7f_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfOTQxMQ_0fcd92c5-e646-4167-b82f-6490dd78c3de">25.0</ix:nonFraction> million, respectively. Investments in certificates of deposit are classified as Level 1 investments in the fair value hierarchy.<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities are reported at fair value. These securities are classified as Level 1 in the valuation hierarchy, where quoted market prices from reputable third-party brokers are available in an active market and unadjusted. The trading volume of certain equity securities we hold is low, thus resulting in our determination that such equity securities do not have an active market with buyers and sellers ready to trade. Accordingly, we classify such equity securities as Level 2 in the valuation hierarchy, and their valuation is based on weighted average share prices from observable market data.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Equity securities held by the Company are primarily comprised of common stock of a payor partner that completed its IPO in June 2021 and Clinigence Holdings, Inc. (&#8220;Clinigence&#8221;). The common stock of a payor partner were acquired as a result of UCAP selling its <ix:nonFraction unitRef="number" contextRef="ib71613c16b2142f097495def3277d766_I20200430" decimals="3" name="ameh:EquityMethodInvestmentOwnershipPercentageDisposed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMjc0ODc3OTE0MjIzOA_a5a8a2a8-b4c6-4023-906d-70f59ca7f9a2">48.9</ix:nonFraction>% ownership interest in Universal Care, Inc. (&#8220;UCI&#8221;) in April 2020. In September 2021, ApolloMed and Clinigence entered into a stock purchase agreement in which ApolloMed purchased shares of common stock, warrants, and potentially additional common stock if certain metrics are not met (&#8220;contingent equity securities&#8221;) for $<ix:nonFraction unitRef="usd" contextRef="i4057678e762644689f10e4ee0607dbed_D20210901-20210930" decimals="-5" name="ameh:PaymentsToAcquireCommonStockAndWarrants" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNDM5ODA0NjU4MjYxNg_f67dc699-6bab-416f-8c09-3d7f75ff3518">3.0</ix:nonFraction>&#160;million. The common stock is included in investments in marketable securities and the warrants and contingent equity securities are classified as derivatives and included in other assets and prepaid expenses and other current assets, respectively, in the accompanying consolidated balance sheets. See Note 2 &#8212; &#8220;Basis of Presentation and Summary of Significant Accounting Policies - Derivative Financial Instruments&#8221; in the accompanying consolidated financial statements for information on the treatment of the derivative instruments. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of March&#160;31, 2022 and December&#160;31, 2021, the equity securities were approximately $<ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMTA5OTUxMTcwMDgzOA_694c99ed-a2c4-4916-bc48-9f5bbfabef48">17.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMTA5OTUxMTcwMDg0Ng_bbd273cf-b9cf-4a4e-966b-017d3d0703a1">28.4</ix:nonFraction>&#160;million, respectively, in the accompanying consolidated balance sheets. For the three months ended March&#160;31, 2022, the Company recognized unrealized losses of $<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMTEwNDQ_7321abb2-b506-4e4a-8f4c-61aa5ad821c2">10.6</ix:nonFraction>&#160;million on all equity securities in unrealized loss on investments in the accompanying consolidated statements of income.</span></div><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="ameh:ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTczMDc_4b8ecc17-e4dc-4fef-a5fe-633c381b7480" continuedAt="i918cba8e3ea9408288292a26c3821d52" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables,  Receivables &#8211; Related Parties, and Loan Receivable - Related Party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements, incentive receivables, management fee income, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables &#8211; related parties are comprised of risk pool settlements, management fee income and incentive receivables, and other receivables. Receivables &#8211; related parties are recorded and stated at the amount expected to be collected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s loan receivable &#8211; related party consist of promissory notes from a related party payee that accrues interest per annum. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation and claims receivables relate to each health plan&#8217;s capitation and are received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#8217;s full risk pool receivable that is recorded quarterly based on reports received from the Company&#8217;s hospital partners and management&#8217;s estimate of the Company&#8217;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately <ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="ameh:RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMTI1MTA_2ace612e-215b-4808-bef6-7b494b42b33a">18</ix:nonNumeric> months after the risk pool performance year is completed. Other receivables consist of recoverable claims paid related to the 2021 APAACO performance year to be administered following instructions from CMS for the NGACO program, receivables from GPDC capitation revenue for the 2022 performance year, fee-for-services (&#8220;FFS&#8221;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop-loss insurance premium reimbursements.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i8801edda6432443fb8566bc4807f46b5" continuedAt="ie4b819776b264a9c822f7f43fef376a7"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i918cba8e3ea9408288292a26c3821d52" continuedAt="ib98b34f20b1f455ba3f98da0681e076d">The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.</ix:continuation></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib98b34f20b1f455ba3f98da0681e076d">Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (&#8220;CECL&#8221;) model.</ix:continuation> </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTczMDM_d0f8e007-0dfc-42a3-ade6-8046776ca87b" continuedAt="idef7847aa21049fdbbcf921e6c25ac5e" escape="true">Concentrations of Credit Risks</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idef7847aa21049fdbbcf921e6c25ac5e">The Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The consolidated statements of income present disaggregated revenue by service type.</ix:continuation> <ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyODg_10e381ae-31bf-42c8-a12d-de1fb4bbebb9" continuedAt="ib8dfc4fa50db499db1540e5df34b892c" escape="true">The following table presents disaggregated revenue generated by payor type for the three months ended March&#160;31, 2022 and 2021 (in thousands):</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="ib8dfc4fa50db499db1540e5df34b892c"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1368e96397d4afb8a5b06c97f9a0e75_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjIyNmUzZDE2MTYzODRkODU4ZWY2MGM1MjEzMmZmNzhkL3RhYmxlcmFuZ2U6MjI2ZTNkMTYxNjM4NGQ4NThlZjYwYzUyMTMyZmY3OGRfMy0xLTEtMS03MDA0Mg_9eba0b54-91ae-454d-bab0-086558141c75">42,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3540b9617bba46ec9221f435473df8d4_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjIyNmUzZDE2MTYzODRkODU4ZWY2MGM1MjEzMmZmNzhkL3RhYmxlcmFuZ2U6MjI2ZTNkMTYxNjM4NGQ4NThlZjYwYzUyMTMyZmY3OGRfMy0zLTEtMS03MDA0Mg_e4569a32-d1d4-40da-a01d-bea04ca93ad2">32,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97b7e4411cac4f46bd0609f16888cd7b_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjIyNmUzZDE2MTYzODRkODU4ZWY2MGM1MjEzMmZmNzhkL3RhYmxlcmFuZ2U6MjI2ZTNkMTYxNjM4NGQ4NThlZjYwYzUyMTMyZmY3OGRfNC0xLTEtMS03MDA0Mg_ca200aae-f8a5-4734-85d6-8b9c32486778">133,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c5d4e729a642c3a0808ffe69396270_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjIyNmUzZDE2MTYzODRkODU4ZWY2MGM1MjEzMmZmNzhkL3RhYmxlcmFuZ2U6MjI2ZTNkMTYxNjM4NGQ4NThlZjYwYzUyMTMyZmY3OGRfNC0zLTEtMS03MDA0Mg_cc9eae2b-80e2-4e4d-a1d5-37d4a86995c9">64,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c16654928bd4eaca5078b4d6cf0e50d_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjIyNmUzZDE2MTYzODRkODU4ZWY2MGM1MjEzMmZmNzhkL3RhYmxlcmFuZ2U6MjI2ZTNkMTYxNjM4NGQ4NThlZjYwYzUyMTMyZmY3OGRfNS0xLTEtMS03MDA0Mg_233bfa59-d55b-4d52-a84a-3a102d77a4e7">71,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5b721f38495479baa1888225f569bae_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjIyNmUzZDE2MTYzODRkODU4ZWY2MGM1MjEzMmZmNzhkL3RhYmxlcmFuZ2U6MjI2ZTNkMTYxNjM4NGQ4NThlZjYwYzUyMTMyZmY3OGRfNS0zLTEtMS03MDA0Mg_2592e166-2102-4a2d-84c2-2744dcf976f4">69,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other third parties</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic00f4d20ec264fa5b0dec1e5c289db51_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjIyNmUzZDE2MTYzODRkODU4ZWY2MGM1MjEzMmZmNzhkL3RhYmxlcmFuZ2U6MjI2ZTNkMTYxNjM4NGQ4NThlZjYwYzUyMTMyZmY3OGRfNi0xLTEtMS03MDA0Mg_02539aca-2e88-4d8d-a0db-2b34f220000a">15,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44447a5bff9d47778021966b6c04440e_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjIyNmUzZDE2MTYzODRkODU4ZWY2MGM1MjEzMmZmNzhkL3RhYmxlcmFuZ2U6MjI2ZTNkMTYxNjM4NGQ4NThlZjYwYzUyMTMyZmY3OGRfNi0zLTEtMS03MDA0Mg_6ab1d588-7ca5-4663-8006-9114098102d9">9,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjIyNmUzZDE2MTYzODRkODU4ZWY2MGM1MjEzMmZmNzhkL3RhYmxlcmFuZ2U6MjI2ZTNkMTYxNjM4NGQ4NThlZjYwYzUyMTMyZmY3OGRfNy0xLTEtMS03MDA0Mg_390d793c-5805-41ed-9699-90b22e6d4d8a">263,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjIyNmUzZDE2MTYzODRkODU4ZWY2MGM1MjEzMmZmNzhkL3RhYmxlcmFuZ2U6MjI2ZTNkMTYxNjM4NGQ4NThlZjYwYzUyMTMyZmY3OGRfNy0zLTEtMS03MDA0Mg_48a1abf4-dce5-4baa-be58-f7ba3df36477">176,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="text-align:center"><span><br/></span></div><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyMTU_707623c8-8111-42bc-8faa-793cd22d2fe7" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payors that contributed the following percentages of net revenue:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor A</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i23c400c680394251b215b33cfde92dbc_D20210101-20210331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjIwMjZjMTg4ZDcyNTQwNGZiNGRmMTM2MTU1NWUzNDdmL3RhYmxlcmFuZ2U6MjAyNmMxODhkNzI1NDA0ZmI0ZGYxMzYxNTU1ZTM0N2ZfMy0zLTEtMS03MDA0Mg_cb482db4-cf60-4214-9691-f8519b268a30">12.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor B</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib41161b4c97242dbb50361fe75def7b4_D20210101-20210331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjIwMjZjMTg4ZDcyNTQwNGZiNGRmMTM2MTU1NWUzNDdmL3RhYmxlcmFuZ2U6MjAyNmMxODhkNzI1NDA0ZmI0ZGYxMzYxNTU1ZTM0N2ZfNC0zLTEtMS03MDA0Mg_1a5fafba-6675-4379-a92d-4bbfac24b276">10.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iab747f9347d841d7bed8d71175fd16b2_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjIwMjZjMTg4ZDcyNTQwNGZiNGRmMTM2MTU1NWUzNDdmL3RhYmxlcmFuZ2U6MjAyNmMxODhkNzI1NDA0ZmI0ZGYxMzYxNTU1ZTM0N2ZfNS0xLTEtMS03MDA0Mg_224bed85-6c47-4273-85e7-dfb6af7b018b">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia9221a81959848e0875b822a89e77723_D20210101-20210331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjIwMjZjMTg4ZDcyNTQwNGZiNGRmMTM2MTU1NWUzNDdmL3RhYmxlcmFuZ2U6MjAyNmMxODhkNzI1NDA0ZmI0ZGYxMzYxNTU1ZTM0N2ZfNS0zLTEtMS03MDA0Mg_3f27212f-4ada-43db-8a79-d095596b31ab">16.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib4a11153cacb478db352c47209bdd22f_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjIwMjZjMTg4ZDcyNTQwNGZiNGRmMTM2MTU1NWUzNDdmL3RhYmxlcmFuZ2U6MjAyNmMxODhkNzI1NDA0ZmI0ZGYxMzYxNTU1ZTM0N2ZfNi0xLTEtMS03MDA0Mg_d631d5ce-2ae4-430f-9b57-5820e12b8250">30.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Less than 10% of total net revenues</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payors that contributed to the following percentages of receivables and receivables &#8211; related parties:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,<br/>2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3b9b5a97cba2458e80bbc32a7003a7b5_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjU0ZGIzZWQ3NWQ4NzRjMGU5ZDFkNzQ5YWUzYzU5MWZhL3RhYmxlcmFuZ2U6NTRkYjNlZDc1ZDg3NGMwZTlkMWQ3NDlhZTNjNTkxZmFfMy0xLTEtMS03MDA0Mg_2732148b-e719-4bc1-be4c-6b6980a8b19e">19.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor E</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ide74daf0c2af45c6b4e6486c2b5f07af_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjU0ZGIzZWQ3NWQ4NzRjMGU5ZDFkNzQ5YWUzYzU5MWZhL3RhYmxlcmFuZ2U6NTRkYjNlZDc1ZDg3NGMwZTlkMWQ3NDlhZTNjNTkxZmFfNC0xLTEtMS03MDA0Mg_ebaaf457-56cb-4595-b301-f264990301f5">28.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i062a900e196f43a8ad8c043ed3e37741_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjU0ZGIzZWQ3NWQ4NzRjMGU5ZDFkNzQ5YWUzYzU5MWZhL3RhYmxlcmFuZ2U6NTRkYjNlZDc1ZDg3NGMwZTlkMWQ3NDlhZTNjNTkxZmFfNC0zLTEtMS03MDA0Mg_0cd5aac1-051e-469d-a508-38c5d4ad851a">45.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor F</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7344d9ece6c54bb7a3445b3b4305a208_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjU0ZGIzZWQ3NWQ4NzRjMGU5ZDFkNzQ5YWUzYzU5MWZhL3RhYmxlcmFuZ2U6NTRkYjNlZDc1ZDg3NGMwZTlkMWQ3NDlhZTNjNTkxZmFfNS0xLTEtMS03MDA0Mg_995fc2b7-be3a-4860-8d96-3e212e7e4c77">19.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8004dd5aaab243ceaebebdd9dfbe5dea_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjU0ZGIzZWQ3NWQ4NzRjMGU5ZDFkNzQ5YWUzYzU5MWZhL3RhYmxlcmFuZ2U6NTRkYjNlZDc1ZDg3NGMwZTlkMWQ3NDlhZTNjNTkxZmFfNS0zLTEtMS03MDA0Mg_28122850-84ff-457f-a0f4-ca48847cd2a5">30.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Less than 10% of total receivables and receivables &#8212; related parties, net</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="ie4b819776b264a9c822f7f43fef376a7" continuedAt="i449fc1c5c21645ee8dbd4833a86eaa1e"><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyNjY_afc2fc4f-df13-46e3-aa15-fae03b45a9c7" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements of Financial Instruments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This hierarchy prioritizes the inputs into three broad levels as follows:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#8217;s own data.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyNzk_a68b8ec0-fb5d-4e7e-b327-2ed016ee75eb" continuedAt="ic2b7984b56cd4895a5ceb4395ad2b8c4" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of March&#160;31, 2022, are presented below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds*</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6526cb352ff14142ad0267923f9b8458_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfMy0xLTEtMS03MDA0Mg_c6a5726e-dce6-4c34-a8a2-56c05a9c2122">96,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf7e945065b4cbb9be75f83ecca429e_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfMy0zLTEtMS03MDA0Mg_073a234b-9d42-46f6-bac0-0675d62b7f4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e0b992a4a41411caa3cf99acedc7773_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfMy01LTEtMS03MDA0Mg_68750817-f32a-43ee-ab01-e508c26800b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfMy03LTEtMS03MDA0Mg_37c9b085-f77a-4225-a4d3-009aff9c5f28">96,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6526cb352ff14142ad0267923f9b8458_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNC0xLTEtMS03MDA0Mg_31c4fd9f-48b1-4684-9605-346d084c46b3">25,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf7e945065b4cbb9be75f83ecca429e_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNC0zLTEtMS03MDA0Mg_8169bb0c-2388-4320-b3ab-de31142d3fc1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e0b992a4a41411caa3cf99acedc7773_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNC01LTEtMS03MDA0Mg_bed420bc-aa48-4d1d-9942-76e23b88a87e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNC03LTEtMS03MDA0Mg_ecceaf3b-1968-4548-842f-5cb92423c3b4">25,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6526cb352ff14142ad0267923f9b8458_I20220331" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNS0xLTEtMS03MDA0Mg_d631256e-ebe0-425b-b278-a733e916ff5d">13,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf7e945065b4cbb9be75f83ecca429e_I20220331" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNS0zLTEtMS03MDA0Mg_efb5ef25-f324-47a0-808a-713bab229075">4,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e0b992a4a41411caa3cf99acedc7773_I20220331" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNS01LTEtMS03MDA0Mg_8d32f7fd-6fe2-4297-a93d-8ce8e69278e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNS03LTEtMS03MDA0Mg_bdce6a6f-7eee-452e-8b80-6efec44fdba5">17,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i812e1314b74e4b39965703038178723e_I20220331" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNi0xLTEtMS03NzUwMQ_48b7fd1b-a40d-4142-a23e-567db24c5ec3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i317853952d064c0aae4c8f6086f08c69_I20220331" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNi0zLTEtMS03NzUxMg_c98b4fd5-9a61-4782-875b-926bbfaf511d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i395def431eb24cc797be851df63b772d_I20220331" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNi01LTEtMS03NzUyMw_9e5df91d-b847-49c3-8356-5a3a03c2a20c">4,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f97d77f9a334dfaa7f626c14651831b_I20220331" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNi03LTEtMS03NzUzNQ_1bc89bd2-4bbb-4083-95d8-f59b0388bee6">4,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedee00e5b814c9ab93ebe0cdd4eefcd_I20220331" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNy0xLTEtMS05NjIxOQ_c8bf9e1d-8020-46ac-a6f3-0b0244994b18">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe65b799ceec4dd4b60d0ed19b877f0c_I20220331" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNy0zLTEtMS05NjIyOA_4cd3af1e-cb3f-41ad-a922-3e464eb3f806">1,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f4a833b59b64e6fa2beeccb4539ee17_I20220331" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNy01LTEtMS05NjIzNw_3010a341-040c-4fe8-8d66-9a84e0d6518e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4f95d0daa5491a9f9b7cf6f20f14f0_I20220331" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNy03LTEtMS05NjI0Ng_be8c729e-b98d-44d4-bab2-41d09129d51a">1,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b31a7f7ad9f4eeba82e05b893d8837b_I20220331" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNi0xLTEtMS03MDA0Mg_72e336aa-7989-4e9e-8298-3f7915c04e12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6c453b31384c85a91a6dac3bd293f9_I20220331" decimals="-3" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNi0zLTEtMS03MDA0Mg_2ced4d93-bc10-456a-bf44-a50f8f561eb3">522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i344120b3c93044e5a4e890535a20389f_I20220331" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNi01LTEtMS03MDA0Mg_26d92b05-19c6-4eb3-be8f-2257ea78f7cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7191ac8fddae474f98a72365faf35498_I20220331" decimals="-3" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNi03LTEtMS03MDA0Mg_0eff2e00-09df-4ea6-a6b0-20b3907d6697">522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6526cb352ff14142ad0267923f9b8458_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNy0xLTEtMS03MDA0Mg_d1840ad7-df95-4996-ae0b-2929ae6a4408">134,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf7e945065b4cbb9be75f83ecca429e_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNy0zLTEtMS03MDA0Mg_09348989-2ef2-4ba5-8b3c-302e40d9223d">5,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e0b992a4a41411caa3cf99acedc7773_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNy01LTEtMS03MDA0Mg_be225356-bfc7-4cac-ba58-e42b13c69315">4,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNy03LTEtMS03MDA0Mg_3775d625-543d-4eae-8e7f-4988ebab23a0">145,033</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APCMG contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6526cb352ff14142ad0267923f9b8458_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfMTEtMS0xLTEtNzAwNDI_d898fa6d-ce5b-4a74-a0c0-8bf9b72d1ed9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf7e945065b4cbb9be75f83ecca429e_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfMTEtMy0xLTEtNzAwNDI_e4c90cc2-2395-463f-8fec-40db5e92e068">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e0b992a4a41411caa3cf99acedc7773_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfMTEtNS0xLTEtNzAwNDI_1f7ae1a9-1b11-40f8-9ccd-7878e77df237">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfMTEtNy0xLTEtNzAwNDI_ca1fa00e-a599-4eba-aeaf-4cd2c8e8e9c7">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6526cb352ff14142ad0267923f9b8458_I20220331" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfMTItMS0xLTEtNzAwNDI_4fde0f77-72f0-4c62-b241-54737d7eed9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf7e945065b4cbb9be75f83ecca429e_I20220331" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfMTItMy0xLTEtNzAwNDI_d2934966-f6f7-4f62-9e8e-0fbb6536b57d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e0b992a4a41411caa3cf99acedc7773_I20220331" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfMTItNS0xLTEtNzAwNDI_2130601b-10a4-4103-a3c5-6f91c02d46c9">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfMTItNy0xLTEtNzAwNDI_aa329bc1-8c93-4f9d-871b-d7b12e265d1a">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i449fc1c5c21645ee8dbd4833a86eaa1e" continuedAt="ib7189c07367d481887c212cbef2b3e76"><ix:continuation id="ic2b7984b56cd4895a5ceb4395ad2b8c4"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Included in cash and cash equivalents</span></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of December&#160;31, 2021, are presented below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market accounts*</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48154c88054d4bfca4aae23d986f326d_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfMy0xLTEtMS03MDA0Mg_b6e2ca55-aeaf-474c-b864-bbc7b77fd6e7">114,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icef23c4f80af41b4a7678b0043957020_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfMy0zLTEtMS03MDA0Mg_7e2050ae-ec47-418a-bc59-78f220e8cd83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id889a0adfcca4b0483674775e3b7017d_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfMy01LTEtMS03MDA0Mg_a9e85623-0e56-41fa-92a2-113bad5e76b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfMy03LTEtMS03MDA0Mg_915f741f-d487-49d8-9307-d6ee75273e31">114,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48154c88054d4bfca4aae23d986f326d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNC0xLTEtMS03NzM1MA_fc0e8594-ccb9-4ecd-8d48-5d609d4a18a1">25,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icef23c4f80af41b4a7678b0043957020_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNC0zLTEtMS03NzM2MQ_44cf5fd7-0d07-4ca5-a170-9602e1aa2ba6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id889a0adfcca4b0483674775e3b7017d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNC01LTEtMS03NzM3MQ_78992787-ffa6-4ba9-a907-c8c25d6c684c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNC03LTEtMS03NzM4Mw_f9914edd-4e8d-4739-9da9-8ace94375402">25,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48154c88054d4bfca4aae23d986f326d_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNS0xLTEtMS03NzM1MA_1b4e12b5-59a0-4125-a727-cf6630f03533">24,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icef23c4f80af41b4a7678b0043957020_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNS0zLTEtMS03NzM2MQ_b9874591-a13b-46cc-9f32-faf8d1f5356c">4,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id889a0adfcca4b0483674775e3b7017d_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNS01LTEtMS03NzM3MQ_de08df9c-f956-41e8-b8a3-c1397b69de03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNS03LTEtMS03NzM4Mw_d8069d2c-9c2d-4bf9-8555-4875623c5a70">28,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i670c182c37f64d7c81e6e512f5a85911_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNC0xLTEtMS03MDA0Mg_a58d65d5-1bf4-490c-a720-a1dc9a818909">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c9680a3ecd2478e8c69cac5c0ca57bc_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNC0zLTEtMS03MDA0Mg_3729a00a-80e6-4e76-b4d8-d45c0b601a89">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i626fc76fa8044b489370befcecb36ff4_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNC01LTEtMS03MDA0Mg_32ff068e-d44b-4b8d-9f76-c16975732ab8">4,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54a2dd1d9f194b41bd57c7a175d4260e_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNC03LTEtMS03MDA0Mg_c667780f-5cfa-456a-8d44-49e89df59d13">4,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb648af0ac4046e19f5473b63dcc3dac_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNS0xLTEtMS03MDA0Mg_f04b1641-b0fd-40f5-b285-3de938795684">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64f9c2d2092e49e2a51aeaedde7588ff_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNS0zLTEtMS03MDA0Mg_411cc620-f99b-4628-99cd-19969482556c">1,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf96d2529f4847d2820cfaff15062529_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNS01LTEtMS03MDA0Mg_4eee1207-3035-457d-a2d9-9ea1847422ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9227a3f5dcdb4fe389f9629762b21c04_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNS03LTEtMS03MDA0Mg_2bde0fb7-6450-4a7a-a68a-448922ad041c">1,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48154c88054d4bfca4aae23d986f326d_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNi0xLTEtMS03MDA0Mg_802421aa-b6da-4ad7-9bc5-2f680007af3a">163,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icef23c4f80af41b4a7678b0043957020_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNi0zLTEtMS03MDA0Mg_7f54a62d-1e5a-44a5-b484-7e8caba66c80">5,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id889a0adfcca4b0483674775e3b7017d_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNi01LTEtMS03MDA0Mg_cc3f43ab-868c-4fdb-9b03-96de7364a251">4,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNi03LTEtMS03MDA0Mg_31a7f50a-986c-4a42-9ab2-455bf704c141">173,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48154c88054d4bfca4aae23d986f326d_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfMTEtMS0xLTEtNzc0NTI_ccac5d1c-45d3-4a64-8193-6c6a3da9e656">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icef23c4f80af41b4a7678b0043957020_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfMTEtMy0xLTEtNzc0NTk_6f9acfef-ecd8-4862-ad3b-5608ac5f1ca5">1,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id889a0adfcca4b0483674775e3b7017d_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfMTEtNS0xLTEtNzc0NjY_0fbb1c57-5ba8-4f4d-a186-4d01a6ab319a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfMTEtNy0xLTEtNzc0NzM_932f795c-3ffa-4013-8d75-3283b66a1dd3">1,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APCMG contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48154c88054d4bfca4aae23d986f326d_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfMTItMS0xLTEtNzc0NTI_c4bb50a8-89a4-457c-803e-2cda0f50c700">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icef23c4f80af41b4a7678b0043957020_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfMTItMy0xLTEtNzc0NTk_45f3ea8b-9092-48d3-9882-a03c2781c928">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id889a0adfcca4b0483674775e3b7017d_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfMTItNS0xLTEtNzc0NjY_381ce428-e6b9-49d1-af52-8a027e283f2e">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfMTItNy0xLTEtNzc0NzM_ae85c4c8-9a20-4e33-96a4-a0e52cfe9d5e">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48154c88054d4bfca4aae23d986f326d_I20211231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfMTMtMS0xLTEtNzc0NTI_46540e52-0f0f-4359-b46c-4456ef5c1cad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icef23c4f80af41b4a7678b0043957020_I20211231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfMTMtMy0xLTEtNzc0NTk_b2d0c7b5-b7e7-4888-86d4-84f85d610fbb">1,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id889a0adfcca4b0483674775e3b7017d_I20211231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfMTMtNS0xLTEtNzc0NjY_110a34a6-9874-4f92-8497-eb43cacdc73e">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfMTMtNy0xLTEtNzc0NzM_bc097f7c-3d22-439f-b879-d6c9e2fb369a">2,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Included in cash and cash equivalents</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in Level 1, Level 2, or Level 3 classification and no changes in valuation techniques for these assets for the three months ended March&#160;31, 2022.</span></div><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyNjc_ffb43809-7953-42cf-8940-b9b76bfcfe08" continuedAt="i1269d3f047b34320b5b8c78a312dbe7d" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Long-Lived Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives include network-payor relationships, management contracts, member relationships, subscriber relationships, and developed technology and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized using the accelerated method based on the discounted cash flow rate or using the straight-line method.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses, and are amortized using the straight-line method.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1269d3f047b34320b5b8c78a312dbe7d">Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques.</ix:continuation> The Company determined that there was <ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMTg4MTM_2304c2d2-4f39-4b0d-a3d0-c5814cb4cf73"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMTg4MTM_535a3427-8ad0-417a-86b1-39fbe2dff4fd"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMTg4MTM_c4a8ef67-11bf-45e9-b7d9-fa3b4cf70169"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMTg4MTM_dbd9b7ea-44bd-457c-9f9c-af5a39f86c3a">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment of its finite-lived intangible or long-lived assets during the three months ended March&#160;31, 2022 and 2021.</span></div><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTczMDk_f0716d91-766c-4002-80cd-c386fdc0959f" continuedAt="ib7393d127efe4fd9b55208529696ce57" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Indefinite-Lived Intangible Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles &#8211; Goodwill and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="ib7189c07367d481887c212cbef2b3e76" continuedAt="i95b0634330d043b0b4daa430315cdafb"><ix:continuation id="ib7393d127efe4fd9b55208529696ce57"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, at the Company&#8217;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#8217;s <ix:nonFraction unitRef="unit" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMTk1NDc_452f1e0d-396f-4587-a340-d9aaeeb07d5b">three</ix:nonFraction> reporting units (1) management services, (2) IPAs, and (3) accountable care organizations. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#8217;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments, and assumptions management believes are appropriate in the circumstances.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had <ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMjA4OTc_94276e99-83ca-45c9-ad08-8e0571de1f36"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMjA4OTc_a4fc4233-be79-40d6-8566-8bbf1f087b27"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMjA4OTc_cb1f5c71-6dfc-46e7-ad57-94566948cd7d"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMjA4OTc_f4dfcd35-ba17-4459-9e46-b5b52898c204">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment of its goodwill or indefinite-lived intangible assets during the three months ended March&#160;31, 2022 and 2021. </span></div><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyMjI_ec84fa6b-5945-46f9-b3ba-e45492cc6651" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Other Entities &#8212; Equity Method</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#8217;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#8217;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under income (loss) from equity method investments and also is adjusted by contributions to, and distributions from, the investee. Equity method investments are subject to impairment evaluation. There was <ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="INF" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNDM5ODA0NjU2OTU4Ng_0e0e1b7e-33fb-48e4-b225-04a20d94b62a"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="INF" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNDM5ODA0NjU2OTU4Ng_4ccc062b-5563-491b-bd17-a0277aecb559">no</ix:nonFraction></ix:nonFraction> impairment loss recorded related to equity method investments for the years ended March&#160;31, 2022 and 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Privately Held Entities </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The investments in privately held entities that do not report net asset value are subject to qualitative assessment for indicators of impairments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:HealthCareCostsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTczMDQ_61a9c1bf-db5e-4a2a-b9a8-d2e4102233bc" escape="true"><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical Liabilities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC, Alpha Care, Accountable Health Care, and APCMG (&#8220;consolidated IPAs&#8221;) and APAACO are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. These IPAs and APAACO provide integrated care to HMOs, Medicare, and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of income.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimated IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="ameh:FiduciaryCashAndPayablePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyNDY_11fd37bc-8ef2-460b-b208-64b7a893e1dc" continuedAt="ic2d1601bff4c4b5fb72efd8b77692807" escape="true">Fiduciary Cash and Payable</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i95b0634330d043b0b4daa430315cdafb" continuedAt="i1d29abe718e6492eb09e8125e67aa95b"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic2d1601bff4c4b5fb72efd8b77692807">The consolidated IPAs collect cash from health plans on behalf of their sub-IPAs and providers and pass the money through to them.</ix:continuation> The fiduciary cash balance of $<ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-5" name="ameh:FiduciaryAccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMjQzMTE_08460ec5-7f1b-4ba5-a797-8d4b59f36069">6.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-5" name="ameh:FiduciaryAccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMjQzMTg_e1ce466c-31e1-41b8-bd3a-b05a83a94ca6">10.5</ix:nonFraction> million as of March&#160;31, 2022 and December&#160;31, 2021, respectively, is presented within prepaid expenses and other current assets and the related payable is presented as fiduciary payable in the accompanying consolidated balance sheets.</span></div><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyMzg_e7769d96-ec89-4a31-aa68-7de2ba5cee08" continuedAt="i88590b7637ee40fd990cae5399d966ab" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Swap Agreements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to interest rate risk on its floating-rate debt. The Company has entered into interest rate swap agreements to effectively convert its floating-rate debt to a fixed-rate basis. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#8217;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. Refer to Note 9 for further information on our debt. Interest rate swap agreements are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income and reflected in the accompanying consolidated statements of cash flows as unrealized gain or loss on interest rate swaps.  </span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the interest rate swap agreements was determined using Level 2 inputs. As of March&#160;31, 2022 the fair value of the interest rate swap was $<ix:nonFraction unitRef="usd" contextRef="i06ded7d511214a6b934ce38ddf56629e_I20220331" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMjU0NzI_4d9b0360-928c-4ae3-a3cf-5e65c929cdd4">0.5</ix:nonFraction> million and is presented within other assets in the accompanying consolidated balance sheets. As of December&#160;31, 2021, the fair value of the interest rate swap was $<ix:nonFraction unitRef="usd" contextRef="iaaeae6dd376a4544a532f6990d6ef02b_I20211231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNDM5ODA0NjU4MzQ4Nw_47556160-6fec-4d87-890e-5a7ef454def9">1.1</ix:nonFraction>&#160;million and is presented within other long-term liabilities in the accompanying consolidated balance sheets.  </span></div><div style="margin-top:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants<br/></span></div></ix:nonNumeric><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i88590b7637ee40fd990cae5399d966ab">In September 2021, ApolloMed and Clinigence entered into a stock purchase agreement in which ApolloMed purchased shares of common stock and warrants for $<ix:nonFraction unitRef="usd" contextRef="ice1126416af04bd8bb625efbc5740cee_D20210901-20210930" decimals="-5" name="ameh:PaymentsToAcquireCommonStockAndWarrants" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTQ5NzU1ODIxMTY3MA_7468d272-edc4-40b6-9a11-7c783c055e28">3.0</ix:nonFraction>&#160;million. The purchased warrants are considered derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income and the accompanying consolidated statements of cash flows. The warrants are classified as a Level 2 instrument as the estimated fair value of the warrants were determined using the Black-Scholes option pricing model and inputs from observable market data. As of March&#160;31, 2022 and December&#160;31, 2021, the fair value of the derivative instrument was $<ix:nonFraction unitRef="usd" contextRef="ibe65b799ceec4dd4b60d0ed19b877f0c_I20220331" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMjYyNTg_5c9a8aaf-984b-45d9-9d01-b6f27fd29000">1.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="icef23c4f80af41b4a7678b0043957020_I20211231" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNDk0NzgwMjQzMzc5MA_d50f180f-75b2-464b-a8c2-709598d706fd">1.1</ix:nonFraction>&#160;million, respectively, and is presented within other assets in the accompanying consolidated balance sheets.</ix:continuation>  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Contingent Equity Securities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the common stock and warrants purchased under the stock purchase agreement between ApolloMed and Clinigence, ApolloMed is entitled to additional common stock if Clinigence does not pay NMM management fees exceeding a threshold by the end of December 31, 2022. The contingent equity securities are considered derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income and the accompanying consolidated statements of cash flows. The Company determined the fair value of the contingent equity security using a probability-weighted model, which includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of recognizing management fees and assigned probabilities to each such scenario in determining fair value. As of March&#160;31, 2022 and December&#160;31, 2021, the contingent consideration was valued at $<ix:nonFraction unitRef="usd" contextRef="i54a2dd1d9f194b41bd57c7a175d4260e_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNDM5ODA0NjU4MTE2Nw_195e26d9-54d2-4f76-9c9c-a8932abe69f5"><ix:nonFraction unitRef="usd" contextRef="i0f97d77f9a334dfaa7f626c14651831b_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNDM5ODA0NjU4MTE2Nw_c26602b4-1d13-4652-8cfb-cc25a4942f4f">4.3</ix:nonFraction></ix:nonFraction>&#160;million, and is presented within prepaid and other current assets in the accompanying consolidated balance sheets. </span></div><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyOTE_5ed25073-c76a-462b-a36d-e323da6a9e08" continuedAt="if892b533854a4dfaa94ad1f742aa7c5d" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Nature of Services and Revenue Streams</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue primarily consists of capitation revenue, risk pool settlements and incentives, GPDC revenue, management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#8217;s billing arrangements and how revenue is recognized for each.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i1d29abe718e6492eb09e8125e67aa95b" continuedAt="ia4057ef657ee472089265f1a1d51e6d1"><ix:continuation id="if892b533854a4dfaa94ad1f742aa7c5d" continuedAt="ia76ed52144ba41858b5ff3791f059fd9"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capitation, Net</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#8217; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#8220;Risk Adjustment&#8221; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PMPM managed care contracts generally have a term of <ix:nonNumeric contextRef="i5f76f479c78d4715a3a1756814601111_D20220101-20220331" name="us-gaap:RevenuePerformanceObligationDescriptionOfTiming" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyOTY_f788ab28-898a-4226-b883-53f4cee3269d">one year</ix:nonNumeric> or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk sharing. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#8217;s net PMPM transaction price relates specifically to the Company&#8217;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GPDC Capitation Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS contracts with Direct Contracting Entities (&#8220;DCEs&#8221;), which is composed of health care providers operating under a common legal structure and accepts financial accountability for the overall quality and cost of medical care furnished to Medicare FFS beneficiaries aligned to the entity. The combination of the FFS model and the GPDC model changes the distribution of responsibilities, risks, costs, and rewards among CMS, DCEs, and providers. By entering into a contract with CMS, a DCE voluntarily takes on operational, financial, and legal responsibilities and risks that no party has, individually or collectively, under the existing FFS model. Each DCE bears the economic costs, and reaps the economic rewards, of fulfilling its responsibilities and managing its risks as a DCE. APAACO has applied, and been accepted, to participate in the GPDC Model for Performance Year 2022, beginning January 1, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, CMS will pay a total benchmark amount, determined unilaterally by CMS in advance but subject to prospective adjustments throughout the year, for the totality of care provided to the DCE&#8217;s population of aligned beneficiaries over the course of that year. The benchmark is net of a quality withholding applied by CMS. At the end of each performance year, a portion, or all, of the quality withholding can be earned based on APAACO&#8217;s performance. GPDC capitation revenue is recognized based on the estimated transaction price to transfer the service for a distinct increment of the series (i.e. month) and is recognized net of quality incentives/penalties. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Pool Settlements and Incentives</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC enters into full-risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging, and paying for institutional risk and APC is responsible for providing, arranging and paying for professional risk. Under a full-risk pool sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#8217;s risk pools with HMOs after deductions for the affiliated hospital&#8217;s costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#8217;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for historical margin, IBNR completion factors and constraint percentages were used by management in applying the most likely amount methodology.</span></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="ia4057ef657ee472089265f1a1d51e6d1" continuedAt="ifb35701ceac34e82bee29e6354cf40f9"><ix:continuation id="ia76ed52144ba41858b5ff3791f059fd9" continuedAt="ia72eaa52ad84439cac447ee29fe17705"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under capitated arrangements with certain HMOs, APC participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans&#8217; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#8217;s risk share revenue is deemed to be fully constrained until APC is notified of the amount by the health plan. Final settlement of risk pools for prior contract years generally occur in the third or fourth quarter of the following year.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to risk-sharing revenues, the Company also receives incentives under &#8220;pay-for-performance&#8221; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#8217;s incentives under &#8220;pay-for-performance&#8221; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#8217;s performance within the annual measurement period, but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NGACO AIPBP Revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the NGACO Model, CMS aligns beneficiaries to the Company to manage direct care and pay providers based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation-like AIPBP payments from CMS on a monthly basis to pay claims from in-network providers. The Company records such AIPBPs received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided, and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS, while claims from APAACO&#8217;s in-network contracted providers are paid by APAACO. The Company&#8217;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#8217;s risk share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#8217;s efficiency in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#8217;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO AIPBP revenues monthly. Excess AIPBPs over claims paid, plus an estimate for the related IBNR claims (see Note 8), are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there were any excess AIPBPs for the performance year and the excess is refunded to CMS.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="ifb35701ceac34e82bee29e6354cf40f9" continuedAt="iccd65edb242e40c991a978e6bfd7d23a"><ix:continuation id="ia72eaa52ad84439cac447ee29fe17705" continuedAt="i1d3cbdf7eb2a46319155f789960a3f35"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company, the risk arrangement for which the Company has been approved by CMS, and as otherwise provided in an NGACO Participation Agreement between APAACO and CMS (the &#8220;Participation Agreement&#8221;). Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within <ix:nonNumeric contextRef="i129c72bde37445abbf565db10f855c61_D20220101-20220331" name="ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMzc3OTM_583456f1-bab8-4046-bf76-72544378ad78">30</ix:nonNumeric> days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within <ix:nonNumeric contextRef="i129c72bde37445abbf565db10f855c61_D20220101-20220331" name="ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMzgwNTM_3feacf27-621e-4416-b6dd-4e56bbc45296">30</ix:nonNumeric> days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within <ix:nonNumeric contextRef="i129c72bde37445abbf565db10f855c61_D20220101-20220331" name="ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMzgxNzY_3feacf27-621e-4416-b6dd-4e56bbc45296">30</ix:nonNumeric> days after the date of a demand letter or settlement report, CMS will assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#8217;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that will likely be recognized in the future and therefore this shared risk pool revenue is considered fully constrained. With the ending of the NGACO Model on December 31, 2021, the Company no longer receives AIPBPs but remains eligible to recognize any shared savings or loss for performance year 2021 upon issuance of the settlement report from CMS. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management Fee Income</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals, and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of gross revenue or fee collections, or amounts fixed on a monthly, quarterly, or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits, or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a significant service of integrating the services selected by the Company&#8217;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#8217;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#8217;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#8217;s performance obligation is satisfied as the Company completes each period&#8217;s obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#8217;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#8217;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management contracts generally have long terms (e.g., <ix:nonNumeric contextRef="i4efb856004934021887d5c4fcd6a352c_D20220101-20220331" name="us-gaap:RevenuePerformanceObligationDescriptionOfTiming" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyOTc_b64e4b63-bf1a-4efa-b7ca-121cc155ebff">10 years</ix:nonNumeric>), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fee-for-Service Revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FFS revenue represents revenue earned under contracts in which the professional component of charges for medical services rendered by the Company&#8217;s affiliated physician-owned medical groups are billed and collected from third-party payors, hospitals, and patients. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and is recognized in the period in which the services are rendered to specific patients. All services provided are </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="iccd65edb242e40c991a978e6bfd7d23a" continuedAt="i33a358b6f932429a8c75a92da9b5dde7"><ix:continuation id="i1d3cbdf7eb2a46319155f789960a3f35" continuedAt="i8e51883ceab74754a1e2aca55958b4e9"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expected to result in cash flows and are therefore reflected as net revenue in the consolidated financial statements. The recognition of net revenue (gross charges, less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#8217;s billing center for medical coding and entering into the Company&#8217;s billing system, and the verification of each patient&#8217;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company&#8217;s billing systems, as well as an estimate of the revenue associated with medical services.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#8217;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#8217;s healthcare plans, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether the patients, to whom services are provided, in the period are insured and the contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of income in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions, and healthcare coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company&#8217;s contract assets are comprised of receivables and receivables &#8211; related parties.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable aging, and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as revenues are recognized. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Liabilities (Deferred Revenue)</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8e51883ceab74754a1e2aca55958b4e9">Contract liabilities are recorded when cash payments are received in advance of the Company&#8217;s performance, or in the case of the Company&#8217;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred.</ix:continuation> The Company&#8217;s contract liability balance was $<ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNDg2NTM_5373fb6f-c4c7-4850-9719-ffcd31fd03c1">20.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNDg2NjA_4287d25d-c729-4b07-adcf-bafbfcaa5339">16.8</ix:nonFraction> million as of March&#160;31, 2022 and December&#160;31, 2021, respectively, and is presented within accounts payable and accrued expenses in the accompanying consolidated balance sheets. During the three months ended March&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="i37c332bfa67d49cea1f207293667f549_D20220101-20220331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNDg4MzY_3a6bdee7-e0f6-49a5-a0e5-fe205289e883">0.5</ix:nonFraction> million of the Company&#8217;s contract liability accrued in 2021 has been recognized as revenue.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyNzg_d693dfa8-5416-40b4-997a-414980a5bcfe" continuedAt="i65eceab482344530bf2542b64f32fe41" escape="true">Income Taxes</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i33a358b6f932429a8c75a92da9b5dde7" continuedAt="i755b02cd7769486d89cab2cfefd41bd0"><ix:continuation id="i65eceab482344530bf2542b64f32fe41"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.</span></div></ix:continuation><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTczMTQ_aca72fad-210f-4fd6-8326-ea30e4ab54b9" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a stock-based compensation program for employees, non-employees, directors, and consultants. The value of share-based awards is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for forfeitures as they occur. From time to time, the Company issues shares of its common stock to its employees, directors, and consultants, which shares may be subject to the Company&#8217;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules. The fair value of options granted are determined using the Black-Scholes option pricing model and include several assumptions, including expected term, expected volatility, expected dividends, and risk-free rates. The expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The expected stock price volatility is determined based on an average of historical volatility. The expected dividend yield is based on the Company&#8217;s expected dividend payouts. The risk-free interest rate is based on the U.S. Constant Maturity curve over the expected term of the option at the time of grant.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyOTg_c0c1baa3-0abf-421c-9b92-f570c29437d1" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basic and Diluted Earnings Per Share</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed by dividing net income attributable to holders of the Company&#8217;s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding, plus the effect of dilutive securities outstanding during the periods presented, using the treasury stock method. Refer to Note 15 for a discussion of shares treated as treasury shares for accounting purposes.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="ameh:MinorityInterestPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyNDc_4130bd04-4b98-4cfc-b708-f946308a5203" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-controlling Interests</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Non-controlling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#8217;s consolidated entities. Net income attributable to non-controlling interests is disclosed in the consolidated statements of income.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="ameh:TemporaryEquityPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyMzU_fda9136b-4262-4e5e-b546-9a304c0fd31f" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mezzanine Equity</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to APC&#8217;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase its shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes non-controlling interests in APC as mezzanine equity in the consolidated financial statements. As of March&#160;31, 2022 and December&#160;31, 2021, APC&#8217;s shares were not redeemable, nor was it probable the shares would become redeemable.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyOTk_003e2d28-5f46-4651-bf81-94ba5c129515" continuedAt="i46d8701cfb9148149f03147e879e1198" escape="true">Leases</ix:nonNumeric><br/></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i755b02cd7769486d89cab2cfefd41bd0"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i46d8701cfb9148149f03147e879e1198">The Company determines if an arrangement is a lease at its inception. The expected term of the lease used for computing the lease liability and right-of-use asset and determining the classification of the lease as operating or financing may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company elected practical expedients for ongoing accounting that is provided by the new standard comprised of the following: (1) the election for classes of underlying asset to not separate non-lease components from lease components, and (2) the election for short-term lease recognition exemption for all leases under a 12-month term. The present value of the lease payments is calculated using a rate implicit in the lease, when readily determinable. However, as most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate to determine the present value of the lease payments for the majority of its leases.</ix:continuation></span></div><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyMTg_940f70cd-e895-4d5f-b4ef-a355aba807d4" continuedAt="i26300e9ed27d4b9eafb0b3f0d19710ec" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2021, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;)  No. 2021-08, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (&#8220;ASU 2021-08&#8221;). This ASU requires the entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 as if it had originated the contracts. The amendments in this ASU are effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. The Company adopted ASU 2021-08 on January 1, 2022. The adoption of ASU 2021-08 did not have a material impact on the consolidated financial statements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With the exception of the new standards discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#8217;s financial position, results of operations, and cash flows.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><ix:continuation id="i26300e9ed27d4b9eafb0b3f0d19710ec"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements Not Yet Adopted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#8217;s financial position, results of operations, and cash flows.</span></div></ix:continuation><div id="i3cbe033f261a4f1ea6a0c939c6847530_52"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81Mi9mcmFnOjYyZmFmNjU1OTljNzRiMTk5YzE1MzJhYWYyOWEzNmUxL3RleHRyZWdpb246NjJmYWY2NTU5OWM3NGIxOTljMTUzMmFhZjI5YTM2ZTFfMjg3Mg_ba0f4707-956b-4885-a522-cd17738db911" continuedAt="i6870bc6dab9a442aa37eea849bf585a6" escape="true">Business Combinations and Goodwill</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i6870bc6dab9a442aa37eea849bf585a6" continuedAt="i83ca1bd708114c19b18c884a915b697c"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orma Health, Inc., and Provider Growth Solutions LLC (together, &#8220;Orma Health&#8221;)</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 27, 2022, the Company acquired <ix:nonFraction unitRef="number" contextRef="i4043dc9bcd1c428faf9de8df64df4c4c_I20220124" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81Mi9mcmFnOjYyZmFmNjU1OTljNzRiMTk5YzE1MzJhYWYyOWEzNmUxL3RleHRyZWdpb246NjJmYWY2NTU5OWM3NGIxOTljMTUzMmFhZjI5YTM2ZTFfMTA5OTUxMTY0MzU4NQ_c07ab4f0-6f31-40ac-83fd-c600e87d7c72">100</ix:nonFraction>% of the capital stock of Orma Health, Inc., and Provider Growth Solutions, LLC (together, &#8220;Orma Health&#8221;) for $<ix:nonFraction unitRef="usd" contextRef="ic90a69d35de04dc89bd59af6b50c84d2_D20220124-20220124" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81Mi9mcmFnOjYyZmFmNjU1OTljNzRiMTk5YzE1MzJhYWYyOWEzNmUxL3RleHRyZWdpb246NjJmYWY2NTU5OWM3NGIxOTljMTUzMmFhZjI5YTM2ZTFfMTA5OTUxMTY0MzYwMA_30d02d56-a4d7-47f7-82c8-0d46096f4baa">1.0</ix:nonFraction> million in cash and $<ix:nonFraction unitRef="usd" contextRef="ic90a69d35de04dc89bd59af6b50c84d2_D20220124-20220124" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81Mi9mcmFnOjYyZmFmNjU1OTljNzRiMTk5YzE1MzJhYWYyOWEzNmUxL3RleHRyZWdpb246NjJmYWY2NTU5OWM3NGIxOTljMTUzMmFhZjI5YTM2ZTFfMTA5OTUxMTY0MzYxNQ_660949ff-6ba3-47d9-9e4d-93518082f585">1.0</ix:nonFraction> million in the Company&#8217;s capital stock. Orma Health&#8217;s real-time Clinical AI platform ingests data from multiple sources and utilizes advanced risk-stratification models to identify patients for various clinical programs, including remote patient monitoring (&#8220;RPM&#8221;), mental health support, chronic disease management, and more. Its clinical platform is also deeply integrated with Orma Health&#8217;s proprietary RPM ecosystem, which consists of smart health devices and a suite of technology tools to help manage patients&#8217; health.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">APCMG</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company acquired an <ix:nonFraction unitRef="number" contextRef="iae649481fa4d4190a0f5b74bc999a510_I20210731" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81Mi9mcmFnOjYyZmFmNjU1OTljNzRiMTk5YzE1MzJhYWYyOWEzNmUxL3RleHRyZWdpb246NjJmYWY2NTU5OWM3NGIxOTljMTUzMmFhZjI5YTM2ZTFfOTQ_0411f803-dad6-4b54-90da-1a656df854ee">80</ix:nonFraction>% equity interest (on a fully diluted basis) in APCMG for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i25fa08dfbba0471ab1f73eb7a33ab853_D20210701-20210731" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81Mi9mcmFnOjYyZmFmNjU1OTljNzRiMTk5YzE1MzJhYWYyOWEzNmUxL3RleHRyZWdpb246NjJmYWY2NTU5OWM3NGIxOTljMTUzMmFhZjI5YTM2ZTFfMTg0_9703afe4-de49-4c57-b0ac-78d493a3d9e4">2.0</ix:nonFraction> million. As part of the transaction, the Company paid $<ix:nonFraction unitRef="usd" contextRef="i25fa08dfbba0471ab1f73eb7a33ab853_D20210701-20210731" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81Mi9mcmFnOjYyZmFmNjU1OTljNzRiMTk5YzE1MzJhYWYyOWEzNmUxL3RleHRyZWdpb246NjJmYWY2NTU5OWM3NGIxOTljMTUzMmFhZjI5YTM2ZTFfMjMz_a58cb6bf-0d65-4130-8ee3-61233c55cd25">1.0</ix:nonFraction> million in cash and the remaining amount will be paid out in cash as a contingent consideration related to APCMG&#8217;s financial performance for fiscal year 2022 (&#8220;APCMG contingent consideration&#8221;). The APCMG contingent consideration is met if gross revenue and earnings before interest, taxes, and depreciation, and amortization (&#8220;EBITDA&#8221;) targets exceed a threshold for fiscal year 2022. The Company determined the fair value of the contingent consideration using a probability-weighted model that includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of gross revenue and EBITDA and assigned probabilities to each such scenario in determining fair value. As of March&#160;31, 2022, the contingent consideration is valued at $<ix:nonFraction unitRef="usd" contextRef="i4326870dc64f4f2f89fd5df3a7f241eb_I20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81Mi9mcmFnOjYyZmFmNjU1OTljNzRiMTk5YzE1MzJhYWYyOWEzNmUxL3RleHRyZWdpb246NjJmYWY2NTU5OWM3NGIxOTljMTUzMmFhZjI5YTM2ZTFfODc0_6ad15c8c-752e-484f-b60a-4ee28f3a4eb8">1.0</ix:nonFraction> million and was included within other long-term liabilities in the accompanying consolidated balance sheets.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sun Labs</span></div></ix:continuation><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i83ca1bd708114c19b18c884a915b697c"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company acquired <ix:nonFraction unitRef="number" contextRef="ic4078597aaf8463a99cbfd3e8f573353_I20210831" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81Mi9mcmFnOjYyZmFmNjU1OTljNzRiMTk5YzE1MzJhYWYyOWEzNmUxL3RleHRyZWdpb246NjJmYWY2NTU5OWM3NGIxOTljMTUzMmFhZjI5YTM2ZTFfMTAzMQ_e2d15bb5-f846-41fb-b378-79118792df1c">49</ix:nonFraction>% of the aggregate issued and outstanding shares of capital stock of Sun Labs for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="ied48cf0dd52b4ecbacf11485317313d5_D20210801-20210831" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81Mi9mcmFnOjYyZmFmNjU1OTljNzRiMTk5YzE1MzJhYWYyOWEzNmUxL3RleHRyZWdpb246NjJmYWY2NTU5OWM3NGIxOTljMTUzMmFhZjI5YTM2ZTFfMTE0NQ_5afcdaf8-ebe2-4287-a604-3e4be73addf2">4.0</ix:nonFraction> million. As Sun Labs was concluded to be a VIE and the Company is the primary beneficiary, Sun Labs is consolidated by the Company. The Company is obligated to purchase the remaining equity interest within three years from the effective date. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets. The Company recognized goodwill as a result of consolidating Sun Labs as a VIE. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DMG</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, DMG entered into an administrative services agreement with a subsidiary of the Company, causing the Company to reevaluate the accounting for the Company&#8217;s investment in DMG. Based on the reevaluation and in accordance with relevant accounting guidance, DMG is determined to be a VIE and the Company is the primary beneficiary; DMG is consolidated by Apollo.  In addition, APC-LSMA is obligated to purchase the remaining equity interest within three years from the effective date. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets. The Company recognized goodwill as a result of consolidating DMG as a VIE. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisitions were accounted for under the acquisition method of accounting. The fair value of the consideration for the acquired companies were allocated to acquired tangible and intangible assets and liabilities based upon their fair values. The excess of the purchase consideration over the fair value of the net tangible and identifiable intangible assets acquired was recorded as goodwill. The determination of the fair value of assets and liabilities acquired requires the Company to make estimates and use valuation techniques when market value is not readily available. The results of operations from the acquisitions have been included in the Company&#8217;s financial statements from the date of acquisition. Transaction costs associated with business acquisitions are expensed as they are incurred.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time of acquisition, the Company estimates the amount of the identifiable intangible assets based on a valuation and the facts and circumstances available at the time. The Company determines the final value of the identifiable intangible assets as soon as information is available, but not more than one year from the date of acquisition.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not deductible for tax purposes.</span></div><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81Mi9mcmFnOjYyZmFmNjU1OTljNzRiMTk5YzE1MzJhYWYyOWEzNmUxL3RleHRyZWdpb246NjJmYWY2NTU5OWM3NGIxOTljMTUzMmFhZjI5YTM2ZTFfMjg3MQ_4f7a43b8-7ca3-48ce-9ffc-211d2f3e91c6" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying value of goodwill for the three months ended March&#160;31, 2022 was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:79.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81Mi9mcmFnOjYyZmFmNjU1OTljNzRiMTk5YzE1MzJhYWYyOWEzNmUxL3RhYmxlOjY2MDI4Njk0NjlhODQwMmY4MWZlYWNlMDQyMWJiOGIxL3RhYmxlcmFuZ2U6NjYwMjg2OTQ2OWE4NDAyZjgxZmVhY2UwNDIxYmI4YjFfMC0xLTEtMS03MDA0Mg_24d133a2-872e-484a-869e-0a072edbb398">253,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81Mi9mcmFnOjYyZmFmNjU1OTljNzRiMTk5YzE1MzJhYWYyOWEzNmUxL3RhYmxlOjY2MDI4Njk0NjlhODQwMmY4MWZlYWNlMDQyMWJiOGIxL3RhYmxlcmFuZ2U6NjYwMjg2OTQ2OWE4NDAyZjgxZmVhY2UwNDIxYmI4YjFfMS0xLTEtMS03MDA0Mg_082f94e7-1698-430b-a539-46985e0a80af">1,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81Mi9mcmFnOjYyZmFmNjU1OTljNzRiMTk5YzE1MzJhYWYyOWEzNmUxL3RhYmxlOjY2MDI4Njk0NjlhODQwMmY4MWZlYWNlMDQyMWJiOGIxL3RhYmxlcmFuZ2U6NjYwMjg2OTQ2OWE4NDAyZjgxZmVhY2UwNDIxYmI4YjFfMi0xLTEtMS05OTIxMA_4cbf4249-306b-4331-b52a-fb519ec8bc59">1,746</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81Mi9mcmFnOjYyZmFmNjU1OTljNzRiMTk5YzE1MzJhYWYyOWEzNmUxL3RhYmxlOjY2MDI4Njk0NjlhODQwMmY4MWZlYWNlMDQyMWJiOGIxL3RhYmxlcmFuZ2U6NjYwMjg2OTQ2OWE4NDAyZjgxZmVhY2UwNDIxYmI4YjFfMi0xLTEtMS03MDA0Mg_4c82f3c9-46ce-4ace-8c6c-e6763e0b68cf">252,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i3cbe033f261a4f1ea6a0c939c6847530_55"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RleHRyZWdpb246NDE5YjNiNzliMjFkNGJkMWFjNjY1NDNiOGY4MmM4YzZfNTc4_633bf33c-f351-409a-a2d9-613f52b95c13" continuedAt="ib2b50b91cb3c4a2fb4d8e2a7f997745c" escape="true">Intangible Assets, Net</ix:nonNumeric></span></div><ix:continuation id="ib2b50b91cb3c4a2fb4d8e2a7f997745c"><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RleHRyZWdpb246NDE5YjNiNzliMjFkNGJkMWFjNjY1NDNiOGY4MmM4YzZfNTcw_3e8cafed-058a-4684-90c2-a226900e778e" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:46.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net March 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i963385d3851043318a55cac8d1d8e584_I20220331" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfMi0zLTEtMS03MDA0Mg_93d2112b-ac23-4f20-be29-233cf1001839">2,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i963385d3851043318a55cac8d1d8e584_I20220331" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfMi03LTEtMS03MDA0Mg_2aeb5653-9fb3-4ccd-a934-99ae8a09f4e6">2,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Network relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i72e8469da6fd456bb61b083d9a9a2852_D20220101-20220331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfNC0xLTEtMS03MDA0Mi90ZXh0cmVnaW9uOmE5MmIyNTFjMDQ2MTQ2ZGE5YzQ4YmI4NTliNWU3Yjk5XzQ_6bc629cc-7731-4b13-9f60-4cfeecef7f5a">11</ix:nonNumeric>-<ix:nonNumeric contextRef="i9449f60b9fc845af955a5c89466e5184_D20220101-20220331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfNC0xLTEtMS03MDA0Mi90ZXh0cmVnaW9uOmE5MmIyNTFjMDQ2MTQ2ZGE5YzQ4YmI4NTliNWU3Yjk5Xzc_c2ca6745-fa7f-4fd0-87f9-ad9c640cc7ea">21</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i505d1f1aced648e2ac90c9458f190dd7_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfNC0zLTEtMS03MDA0Mg_48c3eeb4-78a3-4c70-8d95-e905f5761777">150,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i505d1f1aced648e2ac90c9458f190dd7_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfNC01LTEtMS03MDA0Mg_3ed3d75c-b218-4b0d-ac4a-3e4a86f6426a">87,618</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i505d1f1aced648e2ac90c9458f190dd7_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfNC03LTEtMS03MDA0Mg_aad3e5b3-0c51-4a02-b787-5311a6c41061">63,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib92cc8812a2d47588d05bc790009d105_D20220101-20220331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfNS0xLTEtMS03MDA0Mg_94ada59b-3e6a-40a7-a7d1-6b5577305d9a">15</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f4cf5ddfa684bd38d0791137d1d848f_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfNS0zLTEtMS03MDA0Mg_838d07d3-a2de-488d-8705-c262f52e79a9">22,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f4cf5ddfa684bd38d0791137d1d848f_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfNS01LTEtMS03MDA0Mg_8a0afce8-b2e3-4fed-857b-052f8f835bfb">13,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f4cf5ddfa684bd38d0791137d1d848f_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfNS03LTEtMS03MDA0Mg_651f69db-1459-4b1a-b3c7-5c24a301f357">8,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Member relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i81cd72537a24472dad3429c1494fb9d6_D20220101-20220331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfNi0xLTEtMS03MDA0Mg_185a9d76-e395-46b1-a956-a56c2b2dead9">12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8569af65a8b4eb9b5df3177f8dd7840_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfNi0zLTEtMS03MDA0Mg_88de681b-70ce-40cd-acb4-07c2e1be5378">8,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8569af65a8b4eb9b5df3177f8dd7840_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfNi01LTEtMS03MDA0Mg_c19e123c-a305-485c-8bb1-2958479b1dc3">4,976</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8569af65a8b4eb9b5df3177f8dd7840_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfNi03LTEtMS03MDA0Mg_9c2d60b7-e76d-4105-862d-33c6ada118a6">4,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient management platform</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2b86c52f7f00483faef56f69b319a5ee_D20220101-20220331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfNy0xLTEtMS03MDA0Mg_2f496541-ae0b-4446-9d21-5a41dfd21e64">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01b454e0ae7d40d0aa1b524fc4c468b6_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfNy0zLTEtMS03MDA0Mg_21a3ef44-c32b-4c9c-96b3-ef06e3c30e0a">2,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01b454e0ae7d40d0aa1b524fc4c468b6_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfNy01LTEtMS03MDA0Mg_4dcbd68a-ffb5-487f-ba30-00c3d9497fcb">1,777</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01b454e0ae7d40d0aa1b524fc4c468b6_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfNy03LTEtMS03MDA0Mg_6525bd94-d9d8-4087-b7ec-681b9e8a4c1a">283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade names/trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i120f957d1af8440481f28a0c928f55b4_D20220101-20220331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfOC0xLTEtMS03MDA0Mg_94a86f71-fa64-487d-8a2b-87ff86480c5c">20</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3c1ae4a3ee14160b77a83df27148f53_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfOC0zLTEtMS03MDA0Mg_5aa86f36-17f9-4cb0-8bdb-551fe8d9a253">1,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3c1ae4a3ee14160b77a83df27148f53_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfOC01LTEtMS03MDA0Mg_3846c7f7-54ae-4aa0-b0b4-f96ffdcd1e5c">219</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3c1ae4a3ee14160b77a83df27148f53_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfOC03LTEtMS03MDA0Mg_58584d00-8c85-42b8-9e9c-a0130a5d54dc">792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subscriber relationships </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1d30ca934a1c4d25a5117a64b30e1ec6_D20220101-20220331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfOS0xLTEtMS05ODQ3NA_dab2f07b-9dd1-4510-a1b0-3af2730ae451">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c57be7d1d9b4186b0c62d58ed16439b_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfOS01LTEtMS05ODUxOA_f6bb07c3-e66a-444a-8eba-f8cfde1b4e59">235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c57be7d1d9b4186b0c62d58ed16439b_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfOS03LTEtMS05ODUyNQ_90050c1c-bd4c-4fa6-936a-7153f362dd30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c57be7d1d9b4186b0c62d58ed16439b_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfOS05LTEtMS05ODUzMg_a09b39a0-7ead-4a8a-adac-685afdba832b">235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developed technology </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0d873576e5c74d678a79c2181b0def05_D20220101-20220331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfMTAtMS0xLTEtOTg0ODE_169ebf32-9581-4f03-ae87-96172a3b9ed4">6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f881cf7eb4448d49160c4fbe26a606f_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfMTAtNS0xLTEtOTg1MTg_2fc619c3-7b8d-487a-b71b-06d4518155a8">772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f881cf7eb4448d49160c4fbe26a606f_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfMTAtNy0xLTEtOTg1MjU_ea73eb44-76d5-41cf-b073-23f08fdac1aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f881cf7eb4448d49160c4fbe26a606f_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfMTAtOS0xLTEtOTg1MzI_3cd84aa5-48f0-4cf7-8130-51b32ea4cc3c">772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfOS0zLTEtMS03MDA0Mg_4432afd2-0127-428c-82ee-970d63395976">188,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfOS01LTEtMS03MDA0Mg_47526db0-7b64-4ae0-84e2-d43195d95a4c">108,588</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfOS03LTEtMS03MDA0Mg_64bc5fe5-8f16-4b14-8307-899ec6e2ccdd">80,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare license</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42c656984834bbe802a92fc9c2db0ec_I20211231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfMi0zLTEtMS04NTk4NA_9afdd26f-a2bf-4a8d-9e29-de014a6f4b07">2,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42c656984834bbe802a92fc9c2db0ec_I20211231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfMi03LTEtMS04NjAwNg_822c1687-b892-4b23-9f14-717ab25afdd6">2,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Network relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifb3e802a663f4a6b942e4d29cad772ac_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfMi0xLTEtMS03MDA0Mi90ZXh0cmVnaW9uOjZjYTBmOWMyYWU5ODRjMzc4NjliY2I0ZjZkY2VjZTBmXzQ_36852a3b-2395-49b3-a435-698e3db382fd">11</ix:nonNumeric>-<ix:nonNumeric contextRef="i181ceb45ba734f1e941c3bc5aff82a91_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfMi0xLTEtMS03MDA0Mi90ZXh0cmVnaW9uOjZjYTBmOWMyYWU5ODRjMzc4NjliY2I0ZjZkY2VjZTBmXzc_ed3b46e2-ce25-41d8-8126-692c58284388">15</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fe5dca6b3c94505aeb4f1b8542dce43_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfMi0zLTEtMS03MDA0Mg_b01568ea-fe53-4b71-9c3e-6011bff5903b">150,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2fe5dca6b3c94505aeb4f1b8542dce43_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfMi01LTEtMS03MDA0Mg_86249dd2-1891-4a18-a377-9b09d789c5e1">84,865</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fe5dca6b3c94505aeb4f1b8542dce43_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfMi03LTEtMS03MDA0Mg_61bc366f-52f0-44b9-a741-5ce28c357596">65,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib6f7ecc2ad814ce19177b1caaed8db74_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfMy0xLTEtMS03MDA0Mg_cd74f6d4-c8bb-4c8d-a4dc-0675ab900e21">15</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82294d54cab940218597a90c5e4ee4f7_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfMy0zLTEtMS03MDA0Mg_89ec3c69-5432-4b33-8f93-087b8a324e94">22,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82294d54cab940218597a90c5e4ee4f7_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfMy01LTEtMS03MDA0Mg_7d0f86a3-a998-41a6-86ac-3264ed335dee">13,563</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82294d54cab940218597a90c5e4ee4f7_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfMy03LTEtMS03MDA0Mg_01edf471-44c2-4f9f-8387-903c55e130c0">9,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic7f4421b21eb4d46abaed6eca504bfe6_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfNC0xLTEtMS03MDA0Mg_b4de7b71-bbe3-4396-8af7-9f60a136d2a6">12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iece03f9e8f8a4d22966891f53113f721_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfNC0zLTEtMS03MDA0Mg_0c21e021-421e-4ab6-a19c-b0f15c152452">8,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iece03f9e8f8a4d22966891f53113f721_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfNC01LTEtMS03MDA0Mg_199553c4-0fa2-4481-b49d-1b4665ab4cda">4,606</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iece03f9e8f8a4d22966891f53113f721_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfNC03LTEtMS03MDA0Mg_39612351-8f6f-458f-b16e-30d558572719">4,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient management platform</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i64402309fd5e4e24ad7105d9ff70a80c_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfNS0xLTEtMS03MDA0Mg_69500660-67b9-44c2-a497-8d3e7e7a4562">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f11ce9c14364c19887f12faf318e05b_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfNS0zLTEtMS03MDA0Mg_790699dc-090d-4121-ac89-b58f1b5803ed">2,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f11ce9c14364c19887f12faf318e05b_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfNS01LTEtMS03MDA0Mg_7bf62bcf-21b4-42b5-a6d9-74133f7ca033">1,682</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f11ce9c14364c19887f12faf318e05b_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfNS03LTEtMS03MDA0Mg_32b940ef-222e-4698-9bd4-94df8b5fb8a4">378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tradename/trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i336efd7ddd3a421f8e5bba9c0816384d_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfNi0xLTEtMS03MDA0Mg_c311a7df-d9ac-426b-9fe5-462313ad5e51">20</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43360692494245daa938bbb454eea503_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfNi0zLTEtMS03MDA0Mg_7cbde290-b807-4629-a181-15bb1d84fdf9">1,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i43360692494245daa938bbb454eea503_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfNi01LTEtMS03MDA0Mg_eea9ab69-9d87-471e-86cb-86cfcdd0ae99">206</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43360692494245daa938bbb454eea503_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfNi03LTEtMS03MDA0Mg_f8687bbd-9ff5-4a57-b48b-d79a1ad2cc47">805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfNy0zLTEtMS03MDA0Mg_36bc478b-5e2f-4948-90e3-26b4f00ba7ed">187,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfNy01LTEtMS03MDA0Mg_da9aa456-4537-4876-89e0-4923dc343c37">104,922</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfNy03LTEtMS03MDA0Mg_1bd56e5f-f9a2-4fab-87fd-e2f8eb60e7f0">82,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in depreciation and amortization on the accompanying consolidated statements of income is amortization expense of $<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RleHRyZWdpb246NDE5YjNiNzliMjFkNGJkMWFjNjY1NDNiOGY4MmM4YzZfMzQw_29ce6738-1d40-4f3b-b91a-baa6297912d6">3.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RleHRyZWdpb246NDE5YjNiNzliMjFkNGJkMWFjNjY1NDNiOGY4MmM4YzZfMzQ3_0f8cf90e-816d-4b88-b3bc-a70fc3dcdb64">3.8</ix:nonFraction> million for the three months ended March&#160;31, 2022 and 2021. </span></div><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RleHRyZWdpb246NDE5YjNiNzliMjFkNGJkMWFjNjY1NDNiOGY4MmM4YzZfNTc5_2454d089-e71f-45a2-906a-11194f3a5683" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the three months ended March 31, 2022)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjEwYzMzNzY3ZTNiMjQ4N2ZiYjEyYmNjNjVkYWJiOTNkL3RhYmxlcmFuZ2U6MTBjMzM3NjdlM2IyNDg3ZmJiMTJiY2M2NWRhYmI5M2RfMi0xLTEtMS03MDA0Mg_bf6e8f38-3616-4c75-b267-6d21358ebfe7">10,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjEwYzMzNzY3ZTNiMjQ4N2ZiYjEyYmNjNjVkYWJiOTNkL3RhYmxlcmFuZ2U6MTBjMzM3NjdlM2IyNDg3ZmJiMTJiY2M2NWRhYmI5M2RfMy0xLTEtMS03MDA0Mg_8d359f91-24a9-433e-a53d-9bc9730b1d87">11,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjEwYzMzNzY3ZTNiMjQ4N2ZiYjEyYmNjNjVkYWJiOTNkL3RhYmxlcmFuZ2U6MTBjMzM3NjdlM2IyNDg3ZmJiMTJiY2M2NWRhYmI5M2RfNC0xLTEtMS03MDA0Mg_45769c7f-ef83-46df-883b-4a39ce47487f">10,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjEwYzMzNzY3ZTNiMjQ4N2ZiYjEyYmNjNjVkYWJiOTNkL3RhYmxlcmFuZ2U6MTBjMzM3NjdlM2IyNDg3ZmJiMTJiY2M2NWRhYmI5M2RfNS0xLTEtMS03MDA0Mg_2e76c76e-e857-4d8a-9234-fa191924d29a">9,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjEwYzMzNzY3ZTNiMjQ4N2ZiYjEyYmNjNjVkYWJiOTNkL3RhYmxlcmFuZ2U6MTBjMzM3NjdlM2IyNDg3ZmJiMTJiY2M2NWRhYmI5M2RfNi0xLTEtMS03MDA0Mg_679138dd-18b9-4ffb-9c1e-d6f8395170d5">8,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="ameh:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjEwYzMzNzY3ZTNiMjQ4N2ZiYjEyYmNjNjVkYWJiOTNkL3RhYmxlcmFuZ2U6MTBjMzM3NjdlM2IyNDg3ZmJiMTJiY2M2NWRhYmI5M2RfNy0xLTEtMS03MDA0Mg_9a8bbd0a-3e31-4d6d-9629-22cfefcd6dca">27,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjEwYzMzNzY3ZTNiMjQ4N2ZiYjEyYmNjNjVkYWJiOTNkL3RhYmxlcmFuZ2U6MTBjMzM3NjdlM2IyNDg3ZmJiMTJiY2M2NWRhYmI5M2RfOS0xLTEtMS03MDA0Mg_b12bf2f4-9f50-4112-9755-e1e9db63342b">77,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="ameh:EquityMethodAndOtherEquityInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfOTg4NQ_e61abc74-8dcb-4127-9ad8-49d85fe6202e" continuedAt="ic4950eafbc7b4aa89574e58fc82ea682" escape="true">Investments in Other Entities</ix:nonNumeric></span></div><ix:continuation id="ic4950eafbc7b4aa89574e58fc82ea682" continuedAt="iac477b4aab9c48afa9ea3ff59a88b1f2"><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Equity Method</span></div><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:EquityMethodInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfOTg4Ng_85b30100-0e37-4be6-a1d0-8276455c8e86" continuedAt="i430deb0367e7465c803d497e04ba5e38" escape="true"><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in other entities &#8211; equity method consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:38.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.371%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.886%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allocation of Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Funding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Distribution </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LaSalle Medical Associates &#8211; IPA Line of Business</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36852b2625274d7c94f009efe3625131_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfMS0xLTEtMS03MDA0Mg_46399950-b6db-4ad2-902c-cad9b362273e">3,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefb065d83e134399924dcb98a8810645_D20220101-20220331" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfMS01LTEtMS03MDA0Mg_691a9877-6c41-43a8-b1ec-c4bed1b2285c">1,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefb065d83e134399924dcb98a8810645_D20220101-20220331" decimals="-3" name="ameh:EquityMethodInvestmentsContribution" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfMS03LTEtMS03MDA0Mg_cc31df50-9ea7-4a54-b4c0-acbf8262e139">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefb065d83e134399924dcb98a8810645_D20220101-20220331" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfMS0xMS0xLTEtNzAwNDI_1bb66c6d-581a-4c12-bb2a-f72b310af3cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20b270836e8e4edfad0aac1201a837a4_I20220331" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfMS0xMy0xLTEtNzAwNDI_169e3945-def6-431b-a857-ddb82e70d3e7">4,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pacific Medical Imaging &amp; Oncology Center, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905a801d6f9b4c9ebe17dff9567e4e65_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfMi0xLTEtMS03MDA0Mg_34d1841e-4094-471c-8168-4ed816aacc6a">1,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief0c35819b504b239cc32ffedc16b209_D20220101-20220331" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfMi01LTEtMS03MDA0Mg_650fa4af-774f-4ba2-a2ad-1204e9e426ca">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief0c35819b504b239cc32ffedc16b209_D20220101-20220331" decimals="-3" name="ameh:EquityMethodInvestmentsContribution" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfMi03LTEtMS03MDA0Mg_0f6fc774-20a6-439d-9e12-bcbbf641d2c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief0c35819b504b239cc32ffedc16b209_D20220101-20220331" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfMi0xMS0xLTEtNzAwNDI_4bec13c1-ff0d-4968-a075-831568ef7c99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4103b5415884a2cb86152b06ab31f87_I20220331" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfMi0xMy0xLTEtNzAwNDI_7c77a69f-7214-4e88-b18b-9622b237c1c1">1,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531 W. College, LLC &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98dd8ff17e4643278bde170255559ba3_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfNC0xLTEtMS03MDA0Mg_8811c218-7a25-4f59-b84d-20339be85ef5">17,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia36eb2cd63f7429d942e17270c0144bf_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfNC01LTEtMS03MDA0Mg_fb6f4c71-5f1f-4b89-81d9-5f757a10e8da">182</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia36eb2cd63f7429d942e17270c0144bf_D20220101-20220331" decimals="-3" name="ameh:EquityMethodInvestmentsContribution" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfNC03LTEtMS03MDA0Mg_596e2fff-df04-4b9d-8138-d71abd83ef3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia36eb2cd63f7429d942e17270c0144bf_D20220101-20220331" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfNC0xMS0xLTEtNzAwNDI_b7d76a67-4fe6-40cf-883a-b5e59a0a5ec9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b3e371af52a4f9ab3b9ef33b8762eb8_I20220331" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfNC0xMy0xLTEtNzAwNDI_16ff00d1-287a-4dc9-b6cd-f8be615c35dd">17,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One MSO, LLC &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75681772568f4aed9e00dafa27af9156_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfNS0xLTEtMS03MDA0Mg_e3ca8ff7-1a22-4fe6-b913-8945646ab19d">2,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79f112c0b31c40119270d0df81451392_D20220101-20220331" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfNS01LTEtMS03MDA0Mg_f8a2816d-ea71-4e4c-b36c-eaae2c8accbc">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79f112c0b31c40119270d0df81451392_D20220101-20220331" decimals="-3" name="ameh:EquityMethodInvestmentsContribution" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfNS03LTEtMS03MDA0Mg_ba6a2920-c813-4c74-97bd-f26c88d147f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79f112c0b31c40119270d0df81451392_D20220101-20220331" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfNS0xMS0xLTEtNzAwNDI_aeef9292-85d2-4b13-867c-8e11f3f7dd5e">200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe110e391f1347168555105f65ea038b_I20220331" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfNS0xMy0xLTEtNzAwNDI_234bd6bf-7a52-45f2-a55c-59456cd17d15">2,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tag-6 Medical Investment Group, LLC &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id638b192e4b34caeb8ee0fc5e44f48b5_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfNi0xLTEtMS03MDA0Mg_ebf971fe-22a6-45ce-a0b6-350a25ef0e65">4,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i418e308a689d48d4b3de11c2556a4e0f_D20220101-20220331" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfNi01LTEtMS03MDA0Mg_2c9ab481-1244-498f-9d1b-0524b3c2b9c8">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i418e308a689d48d4b3de11c2556a4e0f_D20220101-20220331" decimals="-3" name="ameh:EquityMethodInvestmentsContribution" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfNi03LTEtMS03MDA0Mg_0298c33d-e682-48d1-a1af-ec182a4720a0">1,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i418e308a689d48d4b3de11c2556a4e0f_D20220101-20220331" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfNi0xMS0xLTEtNzAwNDI_edac1a2e-c16d-4edf-97c1-c41d7eebf11a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f6b860f41b44b04be3fcc1cfe3c2c04_I20220331" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfNi0xMy0xLTEtNzAwNDI_67a3ffe6-3850-4f15-97b5-c8bae847a364">6,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAIPA MSO, LLC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6f6ea60415248a6a49fa2d020393b3d_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfOC0xLTEtMS03MDA0Mg_30b60572-3392-4690-909b-e409eac1786f">11,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7eadc502bc40c6afc071e235c3a98c_D20220101-20220331" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfOC01LTEtMS03MDA0Mg_b713dead-4743-4185-b789-303cd575aad0">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7eadc502bc40c6afc071e235c3a98c_D20220101-20220331" decimals="-3" name="ameh:EquityMethodInvestmentsContribution" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfOC03LTEtMS03MDA0Mg_17ffe6bc-7eb9-402c-9e96-d44bae2b8982">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7eadc502bc40c6afc071e235c3a98c_D20220101-20220331" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfOC0xMS0xLTEtNzAwNDI_1bd7d575-f204-4830-a938-ff5af3d13a9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83299a5c90454ecb81deb339e22e4f52_I20220331" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfOC0xMy0xLTEtNzAwNDI_f50538ed-071a-45d1-952a-f55e3e90c6e1">12,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfOS0xLTEtMS03MDA0Mg_99395733-30e2-4e16-b916-e394ef46bb19">41,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfOS01LTEtMS03MDA0Mg_468465cc-f44a-4d2e-96f7-6993beb07a45">1,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="ameh:EquityMethodInvestmentsContribution" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfOS03LTEtMS03MDA0Mg_f854bb6b-0558-4fa1-8670-d6a3715914dd">1,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfOS0xMS0xLTEtNzAwNDI_3909cc99-5294-4739-a3b7-0272147944e6">200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfOS0xMy0xLTEtNzAwNDI_743a022b-3cd8-4751-8b62-3a86edb1e72f">44,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LaSalle Medical Associates &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPA Line of Business</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMA was founded by Dr. Albert Arteaga in 1996 and operates as an IPA delivering high-quality care. In September 2021, APC-LSMA sold <ix:nonFraction unitRef="number" contextRef="i5bb2d59135f449d3b0e13fa8b28b3809_I20210930" decimals="4" name="ameh:EquityMethodInvestmentOwnershipPercentageSold" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfMTA1OA_9d237b69-2922-4b91-96ab-65b2a9635c49">21.25</ix:nonFraction>% of its interest in LMA back to Dr. Arteaga for $<ix:nonFraction unitRef="usd" contextRef="i5a35e5e78f804b03bb635d5e8df0b4c1_D20210901-20210930" decimals="-5" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfMTEwOA_b27d7444-a31f-4f5c-912a-7e34c6cb0a9d">6.4</ix:nonFraction> million, which resulted in  APC-LSMA owning a <ix:nonFraction unitRef="number" contextRef="i9ef6f6f7c71f41d68d3add3e70068bc2_I20220331" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfMTE0OQ_987884f0-dd10-4a2d-9d3c-d55b81970749">25</ix:nonFraction>% interest in LMA as of March&#160;31, 2022. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC accounts for its investment in LMA under the equity method as APC has the ability to exercise significant influence, but not control over LMA&#8217;s operations. For the three months ended March&#160;31, 2022 and 2021, APC recognized income from this investment of $<ix:nonFraction unitRef="usd" contextRef="ib1e3f77f67924bf1b0442138b0c59dba_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfMTQyMA_e801b70e-d0ac-4727-a162-6810a6666ef2">1.3</ix:nonFraction> million and a loss of $<ix:nonFraction unitRef="usd" contextRef="ic99a2a30fd9144b38c44bd4c90924f6a_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfMTQzNw_a7fb0b67-de52-4ce2-aeda-7dacf6fd0af8">0.7</ix:nonFraction> million, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $<ix:nonFraction unitRef="usd" contextRef="i20b270836e8e4edfad0aac1201a837a4_I20220331" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfMTc3Nw_9606fbb2-30e9-4b52-9682-e4c10eb63b09">4.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i36852b2625274d7c94f009efe3625131_I20211231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfMTc4NA_c00a7528-32ad-4d0b-97c2-7921272e285a">3.0</ix:nonFraction> million at March&#160;31, 2022 and December&#160;31, 2021, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="iac477b4aab9c48afa9ea3ff59a88b1f2" continuedAt="i60d2188fca184cdcab5ed675bedff5df"><ix:continuation id="i430deb0367e7465c803d497e04ba5e38"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMA&#8217;s summarized balance sheets at March&#160;31, 2022 and December&#160;31, 2021, and summarized statements of income for the three months ended March&#160;31, 2022 and 2021, with respect to its IPA line of business are as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Balance Sheets</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33512e53ca8042e592da50359233581e_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmM0ZGUyZDlmNDNmZDQ3ZmVhNTRkODAyYWU3Njk4NmI2L3RhYmxlcmFuZ2U6YzRkZTJkOWY0M2ZkNDdmZWE1NGQ4MDJhZTc2OTg2YjZfMy0xLTEtMS03MDA0Mg_3e352781-f0d3-443a-9b12-18a126243def">10,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id918b0f4941f497f8df9f3953fdf4349_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmM0ZGUyZDlmNDNmZDQ3ZmVhNTRkODAyYWU3Njk4NmI2L3RhYmxlcmFuZ2U6YzRkZTJkOWY0M2ZkNDdmZWE1NGQ4MDJhZTc2OTg2YjZfMy0zLTEtMS03MDA0Mg_19141062-7738-4f90-9f4b-b6d7a1533f12">6,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33512e53ca8042e592da50359233581e_I20220331" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmM0ZGUyZDlmNDNmZDQ3ZmVhNTRkODAyYWU3Njk4NmI2L3RhYmxlcmFuZ2U6YzRkZTJkOWY0M2ZkNDdmZWE1NGQ4MDJhZTc2OTg2YjZfNC0xLTEtMS03MDA0Mg_fe9dd453-0844-4b47-bc2b-9b848e158286">698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id918b0f4941f497f8df9f3953fdf4349_I20211231" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmM0ZGUyZDlmNDNmZDQ3ZmVhNTRkODAyYWU3Njk4NmI2L3RhYmxlcmFuZ2U6YzRkZTJkOWY0M2ZkNDdmZWE1NGQ4MDJhZTc2OTg2YjZfNC0zLTEtMS03MDA0Mg_d25fa41e-707c-43be-a87a-34f9dad2a815">696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33512e53ca8042e592da50359233581e_I20220331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmM0ZGUyZDlmNDNmZDQ3ZmVhNTRkODAyYWU3Njk4NmI2L3RhYmxlcmFuZ2U6YzRkZTJkOWY0M2ZkNDdmZWE1NGQ4MDJhZTc2OTg2YjZfNS0xLTEtMS03MDA0Mg_d500f209-7706-4e23-8213-af82992efcd6">6,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id918b0f4941f497f8df9f3953fdf4349_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmM0ZGUyZDlmNDNmZDQ3ZmVhNTRkODAyYWU3Njk4NmI2L3RhYmxlcmFuZ2U6YzRkZTJkOWY0M2ZkNDdmZWE1NGQ4MDJhZTc2OTg2YjZfNS0zLTEtMS03MDA0Mg_90069473-4e0f-4025-95b5-728997667976">2,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loan receivable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33512e53ca8042e592da50359233581e_I20220331" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmM0ZGUyZDlmNDNmZDQ3ZmVhNTRkODAyYWU3Njk4NmI2L3RhYmxlcmFuZ2U6YzRkZTJkOWY0M2ZkNDdmZWE1NGQ4MDJhZTc2OTg2YjZfNy0xLTEtMS03MDA0Mg_457290b2-cd4d-43d5-a2ee-676669c65dff">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id918b0f4941f497f8df9f3953fdf4349_I20211231" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmM0ZGUyZDlmNDNmZDQ3ZmVhNTRkODAyYWU3Njk4NmI2L3RhYmxlcmFuZ2U6YzRkZTJkOWY0M2ZkNDdmZWE1NGQ4MDJhZTc2OTg2YjZfNy0zLTEtMS03MDA0Mg_f4af708f-4336-4b75-8f58-4837c636001f">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33512e53ca8042e592da50359233581e_I20220331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmM0ZGUyZDlmNDNmZDQ3ZmVhNTRkODAyYWU3Njk4NmI2L3RhYmxlcmFuZ2U6YzRkZTJkOWY0M2ZkNDdmZWE1NGQ4MDJhZTc2OTg2YjZfOS0xLTEtMS03MDA0Mg_65e7d7c8-0c4a-45c7-ae63-aa0aa1688faa">19,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id918b0f4941f497f8df9f3953fdf4349_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmM0ZGUyZDlmNDNmZDQ3ZmVhNTRkODAyYWU3Njk4NmI2L3RhYmxlcmFuZ2U6YzRkZTJkOWY0M2ZkNDdmZWE1NGQ4MDJhZTc2OTg2YjZfOS0zLTEtMS03MDA0Mg_725e912b-a260-4cb0-9e0d-814e953b790c">11,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liabilities and Stockholders&#8217; Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33512e53ca8042e592da50359233581e_I20220331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmM0ZGUyZDlmNDNmZDQ3ZmVhNTRkODAyYWU3Njk4NmI2L3RhYmxlcmFuZ2U6YzRkZTJkOWY0M2ZkNDdmZWE1NGQ4MDJhZTc2OTg2YjZfMTItMS0xLTEtNzAwNDI_889dd43d-4d2a-4dfa-b9fe-aa8977a60ac6">34,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id918b0f4941f497f8df9f3953fdf4349_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmM0ZGUyZDlmNDNmZDQ3ZmVhNTRkODAyYWU3Njk4NmI2L3RhYmxlcmFuZ2U6YzRkZTJkOWY0M2ZkNDdmZWE1NGQ4MDJhZTc2OTg2YjZfMTItMy0xLTEtNzAwNDI_665ac90a-e320-4919-9484-7c93daeedd39">32,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; deficit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33512e53ca8042e592da50359233581e_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmM0ZGUyZDlmNDNmZDQ3ZmVhNTRkODAyYWU3Njk4NmI2L3RhYmxlcmFuZ2U6YzRkZTJkOWY0M2ZkNDdmZWE1NGQ4MDJhZTc2OTg2YjZfMTMtMS0xLTEtNzAwNDI_4ba1331d-7a9a-4175-bf05-28080ad25890">14,790</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id918b0f4941f497f8df9f3953fdf4349_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmM0ZGUyZDlmNDNmZDQ3ZmVhNTRkODAyYWU3Njk4NmI2L3RhYmxlcmFuZ2U6YzRkZTJkOWY0M2ZkNDdmZWE1NGQ4MDJhZTc2OTg2YjZfMTMtMy0xLTEtNzAwNDI_d1e604d6-4ca9-4c47-99f4-8b8646c9fb6c">20,571</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; deficit</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33512e53ca8042e592da50359233581e_I20220331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmM0ZGUyZDlmNDNmZDQ3ZmVhNTRkODAyYWU3Njk4NmI2L3RhYmxlcmFuZ2U6YzRkZTJkOWY0M2ZkNDdmZWE1NGQ4MDJhZTc2OTg2YjZfMTUtMS0xLTEtNzAwNDI_4cfd90ea-8963-4142-8610-4ebb0d52f307">19,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id918b0f4941f497f8df9f3953fdf4349_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmM0ZGUyZDlmNDNmZDQ3ZmVhNTRkODAyYWU3Njk4NmI2L3RhYmxlcmFuZ2U6YzRkZTJkOWY0M2ZkNDdmZWE1NGQ4MDJhZTc2OTg2YjZfMTUtMy0xLTEtNzAwNDI_520a81e8-d068-4d65-acf1-d57ae0bc12b5">11,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Statements of Operations</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i224451997ac146958e193c349e0fb137_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmU3MDk3YTIxY2RiYjRlZDg4MjgwYWVlZjQwM2RhYmVjL3RhYmxlcmFuZ2U6ZTcwOTdhMjFjZGJiNGVkODgyODBhZWVmNDAzZGFiZWNfMy0xLTEtMS03MDA0Mg_cd043e29-09c9-4bbc-a019-ac9877235977">67,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66228b4952d348d9bb6a6f5bd4664a45_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmU3MDk3YTIxY2RiYjRlZDg4MjgwYWVlZjQwM2RhYmVjL3RhYmxlcmFuZ2U6ZTcwOTdhMjFjZGJiNGVkODgyODBhZWVmNDAzZGFiZWNfMy0zLTEtMS03MDA0Mg_06c678ee-4ea5-4653-b6b1-fc728bad51ae">47,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i224451997ac146958e193c349e0fb137_D20220101-20220331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmU3MDk3YTIxY2RiYjRlZDg4MjgwYWVlZjQwM2RhYmVjL3RhYmxlcmFuZ2U6ZTcwOTdhMjFjZGJiNGVkODgyODBhZWVmNDAzZGFiZWNfNC0xLTEtMS03MDA0Mg_ed1cd8be-6199-43d1-ae2d-2a32223c7fa1">61,786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66228b4952d348d9bb6a6f5bd4664a45_D20210101-20210331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmU3MDk3YTIxY2RiYjRlZDg4MjgwYWVlZjQwM2RhYmVjL3RhYmxlcmFuZ2U6ZTcwOTdhMjFjZGJiNGVkODgyODBhZWVmNDAzZGFiZWNfNC0zLTEtMS03MDA0Mg_b854b5ae-915b-41da-b1b8-b751c2379b24">48,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i224451997ac146958e193c349e0fb137_D20220101-20220331" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmU3MDk3YTIxY2RiYjRlZDg4MjgwYWVlZjQwM2RhYmVjL3RhYmxlcmFuZ2U6ZTcwOTdhMjFjZGJiNGVkODgyODBhZWVmNDAzZGFiZWNfNi0xLTEtMS03MDA0Mg_86816da7-6ee6-45b9-b8ff-f2a995e073d6">5,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66228b4952d348d9bb6a6f5bd4664a45_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmU3MDk3YTIxY2RiYjRlZDg4MjgwYWVlZjQwM2RhYmVjL3RhYmxlcmFuZ2U6ZTcwOTdhMjFjZGJiNGVkODgyODBhZWVmNDAzZGFiZWNfNi0zLTEtMS03MDA0Mg_719d1638-4d5f-4d9f-bc20-f2e717e24057">1,552</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><br/>Pacific Medical Imaging and Oncology Center, Inc.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC-LSMA and PMIOC entered into a share purchase agreement whereby APC-LSMA purchased a <ix:nonFraction unitRef="number" contextRef="i2a5eaf12f18d437286bc9774e4ff6a25_I20150731" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfMjUyMw_877450d2-03df-4f09-8bc0-7630ee89e700">40</ix:nonFraction>% ownership interest in PMIOC. Incorporated in California in 2004, PMIOC provides comprehensive diagnostic imaging services using state-of-the-art technology. PMIOC offers high-quality diagnostic services, such as MRI/MRA, PET/CT, CT, nuclear medicine, ultrasound, digital x-rays, bone densitometry, and digital mammography, at its facilities.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC and PMIOC have an Ancillary Service Contract together whereby PMIOC provides covered services on behalf of APC to enrollees of the plans of APC. Under the Ancillary Service Contract, APC paid PMIOC fees of approximately $<ix:nonFraction unitRef="usd" contextRef="ibb7c2acfad5f4d90804dbceb6ca499a1_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsForFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfMjc4MA_68b0cd74-ce0f-419f-97be-d8a8a4735d5f">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia67e2b3c33844eafa88eaa05867d7330_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsForFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfMjc4Nw_c78ef23b-d779-4c32-85e3-701d02354bc1">0.5</ix:nonFraction> million, for the three months ended March&#160;31, 2022 and 2021, respectively. APC accounts for its investment in PMIOC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over PMIOC&#8217;s operations. For the three months ended March&#160;31, 2022 and 2021, APC recognized income from this investment of approximately $<ix:nonFraction unitRef="usd" contextRef="if29bacb1956147fd920ad140828ddf9f_D20220101-20220331" decimals="-2" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfMzE5OA_a9961f0b-aa12-4712-b919-e9bf1b875f82">6,700</ix:nonFraction> and a loss from this investment of $<ix:nonFraction unitRef="usd" contextRef="ie3512656649a4da789290c7c1a39c58e_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfMzIzNg_dfd6684e-9e0d-43d6-8e37-d46c9bb5df9a">15,000</ix:nonFraction>, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets had investment balances of $<ix:nonFraction unitRef="usd" contextRef="ie338e6a85a00449c8cb3d0ff9d028af5_I20220331" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfMzUyOQ_417cb309-f953-4f15-aa26-2419cc8b9e86">1.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id4e2dedbf7694c72b5426585e1f6319e_I20211231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfMzUzNg_b79023aa-dc29-4d73-9c07-f85b2870b154">1.7</ix:nonFraction> million at March&#160;31, 2022 and December&#160;31, 2021, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i60d2188fca184cdcab5ed675bedff5df"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">531 W. College LLC &#8211; Related Party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC has a <ix:nonFraction unitRef="number" contextRef="ibf6b4576ffe04e9896a15272126c5839_I20220331" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfNTI2MA_382c11d0-34c5-445e-9a56-265291e46c0d">50</ix:nonFraction>% ownership in 531 W. College LLC and accounts for its investment in 531 W. College, LLC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over the operations of this joint venture. 531 W. College, LLC owns a former hospital campus in Los Angeles that is now leased to tenants.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2022 and 2021, APC recognized a loss from this investment of $<ix:nonFraction unitRef="usd" contextRef="i6178c9a34de84a89865b60e90b6cf17e_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfNTY0MA_84bfe9d6-c31e-4b75-9502-9d128bceced5">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if344fb7586ce4a30a4cbc6d36795b630_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfNTY0Nw_bb13589d-b170-4d9f-8bd1-ad76d9f77ae4">0.1</ix:nonFraction> million, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $<ix:nonFraction unitRef="usd" contextRef="i6b3e371af52a4f9ab3b9ef33b8762eb8_I20220331" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfNTk3NA_5bd1aa0f-4832-49c7-9782-285457e5a287">17.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i98dd8ff17e4643278bde170255559ba3_I20211231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfNTk4MQ_6ad31f9e-54b9-44fd-8b5b-6665c2377475">17.2</ix:nonFraction> million at March&#160;31, 2022 and December&#160;31, 2021, respectively. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">One MSO, LLC </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Related Party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC has a <ix:nonFraction unitRef="number" contextRef="i77422bd33cbc45a1aa372bb8875076a8_I20220331" decimals="INF" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfMzI5ODUzNDkwNDMzMg_5446e61c-b344-498c-9b3b-5c8d6762208c">50</ix:nonFraction>% interest in One MSO. One MSO owns an office building in Monterey Park, California that is leased to tenants, including NMM. For the three months ended March&#160;31, 2022 and 2021, APC recognized income of $<ix:nonFraction unitRef="usd" contextRef="i79f112c0b31c40119270d0df81451392_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfNjUzMQ_85822e3c-2a3f-4e01-b190-c870cdbc1c72">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if8ed7dfc5ec64dbf909fb3b011b41b8e_D20210101-20210331" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfNDM5ODA0NjUyMzQ3Ng_b4776b47-b968-4dfe-99f2-d25cd14a4e72">0.1</ix:nonFraction>&#160;million in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $<ix:nonFraction unitRef="usd" contextRef="ibe110e391f1347168555105f65ea038b_I20220331" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfNjgwMA_9c330c39-4f78-4fd7-a88d-21803d99532c">2.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i75681772568f4aed9e00dafa27af9156_I20211231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfNDM5ODA0NjUyNzc2NQ_bd87ea04-9caf-471e-9aa3-1b148cf6cf4c">2.9</ix:nonFraction>&#160;million at March&#160;31, 2022 and December&#160;31, 2021, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tag-6 Medical Investment Group, LLC  &#8212; Related Party</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC has a <ix:nonFraction unitRef="number" contextRef="i48cf45716cee43579c307972d6f19091_I20220331" decimals="INF" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfMjc0ODc3OTA5MDQzOA_01e3ff79-45a3-421e-a5ab-c479447e5b06">50</ix:nonFraction>% interest in Tag 6. Tag 6 leases its building to tenants and shares common ownership with certain board members of APC and as such is considered a related party. For the three months ended March&#160;31, 2022, APC recognized income of $<ix:nonFraction unitRef="usd" contextRef="i168c9d857e684999a379e78e91b03f10_D20220101-20220331" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfNzQ3NA_b7c23670-24b4-4e00-975b-b2633e84509c">66,000</ix:nonFraction> in the accompanying consolidated statements of income. APC did <ix:nonFraction unitRef="usd" contextRef="i127fc1bd4bad4c958f81e1514ab97618_D20210101-20210331" decimals="INF" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfMjc0ODc3OTA5MDM4MQ_8b3ab638-8325-42cd-af80-499158dc97d2">no</ix:nonFraction>t recognize any income during the three months ended March&#160;31, 2021.  The accompanying consolidated balance sheets include the Tag 6 investment of $<ix:nonFraction unitRef="usd" contextRef="ib5916967379848d7af484250dae5a588_I20220331" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfNzYzNQ_8a58ca48-ee86-4696-b463-64584f55b373">6.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iea22839056f1415e802909f3740eb6f7_I20211231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfNDM5ODA0NjUyNDM1Nw_2ea8515e-2ce8-4d0c-88ad-a452f1eb819e">4.8</ix:nonFraction>&#160;million at March&#160;31, 2022 and December&#160;31, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CAIPA MSO, LLC</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, ApolloMed purchased <ix:nonFraction unitRef="number" contextRef="ic3691558e51545d9b1a33f630ec3101d_I20210831" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfNzcyNg_f6661cb5-7d04-42e0-a7f9-98375f9ecdbd">30</ix:nonFraction>% interests in CAIPA MSO, LLC for $<ix:nonFraction unitRef="usd" contextRef="ib9fc9a6b261b43fa800eedc49ae6e150_I20210831" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfNzc2MQ_814b0b1f-b236-43fa-91b9-5c1634e09d88">11.7</ix:nonFraction> million. CAIPA MSO is a New York-based management services organization affiliated with Chinese-American IPA d/b/a Coalition of Asian-American IPA (&#8220;CAIPA&#8221;), a leading independent practice association serving the greater New York City area. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ApolloMed accounts for its investment in CAIPA MSO under the equity method of accounting as ApolloMed has the ability to exercise significant influence, but not control over CAIPA MSO&#8217;s operations. For the three months ended March&#160;31, 2022 and 2021, ApolloMed recognized income from investment of $<ix:nonFraction unitRef="usd" contextRef="i6e7eadc502bc40c6afc071e235c3a98c_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfODI3OQ_5e252a1d-a793-4a6e-a928-6c445d9946f0">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idf10dc5a3be94d50a589bf004e41c88f_D20210101-20210331" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfNDM5ODA0NjUyNDM4Ng_47b91665-8f81-41cb-bb86-11958b9808e1">0</ix:nonFraction>, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $<ix:nonFraction unitRef="usd" contextRef="i83299a5c90454ecb81deb339e22e4f52_I20220331" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfODQzMA_ff8d8ae2-c94a-47cc-b2ba-4214100350c6">12.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie6f6ea60415248a6a49fa2d020393b3d_I20211231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfNDM5ODA0NjUyNDQxMA_9b9114eb-d282-4279-b67d-b5d00b008b46">12.0</ix:nonFraction>&#160;million as of March&#160;31, 2022 and December&#160;31, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in privately held entities that do not report net asset value</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MediPortal, LLC</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, APC purchased <ix:nonFraction unitRef="shares" contextRef="ief73fee5943140169a860306e97c01dd_I20180531" decimals="INF" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfODU2MQ_f599f8df-945e-4f97-8e6c-0f17c18644d0">270,000</ix:nonFraction> membership interests of MediPortal LLC, a New York limited liability company, for $<ix:nonFraction unitRef="usd" contextRef="i0a260d4203424cdc969b85797dd116c6_D20180501-20180531" decimals="-5" name="ameh:PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfODY0Ng_bc2e903e-3514-4e5b-b165-fd24f2f7c41f">0.4</ix:nonFraction> million or $<ix:nonFraction unitRef="usdPerShare" contextRef="ief73fee5943140169a860306e97c01dd_I20180531" decimals="INF" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfODY1Mg_90f57263-6dcc-430e-a1cc-63860315dd11">1.50</ix:nonFraction> per membership interest, which represented an approximately <ix:nonFraction unitRef="number" contextRef="ief73fee5943140169a860306e97c01dd_I20180531" decimals="3" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfODcxNQ_595dfa48-8634-4704-ad8f-6262c47fe2a5">2.8</ix:nonFraction>% ownership interest. In connection with the initial purchase, APC received a <ix:nonNumeric contextRef="ief73fee5943140169a860306e97c01dd_I20180531" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfOTg5Nw_10019720-ab3a-4906-afdd-a64e62c4d304">five-year</ix:nonNumeric> warrant to purchase an additional <ix:nonFraction unitRef="shares" contextRef="ief73fee5943140169a860306e97c01dd_I20180531" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfODgzNg_22077f60-5caa-462c-b632-630daefe7f41">270,000</ix:nonFraction> membership interests. A <ix:nonNumeric contextRef="i0a260d4203424cdc969b85797dd116c6_D20180501-20180531" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfOTg5Mg_a77de134-ac7e-4a8a-afde-ebc23886678b">five-year</ix:nonNumeric> option to purchase an additional <ix:nonFraction unitRef="shares" contextRef="i0a260d4203424cdc969b85797dd116c6_D20180501-20180531" decimals="INF" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfODkwNA_2fcda45f-b3d2-4431-8bcb-a19e58d022c5">380,000</ix:nonFraction> membership interests and a <ix:nonNumeric contextRef="ief73fee5943140169a860306e97c01dd_I20180531" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfOTg4OA_d061885f-a659-4ee3-b0bc-5d2adf389c35">five-year</ix:nonNumeric> warrant to purchase <ix:nonFraction unitRef="shares" contextRef="ief73fee5943140169a860306e97c01dd_I20180531" decimals="INF" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfODk2Mg_2aa94333-9942-4ca0-a8f6-ad0b9fdcf1af">480,000</ix:nonFraction> membership interests were contingent upon the portal completion date. However, APC did not exercise the option after completion of the portal. As APC does not have the ability to exercise significant influence, and lacks control over the investee, this investment is accounted for using a measurement alternative, which allows the investment to be measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AchievaMed</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, NMM and AchievaMed, Inc., a California corporation (&#8220;AchievaMed&#8221;), entered into an agreement in which NMM would purchase <ix:nonFraction unitRef="number" contextRef="i1d2082812210428bb7329995875a8388_I20190731" decimals="2" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfOTU3Mg_2f90a111-1a8b-43e7-bcd1-f53f95da08f7">50</ix:nonFraction>% of the aggregate shares of capital stock of AchievaMed over a period of time not to exceed <ix:nonNumeric contextRef="i519cba15a31640d3bead178989c651a5_D20190701-20190731" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfOTY2Ng_f62562af-e6c2-4579-b59f-7d80fcd7caad">five years</ix:nonNumeric>. As a result of this transaction NMM invested $<ix:nonFraction unitRef="usd" contextRef="i1d2082812210428bb7329995875a8388_I20190731" decimals="-5" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfOTcxNQ_a711c9d9-8c2d-45c0-a577-00f729860038">0.5</ix:nonFraction> million for a <ix:nonFraction unitRef="number" contextRef="i1d2082812210428bb7329995875a8388_I20190731" decimals="2" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfOTcyNA_d70b2056-bdfa-4c1a-b9f4-227725dfc405">10</ix:nonFraction>% interest. The related investment balance of $<ix:nonFraction unitRef="usd" contextRef="i6f1f415161e146c9982274d3873b0801_I20220331" decimals="-5" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfOTc3MQ_d199a030-24d0-4454-bf41-7e7e24b69a45">0.5</ix:nonFraction> million is included in investments in privately held entities in the accompanying consolidated balance sheets as of March&#160;31, 2022.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="ameh:LoanReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82Ny9mcmFnOmFmMTJmMzYxZDIwZDQ2MGNhZTA1NWZkNmNiODc1NmNiL3RleHRyZWdpb246YWYxMmYzNjFkMjBkNDYwY2FlMDU1ZmQ2Y2I4NzU2Y2JfMTI1Mg_94966f37-b895-4e9c-b6bd-9298ec4879dc" continuedAt="i83a6838d2a5a49cbbdd22d516e4a78f5" escape="true">Loan Receivable and Loan Receivable &#8211; Related Parties</ix:nonNumeric></span></div><ix:continuation id="i83a6838d2a5a49cbbdd22d516e4a78f5"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loan receivable</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pacific6</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, NMM received a promissory note from Pacific6 totaling $<ix:nonFraction unitRef="usd" contextRef="i23ad757dae0649c281c2c43b079538ea_I20201031" decimals="-5" name="us-gaap:NotesReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82Ny9mcmFnOmFmMTJmMzYxZDIwZDQ2MGNhZTA1NWZkNmNiODc1NmNiL3RleHRyZWdpb246YWYxMmYzNjFkMjBkNDYwY2FlMDU1ZmQ2Y2I4NzU2Y2JfMTU5_e7a8d70f-8872-4cc5-bfae-0aa80b832a91">0.5</ix:nonFraction>&#160;million as a result of the sale of the Company&#8217;s interest in MWN. Interest accrues at a rate of <ix:nonFraction unitRef="number" contextRef="i23ad757dae0649c281c2c43b079538ea_I20201031" decimals="2" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82Ny9mcmFnOmFmMTJmMzYxZDIwZDQ2MGNhZTA1NWZkNmNiODc1NmNiL3RleHRyZWdpb246YWYxMmYzNjFkMjBkNDYwY2FlMDU1ZmQ2Y2I4NzU2Y2JfMjUw_4f2110e2-371c-4e60-9521-d2c1dea95f79">5</ix:nonFraction>% per annum and is payable monthly through the maturity date of December 1, 2023.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loan receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> related party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AHMC</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, APC entered into a promissory note with AHMC (the &#8220;AHMC Note&#8221;) for a principal amount of $<ix:nonFraction unitRef="usd" contextRef="i83913ad0855f49819cfa7c93494153e4_I20201031" decimals="-5" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82Ny9mcmFnOmFmMTJmMzYxZDIwZDQ2MGNhZTA1NWZkNmNiODc1NmNiL3RleHRyZWdpb246YWYxMmYzNjFkMjBkNDYwY2FlMDU1ZmQ2Y2I4NzU2Y2JfNDc4_b23dc8a8-68ef-4c1e-ade5-4cf701c32fee">4.0</ix:nonFraction>&#160;million with a maturity date of April 2022. The contractual interest rate on the AHMC Note is <ix:nonFraction unitRef="number" contextRef="i83913ad0855f49819cfa7c93494153e4_I20201031" decimals="INF" name="ameh:FinanceReceivableInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82Ny9mcmFnOmFmMTJmMzYxZDIwZDQ2MGNhZTA1NWZkNmNiODc1NmNiL3RleHRyZWdpb246YWYxMmYzNjFkMjBkNDYwY2FlMDU1ZmQ2Y2I4NzU2Y2JfNTY3_e6781828-d499-4645-9c1d-e0ab7b54b702">3.75</ix:nonFraction>% per annum. The AHMC Note was entered into using cash strictly related to the Excluded Assets that were generated from the series of transactions with AP-AMH. As of March&#160;31, 2022, the total principal of $<ix:nonFraction unitRef="usd" contextRef="i26c2e65389c446feb05b2d425a1f08c3_I20220331" decimals="-5" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82Ny9mcmFnOmFmMTJmMzYxZDIwZDQ2MGNhZTA1NWZkNmNiODc1NmNiL3RleHRyZWdpb246YWYxMmYzNjFkMjBkNDYwY2FlMDU1ZmQ2Y2I4NzU2Y2JfNzYx_add9215b-98b8-42c9-92a4-f3b1bc8b1464">4.0</ix:nonFraction>&#160;million remains outstanding. One of the Company&#8217;s board members is an officer of AHMC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the outstanding loan receivable under the CECL model by assessing the party&#8217;s ability to pay by reviewing their interest payment history quarterly, financial history annually, and reassessing any insolvency risk that is identified. If a failure to pay occurs, the Company assesses the terms of the notes and estimates an expected credit loss based on the remittance schedule of the note.</span></div></ix:continuation><div id="i3cbe033f261a4f1ea6a0c939c6847530_73"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RleHRyZWdpb246N2VkZGE3ZmIxMGQ0NDRiY2FkNDhkODI5MDM5MzNmZGZfMTQy_03c21ad3-e585-4900-9c5f-6b7cbeab91b0" continuedAt="ic3c9808f861e48f0883dc16daad317e5" escape="true">Accounts Payable and Accrued Expenses</ix:nonNumeric></span></div><ix:continuation id="ic3c9808f861e48f0883dc16daad317e5"><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RleHRyZWdpb246N2VkZGE3ZmIxMGQ0NDRiY2FkNDhkODI5MDM5MzNmZGZfMTQ1_d56e38d6-5de9-4b2d-b5ea-79fb82bcda81" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts payable and accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.329%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RhYmxlOjRhZTI3OWMxZmM0ZTRmM2NiNWJlMDMzNDY1MzEyMDI5L3RhYmxlcmFuZ2U6NGFlMjc5YzFmYzRlNGYzY2I1YmUwMzM0NjUzMTIwMjlfMS0xLTEtMS03MDA0Mg_9082eb41-6434-4488-b760-22eaa3c26d69">9,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RhYmxlOjRhZTI3OWMxZmM0ZTRmM2NiNWJlMDMzNDY1MzEyMDI5L3RhYmxlcmFuZ2U6NGFlMjc5YzFmYzRlNGYzY2I1YmUwMzM0NjUzMTIwMjlfMS0zLTEtMS03MDA0Mg_d8577e2b-0bc4-4596-a55a-fc84cdf88136">9,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="ameh:SpecialtyCapitationPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RhYmxlOjRhZTI3OWMxZmM0ZTRmM2NiNWJlMDMzNDY1MzEyMDI5L3RhYmxlcmFuZ2U6NGFlMjc5YzFmYzRlNGYzY2I1YmUwMzM0NjUzMTIwMjlfMi0xLTEtMS03MDA0Mg_c7a03e14-2010-4e89-b880-9bfed22cab6b">3,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="ameh:SpecialtyCapitationPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RhYmxlOjRhZTI3OWMxZmM0ZTRmM2NiNWJlMDMzNDY1MzEyMDI5L3RhYmxlcmFuZ2U6NGFlMjc5YzFmYzRlNGYzY2I1YmUwMzM0NjUzMTIwMjlfMi0zLTEtMS03MDA0Mg_6fd3badf-6770-463d-9b3d-cd2c6d57c7a2">2,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subcontractor IPA payable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="ameh:SubcontractorIPAPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RhYmxlOjRhZTI3OWMxZmM0ZTRmM2NiNWJlMDMzNDY1MzEyMDI5L3RhYmxlcmFuZ2U6NGFlMjc5YzFmYzRlNGYzY2I1YmUwMzM0NjUzMTIwMjlfMy0xLTEtMS03MDA0Mg_2f9b4fb7-5b21-4579-bba2-1a0b09ede841">1,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="ameh:SubcontractorIPAPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RhYmxlOjRhZTI3OWMxZmM0ZTRmM2NiNWJlMDMzNDY1MzEyMDI5L3RhYmxlcmFuZ2U6NGFlMjc5YzFmYzRlNGYzY2I1YmUwMzM0NjUzMTIwMjlfMy0zLTEtMS03MDA0Mg_b0079efc-9cff-4646-b4bb-c0d264b02077">1,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RhYmxlOjRhZTI3OWMxZmM0ZTRmM2NiNWJlMDMzNDY1MzEyMDI5L3RhYmxlcmFuZ2U6NGFlMjc5YzFmYzRlNGYzY2I1YmUwMzM0NjUzMTIwMjlfNC0xLTEtMS03MDA0Mg_502060c1-e267-4feb-8b2e-3fe75dfd5771">900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RhYmxlOjRhZTI3OWMxZmM0ZTRmM2NiNWJlMDMzNDY1MzEyMDI5L3RhYmxlcmFuZ2U6NGFlMjc5YzFmYzRlNGYzY2I1YmUwMzM0NjUzMTIwMjlfNC0zLTEtMS03MDA0Mg_2df2cd3d-93c1-4942-b0dc-32df89123dbf">878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to related parties</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RhYmxlOjRhZTI3OWMxZmM0ZTRmM2NiNWJlMDMzNDY1MzEyMDI5L3RhYmxlcmFuZ2U6NGFlMjc5YzFmYzRlNGYzY2I1YmUwMzM0NjUzMTIwMjlfNS0xLTEtMS03MDA0Mg_cf6df7d8-33a4-4c63-941a-f14c55f925ca">2,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RhYmxlOjRhZTI3OWMxZmM0ZTRmM2NiNWJlMDMzNDY1MzEyMDI5L3RhYmxlcmFuZ2U6NGFlMjc5YzFmYzRlNGYzY2I1YmUwMzM0NjUzMTIwMjlfNS0zLTEtMS03MDA0Mg_3e9ff0f9-6505-4ebc-a3f0-f8aaeb0feb5c">2,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RhYmxlOjRhZTI3OWMxZmM0ZTRmM2NiNWJlMDMzNDY1MzEyMDI5L3RhYmxlcmFuZ2U6NGFlMjc5YzFmYzRlNGYzY2I1YmUwMzM0NjUzMTIwMjlfNi0xLTEtMS03MDA0Mg_61c9b61f-4a2f-4d95-8171-851ac2fc83c2">20,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RhYmxlOjRhZTI3OWMxZmM0ZTRmM2NiNWJlMDMzNDY1MzEyMDI5L3RhYmxlcmFuZ2U6NGFlMjc5YzFmYzRlNGYzY2I1YmUwMzM0NjUzMTIwMjlfNi0zLTEtMS03MDA0Mg_b565049e-7827-4c14-ae83-d04971d86715">16,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RhYmxlOjRhZTI3OWMxZmM0ZTRmM2NiNWJlMDMzNDY1MzEyMDI5L3RhYmxlcmFuZ2U6NGFlMjc5YzFmYzRlNGYzY2I1YmUwMzM0NjUzMTIwMjlfNy0xLTEtMS03MDA0Mg_c660ca6d-fe8e-4507-abe8-bc0cda222de5">9,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RhYmxlOjRhZTI3OWMxZmM0ZTRmM2NiNWJlMDMzNDY1MzEyMDI5L3RhYmxlcmFuZ2U6NGFlMjc5YzFmYzRlNGYzY2I1YmUwMzM0NjUzMTIwMjlfNy0zLTEtMS03MDA0Mg_7b0299db-7177-4664-aaf2-17bfd8364c60">10,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RhYmxlOjRhZTI3OWMxZmM0ZTRmM2NiNWJlMDMzNDY1MzEyMDI5L3RhYmxlcmFuZ2U6NGFlMjc5YzFmYzRlNGYzY2I1YmUwMzM0NjUzMTIwMjlfOC0xLTEtMS03MDA0Mg_1539671e-5d62-4f4d-80fc-679aef7607e8">48,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RhYmxlOjRhZTI3OWMxZmM0ZTRmM2NiNWJlMDMzNDY1MzEyMDI5L3RhYmxlcmFuZ2U6NGFlMjc5YzFmYzRlNGYzY2I1YmUwMzM0NjUzMTIwMjlfOC0zLTEtMS03MDA0Mg_332f9a64-e7a6-4b79-a9c0-b91c57b3ef39">43,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i3cbe033f261a4f1ea6a0c939c6847530_76"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RleHRyZWdpb246NzFiNzZiZTM2MzU3NDhhMjlkOTkyZTNhMjgxNDU0NDRfMTA3_803e2211-e6d2-4d37-9c32-47fadd7abf15" continuedAt="i19b06c373df1440794aa4ef1468e4b8f" escape="true">Medical Liabilities</ix:nonNumeric></span></div><ix:continuation id="i19b06c373df1440794aa4ef1468e4b8f"><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RleHRyZWdpb246NzFiNzZiZTM2MzU3NDhhMjlkOTkyZTNhMjgxNDU0NDRfMTEx_4fed20c2-c8d7-4df8-83a9-41595d6b9a0e" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s medical liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfMS0xLTEtMS03MDA0Mg_a945e817-6939-40bd-8bdf-811ca79d0db8">55,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib537036edf0744c69646e8a9929a0638_I20201231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfMS0zLTEtMS03MDA0Mg_c66fc493-791e-4f33-8688-39939b2b0073">50,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfNS0xLTEtMS03MDA0Mg_af17daf1-4d1f-4292-9d48-e7959b731201">153,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfNS0zLTEtMS03MDA0Mg_a87d334b-5b73-4fbc-8714-6c07e445d5a8">83,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfNi0xLTEtMS03MDA0Mg_6d05f243-bf4c-4a3f-82e4-27173c55f504">175</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfNi0zLTEtMS03MDA0Mg_d570a285-9fe8-427f-8ad7-9a373da64350">2,018</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfNy0xLTEtMS03MDA0Mg_29bd4027-8059-422d-80b0-e0135d785319">153,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfNy0zLTEtMS03MDA0Mg_1cb1aaeb-d2dd-40d7-b2f9-b608717e4b35">81,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfOS0xLTEtMS03MDA0Mg_9602af03-7680-442d-b797-655876c1ee81">70,120</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfOS0zLTEtMS03MDA0Mg_9dbd07d9-a3c0-445c-b305-5336773fa012">41,713</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfMTAtMS0xLTEtNzAwNDI_7465df9d-86ce-4e52-8ac8-1a11e74ce159">44,035</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfMTAtMy0xLTEtNzAwNDI_4aedb6a6-09e9-4262-983a-1730b63b9306">39,344</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfMTEtMS0xLTEtNzAwNDI_e4b62b51-0700-4436-aa42-f877625c976a">114,155</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfMTEtMy0xLTEtNzAwNDI_0021335c-f95f-4fe0-bcbe-c2dd8dfd25e8">81,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfMTItMS0xLTEtNzAwNDI_2ccb0df8-27df-4825-8145-29d245f8a484">770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfMTItMy0xLTEtNzAwNDI_9f7dbcee-7cd8-49df-a4db-f96ebd96d636">895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfMTQtMS0xLTEtNzAwNDI_85ed9510-32d9-484b-a870-9787279a4234">95,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5144afd8082f4f17afadb8908f6b4051_I20210331" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfMTQtMy0xLTEtNzAwNDI_3561c904-5ca1-4bd0-bce9-1e3fa0a3849f">51,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfMTI0NzE_6c44c364-d8ff-4565-9e2d-d0dd03777645" continuedAt="i87eec43ca72d4e46afab70b4546317ec" escape="true">Credit Facility, Bank Loans, and Lines of Credit</ix:nonNumeric></span></div><ix:continuation id="i87eec43ca72d4e46afab70b4546317ec" continuedAt="ia9b0ea5a02464c86bcde818251a3e2da"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility</span></div><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfMTI0ODE_68d98806-5862-404e-bd29-a79450194639" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s debt balance consists of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolver Loan</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie53154e5f8e44ab2b5b3bc67ed958b95_I20220331" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOmJjMGU4NDVhY2IzMzQyNDBiMjA3N2MwYTY3NjlhYTZiL3RhYmxlcmFuZ2U6YmMwZTg0NWFjYjMzNDI0MGIyMDc3YzBhNjc2OWFhNmJfMy0xLTEtMS03MDA0Mg_c3597f4a-b8ee-4159-9eb9-65bed7c788b5">180,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia038bf044a5d4b0888c9404c8ef66dce_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOmJjMGU4NDVhY2IzMzQyNDBiMjA3N2MwYTY3NjlhYTZiL3RhYmxlcmFuZ2U6YmMwZTg0NWFjYjMzNDI0MGIyMDc3YzBhNjc2OWFhNmJfMy0zLTEtMS03MDA0Mg_857b178f-b6ef-4b6f-b499-352194e87242">180,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real Estate Loans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ead42b914f74b3a87c5e08a25135c1b_I20220331" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOmJjMGU4NDVhY2IzMzQyNDBiMjA3N2MwYTY3NjlhYTZiL3RhYmxlcmFuZ2U6YmMwZTg0NWFjYjMzNDI0MGIyMDc3YzBhNjc2OWFhNmJfNC0xLTEtMS03MDA0Mg_42196fea-16b7-4500-aa08-f2dbabae92f7">7,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9875be1595584e8793d5a44cabe73104_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOmJjMGU4NDVhY2IzMzQyNDBiMjA3N2MwYTY3NjlhYTZiL3RhYmxlcmFuZ2U6YmMwZTg0NWFjYjMzNDI0MGIyMDc3YzBhNjc2OWFhNmJfNC0zLTEtMS03MDA0Mg_db4ea47b-1abc-4332-8536-7efab1a9a04a">7,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5ff5967c0ad489ca405c9a26138a568_I20220331" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOmJjMGU4NDVhY2IzMzQyNDBiMjA3N2MwYTY3NjlhYTZiL3RhYmxlcmFuZ2U6YmMwZTg0NWFjYjMzNDI0MGIyMDc3YzBhNjc2OWFhNmJfNS0xLTEtMS03MDA0Mg_a3990329-9e71-46fe-a987-2ae77d57ad33">1,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04ec29552d16406bb563e4f777751d86_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOmJjMGU4NDVhY2IzMzQyNDBiMjA3N2MwYTY3NjlhYTZiL3RhYmxlcmFuZ2U6YmMwZTg0NWFjYjMzNDI0MGIyMDc3YzBhNjc2OWFhNmJfNS0zLTEtMS03MDA0Mg_7bf5de1d-e8a2-4589-a8ce-8de444871af1">569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOmJjMGU4NDVhY2IzMzQyNDBiMjA3N2MwYTY3NjlhYTZiL3RhYmxlcmFuZ2U6YmMwZTg0NWFjYjMzNDI0MGIyMDc3YzBhNjc2OWFhNmJfNi0xLTEtMS03MDA0Mg_57c06e59-2b49-4372-b73a-acf779356891">188,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOmJjMGU4NDVhY2IzMzQyNDBiMjA3N2MwYTY3NjlhYTZiL3RhYmxlcmFuZ2U6YmMwZTg0NWFjYjMzNDI0MGIyMDc3YzBhNjc2OWFhNmJfNi0zLTEtMS03MDA0Mg_daebb537-b4d2-4594-827b-89b70eb13bd2">187,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOmJjMGU4NDVhY2IzMzQyNDBiMjA3N2MwYTY3NjlhYTZiL3RhYmxlcmFuZ2U6YmMwZTg0NWFjYjMzNDI0MGIyMDc3YzBhNjc2OWFhNmJfOC0xLTEtMS03MDA0Mg_0d232d47-6822-4aae-9497-793c1efc67ed">1,503</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOmJjMGU4NDVhY2IzMzQyNDBiMjA3N2MwYTY3NjlhYTZiL3RhYmxlcmFuZ2U6YmMwZTg0NWFjYjMzNDI0MGIyMDc3YzBhNjc2OWFhNmJfOC0zLTEtMS03MDA0Mg_84728c1d-18db-415d-ae6b-a3a587401703">780</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOmJjMGU4NDVhY2IzMzQyNDBiMjA3N2MwYTY3NjlhYTZiL3RhYmxlcmFuZ2U6YmMwZTg0NWFjYjMzNDI0MGIyMDc3YzBhNjc2OWFhNmJfOS0xLTEtMS03MDA0Mg_080ffc3e-6327-4c73-957f-b53e6aa86f33">4,031</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOmJjMGU4NDVhY2IzMzQyNDBiMjA3N2MwYTY3NjlhYTZiL3RhYmxlcmFuZ2U6YmMwZTg0NWFjYjMzNDI0MGIyMDc3YzBhNjc2OWFhNmJfOS0zLTEtMS03MDA0Mg_6d466b16-3677-44ed-bc16-12100e630100">4,268</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOmJjMGU4NDVhY2IzMzQyNDBiMjA3N2MwYTY3NjlhYTZiL3RhYmxlcmFuZ2U6YmMwZTg0NWFjYjMzNDI0MGIyMDc3YzBhNjc2OWFhNmJfMTEtMS0xLTEtNzAwNDI_5bac48ea-8e9b-41d9-bced-b43ca7d88654">183,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOmJjMGU4NDVhY2IzMzQyNDBiMjA3N2MwYTY3NjlhYTZiL3RhYmxlcmFuZ2U6YmMwZTg0NWFjYjMzNDI0MGIyMDc3YzBhNjc2OWFhNmJfMTEtMy0xLTEtNzAwNDI_b06eb028-4ddb-4ede-92dd-435976384317">182,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our long-term debt was determined using Level 2 inputs primarily related to comparable market prices. As of March&#160;31, 2022 and December&#160;31, 2021, the carrying value was not materially different from fair value, as the interest rates on the Company&#8217;s debt approximated rates currently available to the Company.</span></div><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfMTI0ODI_329effe6-8d23-4657-8202-7dbed5ff0c49" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the future commitments of the Company&#8217;s debt for the years ending </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the three months ended March 31, 2022) </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOjQ0MjkyYWE0NjQ1NDRjMmZiOGEzYTYzMjJjMzhiYjJjL3RhYmxlcmFuZ2U6NDQyOTJhYTQ2NDU0NGMyZmI4YTNhNjMyMmMzOGJiMmNfMS0xLTEtMS03MDA0Mg_b4a4dfec-ac10-4115-b35b-23b33b176e1d">1,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOjQ0MjkyYWE0NjQ1NDRjMmZiOGEzYTYzMjJjMzhiYjJjL3RhYmxlcmFuZ2U6NDQyOTJhYTQ2NDU0NGMyZmI4YTNhNjMyMmMzOGJiMmNfMi0xLTEtMS03MDA0Mg_2a779557-34b1-4948-af5e-451dfce57bf3">215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOjQ0MjkyYWE0NjQ1NDRjMmZiOGEzYTYzMjJjMzhiYjJjL3RhYmxlcmFuZ2U6NDQyOTJhYTQ2NDU0NGMyZmI4YTNhNjMyMmMzOGJiMmNfMy0xLTEtMS03MDA0Mg_2e1fe85a-f5fc-4bda-95db-501d545ec773">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOjQ0MjkyYWE0NjQ1NDRjMmZiOGEzYTYzMjJjMzhiYjJjL3RhYmxlcmFuZ2U6NDQyOTJhYTQ2NDU0NGMyZmI4YTNhNjMyMmMzOGJiMmNfNC0xLTEtMS03MDA0Mg_49735f9f-970d-4686-b5be-2066a4764f46">6,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="ameh:LongTermDebtMaturityAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOjQ0MjkyYWE0NjQ1NDRjMmZiOGEzYTYzMjJjMzhiYjJjL3RhYmxlcmFuZ2U6NDQyOTJhYTQ2NDU0NGMyZmI4YTNhNjMyMmMzOGJiMmNfNS0xLTEtMS03MDA0Mg_a0764627-3778-48b2-b2ae-afad431e1814">180,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOjQ0MjkyYWE0NjQ1NDRjMmZiOGEzYTYzMjJjMzhiYjJjL3RhYmxlcmFuZ2U6NDQyOTJhYTQ2NDU0NGMyZmI4YTNhNjMyMmMzOGJiMmNfNy0xLTEtMS03MDA0Mg_7f8ce824-ee50-4c55-abd8-83cb6b572394">188,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="ia9b0ea5a02464c86bcde818251a3e2da" continuedAt="i943b3109a11a4ef0b1ce78aa5ae5792f"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amended Credit Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2021, the Company entered into an amended and restated credit agreement (the &#8220;Amended Credit Agreement&#8221; and the credit facility thereunder, the &#8220;Amended Credit Facility&#8221;) with Truist Bank, in its capacity as administrative agent for the lenders, issuing bank, swingline lender and lender, Truist Securities, Inc., JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Preferred Bank, Royal Bank of Canada, and Fifth Third Bank, National Association, in their capacities as joint lead arrangers and/or lenders, and the lenders from time to time party thereto, to, among other things, amend and restate that certain credit agreement, dated September 11, 2019, by and among the Company, Truist Bank, and certain lenders thereto (the credit facility thereunder, the &#8220;Credit Facility&#8221;), in its entirety. The Amended Credit Agreement provides for a <ix:nonNumeric contextRef="i93bf4ca5dbf74632b9bcabe542799cf2_D20210616-20210616" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfMjc0ODc3OTA5MTc0OQ_8deeade4-d2fd-4773-a418-49cddbd70a2d">five-year</ix:nonNumeric> revolving credit facility to the Company of $<ix:nonFraction unitRef="usd" contextRef="i6759c2e740754692ab17fe6126840652_I20210616" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUyODMyMg_91940e53-fa45-4c27-bff1-e3e4210083ae">400.0</ix:nonFraction> million, which includes a letter of credit sub-facility of up to $<ix:nonFraction unitRef="usd" contextRef="i121db6aa4f234342a066091bbc811f6d_I20210616" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUyODMzMA_7310b6ba-bfa0-4241-b717-481b7e3e3adf">25.0</ix:nonFraction> million and a swingline loan sub-facility of $<ix:nonFraction unitRef="usd" contextRef="i2ae5de1ac50140b281d6c8428a5ba873_I20210616" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUyODMzOA_bfc11724-1611-476e-be4d-ee74ba1c83de">25.0</ix:nonFraction> million. The revolving credit facility will be used to, among other things, refinance certain existing indebtedness of the Company and certain subsidiaries, finance certain future acquisitions and investments, and provide for working capital needs and other general corporate purposes. Under the Amended Credit Agreement, the terms and conditions of the Guaranty and Security Agreement (the &#8220;Guaranty and Security Agreement&#8221;) between the Company, NMM and Truist Bank remain in effect.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to pay an annual agent fee of $<ix:nonFraction unitRef="usd" contextRef="i958aafc9bd314ec7a793b41fdf0cc64e_D20210616-20210616" decimals="-3" name="us-gaap:LineOfCreditFacilityCommitmentFeeAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUyODM1Mw_c432d807-4565-4567-877f-0f315e38015e">50,000</ix:nonFraction> and an annual facility fee of <ix:nonFraction unitRef="number" contextRef="if3c3078e4a3a4a97a896b1bc5d0087ef_D20210616-20210616" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUyODM2Mw_2c6de9c5-6ebd-4e07-96f7-38e654acceac">0.175</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="id506af9420ac471bab63d3cba404a645_D20210616-20210616" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUyODM2Nw_24ca66b9-1c52-4aeb-9bb9-7f911dcd3b15">0.350</ix:nonFraction>% on the available commitments under the Amended Credit Agreement, regardless of usage, with the applicable fee determined on a quarterly basis based on the Company&#8217;s leverage ratio. The Company will pay fees for standby letters of credit at an annual rate equal to <ix:nonFraction unitRef="number" contextRef="i411a85b04db242d0933b3b997de7b7be_D20210616-20210616" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUyODM3MQ_d6503950-ceb9-4660-beb5-e338c480f615">1.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i18d5ab7831f740cfbce7f376753f0fba_D20210616-20210616" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUyODM3NQ_e0ec9d1a-0689-44bf-91ad-7ae4de23e622">2.50</ix:nonFraction>%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, plus facing fees and standard fees payable to the issuing bank on the respective letter of credit. The Company is also required to pay customary fees between the Company and Truist Bank, the lead arranger of the Amended Credit Agreement.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, amounts borrowed under the Amended Credit Agreement bear interest at an annual rate equal to either, at the Company&#8217;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on LIBOR, adjusted for any reserve requirement in effect, plus a spread of from <ix:nonFraction unitRef="number" contextRef="i73d5e3fe56914cf8b95c7c29e9501364_D20210616-20210616" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUyODM3OQ_7897880f-5d3a-45f4-8d7c-e587d756dfbe">1.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i79fd9f0ba878471db847749cc1aa145b_D20210616-20210616" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUyODM4Mw_ed47bea2-7125-4b78-8af1-9f377b2bec71">2.50</ix:nonFraction>%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, or (b) a base rate, plus a spread of <ix:nonFraction unitRef="number" contextRef="if3c3078e4a3a4a97a896b1bc5d0087ef_D20210616-20210616" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUyODM5NA_a48cbd15-5b68-4e24-9f8b-324f2bbd1579">0.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="id506af9420ac471bab63d3cba404a645_D20210616-20210616" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUyODM5OA_1c1a7f0a-bf3b-48c1-bc81-be0ca7193ecb">1.50</ix:nonFraction>%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio.  As of March&#160;31, 2022, the interest rate on the Credit Agreement was <ix:nonFraction unitRef="number" contextRef="iac76cdf5c1e24249bd2cc8b73cea2d4d_I20220331" decimals="4" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUyODQxMA_49f1048e-03b5-4c79-bd0c-070c4eef1881">2.38</ix:nonFraction>%. Borrowings under the Amended Credit Agreement may be prepaid at any time without penalty. If LIBOR ceases to be reported under the Amended Credit Agreement, the Company will use the secured overnight financing rate or the Company and the Agent will agree to an alternative rate of interest. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement requires the Company to comply with <ix:nonFraction unitRef="financial_ratio" contextRef="iddc202a2a74a429aa384ca0e94f1385f_I20220331" decimals="INF" name="ameh:DebtInstrumentNumberOfKeyFinancialRatios" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfMjc0ODc3OTA5MTc1Ng_683211c2-4580-4465-8009-25cc1f7150cc">two</ix:nonFraction> key financial ratios, each calculated on a consolidated basis. The Company must maintain a maximum consolidated total net leverage ratio of not greater than <ix:nonFraction unitRef="number" contextRef="iddc202a2a74a429aa384ca0e94f1385f_I20220331" decimals="INF" name="ameh:DebtInstrumentCovenantLeverageRatioMaximum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUyODQyMA_415577f5-d2b4-4d5e-a55e-035c77ff87f0">3.75</ix:nonFraction> to 1.00 as of the last day of each fiscal quarter, provided that for any fiscal quarter during which the Company or certain subsidiaries consummate a permitted acquisition or investment, the aggregate purchase price is greater than $<ix:nonFraction unitRef="usd" contextRef="iddc202a2a74a429aa384ca0e94f1385f_I20220331" decimals="-5" name="ameh:DebtCovenantAggregatePurchasePriceMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfMjc0ODc3OTA5MTc2MQ_a1fbd990-752f-46ed-b94d-f43407ea431a">75.0</ix:nonFraction>&#160;million, the maximum consolidated total net leverage ratio may temporarily increase by <ix:nonFraction unitRef="number" contextRef="iddc202a2a74a429aa384ca0e94f1385f_I20220331" decimals="INF" name="ameh:DebtInstrumentCovenantLeverageRatioIncrementalChange" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUyODQ0Nw_7538b3dc-279a-406b-9c17-e52f7fc4b92b">0.25</ix:nonFraction> to 1.00 to <ix:nonFraction unitRef="number" contextRef="iddc202a2a74a429aa384ca0e94f1385f_I20220331" decimals="INF" name="ameh:DebtInstrumentCovenantLeverageRatioAdjustedMaximum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUyODQ1OA_156e3c33-af53-4a1c-8166-25d1a582d8c4">4.00</ix:nonFraction> to 1.00. The Company must maintain a minimum consolidated interest coverage ratio of not less than <ix:nonFraction unitRef="number" contextRef="iab25699159ef422387acd33b3b0c73ae_D20220101-20220331" decimals="INF" name="ameh:DebtInstrumentCovenantInterestCoverageRatioMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUyODQ2NQ_6a8f65e7-d88f-4c9c-9072-791ccbe01696">3.25</ix:nonFraction> to 1.00 as of the last day of each fiscal quarter. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Guaranty and Security Agreement, the Company and NMM have granted the lenders under the Amended Credit Agreement a security interest in all of their assets, including, without limitation, all stock and other equity issued by their subsidiaries (including NMM) and all rights with respect to the AP-AMH Loan. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, certain of the lenders under the Amended Credit Agreement and their affiliates have provided to the Company and its subsidiaries and the associated practices, and may in the future provide, (i) investment banking, commercial banking, cash management, foreign exchange, or other financial services, and (ii) services as a bond trustee and other trust and fiduciary services, for which they have received compensation and may receive compensation in the future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Financing Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company recorded deferred financing costs of $<ix:nonFraction unitRef="usd" contextRef="ia35d32a022eb4f8296d246475815c7be_I20190930" decimals="-5" name="us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNTYyMQ_3b76181c-8b6f-4041-8367-714f9de2f8e0">6.5</ix:nonFraction> million related to its entry into the Credit Facility. In June 2021, the Company recorded additional deferred financing costs of $<ix:nonFraction unitRef="usd" contextRef="i5ceb4bf299aa4fbbb15c38ae65b24964_I20210630" decimals="-5" name="us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNTc0NQ_27e5d989-4415-40de-9854-6b1f7f1b7ed2">0.7</ix:nonFraction>&#160;million related to its entry into the Amended Credit Facility. Deferred financing costs are recorded as a direct reduction of the carrying amount of the related debt liability using straight-line amortization. The remaining unamortized deferred financing costs related to the Credit Facility and the new costs related to the Amended Credit Facility are amortized over the life of the Amended Credit Facility. At March&#160;31, 2022 and December&#160;31, 2021, the unamortized deferred financing cost was $<ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNjIwNw_6f769532-a85f-4963-8b21-f71dd100d294">4.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNjIxNA_8481f5cb-15f1-4091-919e-b6ab15b5616c">4.3</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Real Estate Loans</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="i943b3109a11a4ef0b1ce78aa5ae5792f" continuedAt="if678a24868aa4b208e87212cbf016509"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, using cash comprised solely of Excluded Assets, APC purchased a <ix:nonFraction unitRef="number" contextRef="i6af45110227947abb0e1effa0224037f_I20201231" decimals="INF" name="ameh:AssetAcquisitionPercentageOfSharesAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNjMzNw_98f6a572-ba7c-47bf-81bd-71de71ae9024"><ix:nonFraction unitRef="number" contextRef="i29d27efd274e4640b991eab78aed11b9_I20201231" decimals="INF" name="ameh:AssetAcquisitionPercentageOfSharesAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNjMzNw_c86711c1-cc7f-4a03-98a8-a8a69fd0b9f6"><ix:nonFraction unitRef="number" contextRef="i8159b237bb57472289fa8745bfaf2c2a_I20201231" decimals="INF" name="ameh:AssetAcquisitionPercentageOfSharesAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNjMzNw_ccc3f700-5fb9-4ce3-bda1-f420ccad3df2">100</ix:nonFraction></ix:nonFraction></ix:nonFraction>% interest in MPP, AMG Properties, and ZLL. As a result of this purchase, APC assumed the existing loans held by MPP, AMG Properties, and ZLL. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MPP</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 3, 2020, MPP entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2021, the principal on the loan was $<ix:nonFraction unitRef="usd" contextRef="id327c3f30f5442849d60a0720899b6b3_I20211231" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNjY0MA_dec6ee1b-4372-4e89-a474-dade4bacff0d">6.1</ix:nonFraction>&#160;million with a variable interest rate of <ix:nonFraction unitRef="number" contextRef="i59ee99254c40475f9b21b9cd872385a5_D20200703-20200703" decimals="INF" sign="-" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNjY3Ng_57eeba44-2dd8-4d41-a94d-5235b327b4fd">0.50</ix:nonFraction>% less than the independent index, which is the daily Wall Street Journal &#8220;Prime Rate.&#8221; If the index is not available, East West Bank may designate a substitute index after notifying MPP. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of March&#160;31, 2022, the balance outstanding was $<ix:nonFraction unitRef="usd" contextRef="ibb454af8f35b4571bbc0568a6ef8fabc_I20220331" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNzAwNQ_d57152b5-0b6a-4e3a-8d7d-51131811e82c">6.1</ix:nonFraction> million. MPP must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than <ix:nonFraction unitRef="number" contextRef="i0c1305632b254a819190bb04db42d4b9_D20200703-20200703" decimals="INF" name="ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNzE2OA_e3947f4e-4015-41a3-982c-cadf0591d66e">1.25</ix:nonFraction> to 1. <br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AMG Properties</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2020, AMG Properties entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2021, the principal on the loan was $<ix:nonFraction unitRef="usd" contextRef="if79f0e1f750c4d29acae8c2424f6b5a8_I20211231" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNzM2MA_62cde236-33c0-4e25-b3e1-ebb8278a14a1">0.7</ix:nonFraction>&#160;million with a variable interest rate of <ix:nonFraction unitRef="number" contextRef="i8c965773654f4f76b80d01904268a252_D20200805-20200805" decimals="INF" sign="-" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNzM5Ng_d6ed87ae-9df2-40ca-8bd7-5ac36acacc59">0.30</ix:nonFraction>% less than the independent index, which is the daily Wall Street Journal &#8220;Prime Rate.&#8221; If the index is not available, East West Bank may designate a substitute index after notifying AMG Properties. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of March&#160;31, 2022, the balance outstanding was $<ix:nonFraction unitRef="usd" contextRef="if9463aae35c1447dbc10b94c90792330_I20220331" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNzczNg_02c1797a-ffe0-4af0-a6eb-0fd9cbacb8ff">0.7</ix:nonFraction> million. AMG Properties must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than <ix:nonFraction unitRef="number" contextRef="id9e05712a8f3404c91c7767902090d7c_D20200805-20200805" decimals="INF" name="ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNzkxMA_0be8f520-73c0-4c5d-8dcb-7b62c2fb36e5">1.25</ix:nonFraction> to 1.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ZLL</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2020, ZLL entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2021, the principal on the loan was $<ix:nonFraction unitRef="usd" contextRef="i28e98c01e378431d9b395cc096cd64f1_I20211231" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfODA3OA_b7da852f-9b23-4a51-9878-6dabedeac187">0.6</ix:nonFraction>&#160;million with a variable interest rate of <ix:nonFraction unitRef="number" contextRef="i906733a30f24439e91bed1e3615ea7da_D20200727-20200727" decimals="INF" sign="-" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfODExNA_4b32b66e-2611-4087-ace3-a0d1a4d068b7">0.50</ix:nonFraction>% less than the independent index, which is the daily Wall Street Journal &#8220;Prime Rate.&#8221; If the index is not available, East West Bank may designate a substitute index after notifying ZLL. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of March&#160;31, 2022, the balance outstanding was $<ix:nonFraction unitRef="usd" contextRef="i3860353465b34dcf83559f00d6e7e4c0_I20220331" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfODQ0Mw_7438b475-53f1-47c3-84cb-546b9bcdbaa6">0.6</ix:nonFraction> million. ZLL must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than <ix:nonFraction unitRef="number" contextRef="ifff506fed9ef409ab5281dde682b04df_D20200727-20200727" decimals="INF" name="ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfODYwNg_93239f1a-ff03-4c0f-af54-0c164194d5bc">1.25</ix:nonFraction> to 1.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Construction Loan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, Tag 8 entered into a construction loan agreement with MUFG Union Bank N.A. (&#8220;Construction Loan&#8221;). Tag 8 is a VIE consolidated by the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Construction Loan allows Tag 8 to borrow up to $<ix:nonFraction unitRef="usd" contextRef="i039bfa2066b9445ba0c127c9a6b7d4e6_I20210430" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfODg0NQ_9c4c8d13-d8ca-45d6-85de-4b1eea34c208">10.7</ix:nonFraction> million with a maturity date of December 1, 2022 (&#8220;Construction Loan Term&#8221;). Interest rate is equal to an index rate determined by the bank. Monthly interest payments began on May 1, 2021, or can become part of the principal and bear interest. If construction is completed and, there are no events of default or substantial deterioration in the financial condition of Tag 8 or APC, guarantor on the loan agreement, at the maturity date of the Construction Loan Term, the loan shall convert to an amortizing loan with an extended maturity date of December 1, 2032 (&#8220;Permanent Loan Term&#8221;). Upon conversion to the Permanent Loan Term, monthly principal and interest payments shall be made beginning January 1, 2023. From January 1, 2023 until December 1, 2023, the interest rate will be <ix:nonFraction unitRef="number" contextRef="ifeba7e1f896c47b0bb477b27fd52fe58_D20230101-20231201" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfOTYyNA_46ba6bdb-4d3e-41ec-ac8e-45693ed18863">2.0</ix:nonFraction>% per annum in excess of the LIBOR rate. As of March&#160;31, 2022, the likelihood of the construction being completed by the maturity date was remote. The outstanding balance as of March&#160;31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i3e730da764a64b29b490afda93124c70_I20220331" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUzNDkyNQ_e87aa9df-2008-48f4-95ae-49977045659a">1.3</ix:nonFraction> million and was recorded as a current portion of long-term debt in the accompanying consolidated balance sheets. Once the loan converts to the Permanent Loan Term, APC, as Tag 8&#8217;s guarantor, must maintain a Cash Flow Coverage Ratio (defined as consolidated EBITDA minus unfinanced capital expenditures and distributions paid divided by the sum of current portion of long-term debt, plus interest expense) of not less than <ix:nonFraction unitRef="number" contextRef="i3e730da764a64b29b490afda93124c70_I20220331" decimals="INF" name="ameh:DebtInstrumentCovenantCashFlowCoverageRatioMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfMTAwODU_7747c906-0490-4b12-a361-c3b63e27e74d">1.25</ix:nonFraction> to 1. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effective Interest Rate</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s average effective interest rate on its total debt during the three months ended March&#160;31, 2022 and 2021, was <ix:nonFraction unitRef="number" contextRef="iab25699159ef422387acd33b3b0c73ae_D20220101-20220331" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfMTAyMjc_f4436d73-df1e-49f0-b14a-de97248cf406">1.78</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="idcefe512b59843c5a4b809aa58d86dbf_D20210101-20210331" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDk0NzgwMjMzNzQ4NQ_13cd4671-bd93-424e-b04a-0a37b8700ad1">2.08</ix:nonFraction>%, respectively. Interest expense in the consolidated statements of income included amortization of deferred debt issuance costs for the three months ended March&#160;31, 2022 and 2021, of $<ix:nonFraction unitRef="usd" contextRef="iab25699159ef422387acd33b3b0c73ae_D20220101-20220331" decimals="-5" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfMTA0MTM_8434879e-9304-451b-856b-76f4af37e06c">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idcefe512b59843c5a4b809aa58d86dbf_D20210101-20210331" decimals="-5" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfMTA0MjA_354b6a20-dda7-4de6-bbc9-0ad353386a95">0.3</ix:nonFraction> million, respectively.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lines of Credit</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">APC Business Loan</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="if678a24868aa4b208e87212cbf016509"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;10, 2019, the APC Business Loan Agreement with Preferred Bank (the &#8220;APC Business Loan Agreement&#8221;) was amended to decrease loan availability to $<ix:nonFraction unitRef="usd" contextRef="i8011f60b0322450ba7087bebdbf48e81_I20190910" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfMTA2NTk_84a80bbd-1d09-4e14-8141-dd126eaa556f">4.1</ix:nonFraction> million. This decrease further limited the purpose of the indebtedness under APC Business Loan Agreement to the issuance of standby letters of credit, and added as a permitted lien the security interest in all of its assets granted by APC in favor of NMM under a Security Agreement dated on or about September 11, 2019, securing APC&#8217;s obligations to NMM under, and as required pursuant to, the APC management services agreement dated as of July 1, 1999, as amended.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standby Letters of Credit</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $<ix:nonFraction unitRef="usd" contextRef="i5a5028538cf949dc976825957bdc20fc_I20220331" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfMTE3MzA_c30bca32-6f17-4eab-8931-5cd095acbf5b">0.3</ix:nonFraction> million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional <ix:nonNumeric contextRef="id77595136aad43ce85c81570c5c6ccfd_D20220101-20220331" name="us-gaap:LineOfCreditFacilityExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfMTI0Njk_980e8f1d-ae0e-4630-9ca1-dde25b6041bf">one-year</ix:nonNumeric> periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alpha Care established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $<ix:nonFraction unitRef="usd" contextRef="iaa89643a73ac4d02b199b59ae1e04e17_I20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfMTIxNjc_cdd03403-fdcf-414e-9989-343a24007526">3.8</ix:nonFraction> million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional <ix:nonNumeric contextRef="ic6ec9c984e0f4663b1287c8a1e6f562c_D20220101-20220331" name="us-gaap:LineOfCreditFacilityExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfMTI0NzA_12331c90-bcde-48af-ac8d-8c48d0cb3c5f">one-year</ix:nonNumeric> periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.</span></div></ix:continuation><div id="i3cbe033f261a4f1ea6a0c939c6847530_85"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF84NS9mcmFnOjQzOTVhZWIzZDE2YzRlNzc4ZTFkOGQzNzljZmE2MTJjL3RleHRyZWdpb246NDM5NWFlYjNkMTZjNGU3NzhlMWQ4ZDM3OWNmYTYxMmNfMjAzNw_ca971a15-1696-4d33-b724-9bc6bbafcfa2" continuedAt="i0ee867f9b173409184b72f5b9bdecbb4" escape="true">Mezzanine and Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="i0ee867f9b173409184b72f5b9bdecbb4" continuedAt="i01f2a4346f014342bc816c1f69a5ec12"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mezzanine</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the redemption feature of the APC shares (see Note 2) is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as non-controlling interest in APC as mezzanine or temporary equity. APC&#8217;s shares were not redeemable, and it was not probable that the shares would become redeemable, as of March&#160;31, 2022 and December&#160;31, 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholders&#8217; Equity</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="INF" name="ameh:StockIssuedDuringPeriodSharesMerger" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF84NS9mcmFnOjQzOTVhZWIzZDE2YzRlNzc4ZTFkOGQzNzljZmE2MTJjL3RleHRyZWdpb246NDM5NWFlYjNkMTZjNGU3NzhlMWQ4ZDM3OWNmYTYxMmNfNDQ3_b63b476f-4012-4386-b6fb-54bfa613e454">140,954</ix:nonFraction> holdback shares have not been issued to certain former NMM shareholders who were NMM shareholders at the time of closing of the 2017 Merger, as they have yet to submit properly completed letters of transmittal to ApolloMed in order to receive their pro rata portion of ApolloMed common stock and warrants as contemplated under the 2017 merger agreement. Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the 2017 Merger. The consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares in connection with the 2017 Merger.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/>Treasury Stock</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC owned <ix:nonFraction unitRef="shares" contextRef="if917b814792a44f39620641ac0df4997_I20220331" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF84NS9mcmFnOjQzOTVhZWIzZDE2YzRlNzc4ZTFkOGQzNzljZmE2MTJjL3RleHRyZWdpb246NDM5NWFlYjNkMTZjNGU3NzhlMWQ4ZDM3OWNmYTYxMmNfMTMwMw_3cc65e5f-f2b0-4e3b-899e-75306bcf66c4">10,925,702</ix:nonFraction> shares of ApolloMed&#8217;s common stock as of March&#160;31, 2022 and December&#160;31, 2021, which are legally issued and outstanding but excluded from shares of common stock outstanding in the consolidated financial statements, as such shares are treated as treasury shares for accounting purposes. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i01f2a4346f014342bc816c1f69a5ec12">During the three months ended March&#160;31, 2022 and 2021, CDSC paid dividends of $<ix:nonFraction unitRef="usd" contextRef="iba53eb44c7b14a578bb900cac19accbc_D20220101-20220331" decimals="-5" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF84NS9mcmFnOjQzOTVhZWIzZDE2YzRlNzc4ZTFkOGQzNzljZmE2MTJjL3RleHRyZWdpb246NDM5NWFlYjNkMTZjNGU3NzhlMWQ4ZDM3OWNmYTYxMmNfNDM5ODA0NjUxMzQ5MA_10fd688d-291c-4f26-8482-6b6514b866ca">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3fc704f23ee3440f959bc11b81e7d01f_D20210101-20210331" decimals="-5" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF84NS9mcmFnOjQzOTVhZWIzZDE2YzRlNzc4ZTFkOGQzNzljZmE2MTJjL3RleHRyZWdpb246NDM5NWFlYjNkMTZjNGU3NzhlMWQ4ZDM3OWNmYTYxMmNfNDM5ODA0NjUxMzUzMQ_aabc403e-beac-4d5d-8c84-8ef943eef295">0</ix:nonFraction>, respectively.</ix:continuation> </span></div><div><span><br/></span></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_91"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfMjE0NQ_7d6fd655-629a-4506-bf17-044a21477ca8" continuedAt="i2cda1373a4c7451485c40793c91b9409" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2cda1373a4c7451485c40793c91b9409" continuedAt="i44a057d557f34e0a807a69f924b05e15"><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfMjE0Mg_820a10b4-b064-4722-a5c6-a977b8bc1ed7" continuedAt="i2fc17d2357aa4733b1c9ab98b3b269e7" escape="true">The following table summarizes the stock-based compensation expense recognized under all of the Company&#8217;s stock plans for the three months ended March&#160;31, 2022 and 2021, and associated with the issuance of restricted shares of common stock and vesting of stock options, which are included in general and administrative expenses in the accompanying consolidated statements of income (in thousands):</ix:nonNumeric></ix:continuation></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i44a057d557f34e0a807a69f924b05e15" continuedAt="i168596cb4aa742f5900240b0497a1b92"><div><ix:continuation id="i2fc17d2357aa4733b1c9ab98b3b269e7"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.183%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59a87528beae42e5905d598caee23304_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjlhMmY5YTRiNmQ2MjRlNDBiYzI2MWJiYTFmNGI1OThjL3RhYmxlcmFuZ2U6OWEyZjlhNGI2ZDYyNGU0MGJjMjYxYmJhMWY0YjU5OGNfMi0xLTEtMS03MDA0Mg_2a1b9b9b-c4de-4d69-9bd7-3ebc5c94ef8b">780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c4a21ba18bf43e2baa22838c457ebc6_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjlhMmY5YTRiNmQ2MjRlNDBiYzI2MWJiYTFmNGI1OThjL3RhYmxlcmFuZ2U6OWEyZjlhNGI2ZDYyNGU0MGJjMjYxYmJhMWY0YjU5OGNfMi0zLTEtMS03MDA0Mg_f111a93a-7971-4845-8bc6-7cee21438cf0">589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib33aa0fdefb44c68985101f13840b075_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjlhMmY5YTRiNmQ2MjRlNDBiYzI2MWJiYTFmNGI1OThjL3RhYmxlcmFuZ2U6OWEyZjlhNGI2ZDYyNGU0MGJjMjYxYmJhMWY0YjU5OGNfMy0xLTEtMS03MDA0Mg_ab36b3e9-830f-4d62-83d1-ab0660e6f21d">2,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia57bf156054149e8aed82c44fb4a2e72_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjlhMmY5YTRiNmQ2MjRlNDBiYzI2MWJiYTFmNGI1OThjL3RhYmxlcmFuZ2U6OWEyZjlhNGI2ZDYyNGU0MGJjMjYxYmJhMWY0YjU5OGNfMy0zLTEtMS03MDA0Mg_bd230740-6b08-4c9e-b6c6-4e35cd5123a9">757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjlhMmY5YTRiNmQ2MjRlNDBiYzI2MWJiYTFmNGI1OThjL3RhYmxlcmFuZ2U6OWEyZjlhNGI2ZDYyNGU0MGJjMjYxYmJhMWY0YjU5OGNfNS0xLTEtMS03MDA0Mg_ab6aafdb-0471-42e6-9597-9b97c537a6da">3,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjlhMmY5YTRiNmQ2MjRlNDBiYzI2MWJiYTFmNGI1OThjL3RhYmxlcmFuZ2U6OWEyZjlhNGI2ZDYyNGU0MGJjMjYxYmJhMWY0YjU5OGNfNS0zLTEtMS03MDA0Mg_c9b251d2-5b65-494a-b95b-ac82ab6bc71a">1,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized compensation expense related to total share-based payments outstanding as of March&#160;31, 2022, was $<ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfNTI4_97515503-37b8-436b-854a-dfc969a6aa42">21.6</ix:nonFraction> million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Options</span></div><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfMjE1Mg_317b1026-3bf1-4385-82d2-29613b4d2092" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding stock options consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.917%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding at January&#160;1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfMS0xLTEtMS03MDA0Mg_b383e628-60b6-4b7f-b01b-e442bd3a70d6">813,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfMS0zLTEtMS03MDA0Mg_da8db663-57dc-4667-bfc8-64575b1e6261">22.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id93dea0ce70b4ff2b46f7a49428856fd_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfMS01LTEtMS03MDA0Mg_6bc9523b-2b08-4fbe-af73-b239addc566b">3.20</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfMS03LTEtMS03MDA0Mg_203c87d3-1544-4734-a3ad-7c45ce6e8c55">41.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfMi0xLTEtMS03MDA0Mg_53a5c8d8-4469-4ae1-abd8-5cca34e5aedd">75,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfMi0zLTEtMS03MDA0Mg_07b9e219-3882-4fb0-8597-b1bc49b93724">55.07</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfMy0xLTEtMS03MDA0Mg_093a3a6e-a5f3-4eb6-b0c4-2b3ca90fc18c">38,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfMy0zLTEtMS03MDA0Mg_5464c7f9-23b4-411a-9cad-b4535c442025">17.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfMy03LTEtMS03MDA0Mg_8c03fd60-9aa3-47f6-84fc-67af75c10c0b">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfNC0xLTEtMS03MDA0Mg_c14926bf-cc16-4c55-800e-8ea75a7866ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfNC0zLTEtMS03MDA0Mg_1d4bdee0-7836-4030-8f39-a839e5edfafd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfNi0xLTEtMS03MDA0Mg_ff7a8801-9a65-45d9-a448-203ce000a44d">850,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfNi0zLTEtMS03MDA0Mg_4aedeb0c-a3ef-4233-ada0-4f83a45538e6">25.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfNi01LTEtMS03MDA0Mg_84a9bbe7-3124-4525-b580-10b57a401b7f">2.94</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfNi03LTEtMS03MDA0Mg_c87faaaa-4107-44cd-997c-e34dcfbc7693">22.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfOC0xLTEtMS03MDA0Mg_9ebc742c-6994-4ce4-a95c-796ca8fdaccd">591,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfOC0zLTEtMS03MDA0Mg_bd8885fa-6afc-475a-b172-4417bb3a68ba">9.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfOC01LTEtMS03MDA0Mg_08556ff5-723e-40bd-b5f7-23ab1213d0fa">1.79</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfOC03LTEtMS03MDA0Mg_b0902d6d-ae10-45aa-bf6e-78b2735a8405">20.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, options were exercised for <ix:nonFraction unitRef="shares" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfNjY4_093a3a6e-a5f3-4eb6-b0c4-2b3ca90fc18c">38,500</ix:nonFraction> shares of the Company&#8217;s common stock, resulting in proceeds of $<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfNzM0_6dc201d2-fc0a-42d3-a487-d1810cdad57a">0.7</ix:nonFraction>&#160;million. During the three months ended March&#160;31, 2021, <ix:nonFraction unitRef="shares" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfMjc0ODc3OTA3Mjc1Mg_8fdea6ea-3548-44a3-b579-bb6dc8bd0d90">no</ix:nonFraction> stock options were exercised.</span></div><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfMjE0Mw_20bf2b8a-6008-4303-8aac-64cde6ba516b" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, the Company granted <ix:nonFraction unitRef="shares" contextRef="i2ed7fee6f6304a0998e815c8e5445108_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfNDM5ODA0NjUxNDA0NQ_434845ef-238f-47c2-bad7-319acddd218d">75,271</ix:nonFraction> stock options to certain ApolloMed employees and Board members. The options granted during the three months ended March&#160;31, 2022 were recognized at fair value, as determined using the Black-Scholes option pricing model as follows: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.637%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3d75852709414d64af680d539dcb36be_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjhhZDQ4MWQ4NTQ2ZjQ3ODJiNWM5YmNkZjQwOTNkODc1L3RhYmxlcmFuZ2U6OGFkNDgxZDg1NDZmNDc4MmI1YzliY2RmNDA5M2Q4NzVfMS0xLTEtMS03MDA0Mi90ZXh0cmVnaW9uOjVkNTA5YWYyNDJkYTQxN2U5MzY5NDEwMjUyYmFmZjI0XzI3NDg3NzkwNjk0Nzc_80f6af6b-436d-436e-bbcf-0c1a71a5339e">2.00</ix:nonNumeric> years - <ix:nonNumeric contextRef="ic8fe9de9677f4084b60ffc90c8a538eb_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjhhZDQ4MWQ4NTQ2ZjQ3ODJiNWM5YmNkZjQwOTNkODc1L3RhYmxlcmFuZ2U6OGFkNDgxZDg1NDZmNDc4MmI1YzliY2RmNDA5M2Q4NzVfMS0xLTEtMS03MDA0Mi90ZXh0cmVnaW9uOjVkNTA5YWYyNDJkYTQxN2U5MzY5NDEwMjUyYmFmZjI0XzI3NDg3NzkwNjk0OTA_69570239-3aaa-47e5-a740-f12d85f25dce">2.25</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1274ac1b93074e91b7b5207ef70ffa3f_D20220101-20220331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjhhZDQ4MWQ4NTQ2ZjQ3ODJiNWM5YmNkZjQwOTNkODc1L3RhYmxlcmFuZ2U6OGFkNDgxZDg1NDZmNDc4MmI1YzliY2RmNDA5M2Q4NzVfMi0xLTEtMS03MDA0Mi90ZXh0cmVnaW9uOjkzNTk1NmZhMTdjMzRkMThiMzQwNjJmMThiMDljYjMxXzI3NDg3NzkwNjk0NjU_88326c3a-bf10-4de3-92e0-2f7cdab15e5d">71.47</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i1274ac1b93074e91b7b5207ef70ffa3f_D20220101-20220331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjhhZDQ4MWQ4NTQ2ZjQ3ODJiNWM5YmNkZjQwOTNkODc1L3RhYmxlcmFuZ2U6OGFkNDgxZDg1NDZmNDc4MmI1YzliY2RmNDA5M2Q4NzVfMi0xLTEtMS03MDA0Mi90ZXh0cmVnaW9uOjkzNTk1NmZhMTdjMzRkMThiMzQwNjJmMThiMDljYjMxXzI3NDg3NzkwNjk0NzQ_3353155b-f4b2-4db5-9218-8449c086f7db">75.15</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1274ac1b93074e91b7b5207ef70ffa3f_D20220101-20220331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjhhZDQ4MWQ4NTQ2ZjQ3ODJiNWM5YmNkZjQwOTNkODc1L3RhYmxlcmFuZ2U6OGFkNDgxZDg1NDZmNDc4MmI1YzliY2RmNDA5M2Q4NzVfMy0xLTEtMS03MDA0Mi90ZXh0cmVnaW9uOjE2MWVhYjE4OTc3ZDQzZWZiMjA0NjZhOTIwNGNiMTMyXzI3NDg3NzkwNjk0NjI_13aff88e-de20-49bf-bda1-dc43d4e0d563">1.02</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i1274ac1b93074e91b7b5207ef70ffa3f_D20220101-20220331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjhhZDQ4MWQ4NTQ2ZjQ3ODJiNWM5YmNkZjQwOTNkODc1L3RhYmxlcmFuZ2U6OGFkNDgxZDg1NDZmNDc4MmI1YzliY2RmNDA5M2Q4NzVfMy0xLTEtMS03MDA0Mi90ZXh0cmVnaW9uOjE2MWVhYjE4OTc3ZDQzZWZiMjA0NjZhOTIwNGNiMTMyXzI3NDg3NzkwNjk0NzA_0942eca1-f4ed-4f9d-8589-5d9d67ffca67">1.06</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market value of common stock</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i742b25817ce54efbb408cfa331c5fe5f_I20220331" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjhhZDQ4MWQ4NTQ2ZjQ3ODJiNWM5YmNkZjQwOTNkODc1L3RhYmxlcmFuZ2U6OGFkNDgxZDg1NDZmNDc4MmI1YzliY2RmNDA5M2Q4NzVfNC0xLTEtMS03MDA0Mi90ZXh0cmVnaW9uOmIwNTNjODkzNmUxYTRmODJhM2UzM2U0N2M0MmI5NDBkXzI3NDg3NzkwNjk0NjI_ee4527f9-3896-4826-93b3-235efb1b9072">20.23</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="i52ed974f00584c72870ff83e96c517c6_I20220331" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjhhZDQ4MWQ4NTQ2ZjQ3ODJiNWM5YmNkZjQwOTNkODc1L3RhYmxlcmFuZ2U6OGFkNDgxZDg1NDZmNDc4MmI1YzliY2RmNDA5M2Q4NzVfNC0xLTEtMS03MDA0Mi90ZXh0cmVnaW9uOmIwNTNjODkzNmUxYTRmODJhM2UzM2U0N2M0MmI5NDBkXzI3NDg3NzkwNjk0NzA_b777ee8d-d813-46c5-b151-efa01fa20b94">22.73</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annual dividend yield</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1274ac1b93074e91b7b5207ef70ffa3f_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjhhZDQ4MWQ4NTQ2ZjQ3ODJiNWM5YmNkZjQwOTNkODc1L3RhYmxlcmFuZ2U6OGFkNDgxZDg1NDZmNDc4MmI1YzliY2RmNDA5M2Q4NzVfNS0xLTEtMS03MDA0Mg_f27550b9-e256-404e-85dd-bd38d2734bc5">0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeiture rate</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1274ac1b93074e91b7b5207ef70ffa3f_D20220101-20220331" decimals="INF" name="ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjhhZDQ4MWQ4NTQ2ZjQ3ODJiNWM5YmNkZjQwOTNkODc1L3RhYmxlcmFuZ2U6OGFkNDgxZDg1NDZmNDc4MmI1YzliY2RmNDA5M2Q4NzVfNi0xLTEtMS03MDA0Mg_cf3a9c3c-a775-4746-8947-f51bb9758266">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants restricted stock to officers and employees which are earned based on service conditions. The grant date fair value of the restricted stock is that day&#8217;s closing market price of the Company&#8217;s common stock. During the three months ended March&#160;31, 2022, the Company granted restricted stock totaling <ix:nonFraction unitRef="shares" contextRef="i3c33bc11247c47b3bf81a50827becf69_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfMTUxMw_efb657ca-7891-475c-9fdd-d8b54607b04e">76,828</ix:nonFraction> shares, including <ix:nonFraction unitRef="shares" contextRef="i3c33bc11247c47b3bf81a50827becf69_D20220101-20220331" decimals="INF" name="ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfNjA0NzMxMzk1NjA1NA_0ea534ca-9467-46fe-94a5-96e6534a7f74">49,124</ix:nonFraction> restricted stock with performance conditions, with a weighted average grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i3c33bc11247c47b3bf81a50827becf69_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfMTU3Mg_e3cbad70-f1c4-453d-9a48-96b9e4e97fae">50.76</ix:nonFraction>. Restricted stock with performance conditions are recognized to the extent the performance conditions are probable of being achieved. The grant date fair value of restricted stock and restricted stock with performance conditions that are probable of being achieved were $<ix:nonFraction unitRef="usd" contextRef="i9bc146c68b944c84b6e8aad1dc0a79e5_I20220331" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfMTYzMA_2e161314-d3c2-40eb-9985-c51702d88295">3.9</ix:nonFraction>&#160;million and will be recognized on a straight-line basis over the awards&#8217; vesting period. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i168596cb4aa742f5900240b0497a1b92" continuedAt="i3ed33b08d3a34124a73f85aa6e1bfcca"><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfMjE1MQ_4a2686da-c16c-453c-a98a-2e9e7a77a3de" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding warrants consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants outstanding at January&#160;1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjA4MDJhNDMxN2UzZDRkM2E4MTk2OTE5ZjA0Y2U2YWUwL3RhYmxlcmFuZ2U6MDgwMmE0MzE3ZTNkNGQzYTgxOTY5MTlmMDRjZTZhZTBfMS0xLTEtMS03MDA0Mg_5364ca80-4214-4c39-a169-bb99a06a4d5e">1,001,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjA4MDJhNDMxN2UzZDRkM2E4MTk2OTE5ZjA0Y2U2YWUwL3RhYmxlcmFuZ2U6MDgwMmE0MzE3ZTNkNGQzYTgxOTY5MTlmMDRjZTZhZTBfMS0zLTEtMS03MDA0Mg_1b5b7eb4-d142-4b74-be5f-a32cb4c1f857">10.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id93dea0ce70b4ff2b46f7a49428856fd_D20210101-20211231" name="ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjA4MDJhNDMxN2UzZDRkM2E4MTk2OTE5ZjA0Y2U2YWUwL3RhYmxlcmFuZ2U6MDgwMmE0MzE3ZTNkNGQzYTgxOTY5MTlmMDRjZTZhZTBfMS01LTEtMS03MDA0Mg_9f95214f-808c-4842-b993-3d00f7a6e920">0.94</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-3" name="ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjA4MDJhNDMxN2UzZDRkM2E4MTk2OTE5ZjA0Y2U2YWUwL3RhYmxlcmFuZ2U6MDgwMmE0MzE3ZTNkNGQzYTgxOTY5MTlmMDRjZTZhZTBfMS03LTEtMS03MDA0Mg_c9364970-61cf-491f-90c2-f4000ffaed1b">63.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="INF" name="ameh:NumberOfWarrantsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjA4MDJhNDMxN2UzZDRkM2E4MTk2OTE5ZjA0Y2U2YWUwL3RhYmxlcmFuZ2U6MDgwMmE0MzE3ZTNkNGQzYTgxOTY5MTlmMDRjZTZhZTBfMi0xLTEtMS03MDA0Mg_85e532ac-ef73-493c-8599-096b068782e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjA4MDJhNDMxN2UzZDRkM2E4MTk2OTE5ZjA0Y2U2YWUwL3RhYmxlcmFuZ2U6MDgwMmE0MzE3ZTNkNGQzYTgxOTY5MTlmMDRjZTZhZTBfMi0zLTEtMS03MDA0Mg_2a2e0c45-9dc1-417a-a7b4-c3ae5aae883e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="ameh:ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjA4MDJhNDMxN2UzZDRkM2E4MTk2OTE5ZjA0Y2U2YWUwL3RhYmxlcmFuZ2U6MDgwMmE0MzE3ZTNkNGQzYTgxOTY5MTlmMDRjZTZhZTBfMi03LTEtMS03MDA0Mg_ffa7fecb-6393-4566-8fad-135890d2d41d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="INF" name="ameh:NumberOfWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjA4MDJhNDMxN2UzZDRkM2E4MTk2OTE5ZjA0Y2U2YWUwL3RhYmxlcmFuZ2U6MDgwMmE0MzE3ZTNkNGQzYTgxOTY5MTlmMDRjZTZhZTBfMy0xLTEtMS03MDA0Mg_3b6526bc-6b19-42d3-a4e3-bf1902d7cf2f">86,235</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjA4MDJhNDMxN2UzZDRkM2E4MTk2OTE5ZjA0Y2U2YWUwL3RhYmxlcmFuZ2U6MDgwMmE0MzE3ZTNkNGQzYTgxOTY5MTlmMDRjZTZhZTBfMy0zLTEtMS03MDA0Mg_220cd509-6a86-4ce3-bb38-3633fb7caee0">10.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="ameh:ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjA4MDJhNDMxN2UzZDRkM2E4MTk2OTE5ZjA0Y2U2YWUwL3RhYmxlcmFuZ2U6MDgwMmE0MzE3ZTNkNGQzYTgxOTY5MTlmMDRjZTZhZTBfMy03LTEtMS03MDA0Mg_59a8a6a3-a70f-493b-94d8-59fb917a1ba2">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants expired/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="INF" name="ameh:ClassOfWarrantOrRightCancelledInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjA4MDJhNDMxN2UzZDRkM2E4MTk2OTE5ZjA0Y2U2YWUwL3RhYmxlcmFuZ2U6MDgwMmE0MzE3ZTNkNGQzYTgxOTY5MTlmMDRjZTZhZTBfNC0xLTEtMS03MDA0Mg_0f46ca48-7c50-4b8c-98bb-fbf99059a68c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjA4MDJhNDMxN2UzZDRkM2E4MTk2OTE5ZjA0Y2U2YWUwL3RhYmxlcmFuZ2U6MDgwMmE0MzE3ZTNkNGQzYTgxOTY5MTlmMDRjZTZhZTBfNC0zLTEtMS03MDA0Mg_6911beb3-4025-4fce-8b0a-256656b741ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="ameh:ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjA4MDJhNDMxN2UzZDRkM2E4MTk2OTE5ZjA0Y2U2YWUwL3RhYmxlcmFuZ2U6MDgwMmE0MzE3ZTNkNGQzYTgxOTY5MTlmMDRjZTZhZTBfNC03LTEtMS03MDA0Mg_76fdb2c2-eb29-4c8d-8944-c3548de4d0e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjA4MDJhNDMxN2UzZDRkM2E4MTk2OTE5ZjA0Y2U2YWUwL3RhYmxlcmFuZ2U6MDgwMmE0MzE3ZTNkNGQzYTgxOTY5MTlmMDRjZTZhZTBfNi0xLTEtMS03MDA0Mg_fdf2d559-aa28-44c0-845b-26e192368390">915,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjA4MDJhNDMxN2UzZDRkM2E4MTk2OTE5ZjA0Y2U2YWUwL3RhYmxlcmFuZ2U6MDgwMmE0MzE3ZTNkNGQzYTgxOTY5MTlmMDRjZTZhZTBfNi0zLTEtMS03MDA0Mg_f67b37d6-8c56-4a14-94ca-8ac68950abbf">10.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjA4MDJhNDMxN2UzZDRkM2E4MTk2OTE5ZjA0Y2U2YWUwL3RhYmxlcmFuZ2U6MDgwMmE0MzE3ZTNkNGQzYTgxOTY5MTlmMDRjZTZhZTBfNi01LTEtMS03MDA0Mg_ab910a15-a63d-4d2f-8516-179dd3e7f2c1">0.69</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjA4MDJhNDMxN2UzZDRkM2E4MTk2OTE5ZjA0Y2U2YWUwL3RhYmxlcmFuZ2U6MDgwMmE0MzE3ZTNkNGQzYTgxOTY5MTlmMDRjZTZhZTBfNi03LTEtMS03MDA0Mg_7833d731-f2bb-4f00-b644-0078fdc89ec2">34.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.642%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise&#160;Price&#160;Per Share</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants<br/>Outstanding</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual&#160;Life</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercisable</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise&#160;Price</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Per Share</span></div></td></tr><tr><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i17b21603feaa4b6eac83277e537457e2_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjVhNWUyZmRmMTZiOTRiOWRhZTBkODEwZDkxYzRkNDdiL3RhYmxlcmFuZ2U6NWE1ZTJmZGYxNmI5NGI5ZGFlMGQ4MTBkOTFjNGQ0N2JfMS0wLTEtMS03MDA0Mg_262f1e4f-a485-4887-9394-58edfbb8570c">10.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i481003839719417595b8ccd16571b1b2_D20220101-20220331" decimals="INF" name="ameh:ClassOfWarrantOrRightIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjVhNWUyZmRmMTZiOTRiOWRhZTBkODEwZDkxYzRkNDdiL3RhYmxlcmFuZ2U6NWE1ZTJmZGYxNmI5NGI5ZGFlMGQ4MTBkOTFjNGQ0N2JfMS0yLTEtMS03MDA0Mg_e9b824e8-150d-4247-913c-e2b937f061d4">470,827</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i481003839719417595b8ccd16571b1b2_D20220101-20220331" name="ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjVhNWUyZmRmMTZiOTRiOWRhZTBkODEwZDkxYzRkNDdiL3RhYmxlcmFuZ2U6NWE1ZTJmZGYxNmI5NGI5ZGFlMGQ4MTBkOTFjNGQ0N2JfMS00LTEtMS03MDA0Mg_f3534e48-5802-4733-ad65-69c249e8b148">0.69</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i17b21603feaa4b6eac83277e537457e2_I20220331" decimals="INF" name="ameh:ClassOfWarrantOrRightExercisable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjVhNWUyZmRmMTZiOTRiOWRhZTBkODEwZDkxYzRkNDdiL3RhYmxlcmFuZ2U6NWE1ZTJmZGYxNmI5NGI5ZGFlMGQ4MTBkOTFjNGQ0N2JfMS02LTEtMS03MDA0Mg_ec58e0b0-78f7-4e49-829a-20b6f586c8d9">470,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i17b21603feaa4b6eac83277e537457e2_I20220331" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjVhNWUyZmRmMTZiOTRiOWRhZTBkODEwZDkxYzRkNDdiL3RhYmxlcmFuZ2U6NWE1ZTJmZGYxNmI5NGI5ZGFlMGQ4MTBkOTFjNGQ0N2JfMS04LTEtMS03MDA0Mg_143ee88b-87de-441d-8e9b-3272112a4706">10.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7cfeff39834e4f6c84395e2d7dabac69_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjVhNWUyZmRmMTZiOTRiOWRhZTBkODEwZDkxYzRkNDdiL3RhYmxlcmFuZ2U6NWE1ZTJmZGYxNmI5NGI5ZGFlMGQ4MTBkOTFjNGQ0N2JfMi0wLTEtMS03MDA0Mg_496b6dba-f745-4342-9a64-4253bdb7e002">11.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i22448a574a694a83ad45e720a7b0491c_D20220101-20220331" decimals="INF" name="ameh:ClassOfWarrantOrRightIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjVhNWUyZmRmMTZiOTRiOWRhZTBkODEwZDkxYzRkNDdiL3RhYmxlcmFuZ2U6NWE1ZTJmZGYxNmI5NGI5ZGFlMGQ4MTBkOTFjNGQ0N2JfMi0yLTEtMS03MDA0Mg_f9182235-da13-4e7c-86c1-69560c42b418">444,678</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i22448a574a694a83ad45e720a7b0491c_D20220101-20220331" name="ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjVhNWUyZmRmMTZiOTRiOWRhZTBkODEwZDkxYzRkNDdiL3RhYmxlcmFuZ2U6NWE1ZTJmZGYxNmI5NGI5ZGFlMGQ4MTBkOTFjNGQ0N2JfMi00LTEtMS03MDA0Mg_97863fcc-10ba-49b9-b3c9-de213bacd1fb">0.69</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7cfeff39834e4f6c84395e2d7dabac69_I20220331" decimals="INF" name="ameh:ClassOfWarrantOrRightExercisable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjVhNWUyZmRmMTZiOTRiOWRhZTBkODEwZDkxYzRkNDdiL3RhYmxlcmFuZ2U6NWE1ZTJmZGYxNmI5NGI5ZGFlMGQ4MTBkOTFjNGQ0N2JfMi02LTEtMS03MDA0Mg_10bcacbe-d2d7-4e63-aeeb-95e5f739ac40">444,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7cfeff39834e4f6c84395e2d7dabac69_I20220331" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjVhNWUyZmRmMTZiOTRiOWRhZTBkODEwZDkxYzRkNDdiL3RhYmxlcmFuZ2U6NWE1ZTJmZGYxNmI5NGI5ZGFlMGQ4MTBkOTFjNGQ0N2JfMi04LTEtMS03MDA0Mg_35467506-9bb7-4d2f-80fa-a7d374bf4aae">11.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$                  <ix:nonFraction unitRef="usdPerShare" contextRef="i789d3da0a72b4fb89b415c17b6bd2710_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjVhNWUyZmRmMTZiOTRiOWRhZTBkODEwZDkxYzRkNDdiL3RhYmxlcmFuZ2U6NWE1ZTJmZGYxNmI5NGI5ZGFlMGQ4MTBkOTFjNGQ0N2JfNC0wLTEtMS03MDA0Mi90ZXh0cmVnaW9uOjcwZDYxYzA2ZmMxNDQ0OWM5YTY0MDE5ZmQ2MDBjNGUzXzIz_7730682c-100d-42d1-9b90-b8e715daca8c">10.00</ix:nonFraction> &#8211; <ix:nonFraction unitRef="usdPerShare" contextRef="ia90b2ff413524e3b90acbbb605243bbb_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjVhNWUyZmRmMTZiOTRiOWRhZTBkODEwZDkxYzRkNDdiL3RhYmxlcmFuZ2U6NWE1ZTJmZGYxNmI5NGI5ZGFlMGQ4MTBkOTFjNGQ0N2JfNC0wLTEtMS03MDA0Mi90ZXh0cmVnaW9uOjcwZDYxYzA2ZmMxNDQ0OWM5YTY0MDE5ZmQ2MDBjNGUzXzI4_9939f2f4-cb00-4a2a-b8ac-6344091b3d5a">11.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i297879f201e2401b809e877bc5ca8f1a_D20220101-20220331" decimals="INF" name="ameh:ClassOfWarrantOrRightIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjVhNWUyZmRmMTZiOTRiOWRhZTBkODEwZDkxYzRkNDdiL3RhYmxlcmFuZ2U6NWE1ZTJmZGYxNmI5NGI5ZGFlMGQ4MTBkOTFjNGQ0N2JfNC0yLTEtMS03MDA0Mg_3b332f93-4303-44ff-a88a-b7bec4a9d93a">915,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i297879f201e2401b809e877bc5ca8f1a_D20220101-20220331" name="ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjVhNWUyZmRmMTZiOTRiOWRhZTBkODEwZDkxYzRkNDdiL3RhYmxlcmFuZ2U6NWE1ZTJmZGYxNmI5NGI5ZGFlMGQ4MTBkOTFjNGQ0N2JfNC00LTEtMS03MDA0Mg_3a9b4511-000d-4625-9f5f-587df6d49730">0.69</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaf372c04e8fd4b7fb0fe8f937ab557bd_I20220331" decimals="INF" name="ameh:ClassOfWarrantOrRightExercisable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjVhNWUyZmRmMTZiOTRiOWRhZTBkODEwZDkxYzRkNDdiL3RhYmxlcmFuZ2U6NWE1ZTJmZGYxNmI5NGI5ZGFlMGQ4MTBkOTFjNGQ0N2JfNC02LTEtMS03MDA0Mg_5a823b44-366c-4d71-8e8f-272d6ff4303f">915,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaf372c04e8fd4b7fb0fe8f937ab557bd_I20220331" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjVhNWUyZmRmMTZiOTRiOWRhZTBkODEwZDkxYzRkNDdiL3RhYmxlcmFuZ2U6NWE1ZTJmZGYxNmI5NGI5ZGFlMGQ4MTBkOTFjNGQ0N2JfNC04LTEtMS03MDA0Mg_21cac797-d30f-488f-820e-a0b16df93af6">10.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3ed33b08d3a34124a73f85aa6e1bfcca">During the three months ended March&#160;31, 2022 and 2021, common stock warrants were exercised for <ix:nonFraction unitRef="shares" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="INF" name="ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfMTg5Mg_8e76daa7-c8b4-4b45-acd9-50e8eb8bc222">86,235</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="INF" name="ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfMTg5OQ_7726cd7f-fca2-468c-8dfb-b064ba9c1938">421,002</ix:nonFraction> shares of the Company&#8217;s common stock, respectively, which resulted in proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-5" name="ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfMTk5OA_30e4819f-2c26-48d0-9fd5-dfa8cc33901f">0.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-5" name="ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfMjAwNQ_8c068a23-eb6a-4eda-8f86-ef7afcaf49d3">4.3</ix:nonFraction> million, respectively. The exercise price ranged from $<ix:nonFraction unitRef="usdPerShare" contextRef="i706233a8610b47c986b542c84fc02826_D20220101-20220331" decimals="2" name="ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfMjA1NA_8277d29e-539d-4c0e-a36a-b1d365b7738f">10.00</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="id61632e270d643278e5a45ab9d986834_D20220101-20220331" decimals="2" name="ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfMjA2MA_774110ec-e232-4922-951d-cc9f0212ad65">11.00</ix:nonFraction> per share for the exercises during the three months ended March&#160;31, 2022, and $<ix:nonFraction unitRef="usdPerShare" contextRef="i1501307448a04213aad7bd6a8043ca3c_D20210101-20210331" decimals="2" name="ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfNDk0NzgwMjMyNzg4NA_866f67f4-60ba-4d25-a97e-12aa2b0c047e">9.00</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="i4bee43ded60043dbad50b78762e0cfef_D20210101-20210331" decimals="2" name="ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfNDk0NzgwMjMyNzg5MQ_63529197-1861-46a1-a33f-45eccf38592b">11.00</ix:nonFraction> per share for the exercises during the three months ended March&#160;31, 2021, respectively.</ix:continuation> </span></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_97"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85Ny9mcmFnOjUzM2U5NWQyNmFjMzRkZWZiYTllZmU1NDM2NjYzMGJlL3RleHRyZWdpb246NTMzZTk1ZDI2YWMzNGRlZmJhOWVmZTU0MzY2NjMwYmVfMzkxNQ_65ddb0fd-9422-4b3a-9bf3-7e59f28ae73a" continuedAt="ie8f515549d2243958007c68b642fd288" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="ie8f515549d2243958007c68b642fd288" continuedAt="ic6ca0cfaab364e54817e726ba05485b7"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Matters</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws and regulations governing the Medicare program and healthcare generally are complex and subject to interpretation. The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. While no regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and exclusion from the Medicare and Medi-Cal programs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As risk-bearing organizations, APC, Alpha Care, and Accountable Health Care are required to comply with the California Department of Managed Healthcare (&#8220;DMHC&#8221;) regulations, including maintenance of minimum working capital, tangible net equity (&#8220;TNE&#8221;), cash-to-claims ratio, and claims payment requirements prescribed by the DMHC. TNE is defined as net equity less intangibles, less non-allowable assets (which include unsecured amounts due from affiliates), plus subordinated obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the payor and provider contracts with the Company&#8217;s affiliated physician-owned medical groups are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services. Such differing interpretations may not come to light until a substantial period of time has passed following contract implementation. Liabilities for claims disputes are recorded when the loss is probable and can be estimated. Any adjustments to reserves are reflected in current operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standby Letters of Credit</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="ic6ca0cfaab364e54817e726ba05485b7"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC and Alpha Care established irrevocable standby letters of credit with a Preferred Bank for a total of $<ix:nonFraction unitRef="usd" contextRef="ie54e1b2ff59741a89b0243c59b6ef686_I20220331" decimals="-5" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85Ny9mcmFnOjUzM2U5NWQyNmFjMzRkZWZiYTllZmU1NDM2NjYzMGJlL3RleHRyZWdpb246NTMzZTk1ZDI2YWMzNGRlZmJhOWVmZTU0MzY2NjMwYmVfMjE0Nw_e698e083-9535-484f-bb1e-9e19f819d9b3">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib152b2b747a74eaeb8147b82a52c9e8c_I20220331" decimals="-5" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85Ny9mcmFnOjUzM2U5NWQyNmFjMzRkZWZiYTllZmU1NDM2NjYzMGJlL3RleHRyZWdpb246NTMzZTk1ZDI2YWMzNGRlZmJhOWVmZTU0MzY2NjMwYmVfMjE1NA_56194bd2-7508-4d5f-b0d3-99bbe3f8ea2b">3.8</ix:nonFraction>&#160;million, respectively, for the benefit of certain health plans (see Note 9). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of its business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company&#8217;s financial condition, cash flows, or results of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability Insurance</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its insurance coverage is appropriate based upon the Company&#8217;s claims experience and the nature and risks of the Company&#8217;s business. In addition to the known incidents that have resulted in the assertion of claims, the Company cannot be certain that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against the Company, the Company&#8217;s affiliated professional organizations or the Company&#8217;s affiliated hospitalists in the future where the outcomes of such claims are unfavorable. The Company believes that the ultimate resolution of all pending claims, including liabilities in excess of the Company&#8217;s insurance coverage, will not have a material adverse effect on the Company&#8217;s financial position, results of operations, or cash flows; however, there can be no assurance that future claims will not have such a material adverse effect on the Company&#8217;s business. Contracted physicians are required to obtain their own insurance coverage.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company currently maintains liability insurance policies on a claims-made basis, which are intended to cover malpractice liability and certain other claims, the coverage must be renewed annually, and may&#160;not continue to be available to the Company in future years at acceptable costs, and on favorable terms.</span></div></ix:continuation><div id="i3cbe033f261a4f1ea6a0c939c6847530_100"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzQ2Mzc_4982f485-bb26-481c-b725-4292e821dace" continuedAt="i618dd5b21f8249ab8334a23608ff3801" escape="true">Related-Party Transactions</ix:nonNumeric></span></div><ix:continuation id="i618dd5b21f8249ab8334a23608ff3801" continuedAt="ifb1f6810a3d04b87ace4f7f83c093127"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022 and 2021, NMM earned approximately $<ix:nonFraction unitRef="usd" contextRef="iaa7033a548444263ac0237b0218a1adb_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzEwNw_2dd5be30-2702-493e-ab3a-1483911102a5">6.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib5bf970dcad14a8ba4515f1f82038323_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzExNA_e7ff5d6e-929b-44a6-a40a-e99d60887f24">4.5</ix:nonFraction> million, respectively, in management fees from LMA, which is accounted for under the equity method based on the <ix:nonFraction unitRef="number" contextRef="idc43c382a55f4e86bce82fa55ccdec8b_I20210331" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzI1MA_00f18be5-54fa-49b4-9536-8fec72c2655a"><ix:nonFraction unitRef="number" contextRef="ifa663b2f13a34f278cc8242cfbd66f60_I20220331" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzI1MA_ff446a31-0630-4984-86e7-e2618244fd67">25</ix:nonFraction></ix:nonFraction>% equity ownership interest held by APC in LMA&#8217;s IPA line of business (see Note 5 &#8212; &#8220;Investments in Other Entities &#8212; Equity Method&#8221;).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022 and 2021, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="i9cb30ce0828947b2b67749be5fbf6bfb_D20220101-20220331" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzQwMw_c6599faa-4c38-4761-b5cf-a5b1cc032a8d">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia9fd61dc32854b5794c5219cd64b9c91_D20210101-20210331" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzQxMA_7cbe5153-7da6-4d70-9893-48a460536154">0.5</ix:nonFraction> million, respectively, to PMIOC for provider services, which is accounted for under the equity method based on the <ix:nonFraction unitRef="number" contextRef="i149029e085754aa781bb4c12925033e9_I20220331" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzU0OQ_000eabf0-24ac-4de2-8956-001cc1db5df4"><ix:nonFraction unitRef="number" contextRef="i9a32ef7fa5834e35b4d3446fb2b911d7_I20210331" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzU0OQ_a37a9682-b9de-486e-9432-a3e1a875f9b3">40</ix:nonFraction></ix:nonFraction>% equity ownership interest held by APC (see Note 5 &#8212; &#8220;Investments in Other Entities &#8212; Equity Method&#8221;).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022 and 2021, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="i585cd6801b0a4b76917339116f149737_D20220101-20220331" decimals="-5" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzY3Mg_e2d753af-b169-4ef3-b754-3391325ebafb">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1e581b13ba1943ada689751040932d87_D20210101-20210331" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzY3OQ_60a4fb24-bfed-47f7-8492-a3c26322860f">1.6</ix:nonFraction> million, respectively, to DMG for provider services, which is accounted for under the equity method based on the <ix:nonFraction unitRef="number" contextRef="i7c6d4670d2704e46854a6d362d7ff8dc_I20220331" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzgxNg_b798f00c-46c8-4592-b1e4-cf84c351df0b">40</ix:nonFraction>% equity ownership interest held by APC. In October 2021,  DMG was consolidated by Apollo. As such, DMG is no longer a related party.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022 and 2021, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="i8a544d6c34914e8180df76ac79f9061c_D20220101-20220331" decimals="-3" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzkzOQ_68128e75-d22d-4302-b9c4-ba5b217d2ab8">39,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia407282c4d7c40f69b845a1980e98f90_D20210101-20210331" decimals="-3" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzk0Ng_02dc2723-d586-4161-ad6e-2e71b449067f">22,000</ix:nonFraction>, respectively, to Advanced Diagnostic Surgery Center for services as a provider. Advanced Diagnostic Surgery Center shares common ownership with certain board members of APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022 and 2021, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="i0a710728186e429c9f56a34cae4c7cd8_D20220101-20220331" decimals="-2" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzEyMDY_9a73d765-e357-46c1-ac23-3ddefb5c28c7">5,800</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i119ac7d8ea0849dbb246ad71c51fe403_D20210101-20210331" decimals="-3" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzEyMTM_7c215f37-6103-428d-8b7b-75c00554805c">33,000</ix:nonFraction>, respectively, to Fresenius Medical Care (&#8220;Fresenius&#8221;) and its subsidiaries for services as a provider. During the three months ended March&#160;31, 2022 and 2021, APAACO paid approximately $<ix:nonFraction unitRef="usd" contextRef="ic4788b32e9914d0ca0604092d88f6375_D20220101-20220331" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzE0MjA_4ad78b1d-115b-43cf-a82c-dd88f64cd786">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia7c1281284034e199a945b4fa25a565f_D20210101-20210331" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzE0Mjc_39d6e8c9-3844-4de3-85e8-c0c9b86d39a6">0.2</ix:nonFraction> million, respectively, to Fresenius and its subsidiaries for services as a provider. One of the Company&#8217;s board members is an officer of Fresenius and its subsidiaries. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022 and 2021, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="i81646c8d09a94a9aaeadb368f60bd221_D20220101-20220331" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzE2Njg_cdb8d9ca-bd28-4363-b742-339fc18f8980">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic6a40ab43ad94c908617b8e12ab58ed0_D20210101-20210331" decimals="-3" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzE2NzU_4ea3effd-bd2a-4f8b-b955-8ce453d991ca">21,000</ix:nonFraction>, respectively, to Fulgent Genetics, Inc. for services as a provider. One of the Company&#8217;s board members is a board member of Fulgent Genetics, Inc.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022 and 2021, APC paid an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="i2e92ca4dba96429ca6f565c4a96fae69_D20220101-20220331" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzE5MzI_0eb4fb6b-f050-4ebc-9df1-ae6793660819">9.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5ef6c81ae0d149dcb8f839d22ecdbf4f_D20210101-20210331" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzE5Mzk_962a97bc-5fe1-4f13-a74e-c0a313e38016">7.4</ix:nonFraction> million to shareholders, respectively, which included approximately $<ix:nonFraction unitRef="usd" contextRef="i69208e7b66d34e81be1ece056152eb3d_D20220101-20220331" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzIwMDI_fd0986cc-4561-4aed-8b18-58892ed76a3e">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if7a4db8db1a74901a4e3415b998623f7_D20210101-20210331" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzIwMDk_b0954173-5ed3-4a88-b8f6-446359b9029c">1.7</ix:nonFraction> million, respectively, to shareholders who are also officers of APC. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2022 and 2021, SCHC paid approximately $<ix:nonFraction unitRef="usd" contextRef="iffe651efb930429a8995404b0dc53e6b_D20220101-20220331" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzI2MDA_4de03ac2-93ec-4e9e-b788-f68337bca4e2">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie54eef2ca9b5495ea95cad9493906234_D20210101-20210331" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzI2MDc_62749771-6c48-4efc-84f5-77cf7dd04a00">0.1</ix:nonFraction> million, respectively, to Numen, LLC (&#8220;Numen&#8221;) for an office lease. Numen is owned by a shareholder of APC. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="ifb1f6810a3d04b87ace4f7f83c093127"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022 and 2021, NMM paid approximately $<ix:nonFraction unitRef="usd" contextRef="ie96af2c696c5435d811fd5623d3302c5_D20220101-20220331" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzI4MDE_2514ab7c-9dec-4703-9994-a70d4ff2a12c">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i725a2a08b1e34d65984bdfc031ea6bdb_D20210101-20210331" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzI4MDg_5a391a5e-3af1-4014-8e12-b08029844f63">0.4</ix:nonFraction> million, respectively, to One MSO for an office lease, which is accounted for under the equity method based on <ix:nonFraction unitRef="number" contextRef="i1c049a48265c4b71906a6728352ec4d1_I20220331" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzI5NDM_2d96883d-6290-4426-8c80-a4771aa1a67f"><ix:nonFraction unitRef="number" contextRef="i4608970f45fe4db1a3f4e42e64795259_I20210331" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzI5NDM_73fa4223-9cfa-4257-80fa-c1709da93d63">50</ix:nonFraction></ix:nonFraction>% equity ownership interest held by APC (see Note 5 &#8212; &#8220;Investments in Other Entities &#8212; Equity Method&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022 and 2021, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="ifde0ed94454e448ba35d1211452c3daf_D20220101-20220331" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzU0OTc1NTgxNDQxMzc_f63cccfc-c647-4995-ad57-45fad02dce09">3.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i41d101f6c0b44f5aad791956bdabaa9d_D20210101-20210331" decimals="-5" name="ameh:PaymentMadeToRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzU0OTc1NTgxNDQxNDg_0e27f34a-a35a-409b-a867-c59a1881f2d2">0</ix:nonFraction>, respectively, to Arroyo Vista Family Health Center (&#8220;Arroyo Vista&#8221;) for services as a provider. The CEO of Arroyo Vista became a board member with the Company in 2021. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with Health Source MSO Inc., a California corporation (&#8220;HSMSO&#8221;), Aurion Corporation (&#8220;Aurion&#8221;), and AHMC Healthcare Inc. (&#8220;AHMC&#8221;) for services provided to the Company. One of the Company&#8217;s board members is an officer of AHMC, HSMSO, and Aurion. Aurion is also partially owned by one of the Company&#8217;s board members. <ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzQ2NDQ_fad35a60-092f-4d0e-a3fc-cac4af2ab9b6" continuedAt="i861df02c2da3460381df8b98cc0315aa" escape="true">The following table sets forth fees incurred and income received related to AHMC, HSMSO, and Aurion (in thousands):</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="i861df02c2da3460381df8b98cc0315aa"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.305%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AHMC &#8211; Risk pool, capitation, claims payment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88100c9376d541219eea1723b76e0ce5_D20220101-20220331" decimals="-3" name="ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90YWJsZTozNDc0YTgxMTBiZTg0Njk1YmY2YjBlNTkzOWM2Y2NiOC90YWJsZXJhbmdlOjM0NzRhODExMGJlODQ2OTViZjZiMGU1OTM5YzZjY2I4XzItMS0xLTEtNzAwNDI_584aae52-7727-4aa3-b977-e849bdff9f88">11,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e4fd86eeb0b4ab68d020185faa91a8f_D20210101-20210331" decimals="-3" name="ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90YWJsZTozNDc0YTgxMTBiZTg0Njk1YmY2YjBlNTkzOWM2Y2NiOC90YWJsZXJhbmdlOjM0NzRhODExMGJlODQ2OTViZjZiMGU1OTM5YzZjY2I4XzItMy0xLTEtNzAwNDI_6da02eef-1dcc-42b9-8e44-2a2335d1fb58">13,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HSMSO &#8211; Management fees, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3339dc21c97b4534b86a86264b8aff7b_D20220101-20220331" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90YWJsZTozNDc0YTgxMTBiZTg0Njk1YmY2YjBlNTkzOWM2Y2NiOC90YWJsZXJhbmdlOjM0NzRhODExMGJlODQ2OTViZjZiMGU1OTM5YzZjY2I4XzMtMS0xLTEtNzAwNDI_eefdb25d-6510-468a-902b-50741b5bb5b3">80</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac761ad94565453fb1630b4de5935fbb_D20210101-20210331" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90YWJsZTozNDc0YTgxMTBiZTg0Njk1YmY2YjBlNTkzOWM2Y2NiOC90YWJsZXJhbmdlOjM0NzRhODExMGJlODQ2OTViZjZiMGU1OTM5YzZjY2I4XzMtMy0xLTEtNzAwNDI_7464136f-eb0b-430e-9406-758dca816338">77</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aurion &#8211; Management fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66d10132ebde4c69977f0b31055a0271_D20220101-20220331" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90YWJsZTozNDc0YTgxMTBiZTg0Njk1YmY2YjBlNTkzOWM2Y2NiOC90YWJsZXJhbmdlOjM0NzRhODExMGJlODQ2OTViZjZiMGU1OTM5YzZjY2I4XzQtMS0xLTEtNzAwNDI_0dbdd213-2160-4a2e-902a-f8441d3498e4">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73c05785e9ff4c7cbf5b3cfde9945e78_D20210101-20210331" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90YWJsZTozNDc0YTgxMTBiZTg0Njk1YmY2YjBlNTkzOWM2Y2NiOC90YWJsZXJhbmdlOjM0NzRhODExMGJlODQ2OTViZjZiMGU1OTM5YzZjY2I4XzQtMy0xLTEtNzAwNDI_43c67f3c-7eb0-4b5f-b426-df74375b4965">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receipts, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90YWJsZTozNDc0YTgxMTBiZTg0Njk1YmY2YjBlNTkzOWM2Y2NiOC90YWJsZXJhbmdlOjM0NzRhODExMGJlODQ2OTViZjZiMGU1OTM5YzZjY2I4XzYtMS0xLTEtNzAwNDI_c22c27ee-d792-493c-95ee-514fae2de125">11,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90YWJsZTozNDc0YTgxMTBiZTg0Njk1YmY2YjBlNTkzOWM2Y2NiOC90YWJsZXJhbmdlOjM0NzRhODExMGJlODQ2OTViZjZiMGU1OTM5YzZjY2I4XzYtMy0xLTEtNzAwNDI_f0e500fd-3506-4217-b2bd-bc532962a2b0">12,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and AHMC have a risk-sharing agreement with certain AHMC hospitals to share the surplus and deficits of each of the hospital pools. During the three months ended March&#160;31, 2022 and 2021, the Company has recognized risk pool revenue under this agreement of $<ix:nonFraction unitRef="usd" contextRef="i88100c9376d541219eea1723b76e0ce5_D20220101-20220331" decimals="-5" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzM3MTU_7aa4b51b-32bf-48de-9107-a3b810eec9fb">12.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5e4fd86eeb0b4ab68d020185faa91a8f_D20210101-20210331" decimals="-5" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzM3MjI_4523bfc5-fd17-415a-9f62-03943098d905">16.9</ix:nonFraction> million, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="if14f6b3f9f9143678ca31fa46792180a_I20220331" decimals="-5" name="us-gaap:DeferredCreditsAndOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzM3NjQ_0a041387-34cd-4f90-a4ed-d999cfe89a04">66.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8e487ca262164803a2471112a5aa3b86_I20211231" decimals="-5" name="us-gaap:DeferredCreditsAndOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzM3NzE_c16f363e-3705-468b-a220-299d2c9e9512">58.4</ix:nonFraction> million remained outstanding as of March&#160;31, 2022 and December&#160;31, 2021, respectively.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022 and 2021, NMM paid approximately $<ix:nonFraction unitRef="usd" contextRef="i9ac40763eff9488da386a8f3f515dcd2_D20220101-20220331" decimals="-3" name="ameh:PaymentConsultingFees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzU0OTc1NTgxNDQxNTU_b4aed544-e675-4d3b-8ef3-15fae8b5ee2c">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2437426902314907bb93c3e3a054e882_D20210101-20210331" decimals="-3" name="ameh:PaymentConsultingFees" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzU0OTc1NTgxNDQxNjk_b9efc95d-5699-4ca3-9b1b-ccaf0c771357">44,000</ix:nonFraction>, respectively, to an ApolloMed board member for consulting services. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, affiliates wholly owned by the Company&#8217;s officers, including Dr. Thomas Lam, ApolloMed&#8217;s Co-CEO and President, are reported in the accompanying consolidated statements of income on a consolidated basis, together with the Company&#8217;s subsidiaries, and therefore, the Company does not separately disclose transactions between such affiliates and the Company&#8217;s subsidiaries as related-party transactions.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For equity method investments and loans receivable from related parties, see Notes 5 and 6, respectively.</span></div></ix:continuation><div id="i3cbe033f261a4f1ea6a0c939c6847530_106"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDYvZnJhZzoxMmY5NzlmZGQyNzI0OGJjYmU4Mzk1ZmFiZDZjNjI1NC90ZXh0cmVnaW9uOjEyZjk3OWZkZDI3MjQ4YmNiZTgzOTVmYWJkNmM2MjU0XzI0ODE_301c263b-5bd7-434c-b8a4-b2469adb9668" continuedAt="i9f6b700905a24cf29e331f71d3e419cd" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i9f6b700905a24cf29e331f71d3e419cd" continuedAt="i05b15ca1133e48ff968a155943e15915"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the liability method of accounting for income taxes as set forth in ASC 740</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under the liability method, deferred taxes are determined based on differences between the financial statement and tax bases of assets and liabilities using enacted tax rates.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an interim basis, the Company estimates what its anticipated annual effective tax rate will be and records a quarterly income tax provision in accordance with the estimated annual rate, plus the tax effect of certain discrete items that arise during the quarter. As the fiscal year progresses, the Company refines its estimates based on actual events and financial results during the quarter. This process can result in significant changes to the Company&#8217;s estimated effective tax rate. When this occurs, the income tax provision is adjusted during the quarter in which the estimates are refined so that the year-to-date provision reflects the estimated annual effective tax rate. These changes, along with adjustments to the Company&#8217;s deferred taxes and related valuation allowance, may create fluctuations in the overall effective tax rate from quarter to quarter.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, due to the overall cumulative losses incurred in recent years, the Company maintained a full valuation allowance against its deferred tax assets related to loss entities the Company cannot consolidate under the federal tax consolidation rules, as realization of these assets is uncertain.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i05b15ca1133e48ff968a155943e15915"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective income tax rate for the three months ended March&#160;31, 2022 and March&#160;31, 2021, was <ix:nonFraction unitRef="number" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDYvZnJhZzoxMmY5NzlmZGQyNzI0OGJjYmU4Mzk1ZmFiZDZjNjI1NC90ZXh0cmVnaW9uOjEyZjk3OWZkZDI3MjQ4YmNiZTgzOTVmYWJkNmM2MjU0XzEwOTk1MTE2MzAyNzQ_1c3ea04c-69fb-450c-ac8d-aba3e5e805b4">34.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDYvZnJhZzoxMmY5NzlmZGQyNzI0OGJjYmU4Mzk1ZmFiZDZjNjI1NC90ZXh0cmVnaW9uOjEyZjk3OWZkZDI3MjQ4YmNiZTgzOTVmYWJkNmM2MjU0XzQzOTgwNDY1MTM1ODg_0b9dfb1a-f151-4715-9e3e-c4a42eb76ea1">31.9</ix:nonFraction>%, respectively. The tax rate for the three months ended March&#160;31, 2022, differed from the U.S. federal statutory rate primarily due to state income taxes, income from flow through entities, non-deductible permanent items, and change in valuation allowance.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company does not have any unrecognized tax benefits related to various federal and state income tax matters. The Company will recognize accrued interest and penalties related to unrecognized tax benefits in income tax expense.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal income tax as well as income tax in California. The Company and its subsidiaries&#8217; state and federal income tax returns are open to audit under the statute of limitations for the years ended December 31, 2017 through December&#160;31, 2021, and for the years ended December 31, 2018 through December&#160;31, 2021, respectively. The Company does not anticipate material changes to the unrecognized tax benefits within the next 12 months.</span></div></ix:continuation><div id="i3cbe033f261a4f1ea6a0c939c6847530_109"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90ZXh0cmVnaW9uOmIzNDRmMzk1OTc3ZjRjYjk5MzZkOWZlYmU5MzRmMzFkXzExMTQ_7bd4df3f-4596-478c-8009-62fabc55a125" continuedAt="ife9a30576d0a4c839e1c04b6f6d8124e" escape="true">Earnings Per Share</ix:nonNumeric></span></div><ix:continuation id="ife9a30576d0a4c839e1c04b6f6d8124e"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is calculated using the weighted average number of shares of the Company&#8217;s common stock issued and outstanding during a certain period, and is calculated by dividing net income attributable to ApolloMed by the weighted average number of shares of the Company&#8217;s common stock issued and outstanding during such period. Diluted earnings per share is calculated using the weighted average number of shares of common stock and potentially dilutive shares of common stock outstanding during the period, using the as-if converted method for secured convertible notes, preferred stock, and the treasury stock method for options and common stock warrants.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 and December&#160;31, 2021, APC held <ix:nonFraction unitRef="shares" contextRef="idbab252c85d54d69abb776900de44d5a_D20220101-20220331" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90ZXh0cmVnaW9uOmIzNDRmMzk1OTc3ZjRjYjk5MzZkOWZlYmU5MzRmMzFkXzcyNw_1595fcb1-cf83-4087-beda-21921c0ffbd2">10,925,702</ix:nonFraction> shares of ApolloMed&#8217;s common stock, which are treated as treasury shares for accounting purposes and not included in the number of shares of common stock outstanding used to calculate earnings per share.</span></div><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90ZXh0cmVnaW9uOmIzNDRmMzk1OTc3ZjRjYjk5MzZkOWZlYmU5MzRmMzFkXzExMTc_f66d6ad0-ece3-47f6-b8e3-9bebd419c8e5" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the earnings per share computations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTo0MDc2Zjg1NWYwOGY0ZTMzOWFhNzFjMTY3YjlkMWE5MC90YWJsZXJhbmdlOjQwNzZmODU1ZjA4ZjRlMzM5YWE3MWMxNjdiOWQxYTkwXzEtMi0xLTEtNzAwNDI_fe932702-7148-49d2-9914-21052664fcd6">0.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTo0MDc2Zjg1NWYwOGY0ZTMzOWFhNzFjMTY3YjlkMWE5MC90YWJsZXJhbmdlOjQwNzZmODU1ZjA4ZjRlMzM5YWE3MWMxNjdiOWQxYTkwXzEtNC0xLTEtNzAwNDI_8279af8c-32b9-4a4b-bcfa-1ecb922e9737">0.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTo0MDc2Zjg1NWYwOGY0ZTMzOWFhNzFjMTY3YjlkMWE5MC90YWJsZXJhbmdlOjQwNzZmODU1ZjA4ZjRlMzM5YWE3MWMxNjdiOWQxYTkwXzItMi0xLTEtNzAwNDI_98938bb9-422e-4565-bb1f-ded162a5d8ec">0.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTo0MDc2Zjg1NWYwOGY0ZTMzOWFhNzFjMTY3YjlkMWE5MC90YWJsZXJhbmdlOjQwNzZmODU1ZjA4ZjRlMzM5YWE3MWMxNjdiOWQxYTkwXzItNC0xLTEtNzAwNDI_d8e2291d-4745-4cdd-9460-853823a0e75f">0.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTo0MDc2Zjg1NWYwOGY0ZTMzOWFhNzFjMTY3YjlkMWE5MC90YWJsZXJhbmdlOjQwNzZmODU1ZjA4ZjRlMzM5YWE3MWMxNjdiOWQxYTkwXzMtMi0xLTEtNzAwNDI_7c11bc6b-4f25-4de8-8a10-bbce31269def">44,681,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTo0MDc2Zjg1NWYwOGY0ZTMzOWFhNzFjMTY3YjlkMWE5MC90YWJsZXJhbmdlOjQwNzZmODU1ZjA4ZjRlMzM5YWE3MWMxNjdiOWQxYTkwXzMtNC0xLTEtNzAwNDI_bead3588-939c-463c-9541-7cb25826b9bd">42,336,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTo0MDc2Zjg1NWYwOGY0ZTMzOWFhNzFjMTY3YjlkMWE5MC90YWJsZXJhbmdlOjQwNzZmODU1ZjA4ZjRlMzM5YWE3MWMxNjdiOWQxYTkwXzQtMi0xLTEtNzAwNDI_5dbc0e56-da95-41a3-a1fc-f51e5d66c661">45,994,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTo0MDc2Zjg1NWYwOGY0ZTMzOWFhNzFjMTY3YjlkMWE5MC90YWJsZXJhbmdlOjQwNzZmODU1ZjA4ZjRlMzM5YWE3MWMxNjdiOWQxYTkwXzQtNC0xLTEtNzAwNDI_2f05a272-c35d-40b9-866d-8305bd52d398">43,566,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90ZXh0cmVnaW9uOmIzNDRmMzk1OTc3ZjRjYjk5MzZkOWZlYmU5MzRmMzFkXzExMTI_b92ac836-10af-4f8d-8bda-b3f5ae9e7eb9" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the shares included in the diluted earnings per share computations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTozMTNlYzA0NjJlY2I0NzFiODNhMGFjYTJkYTFjZmY2ZC90YWJsZXJhbmdlOjMxM2VjMDQ2MmVjYjQ3MWI4M2EwYWNhMmRhMWNmZjZkXzEtMi0xLTEtNzAwNDI_fb2a42ed-6cfd-4317-b21b-9f1a1b7f76c9">44,681,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTozMTNlYzA0NjJlY2I0NzFiODNhMGFjYTJkYTFjZmY2ZC90YWJsZXJhbmdlOjMxM2VjMDQ2MmVjYjQ3MWI4M2EwYWNhMmRhMWNmZjZkXzEtNC0xLTEtNzAwNDI_7a31cb25-d850-47ea-b476-714eabcb594c">42,336,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib88b8cbaf9c044f48d97f4585c10e9b1_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTozMTNlYzA0NjJlY2I0NzFiODNhMGFjYTJkYTFjZmY2ZC90YWJsZXJhbmdlOjMxM2VjMDQ2MmVjYjQ3MWI4M2EwYWNhMmRhMWNmZjZkXzMtMi0xLTEtNzAwNDI_676f1f32-e3c5-4018-bd93-264e2939003f">482,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8dc8e8d5b2d3450c82e20483d0b1d396_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTozMTNlYzA0NjJlY2I0NzFiODNhMGFjYTJkYTFjZmY2ZC90YWJsZXJhbmdlOjMxM2VjMDQ2MmVjYjQ3MWI4M2EwYWNhMmRhMWNmZjZkXzMtNC0xLTEtNzAwNDI_e98c44ea-f1c6-4204-a8cc-d7985c0e0d3e">318,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6cfa814cabb748ff9a56f20f22646f52_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTozMTNlYzA0NjJlY2I0NzFiODNhMGFjYTJkYTFjZmY2ZC90YWJsZXJhbmdlOjMxM2VjMDQ2MmVjYjQ3MWI4M2EwYWNhMmRhMWNmZjZkXzQtMi0xLTEtNzAwNDI_abcd7c59-ae3e-4bdf-9800-9c63bb32a8bd">729,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iad0d67abd1ee4eb5a0b58ae347cb78d5_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTozMTNlYzA0NjJlY2I0NzFiODNhMGFjYTJkYTFjZmY2ZC90YWJsZXJhbmdlOjMxM2VjMDQ2MmVjYjQ3MWI4M2EwYWNhMmRhMWNmZjZkXzQtNC0xLTEtNzAwNDI_ab566099-e4da-409c-bb47-78975ecf3ce9">811,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f93afb80fb24f97b3aa96bd0066452e_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTozMTNlYzA0NjJlY2I0NzFiODNhMGFjYTJkYTFjZmY2ZC90YWJsZXJhbmdlOjMxM2VjMDQ2MmVjYjQ3MWI4M2EwYWNhMmRhMWNmZjZkXzUtMi0xLTEtOTc1NTk_1f5b7723-8337-4f79-95e3-7180cff98b14">101,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6687248226604b5aa14b27933ac85631_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTozMTNlYzA0NjJlY2I0NzFiODNhMGFjYTJkYTFjZmY2ZC90YWJsZXJhbmdlOjMxM2VjMDQ2MmVjYjQ3MWI4M2EwYWNhMmRhMWNmZjZkXzUtNC0xLTEtOTc1NzA_eb4ce4b6-9e52-4bab-ad24-be5aa92cba87">99,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTozMTNlYzA0NjJlY2I0NzFiODNhMGFjYTJkYTFjZmY2ZC90YWJsZXJhbmdlOjMxM2VjMDQ2MmVjYjQ3MWI4M2EwYWNhMmRhMWNmZjZkXzYtMi0xLTEtNzAwNDI_8de74ef8-abc0-4392-872e-1c541498e2b6">45,994,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTozMTNlYzA0NjJlY2I0NzFiODNhMGFjYTJkYTFjZmY2ZC90YWJsZXJhbmdlOjMxM2VjMDQ2MmVjYjQ3MWI4M2EwYWNhMmRhMWNmZjZkXzYtNC0xLTEtNzAwNDI_7b8364b8-d300-4f9e-940a-463664f9e966">43,566,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_112"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90ZXh0cmVnaW9uOmIwOGRkNGMxMTk5ZTRiZWZiMjFhNzEzYmI4OTQ2OTUwXzE5MzM_ac59b76e-f2e5-4274-8678-5a6b2801bdaa" continuedAt="i1ab1ce28e5fe4e2a8b4fa6e947071a6c" escape="true">Variable Interest Entities (VIEs)</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1ab1ce28e5fe4e2a8b4fa6e947071a6c" continuedAt="i4814be93b00648b694be478df0d16d3f">A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity&#8217;s economic performance and the obligation to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i4814be93b00648b694be478df0d16d3f" continuedAt="i574070d454d74403abe9ad387d69f643"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows guidance on the consolidation of VIEs that requires companies to utilize a qualitative approach to determine whether it is the primary beneficiary of a VIE. See Note 2 &#8211; &#8220;Basis of Presentation and Summary of Significant Accounting Policies - Variable Interest Entities&#8221; to the accompanying consolidated financial statements for information on how the Company determines VIEs and their treatment.</span></div><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:ScheduleOfVariableInterestEntitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90ZXh0cmVnaW9uOmIwOGRkNGMxMTk5ZTRiZWZiMjFhNzEzYmI4OTQ2OTUwXzE5Mzc_6dd867c6-a750-457b-9d3a-95cdbe4c96ad" continuedAt="i50ee06de21a64b559100de240bda3345" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care, and to which the creditors of ApolloMed have no recourse, and liabilities to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the general credit of ApolloMed, as the primary beneficiary of the VIEs. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands). The assets and liabilities of the Company&#8217;s other consolidated VIEs were not considered significant. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzQtMS0xLTEtNzAwNDI_c77b9d94-70a4-4ff4-a50a-6778f2f87393">142,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzQtMy0xLTEtNzAwNDI_0af2ac04-0f94-4030-b32f-e4a39dad686a">161,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzUtMS0xLTEtNzAwNDI_80b71372-493e-4a7d-bd42-295755031c03">38,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzUtMy0xLTEtNzAwNDI_08248994-8f9c-47b2-935f-f7839ae16a83">49,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzYtMS0xLTEtNzAwNDI_c4faeb99-051c-4659-b10d-805544f69e0e">23,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzYtMy0xLTEtNzAwNDI_5e419d3d-be57-4716-b9a1-2d1d8ae7d45a">7,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzctMS0xLTEtNzAwNDI_73d4ccca-8bdd-49b8-ae72-b02e7033f6dd">69,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzctMy0xLTEtNzAwNDI_891ad2d5-9ded-40c9-9d65-3ae05a9707e3">62,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzgtMS0xLTEtNzAwNDI_7c0f83c0-0940-4ba5-a87d-12889c6c5dcc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzgtMy0xLTEtNzAwNDI_c1d6b031-753f-4732-b59f-4fdbb4ade46b">1,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzktMS0xLTEtNzAwNDI_9673b796-7f0c-4c22-91d6-97433b8ece10">1,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzktMy0xLTEtNzAwNDI_a47dd354-eeb1-4aa1-8adb-40712632892f">1,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzEwLTEtMS0xLTcwMDQy_ecd23213-9193-41f5-b80c-6d26bb6a9c8c">7,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzEwLTMtMS0xLTcwMDQy_65b65d63-5433-4b3a-bf8b-6a730fa56f0a">11,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:NotesReceivableRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzExLTEtMS0xLTcwMDQy_df86a742-2ea7-4f58-826f-eb7654e346bf">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:NotesReceivableRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzExLTMtMS0xLTcwMDQy_18a7cd44-b657-465b-8168-7e24ff801e72">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount due from affiliate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:DueFromAffiliateCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzEyLTEtMS0xLTcwMDQy_999292d0-3c68-4721-a16c-7b984ad38586">25,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:DueFromAffiliateCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzEyLTMtMS0xLTcwMDQy_03a61f12-3965-485e-aaab-248f68ff983a">6,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzEzLTEtMS0xLTcwMDQy_f39e1f32-3d22-4150-840d-542144b989e1">313,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzEzLTMtMS0xLTcwMDQy_e473164f-8ccf-490c-9cfa-ac835fb0c12e">305,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property, and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzE2LTEtMS0xLTcwMDQy_1223fdfc-7365-4d17-9c70-a236e527cdc9">68,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzE2LTMtMS0xLTcwMDQy_5fa6d36e-135c-412f-9fda-7a5e5b54bfd5">49,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzE3LTEtMS0xLTcwMDQy_ab393bd2-cbe8-46c6-8e37-e05ea430f23b">61,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzE3LTMtMS0xLTcwMDQy_500db401-712c-41d0-b259-a37417351e31">58,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzE4LTEtMS0xLTcwMDQy_138f5fd0-16e5-4686-a4b8-e51411a124b6">116,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzE4LTMtMS0xLTcwMDQy_2f3fa9dd-e36d-4fee-8cfe-60a95543a111">109,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans receivable &#8211; related parties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:NotesReceivableRelatedPartiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzE5LTEtMS0xLTcwMDQy_504cff17-2e41-4326-8cb1-229de3b33e42">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:NotesReceivableRelatedPartiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzE5LTMtMS0xLTcwMDQy_5f0f892d-a953-419c-baee-a508f11c1997">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzIwLTEtMS0xLTcwMDQy_8117dfd9-794a-484a-8943-57246eae33d1">529,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzIwLTMtMS0xLTcwMDQy_728037b7-ebb7-479c-9d37-6a1daf93625f">802,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in other entities &#8211; equity method</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzIxLTEtMS0xLTcwMDQy_931bceb6-b45c-431b-a9fb-1e431eee4e42">44,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzIxLTMtMS0xLTcwMDQy_d7eea0dd-03b8-4716-80d8-0792a095b822">41,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in privately held entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzIyLTEtMS0xLTcwMDQy_0fa64e64-3468-45f3-81cd-3ee1c8187bd6">405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzIyLTMtMS0xLTcwMDQy_d541aed8-886d-41a0-a661-cfc9a3e0c431">405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzI0LTEtMS0xLTcwMDQy_cde0e6bc-39ae-4b1e-82d8-a5f089f78732">4,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzI0LTMtMS0xLTcwMDQy_9da71950-ed20-4334-893c-37b3aedf32b7">4,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzI1LTEtMS0xLTcwMDQy_680dd050-157d-4120-a575-ca99c02bf3fe">1,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzI1LTMtMS0xLTcwMDQy_37b3cd5e-5b37-4939-b20b-e169fdb874c8">3,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzI3LTEtMS0xLTcwMDQy_898fd194-3787-464d-9184-d40fed889a7c">827,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzI3LTMtMS0xLTcwMDQy_abc16aab-6732-41df-ac19-8666893496b8">1,070,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total assets</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzI5LTEtMS0xLTcwMDQy_bd376fbb-4350-4695-8e3b-2870df2cde14">1,140,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzI5LTMtMS0xLTcwMDQy_99bec4b9-43b1-4445-bb59-4a24d19d5d2f">1,376,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzMyLTEtMS0xLTcwMDQy_5961d1f6-6424-4647-ab07-301cc7d67a50">14,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzMyLTMtMS0xLTcwMDQy_c05e3769-5cd4-46db-b85f-a6d9eb8abba1">11,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiduciary accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="ameh:FiduciaryAccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzMzLTEtMS0xLTcwMDQy_3842edf0-5efc-4729-ace4-45fa5f2ed74d">6,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="ameh:FiduciaryAccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzMzLTMtMS0xLTcwMDQy_7143eaac-80ac-49d7-98ac-efa97ca49f68">10,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzM0LTEtMS0xLTcwMDQy_0f6e480c-efeb-4d98-a7ac-73afc2ebcfe2">61,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzM0LTMtMS0xLTcwMDQy_3d06acf7-3db2-453f-8a4e-90a0cfd45e91">44,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:TaxesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzM1LTEtMS0xLTcwMDQy_500b2bb8-c24b-41ee-8610-84ebdc69a183">481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzM1LTMtMS0xLTcwMDQy_82b2a4bb-e1eb-4d84-903f-6b920f623a86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:DividendsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzM2LTEtMS0xLTcwMDQy_9ab39196-229d-4c6f-bb9b-6609a2dd170d">556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:DividendsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzM2LTMtMS0xLTcwMDQy_370e069a-743a-448e-959f-a980984c33d1">556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzM4LTEtMS0xLTcwMDQy_f00d88d9-67a4-449a-a10a-13d66f623d31">1,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzM4LTMtMS0xLTcwMDQy_ea84ef20-8e71-4447-815f-a49b553a9beb">780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzM5LTEtMS0xLTcwMDQy_6838ebe2-ddcc-431a-8599-a8b604060762">543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzM5LTMtMS0xLTcwMDQy_674ce8da-fa0e-4374-8e5a-611e3f71ecc4">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div><ix:continuation id="i574070d454d74403abe9ad387d69f643"><ix:continuation id="i50ee06de21a64b559100de240bda3345"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzQwLTEtMS0xLTcwMDQy_e0927c3a-b8e7-4074-937d-a20837db3b12">1,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzQwLTMtMS0xLTcwMDQy_0c3bcad7-3621-43f2-bfd6-9176c1c2dcd5">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzQyLTEtMS0xLTcwMDQy_50cf6f9b-b113-44c2-990a-6d7568c27d12">86,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzQyLTMtMS0xLTcwMDQy_64a21b4a-391c-42c7-844b-4194d0462841">68,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion and deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzQ1LTEtMS0xLTcwMDQy_93aa422d-8771-4f7b-844d-8e0abcb6b74f">7,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzQ1LTMtMS0xLTcwMDQy_1bdec697-c2e8-4c05-87f4-19a3b798e71a">7,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzQ2LTEtMS0xLTcwMDQy_97931584-cdcf-4f58-b4b8-7a642dbfb120">3,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzQ2LTMtMS0xLTcwMDQy_80b293ab-d8d7-4de1-b8c6-b80917496458">1,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzQ3LTEtMS0xLTcwMDQy_03c888a6-7641-4751-856a-e57b7f9cec18">1,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzQ3LTMtMS0xLTcwMDQy_b946a403-b39c-4df1-b5a7-c504fc1bd4fe">193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzQ4LTEtMS0xLTcwMDQy_595f9e7d-f544-4b76-90d2-7dee11204c06">3,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzQ4LTMtMS0xLTcwMDQy_c11bbd1c-17d2-4170-a4e5-0e6cbd7c73bf">3,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzQ5LTEtMS0xLTcwMDQy_ad916381-f5af-4da8-bdcc-b8cd86a579ca">8,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzQ5LTMtMS0xLTcwMDQy_b5828126-6063-4be0-b9e9-aacb4344dca1">9,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzUxLTEtMS0xLTcwMDQy_2931d20d-7063-4013-90f8-d5111c99881d">24,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzUxLTMtMS0xLTcwMDQy_f25cd19c-be93-4854-9457-27462abe71d6">22,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzUzLTEtMS0xLTcwMDQy_98cbb925-f550-46d0-bf51-b5569c263cc7">110,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3e933fec544494a455857f02039dc6_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzUzLTMtMS0xLTcwMDQy_b007d2cc-53e3-4a36-86af-3d8561e55d3f">91,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_115"></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90ZXh0cmVnaW9uOmYxYTYwYTEyYWVmOTRkOGQ5YjU5ZTczZTVkYzI4NjNkXzEwNjA_c5c52838-f1c5-4c7c-87fa-aee4cfc23352" continuedAt="ic65a0cbd98e74b45b9c20eefbce0f9f9" escape="true"><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90ZXh0cmVnaW9uOmYxYTYwYTEyYWVmOTRkOGQ5YjU5ZTczZTVkYzI4NjNkXzEwNjE_a5dcb41d-c3a6-4ee8-8255-b89bdbbbd30c" continuedAt="i6996d381eb9941b0aa802971c838ddf2" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="ic65a0cbd98e74b45b9c20eefbce0f9f9" continuedAt="i43f57a1cc0334f19ba9798bbff9d1724"><ix:continuation id="i6996d381eb9941b0aa802971c838ddf2" continuedAt="i1f29ef1a1fe447fd92efb7bb57ae63bf"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating and finance leases for corporate offices, physicians&#8217; offices, and certain equipment. These leases have remaining lease terms of <ix:nonNumeric contextRef="ib066bd91431342b3ac8d11e80261834a_I20220331" name="us-gaap:LesseeFinanceLeaseRemainingLeaseTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90ZXh0cmVnaW9uOmYxYTYwYTEyYWVmOTRkOGQ5YjU5ZTczZTVkYzI4NjNkXzE3Mw_363539f2-1836-4dbe-9336-09f3380256bf"><ix:nonNumeric contextRef="ib066bd91431342b3ac8d11e80261834a_I20220331" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90ZXh0cmVnaW9uOmYxYTYwYTEyYWVmOTRkOGQ5YjU5ZTczZTVkYzI4NjNkXzE3Mw_9ddeca18-1326-4caf-93eb-3a5ef26e5feb">four months</ix:nonNumeric></ix:nonNumeric> to <ix:nonNumeric contextRef="i6a6d0c95500f4e4bae253dfa35567e77_I20220331" name="us-gaap:LesseeFinanceLeaseRemainingLeaseTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90ZXh0cmVnaW9uOmYxYTYwYTEyYWVmOTRkOGQ5YjU5ZTczZTVkYzI4NjNkXzE3OQ_8c6ce5b7-a2ec-40ab-8cd5-6778960075d9"><ix:nonNumeric contextRef="i6a6d0c95500f4e4bae253dfa35567e77_I20220331" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90ZXh0cmVnaW9uOmYxYTYwYTEyYWVmOTRkOGQ5YjU5ZTczZTVkYzI4NjNkXzE3OQ_940d87cf-5733-4442-8334-90a5aee5a482">eight years</ix:nonNumeric></ix:nonNumeric>, some of which may include options to extend the leases for up to <ix:nonNumeric contextRef="icdb7399a6abd460491239b97b7522507_I20220331" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90ZXh0cmVnaW9uOmYxYTYwYTEyYWVmOTRkOGQ5YjU5ZTczZTVkYzI4NjNkXzI0OA_5c47f118-6c0d-4289-80ff-dcac70d93716"><ix:nonNumeric contextRef="icdb7399a6abd460491239b97b7522507_I20220331" name="us-gaap:LesseeFinanceLeaseRenewalTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90ZXh0cmVnaW9uOmYxYTYwYTEyYWVmOTRkOGQ5YjU5ZTczZTVkYzI4NjNkXzI0OA_a807de5b-043f-4200-b728-7518b786319c">10</ix:nonNumeric></ix:nonNumeric> years, and some of which may include options to terminate the leases within <ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="ameh:LesseeFinanceLeaseTerminationPeriodIfApplicable" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90ZXh0cmVnaW9uOmYxYTYwYTEyYWVmOTRkOGQ5YjU5ZTczZTVkYzI4NjNkXzMyNw_089381cc-88be-4740-a1cf-beb1725c3925"><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="ameh:LesseeOperatingLeaseTerminationPeriodIfApplicable" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90ZXh0cmVnaW9uOmYxYTYwYTEyYWVmOTRkOGQ5YjU5ZTczZTVkYzI4NjNkXzMyNw_bc82e02f-9e26-4ff0-b69b-807448d82f54">one year</ix:nonNumeric></ix:nonNumeric>. As of March&#160;31, 2022 and December&#160;31, 2021, assets recorded under finance leases were $<ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90ZXh0cmVnaW9uOmYxYTYwYTEyYWVmOTRkOGQ5YjU5ZTczZTVkYzI4NjNkXzM5MA_18636272-d24a-40d0-9023-27460be8f196">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90ZXh0cmVnaW9uOmYxYTYwYTEyYWVmOTRkOGQ5YjU5ZTczZTVkYzI4NjNkXzM5Nw_dc2ca131-f6d3-415a-a0eb-bc2109a0322d">1.3</ix:nonFraction> million, respectively, and accumulated depreciation associated with finance leases were $<ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90ZXh0cmVnaW9uOmYxYTYwYTEyYWVmOTRkOGQ5YjU5ZTczZTVkYzI4NjNkXzQ4MA_8b679dad-02e3-4c5b-acf9-f1ece34b7aa1">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90ZXh0cmVnaW9uOmYxYTYwYTEyYWVmOTRkOGQ5YjU5ZTczZTVkYzI4NjNkXzQ4Nw_a5ec9589-b25f-497f-aff6-b2969fdfc23f">0.6</ix:nonFraction> million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the balance sheets.</span></div><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90ZXh0cmVnaW9uOmYxYTYwYTEyYWVmOTRkOGQ5YjU5ZTczZTVkYzI4NjNkXzEwNjY_9d3df3b1-32c0-4431-8d4c-43ab7933eeb1" continuedAt="ieb345b565b7c4ad387fd91519114052a" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.551%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpkNjY4MmY3NDJhNWM0MDZhOTEyNTVhY2MzZDNlNjI2MS90YWJsZXJhbmdlOmQ2NjgyZjc0MmE1YzQwNmE5MTI1NWFjYzNkM2U2MjYxXzMtMS0xLTEtNzAwNDI_a47f6751-0f87-494f-b366-3cb96d6c61dc">1,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpkNjY4MmY3NDJhNWM0MDZhOTEyNTVhY2MzZDNlNjI2MS90YWJsZXJhbmdlOmQ2NjgyZjc0MmE1YzQwNmE5MTI1NWFjYzNkM2U2MjYxXzMtMy0xLTEtNzAwNDI_fc82d33f-7595-4d3f-8bc9-389e9d233002">1,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpkNjY4MmY3NDJhNWM0MDZhOTEyNTVhY2MzZDNlNjI2MS90YWJsZXJhbmdlOmQ2NjgyZjc0MmE1YzQwNmE5MTI1NWFjYzNkM2U2MjYxXzYtMS0xLTEtNzAwNDI_def93669-0482-495a-88b9-fa056036decf">141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpkNjY4MmY3NDJhNWM0MDZhOTEyNTVhY2MzZDNlNjI2MS90YWJsZXJhbmdlOmQ2NjgyZjc0MmE1YzQwNmE5MTI1NWFjYzNkM2U2MjYxXzYtMy0xLTEtNzAwNDI_33dc376c-74bd-416e-8804-2fd3a3901450">27</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpkNjY4MmY3NDJhNWM0MDZhOTEyNTVhY2MzZDNlNjI2MS90YWJsZXJhbmdlOmQ2NjgyZjc0MmE1YzQwNmE5MTI1NWFjYzNkM2U2MjYxXzctMS0xLTEtNzAwNDI_a780a0e6-ac84-40ce-a6ab-ea803aca8ae4">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpkNjY4MmY3NDJhNWM0MDZhOTEyNTVhY2MzZDNlNjI2MS90YWJsZXJhbmdlOmQ2NjgyZjc0MmE1YzQwNmE5MTI1NWFjYzNkM2U2MjYxXzctMy0xLTEtNzAwNDI_f7922031-979e-4ab8-ba48-a515593ef33f">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpkNjY4MmY3NDJhNWM0MDZhOTEyNTVhY2MzZDNlNjI2MS90YWJsZXJhbmdlOmQ2NjgyZjc0MmE1YzQwNmE5MTI1NWFjYzNkM2U2MjYxXzktMS0xLTEtNzAwNDI_bb803478-0a80-4a00-82c5-83367ed9e75e">126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpkNjY4MmY3NDJhNWM0MDZhOTEyNTVhY2MzZDNlNjI2MS90YWJsZXJhbmdlOmQ2NjgyZjc0MmE1YzQwNmE5MTI1NWFjYzNkM2U2MjYxXzktMy0xLTEtNzAwNDI_9ec03d72-f306-40f0-be9f-ca2b7f50418b">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpkNjY4MmY3NDJhNWM0MDZhOTEyNTVhY2MzZDNlNjI2MS90YWJsZXJhbmdlOmQ2NjgyZjc0MmE1YzQwNmE5MTI1NWFjYzNkM2U2MjYxXzExLTEtMS0xLTcwMDQy_f74b4298-710d-4cce-b46e-ee00ed1d8487">1,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpkNjY4MmY3NDJhNWM0MDZhOTEyNTVhY2MzZDNlNjI2MS90YWJsZXJhbmdlOmQ2NjgyZjc0MmE1YzQwNmE5MTI1NWFjYzNkM2U2MjYxXzExLTMtMS0xLTcwMDQy_2269a779-ac7d-4c91-aabd-591bb4573a07">1,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.697%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i43f57a1cc0334f19ba9798bbff9d1724"><ix:continuation id="i1f29ef1a1fe447fd92efb7bb57ae63bf"><ix:continuation id="ieb345b565b7c4ad387fd91519114052a"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.697%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpjYTFkNDk4MDY5NTU0MGI4YmZmNTQwY2ViMmM5Y2VhNS90YWJsZXJhbmdlOmNhMWQ0OTgwNjk1NTQwYjhiZmY1NDBjZWIyYzljZWE1XzYtMS0xLTEtNzAwNDI_48e40ec0-2c11-4f41-b5f7-1bad6205b603">1,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpjYTFkNDk4MDY5NTU0MGI4YmZmNTQwY2ViMmM5Y2VhNS90YWJsZXJhbmdlOmNhMWQ0OTgwNjk1NTQwYjhiZmY1NDBjZWIyYzljZWE1XzYtMy0xLTEtNzAwNDI_66bee838-f99d-4653-a953-38dfb5536b61">1,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpjYTFkNDk4MDY5NTU0MGI4YmZmNTQwY2ViMmM5Y2VhNS90YWJsZXJhbmdlOmNhMWQ0OTgwNjk1NTQwYjhiZmY1NDBjZWIyYzljZWE1XzctMS0xLTEtNzAwNDI_945d5443-55fa-4d10-a739-19cef706dfd2">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpjYTFkNDk4MDY5NTU0MGI4YmZmNTQwY2ViMmM5Y2VhNS90YWJsZXJhbmdlOmNhMWQ0OTgwNjk1NTQwYjhiZmY1NDBjZWIyYzljZWE1XzctMy0xLTEtNzAwNDI_cd1a4155-8ad1-4a69-8716-7be68ec8f379">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpjYTFkNDk4MDY5NTU0MGI4YmZmNTQwY2ViMmM5Y2VhNS90YWJsZXJhbmdlOmNhMWQ0OTgwNjk1NTQwYjhiZmY1NDBjZWIyYzljZWE1XzgtMS0xLTEtNzAwNDI_fca8d4b6-b46e-4149-8f9f-e9299ca542aa">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpjYTFkNDk4MDY5NTU0MGI4YmZmNTQwY2ViMmM5Y2VhNS90YWJsZXJhbmdlOmNhMWQ0OTgwNjk1NTQwYjhiZmY1NDBjZWIyYzljZWE1XzgtMy0xLTEtNzAwNDI_320058f0-e538-43e2-b9a0-e045ab4b4dda">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icdb7399a6abd460491239b97b7522507_I20220331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpjYTFkNDk4MDY5NTU0MGI4YmZmNTQwY2ViMmM5Y2VhNS90YWJsZXJhbmdlOmNhMWQ0OTgwNjk1NTQwYjhiZmY1NDBjZWIyYzljZWE1XzMxLTEtMS0xLTcwMDQy_32ec382f-fed7-40fe-b5bd-c0819437bec2">6.09</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5144afd8082f4f17afadb8908f6b4051_I20210331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpjYTFkNDk4MDY5NTU0MGI4YmZmNTQwY2ViMmM5Y2VhNS90YWJsZXJhbmdlOmNhMWQ0OTgwNjk1NTQwYjhiZmY1NDBjZWIyYzljZWE1XzMxLTMtMS0xLTcwMDQy_eeebcee6-06c9-4d2d-915b-76d744b4963e">6.68</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icdb7399a6abd460491239b97b7522507_I20220331" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpjYTFkNDk4MDY5NTU0MGI4YmZmNTQwY2ViMmM5Y2VhNS90YWJsZXJhbmdlOmNhMWQ0OTgwNjk1NTQwYjhiZmY1NDBjZWIyYzljZWE1XzMyLTEtMS0xLTcwMDQy_4f000613-cc4a-46f8-abe4-64af71b54b6e">3.31</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5144afd8082f4f17afadb8908f6b4051_I20210331" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpjYTFkNDk4MDY5NTU0MGI4YmZmNTQwY2ViMmM5Y2VhNS90YWJsZXJhbmdlOmNhMWQ0OTgwNjk1NTQwYjhiZmY1NDBjZWIyYzljZWE1XzMyLTMtMS0xLTcwMDQy_38520b0f-da97-411c-88db-4a7b949b9d6e">3.42</ix:nonNumeric> years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpjYTFkNDk4MDY5NTU0MGI4YmZmNTQwY2ViMmM5Y2VhNS90YWJsZXJhbmdlOmNhMWQ0OTgwNjk1NTQwYjhiZmY1NDBjZWIyYzljZWE1XzM2LTEtMS0xLTcwMDQy_87bfacf1-466b-4482-8674-88963a39f774">6.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5144afd8082f4f17afadb8908f6b4051_I20210331" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpjYTFkNDk4MDY5NTU0MGI4YmZmNTQwY2ViMmM5Y2VhNS90YWJsZXJhbmdlOmNhMWQ0OTgwNjk1NTQwYjhiZmY1NDBjZWIyYzljZWE1XzM2LTMtMS0xLTcwMDQy_001ba554-903a-43be-a964-889325e02f71">6.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="4" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpjYTFkNDk4MDY5NTU0MGI4YmZmNTQwY2ViMmM5Y2VhNS90YWJsZXJhbmdlOmNhMWQ0OTgwNjk1NTQwYjhiZmY1NDBjZWIyYzljZWE1XzM3LTEtMS0xLTcwMDQy_6f99b201-69fb-4642-95ea-b8ca15b7708d">4.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5144afd8082f4f17afadb8908f6b4051_I20210331" decimals="4" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpjYTFkNDk4MDY5NTU0MGI4YmZmNTQwY2ViMmM5Y2VhNS90YWJsZXJhbmdlOmNhMWQ0OTgwNjk1NTQwYjhiZmY1NDBjZWIyYzljZWE1XzM3LTMtMS0xLTcwMDQy_1eecc980-81b2-4f77-9d23-ae3ea80806bd">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90ZXh0cmVnaW9uOmYxYTYwYTEyYWVmOTRkOGQ5YjU5ZTczZTVkYzI4NjNkXzEwNTY_87bc6776-c8ba-49e1-b6ba-5011e09e0154" escape="true"><ix:nonNumeric contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90ZXh0cmVnaW9uOmYxYTYwYTEyYWVmOTRkOGQ5YjU5ZTczZTVkYzI4NjNkXzEwNTc_5b4833c2-8868-46ae-8725-5f854e35cf3d" escape="true"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of March&#160;31, 2022, is as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the three months ended March&#160;31, 2022)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzEtMS0xLTEtNzAwNDI_09b02e7d-3f4b-4885-8918-8b9786bb4ec0">2,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzEtMy0xLTEtNzAwNDI_df6d6bcb-29cc-4e75-b989-739fe42190eb">470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzItMS0xLTEtNzAwNDI_6ee04f5a-e546-4944-b7d8-9e0d458697c0">3,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzItMy0xLTEtNzAwNDI_e74f20fb-a9d1-42e2-8516-278514b31bd2">539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzMtMS0xLTEtNzAwNDI_eb743d73-2240-4620-af48-29d9591a02a7">2,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzMtMy0xLTEtNzAwNDI_03383ce7-2b37-4e37-8f29-650f1ba92a49">473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzQtMS0xLTEtNzAwNDI_9b805fb0-0d39-477d-913b-ae2197a6fd4d">2,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzQtMy0xLTEtNzAwNDI_8ee129ec-f1c5-458e-adcd-c29c80d2003a">310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzUtMS0xLTEtNzAwNDI_ef67f28e-5f63-4fb9-b622-4307e562b6f7">2,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzUtMy0xLTEtNzAwNDI_d84f4247-676e-4593-ab91-c01a39c0f8ad">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="ameh:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzYtMS0xLTEtNzAwNDI_3eb8cfa1-a177-4417-a43d-9e2ad709704c">4,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="ameh:FinanceLeaseLiabilityToBePaidAfterYearFour" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzYtMy0xLTEtNzAwNDI_956d43cd-b9ea-4ddb-aa50-860a75b049ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzgtMS0xLTEtNzAwNDI_7d3529e0-b3b7-49d3-a0fe-e85610a57e04">18,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzgtMy0xLTEtNzAwNDI_3e541a00-d591-44f6-8a9f-b99f727b4641">1,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzktMS0xLTEtNzAwNDI_0e94958c-b454-4371-aeee-d919906f239c">3,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzktMy0xLTEtNzAwNDI_9ed05ead-6d5c-4c1c-a977-e360c0b60f90">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzEwLTEtMS0xLTcwMDQy_5a307e5b-03a1-4e1d-af05-2b59af9605a7">15,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzEwLTMtMS0xLTcwMDQy_f92f7ff7-742f-4819-b11f-ee3dbae14a28">1,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzExLTEtMS0xLTcwMDQy_035900d1-d7bd-4a5b-b0bc-85cdd962b6dc">2,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzExLTMtMS0xLTcwMDQy_22dff47b-dffb-4a2a-a8dc-05de31120df7">543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzEyLTEtMS0xLTcwMDQy_439550b8-0770-4cf9-a376-06a70dd5887f">12,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7399a6abd460491239b97b7522507_I20220331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzEyLTMtMS0xLTcwMDQy_0a98e08c-5e44-4a3e-96c9-395f15b54ac4">1,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company does not have additional operating and finance leases that have not yet commenced.</span></div></ix:continuation></ix:continuation><div id="i3cbe033f261a4f1ea6a0c939c6847530_127"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the unaudited consolidated financial statements and the notes thereto included in Part I, Item 1, &#8220;Financial Statements&#8221; of this Quarterly Report on Form 10-Q. In addition, reference is made to our audited consolidated financial statements and notes thereto and related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February&#160;28, 2022.</span></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_130"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc. is a leading physician-centric, technology-powered, risk-bearing healthcare management company. Leveraging its proprietary population health management and healthcare delivery platform, ApolloMed operates an integrated, value-based healthcare model, which aims to empower the providers in its network to deliver the highest quality of care to its patients in a cost-effective manner. We, together with our affiliated physician groups and consolidated entities, provide coordinated outcomes-based medical care in a cost-effective manner.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our patients are covered by private or public insurance provided through Medicare, Medicaid, and health maintenance organizations (&#8220;HMOs&#8221;). However, a small portion of our revenue comes from non-insured patients. We provide care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. Our physician network consists of primary care physicians, specialist physicians, physician and specialist extenders, and hospitalists. We operate primarily through Apollo Medical Holdings, Inc. (&#8220;ApolloMed&#8221;) and the following subsidiaries: NMM, AMM, and APAACO and their consolidated entities, including consolidated VIEs.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Led by a management team with several decades of experience, we are focused on physicians providing high-quality medical care, population health management, and care coordination for patients. As a result, we are well positioned to take advantage of the shift in the U.S. healthcare industry toward providing value-based and results-oriented healthcare with a focus on patient satisfaction, high-quality care, and cost efficiency.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our accountable care organization and a network of IPAs with more than 9,600 contracted physicians, we are responsible for coordinating care for approximately 1.2&#160;million patients primarily in California as of March&#160;31, 2022. </span></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_133"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent and Other Developments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Jade Health Care Medical Group</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><br/>&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, the Company completed the previously announced acquisition of 100% of the fully diluted capitalization of Jade Health Care Medical Group (&#8220;Jade Health&#8221;), a primary and specialty care physicians' group focused on providing high-quality care to local San Francisco Bay area communities. Jade Health is committed to delivering high-quality, affordable healthcare to Medicaid, Medicare, and Commercial members through its over 350 primary and specialty care providers. The transaction will add approximately 13,000 members, primarily located in the City and County of San Francisco and San Mateo County, to ApolloMed's membership under capitated arrangements. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_136"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Financial Measures and Indicators</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Revenues</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our revenue, which is recorded in the period in which services are rendered and earned, primarily consists of capitation revenue, risk pool settlements and incentives, GPDC revenue, management fee income, and FFS revenue. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Expenses</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our largest expenses consist of the cost of: (1) patient care paid to contracted physicians; (2) information technology equipment and software and; (3) hiring staff to provide management and administrative support services to our affiliated physician groups, as further described in the following sections. These services include payroll, benefits, physician practice billing, revenue cycle services, physician practice management, administrative oversight, coding services, and other consulting services.</span></div><div><span><br/></span></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_139"></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Income</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.893%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$ Change</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitation, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk pool settlements and incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management fee income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fee-for-services, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,058&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of services, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total expenses</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,770&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) from equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(677)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(312)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,073)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,523)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,962)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,962)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(691)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other expense, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,943)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(547)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,396)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income before provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,966)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(581)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,073&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,458&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,385)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss) income attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,498)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(268)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income attributable to Apollo Medical Holdings, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,264&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,151&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,113&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Percentage change of over 500%</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.308%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income Attributable to Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net income attributable to Apollo Medical Holdings, Inc. for the three months ended March&#160;31, 2022, was $14.3 million, as compared to $13.2 million for the same period in 2021, an increase of $1.1 million. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Physician Groups and Patients</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 and 2021, we managed a total of 12 groups of affiliated physicians, and the total number of patients for whom we managed the delivery of healthcare services was approximately 1.2&#160;million and 1.1&#160;million, respectively. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue for the three months ended March&#160;31, 2022, was $263.3 million, as compared to $176.1 million for the three months ended March&#160;31, 2021, an increase of $87.2 million, or 50%. The increase in revenue was primarily attributable to the following:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) Capitation revenue increased by approximately $77.3 million driven by organic membership growth in our core IPAs and participation in a value-based Medicare fee-for-service model.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) Fee for service increased by approximately $8.0 million driven by the consolidation of Sun Labs, beginning August 2021, and DMG, beginning October 2021, which contributed $6.3 million and increased visits to our surgery center, that had been partially closed in the prior year due to COVID-19, which contributed $1.2 million.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Services, Excluding Depreciation and Amortization</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses related to cost of services for the three months ended March&#160;31, 2022, were $220.7 million, as compared to $140.6 million for the same period in 2021, an increase of $80.1 million. The overall increase was primarily due to expected return to pre-COVID medical expense run rates and growth in membership which was commensurate to our increase in revenue.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses for the three months ended March&#160;31, 2022, were $11.9 million, as compared to $9.5 million for the same period in 2021, an increase of $2.5 million, or 26%. The increase was primarily due to an increase in stock-based compensation and other general and administrative expenses to support operational growth.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Depreciation and Amortization</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses for the three months ended March&#160;31, 2022, were $4.4 million, as compared to $4.2 million for the same period in 2021. This amount includes depreciation of property and equipment and the amortization of intangible assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Expense </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense represents income, or loss, from equity method investments, interest expense, interest income, unrealized loss on investments, and other income. Our total other expense for the three months ended March&#160;31, 2022 was $7.9 million compared to other expenses of $0.5&#160;million in 2021, an increase of $7.4&#160;million. The increase in other expense was due to unrealized loss on investments of $9.0 million and a decrease of $0.7 million due to a stimulus check received during the three months ended March&#160;31, 2021 from the Provider Relief Fund. This was partially offset by an increase in income from equity method investments of $2.1 million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $9.0&#160;million unrealized loss on investments is primarily driven by an unrealized loss of $10.6 million due to fluctuations in the stock price of a payor partner in which we hold shares. There was no unrealized gain or loss for the three months ended March&#160;31, 2021 because the payor partner became a publicly traded company in June 2021. The unrealized loss was partially offset by an unrealized gain of $1.6 million due to fluctuations in Tag 8 and APC&#8217;s interest rate swap. These shares and interest rate swap are deemed Excluded Assets that are solely for the benefit of APC and its shareholders. Any resulting gain or loss does not impact net income attributable to Apollo Medical Holdings, Inc.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $2.1 million increase in income from equity method investments was primarily due to APC&#8217;s equity method investment in LMA. For the three months ended March&#160;31, 2022, $1.3 million in income was recognized as compared to $0.7 million loss recognized for the three months ended March&#160;31, 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes was $6.2 million for the three months ended March&#160;31, 2022, as compared to provision for income taxes of $6.8 million for the same period in 2021. This was due to a decrease in pre-tax income for the three months ended March&#160;31, 2022, period as compared to the same period in 2021, as described above.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net (Loss) Income Attributable to Non-controlling Interests</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to non-controlling interests for the three months ended March&#160;31, 2022, was $2.2 million, as compared to net income attributable to non-controlling interests for the three months ended March&#160;31, 2021 of $1.3 million, respectively, a decrease of $3.5 million. The decrease was primarily driven by an unrealized loss resulting from a decreased fair value in our marketable securities related to shares held of a payor partner.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_145"></div><div style="margin-bottom:5pt;margin-top:5pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022 Guidance</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ApolloMed is raising its guidance for total revenue and the lower end of its guidance ranges for net income, EBITDA, and adjusted EBITDA, previously disclosed on March 14, 2022, as a result of strong organic membership growth and favorable membership mix. Net income and EBITDA include the impact of APC&#8217;s investment in a payer partner, which completed an initial public offering to become a publicly traded company in June 2021. As APC&#8217;s investment is an excluded asset solely for the benefit of APC and its shareholders, any gains or losses as a result of this investment do not affect the net income attributable to ApolloMed and adjusted EBITDA attributable to ApolloMed. The May 5, 2022, revised net income and EBITDA guidance ranges assume a stock price of the payer partner of $1.93. These assumptions are based on the Company&#8217;s existing business, current view of existing market conditions and assumptions for the year ending December 31, 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.939%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 Guidance Range</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 Guidance Range</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(as of March 14, 2022)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(as of May 5, 2022)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Low</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">High</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Low</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">High</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,030.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,080.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,055.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,085.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EBITDA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA&#8221; and &#8220;Use of Non-GAAP Financial Measures&#8221; below for additional information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See &#8220;Forward-Looking Statements&#8221; below for additional information.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 Guidance Range</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(as of May 5, 2022)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Low</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">High</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,000&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,000&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EBITDA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider bonus payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APC excluded assets costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss adjustment for recently acquired IPAs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of Net Income to EBITDA and Adjusted EBITDA</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(349)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EBITDA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,669&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,605&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) loss from equity method investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,433)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(613)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,304)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APC excluded assets costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss adjustment for recently acquired IPAs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,179&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,518&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Other income excludes the impact of fair value of certain equity securities held by the Company.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Non-GAAP Financial Measures</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains the non-GAAP financial measures EBITDA and adjusted EBITDA, of which the most directly comparable financial measure presented in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) is net (loss) income. These measures are not in accordance with, or an alternative to, GAAP, and may be different from other non-GAAP financial measures used by other companies. The Company uses adjusted EBITDA as a supplemental performance measure of our operations,&#160;for financial and operational decision-making, and as a supplemental means of evaluating period-to-period comparisons on a consistent basis. Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation, and amortization, excluding income or loss from equity method investments, unrealized gain or loss, provider bonuses, APC excluded assets costs, stock-based compensation, net loss adjustment for recently acquired IPAs, and other income or expenses recognized that are not related to the Company&#8217;s normal operations. Adjusted EBITDA also excludes the effect on EBITDA of certain IPAs we recently acquired. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes the presentation of these non-GAAP financial measures provides investors with relevant and useful information, as it allows investors to evaluate the operating performance of the business activities without having to account for differences recognized because of non-core or non-recurring financial information. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of the Company&#8217;s ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating operational performance, allocating resources, and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation from, or as a substitute for, GAAP financial measures. To the extent this release contains historical or future non-GAAP financial measures, the Company has provided corresponding GAAP financial measures for comparative purposes. The reconciliation between certain GAAP and non-GAAP measures is provided above.</span></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_148"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and investment in marketable securities at March&#160;31, 2022, totaled $280.8 million as compared to $286.5 million at December&#160;31, 2021. Working capital totaled $284.0 million at March&#160;31, 2022, as compared to $283.4 million at December&#160;31, 2021, an increase of $0.6 million.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically financed our operations primarily through internally generated funds. We generate cash primarily from capitation contracts, risk pool settlements and incentives, fees for medical management services provided to our affiliated physician groups, and FFS reimbursements. We generally invest cash in money market accounts, which are classified as cash and cash equivalents. We believe we have sufficient liquidity to fund our operations through at least the next 12 months.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash, cash equivalents, and restricted cash increased by $4.8 million from $233.1 million at December&#160;31, 2021, to $237.9 million at March&#160;31, 2022. Cash provided by operating activities for the three months ended March&#160;31, 2022, was $24.0 million, as compared to cash provided by operating activities of $10.0 million for the three months ended March&#160;31, 2021. The increase in cash provided by operating activities was primarily driven cash received from revenues and cash paid for cost of revenues and operating expenses, and changes in operating assets and liabilities, including the timing of income tax payments. Our primary source of cash provided by our operations are capitation revenues and timing of our risk pool and incentive settlements. Use of cash from our operating activities include payments to contracted physicians for providing patient care and personnel-related costs to support our continued growth in operations.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities during the three months ended March&#160;31, 2022, was $19.7 million, primarily due to purchases of property and equipment of $17.5 million, payments for business acquisition of $1.0 million, and funding for an equity method investment of $1.4 million. The cash used in investing activities was partially offset by a distribution received from an equity method investment of $0.2 million. Cash provided by investing activities during the three months ended March 31, 2021, was $0.7 million, primarily due to proceeds from sale of marketable securities of $1.1 million offset by purchases of marketable securities of $0.3 million and purchases of property and equipment of $0.1 million.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities during the three months ended March&#160;31, 2022, was $0.5 million as compared to cash provided by financing activities of $1.3 million for the three months ended March&#160;31, 2021. Cash provided by financing activities for the three months ended March&#160;31, 2022 was primarily due to a borrowing on Tag 8&#8217;s Construction Loan for $0.7 million and proceeds from the exercise of options and warrants of $1.6 million. This was partially offset by dividend payment of $1.2 million, repurchase of shares of $0.2 million, purchase of non-controlling interest of $0.2 million and repayment of finance lease obligations of $0.1 million. Cash provided for the three months ended March 31, 2021 was due to proceeds from the exercise of stock options and warrants for $4.3 million offset by the Company&#8217;s repayment of term loan of $2.4 million, repurchase of shares $0.3 million, and distribution of non-controlling interest of $0.2 million.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_154"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Excluded Assets</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2019, APC and AP-AMH entered into Second Amendment to Series A Preferred Stock Purchase Agreement, which clarified the term &#8220;Excluded Assets&#8221;. &#8220;Excluded Assets&#8221; means (i) assets received from the sale of shares of the Series A Preferred Stock equal to the Series A Purchase Price (as defined in the purchase agreement), (ii) the assets of APC that are not Healthcare Services Assets (as defined in the purchase agreement), including APC&#8217;s equity interests in Apollo Medical Holdings, Inc., and any entity that is primarily engaged in the business of owning, leasing, developing, or otherwise operating real estate, (iii) any assets acquired with the proceeds of the sale, assignment, or other disposition of any of the assets described in clauses (i) or (ii), and (iv) any proceeds of the assets described in clauses (i), (ii), and (iii). </span></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Excluded Assets as of March&#160;31, 2022, are primarily comprised of assets and liabilities from operating real estate and proceeds from the sale of UCI. Any dividends issued to APC shareholders are paid using cash from Excluded Assets. As of March&#160;31, 2022 and December&#160;31, 2021, the Excluded Assets balance consisted of the following (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property, and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable &#8211; related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in other entities &#8211; equity method</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivable and assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(295)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,178)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,955)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,645)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Excluded Assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,754&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,802&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_157"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Facilities</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s debt balance consisted of the following (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolver Loan</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real Estate Loans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,635&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,503)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,031)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,101&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the future commitments of the Company&#8217;s debt for the years ending December 31 (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the three months ended March 31, 2022) </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,450&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,635&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On June 16, 2021, the Company entered into an amended and restated credit agreement (the &#8220;Amended Credit Agreement&#8221; and the credit facility thereunder, the &#8220;Amended Credit Facility&#8221;) with Truist Bank, in its capacities as administrative agent for the lenders (in such capacity, the &#8220;Agent&#8221;), issuing bank, swingline lender and a lender, Truist Securities, Inc., JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Preferred Bank, Royal Bank of Canada, and Fifth Third Bank, National Association, in their capacities as joint lead arrangers and/or lenders (the &#8220;Lenders&#8221;), and Bank of the West, The Toronto-Dominion Bank, New York Branch, Well Fargo, National Association, and City National Bank in their capacities as Lenders, to, among other things, amend and restate that certain credit agreement, dated September 11, 2019, by and among the Company, certain Lenders and the Agent, in its entirety.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement provides for a five-year revolving credit facility (&#8220;Revolver Loan&#8221;) to the Company of $400.0 million, which includes a letter of credit sub-facility of up to $25.0 million and a swingline loan sub-facility of $25.0 million. The revolving credit facility will be used to, among other things, refinance certain existing indebtedness of the Company and certain subsidiaries, finance certain future acquisitions and investments, and provide for working capital needs and other general corporate purposes. Under the Amended Credit Agreement, the terms and conditions of the Guaranty and Security Agreement remain in effect. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement requires the Company to comply with two key financial ratios, each calculated on a consolidated basis. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covenant Ratios </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Requirement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated leverage ratio</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 3.75 to 1.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.04</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated interest coverage ratio</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than 3.25 to 1.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.03</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) All covenant ratio titles utilize terms as defined in the respective debt agreements. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 9 &#8211; &#8220;Credit Facility, Bank Loans, and Lines of Credit&#8221; to our consolidated financial statements under Item 1 in this Quarterly Report on Form 10-Q for additional information. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Financing Costs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company recorded deferred financing costs of $6.5 million related to its entry into the Credit Facility. In June 2021, the Company recorded additional deferred financing costs of $0.7&#160;million related to its entry into the Amended Credit Facility. Deferred financing costs are recorded as a direct reduction of the carrying amount of the related debt liability using straight-line amortization. The remaining unamortized deferred financing costs related to the Credit Facility and the new costs related to the Amended Credit Facility are amortized over the life of the Amended Credit Facility. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effective Interest Rate</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s average effective interest rate on its total debt during the three months ended March&#160;31, 2022 and 2021, were 1.78% and 2.08%, respectively.  Interest expense in the consolidated statements of income included amortization of deferred debt issuance costs for the three months ended March&#160;31, 2022 and 2021, of $0.2 million and $0.3 million, respectively.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Real Estate Loans</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, using cash comprised solely of Excluded Assets, APC purchased a 100% interest in MPP, AMG Properties, and ZLL. As a result of the purchase on the date of acquisition, APC assumed $6.4 million, $0.7 million, and $0.7 million of existing loans held by MPP, AMG Properties, and ZLL, respectively. Refer to Note 9 &#8211; &#8220;Credit Facility, Bank Loans, and Lines of Credit&#8221; to our consolidated financial statements under Item 1 in this quarterly report on Form 10-Q for additional information. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Construction Loan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, Tag 8 entered into a construction loan agreement with MUFG Union Bank N.A. (&#8220;Construction Loan&#8221;) that allows Tag 8 to borrow up to $10.7 million. Tag 8 is a VIE consolidated by the Company. Refer to Note 9 &#8211; &#8220;Credit Facility, Bank Loans, and Lines of Credit&#8221; to our consolidated financial statements under Item 1 in this quarterly report on Form 10-Q for additional information.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intercompany Loans</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of AMH, MMG, AKM Medical Group, Inc. (&#8220;AKM&#8221;), SCHC, and Bay Area Hospitalist Associates (&#8220;BAHA&#8221;) has entered into an Intercompany Loan Agreement with AMM under which AMM has agreed to provide a revolving loan commitment to each such affiliated entity in an amount set forth in each Intercompany Loan Agreement. Each Intercompany Loan Agreement provides that AMM&#8217;s obligation to make any advances automatically terminates upon the termination of the management agreement with the applicable affiliated entity. In addition, each Intercompany Loan Agreement provides that (i) any material breach by the shareholder of record of the applicable Physician Shareholder Agreement or (ii) the termination of the management agreement with the applicable affiliated entity constitutes an event of default under the Intercompany Loan Agreement. All the intercompany loans have been eliminated in consolidation (in thousands).  </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.190%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Entity</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intercompany Credit Facility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest<br/>Rate<br/>per Annum</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maximum</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">During</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ending</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principal Paid</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">During&#160;Period</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Paid</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">During</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMH</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MMG</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AKM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SCHC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BAHA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,250&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,679&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,558&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_163"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements and related disclosures in conformity with U.S. GAAP requires our management to make judgments, assumptions, and estimates that affect the amounts of revenue, expenses, income, assets, and liabilities, reported in our consolidated financial statements and accompanying notes. Actual results and the timing of recognition of such amounts could differ from those judgments, assumptions, and estimates. In addition, judgments, assumptions, and estimates routinely require adjustment based on changing circumstances and the receipt of new or better information. Understanding our accounting policies and the extent to which our management uses judgment, assumptions, and estimates in applying these policies, therefore, is integral to understanding our financial statements. Critical accounting policies and estimates are defined as those that are reflective of significant judgments and uncertainties, and potentially result in materially different results under different assumptions and conditions.&#160;We summarize our most significant accounting policies in relation to the accompanying consolidated financial statements in Note 2 &#8212; &#8220;Basis of Presentation&#8221; thereto. Please also refer to the Critical Accounting Policies section of Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021.</span></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_166"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 &#8212; &#8220;Basis of Presentation&#8221; to the accompanying consolidated financial statements for recently issued accounting pronouncements, including information on new accounting standards and the future adoption of such standards.</span></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_169"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we had no off-balance sheet arrangements that are or have been reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that are material to investors.</span></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_172"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inflation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation and changing prices have had de minimis effect on our continuing operations over our two most recent fiscal years.</span></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_175"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under our Amended Credit Agreement exposed us to interest rate risk. As of March&#160;31, 2022, we had $180.0&#160;million in outstanding borrowings under our Amended Credit Agreement. The amount borrowed under the Credit Agreement bears interest at an annual rate equal to either, at the Company&#8217;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on LIBOR, adjusted for any reserve requirement in effect, plus a spread of 1.25% to 2.50%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, or (b) a base rate, plus a spread of 0.25% to 1.50%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio. The base rate is defined in a manner such that it will not be less than LIBOR. In addition, as of March&#160;31, 2022, Tag 8, a VIE consolidated by the Company, had $1.3&#160;million in outstanding borrowings for the Construction Loan.  Interest rate on the &#8220;Construction Loan&#8221; is equal to an index rate determined by the bank. Furthermore, as of March&#160;31, 2022, APC had $7.3 million in outstanding borrowings for real estate loans related to ZLL, MPP, and AMG Properties (&#8220;Real Estate Loans&#8221;). Each agreement bears interest that is subject to change from time to time based on changes in an independent index, which is the daily Wall Street Journal Prime Rate, as quoted in the &#8220;Money Rates&#8221; column of The Wall Street Journal (Western edition) as determined by the Lender (the &#8220;Index&#8221;). On the dates of the agreement, the Index is 3.25% per annum. Under no circumstances will the interest rate on this loan be less than 3.50% per annum or more than the maximum rate allowed by applicable law. The Company has entered into interest rate swap agreements for certain of these agreements to effectively convert its floating-rate debt to a fixed-rate basis. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#8217;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. A hypothetical 1% change in our interest rates for our outstanding borrowings under our Credit Agreement, Construction Loan, and Real Estate Loans would have increased or decreased our interest expense for the three months ended March&#160;31, 2022, by $1.9 million.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_178"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;CONTROLS AND PROCEDURES</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we carried out an evaluation, under the supervision and with the participation of our management, including our Co-Chief Executive Officers and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on that evaluation, our management, including Co-Chief Executive Officers and Chief Financial Officer, concluded that our disclosure controls and procedures as defined in Rules 13a-15(e) and 15(d)-15(e) under the Exchange Act, were effective as of March&#160;31, 2022, to ensure that information required to be disclosed by us in this Quarterly Report on Form 10-Q or submitted under the Exchange Act is (i) recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms and (ii) accumulated and communicated to our management, including our principal executive officers and principal financial officer, as appropriate, to allow timely decisions regarding required disclosures.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined in Rule&#160;13a-15(f)&#160;under Exchange Act) during our first fiscal quarter of 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_181"></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II &#8211; OTHER INFORMATION</span></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_184"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we from time to time become involved in pending and threatened legal actions and proceedings. Many of the Company&#8217;s payor and provider contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services, which may not come to light until a substantial period of time has passed following contract implementation. We may also become subject to other lawsuits which could involve significant claims and/or significant defense costs, but as of the date of this Quarterly Report on Form 10-Q, except as disclosed, we are not a party to any lawsuit or proceeding which management expects to, individually or in the aggregate, have a material adverse effect on us or our business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company&#8217;s financial condition, cash flows, or results of operations.</span></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_187"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business, financial condition, and operating results are affected by a number of factors, whether currently known or unknown, including risks specific to us or the healthcare industry, as well as&#160;risks that affect businesses in general. In addition to the information and risk factors set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, Item 1A, &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February&#160;28, 2022. The risks disclosed in such Annual Report and in this Quarterly Report could materially adversely affect our business, financial condition, cash flows, or results of operations and thus our stock price. We believe there have been no material changes in our risk factors from those disclosed in the Annual Report. However, additional risks and uncertainties not currently known or which we currently deem to be immaterial may also materially adversely affect our business, financial condition, or results of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These risk factors may be important to understanding other statements in this Quarterly Report and should be read in conjunction with the consolidated financial statements and related notes in Part I, Item 1, &#8220;Financial Statements&#8221; and Part I, Item 2, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of this Quarterly Report on Form 10-Q. Because of such risk factors, as well as other factors affecting the Company&#8217;s financial condition and operating results, past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods.</span></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_190"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None for the three months ended March&#160;31, 2022.</span></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_193"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None </span></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_196"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_199"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_202"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;EXHIBITS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are either incorporated by reference into or filed or furnished with this Quarterly Report on Form 10-Q, as indicated below.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.673%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">No.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm">Agreement and Plan of Merger, dated December 21, 2016, among Apollo Medical Holdings, Inc., Network Medical Management, Inc., Apollo Acquisition Corp., and Kenneth Sim, M.D. (the &#8220;Merger Agreement&#8221;) (incorporated herein by reference to Annex A to the joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) on November 15, 2017, that is a part of a Registration Statement on Form S-4)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm">Amendment to the Merger Agreement, dated March 30, 2017, among Apollo Medical Holdings, Inc., Network Medical Management, Inc., Apollo Acquisition Corp., and Kenneth Sim, M.D. (incorporated herein by reference to Annex A to the joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) on November 15, 2017 that is a part of a Registration Statement on Form S-4)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm">Amendment No. 2 to the Merger Agreement, dated October 17, 2017, among Apollo Medical Holdings, Inc., Network Medical Management, Inc., Apollo Acquisition Corp. and Kenneth Sim, M.D. (incorporated herein by reference to Annex A to the joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) on November 15, 2017 that is a part of a Registration Statement on Form S-4)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420419025049/tv520199_ex2-4.htm">Stock purchase agreement dated March 15, 2019 (incorporated herein by reference to Exhibit 2.4 to the Company&#8217;s Quarterly Report on Form 10-Q filed on May 10, 2019)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420415002897/v398912_ex3-1.htm">Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on January 21, 2015)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420415025170/v408340_ex3-1.htm">Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on April 27, 2015)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417063540/tv481301_ex3-1.htm">Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on December 13, 2017)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420418035195/tv496923_ex3-1.htm">Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed June 21, 2018)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420415066090/v423843_ex3-2.htm">Restated Bylaws (incorporated herein by reference to Exhibit 3.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed on November 16, 2015)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417063540/tv481301_ex3-2.htm">Amendment to Sections 3.1 and 3.2 of Article III of Bylaws (incorporated herein by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K filed on December 13, 2017)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420418035195/tv496923_ex3-2.htm">Amendment to Sections 3.1 and 3.2 of Article III of Bylaws (incorporated herein by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K filed on June 21, 2018)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420415059991/v422440_ex3-1.htm">Certificate of Designation of Series A Convertible Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on October 19, 2015).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420416092455/v436045_ex3-1.htm">Amended and Restated Certificate of Designation of Apollo Medical Holdings, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on April 4, 2016).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-1.htm">Form of Certificate for Common Stock of Apollo Medical Holdings, Inc., par value $0.001 per share (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Annual Report on Form 10-K filed on April 2, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-3.htm">Form of Warrant issued as Merger Consideration pursuant to the Merger Agreement for the purchase of Common Stock of Apollo Medical Holdings, Inc., exercisable at $11.00 per share (incorporated herein by reference to Exhibit 4.3 to the Company&#8217;s Annual Report on Form 10-K filed on April 2, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-4.htm">Form of Warrant issued as Merger Consideration pursuant to the Merger Agreement for the purchase of Common Stock of Apollo Medical Holdings, Inc., exercisable at $10.00 per share (incorporated herein by reference to Exhibit 4.4 to the Company&#8217;s Annual Report on Form 10-K filed on April 2, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420415059991/v422440_ex4-1.htm">Common Stock Purchase Warrant (&#8220;Series A Warrant&#8221;) dated October 14, 2015, originally issued by Apollo Medical Holdings, Inc. to Network Medical Management, Inc. to purchase 1,111,111 shares of common stock and subsequently issued as Merger Consideration pursuant to the Merger Agreement (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on October 19, 2015).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.673%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-6.htm">Form of Assignment of Series A Warrant as Merger Consideration pursuant to the Merger Agreement (incorporated herein by reference to Exhibit 4.6 to the Company&#8217;s Annual Report on Form 10-K filed on April 2, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420416092455/v436045_ex4-1.htm">Common Stock Purchase Warrant (&#8220;Series B Warrant&#8221;) dated March 30, 2016, originally issued by Apollo Medical Holdings, Inc. to Network Medical Management, Inc. to purchase 555,555 shares of common stock and subsequently issued as Merger Consideration pursuant to the Merger Agreement (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on April 4, 2016).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-8.htm">Form of Assignment of Series B Warrant as Merger Consideration pursuant to the Merger Agreement (incorporated herein by reference to Exhibit 4.8 to the Company&#8217;s Annual Report on Form 10-K filed on April 2, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000162828020003626/ameh-20191231xexx410.htm">Description of Registered Securities</a></span></div><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex3112022033110-q.htm">Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex3122022033110-q.htm">Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.3*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex3132022033110-q.htm">Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex322022033110-q.htm">Certification of Principal Executive Officers and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Instance Document</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Schema Document</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Definition Linkbase</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filed herewith.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furnished herewith</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The schedules and exhibits thereof have been omitted pursuant to Item&#160;601(b)(2) of Regulation&#160;S-K. A copy of any omitted schedule or exhibit will be furnished to the SEC upon request.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="i3cbe033f261a4f1ea6a0c939c6847530_205"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIGNATURE</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:39.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.367%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: May 10, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Thomas Lam</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas Lam, M.D., M.P.H.<br/>Co-Chief Executive Officer &amp; President<br/>(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: May 10, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Brandon Sim</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brandon Sim<br/>Co-Chief Executive Officer<br/>(Principal Executive Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: May 10, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Chandan Basho</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chandan Basho<br/>Interim Chief Financial Officer<br/>(Principal Financial Officer)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex3112022033110-q.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i64c59f003e34442b8ec8592c32bf1f7f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">PURSUANT TO</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Thomas Lam, M.D., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this quarterly report on Form 10-Q of Apollo Medical Holdings, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Thomas Lam</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Thomas Lam</font></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive Officer and President</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex3122022033110-q.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i96519e6345f145e4bae6677c92afd4b0_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> EXHIBIT 31.2</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">PURSUANT TO</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Brandon Sim, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this quarterly report on Form 10-Q of Apollo Medical Holdings, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Brandon Sim</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Brandon Sim</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.3
<SEQUENCE>4
<FILENAME>ex3132022033110-q.htm
<DESCRIPTION>EX-31.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i80e8148cc96945b48ceb2487e9eb39a7_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> EXHIBIT 31.3</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">PURSUANT TO</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Chandan Basho, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this quarterly report on Form 10-Q of Apollo Medical Holdings, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Chandan Basho</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chandan Basho</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interim Chief Financial Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>5
<FILENAME>ex322022033110-q.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic2a7f75a76724f628a6febf338009efa_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICERS AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Thomas Lam, M.D., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of Apollo Medical Holdings, Inc. for the quarter ended March&#160;31, 2022 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Apollo Medical Holdings, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.391%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Thomas Lam</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Thomas Lam</font></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive Officer and President</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Brandon Sim, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of Apollo Medical Holdings, Inc. for the quarter ended March&#160;31, 2022 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Apollo Medical Holdings, Inc.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.391%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Brandon Sim</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Brandon Sim</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Chandan Basho, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of Apollo Medical Holdings, Inc. for the quarter ended March&#160;31, 2022 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Apollo Medical Holdings, Inc.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.391%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Chandan Basho</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chandan Basho</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interim Chief Financial Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>ameh-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:5baec51e-b1b5-44e5-a5ac-49c0e6499a3f,g:d2f55b59-0a61-4e65-b745-a66f96888c42-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ameh="http://www.apollomed.net/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.apollomed.net/20220331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ameh-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ameh-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ameh-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ameh-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.apollomed.net/role/DocumentandEntityInformation">
        <link:definition>0001001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFINCOME" roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY" roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://www.apollomed.net/role/DescriptionofBusiness">
        <link:definition>2101101 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails">
        <link:definition>2402401 - Disclosure - Description of Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>2406402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails">
        <link:definition>2407403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails">
        <link:definition>2408404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails">
        <link:definition>2409405 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Company's Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsandGoodwill" roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwill">
        <link:definition>2110103 - Disclosure - Business Combinations and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsandGoodwillTables" roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables">
        <link:definition>2311302 - Disclosure - Business Combinations and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsandGoodwillAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails">
        <link:definition>2412406 - Disclosure - Business Combinations and Goodwill - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsandGoodwillSummaryofGoodwillDetails" roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails">
        <link:definition>2413407 - Disclosure - Business Combinations and Goodwill - Summary of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNet" roleURI="http://www.apollomed.net/role/IntangibleAssetsNet">
        <link:definition>2114104 - Disclosure - Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetTables" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetTables">
        <link:definition>2315303 - Disclosure - Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetScheduleofIntangibleAssetsDetails" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails">
        <link:definition>2416408 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1">
        <link:definition>2416408 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails">
        <link:definition>2417409 - Disclosure - Intangible Assets, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetFutureAmortizationExpenseDetails" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails">
        <link:definition>2418410 - Disclosure - Intangible Assets, Net - Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntities" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntities">
        <link:definition>2119105 - Disclosure - Investments in Other Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesTables" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesTables">
        <link:definition>2320304 - Disclosure - Investments in Other Entities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails">
        <link:definition>2421411 - Disclosure - Investments in Other Entities - Equity Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails">
        <link:definition>2422412 - Disclosure - Investments in Other Entities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails">
        <link:definition>2423413 - Disclosure - Investments in Other Entities - Summarized Balance Sheets and Statements of Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoanReceivableandLoanReceivableRelatedParties" roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties">
        <link:definition>2124106 - Disclosure - Loan Receivable and Loan Receivable &#8211; Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails">
        <link:definition>2425414 - Disclosure - Loan Receivable and Loan Receivable &#8211; Related Parties - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedExpenses" roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpenses">
        <link:definition>2126107 - Disclosure - Accounts Payable and Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedExpensesTables" roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables">
        <link:definition>2327305 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails">
        <link:definition>2428415 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalLiabilities" roleURI="http://www.apollomed.net/role/MedicalLiabilities">
        <link:definition>2129108 - Disclosure - Medical Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalLiabilitiesTables" roleURI="http://www.apollomed.net/role/MedicalLiabilitiesTables">
        <link:definition>2330306 - Disclosure - Medical Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" roleURI="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails">
        <link:definition>2431416 - Disclosure - Medical Liabilities - Schedule of Medical Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoansandLinesofCredit" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit">
        <link:definition>2132109 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoansandLinesofCreditTables" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables">
        <link:definition>2333307 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails">
        <link:definition>2434417 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Credit Facility (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails">
        <link:definition>2435418 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Schedule of Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails">
        <link:definition>2436419 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MezzanineandStockholdersEquity" roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquity">
        <link:definition>2137110 - Disclosure - Mezzanine and Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MezzanineandStockholdersEquityAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails">
        <link:definition>2438420 - Disclosure - Mezzanine and Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.apollomed.net/role/StockBasedCompensation">
        <link:definition>2139111 - Disclosure - Stock Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.apollomed.net/role/StockBasedCompensationTables">
        <link:definition>2340308 - Disclosure - Stock Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails">
        <link:definition>2441421 - Disclosure - Stock Based Compensation - Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails">
        <link:definition>2442422 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockOptionActivityDetails" roleURI="http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails">
        <link:definition>2443423 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails" roleURI="http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails">
        <link:definition>2444424 - Disclosure - Stock-Based Compensation - Options, Assumptions Under Black-Scholes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofWarrantDetails" roleURI="http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails">
        <link:definition>2445425 - Disclosure - Stock-Based Compensation - Summary of Warrant (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationWarrantsDetails" roleURI="http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails">
        <link:definition>2446426 - Disclosure - Stock-Based Compensation - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.apollomed.net/role/CommitmentsandContingencies">
        <link:definition>2147112 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>2448427 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.apollomed.net/role/RelatedPartyTransactions">
        <link:definition>2149113 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsTables" roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsTables">
        <link:definition>2350309 - Disclosure - Related-Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>2451428 - Disclosure - Related-Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails">
        <link:definition>2452429 - Disclosure - Related-Party Transactions - Fees Incurred and Income Received (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.apollomed.net/role/IncomeTaxes">
        <link:definition>2153114 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>2454430 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.apollomed.net/role/EarningsPerShare">
        <link:definition>2155115 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.apollomed.net/role/EarningsPerShareTables">
        <link:definition>2356310 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails">
        <link:definition>2457431 - Disclosure - Earnings Per Share - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareEarningsPerShareComputationsDetails" roleURI="http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails">
        <link:definition>2458432 - Disclosure - Earnings Per Share - Earnings Per Share Computations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" roleURI="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails">
        <link:definition>2459433 - Disclosure - Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesVIEs" roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEs">
        <link:definition>2160116 - Disclosure - Variable Interest Entities (VIEs)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesVIEsTables" roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables">
        <link:definition>2361311 - Disclosure - Variable Interest Entities (VIEs) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesVIEsDetails" roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails">
        <link:definition>2462434 - Disclosure - Variable Interest Entities (VIEs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.apollomed.net/role/Leases">
        <link:definition>2163117 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.apollomed.net/role/LeasesTables">
        <link:definition>2364312 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalinformationDetails" roleURI="http://www.apollomed.net/role/LeasesAdditionalinformationDetails">
        <link:definition>2465435 - Disclosure - Leases - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseExpenseDetails" roleURI="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails">
        <link:definition>2466436 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesOtherInformationRelatedtoLeasesDetails" roleURI="http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails">
        <link:definition>2467437 - Disclosure - Leases - Other Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails" roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails">
        <link:definition>2468438 - Disclosure - Leases - Future Minimum Payments Under Non-cancelable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1" roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1">
        <link:definition>2468438 - Disclosure - Leases - Future Minimum Payments Under Non-cancelable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ameh_DmgMember" abstract="true" name="DmgMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_NumberOfWarrantsGranted" abstract="false" name="NumberOfWarrantsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_MedicaidMember" abstract="true" name="MedicaidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ShareholdersAndOfficersMember" abstract="true" name="ShareholdersAndOfficersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" abstract="false" name="ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ameh_LmaMember" abstract="true" name="LmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ApcShareholdersMember" abstract="true" name="ApcShareholdersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_APAMHMedicalCorporationMember" abstract="true" name="APAMHMedicalCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_ClinigenceHoldingsIncMember" abstract="true" name="ClinigenceHoldingsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ArroyoVistaMember" abstract="true" name="ArroyoVistaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_WarrantExercisePriceRangeThreeMember" abstract="true" name="WarrantExercisePriceRangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_FinanceReceivableStatedInterestRate" abstract="false" name="FinanceReceivableStatedInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_MedicalPropertyPartnersLLCMember" abstract="true" name="MedicalPropertyPartnersLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PreferredBankMember" abstract="true" name="PreferredBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_LongTermDebtMaturityAfterYearFour" abstract="false" name="LongTermDebtMaturityAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_TemporaryEquityPolicyTextBlock" abstract="false" name="TemporaryEquityPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ameh_ApcBusinessLoanAgreementMember" abstract="true" name="ApcBusinessLoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="FinanceLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentsContribution" abstract="false" name="EquityMethodInvestmentsContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_EarningsPerShareLineItems" abstract="true" name="EarningsPerShareLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_ApolloSunLabsManagementLLCMember" abstract="true" name="ApolloSunLabsManagementLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" abstract="false" name="BusinessCombinationEquityInterestPurchaseObligationNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_NetworkRelationshipsMember" abstract="true" name="NetworkRelationshipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" abstract="false" name="LesseeFinanceLeaseTerminationPeriodIfApplicable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_OtherThirdPartiesMember" abstract="true" name="OtherThirdPartiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_StockIssuedDuringPeriodSharesMerger" abstract="false" name="StockIssuedDuringPeriodSharesMerger" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_AchievaMedInc.Member" abstract="true" name="AchievaMedInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_AlliedPacificOfCaliforniaIPAMember" abstract="true" name="AlliedPacificOfCaliforniaIPAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_FinanceLeaseCostsAbstract" abstract="true" name="FinanceLeaseCostsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_PayorEMember" abstract="true" name="PayorEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_AurionMember" abstract="true" name="AurionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_DebtCovenantAggregatePurchasePriceMaximum" abstract="false" name="DebtCovenantAggregatePurchasePriceMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_NetworkMedicalManagementMember" abstract="true" name="NetworkMedicalManagementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" abstract="false" name="ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ameh_WarrantExercisePriceRangeOneMember" abstract="true" name="WarrantExercisePriceRangeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_HSMSOMember" abstract="true" name="HSMSOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PacificMedicalImagingAndOncologyCenterIncMember" abstract="true" name="PacificMedicalImagingAndOncologyCenterIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ConcourseDiagnosticSurgeryCenterLlcMember" abstract="true" name="ConcourseDiagnosticSurgeryCenterLlcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ApcLsmaMember" abstract="true" name="ApcLsmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_FiveThreeOneW.CollegeLLCMember" abstract="true" name="FiveThreeOneW.CollegeLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_AmendedCreditAgreementMember" abstract="true" name="AmendedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" abstract="false" name="FinanceReceivableModificationsSubsequentDefaultInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" abstract="false" name="ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" abstract="false" name="ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_PaymentsToAcquireCommonStockAndWarrants" abstract="false" name="PaymentsToAcquireCommonStockAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_CommercialMember" abstract="true" name="CommercialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" abstract="false" name="ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_MedicalCareCostsAbstract" abstract="true" name="MedicalCareCostsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_UniversalCareIncMember" abstract="true" name="UniversalCareIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_AncillaryServiceContractMember" abstract="true" name="AncillaryServiceContractMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" abstract="false" name="RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_PayorFMember" abstract="true" name="PayorFMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentOwnershipPercentageDisposed" abstract="false" name="EquityMethodInvestmentOwnershipPercentageDisposed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_NumberOfWarrantsExercised" abstract="false" name="NumberOfWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_WarrantExercisePriceRangeTwoMember" abstract="true" name="WarrantExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantLeverageRatioMaximum" abstract="false" name="DebtInstrumentCovenantLeverageRatioMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ameh_AmgIncMember" abstract="true" name="AmgIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" abstract="false" name="DebtInstrumentCovenantLeverageRatioIncrementalChange" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" abstract="false" name="NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ApaAcoIncMember" abstract="true" name="ApaAcoIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_SubcontractorIPAPayable" abstract="false" name="SubcontractorIPAPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentsRollForward" abstract="true" name="EquityMethodInvestmentsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" abstract="false" name="ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ameh_EarningsPerShareTable" abstract="true" name="EarningsPerShareTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_CDSCMember" abstract="true" name="CDSCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_Dr.ArteagaMember" abstract="true" name="Dr.ArteagaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_Dr.JayMember" abstract="true" name="Dr.JayMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" abstract="false" name="ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_LoanReceivableTextBlock" abstract="false" name="LoanReceivableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ameh_PatientManagementPlatformMember" abstract="true" name="PatientManagementPlatformMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_PerMemberPerMonthManagedCareContractMember" abstract="true" name="PerMemberPerMonthManagedCareContractMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ProceedsFromSaleOfNoncontrollingInterest" abstract="false" name="ProceedsFromSaleOfNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AccessPrimaryCareMedicalGroupMember" abstract="true" name="AccessPrimaryCareMedicalGroupMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" abstract="false" name="IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" abstract="true" name="OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PayorBMember" abstract="true" name="PayorBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightExercisable" abstract="false" name="ClassOfWarrantOrRightExercisable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_MemberRelationshipsMember" abstract="true" name="MemberRelationshipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_FreseniusMember" abstract="true" name="FreseniusMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" abstract="true" name="MPPAMGPropertiesAndZLLAssetAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" abstract="false" name="PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_Pacific6EnterprisesMember" abstract="true" name="Pacific6EnterprisesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_StockAwardsAndUnitsMember" abstract="true" name="StockAwardsAndUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" abstract="false" name="WarrantIssuedDuringPeriodValueStockOptionsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AdvanceDiagnosticSurgeryCenterMember" abstract="true" name="AdvanceDiagnosticSurgeryCenterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_FinanceReceivableTermOfReceivable" abstract="false" name="FinanceReceivableTermOfReceivable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" abstract="false" name="EquityMethodAndOtherEquityInvestmentsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ameh_MaverickMedicalGroupIncMember" abstract="true" name="MaverickMedicalGroupIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_IncreaseDecreaseInOperatingLeaseAssets" abstract="false" name="IncreaseDecreaseInOperatingLeaseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_SCHCMember" abstract="true" name="SCHCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" abstract="false" name="ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_DescriptionOfBusinessTable" abstract="true" name="DescriptionOfBusinessTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_CreditAgreementMember" abstract="true" name="CreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_MezzanineEquityAbstract" abstract="true" name="MezzanineEquityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_SpecialtyCapitationPayableCurrent" abstract="false" name="SpecialtyCapitationPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_CMSMember" abstract="true" name="CMSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_DescriptionOfBusinessLineItems" abstract="true" name="DescriptionOfBusinessLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_NetworkMedicalManagementIncMember" abstract="true" name="NetworkMedicalManagementIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PayorAMember" abstract="true" name="PayorAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_OneMSOInc.Member" abstract="true" name="OneMSOInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" abstract="false" name="ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ameh_WeightedAverageExercisePriceWarrantsRollForward" abstract="true" name="WeightedAverageExercisePriceWarrantsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" abstract="false" name="StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AggregateintrinsicvalueAbstract" abstract="true" name="AggregateintrinsicvalueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_PayorDMember" abstract="true" name="PayorDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_MediPortalLLCMember" abstract="true" name="MediPortalLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ContractTypeDomain" abstract="true" name="ContractTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" abstract="false" name="ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum" abstract="false" name="DebtInstrumentCovenantLeverageRatioAdjustedMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ameh_IncreaseDecreaseInMedicalLiabilities" abstract="false" name="IncreaseDecreaseInMedicalLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AccountsReceivableAndNetRevenueTable" abstract="true" name="AccountsReceivableAndNetRevenueTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_FulgentGeneticsIncMember" abstract="true" name="FulgentGeneticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PayorCMember" abstract="true" name="PayorCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_LeaseWeightedAverageDiscountRateAbstract" abstract="true" name="LeaseWeightedAverageDiscountRateAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_MinorityInterestPolicyPolicyTextBlock" abstract="false" name="MinorityInterestPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_SummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_FiduciaryAccountsPayableCurrent" abstract="false" name="FiduciaryAccountsPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ContractTypeAxis" abstract="true" name="ContractTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_AssetAcquisitionPercentageOfSharesAcquired" abstract="false" name="AssetAcquisitionPercentageOfSharesAcquired" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" abstract="true" name="LeaseWeightedAverageRemainingLeaseTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" abstract="false" name="NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" abstract="false" name="InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AccountsReceivableAndNetRevenueLineItems" abstract="true" name="AccountsReceivableAndNetRevenueLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightIssuedInPeriod" abstract="false" name="ClassOfWarrantOrRightIssuedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" abstract="true" name="ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" abstract="false" name="ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" abstract="true" name="CashPaidForLeaseLiabilitiesAbstractAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_MezzanineMember" abstract="true" name="MezzanineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EmployeesMember" abstract="true" name="EmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ManagementContractsMember" abstract="true" name="ManagementContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_APCAndAPCLSMAMember" abstract="true" name="APCAndAPCLSMAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_Tag6MedicalInvestmentGroupLLCMember" abstract="true" name="Tag6MedicalInvestmentGroupLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_UnrealizedGainLossFromInvestmentInEquitySecurities" abstract="false" name="UnrealizedGainLossFromInvestmentInEquitySecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_CAIPAMSOLLCMember" abstract="true" name="CAIPAMSOLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" abstract="false" name="ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" abstract="false" name="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_OneMSOLLCMember" abstract="true" name="OneMSOLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_FiduciaryCashAndPayablePolicyTextBlock" abstract="false" name="FiduciaryCashAndPayablePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ameh_MarketableSecuritiesCurrentMaturityPeriod" abstract="false" name="MarketableSecuritiesCurrentMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_NumberOfFederallyQualifiedHealthPlans" abstract="false" name="NumberOfFederallyQualifiedHealthPlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_NumenLLCMember" abstract="true" name="NumenLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_DebtInstrumentNumberOfKeyFinancialRatios" abstract="false" name="DebtInstrumentNumberOfKeyFinancialRatios" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_UniversalCareAcquisitionPartnersLlcMember" abstract="true" name="UniversalCareAcquisitionPartnersLlcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_Tag8MedicalInvestmentGroupLLCMember" abstract="true" name="Tag8MedicalInvestmentGroupLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ZLLPartnersLLCMember" abstract="true" name="ZLLPartnersLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember" abstract="true" name="Tag6MedicalInvestmentGroupLLCRelatedPartyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PmiocMember" abstract="true" name="PmiocMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" abstract="false" name="DebtInstrumentCovenantDebtCoverageRatioMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ameh_AHMCMember" abstract="true" name="AHMCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_AlphaCareMedicalGroupInc.Member" abstract="true" name="AlphaCareMedicalGroupInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ameh_AMGPropertiesLLCMember" abstract="true" name="AMGPropertiesLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PaymentMadeToRelatedParty" abstract="false" name="PaymentMadeToRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_PaymentsForMedicalCareCostsAbstract" abstract="true" name="PaymentsForMedicalCareCostsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" abstract="false" name="InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" abstract="false" name="BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" abstract="false" name="LesseeOperatingLeaseTerminationPeriodIfApplicable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_SharesWarrantsRollForward" abstract="true" name="SharesWarrantsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentOwnershipPercentageSold" abstract="false" name="EquityMethodInvestmentOwnershipPercentageSold" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_PaymentConsultingFees" abstract="false" name="PaymentConsultingFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" abstract="false" name="DebtInstrumentCovenantInterestCoverageRatioMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" abstract="false" name="DebtInstrumentCovenantCashFlowCoverageRatioMinimum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ameh_PaymentsToAcquireNonControllingInterest" abstract="false" name="PaymentsToAcquireNonControllingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AccountsPayableAndAccruedExpensesMember" abstract="true" name="AccountsPayableAndAccruedExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_FinanceReceivableInterestRateStatedPercentage" abstract="false" name="FinanceReceivableInterestRateStatedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" abstract="false" name="StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_ConstructionLoanMember" abstract="true" name="ConstructionLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_HealthCareCapitationRevenueMember" abstract="true" name="HealthCareCapitationRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_NumberOfFamilyPracticeClinics" abstract="false" name="NumberOfFamilyPracticeClinics" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_ContingentEquitySecuritiesMember" abstract="true" name="ContingentEquitySecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ApolloMedicalHoldingsIncMember" abstract="true" name="ApolloMedicalHoldingsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember" abstract="true" name="OrmaHealthIncAndProviderGrowthSolutionsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_LasalleMedicalAssociatesIpaMember" abstract="true" name="LasalleMedicalAssociatesIpaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightCancelledInPeriod" abstract="false" name="ClassOfWarrantOrRightCancelledInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" abstract="false" name="InsuranceServicesRevenueCapitationAndClaimsPaymentNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_WeightedaverageremainingcontractualtermyearsAbstract" abstract="true" name="WeightedaverageremainingcontractualtermyearsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_AccountableHealthCareIPAMember" abstract="true" name="AccountableHealthCareIPAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>ameh-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:5baec51e-b1b5-44e5-a5ac-49c0e6499a3f,g:d2f55b59-0a61-4e65-b745-a66f96888c42-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="ameh-20220331.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_53d21eb0-a047-427e-8c54-456da21a1b18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3039b2bd-a674-4fa4-b4e1-68c8f8b19243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_53d21eb0-a047-427e-8c54-456da21a1b18" xlink:to="loc_us-gaap_LiabilitiesCurrent_3039b2bd-a674-4fa4-b4e1-68c8f8b19243" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_a99e48ce-f90f-4cb9-b300-e4d069be38f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_53d21eb0-a047-427e-8c54-456da21a1b18" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_a99e48ce-f90f-4cb9-b300-e4d069be38f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_413d9a5a-d039-46b2-be67-3ed149ef29c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fd986e5b-3beb-49b8-a846-d4a4d4176b01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_413d9a5a-d039-46b2-be67-3ed149ef29c8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fd986e5b-3beb-49b8-a846-d4a4d4176b01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_daef38b3-d9cd-417a-ba15-59ec46e3bad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_413d9a5a-d039-46b2-be67-3ed149ef29c8" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_daef38b3-d9cd-417a-ba15-59ec46e3bad2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5c26ee7c-7357-439c-bbbe-e7dc422f90ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_413d9a5a-d039-46b2-be67-3ed149ef29c8" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5c26ee7c-7357-439c-bbbe-e7dc422f90ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_335237fe-0c6c-4d67-9517-53b780a10f68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_413d9a5a-d039-46b2-be67-3ed149ef29c8" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_335237fe-0c6c-4d67-9517-53b780a10f68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_a0146964-3a48-4169-9aca-eb5160f07306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_413d9a5a-d039-46b2-be67-3ed149ef29c8" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_a0146964-3a48-4169-9aca-eb5160f07306" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f57990b0-b8d1-4a0a-a3dd-b9d8b2852b63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_413d9a5a-d039-46b2-be67-3ed149ef29c8" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f57990b0-b8d1-4a0a-a3dd-b9d8b2852b63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_df8f7453-729a-4013-b6c9-84db3ce7dfd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_413d9a5a-d039-46b2-be67-3ed149ef29c8" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_df8f7453-729a-4013-b6c9-84db3ce7dfd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ebf1de7a-c2f8-47e1-8e64-461d148e6bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_e8fcd9aa-8d97-4a32-b38d-9781d7e0cae2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ebf1de7a-c2f8-47e1-8e64-461d148e6bb6" xlink:to="loc_us-gaap_PreferredStockValue_e8fcd9aa-8d97-4a32-b38d-9781d7e0cae2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_20eada04-c811-4df2-999a-07f4567fcfd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ebf1de7a-c2f8-47e1-8e64-461d148e6bb6" xlink:to="loc_us-gaap_CommonStockValue_20eada04-c811-4df2-999a-07f4567fcfd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1a4d3193-7a10-4530-9d4d-033bc64b9190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ebf1de7a-c2f8-47e1-8e64-461d148e6bb6" xlink:to="loc_us-gaap_AdditionalPaidInCapital_1a4d3193-7a10-4530-9d4d-033bc64b9190" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bd53db25-99a6-42fc-9d92-290d5ad4a5fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ebf1de7a-c2f8-47e1-8e64-461d148e6bb6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bd53db25-99a6-42fc-9d92-290d5ad4a5fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_30d9f95e-4cc0-466b-b315-c2963a4d2006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6da9bc1f-51da-4be6-9d0d-e7c99dd2f2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_30d9f95e-4cc0-466b-b315-c2963a4d2006" xlink:to="loc_us-gaap_AssetsCurrent_6da9bc1f-51da-4be6-9d0d-e7c99dd2f2bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_e2bc6bfe-fa10-4cce-a29b-e2f58816f349" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_30d9f95e-4cc0-466b-b315-c2963a4d2006" xlink:to="loc_us-gaap_AssetsNoncurrent_e2bc6bfe-fa10-4cce-a29b-e2f58816f349" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f87e4587-276d-4a0d-b62d-4868bc38d329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d6204074-6f9a-4604-9f36-cbfda003cd83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f87e4587-276d-4a0d-b62d-4868bc38d329" xlink:to="loc_us-gaap_StockholdersEquity_d6204074-6f9a-4604-9f36-cbfda003cd83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_0e974e1e-229f-49e7-b3f5-143038c66093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f87e4587-276d-4a0d-b62d-4868bc38d329" xlink:to="loc_us-gaap_MinorityInterest_0e974e1e-229f-49e7-b3f5-143038c66093" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8d2ffb0e-9607-4863-b87f-a1ee9036c7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9fb2343e-ed00-4d94-8d16-1e7fdd33eb7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8d2ffb0e-9607-4863-b87f-a1ee9036c7c3" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9fb2343e-ed00-4d94-8d16-1e7fdd33eb7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_42c05885-0c5c-45d2-a281-a1852ad1341d" xlink:href="ameh-20220331.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8d2ffb0e-9607-4863-b87f-a1ee9036c7c3" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_42c05885-0c5c-45d2-a281-a1852ad1341d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_20ac897f-7743-4d71-ac53-d40f4697f8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8d2ffb0e-9607-4863-b87f-a1ee9036c7c3" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_20ac897f-7743-4d71-ac53-d40f4697f8e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_c4555f0d-fa4a-4d62-a565-d0f930fcb969" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8d2ffb0e-9607-4863-b87f-a1ee9036c7c3" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_c4555f0d-fa4a-4d62-a565-d0f930fcb969" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_18a303a8-2194-4460-949f-104e1c815184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8d2ffb0e-9607-4863-b87f-a1ee9036c7c3" xlink:to="loc_us-gaap_DividendsPayableCurrent_18a303a8-2194-4460-949f-104e1c815184" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_0d78541b-0745-476d-81b1-3766104fac76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8d2ffb0e-9607-4863-b87f-a1ee9036c7c3" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_0d78541b-0745-476d-81b1-3766104fac76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_46a25429-c56a-4f78-a035-6b92e9761367" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8d2ffb0e-9607-4863-b87f-a1ee9036c7c3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_46a25429-c56a-4f78-a035-6b92e9761367" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_40c81871-2ca1-4686-814d-63de0f48f798" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8d2ffb0e-9607-4863-b87f-a1ee9036c7c3" xlink:to="loc_us-gaap_LongTermDebtCurrent_40c81871-2ca1-4686-814d-63de0f48f798" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_b11200c7-a307-4e65-8160-b7b294a02160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c4567dcb-f7a5-42b4-b610-654a5b38719f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_b11200c7-a307-4e65-8160-b7b294a02160" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c4567dcb-f7a5-42b4-b610-654a5b38719f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_500bfcea-184f-4699-91c8-073f4ee4554b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_b11200c7-a307-4e65-8160-b7b294a02160" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_500bfcea-184f-4699-91c8-073f4ee4554b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9b362a22-9f1f-4255-81ef-ff8eb28f1a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_b11200c7-a307-4e65-8160-b7b294a02160" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9b362a22-9f1f-4255-81ef-ff8eb28f1a9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_a8cbf5fc-4a03-4a4a-8d56-627d13ba9779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_b11200c7-a307-4e65-8160-b7b294a02160" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_a8cbf5fc-4a03-4a4a-8d56-627d13ba9779" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_009c5cf0-e0db-402b-94be-33793e1c9c09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_b11200c7-a307-4e65-8160-b7b294a02160" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_009c5cf0-e0db-402b-94be-33793e1c9c09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_fb6800fe-c70a-459c-bdba-efb7bb40eb7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_868a4ad1-2d72-456e-bfa6-90da19203589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_fb6800fe-c70a-459c-bdba-efb7bb40eb7c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_868a4ad1-2d72-456e-bfa6-90da19203589" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_57206acd-c542-4370-ae94-f791342528ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_fb6800fe-c70a-459c-bdba-efb7bb40eb7c" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_57206acd-c542-4370-ae94-f791342528ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9660ef1c-af84-4211-92b9-5f890d022e57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_fb6800fe-c70a-459c-bdba-efb7bb40eb7c" xlink:to="loc_us-gaap_Goodwill_9660ef1c-af84-4211-92b9-5f890d022e57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_40830ebf-5e9a-4ede-92ac-a38f3007cac6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_fb6800fe-c70a-459c-bdba-efb7bb40eb7c" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_40830ebf-5e9a-4ede-92ac-a38f3007cac6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_9f4b5350-f226-48b3-a8a0-e2343beb62e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_fb6800fe-c70a-459c-bdba-efb7bb40eb7c" xlink:to="loc_us-gaap_EquityMethodInvestments_9f4b5350-f226-48b3-a8a0-e2343beb62e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_487b580e-25c9-4353-b9b5-ea015d8f5e5a" xlink:href="ameh-20220331.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_fb6800fe-c70a-459c-bdba-efb7bb40eb7c" xlink:to="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_487b580e-25c9-4353-b9b5-ea015d8f5e5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3d888162-bd78-450c-9bc2-31b6043e93b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_fb6800fe-c70a-459c-bdba-efb7bb40eb7c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3d888162-bd78-450c-9bc2-31b6043e93b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_700f8c1c-28b0-4db4-a041-fbd4d792371f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_fb6800fe-c70a-459c-bdba-efb7bb40eb7c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_700f8c1c-28b0-4db4-a041-fbd4d792371f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_84d14a8f-ec46-4301-a823-8253a0086d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c9ba6d6b-7302-4f12-b72b-cf27bc2a54dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_84d14a8f-ec46-4301-a823-8253a0086d8a" xlink:to="loc_us-gaap_Liabilities_c9ba6d6b-7302-4f12-b72b-cf27bc2a54dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_a0499b62-5573-46fb-989a-cd2eeda38a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_84d14a8f-ec46-4301-a823-8253a0086d8a" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_a0499b62-5573-46fb-989a-cd2eeda38a9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_29cd5085-24d4-4fe0-9fa3-4e4dbc3e6bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_84d14a8f-ec46-4301-a823-8253a0086d8a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_29cd5085-24d4-4fe0-9fa3-4e4dbc3e6bf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_97c12a12-fef4-4dc1-906a-0eb0e627218f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_84d14a8f-ec46-4301-a823-8253a0086d8a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_97c12a12-fef4-4dc1-906a-0eb0e627218f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="ameh-20220331.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a101e30e-91a8-48ad-9b71-21ad4aebc566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_71a397c1-9884-49c3-af31-fe3228a78737" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_a101e30e-91a8-48ad-9b71-21ad4aebc566" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_71a397c1-9884-49c3-af31-fe3228a78737" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_52de96a4-6502-45f0-9ec8-5ac0d1e5f12b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_a101e30e-91a8-48ad-9b71-21ad4aebc566" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_52de96a4-6502-45f0-9ec8-5ac0d1e5f12b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a2686523-e479-47b6-a7b3-da55fcf37fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_48d9bada-552d-4c53-aee8-838b1ee0dd0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a2686523-e479-47b6-a7b3-da55fcf37fe2" xlink:to="loc_us-gaap_OperatingIncomeLoss_48d9bada-552d-4c53-aee8-838b1ee0dd0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_2de1547b-6068-4382-9c59-c57313a9ca34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a2686523-e479-47b6-a7b3-da55fcf37fe2" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_2de1547b-6068-4382-9c59-c57313a9ca34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0919a585-a840-4327-b781-82a4512d153b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b7c3686f-54be-4aca-9c14-0add3e250ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0919a585-a840-4327-b781-82a4512d153b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b7c3686f-54be-4aca-9c14-0add3e250ec2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_c572e60f-c898-4a06-9ef3-ac0c5f87b656" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0919a585-a840-4327-b781-82a4512d153b" xlink:to="loc_us-gaap_CostsAndExpenses_c572e60f-c898-4a06-9ef3-ac0c5f87b656" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_61fde16a-c6b8-4a8c-977b-5818f379c1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2ca1854d-f282-41e5-a2ee-fbe0a9f0d75e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_61fde16a-c6b8-4a8c-977b-5818f379c1ff" xlink:to="loc_us-gaap_ProfitLoss_2ca1854d-f282-41e5-a2ee-fbe0a9f0d75e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_602f056a-1077-4115-9898-bf86480a4636" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_61fde16a-c6b8-4a8c-977b-5818f379c1ff" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_602f056a-1077-4115-9898-bf86480a4636" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_861e859e-ac91-410e-897c-a8ed053b8157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_ebdf450d-a19a-4ff4-8f50-65470e23168c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_861e859e-ac91-410e-897c-a8ed053b8157" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_ebdf450d-a19a-4ff4-8f50-65470e23168c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_758a6dd6-779f-42a7-a0cf-a5cdb5bc9225" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_861e859e-ac91-410e-897c-a8ed053b8157" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_758a6dd6-779f-42a7-a0cf-a5cdb5bc9225" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_b6909e29-e695-4d4e-8cc3-e59ebd88e682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_861e859e-ac91-410e-897c-a8ed053b8157" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_b6909e29-e695-4d4e-8cc3-e59ebd88e682" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d64ca5d9-8dcf-48ca-abe3-15d655e1c30f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_424ce94d-d466-4d95-b069-291696417cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_d64ca5d9-8dcf-48ca-abe3-15d655e1c30f" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_424ce94d-d466-4d95-b069-291696417cdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_8b009fb3-5cae-44e9-ba4d-e121c7346d36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_d64ca5d9-8dcf-48ca-abe3-15d655e1c30f" xlink:to="loc_us-gaap_InterestExpense_8b009fb3-5cae-44e9-ba4d-e121c7346d36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_e64b9cba-536b-4de5-b352-d9c6bfa04697" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_d64ca5d9-8dcf-48ca-abe3-15d655e1c30f" xlink:to="loc_us-gaap_InvestmentIncomeInterest_e64b9cba-536b-4de5-b352-d9c6bfa04697" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_6aa6eb12-6e2d-445f-b01e-8ab2fa1dc166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_d64ca5d9-8dcf-48ca-abe3-15d655e1c30f" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_6aa6eb12-6e2d-445f-b01e-8ab2fa1dc166" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9fc20c40-1e45-471e-bf56-ee89a77b73d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_d64ca5d9-8dcf-48ca-abe3-15d655e1c30f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9fc20c40-1e45-471e-bf56-ee89a77b73d8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="ameh-20220331.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_baa1c16f-6049-4426-b95a-47cafc8e607a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_389f509a-1d65-4a1c-98d8-e0803a00e6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_baa1c16f-6049-4426-b95a-47cafc8e607a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_389f509a-1d65-4a1c-98d8-e0803a00e6fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_36e5abd7-da1b-4106-8fdf-9698367fdbdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_baa1c16f-6049-4426-b95a-47cafc8e607a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_36e5abd7-da1b-4106-8fdf-9698367fdbdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_721a52d0-fb6c-4b35-b4af-ff590727b7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_baa1c16f-6049-4426-b95a-47cafc8e607a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_721a52d0-fb6c-4b35-b4af-ff590727b7b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4d81449c-117f-407f-b405-a74704be9031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_210b48d4-08fd-4d18-9057-61f67eef988a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4d81449c-117f-407f-b405-a74704be9031" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_210b48d4-08fd-4d18-9057-61f67eef988a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_5d52a3da-8418-470d-b43d-917380fe9daf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4d81449c-117f-407f-b405-a74704be9031" xlink:to="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_5d52a3da-8418-470d-b43d-917380fe9daf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_319916a2-60fe-4fca-a2f3-0f40fd33d19d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4d81449c-117f-407f-b405-a74704be9031" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_319916a2-60fe-4fca-a2f3-0f40fd33d19d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a3d4f795-6551-4282-8437-31a1d06b8f16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4d81449c-117f-407f-b405-a74704be9031" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a3d4f795-6551-4282-8437-31a1d06b8f16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_3ca15ad0-215c-4278-b0aa-3009a4e87d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4d81449c-117f-407f-b405-a74704be9031" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_3ca15ad0-215c-4278-b0aa-3009a4e87d8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_0a982f30-2b15-4899-981f-7e9c664cf572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4d81449c-117f-407f-b405-a74704be9031" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_0a982f30-2b15-4899-981f-7e9c664cf572" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_f6d01d77-0eb6-4210-a846-2d01a85570c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4d81449c-117f-407f-b405-a74704be9031" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_f6d01d77-0eb6-4210-a846-2d01a85570c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e0dd4a3-5b4e-43b9-95e4-0d7c920106a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1105ae8f-f8e9-4fc1-844f-41926277420c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e0dd4a3-5b4e-43b9-95e4-0d7c920106a8" xlink:to="loc_us-gaap_ProfitLoss_1105ae8f-f8e9-4fc1-844f-41926277420c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_e450d008-4be2-4082-b404-305d8e358cca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e0dd4a3-5b4e-43b9-95e4-0d7c920106a8" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_e450d008-4be2-4082-b404-305d8e358cca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_55abcfc2-914b-46a6-98fe-bed870578770" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e0dd4a3-5b4e-43b9-95e4-0d7c920106a8" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_55abcfc2-914b-46a6-98fe-bed870578770" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_501c67f5-ad35-473a-8910-ee42d3cbc736" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e0dd4a3-5b4e-43b9-95e4-0d7c920106a8" xlink:to="loc_us-gaap_ShareBasedCompensation_501c67f5-ad35-473a-8910-ee42d3cbc736" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities_68f249ca-6c80-4186-a616-24a0ee17d364" xlink:href="ameh-20220331.xsd#ameh_UnrealizedGainLossFromInvestmentInEquitySecurities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e0dd4a3-5b4e-43b9-95e4-0d7c920106a8" xlink:to="loc_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities_68f249ca-6c80-4186-a616-24a0ee17d364" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ffffafd1-c636-419c-84fe-10d1037875a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e0dd4a3-5b4e-43b9-95e4-0d7c920106a8" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ffffafd1-c636-419c-84fe-10d1037875a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_f0250a5c-801f-4d22-9ffd-37c7d6d24f68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e0dd4a3-5b4e-43b9-95e4-0d7c920106a8" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_f0250a5c-801f-4d22-9ffd-37c7d6d24f68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_780b3495-6091-496a-bfb9-b234ec24b3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e0dd4a3-5b4e-43b9-95e4-0d7c920106a8" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_780b3495-6091-496a-bfb9-b234ec24b3c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7312f35b-89f3-4548-b2ac-cd74868907ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e0dd4a3-5b4e-43b9-95e4-0d7c920106a8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7312f35b-89f3-4548-b2ac-cd74868907ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_9b84fa78-df87-4b3f-b315-89e7950d9363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e0dd4a3-5b4e-43b9-95e4-0d7c920106a8" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_9b84fa78-df87-4b3f-b315-89e7950d9363" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_0df2c6c3-de59-47cf-85f4-b594659129e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e0dd4a3-5b4e-43b9-95e4-0d7c920106a8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_0df2c6c3-de59-47cf-85f4-b594659129e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_62ce37ae-a5cd-48db-b01f-7c37564ff153" xlink:href="ameh-20220331.xsd#ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e0dd4a3-5b4e-43b9-95e4-0d7c920106a8" xlink:to="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_62ce37ae-a5cd-48db-b01f-7c37564ff153" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets_6587beb3-e02c-4e0d-bc7f-3d27e6d0aef3" xlink:href="ameh-20220331.xsd#ameh_IncreaseDecreaseInOperatingLeaseAssets"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e0dd4a3-5b4e-43b9-95e4-0d7c920106a8" xlink:to="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets_6587beb3-e02c-4e0d-bc7f-3d27e6d0aef3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7a609acd-97d3-4cb2-8e7c-e9db57ef493d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e0dd4a3-5b4e-43b9-95e4-0d7c920106a8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7a609acd-97d3-4cb2-8e7c-e9db57ef493d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_34779b2d-e275-423a-bf85-dba881333812" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e0dd4a3-5b4e-43b9-95e4-0d7c920106a8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_34779b2d-e275-423a-bf85-dba881333812" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_32bccae7-fea4-4f01-80ce-2aeee1e512cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e0dd4a3-5b4e-43b9-95e4-0d7c920106a8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_32bccae7-fea4-4f01-80ce-2aeee1e512cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInMedicalLiabilities_45f20f85-b594-410c-a3b6-40652dea4b6a" xlink:href="ameh-20220331.xsd#ameh_IncreaseDecreaseInMedicalLiabilities"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e0dd4a3-5b4e-43b9-95e4-0d7c920106a8" xlink:to="loc_ameh_IncreaseDecreaseInMedicalLiabilities_45f20f85-b594-410c-a3b6-40652dea4b6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_e4c9fede-2ab0-4e08-8e6d-0909472fc2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e0dd4a3-5b4e-43b9-95e4-0d7c920106a8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_e4c9fede-2ab0-4e08-8e6d-0909472fc2c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_f1af8ea1-b4c5-47fa-bf48-de47a190c25a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e0dd4a3-5b4e-43b9-95e4-0d7c920106a8" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_f1af8ea1-b4c5-47fa-bf48-de47a190c25a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5c3300c7-072d-444e-9b87-cade305a7fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_a56ee74a-e068-47fc-8d4a-ed9906c495a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5c3300c7-072d-444e-9b87-cade305a7fe4" xlink:to="loc_us-gaap_PaymentsOfDividends_a56ee74a-e068-47fc-8d4a-ed9906c495a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_c374e128-85ba-49d4-8bec-6aabc6567d30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5c3300c7-072d-444e-9b87-cade305a7fe4" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_c374e128-85ba-49d4-8bec-6aabc6567d30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_dfaf3318-cdf1-460e-9dc9-fca64b417a31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5c3300c7-072d-444e-9b87-cade305a7fe4" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_dfaf3318-cdf1-460e-9dc9-fca64b417a31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_1b0279a7-d603-49ba-bc28-047dc6703822" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5c3300c7-072d-444e-9b87-cade305a7fe4" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_1b0279a7-d603-49ba-bc28-047dc6703822" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_22c3cb5f-8cac-459f-ad29-6fca8cd3a25d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5c3300c7-072d-444e-9b87-cade305a7fe4" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_22c3cb5f-8cac-459f-ad29-6fca8cd3a25d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_4b14c202-afc8-4286-8189-111fccb888f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5c3300c7-072d-444e-9b87-cade305a7fe4" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_4b14c202-afc8-4286-8189-111fccb888f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ProceedsFromSaleOfNoncontrollingInterest_f999ad2e-1d97-4f70-800e-7f37e5bf352c" xlink:href="ameh-20220331.xsd#ameh_ProceedsFromSaleOfNoncontrollingInterest"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5c3300c7-072d-444e-9b87-cade305a7fe4" xlink:to="loc_ameh_ProceedsFromSaleOfNoncontrollingInterest_f999ad2e-1d97-4f70-800e-7f37e5bf352c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireNonControllingInterest_6f2d0332-7835-485c-a564-b31f3eff4293" xlink:href="ameh-20220331.xsd#ameh_PaymentsToAcquireNonControllingInterest"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5c3300c7-072d-444e-9b87-cade305a7fe4" xlink:to="loc_ameh_PaymentsToAcquireNonControllingInterest_6f2d0332-7835-485c-a564-b31f3eff4293" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_d1d9aad2-4edd-4b90-9473-875177d3be24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5c3300c7-072d-444e-9b87-cade305a7fe4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_d1d9aad2-4edd-4b90-9473-875177d3be24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6c53a1b4-8615-4c6a-a482-e1a6484f641a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1e91eab5-6609-4940-a32b-b8655ef9d558" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6c53a1b4-8615-4c6a-a482-e1a6484f641a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1e91eab5-6609-4940-a32b-b8655ef9d558" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsCurrent_d29c15e0-ea0a-49b7-927f-83bfd5f42167" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6c53a1b4-8615-4c6a-a482-e1a6484f641a" xlink:to="loc_us-gaap_RestrictedCashEquivalentsCurrent_d29c15e0-ea0a-49b7-927f-83bfd5f42167" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_52c1c214-6920-4a72-930f-59ddeb6de3e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_f4c7ea2e-b2c8-4ae9-a33a-cd3ebf08f999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_52c1c214-6920-4a72-930f-59ddeb6de3e6" xlink:to="loc_us-gaap_DerivativeLiabilities_f4c7ea2e-b2c8-4ae9-a33a-cd3ebf08f999" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2b501ed3-ccd4-4797-a733-bb2661ecfacd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_52c1c214-6920-4a72-930f-59ddeb6de3e6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2b501ed3-ccd4-4797-a733-bb2661ecfacd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_0253838c-a25c-4cb7-8534-19f9b828b9af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fc19d699-7023-41c5-a312-c36143b8b28c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_0253838c-a25c-4cb7-8534-19f9b828b9af" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fc19d699-7023-41c5-a312-c36143b8b28c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3f9b99d9-0060-499c-81ec-19af1449b075" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_0253838c-a25c-4cb7-8534-19f9b828b9af" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3f9b99d9-0060-499c-81ec-19af1449b075" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_5ebebc77-549e-416e-94b1-00b435606bda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_0253838c-a25c-4cb7-8534-19f9b828b9af" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_5ebebc77-549e-416e-94b1-00b435606bda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_e2c3af97-030e-49e3-bf46-3bf3887e6507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_0253838c-a25c-4cb7-8534-19f9b828b9af" xlink:to="loc_us-gaap_DerivativeAssets_e2c3af97-030e-49e3-bf46-3bf3887e6507" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7df146d7-ae76-464e-ba94-6ed1bbe4d6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3315815-8bb3-494e-a1bf-a20f9b090110" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7df146d7-ae76-464e-ba94-6ed1bbe4d6a7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3315815-8bb3-494e-a1bf-a20f9b090110" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_fd0dad83-99d4-4330-94c3-f986b181aa39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7df146d7-ae76-464e-ba94-6ed1bbe4d6a7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_fd0dad83-99d4-4330-94c3-f986b181aa39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_eeaa9cf6-5b70-43cf-8da9-a8cb9d859e91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f2a3f769-2783-46d3-964e-92a1bf7331c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_eeaa9cf6-5b70-43cf-8da9-a8cb9d859e91" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f2a3f769-2783-46d3-964e-92a1bf7331c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_853cfaba-a395-4eea-a0e0-b124af010165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_eeaa9cf6-5b70-43cf-8da9-a8cb9d859e91" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_853cfaba-a395-4eea-a0e0-b124af010165" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2777ea83-53b7-4085-ad3d-f85630d835d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_097b16f8-869a-4fc9-bf16-4d111529dee0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2777ea83-53b7-4085-ad3d-f85630d835d4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_097b16f8-869a-4fc9-bf16-4d111529dee0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="ameh-20220331.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_52320ee4-fe1c-4d75-980d-2b3aa01bc9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6f75757e-abc3-4a78-b576-ab6f2d227b47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_52320ee4-fe1c-4d75-980d-2b3aa01bc9c1" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6f75757e-abc3-4a78-b576-ab6f2d227b47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4be44935-f0a9-4cdc-8140-9a4119107e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_52320ee4-fe1c-4d75-980d-2b3aa01bc9c1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4be44935-f0a9-4cdc-8140-9a4119107e02" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#IntangibleAssetsNetFutureAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3868f920-452c-499b-9630-770ea03364f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_933e6d81-3f4f-4dfe-9056-6fa59837b0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3868f920-452c-499b-9630-770ea03364f4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_933e6d81-3f4f-4dfe-9056-6fa59837b0b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_62f985ac-64da-47b2-92a4-d40c00114b78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3868f920-452c-499b-9630-770ea03364f4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_62f985ac-64da-47b2-92a4-d40c00114b78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_7c878d7e-159c-4dc5-b215-50839260061c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3868f920-452c-499b-9630-770ea03364f4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_7c878d7e-159c-4dc5-b215-50839260061c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4b39d4a1-a02f-43f6-a7f5-21f6129ffd3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3868f920-452c-499b-9630-770ea03364f4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4b39d4a1-a02f-43f6-a7f5-21f6129ffd3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_06c1360f-b2e1-4cbc-844d-8b2a92ef8daa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3868f920-452c-499b-9630-770ea03364f4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_06c1360f-b2e1-4cbc-844d-8b2a92ef8daa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_1a4177ed-4e01-48ed-b0c0-227ec6308121" xlink:href="ameh-20220331.xsd#ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3868f920-452c-499b-9630-770ea03364f4" xlink:to="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_1a4177ed-4e01-48ed-b0c0-227ec6308121" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_4ea03bf3-d21d-4c1a-a87e-9423acb49ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0b1e3f1b-dde5-4026-b849-a71b7d0f3792" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4ea03bf3-d21d-4c1a-a87e-9423acb49ef8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0b1e3f1b-dde5-4026-b849-a71b7d0f3792" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_3945894d-2571-4067-9ef7-435d0f641ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4ea03bf3-d21d-4c1a-a87e-9423acb49ef8" xlink:to="loc_us-gaap_RestrictedCashCurrent_3945894d-2571-4067-9ef7-435d0f641ec8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4fbe7f2e-ce48-43aa-a177-e736fee31e67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4ea03bf3-d21d-4c1a-a87e-9423acb49ef8" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4fbe7f2e-ce48-43aa-a177-e736fee31e67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_af715dbc-6d78-4431-bbcb-e4d29954f5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4ea03bf3-d21d-4c1a-a87e-9423acb49ef8" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_af715dbc-6d78-4431-bbcb-e4d29954f5d7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ed8e8511-bbb6-4d18-b59f-0084d454c279" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_fbe817c4-a283-4ce7-8a34-31535a790c09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ed8e8511-bbb6-4d18-b59f-0084d454c279" xlink:to="loc_us-gaap_AccountsPayableCurrent_fbe817c4-a283-4ce7-8a34-31535a790c09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SpecialtyCapitationPayableCurrent_e02a2eec-5b8c-4791-b222-663c9c4ecfc6" xlink:href="ameh-20220331.xsd#ameh_SpecialtyCapitationPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ed8e8511-bbb6-4d18-b59f-0084d454c279" xlink:to="loc_ameh_SpecialtyCapitationPayableCurrent_e02a2eec-5b8c-4791-b222-663c9c4ecfc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SubcontractorIPAPayable_821c2674-0af3-4044-a177-01371033bce8" xlink:href="ameh-20220331.xsd#ameh_SubcontractorIPAPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ed8e8511-bbb6-4d18-b59f-0084d454c279" xlink:to="loc_ameh_SubcontractorIPAPayable_821c2674-0af3-4044-a177-01371033bce8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_a32c5061-0277-4c8d-a28e-1908fc0fdfb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ed8e8511-bbb6-4d18-b59f-0084d454c279" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_a32c5061-0277-4c8d-a28e-1908fc0fdfb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_706ed53f-4c92-4b68-8b10-8bc1188227c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ed8e8511-bbb6-4d18-b59f-0084d454c279" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_706ed53f-4c92-4b68-8b10-8bc1188227c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_79b4855a-44ba-4c84-8339-be712223619d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ed8e8511-bbb6-4d18-b59f-0084d454c279" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_79b4855a-44ba-4c84-8339-be712223619d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8d0e2a13-881c-4ef6-81dc-6286365b87ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ed8e8511-bbb6-4d18-b59f-0084d454c279" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8d0e2a13-881c-4ef6-81dc-6286365b87ca" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_2581e849-833a-4461-89cf-ee945c263081" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_41a7e39a-3831-4058-9a84-3f4a57a9f0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_2581e849-833a-4461-89cf-ee945c263081" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_41a7e39a-3831-4058-9a84-3f4a57a9f0ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_80fcefa0-5d02-4e1d-9d8f-98787bd67033" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_2581e849-833a-4461-89cf-ee945c263081" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_80fcefa0-5d02-4e1d-9d8f-98787bd67033" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_448ec5eb-c4fc-4a6e-87dc-4588bd761a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_5f0e7964-77fc-474f-befa-9ddf8125f1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_448ec5eb-c4fc-4a6e-87dc-4588bd761a0a" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_5f0e7964-77fc-474f-befa-9ddf8125f1b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_4f2cdeb2-ef7b-44bd-8cbc-a8a2e70c097b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_448ec5eb-c4fc-4a6e-87dc-4588bd761a0a" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_4f2cdeb2-ef7b-44bd-8cbc-a8a2e70c097b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_4631ae60-9cdf-4e37-8315-30fe496b024c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_6fbd8287-02c6-4de8-a21f-abd1f3625928" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_4631ae60-9cdf-4e37-8315-30fe496b024c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_6fbd8287-02c6-4de8-a21f-abd1f3625928" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_b428e3e8-3cac-45b7-9b1b-f9d2d63292ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_4631ae60-9cdf-4e37-8315-30fe496b024c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_b428e3e8-3cac-45b7-9b1b-f9d2d63292ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_eb83b64f-1535-44fb-949b-c40d59f47e69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_4631ae60-9cdf-4e37-8315-30fe496b024c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_eb83b64f-1535-44fb-949b-c40d59f47e69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ef6ed56d-e870-4831-ac02-1aacb211c2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_4631ae60-9cdf-4e37-8315-30fe496b024c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ef6ed56d-e870-4831-ac02-1aacb211c2a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LongTermDebtMaturityAfterYearFour_bd4ca786-0f4c-409d-9cf3-e28dc695b9c9" xlink:href="ameh-20220331.xsd#ameh_LongTermDebtMaturityAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_4631ae60-9cdf-4e37-8315-30fe496b024c" xlink:to="loc_ameh_LongTermDebtMaturityAfterYearFour_bd4ca786-0f4c-409d-9cf3-e28dc695b9c9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_afae2a2b-2116-46b8-877e-dc2bbb0719c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_dc0b174d-aba8-46eb-8c86-9525f95b3f3b" xlink:href="ameh-20220331.xsd#ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_afae2a2b-2116-46b8-877e-dc2bbb0719c4" xlink:to="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_dc0b174d-aba8-46eb-8c86-9525f95b3f3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementFeeExpense_72ec63ac-1a34-45fe-b176-f13de868d020" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementFeeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_afae2a2b-2116-46b8-877e-dc2bbb0719c4" xlink:to="loc_us-gaap_ManagementFeeExpense_72ec63ac-1a34-45fe-b176-f13de868d020" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2a3d9045-98c4-4466-b5ef-cbad0c293772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_15e17bc4-60c7-4d78-b1d7-42f4b2c87a86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2a3d9045-98c4-4466-b5ef-cbad0c293772" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_15e17bc4-60c7-4d78-b1d7-42f4b2c87a86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_4ac16226-4a99-4491-86e1-23d1a400cbc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2a3d9045-98c4-4466-b5ef-cbad0c293772" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_4ac16226-4a99-4491-86e1-23d1a400cbc6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#VariableInterestEntitiesVIEsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_1aee38ca-d6a9-4853-80c5-0d114f1d026d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2d15f731-a8cc-40b0-b9cf-af6816793436" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_1aee38ca-d6a9-4853-80c5-0d114f1d026d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2d15f731-a8cc-40b0-b9cf-af6816793436" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b40eccad-f883-4b15-9422-eb48ff90bb79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_1aee38ca-d6a9-4853-80c5-0d114f1d026d" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b40eccad-f883-4b15-9422-eb48ff90bb79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a6482aef-9419-4adf-860e-5e3a169420eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_1aee38ca-d6a9-4853-80c5-0d114f1d026d" xlink:to="loc_us-gaap_Goodwill_a6482aef-9419-4adf-860e-5e3a169420eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_416be1af-0c4b-4753-9a26-4e4ddad76f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_1aee38ca-d6a9-4853-80c5-0d114f1d026d" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_416be1af-0c4b-4753-9a26-4e4ddad76f9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_831b51ae-5dcc-416a-b7f0-7b43a8068dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_1aee38ca-d6a9-4853-80c5-0d114f1d026d" xlink:to="loc_us-gaap_OtherLongTermInvestments_831b51ae-5dcc-416a-b7f0-7b43a8068dbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_4cedb519-40c3-451f-ab35-8b25bb6cef04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_1aee38ca-d6a9-4853-80c5-0d114f1d026d" xlink:to="loc_us-gaap_EquityMethodInvestments_4cedb519-40c3-451f-ab35-8b25bb6cef04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_cf489581-a22d-4df5-9c93-c5cd72d9f2df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_1aee38ca-d6a9-4853-80c5-0d114f1d026d" xlink:to="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_cf489581-a22d-4df5-9c93-c5cd72d9f2df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1ce37855-6ce9-4ab5-a344-2ec8dcb83a93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_1aee38ca-d6a9-4853-80c5-0d114f1d026d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1ce37855-6ce9-4ab5-a344-2ec8dcb83a93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_50510d08-4dfd-43b9-8966-4cc220a16e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_1aee38ca-d6a9-4853-80c5-0d114f1d026d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_50510d08-4dfd-43b9-8966-4cc220a16e4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f88686aa-558f-4026-97f6-52c1b6d662c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_24ad6270-406c-4fc8-ac2d-5cefbb94ecca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f88686aa-558f-4026-97f6-52c1b6d662c2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_24ad6270-406c-4fc8-ac2d-5cefbb94ecca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_05c314be-6fc2-4d6c-a3f4-e56153f96f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f88686aa-558f-4026-97f6-52c1b6d662c2" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_05c314be-6fc2-4d6c-a3f4-e56153f96f3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6dd0dda4-9e87-43af-9779-ea67b8276df1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f88686aa-558f-4026-97f6-52c1b6d662c2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6dd0dda4-9e87-43af-9779-ea67b8276df1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_fefc1581-0602-4745-8619-d4458a5eb368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f88686aa-558f-4026-97f6-52c1b6d662c2" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_fefc1581-0602-4745-8619-d4458a5eb368" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_606a2a19-8d0f-440f-a756-c59e6b40a492" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f88686aa-558f-4026-97f6-52c1b6d662c2" xlink:to="loc_us-gaap_IncomeTaxesReceivable_606a2a19-8d0f-440f-a756-c59e6b40a492" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_581ca1fb-32e1-49ca-9bbd-797c93a5f27d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f88686aa-558f-4026-97f6-52c1b6d662c2" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_581ca1fb-32e1-49ca-9bbd-797c93a5f27d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0bb50bbf-f2a0-411a-8208-6a9f53d82e23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f88686aa-558f-4026-97f6-52c1b6d662c2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0bb50bbf-f2a0-411a-8208-6a9f53d82e23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_ae747a98-3a09-4875-88d7-c36993c52c07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f88686aa-558f-4026-97f6-52c1b6d662c2" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_ae747a98-3a09-4875-88d7-c36993c52c07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliateCurrent_ddbc002c-e1e3-48a3-9078-79627e7475fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromAffiliateCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f88686aa-558f-4026-97f6-52c1b6d662c2" xlink:to="loc_us-gaap_DueFromAffiliateCurrent_ddbc002c-e1e3-48a3-9078-79627e7475fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2f0be9d9-b1a5-462d-9cd7-02ec3d22223d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5b9bac1f-4813-4cb6-ae1c-4082d7f8a859" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2f0be9d9-b1a5-462d-9cd7-02ec3d22223d" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5b9bac1f-4813-4cb6-ae1c-4082d7f8a859" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_a3394b8a-b791-4428-baae-c8a81e18a6ba" xlink:href="ameh-20220331.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2f0be9d9-b1a5-462d-9cd7-02ec3d22223d" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_a3394b8a-b791-4428-baae-c8a81e18a6ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_c1d09d1a-a49d-4ed4-9a86-c4a4e3ffb0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2f0be9d9-b1a5-462d-9cd7-02ec3d22223d" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_c1d09d1a-a49d-4ed4-9a86-c4a4e3ffb0bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_2fd43ead-8ea2-4f18-9b42-52b2ef44e90e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2f0be9d9-b1a5-462d-9cd7-02ec3d22223d" xlink:to="loc_us-gaap_TaxesPayableCurrent_2fd43ead-8ea2-4f18-9b42-52b2ef44e90e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_51309f6a-377d-4166-aec2-45a0cdcb5f20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2f0be9d9-b1a5-462d-9cd7-02ec3d22223d" xlink:to="loc_us-gaap_DividendsPayableCurrent_51309f6a-377d-4166-aec2-45a0cdcb5f20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_c393b5f5-c3df-4cfe-8a51-40e154a019f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2f0be9d9-b1a5-462d-9cd7-02ec3d22223d" xlink:to="loc_us-gaap_LongTermDebtCurrent_c393b5f5-c3df-4cfe-8a51-40e154a019f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_179f1e17-1ffd-426c-89e7-fcb6dd4ca345" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2f0be9d9-b1a5-462d-9cd7-02ec3d22223d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_179f1e17-1ffd-426c-89e7-fcb6dd4ca345" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_34423427-89a0-4517-8484-a1c72a474829" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2f0be9d9-b1a5-462d-9cd7-02ec3d22223d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_34423427-89a0-4517-8484-a1c72a474829" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_53628aa0-822f-4e16-8bbd-b3ec9388a44e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_f468fe25-969d-4e1d-8761-d45a0061d1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_53628aa0-822f-4e16-8bbd-b3ec9388a44e" xlink:to="loc_us-gaap_OperatingLeaseCost_f468fe25-969d-4e1d-8761-d45a0061d1aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_2d8a8f48-a4b5-4c81-a6c3-f71c1e9f1599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_53628aa0-822f-4e16-8bbd-b3ec9388a44e" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_2d8a8f48-a4b5-4c81-a6c3-f71c1e9f1599" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_ac0ff543-3292-4356-842e-da97c76d759d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_53628aa0-822f-4e16-8bbd-b3ec9388a44e" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_ac0ff543-3292-4356-842e-da97c76d759d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_ad23975c-a4f6-49a1-be16-282f03663102" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_53628aa0-822f-4e16-8bbd-b3ec9388a44e" xlink:to="loc_us-gaap_SubleaseIncome_ad23975c-a4f6-49a1-be16-282f03663102" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0aa564de-f16e-4427-9504-6e21fdae9c46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_311d7a73-d496-4056-b34d-34775365b159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0aa564de-f16e-4427-9504-6e21fdae9c46" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_311d7a73-d496-4056-b34d-34775365b159" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ede6c85d-2888-41bd-8ed7-222e1bd8dce7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0aa564de-f16e-4427-9504-6e21fdae9c46" xlink:to="loc_us-gaap_OperatingLeaseLiability_ede6c85d-2888-41bd-8ed7-222e1bd8dce7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_39339351-4ae8-4721-9623-cb773f9aa23b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_0b9e508a-fcd2-4a4f-95f4-6085752256e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_39339351-4ae8-4721-9623-cb773f9aa23b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_0b9e508a-fcd2-4a4f-95f4-6085752256e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_ea2bc7bb-3f78-4491-8ce8-49b1e877b9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_39339351-4ae8-4721-9623-cb773f9aa23b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_ea2bc7bb-3f78-4491-8ce8-49b1e877b9ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e60166d1-8cf6-4247-a689-2b2a54a33733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_19e09749-48e0-4a2d-a42a-c122de59dc69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_e60166d1-8cf6-4247-a689-2b2a54a33733" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_19e09749-48e0-4a2d-a42a-c122de59dc69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5ea6045f-28d4-4c09-ba2b-277f476ebd06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_e60166d1-8cf6-4247-a689-2b2a54a33733" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5ea6045f-28d4-4c09-ba2b-277f476ebd06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_7ce95ddc-74f5-481d-8a1a-1b6011909eee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_a993d2a9-ac47-42d0-ae8e-2401a9822562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_7ce95ddc-74f5-481d-8a1a-1b6011909eee" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_a993d2a9-ac47-42d0-ae8e-2401a9822562" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_48885226-5f2e-40d1-a434-e23bb864face" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_7ce95ddc-74f5-481d-8a1a-1b6011909eee" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_48885226-5f2e-40d1-a434-e23bb864face" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_27ecde6e-ec68-4a8b-96bc-8da91af05d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_7ce95ddc-74f5-481d-8a1a-1b6011909eee" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_27ecde6e-ec68-4a8b-96bc-8da91af05d5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_51ae60e9-5d95-4148-9a23-84a8ff121665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_7ce95ddc-74f5-481d-8a1a-1b6011909eee" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_51ae60e9-5d95-4148-9a23-84a8ff121665" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_1ab1fcc0-c3dd-4d44-b0ff-77f9f78d090a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_7ce95ddc-74f5-481d-8a1a-1b6011909eee" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_1ab1fcc0-c3dd-4d44-b0ff-77f9f78d090a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_3bae6619-e77b-439f-8fb1-403c56418bf7" xlink:href="ameh-20220331.xsd#ameh_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_7ce95ddc-74f5-481d-8a1a-1b6011909eee" xlink:to="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_3bae6619-e77b-439f-8fb1-403c56418bf7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1" xlink:type="simple" xlink:href="ameh-20220331.xsd#LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2c0886f7-44c4-4aaa-b1f4-6cf49e9e1fad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6f868c50-eaaf-4bf4-ac6c-a7cb74911011" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2c0886f7-44c4-4aaa-b1f4-6cf49e9e1fad" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6f868c50-eaaf-4bf4-ac6c-a7cb74911011" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b7109889-e3d6-407c-82d8-6d22cd942608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2c0886f7-44c4-4aaa-b1f4-6cf49e9e1fad" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b7109889-e3d6-407c-82d8-6d22cd942608" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2eba89d1-222a-4500-9d67-24f2291cabec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2c0886f7-44c4-4aaa-b1f4-6cf49e9e1fad" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2eba89d1-222a-4500-9d67-24f2291cabec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_26eaf84f-36e8-40c0-9b00-356645a61154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2c0886f7-44c4-4aaa-b1f4-6cf49e9e1fad" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_26eaf84f-36e8-40c0-9b00-356645a61154" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e0318d9f-e5bc-4465-a257-23e793b70b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2c0886f7-44c4-4aaa-b1f4-6cf49e9e1fad" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e0318d9f-e5bc-4465-a257-23e793b70b2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_07c62334-689f-4b3d-968a-06e36f99475e" xlink:href="ameh-20220331.xsd#ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2c0886f7-44c4-4aaa-b1f4-6cf49e9e1fad" xlink:to="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_07c62334-689f-4b3d-968a-06e36f99475e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_02f961cc-19fe-4bcb-8665-c6f64afc36e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_3772ac77-3140-4055-bea4-9e0bf31baa88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_02f961cc-19fe-4bcb-8665-c6f64afc36e1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_3772ac77-3140-4055-bea4-9e0bf31baa88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_06af5198-79b7-42fd-be00-0f411b5218c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_02f961cc-19fe-4bcb-8665-c6f64afc36e1" xlink:to="loc_us-gaap_FinanceLeaseLiability_06af5198-79b7-42fd-be00-0f411b5218c7" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>ameh-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:5baec51e-b1b5-44e5-a5ac-49c0e6499a3f,g:d2f55b59-0a61-4e65-b745-a66f96888c42-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="ameh-20220331.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="ib7ebcb63dad5447d8fe1053421835e19_CONSOLIDATEDBALANCESHEETS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_160f9aeb-374a-49e3-b901-291bfc151bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_d3388696-df8e-4193-9754-d25edc1b80e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_160f9aeb-374a-49e3-b901-291bfc151bd3" xlink:to="loc_us-gaap_AssetsAbstract_d3388696-df8e-4193-9754-d25edc1b80e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_cb7b394a-94c0-4500-8583-78bd4b9d09e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_d3388696-df8e-4193-9754-d25edc1b80e1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_cb7b394a-94c0-4500-8583-78bd4b9d09e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9fc7df05-6b41-42ca-b3ad-7ac844ce0917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cb7b394a-94c0-4500-8583-78bd4b9d09e3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9fc7df05-6b41-42ca-b3ad-7ac844ce0917" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_d0b6d643-6a18-4347-9875-a25432165f75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cb7b394a-94c0-4500-8583-78bd4b9d09e3" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_d0b6d643-6a18-4347-9875-a25432165f75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_649c76af-2cfb-4161-af17-c20b4cecc65c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cb7b394a-94c0-4500-8583-78bd4b9d09e3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_649c76af-2cfb-4161-af17-c20b4cecc65c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_eb64d4ec-f119-49f3-b6f9-8a2f511f9990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cb7b394a-94c0-4500-8583-78bd4b9d09e3" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_eb64d4ec-f119-49f3-b6f9-8a2f511f9990" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_234a6441-6643-43ce-8ba7-da031555b878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cb7b394a-94c0-4500-8583-78bd4b9d09e3" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_234a6441-6643-43ce-8ba7-da031555b878" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1a340c88-bd42-48b8-bf93-d538b74d03b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cb7b394a-94c0-4500-8583-78bd4b9d09e3" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1a340c88-bd42-48b8-bf93-d538b74d03b7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_b5325404-a6e2-46d7-8099-a12d32a91e48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cb7b394a-94c0-4500-8583-78bd4b9d09e3" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_b5325404-a6e2-46d7-8099-a12d32a91e48" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0d345b98-7dd8-4160-9915-818c1b4c56a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cb7b394a-94c0-4500-8583-78bd4b9d09e3" xlink:to="loc_us-gaap_AssetsCurrent_0d345b98-7dd8-4160-9915-818c1b4c56a1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_5292cb9c-741a-4d13-956f-66c46b280ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_d3388696-df8e-4193-9754-d25edc1b80e1" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_5292cb9c-741a-4d13-956f-66c46b280ab6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_80e3556d-89b8-4e70-94c3-0b2ee9b7419a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5292cb9c-741a-4d13-956f-66c46b280ab6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_80e3556d-89b8-4e70-94c3-0b2ee9b7419a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_84049ac2-2e0c-4346-871b-8a8902eb0d86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5292cb9c-741a-4d13-956f-66c46b280ab6" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_84049ac2-2e0c-4346-871b-8a8902eb0d86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_62dc6894-94fa-4d57-82fe-c30a553f2390" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5292cb9c-741a-4d13-956f-66c46b280ab6" xlink:to="loc_us-gaap_Goodwill_62dc6894-94fa-4d57-82fe-c30a553f2390" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_b09b35ad-9b69-4cb1-8d1c-52a4b482c050" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5292cb9c-741a-4d13-956f-66c46b280ab6" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_b09b35ad-9b69-4cb1-8d1c-52a4b482c050" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_dbe92fd6-7724-4c0e-a552-ae9d9c8af9a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5292cb9c-741a-4d13-956f-66c46b280ab6" xlink:to="loc_us-gaap_EquityMethodInvestments_dbe92fd6-7724-4c0e-a552-ae9d9c8af9a2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_12a26ff4-79bf-4c7d-b511-fb5f273609ee" xlink:href="ameh-20220331.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5292cb9c-741a-4d13-956f-66c46b280ab6" xlink:to="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_12a26ff4-79bf-4c7d-b511-fb5f273609ee" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a0faf1ba-04ca-4867-a555-8b7a9cea0759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5292cb9c-741a-4d13-956f-66c46b280ab6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a0faf1ba-04ca-4867-a555-8b7a9cea0759" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a91f3fe9-f05c-4b57-9d35-8593f7073c49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5292cb9c-741a-4d13-956f-66c46b280ab6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a91f3fe9-f05c-4b57-9d35-8593f7073c49" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_c119a537-4d94-440b-98d0-4459ef9b914d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5292cb9c-741a-4d13-956f-66c46b280ab6" xlink:to="loc_us-gaap_AssetsNoncurrent_c119a537-4d94-440b-98d0-4459ef9b914d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_02d99ed3-5fb4-4a8a-8834-27406de2f2aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_d3388696-df8e-4193-9754-d25edc1b80e1" xlink:to="loc_us-gaap_Assets_02d99ed3-5fb4-4a8a-8834-27406de2f2aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83e49c6f-8d5a-40f0-944d-be2ce6e512a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_160f9aeb-374a-49e3-b901-291bfc151bd3" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83e49c6f-8d5a-40f0-944d-be2ce6e512a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_37798ade-8105-48d3-b914-e0b7b2111a38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83e49c6f-8d5a-40f0-944d-be2ce6e512a5" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_37798ade-8105-48d3-b914-e0b7b2111a38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_924363af-4bbb-4f77-8885-c7cd60b92b91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37798ade-8105-48d3-b914-e0b7b2111a38" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_924363af-4bbb-4f77-8885-c7cd60b92b91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_c5ba9a7e-85a6-424a-bd09-799eb6124455" xlink:href="ameh-20220331.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37798ade-8105-48d3-b914-e0b7b2111a38" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_c5ba9a7e-85a6-424a-bd09-799eb6124455" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_7970e082-49e0-4054-af7a-ed47e726b886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37798ade-8105-48d3-b914-e0b7b2111a38" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_7970e082-49e0-4054-af7a-ed47e726b886" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_e258fef2-fd1a-4226-99a6-dcd73a4ff0a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37798ade-8105-48d3-b914-e0b7b2111a38" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_e258fef2-fd1a-4226-99a6-dcd73a4ff0a1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_3c7e4d7d-440c-4c58-b09f-8ee5ccd3375d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37798ade-8105-48d3-b914-e0b7b2111a38" xlink:to="loc_us-gaap_DividendsPayableCurrent_3c7e4d7d-440c-4c58-b09f-8ee5ccd3375d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_964f56ae-a66b-4f8d-b300-99015e3a96f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37798ade-8105-48d3-b914-e0b7b2111a38" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_964f56ae-a66b-4f8d-b300-99015e3a96f8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_57055925-ed40-4107-9a92-c6905f423248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37798ade-8105-48d3-b914-e0b7b2111a38" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_57055925-ed40-4107-9a92-c6905f423248" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_4d03c46d-5a50-482a-9891-4a3a6493d5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37798ade-8105-48d3-b914-e0b7b2111a38" xlink:to="loc_us-gaap_LongTermDebtCurrent_4d03c46d-5a50-482a-9891-4a3a6493d5d4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c36a5f60-925f-44fb-9f78-11bd49a66787" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37798ade-8105-48d3-b914-e0b7b2111a38" xlink:to="loc_us-gaap_LiabilitiesCurrent_c36a5f60-925f-44fb-9f78-11bd49a66787" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_465d6db3-5bb6-44a4-9e85-33c8d3978b06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83e49c6f-8d5a-40f0-944d-be2ce6e512a5" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_465d6db3-5bb6-44a4-9e85-33c8d3978b06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_11b6e430-5eb1-48fe-8ee4-13e22b0ec11b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_465d6db3-5bb6-44a4-9e85-33c8d3978b06" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_11b6e430-5eb1-48fe-8ee4-13e22b0ec11b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_14c5ba08-e54f-4cb9-af10-1c600ccab082" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_465d6db3-5bb6-44a4-9e85-33c8d3978b06" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_14c5ba08-e54f-4cb9-af10-1c600ccab082" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5b23401b-c91e-400e-848e-1f9ba1ef1cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_465d6db3-5bb6-44a4-9e85-33c8d3978b06" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5b23401b-c91e-400e-848e-1f9ba1ef1cfd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_7f1f61c5-220c-4605-b646-9c2d65830fda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_465d6db3-5bb6-44a4-9e85-33c8d3978b06" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_7f1f61c5-220c-4605-b646-9c2d65830fda" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_89221e14-002b-4b41-aaa6-f9cb12b0f895" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_465d6db3-5bb6-44a4-9e85-33c8d3978b06" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_89221e14-002b-4b41-aaa6-f9cb12b0f895" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_9892fa9e-1603-476b-8748-e6e0d7e42c24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_465d6db3-5bb6-44a4-9e85-33c8d3978b06" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_9892fa9e-1603-476b-8748-e6e0d7e42c24" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d924c5e3-6b78-41ec-97de-c3b8a524599b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83e49c6f-8d5a-40f0-944d-be2ce6e512a5" xlink:to="loc_us-gaap_Liabilities_d924c5e3-6b78-41ec-97de-c3b8a524599b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a56424b5-b20f-4842-a048-389d239b4f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83e49c6f-8d5a-40f0-944d-be2ce6e512a5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a56424b5-b20f-4842-a048-389d239b4f3f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineEquityAbstract_d3d0997b-1141-490b-85d4-3815743809f8" xlink:href="ameh-20220331.xsd#ameh_MezzanineEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83e49c6f-8d5a-40f0-944d-be2ce6e512a5" xlink:to="loc_ameh_MezzanineEquityAbstract_d3d0997b-1141-490b-85d4-3815743809f8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_f7fe9a51-f4e7-49b4-b176-21a7de8f254d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_MezzanineEquityAbstract_d3d0997b-1141-490b-85d4-3815743809f8" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_f7fe9a51-f4e7-49b4-b176-21a7de8f254d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_880f69a2-2bdd-4933-b6cc-9708792d17c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83e49c6f-8d5a-40f0-944d-be2ce6e512a5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_880f69a2-2bdd-4933-b6cc-9708792d17c5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a4de836a-220d-4314-8c72-a0b2c44504de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_880f69a2-2bdd-4933-b6cc-9708792d17c5" xlink:to="loc_us-gaap_PreferredStockValue_a4de836a-220d-4314-8c72-a0b2c44504de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_06cfd696-fbfb-484a-b5ea-6f5a2d334a88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_880f69a2-2bdd-4933-b6cc-9708792d17c5" xlink:to="loc_us-gaap_CommonStockValue_06cfd696-fbfb-484a-b5ea-6f5a2d334a88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_d793b72c-4a45-4b6a-8b49-282e99dcbc5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_880f69a2-2bdd-4933-b6cc-9708792d17c5" xlink:to="loc_us-gaap_AdditionalPaidInCapital_d793b72c-4a45-4b6a-8b49-282e99dcbc5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_776f7f3b-dd7d-4894-92e9-7eb8f179bdd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_880f69a2-2bdd-4933-b6cc-9708792d17c5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_776f7f3b-dd7d-4894-92e9-7eb8f179bdd2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_849f8f78-c4df-4161-b7b6-26f062a4355f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_880f69a2-2bdd-4933-b6cc-9708792d17c5" xlink:to="loc_us-gaap_StockholdersEquity_849f8f78-c4df-4161-b7b6-26f062a4355f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_9e64cd4a-f1f0-439f-bd25-60be6e20f5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_880f69a2-2bdd-4933-b6cc-9708792d17c5" xlink:to="loc_us-gaap_MinorityInterest_9e64cd4a-f1f0-439f-bd25-60be6e20f5e2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e2be1aa7-9f2a-4228-a679-d595546fccb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_880f69a2-2bdd-4933-b6cc-9708792d17c5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e2be1aa7-9f2a-4228-a679-d595546fccb5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4d67c83e-5dbb-467f-9a4c-19e446635168" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83e49c6f-8d5a-40f0-944d-be2ce6e512a5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_4d67c83e-5dbb-467f-9a4c-19e446635168" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5270c61e-0477-45a7-851b-a4dbe4b1c5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_160f9aeb-374a-49e3-b901-291bfc151bd3" xlink:to="loc_us-gaap_StatementTable_5270c61e-0477-45a7-851b-a4dbe4b1c5b5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9899eb47-924a-4041-a481-51eb2e293bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5270c61e-0477-45a7-851b-a4dbe4b1c5b5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9899eb47-924a-4041-a481-51eb2e293bf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9899eb47-924a-4041-a481-51eb2e293bf7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9899eb47-924a-4041-a481-51eb2e293bf7" xlink:to="loc_us-gaap_ClassOfStockDomain_9899eb47-924a-4041-a481-51eb2e293bf7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3e6d9bb6-c7cd-45b2-8861-41c67dca7fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9899eb47-924a-4041-a481-51eb2e293bf7" xlink:to="loc_us-gaap_ClassOfStockDomain_3e6d9bb6-c7cd-45b2-8861-41c67dca7fb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_3060cf55-b18b-4672-aad1-701ad45ba3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3e6d9bb6-c7cd-45b2-8861-41c67dca7fb8" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_3060cf55-b18b-4672-aad1-701ad45ba3e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_062396d9-8a46-4f41-bc9c-c256b621d04d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3e6d9bb6-c7cd-45b2-8861-41c67dca7fb8" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_062396d9-8a46-4f41-bc9c-c256b621d04d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="ameh-20220331.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="if65287d78bea41b9905e07ac7af37333_CONSOLIDATEDBALANCESHEETSParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_df229f59-f810-4b0a-8c07-203b6dc97105" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b577f094-4568-4af9-b614-8db30725f7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df229f59-f810-4b0a-8c07-203b6dc97105" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b577f094-4568-4af9-b614-8db30725f7a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3e43c277-8de0-42ae-b9bb-4e1e9b298b92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df229f59-f810-4b0a-8c07-203b6dc97105" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3e43c277-8de0-42ae-b9bb-4e1e9b298b92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_37009701-ac78-4632-9256-e5d9a10e9207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df229f59-f810-4b0a-8c07-203b6dc97105" xlink:to="loc_us-gaap_PreferredStockSharesIssued_37009701-ac78-4632-9256-e5d9a10e9207" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_14f5687c-86f2-448a-b6ab-4ed3c058efc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df229f59-f810-4b0a-8c07-203b6dc97105" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_14f5687c-86f2-448a-b6ab-4ed3c058efc0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_eb2027c0-a68a-4334-bc13-aaa4f07db832" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df229f59-f810-4b0a-8c07-203b6dc97105" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_eb2027c0-a68a-4334-bc13-aaa4f07db832" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_64c071a5-d1c4-447a-adf6-0692b4fb4593" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df229f59-f810-4b0a-8c07-203b6dc97105" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_64c071a5-d1c4-447a-adf6-0692b4fb4593" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a7144e02-c3a1-4687-8297-1a2799fc609f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df229f59-f810-4b0a-8c07-203b6dc97105" xlink:to="loc_us-gaap_CommonStockSharesIssued_a7144e02-c3a1-4687-8297-1a2799fc609f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2c8fccd5-4abd-4100-8226-741dbe3b81d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df229f59-f810-4b0a-8c07-203b6dc97105" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2c8fccd5-4abd-4100-8226-741dbe3b81d1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_7180d587-a242-440f-a0fb-322b740eb875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df229f59-f810-4b0a-8c07-203b6dc97105" xlink:to="loc_us-gaap_TreasuryStockCommonShares_7180d587-a242-440f-a0fb-322b740eb875" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a0ac0eea-4b09-4b47-8386-893d83e8b7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df229f59-f810-4b0a-8c07-203b6dc97105" xlink:to="loc_us-gaap_Assets_a0ac0eea-4b09-4b47-8386-893d83e8b7f7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_dfca48d1-c7bf-4a30-b443-a68ccb9b8312" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df229f59-f810-4b0a-8c07-203b6dc97105" xlink:to="loc_us-gaap_Liabilities_dfca48d1-c7bf-4a30-b443-a68ccb9b8312" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_491e27ef-5f91-4278-8d2a-8ba59642585f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df229f59-f810-4b0a-8c07-203b6dc97105" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_491e27ef-5f91-4278-8d2a-8ba59642585f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliates_d07c144a-0ffa-49d5-a6a8-7604913c0402" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df229f59-f810-4b0a-8c07-203b6dc97105" xlink:to="loc_us-gaap_DueFromAffiliates_d07c144a-0ffa-49d5-a6a8-7604913c0402" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrentAndNoncurrent_9e4fabe1-a9a5-42d5-9ee8-371bd2a6fad0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToAffiliateCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df229f59-f810-4b0a-8c07-203b6dc97105" xlink:to="loc_us-gaap_DueToAffiliateCurrentAndNoncurrent_9e4fabe1-a9a5-42d5-9ee8-371bd2a6fad0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_62e67cb9-5fb7-428a-bb1a-017c0bed486f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_df229f59-f810-4b0a-8c07-203b6dc97105" xlink:to="loc_us-gaap_StatementTable_62e67cb9-5fb7-428a-bb1a-017c0bed486f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_575a8dc5-56b6-4d65-a7c2-63bb461f5517" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_62e67cb9-5fb7-428a-bb1a-017c0bed486f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_575a8dc5-56b6-4d65-a7c2-63bb461f5517" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_575a8dc5-56b6-4d65-a7c2-63bb461f5517_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_575a8dc5-56b6-4d65-a7c2-63bb461f5517" xlink:to="loc_us-gaap_ClassOfStockDomain_575a8dc5-56b6-4d65-a7c2-63bb461f5517_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_69b26404-1d42-4c78-b3b0-45acf6c688cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_575a8dc5-56b6-4d65-a7c2-63bb461f5517" xlink:to="loc_us-gaap_ClassOfStockDomain_69b26404-1d42-4c78-b3b0-45acf6c688cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_e4537fbd-7e2a-429c-8013-49fe71280d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_69b26404-1d42-4c78-b3b0-45acf6c688cd" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_e4537fbd-7e2a-429c-8013-49fe71280d23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_c72b8233-5e7d-4132-9f69-1ec0c4de49cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_69b26404-1d42-4c78-b3b0-45acf6c688cd" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_c72b8233-5e7d-4132-9f69-1ec0c4de49cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_fbb9cbd9-fab3-4d0a-abdd-52e4fad3ec39" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_62e67cb9-5fb7-428a-bb1a-017c0bed486f" xlink:to="loc_srt_ConsolidatedEntitiesAxis_fbb9cbd9-fab3-4d0a-abdd-52e4fad3ec39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_fbb9cbd9-fab3-4d0a-abdd-52e4fad3ec39_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_fbb9cbd9-fab3-4d0a-abdd-52e4fad3ec39" xlink:to="loc_srt_ConsolidatedEntitiesDomain_fbb9cbd9-fab3-4d0a-abdd-52e4fad3ec39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_58b69bb6-89d9-4bcf-8c64-b86bfe0716fe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_fbb9cbd9-fab3-4d0a-abdd-52e4fad3ec39" xlink:to="loc_srt_ConsolidatedEntitiesDomain_58b69bb6-89d9-4bcf-8c64-b86bfe0716fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_85dad8d7-8d1f-4d17-ac1a-6024dc7ed1de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_58b69bb6-89d9-4bcf-8c64-b86bfe0716fe" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_85dad8d7-8d1f-4d17-ac1a-6024dc7ed1de" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="ameh-20220331.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended" id="i87562a0498af429b9ab0e5cf2d540484_CONSOLIDATEDSTATEMENTSOFINCOME">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d5ef6e45-f26a-4917-ad64-61c015dcde1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_f0e83204-bd12-450c-89b8-d1f6287f20e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d5ef6e45-f26a-4917-ad64-61c015dcde1d" xlink:to="loc_us-gaap_RevenuesAbstract_f0e83204-bd12-450c-89b8-d1f6287f20e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fbe64edc-dafc-404b-8740-eb751f97b27f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_f0e83204-bd12-450c-89b8-d1f6287f20e3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fbe64edc-dafc-404b-8740-eb751f97b27f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1a499e20-ccf7-4725-8079-6c1abe68e4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d5ef6e45-f26a-4917-ad64-61c015dcde1d" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1a499e20-ccf7-4725-8079-6c1abe68e4c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_1797bafd-a23d-4901-a1f3-e39c2ea98287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1a499e20-ccf7-4725-8079-6c1abe68e4c1" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_1797bafd-a23d-4901-a1f3-e39c2ea98287" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_c69b362e-da5a-4f67-9479-fe578fb78dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1a499e20-ccf7-4725-8079-6c1abe68e4c1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_c69b362e-da5a-4f67-9479-fe578fb78dc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_f7d517cd-cbca-4e40-9ed0-dccc0485c9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1a499e20-ccf7-4725-8079-6c1abe68e4c1" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_f7d517cd-cbca-4e40-9ed0-dccc0485c9cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_6869d60e-c964-4a18-a0b0-2532e00252ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1a499e20-ccf7-4725-8079-6c1abe68e4c1" xlink:to="loc_us-gaap_CostsAndExpenses_6869d60e-c964-4a18-a0b0-2532e00252ed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e20995f0-42e1-4ab9-ba2b-c0bd90c1ad6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d5ef6e45-f26a-4917-ad64-61c015dcde1d" xlink:to="loc_us-gaap_OperatingIncomeLoss_e20995f0-42e1-4ab9-ba2b-c0bd90c1ad6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4e92e337-c7e6-4c15-8f00-02e737ff385a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d5ef6e45-f26a-4917-ad64-61c015dcde1d" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4e92e337-c7e6-4c15-8f00-02e737ff385a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_67a18f22-c4bb-4d01-b1ba-2191007ab439" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4e92e337-c7e6-4c15-8f00-02e737ff385a" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_67a18f22-c4bb-4d01-b1ba-2191007ab439" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_4d6718c7-fbf7-4189-ae93-a528417bdbf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4e92e337-c7e6-4c15-8f00-02e737ff385a" xlink:to="loc_us-gaap_InterestExpense_4d6718c7-fbf7-4189-ae93-a528417bdbf1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_84ed3e49-7fc4-41e9-8e88-aee3b6cfdfe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4e92e337-c7e6-4c15-8f00-02e737ff385a" xlink:to="loc_us-gaap_InvestmentIncomeInterest_84ed3e49-7fc4-41e9-8e88-aee3b6cfdfe1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_936b8c9f-1c52-4763-aa6f-9991ffaa948f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4e92e337-c7e6-4c15-8f00-02e737ff385a" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_936b8c9f-1c52-4763-aa6f-9991ffaa948f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_169a5d85-7fa7-4231-9a02-b1cc2436ede2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4e92e337-c7e6-4c15-8f00-02e737ff385a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_169a5d85-7fa7-4231-9a02-b1cc2436ede2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1aff5726-4f33-40d3-841e-7111946f872d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4e92e337-c7e6-4c15-8f00-02e737ff385a" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_1aff5726-4f33-40d3-841e-7111946f872d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e5f13959-ace1-48c3-aafb-ffcd86e41c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d5ef6e45-f26a-4917-ad64-61c015dcde1d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e5f13959-ace1-48c3-aafb-ffcd86e41c1e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b4d0b720-d2f6-468a-8926-adf6cd4e9962" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d5ef6e45-f26a-4917-ad64-61c015dcde1d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b4d0b720-d2f6-468a-8926-adf6cd4e9962" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_29487748-0510-4515-aa6c-a3a641ef6a80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d5ef6e45-f26a-4917-ad64-61c015dcde1d" xlink:to="loc_us-gaap_ProfitLoss_29487748-0510-4515-aa6c-a3a641ef6a80" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b4955554-0b9e-4e8d-af22-ce880f064e56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d5ef6e45-f26a-4917-ad64-61c015dcde1d" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b4955554-0b9e-4e8d-af22-ce880f064e56" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6a9a3888-ff94-44d2-a9cf-6fc3a61fd54f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d5ef6e45-f26a-4917-ad64-61c015dcde1d" xlink:to="loc_us-gaap_NetIncomeLoss_6a9a3888-ff94-44d2-a9cf-6fc3a61fd54f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_bd981cb4-7801-48ad-9dd1-3974c47838c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d5ef6e45-f26a-4917-ad64-61c015dcde1d" xlink:to="loc_us-gaap_EarningsPerShareBasic_bd981cb4-7801-48ad-9dd1-3974c47838c2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_73ff38a2-7e67-4391-8cd8-298a60f40d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d5ef6e45-f26a-4917-ad64-61c015dcde1d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_73ff38a2-7e67-4391-8cd8-298a60f40d8f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_70c40192-89b2-4c09-bb72-7a0dd1f19031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d5ef6e45-f26a-4917-ad64-61c015dcde1d" xlink:to="loc_us-gaap_StatementTable_70c40192-89b2-4c09-bb72-7a0dd1f19031" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fa72a03c-31bf-47d4-9a3e-9523313d72f4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_70c40192-89b2-4c09-bb72-7a0dd1f19031" xlink:to="loc_srt_ProductOrServiceAxis_fa72a03c-31bf-47d4-9a3e-9523313d72f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fa72a03c-31bf-47d4-9a3e-9523313d72f4_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_fa72a03c-31bf-47d4-9a3e-9523313d72f4" xlink:to="loc_srt_ProductsAndServicesDomain_fa72a03c-31bf-47d4-9a3e-9523313d72f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2b72ad86-8ae7-40aa-b0c6-8e64d5b2efff" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_fa72a03c-31bf-47d4-9a3e-9523313d72f4" xlink:to="loc_srt_ProductsAndServicesDomain_2b72ad86-8ae7-40aa-b0c6-8e64d5b2efff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HealthCareCapitationRevenueMember_110c53db-be70-41ff-8a60-8c2c06aef0aa" xlink:href="ameh-20220331.xsd#ameh_HealthCareCapitationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2b72ad86-8ae7-40aa-b0c6-8e64d5b2efff" xlink:to="loc_ameh_HealthCareCapitationRevenueMember_110c53db-be70-41ff-8a60-8c2c06aef0aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOtherMember_4c7c9ae6-c395-406b-98f5-6648b13bb2f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2b72ad86-8ae7-40aa-b0c6-8e64d5b2efff" xlink:to="loc_us-gaap_HealthCareOtherMember_4c7c9ae6-c395-406b-98f5-6648b13bb2f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember_2e8fcf72-1571-4d56-92de-ee327f774435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2b72ad86-8ae7-40aa-b0c6-8e64d5b2efff" xlink:to="loc_us-gaap_ManagementServiceMember_2e8fcf72-1571-4d56-92de-ee327f774435" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCarePatientServiceMember_018f345a-b680-494e-8429-784dfa4981dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCarePatientServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2b72ad86-8ae7-40aa-b0c6-8e64d5b2efff" xlink:to="loc_us-gaap_HealthCarePatientServiceMember_018f345a-b680-494e-8429-784dfa4981dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_a215f073-5512-4af4-bed2-3b65ce7ccd2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2b72ad86-8ae7-40aa-b0c6-8e64d5b2efff" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_a215f073-5512-4af4-bed2-3b65ce7ccd2b" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ameh-20220331.xsd#CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY" xlink:type="extended" id="ic21ce819b1294909b272b2d9760c8ac9_CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1d93cdf0-d423-4c2d-9808-644efca57c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_40d9bfd0-1759-4fdd-8921-a9dad94503cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1d93cdf0-d423-4c2d-9808-644efca57c7a" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_40d9bfd0-1759-4fdd-8921-a9dad94503cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_2b3666a7-6a72-49cd-95a6-47e37ab1d2f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_40d9bfd0-1759-4fdd-8921-a9dad94503cd" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_2b3666a7-6a72-49cd-95a6-47e37ab1d2f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome_0b0166da-298d-4db9-885e-e794d956ee56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_40d9bfd0-1759-4fdd-8921-a9dad94503cd" xlink:to="loc_us-gaap_TemporaryEquityNetIncome_0b0166da-298d-4db9-885e-e794d956ee56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionOfDividends_cfa3fc24-af54-4d42-90c8-e32f71cb295a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAccretionOfDividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_40d9bfd0-1759-4fdd-8921-a9dad94503cd" xlink:to="loc_us-gaap_TemporaryEquityAccretionOfDividends_cfa3fc24-af54-4d42-90c8-e32f71cb295a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_ad5006c3-3914-4c7e-8169-16d93eed1ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_40d9bfd0-1759-4fdd-8921-a9dad94503cd" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_ad5006c3-3914-4c7e-8169-16d93eed1ac3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_48ce054e-2c44-4b3a-a16e-ef16f6e3e794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1d93cdf0-d423-4c2d-9808-644efca57c7a" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_a4d64f85-b370-4f45-ada6-c9fa28808d07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_us-gaap_SharesOutstanding_a4d64f85-b370-4f45-ada6-c9fa28808d07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5d691e84-c9c5-448b-b668-b29045e76518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5d691e84-c9c5-448b-b668-b29045e76518" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_f9faa2af-6a99-4517-8d1a-17c6bd7ec979" xlink:href="ameh-20220331.xsd#ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_f9faa2af-6a99-4517-8d1a-17c6bd7ec979" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_766643a1-a03e-483a-ad7b-de9606f92cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_766643a1-a03e-483a-ad7b-de9606f92cd1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_814ffc3e-810a-4eca-b006-015e5d0a5462" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_814ffc3e-810a-4eca-b006-015e5d0a5462" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_5b682004-ebce-48e7-8c02-d22595c1b3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_5b682004-ebce-48e7-8c02-d22595c1b3f6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_e0fa39df-2974-4ce5-a5a8-435504ed13a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_e0fa39df-2974-4ce5-a5a8-435504ed13a1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_8d984a52-919e-4fe6-8f87-f3a756e564c7" xlink:href="ameh-20220331.xsd#ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_8d984a52-919e-4fe6-8f87-f3a756e564c7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_47162966-8fff-4eb1-bdf4-13aae7609f10" xlink:href="ameh-20220331.xsd#ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_47162966-8fff-4eb1-bdf4-13aae7609f10" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_6055ad7c-c66c-4483-b8bb-91c972ac21ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_6055ad7c-c66c-4483-b8bb-91c972ac21ad" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_5b6278f6-b09e-4ec9-b28c-f7f83b49f92c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredParValueMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_5b6278f6-b09e-4ec9-b28c-f7f83b49f92c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_19681713-7a37-48aa-a277-136745f22038" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_19681713-7a37-48aa-a277-136745f22038" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_4f5c80aa-d82f-447f-aa31-9f7bf891838c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_4f5c80aa-d82f-447f-aa31-9f7bf891838c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_06328c4f-da25-4d3c-8187-5a5b8e3efc56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_06328c4f-da25-4d3c-8187-5a5b8e3efc56" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares_c7fc467a-2109-4bc5-9fb2-3feb159da605" xlink:href="ameh-20220331.xsd#ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares_c7fc467a-2109-4bc5-9fb2-3feb159da605" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_28062052-8cc8-47c9-a9d1-393618b46ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_28062052-8cc8-47c9-a9d1-393618b46ad3" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_bc0373cd-841f-42db-b0a5-ef4d6a7e8257" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_bc0373cd-841f-42db-b0a5-ef4d6a7e8257" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_99163973-619a-41b7-99e4-67195955e218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_22c34f5d-d65d-464d-a646-d95b8c7c2b49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d94aeb9c-4613-4914-9a0d-98a6ca07d805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1d93cdf0-d423-4c2d-9808-644efca57c7a" xlink:to="loc_us-gaap_StatementTable_d94aeb9c-4613-4914-9a0d-98a6ca07d805" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_448d4fbc-7c0b-4cd3-91a0-860b0d7443e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d94aeb9c-4613-4914-9a0d-98a6ca07d805" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_448d4fbc-7c0b-4cd3-91a0-860b0d7443e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_448d4fbc-7c0b-4cd3-91a0-860b0d7443e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_448d4fbc-7c0b-4cd3-91a0-860b0d7443e7" xlink:to="loc_us-gaap_EquityComponentDomain_448d4fbc-7c0b-4cd3-91a0-860b0d7443e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_98cbc85f-d6ab-474e-bf36-569c8a102f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_448d4fbc-7c0b-4cd3-91a0-860b0d7443e7" xlink:to="loc_us-gaap_EquityComponentDomain_98cbc85f-d6ab-474e-bf36-569c8a102f6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ac032fa2-b923-4c15-96b5-4888551578ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_98cbc85f-d6ab-474e-bf36-569c8a102f6b" xlink:to="loc_us-gaap_CommonStockMember_ac032fa2-b923-4c15-96b5-4888551578ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1e0c19ce-514e-4e09-8f9e-82f7d1990101" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_98cbc85f-d6ab-474e-bf36-569c8a102f6b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1e0c19ce-514e-4e09-8f9e-82f7d1990101" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_66d7b829-51e5-46b9-907b-14cb009e7244" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_98cbc85f-d6ab-474e-bf36-569c8a102f6b" xlink:to="loc_us-gaap_RetainedEarningsMember_66d7b829-51e5-46b9-907b-14cb009e7244" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_23dcaef2-14c2-40af-a56d-83b97c8e1e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_98cbc85f-d6ab-474e-bf36-569c8a102f6b" xlink:to="loc_us-gaap_NoncontrollingInterestMember_23dcaef2-14c2-40af-a56d-83b97c8e1e2e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a2997023-e854-4b2f-9711-ddcd7f1e417d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d94aeb9c-4613-4914-9a0d-98a6ca07d805" xlink:to="loc_dei_LegalEntityAxis_a2997023-e854-4b2f-9711-ddcd7f1e417d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a2997023-e854-4b2f-9711-ddcd7f1e417d_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_a2997023-e854-4b2f-9711-ddcd7f1e417d" xlink:to="loc_dei_EntityDomain_a2997023-e854-4b2f-9711-ddcd7f1e417d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0444767f-0ef8-47a9-b2bb-b48feca09665" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_a2997023-e854-4b2f-9711-ddcd7f1e417d" xlink:to="loc_dei_EntityDomain_0444767f-0ef8-47a9-b2bb-b48feca09665" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineMember_b325e470-e4aa-4d90-8607-721577948645" xlink:href="ameh-20220331.xsd#ameh_MezzanineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_0444767f-0ef8-47a9-b2bb-b48feca09665" xlink:to="loc_ameh_MezzanineMember_b325e470-e4aa-4d90-8607-721577948645" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#DescriptionofBusinessAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="extended" id="id6b11a12cb464179817977a439da0f4f_DescriptionofBusinessAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:href="ameh-20220331.xsd#ameh_DescriptionOfBusinessLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_08708a6e-1df9-4303-9f95-2827036abf0d" xlink:href="ameh-20220331.xsd#ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_08708a6e-1df9-4303-9f95-2827036abf0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_3411a021-2b9e-4da0-bc83-1ca0fc3502f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_us-gaap_NotesReceivableNet_3411a021-2b9e-4da0-bc83-1ca0fc3502f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableTermOfReceivable_64e0dbba-2302-47fa-a9cf-0f8e5244fbb8" xlink:href="ameh-20220331.xsd#ameh_FinanceReceivableTermOfReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_ameh_FinanceReceivableTermOfReceivable_64e0dbba-2302-47fa-a9cf-0f8e5244fbb8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableStatedInterestRate_f9777ba7-5a0c-45d3-bd7b-9d3b4cb182ee" xlink:href="ameh-20220331.xsd#ameh_FinanceReceivableStatedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_ameh_FinanceReceivableStatedInterestRate_f9777ba7-5a0c-45d3-bd7b-9d3b4cb182ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_401f7866-0a8e-4737-80bc-6854fbf07b62" xlink:href="ameh-20220331.xsd#ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_401f7866-0a8e-4737-80bc-6854fbf07b62" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b57bb0a6-9e98-42f4-b2c7-21261e21e53c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b57bb0a6-9e98-42f4-b2c7-21261e21e53c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_28c3a68e-1b8f-4f6d-912b-b58ecf554875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_28c3a68e-1b8f-4f6d-912b-b58ecf554875" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_6f02e28a-122b-4820-baf4-c1f4d7fd2a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_6f02e28a-122b-4820-baf4-c1f4d7fd2a9f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFederallyQualifiedHealthPlans_36428a4a-a722-4c67-9b23-c2d2efe4f475" xlink:href="ameh-20220331.xsd#ameh_NumberOfFederallyQualifiedHealthPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_ameh_NumberOfFederallyQualifiedHealthPlans_36428a4a-a722-4c67-9b23-c2d2efe4f475" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_7d3e5a69-a25c-4539-95a2-2497f0f5b195" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_7d3e5a69-a25c-4539-95a2-2497f0f5b195" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_0b003b63-1527-46d6-ad1c-f7780aabe7b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_0b003b63-1527-46d6-ad1c-f7780aabe7b8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFamilyPracticeClinics_26632767-2561-44ba-946d-d92b4fdedac7" xlink:href="ameh-20220331.xsd#ameh_NumberOfFamilyPracticeClinics"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_ameh_NumberOfFamilyPracticeClinics_26632767-2561-44ba-946d-d92b4fdedac7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_58ee503d-61ab-4eea-9f84-079358b74d04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_58ee503d-61ab-4eea-9f84-079358b74d04" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_a4baa98c-00cb-4ec6-8fbf-786eed50a89e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_a4baa98c-00cb-4ec6-8fbf-786eed50a89e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_3082a7f6-c36b-48f5-9c5d-d393d84f703a" xlink:href="ameh-20220331.xsd#ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_3082a7f6-c36b-48f5-9c5d-d393d84f703a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_f14f84f6-4bfb-47c1-be82-1f34acfca5ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_us-gaap_EquityMethodInvestments_f14f84f6-4bfb-47c1-be82-1f34acfca5ca" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_0dfe72a3-a49f-4d9a-84cd-9c2897f10dc6" xlink:href="ameh-20220331.xsd#ameh_AssetAcquisitionPercentageOfSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_0dfe72a3-a49f-4d9a-84cd-9c2897f10dc6" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_c114a093-946c-45f5-8f3a-9e67a6626687" xlink:href="ameh-20220331.xsd#ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_c114a093-946c-45f5-8f3a-9e67a6626687" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessTable_85979158-2315-4f17-acca-e3fa34644922" xlink:href="ameh-20220331.xsd#ameh_DescriptionOfBusinessTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_ameh_DescriptionOfBusinessTable_85979158-2315-4f17-acca-e3fa34644922" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_24f21fdd-d56b-45e9-96f2-a696b7d6cd36" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_85979158-2315-4f17-acca-e3fa34644922" xlink:to="loc_dei_LegalEntityAxis_24f21fdd-d56b-45e9-96f2-a696b7d6cd36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_24f21fdd-d56b-45e9-96f2-a696b7d6cd36_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_24f21fdd-d56b-45e9-96f2-a696b7d6cd36" xlink:to="loc_dei_EntityDomain_24f21fdd-d56b-45e9-96f2-a696b7d6cd36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4192acee-44a5-493e-8106-62c249e93cdd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_24f21fdd-d56b-45e9-96f2-a696b7d6cd36" xlink:to="loc_dei_EntityDomain_4192acee-44a5-493e-8106-62c249e93cdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ffa51460-4f12-4c5f-84c6-897072d84d32" xlink:href="ameh-20220331.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4192acee-44a5-493e-8106-62c249e93cdd" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ffa51460-4f12-4c5f-84c6-897072d84d32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_3316c575-df7a-4e1c-a19f-f072f749493f" xlink:href="ameh-20220331.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4192acee-44a5-493e-8106-62c249e93cdd" xlink:to="loc_ameh_AccountableHealthCareIPAMember_3316c575-df7a-4e1c-a19f-f072f749493f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember_44d1997b-023e-405a-922d-aacead1971cf" xlink:href="ameh-20220331.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4192acee-44a5-493e-8106-62c249e93cdd" xlink:to="loc_ameh_APCAndAPCLSMAMember_44d1997b-023e-405a-922d-aacead1971cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_dc299298-9d40-4afd-bb43-75a19bd38863" xlink:href="ameh-20220331.xsd#ameh_AmgIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4192acee-44a5-493e-8106-62c249e93cdd" xlink:to="loc_ameh_AmgIncMember_dc299298-9d40-4afd-bb43-75a19bd38863" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember_cb188193-bf57-4d6a-870d-2655b3bac665" xlink:href="ameh-20220331.xsd#ameh_ApcLsmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4192acee-44a5-493e-8106-62c249e93cdd" xlink:to="loc_ameh_ApcLsmaMember_cb188193-bf57-4d6a-870d-2655b3bac665" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0513f3a4-9e8d-486b-a60b-718976b5a784" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_85979158-2315-4f17-acca-e3fa34644922" xlink:to="loc_srt_CounterpartyNameAxis_0513f3a4-9e8d-486b-a60b-718976b5a784" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0513f3a4-9e8d-486b-a60b-718976b5a784_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0513f3a4-9e8d-486b-a60b-718976b5a784" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0513f3a4-9e8d-486b-a60b-718976b5a784_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b9f98e54-a897-4c42-a9d1-cc0338b4845c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0513f3a4-9e8d-486b-a60b-718976b5a784" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b9f98e54-a897-4c42-a9d1-cc0338b4845c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APAMHMedicalCorporationMember_09fc68aa-352c-47d7-8098-70cedebb7536" xlink:href="ameh-20220331.xsd#ameh_APAMHMedicalCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b9f98e54-a897-4c42-a9d1-cc0338b4845c" xlink:to="loc_ameh_APAMHMedicalCorporationMember_09fc68aa-352c-47d7-8098-70cedebb7536" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_c9fe6d87-1bb8-4253-a111-aee842219059" xlink:href="ameh-20220331.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b9f98e54-a897-4c42-a9d1-cc0338b4845c" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_c9fe6d87-1bb8-4253-a111-aee842219059" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.JayMember_58ebfa9c-8234-42ce-a310-fb1f6a5cef92" xlink:href="ameh-20220331.xsd#ameh_Dr.JayMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b9f98e54-a897-4c42-a9d1-cc0338b4845c" xlink:to="loc_ameh_Dr.JayMember_58ebfa9c-8234-42ce-a310-fb1f6a5cef92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a17e8b2e-5d1b-4780-98bb-ed1b9e085da3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_85979158-2315-4f17-acca-e3fa34644922" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a17e8b2e-5d1b-4780-98bb-ed1b9e085da3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a17e8b2e-5d1b-4780-98bb-ed1b9e085da3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a17e8b2e-5d1b-4780-98bb-ed1b9e085da3" xlink:to="loc_us-gaap_RelatedPartyDomain_a17e8b2e-5d1b-4780-98bb-ed1b9e085da3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_06c28adc-16a3-4971-ab82-388ec12b6fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a17e8b2e-5d1b-4780-98bb-ed1b9e085da3" xlink:to="loc_us-gaap_RelatedPartyDomain_06c28adc-16a3-4971-ab82-388ec12b6fd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_3faf3f93-ba6e-4d89-8ea1-7b62340aae20" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_06c28adc-16a3-4971-ab82-388ec12b6fd8" xlink:to="loc_srt_AffiliatedEntityMember_3faf3f93-ba6e-4d89-8ea1-7b62340aae20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_fbd8e73d-2f96-46a2-9c9a-9913bea663a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_85979158-2315-4f17-acca-e3fa34644922" xlink:to="loc_us-gaap_StatementClassOfStockAxis_fbd8e73d-2f96-46a2-9c9a-9913bea663a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fbd8e73d-2f96-46a2-9c9a-9913bea663a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fbd8e73d-2f96-46a2-9c9a-9913bea663a7" xlink:to="loc_us-gaap_ClassOfStockDomain_fbd8e73d-2f96-46a2-9c9a-9913bea663a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8deed632-c71e-4828-85c3-61f056c57cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fbd8e73d-2f96-46a2-9c9a-9913bea663a7" xlink:to="loc_us-gaap_ClassOfStockDomain_8deed632-c71e-4828-85c3-61f056c57cf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_62264207-95f2-4890-b277-33dadba7a50b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8deed632-c71e-4828-85c3-61f056c57cf1" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_62264207-95f2-4890-b277-33dadba7a50b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7b9993f6-5d70-4db7-b5a0-ff54c0856af8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_85979158-2315-4f17-acca-e3fa34644922" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7b9993f6-5d70-4db7-b5a0-ff54c0856af8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7b9993f6-5d70-4db7-b5a0-ff54c0856af8_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7b9993f6-5d70-4db7-b5a0-ff54c0856af8" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7b9993f6-5d70-4db7-b5a0-ff54c0856af8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1ccd75de-8ee8-4699-9fa0-126f3df75109" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7b9993f6-5d70-4db7-b5a0-ff54c0856af8" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1ccd75de-8ee8-4699-9fa0-126f3df75109" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloMedicalHoldingsIncMember_650a1e82-cf36-42a2-a4fe-3a706870976a" xlink:href="ameh-20220331.xsd#ameh_ApolloMedicalHoldingsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1ccd75de-8ee8-4699-9fa0-126f3df75109" xlink:to="loc_ameh_ApolloMedicalHoldingsIncMember_650a1e82-cf36-42a2-a4fe-3a706870976a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_d8923b37-7cf9-49e7-939c-f91567261178" xlink:href="ameh-20220331.xsd#ameh_ConcourseDiagnosticSurgeryCenterLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1ccd75de-8ee8-4699-9fa0-126f3df75109" xlink:to="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_d8923b37-7cf9-49e7-939c-f91567261178" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_c44e4da6-43f9-497a-aed6-e40d9aa5a8a9" xlink:href="ameh-20220331.xsd#ameh_DmgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1ccd75de-8ee8-4699-9fa0-126f3df75109" xlink:to="loc_ameh_DmgMember_c44e4da6-43f9-497a-aed6-e40d9aa5a8a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_afd154df-7324-49ca-83b8-d07ef65f3f29" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_85979158-2315-4f17-acca-e3fa34644922" xlink:to="loc_srt_OwnershipAxis_afd154df-7324-49ca-83b8-d07ef65f3f29" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_afd154df-7324-49ca-83b8-d07ef65f3f29_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_afd154df-7324-49ca-83b8-d07ef65f3f29" xlink:to="loc_srt_OwnershipDomain_afd154df-7324-49ca-83b8-d07ef65f3f29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_5c22231d-96ee-481d-a176-f916df822362" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_afd154df-7324-49ca-83b8-d07ef65f3f29" xlink:to="loc_srt_OwnershipDomain_5c22231d-96ee-481d-a176-f916df822362" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MaverickMedicalGroupIncMember_3da0d41f-3463-4539-b499-5b62cb174aaa" xlink:href="ameh-20220331.xsd#ameh_MaverickMedicalGroupIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_5c22231d-96ee-481d-a176-f916df822362" xlink:to="loc_ameh_MaverickMedicalGroupIncMember_3da0d41f-3463-4539-b499-5b62cb174aaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_dc14be2a-2fcc-40fd-89db-f6b05555a1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_85979158-2315-4f17-acca-e3fa34644922" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_dc14be2a-2fcc-40fd-89db-f6b05555a1bd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dc14be2a-2fcc-40fd-89db-f6b05555a1bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dc14be2a-2fcc-40fd-89db-f6b05555a1bd" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dc14be2a-2fcc-40fd-89db-f6b05555a1bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_92802ea8-3bfe-4a12-ab42-8b052defa3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dc14be2a-2fcc-40fd-89db-f6b05555a1bd" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_92802ea8-3bfe-4a12-ab42-8b052defa3ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_fe032c41-0474-4058-ae1f-48ca1b8025d2" xlink:href="ameh-20220331.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_92802ea8-3bfe-4a12-ab42-8b052defa3ee" xlink:to="loc_ameh_AccountableHealthCareIPAMember_fe032c41-0474-4058-ae1f-48ca1b8025d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_6dceb106-4603-456b-b65e-bb93f98b88b7" xlink:href="ameh-20220331.xsd#ameh_AmgIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_92802ea8-3bfe-4a12-ab42-8b052defa3ee" xlink:to="loc_ameh_AmgIncMember_6dceb106-4603-456b-b65e-bb93f98b88b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccessPrimaryCareMedicalGroupMember_74103c71-055d-4777-aa6f-fda72b9de142" xlink:href="ameh-20220331.xsd#ameh_AccessPrimaryCareMedicalGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_92802ea8-3bfe-4a12-ab42-8b052defa3ee" xlink:to="loc_ameh_AccessPrimaryCareMedicalGroupMember_74103c71-055d-4777-aa6f-fda72b9de142" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloSunLabsManagementLLCMember_78265ec3-8476-49e4-b6ff-0ba9fbb50faa" xlink:href="ameh-20220331.xsd#ameh_ApolloSunLabsManagementLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_92802ea8-3bfe-4a12-ab42-8b052defa3ee" xlink:to="loc_ameh_ApolloSunLabsManagementLLCMember_78265ec3-8476-49e4-b6ff-0ba9fbb50faa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_f9ac6f68-1e20-48df-8d6f-322210d1ca27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_85979158-2315-4f17-acca-e3fa34644922" xlink:to="loc_us-gaap_AssetAcquisitionAxis_f9ac6f68-1e20-48df-8d6f-322210d1ca27" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_f9ac6f68-1e20-48df-8d6f-322210d1ca27_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_f9ac6f68-1e20-48df-8d6f-322210d1ca27" xlink:to="loc_us-gaap_AssetAcquisitionDomain_f9ac6f68-1e20-48df-8d6f-322210d1ca27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_5f3792dd-da49-4e4e-945b-d1ad6444fb88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_f9ac6f68-1e20-48df-8d6f-322210d1ca27" xlink:to="loc_us-gaap_AssetAcquisitionDomain_5f3792dd-da49-4e4e-945b-d1ad6444fb88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_6a949e53-571a-4a6e-a51e-c85565edd697" xlink:href="ameh-20220331.xsd#ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_5f3792dd-da49-4e4e-945b-d1ad6444fb88" xlink:to="loc_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_6a949e53-571a-4a6e-a51e-c85565edd697" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_9d252fac-83e2-4846-9ed8-d64d6ed66669" xlink:href="ameh-20220331.xsd#ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_5f3792dd-da49-4e4e-945b-d1ad6444fb88" xlink:to="loc_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_9d252fac-83e2-4846-9ed8-d64d6ed66669" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" id="i1f57c64397854a4380e5625c20df0734_BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:href="ameh-20220331.xsd#ameh_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_67f6449a-3b4d-4ce6-8d3a-9c169093f363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_NumberOfOperatingSegments_67f6449a-3b4d-4ce6-8d3a-9c169093f363" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_6fbb5a64-84e4-4f36-b354-fb9864a60e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_NumberOfReportableSegments_6fbb5a64-84e4-4f36-b354-fb9864a60e0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount_961b112f-94ee-4c05-8630-0be41d89a407" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashUninsuredAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_CashUninsuredAmount_961b112f-94ee-4c05-8630-0be41d89a407" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod_559d5802-becb-471b-881d-cda5b4c72147" xlink:href="ameh-20220331.xsd#ameh_MarketableSecuritiesCurrentMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod_559d5802-becb-471b-881d-cda5b4c72147" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_688f7dc1-f78f-47d2-9ea4-7f16738d4776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_688f7dc1-f78f-47d2-9ea4-7f16738d4776" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_c4fcc2bd-793d-4087-bb5f-76487b7e7be5" xlink:href="ameh-20220331.xsd#ameh_EquityMethodInvestmentOwnershipPercentageDisposed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_c4fcc2bd-793d-4087-bb5f-76487b7e7be5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireCommonStockAndWarrants_f982e9b8-0f50-4af3-a1e2-f610b1817e36" xlink:href="ameh-20220331.xsd#ameh_PaymentsToAcquireCommonStockAndWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_ameh_PaymentsToAcquireCommonStockAndWarrants_f982e9b8-0f50-4af3-a1e2-f610b1817e36" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_175b438f-a4d6-4867-9caa-56cb5120e27d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_175b438f-a4d6-4867-9caa-56cb5120e27d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_4f60ab3a-f1a6-4e28-930f-019c3b63da03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_4f60ab3a-f1a6-4e28-930f-019c3b63da03" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_bb8882aa-5770-4515-b7af-694e83dae07e" xlink:href="ameh-20220331.xsd#ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_bb8882aa-5770-4515-b7af-694e83dae07e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_ddd89a55-9360-46cc-9733-5957ea1b2172" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_ddd89a55-9360-46cc-9733-5957ea1b2172" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_c7d62503-11b4-45da-b226-68edc20e3c13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_c7d62503-11b4-45da-b226-68edc20e3c13" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_5661b7b5-00ed-43c2-84a7-4a40c3fa85c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_NumberOfReportingUnits_5661b7b5-00ed-43c2-84a7-4a40c3fa85c2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_c7effae7-3d7c-4d5a-bbd7-141c367377d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_c7effae7-3d7c-4d5a-bbd7-141c367377d3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_86fabcc5-a536-4b16-9538-f8e597dc3f01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_86fabcc5-a536-4b16-9538-f8e597dc3f01" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_b54c36be-e9e1-4ea2-84d1-d9fb14303e50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_b54c36be-e9e1-4ea2-84d1-d9fb14303e50" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_6e3bd5fc-8be9-4c8d-b54f-6a29c8ae1cb2" xlink:href="ameh-20220331.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_6e3bd5fc-8be9-4c8d-b54f-6a29c8ae1cb2" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_e2197499-479f-488d-b620-1d0739bdadff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_e2197499-479f-488d-b620-1d0739bdadff" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_b49aeeff-274a-486e-b926-9c7579d9d494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_b49aeeff-274a-486e-b926-9c7579d9d494" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_1ca3ff6c-f409-4f62-a769-a7256f4937eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_DerivativeAssets_1ca3ff6c-f409-4f62-a769-a7256f4937eb" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_431e6550-35f6-4730-9c19-c00563847495" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_431e6550-35f6-4730-9c19-c00563847495" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_ee35c66b-d8c1-4009-82d0-957696cbfcee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_ee35c66b-d8c1-4009-82d0-957696cbfcee" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_816b704a-150d-46fc-a15f-064986fe790e" xlink:href="ameh-20220331.xsd#ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_816b704a-150d-46fc-a15f-064986fe790e" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6cf443ca-7969-4663-a59d-6b2a6ecde721" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6cf443ca-7969-4663-a59d-6b2a6ecde721" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_f03f17d7-c9e5-4f4f-a26e-af97207835e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_f03f17d7-c9e5-4f4f-a26e-af97207835e6" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_d8079f3d-fccf-443e-9026-cfa2d32c2b5e" xlink:href="ameh-20220331.xsd#ameh_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_d8079f3d-fccf-443e-9026-cfa2d32c2b5e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9ff76691-abb3-428b-a3f1-0aeaca568fcb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_d8079f3d-fccf-443e-9026-cfa2d32c2b5e" xlink:to="loc_srt_RangeAxis_9ff76691-abb3-428b-a3f1-0aeaca568fcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9ff76691-abb3-428b-a3f1-0aeaca568fcb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9ff76691-abb3-428b-a3f1-0aeaca568fcb" xlink:to="loc_srt_RangeMember_9ff76691-abb3-428b-a3f1-0aeaca568fcb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_87eedf3c-db91-437f-a812-4d7f1d90e84d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9ff76691-abb3-428b-a3f1-0aeaca568fcb" xlink:to="loc_srt_RangeMember_87eedf3c-db91-437f-a812-4d7f1d90e84d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bb73c837-85c9-4581-9827-7936fb06bc56" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_87eedf3c-db91-437f-a812-4d7f1d90e84d" xlink:to="loc_srt_MinimumMember_bb73c837-85c9-4581-9827-7936fb06bc56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c14f28dc-4cac-41b1-9bbe-71ac3d6a87a6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_87eedf3c-db91-437f-a812-4d7f1d90e84d" xlink:to="loc_srt_MaximumMember_c14f28dc-4cac-41b1-9bbe-71ac3d6a87a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_da8f3ee8-6749-43d3-a334-cc47238a953a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_d8079f3d-fccf-443e-9026-cfa2d32c2b5e" xlink:to="loc_srt_CounterpartyNameAxis_da8f3ee8-6749-43d3-a334-cc47238a953a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_da8f3ee8-6749-43d3-a334-cc47238a953a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_da8f3ee8-6749-43d3-a334-cc47238a953a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_da8f3ee8-6749-43d3-a334-cc47238a953a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ab96a1a0-dfb5-4fcb-9f7f-b60d40843d1e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_da8f3ee8-6749-43d3-a334-cc47238a953a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ab96a1a0-dfb5-4fcb-9f7f-b60d40843d1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClinigenceHoldingsIncMember_b334bf4b-a863-4e00-9590-39894c9e8078" xlink:href="ameh-20220331.xsd#ameh_ClinigenceHoldingsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ab96a1a0-dfb5-4fcb-9f7f-b60d40843d1e" xlink:to="loc_ameh_ClinigenceHoldingsIncMember_b334bf4b-a863-4e00-9590-39894c9e8078" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CMSMember_a515410f-866a-4c28-bad7-c74a2f1480a7" xlink:href="ameh-20220331.xsd#ameh_CMSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ab96a1a0-dfb5-4fcb-9f7f-b60d40843d1e" xlink:to="loc_ameh_CMSMember_a515410f-866a-4c28-bad7-c74a2f1480a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_29a643a8-929b-48fd-8f4a-f0f1984fd13c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_d8079f3d-fccf-443e-9026-cfa2d32c2b5e" xlink:to="loc_srt_ProductOrServiceAxis_29a643a8-929b-48fd-8f4a-f0f1984fd13c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_29a643a8-929b-48fd-8f4a-f0f1984fd13c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_29a643a8-929b-48fd-8f4a-f0f1984fd13c" xlink:to="loc_srt_ProductsAndServicesDomain_29a643a8-929b-48fd-8f4a-f0f1984fd13c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c582c623-9f5b-49a4-87da-ae6a7702ce02" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_29a643a8-929b-48fd-8f4a-f0f1984fd13c" xlink:to="loc_srt_ProductsAndServicesDomain_c582c623-9f5b-49a4-87da-ae6a7702ce02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PerMemberPerMonthManagedCareContractMember_16f44275-1a7d-4ffa-a4d6-6a2c9068c67f" xlink:href="ameh-20220331.xsd#ameh_PerMemberPerMonthManagedCareContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c582c623-9f5b-49a4-87da-ae6a7702ce02" xlink:to="loc_ameh_PerMemberPerMonthManagedCareContractMember_16f44275-1a7d-4ffa-a4d6-6a2c9068c67f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember_01fd2c8c-6ad2-4bcc-adcc-41c36c097291" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c582c623-9f5b-49a4-87da-ae6a7702ce02" xlink:to="loc_us-gaap_ManagementServiceMember_01fd2c8c-6ad2-4bcc-adcc-41c36c097291" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_d16045a8-9877-4a6f-865e-9fd17413ab57" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_d8079f3d-fccf-443e-9026-cfa2d32c2b5e" xlink:to="loc_srt_OwnershipAxis_d16045a8-9877-4a6f-865e-9fd17413ab57" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_d16045a8-9877-4a6f-865e-9fd17413ab57_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_d16045a8-9877-4a6f-865e-9fd17413ab57" xlink:to="loc_srt_OwnershipDomain_d16045a8-9877-4a6f-865e-9fd17413ab57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_69982f8b-1851-4b98-95e1-00c37519fb6c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_d16045a8-9877-4a6f-865e-9fd17413ab57" xlink:to="loc_srt_OwnershipDomain_69982f8b-1851-4b98-95e1-00c37519fb6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_3cd953b0-51f3-4717-a015-5e9ec5c899dc" xlink:href="ameh-20220331.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_69982f8b-1851-4b98-95e1-00c37519fb6c" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_3cd953b0-51f3-4717-a015-5e9ec5c899dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_cf337cf8-a416-4d42-9b68-008f7ebcc03e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_d8079f3d-fccf-443e-9026-cfa2d32c2b5e" xlink:to="loc_dei_LegalEntityAxis_cf337cf8-a416-4d42-9b68-008f7ebcc03e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_cf337cf8-a416-4d42-9b68-008f7ebcc03e_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_cf337cf8-a416-4d42-9b68-008f7ebcc03e" xlink:to="loc_dei_EntityDomain_cf337cf8-a416-4d42-9b68-008f7ebcc03e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_33959bab-d8f4-4a01-85c8-119586ca6b8e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_cf337cf8-a416-4d42-9b68-008f7ebcc03e" xlink:to="loc_dei_EntityDomain_33959bab-d8f4-4a01-85c8-119586ca6b8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_53466ecc-8c1c-4f07-b463-69f7efd277ff" xlink:href="ameh-20220331.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_33959bab-d8f4-4a01-85c8-119586ca6b8e" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_53466ecc-8c1c-4f07-b463-69f7efd277ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_14d30760-3b6d-40f7-96f9-52e7dc52246a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_d8079f3d-fccf-443e-9026-cfa2d32c2b5e" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_14d30760-3b6d-40f7-96f9-52e7dc52246a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_14d30760-3b6d-40f7-96f9-52e7dc52246a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_14d30760-3b6d-40f7-96f9-52e7dc52246a" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_14d30760-3b6d-40f7-96f9-52e7dc52246a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_4fad1774-4158-4ff7-8dfb-628c20025379" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_14d30760-3b6d-40f7-96f9-52e7dc52246a" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_4fad1774-4158-4ff7-8dfb-628c20025379" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_f7b52854-b2ad-4534-9ef2-16cb9e9d00aa" xlink:href="ameh-20220331.xsd#ameh_UniversalCareIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_4fad1774-4158-4ff7-8dfb-628c20025379" xlink:to="loc_ameh_UniversalCareIncMember_f7b52854-b2ad-4534-9ef2-16cb9e9d00aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_88bd5b98-c0a5-44c2-949f-6488a251547a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_d8079f3d-fccf-443e-9026-cfa2d32c2b5e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_88bd5b98-c0a5-44c2-949f-6488a251547a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_88bd5b98-c0a5-44c2-949f-6488a251547a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_88bd5b98-c0a5-44c2-949f-6488a251547a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_88bd5b98-c0a5-44c2-949f-6488a251547a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5e0e5e7d-2266-419c-9f17-ca1a3579cb51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_88bd5b98-c0a5-44c2-949f-6488a251547a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5e0e5e7d-2266-419c-9f17-ca1a3579cb51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_f2f33f7e-3a8c-464b-9fb7-9d16ac1655fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5e0e5e7d-2266-419c-9f17-ca1a3579cb51" xlink:to="loc_us-gaap_CertificatesOfDepositMember_f2f33f7e-3a8c-464b-9fb7-9d16ac1655fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_0cd29f5b-7bde-46a9-9a4d-16de78a53a55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_d8079f3d-fccf-443e-9026-cfa2d32c2b5e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_0cd29f5b-7bde-46a9-9a4d-16de78a53a55" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_0cd29f5b-7bde-46a9-9a4d-16de78a53a55_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_0cd29f5b-7bde-46a9-9a4d-16de78a53a55" xlink:to="loc_us-gaap_HedgingRelationshipDomain_0cd29f5b-7bde-46a9-9a4d-16de78a53a55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_c964a57d-fefb-454c-898b-92de3e0a9d17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_0cd29f5b-7bde-46a9-9a4d-16de78a53a55" xlink:to="loc_us-gaap_HedgingRelationshipDomain_c964a57d-fefb-454c-898b-92de3e0a9d17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_f14a9b3f-78a8-40e4-8370-130d09370aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_c964a57d-fefb-454c-898b-92de3e0a9d17" xlink:to="loc_us-gaap_CashFlowHedgingMember_f14a9b3f-78a8-40e4-8370-130d09370aa5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_86bc5cad-3bbd-4ac4-922a-e4a08c976b80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_d8079f3d-fccf-443e-9026-cfa2d32c2b5e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_86bc5cad-3bbd-4ac4-922a-e4a08c976b80" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86bc5cad-3bbd-4ac4-922a-e4a08c976b80_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_86bc5cad-3bbd-4ac4-922a-e4a08c976b80" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86bc5cad-3bbd-4ac4-922a-e4a08c976b80_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_801e9d5a-dba0-497c-a11b-54f0e17d8a64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_86bc5cad-3bbd-4ac4-922a-e4a08c976b80" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_801e9d5a-dba0-497c-a11b-54f0e17d8a64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_bb8a43eb-af48-456b-bce4-5955cf05621a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_801e9d5a-dba0-497c-a11b-54f0e17d8a64" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_bb8a43eb-af48-456b-bce4-5955cf05621a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_9f5d7585-433f-430e-a4f1-a21b0d59786e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_d8079f3d-fccf-443e-9026-cfa2d32c2b5e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_9f5d7585-433f-430e-a4f1-a21b0d59786e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9f5d7585-433f-430e-a4f1-a21b0d59786e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9f5d7585-433f-430e-a4f1-a21b0d59786e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9f5d7585-433f-430e-a4f1-a21b0d59786e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_820b7ef4-03a0-4622-a146-742e790d5ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9f5d7585-433f-430e-a4f1-a21b0d59786e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_820b7ef4-03a0-4622-a146-742e790d5ebe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_d76b71b4-da43-4c25-9632-e71f632f927c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_820b7ef4-03a0-4622-a146-742e790d5ebe" xlink:to="loc_us-gaap_InterestRateSwapMember_d76b71b4-da43-4c25-9632-e71f632f927c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContingentEquitySecuritiesMember_8debd1d2-64fb-4edd-bb14-f52d366321b0" xlink:href="ameh-20220331.xsd#ameh_ContingentEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_820b7ef4-03a0-4622-a146-742e790d5ebe" xlink:to="loc_ameh_ContingentEquitySecuritiesMember_8debd1d2-64fb-4edd-bb14-f52d366321b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1880f889-16ab-42a2-b858-bb98ea1d33df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_d8079f3d-fccf-443e-9026-cfa2d32c2b5e" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1880f889-16ab-42a2-b858-bb98ea1d33df" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1880f889-16ab-42a2-b858-bb98ea1d33df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1880f889-16ab-42a2-b858-bb98ea1d33df" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1880f889-16ab-42a2-b858-bb98ea1d33df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_61b8902f-1f40-41c1-8605-f918e313a818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1880f889-16ab-42a2-b858-bb98ea1d33df" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_61b8902f-1f40-41c1-8605-f918e313a818" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_75bf5eea-9f24-4ee9-b3fc-9bd7ae73c8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_61b8902f-1f40-41c1-8605-f918e313a818" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_75bf5eea-9f24-4ee9-b3fc-9bd7ae73c8d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_6c1d3121-7720-4ecc-a5f0-e1776d0e9297" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_61b8902f-1f40-41c1-8605-f918e313a818" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_6c1d3121-7720-4ecc-a5f0-e1776d0e9297" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsPayableAndAccruedExpensesMember_9e3d445f-f233-4dc5-964a-981505c5241e" xlink:href="ameh-20220331.xsd#ameh_AccountsPayableAndAccruedExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_61b8902f-1f40-41c1-8605-f918e313a818" xlink:to="loc_ameh_AccountsPayableAndAccruedExpensesMember_9e3d445f-f233-4dc5-964a-981505c5241e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_7a20763a-b0a0-420b-8dd9-30f2873db140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_d8079f3d-fccf-443e-9026-cfa2d32c2b5e" xlink:to="loc_us-gaap_HedgingDesignationAxis_7a20763a-b0a0-420b-8dd9-30f2873db140" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_7a20763a-b0a0-420b-8dd9-30f2873db140_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_7a20763a-b0a0-420b-8dd9-30f2873db140" xlink:to="loc_us-gaap_HedgingDesignationDomain_7a20763a-b0a0-420b-8dd9-30f2873db140_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_71ced28e-b7f8-4920-a8d4-eb9945fdb16d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_7a20763a-b0a0-420b-8dd9-30f2873db140" xlink:to="loc_us-gaap_HedgingDesignationDomain_71ced28e-b7f8-4920-a8d4-eb9945fdb16d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_54ba45c1-0a3f-45a8-a22f-f448bb62bae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_71ced28e-b7f8-4920-a8d4-eb9945fdb16d" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_54ba45c1-0a3f-45a8-a22f-f448bb62bae3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails" xlink:type="extended" id="i76bc4d2d82294988b4039d2db9f9c01e_BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7dd44bf9-42d2-41eb-ab99-30fe97d14ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_50af25d9-ffc1-4c44-8074-ac6c64cddc70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7dd44bf9-42d2-41eb-ab99-30fe97d14ba5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_50af25d9-ffc1-4c44-8074-ac6c64cddc70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_0cc72044-d3e7-4e8e-b4e2-6140683412bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7dd44bf9-42d2-41eb-ab99-30fe97d14ba5" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_0cc72044-d3e7-4e8e-b4e2-6140683412bb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_ae187167-6357-4f8d-83f7-2fc7a3ed8f2b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0cc72044-d3e7-4e8e-b4e2-6140683412bb" xlink:to="loc_srt_MajorCustomersAxis_ae187167-6357-4f8d-83f7-2fc7a3ed8f2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ae187167-6357-4f8d-83f7-2fc7a3ed8f2b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_ae187167-6357-4f8d-83f7-2fc7a3ed8f2b" xlink:to="loc_srt_NameOfMajorCustomerDomain_ae187167-6357-4f8d-83f7-2fc7a3ed8f2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_14413066-7cf3-4c49-8f23-8358cae370f9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_ae187167-6357-4f8d-83f7-2fc7a3ed8f2b" xlink:to="loc_srt_NameOfMajorCustomerDomain_14413066-7cf3-4c49-8f23-8358cae370f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommercialMember_d2565665-c2d7-49cd-aa18-d38ecfb7cbf8" xlink:href="ameh-20220331.xsd#ameh_CommercialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_14413066-7cf3-4c49-8f23-8358cae370f9" xlink:to="loc_ameh_CommercialMember_d2565665-c2d7-49cd-aa18-d38ecfb7cbf8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicareMember_23fac06a-5130-48b5-a52a-2675730c92ca" xlink:href="ameh-20220331.xsd#ameh_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_14413066-7cf3-4c49-8f23-8358cae370f9" xlink:to="loc_ameh_MedicareMember_23fac06a-5130-48b5-a52a-2675730c92ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicaidMember_b0f167df-cd4c-4bc9-8092-b92e8139e011" xlink:href="ameh-20220331.xsd#ameh_MedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_14413066-7cf3-4c49-8f23-8358cae370f9" xlink:to="loc_ameh_MedicaidMember_b0f167df-cd4c-4bc9-8092-b92e8139e011" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OtherThirdPartiesMember_ea362c65-a73b-479c-a284-7747265196dd" xlink:href="ameh-20220331.xsd#ameh_OtherThirdPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_14413066-7cf3-4c49-8f23-8358cae370f9" xlink:to="loc_ameh_OtherThirdPartiesMember_ea362c65-a73b-479c-a284-7747265196dd" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" xlink:type="extended" id="i9d74c3f7e05d4b30a3a12d8a61b291de_BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueLineItems_dd31c7dd-7fc9-4994-a4bc-39d5f4720d0b" xlink:href="ameh-20220331.xsd#ameh_AccountsReceivableAndNetRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_fee1e2ff-36e6-4e7d-9497-6c6ca972b788" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueLineItems_dd31c7dd-7fc9-4994-a4bc-39d5f4720d0b" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_fee1e2ff-36e6-4e7d-9497-6c6ca972b788" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueTable_b524a06c-8721-45a3-ade7-14a1005fe404" xlink:href="ameh-20220331.xsd#ameh_AccountsReceivableAndNetRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueLineItems_dd31c7dd-7fc9-4994-a4bc-39d5f4720d0b" xlink:to="loc_ameh_AccountsReceivableAndNetRevenueTable_b524a06c-8721-45a3-ade7-14a1005fe404" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_31965470-9257-4a34-a8fd-7b1ed9886d58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_b524a06c-8721-45a3-ade7-14a1005fe404" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_31965470-9257-4a34-a8fd-7b1ed9886d58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_31965470-9257-4a34-a8fd-7b1ed9886d58_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_31965470-9257-4a34-a8fd-7b1ed9886d58" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_31965470-9257-4a34-a8fd-7b1ed9886d58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7cb332a4-a6ed-4b85-9e85-96721dd822b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_31965470-9257-4a34-a8fd-7b1ed9886d58" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7cb332a4-a6ed-4b85-9e85-96721dd822b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_8fd37622-62d2-466a-91de-6dac54fbf8de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7cb332a4-a6ed-4b85-9e85-96721dd822b8" xlink:to="loc_us-gaap_SalesRevenueNetMember_8fd37622-62d2-466a-91de-6dac54fbf8de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_256bfe36-2b75-4344-b396-b3bf735f789f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7cb332a4-a6ed-4b85-9e85-96721dd822b8" xlink:to="loc_us-gaap_AccountsReceivableMember_256bfe36-2b75-4344-b396-b3bf735f789f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_c4e2ebfc-211b-49df-af4e-7c868698ea57" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_b524a06c-8721-45a3-ade7-14a1005fe404" xlink:to="loc_srt_MajorCustomersAxis_c4e2ebfc-211b-49df-af4e-7c868698ea57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_c4e2ebfc-211b-49df-af4e-7c868698ea57_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_c4e2ebfc-211b-49df-af4e-7c868698ea57" xlink:to="loc_srt_NameOfMajorCustomerDomain_c4e2ebfc-211b-49df-af4e-7c868698ea57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_c26adabb-70bf-4499-9165-61c4fd7eb29c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_c4e2ebfc-211b-49df-af4e-7c868698ea57" xlink:to="loc_srt_NameOfMajorCustomerDomain_c26adabb-70bf-4499-9165-61c4fd7eb29c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorAMember_be7b812e-a110-4d2a-844f-89b31062209a" xlink:href="ameh-20220331.xsd#ameh_PayorAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_c26adabb-70bf-4499-9165-61c4fd7eb29c" xlink:to="loc_ameh_PayorAMember_be7b812e-a110-4d2a-844f-89b31062209a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorBMember_2f1b2af9-95e8-401d-83d2-038722865a00" xlink:href="ameh-20220331.xsd#ameh_PayorBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_c26adabb-70bf-4499-9165-61c4fd7eb29c" xlink:to="loc_ameh_PayorBMember_2f1b2af9-95e8-401d-83d2-038722865a00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorCMember_39b12ac1-4363-476c-893c-77b983dacc07" xlink:href="ameh-20220331.xsd#ameh_PayorCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_c26adabb-70bf-4499-9165-61c4fd7eb29c" xlink:to="loc_ameh_PayorCMember_39b12ac1-4363-476c-893c-77b983dacc07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorDMember_70bde5d3-cea7-46d2-bc7d-a0f3bc538feb" xlink:href="ameh-20220331.xsd#ameh_PayorDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_c26adabb-70bf-4499-9165-61c4fd7eb29c" xlink:to="loc_ameh_PayorDMember_70bde5d3-cea7-46d2-bc7d-a0f3bc538feb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorEMember_b27ac13f-010b-4066-9ab2-da0afb0c98ff" xlink:href="ameh-20220331.xsd#ameh_PayorEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_c26adabb-70bf-4499-9165-61c4fd7eb29c" xlink:to="loc_ameh_PayorEMember_b27ac13f-010b-4066-9ab2-da0afb0c98ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorFMember_b2798726-56d1-44cb-b347-1c23d636abd3" xlink:href="ameh-20220331.xsd#ameh_PayorFMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_c26adabb-70bf-4499-9165-61c4fd7eb29c" xlink:to="loc_ameh_PayorFMember_b2798726-56d1-44cb-b347-1c23d636abd3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_15f8c2aa-2b46-4a00-93af-63922d0ccf71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_b524a06c-8721-45a3-ade7-14a1005fe404" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_15f8c2aa-2b46-4a00-93af-63922d0ccf71" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_15f8c2aa-2b46-4a00-93af-63922d0ccf71_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_15f8c2aa-2b46-4a00-93af-63922d0ccf71" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_15f8c2aa-2b46-4a00-93af-63922d0ccf71_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_44f675f3-047b-4684-99d0-b97d7662a8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_15f8c2aa-2b46-4a00-93af-63922d0ccf71" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_44f675f3-047b-4684-99d0-b97d7662a8f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_77911cd1-8d3e-4435-b11a-93a8b419d64b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_44f675f3-047b-4684-99d0-b97d7662a8f7" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_77911cd1-8d3e-4435-b11a-93a8b419d64b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails" xlink:type="extended" id="i339c522d057948169b88454ad43314a6_BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_87a13b01-e56d-471e-8566-231764f391cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_80bd77cd-52d6-46e4-a577-86a974f31ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_87a13b01-e56d-471e-8566-231764f391cd" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_80bd77cd-52d6-46e4-a577-86a974f31ca5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7603e4df-dade-4d08-99cd-3f8bd75c0dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_87a13b01-e56d-471e-8566-231764f391cd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7603e4df-dade-4d08-99cd-3f8bd75c0dcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_e2ed2261-e398-41bf-8649-b199274815a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_87a13b01-e56d-471e-8566-231764f391cd" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_e2ed2261-e398-41bf-8649-b199274815a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_be31fdfd-4742-4d41-9721-4ea2d6932ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_87a13b01-e56d-471e-8566-231764f391cd" xlink:to="loc_us-gaap_DerivativeAssets_be31fdfd-4742-4d41-9721-4ea2d6932ea6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_e53e45f0-afcf-4d6e-9997-e32985ebdd5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_87a13b01-e56d-471e-8566-231764f391cd" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_e53e45f0-afcf-4d6e-9997-e32985ebdd5f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_fd9f3855-fbd2-4f50-bcf8-41e6e9cee0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_87a13b01-e56d-471e-8566-231764f391cd" xlink:to="loc_us-gaap_DerivativeLiabilities_fd9f3855-fbd2-4f50-bcf8-41e6e9cee0d9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f2170c5d-c27d-4b61-b40d-f22ca499673b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_87a13b01-e56d-471e-8566-231764f391cd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f2170c5d-c27d-4b61-b40d-f22ca499673b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_883e38ea-e6dc-4582-a44e-afe3adbf13b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_87a13b01-e56d-471e-8566-231764f391cd" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_883e38ea-e6dc-4582-a44e-afe3adbf13b2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_62ff653f-4c60-4add-b912-58cebc1c6f95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_87a13b01-e56d-471e-8566-231764f391cd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_62ff653f-4c60-4add-b912-58cebc1c6f95" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ef69d04a-cf96-46e9-a0ce-14edd1aae0f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_62ff653f-4c60-4add-b912-58cebc1c6f95" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ef69d04a-cf96-46e9-a0ce-14edd1aae0f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ef69d04a-cf96-46e9-a0ce-14edd1aae0f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ef69d04a-cf96-46e9-a0ce-14edd1aae0f0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ef69d04a-cf96-46e9-a0ce-14edd1aae0f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b450fac-06dd-402b-98e0-d06acfbcdc6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ef69d04a-cf96-46e9-a0ce-14edd1aae0f0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b450fac-06dd-402b-98e0-d06acfbcdc6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_a086fd38-7db5-46fe-8534-08c5b1de2e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b450fac-06dd-402b-98e0-d06acfbcdc6c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_a086fd38-7db5-46fe-8534-08c5b1de2e7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8c4a2945-f6a0-440b-bd8e-a1d35f6c734a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b450fac-06dd-402b-98e0-d06acfbcdc6c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8c4a2945-f6a0-440b-bd8e-a1d35f6c734a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_213f2460-4c18-4d40-b305-c21956971950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b450fac-06dd-402b-98e0-d06acfbcdc6c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_213f2460-4c18-4d40-b305-c21956971950" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_015b61a3-caff-47b1-9e7d-9461c1c0370f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_62ff653f-4c60-4add-b912-58cebc1c6f95" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_015b61a3-caff-47b1-9e7d-9461c1c0370f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_015b61a3-caff-47b1-9e7d-9461c1c0370f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_015b61a3-caff-47b1-9e7d-9461c1c0370f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_015b61a3-caff-47b1-9e7d-9461c1c0370f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_91189b9a-a507-464d-b96e-23d57cf5b986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_015b61a3-caff-47b1-9e7d-9461c1c0370f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_91189b9a-a507-464d-b96e-23d57cf5b986" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContingentEquitySecuritiesMember_f7eaf609-b412-43ba-8fd6-9cabe7d8022a" xlink:href="ameh-20220331.xsd#ameh_ContingentEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_91189b9a-a507-464d-b96e-23d57cf5b986" xlink:to="loc_ameh_ContingentEquitySecuritiesMember_f7eaf609-b412-43ba-8fd6-9cabe7d8022a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_04ddd844-05b0-4bd6-a805-01024197bef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_91189b9a-a507-464d-b96e-23d57cf5b986" xlink:to="loc_us-gaap_WarrantMember_04ddd844-05b0-4bd6-a805-01024197bef9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_87b54848-5b27-4fcf-820d-dceb22bef3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_91189b9a-a507-464d-b96e-23d57cf5b986" xlink:to="loc_us-gaap_InterestRateSwapMember_87b54848-5b27-4fcf-820d-dceb22bef3c7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#BusinessCombinationsandGoodwillAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails" xlink:type="extended" id="i46329cc592c04fc28d65751650adc1fd_BusinessCombinationsandGoodwillAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9be3b283-04ef-452e-bd60-9c6e49a86613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_c50e0a5a-8163-41a2-ae36-bf65b83dda23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9be3b283-04ef-452e-bd60-9c6e49a86613" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_c50e0a5a-8163-41a2-ae36-bf65b83dda23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_44eaac6e-7956-443e-abf7-642dac936f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9be3b283-04ef-452e-bd60-9c6e49a86613" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_44eaac6e-7956-443e-abf7-642dac936f6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_72cf8ff3-57ef-4ada-a156-51795290e84b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9be3b283-04ef-452e-bd60-9c6e49a86613" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_72cf8ff3-57ef-4ada-a156-51795290e84b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_bc962498-72f5-47d5-ac52-6aa9682c7cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9be3b283-04ef-452e-bd60-9c6e49a86613" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_bc962498-72f5-47d5-ac52-6aa9682c7cd1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0f193c2d-655c-4882-8995-9a197afe25cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9be3b283-04ef-452e-bd60-9c6e49a86613" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0f193c2d-655c-4882-8995-9a197afe25cf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_fde417d4-375a-47a2-9fff-2f86648e8f96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9be3b283-04ef-452e-bd60-9c6e49a86613" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_fde417d4-375a-47a2-9fff-2f86648e8f96" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2b44ae7a-28fa-462d-9b7f-1e5e977c4829" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_fde417d4-375a-47a2-9fff-2f86648e8f96" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2b44ae7a-28fa-462d-9b7f-1e5e977c4829" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2b44ae7a-28fa-462d-9b7f-1e5e977c4829_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2b44ae7a-28fa-462d-9b7f-1e5e977c4829" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2b44ae7a-28fa-462d-9b7f-1e5e977c4829_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d6d3da2-630a-42f6-9d47-6659e22e5bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2b44ae7a-28fa-462d-9b7f-1e5e977c4829" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d6d3da2-630a-42f6-9d47-6659e22e5bdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember_aa16bb72-48e5-4b6d-a357-33b57b8d8fae" xlink:href="ameh-20220331.xsd#ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d6d3da2-630a-42f6-9d47-6659e22e5bdc" xlink:to="loc_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember_aa16bb72-48e5-4b6d-a357-33b57b8d8fae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccessPrimaryCareMedicalGroupMember_3954ac9c-311e-41a3-80b4-36f8c8ea7764" xlink:href="ameh-20220331.xsd#ameh_AccessPrimaryCareMedicalGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d6d3da2-630a-42f6-9d47-6659e22e5bdc" xlink:to="loc_ameh_AccessPrimaryCareMedicalGroupMember_3954ac9c-311e-41a3-80b4-36f8c8ea7764" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloSunLabsManagementLLCMember_a8c7d9da-0bde-4c71-bac1-935e91b408fa" xlink:href="ameh-20220331.xsd#ameh_ApolloSunLabsManagementLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d6d3da2-630a-42f6-9d47-6659e22e5bdc" xlink:to="loc_ameh_ApolloSunLabsManagementLLCMember_a8c7d9da-0bde-4c71-bac1-935e91b408fa" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="extended" id="i2c1bcde06e084757bd34fd007984402a_IntangibleAssetsNetScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_875b2c8d-61dd-481f-b222-7814a34821f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_322164a2-11f8-4795-be0f-ee3329f691cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_875b2c8d-61dd-481f-b222-7814a34821f3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_322164a2-11f8-4795-be0f-ee3329f691cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_82a4f1e3-d6a8-41f3-99a5-b32a153eab2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_875b2c8d-61dd-481f-b222-7814a34821f3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_82a4f1e3-d6a8-41f3-99a5-b32a153eab2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f066003a-79f2-4232-afde-441f61673a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_875b2c8d-61dd-481f-b222-7814a34821f3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f066003a-79f2-4232-afde-441f61673a9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bc2da97d-45fd-43af-9d52-60c6a8de817f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_875b2c8d-61dd-481f-b222-7814a34821f3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bc2da97d-45fd-43af-9d52-60c6a8de817f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5dead0a0-b2cb-4b3c-8ad7-1b782b6ae3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_875b2c8d-61dd-481f-b222-7814a34821f3" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5dead0a0-b2cb-4b3c-8ad7-1b782b6ae3c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8140743e-6c26-4591-99bb-7cbc82230040" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5dead0a0-b2cb-4b3c-8ad7-1b782b6ae3c5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8140743e-6c26-4591-99bb-7cbc82230040" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8140743e-6c26-4591-99bb-7cbc82230040_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8140743e-6c26-4591-99bb-7cbc82230040" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8140743e-6c26-4591-99bb-7cbc82230040_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0685ba7c-ff6f-4c5c-8b63-4e49b5273147" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8140743e-6c26-4591-99bb-7cbc82230040" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0685ba7c-ff6f-4c5c-8b63-4e49b5273147" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkRelationshipsMember_759268ef-ee5f-436e-85e1-99cc5308f2dd" xlink:href="ameh-20220331.xsd#ameh_NetworkRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0685ba7c-ff6f-4c5c-8b63-4e49b5273147" xlink:to="loc_ameh_NetworkRelationshipsMember_759268ef-ee5f-436e-85e1-99cc5308f2dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ManagementContractsMember_e3ad4f8c-1632-4ccb-a93e-dc38fdf7ae7b" xlink:href="ameh-20220331.xsd#ameh_ManagementContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0685ba7c-ff6f-4c5c-8b63-4e49b5273147" xlink:to="loc_ameh_ManagementContractsMember_e3ad4f8c-1632-4ccb-a93e-dc38fdf7ae7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MemberRelationshipsMember_46147f08-422f-473f-84c7-67e80fa7b108" xlink:href="ameh-20220331.xsd#ameh_MemberRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0685ba7c-ff6f-4c5c-8b63-4e49b5273147" xlink:to="loc_ameh_MemberRelationshipsMember_46147f08-422f-473f-84c7-67e80fa7b108" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PatientManagementPlatformMember_4c11e4ed-c011-4a7e-b440-acabf028314e" xlink:href="ameh-20220331.xsd#ameh_PatientManagementPlatformMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0685ba7c-ff6f-4c5c-8b63-4e49b5273147" xlink:to="loc_ameh_PatientManagementPlatformMember_4c11e4ed-c011-4a7e-b440-acabf028314e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_25a34862-d932-48cc-87a3-a422a0db7393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0685ba7c-ff6f-4c5c-8b63-4e49b5273147" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_25a34862-d932-48cc-87a3-a422a0db7393" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_29b41437-80a8-4e00-97fd-db310ea98764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0685ba7c-ff6f-4c5c-8b63-4e49b5273147" xlink:to="loc_us-gaap_CustomerRelationshipsMember_29b41437-80a8-4e00-97fd-db310ea98764" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_4ce44328-244d-44be-962d-97f166966961" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0685ba7c-ff6f-4c5c-8b63-4e49b5273147" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_4ce44328-244d-44be-962d-97f166966961" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7de0379e-1180-4e57-ae6d-fdd2090c477b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5dead0a0-b2cb-4b3c-8ad7-1b782b6ae3c5" xlink:to="loc_srt_RangeAxis_7de0379e-1180-4e57-ae6d-fdd2090c477b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7de0379e-1180-4e57-ae6d-fdd2090c477b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7de0379e-1180-4e57-ae6d-fdd2090c477b" xlink:to="loc_srt_RangeMember_7de0379e-1180-4e57-ae6d-fdd2090c477b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c78fb454-c5c4-4e30-bb47-4906d7751dd1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7de0379e-1180-4e57-ae6d-fdd2090c477b" xlink:to="loc_srt_RangeMember_c78fb454-c5c4-4e30-bb47-4906d7751dd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_96c9170f-bfb3-44be-bc41-87dcb1f1eaad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c78fb454-c5c4-4e30-bb47-4906d7751dd1" xlink:to="loc_srt_MinimumMember_96c9170f-bfb3-44be-bc41-87dcb1f1eaad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_982ccec5-d86a-4d4e-a3fd-137bd2a1ef3a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c78fb454-c5c4-4e30-bb47-4906d7751dd1" xlink:to="loc_srt_MaximumMember_982ccec5-d86a-4d4e-a3fd-137bd2a1ef3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_3b34fc1c-5df0-4dc8-8124-721df5efc333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_d4018a42-81d7-4138-be3c-73660ea1800f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_3b34fc1c-5df0-4dc8-8124-721df5efc333" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_d4018a42-81d7-4138-be3c-73660ea1800f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_a5c69e41-c21a-45c8-8c77-e4fab68270d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_3b34fc1c-5df0-4dc8-8124-721df5efc333" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_a5c69e41-c21a-45c8-8c77-e4fab68270d8" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_948b4b98-f163-4c6d-9887-4213d9586a75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_a5c69e41-c21a-45c8-8c77-e4fab68270d8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_948b4b98-f163-4c6d-9887-4213d9586a75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_948b4b98-f163-4c6d-9887-4213d9586a75_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_948b4b98-f163-4c6d-9887-4213d9586a75" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_948b4b98-f163-4c6d-9887-4213d9586a75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dfbd9783-6e62-4838-90a9-c88ca9069b40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_948b4b98-f163-4c6d-9887-4213d9586a75" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dfbd9783-6e62-4838-90a9-c88ca9069b40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_613169b3-16a2-43f2-bbe9-d2908626fc90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dfbd9783-6e62-4838-90a9-c88ca9069b40" xlink:to="loc_us-gaap_TrademarksMember_613169b3-16a2-43f2-bbe9-d2908626fc90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_e3586e93-994c-4596-9f94-23d74180b72d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dfbd9783-6e62-4838-90a9-c88ca9069b40" xlink:to="loc_us-gaap_LicensingAgreementsMember_e3586e93-994c-4596-9f94-23d74180b72d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails" xlink:type="extended" id="i5fe163e51d374a918a1f256d15f91473_InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8f81e65d-9459-46df-9cf3-47ef2028765f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsRollForward_d0542832-0b78-44af-b97f-afc587abe62a" xlink:href="ameh-20220331.xsd#ameh_EquityMethodInvestmentsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8f81e65d-9459-46df-9cf3-47ef2028765f" xlink:to="loc_ameh_EquityMethodInvestmentsRollForward_d0542832-0b78-44af-b97f-afc587abe62a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_6be9bfea-a4ac-47a4-8f47-3623400b1c42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_d0542832-0b78-44af-b97f-afc587abe62a" xlink:to="loc_us-gaap_EquityMethodInvestments_6be9bfea-a4ac-47a4-8f47-3623400b1c42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_f78020de-1829-4d7c-b368-6ce908ed817e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_d0542832-0b78-44af-b97f-afc587abe62a" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_f78020de-1829-4d7c-b368-6ce908ed817e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsContribution_1057a146-c212-47d1-ae81-e0eeeb8a2751" xlink:href="ameh-20220331.xsd#ameh_EquityMethodInvestmentsContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_d0542832-0b78-44af-b97f-afc587abe62a" xlink:to="loc_ameh_EquityMethodInvestmentsContribution_1057a146-c212-47d1-ae81-e0eeeb8a2751" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_5c9e9673-95ed-4392-b41d-73ef2d96917a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_d0542832-0b78-44af-b97f-afc587abe62a" xlink:to="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_5c9e9673-95ed-4392-b41d-73ef2d96917a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_b2b281e3-67e9-4c68-a3e9-436652f59657" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a5eda7d1-3d28-49d2-81ab-ba3eceace017" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8f81e65d-9459-46df-9cf3-47ef2028765f" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a5eda7d1-3d28-49d2-81ab-ba3eceace017" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_66cab5d2-11b3-425c-8aa2-0f2ccf57ea0b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a5eda7d1-3d28-49d2-81ab-ba3eceace017" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_66cab5d2-11b3-425c-8aa2-0f2ccf57ea0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_66cab5d2-11b3-425c-8aa2-0f2ccf57ea0b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_66cab5d2-11b3-425c-8aa2-0f2ccf57ea0b" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_66cab5d2-11b3-425c-8aa2-0f2ccf57ea0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_30be1c86-9038-4397-b486-57d3688cbe13" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_66cab5d2-11b3-425c-8aa2-0f2ccf57ea0b" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_30be1c86-9038-4397-b486-57d3688cbe13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_e38d9e4e-0243-4362-9e9f-a3dafa5c0c2e" xlink:href="ameh-20220331.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_30be1c86-9038-4397-b486-57d3688cbe13" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_e38d9e4e-0243-4362-9e9f-a3dafa5c0c2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_6df4afb0-f4ee-4507-9a5e-c87520db0a62" xlink:href="ameh-20220331.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_30be1c86-9038-4397-b486-57d3688cbe13" xlink:to="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_6df4afb0-f4ee-4507-9a5e-c87520db0a62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_1f563c11-f9eb-4e17-92dc-eb0bf5c55f04" xlink:href="ameh-20220331.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_30be1c86-9038-4397-b486-57d3688cbe13" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_1f563c11-f9eb-4e17-92dc-eb0bf5c55f04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCMember_d0ca356f-d419-43c9-98ea-21a3cf720e7d" xlink:href="ameh-20220331.xsd#ameh_OneMSOLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_30be1c86-9038-4397-b486-57d3688cbe13" xlink:to="loc_ameh_OneMSOLLCMember_d0ca356f-d419-43c9-98ea-21a3cf720e7d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember_c6027b88-d332-425b-810a-6cb7227d3e00" xlink:href="ameh-20220331.xsd#ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_30be1c86-9038-4397-b486-57d3688cbe13" xlink:to="loc_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember_c6027b88-d332-425b-810a-6cb7227d3e00" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CAIPAMSOLLCMember_989f7220-2e74-405e-989a-bcffb17b8db9" xlink:href="ameh-20220331.xsd#ameh_CAIPAMSOLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_30be1c86-9038-4397-b486-57d3688cbe13" xlink:to="loc_ameh_CAIPAMSOLLCMember_989f7220-2e74-405e-989a-bcffb17b8db9" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#InvestmentsinOtherEntitiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails" xlink:type="extended" id="i0cda96a0e86b4b5796c22b8755dfcf7a_InvestmentsinOtherEntitiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOwnershipPercentageSold_9fd2383b-c4cf-4013-9ee7-750ac6cd7a6e" xlink:href="ameh-20220331.xsd#ameh_EquityMethodInvestmentOwnershipPercentageSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_ameh_EquityMethodInvestmentOwnershipPercentageSold_9fd2383b-c4cf-4013-9ee7-750ac6cd7a6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_591b6f26-148a-492e-b3f4-73f610165874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_591b6f26-148a-492e-b3f4-73f610165874" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_81a35f58-a86a-4681-954c-665c9bc1738c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_81a35f58-a86a-4681-954c-665c9bc1738c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_392c9d79-cd05-4e00-9f0e-11efa34f46d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_392c9d79-cd05-4e00-9f0e-11efa34f46d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_49dea12e-7268-4fc0-a6c1-7ba6f962e423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_us-gaap_EquityMethodInvestments_49dea12e-7268-4fc0-a6c1-7ba6f962e423" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForFees_f9ef1a33-5ee4-4603-b3dc-5cf2ac8ae277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_us-gaap_PaymentsForFees_f9ef1a33-5ee4-4603-b3dc-5cf2ac8ae277" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_6bc54d26-a06c-4fcd-8d54-6df1a952b4e2" xlink:href="ameh-20220331.xsd#ameh_AssetAcquisitionPercentageOfSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_6bc54d26-a06c-4fcd-8d54-6df1a952b4e2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_415a0834-0d5e-4aa7-834a-d9a2f39c9e66" xlink:href="ameh-20220331.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_415a0834-0d5e-4aa7-834a-d9a2f39c9e66" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_fc5e660b-aaf9-4743-845b-571c6ea40a1a" xlink:href="ameh-20220331.xsd#ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_fc5e660b-aaf9-4743-845b-571c6ea40a1a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_62f0ec87-58b8-4906-96bb-67fab5568fe6" xlink:href="ameh-20220331.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_62f0ec87-58b8-4906-96bb-67fab5568fe6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_32ea6a3f-6a61-4338-a86d-c3fad698d1a5" xlink:href="ameh-20220331.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_32ea6a3f-6a61-4338-a86d-c3fad698d1a5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_b2cafdfc-2d59-465b-82bc-7cae532741a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_b2cafdfc-2d59-465b-82bc-7cae532741a1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_40aa6cc1-0115-4948-b75e-ca3b4be4c43c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_40aa6cc1-0115-4948-b75e-ca3b4be4c43c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_879ab19b-3da8-42f8-a079-30b193f39c1b" xlink:href="ameh-20220331.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_879ab19b-3da8-42f8-a079-30b193f39c1b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_2f3ec277-d25f-407d-a0ed-0b6dbc0a5198" xlink:href="ameh-20220331.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_2f3ec277-d25f-407d-a0ed-0b6dbc0a5198" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_31280ea8-1a33-453b-b6b6-f828f9c99512" xlink:href="ameh-20220331.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_31280ea8-1a33-453b-b6b6-f828f9c99512" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_c02d76e9-22b2-4d9e-8145-689ae692b56c" xlink:href="ameh-20220331.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_c02d76e9-22b2-4d9e-8145-689ae692b56c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_19467a9d-a778-4a26-9f95-af4765e3f8c3" xlink:href="ameh-20220331.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_19467a9d-a778-4a26-9f95-af4765e3f8c3" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_269a5529-d896-4109-900d-ef4df3f2a313" xlink:href="ameh-20220331.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_269a5529-d896-4109-900d-ef4df3f2a313" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_3ea3eb38-74b7-483f-b7c2-71528c56c537" xlink:href="ameh-20220331.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_3ea3eb38-74b7-483f-b7c2-71528c56c537" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_e88f2f5d-1555-44f3-8f5f-742f04b0dcb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_e88f2f5d-1555-44f3-8f5f-742f04b0dcb2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a9adca8c-477f-498f-a0bc-03d49afccaa2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_e88f2f5d-1555-44f3-8f5f-742f04b0dcb2" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a9adca8c-477f-498f-a0bc-03d49afccaa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_a9adca8c-477f-498f-a0bc-03d49afccaa2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a9adca8c-477f-498f-a0bc-03d49afccaa2" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_a9adca8c-477f-498f-a0bc-03d49afccaa2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_c88fffd8-5ce2-4bf3-b651-c904e1fa4509" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a9adca8c-477f-498f-a0bc-03d49afccaa2" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_c88fffd8-5ce2-4bf3-b651-c904e1fa4509" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_b4b67c11-e69d-4c41-b09d-f3f74dcb4960" xlink:href="ameh-20220331.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c88fffd8-5ce2-4bf3-b651-c904e1fa4509" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_b4b67c11-e69d-4c41-b09d-f3f74dcb4960" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_cd06ef4f-9009-47ff-8f80-6b157744985f" xlink:href="ameh-20220331.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c88fffd8-5ce2-4bf3-b651-c904e1fa4509" xlink:to="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_cd06ef4f-9009-47ff-8f80-6b157744985f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_51f77e41-a0bf-4738-aff6-9dc874f8a6c4" xlink:href="ameh-20220331.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c88fffd8-5ce2-4bf3-b651-c904e1fa4509" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_51f77e41-a0bf-4738-aff6-9dc874f8a6c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCMember_854f523e-c4c0-4b6e-ba81-bcfcba8c7a43" xlink:href="ameh-20220331.xsd#ameh_OneMSOLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c88fffd8-5ce2-4bf3-b651-c904e1fa4509" xlink:to="loc_ameh_OneMSOLLCMember_854f523e-c4c0-4b6e-ba81-bcfcba8c7a43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag6MedicalInvestmentGroupLLCMember_e958c56a-5bd0-4ba5-bb01-e2626ce400e1" xlink:href="ameh-20220331.xsd#ameh_Tag6MedicalInvestmentGroupLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c88fffd8-5ce2-4bf3-b651-c904e1fa4509" xlink:to="loc_ameh_Tag6MedicalInvestmentGroupLLCMember_e958c56a-5bd0-4ba5-bb01-e2626ce400e1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CAIPAMSOLLCMember_85e07d25-fa6a-4f7d-a71b-109d3036d49d" xlink:href="ameh-20220331.xsd#ameh_CAIPAMSOLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c88fffd8-5ce2-4bf3-b651-c904e1fa4509" xlink:to="loc_ameh_CAIPAMSOLLCMember_85e07d25-fa6a-4f7d-a71b-109d3036d49d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f316a98d-d4af-48eb-8005-6cf6dd38fd54" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_e88f2f5d-1555-44f3-8f5f-742f04b0dcb2" xlink:to="loc_dei_LegalEntityAxis_f316a98d-d4af-48eb-8005-6cf6dd38fd54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f316a98d-d4af-48eb-8005-6cf6dd38fd54_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_f316a98d-d4af-48eb-8005-6cf6dd38fd54" xlink:to="loc_dei_EntityDomain_f316a98d-d4af-48eb-8005-6cf6dd38fd54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ac5f5eb0-96e9-40d7-9816-7a3e84783176" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_f316a98d-d4af-48eb-8005-6cf6dd38fd54" xlink:to="loc_dei_EntityDomain_ac5f5eb0-96e9-40d7-9816-7a3e84783176" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember_a56a1fa7-690b-4ecf-a399-bfb46ca10e8a" xlink:href="ameh-20220331.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_ac5f5eb0-96e9-40d7-9816-7a3e84783176" xlink:to="loc_ameh_APCAndAPCLSMAMember_a56a1fa7-690b-4ecf-a399-bfb46ca10e8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember_fe632070-3d77-455e-8be4-aaef4072b8c2" xlink:href="ameh-20220331.xsd#ameh_ApcLsmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_APCAndAPCLSMAMember_a56a1fa7-690b-4ecf-a399-bfb46ca10e8a" xlink:to="loc_ameh_ApcLsmaMember_fe632070-3d77-455e-8be4-aaef4072b8c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_193713dc-04a1-4862-8ae7-ee51ac9ed42e" xlink:href="ameh-20220331.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_APCAndAPCLSMAMember_a56a1fa7-690b-4ecf-a399-bfb46ca10e8a" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_193713dc-04a1-4862-8ae7-ee51ac9ed42e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloMedicalHoldingsIncMember_8c021314-61ae-4ba9-ac73-e43cb1e7c9dd" xlink:href="ameh-20220331.xsd#ameh_ApolloMedicalHoldingsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_ac5f5eb0-96e9-40d7-9816-7a3e84783176" xlink:to="loc_ameh_ApolloMedicalHoldingsIncMember_8c021314-61ae-4ba9-ac73-e43cb1e7c9dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementIncMember_81ad4306-3c95-4324-8882-99da527bab9b" xlink:href="ameh-20220331.xsd#ameh_NetworkMedicalManagementIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_ac5f5eb0-96e9-40d7-9816-7a3e84783176" xlink:to="loc_ameh_NetworkMedicalManagementIncMember_81ad4306-3c95-4324-8882-99da527bab9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeAxis_92978b4b-2856-4ef2-bc65-c9f50898bab8" xlink:href="ameh-20220331.xsd#ameh_ContractTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_e88f2f5d-1555-44f3-8f5f-742f04b0dcb2" xlink:to="loc_ameh_ContractTypeAxis_92978b4b-2856-4ef2-bc65-c9f50898bab8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeDomain_92978b4b-2856-4ef2-bc65-c9f50898bab8_default" xlink:href="ameh-20220331.xsd#ameh_ContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ameh_ContractTypeAxis_92978b4b-2856-4ef2-bc65-c9f50898bab8" xlink:to="loc_ameh_ContractTypeDomain_92978b4b-2856-4ef2-bc65-c9f50898bab8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeDomain_9fd198cd-2425-4920-85f7-85954361dafa" xlink:href="ameh-20220331.xsd#ameh_ContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ameh_ContractTypeAxis_92978b4b-2856-4ef2-bc65-c9f50898bab8" xlink:to="loc_ameh_ContractTypeDomain_9fd198cd-2425-4920-85f7-85954361dafa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AncillaryServiceContractMember_0a869fa5-f2e3-43bc-bea8-cfc244644356" xlink:href="ameh-20220331.xsd#ameh_AncillaryServiceContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_ContractTypeDomain_9fd198cd-2425-4920-85f7-85954361dafa" xlink:to="loc_ameh_AncillaryServiceContractMember_0a869fa5-f2e3-43bc-bea8-cfc244644356" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_c9ea50fd-aebb-4b23-aad9-86734754f12a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_e88f2f5d-1555-44f3-8f5f-742f04b0dcb2" xlink:to="loc_srt_OwnershipAxis_c9ea50fd-aebb-4b23-aad9-86734754f12a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_c9ea50fd-aebb-4b23-aad9-86734754f12a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_c9ea50fd-aebb-4b23-aad9-86734754f12a" xlink:to="loc_srt_OwnershipDomain_c9ea50fd-aebb-4b23-aad9-86734754f12a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_4deacaa7-485b-412a-bf0a-8cc8d78f0def" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_c9ea50fd-aebb-4b23-aad9-86734754f12a" xlink:to="loc_srt_OwnershipDomain_4deacaa7-485b-412a-bf0a-8cc8d78f0def" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MediPortalLLCMember_f97bb837-3ae0-401c-946a-ac1c4606c60f" xlink:href="ameh-20220331.xsd#ameh_MediPortalLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_4deacaa7-485b-412a-bf0a-8cc8d78f0def" xlink:to="loc_ameh_MediPortalLLCMember_f97bb837-3ae0-401c-946a-ac1c4606c60f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AchievaMedInc.Member_3813b31a-54a7-4e14-ae3e-350644d26cd7" xlink:href="ameh-20220331.xsd#ameh_AchievaMedInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_4deacaa7-485b-412a-bf0a-8cc8d78f0def" xlink:to="loc_ameh_AchievaMedInc.Member_3813b31a-54a7-4e14-ae3e-350644d26cd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_442423b6-ed8c-4f7d-8bfc-e515bc73d963" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_e88f2f5d-1555-44f3-8f5f-742f04b0dcb2" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_442423b6-ed8c-4f7d-8bfc-e515bc73d963" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_442423b6-ed8c-4f7d-8bfc-e515bc73d963_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_442423b6-ed8c-4f7d-8bfc-e515bc73d963" xlink:to="loc_us-gaap_ReceivableTypeDomain_442423b6-ed8c-4f7d-8bfc-e515bc73d963_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_6ac08ce7-b84b-4978-8907-e2950cc43b98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_442423b6-ed8c-4f7d-8bfc-e515bc73d963" xlink:to="loc_us-gaap_ReceivableTypeDomain_6ac08ce7-b84b-4978-8907-e2950cc43b98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_4fe67d6f-9fe2-4e7b-ba72-8b9f9a11e830" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_6ac08ce7-b84b-4978-8907-e2950cc43b98" xlink:to="loc_us-gaap_NotesReceivableMember_4fe67d6f-9fe2-4e7b-ba72-8b9f9a11e830" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1838e207-3676-4915-a37b-2182655b34a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_e88f2f5d-1555-44f3-8f5f-742f04b0dcb2" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1838e207-3676-4915-a37b-2182655b34a0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1838e207-3676-4915-a37b-2182655b34a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1838e207-3676-4915-a37b-2182655b34a0" xlink:to="loc_us-gaap_RelatedPartyDomain_1838e207-3676-4915-a37b-2182655b34a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_cd3f383e-a7e3-4c80-bf5d-e86c8149d4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1838e207-3676-4915-a37b-2182655b34a0" xlink:to="loc_us-gaap_RelatedPartyDomain_cd3f383e-a7e3-4c80-bf5d-e86c8149d4e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.ArteagaMember_fa8fd577-b943-4f34-b503-e4ca1d4210eb" xlink:href="ameh-20220331.xsd#ameh_Dr.ArteagaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_cd3f383e-a7e3-4c80-bf5d-e86c8149d4e3" xlink:to="loc_ameh_Dr.ArteagaMember_fa8fd577-b943-4f34-b503-e4ca1d4210eb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="extended" id="i0f6c796f9a4a457caed0903b0589c67e_InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8eb86cdb-dada-4cbb-aed2-a4780f6ab29b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_bc68a20c-b540-489c-9203-4c297a128976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8eb86cdb-dada-4cbb-aed2-a4780f6ab29b" xlink:to="loc_us-gaap_AssetsAbstract_bc68a20c-b540-489c-9203-4c297a128976" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_aa286c4f-79a7-4b6d-a925-c04dc620dd40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_bc68a20c-b540-489c-9203-4c297a128976" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_aa286c4f-79a7-4b6d-a925-c04dc620dd40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_4ae8b561-cc97-482c-ba56-c95d9aad8d01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_bc68a20c-b540-489c-9203-4c297a128976" xlink:to="loc_us-gaap_RestrictedCashCurrent_4ae8b561-cc97-482c-ba56-c95d9aad8d01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_cb338962-a303-47ae-b93e-4efebbb693da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_bc68a20c-b540-489c-9203-4c297a128976" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_cb338962-a303-47ae-b93e-4efebbb693da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_5eeb235b-1766-4c14-92ee-5642b27ed1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_bc68a20c-b540-489c-9203-4c297a128976" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_5eeb235b-1766-4c14-92ee-5642b27ed1e0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_64ef1e32-3f3a-4948-972e-72a38f5d2f14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_bc68a20c-b540-489c-9203-4c297a128976" xlink:to="loc_us-gaap_Assets_64ef1e32-3f3a-4948-972e-72a38f5d2f14" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1c92c65-59cd-4cca-bc0a-a6231e409a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8eb86cdb-dada-4cbb-aed2-a4780f6ab29b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1c92c65-59cd-4cca-bc0a-a6231e409a1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_060c2c27-ae2e-4871-b76e-f2e995310652" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1c92c65-59cd-4cca-bc0a-a6231e409a1c" xlink:to="loc_us-gaap_LiabilitiesCurrent_060c2c27-ae2e-4871-b76e-f2e995310652" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2f1c43a9-1afe-4380-b6e5-688b675b4232" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1c92c65-59cd-4cca-bc0a-a6231e409a1c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2f1c43a9-1afe-4380-b6e5-688b675b4232" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9323987a-c072-413f-bae6-a7d3b7a58431" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1c92c65-59cd-4cca-bc0a-a6231e409a1c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_9323987a-c072-413f-bae6-a7d3b7a58431" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_2d85cc01-2a4b-4270-a517-56caf2cecb46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8eb86cdb-dada-4cbb-aed2-a4780f6ab29b" xlink:to="loc_us-gaap_IncomeStatementAbstract_2d85cc01-2a4b-4270-a517-56caf2cecb46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_14387363-fe08-4435-b468-07f102344a65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_2d85cc01-2a4b-4270-a517-56caf2cecb46" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_14387363-fe08-4435-b468-07f102344a65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_5d9029d1-6c48-472a-bcec-a8c653787745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_2d85cc01-2a4b-4270-a517-56caf2cecb46" xlink:to="loc_us-gaap_CostsAndExpenses_5d9029d1-6c48-472a-bcec-a8c653787745" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_cc94150d-b384-4cab-91cf-dc6c6dd92857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_2d85cc01-2a4b-4270-a517-56caf2cecb46" xlink:to="loc_us-gaap_ProfitLoss_cc94150d-b384-4cab-91cf-dc6c6dd92857" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2f05be37-fd7b-46df-935c-3ba176d9ed12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8eb86cdb-dada-4cbb-aed2-a4780f6ab29b" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2f05be37-fd7b-46df-935c-3ba176d9ed12" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_25ce614e-a768-41c3-9106-283ebfd39b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2f05be37-fd7b-46df-935c-3ba176d9ed12" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_25ce614e-a768-41c3-9106-283ebfd39b4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_25ce614e-a768-41c3-9106-283ebfd39b4d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_25ce614e-a768-41c3-9106-283ebfd39b4d" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_25ce614e-a768-41c3-9106-283ebfd39b4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_20689056-6da8-4129-82f6-f170617fa00e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_25ce614e-a768-41c3-9106-283ebfd39b4d" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_20689056-6da8-4129-82f6-f170617fa00e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_f5cc2cad-8b7b-477c-bc05-4f7f9257a688" xlink:href="ameh-20220331.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_20689056-6da8-4129-82f6-f170617fa00e" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_f5cc2cad-8b7b-477c-bc05-4f7f9257a688" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails" xlink:type="extended" id="idffaf364120a41c6b28dce1a45632e12_LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_5fa852fe-a861-4e7a-a1ec-5cc4f23f18ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_5ff2c4b3-cd85-4cf7-852e-5d5b56ea3f54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_5fa852fe-a861-4e7a-a1ec-5cc4f23f18ab" xlink:to="loc_us-gaap_NotesReceivableNet_5ff2c4b3-cd85-4cf7-852e-5d5b56ea3f54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_64899b4b-05ef-4532-bf52-93a6d7b8c080" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_5fa852fe-a861-4e7a-a1ec-5cc4f23f18ab" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_64899b4b-05ef-4532-bf52-93a6d7b8c080" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableGross_a8795bb9-5a5b-4ecd-8a24-c3ef2ceebd3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_5fa852fe-a861-4e7a-a1ec-5cc4f23f18ab" xlink:to="loc_us-gaap_NotesReceivableGross_a8795bb9-5a5b-4ecd-8a24-c3ef2ceebd3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableInterestRateStatedPercentage_c2ae8b98-50d5-46e2-b751-d978583dda6b" xlink:href="ameh-20220331.xsd#ameh_FinanceReceivableInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_5fa852fe-a861-4e7a-a1ec-5cc4f23f18ab" xlink:to="loc_ameh_FinanceReceivableInterestRateStatedPercentage_c2ae8b98-50d5-46e2-b751-d978583dda6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_cdd99ed4-6fa4-4e37-adb3-520121bccab6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_5fa852fe-a861-4e7a-a1ec-5cc4f23f18ab" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_cdd99ed4-6fa4-4e37-adb3-520121bccab6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_8e95ac13-dfbe-46be-81cf-e5cd38773ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_cdd99ed4-6fa4-4e37-adb3-520121bccab6" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_8e95ac13-dfbe-46be-81cf-e5cd38773ca0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_8e95ac13-dfbe-46be-81cf-e5cd38773ca0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_8e95ac13-dfbe-46be-81cf-e5cd38773ca0" xlink:to="loc_us-gaap_ReceivableTypeDomain_8e95ac13-dfbe-46be-81cf-e5cd38773ca0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_b740bea7-7b23-43b4-84cc-b2a7b8e9e113" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_8e95ac13-dfbe-46be-81cf-e5cd38773ca0" xlink:to="loc_us-gaap_ReceivableTypeDomain_b740bea7-7b23-43b4-84cc-b2a7b8e9e113" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_68d5d48d-704b-4505-a9dd-9904073d836a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_b740bea7-7b23-43b4-84cc-b2a7b8e9e113" xlink:to="loc_us-gaap_NotesReceivableMember_68d5d48d-704b-4505-a9dd-9904073d836a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2347b430-0732-47c9-8cc1-ddd0fb52449a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_cdd99ed4-6fa4-4e37-adb3-520121bccab6" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2347b430-0732-47c9-8cc1-ddd0fb52449a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2347b430-0732-47c9-8cc1-ddd0fb52449a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2347b430-0732-47c9-8cc1-ddd0fb52449a" xlink:to="loc_us-gaap_RelatedPartyDomain_2347b430-0732-47c9-8cc1-ddd0fb52449a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b63a225d-c70d-4da2-abe7-ea240606b06b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2347b430-0732-47c9-8cc1-ddd0fb52449a" xlink:to="loc_us-gaap_RelatedPartyDomain_b63a225d-c70d-4da2-abe7-ea240606b06b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Pacific6EnterprisesMember_7a395088-58ee-4aed-8c42-be9726df9394" xlink:href="ameh-20220331.xsd#ameh_Pacific6EnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_b63a225d-c70d-4da2-abe7-ea240606b06b" xlink:to="loc_ameh_Pacific6EnterprisesMember_7a395088-58ee-4aed-8c42-be9726df9394" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_4a73c86b-3b0e-4eb0-86b3-1d5fedcb9441" xlink:href="ameh-20220331.xsd#ameh_AHMCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_b63a225d-c70d-4da2-abe7-ea240606b06b" xlink:to="loc_ameh_AHMCMember_4a73c86b-3b0e-4eb0-86b3-1d5fedcb9441" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_50a91db7-cd03-4398-b77d-7947c1791244" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_cdd99ed4-6fa4-4e37-adb3-520121bccab6" xlink:to="loc_dei_LegalEntityAxis_50a91db7-cd03-4398-b77d-7947c1791244" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_50a91db7-cd03-4398-b77d-7947c1791244_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_50a91db7-cd03-4398-b77d-7947c1791244" xlink:to="loc_dei_EntityDomain_50a91db7-cd03-4398-b77d-7947c1791244_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_852538b6-f5dc-40bd-9368-4e70aeaf7a87" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_50a91db7-cd03-4398-b77d-7947c1791244" xlink:to="loc_dei_EntityDomain_852538b6-f5dc-40bd-9368-4e70aeaf7a87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember_5a0cd678-fa68-4236-ae1a-5942b83ba7a2" xlink:href="ameh-20220331.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_852538b6-f5dc-40bd-9368-4e70aeaf7a87" xlink:to="loc_ameh_NetworkMedicalManagementMember_5a0cd678-fa68-4236-ae1a-5942b83ba7a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ddd8f012-64da-4f51-a827-dfdb44963d26" xlink:href="ameh-20220331.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_852538b6-f5dc-40bd-9368-4e70aeaf7a87" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ddd8f012-64da-4f51-a827-dfdb44963d26" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails" xlink:type="extended" id="i1f8bba39df17408387bc7ddeeb6123b1_CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_7ca900df-0840-41f5-b379-0aea8cac1a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0b53c731-66e7-4a98-919e-59af98b2cc8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ca900df-0840-41f5-b379-0aea8cac1a8a" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_0b53c731-66e7-4a98-919e-59af98b2cc8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_f120a3ab-8688-4d11-ab17-f51a1e0d1a58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ca900df-0840-41f5-b379-0aea8cac1a8a" xlink:to="loc_us-gaap_LongTermDebtCurrent_f120a3ab-8688-4d11-ab17-f51a1e0d1a58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_aea7cd7a-74e5-4433-919e-2162d79c7d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ca900df-0840-41f5-b379-0aea8cac1a8a" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_aea7cd7a-74e5-4433-919e-2162d79c7d2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_67408f4e-32e6-4206-bacb-2f04c58457a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ca900df-0840-41f5-b379-0aea8cac1a8a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_67408f4e-32e6-4206-bacb-2f04c58457a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_3373bdc3-21cb-477e-9c83-64927009d59c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ca900df-0840-41f5-b379-0aea8cac1a8a" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_3373bdc3-21cb-477e-9c83-64927009d59c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_9c5f0b3f-33a8-450c-b40e-a57ad27989cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_3373bdc3-21cb-477e-9c83-64927009d59c" xlink:to="loc_us-gaap_CreditFacilityAxis_9c5f0b3f-33a8-450c-b40e-a57ad27989cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_9c5f0b3f-33a8-450c-b40e-a57ad27989cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_9c5f0b3f-33a8-450c-b40e-a57ad27989cd" xlink:to="loc_us-gaap_CreditFacilityDomain_9c5f0b3f-33a8-450c-b40e-a57ad27989cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_f847eba7-0a9a-4f9d-be2e-4fb0fe127cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_9c5f0b3f-33a8-450c-b40e-a57ad27989cd" xlink:to="loc_us-gaap_CreditFacilityDomain_f847eba7-0a9a-4f9d-be2e-4fb0fe127cb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_0e607eef-c2db-49c5-9410-0680ec0a8396" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_f847eba7-0a9a-4f9d-be2e-4fb0fe127cb2" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_0e607eef-c2db-49c5-9410-0680ec0a8396" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e300e88a-6e3a-4f03-9b7a-728da8ef5300" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_3373bdc3-21cb-477e-9c83-64927009d59c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e300e88a-6e3a-4f03-9b7a-728da8ef5300" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e300e88a-6e3a-4f03-9b7a-728da8ef5300_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e300e88a-6e3a-4f03-9b7a-728da8ef5300" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e300e88a-6e3a-4f03-9b7a-728da8ef5300_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_beeca2aa-ead4-488e-8504-e8dd93988d91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e300e88a-6e3a-4f03-9b7a-728da8ef5300" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_beeca2aa-ead4-488e-8504-e8dd93988d91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateLoanMember_fe527829-441f-4bc5-a86d-9a46ebd4d401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealEstateLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_beeca2aa-ead4-488e-8504-e8dd93988d91" xlink:to="loc_us-gaap_RealEstateLoanMember_fe527829-441f-4bc5-a86d-9a46ebd4d401" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConstructionLoanMember_e38d5517-633a-4b5a-b2f5-64c5e013e7c5" xlink:href="ameh-20220331.xsd#ameh_ConstructionLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_beeca2aa-ead4-488e-8504-e8dd93988d91" xlink:to="loc_ameh_ConstructionLoanMember_e38d5517-633a-4b5a-b2f5-64c5e013e7c5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails" xlink:type="extended" id="id41146c55a4a49c08752e7752e04e20c_CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_d0a85bc0-aba8-4650-ba40-e3a52a58a9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_us-gaap_DebtInstrumentTerm_d0a85bc0-aba8-4650-ba40-e3a52a58a9a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_39591ec9-e9ce-411b-8065-e37845b76f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_39591ec9-e9ce-411b-8065-e37845b76f9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_3ef9109b-50d6-4e08-bdec-195575afc3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_3ef9109b-50d6-4e08-bdec-195575afc3ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_6e41efac-f508-454a-a2c0-c664e0f2391b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_6e41efac-f508-454a-a2c0-c664e0f2391b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_30891a3e-84b9-4dec-8172-2071cd319ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_30891a3e-84b9-4dec-8172-2071cd319ee3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_153f3895-e402-4f94-be60-0b7a4a8bb295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_153f3895-e402-4f94-be60-0b7a4a8bb295" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios_c5c7de66-84e0-475d-a6d9-9f06461951d7" xlink:href="ameh-20220331.xsd#ameh_DebtInstrumentNumberOfKeyFinancialRatios"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios_c5c7de66-84e0-475d-a6d9-9f06461951d7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum_9528425d-786a-4f17-9eb6-c1ee3c631766" xlink:href="ameh-20220331.xsd#ameh_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum_9528425d-786a-4f17-9eb6-c1ee3c631766" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtCovenantAggregatePurchasePriceMaximum_04648875-a3f8-4b0e-8b73-727db77c4587" xlink:href="ameh-20220331.xsd#ameh_DebtCovenantAggregatePurchasePriceMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_ameh_DebtCovenantAggregatePurchasePriceMaximum_04648875-a3f8-4b0e-8b73-727db77c4587" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_566f4148-bd6b-497a-9481-83853a0d5df0" xlink:href="ameh-20220331.xsd#ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_566f4148-bd6b-497a-9481-83853a0d5df0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum_d6ffd257-db9d-4a82-8541-4731acaa5386" xlink:href="ameh-20220331.xsd#ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum_d6ffd257-db9d-4a82-8541-4731acaa5386" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_4c3fd532-e467-4290-8a78-c7323e1cc7c7" xlink:href="ameh-20220331.xsd#ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_4c3fd532-e467-4290-8a78-c7323e1cc7c7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_b47ffb37-07f9-481b-9808-c98eefac0901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_b47ffb37-07f9-481b-9808-c98eefac0901" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_ad7a5319-0e40-4ec9-969d-cb9a05ded9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_ad7a5319-0e40-4ec9-969d-cb9a05ded9ca" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_df034d20-f343-4960-9a94-f37c98efeeb6" xlink:href="ameh-20220331.xsd#ameh_AssetAcquisitionPercentageOfSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_df034d20-f343-4960-9a94-f37c98efeeb6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_b38de570-e864-4e7d-ba6d-2a23f443d5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_b38de570-e864-4e7d-ba6d-2a23f443d5e9" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_a04a1163-96ec-4be3-972c-63de37659555" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_us-gaap_LongTermDebt_a04a1163-96ec-4be3-972c-63de37659555" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_6d13200a-b0e7-481a-816f-8236c3d5848c" xlink:href="ameh-20220331.xsd#ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_6d13200a-b0e7-481a-816f-8236c3d5848c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_34db29d0-49ca-4a00-85b1-26813aaca697" xlink:href="ameh-20220331.xsd#ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_34db29d0-49ca-4a00-85b1-26813aaca697" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_364883f5-22e3-404a-9e99-7d767b61e5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_364883f5-22e3-404a-9e99-7d767b61e5f2" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_9a9ebf0d-e717-49c3-acaf-695185c7d16e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_us-gaap_InterestExpense_9a9ebf0d-e717-49c3-acaf-695185c7d16e" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_4d569eba-6ffe-4ecf-88b0-8eeb8b9494b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_4d569eba-6ffe-4ecf-88b0-8eeb8b9494b2" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_cef03fc1-cd12-4c06-b71b-b3a78c9eabfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_us-gaap_DebtInstrumentTable_cef03fc1-cd12-4c06-b71b-b3a78c9eabfd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_7e97d1d8-ba39-4eb9-81f5-684b31be5d85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_cef03fc1-cd12-4c06-b71b-b3a78c9eabfd" xlink:to="loc_us-gaap_CreditFacilityAxis_7e97d1d8-ba39-4eb9-81f5-684b31be5d85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_7e97d1d8-ba39-4eb9-81f5-684b31be5d85_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_7e97d1d8-ba39-4eb9-81f5-684b31be5d85" xlink:to="loc_us-gaap_CreditFacilityDomain_7e97d1d8-ba39-4eb9-81f5-684b31be5d85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d6f814cc-d5c3-4a45-a3f0-23602437bbfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_7e97d1d8-ba39-4eb9-81f5-684b31be5d85" xlink:to="loc_us-gaap_CreditFacilityDomain_d6f814cc-d5c3-4a45-a3f0-23602437bbfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_c4d333ed-c0aa-475b-84ea-88c01c1b94dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_d6f814cc-d5c3-4a45-a3f0-23602437bbfd" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_c4d333ed-c0aa-475b-84ea-88c01c1b94dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_87de3b2e-dd67-42ba-8c3d-1a0eee5e78e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_d6f814cc-d5c3-4a45-a3f0-23602437bbfd" xlink:to="loc_us-gaap_LineOfCreditMember_87de3b2e-dd67-42ba-8c3d-1a0eee5e78e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_b1c887f9-759d-4414-b0b7-281cc00a1736" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_d6f814cc-d5c3-4a45-a3f0-23602437bbfd" xlink:to="loc_us-gaap_LetterOfCreditMember_b1c887f9-759d-4414-b0b7-281cc00a1736" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember_9621ed90-0006-4e2e-8cc3-f252dfa5d974" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BridgeLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_d6f814cc-d5c3-4a45-a3f0-23602437bbfd" xlink:to="loc_us-gaap_BridgeLoanMember_9621ed90-0006-4e2e-8cc3-f252dfa5d974" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_844fd056-fd01-48cc-a2f5-bfa9ca4b2d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_d6f814cc-d5c3-4a45-a3f0-23602437bbfd" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_844fd056-fd01-48cc-a2f5-bfa9ca4b2d0f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6df5da38-1337-43ee-ab63-4cd22edb1002" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_cef03fc1-cd12-4c06-b71b-b3a78c9eabfd" xlink:to="loc_us-gaap_DebtInstrumentAxis_6df5da38-1337-43ee-ab63-4cd22edb1002" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6df5da38-1337-43ee-ab63-4cd22edb1002_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_6df5da38-1337-43ee-ab63-4cd22edb1002" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6df5da38-1337-43ee-ab63-4cd22edb1002_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2767d10e-52e9-4903-a3f1-b7f36550f305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_6df5da38-1337-43ee-ab63-4cd22edb1002" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2767d10e-52e9-4903-a3f1-b7f36550f305" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmendedCreditAgreementMember_8597fbba-fa8e-4568-b8da-91e6b12ade7d" xlink:href="ameh-20220331.xsd#ameh_AmendedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2767d10e-52e9-4903-a3f1-b7f36550f305" xlink:to="loc_ameh_AmendedCreditAgreementMember_8597fbba-fa8e-4568-b8da-91e6b12ade7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CreditAgreementMember_931bf8f3-58c3-45f9-80d1-649bbb6cda8e" xlink:href="ameh-20220331.xsd#ameh_CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2767d10e-52e9-4903-a3f1-b7f36550f305" xlink:to="loc_ameh_CreditAgreementMember_931bf8f3-58c3-45f9-80d1-649bbb6cda8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConstructionLoanMember_44fb899c-ceb5-4662-a954-74e29677488c" xlink:href="ameh-20220331.xsd#ameh_ConstructionLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2767d10e-52e9-4903-a3f1-b7f36550f305" xlink:to="loc_ameh_ConstructionLoanMember_44fb899c-ceb5-4662-a954-74e29677488c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcBusinessLoanAgreementMember_8d9cbfaa-2380-47a1-9778-9aa8c7bc06be" xlink:href="ameh-20220331.xsd#ameh_ApcBusinessLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2767d10e-52e9-4903-a3f1-b7f36550f305" xlink:to="loc_ameh_ApcBusinessLoanAgreementMember_8d9cbfaa-2380-47a1-9778-9aa8c7bc06be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b13d2d5c-7682-4c8b-b3a7-9f9cbaf2d359" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_cef03fc1-cd12-4c06-b71b-b3a78c9eabfd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b13d2d5c-7682-4c8b-b3a7-9f9cbaf2d359" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b13d2d5c-7682-4c8b-b3a7-9f9cbaf2d359_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b13d2d5c-7682-4c8b-b3a7-9f9cbaf2d359" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b13d2d5c-7682-4c8b-b3a7-9f9cbaf2d359_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dd4adb57-822c-49e2-b8b9-f3652c2df09a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b13d2d5c-7682-4c8b-b3a7-9f9cbaf2d359" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dd4adb57-822c-49e2-b8b9-f3652c2df09a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_5929f4c3-1443-4e65-8413-ee7a16a9b768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dd4adb57-822c-49e2-b8b9-f3652c2df09a" xlink:to="loc_us-gaap_LineOfCreditMember_5929f4c3-1443-4e65-8413-ee7a16a9b768" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_aa07fc8e-0bdd-4981-8b4b-d7eeb4618528" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_cef03fc1-cd12-4c06-b71b-b3a78c9eabfd" xlink:to="loc_srt_RangeAxis_aa07fc8e-0bdd-4981-8b4b-d7eeb4618528" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aa07fc8e-0bdd-4981-8b4b-d7eeb4618528_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_aa07fc8e-0bdd-4981-8b4b-d7eeb4618528" xlink:to="loc_srt_RangeMember_aa07fc8e-0bdd-4981-8b4b-d7eeb4618528_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_09e56016-8f83-409a-a0f4-197c991c11d4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_aa07fc8e-0bdd-4981-8b4b-d7eeb4618528" xlink:to="loc_srt_RangeMember_09e56016-8f83-409a-a0f4-197c991c11d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_62994b29-bd77-4477-bcc5-3916ed27c566" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_09e56016-8f83-409a-a0f4-197c991c11d4" xlink:to="loc_srt_MinimumMember_62994b29-bd77-4477-bcc5-3916ed27c566" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9ef3be27-89d8-4e39-a191-f8e8fcaa932e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_09e56016-8f83-409a-a0f4-197c991c11d4" xlink:to="loc_srt_MaximumMember_9ef3be27-89d8-4e39-a191-f8e8fcaa932e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_9152d646-20ea-48bb-ad0e-48c5d0d993f3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_cef03fc1-cd12-4c06-b71b-b3a78c9eabfd" xlink:to="loc_dei_LegalEntityAxis_9152d646-20ea-48bb-ad0e-48c5d0d993f3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_9152d646-20ea-48bb-ad0e-48c5d0d993f3_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_9152d646-20ea-48bb-ad0e-48c5d0d993f3" xlink:to="loc_dei_EntityDomain_9152d646-20ea-48bb-ad0e-48c5d0d993f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1fcf21b1-5c85-42ee-96c0-c153c49e125f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_9152d646-20ea-48bb-ad0e-48c5d0d993f3" xlink:to="loc_dei_EntityDomain_1fcf21b1-5c85-42ee-96c0-c153c49e125f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_8a435493-b950-405f-8569-292c4e6be101" xlink:href="ameh-20220331.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1fcf21b1-5c85-42ee-96c0-c153c49e125f" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_8a435493-b950-405f-8569-292c4e6be101" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalPropertyPartnersLLCMember_347845ba-bdc5-4d5a-b728-b3f66b756665" xlink:href="ameh-20220331.xsd#ameh_MedicalPropertyPartnersLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1fcf21b1-5c85-42ee-96c0-c153c49e125f" xlink:to="loc_ameh_MedicalPropertyPartnersLLCMember_347845ba-bdc5-4d5a-b728-b3f66b756665" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AMGPropertiesLLCMember_bb92ba73-dbeb-430f-9fcc-63d40bace799" xlink:href="ameh-20220331.xsd#ameh_AMGPropertiesLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1fcf21b1-5c85-42ee-96c0-c153c49e125f" xlink:to="loc_ameh_AMGPropertiesLLCMember_bb92ba73-dbeb-430f-9fcc-63d40bace799" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ZLLPartnersLLCMember_5652282c-151c-4288-b56b-f11b1934875a" xlink:href="ameh-20220331.xsd#ameh_ZLLPartnersLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1fcf21b1-5c85-42ee-96c0-c153c49e125f" xlink:to="loc_ameh_ZLLPartnersLLCMember_5652282c-151c-4288-b56b-f11b1934875a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_f9d0ddd5-c558-4a2a-8623-2a5a59270fff" xlink:href="ameh-20220331.xsd#ameh_Tag8MedicalInvestmentGroupLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1fcf21b1-5c85-42ee-96c0-c153c49e125f" xlink:to="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_f9d0ddd5-c558-4a2a-8623-2a5a59270fff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_c4773de4-9613-407a-a28f-1bdbe6a6d3d2" xlink:href="ameh-20220331.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1fcf21b1-5c85-42ee-96c0-c153c49e125f" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_c4773de4-9613-407a-a28f-1bdbe6a6d3d2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_8cfecb6e-832d-4ed0-93af-e9c30950f007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_cef03fc1-cd12-4c06-b71b-b3a78c9eabfd" xlink:to="loc_us-gaap_VariableRateAxis_8cfecb6e-832d-4ed0-93af-e9c30950f007" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_8cfecb6e-832d-4ed0-93af-e9c30950f007_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_8cfecb6e-832d-4ed0-93af-e9c30950f007" xlink:to="loc_us-gaap_VariableRateDomain_8cfecb6e-832d-4ed0-93af-e9c30950f007_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_9eb65aef-9602-4a93-85ea-dab39867eab3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_8cfecb6e-832d-4ed0-93af-e9c30950f007" xlink:to="loc_us-gaap_VariableRateDomain_9eb65aef-9602-4a93-85ea-dab39867eab3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_d64b0a6f-9dd8-418c-be5a-c4ec4f83a8a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_9eb65aef-9602-4a93-85ea-dab39867eab3" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_d64b0a6f-9dd8-418c-be5a-c4ec4f83a8a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_561238a0-8825-4ebd-a344-857c79714274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_9eb65aef-9602-4a93-85ea-dab39867eab3" xlink:to="loc_us-gaap_PrimeRateMember_561238a0-8825-4ebd-a344-857c79714274" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_16ecd60b-6c26-42a8-9c00-77a6364d456e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_cef03fc1-cd12-4c06-b71b-b3a78c9eabfd" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_16ecd60b-6c26-42a8-9c00-77a6364d456e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_16ecd60b-6c26-42a8-9c00-77a6364d456e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_16ecd60b-6c26-42a8-9c00-77a6364d456e" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_16ecd60b-6c26-42a8-9c00-77a6364d456e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_759c0481-e81d-4411-bfbc-9f1ab5050c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_16ecd60b-6c26-42a8-9c00-77a6364d456e" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_759c0481-e81d-4411-bfbc-9f1ab5050c9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PreferredBankMember_58e7899b-beb5-48ea-9b3a-9c40996a529e" xlink:href="ameh-20220331.xsd#ameh_PreferredBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_759c0481-e81d-4411-bfbc-9f1ab5050c9a" xlink:to="loc_ameh_PreferredBankMember_58e7899b-beb5-48ea-9b3a-9c40996a529e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_30ed8e29-c0d3-4eba-a04d-cbb3edd17187" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_cef03fc1-cd12-4c06-b71b-b3a78c9eabfd" xlink:to="loc_us-gaap_AssetAcquisitionAxis_30ed8e29-c0d3-4eba-a04d-cbb3edd17187" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_30ed8e29-c0d3-4eba-a04d-cbb3edd17187_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_30ed8e29-c0d3-4eba-a04d-cbb3edd17187" xlink:to="loc_us-gaap_AssetAcquisitionDomain_30ed8e29-c0d3-4eba-a04d-cbb3edd17187_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_eafb8a73-7ba1-4aee-88f3-4964328f2bba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_30ed8e29-c0d3-4eba-a04d-cbb3edd17187" xlink:to="loc_us-gaap_AssetAcquisitionDomain_eafb8a73-7ba1-4aee-88f3-4964328f2bba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalPropertyPartnersLLCMember_c134fe95-bace-4a56-b0ee-1efaffab1e3a" xlink:href="ameh-20220331.xsd#ameh_MedicalPropertyPartnersLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_eafb8a73-7ba1-4aee-88f3-4964328f2bba" xlink:to="loc_ameh_MedicalPropertyPartnersLLCMember_c134fe95-bace-4a56-b0ee-1efaffab1e3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AMGPropertiesLLCMember_16dd3f71-9149-4d47-adef-11a8bf459733" xlink:href="ameh-20220331.xsd#ameh_AMGPropertiesLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_eafb8a73-7ba1-4aee-88f3-4964328f2bba" xlink:to="loc_ameh_AMGPropertiesLLCMember_16dd3f71-9149-4d47-adef-11a8bf459733" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ZLLPartnersLLCMember_e560e84e-561d-41ae-af7d-5d174d4fc753" xlink:href="ameh-20220331.xsd#ameh_ZLLPartnersLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_eafb8a73-7ba1-4aee-88f3-4964328f2bba" xlink:to="loc_ameh_ZLLPartnersLLCMember_e560e84e-561d-41ae-af7d-5d174d4fc753" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_6dc38bbb-d5a1-420d-8849-dbf888a41b96" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_cef03fc1-cd12-4c06-b71b-b3a78c9eabfd" xlink:to="loc_srt_StatementScenarioAxis_6dc38bbb-d5a1-420d-8849-dbf888a41b96" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_6dc38bbb-d5a1-420d-8849-dbf888a41b96_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_6dc38bbb-d5a1-420d-8849-dbf888a41b96" xlink:to="loc_srt_ScenarioUnspecifiedDomain_6dc38bbb-d5a1-420d-8849-dbf888a41b96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_f041785f-b596-493b-a697-c02ecf7a8cd9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_6dc38bbb-d5a1-420d-8849-dbf888a41b96" xlink:to="loc_srt_ScenarioUnspecifiedDomain_f041785f-b596-493b-a697-c02ecf7a8cd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_0493f23b-0ac0-463e-9512-3f57d669ae71" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_f041785f-b596-493b-a697-c02ecf7a8cd9" xlink:to="loc_srt_ScenarioForecastMember_0493f23b-0ac0-463e-9512-3f57d669ae71" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#MezzanineandStockholdersEquityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails" xlink:type="extended" id="i87bccf3e65e249269330f0aec0d9c0ba_MezzanineandStockholdersEquityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_faacb82c-fc98-408a-9ab6-0688a2b5eb27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesMerger_88082377-2705-4538-b5c8-0fd3c8baa785" xlink:href="ameh-20220331.xsd#ameh_StockIssuedDuringPeriodSharesMerger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_faacb82c-fc98-408a-9ab6-0688a2b5eb27" xlink:to="loc_ameh_StockIssuedDuringPeriodSharesMerger_88082377-2705-4538-b5c8-0fd3c8baa785" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_b9114efa-f51c-46e0-9853-3c60a9bb57bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_faacb82c-fc98-408a-9ab6-0688a2b5eb27" xlink:to="loc_us-gaap_TreasuryStockCommonShares_b9114efa-f51c-46e0-9853-3c60a9bb57bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_52d3ee5c-143d-416d-8a8a-961006d9f6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_faacb82c-fc98-408a-9ab6-0688a2b5eb27" xlink:to="loc_us-gaap_Dividends_52d3ee5c-143d-416d-8a8a-961006d9f6cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a0a510a7-14a3-4596-9e93-bc88b89c0569" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_faacb82c-fc98-408a-9ab6-0688a2b5eb27" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a0a510a7-14a3-4596-9e93-bc88b89c0569" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_7ecc1a04-e623-4c4c-8366-ee52cdc9539d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a0a510a7-14a3-4596-9e93-bc88b89c0569" xlink:to="loc_dei_LegalEntityAxis_7ecc1a04-e623-4c4c-8366-ee52cdc9539d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_7ecc1a04-e623-4c4c-8366-ee52cdc9539d_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_7ecc1a04-e623-4c4c-8366-ee52cdc9539d" xlink:to="loc_dei_EntityDomain_7ecc1a04-e623-4c4c-8366-ee52cdc9539d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_103c3995-8cc2-466b-b96c-c920327b5c0a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_7ecc1a04-e623-4c4c-8366-ee52cdc9539d" xlink:to="loc_dei_EntityDomain_103c3995-8cc2-466b-b96c-c920327b5c0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ebdb37ea-0a06-4e71-b1d6-9cf48e7fed88" xlink:href="ameh-20220331.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_103c3995-8cc2-466b-b96c-c920327b5c0a" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ebdb37ea-0a06-4e71-b1d6-9cf48e7fed88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CDSCMember_5021e217-aedc-4696-afbf-05588b19cea5" xlink:href="ameh-20220331.xsd#ameh_CDSCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_103c3995-8cc2-466b-b96c-c920327b5c0a" xlink:to="loc_ameh_CDSCMember_5021e217-aedc-4696-afbf-05588b19cea5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#StockBasedCompensationShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended" id="i2845e19bb2ea415c96f83df14c98e713_StockBasedCompensationShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2f040e48-d2e0-4d7a-a8ec-48a00093aac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a1e6156c-6cfb-4227-804b-f287a37da1c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2f040e48-d2e0-4d7a-a8ec-48a00093aac9" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a1e6156c-6cfb-4227-804b-f287a37da1c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_50607b2e-dda2-43c2-b19f-a6d702bbb890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2f040e48-d2e0-4d7a-a8ec-48a00093aac9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_50607b2e-dda2-43c2-b19f-a6d702bbb890" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_26aaf992-0823-43c3-bc5d-1c7f4b7c5fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_50607b2e-dda2-43c2-b19f-a6d702bbb890" xlink:to="loc_us-gaap_AwardTypeAxis_26aaf992-0823-43c3-bc5d-1c7f4b7c5fc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26aaf992-0823-43c3-bc5d-1c7f4b7c5fc6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_26aaf992-0823-43c3-bc5d-1c7f4b7c5fc6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26aaf992-0823-43c3-bc5d-1c7f4b7c5fc6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_07868c55-ce62-48ca-8d41-0a79a4176880" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_26aaf992-0823-43c3-bc5d-1c7f4b7c5fc6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_07868c55-ce62-48ca-8d41-0a79a4176880" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c0f39e0c-7c6f-44c0-92be-530701503d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_07868c55-ce62-48ca-8d41-0a79a4176880" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c0f39e0c-7c6f-44c0-92be-530701503d9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockAwardsAndUnitsMember_18daf8c3-e33b-4d26-9110-615a1dab160b" xlink:href="ameh-20220331.xsd#ameh_StockAwardsAndUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_07868c55-ce62-48ca-8d41-0a79a4176880" xlink:to="loc_ameh_StockAwardsAndUnitsMember_18daf8c3-e33b-4d26-9110-615a1dab160b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended" id="i317ec25384d54e519b3a82e8cb86d6cb_StockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6dd44af-0064-42eb-aeac-c0078c094509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_85301234-accc-4892-b5af-0e132c33c0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6dd44af-0064-42eb-aeac-c0078c094509" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_85301234-accc-4892-b5af-0e132c33c0bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_21b16a4a-a6c1-4c73-afdb-45a4c364b4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6dd44af-0064-42eb-aeac-c0078c094509" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_21b16a4a-a6c1-4c73-afdb-45a4c364b4c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f74d885e-3643-4651-85be-018b86fe6c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6dd44af-0064-42eb-aeac-c0078c094509" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f74d885e-3643-4651-85be-018b86fe6c3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_01575647-3dca-40e9-90ea-d785c42cae6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6dd44af-0064-42eb-aeac-c0078c094509" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_01575647-3dca-40e9-90ea-d785c42cae6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d74eecad-8ed6-45b8-87f0-870a6e8d9954" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6dd44af-0064-42eb-aeac-c0078c094509" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d74eecad-8ed6-45b8-87f0-870a6e8d9954" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance_9fe604c3-4756-4e3c-8c81-6e1c0eac612a" xlink:href="ameh-20220331.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6dd44af-0064-42eb-aeac-c0078c094509" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance_9fe604c3-4756-4e3c-8c81-6e1c0eac612a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2c67a108-6567-4061-9066-f9e9cb6c898c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6dd44af-0064-42eb-aeac-c0078c094509" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2c67a108-6567-4061-9066-f9e9cb6c898c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_c78c4d9c-a958-43df-b16c-c416bb89d98f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6dd44af-0064-42eb-aeac-c0078c094509" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_c78c4d9c-a958-43df-b16c-c416bb89d98f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_b4ca6a37-dae7-47e5-bb4f-63cdd66f4f36" xlink:href="ameh-20220331.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6dd44af-0064-42eb-aeac-c0078c094509" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_b4ca6a37-dae7-47e5-bb4f-63cdd66f4f36" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_243c31ef-09c2-41bc-a81b-2b8bce7c137b" xlink:href="ameh-20220331.xsd#ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6dd44af-0064-42eb-aeac-c0078c094509" xlink:to="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_243c31ef-09c2-41bc-a81b-2b8bce7c137b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_db52ed8a-e3bc-4b09-86f7-eb60e336368a" xlink:href="ameh-20220331.xsd#ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6dd44af-0064-42eb-aeac-c0078c094509" xlink:to="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_db52ed8a-e3bc-4b09-86f7-eb60e336368a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7dcd807d-1e8a-4733-a2e4-5b87d0205785" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6dd44af-0064-42eb-aeac-c0078c094509" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7dcd807d-1e8a-4733-a2e4-5b87d0205785" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5fec3150-d980-4354-8670-182e1cdb9572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7dcd807d-1e8a-4733-a2e4-5b87d0205785" xlink:to="loc_us-gaap_AwardTypeAxis_5fec3150-d980-4354-8670-182e1cdb9572" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5fec3150-d980-4354-8670-182e1cdb9572_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5fec3150-d980-4354-8670-182e1cdb9572" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5fec3150-d980-4354-8670-182e1cdb9572_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_031c89ff-5a57-45e7-9e6e-a5ec9826936a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5fec3150-d980-4354-8670-182e1cdb9572" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_031c89ff-5a57-45e7-9e6e-a5ec9826936a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c906337f-8d62-47dc-b8af-2191e4bf79bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_031c89ff-5a57-45e7-9e6e-a5ec9826936a" xlink:to="loc_us-gaap_RestrictedStockMember_c906337f-8d62-47dc-b8af-2191e4bf79bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_1f4ea1d5-e8f4-47ed-b326-db2efe2d4657" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7dcd807d-1e8a-4733-a2e4-5b87d0205785" xlink:to="loc_srt_TitleOfIndividualAxis_1f4ea1d5-e8f4-47ed-b326-db2efe2d4657" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1f4ea1d5-e8f4-47ed-b326-db2efe2d4657_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_1f4ea1d5-e8f4-47ed-b326-db2efe2d4657" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1f4ea1d5-e8f4-47ed-b326-db2efe2d4657_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_31ed96db-ad33-46ac-b92d-dd1d07b72792" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_1f4ea1d5-e8f4-47ed-b326-db2efe2d4657" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_31ed96db-ad33-46ac-b92d-dd1d07b72792" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EmployeesMember_a92ea827-9588-43ac-845d-79a55665a6d1" xlink:href="ameh-20220331.xsd#ameh_EmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_31ed96db-ad33-46ac-b92d-dd1d07b72792" xlink:to="loc_ameh_EmployeesMember_a92ea827-9588-43ac-845d-79a55665a6d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_454afada-e973-44b0-a30a-5d404278ec91" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7dcd807d-1e8a-4733-a2e4-5b87d0205785" xlink:to="loc_srt_RangeAxis_454afada-e973-44b0-a30a-5d404278ec91" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_454afada-e973-44b0-a30a-5d404278ec91_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_454afada-e973-44b0-a30a-5d404278ec91" xlink:to="loc_srt_RangeMember_454afada-e973-44b0-a30a-5d404278ec91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_44546b01-4608-48bc-b3d5-dc6df526fc70" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_454afada-e973-44b0-a30a-5d404278ec91" xlink:to="loc_srt_RangeMember_44546b01-4608-48bc-b3d5-dc6df526fc70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5f32a1ba-0668-4e90-9ba4-e5f413ddf127" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_44546b01-4608-48bc-b3d5-dc6df526fc70" xlink:to="loc_srt_MinimumMember_5f32a1ba-0668-4e90-9ba4-e5f413ddf127" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d9272878-4687-416b-8eb0-03d4e2f05aaf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_44546b01-4608-48bc-b3d5-dc6df526fc70" xlink:to="loc_srt_MaximumMember_d9272878-4687-416b-8eb0-03d4e2f05aaf" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails" xlink:type="extended" id="ib187e115397042ffb000fe39413b072c_StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8c51517-3869-4581-8ca2-4b9760e5a615" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f17665e7-ab54-4600-a742-28ee22e80a87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8c51517-3869-4581-8ca2-4b9760e5a615" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f17665e7-ab54-4600-a742-28ee22e80a87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_9474a165-73f5-40e3-8b54-d0a6b91c0148" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8c51517-3869-4581-8ca2-4b9760e5a615" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_9474a165-73f5-40e3-8b54-d0a6b91c0148" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_3079a03c-ee9d-41a0-8cc0-219c9e3c8b89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8c51517-3869-4581-8ca2-4b9760e5a615" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_3079a03c-ee9d-41a0-8cc0-219c9e3c8b89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_537fe096-78bc-4d08-a9c6-176662810202" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8c51517-3869-4581-8ca2-4b9760e5a615" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_537fe096-78bc-4d08-a9c6-176662810202" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7f580497-917f-4ecc-9c08-853dfe3734bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8c51517-3869-4581-8ca2-4b9760e5a615" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7f580497-917f-4ecc-9c08-853dfe3734bc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_bf24fbc3-7a86-4d78-9636-5c4c765f065d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8c51517-3869-4581-8ca2-4b9760e5a615" xlink:to="loc_us-gaap_SharePrice_bf24fbc3-7a86-4d78-9636-5c4c765f065d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_51662ebf-ee43-4502-bc84-36a31e378c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8c51517-3869-4581-8ca2-4b9760e5a615" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_51662ebf-ee43-4502-bc84-36a31e378c4e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_1440e356-5c65-4a33-982b-a2526b743847" xlink:href="ameh-20220331.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8c51517-3869-4581-8ca2-4b9760e5a615" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_1440e356-5c65-4a33-982b-a2526b743847" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_687a38f4-b3e5-4912-94e8-7cfd5bcd5291" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8c51517-3869-4581-8ca2-4b9760e5a615" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_687a38f4-b3e5-4912-94e8-7cfd5bcd5291" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_0666f3d5-7a73-48f4-8367-53b8c62825d8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_687a38f4-b3e5-4912-94e8-7cfd5bcd5291" xlink:to="loc_srt_TitleOfIndividualAxis_0666f3d5-7a73-48f4-8367-53b8c62825d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0666f3d5-7a73-48f4-8367-53b8c62825d8_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_0666f3d5-7a73-48f4-8367-53b8c62825d8" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0666f3d5-7a73-48f4-8367-53b8c62825d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_449f8b05-2863-4ede-8d70-8d34afd15fff" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_0666f3d5-7a73-48f4-8367-53b8c62825d8" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_449f8b05-2863-4ede-8d70-8d34afd15fff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_92f37a07-2902-41b7-9948-b3c677227331" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_449f8b05-2863-4ede-8d70-8d34afd15fff" xlink:to="loc_srt_DirectorMember_92f37a07-2902-41b7-9948-b3c677227331" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8bf92a17-6550-4753-9054-880e0a9d4c80" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_687a38f4-b3e5-4912-94e8-7cfd5bcd5291" xlink:to="loc_srt_RangeAxis_8bf92a17-6550-4753-9054-880e0a9d4c80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8bf92a17-6550-4753-9054-880e0a9d4c80_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8bf92a17-6550-4753-9054-880e0a9d4c80" xlink:to="loc_srt_RangeMember_8bf92a17-6550-4753-9054-880e0a9d4c80_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_29706667-e15c-4357-919b-809e804d382a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8bf92a17-6550-4753-9054-880e0a9d4c80" xlink:to="loc_srt_RangeMember_29706667-e15c-4357-919b-809e804d382a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8982aa92-4ff8-4943-b706-82727d7be50c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_29706667-e15c-4357-919b-809e804d382a" xlink:to="loc_srt_MinimumMember_8982aa92-4ff8-4943-b706-82727d7be50c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3429045e-6f55-4796-8392-1225e60e95c2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_29706667-e15c-4357-919b-809e804d382a" xlink:to="loc_srt_MaximumMember_3429045e-6f55-4796-8392-1225e60e95c2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#StockBasedCompensationWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails" xlink:type="extended" id="i46237eb1c29d45e5b56dd5cc03da7aba_StockBasedCompensationWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_ae8cc0a6-98cf-4f44-baad-f83a8ccd2f59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_348a0e31-7f20-417a-9692-44f1f27ba1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ae8cc0a6-98cf-4f44-baad-f83a8ccd2f59" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_348a0e31-7f20-417a-9692-44f1f27ba1a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod_f7bda742-09e3-4195-a3a5-f578584a5344" xlink:href="ameh-20220331.xsd#ameh_ClassOfWarrantOrRightIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ae8cc0a6-98cf-4f44-baad-f83a8ccd2f59" xlink:to="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod_f7bda742-09e3-4195-a3a5-f578584a5344" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_58e362ac-6054-478f-be19-3b7fd6527523" xlink:href="ameh-20220331.xsd#ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ae8cc0a6-98cf-4f44-baad-f83a8ccd2f59" xlink:to="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_58e362ac-6054-478f-be19-3b7fd6527523" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightExercisable_bbd6e028-799c-4d2a-aade-3dd1077d9c73" xlink:href="ameh-20220331.xsd#ameh_ClassOfWarrantOrRightExercisable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ae8cc0a6-98cf-4f44-baad-f83a8ccd2f59" xlink:to="loc_ameh_ClassOfWarrantOrRightExercisable_bbd6e028-799c-4d2a-aade-3dd1077d9c73" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_0a8a1e9e-d63c-4f84-8d0c-539e2f731963" xlink:href="ameh-20220331.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ae8cc0a6-98cf-4f44-baad-f83a8ccd2f59" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_0a8a1e9e-d63c-4f84-8d0c-539e2f731963" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_eeba984b-2988-4a22-9108-c0e96419a5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ae8cc0a6-98cf-4f44-baad-f83a8ccd2f59" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_eeba984b-2988-4a22-9108-c0e96419a5fa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_68222c98-8bb8-49ab-ba8d-d5306d62b6d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_eeba984b-2988-4a22-9108-c0e96419a5fa" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_68222c98-8bb8-49ab-ba8d-d5306d62b6d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_68222c98-8bb8-49ab-ba8d-d5306d62b6d9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_68222c98-8bb8-49ab-ba8d-d5306d62b6d9" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_68222c98-8bb8-49ab-ba8d-d5306d62b6d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f79dcd7f-52f2-49c2-b63a-c5c83e955537" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_68222c98-8bb8-49ab-ba8d-d5306d62b6d9" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f79dcd7f-52f2-49c2-b63a-c5c83e955537" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeOneMember_6630daa6-f242-4d12-8e6f-baadb1a07f65" xlink:href="ameh-20220331.xsd#ameh_WarrantExercisePriceRangeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f79dcd7f-52f2-49c2-b63a-c5c83e955537" xlink:to="loc_ameh_WarrantExercisePriceRangeOneMember_6630daa6-f242-4d12-8e6f-baadb1a07f65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeTwoMember_f2a584df-68e0-4c33-bc54-4f108185fe2d" xlink:href="ameh-20220331.xsd#ameh_WarrantExercisePriceRangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f79dcd7f-52f2-49c2-b63a-c5c83e955537" xlink:to="loc_ameh_WarrantExercisePriceRangeTwoMember_f2a584df-68e0-4c33-bc54-4f108185fe2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeThreeMember_b67c736f-10cf-4c23-a3dc-281165331e49" xlink:href="ameh-20220331.xsd#ameh_WarrantExercisePriceRangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f79dcd7f-52f2-49c2-b63a-c5c83e955537" xlink:to="loc_ameh_WarrantExercisePriceRangeThreeMember_b67c736f-10cf-4c23-a3dc-281165331e49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6de96777-4e5e-46f6-86d0-3a1ea8cc6158" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_eeba984b-2988-4a22-9108-c0e96419a5fa" xlink:to="loc_srt_RangeAxis_6de96777-4e5e-46f6-86d0-3a1ea8cc6158" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6de96777-4e5e-46f6-86d0-3a1ea8cc6158_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6de96777-4e5e-46f6-86d0-3a1ea8cc6158" xlink:to="loc_srt_RangeMember_6de96777-4e5e-46f6-86d0-3a1ea8cc6158_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7f66bca5-adad-43e9-8c21-079689c46878" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6de96777-4e5e-46f6-86d0-3a1ea8cc6158" xlink:to="loc_srt_RangeMember_7f66bca5-adad-43e9-8c21-079689c46878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4acf0541-9a76-4737-b719-b5d514c7f68e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7f66bca5-adad-43e9-8c21-079689c46878" xlink:to="loc_srt_MinimumMember_4acf0541-9a76-4737-b719-b5d514c7f68e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3b970916-2066-42b5-815c-61dbf7fdacb4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7f66bca5-adad-43e9-8c21-079689c46878" xlink:to="loc_srt_MaximumMember_3b970916-2066-42b5-815c-61dbf7fdacb4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended" id="i37b00800438042fe810bd93daacf02ff_CommitmentsandContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesLineItems_cc25ceec-0f36-45e2-a5c2-f7db669eccd4" xlink:href="ameh-20220331.xsd#ameh_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_16c6fcda-9b6e-4d5f-874c-6aad6a5b5a34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_cc25ceec-0f36-45e2-a5c2-f7db669eccd4" xlink:to="loc_us-gaap_LineOfCredit_16c6fcda-9b6e-4d5f-874c-6aad6a5b5a34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesTable_dbb10868-2c44-4379-b902-2e993621c07f" xlink:href="ameh-20220331.xsd#ameh_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_cc25ceec-0f36-45e2-a5c2-f7db669eccd4" xlink:to="loc_ameh_CommitmentsAndContingenciesTable_dbb10868-2c44-4379-b902-2e993621c07f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_748a9bb1-3d3e-4831-a32d-616d9eba1147" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_dbb10868-2c44-4379-b902-2e993621c07f" xlink:to="loc_us-gaap_CreditFacilityAxis_748a9bb1-3d3e-4831-a32d-616d9eba1147" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_748a9bb1-3d3e-4831-a32d-616d9eba1147_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_748a9bb1-3d3e-4831-a32d-616d9eba1147" xlink:to="loc_us-gaap_CreditFacilityDomain_748a9bb1-3d3e-4831-a32d-616d9eba1147_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c295691a-a542-425f-8601-360eea84348c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_748a9bb1-3d3e-4831-a32d-616d9eba1147" xlink:to="loc_us-gaap_CreditFacilityDomain_c295691a-a542-425f-8601-360eea84348c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_c810054c-1024-499c-97c0-894c8d513b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_c295691a-a542-425f-8601-360eea84348c" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_c810054c-1024-499c-97c0-894c8d513b1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_d11f7887-3766-4b85-b18b-023047b750b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_dbb10868-2c44-4379-b902-2e993621c07f" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_d11f7887-3766-4b85-b18b-023047b750b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_d11f7887-3766-4b85-b18b-023047b750b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_d11f7887-3766-4b85-b18b-023047b750b5" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_d11f7887-3766-4b85-b18b-023047b750b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_4812b828-3e99-4678-bdaa-ef80bf220e87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_d11f7887-3766-4b85-b18b-023047b750b5" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_4812b828-3e99-4678-bdaa-ef80bf220e87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_3b1928de-8712-49ae-b238-a4750c43a7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_4812b828-3e99-4678-bdaa-ef80bf220e87" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_3b1928de-8712-49ae-b238-a4750c43a7c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f23cd225-cd41-40e5-8624-16b69be39b13" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_dbb10868-2c44-4379-b902-2e993621c07f" xlink:to="loc_dei_LegalEntityAxis_f23cd225-cd41-40e5-8624-16b69be39b13" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f23cd225-cd41-40e5-8624-16b69be39b13_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_f23cd225-cd41-40e5-8624-16b69be39b13" xlink:to="loc_dei_EntityDomain_f23cd225-cd41-40e5-8624-16b69be39b13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6e6ea09c-28d0-480c-9fb5-f5bd9b4d0cf0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_f23cd225-cd41-40e5-8624-16b69be39b13" xlink:to="loc_dei_EntityDomain_6e6ea09c-28d0-480c-9fb5-f5bd9b4d0cf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_e7005d51-fd49-4cbf-848c-b06792d785d9" xlink:href="ameh-20220331.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6e6ea09c-28d0-480c-9fb5-f5bd9b4d0cf0" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_e7005d51-fd49-4cbf-848c-b06792d785d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_ec732565-668e-4039-99c2-f27b9087ca5e" xlink:href="ameh-20220331.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6e6ea09c-28d0-480c-9fb5-f5bd9b4d0cf0" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_ec732565-668e-4039-99c2-f27b9087ca5e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended" id="if927be5e99704ca3a1c7da37a44aefdc_RelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_d0ef6fc4-6532-457d-b66a-368593ddf9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_a951f97a-17fe-4d8e-947e-1ea6c69598ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d0ef6fc4-6532-457d-b66a-368593ddf9b3" xlink:to="loc_us-gaap_RevenueFromRelatedParties_a951f97a-17fe-4d8e-947e-1ea6c69598ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4ad3ef6c-7e4c-4952-a544-36dbb33194d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d0ef6fc4-6532-457d-b66a-368593ddf9b3" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4ad3ef6c-7e4c-4952-a544-36dbb33194d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentMadeToRelatedParty_58d3e6ac-2c72-418a-9305-8ffaec9d723f" xlink:href="ameh-20220331.xsd#ameh_PaymentMadeToRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d0ef6fc4-6532-457d-b66a-368593ddf9b3" xlink:to="loc_ameh_PaymentMadeToRelatedParty_58d3e6ac-2c72-418a-9305-8ffaec9d723f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_1f5e288d-6fea-4b1a-b373-f092ade44a53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d0ef6fc4-6532-457d-b66a-368593ddf9b3" xlink:to="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_1f5e288d-6fea-4b1a-b373-f092ade44a53" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities_bcb3447d-dbb5-45fb-977c-45bd45044dca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d0ef6fc4-6532-457d-b66a-368593ddf9b3" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilities_bcb3447d-dbb5-45fb-977c-45bd45044dca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentConsultingFees_82209874-7d2a-490f-b509-abfe4b2ea4d1" xlink:href="ameh-20220331.xsd#ameh_PaymentConsultingFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d0ef6fc4-6532-457d-b66a-368593ddf9b3" xlink:to="loc_ameh_PaymentConsultingFees_82209874-7d2a-490f-b509-abfe4b2ea4d1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_20d31040-3997-42b2-94a4-934a888cb43b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d0ef6fc4-6532-457d-b66a-368593ddf9b3" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_20d31040-3997-42b2-94a4-934a888cb43b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8f049678-51df-446a-8c0b-7e95281be8af" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_20d31040-3997-42b2-94a4-934a888cb43b" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8f049678-51df-446a-8c0b-7e95281be8af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8f049678-51df-446a-8c0b-7e95281be8af_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8f049678-51df-446a-8c0b-7e95281be8af" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8f049678-51df-446a-8c0b-7e95281be8af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_105c562a-e830-4d0a-b3b3-c613a60d8c73" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8f049678-51df-446a-8c0b-7e95281be8af" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_105c562a-e830-4d0a-b3b3-c613a60d8c73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember_00282d29-ea4e-4423-a27a-5d2bf0961dc9" xlink:href="ameh-20220331.xsd#ameh_LmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_105c562a-e830-4d0a-b3b3-c613a60d8c73" xlink:to="loc_ameh_LmaMember_00282d29-ea4e-4423-a27a-5d2bf0961dc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember_9e695c91-7647-4978-b82f-30ef1d841a0f" xlink:href="ameh-20220331.xsd#ameh_PmiocMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_105c562a-e830-4d0a-b3b3-c613a60d8c73" xlink:to="loc_ameh_PmiocMember_9e695c91-7647-4978-b82f-30ef1d841a0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_55a34d91-058a-4116-b9cb-5b2433cbb89e" xlink:href="ameh-20220331.xsd#ameh_DmgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_105c562a-e830-4d0a-b3b3-c613a60d8c73" xlink:to="loc_ameh_DmgMember_55a34d91-058a-4116-b9cb-5b2433cbb89e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member_8c962a2d-1f67-40cb-aafb-a2fc328f2cc5" xlink:href="ameh-20220331.xsd#ameh_OneMSOInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_105c562a-e830-4d0a-b3b3-c613a60d8c73" xlink:to="loc_ameh_OneMSOInc.Member_8c962a2d-1f67-40cb-aafb-a2fc328f2cc5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cdf28d76-4a81-4467-91e7-976a1bce3b29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_20d31040-3997-42b2-94a4-934a888cb43b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cdf28d76-4a81-4467-91e7-976a1bce3b29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_cdf28d76-4a81-4467-91e7-976a1bce3b29_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cdf28d76-4a81-4467-91e7-976a1bce3b29" xlink:to="loc_us-gaap_RelatedPartyDomain_cdf28d76-4a81-4467-91e7-976a1bce3b29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_06039f2c-e454-405e-9ce8-300d5aebd9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cdf28d76-4a81-4467-91e7-976a1bce3b29" xlink:to="loc_us-gaap_RelatedPartyDomain_06039f2c-e454-405e-9ce8-300d5aebd9ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcShareholdersMember_6a20d027-0a61-449d-9bd5-7d6a98f38f01" xlink:href="ameh-20220331.xsd#ameh_ApcShareholdersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_06039f2c-e454-405e-9ce8-300d5aebd9ee" xlink:to="loc_ameh_ApcShareholdersMember_6a20d027-0a61-449d-9bd5-7d6a98f38f01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdvanceDiagnosticSurgeryCenterMember_8153367b-8f3d-49f5-8c19-4a2ba824f9c8" xlink:href="ameh-20220331.xsd#ameh_AdvanceDiagnosticSurgeryCenterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_06039f2c-e454-405e-9ce8-300d5aebd9ee" xlink:to="loc_ameh_AdvanceDiagnosticSurgeryCenterMember_8153367b-8f3d-49f5-8c19-4a2ba824f9c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FreseniusMember_9be5e04b-3087-4f5d-9dfd-59d0e12d37c7" xlink:href="ameh-20220331.xsd#ameh_FreseniusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_06039f2c-e454-405e-9ce8-300d5aebd9ee" xlink:to="loc_ameh_FreseniusMember_9be5e04b-3087-4f5d-9dfd-59d0e12d37c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FulgentGeneticsIncMember_fbad3df3-a205-4d44-89af-1035e3ec3ecf" xlink:href="ameh-20220331.xsd#ameh_FulgentGeneticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_06039f2c-e454-405e-9ce8-300d5aebd9ee" xlink:to="loc_ameh_FulgentGeneticsIncMember_fbad3df3-a205-4d44-89af-1035e3ec3ecf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareholdersAndOfficersMember_d4571a6c-90a0-4627-8c12-11c23a392ea0" xlink:href="ameh-20220331.xsd#ameh_ShareholdersAndOfficersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_06039f2c-e454-405e-9ce8-300d5aebd9ee" xlink:to="loc_ameh_ShareholdersAndOfficersMember_d4571a6c-90a0-4627-8c12-11c23a392ea0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumenLLCMember_5b08f070-d63e-4887-80cc-7839d23cfa79" xlink:href="ameh-20220331.xsd#ameh_NumenLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_06039f2c-e454-405e-9ce8-300d5aebd9ee" xlink:to="loc_ameh_NumenLLCMember_5b08f070-d63e-4887-80cc-7839d23cfa79" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member_112e5e6f-0ba2-422f-b879-e86cf5827466" xlink:href="ameh-20220331.xsd#ameh_OneMSOInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_06039f2c-e454-405e-9ce8-300d5aebd9ee" xlink:to="loc_ameh_OneMSOInc.Member_112e5e6f-0ba2-422f-b879-e86cf5827466" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ArroyoVistaMember_7f777623-ea4a-4268-9f14-0b11ea0b476c" xlink:href="ameh-20220331.xsd#ameh_ArroyoVistaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_06039f2c-e454-405e-9ce8-300d5aebd9ee" xlink:to="loc_ameh_ArroyoVistaMember_7f777623-ea4a-4268-9f14-0b11ea0b476c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_e426913f-4eb1-4ad9-a82a-1ee73b3ef017" xlink:href="ameh-20220331.xsd#ameh_AHMCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_06039f2c-e454-405e-9ce8-300d5aebd9ee" xlink:to="loc_ameh_AHMCMember_e426913f-4eb1-4ad9-a82a-1ee73b3ef017" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_29a84269-bd02-44f5-b5db-23ea627852e8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_20d31040-3997-42b2-94a4-934a888cb43b" xlink:to="loc_dei_LegalEntityAxis_29a84269-bd02-44f5-b5db-23ea627852e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_29a84269-bd02-44f5-b5db-23ea627852e8_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_29a84269-bd02-44f5-b5db-23ea627852e8" xlink:to="loc_dei_EntityDomain_29a84269-bd02-44f5-b5db-23ea627852e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ae5faaaf-4431-4d7f-bc10-162f42592e44" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_29a84269-bd02-44f5-b5db-23ea627852e8" xlink:to="loc_dei_EntityDomain_ae5faaaf-4431-4d7f-bc10-162f42592e44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember_6b22de91-4419-410f-b63f-89bc33f8e8de" xlink:href="ameh-20220331.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_ae5faaaf-4431-4d7f-bc10-162f42592e44" xlink:to="loc_ameh_NetworkMedicalManagementMember_6b22de91-4419-410f-b63f-89bc33f8e8de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_e4627985-7001-4c49-a901-80b770464853" xlink:href="ameh-20220331.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_ae5faaaf-4431-4d7f-bc10-162f42592e44" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_e4627985-7001-4c49-a901-80b770464853" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApaAcoIncMember_401fd286-1139-4f56-b673-92c2f149c226" xlink:href="ameh-20220331.xsd#ameh_ApaAcoIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_ae5faaaf-4431-4d7f-bc10-162f42592e44" xlink:to="loc_ameh_ApaAcoIncMember_401fd286-1139-4f56-b673-92c2f149c226" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SCHCMember_96bfee05-7f02-487b-893d-47114a37d44d" xlink:href="ameh-20220331.xsd#ameh_SCHCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_ae5faaaf-4431-4d7f-bc10-162f42592e44" xlink:to="loc_ameh_SCHCMember_96bfee05-7f02-487b-893d-47114a37d44d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_0f4d5c9d-9fc3-420a-9bd5-fc913d4966bb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_20d31040-3997-42b2-94a4-934a888cb43b" xlink:to="loc_srt_ConsolidatedEntitiesAxis_0f4d5c9d-9fc3-420a-9bd5-fc913d4966bb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_0f4d5c9d-9fc3-420a-9bd5-fc913d4966bb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_0f4d5c9d-9fc3-420a-9bd5-fc913d4966bb" xlink:to="loc_srt_ConsolidatedEntitiesDomain_0f4d5c9d-9fc3-420a-9bd5-fc913d4966bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_a2c279c8-e7f9-4dfd-8c68-9a100fa064b0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_0f4d5c9d-9fc3-420a-9bd5-fc913d4966bb" xlink:to="loc_srt_ConsolidatedEntitiesDomain_a2c279c8-e7f9-4dfd-8c68-9a100fa064b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember_c65eb5a1-f2e9-4982-a3b1-4638f3fbe238" xlink:href="ameh-20220331.xsd#ameh_LmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_a2c279c8-e7f9-4dfd-8c68-9a100fa064b0" xlink:to="loc_ameh_LmaMember_c65eb5a1-f2e9-4982-a3b1-4638f3fbe238" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember_b597f97f-819b-4d66-b4a1-33ad0d3fba8e" xlink:href="ameh-20220331.xsd#ameh_PmiocMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_a2c279c8-e7f9-4dfd-8c68-9a100fa064b0" xlink:to="loc_ameh_PmiocMember_b597f97f-819b-4d66-b4a1-33ad0d3fba8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_1f3a1b86-e7ca-4e8b-a63b-1b5674d54423" xlink:href="ameh-20220331.xsd#ameh_DmgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_a2c279c8-e7f9-4dfd-8c68-9a100fa064b0" xlink:to="loc_ameh_DmgMember_1f3a1b86-e7ca-4e8b-a63b-1b5674d54423" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_bea97aec-7594-490e-a9d6-d8da6e327e43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_20d31040-3997-42b2-94a4-934a888cb43b" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_bea97aec-7594-490e-a9d6-d8da6e327e43" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_bea97aec-7594-490e-a9d6-d8da6e327e43_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_bea97aec-7594-490e-a9d6-d8da6e327e43" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_bea97aec-7594-490e-a9d6-d8da6e327e43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_820ccec0-668e-4ea9-9e6e-2a12890f503d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_bea97aec-7594-490e-a9d6-d8da6e327e43" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_820ccec0-668e-4ea9-9e6e-2a12890f503d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_7257beb8-476c-42d3-bea7-54f358ee8aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_820ccec0-668e-4ea9-9e6e-2a12890f503d" xlink:to="loc_us-gaap_ServiceMember_7257beb8-476c-42d3-bea7-54f358ee8aa2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_ab313042-d6c5-4d80-9804-11292ce37b47" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_20d31040-3997-42b2-94a4-934a888cb43b" xlink:to="loc_srt_TitleOfIndividualAxis_ab313042-d6c5-4d80-9804-11292ce37b47" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ab313042-d6c5-4d80-9804-11292ce37b47_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_ab313042-d6c5-4d80-9804-11292ce37b47" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ab313042-d6c5-4d80-9804-11292ce37b47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_076caf1c-b2b6-43c0-a2e1-96fb95ce4f22" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_ab313042-d6c5-4d80-9804-11292ce37b47" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_076caf1c-b2b6-43c0-a2e1-96fb95ce4f22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_79110391-c9ca-45a7-87fe-6a21c3f4ccad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_076caf1c-b2b6-43c0-a2e1-96fb95ce4f22" xlink:to="loc_srt_DirectorMember_79110391-c9ca-45a7-87fe-6a21c3f4ccad" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="extended" id="i0f0c9a49e5734e399703112004ecc8d0_RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_ba15d14d-9558-482f-9e49-79f3add98ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_0a1f74f5-0526-426d-b949-e7f7f40ac8c5" xlink:href="ameh-20220331.xsd#ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ba15d14d-9558-482f-9e49-79f3add98ab7" xlink:to="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_0a1f74f5-0526-426d-b949-e7f7f40ac8c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementFeeExpense_16f78414-364b-4594-814b-7260e1e46fed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementFeeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ba15d14d-9558-482f-9e49-79f3add98ab7" xlink:to="loc_us-gaap_ManagementFeeExpense_16f78414-364b-4594-814b-7260e1e46fed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_f615f336-6c5e-40a7-9ee6-86daaf43ca9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ba15d14d-9558-482f-9e49-79f3add98ab7" xlink:to="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_f615f336-6c5e-40a7-9ee6-86daaf43ca9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_12dfbdde-8f1a-4995-95ff-c4488d3fe905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ba15d14d-9558-482f-9e49-79f3add98ab7" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_12dfbdde-8f1a-4995-95ff-c4488d3fe905" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d5cbeb0f-fbf7-469f-87ed-b48d6c633e97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_12dfbdde-8f1a-4995-95ff-c4488d3fe905" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d5cbeb0f-fbf7-469f-87ed-b48d6c633e97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d5cbeb0f-fbf7-469f-87ed-b48d6c633e97_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d5cbeb0f-fbf7-469f-87ed-b48d6c633e97" xlink:to="loc_us-gaap_RelatedPartyDomain_d5cbeb0f-fbf7-469f-87ed-b48d6c633e97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5e280d68-6e90-4db6-ac52-dbcf4ee37ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d5cbeb0f-fbf7-469f-87ed-b48d6c633e97" xlink:to="loc_us-gaap_RelatedPartyDomain_5e280d68-6e90-4db6-ac52-dbcf4ee37ac1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_6ed1e194-c6f0-4dcc-8d3e-6c59eb49d61b" xlink:href="ameh-20220331.xsd#ameh_AHMCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_5e280d68-6e90-4db6-ac52-dbcf4ee37ac1" xlink:to="loc_ameh_AHMCMember_6ed1e194-c6f0-4dcc-8d3e-6c59eb49d61b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HSMSOMember_38c2bd06-b3bd-4969-a177-e4adb695eaa5" xlink:href="ameh-20220331.xsd#ameh_HSMSOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_5e280d68-6e90-4db6-ac52-dbcf4ee37ac1" xlink:to="loc_ameh_HSMSOMember_38c2bd06-b3bd-4969-a177-e4adb695eaa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AurionMember_defa55cc-50d0-4ff8-905f-5f295cdd2489" xlink:href="ameh-20220331.xsd#ameh_AurionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_5e280d68-6e90-4db6-ac52-dbcf4ee37ac1" xlink:to="loc_ameh_AurionMember_defa55cc-50d0-4ff8-905f-5f295cdd2489" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#EarningsPerShareAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="extended" id="i4bae4da2c3df4d288cf491a329238121_EarningsPerShareAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareLineItems_54548c29-7b97-4c0f-bd59-cde638406fd7" xlink:href="ameh-20220331.xsd#ameh_EarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c5b58f4a-17aa-47a7-9084-95715fae2383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EarningsPerShareLineItems_54548c29-7b97-4c0f-bd59-cde638406fd7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c5b58f4a-17aa-47a7-9084-95715fae2383" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareTable_0cae09dd-c5d8-40ab-868d-764620559c8f" xlink:href="ameh-20220331.xsd#ameh_EarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_EarningsPerShareLineItems_54548c29-7b97-4c0f-bd59-cde638406fd7" xlink:to="loc_ameh_EarningsPerShareTable_0cae09dd-c5d8-40ab-868d-764620559c8f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_b21056ed-6678-4c81-8b45-f4e1557a0433" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_EarningsPerShareTable_0cae09dd-c5d8-40ab-868d-764620559c8f" xlink:to="loc_dei_LegalEntityAxis_b21056ed-6678-4c81-8b45-f4e1557a0433" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b21056ed-6678-4c81-8b45-f4e1557a0433_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_b21056ed-6678-4c81-8b45-f4e1557a0433" xlink:to="loc_dei_EntityDomain_b21056ed-6678-4c81-8b45-f4e1557a0433_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e1246960-3244-4e2a-a80d-f079a4bc2d2f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_b21056ed-6678-4c81-8b45-f4e1557a0433" xlink:to="loc_dei_EntityDomain_e1246960-3244-4e2a-a80d-f079a4bc2d2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_2c903752-bccc-4e4b-a647-36963b288968" xlink:href="ameh-20220331.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e1246960-3244-4e2a-a80d-f079a4bc2d2f" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_2c903752-bccc-4e4b-a647-36963b288968" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="extended" id="i7af3d00f4bfe44fdad873289d4142d94_EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareLineItems_cec75e87-e187-4a7e-8456-1192285fa3ea" xlink:href="ameh-20220331.xsd#ameh_EarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1a9eeca6-5ded-463f-b8d6-8597c9d9b914" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EarningsPerShareLineItems_cec75e87-e187-4a7e-8456-1192285fa3ea" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1a9eeca6-5ded-463f-b8d6-8597c9d9b914" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_b43b74ae-f5e8-44ae-b56f-8b4186f6afc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EarningsPerShareLineItems_cec75e87-e187-4a7e-8456-1192285fa3ea" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_b43b74ae-f5e8-44ae-b56f-8b4186f6afc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_69423a6a-6e51-430c-b641-0aab302d2e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EarningsPerShareLineItems_cec75e87-e187-4a7e-8456-1192285fa3ea" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_69423a6a-6e51-430c-b641-0aab302d2e9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareTable_b2180df0-6af8-4b97-aacb-71c99a5f4b0c" xlink:href="ameh-20220331.xsd#ameh_EarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_EarningsPerShareLineItems_cec75e87-e187-4a7e-8456-1192285fa3ea" xlink:to="loc_ameh_EarningsPerShareTable_b2180df0-6af8-4b97-aacb-71c99a5f4b0c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_598558e0-0473-422f-90dd-85790fd54a95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_EarningsPerShareTable_b2180df0-6af8-4b97-aacb-71c99a5f4b0c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_598558e0-0473-422f-90dd-85790fd54a95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_598558e0-0473-422f-90dd-85790fd54a95_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_598558e0-0473-422f-90dd-85790fd54a95" xlink:to="loc_us-gaap_EquityComponentDomain_598558e0-0473-422f-90dd-85790fd54a95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2a504e63-1abd-4ffe-82eb-ed5077a3cf57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_598558e0-0473-422f-90dd-85790fd54a95" xlink:to="loc_us-gaap_EquityComponentDomain_2a504e63-1abd-4ffe-82eb-ed5077a3cf57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_c09aec26-03c5-4471-9616-53b376954333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2a504e63-1abd-4ffe-82eb-ed5077a3cf57" xlink:to="loc_us-gaap_WarrantMember_c09aec26-03c5-4471-9616-53b376954333" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fe589e8c-4c9f-41cf-9067-8b272bde13a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_EarningsPerShareTable_b2180df0-6af8-4b97-aacb-71c99a5f4b0c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fe589e8c-4c9f-41cf-9067-8b272bde13a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fe589e8c-4c9f-41cf-9067-8b272bde13a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fe589e8c-4c9f-41cf-9067-8b272bde13a8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fe589e8c-4c9f-41cf-9067-8b272bde13a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_66d0f76e-0a89-4b83-8c77-5156cf6572fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fe589e8c-4c9f-41cf-9067-8b272bde13a8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_66d0f76e-0a89-4b83-8c77-5156cf6572fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_06b8b7bb-c34b-405c-bb21-5be0d03b077d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_66d0f76e-0a89-4b83-8c77-5156cf6572fc" xlink:to="loc_us-gaap_EmployeeStockOptionMember_06b8b7bb-c34b-405c-bb21-5be0d03b077d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_67b88653-4f86-4040-8540-b69966aec678" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_66d0f76e-0a89-4b83-8c77-5156cf6572fc" xlink:to="loc_us-gaap_RestrictedStockMember_67b88653-4f86-4040-8540-b69966aec678" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#VariableInterestEntitiesVIEsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="extended" id="i5383244b6dbf489c931917cfba5d966d_VariableInterestEntitiesVIEsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_95572f5f-defe-4918-a206-c86f0b2771ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_a1b4ba29-ad58-4527-8530-c6db05f2c3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_95572f5f-defe-4918-a206-c86f0b2771ba" xlink:to="loc_us-gaap_AssetsAbstract_a1b4ba29-ad58-4527-8530-c6db05f2c3f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_ef6c2214-0c35-4045-a93a-3971cc6a1e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_a1b4ba29-ad58-4527-8530-c6db05f2c3f1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_ef6c2214-0c35-4045-a93a-3971cc6a1e9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f3d23e6b-f89f-4de1-b531-3fd93ddff11e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ef6c2214-0c35-4045-a93a-3971cc6a1e9a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f3d23e6b-f89f-4de1-b531-3fd93ddff11e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_ba25589e-564b-4619-a79f-e61d6584a3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ef6c2214-0c35-4045-a93a-3971cc6a1e9a" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_ba25589e-564b-4619-a79f-e61d6584a3ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_0c1e2f70-ef43-463b-8f69-c6484965281a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ef6c2214-0c35-4045-a93a-3971cc6a1e9a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_0c1e2f70-ef43-463b-8f69-c6484965281a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_4521fbe8-9ae1-4188-bf2c-d390ea7a7bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ef6c2214-0c35-4045-a93a-3971cc6a1e9a" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_4521fbe8-9ae1-4188-bf2c-d390ea7a7bd4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_77fd8299-509d-4453-b2f7-a6e17dc83344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ef6c2214-0c35-4045-a93a-3971cc6a1e9a" xlink:to="loc_us-gaap_IncomeTaxesReceivable_77fd8299-509d-4453-b2f7-a6e17dc83344" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_65045df6-07da-4e0e-93b0-5222527ce1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ef6c2214-0c35-4045-a93a-3971cc6a1e9a" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_65045df6-07da-4e0e-93b0-5222527ce1d3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c6a7a5cd-aa9f-41cc-8662-4b4c1cc39d71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ef6c2214-0c35-4045-a93a-3971cc6a1e9a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c6a7a5cd-aa9f-41cc-8662-4b4c1cc39d71" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_605e81a2-c57a-4153-b277-4f36cdc7d0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ef6c2214-0c35-4045-a93a-3971cc6a1e9a" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_605e81a2-c57a-4153-b277-4f36cdc7d0d5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliateCurrent_f97d6153-2c78-44e8-bfc4-1e86adcb2a59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromAffiliateCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ef6c2214-0c35-4045-a93a-3971cc6a1e9a" xlink:to="loc_us-gaap_DueFromAffiliateCurrent_f97d6153-2c78-44e8-bfc4-1e86adcb2a59" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8904242a-251a-4c96-96e7-d8477cfda87a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ef6c2214-0c35-4045-a93a-3971cc6a1e9a" xlink:to="loc_us-gaap_AssetsCurrent_8904242a-251a-4c96-96e7-d8477cfda87a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_aaca5a24-f2a2-41d0-9e83-bd15ac6a1c46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_a1b4ba29-ad58-4527-8530-c6db05f2c3f1" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_aaca5a24-f2a2-41d0-9e83-bd15ac6a1c46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_534a10b2-aa16-4751-81d4-f82289c225dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_aaca5a24-f2a2-41d0-9e83-bd15ac6a1c46" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_534a10b2-aa16-4751-81d4-f82289c225dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_fe12650b-18f3-4afe-a866-48819ad44236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_aaca5a24-f2a2-41d0-9e83-bd15ac6a1c46" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_fe12650b-18f3-4afe-a866-48819ad44236" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_69c701c5-dc9b-4928-bd18-99c316e0a7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_aaca5a24-f2a2-41d0-9e83-bd15ac6a1c46" xlink:to="loc_us-gaap_Goodwill_69c701c5-dc9b-4928-bd18-99c316e0a7dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_499ff247-b641-4baa-ba33-6cc333dab8f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_aaca5a24-f2a2-41d0-9e83-bd15ac6a1c46" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_499ff247-b641-4baa-ba33-6cc333dab8f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_28b2ccc8-0539-43da-a5e7-0ff39d8d7a58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_aaca5a24-f2a2-41d0-9e83-bd15ac6a1c46" xlink:to="loc_us-gaap_OtherLongTermInvestments_28b2ccc8-0539-43da-a5e7-0ff39d8d7a58" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_0368bd9f-bff8-4cfe-8c86-5194a183080d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_aaca5a24-f2a2-41d0-9e83-bd15ac6a1c46" xlink:to="loc_us-gaap_EquityMethodInvestments_0368bd9f-bff8-4cfe-8c86-5194a183080d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_ca4cb797-06e5-4f22-a33d-97f7991e3ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_aaca5a24-f2a2-41d0-9e83-bd15ac6a1c46" xlink:to="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_ca4cb797-06e5-4f22-a33d-97f7991e3ca5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b09dcc77-07b8-42dc-847d-a348b433d7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_aaca5a24-f2a2-41d0-9e83-bd15ac6a1c46" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b09dcc77-07b8-42dc-847d-a348b433d7e4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b0d508f8-475b-4e20-86d3-9f461c72d3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_aaca5a24-f2a2-41d0-9e83-bd15ac6a1c46" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b0d508f8-475b-4e20-86d3-9f461c72d3fe" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_018e1b1c-a70d-4ae0-b30c-9ffa08f8b8ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_aaca5a24-f2a2-41d0-9e83-bd15ac6a1c46" xlink:to="loc_us-gaap_AssetsNoncurrent_018e1b1c-a70d-4ae0-b30c-9ffa08f8b8ef" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e5bb5f3e-938e-4280-9bb4-ab9e6a445e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_a1b4ba29-ad58-4527-8530-c6db05f2c3f1" xlink:to="loc_us-gaap_Assets_e5bb5f3e-938e-4280-9bb4-ab9e6a445e6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_d94ebc30-0cd5-443e-9eb8-0bb5118902a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_95572f5f-defe-4918-a206-c86f0b2771ba" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_d94ebc30-0cd5-443e-9eb8-0bb5118902a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_3c661136-dba4-48d7-8abb-28daea2dd67f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d94ebc30-0cd5-443e-9eb8-0bb5118902a5" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_3c661136-dba4-48d7-8abb-28daea2dd67f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_76a5f634-2dd4-4b92-bcf1-00b2223e80e1" xlink:href="ameh-20220331.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d94ebc30-0cd5-443e-9eb8-0bb5118902a5" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_76a5f634-2dd4-4b92-bcf1-00b2223e80e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_51c5de5e-844f-438d-a284-3ba1a6c44c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d94ebc30-0cd5-443e-9eb8-0bb5118902a5" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_51c5de5e-844f-438d-a284-3ba1a6c44c7e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_7bb378ab-0061-47b4-a703-0724670de47d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d94ebc30-0cd5-443e-9eb8-0bb5118902a5" xlink:to="loc_us-gaap_TaxesPayableCurrent_7bb378ab-0061-47b4-a703-0724670de47d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_43ca93fd-2787-4a4c-bd46-a50b3394d022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d94ebc30-0cd5-443e-9eb8-0bb5118902a5" xlink:to="loc_us-gaap_DividendsPayableCurrent_43ca93fd-2787-4a4c-bd46-a50b3394d022" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_85801683-b302-4691-8645-f6bccdbfaf2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d94ebc30-0cd5-443e-9eb8-0bb5118902a5" xlink:to="loc_us-gaap_LongTermDebtCurrent_85801683-b302-4691-8645-f6bccdbfaf2a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_6f38c83a-306a-4c5f-af19-a0a864a59d17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d94ebc30-0cd5-443e-9eb8-0bb5118902a5" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_6f38c83a-306a-4c5f-af19-a0a864a59d17" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_fcc33df8-92cc-4586-9005-31c78be0eb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d94ebc30-0cd5-443e-9eb8-0bb5118902a5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_fcc33df8-92cc-4586-9005-31c78be0eb1a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1348bad8-ad4d-4a62-b122-ccd2f3e76f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d94ebc30-0cd5-443e-9eb8-0bb5118902a5" xlink:to="loc_us-gaap_LiabilitiesCurrent_1348bad8-ad4d-4a62-b122-ccd2f3e76f5e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_b5e15fba-584f-4006-b93b-3da6aa0bbe11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_95572f5f-defe-4918-a206-c86f0b2771ba" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_b5e15fba-584f-4006-b93b-3da6aa0bbe11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_a521bab2-2428-4a19-8da1-de20a40ada92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_b5e15fba-584f-4006-b93b-3da6aa0bbe11" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_a521bab2-2428-4a19-8da1-de20a40ada92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e84eb2a1-03a1-4bf6-be92-2d8ffee46929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_b5e15fba-584f-4006-b93b-3da6aa0bbe11" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e84eb2a1-03a1-4bf6-be92-2d8ffee46929" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1846d161-b11b-46bb-a64e-47df97db47bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_b5e15fba-584f-4006-b93b-3da6aa0bbe11" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1846d161-b11b-46bb-a64e-47df97db47bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_835104de-c661-4573-90ec-431ea11afc1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_b5e15fba-584f-4006-b93b-3da6aa0bbe11" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_835104de-c661-4573-90ec-431ea11afc1b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2f86afc9-05c3-4691-b130-f3b1443bd676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_b5e15fba-584f-4006-b93b-3da6aa0bbe11" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_2f86afc9-05c3-4691-b130-f3b1443bd676" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_b5b77b1e-4d2a-48b3-bf2a-de0d6ae71daa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_b5e15fba-584f-4006-b93b-3da6aa0bbe11" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_b5b77b1e-4d2a-48b3-bf2a-de0d6ae71daa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_99ffa897-c337-444f-bb3f-b9e75dc03b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_95572f5f-defe-4918-a206-c86f0b2771ba" xlink:to="loc_us-gaap_Liabilities_99ffa897-c337-444f-bb3f-b9e75dc03b8b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_694eae0d-8b40-470c-9f00-f658b5685d51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_95572f5f-defe-4918-a206-c86f0b2771ba" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_694eae0d-8b40-470c-9f00-f658b5685d51" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_63529dd6-afa3-495b-9d4a-6fc739ea257c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_694eae0d-8b40-470c-9f00-f658b5685d51" xlink:to="loc_srt_ConsolidatedEntitiesAxis_63529dd6-afa3-495b-9d4a-6fc739ea257c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_63529dd6-afa3-495b-9d4a-6fc739ea257c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_63529dd6-afa3-495b-9d4a-6fc739ea257c" xlink:to="loc_srt_ConsolidatedEntitiesDomain_63529dd6-afa3-495b-9d4a-6fc739ea257c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_4c60d2f2-20b5-4dc9-bbe7-ffe99189fcbb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_63529dd6-afa3-495b-9d4a-6fc739ea257c" xlink:to="loc_srt_ConsolidatedEntitiesDomain_4c60d2f2-20b5-4dc9-bbe7-ffe99189fcbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_77d470cd-3e58-4943-9b0d-266dbf6e34bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_4c60d2f2-20b5-4dc9-bbe7-ffe99189fcbb" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_77d470cd-3e58-4943-9b0d-266dbf6e34bb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#LeasesAdditionalinformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="extended" id="i406008de249e45b39a31a1b7d2bdf4ca_LeasesAdditionalinformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_c1011f45-40c9-40a5-bf53-e8b776262912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_d3f83023-b7ad-48c4-a694-712f9eafa0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c1011f45-40c9-40a5-bf53-e8b776262912" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_d3f83023-b7ad-48c4-a694-712f9eafa0e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_5ce18a17-52b9-41e4-8263-eb252ec58992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c1011f45-40c9-40a5-bf53-e8b776262912" xlink:to="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_5ce18a17-52b9-41e4-8263-eb252ec58992" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a058e6c7-786b-4936-8039-7e66ada10a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c1011f45-40c9-40a5-bf53-e8b776262912" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a058e6c7-786b-4936-8039-7e66ada10a8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_793de193-627d-4d82-aed9-a251d594d63a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c1011f45-40c9-40a5-bf53-e8b776262912" xlink:to="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_793de193-627d-4d82-aed9-a251d594d63a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_b486ec78-4826-4dc5-9157-c2d0733ac12e" xlink:href="ameh-20220331.xsd#ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c1011f45-40c9-40a5-bf53-e8b776262912" xlink:to="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_b486ec78-4826-4dc5-9157-c2d0733ac12e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_c2498eed-cef2-47f2-ae9f-f5fa697bf558" xlink:href="ameh-20220331.xsd#ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c1011f45-40c9-40a5-bf53-e8b776262912" xlink:to="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_c2498eed-cef2-47f2-ae9f-f5fa697bf558" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_d3b195ea-7880-4bd2-9cf9-f1d5d4960717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c1011f45-40c9-40a5-bf53-e8b776262912" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_d3b195ea-7880-4bd2-9cf9-f1d5d4960717" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_314d71d9-0125-4995-8b6b-ee6709036adc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c1011f45-40c9-40a5-bf53-e8b776262912" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_314d71d9-0125-4995-8b6b-ee6709036adc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_3cbb17a4-16de-42ae-99a9-068e8f1d0e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c1011f45-40c9-40a5-bf53-e8b776262912" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_3cbb17a4-16de-42ae-99a9-068e8f1d0e0f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fd4d691d-df2a-4a85-82b2-ff64880c95da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3cbb17a4-16de-42ae-99a9-068e8f1d0e0f" xlink:to="loc_srt_RangeAxis_fd4d691d-df2a-4a85-82b2-ff64880c95da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fd4d691d-df2a-4a85-82b2-ff64880c95da_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fd4d691d-df2a-4a85-82b2-ff64880c95da" xlink:to="loc_srt_RangeMember_fd4d691d-df2a-4a85-82b2-ff64880c95da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7e89ab6e-dec7-4a68-bf05-591e33323106" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fd4d691d-df2a-4a85-82b2-ff64880c95da" xlink:to="loc_srt_RangeMember_7e89ab6e-dec7-4a68-bf05-591e33323106" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fde24ac7-482c-4b7c-bf50-abe40782b56d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7e89ab6e-dec7-4a68-bf05-591e33323106" xlink:to="loc_srt_MinimumMember_fde24ac7-482c-4b7c-bf50-abe40782b56d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_12465602-fb6d-462c-98e5-be2fb986bc92" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7e89ab6e-dec7-4a68-bf05-591e33323106" xlink:to="loc_srt_MaximumMember_12465602-fb6d-462c-98e5-be2fb986bc92" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>ameh-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:5baec51e-b1b5-44e5-a5ac-49c0e6499a3f,g:d2f55b59-0a61-4e65-b745-a66f96888c42-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_f89f1ac2-cd00-424f-ad58-0fa9accc31e3_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary disclosures of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent_6babe3fd-8ee2-46fc-ad84-60a98bc57e49_terseLabel_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans receivable</link:label>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:to="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_c052f143-6dd6-43fa-b551-1ebaf06ada7f_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_96170f77-a27a-496f-b9dc-03fd9a74a994_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_53fe655f-ccda-4327-89d1-570c649c846a_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_57012db6-d577-4695-8a15-f1c71caf6572_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_75831352-2d5a-46da-b28a-b6dfa950b6c0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MedicaidMember_9b469d05-564e-4f17-86a0-d68c34e1d104_terseLabel_en-US" xlink:label="lab_ameh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid</link:label>
    <link:label id="lab_ameh_MedicaidMember_label_en-US" xlink:label="lab_ameh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid [Member]</link:label>
    <link:label id="lab_ameh_MedicaidMember_documentation_en-US" xlink:label="lab_ameh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh:MedicaidMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicaidMember" xlink:href="ameh-20220331.xsd#ameh_MedicaidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicaidMember" xlink:to="lab_ameh_MedicaidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember_8f007fd6-464c-4cff-9f14-98ef9c7ad2d9_terseLabel_en-US" xlink:label="lab_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-6 Medical Investment Group, LLC &#8211; related party</link:label>
    <link:label id="lab_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember_label_en-US" xlink:label="lab_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-6 Medical Investment Group, LLC - Related Party [Member]</link:label>
    <link:label id="lab_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember_documentation_en-US" xlink:label="lab_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-6 Medical Investment Group, LLC - Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember" xlink:href="ameh-20220331.xsd#ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember" xlink:to="lab_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_cf53e4bd-8bd5-4985-a466-f23af20ee1bc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swaps</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_f1275bb2-43b9-48f4-ac7a-43377b7c00c7_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_b128aea0-7788-4ddc-9a75-d96129721add_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_602399d0-928f-42a7-a213-f39b8c2694a7_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_90810ef2-80de-4e8a-ae02-cb9984abce75_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Rights outstanding Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:href="ameh-20220331.xsd#ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NetworkMedicalManagementIncMember_81351174-3407-4e24-bb68-9d620021a51b_terseLabel_en-US" xlink:label="lab_ameh_NetworkMedicalManagementIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Medical Management, Inc.</link:label>
    <link:label id="lab_ameh_NetworkMedicalManagementIncMember_label_en-US" xlink:label="lab_ameh_NetworkMedicalManagementIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Medical Management, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementIncMember" xlink:href="ameh-20220331.xsd#ameh_NetworkMedicalManagementIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NetworkMedicalManagementIncMember" xlink:to="lab_ameh_NetworkMedicalManagementIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetCurrent_342e606c-4fbe-48ea-a9f2-fabebec67063_terseLabel_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan receivable &#8211; related party</link:label>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetCurrent_9f77ee3d-59ca-4347-9c39-cb9bc9aa0503_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan receivable</link:label>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fa557e78-e714-456b-9a77-5809d7315175_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ce14e8a9-06b2-4468-bf7b-b1343b933792_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_3477ec94-e1d9-46fa-ab6d-df016d94f64a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_803dbe3e-1696-4e63-bb22-cb3af39e75b4_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_68ff2160-6a3b-4634-aa6d-b39d9ca2bcdd_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CommercialMember_084569ac-bd57-4919-bec9-fe59161dfc49_terseLabel_en-US" xlink:label="lab_ameh_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial</link:label>
    <link:label id="lab_ameh_CommercialMember_label_en-US" xlink:label="lab_ameh_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial [Member]</link:label>
    <link:label id="lab_ameh_CommercialMember_documentation_en-US" xlink:label="lab_ameh_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh:CommercialMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommercialMember" xlink:href="ameh-20220331.xsd#ameh_CommercialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CommercialMember" xlink:to="lab_ameh_CommercialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_0e1b355a-70aa-4fd6-8f7b-797861fa899d_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7a6ecf75-4aba-483f-8fb3-6567daf2a2c5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_9eaf1563-d6e0-47cb-93f4-3c2568f4e3ee_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_36ccadb8-f300-4a3c-a40f-d5043d78f2c5_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AggregateintrinsicvalueAbstract_ef6b8cfe-d143-431d-a2f5-3a3c261074de_terseLabel_en-US" xlink:label="lab_ameh_AggregateintrinsicvalueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_ameh_AggregateintrinsicvalueAbstract_label_en-US" xlink:label="lab_ameh_AggregateintrinsicvalueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AggregateintrinsicvalueAbstract" xlink:href="ameh-20220331.xsd#ameh_AggregateintrinsicvalueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract" xlink:to="lab_ameh_AggregateintrinsicvalueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_7d75e5be-3b2d-47cc-b42b-2a5d60e051f1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashUninsuredAmount_0f82f24f-3421-4b73-9cbe-04a88c48dde9_terseLabel_en-US" xlink:label="lab_us-gaap_CashUninsuredAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount deposit accounts exceeded FDIC insured limit</link:label>
    <link:label id="lab_us-gaap_CashUninsuredAmount_label_en-US" xlink:label="lab_us-gaap_CashUninsuredAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Uninsured Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashUninsuredAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashUninsuredAmount" xlink:to="lab_us-gaap_CashUninsuredAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CDSCMember_858066c1-8cce-4e39-b986-b2775fe041a9_terseLabel_en-US" xlink:label="lab_ameh_CDSCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CDSC</link:label>
    <link:label id="lab_ameh_CDSCMember_label_en-US" xlink:label="lab_ameh_CDSCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CDSC [Member]</link:label>
    <link:label id="lab_ameh_CDSCMember_documentation_en-US" xlink:label="lab_ameh_CDSCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CDSC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CDSCMember" xlink:href="ameh-20220331.xsd#ameh_CDSCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CDSCMember" xlink:to="lab_ameh_CDSCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_20a43424-f989-4a21-a313-9795eae8bc0f_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_IncreaseDecreaseInMedicalLiabilities_f703f607-6add-43a7-b2a9-5c36a1e94402_verboseLabel_en-US" xlink:label="lab_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical liabilities</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInMedicalLiabilities_label_en-US" xlink:label="lab_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Medical Liabilities</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInMedicalLiabilities_documentation_en-US" xlink:label="lab_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in the aggregate amount of medical liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:href="ameh-20220331.xsd#ameh_IncreaseDecreaseInMedicalLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:to="lab_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MinorityInterestPolicyPolicyTextBlock_85123c47-3fc4-4001-8cb5-9feaa4fe8446_terseLabel_en-US" xlink:label="lab_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_ameh_MinorityInterestPolicyPolicyTextBlock_label_en-US" xlink:label="lab_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minority Interest Policy [Policy Text Block]</link:label>
    <link:label id="lab_ameh_MinorityInterestPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minority Interest Policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:href="ameh-20220331.xsd#ameh_MinorityInterestPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:to="lab_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9735e6f4-300b-44d7-b63d-892803dc85db_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e601cc6a-d30c-4fc2-a5c1-532afafe61a6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares not included in the calculation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_c13ef288-2138-471e-8ae2-5f53714c3604_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued contract liability recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AncillaryServiceContractMember_b7e9f247-5d8d-4c2f-9116-ce324ab8526e_terseLabel_en-US" xlink:label="lab_ameh_AncillaryServiceContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ancillary Service Contract</link:label>
    <link:label id="lab_ameh_AncillaryServiceContractMember_label_en-US" xlink:label="lab_ameh_AncillaryServiceContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ancillary Service Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AncillaryServiceContractMember" xlink:href="ameh-20220331.xsd#ameh_AncillaryServiceContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AncillaryServiceContractMember" xlink:to="lab_ameh_AncillaryServiceContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_c3e4a5d4-99af-433d-8bae-a426ab67832b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_ca66d204-8045-41df-852d-fe59e13b6f1f_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges:</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_0ae8b96c-5460-44b7-8908-55435c60c3d9_terseLabel_en-US" xlink:label="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate in the event of default</link:label>
    <link:label id="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_label_en-US" xlink:label="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Modifications, Subsequent Default, Interest Rate</link:label>
    <link:label id="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_documentation_en-US" xlink:label="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Modifications, Subsequent Default, Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:href="ameh-20220331.xsd#ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:to="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_b3fe5f65-17e4-4972-9421-bc936d16903b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value of restricted stock to be recognized straight-line</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_74de1d1b-769e-443b-a19e-8c4ed2d9920f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_f148d163-525c-4410-acd8-ffd982268d83_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a8fab904-4ce0-4dc2-8f6a-d86d870bb49d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentMadeToRelatedParty_20422b57-954b-4519-ba0d-ebd57f4dbe0f_terseLabel_en-US" xlink:label="lab_ameh_PaymentMadeToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to related parties</link:label>
    <link:label id="lab_ameh_PaymentMadeToRelatedParty_label_en-US" xlink:label="lab_ameh_PaymentMadeToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Made To Related Party</link:label>
    <link:label id="lab_ameh_PaymentMadeToRelatedParty_documentation_en-US" xlink:label="lab_ameh_PaymentMadeToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit/Duration (Amount paid to related party in relation to providing services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentMadeToRelatedParty" xlink:href="ameh-20220331.xsd#ameh_PaymentMadeToRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentMadeToRelatedParty" xlink:to="lab_ameh_PaymentMadeToRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_cca31ffb-a339-447a-82df-e1b347ba3b7d_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_6f88007a-f6b2-4836-ab50-b85aa6379164_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_c4a5b915-e998-4ae9-aa0f-7237ce60a321_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Liabilities [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_3ac2a362-38b3-4a66-9536-b12a97873791_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_beb59461-ec2a-415a-9eee-cc2d8ae7c602_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_a072ec3e-992a-4181-889e-c97f4ab15e88_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SubcontractorIPAPayable_a18aafca-fabb-4762-b760-c10d22e1af5c_verboseLabel_en-US" xlink:label="lab_ameh_SubcontractorIPAPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subcontractor IPA payable</link:label>
    <link:label id="lab_ameh_SubcontractorIPAPayable_label_en-US" xlink:label="lab_ameh_SubcontractorIPAPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subcontractor IPA Payable</link:label>
    <link:label id="lab_ameh_SubcontractorIPAPayable_documentation_en-US" xlink:label="lab_ameh_SubcontractorIPAPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subcontractor IPA Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SubcontractorIPAPayable" xlink:href="ameh-20220331.xsd#ameh_SubcontractorIPAPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SubcontractorIPAPayable" xlink:to="lab_ameh_SubcontractorIPAPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_902eb3d8-49fb-47e4-bc43-ba0e69a53c6b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_b5ba9667-7b39-4776-8ea7-b3c7a27dc49b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_022fc48b-4f6f-4319-9e73-14490b0b3ec9_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorEMember_dc8a4d7c-03fa-4f4b-930a-3b7261864f35_terseLabel_en-US" xlink:label="lab_ameh_PayorEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor E</link:label>
    <link:label id="lab_ameh_PayorEMember_label_en-US" xlink:label="lab_ameh_PayorEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor E [Member]</link:label>
    <link:label id="lab_ameh_PayorEMember_documentation_en-US" xlink:label="lab_ameh_PayorEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor E</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorEMember" xlink:href="ameh-20220331.xsd#ameh_PayorEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorEMember" xlink:to="lab_ameh_PayorEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_1b16d2ca-ae3b-49da-8c2e-76ae24715db3_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior periods</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_7fcea429-f2d8-4b63-8737-2d6733488102_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share &#8211; basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_ba565e09-bef5-49de-8091-8dc8af9c37bf_negatedLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromAffiliates_e1fdeda3-effb-4143-ae38-662f02592ce3_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from affiliates</link:label>
    <link:label id="lab_us-gaap_DueFromAffiliates_label_en-US" xlink:label="lab_us-gaap_DueFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromAffiliates" xlink:to="lab_us-gaap_DueFromAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_5872aa13-56f6-4900-af0c-fbc0e8937ef9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod_9f90e7e2-98a6-4840-92db-8117a697c972_terseLabel_en-US" xlink:label="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable securities, maturity period</link:label>
    <link:label id="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod_label_en-US" xlink:label="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current, Maturity Period</link:label>
    <link:label id="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod_documentation_en-US" xlink:label="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current, Maturity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:href="ameh-20220331.xsd#ameh_MarketableSecuritiesCurrentMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:to="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PmiocMember_4a4e84be-592b-4369-90ee-b1e99047bf93_terseLabel_en-US" xlink:label="lab_ameh_PmiocMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PMIOC</link:label>
    <link:label id="lab_ameh_PmiocMember_label_en-US" xlink:label="lab_ameh_PmiocMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PMIOC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember" xlink:href="ameh-20220331.xsd#ameh_PmiocMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PmiocMember" xlink:to="lab_ameh_PmiocMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_2f65057f-be0c-49f7-9eba-5faaaf0d202e_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_45c75484-6e70-4250-a807-e9587b36fbd7_terseLabel_en-US" xlink:label="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk pool surplus or deficits, settlement period after risk pool performance year</link:label>
    <link:label id="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_label_en-US" xlink:label="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Pool Surplus Or Deficits, Settlement Period After Performance Year</link:label>
    <link:label id="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_documentation_en-US" xlink:label="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Pool Surplus Or Deficits, Settlement Period After Performance Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:href="ameh-20220331.xsd#ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:to="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_85a97ded-3dbb-4d3f-8289-8549a3a2d4b3_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion and deferred financing costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AmendedCreditAgreementMember_b25fc020-bd0b-4349-ba22-1ff4280378bc_terseLabel_en-US" xlink:label="lab_ameh_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement</link:label>
    <link:label id="lab_ameh_AmendedCreditAgreementMember_label_en-US" xlink:label="lab_ameh_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:label id="lab_ameh_AmendedCreditAgreementMember_documentation_en-US" xlink:label="lab_ameh_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmendedCreditAgreementMember" xlink:href="ameh-20220331.xsd#ameh_AmendedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AmendedCreditAgreementMember" xlink:to="lab_ameh_AmendedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_185488a0-3c51-462d-ba73-c7aab5cf58b3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution from investment - equity method</link:label>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_label_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution, Return of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:to="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_f687030f-3437-4c48-957b-b7e496d8d9aa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4ae6689a-2635-45bd-aaeb-0ec0d22e812e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_53765094-e444-4161-a7cd-f051ff5ee827_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_5999461d-7648-4255-a8e2-1bc0313f2194_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AlliedPacificOfCaliforniaIPAMember_6ed50841-a89b-413f-9750-0c206063f839_verboseLabel_en-US" xlink:label="lab_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC</link:label>
    <link:label id="lab_ameh_AlliedPacificOfCaliforniaIPAMember_label_en-US" xlink:label="lab_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allied Pacific Of California IPA [Member]</link:label>
    <link:label id="lab_ameh_AlliedPacificOfCaliforniaIPAMember_documentation_en-US" xlink:label="lab_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allied Pacific Of California IPA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:href="ameh-20220331.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:to="lab_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_95bd1bc1-1ac1-47cf-89a3-8730beb673ea_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_108eccb4-12e3-4f0c-a557-7eada3495a2e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AMGPropertiesLLCMember_78170761-a757-4085-8176-3e5a388e6f97_terseLabel_en-US" xlink:label="lab_ameh_AMGPropertiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG Properties LLC</link:label>
    <link:label id="lab_ameh_AMGPropertiesLLCMember_label_en-US" xlink:label="lab_ameh_AMGPropertiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG Properties LLC [Member]</link:label>
    <link:label id="lab_ameh_AMGPropertiesLLCMember_documentation_en-US" xlink:label="lab_ameh_AMGPropertiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG Properties LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AMGPropertiesLLCMember" xlink:href="ameh-20220331.xsd#ameh_AMGPropertiesLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AMGPropertiesLLCMember" xlink:to="lab_ameh_AMGPropertiesLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_521d0161-36bb-4ec9-8646-4010babb45b6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_0ba852ee-4729-425b-bac4-536db5a483dd_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Other Entities - Equity Method and Investments in Privately Held Entities</link:label>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:to="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_e22be5bd-8b0c-4828-954a-9561ad86cf33_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_6c35a6f8-52d0-4e5d-99de-c577c895674b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_7cfcd3f3-629f-40d8-9ee4-0193befe704b_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0725de06-1218-4807-8e29-a59ce8e852d3_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, mezzanine equity, and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dce7b2e7-1ea3-4d4c-ba1b-3b4637bc529e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApcShareholdersMember_d9e5ec9a-7540-4aa5-a296-54294466a19d_terseLabel_en-US" xlink:label="lab_ameh_ApcShareholdersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Shareholders</link:label>
    <link:label id="lab_ameh_ApcShareholdersMember_label_en-US" xlink:label="lab_ameh_ApcShareholdersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Shareholders [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcShareholdersMember" xlink:href="ameh-20220331.xsd#ameh_ApcShareholdersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApcShareholdersMember" xlink:to="lab_ameh_ApcShareholdersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_2bba98d9-c5e7-41bb-a104-7f5d30bd3f68_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_0023815a-c7e3-4e2d-bd39-ddb7a3fce714_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_73768d79-65ba-47e5-b239-c64e19eb9fbb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_85b7aa8a-49be-4007-b419-b9e072cdface_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_8b3b0a5e-6143-4b3d-bae7-f48f9d382f61_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0d7ea19a-e3cc-4aa9-9a68-4680e63c372d_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1f2d506b-2a24-441c-83db-529d4f8796b5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price adjustment from Merger</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_a4103e52-180a-43d2-958f-e63be9e66d21_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_bddeef75-e0fc-4317-ab3c-8ae650fe6fbe_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorAMember_a8798ddc-04b8-4841-945a-9a9725f396ff_terseLabel_en-US" xlink:label="lab_ameh_PayorAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor A</link:label>
    <link:label id="lab_ameh_PayorAMember_label_en-US" xlink:label="lab_ameh_PayorAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor A [Member]</link:label>
    <link:label id="lab_ameh_PayorAMember_documentation_en-US" xlink:label="lab_ameh_PayorAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorAMember" xlink:href="ameh-20220331.xsd#ameh_PayorAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorAMember" xlink:to="lab_ameh_PayorAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_fa59779f-32ad-489d-b397-409301cb8c87_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_9d7fff7c-a880-41b8-b321-8f0f2a8600d0_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_348025dd-f09b-4f4d-89b6-f2d16db67f01_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_5a5530d3-fb1d-4dfc-8f2c-051e6e1fda3d_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios_779fd60f-3d7a-4121-8e66-b18259a6eb9b_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of key financial ratios</link:label>
    <link:label id="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios_label_en-US" xlink:label="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Key Financial Ratios</link:label>
    <link:label id="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Key Financial Ratios</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:href="ameh-20220331.xsd#ameh_DebtInstrumentNumberOfKeyFinancialRatios"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:to="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_f5a8d511-570b-426b-a44b-afd8d29bc3e1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent equity securities</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsCurrent" xlink:to="lab_us-gaap_DerivativeAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_db8b52b1-c76a-4e16-81c5-9ca1b502f8d3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_1fc2d415-31db-4fdb-a358-cb0d03fb97e6_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Sale of Parent Equity Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_4a4c44fd-3b85-462a-b59b-1125d04f0494_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_5afe7a21-99cd-4291-a43b-58353b20008d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from repayment of loans receivable &#8211; related parties</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collection of Long-term Loans to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:to="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_0751f5c7-8c02-47a8-aa21-b31c712e5bcf_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares for business acquisition</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_cf7829ac-4f59-4d22-ab2d-49d59fd50fc4_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_7553c205-3096-4011-a3bb-0308af1b29a2_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ManagementFeeExpense_af66e115-690d-459f-8383-22f7c65529e4_negatedLabel_en-US" xlink:label="lab_us-gaap_ManagementFeeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management fees</link:label>
    <link:label id="lab_us-gaap_ManagementFeeExpense_label_en-US" xlink:label="lab_us-gaap_ManagementFeeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Fee Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementFeeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementFeeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManagementFeeExpense" xlink:to="lab_us-gaap_ManagementFeeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ecca27bb-2040-47d8-8e15-23bb83aa75d8_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_f859680d-0f92-41b6-aca3-43b0d2277632_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_55e7166e-360c-4223-9448-7e188312c128_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_5daeccf5-1908-421b-aa8f-7d1a85901348_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_dc59ad5a-2a0c-4942-a395-5e04f772e269_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for vesting of restricted stock awards</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount_16df5d41-3fe8-4274-aeac-6562fb65c005_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount_d4bb1db4-8215-461b-8139-a343854a7007_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Amount Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:to="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_b2f1512a-df2f-434e-a0cf-33a49769bbaa_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2a65a873-b1a4-4399-8fa4-fceeed7cbcff_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_778d7d5a-bfc5-4f73-a457-7793a72f3950_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesMerger_a611eac7-63ea-4fba-8200-59f1e4b1088c_terseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesMerger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Holdback shares not issued to former shareholders (in shares)</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesMerger_label_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesMerger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Merger</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesMerger_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesMerger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of stock issued during the period pursuant to merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesMerger" xlink:href="ameh-20220331.xsd#ameh_StockIssuedDuringPeriodSharesMerger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringPeriodSharesMerger" xlink:to="lab_ameh_StockIssuedDuringPeriodSharesMerger" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SharesWarrantsRollForward_9dcca512-6a92-4d00-b453-69abe759b810_terseLabel_en-US" xlink:label="lab_ameh_SharesWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Warrants [Roll Forward]</link:label>
    <link:label id="lab_ameh_SharesWarrantsRollForward_label_en-US" xlink:label="lab_ameh_SharesWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Warrants [Roll Forward]</link:label>
    <link:label id="lab_ameh_SharesWarrantsRollForward_documentation_en-US" xlink:label="lab_ameh_SharesWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Warrants [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SharesWarrantsRollForward" xlink:href="ameh-20220331.xsd#ameh_SharesWarrantsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SharesWarrantsRollForward" xlink:to="lab_ameh_SharesWarrantsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_c619a144-29a8-4ec3-9f69-e18fae4c48a7_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_bbdd1533-b24a-4ca0-87e7-09425517cf65_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AccountsPayableAndAccruedExpensesMember_77a087b2-7c97-446a-8e45-c83fbac3a4da_terseLabel_en-US" xlink:label="lab_ameh_AccountsPayableAndAccruedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_ameh_AccountsPayableAndAccruedExpensesMember_label_en-US" xlink:label="lab_ameh_AccountsPayableAndAccruedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable And Accrued Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsPayableAndAccruedExpensesMember" xlink:href="ameh-20220331.xsd#ameh_AccountsPayableAndAccruedExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccountsPayableAndAccruedExpensesMember" xlink:to="lab_ameh_AccountsPayableAndAccruedExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_ac2d329f-7ded-4d56-806d-e70ed72e5871_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value per share; 100,000,000 shares authorized, 44,845,059 and 44,630,873 shares issued and outstanding, excluding 10,925,702 and 10,925,702 treasury shares, as of March&#160;31, 2022 and December&#160;31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_2e28794c-85fa-4b8f-b83f-4043f55f7ff6_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ContractTypeDomain_6cf6839d-01ce-4618-a222-10a1a8d564f3_terseLabel_en-US" xlink:label="lab_ameh_ContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Type [Domain]</link:label>
    <link:label id="lab_ameh_ContractTypeDomain_label_en-US" xlink:label="lab_ameh_ContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeDomain" xlink:href="ameh-20220331.xsd#ameh_ContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ContractTypeDomain" xlink:to="lab_ameh_ContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_fb795cf0-9cc8-4fee-8ee1-3b926ff58ecc_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_7c942677-842c-48a3-91db-740f26eb7ef1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_752cbeb7-7132-4ffa-8252-f9b56fa52882_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation associated with finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ManagementServiceMember_beb5e02a-9f6e-4b37-adeb-3265f4ef3c53_terseLabel_en-US" xlink:label="lab_us-gaap_ManagementServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management fee income</link:label>
    <link:label id="lab_us-gaap_ManagementServiceMember_f2f0212a-b1c3-4d46-9231-8cec456ce29d_verboseLabel_en-US" xlink:label="lab_us-gaap_ManagementServiceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Fee Income Contract</link:label>
    <link:label id="lab_us-gaap_ManagementServiceMember_label_en-US" xlink:label="lab_us-gaap_ManagementServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManagementServiceMember" xlink:to="lab_us-gaap_ManagementServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_793a3e3e-8c8b-4410-b452-3b7a98264fba_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 (excluding the three months ended March&#160;31, 2022)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_e3c5bc3d-c027-468c-9833-c09b41c0ca3f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations and Goodwill</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2caec39d-dc18-4b63-89fb-f6f340c66ace_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_d9f316ed-df57-4bbe-9c60-f1842ec77c6d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_13496fd0-7153-4981-8c21-30cef68adb9d_terseLabel_en-US" xlink:label="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from warrants exercised</link:label>
    <link:label id="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Issued During Period Value Stock Options Exercised</link:label>
    <link:label id="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_documentation_en-US" xlink:label="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:href="ameh-20220331.xsd#ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_a1e67cb7-3abc-4ccf-b44d-cb3861e63361_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_b841be4a-7a56-4aae-92cf-f5143774c6a0_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_24a5df33-8e51-4883-8dc1-2c77ac856441_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_3b40b46d-0c1c-4978-bd16-096dfc0bb083_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FulgentGeneticsIncMember_ebf7e128-0bce-447b-9d69-2555cc03edf7_terseLabel_en-US" xlink:label="lab_ameh_FulgentGeneticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fulgent Genetics, Inc.</link:label>
    <link:label id="lab_ameh_FulgentGeneticsIncMember_label_en-US" xlink:label="lab_ameh_FulgentGeneticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fulgent Genetics, Inc. [Member]</link:label>
    <link:label id="lab_ameh_FulgentGeneticsIncMember_documentation_en-US" xlink:label="lab_ameh_FulgentGeneticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fulgent Genetics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FulgentGeneticsIncMember" xlink:href="ameh-20220331.xsd#ameh_FulgentGeneticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FulgentGeneticsIncMember" xlink:to="lab_ameh_FulgentGeneticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_d918750b-3d19-41f7-9ad9-f307ecaaeab7_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duration of investment</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:href="ameh-20220331.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_OtherThirdPartiesMember_fe453676-f08f-40a1-b818-bc6c73fd0771_terseLabel_en-US" xlink:label="lab_ameh_OtherThirdPartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other third parties</link:label>
    <link:label id="lab_ameh_OtherThirdPartiesMember_label_en-US" xlink:label="lab_ameh_OtherThirdPartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Third Parties [Member]</link:label>
    <link:label id="lab_ameh_OtherThirdPartiesMember_documentation_en-US" xlink:label="lab_ameh_OtherThirdPartiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh:OtherThirdPartiesMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OtherThirdPartiesMember" xlink:href="ameh-20220331.xsd#ameh_OtherThirdPartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_OtherThirdPartiesMember" xlink:to="lab_ameh_OtherThirdPartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_APAMHMedicalCorporationMember_17744d39-532c-473a-8ac2-ba276b272a7b_terseLabel_en-US" xlink:label="lab_ameh_APAMHMedicalCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AP-AMH Medical Corporation</link:label>
    <link:label id="lab_ameh_APAMHMedicalCorporationMember_label_en-US" xlink:label="lab_ameh_APAMHMedicalCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AP-AMH Medical Corporation [Member]</link:label>
    <link:label id="lab_ameh_APAMHMedicalCorporationMember_documentation_en-US" xlink:label="lab_ameh_APAMHMedicalCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AP-AMH Medical Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APAMHMedicalCorporationMember" xlink:href="ameh-20220331.xsd#ameh_APAMHMedicalCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_APAMHMedicalCorporationMember" xlink:to="lab_ameh_APAMHMedicalCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCarePatientServiceMember_bb508af3-9e49-4a07-a664-d95926b9c1dc_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCarePatientServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee-for-service, net</link:label>
    <link:label id="lab_us-gaap_HealthCarePatientServiceMember_label_en-US" xlink:label="lab_us-gaap_HealthCarePatientServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care, Patient Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCarePatientServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCarePatientServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCarePatientServiceMember" xlink:to="lab_us-gaap_HealthCarePatientServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_299c1e44-9280-42de-b031-4f9213260ed9_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4ddcf47a-c5e5-42e5-a54b-37ed93a61f0c_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_5b0a725f-d305-4000-85d1-819ec130cf31_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from related parties</link:label>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties" xlink:to="lab_us-gaap_RevenueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_41fbb41f-f2e4-43a3-b4d4-7ab939bc4c2f_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0c3d4adf-9638-49df-bc85-611617e34bd5_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c82ec968-95c4-4932-a992-2fe7c3647929_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApaAcoIncMember_b2d48bc5-e9d4-449a-847e-f53e64072d67_terseLabel_en-US" xlink:label="lab_ameh_ApaAcoIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APA ACO Inc</link:label>
    <link:label id="lab_ameh_ApaAcoIncMember_label_en-US" xlink:label="lab_ameh_ApaAcoIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APA ACO Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApaAcoIncMember" xlink:href="ameh-20220331.xsd#ameh_ApaAcoIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApaAcoIncMember" xlink:to="lab_ameh_ApaAcoIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_c72f97dc-afe3-44f3-a498-3ebde53b4f34_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_250dfd4d-6751-4161-ae99-6662daf57299_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_d2d1b70e-c576-4142-a8a1-40b3d8debcda_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_4149a489-2661-40a4-a24b-4e7b74d9baf7_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_025fcb23-6677-4b67-97c6-15590642862a_terseLabel_en-US" xlink:label="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concourse Diagnostic Surgery Center, LLC</link:label>
    <link:label id="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_label_en-US" xlink:label="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concourse Diagnostic Surgery Center, LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:href="ameh-20220331.xsd#ameh_ConcourseDiagnosticSurgeryCenterLlcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:to="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_94667243-3a4f-4799-8148-0742ea6019af_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_56a080aa-150b-4f1e-99e0-618cab153186_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_a634808f-ee88-4d3b-be2e-c1dc9425971c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForFees_ea8c08ac-887e-4cb6-9dd0-7f746a0359b6_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fees paid</link:label>
    <link:label id="lab_us-gaap_PaymentsForFees_label_en-US" xlink:label="lab_us-gaap_PaymentsForFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Other Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForFees" xlink:to="lab_us-gaap_PaymentsForFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_17ec820c-7f71-4b24-9d9e-f6482cf2a85f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_13a91823-db24-4e40-a7f2-2b03f086b765_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_8df917f3-2baa-4dde-a1bd-45c307e155ec_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_402d02b3-c472-482d-9701-5980095ae2c8_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in&#160;Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CommitmentsAndContingenciesTable_32b00130-22dd-4fb1-9b5b-6b06450cffae_terseLabel_en-US" xlink:label="lab_ameh_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_ameh_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_ameh_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesTable" xlink:href="ameh-20220331.xsd#ameh_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CommitmentsAndContingenciesTable" xlink:to="lab_ameh_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PerMemberPerMonthManagedCareContractMember_c95ab32a-7398-4816-ad01-bc27ae8f7f82_terseLabel_en-US" xlink:label="lab_ameh_PerMemberPerMonthManagedCareContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PMPM Managed Care Contract</link:label>
    <link:label id="lab_ameh_PerMemberPerMonthManagedCareContractMember_label_en-US" xlink:label="lab_ameh_PerMemberPerMonthManagedCareContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per-Member-Per-Month Managed Care Contract [Member]</link:label>
    <link:label id="lab_ameh_PerMemberPerMonthManagedCareContractMember_documentation_en-US" xlink:label="lab_ameh_PerMemberPerMonthManagedCareContractMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per-Member-Per-Month Managed Care Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PerMemberPerMonthManagedCareContractMember" xlink:href="ameh-20220331.xsd#ameh_PerMemberPerMonthManagedCareContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PerMemberPerMonthManagedCareContractMember" xlink:to="lab_ameh_PerMemberPerMonthManagedCareContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_80a1835b-28a9-478c-8a7f-e8fc4587c38c_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_96aee887-bf18-455f-91a9-34488d982164_terseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:href="ameh-20220331.xsd#ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:to="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_27fd8f00-fa1b-46b2-8e58-5b8afca1b70e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_8e35c7ac-a140-4bd5-87dc-4d6e07ce9b84_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_bd5fbbf4-3ac6-4939-843d-0a5f39092189_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants received (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableNet_15c98b3e-f7ec-4841-821a-89205c2bfbd2_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of loan</link:label>
    <link:label id="lab_us-gaap_NotesReceivableNet_label_en-US" xlink:label="lab_us-gaap_NotesReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableNet" xlink:to="lab_us-gaap_NotesReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_4d143858-53f6-440a-8a96-9edbdd42a7fc_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_5a8b196f-b563-43d6-a7bb-2c6eb786aa2a_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of voting common stock, within five years</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:href="ameh-20220331.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_4e73a9c8-ce7a-41e3-a5a5-2e62e538db65_terseLabel_en-US" xlink:label="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed term of amended and restated management and administrative services agreement</link:label>
    <link:label id="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_label_en-US" xlink:label="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Fixed Term Of Amended And Restated Management And Administrative Services Agreement</link:label>
    <link:label id="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_documentation_en-US" xlink:label="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The initial fixed term of amended and restated management and administrative services agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:href="ameh-20220331.xsd#ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:to="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NetworkRelationshipsMember_d025522e-3cc3-4809-a86f-0261b44a1ff1_terseLabel_en-US" xlink:label="lab_ameh_NetworkRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network relationships</link:label>
    <link:label id="lab_ameh_NetworkRelationshipsMember_label_en-US" xlink:label="lab_ameh_NetworkRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Relationships [Member]</link:label>
    <link:label id="lab_ameh_NetworkRelationshipsMember_documentation_en-US" xlink:label="lab_ameh_NetworkRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Relationships</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkRelationshipsMember" xlink:href="ameh-20220331.xsd#ameh_NetworkRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NetworkRelationshipsMember" xlink:to="lab_ameh_NetworkRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_295171d2-e17e-490a-97ec-d231e9582df5_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ZLLPartnersLLCMember_9e8260bc-d5dc-4d6f-818c-e4d7b08e1981_terseLabel_en-US" xlink:label="lab_ameh_ZLLPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZLL Partners LLC</link:label>
    <link:label id="lab_ameh_ZLLPartnersLLCMember_label_en-US" xlink:label="lab_ameh_ZLLPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZLL Partners LLC [Member]</link:label>
    <link:label id="lab_ameh_ZLLPartnersLLCMember_documentation_en-US" xlink:label="lab_ameh_ZLLPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZLL Partners LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ZLLPartnersLLCMember" xlink:href="ameh-20220331.xsd#ameh_ZLLPartnersLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ZLLPartnersLLCMember" xlink:to="lab_ameh_ZLLPartnersLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MedicalPropertyPartnersLLCMember_815b5a87-efc4-49eb-af17-4520c11998d9_terseLabel_en-US" xlink:label="lab_ameh_MedicalPropertyPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Property Partners LLC</link:label>
    <link:label id="lab_ameh_MedicalPropertyPartnersLLCMember_label_en-US" xlink:label="lab_ameh_MedicalPropertyPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Property Partners LLC [Member]</link:label>
    <link:label id="lab_ameh_MedicalPropertyPartnersLLCMember_documentation_en-US" xlink:label="lab_ameh_MedicalPropertyPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Property Partners LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalPropertyPartnersLLCMember" xlink:href="ameh-20220331.xsd#ameh_MedicalPropertyPartnersLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicalPropertyPartnersLLCMember" xlink:to="lab_ameh_MedicalPropertyPartnersLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_7c7f38a2-f022-40a8-a69d-7987261c9b3a_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f0d8107b-5e50-4742-ab48-7275b89deaac_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod_781e2658-b0ac-4d73-bcb7-9f788f75e46f_negatedLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants expired/forfeited (in shares)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Cancelled In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right, cancelled in period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:href="ameh-20220331.xsd#ameh_ClassOfWarrantOrRightCancelledInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:to="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d083132a-7661-46de-a9cb-90e3836bafdf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Operating Lease Payments After Adoption of 842</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_126f8aee-7efb-4ee9-aeb3-022def28a39d_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contributions to Revenue and Receivables by Payor</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_a265a953-3850-47cf-8ca2-7f0b0a16362e_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity, parent</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_0b0cf99c-567d-4e80-834b-3192085659d7_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_c5d657f3-3d7c-415f-b8ad-55526b5cba80_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6e7ee505-004c-4fc7-9620-a2dd85aaa4e1_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_32f739ac-fa54-4a28-bd28-c6c40d25962f_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedging instruments:</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_dff3fe3a-be7c-4df1-926d-808108db6208_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_6ce016d7-0ffb-4b4e-8166-3c789519d10f_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApolloSunLabsManagementLLCMember_9525f17e-20c4-41d5-8be9-45a4ed5d3898_terseLabel_en-US" xlink:label="lab_ameh_ApolloSunLabsManagementLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apollo-Sun Labs Management, LLC</link:label>
    <link:label id="lab_ameh_ApolloSunLabsManagementLLCMember_label_en-US" xlink:label="lab_ameh_ApolloSunLabsManagementLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apollo-Sun Labs Management, LLC [Member]</link:label>
    <link:label id="lab_ameh_ApolloSunLabsManagementLLCMember_documentation_en-US" xlink:label="lab_ameh_ApolloSunLabsManagementLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apollo-Sun Labs Management, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloSunLabsManagementLLCMember" xlink:href="ameh-20220331.xsd#ameh_ApolloSunLabsManagementLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApolloSunLabsManagementLLCMember" xlink:to="lab_ameh_ApolloSunLabsManagementLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_a7967181-39bf-47f8-a3be-db0fc1cf0be0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilities_3a81101e-e5e1-4f01-bda5-c8fdc4d34fbf_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount outstanding under agreement</link:label>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Credits and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:to="lab_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_e844093f-7501-415f-a8b9-00fe7adbcb47_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risks</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_bc2eb328-bdc6-42d5-9491-9e79227bc332_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_829a8dc0-d5a6-4faf-9208-c4855f725f55_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_c7c990a0-63d1-4574-9f02-da349d275008_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_ca87951e-768b-4f76-8f01-d1d3d00ad217_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, principal sum</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_eb75f34e-94d9-44d3-9c58-d43316a3db4b_terseLabel_en-US" xlink:label="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to purchase membership interests</link:label>
    <link:label id="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_label_en-US" xlink:label="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments</link:label>
    <link:label id="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_documentation_en-US" xlink:label="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:href="ameh-20220331.xsd#ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:to="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_3f11931f-1fba-4c7a-b262-3737de0f91cb_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_d8a1ced9-4dc0-49c9-b652-42142fb03238_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AdvanceDiagnosticSurgeryCenterMember_c50f1f98-8fff-446c-b19e-2ef2a90740fb_terseLabel_en-US" xlink:label="lab_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Diagnostic Surgery Center</link:label>
    <link:label id="lab_ameh_AdvanceDiagnosticSurgeryCenterMember_label_en-US" xlink:label="lab_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Diagnostic Surgery Center [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:href="ameh-20220331.xsd#ameh_AdvanceDiagnosticSurgeryCenterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:to="lab_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_cab9f638-f954-4cdd-b752-6bfc87919d76_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_OneMSOInc.Member_ce790f3a-e6af-4e0a-ad15-6e7ffe1aac05_terseLabel_en-US" xlink:label="lab_ameh_OneMSOInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, Inc.</link:label>
    <link:label id="lab_ameh_OneMSOInc.Member_label_en-US" xlink:label="lab_ameh_OneMSOInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, Inc. [Member]</link:label>
    <link:label id="lab_ameh_OneMSOInc.Member_documentation_en-US" xlink:label="lab_ameh_OneMSOInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member" xlink:href="ameh-20220331.xsd#ameh_OneMSOInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_OneMSOInc.Member" xlink:to="lab_ameh_OneMSOInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_c0fd4572-7d4e-46fe-8a80-0421d101f3f2_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market value of common stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_4ab57b10-3b3d-44b3-aae1-ebf5481aea60_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_c6d222f9-a48f-4d27-8b16-c9430c757669_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease term, operating</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_40f06c3d-3971-41a6-a612-234de490e39f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_5431eba2-1c9d-4fa7-aacd-1b7536a4158d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Operations</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_bdf31216-e982-4e9c-92bc-79cba2f6ed21_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in other entities &#8211; equity method</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_629ed948-f540-4e37-b9a5-22d130d938cd_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in other entities &#8211; equity method</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_454dc960-d0f4-495e-9c54-fbcc2d19918e_periodStartLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_2c7ad479-8785-464b-97f3-fcc858a5f90e_periodEndLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DescriptionOfBusinessTable_0e198b3a-d25a-472f-a624-bcb7e10f82f8_terseLabel_en-US" xlink:label="lab_ameh_DescriptionOfBusinessTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Business [Table]</link:label>
    <link:label id="lab_ameh_DescriptionOfBusinessTable_label_en-US" xlink:label="lab_ameh_DescriptionOfBusinessTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Business [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessTable" xlink:href="ameh-20220331.xsd#ameh_DescriptionOfBusinessTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DescriptionOfBusinessTable" xlink:to="lab_ameh_DescriptionOfBusinessTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_3255f17f-5884-482b-8b3d-fba33dd49451_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_c55fa2cf-054f-40a1-ab5b-ca1231d6f300_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrants exercised (in dollars per share)</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:href="ameh-20220331.xsd#ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:to="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_5d7a8497-88a3-4b76-813d-50c9b4a5df78_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_9878353e-7515-4855-9a94-d85272ee926f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_314ad2dc-8ec4-4ded-91d7-7b496ffbaf95_terseLabel_en-US" xlink:label="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHMC &#8211; Risk pool, capitation, claims payment</link:label>
    <link:label id="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_label_en-US" xlink:label="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Services Revenue, Capitation, And Claims Payment, Net</link:label>
    <link:label id="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_documentation_en-US" xlink:label="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Services Revenue, Capitation, And Claims Payment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:href="ameh-20220331.xsd#ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:to="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_b026abc5-014e-40ec-954e-137bade02ddf_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_23a7a4a9-346c-4b25-a308-d9581797db74_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_6a30778f-9678-4675-bb34-cadef30d2015_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_43b7a3ca-2ece-456d-bd22-02b9617ee43e_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceLeaseCostsAbstract_994b469b-463c-4776-9cd5-aea3ca7165bf_terseLabel_en-US" xlink:label="lab_ameh_FinanceLeaseCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Cost [Abstract]</link:label>
    <link:label id="lab_ameh_FinanceLeaseCostsAbstract_label_en-US" xlink:label="lab_ameh_FinanceLeaseCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Costs [Abstract]</link:label>
    <link:label id="lab_ameh_FinanceLeaseCostsAbstract_documentation_en-US" xlink:label="lab_ameh_FinanceLeaseCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceLeaseCostsAbstract" xlink:href="ameh-20220331.xsd#ameh_FinanceLeaseCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceLeaseCostsAbstract" xlink:to="lab_ameh_FinanceLeaseCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_8b5165cd-809f-4a25-9615-264cab75d97f_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, covenant, debt coverage ratio, minimum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Debt Coverage Ratio, Minimum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Debt Coverage Ratio, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" xlink:href="ameh-20220331.xsd#ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" xlink:to="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_05c757cc-e39a-49e2-8976-30e8b1fa59f4_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareOtherMember_6063764c-056e-4c75-9bed-cea9972c1482_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk pool settlements and incentives</link:label>
    <link:label id="lab_us-gaap_HealthCareOtherMember_label_en-US" xlink:label="lab_us-gaap_HealthCareOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOtherMember" xlink:to="lab_us-gaap_HealthCareOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentConsultingFees_8fd0a451-5517-46d0-b930-85d1d3731a26_terseLabel_en-US" xlink:label="lab_ameh_PaymentConsultingFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting services paid</link:label>
    <link:label id="lab_ameh_PaymentConsultingFees_label_en-US" xlink:label="lab_ameh_PaymentConsultingFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Consulting Fees</link:label>
    <link:label id="lab_ameh_PaymentConsultingFees_documentation_en-US" xlink:label="lab_ameh_PaymentConsultingFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Consulting Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentConsultingFees" xlink:href="ameh-20220331.xsd#ameh_PaymentConsultingFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentConsultingFees" xlink:to="lab_ameh_PaymentConsultingFees" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_4aefbcb6-fecc-479f-8df3-bfc1247bc67a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_926d76c1-0201-4fc1-b8eb-cac560a28c08_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8e92ca76-c203-446f-a19a-85a714ca3c58_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_e98d1e66-7997-4b59-9c52-018cb77b120f_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables and Receivables-Related Parties</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_3d815585-0d2d-4cd2-a0e2-3bad14b7e2fa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ba93d5ec-78c1-4e8f-aae6-cb1982a3d868_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_f384647a-a2af-4a4d-8452-d58e1fa12397_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share buy back</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_51469dba-f43b-4867-85bc-e2da3774e9ee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_bf9d8573-7fba-41a3-931c-1de2b2c393aa_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_0c083dc3-82bd-4a74-a3fd-27a5362df872_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_2e223664-b67b-4a07-913f-889cf8c35a76_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_8abab135-c4eb-4c38-b7d7-560da0b60860_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Exercises In Period, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of warrants or rights exercised in period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:href="ameh-20220331.xsd#ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:to="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_1402ea85-78bf-4b5a-bb66-b938518b21a4_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Shares Included in the Diluted Earnings Per Share Computations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_21f205b1-20f3-4aff-ae4f-fe6b11bd2c0e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_2ec290d9-c528-4acd-8dc5-f8dc5f26d577_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_17a62d8a-3c6d-4187-8c8d-afde69d3aeba_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2a487b96-9f1d-495f-a5b0-4b2374352a4b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_44af7b7d-0194-4f56-b61b-fde2e241ed2e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_2b127f36-f314-456c-9f85-e65f4ea9f406_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_60725527-9fa1-4efe-a8d4-4d6752946f1a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_a0ee7cc9-8e2d-45e3-a815-0008cdcb7fd4_terseLabel_en-US" xlink:label="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:href="ameh-20220331.xsd#ameh_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_8be163ae-7378-4f34-beab-68d0530578e8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares transferred in acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_e92e53ab-5820-4a50-a69b-56e38e6d1147_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land, property, and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_05043d9c-3b18-4b0d-9d21-2fa9b4159447_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares for business acquisition (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_2ecb05bc-d21e-4fe7-a9b2-33112eadd7aa_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_abcad09e-3d4a-49b1-a44d-9807571ec060_verboseLabel_en-US" xlink:label="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in privately held entities</link:label>
    <link:label id="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_label_en-US" xlink:label="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment In Privately Held Entity That Does Not Report Net Asset Value</link:label>
    <link:label id="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_documentation_en-US" xlink:label="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total of Investment in privately held entity that does not report net asset value per share .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:href="ameh-20220331.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:to="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_15a0eb6f-dca5-449a-b48d-bbd8295bf47f_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_us-gaap_SeriesBPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_6b209c5b-5ab9-4b81-b71c-b2dab9712fea_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_25e0dfdc-eea7-4d28-8c92-4da251c88c2e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6714db7c-c1d7-433e-ab68-0e7a14fc9bde_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_4a7d3b05-711a-4f89-8bae-acd607bcd6f6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_545b92a0-3a57-4050-8bf4-a63cb806a4eb_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_f108e3d4-50bb-4f54-85b8-30100222931b_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_adf46913-c75f-4e2e-b8ef-a8f2e1701ac2_netLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_25d39e26-4478-4cec-8eaa-cbe3fda02f2c_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_5c26e3bf-6121-42a6-9517-c6e390822b88_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_aed90afa-b12f-46f6-8e64-301c972f2162_terseLabel_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, termination period, if applicable</link:label>
    <link:label id="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_label_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Termination Period, If Applicable</link:label>
    <link:label id="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_documentation_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Termination Period, If Applicable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:href="ameh-20220331.xsd#ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:to="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ade7b6de-a597-480a-8336-550a85c6833f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful Life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems_1685d616-67fe-4295-b766-5436d28f70f7_terseLabel_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:href="ameh-20220331.xsd#ameh_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_85069cc3-c5ed-4025-ad84-b31d77ab9685_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_TemporaryEquityPolicyTextBlock_9e026f72-fb53-4ec5-9aec-fb2d96c25ac8_terseLabel_en-US" xlink:label="lab_ameh_TemporaryEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine Equity</link:label>
    <link:label id="lab_ameh_TemporaryEquityPolicyTextBlock_label_en-US" xlink:label="lab_ameh_TemporaryEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Policy Text Block]</link:label>
    <link:label id="lab_ameh_TemporaryEquityPolicyTextBlock_documentation_en-US" xlink:label="lab_ameh_TemporaryEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityPolicyTextBlock" xlink:href="ameh-20220331.xsd#ameh_TemporaryEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_TemporaryEquityPolicyTextBlock" xlink:to="lab_ameh_TemporaryEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_e7b00671-9a7f-43ac-bbb7-e0fe4d7c462c_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_cf127425-dd5e-4fbf-aa07-10a8107a2369_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share Computations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_a0115401-46f4-4345-b9e8-e520a4c9aba1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_b1ce2e92-37e6-4814-bee9-ecb2df4475bc_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_19c9b19f-eec9-4378-8946-7641d01b11d0_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Support to Nonconsolidated Legal Entity [Domain]</link:label>
    <link:label id="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_label_en-US" xlink:label="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Support to Nonconsolidated Legal Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:to="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_4743cd05-3ead-4efd-98b2-23aa897818bb_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_63b8316c-6138-4d2b-ba90-d4153d784a54_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_31891a3c-fb8c-4000-b2f6-a030a7cb6673_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_db9db378-d89a-4282-b297-949342eb7659_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_86ed7cdd-e4c9-4189-9882-d4252b2bf793_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_a5fc8479-c147-4108-a28e-e4ada57329d0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in affiliates</link:label>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_label_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermInvestments" xlink:to="lab_us-gaap_OtherLongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_9304c988-3832-49a0-9451-976d7bc85f8e_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_d6e33e6e-7e64-4e42-b1ce-875cd1b9be0c_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_f1fc6586-0d70-4c7e-8a1c-52b9986250ab_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_a29523f0-e0be-4372-891d-333a67a53664_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Medical Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_dc99685e-ba98-4b22-96b4-2a1ea64c0f64_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate on loan receivable</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Dr.ArteagaMember_8695fc09-a3dc-41b6-a030-db8b8c4e2e53_verboseLabel_en-US" xlink:label="lab_ameh_Dr.ArteagaMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Arteaga</link:label>
    <link:label id="lab_ameh_Dr.ArteagaMember_label_en-US" xlink:label="lab_ameh_Dr.ArteagaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Arteaga [Member]</link:label>
    <link:label id="lab_ameh_Dr.ArteagaMember_documentation_en-US" xlink:label="lab_ameh_Dr.ArteagaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Arteaga [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.ArteagaMember" xlink:href="ameh-20220331.xsd#ameh_Dr.ArteagaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Dr.ArteagaMember" xlink:to="lab_ameh_Dr.ArteagaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock_c2890bb0-2918-4b9e-b751-5fe21a527f1b_verboseLabel_en-US" xlink:label="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Other Entities</link:label>
    <link:label id="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock_label_en-US" xlink:label="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method And Other Equity Investments [Text Block]</link:label>
    <link:label id="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock_documentation_en-US" xlink:label="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method And Other Equity Investments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:href="ameh-20220331.xsd#ameh_EquityMethodAndOtherEquityInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:to="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_0da73972-b131-4f6b-9a4f-e0c1fb7660fa_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease option to extend (up to)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e8b397bb-06a6-4469-a3d5-be3566fb28bd_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_ac5c1c66-ee84-42ee-b531-caa35153546b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APCMG contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a1594a35-3c51-4c08-9b2f-35c05c2195c3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_5cf50506-dbc7-4069-aa80-0e6e31790cab_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolver Loan</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_710a9511-91ea-4059-bcbb-ee888422df83_verboseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolver Loan</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_HealthCareCapitationRevenueMember_790208b1-4a08-416a-a813-05d4bcf51ca0_verboseLabel_en-US" xlink:label="lab_ameh_HealthCareCapitationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitation, net</link:label>
    <link:label id="lab_ameh_HealthCareCapitationRevenueMember_label_en-US" xlink:label="lab_ameh_HealthCareCapitationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Capitation Revenue [Member]</link:label>
    <link:label id="lab_ameh_HealthCareCapitationRevenueMember_documentation_en-US" xlink:label="lab_ameh_HealthCareCapitationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh_HealthCareCapitationRevenueMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HealthCareCapitationRevenueMember" xlink:href="ameh-20220331.xsd#ameh_HealthCareCapitationRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_HealthCareCapitationRevenueMember" xlink:to="lab_ameh_HealthCareCapitationRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_a0cbb97d-11b1-4e43-adce-ac2c3594e998_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information Related to Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_UniversalCareIncMember_3463448c-c6af-4228-bdbf-93b4433ec407_terseLabel_en-US" xlink:label="lab_ameh_UniversalCareIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Universal Care Inc</link:label>
    <link:label id="lab_ameh_UniversalCareIncMember_label_en-US" xlink:label="lab_ameh_UniversalCareIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Universal Care Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember" xlink:href="ameh-20220331.xsd#ameh_UniversalCareIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_UniversalCareIncMember" xlink:to="lab_ameh_UniversalCareIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_4f261fb8-ad57-4050-a837-042433eecd14_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:href="ameh-20220331.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_c40077fb-9736-4d63-921b-e4a0f5d95365_verboseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to related parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceReceivableStatedInterestRate_2f24b42e-782c-4e19-98a7-8ea02f05af5f_terseLabel_en-US" xlink:label="lab_ameh_FinanceReceivableStatedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated rate of note of loan receivable</link:label>
    <link:label id="lab_ameh_FinanceReceivableStatedInterestRate_label_en-US" xlink:label="lab_ameh_FinanceReceivableStatedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Stated Interest Rate</link:label>
    <link:label id="lab_ameh_FinanceReceivableStatedInterestRate_documentation_en-US" xlink:label="lab_ameh_FinanceReceivableStatedInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Stated Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableStatedInterestRate" xlink:href="ameh-20220331.xsd#ameh_FinanceReceivableStatedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceReceivableStatedInterestRate" xlink:to="lab_ameh_FinanceReceivableStatedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_bd80eaff-c255-4304-8de5-ce785337c7df_totalLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_151a9467-09b0-4941-929a-529488795980_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_23cc003b-3940-416b-b702-19838e3ba851_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:to="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_78c65b9d-3e84-4a80-be49-ef9a2b174495_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_ce2b36ce-a2a7-4100-9552-5824a627b38f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_4ad51271-7084-4e5c-a877-ed03808f7a0d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_8213df6a-d1e2-4047-89a2-d83fc6bcfc0a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_95d02298-1220-45b6-a92c-0f388c0306b6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Income) loss from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_c0488b79-3ce7-47de-9b45-c39929c412f4_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocation of Income (Loss)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_e9e0a86c-b9c6-4334-a3d2-4acade87877f_netLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PreferredBankMember_da1469fa-f2ee-4d19-85f3-0ddc1b259fe1_terseLabel_en-US" xlink:label="lab_ameh_PreferredBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Bank</link:label>
    <link:label id="lab_ameh_PreferredBankMember_label_en-US" xlink:label="lab_ameh_PreferredBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Bank [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PreferredBankMember" xlink:href="ameh-20220331.xsd#ameh_PreferredBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PreferredBankMember" xlink:to="lab_ameh_PreferredBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Dr.JayMember_3ba0e495-f32b-4c29-a5b2-945eb8bbb113_terseLabel_en-US" xlink:label="lab_ameh_Dr.JayMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Jay</link:label>
    <link:label id="lab_ameh_Dr.JayMember_label_en-US" xlink:label="lab_ameh_Dr.JayMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Jay [Member]</link:label>
    <link:label id="lab_ameh_Dr.JayMember_documentation_en-US" xlink:label="lab_ameh_Dr.JayMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Jay [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.JayMember" xlink:href="ameh-20220331.xsd#ameh_Dr.JayMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Dr.JayMember" xlink:to="lab_ameh_Dr.JayMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_d28a13f4-c722-46f6-9362-61aae036391a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation of restricted stock awards</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_df952927-64a9-450e-9751-b79015675a4c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Finance Lease Payments After Adoption of 842</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AccountsReceivableAndNetRevenueTable_f2a3159c-e922-4e59-b74f-4ed8aec4b475_terseLabel_en-US" xlink:label="lab_ameh_AccountsReceivableAndNetRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable And Net Revenue [Table]</link:label>
    <link:label id="lab_ameh_AccountsReceivableAndNetRevenueTable_label_en-US" xlink:label="lab_ameh_AccountsReceivableAndNetRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable And Net Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueTable" xlink:href="ameh-20220331.xsd#ameh_AccountsReceivableAndNetRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable" xlink:to="lab_ameh_AccountsReceivableAndNetRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_bbf23c76-66f0-4846-810e-b1fc15a3a248_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AmgIncMember_4d34e863-00fd-4b15-81f0-96a06a438b10_terseLabel_en-US" xlink:label="lab_ameh_AmgIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG, Inc</link:label>
    <link:label id="lab_ameh_AmgIncMember_label_en-US" xlink:label="lab_ameh_AmgIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember" xlink:href="ameh-20220331.xsd#ameh_AmgIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AmgIncMember" xlink:to="lab_ameh_AmgIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_68d8b551-a984-408b-9211-c97329b7c5cd_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_85e87280-f709-4898-ad84-6e99d23ca54c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_dd915196-7e27-4b64-9d26-d4c9c14f846c_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized risk pool revenue</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_0a4b8c38-a3bf-4744-b25e-f1ebecc90e2f_totalLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receipts, net</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Other Revenues from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_b5499836-3a98-4231-be38-64efb886e602_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_4bd12ba7-32f4-4272-91fc-6e3131177ce9_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_6932dcd7-1559-4806-9ee6-a4392cf3561f_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Exercised In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price per share of warrants or rights exercised during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:href="ameh-20220331.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:to="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_5123e46c-3466-480f-8334-f83135b8be8b_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of main reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_0742dec3-0e35-42dd-b216-5deab13550e8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_152803c7-3ee5-4f28-bd0a-86fa69f34839_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CAIPAMSOLLCMember_972525e4-55d6-48a5-b821-c09158135ffd_terseLabel_en-US" xlink:label="lab_ameh_CAIPAMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CAIPA MSO, LLC</link:label>
    <link:label id="lab_ameh_CAIPAMSOLLCMember_label_en-US" xlink:label="lab_ameh_CAIPAMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CAIPA MSO, LLC [Member]</link:label>
    <link:label id="lab_ameh_CAIPAMSOLLCMember_documentation_en-US" xlink:label="lab_ameh_CAIPAMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CAIPA MSO, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CAIPAMSOLLCMember" xlink:href="ameh-20220331.xsd#ameh_CAIPAMSOLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CAIPAMSOLLCMember" xlink:to="lab_ameh_CAIPAMSOLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_b68fb55b-46a9-4245-a512-56b1d4ad0ecb_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MemberRelationshipsMember_ae00384e-d799-43b6-b953-b5992594d867_terseLabel_en-US" xlink:label="lab_ameh_MemberRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member relationships</link:label>
    <link:label id="lab_ameh_MemberRelationshipsMember_label_en-US" xlink:label="lab_ameh_MemberRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member Relationships [Member]</link:label>
    <link:label id="lab_ameh_MemberRelationshipsMember_documentation_en-US" xlink:label="lab_ameh_MemberRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member Relationships</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MemberRelationshipsMember" xlink:href="ameh-20220331.xsd#ameh_MemberRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MemberRelationshipsMember" xlink:to="lab_ameh_MemberRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_e8ebfd42-ed8b-4534-8a4e-d206c4917596_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving credit facility term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BridgeLoanMember_253c4d7b-1b8c-4cd5-8262-a9243e9b8ed5_terseLabel_en-US" xlink:label="lab_us-gaap_BridgeLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Loan</link:label>
    <link:label id="lab_us-gaap_BridgeLoanMember_label_en-US" xlink:label="lab_us-gaap_BridgeLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BridgeLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoanMember" xlink:to="lab_us-gaap_BridgeLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_fffe6c26-e0d6-49b9-8ea4-0c86a1411fb8_verboseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_180bb839-0b48-4dce-a5e2-1b9acf541c61_verboseLabel_en-US" xlink:label="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Receivables &#8211; Related Parties, and Loan Receivable - Related Party</link:label>
    <link:label id="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_label_en-US" xlink:label="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables And Related parties Receivables Policy Text Block [Policy Text Block]</link:label>
    <link:label id="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_documentation_en-US" xlink:label="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Receivables and receivables from related parties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:href="ameh-20220331.xsd#ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:to="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2997d238-3d1f-44b8-84cc-04a9c2789b26_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land, property, and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_b4d58ae2-faff-454c-a335-c1106177a522_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, covenant, cash flow coverage ratio, minimum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Cash Flow Coverage Ratio, Minimum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Cash Flow Coverage Ratio, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" xlink:href="ameh-20220331.xsd#ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" xlink:to="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_0ea3f576-c09f-4a0d-ae00-e65f40fa448b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_b385b3d6-9868-474f-bf86-c4e3d3485212_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_c790e647-0f3f-4246-a85d-f2d108ebd37d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareholdersAndOfficersMember_8437e5c1-07dc-48ea-9eb5-5e22ae677b84_terseLabel_en-US" xlink:label="lab_ameh_ShareholdersAndOfficersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Shareholders and Officers</link:label>
    <link:label id="lab_ameh_ShareholdersAndOfficersMember_label_en-US" xlink:label="lab_ameh_ShareholdersAndOfficersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders And Officers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareholdersAndOfficersMember" xlink:href="ameh-20220331.xsd#ameh_ShareholdersAndOfficersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareholdersAndOfficersMember" xlink:to="lab_ameh_ShareholdersAndOfficersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AccountableHealthCareIPAMember_8a80a7e8-4395-4c8e-8124-b5db7d5d483a_verboseLabel_en-US" xlink:label="lab_ameh_AccountableHealthCareIPAMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accountable Health Care</link:label>
    <link:label id="lab_ameh_AccountableHealthCareIPAMember_label_en-US" xlink:label="lab_ameh_AccountableHealthCareIPAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accountable Health Care IPA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember" xlink:href="ameh-20220331.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccountableHealthCareIPAMember" xlink:to="lab_ameh_AccountableHealthCareIPAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_921d952a-64d6-4569-8a4d-a320e8bb755c_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities, FV-NI, unrealized gain (loss)</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_2d468dc0-e176-46a8-b6e7-e05ab4d6a746_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_38cc373a-8bbe-43cc-9e19-d3c83ee13afe_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1c029c83-1dca-428f-ad58-aeac4f6a5bb1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_236b3498-17de-41e4-9d05-c3fe23eda04c_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of warrant</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_6fb34447-f9b6-4912-af10-65c71489713c_verboseLabel_en-US" xlink:label="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_label_en-US" xlink:label="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid For Lease Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:href="ameh-20220331.xsd#ameh_CashPaidForLeaseLiabilitiesAbstractAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:to="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NetworkMedicalManagementMember_0c49abe3-ebd8-4d05-9a87-ee2c8473ecf1_terseLabel_en-US" xlink:label="lab_ameh_NetworkMedicalManagementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NMM</link:label>
    <link:label id="lab_ameh_NetworkMedicalManagementMember_label_en-US" xlink:label="lab_ameh_NetworkMedicalManagementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Medical Management [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember" xlink:href="ameh-20220331.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NetworkMedicalManagementMember" xlink:to="lab_ameh_NetworkMedicalManagementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_2a7ac6a5-4fb7-41e4-9a72-841659ffe72b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_142fb233-df81-422b-a33c-b46bbae20cb9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_bc11f31b-5438-430e-bc93-08517e98b807_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation associated with finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7fdd36af-d4b3-428a-a6dc-e1f6f9741675_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_b43e96f5-6979-4cc3-9234-c1463cd1b4eb_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ArroyoVistaMember_9af7a7e5-716e-437c-9999-871694c55574_terseLabel_en-US" xlink:label="lab_ameh_ArroyoVistaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arroyo Vista</link:label>
    <link:label id="lab_ameh_ArroyoVistaMember_label_en-US" xlink:label="lab_ameh_ArroyoVistaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arroyo Vista [Member]</link:label>
    <link:label id="lab_ameh_ArroyoVistaMember_documentation_en-US" xlink:label="lab_ameh_ArroyoVistaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arroyo Vista</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ArroyoVistaMember" xlink:href="ameh-20220331.xsd#ameh_ArroyoVistaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ArroyoVistaMember" xlink:to="lab_ameh_ArroyoVistaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_18bdd683-a13e-420c-a081-137b77c215b2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3a96bf1e-0b42-43c3-971e-9ac5824eee8c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities_ea82b384-b130-4cb7-bf73-88150eaef4cd_negatedLabel_en-US" xlink:label="lab_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss (gain) from investment in equity securities</link:label>
    <link:label id="lab_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities_label_en-US" xlink:label="lab_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (Gain) Loss from Investment in Equity Securities</link:label>
    <link:label id="lab_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities_documentation_en-US" xlink:label="lab_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (Gain) Loss from Investment in Equity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities" xlink:href="ameh-20220331.xsd#ameh_UnrealizedGainLossFromInvestmentInEquitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities" xlink:to="lab_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_613789c1-efc7-4c28-b8bf-5b6b49cd9010_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_7ec9f0d7-183e-4f2f-8af1-6ca5999a60b1_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance cost</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_4ca23ac7-23af-41d6-bb97-c5142a780cb3_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_fc7ab25a-683e-49b9-8453-7d88342484f2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WarrantExercisePriceRangeOneMember_365064c6-5bac-4357-9237-e7a14670ed76_verboseLabel_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range One</link:label>
    <link:label id="lab_ameh_WarrantExercisePriceRangeOneMember_label_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeOneMember" xlink:href="ameh-20220331.xsd#ameh_WarrantExercisePriceRangeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantExercisePriceRangeOneMember" xlink:to="lab_ameh_WarrantExercisePriceRangeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_531a28bf-5611-4b9c-8585-ce25029593a1_verboseLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentsForMedicalCareCostsAbstract_ed012f15-ca12-4427-814d-2517a291561d_terseLabel_en-US" xlink:label="lab_ameh_PaymentsForMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for medical care costs related to claims incurred:</link:label>
    <link:label id="lab_ameh_PaymentsForMedicalCareCostsAbstract_label_en-US" xlink:label="lab_ameh_PaymentsForMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Medical Care Costs [Abstract]</link:label>
    <link:label id="lab_ameh_PaymentsForMedicalCareCostsAbstract_documentation_en-US" xlink:label="lab_ameh_PaymentsForMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Medical Care Costs [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsForMedicalCareCostsAbstract" xlink:href="ameh-20220331.xsd#ameh_PaymentsForMedicalCareCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentsForMedicalCareCostsAbstract" xlink:to="lab_ameh_PaymentsForMedicalCareCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_b88ac64a-2315-4a92-9655-dae342348a46_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated leverage ratio, annual decrease</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Incremental Change</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Incremental Change</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:href="ameh-20220331.xsd#ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:to="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_bad80e63-f05f-4324-ba12-8f10a572f5d1_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities (VIEs)</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_4a1632ba-132d-49e1-b4b1-b10da1d61f85_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_388f34df-bb3d-4990-8550-2e58913f8f59_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EarningsPerShareTable_51c7edf6-824f-4900-ac35-3ce388140a07_terseLabel_en-US" xlink:label="lab_ameh_EarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Table]</link:label>
    <link:label id="lab_ameh_EarningsPerShareTable_label_en-US" xlink:label="lab_ameh_EarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Table]</link:label>
    <link:label id="lab_ameh_EarningsPerShareTable_documentation_en-US" xlink:label="lab_ameh_EarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareTable" xlink:href="ameh-20220331.xsd#ameh_EarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EarningsPerShareTable" xlink:to="lab_ameh_EarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_1bc14e05-3514-4f10-9dcc-da1d2659ad02_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_1ea00b23-7cc0-4bd5-8d79-b4814de69a55_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR)</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_bee8c972-01a4-401d-a6d5-622485e76251_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_563f8f35-d403-4160-b92e-e8198b298590_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical liabilities, beginning of period</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_19b91a09-ad5b-4b8d-945f-d2b0bd9ecd34_periodEndLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical liabilities, end of period</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_b4096e20-b9ab-4052-8c72-60aeb3344a81_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_86a92c64-7f08-4ef2-8113-8cedc9624ff9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_2dc20b8b-f3f3-4d44-8364-9c5d77e9a0a1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6eda5534-4e4c-40c2-a903-0a344a63c20d_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares of common stock outstanding &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1703e98d-16e4-4a19-b504-a65ac38b2046_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares of common stock outstanding &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_4fcf7d02-ac58-4e71-b561-e73d24d7389e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_461d1339-aa7b-4d6f-8dca-b4d72fb23160_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_75612708-24ad-47a1-bae7-9fabcc6c71d3_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2f7b5bcc-fd78-44dc-8edd-11cc8f438770_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Transactions Under Stock Option Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_054466fe-17b1-4913-8e4a-7f925866b31e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_bd83d39b-4571-4c48-af96-681a35a3576c_terseLabel_en-US" xlink:label="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, termination period, if applicable</link:label>
    <link:label id="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_label_en-US" xlink:label="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Termination Period, If Applicable</link:label>
    <link:label id="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_documentation_en-US" xlink:label="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Termination Period, If Applicable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:href="ameh-20220331.xsd#ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:to="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_67332021-01ad-4160-bc9d-4c7b74fe9e1d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total medical care costs</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Pacific6EnterprisesMember_471fe17b-9acd-4dca-8f5d-7dcef9ae5e92_terseLabel_en-US" xlink:label="lab_ameh_Pacific6EnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific6 Enterprises</link:label>
    <link:label id="lab_ameh_Pacific6EnterprisesMember_label_en-US" xlink:label="lab_ameh_Pacific6EnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific6 Enterprises [Member]</link:label>
    <link:label id="lab_ameh_Pacific6EnterprisesMember_documentation_en-US" xlink:label="lab_ameh_Pacific6EnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific6 Enterprises [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Pacific6EnterprisesMember" xlink:href="ameh-20220331.xsd#ameh_Pacific6EnterprisesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Pacific6EnterprisesMember" xlink:to="lab_ameh_Pacific6EnterprisesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_a05da863-aade-4f44-bbfb-1b3039683b65_terseLabel_en-US" xlink:label="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest purchase obligation, noncurrent</link:label>
    <link:label id="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_label_en-US" xlink:label="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Equity Interest Purchase Obligation, Noncurrent</link:label>
    <link:label id="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_documentation_en-US" xlink:label="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Equity Interest Purchase Obligation, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" xlink:href="ameh-20220331.xsd#ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" xlink:to="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_395aa9e1-cb22-4c5a-8089-f772cd367761_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_1cd8bac9-65ba-4be3-a2fe-74eefd5074c6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_a6ca6144-32e4-4337-8e0c-781b37e49359_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_5283c778-2c3f-4caa-98d2-a8aea13e4502_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_71dbc9b3-d936-4f10-b4dd-242eb3e97dc9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_bbc0c35f-344c-4003-afc1-5a158599268f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_42f94249-8ab9-4ace-b736-be49bf46e5d1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_74354a68-d5d5-465f-994f-fa930d570506_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Line of Credit Arrangements, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:to="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1e76c0af-b28b-42b6-b5a6-66da8dbc5bd2_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_8ba32084-9be4-4b5a-aeb3-41213e57d852_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_4a825f1a-6c78-4eb2-b1a6-6728f884f27f_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_be1e9df9-0c5e-44ba-ab0a-dc615bb061c7_verboseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeiture rate</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the forfeiture rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:href="ameh-20220331.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9326f95c-7e49-439d-8b36-62f46fddec59_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_ebb0d39e-4b72-40dc-884e-6c3e182683f8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_e1d994be-0379-488f-b22c-7333bb25e947_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableRelatedPartiesNoncurrent_57f6bb2d-1d0f-41ce-a95b-c7561494fc7a_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableRelatedPartiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans receivable &#8211; related party</link:label>
    <link:label id="lab_us-gaap_NotesReceivableRelatedPartiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_NotesReceivableRelatedPartiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable, Related Parties, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent" xlink:to="lab_us-gaap_NotesReceivableRelatedPartiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_6fe4636d-1454-42bf-9e36-b67d46ce70d9_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2da6fc64-696f-4fe0-9a88-c48ae8b30fe0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Unamortized financing costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_88907df0-b5b5-4cb0-9c01-c853446d3749_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized financing costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableGross_edaff9e0-2c2c-4cb8-aece-29107d0e4496_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note receivable, amount</link:label>
    <link:label id="lab_us-gaap_NotesReceivableGross_label_en-US" xlink:label="lab_us-gaap_NotesReceivableGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableGross" xlink:to="lab_us-gaap_NotesReceivableGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_71297019-855f-4f7d-b55b-6218b0fd76ab_verboseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for exercise of options and warrants (in shares)</link:label>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_label_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during the period shares of exercise of option and warrants</link:label>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">It represents number of share issued exercise of option and warrants during the period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:href="ameh-20220331.xsd#ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:to="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_4b63378b-896c-4df2-9d71-0ee03d0ace16_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 (excluding the three months ended March&#160;31, 2022)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_cd047a7d-a25c-49bb-81d5-b76810ce6c50_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_449abf06-1143-41bb-aaf9-00696315ce6f_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total paid</link:label>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:to="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fbafefb0-880a-4b3f-b51c-b59183403fe1_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1_652af452-e163-4d9b-885b-bda1a439a362_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease option to extend (up to)</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:to="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_a2dae84a-2618-42e0-b52a-da239597b9b1_verboseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:href="ameh-20220331.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_c8fbbaf6-d8fd-4f50-97d2-9b25a1c02e10_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MedicalCareCostsAbstract_787e9fab-b975-4ac2-a830-b87b025b62e9_terseLabel_en-US" xlink:label="lab_ameh_MedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of medical care costs related to claims incurred:</link:label>
    <link:label id="lab_ameh_MedicalCareCostsAbstract_label_en-US" xlink:label="lab_ameh_MedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Care Costs [Abstract]</link:label>
    <link:label id="lab_ameh_MedicalCareCostsAbstract_documentation_en-US" xlink:label="lab_ameh_MedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Care Costs [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalCareCostsAbstract" xlink:href="ameh-20220331.xsd#ameh_MedicalCareCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicalCareCostsAbstract" xlink:to="lab_ameh_MedicalCareCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_6dd1635a-147d-49bf-a4c0-2dc39d4779a7_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_56a90fac-7bd5-44e4-baee-a6324643717b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_95be2f2d-87ed-4a47-8246-af93026f21e4_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_59df17b6-7dad-4e60-9f6c-07f1256265bc_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_3cf28850-0243-4368-9a01-af710bcbe3b3_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_5e6a60cd-3e3d-4a7a-bd0e-7300968c223b_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AccessPrimaryCareMedicalGroupMember_edd0388a-a3a0-45a1-be80-4fb9d98a841f_terseLabel_en-US" xlink:label="lab_ameh_AccessPrimaryCareMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Access Primary Care Medical Group</link:label>
    <link:label id="lab_ameh_AccessPrimaryCareMedicalGroupMember_label_en-US" xlink:label="lab_ameh_AccessPrimaryCareMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Access Primary Care Medical Group [Member]</link:label>
    <link:label id="lab_ameh_AccessPrimaryCareMedicalGroupMember_documentation_en-US" xlink:label="lab_ameh_AccessPrimaryCareMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Access Primary Care Medical Group</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccessPrimaryCareMedicalGroupMember" xlink:href="ameh-20220331.xsd#ameh_AccessPrimaryCareMedicalGroupMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccessPrimaryCareMedicalGroupMember" xlink:to="lab_ameh_AccessPrimaryCareMedicalGroupMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_600254cc-fe77-4960-bdc5-a493ee53480c_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_6a895c55-e654-4813-93f3-ba702eaa81db_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of option</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investment, Options Issued, Term Of Option</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Term Of Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:href="ameh-20220331.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_bd09fc08-f01b-4c9e-a723-bb5285b201c1_verboseLabel_en-US" xlink:label="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_label_en-US" xlink:label="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Cash Cash Equivalents And Restricted Cash [Abstract]</link:label>
    <link:label id="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_documentation_en-US" xlink:label="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:href="ameh-20220331.xsd#ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_95662823-d8e8-4936-b96e-e491efa06606_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_9c4793b8-19a4-4fb9-b8e1-056bdb1e6ece_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Change in Carrying Value of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9794236f-77a1-4bbd-ba80-f60e23b8d6b6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentsRollForward_a8f41336-4fec-42f9-add0-1f8ff422b3eb_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Roll Forward]</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsRollForward_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Roll Forward]</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsRollForward_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsRollForward" xlink:href="ameh-20220331.xsd#ameh_EquityMethodInvestmentsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward" xlink:to="lab_ameh_EquityMethodInvestmentsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_681ff967-970e-4278-816b-d31a35b7bc50_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_01c20c9d-5528-416d-af03-9e622b8d517f_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related-Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_10b5ce33-cabc-4139-8e12-2ed25e80cc92_terseLabel_en-US" xlink:label="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_label_en-US" xlink:label="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity</link:label>
    <link:label id="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_documentation_en-US" xlink:label="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:href="ameh-20220331.xsd#ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:to="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_cba35a83-dea6-4e6c-b820-e6d24d353c56_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of stock options and warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CreditAgreementMember_2645633f-2bb9-4bf8-8e0f-68d63bb85299_terseLabel_en-US" xlink:label="lab_ameh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement</link:label>
    <link:label id="lab_ameh_CreditAgreementMember_label_en-US" xlink:label="lab_ameh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:label id="lab_ameh_CreditAgreementMember_documentation_en-US" xlink:label="lab_ameh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CreditAgreementMember" xlink:href="ameh-20220331.xsd#ameh_CreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CreditAgreementMember" xlink:to="lab_ameh_CreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_ee7262ac-d24c-443f-86b0-ec3b6f273dc8_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_1d656fb5-70c1-4fa4-839a-9f41db33ad63_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_366ccb6a-dc3e-4e77-ba13-85b0d8936f04_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_ae9f5d8c-0df7-4394-ba27-7a47009ccdcf_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade names/trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c563d633-89e0-4b35-bd14-025db3bef7f7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_f1bc6cdc-65dc-4632-8142-de70ed708521_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Apollo Medical Holdings, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_92f3458d-ed6a-4aed-be0f-b29fdc45c0d1_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_5c28847e-a781-48eb-bbf5-55e98f2a9bd8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_24186f2a-88b2-49ed-adeb-72389946cb44_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f7c68946-aa14-43c1-a992-29226ccfc5a8_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_bdd1d10b-1288-4de6-82fd-c6c571ee7181_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_c688820d-a730-4a2c-b6ae-b13218dd34e8_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_efaebdf1-fbf4-4e6c-aead-c330b39f418b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Commitments of Credit Facility</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_1de846b5-eb49-4ba2-9e28-a4b869af5285_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reportable Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_4185cd99-c560-44c9-af0c-8db35d8d08ea_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightExercisable_13f39128-8189-44e3-943e-38a243e38086_terseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightExercisable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Exercisable (in shares)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightExercisable_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightExercisable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Exercisable</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightExercisable_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightExercisable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightExercisable" xlink:href="ameh-20220331.xsd#ameh_ClassOfWarrantOrRightExercisable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightExercisable" xlink:to="lab_ameh_ClassOfWarrantOrRightExercisable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_86803003-cf85-4d58-861f-eae3ddf77570_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_0075b712-29ff-4497-a605-8d049a4d7036_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_3df9889d-7d74-4540-acad-7cf90f523b6a_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in privately held entities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI and without Readily Determinable Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:to="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_449f880e-3d10-4bd9-bd2e-558b30d17996_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_6494d450-371f-4de4-a092-0421eb978957_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockAwardsAndUnitsMember_17160012-0acc-42a6-8743-f7002fa78ae3_terseLabel_en-US" xlink:label="lab_ameh_StockAwardsAndUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards</link:label>
    <link:label id="lab_ameh_StockAwardsAndUnitsMember_label_en-US" xlink:label="lab_ameh_StockAwardsAndUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Awards And Units [Member]</link:label>
    <link:label id="lab_ameh_StockAwardsAndUnitsMember_documentation_en-US" xlink:label="lab_ameh_StockAwardsAndUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Awards And Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockAwardsAndUnitsMember" xlink:href="ameh-20220331.xsd#ameh_StockAwardsAndUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockAwardsAndUnitsMember" xlink:to="lab_ameh_StockAwardsAndUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_b00ddb72-8225-4775-b8e0-fbea364828bd_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 (excluding the three months ended March 31, 2022)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember_4d0d4eb7-4ff5-48af-ba68-2298c2586d8f_terseLabel_en-US" xlink:label="lab_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orma Health, Inc., and Provider Growth Solutions LLC</link:label>
    <link:label id="lab_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember_label_en-US" xlink:label="lab_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orma Health, Inc., and Provider Growth Solutions LLC [Member]</link:label>
    <link:label id="lab_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember_documentation_en-US" xlink:label="lab_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orma Health, Inc., and Provider Growth Solutions LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember" xlink:href="ameh-20220331.xsd#ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember" xlink:to="lab_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentsContribution_bd7c4ee3-ac08-46ec-92c2-3fe4a51d63a5_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsContribution_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Contribution</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsContribution_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsContribution" xlink:href="ameh-20220331.xsd#ameh_EquityMethodInvestmentsContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentsContribution" xlink:to="lab_ameh_EquityMethodInvestmentsContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1f0d42a0-dc93-4e8d-97cc-dd2f0b977cd0_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApolloMedicalHoldingsIncMember_8ea5f567-640e-40fc-8e13-38ebaadcc2ad_terseLabel_en-US" xlink:label="lab_ameh_ApolloMedicalHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apollo Medical Holdings, Inc</link:label>
    <link:label id="lab_ameh_ApolloMedicalHoldingsIncMember_label_en-US" xlink:label="lab_ameh_ApolloMedicalHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apollo Medical Holdings, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloMedicalHoldingsIncMember" xlink:href="ameh-20220331.xsd#ameh_ApolloMedicalHoldingsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApolloMedicalHoldingsIncMember" xlink:to="lab_ameh_ApolloMedicalHoldingsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DmgMember_4aba04e8-6b3a-4aef-8cb5-a861d9f7222d_terseLabel_en-US" xlink:label="lab_ameh_DmgMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DMG</link:label>
    <link:label id="lab_ameh_DmgMember_label_en-US" xlink:label="lab_ameh_DmgMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DMG [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember" xlink:href="ameh-20220331.xsd#ameh_DmgMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DmgMember" xlink:to="lab_ameh_DmgMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_bf7021bf-8381-4590-bbed-915e0e1b23e0_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual agent fee</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_3fac7597-6d20-4965-aedf-3d7d98b0d572_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_055deb7b-b6fe-439c-8d01-dc6e17168624_verboseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrent" xlink:to="lab_us-gaap_DividendsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_970384e4-ac71-4ef6-b2c8-47537218eef6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, other than temporary impairment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Other than Temporary Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:to="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c9ef3337-3e7f-4596-940f-0a77a46a9bc5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_d2122e71-c27b-44e3-a813-f7f2f97b613a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Required annual facility fee</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_ed562dee-93dd-4787-882c-b065c6332a85_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_b9e0f8ac-ede3-4668-90b5-15a560168d29_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Membership interests acquired (in dollars per share)</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:href="ameh-20220331.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentsToAcquireCommonStockAndWarrants_8f35a50f-62cf-4dfb-8570-fd2b191f596a_terseLabel_en-US" xlink:label="lab_ameh_PaymentsToAcquireCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire common stock and warrants</link:label>
    <link:label id="lab_ameh_PaymentsToAcquireCommonStockAndWarrants_label_en-US" xlink:label="lab_ameh_PaymentsToAcquireCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Common Stock And Warrants</link:label>
    <link:label id="lab_ameh_PaymentsToAcquireCommonStockAndWarrants_documentation_en-US" xlink:label="lab_ameh_PaymentsToAcquireCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Common Stock And Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireCommonStockAndWarrants" xlink:href="ameh-20220331.xsd#ameh_PaymentsToAcquireCommonStockAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentsToAcquireCommonStockAndWarrants" xlink:to="lab_ameh_PaymentsToAcquireCommonStockAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_0da4d0bc-1ddd-4c9f-9db8-f93a32810f9e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_3d32655d-2136-4d98-86f2-f5d77e458481_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_caf9a77a-0875-4922-bf74-8df16bc77534_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_13a1f1c6-88e6-4c4b-843e-ca5292e0c704_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_b56250d6-5643-4858-8dfe-5e20867e4672_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_329c0a7d-0a59-481c-8400-0aeffcd02e8b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_aaf60d36-e682-4087-bb43-d64f1d11f4fd_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_148d603f-5bf0-4aa4-b268-eec2b80afe5d_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed asset obtained in exchange for finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b78813b3-d964-4ae3-bd20-3ee2346e8a95_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_b8ffb1b1-2019-4bb0-a0e7-51a1a5a3079c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cb62829a-27d7-41bb-9b31-c4eb28b87202_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1824155b-a00e-4bcb-9708-83c702553512_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_daff846c-33d1-46e8-9224-2f1fb7df2554_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_277e69a7-8311-44ce-9304-39e962b18098_terseLabel_en-US" xlink:label="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]</link:label>
    <link:label id="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:to="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MediPortalLLCMember_0d3f836c-0f67-449d-8001-874b707aa1d5_terseLabel_en-US" xlink:label="lab_ameh_MediPortalLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MediPortal LLC</link:label>
    <link:label id="lab_ameh_MediPortalLLCMember_label_en-US" xlink:label="lab_ameh_MediPortalLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MediPortal LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MediPortalLLCMember" xlink:href="ameh-20220331.xsd#ameh_MediPortalLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MediPortalLLCMember" xlink:to="lab_ameh_MediPortalLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_90806ee2-bbef-4396-b078-6d279f1c629b_terseLabel_en-US" xlink:label="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest purchase obligation, period to purchase</link:label>
    <link:label id="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_label_en-US" xlink:label="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Equity Interest Purchase Obligation, Period to Purchase</link:label>
    <link:label id="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_documentation_en-US" xlink:label="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Equity Interest Purchase Obligation, Period to Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" xlink:href="ameh-20220331.xsd#ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" xlink:to="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable_6b0253e7-977e-4bac-ab9f-fbb37f989461_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_cca013af-0364-46ea-8a9a-cbd2bda92cb4_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_fa30dead-1e9d-426f-b6a3-275fd8e86663_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c2fbdc26-8d67-4f6d-83b6-8422f0c59ba1_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_efadafbc-178f-42d1-9a0d-27b9e17eb296_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants expired/forfeited (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Forfeited In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price per share of warrants or rights forfeited during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:href="ameh-20220331.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:to="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dadb3879-016d-4cf3-9ce6-ab516cb1be51_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_bca52123-1dfe-4778-965f-ebf66a86b6c7_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants expired/forfeited</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Forfeitures In Period, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of warrants or rights forfeited in period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:href="ameh-20220331.xsd#ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:to="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ManagementContractsMember_91c5b44c-fcf9-4b39-a136-a1c03fba0617_verboseLabel_en-US" xlink:label="lab_ameh_ManagementContractsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management contracts</link:label>
    <link:label id="lab_ameh_ManagementContractsMember_label_en-US" xlink:label="lab_ameh_ManagementContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Contracts [Member]</link:label>
    <link:label id="lab_ameh_ManagementContractsMember_documentation_en-US" xlink:label="lab_ameh_ManagementContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ManagementContractsMember" xlink:href="ameh-20220331.xsd#ameh_ManagementContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ManagementContractsMember" xlink:to="lab_ameh_ManagementContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_32ad49b4-f36f-4635-be9e-82534a38b05c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_3878bf70-77b7-447e-8e1e-831323e5de80_negatedLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior periods</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LasalleMedicalAssociatesIpaMember_0f8bc045-f1c5-4cb3-a962-0bbcc71cd0e4_terseLabel_en-US" xlink:label="lab_ameh_LasalleMedicalAssociatesIpaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LaSalle Medical Associates &#8211; IPA Line of Business</link:label>
    <link:label id="lab_ameh_LasalleMedicalAssociatesIpaMember_a8443874-7e31-4c3e-8c1d-aa7688d92004_verboseLabel_en-US" xlink:label="lab_ameh_LasalleMedicalAssociatesIpaMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LaSalle Medical Associates</link:label>
    <link:label id="lab_ameh_LasalleMedicalAssociatesIpaMember_label_en-US" xlink:label="lab_ameh_LasalleMedicalAssociatesIpaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LaSalle Medical Associates IPA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember" xlink:href="ameh-20220331.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LasalleMedicalAssociatesIpaMember" xlink:to="lab_ameh_LasalleMedicalAssociatesIpaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrimeRateMember_7d341655-8709-4727-88c3-3b99ff27a319_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_2fc4c538-a26e-47db-809c-f5ba3990bc20_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6f3a1ab2-75dd-4378-a89a-0e5f609600ef_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0d0c2e0f-3c29-4dd1-a8d9-19edf5b7d122_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_HSMSOMember_9fb34dd6-4dac-49f1-b081-aaa53f564d58_verboseLabel_en-US" xlink:label="lab_ameh_HSMSOMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HSMSO</link:label>
    <link:label id="lab_ameh_HSMSOMember_label_en-US" xlink:label="lab_ameh_HSMSOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HSMSO [Member]</link:label>
    <link:label id="lab_ameh_HSMSOMember_documentation_en-US" xlink:label="lab_ameh_HSMSOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">xxx_HSMSO Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HSMSOMember" xlink:href="ameh-20220331.xsd#ameh_HSMSOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_HSMSOMember" xlink:to="lab_ameh_HSMSOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_c45a4c3e-8140-4218-806f-839b6de2167e_verboseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregated Revenue by Each Payor Type</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_004352fb-d8a6-4a5f-9b10-cda2a95d44da_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on interest rate swaps</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesTable_94c56802-3848-4899-8438-cceca892920c_terseLabel_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:href="ameh-20220331.xsd#ameh_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AurionMember_0ddba496-6293-4be9-80f0-5b7e6d12ccba_verboseLabel_en-US" xlink:label="lab_ameh_AurionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aurion</link:label>
    <link:label id="lab_ameh_AurionMember_label_en-US" xlink:label="lab_ameh_AurionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aurion [Member]</link:label>
    <link:label id="lab_ameh_AurionMember_documentation_en-US" xlink:label="lab_ameh_AurionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">xxx_Aurion Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AurionMember" xlink:href="ameh-20220331.xsd#ameh_AurionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AurionMember" xlink:to="lab_ameh_AurionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_aeaf51a2-fe3d-46ec-ab5f-8450cf205d6e_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfFamilyPracticeClinics_11a7a8fb-2fc4-4c19-be6f-12374343db3b_terseLabel_en-US" xlink:label="lab_ameh_NumberOfFamilyPracticeClinics" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of family practice clinics</link:label>
    <link:label id="lab_ameh_NumberOfFamilyPracticeClinics_label_en-US" xlink:label="lab_ameh_NumberOfFamilyPracticeClinics" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Family Practice Clinics</link:label>
    <link:label id="lab_ameh_NumberOfFamilyPracticeClinics_documentation_en-US" xlink:label="lab_ameh_NumberOfFamilyPracticeClinics" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Family Practice Clinics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFamilyPracticeClinics" xlink:href="ameh-20220331.xsd#ameh_NumberOfFamilyPracticeClinics"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfFamilyPracticeClinics" xlink:to="lab_ameh_NumberOfFamilyPracticeClinics" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_d8f151b3-9b53-49c4-864e-7923629e099d_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value, Ownership Percentage</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:href="ameh-20220331.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_ae963afd-851c-42eb-bd20-8e0161cf185b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_831da897-778b-4dc8-b491-619547512726_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_df802616-f7a1-4255-8bc1-1666da089a85_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_ae46f493-d267-4b39-86eb-2ecd0f16ae29_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets recorded under finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_509e3d2c-44f9-4292-ac1d-b8d7df320988_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MezzanineEquityAbstract_cf4d68f9-3afd-489a-8f14-7cecdac8e78a_verboseLabel_en-US" xlink:label="lab_ameh_MezzanineEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine equity</link:label>
    <link:label id="lab_ameh_MezzanineEquityAbstract_label_en-US" xlink:label="lab_ameh_MezzanineEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MEZZANINE EQUITY [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineEquityAbstract" xlink:href="ameh-20220331.xsd#ameh_MezzanineEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MezzanineEquityAbstract" xlink:to="lab_ameh_MezzanineEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FiduciaryAccountsPayableCurrent_25e6a56b-732e-4c12-9d4e-bdfb9051407a_terseLabel_en-US" xlink:label="lab_ameh_FiduciaryAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary accounts payable</link:label>
    <link:label id="lab_ameh_FiduciaryAccountsPayableCurrent_label_en-US" xlink:label="lab_ameh_FiduciaryAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary Accounts Payable Current</link:label>
    <link:label id="lab_ameh_FiduciaryAccountsPayableCurrent_documentation_en-US" xlink:label="lab_ameh_FiduciaryAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent" xlink:href="ameh-20220331.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FiduciaryAccountsPayableCurrent" xlink:to="lab_ameh_FiduciaryAccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealEstateLoanMember_6666eda0-2816-40e7-a048-7eb3f7ec39a0_terseLabel_en-US" xlink:label="lab_us-gaap_RealEstateLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Loan</link:label>
    <link:label id="lab_us-gaap_RealEstateLoanMember_label_en-US" xlink:label="lab_us-gaap_RealEstateLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateLoanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealEstateLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealEstateLoanMember" xlink:to="lab_us-gaap_RealEstateLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MaverickMedicalGroupIncMember_102edd8a-0cce-43ee-8444-07df38f6af98_terseLabel_en-US" xlink:label="lab_ameh_MaverickMedicalGroupIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maverick Medical Group, Inc</link:label>
    <link:label id="lab_ameh_MaverickMedicalGroupIncMember_label_en-US" xlink:label="lab_ameh_MaverickMedicalGroupIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maverick Medical Group, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MaverickMedicalGroupIncMember" xlink:href="ameh-20220331.xsd#ameh_MaverickMedicalGroupIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MaverickMedicalGroupIncMember" xlink:to="lab_ameh_MaverickMedicalGroupIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_4b6b2b6c-4aa4-40f6-94dd-ff4f72b64b03_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities, mezzanine equity, and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_ee7e6d6e-d09f-4da7-8905-8c053333eb4a_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum consolidated interest coverage ratio (not less than)</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:href="ameh-20220331.xsd#ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:to="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_63277727-0cfd-452c-8e53-f38c72ad0934_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorCMember_d61ad4cc-396d-4a50-a044-6ed9173f219c_terseLabel_en-US" xlink:label="lab_ameh_PayorCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor C</link:label>
    <link:label id="lab_ameh_PayorCMember_label_en-US" xlink:label="lab_ameh_PayorCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor C [Member]</link:label>
    <link:label id="lab_ameh_PayorCMember_documentation_en-US" xlink:label="lab_ameh_PayorCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor C [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorCMember" xlink:href="ameh-20220331.xsd#ameh_PayorCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorCMember" xlink:to="lab_ameh_PayorCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_3b55ab06-747a-4eb9-b89e-7edb702cadd4_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_81ae9d60-9add-4651-b14e-03c44bea29ad_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AccountsReceivableAndNetRevenueLineItems_5fe8aee6-0917-4d1e-ad4f-0d1da51a668c_terseLabel_en-US" xlink:label="lab_ameh_AccountsReceivableAndNetRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable And Net Revenue [Line Items]</link:label>
    <link:label id="lab_ameh_AccountsReceivableAndNetRevenueLineItems_label_en-US" xlink:label="lab_ameh_AccountsReceivableAndNetRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable And Net Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueLineItems" xlink:href="ameh-20220331.xsd#ameh_AccountsReceivableAndNetRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueLineItems" xlink:to="lab_ameh_AccountsReceivableAndNetRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_30b1b6b7-a6c1-45a0-914b-571c064fb867_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_1385362f-269f-4836-aad0-56d37b66c3bb_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_2939d6e8-e28e-4ae4-ae8c-040247131855_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_856ea57d-9d9c-4dee-a908-056b162aea7f_periodStartLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, beginning balance</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_f58b69bc-2864-4583-8250-028b2d89ff22_periodEndLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, ending balance</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of warrants or rights outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:href="ameh-20220331.xsd#ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:to="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_aaee4c5f-d20e-4f94-8c0c-85fab55ad3a1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_34dcfe2c-bf57-4867-8702-608b14975e50_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ProceedsFromSaleOfNoncontrollingInterest_e9b7bedc-72fb-4f0f-b5e7-735815c5eb07_terseLabel_en-US" xlink:label="lab_ameh_ProceedsFromSaleOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of non-controlling interest</link:label>
    <link:label id="lab_ameh_ProceedsFromSaleOfNoncontrollingInterest_label_en-US" xlink:label="lab_ameh_ProceedsFromSaleOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Noncontrolling Interest</link:label>
    <link:label id="lab_ameh_ProceedsFromSaleOfNoncontrollingInterest_documentation_en-US" xlink:label="lab_ameh_ProceedsFromSaleOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ProceedsFromSaleOfNoncontrollingInterest" xlink:href="ameh-20220331.xsd#ameh_ProceedsFromSaleOfNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ProceedsFromSaleOfNoncontrollingInterest" xlink:to="lab_ameh_ProceedsFromSaleOfNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance_0f0f0284-19af-470c-913c-4de64d68b902_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent on performance (shares)</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Contingent on Performance</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Contingent on Performance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance" xlink:href="ameh-20220331.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_eceb8b91-1f0e-4ac7-8979-67d5ef49a574_terseLabel_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standby Letters of Credit</link:label>
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_label_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standby Letters of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandbyLettersOfCreditMember" xlink:to="lab_us-gaap_StandbyLettersOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_71a2de16-a428-478d-82aa-a5817d8e1424_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_477f0a9e-b683-4d5a-9065-d035f08d5842_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AHMCMember_5d5ef24c-0806-4fd6-b5f9-4fa0a1d60776_terseLabel_en-US" xlink:label="lab_ameh_AHMCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHMC</link:label>
    <link:label id="lab_ameh_AHMCMember_229ee278-c38e-479e-b678-108d66447ee1_verboseLabel_en-US" xlink:label="lab_ameh_AHMCMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHMC</link:label>
    <link:label id="lab_ameh_AHMCMember_label_en-US" xlink:label="lab_ameh_AHMCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHMC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember" xlink:href="ameh-20220331.xsd#ameh_AHMCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AHMCMember" xlink:to="lab_ameh_AHMCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_dc152acb-0ded-458f-877d-17ce0f4a3748_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EmployeesMember_04e89b7a-d060-44b5-bdef-49c90fc18953_terseLabel_en-US" xlink:label="lab_ameh_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees</link:label>
    <link:label id="lab_ameh_EmployeesMember_label_en-US" xlink:label="lab_ameh_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees [Member]</link:label>
    <link:label id="lab_ameh_EmployeesMember_documentation_en-US" xlink:label="lab_ameh_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EmployeesMember" xlink:href="ameh-20220331.xsd#ameh_EmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EmployeesMember" xlink:to="lab_ameh_EmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_5d2bcea9-46bd-4db0-b58c-5a5c52daf253_totalLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_2dc68030-66d4-4ee7-9f8f-82b81c05ee85_verboseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount outstanding</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f47d205b-dbd0-4cd1-805b-6949a8017cf1_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_07a8c107-984e-4b43-a50e-8c3a093ea5fd_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceReceivableTermOfReceivable_20e77718-1380-4397-9367-9420c9cf8d72_terseLabel_en-US" xlink:label="lab_ameh_FinanceReceivableTermOfReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of receivable</link:label>
    <link:label id="lab_ameh_FinanceReceivableTermOfReceivable_label_en-US" xlink:label="lab_ameh_FinanceReceivableTermOfReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Term Of Receivable</link:label>
    <link:label id="lab_ameh_FinanceReceivableTermOfReceivable_documentation_en-US" xlink:label="lab_ameh_FinanceReceivableTermOfReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Term Of Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableTermOfReceivable" xlink:href="ameh-20220331.xsd#ameh_FinanceReceivableTermOfReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceReceivableTermOfReceivable" xlink:to="lab_ameh_FinanceReceivableTermOfReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_5f04e347-bda3-477a-9e40-d53ad41965db_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FreseniusMember_9fdba17b-15ac-4a4b-a37c-490d02303464_terseLabel_en-US" xlink:label="lab_ameh_FreseniusMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fresenius</link:label>
    <link:label id="lab_ameh_FreseniusMember_label_en-US" xlink:label="lab_ameh_FreseniusMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fresenius [Member]</link:label>
    <link:label id="lab_ameh_FreseniusMember_documentation_en-US" xlink:label="lab_ameh_FreseniusMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fresenius</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FreseniusMember" xlink:href="ameh-20220331.xsd#ameh_FreseniusMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FreseniusMember" xlink:to="lab_ameh_FreseniusMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_44976bf0-034c-420d-a98d-f261df010fae_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_a4641da8-5680-428f-9d84-981edac461fd_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for business acquisition, net of cash acquired and shares issued</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_6085544d-d5d1-468e-93b4-48d313c6f1fc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Bank Loans, and Lines of Credit</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_cf7689bb-6a61-496a-89ec-c4af3f5b883a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5b50a8f3-80d6-46df-8fd1-a556d2b378a1_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_bc51a272-83e3-4f45-b623-304eca606529_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_271cf456-8821-4f12-9372-b6a6ce20e796_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Support to Nonconsolidated Legal Entity [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_label_en-US" xlink:label="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Support to Nonconsolidated Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:to="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_25fdd907-fd1f-4b11-af8f-6c4ff6dc1d90_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_16809682-4c25-4052-9193-85c35e923a42_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares purchased by related party</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_6efc6043-bf81-432e-84c5-f6eb296d4d1d_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AlphaCareMedicalGroupInc.Member_d4574074-d276-45e0-9e79-7caed92fe1a2_terseLabel_en-US" xlink:label="lab_ameh_AlphaCareMedicalGroupInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alpha Care Medical Group, Inc.</link:label>
    <link:label id="lab_ameh_AlphaCareMedicalGroupInc.Member_label_en-US" xlink:label="lab_ameh_AlphaCareMedicalGroupInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alpha Care Medical Group, Inc. [Member]</link:label>
    <link:label id="lab_ameh_AlphaCareMedicalGroupInc.Member_documentation_en-US" xlink:label="lab_ameh_AlphaCareMedicalGroupInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alpha Care Medical Group, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member" xlink:href="ameh-20220331.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AlphaCareMedicalGroupInc.Member" xlink:to="lab_ameh_AlphaCareMedicalGroupInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_4b7db089-45c9-418c-9e9b-e776258016d8_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_664f1e67-61a4-400e-9075-768130b10006_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_b6d43fbb-48aa-4701-bbd2-e604118ddbe8_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_ad838c07-3da9-407c-bc55-90aebb46ecbb_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c72c4d02-c9c7-4d1a-b0de-5153923df36b_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_b26a3d32-c9c5-4340-aa74-f45546343055_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 12)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod_81407756-5b40-4012-badc-435cbe483841_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Par Value Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredParValueMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_0597876d-6060-441b-a623-c9142695937d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f399acf7-8fc4-47a9-a6a4-0931a731e5a9_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsCurrent_27bd41a4-a6e4-434e-bb97-f3ac3c66e8f8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash - current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashEquivalentsCurrent" xlink:to="lab_us-gaap_RestrictedCashEquivalentsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_4cbd3f36-bedb-4a3d-8b83-4fc8c4f8c1aa_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related investment balance</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:href="ameh-20220331.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_OneMSOLLCMember_ee45971c-6910-428b-8910-6a56dafc95f8_terseLabel_en-US" xlink:label="lab_ameh_OneMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, LLC &#8211; related party</link:label>
    <link:label id="lab_ameh_OneMSOLLCMember_label_en-US" xlink:label="lab_ameh_OneMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, LLC [Member]</link:label>
    <link:label id="lab_ameh_OneMSOLLCMember_documentation_en-US" xlink:label="lab_ameh_OneMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCMember" xlink:href="ameh-20220331.xsd#ameh_OneMSOLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_OneMSOLLCMember" xlink:to="lab_ameh_OneMSOLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_488e4ac0-c7bb-41c8-977f-9599d7053360_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_f5678105-898f-4348-9a96-3847fc87e603_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Membership interests purchased (in shares)</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:href="ameh-20220331.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets_bc8934e7-bf3f-4ad1-bddf-b3648be4bfd4_verboseLabel_en-US" xlink:label="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets_label_en-US" xlink:label="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Assets</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets_documentation_en-US" xlink:label="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents increase in operating lease assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:href="ameh-20220331.xsd#ameh_IncreaseDecreaseInOperatingLeaseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:to="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_96e0b1ac-76c9-4930-918f-12fac19157f9_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_f96d22e9-db6d-484d-ac62-f2b6ef25b78c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings on loans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_9589da12-9c9d-4374-9bcc-ef206528fd34_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_30d5cf0c-3c1b-4ddd-b479-52dc273f717a_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_6a20f1a3-25ab-4ba4-8b4c-d10a58a556c8_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_878c982e-2145-48a8-9e6d-2871af49bb06_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum_4764c70e-c74b-4254-b128-9cbd7068ee88_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, covenant, leverage ratio, adjusted maximum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Adjusted Maximum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Adjusted Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum" xlink:href="ameh-20220331.xsd#ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum" xlink:to="lab_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_f56f8f0c-5ee0-4ab0-9539-f0237bf70686_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants granted (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Grant In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price per share of warrants or rights granted during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:href="ameh-20220331.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:to="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_ca7cd299-e86c-4b99-92ae-3c5686eeb797_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_0c4d7628-bb94-480c-889e-29296486da39_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LoanReceivableTextBlock_2bdc4d44-b496-461c-a04a-d5f64beaa8b3_verboseLabel_en-US" xlink:label="lab_ameh_LoanReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Receivable and Loan Receivable &#8211; Related Parties</link:label>
    <link:label id="lab_ameh_LoanReceivableTextBlock_label_en-US" xlink:label="lab_ameh_LoanReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Receivable [Text Block]</link:label>
    <link:label id="lab_ameh_LoanReceivableTextBlock_documentation_en-US" xlink:label="lab_ameh_LoanReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LoanReceivableTextBlock" xlink:href="ameh-20220331.xsd#ameh_LoanReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LoanReceivableTextBlock" xlink:to="lab_ameh_LoanReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_250bcb79-36e8-42fa-bacc-cd1a8d83cd6c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_eced5f3a-3ec2-4a9e-a71d-2bff94a32363_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net &#8211; related parties</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_db4f0642-ab03-4064-9fa6-4e9185d1ba55_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net &#8211; related party</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:to="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumenLLCMember_72ac0675-2422-4110-bbbf-2d20402ed30a_terseLabel_en-US" xlink:label="lab_ameh_NumenLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numen LLC</link:label>
    <link:label id="lab_ameh_NumenLLCMember_label_en-US" xlink:label="lab_ameh_NumenLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numen LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumenLLCMember" xlink:href="ameh-20220331.xsd#ameh_NumenLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumenLLCMember" xlink:to="lab_ameh_NumenLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LongTermDebtMaturityAfterYearFour_351a8d88-558c-4b70-a534-786be94db914_terseLabel_en-US" xlink:label="lab_ameh_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026 and thereafter</link:label>
    <link:label id="lab_ameh_LongTermDebtMaturityAfterYearFour_label_en-US" xlink:label="lab_ameh_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, After Year Four</link:label>
    <link:label id="lab_ameh_LongTermDebtMaturityAfterYearFour_documentation_en-US" xlink:label="lab_ameh_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LongTermDebtMaturityAfterYearFour" xlink:href="ameh-20220331.xsd#ameh_LongTermDebtMaturityAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LongTermDebtMaturityAfterYearFour" xlink:to="lab_ameh_LongTermDebtMaturityAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_1290e85c-6e0b-4b2f-9ea5-d31dd3af505c_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CommitmentsAndContingenciesLineItems_be28f723-05db-4f5d-9a24-ec14710b4dea_terseLabel_en-US" xlink:label="lab_ameh_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_ameh_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_ameh_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesLineItems" xlink:href="ameh-20220331.xsd#ameh_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems" xlink:to="lab_ameh_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_2a23bd48-918a-4ff2-b555-6620708264a4_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SCHCMember_99d49a8e-2148-4d15-90bc-f2f35badfad2_terseLabel_en-US" xlink:label="lab_ameh_SCHCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCHC</link:label>
    <link:label id="lab_ameh_SCHCMember_label_en-US" xlink:label="lab_ameh_SCHCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCHC [Member]</link:label>
    <link:label id="lab_ameh_SCHCMember_documentation_en-US" xlink:label="lab_ameh_SCHCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCHC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SCHCMember" xlink:href="ameh-20220331.xsd#ameh_SCHCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SCHCMember" xlink:to="lab_ameh_SCHCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividends_b5502584-4022-41e9-822d-73b3279669ab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LmaMember_2cb6d76d-c7a0-4190-8c0b-f8867f438b72_terseLabel_en-US" xlink:label="lab_ameh_LmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LMA</link:label>
    <link:label id="lab_ameh_LmaMember_label_en-US" xlink:label="lab_ameh_LmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LMA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember" xlink:href="ameh-20220331.xsd#ameh_LmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LmaMember" xlink:to="lab_ameh_LmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToAffiliateCurrentAndNoncurrent_1236fdd2-5e9f-4432-b5ce-6df9cd19e8a0_terseLabel_en-US" xlink:label="lab_us-gaap_DueToAffiliateCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to affiliate</link:label>
    <link:label id="lab_us-gaap_DueToAffiliateCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToAffiliateCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Affiliate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToAffiliateCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToAffiliateCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToAffiliateCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_296fb606-9791-4276-abe2-ee92a02de10c_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock&#160;Outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_6c8771b3-1c81-493b-b39d-be72b52df2e1_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_7f42e53c-21e2-43e1-b4c0-f70d4cf90519_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableRelatedPartiesCurrent_e5b12f0a-589c-4e64-886b-8ebd1f1f6da4_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan receivable &#8211; related party</link:label>
    <link:label id="lab_us-gaap_NotesReceivableRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable, Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:to="lab_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_ebd61983-4ae1-432c-b123-9a9bb741c008_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_697e98f8-96de-419f-9807-6af3a45e585c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3bb845a9-edc1-4600-a083-8dcfd0321796_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_ba5a627b-6727-473c-9ae0-fe6c35d5138c_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_59970754-e1c9-49df-9817-857ecf0fa868_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_658354d8-cf88-48b1-940d-65b360125b85_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4afd8930-34d0-4cd3-8d8b-44ddcaac63b4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_271e4943-aedc-487e-8e93-6020f749d00f_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MedicareMember_a9af2f70-883d-46d9-a3ae-1e444b916de6_terseLabel_en-US" xlink:label="lab_ameh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_ameh_MedicareMember_label_en-US" xlink:label="lab_ameh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_ameh_MedicareMember_documentation_en-US" xlink:label="lab_ameh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh:MedicareMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicareMember" xlink:href="ameh-20220331.xsd#ameh_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicareMember" xlink:to="lab_ameh_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_037f18cd-96c1-4a6e-bfb9-67becab0fa5b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CMSMember_76bddf90-6bbf-4e21-9c86-a892b4b769b5_terseLabel_en-US" xlink:label="lab_ameh_CMSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMS</link:label>
    <link:label id="lab_ameh_CMSMember_label_en-US" xlink:label="lab_ameh_CMSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMS [Member]</link:label>
    <link:label id="lab_ameh_CMSMember_documentation_en-US" xlink:label="lab_ameh_CMSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMS [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CMSMember" xlink:href="ameh-20220331.xsd#ameh_CMSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CMSMember" xlink:to="lab_ameh_CMSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_e4b241f0-fc21-42b9-b16e-b482826d0717_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued in business combination</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9ffe27ce-5998-4da7-88a0-250ce2f03844_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_3a0259cf-befb-4499-9e06-fa3ab60f768b_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Interest Rate at Period End</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_581a01d2-a5b4-47aa-b345-6af59a4b1ab7_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_a67c5480-aeab-4e8c-bedd-4dd76d40a3c1_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityNetIncome_d77931f8-09c5-487a-ab22-466553c274d7_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityNetIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityNetIncome_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityNetIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Net Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityNetIncome" xlink:to="lab_us-gaap_TemporaryEquityNetIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_a78411ce-44bb-4700-a02c-ab989171a60a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4ba2e694-8401-4f2e-b715-69f6782187af_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5a56eff4-7171-441d-aae4-0a620a79dc6f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_3ffa49fa-2caa-42cf-82a7-f63d627fe912_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest in Allied Physicians of California, a Professional Medical Corporation</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_43faa51a-9737-46f5-96ee-fe81ee3e43e4_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, carrying amount, beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_bc4a9825-5d66-466d-86fc-6798ccb12357_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, carrying amount, ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_ecc58473-69cb-40d2-a751-c301707eb144_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AchievaMedInc.Member_27fc43c0-d550-4e01-bd02-50f1e123f6fe_terseLabel_en-US" xlink:label="lab_ameh_AchievaMedInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AchievaMed, Inc.</link:label>
    <link:label id="lab_ameh_AchievaMedInc.Member_label_en-US" xlink:label="lab_ameh_AchievaMedInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AchievaMed, Inc. [Member]</link:label>
    <link:label id="lab_ameh_AchievaMedInc.Member_documentation_en-US" xlink:label="lab_ameh_AchievaMedInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AchievaMed, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AchievaMedInc.Member" xlink:href="ameh-20220331.xsd#ameh_AchievaMedInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AchievaMedInc.Member" xlink:to="lab_ameh_AchievaMedInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_4936c3a2-0e06-41b4-8adb-ea4c88851be8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_62c5addf-44ac-45e2-8f94-e8d071f2f175_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract_9d540535-b8e9-4f5d-8035-11aa0d78bea0_terseLabel_en-US" xlink:label="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term Years [Abstract]</link:label>
    <link:label id="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract_label_en-US" xlink:label="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term Years [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:href="ameh-20220331.xsd#ameh_WeightedaverageremainingcontractualtermyearsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:to="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_e2f00da8-883e-440c-836e-a18bb2a2dd5e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_435c68da-f1cb-4321-b61b-88192a3799b7_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentsToAcquireNonControllingInterest_f0ebc4dd-b4fc-405f-bb3f-368807c5deb0_negatedLabel_en-US" xlink:label="lab_ameh_PaymentsToAcquireNonControllingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of non-controlling interest</link:label>
    <link:label id="lab_ameh_PaymentsToAcquireNonControllingInterest_label_en-US" xlink:label="lab_ameh_PaymentsToAcquireNonControllingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Non-controlling Interest</link:label>
    <link:label id="lab_ameh_PaymentsToAcquireNonControllingInterest_documentation_en-US" xlink:label="lab_ameh_PaymentsToAcquireNonControllingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Non-controlling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireNonControllingInterest" xlink:href="ameh-20220331.xsd#ameh_PaymentsToAcquireNonControllingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentsToAcquireNonControllingInterest" xlink:to="lab_ameh_PaymentsToAcquireNonControllingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_529b0f3c-8ff1-40c5-912f-c52fdd6efdaa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_c65fec8c-6ec9-43b7-9472-dee1411a51cb_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2025005d-ddae-45ba-a081-d64f64071f38_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceReceivableInterestRateStatedPercentage_94234fe5-5b21-4c0c-95cf-aa019dcb0467_terseLabel_en-US" xlink:label="lab_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note receivable, interest rate</link:label>
    <link:label id="lab_ameh_FinanceReceivableInterestRateStatedPercentage_label_en-US" xlink:label="lab_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Interest Rate, Stated Percentage</link:label>
    <link:label id="lab_ameh_FinanceReceivableInterestRateStatedPercentage_documentation_en-US" xlink:label="lab_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:href="ameh-20220331.xsd#ameh_FinanceReceivableInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:to="lab_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_8a60dacc-5716-4db6-be0b-068a30597848_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_6ee842e9-2834-4b56-b4e8-6d7865cdc2d4_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_13cf1271-24ce-43cf-938f-83240ffd131e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_59294f69-93ab-4042-a552-fe90682d47f4_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableMember_ca527c73-452d-48f5-91c8-05d29e4be61b_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Secured Promissory Note</link:label>
    <link:label id="lab_us-gaap_NotesReceivableMember_label_en-US" xlink:label="lab_us-gaap_NotesReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableMember" xlink:to="lab_us-gaap_NotesReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_a8c15b58-50db-42f7-af63-e5e6e912ddbd_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorDMember_580a5b2e-33e6-4c19-bdcd-b048f6c0d779_terseLabel_en-US" xlink:label="lab_ameh_PayorDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor D</link:label>
    <link:label id="lab_ameh_PayorDMember_label_en-US" xlink:label="lab_ameh_PayorDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor D [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorDMember" xlink:href="ameh-20220331.xsd#ameh_PayorDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorDMember" xlink:to="lab_ameh_PayorDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_1388d230-6a63-4335-9968-1ce6d96b3cb7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_dc7e6e39-dc6b-4f01-b7f5-ca67763382db_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_b529c6b1-4dbf-4f3c-9a64-9b5e75afce4b_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_UniversalCareAcquisitionPartnersLlcMember_328239e0-7e0b-4c71-a6c5-046a09386b50_terseLabel_en-US" xlink:label="lab_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Universal Care Acquisition Partners, LLC</link:label>
    <link:label id="lab_ameh_UniversalCareAcquisitionPartnersLlcMember_label_en-US" xlink:label="lab_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Universal Care Acquisition Partners, LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:href="ameh-20220331.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:to="lab_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfFederallyQualifiedHealthPlans_19eeec4e-fc3f-4fb8-965f-8005a6da4783_terseLabel_en-US" xlink:label="lab_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number federally qualified health plans</link:label>
    <link:label id="lab_ameh_NumberOfFederallyQualifiedHealthPlans_label_en-US" xlink:label="lab_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Federally Qualified Health Plans</link:label>
    <link:label id="lab_ameh_NumberOfFederallyQualifiedHealthPlans_documentation_en-US" xlink:label="lab_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Federally Qualified Health Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:href="ameh-20220331.xsd#ameh_NumberOfFederallyQualifiedHealthPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:to="lab_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock_04d8af4f-49d2-477c-af58-8117ac544b9e_verboseLabel_en-US" xlink:label="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Liabilities</link:label>
    <link:label id="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareCostsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Tag6MedicalInvestmentGroupLLCMember_67107e9c-54b8-4f9e-b200-16566e7bf36d_terseLabel_en-US" xlink:label="lab_ameh_Tag6MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-6 Medical Investment Group, LLC</link:label>
    <link:label id="lab_ameh_Tag6MedicalInvestmentGroupLLCMember_label_en-US" xlink:label="lab_ameh_Tag6MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-6 Medical Investment Group, LLC [Member]</link:label>
    <link:label id="lab_ameh_Tag6MedicalInvestmentGroupLLCMember_documentation_en-US" xlink:label="lab_ameh_Tag6MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-6 Medical Investment Group, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag6MedicalInvestmentGroupLLCMember" xlink:href="ameh-20220331.xsd#ameh_Tag6MedicalInvestmentGroupLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Tag6MedicalInvestmentGroupLLCMember" xlink:to="lab_ameh_Tag6MedicalInvestmentGroupLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_c7f699d4-e961-4a7a-990a-7de92af55b07_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_f34d4a71-9e38-4517-a4ca-2269e8faf343_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite lived assets:</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WarrantExercisePriceRangeThreeMember_d41953c8-5779-4ac4-afb9-a660d218362b_verboseLabel_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range Three</link:label>
    <link:label id="lab_ameh_WarrantExercisePriceRangeThreeMember_label_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeThreeMember" xlink:href="ameh-20220331.xsd#ameh_WarrantExercisePriceRangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantExercisePriceRangeThreeMember" xlink:to="lab_ameh_WarrantExercisePriceRangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod_ae58dfd1-a9bf-4ab7-b261-89b8cfd3531a_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Outstanding (in shares)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Issued In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:href="ameh-20220331.xsd#ameh_ClassOfWarrantOrRightIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:to="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_2413dc7b-8ad7-4f9b-a93a-e3f312ab42b1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c0bf86f0-32aa-46e1-b107-1149de2e2d18_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for vesting of restricted stock awards (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eb7f2da2-aa62-4ecd-b2c3-de1c607f57b4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5e3521c3-be25-4139-b820-f94a09c1bff9_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_826e0ba8-f857-4d41-8017-95600e6b86bc_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8d4bbd74-a873-414c-a0c1-a04c426c24b6_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7149585d-3497-49dc-8381-d790de9ecde6_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_83e4164c-55e9-4da6-b97c-3a2c731d9024_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_29a4aa74-b839-4d30-8414-929b1d95a0b0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_57adaf59-5e00-4760-aa48-b9faba32a8ca_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_8a69f446-a489-474c-8b5d-572ede7a01f5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_98562f50-30b7-4762-8d6d-db6c9eaee67a_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_f702472c-f380-4292-8720-bb0f7243921d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_c655faf1-fdd8-4a20-9548-3a4ae9acb904_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_e6776638-dbb1-4338-b723-d28b18d89ccd_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_db0a89bb-b8fc-4e5e-aac5-d54ff0637c02_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_9aec0c88-6fd2-460b-8871-53f579c7da91_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fees Incurred and Revenue Earned from Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_86143554-6a7e-48c4-9c6d-47981623c9b1_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_9d4e1585-e5a6-43df-b959-b5761e79cb29_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Outstanding Warrants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_f8cd2330-62eb-41c7-9d7c-a8ba67a98821_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net &#8211; related parties</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Due from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LeaseWeightedAverageDiscountRateAbstract_7d31dfd5-dfc9-4124-b853-c3105d8a1efa_verboseLabel_en-US" xlink:label="lab_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Discount Rate</link:label>
    <link:label id="lab_ameh_LeaseWeightedAverageDiscountRateAbstract_label_en-US" xlink:label="lab_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Weighted Average Discount Rate [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:href="ameh-20220331.xsd#ameh_LeaseWeightedAverageDiscountRateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:to="lab_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_84d49dca-3828-4785-a433-571cd410226c_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_4420ccd1-5d0f-4ca3-a5ef-050fa8366b37_terseLabel_en-US" xlink:label="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC</link:label>
    <link:label id="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_label_en-US" xlink:label="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC [Member]</link:label>
    <link:label id="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_documentation_en-US" xlink:label="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" xlink:href="ameh-20220331.xsd#ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" xlink:to="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EarningsPerShareLineItems_986537b3-0fee-4bb7-b2c4-644151ce30be_terseLabel_en-US" xlink:label="lab_ameh_EarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_ameh_EarningsPerShareLineItems_label_en-US" xlink:label="lab_ameh_EarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_ameh_EarningsPerShareLineItems_documentation_en-US" xlink:label="lab_ameh_EarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareLineItems" xlink:href="ameh-20220331.xsd#ameh_EarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EarningsPerShareLineItems" xlink:to="lab_ameh_EarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired_b2248edf-4db9-4364-b372-3cf8bcbbb7f0_terseLabel_en-US" xlink:label="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, percentage of shares acquired</link:label>
    <link:label id="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired_label_en-US" xlink:label="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Percentage Of Shares Acquired</link:label>
    <link:label id="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired_documentation_en-US" xlink:label="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Percentage Of Shares Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired" xlink:href="ameh-20220331.xsd#ameh_AssetAcquisitionPercentageOfSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired" xlink:to="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_b6ef06a9-9e4c-4851-a20e-da9a55708b6d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_578a3c46-c596-4a8c-989e-2f9e13190bfd_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation of restricted stock awards (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_6dc92ea5-ed47-415d-a035-0726cc96b7ca_terseLabel_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="ameh-20220331.xsd#ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1d459671-f06f-45c0-bd39-0d57ba678025_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_e6aaec06-7e7c-4a82-9aa9-436bc01adaad_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract term</link:label>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_label_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Description of Timing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:to="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_74d99c55-762f-46c3-9dec-1f7e9959f781_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities &#8211; certificates of deposit</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_bc1701d2-f1ae-46b5-ad5e-b983b71d2b66_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromAffiliateCurrent_58ccc065-8e3e-4326-9af6-8e6f8476aa86_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount due from affiliate</link:label>
    <link:label id="lab_us-gaap_DueFromAffiliateCurrent_label_en-US" xlink:label="lab_us-gaap_DueFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Affiliate, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliateCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromAffiliateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromAffiliateCurrent" xlink:to="lab_us-gaap_DueFromAffiliateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_d3aa9f3d-583f-44d7-ba4e-713c6fb889c8_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_56678567-069a-4ff4-94d9-d7a69c40a6c9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, grants in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b62b5d18-319a-431c-9e1e-7bc910c4aa12_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1ad51b3a-df54-4b00-896d-99411cc85bf0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_e1112ece-8f9d-405d-9241-f1810b731077_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_841534d2-d462-4266-9c63-9465da785d41_verboseLabel_en-US" xlink:label="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Lease Term</link:label>
    <link:label id="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_label_en-US" xlink:label="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Weighted Average Remaining Lease Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:href="ameh-20220331.xsd#ameh_LeaseWeightedAverageRemainingLeaseTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:to="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_d9b82712-a559-4ee2-a63b-4687efad5835_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_4f3f259f-56b4-49fc-8bc6-598cb45912f2_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_5ca7202c-72ca-4a49-bc76-62c4b35034bb_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board members</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_d2fd980e-fff9-41e9-ae75-58b597a5202c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_23c07d1d-0ddf-4c66-b3e1-61d73b917225_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorBMember_7e14fe87-61b4-492a-97c3-851fecf03e72_terseLabel_en-US" xlink:label="lab_ameh_PayorBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor B</link:label>
    <link:label id="lab_ameh_PayorBMember_label_en-US" xlink:label="lab_ameh_PayorBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor B [Member]</link:label>
    <link:label id="lab_ameh_PayorBMember_documentation_en-US" xlink:label="lab_ameh_PayorBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorBMember" xlink:href="ameh-20220331.xsd#ameh_PayorBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorBMember" xlink:to="lab_ameh_PayorBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_b9919974-7c8b-4c99-982e-99c8f8e33577_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_53917d7d-1f74-41e7-a322-8175d828e2bb_verboseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for exercise of options and warrants</link:label>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_label_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during the period value of exercise of option and warrants</link:label>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">It represents value of stock issued during the period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:href="ameh-20220331.xsd#ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:to="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfWarrantsExercised_664354c9-c7e1-4873-887d-24f15272de7a_negatedLabel_en-US" xlink:label="lab_ameh_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_ameh_NumberOfWarrantsExercised_label_en-US" xlink:label="lab_ameh_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Warrants Exercised</link:label>
    <link:label id="lab_ameh_NumberOfWarrantsExercised_documentation_en-US" xlink:label="lab_ameh_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfWarrantsExercised" xlink:href="ameh-20220331.xsd#ameh_NumberOfWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfWarrantsExercised" xlink:to="lab_ameh_NumberOfWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_e1793245-084a-48ec-a299-d7462d6579ce_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_4a7405fa-b6a2-4868-8fe0-f6c708428c65_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Credit Facility</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Line of Credit Facilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0b8c8628-8ac7-4efd-bcc8-45682dbf4dd5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_a4b3cb2b-52f7-4cbb-95c2-74372d03650d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5f23bdae-9e56-493c-8309-eeb4a6003d9a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_b67a9ffd-0cf4-4fc8-b6c8-8a21c0c82d34_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_425b2beb-6fcd-4b4f-83e9-5766ebe3a82c_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_79708062-bee4-4a64-90e1-e1b71e027860_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SpecialtyCapitationPayableCurrent_e67c085c-0a1f-4f8d-b211-10b0aeada68e_verboseLabel_en-US" xlink:label="lab_ameh_SpecialtyCapitationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitation payable</link:label>
    <link:label id="lab_ameh_SpecialtyCapitationPayableCurrent_label_en-US" xlink:label="lab_ameh_SpecialtyCapitationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specialty Capitation Payable Current</link:label>
    <link:label id="lab_ameh_SpecialtyCapitationPayableCurrent_documentation_en-US" xlink:label="lab_ameh_SpecialtyCapitationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of specialty capitation payable current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SpecialtyCapitationPayableCurrent" xlink:href="ameh-20220331.xsd#ameh_SpecialtyCapitationPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SpecialtyCapitationPayableCurrent" xlink:to="lab_ameh_SpecialtyCapitationPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9f7fd8fa-bf92-4b2e-b4e9-7dcfb3071a50_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares of common stock outstanding &#8211; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_3ca49154-4687-40eb-94a2-87f7c402bed0_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share &#8211; diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_23c01707-26b7-4c48-8cd5-ba912fa8ec61_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to weighted average shares of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_d91980cd-1955-49d5-bdfc-9bf8d33a94a9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in affiliates</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_79a0e9e8-a711-4363-bd7e-7c633db20ee2_periodStartLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_d3e43036-dda4-48b0-96e5-305a4c7a066a_periodEndLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_33f37b05-ca3e-4917-9b5d-3806d76720ef_terseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:href="ameh-20220331.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:to="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_bc930c00-e74e-4214-9dfe-4c9fed070f7d_terseLabel_en-US" xlink:label="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MPP, AMG Properties, and ZLL Asset Acquisition</link:label>
    <link:label id="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_label_en-US" xlink:label="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MPP, AMG Properties, and ZLL Asset Acquisition [Member]</link:label>
    <link:label id="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_documentation_en-US" xlink:label="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MPP, AMG Properties, and ZLL Asset Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" xlink:href="ameh-20220331.xsd#ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" xlink:to="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_3e9ea3da-18e4-4427-9b24-da8871518f56_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_01643dc0-aeea-4bc3-a309-81871ddb0fb0_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_77a31c41-035f-48da-9b36-f64f27a6a41f_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_9a13f57d-c4c1-4c31-a526-7438a009692b_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants granted</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Grant In Period, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of warrants or rights granted in period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:href="ameh-20220331.xsd#ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:to="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FiveThreeOneW.CollegeLLCMember_2e2fd93b-c125-4fe0-9f42-2a7d89350c51_verboseLabel_en-US" xlink:label="lab_ameh_FiveThreeOneW.CollegeLLCMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">531 W. College, LLC &#8211; related party</link:label>
    <link:label id="lab_ameh_FiveThreeOneW.CollegeLLCMember_2bcfb90a-fc38-4bf9-8a98-69622e25653e_terseLabel_en-US" xlink:label="lab_ameh_FiveThreeOneW.CollegeLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">531 W. College LLC</link:label>
    <link:label id="lab_ameh_FiveThreeOneW.CollegeLLCMember_label_en-US" xlink:label="lab_ameh_FiveThreeOneW.CollegeLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Three One W. College LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember" xlink:href="ameh-20220331.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FiveThreeOneW.CollegeLLCMember" xlink:to="lab_ameh_FiveThreeOneW.CollegeLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_081d8ee6-ec3f-4918-a6a5-f3cc9c0a6c04_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_69fb68c8-fefe-40fe-825b-984487b7205f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_dba207eb-3beb-48ab-87a8-265d0b1a2c2d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_b56ae419-3245-46d5-abe0-724f62e03c39_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_c1b748ea-d6b2-4701-9169-398c13ba316a_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_11ca6c4b-73b8-46da-9331-bf0041346019_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_a66ffec6-27e1-4938-ae31-89873a022e01_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_6a38c74f-987a-4605-bb10-7e4511044d31_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentOwnershipPercentageSold_9f8868fb-ef4f-4485-ac5e-0de4c6b1ecc6_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentOwnershipPercentageSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage sold</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentOwnershipPercentageSold_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentOwnershipPercentageSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage, Sold</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentOwnershipPercentageSold_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentOwnershipPercentageSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage, Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOwnershipPercentageSold" xlink:href="ameh-20220331.xsd#ameh_EquityMethodInvestmentOwnershipPercentageSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentOwnershipPercentageSold" xlink:to="lab_ameh_EquityMethodInvestmentOwnershipPercentageSold" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_APCAndAPCLSMAMember_8382bd07-842b-460d-82b1-ab2478dd9b3b_terseLabel_en-US" xlink:label="lab_ameh_APCAndAPCLSMAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC and APC-LSMA</link:label>
    <link:label id="lab_ameh_APCAndAPCLSMAMember_label_en-US" xlink:label="lab_ameh_APCAndAPCLSMAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC And APC-LSMA [Member]</link:label>
    <link:label id="lab_ameh_APCAndAPCLSMAMember_documentation_en-US" xlink:label="lab_ameh_APCAndAPCLSMAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC And APC-LSMA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember" xlink:href="ameh-20220331.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_APCAndAPCLSMAMember" xlink:to="lab_ameh_APCAndAPCLSMAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_a6c01b97-cf8f-434f-b120-832d06aac406_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets and Liabilities, Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_ece7ec98-73d3-42dc-bc75-cd7541cc008e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 (excluding the three months ended March 31, 2022)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f84ec149-c125-4510-ba11-4bad520649eb_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_35247d3b-5acd-404b-83b5-c5380e2b82af_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_7104cc63-471c-432c-8113-fe80d5f7eb68_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_4552d88a-f4ab-4b50-b5a6-61173ea44f3e_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_f06cdae4-ad04-4a63-8a5c-ea2be68417f0_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_6c4214c6-3234-4ab4-b722-b2aa444c24f7_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_6c1f11df-0b1c-42a0-8b3b-44fa86e4dd1d_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost, net</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_561553a6-0876-4819-9760-7438460d84b3_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_fb37fc97-6349-4086-ad33-cfbcee70f7f1_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subscriber relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ContingentEquitySecuritiesMember_f0a555e7-e62a-478d-8d5d-35121f01e9c0_terseLabel_en-US" xlink:label="lab_ameh_ContingentEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Equity Securities</link:label>
    <link:label id="lab_ameh_ContingentEquitySecuritiesMember_label_en-US" xlink:label="lab_ameh_ContingentEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Equity Securities [Member]</link:label>
    <link:label id="lab_ameh_ContingentEquitySecuritiesMember_documentation_en-US" xlink:label="lab_ameh_ContingentEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Equity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContingentEquitySecuritiesMember" xlink:href="ameh-20220331.xsd#ameh_ContingentEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ContingentEquitySecuritiesMember" xlink:to="lab_ameh_ContingentEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_13c6a286-14d3-4c89-8713-58d9cd515e59_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_45aaf0c4-634b-4f90-9b30-4b041e35e2c5_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_6c72377b-b9e4-4097-bc34-002721f29d48_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_84536e46-1743-4b69-9fa2-d33b7fb121cf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_da1b5a99-137f-4577-8532-d4157dcfcea0_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_71f4337f-8355-4d65-b431-be3e3fdff301_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_c0fdfecb-9201-496c-a037-14a0961c6a07_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_192b4922-49f0-47a8-8e36-168e200d64ee_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5de46a07-b2b7-4dbe-9671-18de4753d3b9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6ea5bf05-0e2e-43e7-9c5a-f0abb604e3f5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise&#160;Price&#160;Per Share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PatientManagementPlatformMember_1dae472d-6353-4049-8e1f-f657ae71e5f3_terseLabel_en-US" xlink:label="lab_ameh_PatientManagementPlatformMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient management platform</link:label>
    <link:label id="lab_ameh_PatientManagementPlatformMember_label_en-US" xlink:label="lab_ameh_PatientManagementPlatformMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Management Platform [Member]</link:label>
    <link:label id="lab_ameh_PatientManagementPlatformMember_documentation_en-US" xlink:label="lab_ameh_PatientManagementPlatformMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Management Platform</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PatientManagementPlatformMember" xlink:href="ameh-20220331.xsd#ameh_PatientManagementPlatformMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PatientManagementPlatformMember" xlink:to="lab_ameh_PatientManagementPlatformMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_ac38ab96-5af0-44fd-981b-d811e0358828_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorFMember_fda90552-cfed-4b64-b441-43dd3a1aceb9_terseLabel_en-US" xlink:label="lab_ameh_PayorFMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor F</link:label>
    <link:label id="lab_ameh_PayorFMember_label_en-US" xlink:label="lab_ameh_PayorFMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor F [Member]</link:label>
    <link:label id="lab_ameh_PayorFMember_documentation_en-US" xlink:label="lab_ameh_PayorFMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor F [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorFMember" xlink:href="ameh-20220331.xsd#ameh_PayorFMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorFMember" xlink:to="lab_ameh_PayorFMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares_2329f3e8-d0f5-4851-a183-17e48acba9e8_terseLabel_en-US" xlink:label="lab_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares_label_en-US" xlink:label="lab_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders And Stock Repurchased During Period, Value, Release Of Hold Back Shares</link:label>
    <link:label id="lab_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares_documentation_en-US" xlink:label="lab_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders And Stock Repurchased During Period, Value, Release Of Hold Back Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" xlink:href="ameh-20220331.xsd#ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" xlink:to="lab_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_76705434-e91d-4454-b227-5104aee71cbc_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_72558565-2ac7-4859-8453-8df1cf31504e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion and deferred financing costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_6e41ffa7-22e5-4300-8630-c128daede0f4_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion and deferred financing costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_0b78c63c-33ff-4cb0-a47c-895310779247_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_8f7f6d57-8c6b-4925-aeb2-d655a155ed75_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest disposed</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage Disposed</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage Disposed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:href="ameh-20220331.xsd#ameh_EquityMethodInvestmentOwnershipPercentageDisposed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:to="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_b40cf1e2-c738-4b36-b019-295c171a7a92_terseLabel_en-US" xlink:label="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected period of payment upon termination of agreement</link:label>
    <link:label id="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_label_en-US" xlink:label="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report</link:label>
    <link:label id="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_documentation_en-US" xlink:label="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:href="ameh-20220331.xsd#ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:to="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MezzanineMember_4a73d315-e537-4756-a922-7d9b2f5523af_terseLabel_en-US" xlink:label="lab_ameh_MezzanineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine</link:label>
    <link:label id="lab_ameh_MezzanineMember_label_en-US" xlink:label="lab_ameh_MezzanineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineMember" xlink:href="ameh-20220331.xsd#ameh_MezzanineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MezzanineMember" xlink:to="lab_ameh_MezzanineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApcBusinessLoanAgreementMember_894c8b82-3274-4d96-91f7-50c005a887a9_terseLabel_en-US" xlink:label="lab_ameh_ApcBusinessLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Business Loan Agreement</link:label>
    <link:label id="lab_ameh_ApcBusinessLoanAgreementMember_label_en-US" xlink:label="lab_ameh_ApcBusinessLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Business Loan Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcBusinessLoanAgreementMember" xlink:href="ameh-20220331.xsd#ameh_ApcBusinessLoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApcBusinessLoanAgreementMember" xlink:to="lab_ameh_ApcBusinessLoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_0ceafc40-f86e-4035-ab00-63e51c34d773_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_f23f8f7b-44b2-449a-aaad-0e69cd37d74b_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_4d472264-9e6a-4d4c-9be1-282e146c3279_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_e3745345-e0af-4743-8f31-fda0827239a0_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClinigenceHoldingsIncMember_b0e27125-d819-4690-8c0d-389802e84d0d_terseLabel_en-US" xlink:label="lab_ameh_ClinigenceHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigence Holdings, Inc.</link:label>
    <link:label id="lab_ameh_ClinigenceHoldingsIncMember_label_en-US" xlink:label="lab_ameh_ClinigenceHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigence Holdings, Inc. [Member]</link:label>
    <link:label id="lab_ameh_ClinigenceHoldingsIncMember_documentation_en-US" xlink:label="lab_ameh_ClinigenceHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigence Holdings, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClinigenceHoldingsIncMember" xlink:href="ameh-20220331.xsd#ameh_ClinigenceHoldingsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClinigenceHoldingsIncMember" xlink:to="lab_ameh_ClinigenceHoldingsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_85d6ea5e-4aae-4d40-9ecc-4314197962ab_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d8e468df-9bd2-471a-b3fd-41dfc01bae52_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e2f03374-cc5b-4246-ba87-b1963a0144e7_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash total</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_1c01dd47-6c66-404c-84d7-859869bee087_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_f3ac5982-0a07-4297-9a6e-f46621b94e3f_negatedLabel_en-US" xlink:label="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_label_en-US" xlink:label="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Prepaid Expenses And Other Current Assets</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_documentation_en-US" xlink:label="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in the value of prepaid expenses and other current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:href="ameh-20220331.xsd#ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:to="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_211c179a-ef93-4ee9-9778-4968f23bfcb1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_0f9a26bc-b9bf-4a88-9394-4dd617c6dd1c_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_ba912219-aa83-4e5d-9e73-fe8af0ab0925_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized intangible assets, Gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_21671322-73c3-493d-af24-e2338412aec0_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value (in millions)</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:href="ameh-20220331.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_f0c628ae-5650-42dc-9d5d-ee936d9fb476_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_3823b909-a396-46bb-9985-2d127dd64cb0_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1012d2df-8ecd-4b9d-bd5c-f849fc5134c7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WarrantExercisePriceRangeTwoMember_63326172-eded-42f7-9b42-df4b0dadcdce_verboseLabel_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range Two</link:label>
    <link:label id="lab_ameh_WarrantExercisePriceRangeTwoMember_label_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeTwoMember" xlink:href="ameh-20220331.xsd#ameh_WarrantExercisePriceRangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantExercisePriceRangeTwoMember" xlink:to="lab_ameh_WarrantExercisePriceRangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a2cf7480-1013-4a55-bc96-d1edc1f45bb6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for exercise of options and warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e7eec383-3556-4335-92a8-abb85bb6fa0a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApcLsmaMember_418e1325-f268-4e92-9cd2-9898dc183819_terseLabel_en-US" xlink:label="lab_ameh_ApcLsmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC LSMA</link:label>
    <link:label id="lab_ameh_ApcLsmaMember_label_en-US" xlink:label="lab_ameh_ApcLsmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC LSMA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember" xlink:href="ameh-20220331.xsd#ameh_ApcLsmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApcLsmaMember" xlink:to="lab_ameh_ApcLsmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Tag8MedicalInvestmentGroupLLCMember_17ea184c-4134-424e-8ef6-49927be519e6_terseLabel_en-US" xlink:label="lab_ameh_Tag8MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-8 Medical Investment Group, LLC</link:label>
    <link:label id="lab_ameh_Tag8MedicalInvestmentGroupLLCMember_label_en-US" xlink:label="lab_ameh_Tag8MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-8 Medical Investment Group, LLC [Member]</link:label>
    <link:label id="lab_ameh_Tag8MedicalInvestmentGroupLLCMember_documentation_en-US" xlink:label="lab_ameh_Tag8MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-8 Medical Investment Group, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag8MedicalInvestmentGroupLLCMember" xlink:href="ameh-20220331.xsd#ameh_Tag8MedicalInvestmentGroupLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Tag8MedicalInvestmentGroupLLCMember" xlink:to="lab_ameh_Tag8MedicalInvestmentGroupLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4f52cfc6-faae-47fc-942b-bc2daee27b82_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_5f7be940-6970-45e5-a0e0-fb51978bc5df_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants available to purchase, contingent upon the portal completion date (in shares)</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Options Issues, Options To Purchase Additional Interests, If Circumstances Met</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Options Issues, Options To Purchase Additional Interests, If Circumstances Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:href="ameh-20220331.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6a29acaf-66b7-4c8e-9218-24c3238272d5_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_b1ee4645-2224-4522-97fd-c75c8707525c_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase additional membership interests (in shares)</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:href="ameh-20220331.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_f3fab7be-be10-4c6e-9783-57598f1bd733_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:href="ameh-20220331.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_a7c1006c-6a4a-49ad-bf71-04c1e3ce44af_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_31078b42-1033-4c04-b869-485c2f20e01e_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_0ef1253e-cfe0-486f-bce4-247f0dfd0ac7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution to investment - equity method</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock_d18e8b23-9e61-405f-b8ca-99bffdca0e1a_terseLabel_en-US" xlink:label="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary Cash and Payable</link:label>
    <link:label id="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock_label_en-US" xlink:label="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary Cash and Payable [Policy Text Block]</link:label>
    <link:label id="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock_documentation_en-US" xlink:label="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary Cash and Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryCashAndPayablePolicyTextBlock" xlink:href="ameh-20220331.xsd#ameh_FiduciaryCashAndPayablePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FiduciaryCashAndPayablePolicyTextBlock" xlink:to="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_bb297eb7-b570-4229-9f07-3553af2290a4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0eecaf3f-3fef-4808-9ffb-d1462a33dc4e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of business combinations:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_291ca3a4-ef31-475c-b263-1b2fd1d6802a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfWarrantsGranted_d79e1672-ac5b-4177-9e27-f572cd243c70_verboseLabel_en-US" xlink:label="lab_ameh_NumberOfWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants granted (in shares)</link:label>
    <link:label id="lab_ameh_NumberOfWarrantsGranted_label_en-US" xlink:label="lab_ameh_NumberOfWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Warrants Granted</link:label>
    <link:label id="lab_ameh_NumberOfWarrantsGranted_documentation_en-US" xlink:label="lab_ameh_NumberOfWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Warrants Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfWarrantsGranted" xlink:href="ameh-20220331.xsd#ameh_NumberOfWarrantsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfWarrantsGranted" xlink:to="lab_ameh_NumberOfWarrantsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ConstructionLoanMember_7a5b1f0a-047d-4a4b-9877-71c7ccb6722a_terseLabel_en-US" xlink:label="lab_ameh_ConstructionLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction Loan</link:label>
    <link:label id="lab_ameh_ConstructionLoanMember_label_en-US" xlink:label="lab_ameh_ConstructionLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction Loan [Member]</link:label>
    <link:label id="lab_ameh_ConstructionLoanMember_documentation_en-US" xlink:label="lab_ameh_ConstructionLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConstructionLoanMember" xlink:href="ameh-20220331.xsd#ameh_ConstructionLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ConstructionLoanMember" xlink:to="lab_ameh_ConstructionLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_9cdc0aaf-1916-4c5d-87f8-fd51d6aaabbb_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_f3628d2b-8bba-4c6d-9381-d57432203713_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire business</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_50821935-3fe7-44a7-8051-7d15fb07c160_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8b97bbfd-cf2a-4caa-8270-cd8962a5e2a8_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum loan availability</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_0463b3c4-20f4-4ec3-bc20-3c4830dd4869_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_faa795a2-65f6-4586-9ef3-1164d5fa24e9_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_90537bcf-f548-47f7-a329-2704f7d3d74a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_27baa251-3aba-4f9f-bbfe-a3644546722c_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Amounts and Fair Values of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_fe0aedd5-4904-4dd2-9673-8ea20338f463_terseLabel_en-US" xlink:label="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:label id="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="ameh-20220331.xsd#ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_df32b03e-3e0d-4267-9bf7-4d9bba77851c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease term, finance</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_fdbd0456-2faa-4f00-a11a-5d2c17f40e3b_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment amount</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:href="ameh-20220331.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_2f278eb3-6556-44e3-b22a-108448408441_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of services, excluding depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_52a93e87-2d16-4b99-ab11-40c370db10d9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_d6818701-1d73-4dee-9cef-c1fc50ea79af_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_d007c41a-55b2-4af2-ae80-69fce1337623_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum_46f22590-62cf-4b6f-b86e-ea27deda140e_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum consolidated leverage ratio (not greater than)</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Maximum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:href="ameh-20220331.xsd#ameh_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:to="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_fa334820-e407-4073-8ee9-3676bbd55532_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_ed5d3546-822e-4434-b0ee-810dc87d2bad_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_b5c0031e-c0a7-4546-9ede-9c7c62fa64fb_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember_8f5dbd65-632d-4da6-92fd-f3ab090e37ca_terseLabel_en-US" xlink:label="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific Medical Imaging &amp; Oncology Center, Inc.</link:label>
    <link:label id="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember_label_en-US" xlink:label="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific Medical Imaging and Oncology Center, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:href="ameh-20220331.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:to="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_4586a601-1e3c-43bd-8811-864a9bf3edbf_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtCovenantAggregatePurchasePriceMaximum_2eecef00-a055-4ff2-a473-1d33a6a71add_terseLabel_en-US" xlink:label="lab_ameh_DebtCovenantAggregatePurchasePriceMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt covenant, aggregate purchase price, maximum</link:label>
    <link:label id="lab_ameh_DebtCovenantAggregatePurchasePriceMaximum_label_en-US" xlink:label="lab_ameh_DebtCovenantAggregatePurchasePriceMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Aggregate Purchase Price, Maximum</link:label>
    <link:label id="lab_ameh_DebtCovenantAggregatePurchasePriceMaximum_documentation_en-US" xlink:label="lab_ameh_DebtCovenantAggregatePurchasePriceMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Aggregate Purchase Price, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtCovenantAggregatePurchasePriceMaximum" xlink:href="ameh-20220331.xsd#ameh_DebtCovenantAggregatePurchasePriceMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtCovenantAggregatePurchasePriceMaximum" xlink:to="lab_ameh_DebtCovenantAggregatePurchasePriceMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_0c29b9d5-4efb-49ca-b79b-38c34c3bfcc9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward_150123cf-ff44-4e81-908f-167366de4d13_terseLabel_en-US" xlink:label="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants [Roll Forward]</link:label>
    <link:label id="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward_label_en-US" xlink:label="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants [Roll Forward]</link:label>
    <link:label id="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward_documentation_en-US" xlink:label="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:href="ameh-20220331.xsd#ameh_WeightedAverageExercisePriceWarrantsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:to="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ContractTypeAxis_b89fa214-b61f-4da2-ac83-5b9dbde8c260_terseLabel_en-US" xlink:label="lab_ameh_ContractTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Type [Axis]</link:label>
    <link:label id="lab_ameh_ContractTypeAxis_label_en-US" xlink:label="lab_ameh_ContractTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeAxis" xlink:href="ameh-20220331.xsd#ameh_ContractTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ContractTypeAxis" xlink:to="lab_ameh_ContractTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_01173a1c-acd6-4f96-acb8-6cf7c867f807_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_80df8b26-b990-4ce8-b17d-e1d933f8ae80_negatedLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DescriptionOfBusinessLineItems_3e97a085-2cb8-49e1-9b86-f10bf361c23d_terseLabel_en-US" xlink:label="lab_ameh_DescriptionOfBusinessLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Business [Line Items]</link:label>
    <link:label id="lab_ameh_DescriptionOfBusinessLineItems_label_en-US" xlink:label="lab_ameh_DescriptionOfBusinessLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Business [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessLineItems" xlink:href="ameh-20220331.xsd#ameh_DescriptionOfBusinessLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DescriptionOfBusinessLineItems" xlink:to="lab_ameh_DescriptionOfBusinessLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionOfDividends_c2745808-c13c-4839-840b-8fefed88d09e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionOfDividends_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Accretion of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAccretionOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAccretionOfDividends" xlink:to="lab_us-gaap_TemporaryEquityAccretionOfDividends" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>ameh-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:5baec51e-b1b5-44e5-a5ac-49c0e6499a3f,g:d2f55b59-0a61-4e65-b745-a66f96888c42-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.apollomed.net/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="ameh-20220331.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_033d4560-f94d-40c9-972b-8a94a3baf165" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9261f000-231d-47c6-a49b-035f1ad48792" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_033d4560-f94d-40c9-972b-8a94a3baf165" xlink:to="loc_dei_DocumentType_9261f000-231d-47c6-a49b-035f1ad48792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_d98a2798-9880-4cde-b966-61b4dc0231b6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_033d4560-f94d-40c9-972b-8a94a3baf165" xlink:to="loc_dei_DocumentQuarterlyReport_d98a2798-9880-4cde-b966-61b4dc0231b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_57cb44cf-9745-4841-bd87-07e24c35576d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_033d4560-f94d-40c9-972b-8a94a3baf165" xlink:to="loc_dei_DocumentPeriodEndDate_57cb44cf-9745-4841-bd87-07e24c35576d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_1f51307f-2329-4a12-b23f-5bb4f01c4c6d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_033d4560-f94d-40c9-972b-8a94a3baf165" xlink:to="loc_dei_DocumentTransitionReport_1f51307f-2329-4a12-b23f-5bb4f01c4c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_91957e47-64a2-4dfa-8f62-3755920e8b07" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_033d4560-f94d-40c9-972b-8a94a3baf165" xlink:to="loc_dei_EntityFileNumber_91957e47-64a2-4dfa-8f62-3755920e8b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d174b4ff-72c8-4f58-a0a8-b40d04f8018b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_033d4560-f94d-40c9-972b-8a94a3baf165" xlink:to="loc_dei_EntityRegistrantName_d174b4ff-72c8-4f58-a0a8-b40d04f8018b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_c34b441a-4de7-4aa7-9f7f-c6d17b32ff15" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_033d4560-f94d-40c9-972b-8a94a3baf165" xlink:to="loc_dei_EntityIncorporationStateCountryCode_c34b441a-4de7-4aa7-9f7f-c6d17b32ff15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_267d34d3-53a9-469c-ab57-2b4298a3d756" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_033d4560-f94d-40c9-972b-8a94a3baf165" xlink:to="loc_dei_EntityTaxIdentificationNumber_267d34d3-53a9-469c-ab57-2b4298a3d756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_332b25fc-7065-44d9-ab57-c8457bc65180" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_033d4560-f94d-40c9-972b-8a94a3baf165" xlink:to="loc_dei_EntityAddressAddressLine1_332b25fc-7065-44d9-ab57-c8457bc65180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_383cb8e3-af34-4fcc-9e2e-dc239d441f20" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_033d4560-f94d-40c9-972b-8a94a3baf165" xlink:to="loc_dei_EntityAddressAddressLine2_383cb8e3-af34-4fcc-9e2e-dc239d441f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_3b82b847-8d69-4887-8069-edebd7ef17b0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_033d4560-f94d-40c9-972b-8a94a3baf165" xlink:to="loc_dei_EntityAddressCityOrTown_3b82b847-8d69-4887-8069-edebd7ef17b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_acbe26ac-f881-491b-9d43-267e3ac6fa22" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_033d4560-f94d-40c9-972b-8a94a3baf165" xlink:to="loc_dei_EntityAddressStateOrProvince_acbe26ac-f881-491b-9d43-267e3ac6fa22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_0c7ba3f9-3f4c-46a2-840c-41331deeda55" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_033d4560-f94d-40c9-972b-8a94a3baf165" xlink:to="loc_dei_EntityAddressPostalZipCode_0c7ba3f9-3f4c-46a2-840c-41331deeda55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_91cc8d5b-7916-4974-bb04-69c9f1641d0f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_033d4560-f94d-40c9-972b-8a94a3baf165" xlink:to="loc_dei_CityAreaCode_91cc8d5b-7916-4974-bb04-69c9f1641d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d4ae3e7d-789f-4f0d-b766-aa8af6b98f13" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_033d4560-f94d-40c9-972b-8a94a3baf165" xlink:to="loc_dei_LocalPhoneNumber_d4ae3e7d-789f-4f0d-b766-aa8af6b98f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_d5f54993-b537-4f1f-96f6-7bb5e481d203" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_033d4560-f94d-40c9-972b-8a94a3baf165" xlink:to="loc_dei_Security12bTitle_d5f54993-b537-4f1f-96f6-7bb5e481d203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_12df7424-7b64-4ffe-852f-f93b65aae037" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_033d4560-f94d-40c9-972b-8a94a3baf165" xlink:to="loc_dei_TradingSymbol_12df7424-7b64-4ffe-852f-f93b65aae037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_1562e4da-9d92-4a1a-868a-51ff6c346ada" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_033d4560-f94d-40c9-972b-8a94a3baf165" xlink:to="loc_dei_EntityCurrentReportingStatus_1562e4da-9d92-4a1a-868a-51ff6c346ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_71132352-a9e5-42c2-9409-00c4adcc0bde" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_033d4560-f94d-40c9-972b-8a94a3baf165" xlink:to="loc_dei_EntityInteractiveDataCurrent_71132352-a9e5-42c2-9409-00c4adcc0bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_6d2b1640-f69b-40c9-a6bc-f7fe66a8cd9a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_033d4560-f94d-40c9-972b-8a94a3baf165" xlink:to="loc_dei_EntityFilerCategory_6d2b1640-f69b-40c9-a6bc-f7fe66a8cd9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_8e7a181b-ea9e-4022-b757-db186065e5fe" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_033d4560-f94d-40c9-972b-8a94a3baf165" xlink:to="loc_dei_EntitySmallBusiness_8e7a181b-ea9e-4022-b757-db186065e5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_a2ec3974-33f5-42cc-bd4f-e4451cb65852" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_033d4560-f94d-40c9-972b-8a94a3baf165" xlink:to="loc_dei_EntityEmergingGrowthCompany_a2ec3974-33f5-42cc-bd4f-e4451cb65852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_83cfb4c1-c57b-4f71-81ad-55c75d6db370" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_033d4560-f94d-40c9-972b-8a94a3baf165" xlink:to="loc_dei_EntityShellCompany_83cfb4c1-c57b-4f71-81ad-55c75d6db370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_22da3487-95ee-4aad-856f-0ff8dfcf7d91" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_033d4560-f94d-40c9-972b-8a94a3baf165" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_22da3487-95ee-4aad-856f-0ff8dfcf7d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f5732319-6b7f-4eea-a705-8f761d034a42" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_033d4560-f94d-40c9-972b-8a94a3baf165" xlink:to="loc_dei_AmendmentFlag_f5732319-6b7f-4eea-a705-8f761d034a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_0618df5e-1853-40fd-a73c-0279a6596867" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_033d4560-f94d-40c9-972b-8a94a3baf165" xlink:to="loc_dei_DocumentFiscalYearFocus_0618df5e-1853-40fd-a73c-0279a6596867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_df0871e5-134b-4512-b7e7-687f7693b1c0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_033d4560-f94d-40c9-972b-8a94a3baf165" xlink:to="loc_dei_DocumentFiscalPeriodFocus_df0871e5-134b-4512-b7e7-687f7693b1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_7bee2a7a-2b07-406d-b084-0f734dc66651" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_033d4560-f94d-40c9-972b-8a94a3baf165" xlink:to="loc_dei_EntityCentralIndexKey_7bee2a7a-2b07-406d-b084-0f734dc66651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_52e0739a-e11f-4c45-a582-4f1299ef5db2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_033d4560-f94d-40c9-972b-8a94a3baf165" xlink:to="loc_dei_CurrentFiscalYearEndDate_52e0739a-e11f-4c45-a582-4f1299ef5db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="ameh-20220331.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_cced5f04-57d4-4206-9362-a6624695dbf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5270c61e-0477-45a7-851b-a4dbe4b1c5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cced5f04-57d4-4206-9362-a6624695dbf3" xlink:to="loc_us-gaap_StatementTable_5270c61e-0477-45a7-851b-a4dbe4b1c5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9899eb47-924a-4041-a481-51eb2e293bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5270c61e-0477-45a7-851b-a4dbe4b1c5b5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9899eb47-924a-4041-a481-51eb2e293bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3e6d9bb6-c7cd-45b2-8861-41c67dca7fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9899eb47-924a-4041-a481-51eb2e293bf7" xlink:to="loc_us-gaap_ClassOfStockDomain_3e6d9bb6-c7cd-45b2-8861-41c67dca7fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_3060cf55-b18b-4672-aad1-701ad45ba3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3e6d9bb6-c7cd-45b2-8861-41c67dca7fb8" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_3060cf55-b18b-4672-aad1-701ad45ba3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_062396d9-8a46-4f41-bc9c-c256b621d04d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3e6d9bb6-c7cd-45b2-8861-41c67dca7fb8" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_062396d9-8a46-4f41-bc9c-c256b621d04d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_160f9aeb-374a-49e3-b901-291bfc151bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5270c61e-0477-45a7-851b-a4dbe4b1c5b5" xlink:to="loc_us-gaap_StatementLineItems_160f9aeb-374a-49e3-b901-291bfc151bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_d3388696-df8e-4193-9754-d25edc1b80e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_160f9aeb-374a-49e3-b901-291bfc151bd3" xlink:to="loc_us-gaap_AssetsAbstract_d3388696-df8e-4193-9754-d25edc1b80e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_cb7b394a-94c0-4500-8583-78bd4b9d09e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d3388696-df8e-4193-9754-d25edc1b80e1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_cb7b394a-94c0-4500-8583-78bd4b9d09e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9fc7df05-6b41-42ca-b3ad-7ac844ce0917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cb7b394a-94c0-4500-8583-78bd4b9d09e3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9fc7df05-6b41-42ca-b3ad-7ac844ce0917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_d0b6d643-6a18-4347-9875-a25432165f75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cb7b394a-94c0-4500-8583-78bd4b9d09e3" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_d0b6d643-6a18-4347-9875-a25432165f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_649c76af-2cfb-4161-af17-c20b4cecc65c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cb7b394a-94c0-4500-8583-78bd4b9d09e3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_649c76af-2cfb-4161-af17-c20b4cecc65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_eb64d4ec-f119-49f3-b6f9-8a2f511f9990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cb7b394a-94c0-4500-8583-78bd4b9d09e3" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_eb64d4ec-f119-49f3-b6f9-8a2f511f9990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_234a6441-6643-43ce-8ba7-da031555b878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cb7b394a-94c0-4500-8583-78bd4b9d09e3" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_234a6441-6643-43ce-8ba7-da031555b878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1a340c88-bd42-48b8-bf93-d538b74d03b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cb7b394a-94c0-4500-8583-78bd4b9d09e3" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1a340c88-bd42-48b8-bf93-d538b74d03b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_b5325404-a6e2-46d7-8099-a12d32a91e48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cb7b394a-94c0-4500-8583-78bd4b9d09e3" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_b5325404-a6e2-46d7-8099-a12d32a91e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0d345b98-7dd8-4160-9915-818c1b4c56a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cb7b394a-94c0-4500-8583-78bd4b9d09e3" xlink:to="loc_us-gaap_AssetsCurrent_0d345b98-7dd8-4160-9915-818c1b4c56a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_5292cb9c-741a-4d13-956f-66c46b280ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d3388696-df8e-4193-9754-d25edc1b80e1" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_5292cb9c-741a-4d13-956f-66c46b280ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_80e3556d-89b8-4e70-94c3-0b2ee9b7419a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5292cb9c-741a-4d13-956f-66c46b280ab6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_80e3556d-89b8-4e70-94c3-0b2ee9b7419a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_84049ac2-2e0c-4346-871b-8a8902eb0d86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5292cb9c-741a-4d13-956f-66c46b280ab6" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_84049ac2-2e0c-4346-871b-8a8902eb0d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_62dc6894-94fa-4d57-82fe-c30a553f2390" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5292cb9c-741a-4d13-956f-66c46b280ab6" xlink:to="loc_us-gaap_Goodwill_62dc6894-94fa-4d57-82fe-c30a553f2390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_b09b35ad-9b69-4cb1-8d1c-52a4b482c050" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5292cb9c-741a-4d13-956f-66c46b280ab6" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_b09b35ad-9b69-4cb1-8d1c-52a4b482c050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_dbe92fd6-7724-4c0e-a552-ae9d9c8af9a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5292cb9c-741a-4d13-956f-66c46b280ab6" xlink:to="loc_us-gaap_EquityMethodInvestments_dbe92fd6-7724-4c0e-a552-ae9d9c8af9a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_12a26ff4-79bf-4c7d-b511-fb5f273609ee" xlink:href="ameh-20220331.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5292cb9c-741a-4d13-956f-66c46b280ab6" xlink:to="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_12a26ff4-79bf-4c7d-b511-fb5f273609ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a0faf1ba-04ca-4867-a555-8b7a9cea0759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5292cb9c-741a-4d13-956f-66c46b280ab6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a0faf1ba-04ca-4867-a555-8b7a9cea0759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a91f3fe9-f05c-4b57-9d35-8593f7073c49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5292cb9c-741a-4d13-956f-66c46b280ab6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a91f3fe9-f05c-4b57-9d35-8593f7073c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_c119a537-4d94-440b-98d0-4459ef9b914d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5292cb9c-741a-4d13-956f-66c46b280ab6" xlink:to="loc_us-gaap_AssetsNoncurrent_c119a537-4d94-440b-98d0-4459ef9b914d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_02d99ed3-5fb4-4a8a-8834-27406de2f2aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d3388696-df8e-4193-9754-d25edc1b80e1" xlink:to="loc_us-gaap_Assets_02d99ed3-5fb4-4a8a-8834-27406de2f2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83e49c6f-8d5a-40f0-944d-be2ce6e512a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_160f9aeb-374a-49e3-b901-291bfc151bd3" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83e49c6f-8d5a-40f0-944d-be2ce6e512a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_37798ade-8105-48d3-b914-e0b7b2111a38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83e49c6f-8d5a-40f0-944d-be2ce6e512a5" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_37798ade-8105-48d3-b914-e0b7b2111a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_924363af-4bbb-4f77-8885-c7cd60b92b91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37798ade-8105-48d3-b914-e0b7b2111a38" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_924363af-4bbb-4f77-8885-c7cd60b92b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_c5ba9a7e-85a6-424a-bd09-799eb6124455" xlink:href="ameh-20220331.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37798ade-8105-48d3-b914-e0b7b2111a38" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_c5ba9a7e-85a6-424a-bd09-799eb6124455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_7970e082-49e0-4054-af7a-ed47e726b886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37798ade-8105-48d3-b914-e0b7b2111a38" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_7970e082-49e0-4054-af7a-ed47e726b886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_e258fef2-fd1a-4226-99a6-dcd73a4ff0a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37798ade-8105-48d3-b914-e0b7b2111a38" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_e258fef2-fd1a-4226-99a6-dcd73a4ff0a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_3c7e4d7d-440c-4c58-b09f-8ee5ccd3375d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37798ade-8105-48d3-b914-e0b7b2111a38" xlink:to="loc_us-gaap_DividendsPayableCurrent_3c7e4d7d-440c-4c58-b09f-8ee5ccd3375d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_964f56ae-a66b-4f8d-b300-99015e3a96f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37798ade-8105-48d3-b914-e0b7b2111a38" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_964f56ae-a66b-4f8d-b300-99015e3a96f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_57055925-ed40-4107-9a92-c6905f423248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37798ade-8105-48d3-b914-e0b7b2111a38" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_57055925-ed40-4107-9a92-c6905f423248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_4d03c46d-5a50-482a-9891-4a3a6493d5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37798ade-8105-48d3-b914-e0b7b2111a38" xlink:to="loc_us-gaap_LongTermDebtCurrent_4d03c46d-5a50-482a-9891-4a3a6493d5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c36a5f60-925f-44fb-9f78-11bd49a66787" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37798ade-8105-48d3-b914-e0b7b2111a38" xlink:to="loc_us-gaap_LiabilitiesCurrent_c36a5f60-925f-44fb-9f78-11bd49a66787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_465d6db3-5bb6-44a4-9e85-33c8d3978b06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83e49c6f-8d5a-40f0-944d-be2ce6e512a5" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_465d6db3-5bb6-44a4-9e85-33c8d3978b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_11b6e430-5eb1-48fe-8ee4-13e22b0ec11b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_465d6db3-5bb6-44a4-9e85-33c8d3978b06" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_11b6e430-5eb1-48fe-8ee4-13e22b0ec11b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_14c5ba08-e54f-4cb9-af10-1c600ccab082" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_465d6db3-5bb6-44a4-9e85-33c8d3978b06" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_14c5ba08-e54f-4cb9-af10-1c600ccab082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5b23401b-c91e-400e-848e-1f9ba1ef1cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_465d6db3-5bb6-44a4-9e85-33c8d3978b06" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5b23401b-c91e-400e-848e-1f9ba1ef1cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_7f1f61c5-220c-4605-b646-9c2d65830fda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_465d6db3-5bb6-44a4-9e85-33c8d3978b06" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_7f1f61c5-220c-4605-b646-9c2d65830fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_89221e14-002b-4b41-aaa6-f9cb12b0f895" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_465d6db3-5bb6-44a4-9e85-33c8d3978b06" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_89221e14-002b-4b41-aaa6-f9cb12b0f895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_9892fa9e-1603-476b-8748-e6e0d7e42c24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_465d6db3-5bb6-44a4-9e85-33c8d3978b06" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_9892fa9e-1603-476b-8748-e6e0d7e42c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d924c5e3-6b78-41ec-97de-c3b8a524599b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83e49c6f-8d5a-40f0-944d-be2ce6e512a5" xlink:to="loc_us-gaap_Liabilities_d924c5e3-6b78-41ec-97de-c3b8a524599b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a56424b5-b20f-4842-a048-389d239b4f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83e49c6f-8d5a-40f0-944d-be2ce6e512a5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a56424b5-b20f-4842-a048-389d239b4f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineEquityAbstract_d3d0997b-1141-490b-85d4-3815743809f8" xlink:href="ameh-20220331.xsd#ameh_MezzanineEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83e49c6f-8d5a-40f0-944d-be2ce6e512a5" xlink:to="loc_ameh_MezzanineEquityAbstract_d3d0997b-1141-490b-85d4-3815743809f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_f7fe9a51-f4e7-49b4-b176-21a7de8f254d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_MezzanineEquityAbstract_d3d0997b-1141-490b-85d4-3815743809f8" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_f7fe9a51-f4e7-49b4-b176-21a7de8f254d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_880f69a2-2bdd-4933-b6cc-9708792d17c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83e49c6f-8d5a-40f0-944d-be2ce6e512a5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_880f69a2-2bdd-4933-b6cc-9708792d17c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a4de836a-220d-4314-8c72-a0b2c44504de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_880f69a2-2bdd-4933-b6cc-9708792d17c5" xlink:to="loc_us-gaap_PreferredStockValue_a4de836a-220d-4314-8c72-a0b2c44504de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_06cfd696-fbfb-484a-b5ea-6f5a2d334a88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_880f69a2-2bdd-4933-b6cc-9708792d17c5" xlink:to="loc_us-gaap_CommonStockValue_06cfd696-fbfb-484a-b5ea-6f5a2d334a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_d793b72c-4a45-4b6a-8b49-282e99dcbc5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_880f69a2-2bdd-4933-b6cc-9708792d17c5" xlink:to="loc_us-gaap_AdditionalPaidInCapital_d793b72c-4a45-4b6a-8b49-282e99dcbc5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_776f7f3b-dd7d-4894-92e9-7eb8f179bdd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_880f69a2-2bdd-4933-b6cc-9708792d17c5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_776f7f3b-dd7d-4894-92e9-7eb8f179bdd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_849f8f78-c4df-4161-b7b6-26f062a4355f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_880f69a2-2bdd-4933-b6cc-9708792d17c5" xlink:to="loc_us-gaap_StockholdersEquity_849f8f78-c4df-4161-b7b6-26f062a4355f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_9e64cd4a-f1f0-439f-bd25-60be6e20f5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_880f69a2-2bdd-4933-b6cc-9708792d17c5" xlink:to="loc_us-gaap_MinorityInterest_9e64cd4a-f1f0-439f-bd25-60be6e20f5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e2be1aa7-9f2a-4228-a679-d595546fccb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_880f69a2-2bdd-4933-b6cc-9708792d17c5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e2be1aa7-9f2a-4228-a679-d595546fccb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4d67c83e-5dbb-467f-9a4c-19e446635168" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83e49c6f-8d5a-40f0-944d-be2ce6e512a5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_4d67c83e-5dbb-467f-9a4c-19e446635168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="ameh-20220331.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ad645a73-e0ce-4336-a8d9-1f0864383fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_62e67cb9-5fb7-428a-bb1a-017c0bed486f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ad645a73-e0ce-4336-a8d9-1f0864383fa4" xlink:to="loc_us-gaap_StatementTable_62e67cb9-5fb7-428a-bb1a-017c0bed486f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_575a8dc5-56b6-4d65-a7c2-63bb461f5517" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_62e67cb9-5fb7-428a-bb1a-017c0bed486f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_575a8dc5-56b6-4d65-a7c2-63bb461f5517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_69b26404-1d42-4c78-b3b0-45acf6c688cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_575a8dc5-56b6-4d65-a7c2-63bb461f5517" xlink:to="loc_us-gaap_ClassOfStockDomain_69b26404-1d42-4c78-b3b0-45acf6c688cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_e4537fbd-7e2a-429c-8013-49fe71280d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_69b26404-1d42-4c78-b3b0-45acf6c688cd" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_e4537fbd-7e2a-429c-8013-49fe71280d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_c72b8233-5e7d-4132-9f69-1ec0c4de49cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_69b26404-1d42-4c78-b3b0-45acf6c688cd" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_c72b8233-5e7d-4132-9f69-1ec0c4de49cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_fbb9cbd9-fab3-4d0a-abdd-52e4fad3ec39" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_62e67cb9-5fb7-428a-bb1a-017c0bed486f" xlink:to="loc_srt_ConsolidatedEntitiesAxis_fbb9cbd9-fab3-4d0a-abdd-52e4fad3ec39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_58b69bb6-89d9-4bcf-8c64-b86bfe0716fe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_fbb9cbd9-fab3-4d0a-abdd-52e4fad3ec39" xlink:to="loc_srt_ConsolidatedEntitiesDomain_58b69bb6-89d9-4bcf-8c64-b86bfe0716fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_85dad8d7-8d1f-4d17-ac1a-6024dc7ed1de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_58b69bb6-89d9-4bcf-8c64-b86bfe0716fe" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_85dad8d7-8d1f-4d17-ac1a-6024dc7ed1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_df229f59-f810-4b0a-8c07-203b6dc97105" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_62e67cb9-5fb7-428a-bb1a-017c0bed486f" xlink:to="loc_us-gaap_StatementLineItems_df229f59-f810-4b0a-8c07-203b6dc97105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b577f094-4568-4af9-b614-8db30725f7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df229f59-f810-4b0a-8c07-203b6dc97105" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b577f094-4568-4af9-b614-8db30725f7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3e43c277-8de0-42ae-b9bb-4e1e9b298b92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df229f59-f810-4b0a-8c07-203b6dc97105" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3e43c277-8de0-42ae-b9bb-4e1e9b298b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_37009701-ac78-4632-9256-e5d9a10e9207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df229f59-f810-4b0a-8c07-203b6dc97105" xlink:to="loc_us-gaap_PreferredStockSharesIssued_37009701-ac78-4632-9256-e5d9a10e9207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_14f5687c-86f2-448a-b6ab-4ed3c058efc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df229f59-f810-4b0a-8c07-203b6dc97105" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_14f5687c-86f2-448a-b6ab-4ed3c058efc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_eb2027c0-a68a-4334-bc13-aaa4f07db832" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df229f59-f810-4b0a-8c07-203b6dc97105" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_eb2027c0-a68a-4334-bc13-aaa4f07db832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_64c071a5-d1c4-447a-adf6-0692b4fb4593" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df229f59-f810-4b0a-8c07-203b6dc97105" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_64c071a5-d1c4-447a-adf6-0692b4fb4593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a7144e02-c3a1-4687-8297-1a2799fc609f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df229f59-f810-4b0a-8c07-203b6dc97105" xlink:to="loc_us-gaap_CommonStockSharesIssued_a7144e02-c3a1-4687-8297-1a2799fc609f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2c8fccd5-4abd-4100-8226-741dbe3b81d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df229f59-f810-4b0a-8c07-203b6dc97105" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2c8fccd5-4abd-4100-8226-741dbe3b81d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_7180d587-a242-440f-a0fb-322b740eb875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df229f59-f810-4b0a-8c07-203b6dc97105" xlink:to="loc_us-gaap_TreasuryStockCommonShares_7180d587-a242-440f-a0fb-322b740eb875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a0ac0eea-4b09-4b47-8386-893d83e8b7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df229f59-f810-4b0a-8c07-203b6dc97105" xlink:to="loc_us-gaap_Assets_a0ac0eea-4b09-4b47-8386-893d83e8b7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_dfca48d1-c7bf-4a30-b443-a68ccb9b8312" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df229f59-f810-4b0a-8c07-203b6dc97105" xlink:to="loc_us-gaap_Liabilities_dfca48d1-c7bf-4a30-b443-a68ccb9b8312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_491e27ef-5f91-4278-8d2a-8ba59642585f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df229f59-f810-4b0a-8c07-203b6dc97105" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_491e27ef-5f91-4278-8d2a-8ba59642585f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliates_d07c144a-0ffa-49d5-a6a8-7604913c0402" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromAffiliates"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df229f59-f810-4b0a-8c07-203b6dc97105" xlink:to="loc_us-gaap_DueFromAffiliates_d07c144a-0ffa-49d5-a6a8-7604913c0402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrentAndNoncurrent_9e4fabe1-a9a5-42d5-9ee8-371bd2a6fad0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToAffiliateCurrentAndNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df229f59-f810-4b0a-8c07-203b6dc97105" xlink:to="loc_us-gaap_DueToAffiliateCurrentAndNoncurrent_9e4fabe1-a9a5-42d5-9ee8-371bd2a6fad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="ameh-20220331.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_e7310a1d-3467-4548-8225-e71f9dc3380e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_70c40192-89b2-4c09-bb72-7a0dd1f19031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e7310a1d-3467-4548-8225-e71f9dc3380e" xlink:to="loc_us-gaap_StatementTable_70c40192-89b2-4c09-bb72-7a0dd1f19031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fa72a03c-31bf-47d4-9a3e-9523313d72f4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_70c40192-89b2-4c09-bb72-7a0dd1f19031" xlink:to="loc_srt_ProductOrServiceAxis_fa72a03c-31bf-47d4-9a3e-9523313d72f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2b72ad86-8ae7-40aa-b0c6-8e64d5b2efff" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_fa72a03c-31bf-47d4-9a3e-9523313d72f4" xlink:to="loc_srt_ProductsAndServicesDomain_2b72ad86-8ae7-40aa-b0c6-8e64d5b2efff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HealthCareCapitationRevenueMember_110c53db-be70-41ff-8a60-8c2c06aef0aa" xlink:href="ameh-20220331.xsd#ameh_HealthCareCapitationRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2b72ad86-8ae7-40aa-b0c6-8e64d5b2efff" xlink:to="loc_ameh_HealthCareCapitationRevenueMember_110c53db-be70-41ff-8a60-8c2c06aef0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOtherMember_4c7c9ae6-c395-406b-98f5-6648b13bb2f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2b72ad86-8ae7-40aa-b0c6-8e64d5b2efff" xlink:to="loc_us-gaap_HealthCareOtherMember_4c7c9ae6-c395-406b-98f5-6648b13bb2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember_2e8fcf72-1571-4d56-92de-ee327f774435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementServiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2b72ad86-8ae7-40aa-b0c6-8e64d5b2efff" xlink:to="loc_us-gaap_ManagementServiceMember_2e8fcf72-1571-4d56-92de-ee327f774435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCarePatientServiceMember_018f345a-b680-494e-8429-784dfa4981dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCarePatientServiceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2b72ad86-8ae7-40aa-b0c6-8e64d5b2efff" xlink:to="loc_us-gaap_HealthCarePatientServiceMember_018f345a-b680-494e-8429-784dfa4981dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_a215f073-5512-4af4-bed2-3b65ce7ccd2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2b72ad86-8ae7-40aa-b0c6-8e64d5b2efff" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_a215f073-5512-4af4-bed2-3b65ce7ccd2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d5ef6e45-f26a-4917-ad64-61c015dcde1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_70c40192-89b2-4c09-bb72-7a0dd1f19031" xlink:to="loc_us-gaap_StatementLineItems_d5ef6e45-f26a-4917-ad64-61c015dcde1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_f0e83204-bd12-450c-89b8-d1f6287f20e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d5ef6e45-f26a-4917-ad64-61c015dcde1d" xlink:to="loc_us-gaap_RevenuesAbstract_f0e83204-bd12-450c-89b8-d1f6287f20e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fbe64edc-dafc-404b-8740-eb751f97b27f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_f0e83204-bd12-450c-89b8-d1f6287f20e3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fbe64edc-dafc-404b-8740-eb751f97b27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1a499e20-ccf7-4725-8079-6c1abe68e4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d5ef6e45-f26a-4917-ad64-61c015dcde1d" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1a499e20-ccf7-4725-8079-6c1abe68e4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_1797bafd-a23d-4901-a1f3-e39c2ea98287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1a499e20-ccf7-4725-8079-6c1abe68e4c1" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_1797bafd-a23d-4901-a1f3-e39c2ea98287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_c69b362e-da5a-4f67-9479-fe578fb78dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1a499e20-ccf7-4725-8079-6c1abe68e4c1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_c69b362e-da5a-4f67-9479-fe578fb78dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_f7d517cd-cbca-4e40-9ed0-dccc0485c9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1a499e20-ccf7-4725-8079-6c1abe68e4c1" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_f7d517cd-cbca-4e40-9ed0-dccc0485c9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_6869d60e-c964-4a18-a0b0-2532e00252ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1a499e20-ccf7-4725-8079-6c1abe68e4c1" xlink:to="loc_us-gaap_CostsAndExpenses_6869d60e-c964-4a18-a0b0-2532e00252ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e20995f0-42e1-4ab9-ba2b-c0bd90c1ad6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d5ef6e45-f26a-4917-ad64-61c015dcde1d" xlink:to="loc_us-gaap_OperatingIncomeLoss_e20995f0-42e1-4ab9-ba2b-c0bd90c1ad6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4e92e337-c7e6-4c15-8f00-02e737ff385a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d5ef6e45-f26a-4917-ad64-61c015dcde1d" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4e92e337-c7e6-4c15-8f00-02e737ff385a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_67a18f22-c4bb-4d01-b1ba-2191007ab439" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4e92e337-c7e6-4c15-8f00-02e737ff385a" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_67a18f22-c4bb-4d01-b1ba-2191007ab439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_4d6718c7-fbf7-4189-ae93-a528417bdbf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4e92e337-c7e6-4c15-8f00-02e737ff385a" xlink:to="loc_us-gaap_InterestExpense_4d6718c7-fbf7-4189-ae93-a528417bdbf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_84ed3e49-7fc4-41e9-8e88-aee3b6cfdfe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4e92e337-c7e6-4c15-8f00-02e737ff385a" xlink:to="loc_us-gaap_InvestmentIncomeInterest_84ed3e49-7fc4-41e9-8e88-aee3b6cfdfe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_936b8c9f-1c52-4763-aa6f-9991ffaa948f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4e92e337-c7e6-4c15-8f00-02e737ff385a" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_936b8c9f-1c52-4763-aa6f-9991ffaa948f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_169a5d85-7fa7-4231-9a02-b1cc2436ede2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4e92e337-c7e6-4c15-8f00-02e737ff385a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_169a5d85-7fa7-4231-9a02-b1cc2436ede2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1aff5726-4f33-40d3-841e-7111946f872d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4e92e337-c7e6-4c15-8f00-02e737ff385a" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_1aff5726-4f33-40d3-841e-7111946f872d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e5f13959-ace1-48c3-aafb-ffcd86e41c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d5ef6e45-f26a-4917-ad64-61c015dcde1d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e5f13959-ace1-48c3-aafb-ffcd86e41c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b4d0b720-d2f6-468a-8926-adf6cd4e9962" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d5ef6e45-f26a-4917-ad64-61c015dcde1d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b4d0b720-d2f6-468a-8926-adf6cd4e9962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_29487748-0510-4515-aa6c-a3a641ef6a80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d5ef6e45-f26a-4917-ad64-61c015dcde1d" xlink:to="loc_us-gaap_ProfitLoss_29487748-0510-4515-aa6c-a3a641ef6a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b4955554-0b9e-4e8d-af22-ce880f064e56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d5ef6e45-f26a-4917-ad64-61c015dcde1d" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b4955554-0b9e-4e8d-af22-ce880f064e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6a9a3888-ff94-44d2-a9cf-6fc3a61fd54f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d5ef6e45-f26a-4917-ad64-61c015dcde1d" xlink:to="loc_us-gaap_NetIncomeLoss_6a9a3888-ff94-44d2-a9cf-6fc3a61fd54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_bd981cb4-7801-48ad-9dd1-3974c47838c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d5ef6e45-f26a-4917-ad64-61c015dcde1d" xlink:to="loc_us-gaap_EarningsPerShareBasic_bd981cb4-7801-48ad-9dd1-3974c47838c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_73ff38a2-7e67-4391-8cd8-298a60f40d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d5ef6e45-f26a-4917-ad64-61c015dcde1d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_73ff38a2-7e67-4391-8cd8-298a60f40d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ameh-20220331.xsd#CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_e3f85f69-5162-4620-bd92-da0c85ad25a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d94aeb9c-4613-4914-9a0d-98a6ca07d805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_e3f85f69-5162-4620-bd92-da0c85ad25a4" xlink:to="loc_us-gaap_StatementTable_d94aeb9c-4613-4914-9a0d-98a6ca07d805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_448d4fbc-7c0b-4cd3-91a0-860b0d7443e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d94aeb9c-4613-4914-9a0d-98a6ca07d805" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_448d4fbc-7c0b-4cd3-91a0-860b0d7443e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_98cbc85f-d6ab-474e-bf36-569c8a102f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_448d4fbc-7c0b-4cd3-91a0-860b0d7443e7" xlink:to="loc_us-gaap_EquityComponentDomain_98cbc85f-d6ab-474e-bf36-569c8a102f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ac032fa2-b923-4c15-96b5-4888551578ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_98cbc85f-d6ab-474e-bf36-569c8a102f6b" xlink:to="loc_us-gaap_CommonStockMember_ac032fa2-b923-4c15-96b5-4888551578ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1e0c19ce-514e-4e09-8f9e-82f7d1990101" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_98cbc85f-d6ab-474e-bf36-569c8a102f6b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1e0c19ce-514e-4e09-8f9e-82f7d1990101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_66d7b829-51e5-46b9-907b-14cb009e7244" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_98cbc85f-d6ab-474e-bf36-569c8a102f6b" xlink:to="loc_us-gaap_RetainedEarningsMember_66d7b829-51e5-46b9-907b-14cb009e7244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_23dcaef2-14c2-40af-a56d-83b97c8e1e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_98cbc85f-d6ab-474e-bf36-569c8a102f6b" xlink:to="loc_us-gaap_NoncontrollingInterestMember_23dcaef2-14c2-40af-a56d-83b97c8e1e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a2997023-e854-4b2f-9711-ddcd7f1e417d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d94aeb9c-4613-4914-9a0d-98a6ca07d805" xlink:to="loc_dei_LegalEntityAxis_a2997023-e854-4b2f-9711-ddcd7f1e417d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0444767f-0ef8-47a9-b2bb-b48feca09665" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_a2997023-e854-4b2f-9711-ddcd7f1e417d" xlink:to="loc_dei_EntityDomain_0444767f-0ef8-47a9-b2bb-b48feca09665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineMember_b325e470-e4aa-4d90-8607-721577948645" xlink:href="ameh-20220331.xsd#ameh_MezzanineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_0444767f-0ef8-47a9-b2bb-b48feca09665" xlink:to="loc_ameh_MezzanineMember_b325e470-e4aa-4d90-8607-721577948645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1d93cdf0-d423-4c2d-9808-644efca57c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d94aeb9c-4613-4914-9a0d-98a6ca07d805" xlink:to="loc_us-gaap_StatementLineItems_1d93cdf0-d423-4c2d-9808-644efca57c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_40d9bfd0-1759-4fdd-8921-a9dad94503cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1d93cdf0-d423-4c2d-9808-644efca57c7a" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_40d9bfd0-1759-4fdd-8921-a9dad94503cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_2b3666a7-6a72-49cd-95a6-47e37ab1d2f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_40d9bfd0-1759-4fdd-8921-a9dad94503cd" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_2b3666a7-6a72-49cd-95a6-47e37ab1d2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome_0b0166da-298d-4db9-885e-e794d956ee56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_40d9bfd0-1759-4fdd-8921-a9dad94503cd" xlink:to="loc_us-gaap_TemporaryEquityNetIncome_0b0166da-298d-4db9-885e-e794d956ee56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionOfDividends_cfa3fc24-af54-4d42-90c8-e32f71cb295a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAccretionOfDividends"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_40d9bfd0-1759-4fdd-8921-a9dad94503cd" xlink:to="loc_us-gaap_TemporaryEquityAccretionOfDividends_cfa3fc24-af54-4d42-90c8-e32f71cb295a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_ad5006c3-3914-4c7e-8169-16d93eed1ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_40d9bfd0-1759-4fdd-8921-a9dad94503cd" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_ad5006c3-3914-4c7e-8169-16d93eed1ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_48ce054e-2c44-4b3a-a16e-ef16f6e3e794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_40d9bfd0-1759-4fdd-8921-a9dad94503cd" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_48ce054e-2c44-4b3a-a16e-ef16f6e3e794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1d93cdf0-d423-4c2d-9808-644efca57c7a" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_a4d64f85-b370-4f45-ada6-c9fa28808d07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_us-gaap_SharesOutstanding_a4d64f85-b370-4f45-ada6-c9fa28808d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5d691e84-c9c5-448b-b668-b29045e76518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5d691e84-c9c5-448b-b668-b29045e76518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_f9faa2af-6a99-4517-8d1a-17c6bd7ec979" xlink:href="ameh-20220331.xsd#ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_f9faa2af-6a99-4517-8d1a-17c6bd7ec979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_766643a1-a03e-483a-ad7b-de9606f92cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_766643a1-a03e-483a-ad7b-de9606f92cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_814ffc3e-810a-4eca-b006-015e5d0a5462" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_814ffc3e-810a-4eca-b006-015e5d0a5462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_5b682004-ebce-48e7-8c02-d22595c1b3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_5b682004-ebce-48e7-8c02-d22595c1b3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_e0fa39df-2974-4ce5-a5a8-435504ed13a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_e0fa39df-2974-4ce5-a5a8-435504ed13a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_8d984a52-919e-4fe6-8f87-f3a756e564c7" xlink:href="ameh-20220331.xsd#ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_8d984a52-919e-4fe6-8f87-f3a756e564c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_47162966-8fff-4eb1-bdf4-13aae7609f10" xlink:href="ameh-20220331.xsd#ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_47162966-8fff-4eb1-bdf4-13aae7609f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_6055ad7c-c66c-4483-b8bb-91c972ac21ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_6055ad7c-c66c-4483-b8bb-91c972ac21ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_5b6278f6-b09e-4ec9-b28c-f7f83b49f92c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredParValueMethod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_5b6278f6-b09e-4ec9-b28c-f7f83b49f92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_19681713-7a37-48aa-a277-136745f22038" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_19681713-7a37-48aa-a277-136745f22038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_4f5c80aa-d82f-447f-aa31-9f7bf891838c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_4f5c80aa-d82f-447f-aa31-9f7bf891838c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_06328c4f-da25-4d3c-8187-5a5b8e3efc56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_06328c4f-da25-4d3c-8187-5a5b8e3efc56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares_c7fc467a-2109-4bc5-9fb2-3feb159da605" xlink:href="ameh-20220331.xsd#ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares_c7fc467a-2109-4bc5-9fb2-3feb159da605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_28062052-8cc8-47c9-a9d1-393618b46ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_28062052-8cc8-47c9-a9d1-393618b46ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_bc0373cd-841f-42db-b0a5-ef4d6a7e8257" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_bc0373cd-841f-42db-b0a5-ef4d6a7e8257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_99163973-619a-41b7-99e4-67195955e218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_99163973-619a-41b7-99e4-67195955e218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_22c34f5d-d65d-464d-a646-d95b8c7c2b49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09448234-a6db-460f-9bde-9858b1725729" xlink:to="loc_us-gaap_SharesOutstanding_22c34f5d-d65d-464d-a646-d95b8c7c2b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="ameh-20220331.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_7ce2ede5-c320-4603-bd82-a5388da5be5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b5c4f71a-7f41-49cf-941b-e7dc79c50783" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7ce2ede5-c320-4603-bd82-a5388da5be5c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b5c4f71a-7f41-49cf-941b-e7dc79c50783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_74fe3dba-dace-4e07-9423-637e5d459e81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b5c4f71a-7f41-49cf-941b-e7dc79c50783" xlink:to="loc_us-gaap_ProfitLoss_74fe3dba-dace-4e07-9423-637e5d459e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_95c6c7e0-c180-45fd-87a9-f5fa83499f21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b5c4f71a-7f41-49cf-941b-e7dc79c50783" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_95c6c7e0-c180-45fd-87a9-f5fa83499f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f3983318-2e55-447a-a4a5-f08dd2b1470e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_95c6c7e0-c180-45fd-87a9-f5fa83499f21" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f3983318-2e55-447a-a4a5-f08dd2b1470e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_831f6b6b-0aee-42c9-83a0-e90fdf58284f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_95c6c7e0-c180-45fd-87a9-f5fa83499f21" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_831f6b6b-0aee-42c9-83a0-e90fdf58284f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_78db4f2e-bce3-4493-b636-6f8a6c84cf46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_95c6c7e0-c180-45fd-87a9-f5fa83499f21" xlink:to="loc_us-gaap_ShareBasedCompensation_78db4f2e-bce3-4493-b636-6f8a6c84cf46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities_26395ed4-65e9-4a4d-a15f-004fc9e6ee4c" xlink:href="ameh-20220331.xsd#ameh_UnrealizedGainLossFromInvestmentInEquitySecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_95c6c7e0-c180-45fd-87a9-f5fa83499f21" xlink:to="loc_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities_26395ed4-65e9-4a4d-a15f-004fc9e6ee4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_68513ff5-31b8-410e-9256-40383b3b9b15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_95c6c7e0-c180-45fd-87a9-f5fa83499f21" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_68513ff5-31b8-410e-9256-40383b3b9b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_884833c1-064f-44f3-81ff-8c793424cde0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_95c6c7e0-c180-45fd-87a9-f5fa83499f21" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_884833c1-064f-44f3-81ff-8c793424cde0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_2aa6e0a8-e97e-48d4-837e-acb89081e07b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_95c6c7e0-c180-45fd-87a9-f5fa83499f21" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_2aa6e0a8-e97e-48d4-837e-acb89081e07b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b21ab3b2-688c-46f8-ae6e-c497ca760b34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_95c6c7e0-c180-45fd-87a9-f5fa83499f21" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b21ab3b2-688c-46f8-ae6e-c497ca760b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_02ec40a3-1e35-4911-bcc0-62d34c1d8427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b21ab3b2-688c-46f8-ae6e-c497ca760b34" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_02ec40a3-1e35-4911-bcc0-62d34c1d8427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_5b7c4822-5c27-44d4-ac66-2efa47d010fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b21ab3b2-688c-46f8-ae6e-c497ca760b34" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_5b7c4822-5c27-44d4-ac66-2efa47d010fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_72aad256-48f9-4eb1-b60c-e31556c2b893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b21ab3b2-688c-46f8-ae6e-c497ca760b34" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_72aad256-48f9-4eb1-b60c-e31556c2b893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_1fca9dc0-57ec-4c94-bffa-18fb9b7e281c" xlink:href="ameh-20220331.xsd#ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b21ab3b2-688c-46f8-ae6e-c497ca760b34" xlink:to="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_1fca9dc0-57ec-4c94-bffa-18fb9b7e281c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets_3f70cf74-3b1a-4f66-90e8-99ffd64991ef" xlink:href="ameh-20220331.xsd#ameh_IncreaseDecreaseInOperatingLeaseAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b21ab3b2-688c-46f8-ae6e-c497ca760b34" xlink:to="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets_3f70cf74-3b1a-4f66-90e8-99ffd64991ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_51cf6afe-60fd-4705-8f98-d2951efacfde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b21ab3b2-688c-46f8-ae6e-c497ca760b34" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_51cf6afe-60fd-4705-8f98-d2951efacfde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ef13e651-724d-4256-8b56-c188ec2e8894" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b21ab3b2-688c-46f8-ae6e-c497ca760b34" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ef13e651-724d-4256-8b56-c188ec2e8894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_87d377e4-bcb8-4c12-a129-33c080c467b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b21ab3b2-688c-46f8-ae6e-c497ca760b34" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_87d377e4-bcb8-4c12-a129-33c080c467b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInMedicalLiabilities_457b3d52-d30c-4a17-b18b-c0e8381c12d0" xlink:href="ameh-20220331.xsd#ameh_IncreaseDecreaseInMedicalLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b21ab3b2-688c-46f8-ae6e-c497ca760b34" xlink:to="loc_ameh_IncreaseDecreaseInMedicalLiabilities_457b3d52-d30c-4a17-b18b-c0e8381c12d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_af31b579-380d-4286-ab02-5d98dc6d01e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b21ab3b2-688c-46f8-ae6e-c497ca760b34" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_af31b579-380d-4286-ab02-5d98dc6d01e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_d09390d2-05fb-42aa-a656-fd586be962ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b21ab3b2-688c-46f8-ae6e-c497ca760b34" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_d09390d2-05fb-42aa-a656-fd586be962ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0cd521f3-5a32-4a59-83d1-669afbd52061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b5c4f71a-7f41-49cf-941b-e7dc79c50783" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0cd521f3-5a32-4a59-83d1-669afbd52061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f761dd0-29c5-4e6f-9031-b33e51ee44fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7ce2ede5-c320-4603-bd82-a5388da5be5c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f761dd0-29c5-4e6f-9031-b33e51ee44fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_bdf217b3-8a04-4dcc-bf9c-e2079bf8271f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f761dd0-29c5-4e6f-9031-b33e51ee44fb" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_bdf217b3-8a04-4dcc-bf9c-e2079bf8271f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_816f50dc-065a-482b-8dc9-c7d4a127fbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f761dd0-29c5-4e6f-9031-b33e51ee44fb" xlink:to="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_816f50dc-065a-482b-8dc9-c7d4a127fbf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_65b432a1-6c63-420f-b542-c66088265b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f761dd0-29c5-4e6f-9031-b33e51ee44fb" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_65b432a1-6c63-420f-b542-c66088265b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3102d32d-0adc-4228-90d0-172269003fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f761dd0-29c5-4e6f-9031-b33e51ee44fb" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3102d32d-0adc-4228-90d0-172269003fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_f24814e9-6b7c-48c8-9fac-354a78d24ace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f761dd0-29c5-4e6f-9031-b33e51ee44fb" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_f24814e9-6b7c-48c8-9fac-354a78d24ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_480b6e3d-a07a-4cc1-962c-fd028f2ef6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f761dd0-29c5-4e6f-9031-b33e51ee44fb" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_480b6e3d-a07a-4cc1-962c-fd028f2ef6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_590d860d-3ffd-46fe-8356-47b4e343523c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f761dd0-29c5-4e6f-9031-b33e51ee44fb" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_590d860d-3ffd-46fe-8356-47b4e343523c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4d111cab-1b76-45d2-85b5-47a74d352edc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f761dd0-29c5-4e6f-9031-b33e51ee44fb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4d111cab-1b76-45d2-85b5-47a74d352edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc8c080b-5364-4ad7-a723-4ea7c09557aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7ce2ede5-c320-4603-bd82-a5388da5be5c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc8c080b-5364-4ad7-a723-4ea7c09557aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_ef47ada2-914d-4227-885d-302256776dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc8c080b-5364-4ad7-a723-4ea7c09557aa" xlink:to="loc_us-gaap_PaymentsOfDividends_ef47ada2-914d-4227-885d-302256776dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_4d06cb92-6781-474b-b754-e654527934d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc8c080b-5364-4ad7-a723-4ea7c09557aa" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_4d06cb92-6781-474b-b754-e654527934d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_692e5212-5e8d-4686-8989-9ba7ea012e33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc8c080b-5364-4ad7-a723-4ea7c09557aa" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_692e5212-5e8d-4686-8989-9ba7ea012e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_c49afe50-edbb-4abe-8f41-4960ae47f6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc8c080b-5364-4ad7-a723-4ea7c09557aa" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_c49afe50-edbb-4abe-8f41-4960ae47f6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_fdf8f580-31a9-4d9e-88de-68161c165ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc8c080b-5364-4ad7-a723-4ea7c09557aa" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_fdf8f580-31a9-4d9e-88de-68161c165ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_ccdf3495-fce8-403e-9234-87691411d8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc8c080b-5364-4ad7-a723-4ea7c09557aa" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_ccdf3495-fce8-403e-9234-87691411d8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ProceedsFromSaleOfNoncontrollingInterest_2eae0750-ac52-4e97-b2f0-89544c11e4c8" xlink:href="ameh-20220331.xsd#ameh_ProceedsFromSaleOfNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc8c080b-5364-4ad7-a723-4ea7c09557aa" xlink:to="loc_ameh_ProceedsFromSaleOfNoncontrollingInterest_2eae0750-ac52-4e97-b2f0-89544c11e4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireNonControllingInterest_dab1e45d-0e19-42ea-a81d-be066ab0cc72" xlink:href="ameh-20220331.xsd#ameh_PaymentsToAcquireNonControllingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc8c080b-5364-4ad7-a723-4ea7c09557aa" xlink:to="loc_ameh_PaymentsToAcquireNonControllingInterest_dab1e45d-0e19-42ea-a81d-be066ab0cc72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_e9371d1c-6a1e-4c5c-abd7-fa6b76fb86a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc8c080b-5364-4ad7-a723-4ea7c09557aa" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_e9371d1c-6a1e-4c5c-abd7-fa6b76fb86a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_53d1b63c-d44d-49a8-9e9d-43af945f3c14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc8c080b-5364-4ad7-a723-4ea7c09557aa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_53d1b63c-d44d-49a8-9e9d-43af945f3c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7637b15a-304a-46b5-8a39-a4bfb33d7b34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7ce2ede5-c320-4603-bd82-a5388da5be5c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7637b15a-304a-46b5-8a39-a4bfb33d7b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8a8ce0a1-5d12-4b00-8420-6028e678414a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7ce2ede5-c320-4603-bd82-a5388da5be5c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8a8ce0a1-5d12-4b00-8420-6028e678414a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b334d240-edbc-4e54-b8e9-c8036b44ac29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7ce2ede5-c320-4603-bd82-a5388da5be5c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b334d240-edbc-4e54-b8e9-c8036b44ac29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_023ee5bf-e106-42e9-a4d0-9fe4975c4978" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7ce2ede5-c320-4603-bd82-a5388da5be5c" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_023ee5bf-e106-42e9-a4d0-9fe4975c4978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_69ff9937-83a4-4f2c-8a00-0368b74ac603" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_023ee5bf-e106-42e9-a4d0-9fe4975c4978" xlink:to="loc_us-gaap_IncomeTaxesPaid_69ff9937-83a4-4f2c-8a00-0368b74ac603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_c36c3e5d-223d-4809-b605-c2940cd7911b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_023ee5bf-e106-42e9-a4d0-9fe4975c4978" xlink:to="loc_us-gaap_InterestPaidNet_c36c3e5d-223d-4809-b605-c2940cd7911b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6c04f143-8b82-4aad-abda-7e2df933342b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7ce2ede5-c320-4603-bd82-a5388da5be5c" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6c04f143-8b82-4aad-abda-7e2df933342b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_c32a1642-c924-4977-8bdf-2a6d137cd2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6c04f143-8b82-4aad-abda-7e2df933342b" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_c32a1642-c924-4977-8bdf-2a6d137cd2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_e7def77b-da1a-4091-8662-62f2a2730067" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6c04f143-8b82-4aad-abda-7e2df933342b" xlink:to="loc_us-gaap_StockIssued1_e7def77b-da1a-4091-8662-62f2a2730067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_f9d1716e-f007-44e9-b175-7515f398730e" xlink:href="ameh-20220331.xsd#ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7ce2ede5-c320-4603-bd82-a5388da5be5c" xlink:to="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_f9d1716e-f007-44e9-b175-7515f398730e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e961c2c5-8e8f-4d73-8da4-87cae3f0dc83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_f9d1716e-f007-44e9-b175-7515f398730e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e961c2c5-8e8f-4d73-8da4-87cae3f0dc83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsCurrent_b49df4c4-e1f8-446c-9dd4-123790a3d97d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_f9d1716e-f007-44e9-b175-7515f398730e" xlink:to="loc_us-gaap_RestrictedCashEquivalentsCurrent_b49df4c4-e1f8-446c-9dd4-123790a3d97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_44e0e944-0fe4-46bc-af72-de9fd67c9726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_f9d1716e-f007-44e9-b175-7515f398730e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_44e0e944-0fe4-46bc-af72-de9fd67c9726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/DescriptionofBusiness" xlink:type="simple" xlink:href="ameh-20220331.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a8adf3fa-07eb-4512-a7ea-e4f505c10664" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_2c8924c8-74c5-4c01-b712-230ed39b0de7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a8adf3fa-07eb-4512-a7ea-e4f505c10664" xlink:to="loc_us-gaap_NatureOfOperations_2c8924c8-74c5-4c01-b712-230ed39b0de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#DescriptionofBusinessAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_33acc7d7-f77e-4206-abb2-3e80bc33b59e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessTable_85979158-2315-4f17-acca-e3fa34644922" xlink:href="ameh-20220331.xsd#ameh_DescriptionOfBusinessTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_33acc7d7-f77e-4206-abb2-3e80bc33b59e" xlink:to="loc_ameh_DescriptionOfBusinessTable_85979158-2315-4f17-acca-e3fa34644922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_24f21fdd-d56b-45e9-96f2-a696b7d6cd36" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_85979158-2315-4f17-acca-e3fa34644922" xlink:to="loc_dei_LegalEntityAxis_24f21fdd-d56b-45e9-96f2-a696b7d6cd36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4192acee-44a5-493e-8106-62c249e93cdd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_24f21fdd-d56b-45e9-96f2-a696b7d6cd36" xlink:to="loc_dei_EntityDomain_4192acee-44a5-493e-8106-62c249e93cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ffa51460-4f12-4c5f-84c6-897072d84d32" xlink:href="ameh-20220331.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4192acee-44a5-493e-8106-62c249e93cdd" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ffa51460-4f12-4c5f-84c6-897072d84d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_3316c575-df7a-4e1c-a19f-f072f749493f" xlink:href="ameh-20220331.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4192acee-44a5-493e-8106-62c249e93cdd" xlink:to="loc_ameh_AccountableHealthCareIPAMember_3316c575-df7a-4e1c-a19f-f072f749493f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember_44d1997b-023e-405a-922d-aacead1971cf" xlink:href="ameh-20220331.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4192acee-44a5-493e-8106-62c249e93cdd" xlink:to="loc_ameh_APCAndAPCLSMAMember_44d1997b-023e-405a-922d-aacead1971cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_dc299298-9d40-4afd-bb43-75a19bd38863" xlink:href="ameh-20220331.xsd#ameh_AmgIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4192acee-44a5-493e-8106-62c249e93cdd" xlink:to="loc_ameh_AmgIncMember_dc299298-9d40-4afd-bb43-75a19bd38863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember_cb188193-bf57-4d6a-870d-2655b3bac665" xlink:href="ameh-20220331.xsd#ameh_ApcLsmaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4192acee-44a5-493e-8106-62c249e93cdd" xlink:to="loc_ameh_ApcLsmaMember_cb188193-bf57-4d6a-870d-2655b3bac665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0513f3a4-9e8d-486b-a60b-718976b5a784" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_85979158-2315-4f17-acca-e3fa34644922" xlink:to="loc_srt_CounterpartyNameAxis_0513f3a4-9e8d-486b-a60b-718976b5a784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b9f98e54-a897-4c42-a9d1-cc0338b4845c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0513f3a4-9e8d-486b-a60b-718976b5a784" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b9f98e54-a897-4c42-a9d1-cc0338b4845c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APAMHMedicalCorporationMember_09fc68aa-352c-47d7-8098-70cedebb7536" xlink:href="ameh-20220331.xsd#ameh_APAMHMedicalCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b9f98e54-a897-4c42-a9d1-cc0338b4845c" xlink:to="loc_ameh_APAMHMedicalCorporationMember_09fc68aa-352c-47d7-8098-70cedebb7536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_c9fe6d87-1bb8-4253-a111-aee842219059" xlink:href="ameh-20220331.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b9f98e54-a897-4c42-a9d1-cc0338b4845c" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_c9fe6d87-1bb8-4253-a111-aee842219059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.JayMember_58ebfa9c-8234-42ce-a310-fb1f6a5cef92" xlink:href="ameh-20220331.xsd#ameh_Dr.JayMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b9f98e54-a897-4c42-a9d1-cc0338b4845c" xlink:to="loc_ameh_Dr.JayMember_58ebfa9c-8234-42ce-a310-fb1f6a5cef92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a17e8b2e-5d1b-4780-98bb-ed1b9e085da3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_85979158-2315-4f17-acca-e3fa34644922" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a17e8b2e-5d1b-4780-98bb-ed1b9e085da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_06c28adc-16a3-4971-ab82-388ec12b6fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a17e8b2e-5d1b-4780-98bb-ed1b9e085da3" xlink:to="loc_us-gaap_RelatedPartyDomain_06c28adc-16a3-4971-ab82-388ec12b6fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_3faf3f93-ba6e-4d89-8ea1-7b62340aae20" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_06c28adc-16a3-4971-ab82-388ec12b6fd8" xlink:to="loc_srt_AffiliatedEntityMember_3faf3f93-ba6e-4d89-8ea1-7b62340aae20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_fbd8e73d-2f96-46a2-9c9a-9913bea663a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_85979158-2315-4f17-acca-e3fa34644922" xlink:to="loc_us-gaap_StatementClassOfStockAxis_fbd8e73d-2f96-46a2-9c9a-9913bea663a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8deed632-c71e-4828-85c3-61f056c57cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fbd8e73d-2f96-46a2-9c9a-9913bea663a7" xlink:to="loc_us-gaap_ClassOfStockDomain_8deed632-c71e-4828-85c3-61f056c57cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_62264207-95f2-4890-b277-33dadba7a50b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8deed632-c71e-4828-85c3-61f056c57cf1" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_62264207-95f2-4890-b277-33dadba7a50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7b9993f6-5d70-4db7-b5a0-ff54c0856af8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_85979158-2315-4f17-acca-e3fa34644922" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7b9993f6-5d70-4db7-b5a0-ff54c0856af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1ccd75de-8ee8-4699-9fa0-126f3df75109" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7b9993f6-5d70-4db7-b5a0-ff54c0856af8" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1ccd75de-8ee8-4699-9fa0-126f3df75109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloMedicalHoldingsIncMember_650a1e82-cf36-42a2-a4fe-3a706870976a" xlink:href="ameh-20220331.xsd#ameh_ApolloMedicalHoldingsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1ccd75de-8ee8-4699-9fa0-126f3df75109" xlink:to="loc_ameh_ApolloMedicalHoldingsIncMember_650a1e82-cf36-42a2-a4fe-3a706870976a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_d8923b37-7cf9-49e7-939c-f91567261178" xlink:href="ameh-20220331.xsd#ameh_ConcourseDiagnosticSurgeryCenterLlcMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1ccd75de-8ee8-4699-9fa0-126f3df75109" xlink:to="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_d8923b37-7cf9-49e7-939c-f91567261178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_c44e4da6-43f9-497a-aed6-e40d9aa5a8a9" xlink:href="ameh-20220331.xsd#ameh_DmgMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1ccd75de-8ee8-4699-9fa0-126f3df75109" xlink:to="loc_ameh_DmgMember_c44e4da6-43f9-497a-aed6-e40d9aa5a8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_afd154df-7324-49ca-83b8-d07ef65f3f29" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_85979158-2315-4f17-acca-e3fa34644922" xlink:to="loc_srt_OwnershipAxis_afd154df-7324-49ca-83b8-d07ef65f3f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_5c22231d-96ee-481d-a176-f916df822362" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_afd154df-7324-49ca-83b8-d07ef65f3f29" xlink:to="loc_srt_OwnershipDomain_5c22231d-96ee-481d-a176-f916df822362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MaverickMedicalGroupIncMember_3da0d41f-3463-4539-b499-5b62cb174aaa" xlink:href="ameh-20220331.xsd#ameh_MaverickMedicalGroupIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_5c22231d-96ee-481d-a176-f916df822362" xlink:to="loc_ameh_MaverickMedicalGroupIncMember_3da0d41f-3463-4539-b499-5b62cb174aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_dc14be2a-2fcc-40fd-89db-f6b05555a1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_85979158-2315-4f17-acca-e3fa34644922" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_dc14be2a-2fcc-40fd-89db-f6b05555a1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_92802ea8-3bfe-4a12-ab42-8b052defa3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dc14be2a-2fcc-40fd-89db-f6b05555a1bd" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_92802ea8-3bfe-4a12-ab42-8b052defa3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_fe032c41-0474-4058-ae1f-48ca1b8025d2" xlink:href="ameh-20220331.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_92802ea8-3bfe-4a12-ab42-8b052defa3ee" xlink:to="loc_ameh_AccountableHealthCareIPAMember_fe032c41-0474-4058-ae1f-48ca1b8025d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_6dceb106-4603-456b-b65e-bb93f98b88b7" xlink:href="ameh-20220331.xsd#ameh_AmgIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_92802ea8-3bfe-4a12-ab42-8b052defa3ee" xlink:to="loc_ameh_AmgIncMember_6dceb106-4603-456b-b65e-bb93f98b88b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccessPrimaryCareMedicalGroupMember_74103c71-055d-4777-aa6f-fda72b9de142" xlink:href="ameh-20220331.xsd#ameh_AccessPrimaryCareMedicalGroupMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_92802ea8-3bfe-4a12-ab42-8b052defa3ee" xlink:to="loc_ameh_AccessPrimaryCareMedicalGroupMember_74103c71-055d-4777-aa6f-fda72b9de142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloSunLabsManagementLLCMember_78265ec3-8476-49e4-b6ff-0ba9fbb50faa" xlink:href="ameh-20220331.xsd#ameh_ApolloSunLabsManagementLLCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_92802ea8-3bfe-4a12-ab42-8b052defa3ee" xlink:to="loc_ameh_ApolloSunLabsManagementLLCMember_78265ec3-8476-49e4-b6ff-0ba9fbb50faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_f9ac6f68-1e20-48df-8d6f-322210d1ca27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_85979158-2315-4f17-acca-e3fa34644922" xlink:to="loc_us-gaap_AssetAcquisitionAxis_f9ac6f68-1e20-48df-8d6f-322210d1ca27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_5f3792dd-da49-4e4e-945b-d1ad6444fb88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_f9ac6f68-1e20-48df-8d6f-322210d1ca27" xlink:to="loc_us-gaap_AssetAcquisitionDomain_5f3792dd-da49-4e4e-945b-d1ad6444fb88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_6a949e53-571a-4a6e-a51e-c85565edd697" xlink:href="ameh-20220331.xsd#ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_5f3792dd-da49-4e4e-945b-d1ad6444fb88" xlink:to="loc_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_6a949e53-571a-4a6e-a51e-c85565edd697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_9d252fac-83e2-4846-9ed8-d64d6ed66669" xlink:href="ameh-20220331.xsd#ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_5f3792dd-da49-4e4e-945b-d1ad6444fb88" xlink:to="loc_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_9d252fac-83e2-4846-9ed8-d64d6ed66669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:href="ameh-20220331.xsd#ameh_DescriptionOfBusinessLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_85979158-2315-4f17-acca-e3fa34644922" xlink:to="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_08708a6e-1df9-4303-9f95-2827036abf0d" xlink:href="ameh-20220331.xsd#ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_08708a6e-1df9-4303-9f95-2827036abf0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_3411a021-2b9e-4da0-bc83-1ca0fc3502f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_us-gaap_NotesReceivableNet_3411a021-2b9e-4da0-bc83-1ca0fc3502f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableTermOfReceivable_64e0dbba-2302-47fa-a9cf-0f8e5244fbb8" xlink:href="ameh-20220331.xsd#ameh_FinanceReceivableTermOfReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_ameh_FinanceReceivableTermOfReceivable_64e0dbba-2302-47fa-a9cf-0f8e5244fbb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableStatedInterestRate_f9777ba7-5a0c-45d3-bd7b-9d3b4cb182ee" xlink:href="ameh-20220331.xsd#ameh_FinanceReceivableStatedInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_ameh_FinanceReceivableStatedInterestRate_f9777ba7-5a0c-45d3-bd7b-9d3b4cb182ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_401f7866-0a8e-4737-80bc-6854fbf07b62" xlink:href="ameh-20220331.xsd#ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_401f7866-0a8e-4737-80bc-6854fbf07b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b57bb0a6-9e98-42f4-b2c7-21261e21e53c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b57bb0a6-9e98-42f4-b2c7-21261e21e53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_28c3a68e-1b8f-4f6d-912b-b58ecf554875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_28c3a68e-1b8f-4f6d-912b-b58ecf554875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_6f02e28a-122b-4820-baf4-c1f4d7fd2a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_6f02e28a-122b-4820-baf4-c1f4d7fd2a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFederallyQualifiedHealthPlans_36428a4a-a722-4c67-9b23-c2d2efe4f475" xlink:href="ameh-20220331.xsd#ameh_NumberOfFederallyQualifiedHealthPlans"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_ameh_NumberOfFederallyQualifiedHealthPlans_36428a4a-a722-4c67-9b23-c2d2efe4f475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_7d3e5a69-a25c-4539-95a2-2497f0f5b195" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_7d3e5a69-a25c-4539-95a2-2497f0f5b195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_0b003b63-1527-46d6-ad1c-f7780aabe7b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_0b003b63-1527-46d6-ad1c-f7780aabe7b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFamilyPracticeClinics_26632767-2561-44ba-946d-d92b4fdedac7" xlink:href="ameh-20220331.xsd#ameh_NumberOfFamilyPracticeClinics"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_ameh_NumberOfFamilyPracticeClinics_26632767-2561-44ba-946d-d92b4fdedac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_58ee503d-61ab-4eea-9f84-079358b74d04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_58ee503d-61ab-4eea-9f84-079358b74d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_a4baa98c-00cb-4ec6-8fbf-786eed50a89e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_a4baa98c-00cb-4ec6-8fbf-786eed50a89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_3082a7f6-c36b-48f5-9c5d-d393d84f703a" xlink:href="ameh-20220331.xsd#ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_3082a7f6-c36b-48f5-9c5d-d393d84f703a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_f14f84f6-4bfb-47c1-be82-1f34acfca5ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_us-gaap_EquityMethodInvestments_f14f84f6-4bfb-47c1-be82-1f34acfca5ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_0dfe72a3-a49f-4d9a-84cd-9c2897f10dc6" xlink:href="ameh-20220331.xsd#ameh_AssetAcquisitionPercentageOfSharesAcquired"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_0dfe72a3-a49f-4d9a-84cd-9c2897f10dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_c114a093-946c-45f5-8f3a-9e67a6626687" xlink:href="ameh-20220331.xsd#ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ca584a74-8465-4293-8ef8-785885e8663c" xlink:to="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_c114a093-946c-45f5-8f3a-9e67a6626687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="ameh-20220331.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6b200d08-51c1-435a-8960-4b97bf297c48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_697977d7-0a5e-4089-b46f-2f97ade42135" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6b200d08-51c1-435a-8960-4b97bf297c48" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_697977d7-0a5e-4089-b46f-2f97ade42135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ameh-20220331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ca73b678-f819-4874-a68e-00c869df7dca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b0cb8798-4964-4e7b-94b3-b86096ce363b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca73b678-f819-4874-a68e-00c869df7dca" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b0cb8798-4964-4e7b-94b3-b86096ce363b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_6f541c88-cd03-4319-915e-e423f4e99d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca73b678-f819-4874-a68e-00c869df7dca" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_6f541c88-cd03-4319-915e-e423f4e99d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_d54d99b6-b6c8-45a7-902e-563ce28d91a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca73b678-f819-4874-a68e-00c869df7dca" xlink:to="loc_us-gaap_UseOfEstimates_d54d99b6-b6c8-45a7-902e-563ce28d91a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_b3d68e5a-54af-4e5c-88ce-828d328aee1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca73b678-f819-4874-a68e-00c869df7dca" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_b3d68e5a-54af-4e5c-88ce-828d328aee1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_736f79bb-4ca0-4e7e-a980-2f557e1edacf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca73b678-f819-4874-a68e-00c869df7dca" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_736f79bb-4ca0-4e7e-a980-2f557e1edacf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_6324d69c-b49d-4f5a-99b2-e6e27818c588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca73b678-f819-4874-a68e-00c869df7dca" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_6324d69c-b49d-4f5a-99b2-e6e27818c588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_c24f6437-c308-442c-9602-81dd575b858c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca73b678-f819-4874-a68e-00c869df7dca" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_c24f6437-c308-442c-9602-81dd575b858c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_2d3e1511-2053-44fa-a7ce-4a52df734c84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca73b678-f819-4874-a68e-00c869df7dca" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_2d3e1511-2053-44fa-a7ce-4a52df734c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_7969776a-0aa0-4830-bff4-953361009879" xlink:href="ameh-20220331.xsd#ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca73b678-f819-4874-a68e-00c869df7dca" xlink:to="loc_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_7969776a-0aa0-4830-bff4-953361009879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_cb6575dd-005e-4b15-b247-444c9616358f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca73b678-f819-4874-a68e-00c869df7dca" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_cb6575dd-005e-4b15-b247-444c9616358f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_1d9ed407-95c2-46a3-8a94-883b6ef159b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca73b678-f819-4874-a68e-00c869df7dca" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_1d9ed407-95c2-46a3-8a94-883b6ef159b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_70d9ecfd-1c43-4782-bc88-11a48f0ab49b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca73b678-f819-4874-a68e-00c869df7dca" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_70d9ecfd-1c43-4782-bc88-11a48f0ab49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_99fe2161-3bed-4de7-9b15-6baaf958cfc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca73b678-f819-4874-a68e-00c869df7dca" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_99fe2161-3bed-4de7-9b15-6baaf958cfc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_ae551d9c-6f1a-4098-a324-eb5ac31e7faa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca73b678-f819-4874-a68e-00c869df7dca" xlink:to="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_ae551d9c-6f1a-4098-a324-eb5ac31e7faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock_e2564aca-e9c5-4f38-975c-c7289aad115a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareCostsPolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca73b678-f819-4874-a68e-00c869df7dca" xlink:to="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock_e2564aca-e9c5-4f38-975c-c7289aad115a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryCashAndPayablePolicyTextBlock_8fbddf39-f6fc-40fa-ae14-10e69d16aa5a" xlink:href="ameh-20220331.xsd#ameh_FiduciaryCashAndPayablePolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca73b678-f819-4874-a68e-00c869df7dca" xlink:to="loc_ameh_FiduciaryCashAndPayablePolicyTextBlock_8fbddf39-f6fc-40fa-ae14-10e69d16aa5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_006cc1f3-74df-4096-adb4-97da09e8e1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca73b678-f819-4874-a68e-00c869df7dca" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_006cc1f3-74df-4096-adb4-97da09e8e1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_f12be1fd-67fd-4957-88bc-ed491f4ffe4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca73b678-f819-4874-a68e-00c869df7dca" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_f12be1fd-67fd-4957-88bc-ed491f4ffe4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_7dc6654a-b7a2-4743-abe1-fed22a54fdf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca73b678-f819-4874-a68e-00c869df7dca" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_7dc6654a-b7a2-4743-abe1-fed22a54fdf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_4e3141be-4043-446e-9783-8ef04ee4065b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca73b678-f819-4874-a68e-00c869df7dca" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_4e3141be-4043-446e-9783-8ef04ee4065b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_663884e8-add6-4ae2-a44c-28fa0c40837c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca73b678-f819-4874-a68e-00c869df7dca" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_663884e8-add6-4ae2-a44c-28fa0c40837c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MinorityInterestPolicyPolicyTextBlock_761e030a-2759-4c4a-868e-d218312c56f9" xlink:href="ameh-20220331.xsd#ameh_MinorityInterestPolicyPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca73b678-f819-4874-a68e-00c869df7dca" xlink:to="loc_ameh_MinorityInterestPolicyPolicyTextBlock_761e030a-2759-4c4a-868e-d218312c56f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityPolicyTextBlock_89c8b1a0-f883-4373-af8e-870331f5a2c0" xlink:href="ameh-20220331.xsd#ameh_TemporaryEquityPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca73b678-f819-4874-a68e-00c869df7dca" xlink:to="loc_ameh_TemporaryEquityPolicyTextBlock_89c8b1a0-f883-4373-af8e-870331f5a2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_7ef978b6-87ef-4558-b44c-0659d15971de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca73b678-f819-4874-a68e-00c869df7dca" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_7ef978b6-87ef-4558-b44c-0659d15971de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8a8f5765-bf75-4e78-a178-90d19dac2e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca73b678-f819-4874-a68e-00c869df7dca" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8a8f5765-bf75-4e78-a178-90d19dac2e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="ameh-20220331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ddb7a0c2-10e6-45e2-9ff8-0d67bfe57ead" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_3c5df5d2-607d-4b0d-8221-957d9bab6a01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ddb7a0c2-10e6-45e2-9ff8-0d67bfe57ead" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_3c5df5d2-607d-4b0d-8221-957d9bab6a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_3a403cd5-405d-4add-a1c8-c4807377969f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ddb7a0c2-10e6-45e2-9ff8-0d67bfe57ead" xlink:to="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_3a403cd5-405d-4add-a1c8-c4807377969f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_9209837f-1be9-4a7e-a74d-358bef03264c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ddb7a0c2-10e6-45e2-9ff8-0d67bfe57ead" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_9209837f-1be9-4a7e-a74d-358bef03264c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9d32c2e5-98f5-4dc2-bcfe-a212e74e6c54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_d8079f3d-fccf-443e-9026-cfa2d32c2b5e" xlink:href="ameh-20220331.xsd#ameh_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d32c2e5-98f5-4dc2-bcfe-a212e74e6c54" xlink:to="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_d8079f3d-fccf-443e-9026-cfa2d32c2b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9ff76691-abb3-428b-a3f1-0aeaca568fcb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_d8079f3d-fccf-443e-9026-cfa2d32c2b5e" xlink:to="loc_srt_RangeAxis_9ff76691-abb3-428b-a3f1-0aeaca568fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_87eedf3c-db91-437f-a812-4d7f1d90e84d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9ff76691-abb3-428b-a3f1-0aeaca568fcb" xlink:to="loc_srt_RangeMember_87eedf3c-db91-437f-a812-4d7f1d90e84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bb73c837-85c9-4581-9827-7936fb06bc56" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_87eedf3c-db91-437f-a812-4d7f1d90e84d" xlink:to="loc_srt_MinimumMember_bb73c837-85c9-4581-9827-7936fb06bc56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c14f28dc-4cac-41b1-9bbe-71ac3d6a87a6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_87eedf3c-db91-437f-a812-4d7f1d90e84d" xlink:to="loc_srt_MaximumMember_c14f28dc-4cac-41b1-9bbe-71ac3d6a87a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_da8f3ee8-6749-43d3-a334-cc47238a953a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_d8079f3d-fccf-443e-9026-cfa2d32c2b5e" xlink:to="loc_srt_CounterpartyNameAxis_da8f3ee8-6749-43d3-a334-cc47238a953a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ab96a1a0-dfb5-4fcb-9f7f-b60d40843d1e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_da8f3ee8-6749-43d3-a334-cc47238a953a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ab96a1a0-dfb5-4fcb-9f7f-b60d40843d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClinigenceHoldingsIncMember_b334bf4b-a863-4e00-9590-39894c9e8078" xlink:href="ameh-20220331.xsd#ameh_ClinigenceHoldingsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ab96a1a0-dfb5-4fcb-9f7f-b60d40843d1e" xlink:to="loc_ameh_ClinigenceHoldingsIncMember_b334bf4b-a863-4e00-9590-39894c9e8078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CMSMember_a515410f-866a-4c28-bad7-c74a2f1480a7" xlink:href="ameh-20220331.xsd#ameh_CMSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ab96a1a0-dfb5-4fcb-9f7f-b60d40843d1e" xlink:to="loc_ameh_CMSMember_a515410f-866a-4c28-bad7-c74a2f1480a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_29a643a8-929b-48fd-8f4a-f0f1984fd13c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_d8079f3d-fccf-443e-9026-cfa2d32c2b5e" xlink:to="loc_srt_ProductOrServiceAxis_29a643a8-929b-48fd-8f4a-f0f1984fd13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c582c623-9f5b-49a4-87da-ae6a7702ce02" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_29a643a8-929b-48fd-8f4a-f0f1984fd13c" xlink:to="loc_srt_ProductsAndServicesDomain_c582c623-9f5b-49a4-87da-ae6a7702ce02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PerMemberPerMonthManagedCareContractMember_16f44275-1a7d-4ffa-a4d6-6a2c9068c67f" xlink:href="ameh-20220331.xsd#ameh_PerMemberPerMonthManagedCareContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c582c623-9f5b-49a4-87da-ae6a7702ce02" xlink:to="loc_ameh_PerMemberPerMonthManagedCareContractMember_16f44275-1a7d-4ffa-a4d6-6a2c9068c67f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember_01fd2c8c-6ad2-4bcc-adcc-41c36c097291" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c582c623-9f5b-49a4-87da-ae6a7702ce02" xlink:to="loc_us-gaap_ManagementServiceMember_01fd2c8c-6ad2-4bcc-adcc-41c36c097291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_d16045a8-9877-4a6f-865e-9fd17413ab57" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_d8079f3d-fccf-443e-9026-cfa2d32c2b5e" xlink:to="loc_srt_OwnershipAxis_d16045a8-9877-4a6f-865e-9fd17413ab57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_69982f8b-1851-4b98-95e1-00c37519fb6c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_d16045a8-9877-4a6f-865e-9fd17413ab57" xlink:to="loc_srt_OwnershipDomain_69982f8b-1851-4b98-95e1-00c37519fb6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_3cd953b0-51f3-4717-a015-5e9ec5c899dc" xlink:href="ameh-20220331.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_69982f8b-1851-4b98-95e1-00c37519fb6c" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_3cd953b0-51f3-4717-a015-5e9ec5c899dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_cf337cf8-a416-4d42-9b68-008f7ebcc03e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_d8079f3d-fccf-443e-9026-cfa2d32c2b5e" xlink:to="loc_dei_LegalEntityAxis_cf337cf8-a416-4d42-9b68-008f7ebcc03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_33959bab-d8f4-4a01-85c8-119586ca6b8e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_cf337cf8-a416-4d42-9b68-008f7ebcc03e" xlink:to="loc_dei_EntityDomain_33959bab-d8f4-4a01-85c8-119586ca6b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_53466ecc-8c1c-4f07-b463-69f7efd277ff" xlink:href="ameh-20220331.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_33959bab-d8f4-4a01-85c8-119586ca6b8e" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_53466ecc-8c1c-4f07-b463-69f7efd277ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_14d30760-3b6d-40f7-96f9-52e7dc52246a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_d8079f3d-fccf-443e-9026-cfa2d32c2b5e" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_14d30760-3b6d-40f7-96f9-52e7dc52246a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_4fad1774-4158-4ff7-8dfb-628c20025379" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_14d30760-3b6d-40f7-96f9-52e7dc52246a" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_4fad1774-4158-4ff7-8dfb-628c20025379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_f7b52854-b2ad-4534-9ef2-16cb9e9d00aa" xlink:href="ameh-20220331.xsd#ameh_UniversalCareIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_4fad1774-4158-4ff7-8dfb-628c20025379" xlink:to="loc_ameh_UniversalCareIncMember_f7b52854-b2ad-4534-9ef2-16cb9e9d00aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_88bd5b98-c0a5-44c2-949f-6488a251547a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_d8079f3d-fccf-443e-9026-cfa2d32c2b5e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_88bd5b98-c0a5-44c2-949f-6488a251547a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5e0e5e7d-2266-419c-9f17-ca1a3579cb51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_88bd5b98-c0a5-44c2-949f-6488a251547a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5e0e5e7d-2266-419c-9f17-ca1a3579cb51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_f2f33f7e-3a8c-464b-9fb7-9d16ac1655fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5e0e5e7d-2266-419c-9f17-ca1a3579cb51" xlink:to="loc_us-gaap_CertificatesOfDepositMember_f2f33f7e-3a8c-464b-9fb7-9d16ac1655fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_0cd29f5b-7bde-46a9-9a4d-16de78a53a55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_d8079f3d-fccf-443e-9026-cfa2d32c2b5e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_0cd29f5b-7bde-46a9-9a4d-16de78a53a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_c964a57d-fefb-454c-898b-92de3e0a9d17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_0cd29f5b-7bde-46a9-9a4d-16de78a53a55" xlink:to="loc_us-gaap_HedgingRelationshipDomain_c964a57d-fefb-454c-898b-92de3e0a9d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_f14a9b3f-78a8-40e4-8370-130d09370aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_c964a57d-fefb-454c-898b-92de3e0a9d17" xlink:to="loc_us-gaap_CashFlowHedgingMember_f14a9b3f-78a8-40e4-8370-130d09370aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_86bc5cad-3bbd-4ac4-922a-e4a08c976b80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_d8079f3d-fccf-443e-9026-cfa2d32c2b5e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_86bc5cad-3bbd-4ac4-922a-e4a08c976b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_801e9d5a-dba0-497c-a11b-54f0e17d8a64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_86bc5cad-3bbd-4ac4-922a-e4a08c976b80" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_801e9d5a-dba0-497c-a11b-54f0e17d8a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_bb8a43eb-af48-456b-bce4-5955cf05621a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_801e9d5a-dba0-497c-a11b-54f0e17d8a64" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_bb8a43eb-af48-456b-bce4-5955cf05621a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_9f5d7585-433f-430e-a4f1-a21b0d59786e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_d8079f3d-fccf-443e-9026-cfa2d32c2b5e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_9f5d7585-433f-430e-a4f1-a21b0d59786e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_820b7ef4-03a0-4622-a146-742e790d5ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9f5d7585-433f-430e-a4f1-a21b0d59786e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_820b7ef4-03a0-4622-a146-742e790d5ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_d76b71b4-da43-4c25-9632-e71f632f927c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_820b7ef4-03a0-4622-a146-742e790d5ebe" xlink:to="loc_us-gaap_InterestRateSwapMember_d76b71b4-da43-4c25-9632-e71f632f927c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContingentEquitySecuritiesMember_8debd1d2-64fb-4edd-bb14-f52d366321b0" xlink:href="ameh-20220331.xsd#ameh_ContingentEquitySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_820b7ef4-03a0-4622-a146-742e790d5ebe" xlink:to="loc_ameh_ContingentEquitySecuritiesMember_8debd1d2-64fb-4edd-bb14-f52d366321b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1880f889-16ab-42a2-b858-bb98ea1d33df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_d8079f3d-fccf-443e-9026-cfa2d32c2b5e" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1880f889-16ab-42a2-b858-bb98ea1d33df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_61b8902f-1f40-41c1-8605-f918e313a818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1880f889-16ab-42a2-b858-bb98ea1d33df" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_61b8902f-1f40-41c1-8605-f918e313a818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_75bf5eea-9f24-4ee9-b3fc-9bd7ae73c8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_61b8902f-1f40-41c1-8605-f918e313a818" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_75bf5eea-9f24-4ee9-b3fc-9bd7ae73c8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_6c1d3121-7720-4ecc-a5f0-e1776d0e9297" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_61b8902f-1f40-41c1-8605-f918e313a818" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_6c1d3121-7720-4ecc-a5f0-e1776d0e9297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsPayableAndAccruedExpensesMember_9e3d445f-f233-4dc5-964a-981505c5241e" xlink:href="ameh-20220331.xsd#ameh_AccountsPayableAndAccruedExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_61b8902f-1f40-41c1-8605-f918e313a818" xlink:to="loc_ameh_AccountsPayableAndAccruedExpensesMember_9e3d445f-f233-4dc5-964a-981505c5241e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_7a20763a-b0a0-420b-8dd9-30f2873db140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_d8079f3d-fccf-443e-9026-cfa2d32c2b5e" xlink:to="loc_us-gaap_HedgingDesignationAxis_7a20763a-b0a0-420b-8dd9-30f2873db140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_71ced28e-b7f8-4920-a8d4-eb9945fdb16d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_7a20763a-b0a0-420b-8dd9-30f2873db140" xlink:to="loc_us-gaap_HedgingDesignationDomain_71ced28e-b7f8-4920-a8d4-eb9945fdb16d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_54ba45c1-0a3f-45a8-a22f-f448bb62bae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_71ced28e-b7f8-4920-a8d4-eb9945fdb16d" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_54ba45c1-0a3f-45a8-a22f-f448bb62bae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:href="ameh-20220331.xsd#ameh_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_d8079f3d-fccf-443e-9026-cfa2d32c2b5e" xlink:to="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_67f6449a-3b4d-4ce6-8d3a-9c169093f363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_NumberOfOperatingSegments_67f6449a-3b4d-4ce6-8d3a-9c169093f363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_6fbb5a64-84e4-4f36-b354-fb9864a60e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_NumberOfReportableSegments_6fbb5a64-84e4-4f36-b354-fb9864a60e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount_961b112f-94ee-4c05-8630-0be41d89a407" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashUninsuredAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_CashUninsuredAmount_961b112f-94ee-4c05-8630-0be41d89a407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod_559d5802-becb-471b-881d-cda5b4c72147" xlink:href="ameh-20220331.xsd#ameh_MarketableSecuritiesCurrentMaturityPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod_559d5802-becb-471b-881d-cda5b4c72147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_688f7dc1-f78f-47d2-9ea4-7f16738d4776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_688f7dc1-f78f-47d2-9ea4-7f16738d4776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_c4fcc2bd-793d-4087-bb5f-76487b7e7be5" xlink:href="ameh-20220331.xsd#ameh_EquityMethodInvestmentOwnershipPercentageDisposed"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_c4fcc2bd-793d-4087-bb5f-76487b7e7be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireCommonStockAndWarrants_f982e9b8-0f50-4af3-a1e2-f610b1817e36" xlink:href="ameh-20220331.xsd#ameh_PaymentsToAcquireCommonStockAndWarrants"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_ameh_PaymentsToAcquireCommonStockAndWarrants_f982e9b8-0f50-4af3-a1e2-f610b1817e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_175b438f-a4d6-4867-9caa-56cb5120e27d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_175b438f-a4d6-4867-9caa-56cb5120e27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_4f60ab3a-f1a6-4e28-930f-019c3b63da03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_4f60ab3a-f1a6-4e28-930f-019c3b63da03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_bb8882aa-5770-4515-b7af-694e83dae07e" xlink:href="ameh-20220331.xsd#ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_bb8882aa-5770-4515-b7af-694e83dae07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_ddd89a55-9360-46cc-9733-5957ea1b2172" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_ddd89a55-9360-46cc-9733-5957ea1b2172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_c7d62503-11b4-45da-b226-68edc20e3c13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_c7d62503-11b4-45da-b226-68edc20e3c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_5661b7b5-00ed-43c2-84a7-4a40c3fa85c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_NumberOfReportingUnits_5661b7b5-00ed-43c2-84a7-4a40c3fa85c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_c7effae7-3d7c-4d5a-bbd7-141c367377d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_c7effae7-3d7c-4d5a-bbd7-141c367377d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_86fabcc5-a536-4b16-9538-f8e597dc3f01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_86fabcc5-a536-4b16-9538-f8e597dc3f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_b54c36be-e9e1-4ea2-84d1-d9fb14303e50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_b54c36be-e9e1-4ea2-84d1-d9fb14303e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_6e3bd5fc-8be9-4c8d-b54f-6a29c8ae1cb2" xlink:href="ameh-20220331.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_6e3bd5fc-8be9-4c8d-b54f-6a29c8ae1cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_e2197499-479f-488d-b620-1d0739bdadff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_e2197499-479f-488d-b620-1d0739bdadff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_b49aeeff-274a-486e-b926-9c7579d9d494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_b49aeeff-274a-486e-b926-9c7579d9d494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_1ca3ff6c-f409-4f62-a769-a7256f4937eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_DerivativeAssets_1ca3ff6c-f409-4f62-a769-a7256f4937eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_431e6550-35f6-4730-9c19-c00563847495" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_431e6550-35f6-4730-9c19-c00563847495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_ee35c66b-d8c1-4009-82d0-957696cbfcee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_ee35c66b-d8c1-4009-82d0-957696cbfcee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_816b704a-150d-46fc-a15f-064986fe790e" xlink:href="ameh-20220331.xsd#ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_816b704a-150d-46fc-a15f-064986fe790e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6cf443ca-7969-4663-a59d-6b2a6ecde721" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6cf443ca-7969-4663-a59d-6b2a6ecde721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_f03f17d7-c9e5-4f4f-a26e-af97207835e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_11071ee0-67ec-4a2f-a23d-2c0b4642645b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_f03f17d7-c9e5-4f4f-a26e-af97207835e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_334098ee-441e-4dc0-a747-1ba32d6f748d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_0cc72044-d3e7-4e8e-b4e2-6140683412bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_334098ee-441e-4dc0-a747-1ba32d6f748d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_0cc72044-d3e7-4e8e-b4e2-6140683412bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_ae187167-6357-4f8d-83f7-2fc7a3ed8f2b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0cc72044-d3e7-4e8e-b4e2-6140683412bb" xlink:to="loc_srt_MajorCustomersAxis_ae187167-6357-4f8d-83f7-2fc7a3ed8f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_14413066-7cf3-4c49-8f23-8358cae370f9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_ae187167-6357-4f8d-83f7-2fc7a3ed8f2b" xlink:to="loc_srt_NameOfMajorCustomerDomain_14413066-7cf3-4c49-8f23-8358cae370f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommercialMember_d2565665-c2d7-49cd-aa18-d38ecfb7cbf8" xlink:href="ameh-20220331.xsd#ameh_CommercialMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_14413066-7cf3-4c49-8f23-8358cae370f9" xlink:to="loc_ameh_CommercialMember_d2565665-c2d7-49cd-aa18-d38ecfb7cbf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicareMember_23fac06a-5130-48b5-a52a-2675730c92ca" xlink:href="ameh-20220331.xsd#ameh_MedicareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_14413066-7cf3-4c49-8f23-8358cae370f9" xlink:to="loc_ameh_MedicareMember_23fac06a-5130-48b5-a52a-2675730c92ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicaidMember_b0f167df-cd4c-4bc9-8092-b92e8139e011" xlink:href="ameh-20220331.xsd#ameh_MedicaidMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_14413066-7cf3-4c49-8f23-8358cae370f9" xlink:to="loc_ameh_MedicaidMember_b0f167df-cd4c-4bc9-8092-b92e8139e011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OtherThirdPartiesMember_ea362c65-a73b-479c-a284-7747265196dd" xlink:href="ameh-20220331.xsd#ameh_OtherThirdPartiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_14413066-7cf3-4c49-8f23-8358cae370f9" xlink:to="loc_ameh_OtherThirdPartiesMember_ea362c65-a73b-479c-a284-7747265196dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7dd44bf9-42d2-41eb-ab99-30fe97d14ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0cc72044-d3e7-4e8e-b4e2-6140683412bb" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_7dd44bf9-42d2-41eb-ab99-30fe97d14ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_50af25d9-ffc1-4c44-8074-ac6c64cddc70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7dd44bf9-42d2-41eb-ab99-30fe97d14ba5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_50af25d9-ffc1-4c44-8074-ac6c64cddc70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_075dacda-6ffb-4884-a6dd-681f76e096a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueTable_b524a06c-8721-45a3-ade7-14a1005fe404" xlink:href="ameh-20220331.xsd#ameh_AccountsReceivableAndNetRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_075dacda-6ffb-4884-a6dd-681f76e096a2" xlink:to="loc_ameh_AccountsReceivableAndNetRevenueTable_b524a06c-8721-45a3-ade7-14a1005fe404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_31965470-9257-4a34-a8fd-7b1ed9886d58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_b524a06c-8721-45a3-ade7-14a1005fe404" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_31965470-9257-4a34-a8fd-7b1ed9886d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7cb332a4-a6ed-4b85-9e85-96721dd822b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_31965470-9257-4a34-a8fd-7b1ed9886d58" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7cb332a4-a6ed-4b85-9e85-96721dd822b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_8fd37622-62d2-466a-91de-6dac54fbf8de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7cb332a4-a6ed-4b85-9e85-96721dd822b8" xlink:to="loc_us-gaap_SalesRevenueNetMember_8fd37622-62d2-466a-91de-6dac54fbf8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_256bfe36-2b75-4344-b396-b3bf735f789f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7cb332a4-a6ed-4b85-9e85-96721dd822b8" xlink:to="loc_us-gaap_AccountsReceivableMember_256bfe36-2b75-4344-b396-b3bf735f789f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_c4e2ebfc-211b-49df-af4e-7c868698ea57" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_b524a06c-8721-45a3-ade7-14a1005fe404" xlink:to="loc_srt_MajorCustomersAxis_c4e2ebfc-211b-49df-af4e-7c868698ea57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_c26adabb-70bf-4499-9165-61c4fd7eb29c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_c4e2ebfc-211b-49df-af4e-7c868698ea57" xlink:to="loc_srt_NameOfMajorCustomerDomain_c26adabb-70bf-4499-9165-61c4fd7eb29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorAMember_be7b812e-a110-4d2a-844f-89b31062209a" xlink:href="ameh-20220331.xsd#ameh_PayorAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_c26adabb-70bf-4499-9165-61c4fd7eb29c" xlink:to="loc_ameh_PayorAMember_be7b812e-a110-4d2a-844f-89b31062209a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorBMember_2f1b2af9-95e8-401d-83d2-038722865a00" xlink:href="ameh-20220331.xsd#ameh_PayorBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_c26adabb-70bf-4499-9165-61c4fd7eb29c" xlink:to="loc_ameh_PayorBMember_2f1b2af9-95e8-401d-83d2-038722865a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorCMember_39b12ac1-4363-476c-893c-77b983dacc07" xlink:href="ameh-20220331.xsd#ameh_PayorCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_c26adabb-70bf-4499-9165-61c4fd7eb29c" xlink:to="loc_ameh_PayorCMember_39b12ac1-4363-476c-893c-77b983dacc07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorDMember_70bde5d3-cea7-46d2-bc7d-a0f3bc538feb" xlink:href="ameh-20220331.xsd#ameh_PayorDMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_c26adabb-70bf-4499-9165-61c4fd7eb29c" xlink:to="loc_ameh_PayorDMember_70bde5d3-cea7-46d2-bc7d-a0f3bc538feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorEMember_b27ac13f-010b-4066-9ab2-da0afb0c98ff" xlink:href="ameh-20220331.xsd#ameh_PayorEMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_c26adabb-70bf-4499-9165-61c4fd7eb29c" xlink:to="loc_ameh_PayorEMember_b27ac13f-010b-4066-9ab2-da0afb0c98ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorFMember_b2798726-56d1-44cb-b347-1c23d636abd3" xlink:href="ameh-20220331.xsd#ameh_PayorFMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_c26adabb-70bf-4499-9165-61c4fd7eb29c" xlink:to="loc_ameh_PayorFMember_b2798726-56d1-44cb-b347-1c23d636abd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_15f8c2aa-2b46-4a00-93af-63922d0ccf71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_b524a06c-8721-45a3-ade7-14a1005fe404" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_15f8c2aa-2b46-4a00-93af-63922d0ccf71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_44f675f3-047b-4684-99d0-b97d7662a8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_15f8c2aa-2b46-4a00-93af-63922d0ccf71" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_44f675f3-047b-4684-99d0-b97d7662a8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_77911cd1-8d3e-4435-b11a-93a8b419d64b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_44f675f3-047b-4684-99d0-b97d7662a8f7" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_77911cd1-8d3e-4435-b11a-93a8b419d64b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueLineItems_dd31c7dd-7fc9-4994-a4bc-39d5f4720d0b" xlink:href="ameh-20220331.xsd#ameh_AccountsReceivableAndNetRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_b524a06c-8721-45a3-ade7-14a1005fe404" xlink:to="loc_ameh_AccountsReceivableAndNetRevenueLineItems_dd31c7dd-7fc9-4994-a4bc-39d5f4720d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_fee1e2ff-36e6-4e7d-9497-6c6ca972b788" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueLineItems_dd31c7dd-7fc9-4994-a4bc-39d5f4720d0b" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_fee1e2ff-36e6-4e7d-9497-6c6ca972b788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_11d4ca49-9460-4c5d-bbe8-ca7adf4c4352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_62ff653f-4c60-4add-b912-58cebc1c6f95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_11d4ca49-9460-4c5d-bbe8-ca7adf4c4352" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_62ff653f-4c60-4add-b912-58cebc1c6f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ef69d04a-cf96-46e9-a0ce-14edd1aae0f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_62ff653f-4c60-4add-b912-58cebc1c6f95" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ef69d04a-cf96-46e9-a0ce-14edd1aae0f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b450fac-06dd-402b-98e0-d06acfbcdc6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ef69d04a-cf96-46e9-a0ce-14edd1aae0f0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b450fac-06dd-402b-98e0-d06acfbcdc6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_a086fd38-7db5-46fe-8534-08c5b1de2e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b450fac-06dd-402b-98e0-d06acfbcdc6c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_a086fd38-7db5-46fe-8534-08c5b1de2e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8c4a2945-f6a0-440b-bd8e-a1d35f6c734a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b450fac-06dd-402b-98e0-d06acfbcdc6c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8c4a2945-f6a0-440b-bd8e-a1d35f6c734a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_213f2460-4c18-4d40-b305-c21956971950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b450fac-06dd-402b-98e0-d06acfbcdc6c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_213f2460-4c18-4d40-b305-c21956971950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_015b61a3-caff-47b1-9e7d-9461c1c0370f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_62ff653f-4c60-4add-b912-58cebc1c6f95" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_015b61a3-caff-47b1-9e7d-9461c1c0370f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_91189b9a-a507-464d-b96e-23d57cf5b986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_015b61a3-caff-47b1-9e7d-9461c1c0370f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_91189b9a-a507-464d-b96e-23d57cf5b986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContingentEquitySecuritiesMember_f7eaf609-b412-43ba-8fd6-9cabe7d8022a" xlink:href="ameh-20220331.xsd#ameh_ContingentEquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_91189b9a-a507-464d-b96e-23d57cf5b986" xlink:to="loc_ameh_ContingentEquitySecuritiesMember_f7eaf609-b412-43ba-8fd6-9cabe7d8022a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_04ddd844-05b0-4bd6-a805-01024197bef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_91189b9a-a507-464d-b96e-23d57cf5b986" xlink:to="loc_us-gaap_WarrantMember_04ddd844-05b0-4bd6-a805-01024197bef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_87b54848-5b27-4fcf-820d-dceb22bef3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_91189b9a-a507-464d-b96e-23d57cf5b986" xlink:to="loc_us-gaap_InterestRateSwapMember_87b54848-5b27-4fcf-820d-dceb22bef3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_87a13b01-e56d-471e-8566-231764f391cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_62ff653f-4c60-4add-b912-58cebc1c6f95" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_87a13b01-e56d-471e-8566-231764f391cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_80bd77cd-52d6-46e4-a577-86a974f31ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_87a13b01-e56d-471e-8566-231764f391cd" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_80bd77cd-52d6-46e4-a577-86a974f31ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7603e4df-dade-4d08-99cd-3f8bd75c0dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_87a13b01-e56d-471e-8566-231764f391cd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7603e4df-dade-4d08-99cd-3f8bd75c0dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_e2ed2261-e398-41bf-8649-b199274815a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_87a13b01-e56d-471e-8566-231764f391cd" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_e2ed2261-e398-41bf-8649-b199274815a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_be31fdfd-4742-4d41-9721-4ea2d6932ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_87a13b01-e56d-471e-8566-231764f391cd" xlink:to="loc_us-gaap_DerivativeAssets_be31fdfd-4742-4d41-9721-4ea2d6932ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_e53e45f0-afcf-4d6e-9997-e32985ebdd5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_87a13b01-e56d-471e-8566-231764f391cd" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_e53e45f0-afcf-4d6e-9997-e32985ebdd5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_fd9f3855-fbd2-4f50-bcf8-41e6e9cee0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_87a13b01-e56d-471e-8566-231764f391cd" xlink:to="loc_us-gaap_DerivativeLiabilities_fd9f3855-fbd2-4f50-bcf8-41e6e9cee0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f2170c5d-c27d-4b61-b40d-f22ca499673b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_87a13b01-e56d-471e-8566-231764f391cd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f2170c5d-c27d-4b61-b40d-f22ca499673b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_883e38ea-e6dc-4582-a44e-afe3adbf13b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_87a13b01-e56d-471e-8566-231764f391cd" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_883e38ea-e6dc-4582-a44e-afe3adbf13b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwill" xlink:type="simple" xlink:href="ameh-20220331.xsd#BusinessCombinationsandGoodwill"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7e269ea6-1730-46fe-a232-5856443bdac7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_322d2647-5522-4506-a05d-dd55a4c0fa7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7e269ea6-1730-46fe-a232-5856443bdac7" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_322d2647-5522-4506-a05d-dd55a4c0fa7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables" xlink:type="simple" xlink:href="ameh-20220331.xsd#BusinessCombinationsandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_81667b4a-b278-48b1-a61f-467af9099380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_a4fe8561-4f0b-4a00-bd36-0844b54da6df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_81667b4a-b278-48b1-a61f-467af9099380" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_a4fe8561-4f0b-4a00-bd36-0844b54da6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#BusinessCombinationsandGoodwillAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a98cd041-0d32-4a8d-854a-837be339f514" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_fde417d4-375a-47a2-9fff-2f86648e8f96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a98cd041-0d32-4a8d-854a-837be339f514" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_fde417d4-375a-47a2-9fff-2f86648e8f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2b44ae7a-28fa-462d-9b7f-1e5e977c4829" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_fde417d4-375a-47a2-9fff-2f86648e8f96" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2b44ae7a-28fa-462d-9b7f-1e5e977c4829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d6d3da2-630a-42f6-9d47-6659e22e5bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2b44ae7a-28fa-462d-9b7f-1e5e977c4829" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d6d3da2-630a-42f6-9d47-6659e22e5bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember_aa16bb72-48e5-4b6d-a357-33b57b8d8fae" xlink:href="ameh-20220331.xsd#ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d6d3da2-630a-42f6-9d47-6659e22e5bdc" xlink:to="loc_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember_aa16bb72-48e5-4b6d-a357-33b57b8d8fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccessPrimaryCareMedicalGroupMember_3954ac9c-311e-41a3-80b4-36f8c8ea7764" xlink:href="ameh-20220331.xsd#ameh_AccessPrimaryCareMedicalGroupMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d6d3da2-630a-42f6-9d47-6659e22e5bdc" xlink:to="loc_ameh_AccessPrimaryCareMedicalGroupMember_3954ac9c-311e-41a3-80b4-36f8c8ea7764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloSunLabsManagementLLCMember_a8c7d9da-0bde-4c71-bac1-935e91b408fa" xlink:href="ameh-20220331.xsd#ameh_ApolloSunLabsManagementLLCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d6d3da2-630a-42f6-9d47-6659e22e5bdc" xlink:to="loc_ameh_ApolloSunLabsManagementLLCMember_a8c7d9da-0bde-4c71-bac1-935e91b408fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9be3b283-04ef-452e-bd60-9c6e49a86613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_fde417d4-375a-47a2-9fff-2f86648e8f96" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_9be3b283-04ef-452e-bd60-9c6e49a86613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_c50e0a5a-8163-41a2-ae36-bf65b83dda23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9be3b283-04ef-452e-bd60-9c6e49a86613" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_c50e0a5a-8163-41a2-ae36-bf65b83dda23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_44eaac6e-7956-443e-abf7-642dac936f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9be3b283-04ef-452e-bd60-9c6e49a86613" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_44eaac6e-7956-443e-abf7-642dac936f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_72cf8ff3-57ef-4ada-a156-51795290e84b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9be3b283-04ef-452e-bd60-9c6e49a86613" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_72cf8ff3-57ef-4ada-a156-51795290e84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_bc962498-72f5-47d5-ac52-6aa9682c7cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9be3b283-04ef-452e-bd60-9c6e49a86613" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_bc962498-72f5-47d5-ac52-6aa9682c7cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0f193c2d-655c-4882-8995-9a197afe25cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9be3b283-04ef-452e-bd60-9c6e49a86613" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0f193c2d-655c-4882-8995-9a197afe25cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#BusinessCombinationsandGoodwillSummaryofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_115ddd50-87c7-4b4c-8d10-f70f9e709484" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_ad501e27-5604-41b8-af9b-c901d6171e57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_115ddd50-87c7-4b4c-8d10-f70f9e709484" xlink:to="loc_us-gaap_GoodwillRollForward_ad501e27-5604-41b8-af9b-c901d6171e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b329c7e6-abc9-422c-acd9-3132bb30295f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ad501e27-5604-41b8-af9b-c901d6171e57" xlink:to="loc_us-gaap_Goodwill_b329c7e6-abc9-422c-acd9-3132bb30295f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_4daa0f24-f74b-48df-9c47-47b8b47faaeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ad501e27-5604-41b8-af9b-c901d6171e57" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_4daa0f24-f74b-48df-9c47-47b8b47faaeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_d69593e4-18f5-464c-a9e2-f741db7df5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ad501e27-5604-41b8-af9b-c901d6171e57" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_d69593e4-18f5-464c-a9e2-f741db7df5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_28071351-ba08-4cf0-86d7-85f4472fd023" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ad501e27-5604-41b8-af9b-c901d6171e57" xlink:to="loc_us-gaap_Goodwill_28071351-ba08-4cf0-86d7-85f4472fd023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNet" xlink:type="simple" xlink:href="ameh-20220331.xsd#IntangibleAssetsNet"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4a0a39db-6072-4fc4-a2b1-f6d875e8a05b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_019809a7-856c-4ff4-84b7-40d098859560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4a0a39db-6072-4fc4-a2b1-f6d875e8a05b" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_019809a7-856c-4ff4-84b7-40d098859560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetTables" xlink:type="simple" xlink:href="ameh-20220331.xsd#IntangibleAssetsNetTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c7afbbc5-ad13-460a-8634-3db65c268dda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_fe116bb5-c263-403a-9a20-aa5cef2490aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c7afbbc5-ad13-460a-8634-3db65c268dda" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_fe116bb5-c263-403a-9a20-aa5cef2490aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_b6ec9c44-d132-4bda-8029-437bb35e9760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c7afbbc5-ad13-460a-8634-3db65c268dda" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_b6ec9c44-d132-4bda-8029-437bb35e9760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3c40eeda-ecb2-4235-9a14-3b347a5a18e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5dead0a0-b2cb-4b3c-8ad7-1b782b6ae3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3c40eeda-ecb2-4235-9a14-3b347a5a18e3" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5dead0a0-b2cb-4b3c-8ad7-1b782b6ae3c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8140743e-6c26-4591-99bb-7cbc82230040" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5dead0a0-b2cb-4b3c-8ad7-1b782b6ae3c5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8140743e-6c26-4591-99bb-7cbc82230040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0685ba7c-ff6f-4c5c-8b63-4e49b5273147" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8140743e-6c26-4591-99bb-7cbc82230040" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0685ba7c-ff6f-4c5c-8b63-4e49b5273147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkRelationshipsMember_759268ef-ee5f-436e-85e1-99cc5308f2dd" xlink:href="ameh-20220331.xsd#ameh_NetworkRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0685ba7c-ff6f-4c5c-8b63-4e49b5273147" xlink:to="loc_ameh_NetworkRelationshipsMember_759268ef-ee5f-436e-85e1-99cc5308f2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ManagementContractsMember_e3ad4f8c-1632-4ccb-a93e-dc38fdf7ae7b" xlink:href="ameh-20220331.xsd#ameh_ManagementContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0685ba7c-ff6f-4c5c-8b63-4e49b5273147" xlink:to="loc_ameh_ManagementContractsMember_e3ad4f8c-1632-4ccb-a93e-dc38fdf7ae7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MemberRelationshipsMember_46147f08-422f-473f-84c7-67e80fa7b108" xlink:href="ameh-20220331.xsd#ameh_MemberRelationshipsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0685ba7c-ff6f-4c5c-8b63-4e49b5273147" xlink:to="loc_ameh_MemberRelationshipsMember_46147f08-422f-473f-84c7-67e80fa7b108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PatientManagementPlatformMember_4c11e4ed-c011-4a7e-b440-acabf028314e" xlink:href="ameh-20220331.xsd#ameh_PatientManagementPlatformMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0685ba7c-ff6f-4c5c-8b63-4e49b5273147" xlink:to="loc_ameh_PatientManagementPlatformMember_4c11e4ed-c011-4a7e-b440-acabf028314e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_25a34862-d932-48cc-87a3-a422a0db7393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0685ba7c-ff6f-4c5c-8b63-4e49b5273147" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_25a34862-d932-48cc-87a3-a422a0db7393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_29b41437-80a8-4e00-97fd-db310ea98764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0685ba7c-ff6f-4c5c-8b63-4e49b5273147" xlink:to="loc_us-gaap_CustomerRelationshipsMember_29b41437-80a8-4e00-97fd-db310ea98764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_4ce44328-244d-44be-962d-97f166966961" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0685ba7c-ff6f-4c5c-8b63-4e49b5273147" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_4ce44328-244d-44be-962d-97f166966961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7de0379e-1180-4e57-ae6d-fdd2090c477b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5dead0a0-b2cb-4b3c-8ad7-1b782b6ae3c5" xlink:to="loc_srt_RangeAxis_7de0379e-1180-4e57-ae6d-fdd2090c477b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c78fb454-c5c4-4e30-bb47-4906d7751dd1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7de0379e-1180-4e57-ae6d-fdd2090c477b" xlink:to="loc_srt_RangeMember_c78fb454-c5c4-4e30-bb47-4906d7751dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_96c9170f-bfb3-44be-bc41-87dcb1f1eaad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c78fb454-c5c4-4e30-bb47-4906d7751dd1" xlink:to="loc_srt_MinimumMember_96c9170f-bfb3-44be-bc41-87dcb1f1eaad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_982ccec5-d86a-4d4e-a3fd-137bd2a1ef3a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c78fb454-c5c4-4e30-bb47-4906d7751dd1" xlink:to="loc_srt_MaximumMember_982ccec5-d86a-4d4e-a3fd-137bd2a1ef3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_875b2c8d-61dd-481f-b222-7814a34821f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5dead0a0-b2cb-4b3c-8ad7-1b782b6ae3c5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_875b2c8d-61dd-481f-b222-7814a34821f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_322164a2-11f8-4795-be0f-ee3329f691cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_875b2c8d-61dd-481f-b222-7814a34821f3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_322164a2-11f8-4795-be0f-ee3329f691cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_82a4f1e3-d6a8-41f3-99a5-b32a153eab2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_875b2c8d-61dd-481f-b222-7814a34821f3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_82a4f1e3-d6a8-41f3-99a5-b32a153eab2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f066003a-79f2-4232-afde-441f61673a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_875b2c8d-61dd-481f-b222-7814a34821f3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f066003a-79f2-4232-afde-441f61673a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bc2da97d-45fd-43af-9d52-60c6a8de817f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_875b2c8d-61dd-481f-b222-7814a34821f3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bc2da97d-45fd-43af-9d52-60c6a8de817f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_a5c69e41-c21a-45c8-8c77-e4fab68270d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3c40eeda-ecb2-4235-9a14-3b347a5a18e3" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_a5c69e41-c21a-45c8-8c77-e4fab68270d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_948b4b98-f163-4c6d-9887-4213d9586a75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_a5c69e41-c21a-45c8-8c77-e4fab68270d8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_948b4b98-f163-4c6d-9887-4213d9586a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dfbd9783-6e62-4838-90a9-c88ca9069b40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_948b4b98-f163-4c6d-9887-4213d9586a75" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dfbd9783-6e62-4838-90a9-c88ca9069b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_613169b3-16a2-43f2-bbe9-d2908626fc90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dfbd9783-6e62-4838-90a9-c88ca9069b40" xlink:to="loc_us-gaap_TrademarksMember_613169b3-16a2-43f2-bbe9-d2908626fc90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_e3586e93-994c-4596-9f94-23d74180b72d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dfbd9783-6e62-4838-90a9-c88ca9069b40" xlink:to="loc_us-gaap_LicensingAgreementsMember_e3586e93-994c-4596-9f94-23d74180b72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_3b34fc1c-5df0-4dc8-8124-721df5efc333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_a5c69e41-c21a-45c8-8c77-e4fab68270d8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_3b34fc1c-5df0-4dc8-8124-721df5efc333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_d4018a42-81d7-4138-be3c-73660ea1800f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_3b34fc1c-5df0-4dc8-8124-721df5efc333" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_d4018a42-81d7-4138-be3c-73660ea1800f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6f8f139b-2afa-4a30-9af3-2ce2203d281b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3c40eeda-ecb2-4235-9a14-3b347a5a18e3" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6f8f139b-2afa-4a30-9af3-2ce2203d281b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_83517e30-f57d-48e2-a21a-0b9c8a2ca7ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3c40eeda-ecb2-4235-9a14-3b347a5a18e3" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_83517e30-f57d-48e2-a21a-0b9c8a2ca7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="ameh-20220331.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#IntangibleAssetsNetAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8c716f63-9c22-402f-90d1-54cd901c7099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_dc0570c8-4ad1-4185-9f39-2d44da4d3c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8c716f63-9c22-402f-90d1-54cd901c7099" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_dc0570c8-4ad1-4185-9f39-2d44da4d3c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#IntangibleAssetsNetFutureAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_32fc5f4f-eaf6-43cf-a8ef-579ade00b920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2a815d1b-461c-44c8-9855-81f14b2842ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_32fc5f4f-eaf6-43cf-a8ef-579ade00b920" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2a815d1b-461c-44c8-9855-81f14b2842ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b8efefbc-ec98-4bbc-b309-9391bff293d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_32fc5f4f-eaf6-43cf-a8ef-579ade00b920" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b8efefbc-ec98-4bbc-b309-9391bff293d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b63aa4db-3f5f-4061-a68c-24b2a0751083" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_32fc5f4f-eaf6-43cf-a8ef-579ade00b920" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b63aa4db-3f5f-4061-a68c-24b2a0751083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_ae4abfbe-eaef-40ef-875c-a7f1f0c1656e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_32fc5f4f-eaf6-43cf-a8ef-579ade00b920" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_ae4abfbe-eaef-40ef-875c-a7f1f0c1656e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_197236d6-2ca6-4177-a62f-6054db311412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_32fc5f4f-eaf6-43cf-a8ef-579ade00b920" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_197236d6-2ca6-4177-a62f-6054db311412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_2d86f3e7-da82-42a0-b859-8c796e9d6694" xlink:href="ameh-20220331.xsd#ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_32fc5f4f-eaf6-43cf-a8ef-579ade00b920" xlink:to="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_2d86f3e7-da82-42a0-b859-8c796e9d6694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_09527025-f97a-432f-aec8-63ea54b0cb26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_32fc5f4f-eaf6-43cf-a8ef-579ade00b920" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_09527025-f97a-432f-aec8-63ea54b0cb26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntities" xlink:type="simple" xlink:href="ameh-20220331.xsd#InvestmentsinOtherEntities"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_38e5de4c-e464-48d0-8289-9af82a6de817" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock_b1724a6c-526d-4f63-b795-1b878985c0c5" xlink:href="ameh-20220331.xsd#ameh_EquityMethodAndOtherEquityInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_38e5de4c-e464-48d0-8289-9af82a6de817" xlink:to="loc_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock_b1724a6c-526d-4f63-b795-1b878985c0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesTables" xlink:type="simple" xlink:href="ameh-20220331.xsd#InvestmentsinOtherEntitiesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_92ac8721-f34d-48e5-a394-b341c1920c43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_edeab9ce-7a2e-43d2-9ea8-2a473a29dd2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_92ac8721-f34d-48e5-a394-b341c1920c43" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_edeab9ce-7a2e-43d2-9ea8-2a473a29dd2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_7477bb8d-f962-4752-bdc9-6ed26b7d7569" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a5eda7d1-3d28-49d2-81ab-ba3eceace017" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_7477bb8d-f962-4752-bdc9-6ed26b7d7569" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a5eda7d1-3d28-49d2-81ab-ba3eceace017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_66cab5d2-11b3-425c-8aa2-0f2ccf57ea0b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a5eda7d1-3d28-49d2-81ab-ba3eceace017" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_66cab5d2-11b3-425c-8aa2-0f2ccf57ea0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_30be1c86-9038-4397-b486-57d3688cbe13" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_66cab5d2-11b3-425c-8aa2-0f2ccf57ea0b" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_30be1c86-9038-4397-b486-57d3688cbe13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_e38d9e4e-0243-4362-9e9f-a3dafa5c0c2e" xlink:href="ameh-20220331.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_30be1c86-9038-4397-b486-57d3688cbe13" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_e38d9e4e-0243-4362-9e9f-a3dafa5c0c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_6df4afb0-f4ee-4507-9a5e-c87520db0a62" xlink:href="ameh-20220331.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_30be1c86-9038-4397-b486-57d3688cbe13" xlink:to="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_6df4afb0-f4ee-4507-9a5e-c87520db0a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_1f563c11-f9eb-4e17-92dc-eb0bf5c55f04" xlink:href="ameh-20220331.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_30be1c86-9038-4397-b486-57d3688cbe13" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_1f563c11-f9eb-4e17-92dc-eb0bf5c55f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCMember_d0ca356f-d419-43c9-98ea-21a3cf720e7d" xlink:href="ameh-20220331.xsd#ameh_OneMSOLLCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_30be1c86-9038-4397-b486-57d3688cbe13" xlink:to="loc_ameh_OneMSOLLCMember_d0ca356f-d419-43c9-98ea-21a3cf720e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember_c6027b88-d332-425b-810a-6cb7227d3e00" xlink:href="ameh-20220331.xsd#ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_30be1c86-9038-4397-b486-57d3688cbe13" xlink:to="loc_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember_c6027b88-d332-425b-810a-6cb7227d3e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CAIPAMSOLLCMember_989f7220-2e74-405e-989a-bcffb17b8db9" xlink:href="ameh-20220331.xsd#ameh_CAIPAMSOLLCMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_30be1c86-9038-4397-b486-57d3688cbe13" xlink:to="loc_ameh_CAIPAMSOLLCMember_989f7220-2e74-405e-989a-bcffb17b8db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8f81e65d-9459-46df-9cf3-47ef2028765f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a5eda7d1-3d28-49d2-81ab-ba3eceace017" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8f81e65d-9459-46df-9cf3-47ef2028765f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsRollForward_d0542832-0b78-44af-b97f-afc587abe62a" xlink:href="ameh-20220331.xsd#ameh_EquityMethodInvestmentsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8f81e65d-9459-46df-9cf3-47ef2028765f" xlink:to="loc_ameh_EquityMethodInvestmentsRollForward_d0542832-0b78-44af-b97f-afc587abe62a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_6be9bfea-a4ac-47a4-8f47-3623400b1c42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_d0542832-0b78-44af-b97f-afc587abe62a" xlink:to="loc_us-gaap_EquityMethodInvestments_6be9bfea-a4ac-47a4-8f47-3623400b1c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_f78020de-1829-4d7c-b368-6ce908ed817e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_d0542832-0b78-44af-b97f-afc587abe62a" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_f78020de-1829-4d7c-b368-6ce908ed817e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsContribution_1057a146-c212-47d1-ae81-e0eeeb8a2751" xlink:href="ameh-20220331.xsd#ameh_EquityMethodInvestmentsContribution"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_d0542832-0b78-44af-b97f-afc587abe62a" xlink:to="loc_ameh_EquityMethodInvestmentsContribution_1057a146-c212-47d1-ae81-e0eeeb8a2751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_5c9e9673-95ed-4392-b41d-73ef2d96917a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_d0542832-0b78-44af-b97f-afc587abe62a" xlink:to="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_5c9e9673-95ed-4392-b41d-73ef2d96917a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_b2b281e3-67e9-4c68-a3e9-436652f59657" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_d0542832-0b78-44af-b97f-afc587abe62a" xlink:to="loc_us-gaap_EquityMethodInvestments_b2b281e3-67e9-4c68-a3e9-436652f59657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#InvestmentsinOtherEntitiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_3eb87498-1096-4d24-8ced-1d67a706249c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_e88f2f5d-1555-44f3-8f5f-742f04b0dcb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_3eb87498-1096-4d24-8ced-1d67a706249c" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_e88f2f5d-1555-44f3-8f5f-742f04b0dcb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a9adca8c-477f-498f-a0bc-03d49afccaa2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_e88f2f5d-1555-44f3-8f5f-742f04b0dcb2" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a9adca8c-477f-498f-a0bc-03d49afccaa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_c88fffd8-5ce2-4bf3-b651-c904e1fa4509" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a9adca8c-477f-498f-a0bc-03d49afccaa2" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_c88fffd8-5ce2-4bf3-b651-c904e1fa4509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_b4b67c11-e69d-4c41-b09d-f3f74dcb4960" xlink:href="ameh-20220331.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c88fffd8-5ce2-4bf3-b651-c904e1fa4509" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_b4b67c11-e69d-4c41-b09d-f3f74dcb4960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_cd06ef4f-9009-47ff-8f80-6b157744985f" xlink:href="ameh-20220331.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c88fffd8-5ce2-4bf3-b651-c904e1fa4509" xlink:to="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_cd06ef4f-9009-47ff-8f80-6b157744985f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_51f77e41-a0bf-4738-aff6-9dc874f8a6c4" xlink:href="ameh-20220331.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c88fffd8-5ce2-4bf3-b651-c904e1fa4509" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_51f77e41-a0bf-4738-aff6-9dc874f8a6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCMember_854f523e-c4c0-4b6e-ba81-bcfcba8c7a43" xlink:href="ameh-20220331.xsd#ameh_OneMSOLLCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c88fffd8-5ce2-4bf3-b651-c904e1fa4509" xlink:to="loc_ameh_OneMSOLLCMember_854f523e-c4c0-4b6e-ba81-bcfcba8c7a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag6MedicalInvestmentGroupLLCMember_e958c56a-5bd0-4ba5-bb01-e2626ce400e1" xlink:href="ameh-20220331.xsd#ameh_Tag6MedicalInvestmentGroupLLCMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c88fffd8-5ce2-4bf3-b651-c904e1fa4509" xlink:to="loc_ameh_Tag6MedicalInvestmentGroupLLCMember_e958c56a-5bd0-4ba5-bb01-e2626ce400e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CAIPAMSOLLCMember_85e07d25-fa6a-4f7d-a71b-109d3036d49d" xlink:href="ameh-20220331.xsd#ameh_CAIPAMSOLLCMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c88fffd8-5ce2-4bf3-b651-c904e1fa4509" xlink:to="loc_ameh_CAIPAMSOLLCMember_85e07d25-fa6a-4f7d-a71b-109d3036d49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f316a98d-d4af-48eb-8005-6cf6dd38fd54" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_e88f2f5d-1555-44f3-8f5f-742f04b0dcb2" xlink:to="loc_dei_LegalEntityAxis_f316a98d-d4af-48eb-8005-6cf6dd38fd54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ac5f5eb0-96e9-40d7-9816-7a3e84783176" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_f316a98d-d4af-48eb-8005-6cf6dd38fd54" xlink:to="loc_dei_EntityDomain_ac5f5eb0-96e9-40d7-9816-7a3e84783176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember_a56a1fa7-690b-4ecf-a399-bfb46ca10e8a" xlink:href="ameh-20220331.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_ac5f5eb0-96e9-40d7-9816-7a3e84783176" xlink:to="loc_ameh_APCAndAPCLSMAMember_a56a1fa7-690b-4ecf-a399-bfb46ca10e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember_fe632070-3d77-455e-8be4-aaef4072b8c2" xlink:href="ameh-20220331.xsd#ameh_ApcLsmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_APCAndAPCLSMAMember_a56a1fa7-690b-4ecf-a399-bfb46ca10e8a" xlink:to="loc_ameh_ApcLsmaMember_fe632070-3d77-455e-8be4-aaef4072b8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_193713dc-04a1-4862-8ae7-ee51ac9ed42e" xlink:href="ameh-20220331.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_APCAndAPCLSMAMember_a56a1fa7-690b-4ecf-a399-bfb46ca10e8a" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_193713dc-04a1-4862-8ae7-ee51ac9ed42e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloMedicalHoldingsIncMember_8c021314-61ae-4ba9-ac73-e43cb1e7c9dd" xlink:href="ameh-20220331.xsd#ameh_ApolloMedicalHoldingsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_ac5f5eb0-96e9-40d7-9816-7a3e84783176" xlink:to="loc_ameh_ApolloMedicalHoldingsIncMember_8c021314-61ae-4ba9-ac73-e43cb1e7c9dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementIncMember_81ad4306-3c95-4324-8882-99da527bab9b" xlink:href="ameh-20220331.xsd#ameh_NetworkMedicalManagementIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_ac5f5eb0-96e9-40d7-9816-7a3e84783176" xlink:to="loc_ameh_NetworkMedicalManagementIncMember_81ad4306-3c95-4324-8882-99da527bab9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeAxis_92978b4b-2856-4ef2-bc65-c9f50898bab8" xlink:href="ameh-20220331.xsd#ameh_ContractTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_e88f2f5d-1555-44f3-8f5f-742f04b0dcb2" xlink:to="loc_ameh_ContractTypeAxis_92978b4b-2856-4ef2-bc65-c9f50898bab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeDomain_9fd198cd-2425-4920-85f7-85954361dafa" xlink:href="ameh-20220331.xsd#ameh_ContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ContractTypeAxis_92978b4b-2856-4ef2-bc65-c9f50898bab8" xlink:to="loc_ameh_ContractTypeDomain_9fd198cd-2425-4920-85f7-85954361dafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AncillaryServiceContractMember_0a869fa5-f2e3-43bc-bea8-cfc244644356" xlink:href="ameh-20220331.xsd#ameh_AncillaryServiceContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ContractTypeDomain_9fd198cd-2425-4920-85f7-85954361dafa" xlink:to="loc_ameh_AncillaryServiceContractMember_0a869fa5-f2e3-43bc-bea8-cfc244644356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_c9ea50fd-aebb-4b23-aad9-86734754f12a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_e88f2f5d-1555-44f3-8f5f-742f04b0dcb2" xlink:to="loc_srt_OwnershipAxis_c9ea50fd-aebb-4b23-aad9-86734754f12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_4deacaa7-485b-412a-bf0a-8cc8d78f0def" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_c9ea50fd-aebb-4b23-aad9-86734754f12a" xlink:to="loc_srt_OwnershipDomain_4deacaa7-485b-412a-bf0a-8cc8d78f0def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MediPortalLLCMember_f97bb837-3ae0-401c-946a-ac1c4606c60f" xlink:href="ameh-20220331.xsd#ameh_MediPortalLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_4deacaa7-485b-412a-bf0a-8cc8d78f0def" xlink:to="loc_ameh_MediPortalLLCMember_f97bb837-3ae0-401c-946a-ac1c4606c60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AchievaMedInc.Member_3813b31a-54a7-4e14-ae3e-350644d26cd7" xlink:href="ameh-20220331.xsd#ameh_AchievaMedInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_4deacaa7-485b-412a-bf0a-8cc8d78f0def" xlink:to="loc_ameh_AchievaMedInc.Member_3813b31a-54a7-4e14-ae3e-350644d26cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_442423b6-ed8c-4f7d-8bfc-e515bc73d963" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_e88f2f5d-1555-44f3-8f5f-742f04b0dcb2" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_442423b6-ed8c-4f7d-8bfc-e515bc73d963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_6ac08ce7-b84b-4978-8907-e2950cc43b98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_442423b6-ed8c-4f7d-8bfc-e515bc73d963" xlink:to="loc_us-gaap_ReceivableTypeDomain_6ac08ce7-b84b-4978-8907-e2950cc43b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_4fe67d6f-9fe2-4e7b-ba72-8b9f9a11e830" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_6ac08ce7-b84b-4978-8907-e2950cc43b98" xlink:to="loc_us-gaap_NotesReceivableMember_4fe67d6f-9fe2-4e7b-ba72-8b9f9a11e830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1838e207-3676-4915-a37b-2182655b34a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_e88f2f5d-1555-44f3-8f5f-742f04b0dcb2" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1838e207-3676-4915-a37b-2182655b34a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_cd3f383e-a7e3-4c80-bf5d-e86c8149d4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1838e207-3676-4915-a37b-2182655b34a0" xlink:to="loc_us-gaap_RelatedPartyDomain_cd3f383e-a7e3-4c80-bf5d-e86c8149d4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.ArteagaMember_fa8fd577-b943-4f34-b503-e4ca1d4210eb" xlink:href="ameh-20220331.xsd#ameh_Dr.ArteagaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_cd3f383e-a7e3-4c80-bf5d-e86c8149d4e3" xlink:to="loc_ameh_Dr.ArteagaMember_fa8fd577-b943-4f34-b503-e4ca1d4210eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_e88f2f5d-1555-44f3-8f5f-742f04b0dcb2" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOwnershipPercentageSold_9fd2383b-c4cf-4013-9ee7-750ac6cd7a6e" xlink:href="ameh-20220331.xsd#ameh_EquityMethodInvestmentOwnershipPercentageSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_ameh_EquityMethodInvestmentOwnershipPercentageSold_9fd2383b-c4cf-4013-9ee7-750ac6cd7a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_591b6f26-148a-492e-b3f4-73f610165874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_591b6f26-148a-492e-b3f4-73f610165874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_81a35f58-a86a-4681-954c-665c9bc1738c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_81a35f58-a86a-4681-954c-665c9bc1738c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_392c9d79-cd05-4e00-9f0e-11efa34f46d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_392c9d79-cd05-4e00-9f0e-11efa34f46d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_49dea12e-7268-4fc0-a6c1-7ba6f962e423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_us-gaap_EquityMethodInvestments_49dea12e-7268-4fc0-a6c1-7ba6f962e423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForFees_f9ef1a33-5ee4-4603-b3dc-5cf2ac8ae277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForFees"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_us-gaap_PaymentsForFees_f9ef1a33-5ee4-4603-b3dc-5cf2ac8ae277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_6bc54d26-a06c-4fcd-8d54-6df1a952b4e2" xlink:href="ameh-20220331.xsd#ameh_AssetAcquisitionPercentageOfSharesAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_6bc54d26-a06c-4fcd-8d54-6df1a952b4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_415a0834-0d5e-4aa7-834a-d9a2f39c9e66" xlink:href="ameh-20220331.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_415a0834-0d5e-4aa7-834a-d9a2f39c9e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_fc5e660b-aaf9-4743-845b-571c6ea40a1a" xlink:href="ameh-20220331.xsd#ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_fc5e660b-aaf9-4743-845b-571c6ea40a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_62f0ec87-58b8-4906-96bb-67fab5568fe6" xlink:href="ameh-20220331.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_62f0ec87-58b8-4906-96bb-67fab5568fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_32ea6a3f-6a61-4338-a86d-c3fad698d1a5" xlink:href="ameh-20220331.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_32ea6a3f-6a61-4338-a86d-c3fad698d1a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_b2cafdfc-2d59-465b-82bc-7cae532741a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_b2cafdfc-2d59-465b-82bc-7cae532741a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_40aa6cc1-0115-4948-b75e-ca3b4be4c43c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_40aa6cc1-0115-4948-b75e-ca3b4be4c43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_879ab19b-3da8-42f8-a079-30b193f39c1b" xlink:href="ameh-20220331.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_879ab19b-3da8-42f8-a079-30b193f39c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_2f3ec277-d25f-407d-a0ed-0b6dbc0a5198" xlink:href="ameh-20220331.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_2f3ec277-d25f-407d-a0ed-0b6dbc0a5198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_31280ea8-1a33-453b-b6b6-f828f9c99512" xlink:href="ameh-20220331.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_31280ea8-1a33-453b-b6b6-f828f9c99512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_c02d76e9-22b2-4d9e-8145-689ae692b56c" xlink:href="ameh-20220331.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_c02d76e9-22b2-4d9e-8145-689ae692b56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_19467a9d-a778-4a26-9f95-af4765e3f8c3" xlink:href="ameh-20220331.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_19467a9d-a778-4a26-9f95-af4765e3f8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_269a5529-d896-4109-900d-ef4df3f2a313" xlink:href="ameh-20220331.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_269a5529-d896-4109-900d-ef4df3f2a313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_3ea3eb38-74b7-483f-b7c2-71528c56c537" xlink:href="ameh-20220331.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d6fcfe05-6898-469b-b062-3b6c31c7b0c0" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_3ea3eb38-74b7-483f-b7c2-71528c56c537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_b1dfc915-4c98-4ee4-8640-0fa3784a6849" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2f05be37-fd7b-46df-935c-3ba176d9ed12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_b1dfc915-4c98-4ee4-8640-0fa3784a6849" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2f05be37-fd7b-46df-935c-3ba176d9ed12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_25ce614e-a768-41c3-9106-283ebfd39b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2f05be37-fd7b-46df-935c-3ba176d9ed12" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_25ce614e-a768-41c3-9106-283ebfd39b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_20689056-6da8-4129-82f6-f170617fa00e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_25ce614e-a768-41c3-9106-283ebfd39b4d" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_20689056-6da8-4129-82f6-f170617fa00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_f5cc2cad-8b7b-477c-bc05-4f7f9257a688" xlink:href="ameh-20220331.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_20689056-6da8-4129-82f6-f170617fa00e" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_f5cc2cad-8b7b-477c-bc05-4f7f9257a688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8eb86cdb-dada-4cbb-aed2-a4780f6ab29b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2f05be37-fd7b-46df-935c-3ba176d9ed12" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8eb86cdb-dada-4cbb-aed2-a4780f6ab29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_bc68a20c-b540-489c-9203-4c297a128976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8eb86cdb-dada-4cbb-aed2-a4780f6ab29b" xlink:to="loc_us-gaap_AssetsAbstract_bc68a20c-b540-489c-9203-4c297a128976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_aa286c4f-79a7-4b6d-a925-c04dc620dd40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bc68a20c-b540-489c-9203-4c297a128976" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_aa286c4f-79a7-4b6d-a925-c04dc620dd40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_4ae8b561-cc97-482c-ba56-c95d9aad8d01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bc68a20c-b540-489c-9203-4c297a128976" xlink:to="loc_us-gaap_RestrictedCashCurrent_4ae8b561-cc97-482c-ba56-c95d9aad8d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_cb338962-a303-47ae-b93e-4efebbb693da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bc68a20c-b540-489c-9203-4c297a128976" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_cb338962-a303-47ae-b93e-4efebbb693da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_5eeb235b-1766-4c14-92ee-5642b27ed1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bc68a20c-b540-489c-9203-4c297a128976" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_5eeb235b-1766-4c14-92ee-5642b27ed1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_64ef1e32-3f3a-4948-972e-72a38f5d2f14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bc68a20c-b540-489c-9203-4c297a128976" xlink:to="loc_us-gaap_Assets_64ef1e32-3f3a-4948-972e-72a38f5d2f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1c92c65-59cd-4cca-bc0a-a6231e409a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8eb86cdb-dada-4cbb-aed2-a4780f6ab29b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1c92c65-59cd-4cca-bc0a-a6231e409a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_060c2c27-ae2e-4871-b76e-f2e995310652" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1c92c65-59cd-4cca-bc0a-a6231e409a1c" xlink:to="loc_us-gaap_LiabilitiesCurrent_060c2c27-ae2e-4871-b76e-f2e995310652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2f1c43a9-1afe-4380-b6e5-688b675b4232" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1c92c65-59cd-4cca-bc0a-a6231e409a1c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2f1c43a9-1afe-4380-b6e5-688b675b4232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9323987a-c072-413f-bae6-a7d3b7a58431" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1c92c65-59cd-4cca-bc0a-a6231e409a1c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_9323987a-c072-413f-bae6-a7d3b7a58431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_2d85cc01-2a4b-4270-a517-56caf2cecb46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8eb86cdb-dada-4cbb-aed2-a4780f6ab29b" xlink:to="loc_us-gaap_IncomeStatementAbstract_2d85cc01-2a4b-4270-a517-56caf2cecb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_14387363-fe08-4435-b468-07f102344a65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2d85cc01-2a4b-4270-a517-56caf2cecb46" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_14387363-fe08-4435-b468-07f102344a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_5d9029d1-6c48-472a-bcec-a8c653787745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2d85cc01-2a4b-4270-a517-56caf2cecb46" xlink:to="loc_us-gaap_CostsAndExpenses_5d9029d1-6c48-472a-bcec-a8c653787745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_cc94150d-b384-4cab-91cf-dc6c6dd92857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2d85cc01-2a4b-4270-a517-56caf2cecb46" xlink:to="loc_us-gaap_ProfitLoss_cc94150d-b384-4cab-91cf-dc6c6dd92857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties" xlink:type="simple" xlink:href="ameh-20220331.xsd#LoanReceivableandLoanReceivableRelatedParties"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_da12b6c4-3256-490b-ba3c-642d9029bbd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LoanReceivableTextBlock_09cb2722-3a8e-4824-bbc5-23a61dce5e35" xlink:href="ameh-20220331.xsd#ameh_LoanReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_da12b6c4-3256-490b-ba3c-642d9029bbd3" xlink:to="loc_ameh_LoanReceivableTextBlock_09cb2722-3a8e-4824-bbc5-23a61dce5e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_1132bd12-d727-47c9-b9a6-b7304ade752f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_cdd99ed4-6fa4-4e37-adb3-520121bccab6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_1132bd12-d727-47c9-b9a6-b7304ade752f" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_cdd99ed4-6fa4-4e37-adb3-520121bccab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_8e95ac13-dfbe-46be-81cf-e5cd38773ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_cdd99ed4-6fa4-4e37-adb3-520121bccab6" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_8e95ac13-dfbe-46be-81cf-e5cd38773ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_b740bea7-7b23-43b4-84cc-b2a7b8e9e113" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_8e95ac13-dfbe-46be-81cf-e5cd38773ca0" xlink:to="loc_us-gaap_ReceivableTypeDomain_b740bea7-7b23-43b4-84cc-b2a7b8e9e113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_68d5d48d-704b-4505-a9dd-9904073d836a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_b740bea7-7b23-43b4-84cc-b2a7b8e9e113" xlink:to="loc_us-gaap_NotesReceivableMember_68d5d48d-704b-4505-a9dd-9904073d836a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2347b430-0732-47c9-8cc1-ddd0fb52449a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_cdd99ed4-6fa4-4e37-adb3-520121bccab6" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2347b430-0732-47c9-8cc1-ddd0fb52449a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b63a225d-c70d-4da2-abe7-ea240606b06b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2347b430-0732-47c9-8cc1-ddd0fb52449a" xlink:to="loc_us-gaap_RelatedPartyDomain_b63a225d-c70d-4da2-abe7-ea240606b06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Pacific6EnterprisesMember_7a395088-58ee-4aed-8c42-be9726df9394" xlink:href="ameh-20220331.xsd#ameh_Pacific6EnterprisesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_b63a225d-c70d-4da2-abe7-ea240606b06b" xlink:to="loc_ameh_Pacific6EnterprisesMember_7a395088-58ee-4aed-8c42-be9726df9394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_4a73c86b-3b0e-4eb0-86b3-1d5fedcb9441" xlink:href="ameh-20220331.xsd#ameh_AHMCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_b63a225d-c70d-4da2-abe7-ea240606b06b" xlink:to="loc_ameh_AHMCMember_4a73c86b-3b0e-4eb0-86b3-1d5fedcb9441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_50a91db7-cd03-4398-b77d-7947c1791244" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_cdd99ed4-6fa4-4e37-adb3-520121bccab6" xlink:to="loc_dei_LegalEntityAxis_50a91db7-cd03-4398-b77d-7947c1791244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_852538b6-f5dc-40bd-9368-4e70aeaf7a87" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_50a91db7-cd03-4398-b77d-7947c1791244" xlink:to="loc_dei_EntityDomain_852538b6-f5dc-40bd-9368-4e70aeaf7a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember_5a0cd678-fa68-4236-ae1a-5942b83ba7a2" xlink:href="ameh-20220331.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_852538b6-f5dc-40bd-9368-4e70aeaf7a87" xlink:to="loc_ameh_NetworkMedicalManagementMember_5a0cd678-fa68-4236-ae1a-5942b83ba7a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ddd8f012-64da-4f51-a827-dfdb44963d26" xlink:href="ameh-20220331.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_852538b6-f5dc-40bd-9368-4e70aeaf7a87" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ddd8f012-64da-4f51-a827-dfdb44963d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_5fa852fe-a861-4e7a-a1ec-5cc4f23f18ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_cdd99ed4-6fa4-4e37-adb3-520121bccab6" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_5fa852fe-a861-4e7a-a1ec-5cc4f23f18ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_5ff2c4b3-cd85-4cf7-852e-5d5b56ea3f54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_5fa852fe-a861-4e7a-a1ec-5cc4f23f18ab" xlink:to="loc_us-gaap_NotesReceivableNet_5ff2c4b3-cd85-4cf7-852e-5d5b56ea3f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_64899b4b-05ef-4532-bf52-93a6d7b8c080" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_5fa852fe-a861-4e7a-a1ec-5cc4f23f18ab" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_64899b4b-05ef-4532-bf52-93a6d7b8c080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableGross_a8795bb9-5a5b-4ecd-8a24-c3ef2ceebd3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_5fa852fe-a861-4e7a-a1ec-5cc4f23f18ab" xlink:to="loc_us-gaap_NotesReceivableGross_a8795bb9-5a5b-4ecd-8a24-c3ef2ceebd3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableInterestRateStatedPercentage_c2ae8b98-50d5-46e2-b751-d978583dda6b" xlink:href="ameh-20220331.xsd#ameh_FinanceReceivableInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_5fa852fe-a861-4e7a-a1ec-5cc4f23f18ab" xlink:to="loc_ameh_FinanceReceivableInterestRateStatedPercentage_c2ae8b98-50d5-46e2-b751-d978583dda6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpenses" xlink:type="simple" xlink:href="ameh-20220331.xsd#AccountsPayableandAccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_db4786bc-cbca-4a29-8dfb-589b76b32b30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_5e07bc7a-8721-4b7a-bb1b-21725b2d2482" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_db4786bc-cbca-4a29-8dfb-589b76b32b30" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_5e07bc7a-8721-4b7a-bb1b-21725b2d2482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables" xlink:type="simple" xlink:href="ameh-20220331.xsd#AccountsPayableandAccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_ac7fe637-b587-4459-9595-05de8b036080" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_b2c0d607-1db9-4b0a-9bf1-05da4a164ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ac7fe637-b587-4459-9595-05de8b036080" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_b2c0d607-1db9-4b0a-9bf1-05da4a164ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_7b8e18fc-f142-4ebf-9abf-b3de6cbbf2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e0dc2f77-6d79-491e-8ff7-962e02990920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7b8e18fc-f142-4ebf-9abf-b3de6cbbf2b7" xlink:to="loc_us-gaap_AccountsPayableCurrent_e0dc2f77-6d79-491e-8ff7-962e02990920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SpecialtyCapitationPayableCurrent_2299977b-6844-41cf-97ba-99e520264976" xlink:href="ameh-20220331.xsd#ameh_SpecialtyCapitationPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7b8e18fc-f142-4ebf-9abf-b3de6cbbf2b7" xlink:to="loc_ameh_SpecialtyCapitationPayableCurrent_2299977b-6844-41cf-97ba-99e520264976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SubcontractorIPAPayable_b780ba4c-793a-4b13-90ee-d9ebbc3d1aac" xlink:href="ameh-20220331.xsd#ameh_SubcontractorIPAPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7b8e18fc-f142-4ebf-9abf-b3de6cbbf2b7" xlink:to="loc_ameh_SubcontractorIPAPayable_b780ba4c-793a-4b13-90ee-d9ebbc3d1aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_cf360f1d-802a-4338-9957-897e39def997" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7b8e18fc-f142-4ebf-9abf-b3de6cbbf2b7" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_cf360f1d-802a-4338-9957-897e39def997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_6a614911-7e7b-49ce-b7f7-3ff1f6b14638" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7b8e18fc-f142-4ebf-9abf-b3de6cbbf2b7" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_6a614911-7e7b-49ce-b7f7-3ff1f6b14638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d87492a9-d410-4058-9736-cd7d49effc87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7b8e18fc-f142-4ebf-9abf-b3de6cbbf2b7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d87492a9-d410-4058-9736-cd7d49effc87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9b9c8414-01bc-4ff4-91b8-04ad6b7e7b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7b8e18fc-f142-4ebf-9abf-b3de6cbbf2b7" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9b9c8414-01bc-4ff4-91b8-04ad6b7e7b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2ee7950c-27c2-42b0-a659-f6e9ce88552f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7b8e18fc-f142-4ebf-9abf-b3de6cbbf2b7" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2ee7950c-27c2-42b0-a659-f6e9ce88552f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilities" xlink:type="simple" xlink:href="ameh-20220331.xsd#MedicalLiabilities"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_e23d7819-6a09-496d-a32d-d8fbddec6e06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_85a952ac-805b-4eed-bfb3-f9791721301d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_e23d7819-6a09-496d-a32d-d8fbddec6e06" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_85a952ac-805b-4eed-bfb3-f9791721301d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilitiesTables" xlink:type="simple" xlink:href="ameh-20220331.xsd#MedicalLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_c5685f14-d9e2-4eca-8f39-51efd445851a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_19e51a38-46da-4921-8aaf-8624dd9810c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_c5685f14-d9e2-4eca-8f39-51efd445851a" xlink:to="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_19e51a38-46da-4921-8aaf-8624dd9810c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_71b04b8d-25ba-459e-b2d5-a660a8c3a0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_0f026c75-7edc-4222-83d7-07811954381a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_71b04b8d-25ba-459e-b2d5-a660a8c3a0a7" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_0f026c75-7edc-4222-83d7-07811954381a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_5cb5978b-55b6-42da-947a-dfcc175a79c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_0f026c75-7edc-4222-83d7-07811954381a" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_5cb5978b-55b6-42da-947a-dfcc175a79c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalCareCostsAbstract_75545c69-2349-453d-82f7-be73ee27685d" xlink:href="ameh-20220331.xsd#ameh_MedicalCareCostsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_0f026c75-7edc-4222-83d7-07811954381a" xlink:to="loc_ameh_MedicalCareCostsAbstract_75545c69-2349-453d-82f7-be73ee27685d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_16c2600e-a8d0-4ab2-bf0e-514d3e835bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_MedicalCareCostsAbstract_75545c69-2349-453d-82f7-be73ee27685d" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_16c2600e-a8d0-4ab2-bf0e-514d3e835bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_7165ff07-3fe1-4b7f-9d6c-54d7a56d3760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_MedicalCareCostsAbstract_75545c69-2349-453d-82f7-be73ee27685d" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_7165ff07-3fe1-4b7f-9d6c-54d7a56d3760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_2138f846-2407-40f7-b9fc-46cb0b5180e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_MedicalCareCostsAbstract_75545c69-2349-453d-82f7-be73ee27685d" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_2138f846-2407-40f7-b9fc-46cb0b5180e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsForMedicalCareCostsAbstract_910f8a7a-c1ed-4ee2-8bf1-a860e208f4ab" xlink:href="ameh-20220331.xsd#ameh_PaymentsForMedicalCareCostsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_0f026c75-7edc-4222-83d7-07811954381a" xlink:to="loc_ameh_PaymentsForMedicalCareCostsAbstract_910f8a7a-c1ed-4ee2-8bf1-a860e208f4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_c9af7331-6bd2-4ad8-9a17-6c76c2f4dcff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_PaymentsForMedicalCareCostsAbstract_910f8a7a-c1ed-4ee2-8bf1-a860e208f4ab" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_c9af7331-6bd2-4ad8-9a17-6c76c2f4dcff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_191d8498-5a51-4b1c-8c54-b66ebcc98c86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_PaymentsForMedicalCareCostsAbstract_910f8a7a-c1ed-4ee2-8bf1-a860e208f4ab" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_191d8498-5a51-4b1c-8c54-b66ebcc98c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_d02602fd-0e05-40e8-84d8-61346f2fbfa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_PaymentsForMedicalCareCostsAbstract_910f8a7a-c1ed-4ee2-8bf1-a860e208f4ab" xlink:to="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_d02602fd-0e05-40e8-84d8-61346f2fbfa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_a858c758-b8df-4795-8c18-3a2e31bb1f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_0f026c75-7edc-4222-83d7-07811954381a" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_a858c758-b8df-4795-8c18-3a2e31bb1f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_e3111ae9-0e7b-42cf-b32c-7d09caf2a2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_0f026c75-7edc-4222-83d7-07811954381a" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_e3111ae9-0e7b-42cf-b32c-7d09caf2a2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit" xlink:type="simple" xlink:href="ameh-20220331.xsd#CreditFacilityBankLoansandLinesofCredit"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5f5c93a9-f539-4035-9bc4-fb5778939af5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_112601fd-6670-4bba-a499-be72c194a078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5f5c93a9-f539-4035-9bc4-fb5778939af5" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_112601fd-6670-4bba-a499-be72c194a078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables" xlink:type="simple" xlink:href="ameh-20220331.xsd#CreditFacilityBankLoansandLinesofCreditTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_19997615-87de-41e6-a66b-73c40c85aa1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_35f1f8c1-f667-4dc9-ad1b-7b4870e5c253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_19997615-87de-41e6-a66b-73c40c85aa1a" xlink:to="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_35f1f8c1-f667-4dc9-ad1b-7b4870e5c253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_c44e23fa-39d9-4cdc-8e25-d06b8660743c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_19997615-87de-41e6-a66b-73c40c85aa1a" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_c44e23fa-39d9-4cdc-8e25-d06b8660743c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c75e208f-bf4b-413f-9cad-47c79a78ebda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_3373bdc3-21cb-477e-9c83-64927009d59c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c75e208f-bf4b-413f-9cad-47c79a78ebda" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_3373bdc3-21cb-477e-9c83-64927009d59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_9c5f0b3f-33a8-450c-b40e-a57ad27989cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_3373bdc3-21cb-477e-9c83-64927009d59c" xlink:to="loc_us-gaap_CreditFacilityAxis_9c5f0b3f-33a8-450c-b40e-a57ad27989cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_f847eba7-0a9a-4f9d-be2e-4fb0fe127cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_9c5f0b3f-33a8-450c-b40e-a57ad27989cd" xlink:to="loc_us-gaap_CreditFacilityDomain_f847eba7-0a9a-4f9d-be2e-4fb0fe127cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_0e607eef-c2db-49c5-9410-0680ec0a8396" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_f847eba7-0a9a-4f9d-be2e-4fb0fe127cb2" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_0e607eef-c2db-49c5-9410-0680ec0a8396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e300e88a-6e3a-4f03-9b7a-728da8ef5300" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_3373bdc3-21cb-477e-9c83-64927009d59c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e300e88a-6e3a-4f03-9b7a-728da8ef5300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_beeca2aa-ead4-488e-8504-e8dd93988d91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e300e88a-6e3a-4f03-9b7a-728da8ef5300" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_beeca2aa-ead4-488e-8504-e8dd93988d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateLoanMember_fe527829-441f-4bc5-a86d-9a46ebd4d401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealEstateLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_beeca2aa-ead4-488e-8504-e8dd93988d91" xlink:to="loc_us-gaap_RealEstateLoanMember_fe527829-441f-4bc5-a86d-9a46ebd4d401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConstructionLoanMember_e38d5517-633a-4b5a-b2f5-64c5e013e7c5" xlink:href="ameh-20220331.xsd#ameh_ConstructionLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_beeca2aa-ead4-488e-8504-e8dd93988d91" xlink:to="loc_ameh_ConstructionLoanMember_e38d5517-633a-4b5a-b2f5-64c5e013e7c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_7ca900df-0840-41f5-b379-0aea8cac1a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_3373bdc3-21cb-477e-9c83-64927009d59c" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_7ca900df-0840-41f5-b379-0aea8cac1a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0b53c731-66e7-4a98-919e-59af98b2cc8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ca900df-0840-41f5-b379-0aea8cac1a8a" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_0b53c731-66e7-4a98-919e-59af98b2cc8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_f120a3ab-8688-4d11-ab17-f51a1e0d1a58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ca900df-0840-41f5-b379-0aea8cac1a8a" xlink:to="loc_us-gaap_LongTermDebtCurrent_f120a3ab-8688-4d11-ab17-f51a1e0d1a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_aea7cd7a-74e5-4433-919e-2162d79c7d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ca900df-0840-41f5-b379-0aea8cac1a8a" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_aea7cd7a-74e5-4433-919e-2162d79c7d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_67408f4e-32e6-4206-bacb-2f04c58457a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ca900df-0840-41f5-b379-0aea8cac1a8a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_67408f4e-32e6-4206-bacb-2f04c58457a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b8d69fb2-8082-46df-862d-56abcba402a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_e8d92b8c-4a70-4b55-ad0d-a530ed92a9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b8d69fb2-8082-46df-862d-56abcba402a4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_e8d92b8c-4a70-4b55-ad0d-a530ed92a9f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_7c6ceef9-2427-4a2a-99fc-86ab248948a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b8d69fb2-8082-46df-862d-56abcba402a4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_7c6ceef9-2427-4a2a-99fc-86ab248948a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_c522743b-1968-4409-8f09-47f1e2dea588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b8d69fb2-8082-46df-862d-56abcba402a4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_c522743b-1968-4409-8f09-47f1e2dea588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_bbad1fcd-46ae-45fd-bcda-d86276047341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b8d69fb2-8082-46df-862d-56abcba402a4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_bbad1fcd-46ae-45fd-bcda-d86276047341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LongTermDebtMaturityAfterYearFour_c017b1da-c706-4249-859e-68cc17092d38" xlink:href="ameh-20220331.xsd#ameh_LongTermDebtMaturityAfterYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b8d69fb2-8082-46df-862d-56abcba402a4" xlink:to="loc_ameh_LongTermDebtMaturityAfterYearFour_c017b1da-c706-4249-859e-68cc17092d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_63a5ec93-ab87-4552-a93d-d2a999d8e70c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b8d69fb2-8082-46df-862d-56abcba402a4" xlink:to="loc_us-gaap_LineOfCredit_63a5ec93-ab87-4552-a93d-d2a999d8e70c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d20aedd5-3d7d-4684-be2c-0c1f6c83d9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_cef03fc1-cd12-4c06-b71b-b3a78c9eabfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d20aedd5-3d7d-4684-be2c-0c1f6c83d9a1" xlink:to="loc_us-gaap_DebtInstrumentTable_cef03fc1-cd12-4c06-b71b-b3a78c9eabfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_7e97d1d8-ba39-4eb9-81f5-684b31be5d85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cef03fc1-cd12-4c06-b71b-b3a78c9eabfd" xlink:to="loc_us-gaap_CreditFacilityAxis_7e97d1d8-ba39-4eb9-81f5-684b31be5d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d6f814cc-d5c3-4a45-a3f0-23602437bbfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_7e97d1d8-ba39-4eb9-81f5-684b31be5d85" xlink:to="loc_us-gaap_CreditFacilityDomain_d6f814cc-d5c3-4a45-a3f0-23602437bbfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_c4d333ed-c0aa-475b-84ea-88c01c1b94dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_d6f814cc-d5c3-4a45-a3f0-23602437bbfd" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_c4d333ed-c0aa-475b-84ea-88c01c1b94dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_87de3b2e-dd67-42ba-8c3d-1a0eee5e78e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_d6f814cc-d5c3-4a45-a3f0-23602437bbfd" xlink:to="loc_us-gaap_LineOfCreditMember_87de3b2e-dd67-42ba-8c3d-1a0eee5e78e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_b1c887f9-759d-4414-b0b7-281cc00a1736" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_d6f814cc-d5c3-4a45-a3f0-23602437bbfd" xlink:to="loc_us-gaap_LetterOfCreditMember_b1c887f9-759d-4414-b0b7-281cc00a1736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember_9621ed90-0006-4e2e-8cc3-f252dfa5d974" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BridgeLoanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_d6f814cc-d5c3-4a45-a3f0-23602437bbfd" xlink:to="loc_us-gaap_BridgeLoanMember_9621ed90-0006-4e2e-8cc3-f252dfa5d974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_844fd056-fd01-48cc-a2f5-bfa9ca4b2d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_d6f814cc-d5c3-4a45-a3f0-23602437bbfd" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_844fd056-fd01-48cc-a2f5-bfa9ca4b2d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6df5da38-1337-43ee-ab63-4cd22edb1002" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cef03fc1-cd12-4c06-b71b-b3a78c9eabfd" xlink:to="loc_us-gaap_DebtInstrumentAxis_6df5da38-1337-43ee-ab63-4cd22edb1002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2767d10e-52e9-4903-a3f1-b7f36550f305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_6df5da38-1337-43ee-ab63-4cd22edb1002" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2767d10e-52e9-4903-a3f1-b7f36550f305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmendedCreditAgreementMember_8597fbba-fa8e-4568-b8da-91e6b12ade7d" xlink:href="ameh-20220331.xsd#ameh_AmendedCreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2767d10e-52e9-4903-a3f1-b7f36550f305" xlink:to="loc_ameh_AmendedCreditAgreementMember_8597fbba-fa8e-4568-b8da-91e6b12ade7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CreditAgreementMember_931bf8f3-58c3-45f9-80d1-649bbb6cda8e" xlink:href="ameh-20220331.xsd#ameh_CreditAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2767d10e-52e9-4903-a3f1-b7f36550f305" xlink:to="loc_ameh_CreditAgreementMember_931bf8f3-58c3-45f9-80d1-649bbb6cda8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConstructionLoanMember_44fb899c-ceb5-4662-a954-74e29677488c" xlink:href="ameh-20220331.xsd#ameh_ConstructionLoanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2767d10e-52e9-4903-a3f1-b7f36550f305" xlink:to="loc_ameh_ConstructionLoanMember_44fb899c-ceb5-4662-a954-74e29677488c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcBusinessLoanAgreementMember_8d9cbfaa-2380-47a1-9778-9aa8c7bc06be" xlink:href="ameh-20220331.xsd#ameh_ApcBusinessLoanAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2767d10e-52e9-4903-a3f1-b7f36550f305" xlink:to="loc_ameh_ApcBusinessLoanAgreementMember_8d9cbfaa-2380-47a1-9778-9aa8c7bc06be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b13d2d5c-7682-4c8b-b3a7-9f9cbaf2d359" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cef03fc1-cd12-4c06-b71b-b3a78c9eabfd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b13d2d5c-7682-4c8b-b3a7-9f9cbaf2d359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dd4adb57-822c-49e2-b8b9-f3652c2df09a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b13d2d5c-7682-4c8b-b3a7-9f9cbaf2d359" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dd4adb57-822c-49e2-b8b9-f3652c2df09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_5929f4c3-1443-4e65-8413-ee7a16a9b768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dd4adb57-822c-49e2-b8b9-f3652c2df09a" xlink:to="loc_us-gaap_LineOfCreditMember_5929f4c3-1443-4e65-8413-ee7a16a9b768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_aa07fc8e-0bdd-4981-8b4b-d7eeb4618528" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cef03fc1-cd12-4c06-b71b-b3a78c9eabfd" xlink:to="loc_srt_RangeAxis_aa07fc8e-0bdd-4981-8b4b-d7eeb4618528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_09e56016-8f83-409a-a0f4-197c991c11d4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_aa07fc8e-0bdd-4981-8b4b-d7eeb4618528" xlink:to="loc_srt_RangeMember_09e56016-8f83-409a-a0f4-197c991c11d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_62994b29-bd77-4477-bcc5-3916ed27c566" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_09e56016-8f83-409a-a0f4-197c991c11d4" xlink:to="loc_srt_MinimumMember_62994b29-bd77-4477-bcc5-3916ed27c566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9ef3be27-89d8-4e39-a191-f8e8fcaa932e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_09e56016-8f83-409a-a0f4-197c991c11d4" xlink:to="loc_srt_MaximumMember_9ef3be27-89d8-4e39-a191-f8e8fcaa932e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_9152d646-20ea-48bb-ad0e-48c5d0d993f3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cef03fc1-cd12-4c06-b71b-b3a78c9eabfd" xlink:to="loc_dei_LegalEntityAxis_9152d646-20ea-48bb-ad0e-48c5d0d993f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1fcf21b1-5c85-42ee-96c0-c153c49e125f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_9152d646-20ea-48bb-ad0e-48c5d0d993f3" xlink:to="loc_dei_EntityDomain_1fcf21b1-5c85-42ee-96c0-c153c49e125f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_8a435493-b950-405f-8569-292c4e6be101" xlink:href="ameh-20220331.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1fcf21b1-5c85-42ee-96c0-c153c49e125f" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_8a435493-b950-405f-8569-292c4e6be101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalPropertyPartnersLLCMember_347845ba-bdc5-4d5a-b728-b3f66b756665" xlink:href="ameh-20220331.xsd#ameh_MedicalPropertyPartnersLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1fcf21b1-5c85-42ee-96c0-c153c49e125f" xlink:to="loc_ameh_MedicalPropertyPartnersLLCMember_347845ba-bdc5-4d5a-b728-b3f66b756665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AMGPropertiesLLCMember_bb92ba73-dbeb-430f-9fcc-63d40bace799" xlink:href="ameh-20220331.xsd#ameh_AMGPropertiesLLCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1fcf21b1-5c85-42ee-96c0-c153c49e125f" xlink:to="loc_ameh_AMGPropertiesLLCMember_bb92ba73-dbeb-430f-9fcc-63d40bace799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ZLLPartnersLLCMember_5652282c-151c-4288-b56b-f11b1934875a" xlink:href="ameh-20220331.xsd#ameh_ZLLPartnersLLCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1fcf21b1-5c85-42ee-96c0-c153c49e125f" xlink:to="loc_ameh_ZLLPartnersLLCMember_5652282c-151c-4288-b56b-f11b1934875a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_f9d0ddd5-c558-4a2a-8623-2a5a59270fff" xlink:href="ameh-20220331.xsd#ameh_Tag8MedicalInvestmentGroupLLCMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1fcf21b1-5c85-42ee-96c0-c153c49e125f" xlink:to="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_f9d0ddd5-c558-4a2a-8623-2a5a59270fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_c4773de4-9613-407a-a28f-1bdbe6a6d3d2" xlink:href="ameh-20220331.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1fcf21b1-5c85-42ee-96c0-c153c49e125f" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_c4773de4-9613-407a-a28f-1bdbe6a6d3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_8cfecb6e-832d-4ed0-93af-e9c30950f007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cef03fc1-cd12-4c06-b71b-b3a78c9eabfd" xlink:to="loc_us-gaap_VariableRateAxis_8cfecb6e-832d-4ed0-93af-e9c30950f007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_9eb65aef-9602-4a93-85ea-dab39867eab3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_8cfecb6e-832d-4ed0-93af-e9c30950f007" xlink:to="loc_us-gaap_VariableRateDomain_9eb65aef-9602-4a93-85ea-dab39867eab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_d64b0a6f-9dd8-418c-be5a-c4ec4f83a8a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_9eb65aef-9602-4a93-85ea-dab39867eab3" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_d64b0a6f-9dd8-418c-be5a-c4ec4f83a8a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_561238a0-8825-4ebd-a344-857c79714274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_9eb65aef-9602-4a93-85ea-dab39867eab3" xlink:to="loc_us-gaap_PrimeRateMember_561238a0-8825-4ebd-a344-857c79714274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_16ecd60b-6c26-42a8-9c00-77a6364d456e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cef03fc1-cd12-4c06-b71b-b3a78c9eabfd" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_16ecd60b-6c26-42a8-9c00-77a6364d456e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_759c0481-e81d-4411-bfbc-9f1ab5050c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_16ecd60b-6c26-42a8-9c00-77a6364d456e" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_759c0481-e81d-4411-bfbc-9f1ab5050c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PreferredBankMember_58e7899b-beb5-48ea-9b3a-9c40996a529e" xlink:href="ameh-20220331.xsd#ameh_PreferredBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_759c0481-e81d-4411-bfbc-9f1ab5050c9a" xlink:to="loc_ameh_PreferredBankMember_58e7899b-beb5-48ea-9b3a-9c40996a529e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_30ed8e29-c0d3-4eba-a04d-cbb3edd17187" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cef03fc1-cd12-4c06-b71b-b3a78c9eabfd" xlink:to="loc_us-gaap_AssetAcquisitionAxis_30ed8e29-c0d3-4eba-a04d-cbb3edd17187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_eafb8a73-7ba1-4aee-88f3-4964328f2bba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_30ed8e29-c0d3-4eba-a04d-cbb3edd17187" xlink:to="loc_us-gaap_AssetAcquisitionDomain_eafb8a73-7ba1-4aee-88f3-4964328f2bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalPropertyPartnersLLCMember_c134fe95-bace-4a56-b0ee-1efaffab1e3a" xlink:href="ameh-20220331.xsd#ameh_MedicalPropertyPartnersLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_eafb8a73-7ba1-4aee-88f3-4964328f2bba" xlink:to="loc_ameh_MedicalPropertyPartnersLLCMember_c134fe95-bace-4a56-b0ee-1efaffab1e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AMGPropertiesLLCMember_16dd3f71-9149-4d47-adef-11a8bf459733" xlink:href="ameh-20220331.xsd#ameh_AMGPropertiesLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_eafb8a73-7ba1-4aee-88f3-4964328f2bba" xlink:to="loc_ameh_AMGPropertiesLLCMember_16dd3f71-9149-4d47-adef-11a8bf459733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ZLLPartnersLLCMember_e560e84e-561d-41ae-af7d-5d174d4fc753" xlink:href="ameh-20220331.xsd#ameh_ZLLPartnersLLCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_eafb8a73-7ba1-4aee-88f3-4964328f2bba" xlink:to="loc_ameh_ZLLPartnersLLCMember_e560e84e-561d-41ae-af7d-5d174d4fc753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_6dc38bbb-d5a1-420d-8849-dbf888a41b96" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cef03fc1-cd12-4c06-b71b-b3a78c9eabfd" xlink:to="loc_srt_StatementScenarioAxis_6dc38bbb-d5a1-420d-8849-dbf888a41b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_f041785f-b596-493b-a697-c02ecf7a8cd9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_6dc38bbb-d5a1-420d-8849-dbf888a41b96" xlink:to="loc_srt_ScenarioUnspecifiedDomain_f041785f-b596-493b-a697-c02ecf7a8cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_0493f23b-0ac0-463e-9512-3f57d669ae71" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_f041785f-b596-493b-a697-c02ecf7a8cd9" xlink:to="loc_srt_ScenarioForecastMember_0493f23b-0ac0-463e-9512-3f57d669ae71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cef03fc1-cd12-4c06-b71b-b3a78c9eabfd" xlink:to="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_d0a85bc0-aba8-4650-ba40-e3a52a58a9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_us-gaap_DebtInstrumentTerm_d0a85bc0-aba8-4650-ba40-e3a52a58a9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_39591ec9-e9ce-411b-8065-e37845b76f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_39591ec9-e9ce-411b-8065-e37845b76f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_3ef9109b-50d6-4e08-bdec-195575afc3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_3ef9109b-50d6-4e08-bdec-195575afc3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_6e41efac-f508-454a-a2c0-c664e0f2391b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_6e41efac-f508-454a-a2c0-c664e0f2391b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_30891a3e-84b9-4dec-8172-2071cd319ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_30891a3e-84b9-4dec-8172-2071cd319ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_153f3895-e402-4f94-be60-0b7a4a8bb295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_153f3895-e402-4f94-be60-0b7a4a8bb295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios_c5c7de66-84e0-475d-a6d9-9f06461951d7" xlink:href="ameh-20220331.xsd#ameh_DebtInstrumentNumberOfKeyFinancialRatios"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios_c5c7de66-84e0-475d-a6d9-9f06461951d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum_9528425d-786a-4f17-9eb6-c1ee3c631766" xlink:href="ameh-20220331.xsd#ameh_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum_9528425d-786a-4f17-9eb6-c1ee3c631766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtCovenantAggregatePurchasePriceMaximum_04648875-a3f8-4b0e-8b73-727db77c4587" xlink:href="ameh-20220331.xsd#ameh_DebtCovenantAggregatePurchasePriceMaximum"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_ameh_DebtCovenantAggregatePurchasePriceMaximum_04648875-a3f8-4b0e-8b73-727db77c4587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_566f4148-bd6b-497a-9481-83853a0d5df0" xlink:href="ameh-20220331.xsd#ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_566f4148-bd6b-497a-9481-83853a0d5df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum_d6ffd257-db9d-4a82-8541-4731acaa5386" xlink:href="ameh-20220331.xsd#ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum_d6ffd257-db9d-4a82-8541-4731acaa5386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_4c3fd532-e467-4290-8a78-c7323e1cc7c7" xlink:href="ameh-20220331.xsd#ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_4c3fd532-e467-4290-8a78-c7323e1cc7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_b47ffb37-07f9-481b-9808-c98eefac0901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_b47ffb37-07f9-481b-9808-c98eefac0901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_ad7a5319-0e40-4ec9-969d-cb9a05ded9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_ad7a5319-0e40-4ec9-969d-cb9a05ded9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_df034d20-f343-4960-9a94-f37c98efeeb6" xlink:href="ameh-20220331.xsd#ameh_AssetAcquisitionPercentageOfSharesAcquired"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_df034d20-f343-4960-9a94-f37c98efeeb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_b38de570-e864-4e7d-ba6d-2a23f443d5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_b38de570-e864-4e7d-ba6d-2a23f443d5e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_a04a1163-96ec-4be3-972c-63de37659555" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_us-gaap_LongTermDebt_a04a1163-96ec-4be3-972c-63de37659555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_6d13200a-b0e7-481a-816f-8236c3d5848c" xlink:href="ameh-20220331.xsd#ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_6d13200a-b0e7-481a-816f-8236c3d5848c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_34db29d0-49ca-4a00-85b1-26813aaca697" xlink:href="ameh-20220331.xsd#ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_34db29d0-49ca-4a00-85b1-26813aaca697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_364883f5-22e3-404a-9e99-7d767b61e5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_364883f5-22e3-404a-9e99-7d767b61e5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_9a9ebf0d-e717-49c3-acaf-695185c7d16e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_us-gaap_InterestExpense_9a9ebf0d-e717-49c3-acaf-695185c7d16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_4d569eba-6ffe-4ecf-88b0-8eeb8b9494b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82bd85a4-3169-4958-bd67-22c7321f23b1" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_4d569eba-6ffe-4ecf-88b0-8eeb8b9494b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquity" xlink:type="simple" xlink:href="ameh-20220331.xsd#MezzanineandStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_e39d3efa-36fe-4ce1-8585-c3cc138fb2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6e7444d1-6b19-4f3c-bfa5-b1e06ce9e050" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_e39d3efa-36fe-4ce1-8585-c3cc138fb2bd" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6e7444d1-6b19-4f3c-bfa5-b1e06ce9e050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#MezzanineandStockholdersEquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_9873ee5f-739c-472c-92f5-7e9092f66b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a0a510a7-14a3-4596-9e93-bc88b89c0569" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_9873ee5f-739c-472c-92f5-7e9092f66b7a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a0a510a7-14a3-4596-9e93-bc88b89c0569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_7ecc1a04-e623-4c4c-8366-ee52cdc9539d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a0a510a7-14a3-4596-9e93-bc88b89c0569" xlink:to="loc_dei_LegalEntityAxis_7ecc1a04-e623-4c4c-8366-ee52cdc9539d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_103c3995-8cc2-466b-b96c-c920327b5c0a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_7ecc1a04-e623-4c4c-8366-ee52cdc9539d" xlink:to="loc_dei_EntityDomain_103c3995-8cc2-466b-b96c-c920327b5c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ebdb37ea-0a06-4e71-b1d6-9cf48e7fed88" xlink:href="ameh-20220331.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_103c3995-8cc2-466b-b96c-c920327b5c0a" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ebdb37ea-0a06-4e71-b1d6-9cf48e7fed88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CDSCMember_5021e217-aedc-4696-afbf-05588b19cea5" xlink:href="ameh-20220331.xsd#ameh_CDSCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_103c3995-8cc2-466b-b96c-c920327b5c0a" xlink:to="loc_ameh_CDSCMember_5021e217-aedc-4696-afbf-05588b19cea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_faacb82c-fc98-408a-9ab6-0688a2b5eb27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a0a510a7-14a3-4596-9e93-bc88b89c0569" xlink:to="loc_us-gaap_ClassOfStockLineItems_faacb82c-fc98-408a-9ab6-0688a2b5eb27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesMerger_88082377-2705-4538-b5c8-0fd3c8baa785" xlink:href="ameh-20220331.xsd#ameh_StockIssuedDuringPeriodSharesMerger"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_faacb82c-fc98-408a-9ab6-0688a2b5eb27" xlink:to="loc_ameh_StockIssuedDuringPeriodSharesMerger_88082377-2705-4538-b5c8-0fd3c8baa785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_b9114efa-f51c-46e0-9853-3c60a9bb57bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_faacb82c-fc98-408a-9ab6-0688a2b5eb27" xlink:to="loc_us-gaap_TreasuryStockCommonShares_b9114efa-f51c-46e0-9853-3c60a9bb57bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_52d3ee5c-143d-416d-8a8a-961006d9f6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_faacb82c-fc98-408a-9ab6-0688a2b5eb27" xlink:to="loc_us-gaap_Dividends_52d3ee5c-143d-416d-8a8a-961006d9f6cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensation" xlink:type="simple" xlink:href="ameh-20220331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b3a23f1c-9716-45a5-82b4-4bcdbc1748ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_41307308-f1d0-434a-b8a8-054b05c8ee40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b3a23f1c-9716-45a5-82b4-4bcdbc1748ee" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_41307308-f1d0-434a-b8a8-054b05c8ee40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="ameh-20220331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_99e06c14-c4d0-4ae0-8f31-c3fe306ddfce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ee2951cd-6ef4-425e-bae2-0be903422cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_99e06c14-c4d0-4ae0-8f31-c3fe306ddfce" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ee2951cd-6ef4-425e-bae2-0be903422cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_84c75c7b-1c23-4b87-bfed-06a25fc9bb99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_99e06c14-c4d0-4ae0-8f31-c3fe306ddfce" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_84c75c7b-1c23-4b87-bfed-06a25fc9bb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_51332b5c-0434-4589-82fa-32bb415c6975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_99e06c14-c4d0-4ae0-8f31-c3fe306ddfce" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_51332b5c-0434-4589-82fa-32bb415c6975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_c490551b-336e-4789-8db8-afc65cf8614a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_99e06c14-c4d0-4ae0-8f31-c3fe306ddfce" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_c490551b-336e-4789-8db8-afc65cf8614a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#StockBasedCompensationShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_877de47e-a447-4cd5-bf08-2384c985d05f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_50607b2e-dda2-43c2-b19f-a6d702bbb890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_877de47e-a447-4cd5-bf08-2384c985d05f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_50607b2e-dda2-43c2-b19f-a6d702bbb890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_26aaf992-0823-43c3-bc5d-1c7f4b7c5fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_50607b2e-dda2-43c2-b19f-a6d702bbb890" xlink:to="loc_us-gaap_AwardTypeAxis_26aaf992-0823-43c3-bc5d-1c7f4b7c5fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_07868c55-ce62-48ca-8d41-0a79a4176880" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_26aaf992-0823-43c3-bc5d-1c7f4b7c5fc6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_07868c55-ce62-48ca-8d41-0a79a4176880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c0f39e0c-7c6f-44c0-92be-530701503d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_07868c55-ce62-48ca-8d41-0a79a4176880" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c0f39e0c-7c6f-44c0-92be-530701503d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockAwardsAndUnitsMember_18daf8c3-e33b-4d26-9110-615a1dab160b" xlink:href="ameh-20220331.xsd#ameh_StockAwardsAndUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_07868c55-ce62-48ca-8d41-0a79a4176880" xlink:to="loc_ameh_StockAwardsAndUnitsMember_18daf8c3-e33b-4d26-9110-615a1dab160b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2f040e48-d2e0-4d7a-a8ec-48a00093aac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_50607b2e-dda2-43c2-b19f-a6d702bbb890" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2f040e48-d2e0-4d7a-a8ec-48a00093aac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a1e6156c-6cfb-4227-804b-f287a37da1c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2f040e48-d2e0-4d7a-a8ec-48a00093aac9" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a1e6156c-6cfb-4227-804b-f287a37da1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a08ec570-a2eb-4163-bc6b-336c8fe321e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7dcd807d-1e8a-4733-a2e4-5b87d0205785" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a08ec570-a2eb-4163-bc6b-336c8fe321e7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7dcd807d-1e8a-4733-a2e4-5b87d0205785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5fec3150-d980-4354-8670-182e1cdb9572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7dcd807d-1e8a-4733-a2e4-5b87d0205785" xlink:to="loc_us-gaap_AwardTypeAxis_5fec3150-d980-4354-8670-182e1cdb9572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_031c89ff-5a57-45e7-9e6e-a5ec9826936a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5fec3150-d980-4354-8670-182e1cdb9572" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_031c89ff-5a57-45e7-9e6e-a5ec9826936a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c906337f-8d62-47dc-b8af-2191e4bf79bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_031c89ff-5a57-45e7-9e6e-a5ec9826936a" xlink:to="loc_us-gaap_RestrictedStockMember_c906337f-8d62-47dc-b8af-2191e4bf79bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_1f4ea1d5-e8f4-47ed-b326-db2efe2d4657" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7dcd807d-1e8a-4733-a2e4-5b87d0205785" xlink:to="loc_srt_TitleOfIndividualAxis_1f4ea1d5-e8f4-47ed-b326-db2efe2d4657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_31ed96db-ad33-46ac-b92d-dd1d07b72792" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_1f4ea1d5-e8f4-47ed-b326-db2efe2d4657" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_31ed96db-ad33-46ac-b92d-dd1d07b72792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EmployeesMember_a92ea827-9588-43ac-845d-79a55665a6d1" xlink:href="ameh-20220331.xsd#ameh_EmployeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_31ed96db-ad33-46ac-b92d-dd1d07b72792" xlink:to="loc_ameh_EmployeesMember_a92ea827-9588-43ac-845d-79a55665a6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_454afada-e973-44b0-a30a-5d404278ec91" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7dcd807d-1e8a-4733-a2e4-5b87d0205785" xlink:to="loc_srt_RangeAxis_454afada-e973-44b0-a30a-5d404278ec91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_44546b01-4608-48bc-b3d5-dc6df526fc70" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_454afada-e973-44b0-a30a-5d404278ec91" xlink:to="loc_srt_RangeMember_44546b01-4608-48bc-b3d5-dc6df526fc70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5f32a1ba-0668-4e90-9ba4-e5f413ddf127" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_44546b01-4608-48bc-b3d5-dc6df526fc70" xlink:to="loc_srt_MinimumMember_5f32a1ba-0668-4e90-9ba4-e5f413ddf127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d9272878-4687-416b-8eb0-03d4e2f05aaf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_44546b01-4608-48bc-b3d5-dc6df526fc70" xlink:to="loc_srt_MaximumMember_d9272878-4687-416b-8eb0-03d4e2f05aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6dd44af-0064-42eb-aeac-c0078c094509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7dcd807d-1e8a-4733-a2e4-5b87d0205785" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6dd44af-0064-42eb-aeac-c0078c094509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_85301234-accc-4892-b5af-0e132c33c0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6dd44af-0064-42eb-aeac-c0078c094509" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_85301234-accc-4892-b5af-0e132c33c0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_21b16a4a-a6c1-4c73-afdb-45a4c364b4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6dd44af-0064-42eb-aeac-c0078c094509" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_21b16a4a-a6c1-4c73-afdb-45a4c364b4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f74d885e-3643-4651-85be-018b86fe6c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6dd44af-0064-42eb-aeac-c0078c094509" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f74d885e-3643-4651-85be-018b86fe6c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_01575647-3dca-40e9-90ea-d785c42cae6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6dd44af-0064-42eb-aeac-c0078c094509" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_01575647-3dca-40e9-90ea-d785c42cae6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d74eecad-8ed6-45b8-87f0-870a6e8d9954" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6dd44af-0064-42eb-aeac-c0078c094509" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d74eecad-8ed6-45b8-87f0-870a6e8d9954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance_9fe604c3-4756-4e3c-8c81-6e1c0eac612a" xlink:href="ameh-20220331.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6dd44af-0064-42eb-aeac-c0078c094509" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance_9fe604c3-4756-4e3c-8c81-6e1c0eac612a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2c67a108-6567-4061-9066-f9e9cb6c898c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6dd44af-0064-42eb-aeac-c0078c094509" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2c67a108-6567-4061-9066-f9e9cb6c898c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_c78c4d9c-a958-43df-b16c-c416bb89d98f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6dd44af-0064-42eb-aeac-c0078c094509" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_c78c4d9c-a958-43df-b16c-c416bb89d98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_b4ca6a37-dae7-47e5-bb4f-63cdd66f4f36" xlink:href="ameh-20220331.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6dd44af-0064-42eb-aeac-c0078c094509" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_b4ca6a37-dae7-47e5-bb4f-63cdd66f4f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_243c31ef-09c2-41bc-a81b-2b8bce7c137b" xlink:href="ameh-20220331.xsd#ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6dd44af-0064-42eb-aeac-c0078c094509" xlink:to="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_243c31ef-09c2-41bc-a81b-2b8bce7c137b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_db52ed8a-e3bc-4b09-86f7-eb60e336368a" xlink:href="ameh-20220331.xsd#ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6dd44af-0064-42eb-aeac-c0078c094509" xlink:to="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_db52ed8a-e3bc-4b09-86f7-eb60e336368a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#StockBasedCompensationSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8581f52c-9b4e-4b57-8e8c-002169b3a7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4089a866-7c78-4d83-81ea-6b4e3c202e61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8581f52c-9b4e-4b57-8e8c-002169b3a7ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4089a866-7c78-4d83-81ea-6b4e3c202e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1142a237-5a3c-4718-8fd1-5be55d735458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4089a866-7c78-4d83-81ea-6b4e3c202e61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1142a237-5a3c-4718-8fd1-5be55d735458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_442505ca-7dc2-41ba-8030-aa3319e66f98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4089a866-7c78-4d83-81ea-6b4e3c202e61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_442505ca-7dc2-41ba-8030-aa3319e66f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5e115048-27f4-404f-b5e3-237d84ab81b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4089a866-7c78-4d83-81ea-6b4e3c202e61" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5e115048-27f4-404f-b5e3-237d84ab81b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ba358ceb-25a8-4b7b-93ef-21b203c10f15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4089a866-7c78-4d83-81ea-6b4e3c202e61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ba358ceb-25a8-4b7b-93ef-21b203c10f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e178b1c7-1849-4017-a040-2a743a9724d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4089a866-7c78-4d83-81ea-6b4e3c202e61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e178b1c7-1849-4017-a040-2a743a9724d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6f359c7e-61b2-4dec-9483-7447edc602b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8581f52c-9b4e-4b57-8e8c-002169b3a7ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6f359c7e-61b2-4dec-9483-7447edc602b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_d17d06dc-a779-49ed-a8d8-4fbcda3bfd00" xlink:href="ameh-20220331.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8581f52c-9b4e-4b57-8e8c-002169b3a7ff" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_d17d06dc-a779-49ed-a8d8-4fbcda3bfd00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2c8f9b06-8f53-496a-998d-960a9a10ed01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_d17d06dc-a779-49ed-a8d8-4fbcda3bfd00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2c8f9b06-8f53-496a-998d-960a9a10ed01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_654d608b-5700-453d-b68d-6c836ec63853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_d17d06dc-a779-49ed-a8d8-4fbcda3bfd00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_654d608b-5700-453d-b68d-6c836ec63853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5ead0de3-7e56-4811-b2ee-42ac1b7507df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_d17d06dc-a779-49ed-a8d8-4fbcda3bfd00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5ead0de3-7e56-4811-b2ee-42ac1b7507df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_15a32b8e-c548-48b2-bb86-37f8551e974d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_d17d06dc-a779-49ed-a8d8-4fbcda3bfd00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_15a32b8e-c548-48b2-bb86-37f8551e974d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8f25a11d-6706-4709-86ec-7eb6225856f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_d17d06dc-a779-49ed-a8d8-4fbcda3bfd00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8f25a11d-6706-4709-86ec-7eb6225856f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_15e40d6b-194d-4737-8b46-15223085f698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8581f52c-9b4e-4b57-8e8c-002169b3a7ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_15e40d6b-194d-4737-8b46-15223085f698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_8153b9fc-6663-4c32-b2c7-5a29c7524d6b" xlink:href="ameh-20220331.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8581f52c-9b4e-4b57-8e8c-002169b3a7ff" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_8153b9fc-6663-4c32-b2c7-5a29c7524d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_cf9a2834-235a-4364-a6f8-eb835855b5c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_8153b9fc-6663-4c32-b2c7-5a29c7524d6b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_cf9a2834-235a-4364-a6f8-eb835855b5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_2c8add1d-ca6f-4bb2-8fe5-eaa965f47bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_8153b9fc-6663-4c32-b2c7-5a29c7524d6b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_2c8add1d-ca6f-4bb2-8fe5-eaa965f47bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_7ece36b9-66eb-42a9-b56d-13d1fe870de4" xlink:href="ameh-20220331.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8581f52c-9b4e-4b57-8e8c-002169b3a7ff" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_7ece36b9-66eb-42a9-b56d-13d1fe870de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3a01726b-43a0-4e46-a8d3-950ee6d47cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_7ece36b9-66eb-42a9-b56d-13d1fe870de4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3a01726b-43a0-4e46-a8d3-950ee6d47cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_a69fd010-9128-403f-819d-2764fe471cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_7ece36b9-66eb-42a9-b56d-13d1fe870de4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_a69fd010-9128-403f-819d-2764fe471cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_102acb31-c0cd-487e-8761-f1a424524b89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_7ece36b9-66eb-42a9-b56d-13d1fe870de4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_102acb31-c0cd-487e-8761-f1a424524b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1ccdb310-9031-4ff0-921a-5a9653afc823" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_687a38f4-b3e5-4912-94e8-7cfd5bcd5291" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1ccdb310-9031-4ff0-921a-5a9653afc823" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_687a38f4-b3e5-4912-94e8-7cfd5bcd5291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_0666f3d5-7a73-48f4-8367-53b8c62825d8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_687a38f4-b3e5-4912-94e8-7cfd5bcd5291" xlink:to="loc_srt_TitleOfIndividualAxis_0666f3d5-7a73-48f4-8367-53b8c62825d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_449f8b05-2863-4ede-8d70-8d34afd15fff" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_0666f3d5-7a73-48f4-8367-53b8c62825d8" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_449f8b05-2863-4ede-8d70-8d34afd15fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_92f37a07-2902-41b7-9948-b3c677227331" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_449f8b05-2863-4ede-8d70-8d34afd15fff" xlink:to="loc_srt_DirectorMember_92f37a07-2902-41b7-9948-b3c677227331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8bf92a17-6550-4753-9054-880e0a9d4c80" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_687a38f4-b3e5-4912-94e8-7cfd5bcd5291" xlink:to="loc_srt_RangeAxis_8bf92a17-6550-4753-9054-880e0a9d4c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_29706667-e15c-4357-919b-809e804d382a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8bf92a17-6550-4753-9054-880e0a9d4c80" xlink:to="loc_srt_RangeMember_29706667-e15c-4357-919b-809e804d382a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8982aa92-4ff8-4943-b706-82727d7be50c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_29706667-e15c-4357-919b-809e804d382a" xlink:to="loc_srt_MinimumMember_8982aa92-4ff8-4943-b706-82727d7be50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3429045e-6f55-4796-8392-1225e60e95c2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_29706667-e15c-4357-919b-809e804d382a" xlink:to="loc_srt_MaximumMember_3429045e-6f55-4796-8392-1225e60e95c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8c51517-3869-4581-8ca2-4b9760e5a615" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_687a38f4-b3e5-4912-94e8-7cfd5bcd5291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8c51517-3869-4581-8ca2-4b9760e5a615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f17665e7-ab54-4600-a742-28ee22e80a87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8c51517-3869-4581-8ca2-4b9760e5a615" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f17665e7-ab54-4600-a742-28ee22e80a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_9474a165-73f5-40e3-8b54-d0a6b91c0148" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8c51517-3869-4581-8ca2-4b9760e5a615" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_9474a165-73f5-40e3-8b54-d0a6b91c0148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_3079a03c-ee9d-41a0-8cc0-219c9e3c8b89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8c51517-3869-4581-8ca2-4b9760e5a615" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_3079a03c-ee9d-41a0-8cc0-219c9e3c8b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_537fe096-78bc-4d08-a9c6-176662810202" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8c51517-3869-4581-8ca2-4b9760e5a615" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_537fe096-78bc-4d08-a9c6-176662810202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7f580497-917f-4ecc-9c08-853dfe3734bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8c51517-3869-4581-8ca2-4b9760e5a615" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7f580497-917f-4ecc-9c08-853dfe3734bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_bf24fbc3-7a86-4d78-9636-5c4c765f065d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8c51517-3869-4581-8ca2-4b9760e5a615" xlink:to="loc_us-gaap_SharePrice_bf24fbc3-7a86-4d78-9636-5c4c765f065d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_51662ebf-ee43-4502-bc84-36a31e378c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8c51517-3869-4581-8ca2-4b9760e5a615" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_51662ebf-ee43-4502-bc84-36a31e378c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_1440e356-5c65-4a33-982b-a2526b743847" xlink:href="ameh-20220331.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8c51517-3869-4581-8ca2-4b9760e5a615" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_1440e356-5c65-4a33-982b-a2526b743847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#StockBasedCompensationSummaryofWarrantDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d9368502-b7f7-4f06-bb91-18bf1e28ea1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SharesWarrantsRollForward_4c5dd2dc-8bbc-4a25-869b-59c04530c883" xlink:href="ameh-20220331.xsd#ameh_SharesWarrantsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d9368502-b7f7-4f06-bb91-18bf1e28ea1c" xlink:to="loc_ameh_SharesWarrantsRollForward_4c5dd2dc-8bbc-4a25-869b-59c04530c883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_34956766-5e47-4b4f-b315-56a2718af81d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_4c5dd2dc-8bbc-4a25-869b-59c04530c883" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_34956766-5e47-4b4f-b315-56a2718af81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfWarrantsGranted_b5cb7229-c1e4-4a6c-ad4a-5e780037a920" xlink:href="ameh-20220331.xsd#ameh_NumberOfWarrantsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_4c5dd2dc-8bbc-4a25-869b-59c04530c883" xlink:to="loc_ameh_NumberOfWarrantsGranted_b5cb7229-c1e4-4a6c-ad4a-5e780037a920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfWarrantsExercised_352a27c7-b177-4e2d-9c74-16fcf01a51a1" xlink:href="ameh-20220331.xsd#ameh_NumberOfWarrantsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_4c5dd2dc-8bbc-4a25-869b-59c04530c883" xlink:to="loc_ameh_NumberOfWarrantsExercised_352a27c7-b177-4e2d-9c74-16fcf01a51a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightCancelledInPeriod_8f87e7c6-e96b-4246-95f0-76844a0b3b55" xlink:href="ameh-20220331.xsd#ameh_ClassOfWarrantOrRightCancelledInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_4c5dd2dc-8bbc-4a25-869b-59c04530c883" xlink:to="loc_ameh_ClassOfWarrantOrRightCancelledInPeriod_8f87e7c6-e96b-4246-95f0-76844a0b3b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7755d7ad-1a4c-457f-87ea-b877169053bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_4c5dd2dc-8bbc-4a25-869b-59c04530c883" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7755d7ad-1a4c-457f-87ea-b877169053bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_188afac7-8d64-4e8f-a2e5-d5d3c439d93b" xlink:href="ameh-20220331.xsd#ameh_WeightedAverageExercisePriceWarrantsRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d9368502-b7f7-4f06-bb91-18bf1e28ea1c" xlink:to="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_188afac7-8d64-4e8f-a2e5-d5d3c439d93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_785c329b-cf8c-416f-b404-f415df61d7f9" xlink:href="ameh-20220331.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_188afac7-8d64-4e8f-a2e5-d5d3c439d93b" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_785c329b-cf8c-416f-b404-f415df61d7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_3a983b20-703b-43cc-b1a9-807da4577fdf" xlink:href="ameh-20220331.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_188afac7-8d64-4e8f-a2e5-d5d3c439d93b" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_3a983b20-703b-43cc-b1a9-807da4577fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_0f60171c-254f-4042-9717-21164813d54c" xlink:href="ameh-20220331.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_188afac7-8d64-4e8f-a2e5-d5d3c439d93b" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_0f60171c-254f-4042-9717-21164813d54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_2fb9cfce-6342-4014-a35c-18aebaa7fdee" xlink:href="ameh-20220331.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_188afac7-8d64-4e8f-a2e5-d5d3c439d93b" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_2fb9cfce-6342-4014-a35c-18aebaa7fdee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_de59682f-f9bc-41fd-8611-1f0b29f370f2" xlink:href="ameh-20220331.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_188afac7-8d64-4e8f-a2e5-d5d3c439d93b" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_de59682f-f9bc-41fd-8611-1f0b29f370f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract_1473ab65-d7cd-4d92-828e-0f4c3ad63511" xlink:href="ameh-20220331.xsd#ameh_WeightedaverageremainingcontractualtermyearsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d9368502-b7f7-4f06-bb91-18bf1e28ea1c" xlink:to="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract_1473ab65-d7cd-4d92-828e-0f4c3ad63511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_a847042b-a499-4cfc-8413-cb523a830683" xlink:href="ameh-20220331.xsd#ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract_1473ab65-d7cd-4d92-828e-0f4c3ad63511" xlink:to="loc_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_a847042b-a499-4cfc-8413-cb523a830683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AggregateintrinsicvalueAbstract_17867e57-0245-40a0-a1ce-12290bc9c921" xlink:href="ameh-20220331.xsd#ameh_AggregateintrinsicvalueAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d9368502-b7f7-4f06-bb91-18bf1e28ea1c" xlink:to="loc_ameh_AggregateintrinsicvalueAbstract_17867e57-0245-40a0-a1ce-12290bc9c921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_0140e175-c4fa-40de-8154-f074547c76b8" xlink:href="ameh-20220331.xsd#ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_17867e57-0245-40a0-a1ce-12290bc9c921" xlink:to="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_0140e175-c4fa-40de-8154-f074547c76b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_ae460da1-ef8f-4e96-80c8-38556fe86e0f" xlink:href="ameh-20220331.xsd#ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_17867e57-0245-40a0-a1ce-12290bc9c921" xlink:to="loc_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_ae460da1-ef8f-4e96-80c8-38556fe86e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_2ff3558b-07ad-467a-b80b-bc5a2167dc09" xlink:href="ameh-20220331.xsd#ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_17867e57-0245-40a0-a1ce-12290bc9c921" xlink:to="loc_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_2ff3558b-07ad-467a-b80b-bc5a2167dc09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_0442e880-ef60-40b6-91c5-569c300dad62" xlink:href="ameh-20220331.xsd#ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_17867e57-0245-40a0-a1ce-12290bc9c921" xlink:to="loc_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_0442e880-ef60-40b6-91c5-569c300dad62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_aa736baa-7635-4c1c-b61b-1457b829b55c" xlink:href="ameh-20220331.xsd#ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_17867e57-0245-40a0-a1ce-12290bc9c921" xlink:to="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_aa736baa-7635-4c1c-b61b-1457b829b55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#StockBasedCompensationWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_67c6776b-0682-466d-b4c0-c698a8122c05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_eeba984b-2988-4a22-9108-c0e96419a5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_67c6776b-0682-466d-b4c0-c698a8122c05" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_eeba984b-2988-4a22-9108-c0e96419a5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_68222c98-8bb8-49ab-ba8d-d5306d62b6d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_eeba984b-2988-4a22-9108-c0e96419a5fa" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_68222c98-8bb8-49ab-ba8d-d5306d62b6d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f79dcd7f-52f2-49c2-b63a-c5c83e955537" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_68222c98-8bb8-49ab-ba8d-d5306d62b6d9" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f79dcd7f-52f2-49c2-b63a-c5c83e955537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeOneMember_6630daa6-f242-4d12-8e6f-baadb1a07f65" xlink:href="ameh-20220331.xsd#ameh_WarrantExercisePriceRangeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f79dcd7f-52f2-49c2-b63a-c5c83e955537" xlink:to="loc_ameh_WarrantExercisePriceRangeOneMember_6630daa6-f242-4d12-8e6f-baadb1a07f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeTwoMember_f2a584df-68e0-4c33-bc54-4f108185fe2d" xlink:href="ameh-20220331.xsd#ameh_WarrantExercisePriceRangeTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f79dcd7f-52f2-49c2-b63a-c5c83e955537" xlink:to="loc_ameh_WarrantExercisePriceRangeTwoMember_f2a584df-68e0-4c33-bc54-4f108185fe2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeThreeMember_b67c736f-10cf-4c23-a3dc-281165331e49" xlink:href="ameh-20220331.xsd#ameh_WarrantExercisePriceRangeThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f79dcd7f-52f2-49c2-b63a-c5c83e955537" xlink:to="loc_ameh_WarrantExercisePriceRangeThreeMember_b67c736f-10cf-4c23-a3dc-281165331e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6de96777-4e5e-46f6-86d0-3a1ea8cc6158" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_eeba984b-2988-4a22-9108-c0e96419a5fa" xlink:to="loc_srt_RangeAxis_6de96777-4e5e-46f6-86d0-3a1ea8cc6158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7f66bca5-adad-43e9-8c21-079689c46878" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6de96777-4e5e-46f6-86d0-3a1ea8cc6158" xlink:to="loc_srt_RangeMember_7f66bca5-adad-43e9-8c21-079689c46878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4acf0541-9a76-4737-b719-b5d514c7f68e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7f66bca5-adad-43e9-8c21-079689c46878" xlink:to="loc_srt_MinimumMember_4acf0541-9a76-4737-b719-b5d514c7f68e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3b970916-2066-42b5-815c-61dbf7fdacb4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7f66bca5-adad-43e9-8c21-079689c46878" xlink:to="loc_srt_MaximumMember_3b970916-2066-42b5-815c-61dbf7fdacb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_ae8cc0a6-98cf-4f44-baad-f83a8ccd2f59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_eeba984b-2988-4a22-9108-c0e96419a5fa" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_ae8cc0a6-98cf-4f44-baad-f83a8ccd2f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_348a0e31-7f20-417a-9692-44f1f27ba1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ae8cc0a6-98cf-4f44-baad-f83a8ccd2f59" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_348a0e31-7f20-417a-9692-44f1f27ba1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod_f7bda742-09e3-4195-a3a5-f578584a5344" xlink:href="ameh-20220331.xsd#ameh_ClassOfWarrantOrRightIssuedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ae8cc0a6-98cf-4f44-baad-f83a8ccd2f59" xlink:to="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod_f7bda742-09e3-4195-a3a5-f578584a5344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_58e362ac-6054-478f-be19-3b7fd6527523" xlink:href="ameh-20220331.xsd#ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ae8cc0a6-98cf-4f44-baad-f83a8ccd2f59" xlink:to="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_58e362ac-6054-478f-be19-3b7fd6527523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightExercisable_bbd6e028-799c-4d2a-aade-3dd1077d9c73" xlink:href="ameh-20220331.xsd#ameh_ClassOfWarrantOrRightExercisable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ae8cc0a6-98cf-4f44-baad-f83a8ccd2f59" xlink:to="loc_ameh_ClassOfWarrantOrRightExercisable_bbd6e028-799c-4d2a-aade-3dd1077d9c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_0a8a1e9e-d63c-4f84-8d0c-539e2f731963" xlink:href="ameh-20220331.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ae8cc0a6-98cf-4f44-baad-f83a8ccd2f59" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_0a8a1e9e-d63c-4f84-8d0c-539e2f731963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="ameh-20220331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ff899c9e-3204-4ffe-a29c-625501a37642" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8a223fff-81ba-4cd4-a53d-03b04d64e94b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ff899c9e-3204-4ffe-a29c-625501a37642" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8a223fff-81ba-4cd4-a53d-03b04d64e94b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_092a99f0-9e2b-4099-bd33-ececbded7fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesTable_dbb10868-2c44-4379-b902-2e993621c07f" xlink:href="ameh-20220331.xsd#ameh_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_092a99f0-9e2b-4099-bd33-ececbded7fb2" xlink:to="loc_ameh_CommitmentsAndContingenciesTable_dbb10868-2c44-4379-b902-2e993621c07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_748a9bb1-3d3e-4831-a32d-616d9eba1147" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_dbb10868-2c44-4379-b902-2e993621c07f" xlink:to="loc_us-gaap_CreditFacilityAxis_748a9bb1-3d3e-4831-a32d-616d9eba1147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c295691a-a542-425f-8601-360eea84348c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_748a9bb1-3d3e-4831-a32d-616d9eba1147" xlink:to="loc_us-gaap_CreditFacilityDomain_c295691a-a542-425f-8601-360eea84348c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_c810054c-1024-499c-97c0-894c8d513b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_c295691a-a542-425f-8601-360eea84348c" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_c810054c-1024-499c-97c0-894c8d513b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_d11f7887-3766-4b85-b18b-023047b750b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_dbb10868-2c44-4379-b902-2e993621c07f" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_d11f7887-3766-4b85-b18b-023047b750b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_4812b828-3e99-4678-bdaa-ef80bf220e87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_d11f7887-3766-4b85-b18b-023047b750b5" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_4812b828-3e99-4678-bdaa-ef80bf220e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_3b1928de-8712-49ae-b238-a4750c43a7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_4812b828-3e99-4678-bdaa-ef80bf220e87" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_3b1928de-8712-49ae-b238-a4750c43a7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f23cd225-cd41-40e5-8624-16b69be39b13" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_dbb10868-2c44-4379-b902-2e993621c07f" xlink:to="loc_dei_LegalEntityAxis_f23cd225-cd41-40e5-8624-16b69be39b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6e6ea09c-28d0-480c-9fb5-f5bd9b4d0cf0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_f23cd225-cd41-40e5-8624-16b69be39b13" xlink:to="loc_dei_EntityDomain_6e6ea09c-28d0-480c-9fb5-f5bd9b4d0cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_e7005d51-fd49-4cbf-848c-b06792d785d9" xlink:href="ameh-20220331.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6e6ea09c-28d0-480c-9fb5-f5bd9b4d0cf0" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_e7005d51-fd49-4cbf-848c-b06792d785d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_ec732565-668e-4039-99c2-f27b9087ca5e" xlink:href="ameh-20220331.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6e6ea09c-28d0-480c-9fb5-f5bd9b4d0cf0" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_ec732565-668e-4039-99c2-f27b9087ca5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesLineItems_cc25ceec-0f36-45e2-a5c2-f7db669eccd4" xlink:href="ameh-20220331.xsd#ameh_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_dbb10868-2c44-4379-b902-2e993621c07f" xlink:to="loc_ameh_CommitmentsAndContingenciesLineItems_cc25ceec-0f36-45e2-a5c2-f7db669eccd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_16c6fcda-9b6e-4d5f-874c-6aad6a5b5a34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_cc25ceec-0f36-45e2-a5c2-f7db669eccd4" xlink:to="loc_us-gaap_LineOfCredit_16c6fcda-9b6e-4d5f-874c-6aad6a5b5a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ameh-20220331.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_b635619b-a27b-47c1-ae9a-6d599ec63f35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_e9964618-3467-4e84-b0d9-6774ba54b8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_b635619b-a27b-47c1-ae9a-6d599ec63f35" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_e9964618-3467-4e84-b0d9-6774ba54b8aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsTables" xlink:type="simple" xlink:href="ameh-20220331.xsd#RelatedPartyTransactionsTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_9c0ea2f3-5424-4781-a291-c7dd9d5b8358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_95331d25-5d1d-4df3-8862-d15e64589d36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_9c0ea2f3-5424-4781-a291-c7dd9d5b8358" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_95331d25-5d1d-4df3-8862-d15e64589d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_efc1de5e-f6a4-4788-afa6-82bd60a6e135" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_20d31040-3997-42b2-94a4-934a888cb43b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_efc1de5e-f6a4-4788-afa6-82bd60a6e135" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_20d31040-3997-42b2-94a4-934a888cb43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8f049678-51df-446a-8c0b-7e95281be8af" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_20d31040-3997-42b2-94a4-934a888cb43b" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8f049678-51df-446a-8c0b-7e95281be8af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_105c562a-e830-4d0a-b3b3-c613a60d8c73" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8f049678-51df-446a-8c0b-7e95281be8af" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_105c562a-e830-4d0a-b3b3-c613a60d8c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember_00282d29-ea4e-4423-a27a-5d2bf0961dc9" xlink:href="ameh-20220331.xsd#ameh_LmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_105c562a-e830-4d0a-b3b3-c613a60d8c73" xlink:to="loc_ameh_LmaMember_00282d29-ea4e-4423-a27a-5d2bf0961dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember_9e695c91-7647-4978-b82f-30ef1d841a0f" xlink:href="ameh-20220331.xsd#ameh_PmiocMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_105c562a-e830-4d0a-b3b3-c613a60d8c73" xlink:to="loc_ameh_PmiocMember_9e695c91-7647-4978-b82f-30ef1d841a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_55a34d91-058a-4116-b9cb-5b2433cbb89e" xlink:href="ameh-20220331.xsd#ameh_DmgMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_105c562a-e830-4d0a-b3b3-c613a60d8c73" xlink:to="loc_ameh_DmgMember_55a34d91-058a-4116-b9cb-5b2433cbb89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member_8c962a2d-1f67-40cb-aafb-a2fc328f2cc5" xlink:href="ameh-20220331.xsd#ameh_OneMSOInc.Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_105c562a-e830-4d0a-b3b3-c613a60d8c73" xlink:to="loc_ameh_OneMSOInc.Member_8c962a2d-1f67-40cb-aafb-a2fc328f2cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cdf28d76-4a81-4467-91e7-976a1bce3b29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_20d31040-3997-42b2-94a4-934a888cb43b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cdf28d76-4a81-4467-91e7-976a1bce3b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_06039f2c-e454-405e-9ce8-300d5aebd9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cdf28d76-4a81-4467-91e7-976a1bce3b29" xlink:to="loc_us-gaap_RelatedPartyDomain_06039f2c-e454-405e-9ce8-300d5aebd9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcShareholdersMember_6a20d027-0a61-449d-9bd5-7d6a98f38f01" xlink:href="ameh-20220331.xsd#ameh_ApcShareholdersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_06039f2c-e454-405e-9ce8-300d5aebd9ee" xlink:to="loc_ameh_ApcShareholdersMember_6a20d027-0a61-449d-9bd5-7d6a98f38f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdvanceDiagnosticSurgeryCenterMember_8153367b-8f3d-49f5-8c19-4a2ba824f9c8" xlink:href="ameh-20220331.xsd#ameh_AdvanceDiagnosticSurgeryCenterMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_06039f2c-e454-405e-9ce8-300d5aebd9ee" xlink:to="loc_ameh_AdvanceDiagnosticSurgeryCenterMember_8153367b-8f3d-49f5-8c19-4a2ba824f9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FreseniusMember_9be5e04b-3087-4f5d-9dfd-59d0e12d37c7" xlink:href="ameh-20220331.xsd#ameh_FreseniusMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_06039f2c-e454-405e-9ce8-300d5aebd9ee" xlink:to="loc_ameh_FreseniusMember_9be5e04b-3087-4f5d-9dfd-59d0e12d37c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FulgentGeneticsIncMember_fbad3df3-a205-4d44-89af-1035e3ec3ecf" xlink:href="ameh-20220331.xsd#ameh_FulgentGeneticsIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_06039f2c-e454-405e-9ce8-300d5aebd9ee" xlink:to="loc_ameh_FulgentGeneticsIncMember_fbad3df3-a205-4d44-89af-1035e3ec3ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareholdersAndOfficersMember_d4571a6c-90a0-4627-8c12-11c23a392ea0" xlink:href="ameh-20220331.xsd#ameh_ShareholdersAndOfficersMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_06039f2c-e454-405e-9ce8-300d5aebd9ee" xlink:to="loc_ameh_ShareholdersAndOfficersMember_d4571a6c-90a0-4627-8c12-11c23a392ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumenLLCMember_5b08f070-d63e-4887-80cc-7839d23cfa79" xlink:href="ameh-20220331.xsd#ameh_NumenLLCMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_06039f2c-e454-405e-9ce8-300d5aebd9ee" xlink:to="loc_ameh_NumenLLCMember_5b08f070-d63e-4887-80cc-7839d23cfa79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member_112e5e6f-0ba2-422f-b879-e86cf5827466" xlink:href="ameh-20220331.xsd#ameh_OneMSOInc.Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_06039f2c-e454-405e-9ce8-300d5aebd9ee" xlink:to="loc_ameh_OneMSOInc.Member_112e5e6f-0ba2-422f-b879-e86cf5827466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ArroyoVistaMember_7f777623-ea4a-4268-9f14-0b11ea0b476c" xlink:href="ameh-20220331.xsd#ameh_ArroyoVistaMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_06039f2c-e454-405e-9ce8-300d5aebd9ee" xlink:to="loc_ameh_ArroyoVistaMember_7f777623-ea4a-4268-9f14-0b11ea0b476c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_e426913f-4eb1-4ad9-a82a-1ee73b3ef017" xlink:href="ameh-20220331.xsd#ameh_AHMCMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_06039f2c-e454-405e-9ce8-300d5aebd9ee" xlink:to="loc_ameh_AHMCMember_e426913f-4eb1-4ad9-a82a-1ee73b3ef017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_29a84269-bd02-44f5-b5db-23ea627852e8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_20d31040-3997-42b2-94a4-934a888cb43b" xlink:to="loc_dei_LegalEntityAxis_29a84269-bd02-44f5-b5db-23ea627852e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ae5faaaf-4431-4d7f-bc10-162f42592e44" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_29a84269-bd02-44f5-b5db-23ea627852e8" xlink:to="loc_dei_EntityDomain_ae5faaaf-4431-4d7f-bc10-162f42592e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember_6b22de91-4419-410f-b63f-89bc33f8e8de" xlink:href="ameh-20220331.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_ae5faaaf-4431-4d7f-bc10-162f42592e44" xlink:to="loc_ameh_NetworkMedicalManagementMember_6b22de91-4419-410f-b63f-89bc33f8e8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_e4627985-7001-4c49-a901-80b770464853" xlink:href="ameh-20220331.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_ae5faaaf-4431-4d7f-bc10-162f42592e44" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_e4627985-7001-4c49-a901-80b770464853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApaAcoIncMember_401fd286-1139-4f56-b673-92c2f149c226" xlink:href="ameh-20220331.xsd#ameh_ApaAcoIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_ae5faaaf-4431-4d7f-bc10-162f42592e44" xlink:to="loc_ameh_ApaAcoIncMember_401fd286-1139-4f56-b673-92c2f149c226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SCHCMember_96bfee05-7f02-487b-893d-47114a37d44d" xlink:href="ameh-20220331.xsd#ameh_SCHCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_ae5faaaf-4431-4d7f-bc10-162f42592e44" xlink:to="loc_ameh_SCHCMember_96bfee05-7f02-487b-893d-47114a37d44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_0f4d5c9d-9fc3-420a-9bd5-fc913d4966bb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_20d31040-3997-42b2-94a4-934a888cb43b" xlink:to="loc_srt_ConsolidatedEntitiesAxis_0f4d5c9d-9fc3-420a-9bd5-fc913d4966bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_a2c279c8-e7f9-4dfd-8c68-9a100fa064b0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_0f4d5c9d-9fc3-420a-9bd5-fc913d4966bb" xlink:to="loc_srt_ConsolidatedEntitiesDomain_a2c279c8-e7f9-4dfd-8c68-9a100fa064b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember_c65eb5a1-f2e9-4982-a3b1-4638f3fbe238" xlink:href="ameh-20220331.xsd#ameh_LmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_a2c279c8-e7f9-4dfd-8c68-9a100fa064b0" xlink:to="loc_ameh_LmaMember_c65eb5a1-f2e9-4982-a3b1-4638f3fbe238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember_b597f97f-819b-4d66-b4a1-33ad0d3fba8e" xlink:href="ameh-20220331.xsd#ameh_PmiocMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_a2c279c8-e7f9-4dfd-8c68-9a100fa064b0" xlink:to="loc_ameh_PmiocMember_b597f97f-819b-4d66-b4a1-33ad0d3fba8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_1f3a1b86-e7ca-4e8b-a63b-1b5674d54423" xlink:href="ameh-20220331.xsd#ameh_DmgMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_a2c279c8-e7f9-4dfd-8c68-9a100fa064b0" xlink:to="loc_ameh_DmgMember_1f3a1b86-e7ca-4e8b-a63b-1b5674d54423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_bea97aec-7594-490e-a9d6-d8da6e327e43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_20d31040-3997-42b2-94a4-934a888cb43b" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_bea97aec-7594-490e-a9d6-d8da6e327e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_820ccec0-668e-4ea9-9e6e-2a12890f503d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_bea97aec-7594-490e-a9d6-d8da6e327e43" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_820ccec0-668e-4ea9-9e6e-2a12890f503d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_7257beb8-476c-42d3-bea7-54f358ee8aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_820ccec0-668e-4ea9-9e6e-2a12890f503d" xlink:to="loc_us-gaap_ServiceMember_7257beb8-476c-42d3-bea7-54f358ee8aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_ab313042-d6c5-4d80-9804-11292ce37b47" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_20d31040-3997-42b2-94a4-934a888cb43b" xlink:to="loc_srt_TitleOfIndividualAxis_ab313042-d6c5-4d80-9804-11292ce37b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_076caf1c-b2b6-43c0-a2e1-96fb95ce4f22" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_ab313042-d6c5-4d80-9804-11292ce37b47" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_076caf1c-b2b6-43c0-a2e1-96fb95ce4f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_79110391-c9ca-45a7-87fe-6a21c3f4ccad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_076caf1c-b2b6-43c0-a2e1-96fb95ce4f22" xlink:to="loc_srt_DirectorMember_79110391-c9ca-45a7-87fe-6a21c3f4ccad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_d0ef6fc4-6532-457d-b66a-368593ddf9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_20d31040-3997-42b2-94a4-934a888cb43b" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_d0ef6fc4-6532-457d-b66a-368593ddf9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_a951f97a-17fe-4d8e-947e-1ea6c69598ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d0ef6fc4-6532-457d-b66a-368593ddf9b3" xlink:to="loc_us-gaap_RevenueFromRelatedParties_a951f97a-17fe-4d8e-947e-1ea6c69598ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4ad3ef6c-7e4c-4952-a544-36dbb33194d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d0ef6fc4-6532-457d-b66a-368593ddf9b3" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4ad3ef6c-7e4c-4952-a544-36dbb33194d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentMadeToRelatedParty_58d3e6ac-2c72-418a-9305-8ffaec9d723f" xlink:href="ameh-20220331.xsd#ameh_PaymentMadeToRelatedParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d0ef6fc4-6532-457d-b66a-368593ddf9b3" xlink:to="loc_ameh_PaymentMadeToRelatedParty_58d3e6ac-2c72-418a-9305-8ffaec9d723f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_1f5e288d-6fea-4b1a-b373-f092ade44a53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d0ef6fc4-6532-457d-b66a-368593ddf9b3" xlink:to="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_1f5e288d-6fea-4b1a-b373-f092ade44a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities_bcb3447d-dbb5-45fb-977c-45bd45044dca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d0ef6fc4-6532-457d-b66a-368593ddf9b3" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilities_bcb3447d-dbb5-45fb-977c-45bd45044dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentConsultingFees_82209874-7d2a-490f-b509-abfe4b2ea4d1" xlink:href="ameh-20220331.xsd#ameh_PaymentConsultingFees"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d0ef6fc4-6532-457d-b66a-368593ddf9b3" xlink:to="loc_ameh_PaymentConsultingFees_82209874-7d2a-490f-b509-abfe4b2ea4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_7d0645b8-943d-4672-bca9-dd62c6282702" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_12dfbdde-8f1a-4995-95ff-c4488d3fe905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_7d0645b8-943d-4672-bca9-dd62c6282702" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_12dfbdde-8f1a-4995-95ff-c4488d3fe905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d5cbeb0f-fbf7-469f-87ed-b48d6c633e97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_12dfbdde-8f1a-4995-95ff-c4488d3fe905" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d5cbeb0f-fbf7-469f-87ed-b48d6c633e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5e280d68-6e90-4db6-ac52-dbcf4ee37ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d5cbeb0f-fbf7-469f-87ed-b48d6c633e97" xlink:to="loc_us-gaap_RelatedPartyDomain_5e280d68-6e90-4db6-ac52-dbcf4ee37ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_6ed1e194-c6f0-4dcc-8d3e-6c59eb49d61b" xlink:href="ameh-20220331.xsd#ameh_AHMCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_5e280d68-6e90-4db6-ac52-dbcf4ee37ac1" xlink:to="loc_ameh_AHMCMember_6ed1e194-c6f0-4dcc-8d3e-6c59eb49d61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HSMSOMember_38c2bd06-b3bd-4969-a177-e4adb695eaa5" xlink:href="ameh-20220331.xsd#ameh_HSMSOMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_5e280d68-6e90-4db6-ac52-dbcf4ee37ac1" xlink:to="loc_ameh_HSMSOMember_38c2bd06-b3bd-4969-a177-e4adb695eaa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AurionMember_defa55cc-50d0-4ff8-905f-5f295cdd2489" xlink:href="ameh-20220331.xsd#ameh_AurionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_5e280d68-6e90-4db6-ac52-dbcf4ee37ac1" xlink:to="loc_ameh_AurionMember_defa55cc-50d0-4ff8-905f-5f295cdd2489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_ba15d14d-9558-482f-9e49-79f3add98ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_12dfbdde-8f1a-4995-95ff-c4488d3fe905" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_ba15d14d-9558-482f-9e49-79f3add98ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_0a1f74f5-0526-426d-b949-e7f7f40ac8c5" xlink:href="ameh-20220331.xsd#ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ba15d14d-9558-482f-9e49-79f3add98ab7" xlink:to="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_0a1f74f5-0526-426d-b949-e7f7f40ac8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementFeeExpense_16f78414-364b-4594-814b-7260e1e46fed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementFeeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ba15d14d-9558-482f-9e49-79f3add98ab7" xlink:to="loc_us-gaap_ManagementFeeExpense_16f78414-364b-4594-814b-7260e1e46fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_f615f336-6c5e-40a7-9ee6-86daaf43ca9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ba15d14d-9558-482f-9e49-79f3add98ab7" xlink:to="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_f615f336-6c5e-40a7-9ee6-86daaf43ca9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IncomeTaxes" xlink:type="simple" xlink:href="ameh-20220331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7de155fb-548b-4b45-9317-e4b1cfb7780a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_0e43900b-64e7-473d-9ef7-cec668ec9179" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7de155fb-548b-4b45-9317-e4b1cfb7780a" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_0e43900b-64e7-473d-9ef7-cec668ec9179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_999c66d3-2302-4b72-8ede-759b36241651" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1a5adc57-ac5e-4faf-a0a6-90c06810245a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_999c66d3-2302-4b72-8ede-759b36241651" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1a5adc57-ac5e-4faf-a0a6-90c06810245a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShare" xlink:type="simple" xlink:href="ameh-20220331.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0e4718c1-9eb0-4556-ba43-f113538e1659" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1a059ae4-6912-4c90-8eb3-f89e9e4c65d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0e4718c1-9eb0-4556-ba43-f113538e1659" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1a059ae4-6912-4c90-8eb3-f89e9e4c65d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareTables" xlink:type="simple" xlink:href="ameh-20220331.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f17837e7-b818-4a50-a22c-7791a425e6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e24559c8-b915-45e6-bf56-48e1dfcd89f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f17837e7-b818-4a50-a22c-7791a425e6f5" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e24559c8-b915-45e6-bf56-48e1dfcd89f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_7701366b-dee8-4599-b34d-892886427171" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f17837e7-b818-4a50-a22c-7791a425e6f5" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_7701366b-dee8-4599-b34d-892886427171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#EarningsPerShareAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_37e4bbef-e6fb-4866-b9e6-aae63758f6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareTable_0cae09dd-c5d8-40ab-868d-764620559c8f" xlink:href="ameh-20220331.xsd#ameh_EarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_37e4bbef-e6fb-4866-b9e6-aae63758f6ec" xlink:to="loc_ameh_EarningsPerShareTable_0cae09dd-c5d8-40ab-868d-764620559c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_b21056ed-6678-4c81-8b45-f4e1557a0433" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareTable_0cae09dd-c5d8-40ab-868d-764620559c8f" xlink:to="loc_dei_LegalEntityAxis_b21056ed-6678-4c81-8b45-f4e1557a0433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e1246960-3244-4e2a-a80d-f079a4bc2d2f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_b21056ed-6678-4c81-8b45-f4e1557a0433" xlink:to="loc_dei_EntityDomain_e1246960-3244-4e2a-a80d-f079a4bc2d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_2c903752-bccc-4e4b-a647-36963b288968" xlink:href="ameh-20220331.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e1246960-3244-4e2a-a80d-f079a4bc2d2f" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_2c903752-bccc-4e4b-a647-36963b288968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareLineItems_54548c29-7b97-4c0f-bd59-cde638406fd7" xlink:href="ameh-20220331.xsd#ameh_EarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareTable_0cae09dd-c5d8-40ab-868d-764620559c8f" xlink:to="loc_ameh_EarningsPerShareLineItems_54548c29-7b97-4c0f-bd59-cde638406fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c5b58f4a-17aa-47a7-9084-95715fae2383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareLineItems_54548c29-7b97-4c0f-bd59-cde638406fd7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c5b58f4a-17aa-47a7-9084-95715fae2383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#EarningsPerShareEarningsPerShareComputationsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3a3b197e-558e-44d2-92a2-16d2dbbe8a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_497770a5-3a62-454b-a207-0730f177e1af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3a3b197e-558e-44d2-92a2-16d2dbbe8a5a" xlink:to="loc_us-gaap_EarningsPerShareBasic_497770a5-3a62-454b-a207-0730f177e1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_67576ea6-1fda-4792-b812-e7304a345deb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3a3b197e-558e-44d2-92a2-16d2dbbe8a5a" xlink:to="loc_us-gaap_EarningsPerShareDiluted_67576ea6-1fda-4792-b812-e7304a345deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ee0f651e-565e-4607-aa51-1c0d825a949c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3a3b197e-558e-44d2-92a2-16d2dbbe8a5a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ee0f651e-565e-4607-aa51-1c0d825a949c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c99135cb-2fe7-488a-821e-9445007b9d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3a3b197e-558e-44d2-92a2-16d2dbbe8a5a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c99135cb-2fe7-488a-821e-9445007b9d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ae97aa4e-a28d-4c16-9ebe-dffdb5cd53c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareTable_b2180df0-6af8-4b97-aacb-71c99a5f4b0c" xlink:href="ameh-20220331.xsd#ameh_EarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ae97aa4e-a28d-4c16-9ebe-dffdb5cd53c4" xlink:to="loc_ameh_EarningsPerShareTable_b2180df0-6af8-4b97-aacb-71c99a5f4b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_598558e0-0473-422f-90dd-85790fd54a95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareTable_b2180df0-6af8-4b97-aacb-71c99a5f4b0c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_598558e0-0473-422f-90dd-85790fd54a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2a504e63-1abd-4ffe-82eb-ed5077a3cf57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_598558e0-0473-422f-90dd-85790fd54a95" xlink:to="loc_us-gaap_EquityComponentDomain_2a504e63-1abd-4ffe-82eb-ed5077a3cf57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_c09aec26-03c5-4471-9616-53b376954333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2a504e63-1abd-4ffe-82eb-ed5077a3cf57" xlink:to="loc_us-gaap_WarrantMember_c09aec26-03c5-4471-9616-53b376954333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fe589e8c-4c9f-41cf-9067-8b272bde13a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareTable_b2180df0-6af8-4b97-aacb-71c99a5f4b0c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fe589e8c-4c9f-41cf-9067-8b272bde13a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_66d0f76e-0a89-4b83-8c77-5156cf6572fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fe589e8c-4c9f-41cf-9067-8b272bde13a8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_66d0f76e-0a89-4b83-8c77-5156cf6572fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_06b8b7bb-c34b-405c-bb21-5be0d03b077d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_66d0f76e-0a89-4b83-8c77-5156cf6572fc" xlink:to="loc_us-gaap_EmployeeStockOptionMember_06b8b7bb-c34b-405c-bb21-5be0d03b077d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_67b88653-4f86-4040-8540-b69966aec678" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_66d0f76e-0a89-4b83-8c77-5156cf6572fc" xlink:to="loc_us-gaap_RestrictedStockMember_67b88653-4f86-4040-8540-b69966aec678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareLineItems_cec75e87-e187-4a7e-8456-1192285fa3ea" xlink:href="ameh-20220331.xsd#ameh_EarningsPerShareLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareTable_b2180df0-6af8-4b97-aacb-71c99a5f4b0c" xlink:to="loc_ameh_EarningsPerShareLineItems_cec75e87-e187-4a7e-8456-1192285fa3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1a9eeca6-5ded-463f-b8d6-8597c9d9b914" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareLineItems_cec75e87-e187-4a7e-8456-1192285fa3ea" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1a9eeca6-5ded-463f-b8d6-8597c9d9b914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_b43b74ae-f5e8-44ae-b56f-8b4186f6afc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareLineItems_cec75e87-e187-4a7e-8456-1192285fa3ea" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_b43b74ae-f5e8-44ae-b56f-8b4186f6afc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_69423a6a-6e51-430c-b641-0aab302d2e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareLineItems_cec75e87-e187-4a7e-8456-1192285fa3ea" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_69423a6a-6e51-430c-b641-0aab302d2e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEs" xlink:type="simple" xlink:href="ameh-20220331.xsd#VariableInterestEntitiesVIEs"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEs" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_84a97f9f-28f1-48ab-8b2e-c3f77b0e1edc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_9ea584f6-7485-4648-ac1c-1988cb9e93d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_84a97f9f-28f1-48ab-8b2e-c3f77b0e1edc" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_9ea584f6-7485-4648-ac1c-1988cb9e93d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables" xlink:type="simple" xlink:href="ameh-20220331.xsd#VariableInterestEntitiesVIEsTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dcdf4cc2-5cef-4c35-9aa8-4a4eb239a421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_dbc9eb6d-5822-48b9-b552-35289cc9b6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dcdf4cc2-5cef-4c35-9aa8-4a4eb239a421" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_dbc9eb6d-5822-48b9-b552-35289cc9b6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#VariableInterestEntitiesVIEsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_53a74ebc-456d-4582-8e5f-e224bad08913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_694eae0d-8b40-470c-9f00-f658b5685d51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_53a74ebc-456d-4582-8e5f-e224bad08913" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_694eae0d-8b40-470c-9f00-f658b5685d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_63529dd6-afa3-495b-9d4a-6fc739ea257c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_694eae0d-8b40-470c-9f00-f658b5685d51" xlink:to="loc_srt_ConsolidatedEntitiesAxis_63529dd6-afa3-495b-9d4a-6fc739ea257c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_4c60d2f2-20b5-4dc9-bbe7-ffe99189fcbb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_63529dd6-afa3-495b-9d4a-6fc739ea257c" xlink:to="loc_srt_ConsolidatedEntitiesDomain_4c60d2f2-20b5-4dc9-bbe7-ffe99189fcbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_77d470cd-3e58-4943-9b0d-266dbf6e34bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_4c60d2f2-20b5-4dc9-bbe7-ffe99189fcbb" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_77d470cd-3e58-4943-9b0d-266dbf6e34bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_95572f5f-defe-4918-a206-c86f0b2771ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_694eae0d-8b40-470c-9f00-f658b5685d51" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_95572f5f-defe-4918-a206-c86f0b2771ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_a1b4ba29-ad58-4527-8530-c6db05f2c3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_95572f5f-defe-4918-a206-c86f0b2771ba" xlink:to="loc_us-gaap_AssetsAbstract_a1b4ba29-ad58-4527-8530-c6db05f2c3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_ef6c2214-0c35-4045-a93a-3971cc6a1e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a1b4ba29-ad58-4527-8530-c6db05f2c3f1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_ef6c2214-0c35-4045-a93a-3971cc6a1e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f3d23e6b-f89f-4de1-b531-3fd93ddff11e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ef6c2214-0c35-4045-a93a-3971cc6a1e9a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f3d23e6b-f89f-4de1-b531-3fd93ddff11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_ba25589e-564b-4619-a79f-e61d6584a3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ef6c2214-0c35-4045-a93a-3971cc6a1e9a" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_ba25589e-564b-4619-a79f-e61d6584a3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_0c1e2f70-ef43-463b-8f69-c6484965281a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ef6c2214-0c35-4045-a93a-3971cc6a1e9a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_0c1e2f70-ef43-463b-8f69-c6484965281a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_4521fbe8-9ae1-4188-bf2c-d390ea7a7bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ef6c2214-0c35-4045-a93a-3971cc6a1e9a" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_4521fbe8-9ae1-4188-bf2c-d390ea7a7bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_77fd8299-509d-4453-b2f7-a6e17dc83344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ef6c2214-0c35-4045-a93a-3971cc6a1e9a" xlink:to="loc_us-gaap_IncomeTaxesReceivable_77fd8299-509d-4453-b2f7-a6e17dc83344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_65045df6-07da-4e0e-93b0-5222527ce1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ef6c2214-0c35-4045-a93a-3971cc6a1e9a" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_65045df6-07da-4e0e-93b0-5222527ce1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c6a7a5cd-aa9f-41cc-8662-4b4c1cc39d71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ef6c2214-0c35-4045-a93a-3971cc6a1e9a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c6a7a5cd-aa9f-41cc-8662-4b4c1cc39d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_605e81a2-c57a-4153-b277-4f36cdc7d0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ef6c2214-0c35-4045-a93a-3971cc6a1e9a" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_605e81a2-c57a-4153-b277-4f36cdc7d0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliateCurrent_f97d6153-2c78-44e8-bfc4-1e86adcb2a59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromAffiliateCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ef6c2214-0c35-4045-a93a-3971cc6a1e9a" xlink:to="loc_us-gaap_DueFromAffiliateCurrent_f97d6153-2c78-44e8-bfc4-1e86adcb2a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8904242a-251a-4c96-96e7-d8477cfda87a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ef6c2214-0c35-4045-a93a-3971cc6a1e9a" xlink:to="loc_us-gaap_AssetsCurrent_8904242a-251a-4c96-96e7-d8477cfda87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_aaca5a24-f2a2-41d0-9e83-bd15ac6a1c46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a1b4ba29-ad58-4527-8530-c6db05f2c3f1" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_aaca5a24-f2a2-41d0-9e83-bd15ac6a1c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_534a10b2-aa16-4751-81d4-f82289c225dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_aaca5a24-f2a2-41d0-9e83-bd15ac6a1c46" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_534a10b2-aa16-4751-81d4-f82289c225dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_fe12650b-18f3-4afe-a866-48819ad44236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_aaca5a24-f2a2-41d0-9e83-bd15ac6a1c46" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_fe12650b-18f3-4afe-a866-48819ad44236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_69c701c5-dc9b-4928-bd18-99c316e0a7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_aaca5a24-f2a2-41d0-9e83-bd15ac6a1c46" xlink:to="loc_us-gaap_Goodwill_69c701c5-dc9b-4928-bd18-99c316e0a7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_499ff247-b641-4baa-ba33-6cc333dab8f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_aaca5a24-f2a2-41d0-9e83-bd15ac6a1c46" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_499ff247-b641-4baa-ba33-6cc333dab8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_28b2ccc8-0539-43da-a5e7-0ff39d8d7a58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_aaca5a24-f2a2-41d0-9e83-bd15ac6a1c46" xlink:to="loc_us-gaap_OtherLongTermInvestments_28b2ccc8-0539-43da-a5e7-0ff39d8d7a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_0368bd9f-bff8-4cfe-8c86-5194a183080d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_aaca5a24-f2a2-41d0-9e83-bd15ac6a1c46" xlink:to="loc_us-gaap_EquityMethodInvestments_0368bd9f-bff8-4cfe-8c86-5194a183080d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_ca4cb797-06e5-4f22-a33d-97f7991e3ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_aaca5a24-f2a2-41d0-9e83-bd15ac6a1c46" xlink:to="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_ca4cb797-06e5-4f22-a33d-97f7991e3ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b09dcc77-07b8-42dc-847d-a348b433d7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_aaca5a24-f2a2-41d0-9e83-bd15ac6a1c46" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b09dcc77-07b8-42dc-847d-a348b433d7e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b0d508f8-475b-4e20-86d3-9f461c72d3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_aaca5a24-f2a2-41d0-9e83-bd15ac6a1c46" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b0d508f8-475b-4e20-86d3-9f461c72d3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_018e1b1c-a70d-4ae0-b30c-9ffa08f8b8ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_aaca5a24-f2a2-41d0-9e83-bd15ac6a1c46" xlink:to="loc_us-gaap_AssetsNoncurrent_018e1b1c-a70d-4ae0-b30c-9ffa08f8b8ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e5bb5f3e-938e-4280-9bb4-ab9e6a445e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a1b4ba29-ad58-4527-8530-c6db05f2c3f1" xlink:to="loc_us-gaap_Assets_e5bb5f3e-938e-4280-9bb4-ab9e6a445e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_d94ebc30-0cd5-443e-9eb8-0bb5118902a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_95572f5f-defe-4918-a206-c86f0b2771ba" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_d94ebc30-0cd5-443e-9eb8-0bb5118902a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_3c661136-dba4-48d7-8abb-28daea2dd67f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d94ebc30-0cd5-443e-9eb8-0bb5118902a5" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_3c661136-dba4-48d7-8abb-28daea2dd67f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_76a5f634-2dd4-4b92-bcf1-00b2223e80e1" xlink:href="ameh-20220331.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d94ebc30-0cd5-443e-9eb8-0bb5118902a5" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_76a5f634-2dd4-4b92-bcf1-00b2223e80e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_51c5de5e-844f-438d-a284-3ba1a6c44c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d94ebc30-0cd5-443e-9eb8-0bb5118902a5" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_51c5de5e-844f-438d-a284-3ba1a6c44c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_7bb378ab-0061-47b4-a703-0724670de47d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d94ebc30-0cd5-443e-9eb8-0bb5118902a5" xlink:to="loc_us-gaap_TaxesPayableCurrent_7bb378ab-0061-47b4-a703-0724670de47d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_43ca93fd-2787-4a4c-bd46-a50b3394d022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d94ebc30-0cd5-443e-9eb8-0bb5118902a5" xlink:to="loc_us-gaap_DividendsPayableCurrent_43ca93fd-2787-4a4c-bd46-a50b3394d022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_85801683-b302-4691-8645-f6bccdbfaf2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d94ebc30-0cd5-443e-9eb8-0bb5118902a5" xlink:to="loc_us-gaap_LongTermDebtCurrent_85801683-b302-4691-8645-f6bccdbfaf2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_6f38c83a-306a-4c5f-af19-a0a864a59d17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d94ebc30-0cd5-443e-9eb8-0bb5118902a5" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_6f38c83a-306a-4c5f-af19-a0a864a59d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_fcc33df8-92cc-4586-9005-31c78be0eb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d94ebc30-0cd5-443e-9eb8-0bb5118902a5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_fcc33df8-92cc-4586-9005-31c78be0eb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1348bad8-ad4d-4a62-b122-ccd2f3e76f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d94ebc30-0cd5-443e-9eb8-0bb5118902a5" xlink:to="loc_us-gaap_LiabilitiesCurrent_1348bad8-ad4d-4a62-b122-ccd2f3e76f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_b5e15fba-584f-4006-b93b-3da6aa0bbe11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_95572f5f-defe-4918-a206-c86f0b2771ba" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_b5e15fba-584f-4006-b93b-3da6aa0bbe11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_a521bab2-2428-4a19-8da1-de20a40ada92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_b5e15fba-584f-4006-b93b-3da6aa0bbe11" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_a521bab2-2428-4a19-8da1-de20a40ada92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e84eb2a1-03a1-4bf6-be92-2d8ffee46929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_b5e15fba-584f-4006-b93b-3da6aa0bbe11" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e84eb2a1-03a1-4bf6-be92-2d8ffee46929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1846d161-b11b-46bb-a64e-47df97db47bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_b5e15fba-584f-4006-b93b-3da6aa0bbe11" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1846d161-b11b-46bb-a64e-47df97db47bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_835104de-c661-4573-90ec-431ea11afc1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_b5e15fba-584f-4006-b93b-3da6aa0bbe11" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_835104de-c661-4573-90ec-431ea11afc1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2f86afc9-05c3-4691-b130-f3b1443bd676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_b5e15fba-584f-4006-b93b-3da6aa0bbe11" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_2f86afc9-05c3-4691-b130-f3b1443bd676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_b5b77b1e-4d2a-48b3-bf2a-de0d6ae71daa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_b5e15fba-584f-4006-b93b-3da6aa0bbe11" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_b5b77b1e-4d2a-48b3-bf2a-de0d6ae71daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_99ffa897-c337-444f-bb3f-b9e75dc03b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_95572f5f-defe-4918-a206-c86f0b2771ba" xlink:to="loc_us-gaap_Liabilities_99ffa897-c337-444f-bb3f-b9e75dc03b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/Leases" xlink:type="simple" xlink:href="ameh-20220331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_bb1ea5ad-4284-452d-b751-3e84a00b6188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_86cf216e-6b2a-4947-9667-7870c05996e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bb1ea5ad-4284-452d-b751-3e84a00b6188" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_86cf216e-6b2a-4947-9667-7870c05996e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_776a7500-a05b-4843-af76-3ef0ea3c7be2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bb1ea5ad-4284-452d-b751-3e84a00b6188" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_776a7500-a05b-4843-af76-3ef0ea3c7be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesTables" xlink:type="simple" xlink:href="ameh-20220331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_002d2dd3-c2a2-4427-858a-c55ee1ec3fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_24e0cbbf-7b70-4ab8-8f2d-74a75c750b29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_002d2dd3-c2a2-4427-858a-c55ee1ec3fb2" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_24e0cbbf-7b70-4ab8-8f2d-74a75c750b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_490c71c3-5d17-4e78-b8e4-5d8423924f62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_002d2dd3-c2a2-4427-858a-c55ee1ec3fb2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_490c71c3-5d17-4e78-b8e4-5d8423924f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_114cfaa8-32af-4290-9762-b2bf2d121111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_002d2dd3-c2a2-4427-858a-c55ee1ec3fb2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_114cfaa8-32af-4290-9762-b2bf2d121111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#LeasesAdditionalinformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9888cc79-fa39-4bfe-bab7-8d8733cd8171" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_3cbb17a4-16de-42ae-99a9-068e8f1d0e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9888cc79-fa39-4bfe-bab7-8d8733cd8171" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_3cbb17a4-16de-42ae-99a9-068e8f1d0e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fd4d691d-df2a-4a85-82b2-ff64880c95da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3cbb17a4-16de-42ae-99a9-068e8f1d0e0f" xlink:to="loc_srt_RangeAxis_fd4d691d-df2a-4a85-82b2-ff64880c95da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7e89ab6e-dec7-4a68-bf05-591e33323106" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fd4d691d-df2a-4a85-82b2-ff64880c95da" xlink:to="loc_srt_RangeMember_7e89ab6e-dec7-4a68-bf05-591e33323106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fde24ac7-482c-4b7c-bf50-abe40782b56d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7e89ab6e-dec7-4a68-bf05-591e33323106" xlink:to="loc_srt_MinimumMember_fde24ac7-482c-4b7c-bf50-abe40782b56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_12465602-fb6d-462c-98e5-be2fb986bc92" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7e89ab6e-dec7-4a68-bf05-591e33323106" xlink:to="loc_srt_MaximumMember_12465602-fb6d-462c-98e5-be2fb986bc92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_c1011f45-40c9-40a5-bf53-e8b776262912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3cbb17a4-16de-42ae-99a9-068e8f1d0e0f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_c1011f45-40c9-40a5-bf53-e8b776262912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_d3f83023-b7ad-48c4-a694-712f9eafa0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c1011f45-40c9-40a5-bf53-e8b776262912" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_d3f83023-b7ad-48c4-a694-712f9eafa0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_5ce18a17-52b9-41e4-8263-eb252ec58992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c1011f45-40c9-40a5-bf53-e8b776262912" xlink:to="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_5ce18a17-52b9-41e4-8263-eb252ec58992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a058e6c7-786b-4936-8039-7e66ada10a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c1011f45-40c9-40a5-bf53-e8b776262912" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a058e6c7-786b-4936-8039-7e66ada10a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_793de193-627d-4d82-aed9-a251d594d63a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c1011f45-40c9-40a5-bf53-e8b776262912" xlink:to="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_793de193-627d-4d82-aed9-a251d594d63a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_b486ec78-4826-4dc5-9157-c2d0733ac12e" xlink:href="ameh-20220331.xsd#ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c1011f45-40c9-40a5-bf53-e8b776262912" xlink:to="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_b486ec78-4826-4dc5-9157-c2d0733ac12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_c2498eed-cef2-47f2-ae9f-f5fa697bf558" xlink:href="ameh-20220331.xsd#ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c1011f45-40c9-40a5-bf53-e8b776262912" xlink:to="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_c2498eed-cef2-47f2-ae9f-f5fa697bf558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_d3b195ea-7880-4bd2-9cf9-f1d5d4960717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c1011f45-40c9-40a5-bf53-e8b776262912" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_d3b195ea-7880-4bd2-9cf9-f1d5d4960717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_314d71d9-0125-4995-8b6b-ee6709036adc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c1011f45-40c9-40a5-bf53-e8b776262912" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_314d71d9-0125-4995-8b6b-ee6709036adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9f9665f7-3b57-4738-9b9d-5adf8b312400" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_00fb7cc1-a124-458f-921c-1f74f2da89da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9f9665f7-3b57-4738-9b9d-5adf8b312400" xlink:to="loc_us-gaap_OperatingLeaseCost_00fb7cc1-a124-458f-921c-1f74f2da89da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceLeaseCostsAbstract_b702696d-e55f-4c38-82c8-194b9e839cec" xlink:href="ameh-20220331.xsd#ameh_FinanceLeaseCostsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9f9665f7-3b57-4738-9b9d-5adf8b312400" xlink:to="loc_ameh_FinanceLeaseCostsAbstract_b702696d-e55f-4c38-82c8-194b9e839cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_b990fab9-d1c9-4b4c-bc81-7b39189c4058" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_FinanceLeaseCostsAbstract_b702696d-e55f-4c38-82c8-194b9e839cec" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_b990fab9-d1c9-4b4c-bc81-7b39189c4058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_3aa89352-21b0-4c90-af8a-5b36061bf316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_FinanceLeaseCostsAbstract_b702696d-e55f-4c38-82c8-194b9e839cec" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_3aa89352-21b0-4c90-af8a-5b36061bf316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_f409e53c-b5cd-4d9e-b72a-19a468ca6f77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9f9665f7-3b57-4738-9b9d-5adf8b312400" xlink:to="loc_us-gaap_SubleaseIncome_f409e53c-b5cd-4d9e-b72a-19a468ca6f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_8c924af7-c12d-4096-b5a9-7b4db8db2a78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9f9665f7-3b57-4738-9b9d-5adf8b312400" xlink:to="loc_us-gaap_LeaseCost_8c924af7-c12d-4096-b5a9-7b4db8db2a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#LeasesOtherInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3e5f8aa3-05fc-4cf6-b267-7fab968a99dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_43e1a558-be1d-4401-9951-c55d5bfac1bd" xlink:href="ameh-20220331.xsd#ameh_CashPaidForLeaseLiabilitiesAbstractAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3e5f8aa3-05fc-4cf6-b267-7fab968a99dd" xlink:to="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_43e1a558-be1d-4401-9951-c55d5bfac1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_1f469cfa-840e-4adc-a600-f479696d52c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_43e1a558-be1d-4401-9951-c55d5bfac1bd" xlink:to="loc_us-gaap_OperatingLeasePayments_1f469cfa-840e-4adc-a600-f479696d52c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_eea78cd3-1a52-4643-9c1a-1bf87dfb4862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_43e1a558-be1d-4401-9951-c55d5bfac1bd" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_eea78cd3-1a52-4643-9c1a-1bf87dfb4862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_6588ebba-75e7-4cd5-802b-9b3fd4d78847" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_43e1a558-be1d-4401-9951-c55d5bfac1bd" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_6588ebba-75e7-4cd5-802b-9b3fd4d78847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_26b95748-4575-46f4-9fef-219c7c89414f" xlink:href="ameh-20220331.xsd#ameh_LeaseWeightedAverageRemainingLeaseTermAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3e5f8aa3-05fc-4cf6-b267-7fab968a99dd" xlink:to="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_26b95748-4575-46f4-9fef-219c7c89414f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a9a72fd5-aa80-43ed-bc2e-4b1254532182" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_26b95748-4575-46f4-9fef-219c7c89414f" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a9a72fd5-aa80-43ed-bc2e-4b1254532182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_3566bd69-ac97-48e6-9397-04033a0ad5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_26b95748-4575-46f4-9fef-219c7c89414f" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_3566bd69-ac97-48e6-9397-04033a0ad5b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseWeightedAverageDiscountRateAbstract_23d68ed9-2f06-43c7-9baf-5b415fbcbddd" xlink:href="ameh-20220331.xsd#ameh_LeaseWeightedAverageDiscountRateAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3e5f8aa3-05fc-4cf6-b267-7fab968a99dd" xlink:to="loc_ameh_LeaseWeightedAverageDiscountRateAbstract_23d68ed9-2f06-43c7-9baf-5b415fbcbddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0aa4842b-43e4-48ed-b34b-aabf94043093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LeaseWeightedAverageDiscountRateAbstract_23d68ed9-2f06-43c7-9baf-5b415fbcbddd" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0aa4842b-43e4-48ed-b34b-aabf94043093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_8f8c2d6a-e99b-407d-a608-d13224a45ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LeaseWeightedAverageDiscountRateAbstract_23d68ed9-2f06-43c7-9baf-5b415fbcbddd" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_8f8c2d6a-e99b-407d-a608-d13224a45ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails" xlink:type="simple" xlink:href="ameh-20220331.xsd#LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a731f69c-2b15-45c0-b26d-203e4f124bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7e9fe9da-827e-4885-aa1b-237a113ccdd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a731f69c-2b15-45c0-b26d-203e4f124bfb" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7e9fe9da-827e-4885-aa1b-237a113ccdd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_37f853ec-82ba-4c05-b3e2-7dea1878510b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7e9fe9da-827e-4885-aa1b-237a113ccdd0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_37f853ec-82ba-4c05-b3e2-7dea1878510b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7926b4bb-e8a1-4e3a-b2cf-6b12c805c5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7e9fe9da-827e-4885-aa1b-237a113ccdd0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7926b4bb-e8a1-4e3a-b2cf-6b12c805c5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_aaf223ed-7094-4c2e-b075-a1fe037ab1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7e9fe9da-827e-4885-aa1b-237a113ccdd0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_aaf223ed-7094-4c2e-b075-a1fe037ab1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_46dfd83e-6fff-4b6a-9751-83aadb0effb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7e9fe9da-827e-4885-aa1b-237a113ccdd0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_46dfd83e-6fff-4b6a-9751-83aadb0effb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0fb92810-0ce7-45df-8527-8b83f8f3c759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7e9fe9da-827e-4885-aa1b-237a113ccdd0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0fb92810-0ce7-45df-8527-8b83f8f3c759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_6385dafa-06bb-48d2-ba09-d966977939b6" xlink:href="ameh-20220331.xsd#ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7e9fe9da-827e-4885-aa1b-237a113ccdd0" xlink:to="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_6385dafa-06bb-48d2-ba09-d966977939b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ceddc142-469a-4073-8528-0325660ab4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7e9fe9da-827e-4885-aa1b-237a113ccdd0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ceddc142-469a-4073-8528-0325660ab4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9f22f6ce-736b-4000-83af-408f28e81c60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7e9fe9da-827e-4885-aa1b-237a113ccdd0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9f22f6ce-736b-4000-83af-408f28e81c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_bb6075e2-a36b-4b79-bb85-2c8c2b4a8d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7e9fe9da-827e-4885-aa1b-237a113ccdd0" xlink:to="loc_us-gaap_OperatingLeaseLiability_bb6075e2-a36b-4b79-bb85-2c8c2b4a8d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4583f07b-1365-4044-bea6-c7b905f90338" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7e9fe9da-827e-4885-aa1b-237a113ccdd0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4583f07b-1365-4044-bea6-c7b905f90338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_75b21ecb-78b1-4d25-9cff-1dc33672ea27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7e9fe9da-827e-4885-aa1b-237a113ccdd0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_75b21ecb-78b1-4d25-9cff-1dc33672ea27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_17fa747f-7234-4b11-83f7-3e09581964fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a731f69c-2b15-45c0-b26d-203e4f124bfb" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_17fa747f-7234-4b11-83f7-3e09581964fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_f01e2dfe-a4cf-4548-9fb5-94108be755f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_17fa747f-7234-4b11-83f7-3e09581964fb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_f01e2dfe-a4cf-4548-9fb5-94108be755f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_2df1fda6-3329-4f29-9e32-ac30e01c73a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_17fa747f-7234-4b11-83f7-3e09581964fb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_2df1fda6-3329-4f29-9e32-ac30e01c73a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_7a47d2d4-fc42-444e-ad4a-6a03eaa93064" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_17fa747f-7234-4b11-83f7-3e09581964fb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_7a47d2d4-fc42-444e-ad4a-6a03eaa93064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_3b46d88d-a413-4123-bdad-7a1bff062d59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_17fa747f-7234-4b11-83f7-3e09581964fb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_3b46d88d-a413-4123-bdad-7a1bff062d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_cc5e6b30-738d-4473-a2a6-5f482b819fea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_17fa747f-7234-4b11-83f7-3e09581964fb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_cc5e6b30-738d-4473-a2a6-5f482b819fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_f66402de-b580-456a-8419-a9d0a0b4c7c5" xlink:href="ameh-20220331.xsd#ameh_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_17fa747f-7234-4b11-83f7-3e09581964fb" xlink:to="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_f66402de-b580-456a-8419-a9d0a0b4c7c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_6333fa46-ad1a-40f7-8dd1-03667adc6ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_17fa747f-7234-4b11-83f7-3e09581964fb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_6333fa46-ad1a-40f7-8dd1-03667adc6ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_cd9828ce-cdff-48a5-acf0-458569b38e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_17fa747f-7234-4b11-83f7-3e09581964fb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_cd9828ce-cdff-48a5-acf0-458569b38e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_8ab3c810-d413-42c7-b401-76b4a769bb51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_17fa747f-7234-4b11-83f7-3e09581964fb" xlink:to="loc_us-gaap_FinanceLeaseLiability_8ab3c810-d413-42c7-b401-76b4a769bb51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_425265cc-6938-4e70-9c86-1a70f2aafc01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_17fa747f-7234-4b11-83f7-3e09581964fb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_425265cc-6938-4e70-9c86-1a70f2aafc01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_68216eef-c2c9-46cd-81ef-decfe047656f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_17fa747f-7234-4b11-83f7-3e09581964fb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_68216eef-c2c9-46cd-81ef-decfe047656f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1" xlink:type="simple" xlink:href="ameh-20220331.xsd#LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661155324776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Apollo Medical Holdings, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-4472349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1668 S. Garfield Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">2nd Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alhambra<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">282-0288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMEH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,048,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001083446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661154309640">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 237,942<span></span>
</td>
<td class="nump">$ 233,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments in marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">42,893<span></span>
</td>
<td class="nump">53,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">55,280<span></span>
</td>
<td class="nump">10,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Receivables, net &#8211; related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">76,410<span></span>
</td>
<td class="nump">69,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,260<span></span>
</td>
<td class="nump">9,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,631<span></span>
</td>
<td class="nump">18,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loan receivable &#8211; related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">444,416<span></span>
</td>
<td class="nump">398,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Land, property, and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">70,366<span></span>
</td>
<td class="nump">53,186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">80,148<span></span>
</td>
<td class="nump">82,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">252,379<span></span>
</td>
<td class="nump">253,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetNoncurrent', window );">Loans receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">549<span></span>
</td>
<td class="nump">569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44,383<span></span>
</td>
<td class="nump">41,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue', window );">Investments in privately held entities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">896<span></span>
</td>
<td class="nump">896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,770<span></span>
</td>
<td class="nump">15,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,424<span></span>
</td>
<td class="nump">5,928<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">467,915<span></span>
</td>
<td class="nump">453,581<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">912,331<span></span>
</td>
<td class="nump">852,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">48,252<span></span>
</td>
<td class="nump">43,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryAccountsPayableCurrent', window );">Fiduciary accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,305<span></span>
</td>
<td class="nump">10,534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">95,758<span></span>
</td>
<td class="nump">55,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,894<span></span>
</td>
<td class="nump">652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividend payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">556<span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">543<span></span>
</td>
<td class="nump">486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,625<span></span>
</td>
<td class="nump">2,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,503<span></span>
</td>
<td class="nump">780<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">160,436<span></span>
</td>
<td class="nump">115,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,686<span></span>
</td>
<td class="nump">9,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,172<span></span>
</td>
<td class="nump">973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,558<span></span>
</td>
<td class="nump">13,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">183,101<span></span>
</td>
<td class="nump">182,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,706<span></span>
</td>
<td class="nump">14,777<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">220,223<span></span>
</td>
<td class="nump">220,992<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">380,659<span></span>
</td>
<td class="nump">336,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MezzanineEquityAbstract', window );"><strong>Mezzanine equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Non-controlling interest in Allied Physicians of California, a Professional Medical Corporation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">52,151<span></span>
</td>
<td class="nump">55,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value per share; 100,000,000 shares authorized, 44,845,059 and 44,630,873 shares issued and outstanding, excluding 10,925,702 and 10,925,702 treasury shares, as of March&#160;31, 2022 and December&#160;31, 2021, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">316,047<span></span>
</td>
<td class="nump">310,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">157,893<span></span>
</td>
<td class="nump">143,629<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity, parent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">473,985<span></span>
</td>
<td class="nump">454,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,536<span></span>
</td>
<td class="nump">5,940<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">479,521<span></span>
</td>
<td class="nump">460,490<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, mezzanine equity, and stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">912,331<span></span>
</td>
<td class="nump">852,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Company&#8217;s consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#8217;s consolidated VIEs totaling $585.9&#160;million and $567.0&#160;million as of March&#160;31, 2022 and December&#160;31, 2021, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $111.0&#160;million and $91.7&#160;million as of March&#160;31, 2022 and December&#160;31, 2021, respectively. The VIE balances do not include $529.6&#160;million of investment in affiliates and $25.2&#160;million of amounts due from affiliates as of March&#160;31, 2022 and $802.8&#160;million of investment in affiliates and $6.6&#160;million of amounts due to affiliates as of December&#160;31, 2021 as these are eliminated upon consolidation and not presented within the consolidated balance sheets. See Note 16 &#8211; Variable Interest Entities (VIEs) for further detail.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiduciaryAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiduciaryAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of Investment in privately held entity that does not report net asset value per share .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MezzanineEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MezzanineEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661154226936">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44,845,059<span></span>
</td>
<td class="nump">44,630,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44,845,059<span></span>
</td>
<td class="nump">44,630,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,925,702<span></span>
</td>
<td class="nump">10,925,702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 912,331<span></span>
</td>
<td class="nump">$ 852,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">380,659<span></span>
</td>
<td class="nump">336,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember', window );">Variable Interest Entity, Not Primary Beneficiary</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">585,900<span></span>
</td>
<td class="nump">567,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">111,000<span></span>
</td>
<td class="nump">91,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investments in affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">529,600<span></span>
</td>
<td class="nump">802,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromAffiliates', window );">Due from affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 25,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToAffiliateCurrentAndNoncurrent', window );">Due to affiliate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,111,111<span></span>
</td>
<td class="nump">1,111,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">555,555<span></span>
</td>
<td class="nump">555,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Company&#8217;s consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#8217;s consolidated VIEs totaling $585.9&#160;million and $567.0&#160;million as of March&#160;31, 2022 and December&#160;31, 2021, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $111.0&#160;million and $91.7&#160;million as of March&#160;31, 2022 and December&#160;31, 2021, respectively. The VIE balances do not include $529.6&#160;million of investment in affiliates and $25.2&#160;million of amounts due from affiliates as of March&#160;31, 2022 and $802.8&#160;million of investment in affiliates and $6.6&#160;million of amounts due to affiliates as of December&#160;31, 2021 as these are eliminated upon consolidation and not presented within the consolidated balance sheets. See Note 16 &#8211; Variable Interest Entities (VIEs) for further detail.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39599-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToAffiliateCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04.12(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=d3e56071-112765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToAffiliateCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661155495400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF INCOME - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 263,258<span></span>
</td>
<td class="nump">$ 176,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of services, excluding depreciation and amortization</a></td>
<td class="nump">220,730<span></span>
</td>
<td class="nump">140,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">11,943<span></span>
</td>
<td class="nump">9,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,374<span></span>
</td>
<td class="nump">4,197<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
<td class="nump">237,047<span></span>
</td>
<td class="nump">154,277<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">26,211<span></span>
</td>
<td class="nump">21,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="nump">1,433<span></span>
</td>
<td class="num">(677)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,073)<span></span>
</td>
<td class="num">(1,523)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss on investments</a></td>
<td class="num">(8,962)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">613<span></span>
</td>
<td class="nump">1,304<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(7,943)<span></span>
</td>
<td class="num">(547)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before provision for income taxes</a></td>
<td class="nump">18,268<span></span>
</td>
<td class="nump">21,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">6,195<span></span>
</td>
<td class="nump">6,776<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">12,073<span></span>
</td>
<td class="nump">14,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (loss) income attributable to non-controlling interest</a></td>
<td class="num">(2,191)<span></span>
</td>
<td class="nump">1,307<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Apollo Medical Holdings, Inc.</a></td>
<td class="nump">$ 14,264<span></span>
</td>
<td class="nump">$ 13,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share &#8211; basic (in dollars per share)</a></td>
<td class="nump">$ 0.32<span></span>
</td>
<td class="nump">$ 0.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share &#8211; diluted (in dollars per share)</a></td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ameh_HealthCareCapitationRevenueMember', window );">Capitation, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 222,060<span></span>
</td>
<td class="nump">$ 144,740<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_HealthCareOtherMember', window );">Risk pool settlements and incentives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">18,075<span></span>
</td>
<td class="nump">18,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember', window );">Management fee income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">10,473<span></span>
</td>
<td class="nump">8,550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember', window );">Fee-for-service, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">11,095<span></span>
</td>
<td class="nump">3,086<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 1,555<span></span>
</td>
<td class="nump">$ 1,672<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ameh_HealthCareCapitationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ameh_HealthCareCapitationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_HealthCareOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_HealthCareOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661153846072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common&#160;Stock&#160;Outstanding</div></th>
<th class="th"><div>Additional Paid-in&#160;Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Non-controlling Interest</div></th>
<th class="th">
<div>Non-controlling Interest </div>
<div>Mezzanine</div>
</th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, carrying amount, beginning balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">760<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, carrying amount, ending balance at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,847<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,249,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 330,911<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">$ 261,011<span></span>
</td>
<td class="nump">$ 69,771<span></span>
</td>
<td class="nump">$ 87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity', window );">Net (loss) income</a></td>
<td class="nump">13,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,151<span></span>
</td>
<td class="nump">547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Purchase of non-controlling interest</a></td>
<td class="num">(75)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest', window );">Sale of non-controlling interest</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">421,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants</a></td>
<td class="nump">4,256<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,158)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredParValueMethod', window );">Purchase of treasury shares</a></td>
<td class="num">(342)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(342)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Cancellation of restricted stock awards (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Cancellation of restricted stock awards</a></td>
<td class="num">(144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance at Mar. 31, 2021</a></td>
<td class="nump">349,687<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">266,126<span></span>
</td>
<td class="nump">82,922<span></span>
</td>
<td class="nump">596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,638,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, carrying amount, beginning balance at Dec. 31, 2021</a></td>
<td class="nump">55,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,129)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionOfDividends', window );">Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Share buy back</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(230)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, carrying amount, ending balance at Mar. 31, 2022</a></td>
<td class="nump">52,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,151<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,630,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance at Dec. 31, 2021</a></td>
<td class="nump">460,490<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">310,876<span></span>
</td>
<td class="nump">143,629<span></span>
</td>
<td class="nump">5,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity', window );">Net (loss) income</a></td>
<td class="nump">15,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,264<span></span>
</td>
<td class="nump">938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Purchase of non-controlling interest</a></td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest', window );">Sale of non-controlling interest</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants</a></td>
<td class="nump">1,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">3,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of shares for business acquisition (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of shares for business acquisition</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares', window );">Dividends</a></td>
<td class="num">(1,178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Cancellation of restricted stock awards (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,084)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Cancellation of restricted stock awards</a></td>
<td class="num">(457)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(457)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 479,521<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 316,047<span></span>
</td>
<td class="nump">$ 157,893<span></span>
</td>
<td class="nump">$ 5,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,845,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders And Stock Repurchased During Period, Value, Release Of Hold Back Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents number of share issued exercise of option and warrants during the period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents value of stock issued during the period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569655-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity during the period due to unpaid dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityNetIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of net income or loss attributable to temporary equity interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityNetIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredParValueMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the par value method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredParValueMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661155333384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 12,073<span></span>
</td>
<td class="nump">$ 14,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,374<span></span>
</td>
<td class="nump">4,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance cost</a></td>
<td class="nump">237<span></span>
</td>
<td class="nump">351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">3,055<span></span>
</td>
<td class="nump">1,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities', window );">Unrealized loss (gain) from investment in equity securities</a></td>
<td class="nump">10,556<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Income) loss from equity method investments</a></td>
<td class="num">(1,433)<span></span>
</td>
<td class="nump">677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Unrealized gain on interest rate swaps</a></td>
<td class="num">(1,593)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred tax</a></td>
<td class="nump">1,985<span></span>
</td>
<td class="num">(921)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of business combinations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Receivables, net</a></td>
<td class="num">(44,673)<span></span>
</td>
<td class="num">(9,390)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties', window );">Receivables, net &#8211; related parties</a></td>
<td class="num">(6,865)<span></span>
</td>
<td class="num">(17,612)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="num">(3,613)<span></span>
</td>
<td class="num">(223)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,171<span></span>
</td>
<td class="nump">7,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_IncreaseDecreaseInOperatingLeaseAssets', window );">Right-of-use assets</a></td>
<td class="nump">672<span></span>
</td>
<td class="nump">836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">2,016<span></span>
</td>
<td class="num">(192)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">3,735<span></span>
</td>
<td class="nump">3,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">Fiduciary accounts payable</a></td>
<td class="num">(4,229)<span></span>
</td>
<td class="num">(2,771)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_IncreaseDecreaseInMedicalLiabilities', window );">Medical liabilities</a></td>
<td class="nump">39,974<span></span>
</td>
<td class="nump">1,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="nump">4,241<span></span>
</td>
<td class="nump">7,835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(645)<span></span>
</td>
<td class="num">(859)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">24,038<span></span>
</td>
<td class="nump">9,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payments for business acquisition, net of cash acquired and shares issued</a></td>
<td class="num">(999)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties', window );">Proceeds from repayment of loans receivable &#8211; related parties</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(332)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(17,489)<span></span>
</td>
<td class="num">(98)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sale of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital', window );">Distribution from investment - equity method</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Contribution to investment - equity method</a></td>
<td class="num">(1,435)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(19,725)<span></span>
</td>
<td class="nump">692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Dividends paid</a></td>
<td class="num">(1,178)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="num">(52)<span></span>
</td>
<td class="num">(2,434)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of finance lease obligations</a></td>
<td class="num">(141)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of stock options and warrants</a></td>
<td class="nump">1,573<span></span>
</td>
<td class="nump">4,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of shares</a></td>
<td class="num">(230)<span></span>
</td>
<td class="num">(342)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Distribution to non-controlling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(225)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ProceedsFromSaleOfNoncontrollingInterest', window );">Proceeds from sale of non-controlling interest</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentsToAcquireNonControllingInterest', window );">Purchase of non-controlling interest</a></td>
<td class="num">(200)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Borrowings on loans</a></td>
<td class="nump">722<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">532<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">4,845<span></span>
</td>
<td class="nump">11,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, beginning of period</a></td>
<td class="nump">233,097<span></span>
</td>
<td class="nump">193,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, end of period</a></td>
<td class="nump">237,942<span></span>
</td>
<td class="nump">205,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">845<span></span>
</td>
<td class="nump">1,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Fixed asset obtained in exchange for finance lease liabilities</a></td>
<td class="nump">398<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Common stock issued in business combination</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract', window );"><strong>Reconciliation of cash, cash equivalents, and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">237,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, restricted cash total</a></td>
<td class="nump">$ 237,942<span></span>
</td>
<td class="nump">$ 205,876<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_IncreaseDecreaseInMedicalLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of medical liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_IncreaseDecreaseInMedicalLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_IncreaseDecreaseInOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents increase in operating lease assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_IncreaseDecreaseInOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentsToAcquireNonControllingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to Acquire Non-controlling Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentsToAcquireNonControllingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ProceedsFromSaleOfNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Sale of Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ProceedsFromSaleOfNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrealized (Gain) Loss from Investment in Equity Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_UnrealizedGainLossFromInvestmentInEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with collection, whether partial or full, of long-term loans to a related party. Alternate caption: Proceeds from Advances to Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=SL94080555-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661157595288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of Business</a></td>
<td class="text">Description of Business<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Apollo Medical Holdings, Inc. (&#8220;ApolloMed&#8221;) is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high-quality care to patients in a cost-effective manner. ApolloMed was merged with Network Medical Management (&#8220;NMM&#8221;) in December 2017 (the &#8220;2017 Merger&#8221;). As a result of the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed, and the former NMM shareholders own a majority of the issued and outstanding common stock of ApolloMed and maintain control of the board of directors of ApolloMed. Unless the context dictates otherwise, references in these notes to the financial statements, the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and similar words are references to ApolloMed and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (&#8220;VIEs&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Headquartered in Alhambra, California, ApolloMed&#8217;s subsidiaries and VIEs include management services organizations (&#8220;MSOs&#8221;), affiliated independent practice associations (&#8220;IPAs&#8221;), and an accountable care organization (&#8220;ACO&#8221;) participating in the GPDC model. NMM and Apollo Medical Management, Inc. (&#8220;AMM&#8221;) are the administrative and managerial services companies for the affiliated physician-owned professional corporations that contract with independent physicians to deliver medical services in-office and virtually under the following brands: (i) Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA (&#8220;APC&#8221;), (ii) Alpha Care Medical Group, Inc. (&#8220;Alpha Care&#8221;), and (iii) Accountable Health Care IPA, a Professional Medical Corporation (&#8220;Accountable Health Care&#8221;). These affiliates are supported by ApolloMed Hospitalists, a Medical Corporation (&#8220;AMH&#8221;) and Southern California Heart Centers, a Medical Corporation (&#8220;SCHC&#8221;). The Company&#8217;s ACO operates under the APA ACO, Inc. (&#8220;APAACO&#8221;) brand and participates in the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participation in the program&#8217;s attribution-based risk-sharing model.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company&#8217;s physician network consists of primary care physicians, specialist physicians, and hospitalists. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSOs and Affiliates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMM, a wholly owned subsidiary of ApolloMed, manages affiliated medical groups, ApolloMed Hospitalists, a Medical Corporation (&#8220;AMH&#8221;) and Southern California Heart Centers, a Medical Corporation (&#8220;SCHC&#8221;). AMH provides hospitalist, intensivist, and physician advisory services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NMM was formed in 1994 as an MSO for the purposes of providing management services to medical companies and IPAs. The management services primarily include billing, collection, accounting, administration, quality assurance, marketing, compliance, and education. Following the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPAs and Affiliates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">APC was incorporated in 1992 for the purpose of arranging healthcare services as an IPA. APC is owned by California-licensed physicians and professional medical corporations, and contracts with various health maintenance organizations (&#8220;HMOs&#8221;) and other licensed healthcare service plans, as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (&#8220;PMPM&#8221;) that is to be paid to APC. In return, APC arranges for the delivery of healthcare services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering healthcare services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is subject to stop-loss provisions in contracts with HMOs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 1999, APC entered into an amended and restated management and administrative services agreement with NMM (the initial management services agreement was entered into in 1997) for an initial fixed term of 30 years. Under this management arrangement, NMM performs only non-medical administrative services, does not represent that it offers medical services, and does not exercise influence or control over the practice of medicine by APC or its physicians. In accordance with relevant accounting guidance, APC is determined to be a VIE of the Company and is consolidated by NMM.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AP-AMH Medical Corporation (&#8220;AP-AMH&#8221;) and AP-AMH 2 Medical Corporation (&#8220;AP-AMH 2&#8221;) was formed in May 2019 and July 2021, respectively, as a designated shareholder professional corporation. Dr. Thomas Lam, a shareholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is the sole shareholder of AP-AMH and AP-AMH 2. In accordance with relevant accounting guidance, AP-AMH and AP-AMH 2 is determined to be a VIE of ApolloMed and is consolidated by ApolloMed.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, ApolloMed completed the following series of transactions with its affiliates, AP-AMH and APC:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">A $545.0&#160;million loan to AP-AMH, pursuant to a 10-year secured loan agreement (the &#8220;AP-AMH Loan&#8221;). The loan bears interest at a rate of 10% per annum simple interest, is not prepayable, (except in certain limited circumstances), requires quarterly payments of interest only in arrears, and is secured by a first priority security interest in all of AP-AMH&#8217;s assets. To the extent that AP-AMH is unable to make any interest payment when due because it has received dividends on the APC Series A Preferred Stock insufficient to pay in full such interest payment, then the outstanding principal amount of the loan will be increased by the amount of any such accrued but unpaid interest, and any such increased principal amounts will bear interest at the rate of 10.75% per annum simple interest.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">A $545.0&#160;million private placement, where AP-AMH purchased 1,000,000 shares of APC Series A Preferred Stock which entitle AP-AMH to receive preferential, cumulative dividends that accrue on a daily basis. </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">A $300.0&#160;million private placement, where APC purchased 15,015,015 shares of the Company&#8217;s common stock and in  connection therewith, the Company granted APC certain registration rights with respect to the purchased shares.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">ApolloMed licensed to AP-AMH the right to use certain tradenames for specified purposes for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The license fee is payable out of any Series A Preferred Stock dividends received by AP-AMH from APC.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Through its subsidiary, NMM, the Company agreed to provide certain administrative services to AP-AMH for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The administrative fee is also payable out of any APC Series A Preferred Stock dividends received by AP-AMH from APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of the series of transactions, in September 2019, APC and AP-AMH entered into a Second Amendment to the Series A Preferred Stock Purchase Agreement clarifying the term excluded assets (&#8220;Excluded Assets&#8221;). Excluded Assets means (i) assets received from the sale of shares of the Series A Preferred equal to the Series A Purchase Price, (ii) the assets of the Company that are not Healthcare Services Assets, including the Company&#8217;s equity interests in Apollo Medical Holdings, Inc., and any entity that is primarily engaged in the business of owning, leasing, developing, or otherwise operating real estate, (iii) any assets acquired with the proceeds of the sale, assignment, or other disposition of any of the assets described in clauses (i) or (ii), and (iv) any proceeds of the assets described in clauses (i), (ii), and (iii). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC&#8217;s ownership in ApolloMed was 19.61% as of March&#160;31, 2022 and 19.68% as of December&#160;31, 2021. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concourse Diagnostic Surgery Center, LLC (&#8220;CDSC&#8221;) was formed in March&#160;2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California organized by a group of highly qualified physicians, which utilizes some of the most advanced equipment in the eastern part of Los Angeles County and the San Gabriel Valley. The facility is Medicare-certified and accredited by the Accreditation Association for Ambulatory Healthcare. As of March&#160;31, 2022, APC owned 44.50% of CDSC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s capital stock. In accordance with relevant accounting guidance, CDSC is determined to be a VIE of APC and is consolidated by APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC-LSMA Designated Shareholder Medical Corporation (&#8220;APC-LSMA&#8221;) was formed in October&#160;2012 as a designated shareholder professional corporation. Dr. Thomas Lam, a stockholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is a nominee shareholder of APC-LSMA. APC makes all investment decisions on behalf of APC-LSMA, funds all investments and receives all distributions from the investments. APC has the obligation to absorb losses and right to receive benefits from all investments made by APC-LSMA. APC-LSMA&#8217;s sole function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC as the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, including the IPA lines of business of LaSalle Medical Associates (&#8220;LMA&#8221;), Pacific Medical Imaging and Oncology Center, Inc. (&#8220;PMIOC&#8221;), Diagnostic Medical Group of Southern California (&#8220;DMG&#8221;), and AHMC International Cancer Center, a Medical Corporation (&#8220;ICC&#8221;). APC-LSMA also holds a 100% ownership interest in Maverick Medical Group, Inc. (&#8220;MMG&#8221;), Alpha Care, Accountable Health Care, and AMG, a Professional Medical Corporation (&#8220;AMG&#8221;). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alpha Care, an IPA acquired by the Company in May 2019, has been operating in California since 1993 as a risk-bearing organization engaged in providing professional services under capitation arrangements with its contracted health plans through a provider network consisting of primary care and specialty care physicians. Alpha Care specializes in delivering high-quality healthcare to its enrollees and focuses on Medi-Cal/Medicaid, Commercial, and Medicare and Dual Eligible members in the Riverside and San Bernardino counties of Southern California.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accountable Health Care is a California-based IPA that has served the local community in the greater Los Angeles County area through a network of physicians and healthcare providers for more than 20 years. Accountable Health Care provides quality healthcare services to its members through three federally qualified health plans and multiple product lines, including Medi-Cal, Commercial, and Medicare. In August 2019, APC and APC-LSMA acquired the remaining outstanding shares of Accountable Health Care&#8217;s capital stock that they did not already own (comprising 75%) for&#160;$7.3 million&#160;in cash.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMG is a network of family practice clinics operating out of three main locations in Southern California. AMG provides professional and post-acute care services to Medicare, Medi-Cal/Medicaid, and Commercial patients through its network of doctors and nurse practitioners. In September 2019, APC-LSMA purchased 100% of the shares of capital stock of AMG for $1.2 million in cash and $0.4 million of APC common stock.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DMG is a professional medical California corporation and a complete outpatient imaging center. APC accounted for its 40% investment in DMG, under the equity method of accounting. In October 2021, DMG entered into an administrative services agreement with a subsidiary of the Company, causing the Company to reevaluate the accounting for the Company&#8217;s investment in DMG. Based on the reevaluation and in accordance with relevant accounting guidance, DMG is determined to be a VIE of the Company and is consolidated by the Company. In addition, APC-LSMA is obligated to purchase the remaining equity interest within three years from the effective date. The purchase of the remaining equity value is considered a financing obligation with a carrying value of $8.5&#160;million as of March&#160;31, 2022. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, using cash comprised solely of Excluded Assets, APC purchased a 100% interest in each of Medical Property Partners, LLC (&#8220;MPP&#8221;), AMG Properties, LLC (&#8220;AMG Properties&#8221;), and ZLL Partners, LLC (&#8220;ZLL&#8221;) and a 50% interest in each of One MSO, LLC (&#8220;One MSO&#8221;), Tag-6 Medical Investment Group, LLC (&#8220;Tag 6&#8221;), and Tag-8 Medical Investment Group, LLC (&#8220;Tag 8&#8221;). These entities own buildings that are currently leased to tenants, as well as vacant land that is being developed. MPP, AMG Properties, and ZLL are 100% owned subsidiaries of APC and are included in the consolidated financial statements. In April 2021, Tag 8 entered into a loan agreement with MUFG Union Bank N.A. with APC as their guarantor, causing the Company to reevaluate their consolidation of Tag 8. Based on the reevaluation and in accordance with relevant accounting guidance, it was concluded that Tag 8 is a VIE and is consolidated by APC. One MSO and Tag 6 are accounted for as equity method investments, as APC has the ability to exercise significant influence, but not control over the operations of the entity. These purchases are deemed Excluded Assets that are solely for the benefit of APC and its shareholders. As such, any income pertaining to APC&#8217;s interests in these properties has no impact on the Series A Dividend payable by APC to AP-AMH Medical Corporation, and consequently will not affect net income attributable to ApolloMed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, AP-AMH 2, a VIE of the Company, purchased an 80% equity interest (on a fully diluted basis) in Access Primary Care Medical Group (&#8220;APCMG&#8221;), a primary care physicians&#8217; group focused on providing high-quality care to senior patients in the northern California cities of Daly City and San Francisco. As a result, APCMG is consolidated by the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, Apollo Medical Holdings, Inc. acquired 49% of the aggregate issued and outstanding shares of capital stock of Sun Clinical Laboratories (&#8220;Sun Labs&#8221;) for an aggregate purchase price of $4.0 million. Sun Labs is a Clinical Laboratory Improvement Amendments certified full-service lab that operates across the San Gabriel Valley in Southern California. In accordance with relevant accounting guidance, Sun Labs is determined to be a VIE of the Company and is consolidated by the Company (see Note 3). The Company is obligated to purchase the remaining equity interest within three years from the effective date. The purchase of the remaining equity value is considered a financing obligation with a carrying value of at $4.2 million at March&#160;31, 2022. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NGACO, GPDC / ACO REACH<br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APAACO began participating in the NGACO Model of CMS in January 2017. The NGACO Model was a CMS program that allowed provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk-sharing model. With the ending of the NGACO Model on December 31, 2021, APAACO applied, and has been selected by CMS, to participate as a Direct Contracting Entity (&#8220;DCE&#8221;) in the standard track of CMS&#8217;s GPDC Model for Performance Year 2022 (&#8220;PY22&#8221;), beginning January 1, 2022. CMS has since redesigned the GPDC Model in response to Administration priorities, including their commitment to advancing health equity, stakeholder feedback, and participant experience, and renamed the GPDC Model to ACO Realizing Equity, Access, and Community Health (&#8220;ACO REACH&#8221;) Model. The ACO REACH Model will begin participation on January 1, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661158020872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Summary of Significant Accounting Policies<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated balance sheets at December&#160;31, 2021, have been derived from the Company&#8217;s audited consolidated financial statements, but do not include all annual disclosures required by generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). The accompanying unaudited consolidated financial statements as of March&#160;31, 2022, and for the three months ended March&#160;31, 2022 and 2021, have been prepared in accordance with U.S. GAAP for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, these unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC on February&#160;28, 2022. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made to make the consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01. Operating results for the three months ended March&#160;31, 2022, are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022, or any future periods.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated balance sheets as of March&#160;31, 2022 and December&#160;31, 2021, and the consolidated statements of income for the three months ended March&#160;31, 2022 and 2021, include the accounts of (1) ApolloMed, ApolloMed&#8217;s consolidated subsidiaries, NMM, AMM, and APAACO, and its VIEs, AP-AMH, AP-AMH 2, Sun Labs, and DMG; (2) AP-AMH 2&#8217;s consolidated subsidiary, APCMG; (3) AMM&#8217;s consolidated VIEs, SCHC and AMH; (4) NMM&#8217;s VIE, APC; (5) APC&#8217;s consolidated subsidiaries, Universal Care Acquisition Partners, LLC (&#8220;UCAP&#8221;), MPP, AMG Properties, ZLL, and its VIEs, CDSC, APC-LSMA, ICC, and Tag 8; and (6) APC-LSMA&#8217;s consolidated subsidiaries, Alpha Care, Accountable Health Care, and AMG.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred but not reported (&#8220;IBNR&#8221;) claims), determination of full-risk and shared-risk revenue and receivables (including constraints, completion factors and historical margins), income tax-valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Interest Entities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly owned by the Company in accordance with the consolidation guidance. The evaluation considers all of the Company&#8217;s variable interests, including equity ownership, as well as management services agreements. To fall within the scope of the consolidation guidance, an entity must meet both of the following criteria:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity can be in the form of a partnership, limited liability company, or corporation, among others; and</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company has a variable interest in the legal entity &#8211; i.e., variable interests that are contractual, such as equity ownership, or other financial interests that change with changes in the fair value of the entity&#8217;s net assets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting. If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A legal entity is determined to be a VIE if it has any of the following three characteristics:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The entity does not have sufficient equity to finance its activities without additional subordinated financial support;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s) of voting rights); or</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they lack any of the following:</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entity&#8217;s economic performance, as evidenced by:</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">Substantive participating rights in day-to-day management of the entity&#8217;s activities; or</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Substantive kick-out rights over the party responsible for significant decisions;</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt">The obligation to absorb the entity&#8217;s expected losses; or</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt">The right to receive the entity&#8217;s expected residual returns.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company determines that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and evaluate it for consolidation under the variable interest model.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable interest model</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company &#8211; that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE&#8217;s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (economics). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer to Note 16 &#8211; &#8220;Variable Interest Entities (VIEs)&#8221; to the consolidated financial statements for information on the Company&#8217;s consolidated VIEs. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting.<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition-related costs separately from the business combination.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/>Reportable Segments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative healthcare models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in one reportable segment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents, and restricted cash. As of March&#160;31, 2022 and December&#160;31, 2021, the Company&#8217;s deposit accounts with banks exceeded the FDIC&#8217;s insured limit by approximately $282.4 million and $285.9 million, respectively. The Company has not experienced any losses to date and performs ongoing evaluations of these financial institutions to limit the Company&#8217;s concentration of risk exposure.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Marketable Securities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in marketable securities consist of equity securities and certificates of deposit with various financial institutions. The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit are reported at par value, plus accrued interest, with maturity dates from four months to 24 months. As of March&#160;31, 2022 and December&#160;31, 2021, certificates of deposit amounted to approximately $25.0 million and $25.0 million, respectively. Investments in certificates of deposit are classified as Level 1 investments in the fair value hierarchy.<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities are reported at fair value. These securities are classified as Level 1 in the valuation hierarchy, where quoted market prices from reputable third-party brokers are available in an active market and unadjusted. The trading volume of certain equity securities we hold is low, thus resulting in our determination that such equity securities do not have an active market with buyers and sellers ready to trade. Accordingly, we classify such equity securities as Level 2 in the valuation hierarchy, and their valuation is based on weighted average share prices from observable market data.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Equity securities held by the Company are primarily comprised of common stock of a payor partner that completed its IPO in June 2021 and Clinigence Holdings, Inc. (&#8220;Clinigence&#8221;). The common stock of a payor partner were acquired as a result of UCAP selling its 48.9% ownership interest in Universal Care, Inc. (&#8220;UCI&#8221;) in April 2020. In September 2021, ApolloMed and Clinigence entered into a stock purchase agreement in which ApolloMed purchased shares of common stock, warrants, and potentially additional common stock if certain metrics are not met (&#8220;contingent equity securities&#8221;) for $3.0&#160;million. The common stock is included in investments in marketable securities and the warrants and contingent equity securities are classified as derivatives and included in other assets and prepaid expenses and other current assets, respectively, in the accompanying consolidated balance sheets. See Note 2 &#8212; &#8220;Basis of Presentation and Summary of Significant Accounting Policies - Derivative Financial Instruments&#8221; in the accompanying consolidated financial statements for information on the treatment of the derivative instruments. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of March&#160;31, 2022 and December&#160;31, 2021, the equity securities were approximately $17.8 million and $28.4&#160;million, respectively, in the accompanying consolidated balance sheets. For the three months ended March&#160;31, 2022, the Company recognized unrealized losses of $10.6&#160;million on all equity securities in unrealized loss on investments in the accompanying consolidated statements of income.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables,  Receivables &#8211; Related Parties, and Loan Receivable - Related Party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements, incentive receivables, management fee income, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables &#8211; related parties are comprised of risk pool settlements, management fee income and incentive receivables, and other receivables. Receivables &#8211; related parties are recorded and stated at the amount expected to be collected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s loan receivable &#8211; related party consist of promissory notes from a related party payee that accrues interest per annum. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation and claims receivables relate to each health plan&#8217;s capitation and are received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#8217;s full risk pool receivable that is recorded quarterly based on reports received from the Company&#8217;s hospital partners and management&#8217;s estimate of the Company&#8217;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consist of recoverable claims paid related to the 2021 APAACO performance year to be administered following instructions from CMS for the NGACO program, receivables from GPDC capitation revenue for the 2022 performance year, fee-for-services (&#8220;FFS&#8221;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop-loss insurance premium reimbursements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (&#8220;CECL&#8221;) model. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risks</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The consolidated statements of income present disaggregated revenue by service type. The following table presents disaggregated revenue generated by payor type for the three months ended March&#160;31, 2022 and 2021 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,677&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other third parties</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,258&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,058&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payors that contributed the following percentages of net revenue:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor A</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor B</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Less than 10% of total net revenues</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payors that contributed to the following percentages of receivables and receivables &#8211; related parties:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,<br/>2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor E</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor F</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Less than 10% of total receivables and receivables &#8212; related parties, net</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements of Financial Instruments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This hierarchy prioritizes the inputs into three broad levels as follows:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#8217;s own data.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of March&#160;31, 2022, are presented below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds*</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,836&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,927&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,270&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,033&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APCMG contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Included in cash and cash equivalents</span></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of December&#160;31, 2021, are presented below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market accounts*</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APCMG contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Included in cash and cash equivalents</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in Level 1, Level 2, or Level 3 classification and no changes in valuation techniques for these assets for the three months ended March&#160;31, 2022.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Long-Lived Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives include network-payor relationships, management contracts, member relationships, subscriber relationships, and developed technology and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized using the accelerated method based on the discounted cash flow rate or using the straight-line method.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses, and are amortized using the straight-line method.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques. The Company determined that there was no impairment of its finite-lived intangible or long-lived assets during the three months ended March&#160;31, 2022 and 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Indefinite-Lived Intangible Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles &#8211; Goodwill and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, at the Company&#8217;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#8217;s three reporting units (1) management services, (2) IPAs, and (3) accountable care organizations. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#8217;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments, and assumptions management believes are appropriate in the circumstances.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had no impairment of its goodwill or indefinite-lived intangible assets during the three months ended March&#160;31, 2022 and 2021. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Other Entities &#8212; Equity Method</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#8217;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#8217;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under income (loss) from equity method investments and also is adjusted by contributions to, and distributions from, the investee. Equity method investments are subject to impairment evaluation. There was no impairment loss recorded related to equity method investments for the years ended March&#160;31, 2022 and 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Privately Held Entities </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The investments in privately held entities that do not report net asset value are subject to qualitative assessment for indicators of impairments.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical Liabilities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC, Alpha Care, Accountable Health Care, and APCMG (&#8220;consolidated IPAs&#8221;) and APAACO are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. These IPAs and APAACO provide integrated care to HMOs, Medicare, and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of income.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimated IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fiduciary Cash and Payable</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated IPAs collect cash from health plans on behalf of their sub-IPAs and providers and pass the money through to them. The fiduciary cash balance of $6.3 million and $10.5 million as of March&#160;31, 2022 and December&#160;31, 2021, respectively, is presented within prepaid expenses and other current assets and the related payable is presented as fiduciary payable in the accompanying consolidated balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Swap Agreements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to interest rate risk on its floating-rate debt. The Company has entered into interest rate swap agreements to effectively convert its floating-rate debt to a fixed-rate basis. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#8217;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. Refer to Note 9 for further information on our debt. Interest rate swap agreements are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income and reflected in the accompanying consolidated statements of cash flows as unrealized gain or loss on interest rate swaps.  </span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the interest rate swap agreements was determined using Level 2 inputs. As of March&#160;31, 2022 the fair value of the interest rate swap was $0.5 million and is presented within other assets in the accompanying consolidated balance sheets. As of December&#160;31, 2021, the fair value of the interest rate swap was $1.1&#160;million and is presented within other long-term liabilities in the accompanying consolidated balance sheets.  </span></div><div style="margin-top:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2021, ApolloMed and Clinigence entered into a stock purchase agreement in which ApolloMed purchased shares of common stock and warrants for $3.0&#160;million. The purchased warrants are considered derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income and the accompanying consolidated statements of cash flows. The warrants are classified as a Level 2 instrument as the estimated fair value of the warrants were determined using the Black-Scholes option pricing model and inputs from observable market data. As of March&#160;31, 2022 and December&#160;31, 2021, the fair value of the derivative instrument was $1.1&#160;million and $1.1&#160;million, respectively, and is presented within other assets in the accompanying consolidated balance sheets.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Contingent Equity Securities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the common stock and warrants purchased under the stock purchase agreement between ApolloMed and Clinigence, ApolloMed is entitled to additional common stock if Clinigence does not pay NMM management fees exceeding a threshold by the end of December 31, 2022. The contingent equity securities are considered derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income and the accompanying consolidated statements of cash flows. The Company determined the fair value of the contingent equity security using a probability-weighted model, which includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of recognizing management fees and assigned probabilities to each such scenario in determining fair value. As of March&#160;31, 2022 and December&#160;31, 2021, the contingent consideration was valued at $4.3&#160;million, and is presented within prepaid and other current assets in the accompanying consolidated balance sheets. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Nature of Services and Revenue Streams</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue primarily consists of capitation revenue, risk pool settlements and incentives, GPDC revenue, management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#8217;s billing arrangements and how revenue is recognized for each.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capitation, Net</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#8217; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#8220;Risk Adjustment&#8221; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PMPM managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk sharing. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#8217;s net PMPM transaction price relates specifically to the Company&#8217;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GPDC Capitation Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS contracts with Direct Contracting Entities (&#8220;DCEs&#8221;), which is composed of health care providers operating under a common legal structure and accepts financial accountability for the overall quality and cost of medical care furnished to Medicare FFS beneficiaries aligned to the entity. The combination of the FFS model and the GPDC model changes the distribution of responsibilities, risks, costs, and rewards among CMS, DCEs, and providers. By entering into a contract with CMS, a DCE voluntarily takes on operational, financial, and legal responsibilities and risks that no party has, individually or collectively, under the existing FFS model. Each DCE bears the economic costs, and reaps the economic rewards, of fulfilling its responsibilities and managing its risks as a DCE. APAACO has applied, and been accepted, to participate in the GPDC Model for Performance Year 2022, beginning January 1, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, CMS will pay a total benchmark amount, determined unilaterally by CMS in advance but subject to prospective adjustments throughout the year, for the totality of care provided to the DCE&#8217;s population of aligned beneficiaries over the course of that year. The benchmark is net of a quality withholding applied by CMS. At the end of each performance year, a portion, or all, of the quality withholding can be earned based on APAACO&#8217;s performance. GPDC capitation revenue is recognized based on the estimated transaction price to transfer the service for a distinct increment of the series (i.e. month) and is recognized net of quality incentives/penalties. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Pool Settlements and Incentives</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC enters into full-risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging, and paying for institutional risk and APC is responsible for providing, arranging and paying for professional risk. Under a full-risk pool sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#8217;s risk pools with HMOs after deductions for the affiliated hospital&#8217;s costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#8217;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for historical margin, IBNR completion factors and constraint percentages were used by management in applying the most likely amount methodology.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under capitated arrangements with certain HMOs, APC participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans&#8217; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#8217;s risk share revenue is deemed to be fully constrained until APC is notified of the amount by the health plan. Final settlement of risk pools for prior contract years generally occur in the third or fourth quarter of the following year.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to risk-sharing revenues, the Company also receives incentives under &#8220;pay-for-performance&#8221; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#8217;s incentives under &#8220;pay-for-performance&#8221; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#8217;s performance within the annual measurement period, but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NGACO AIPBP Revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the NGACO Model, CMS aligns beneficiaries to the Company to manage direct care and pay providers based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation-like AIPBP payments from CMS on a monthly basis to pay claims from in-network providers. The Company records such AIPBPs received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided, and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS, while claims from APAACO&#8217;s in-network contracted providers are paid by APAACO. The Company&#8217;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#8217;s risk share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#8217;s efficiency in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#8217;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO AIPBP revenues monthly. Excess AIPBPs over claims paid, plus an estimate for the related IBNR claims (see Note 8), are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there were any excess AIPBPs for the performance year and the excess is refunded to CMS.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company, the risk arrangement for which the Company has been approved by CMS, and as otherwise provided in an NGACO Participation Agreement between APAACO and CMS (the &#8220;Participation Agreement&#8221;). Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within 30 days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within 30 days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within 30 days after the date of a demand letter or settlement report, CMS will assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#8217;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that will likely be recognized in the future and therefore this shared risk pool revenue is considered fully constrained. With the ending of the NGACO Model on December 31, 2021, the Company no longer receives AIPBPs but remains eligible to recognize any shared savings or loss for performance year 2021 upon issuance of the settlement report from CMS. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management Fee Income</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals, and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of gross revenue or fee collections, or amounts fixed on a monthly, quarterly, or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits, or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a significant service of integrating the services selected by the Company&#8217;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#8217;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#8217;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#8217;s performance obligation is satisfied as the Company completes each period&#8217;s obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#8217;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#8217;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management contracts generally have long terms (e.g., 10 years), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fee-for-Service Revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FFS revenue represents revenue earned under contracts in which the professional component of charges for medical services rendered by the Company&#8217;s affiliated physician-owned medical groups are billed and collected from third-party payors, hospitals, and patients. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and is recognized in the period in which the services are rendered to specific patients. All services provided are </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expected to result in cash flows and are therefore reflected as net revenue in the consolidated financial statements. The recognition of net revenue (gross charges, less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#8217;s billing center for medical coding and entering into the Company&#8217;s billing system, and the verification of each patient&#8217;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company&#8217;s billing systems, as well as an estimate of the revenue associated with medical services.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#8217;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#8217;s healthcare plans, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether the patients, to whom services are provided, in the period are insured and the contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of income in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions, and healthcare coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company&#8217;s contract assets are comprised of receivables and receivables &#8211; related parties.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable aging, and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as revenues are recognized. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Liabilities (Deferred Revenue)</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities are recorded when cash payments are received in advance of the Company&#8217;s performance, or in the case of the Company&#8217;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred. The Company&#8217;s contract liability balance was $20.0 million and $16.8 million as of March&#160;31, 2022 and December&#160;31, 2021, respectively, and is presented within accounts payable and accrued expenses in the accompanying consolidated balance sheets. During the three months ended March&#160;31, 2022, $0.5 million of the Company&#8217;s contract liability accrued in 2021 has been recognized as revenue.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a stock-based compensation program for employees, non-employees, directors, and consultants. The value of share-based awards is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for forfeitures as they occur. From time to time, the Company issues shares of its common stock to its employees, directors, and consultants, which shares may be subject to the Company&#8217;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules. The fair value of options granted are determined using the Black-Scholes option pricing model and include several assumptions, including expected term, expected volatility, expected dividends, and risk-free rates. The expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The expected stock price volatility is determined based on an average of historical volatility. The expected dividend yield is based on the Company&#8217;s expected dividend payouts. The risk-free interest rate is based on the U.S. Constant Maturity curve over the expected term of the option at the time of grant.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basic and Diluted Earnings Per Share</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed by dividing net income attributable to holders of the Company&#8217;s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding, plus the effect of dilutive securities outstanding during the periods presented, using the treasury stock method. Refer to Note 15 for a discussion of shares treated as treasury shares for accounting purposes.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-controlling Interests</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Non-controlling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#8217;s consolidated entities. Net income attributable to non-controlling interests is disclosed in the consolidated statements of income.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mezzanine Equity</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to APC&#8217;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase its shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes non-controlling interests in APC as mezzanine equity in the consolidated financial statements. As of March&#160;31, 2022 and December&#160;31, 2021, APC&#8217;s shares were not redeemable, nor was it probable the shares would become redeemable.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at its inception. The expected term of the lease used for computing the lease liability and right-of-use asset and determining the classification of the lease as operating or financing may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company elected practical expedients for ongoing accounting that is provided by the new standard comprised of the following: (1) the election for classes of underlying asset to not separate non-lease components from lease components, and (2) the election for short-term lease recognition exemption for all leases under a 12-month term. The present value of the lease payments is calculated using a rate implicit in the lease, when readily determinable. However, as most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate to determine the present value of the lease payments for the majority of its leases.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2021, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;)  No. 2021-08, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (&#8220;ASU 2021-08&#8221;). This ASU requires the entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 as if it had originated the contracts. The amendments in this ASU are effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. The Company adopted ASU 2021-08 on January 1, 2022. The adoption of ASU 2021-08 did not have a material impact on the consolidated financial statements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With the exception of the new standards discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#8217;s financial position, results of operations, and cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661157705832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations and Goodwill<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combinations and Goodwill</a></td>
<td class="text">Business Combinations and Goodwill<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orma Health, Inc., and Provider Growth Solutions LLC (together, &#8220;Orma Health&#8221;)</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 27, 2022, the Company acquired 100% of the capital stock of Orma Health, Inc., and Provider Growth Solutions, LLC (together, &#8220;Orma Health&#8221;) for $1.0 million in cash and $1.0 million in the Company&#8217;s capital stock. Orma Health&#8217;s real-time Clinical AI platform ingests data from multiple sources and utilizes advanced risk-stratification models to identify patients for various clinical programs, including remote patient monitoring (&#8220;RPM&#8221;), mental health support, chronic disease management, and more. Its clinical platform is also deeply integrated with Orma Health&#8217;s proprietary RPM ecosystem, which consists of smart health devices and a suite of technology tools to help manage patients&#8217; health.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">APCMG</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company acquired an 80% equity interest (on a fully diluted basis) in APCMG for an aggregate purchase price of $2.0 million. As part of the transaction, the Company paid $1.0 million in cash and the remaining amount will be paid out in cash as a contingent consideration related to APCMG&#8217;s financial performance for fiscal year 2022 (&#8220;APCMG contingent consideration&#8221;). The APCMG contingent consideration is met if gross revenue and earnings before interest, taxes, and depreciation, and amortization (&#8220;EBITDA&#8221;) targets exceed a threshold for fiscal year 2022. The Company determined the fair value of the contingent consideration using a probability-weighted model that includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of gross revenue and EBITDA and assigned probabilities to each such scenario in determining fair value. As of March&#160;31, 2022, the contingent consideration is valued at $1.0 million and was included within other long-term liabilities in the accompanying consolidated balance sheets.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sun Labs</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company acquired 49% of the aggregate issued and outstanding shares of capital stock of Sun Labs for an aggregate purchase price of $4.0 million. As Sun Labs was concluded to be a VIE and the Company is the primary beneficiary, Sun Labs is consolidated by the Company. The Company is obligated to purchase the remaining equity interest within three years from the effective date. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets. The Company recognized goodwill as a result of consolidating Sun Labs as a VIE. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DMG</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, DMG entered into an administrative services agreement with a subsidiary of the Company, causing the Company to reevaluate the accounting for the Company&#8217;s investment in DMG. Based on the reevaluation and in accordance with relevant accounting guidance, DMG is determined to be a VIE and the Company is the primary beneficiary; DMG is consolidated by Apollo.  In addition, APC-LSMA is obligated to purchase the remaining equity interest within three years from the effective date. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets. The Company recognized goodwill as a result of consolidating DMG as a VIE. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisitions were accounted for under the acquisition method of accounting. The fair value of the consideration for the acquired companies were allocated to acquired tangible and intangible assets and liabilities based upon their fair values. The excess of the purchase consideration over the fair value of the net tangible and identifiable intangible assets acquired was recorded as goodwill. The determination of the fair value of assets and liabilities acquired requires the Company to make estimates and use valuation techniques when market value is not readily available. The results of operations from the acquisitions have been included in the Company&#8217;s financial statements from the date of acquisition. Transaction costs associated with business acquisitions are expensed as they are incurred.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time of acquisition, the Company estimates the amount of the identifiable intangible assets based on a valuation and the facts and circumstances available at the time. The Company determines the final value of the identifiable intangible assets as soon as information is available, but not more than one year from the date of acquisition.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not deductible for tax purposes.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying value of goodwill for the three months ended March&#160;31, 2022 was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,746)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,379&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661157696072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets, Net</a></td>
<td class="text">Intangible Assets, Net<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:46.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net March 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Network relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-21</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87,618)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,998)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Member relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,976)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient management platform</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,777)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade names/trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subscriber relationships </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developed technology </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,736&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108,588)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,148&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare license</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Network relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,865)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,563)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,606)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient management platform</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,682)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tradename/trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,729&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104,922)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,807&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in depreciation and amortization on the accompanying consolidated statements of income is amortization expense of $3.7 million and $3.8 million for the three months ended March&#160;31, 2022 and 2021. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the three months ended March 31, 2022)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,558&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,998&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661157717528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock', window );">Investments in Other Entities</a></td>
<td class="text">Investments in Other Entities<div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Equity Method</span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in other entities &#8211; equity method consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:38.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.886%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allocation of Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Funding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Distribution </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LaSalle Medical Associates &#8211; IPA Line of Business</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,034&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,292&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pacific Medical Imaging &amp; Oncology Center, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531 W. College, LLC &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,048&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One MSO, LLC &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tag-6 Medical Investment Group, LLC &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAIPA MSO, LLC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,715&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,433&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,383&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LaSalle Medical Associates &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPA Line of Business</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMA was founded by Dr. Albert Arteaga in 1996 and operates as an IPA delivering high-quality care. In September 2021, APC-LSMA sold 21.25% of its interest in LMA back to Dr. Arteaga for $6.4 million, which resulted in  APC-LSMA owning a 25% interest in LMA as of March&#160;31, 2022. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC accounts for its investment in LMA under the equity method as APC has the ability to exercise significant influence, but not control over LMA&#8217;s operations. For the three months ended March&#160;31, 2022 and 2021, APC recognized income from this investment of $1.3 million and a loss of $0.7 million, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $4.3 million and $3.0 million at March&#160;31, 2022 and December&#160;31, 2021, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMA&#8217;s summarized balance sheets at March&#160;31, 2022 and December&#160;31, 2021, and summarized statements of income for the three months ended March&#160;31, 2022 and 2021, with respect to its IPA line of business are as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Balance Sheets</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loan receivable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liabilities and Stockholders&#8217; Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; deficit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,790)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,571)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; deficit</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,740&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,834&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Statements of Operations</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,780&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,552)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><br/>Pacific Medical Imaging and Oncology Center, Inc.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC-LSMA and PMIOC entered into a share purchase agreement whereby APC-LSMA purchased a 40% ownership interest in PMIOC. Incorporated in California in 2004, PMIOC provides comprehensive diagnostic imaging services using state-of-the-art technology. PMIOC offers high-quality diagnostic services, such as MRI/MRA, PET/CT, CT, nuclear medicine, ultrasound, digital x-rays, bone densitometry, and digital mammography, at its facilities.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC and PMIOC have an Ancillary Service Contract together whereby PMIOC provides covered services on behalf of APC to enrollees of the plans of APC. Under the Ancillary Service Contract, APC paid PMIOC fees of approximately $0.7 million and $0.5 million, for the three months ended March&#160;31, 2022 and 2021, respectively. APC accounts for its investment in PMIOC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over PMIOC&#8217;s operations. For the three months ended March&#160;31, 2022 and 2021, APC recognized income from this investment of approximately $6,700 and a loss from this investment of $15,000, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets had investment balances of $1.7 million and $1.7 million at March&#160;31, 2022 and December&#160;31, 2021, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">531 W. College LLC &#8211; Related Party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC has a 50% ownership in 531 W. College LLC and accounts for its investment in 531 W. College, LLC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over the operations of this joint venture. 531 W. College, LLC owns a former hospital campus in Los Angeles that is now leased to tenants.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2022 and 2021, APC recognized a loss from this investment of $0.2 million and $0.1 million, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $17.0 million and $17.2 million at March&#160;31, 2022 and December&#160;31, 2021, respectively. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">One MSO, LLC </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Related Party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC has a 50% interest in One MSO. One MSO owns an office building in Monterey Park, California that is leased to tenants, including NMM. For the three months ended March&#160;31, 2022 and 2021, APC recognized income of $0.1 million and $0.1&#160;million in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $2.8 million and $2.9&#160;million at March&#160;31, 2022 and December&#160;31, 2021, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tag-6 Medical Investment Group, LLC  &#8212; Related Party</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC has a 50% interest in Tag 6. Tag 6 leases its building to tenants and shares common ownership with certain board members of APC and as such is considered a related party. For the three months ended March&#160;31, 2022, APC recognized income of $66,000 in the accompanying consolidated statements of income. APC did not recognize any income during the three months ended March&#160;31, 2021.  The accompanying consolidated balance sheets include the Tag 6 investment of $6.3 million and $4.8&#160;million at March&#160;31, 2022 and December&#160;31, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CAIPA MSO, LLC</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, ApolloMed purchased 30% interests in CAIPA MSO, LLC for $11.7 million. CAIPA MSO is a New York-based management services organization affiliated with Chinese-American IPA d/b/a Coalition of Asian-American IPA (&#8220;CAIPA&#8221;), a leading independent practice association serving the greater New York City area. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ApolloMed accounts for its investment in CAIPA MSO under the equity method of accounting as ApolloMed has the ability to exercise significant influence, but not control over CAIPA MSO&#8217;s operations. For the three months ended March&#160;31, 2022 and 2021, ApolloMed recognized income from investment of $0.1 million and $0, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $12.1 million and $12.0&#160;million as of March&#160;31, 2022 and December&#160;31, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in privately held entities that do not report net asset value</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MediPortal, LLC</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, APC purchased 270,000 membership interests of MediPortal LLC, a New York limited liability company, for $0.4 million or $1.50 per membership interest, which represented an approximately 2.8% ownership interest. In connection with the initial purchase, APC received a five-year warrant to purchase an additional 270,000 membership interests. A five-year option to purchase an additional 380,000 membership interests and a five-year warrant to purchase 480,000 membership interests were contingent upon the portal completion date. However, APC did not exercise the option after completion of the portal. As APC does not have the ability to exercise significant influence, and lacks control over the investee, this investment is accounted for using a measurement alternative, which allows the investment to be measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AchievaMed</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, NMM and AchievaMed, Inc., a California corporation (&#8220;AchievaMed&#8221;), entered into an agreement in which NMM would purchase 50% of the aggregate shares of capital stock of AchievaMed over a period of time not to exceed five years. As a result of this transaction NMM invested $0.5 million for a 10% interest. The related investment balance of $0.5 million is included in investments in privately held entities in the accompanying consolidated balance sheets as of March&#160;31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method And Other Equity Investments [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodAndOtherEquityInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661157539576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan Receivable and Loan Receivable &#8211; Related Parties<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LoanReceivableTextBlock', window );">Loan Receivable and Loan Receivable &#8211; Related Parties</a></td>
<td class="text">Loan Receivable and Loan Receivable &#8211; Related Parties<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loan receivable</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pacific6</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, NMM received a promissory note from Pacific6 totaling $0.5&#160;million as a result of the sale of the Company&#8217;s interest in MWN. Interest accrues at a rate of 5% per annum and is payable monthly through the maturity date of December 1, 2023.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loan receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> related party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AHMC</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, APC entered into a promissory note with AHMC (the &#8220;AHMC Note&#8221;) for a principal amount of $4.0&#160;million with a maturity date of April 2022. The contractual interest rate on the AHMC Note is 3.75% per annum. The AHMC Note was entered into using cash strictly related to the Excluded Assets that were generated from the series of transactions with AP-AMH. As of March&#160;31, 2022, the total principal of $4.0&#160;million remains outstanding. One of the Company&#8217;s board members is an officer of AHMC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the outstanding loan receivable under the CECL model by assessing the party&#8217;s ability to pay by reviewing their interest payment history quarterly, financial history annually, and reassessing any insolvency risk that is identified. If a failure to pay occurs, the Company assesses the terms of the notes and estimates an expected credit loss based on the remittance schedule of the note.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LoanReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LoanReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661157992696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="text">Accounts Payable and Accrued Expenses<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts payable and accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,868&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,583&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subcontractor IPA payable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,918&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to related parties</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,252&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,951&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661157517400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock', window );">Medical Liabilities</a></td>
<td class="text">Medical Liabilities<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s medical liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,783&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,018)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,360&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,311&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,120)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,713)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,035)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,344)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114,155)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81,057)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,758&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,479&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=2560295<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661157522344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility, Bank Loans, and Lines of Credit<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Credit Facility, Bank Loans, and Lines of Credit</a></td>
<td class="text">Credit Facility, Bank Loans, and Lines of Credit<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s debt balance consists of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolver Loan</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real Estate Loans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,635&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,965&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,503)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(780)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,031)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,268)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,101&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,917&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our long-term debt was determined using Level 2 inputs primarily related to comparable market prices. As of March&#160;31, 2022 and December&#160;31, 2021, the carrying value was not materially different from fair value, as the interest rates on the Company&#8217;s debt approximated rates currently available to the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the future commitments of the Company&#8217;s debt for the years ending </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.836%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the three months ended March 31, 2022) </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,450&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,635&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amended Credit Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2021, the Company entered into an amended and restated credit agreement (the &#8220;Amended Credit Agreement&#8221; and the credit facility thereunder, the &#8220;Amended Credit Facility&#8221;) with Truist Bank, in its capacity as administrative agent for the lenders, issuing bank, swingline lender and lender, Truist Securities, Inc., JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Preferred Bank, Royal Bank of Canada, and Fifth Third Bank, National Association, in their capacities as joint lead arrangers and/or lenders, and the lenders from time to time party thereto, to, among other things, amend and restate that certain credit agreement, dated September 11, 2019, by and among the Company, Truist Bank, and certain lenders thereto (the credit facility thereunder, the &#8220;Credit Facility&#8221;), in its entirety. The Amended Credit Agreement provides for a five-year revolving credit facility to the Company of $400.0 million, which includes a letter of credit sub-facility of up to $25.0 million and a swingline loan sub-facility of $25.0 million. The revolving credit facility will be used to, among other things, refinance certain existing indebtedness of the Company and certain subsidiaries, finance certain future acquisitions and investments, and provide for working capital needs and other general corporate purposes. Under the Amended Credit Agreement, the terms and conditions of the Guaranty and Security Agreement (the &#8220;Guaranty and Security Agreement&#8221;) between the Company, NMM and Truist Bank remain in effect.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to pay an annual agent fee of $50,000 and an annual facility fee of 0.175% to 0.350% on the available commitments under the Amended Credit Agreement, regardless of usage, with the applicable fee determined on a quarterly basis based on the Company&#8217;s leverage ratio. The Company will pay fees for standby letters of credit at an annual rate equal to 1.25% to 2.50%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, plus facing fees and standard fees payable to the issuing bank on the respective letter of credit. The Company is also required to pay customary fees between the Company and Truist Bank, the lead arranger of the Amended Credit Agreement.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, amounts borrowed under the Amended Credit Agreement bear interest at an annual rate equal to either, at the Company&#8217;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on LIBOR, adjusted for any reserve requirement in effect, plus a spread of from 1.25% to 2.50%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, or (b) a base rate, plus a spread of 0.25% to 1.50%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio.  As of March&#160;31, 2022, the interest rate on the Credit Agreement was 2.38%. Borrowings under the Amended Credit Agreement may be prepaid at any time without penalty. If LIBOR ceases to be reported under the Amended Credit Agreement, the Company will use the secured overnight financing rate or the Company and the Agent will agree to an alternative rate of interest. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement requires the Company to comply with two key financial ratios, each calculated on a consolidated basis. The Company must maintain a maximum consolidated total net leverage ratio of not greater than 3.75 to 1.00 as of the last day of each fiscal quarter, provided that for any fiscal quarter during which the Company or certain subsidiaries consummate a permitted acquisition or investment, the aggregate purchase price is greater than $75.0&#160;million, the maximum consolidated total net leverage ratio may temporarily increase by 0.25 to 1.00 to 4.00 to 1.00. The Company must maintain a minimum consolidated interest coverage ratio of not less than 3.25 to 1.00 as of the last day of each fiscal quarter. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Guaranty and Security Agreement, the Company and NMM have granted the lenders under the Amended Credit Agreement a security interest in all of their assets, including, without limitation, all stock and other equity issued by their subsidiaries (including NMM) and all rights with respect to the AP-AMH Loan. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, certain of the lenders under the Amended Credit Agreement and their affiliates have provided to the Company and its subsidiaries and the associated practices, and may in the future provide, (i) investment banking, commercial banking, cash management, foreign exchange, or other financial services, and (ii) services as a bond trustee and other trust and fiduciary services, for which they have received compensation and may receive compensation in the future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Financing Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company recorded deferred financing costs of $6.5 million related to its entry into the Credit Facility. In June 2021, the Company recorded additional deferred financing costs of $0.7&#160;million related to its entry into the Amended Credit Facility. Deferred financing costs are recorded as a direct reduction of the carrying amount of the related debt liability using straight-line amortization. The remaining unamortized deferred financing costs related to the Credit Facility and the new costs related to the Amended Credit Facility are amortized over the life of the Amended Credit Facility. At March&#160;31, 2022 and December&#160;31, 2021, the unamortized deferred financing cost was $4.0&#160;million and $4.3&#160;million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Real Estate Loans</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, using cash comprised solely of Excluded Assets, APC purchased a 100% interest in MPP, AMG Properties, and ZLL. As a result of this purchase, APC assumed the existing loans held by MPP, AMG Properties, and ZLL. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MPP</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 3, 2020, MPP entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2021, the principal on the loan was $6.1&#160;million with a variable interest rate of 0.50% less than the independent index, which is the daily Wall Street Journal &#8220;Prime Rate.&#8221; If the index is not available, East West Bank may designate a substitute index after notifying MPP. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of March&#160;31, 2022, the balance outstanding was $6.1 million. MPP must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1. <br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AMG Properties</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2020, AMG Properties entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2021, the principal on the loan was $0.7&#160;million with a variable interest rate of 0.30% less than the independent index, which is the daily Wall Street Journal &#8220;Prime Rate.&#8221; If the index is not available, East West Bank may designate a substitute index after notifying AMG Properties. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of March&#160;31, 2022, the balance outstanding was $0.7 million. AMG Properties must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ZLL</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2020, ZLL entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2021, the principal on the loan was $0.6&#160;million with a variable interest rate of 0.50% less than the independent index, which is the daily Wall Street Journal &#8220;Prime Rate.&#8221; If the index is not available, East West Bank may designate a substitute index after notifying ZLL. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of March&#160;31, 2022, the balance outstanding was $0.6 million. ZLL must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Construction Loan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, Tag 8 entered into a construction loan agreement with MUFG Union Bank N.A. (&#8220;Construction Loan&#8221;). Tag 8 is a VIE consolidated by the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Construction Loan allows Tag 8 to borrow up to $10.7 million with a maturity date of December 1, 2022 (&#8220;Construction Loan Term&#8221;). Interest rate is equal to an index rate determined by the bank. Monthly interest payments began on May 1, 2021, or can become part of the principal and bear interest. If construction is completed and, there are no events of default or substantial deterioration in the financial condition of Tag 8 or APC, guarantor on the loan agreement, at the maturity date of the Construction Loan Term, the loan shall convert to an amortizing loan with an extended maturity date of December 1, 2032 (&#8220;Permanent Loan Term&#8221;). Upon conversion to the Permanent Loan Term, monthly principal and interest payments shall be made beginning January 1, 2023. From January 1, 2023 until December 1, 2023, the interest rate will be 2.0% per annum in excess of the LIBOR rate. As of March&#160;31, 2022, the likelihood of the construction being completed by the maturity date was remote. The outstanding balance as of March&#160;31, 2022 was $1.3 million and was recorded as a current portion of long-term debt in the accompanying consolidated balance sheets. Once the loan converts to the Permanent Loan Term, APC, as Tag 8&#8217;s guarantor, must maintain a Cash Flow Coverage Ratio (defined as consolidated EBITDA minus unfinanced capital expenditures and distributions paid divided by the sum of current portion of long-term debt, plus interest expense) of not less than 1.25 to 1. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effective Interest Rate</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s average effective interest rate on its total debt during the three months ended March&#160;31, 2022 and 2021, was 1.78% and 2.08%, respectively. Interest expense in the consolidated statements of income included amortization of deferred debt issuance costs for the three months ended March&#160;31, 2022 and 2021, of $0.2 million and $0.3 million, respectively.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lines of Credit</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">APC Business Loan</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;10, 2019, the APC Business Loan Agreement with Preferred Bank (the &#8220;APC Business Loan Agreement&#8221;) was amended to decrease loan availability to $4.1 million. This decrease further limited the purpose of the indebtedness under APC Business Loan Agreement to the issuance of standby letters of credit, and added as a permitted lien the security interest in all of its assets granted by APC in favor of NMM under a Security Agreement dated on or about September 11, 2019, securing APC&#8217;s obligations to NMM under, and as required pursuant to, the APC management services agreement dated as of July 1, 1999, as amended.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standby Letters of Credit</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $0.3 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alpha Care established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $3.8 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661157589160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mezzanine and Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Mezzanine and Stockholders' Equity</a></td>
<td class="text">Mezzanine and Stockholders&#8217; Equity<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mezzanine</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the redemption feature of the APC shares (see Note 2) is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as non-controlling interest in APC as mezzanine or temporary equity. APC&#8217;s shares were not redeemable, and it was not probable that the shares would become redeemable, as of March&#160;31, 2022 and December&#160;31, 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholders&#8217; Equity</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, 140,954 holdback shares have not been issued to certain former NMM shareholders who were NMM shareholders at the time of closing of the 2017 Merger, as they have yet to submit properly completed letters of transmittal to ApolloMed in order to receive their pro rata portion of ApolloMed common stock and warrants as contemplated under the 2017 merger agreement. Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the 2017 Merger. The consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares in connection with the 2017 Merger.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/>Treasury Stock</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC owned 10,925,702 shares of ApolloMed&#8217;s common stock as of March&#160;31, 2022 and December&#160;31, 2021, which are legally issued and outstanding but excluded from shares of common stock outstanding in the consolidated financial statements, as such shares are treated as treasury shares for accounting purposes. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div>During the three months ended March&#160;31, 2022 and 2021, CDSC paid dividends of $1.5 million and $0, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661159298216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Based Compensation</a></td>
<td class="text">Stock-Based CompensationThe following table summarizes the stock-based compensation expense recognized under all of the Company&#8217;s stock plans for the three months ended March&#160;31, 2022 and 2021, and associated with the issuance of restricted shares of common stock and vesting of stock options, which are included in general and administrative expenses in the accompanying consolidated statements of income (in thousands):<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.753%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.183%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,055&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,346&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized compensation expense related to total share-based payments outstanding as of March&#160;31, 2022, was $21.6 million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Options</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding stock options consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.917%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding at January&#160;1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813,965&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.94</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591,725&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.33&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.79</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, options were exercised for 38,500 shares of the Company&#8217;s common stock, resulting in proceeds of $0.7&#160;million. During the three months ended March&#160;31, 2021, no stock options were exercised.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, the Company granted 75,271 stock options to certain ApolloMed employees and Board members. The options granted during the three months ended March&#160;31, 2022 were recognized at fair value, as determined using the Black-Scholes option pricing model as follows: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.637%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00 years - 2.25 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.47% - 75.15%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.02% - 1.06%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market value of common stock</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$20.23 - $22.73</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annual dividend yield</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeiture rate</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants restricted stock to officers and employees which are earned based on service conditions. The grant date fair value of the restricted stock is that day&#8217;s closing market price of the Company&#8217;s common stock. During the three months ended March&#160;31, 2022, the Company granted restricted stock totaling 76,828 shares, including 49,124 restricted stock with performance conditions, with a weighted average grant date fair value of $50.76. Restricted stock with performance conditions are recognized to the extent the performance conditions are probable of being achieved. The grant date fair value of restricted stock and restricted stock with performance conditions that are probable of being achieved were $3.9&#160;million and will be recognized on a straight-line basis over the awards&#8217; vesting period. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding warrants consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants outstanding at January&#160;1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.94</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86,235)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants expired/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915,505&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.69</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise&#160;Price&#160;Per Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants<br/>Outstanding</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual&#160;Life</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercisable</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise&#160;Price</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Per Share</span></div></td></tr><tr><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470,827</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.69</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444,678</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.69</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$                  10.00 &#8211; 11.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915,505&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.69</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915,505&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>During the three months ended March&#160;31, 2022 and 2021, common stock warrants were exercised for 86,235 and 421,002 shares of the Company&#8217;s common stock, respectively, which resulted in proceeds of approximately $0.9&#160;million and $4.3 million, respectively. The exercise price ranged from $10.00 to $11.00 per share for the exercises during the three months ended March&#160;31, 2022, and $9.00 to $11.00 per share for the exercises during the three months ended March&#160;31, 2021, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661157636440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Matters</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws and regulations governing the Medicare program and healthcare generally are complex and subject to interpretation. The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. While no regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and exclusion from the Medicare and Medi-Cal programs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As risk-bearing organizations, APC, Alpha Care, and Accountable Health Care are required to comply with the California Department of Managed Healthcare (&#8220;DMHC&#8221;) regulations, including maintenance of minimum working capital, tangible net equity (&#8220;TNE&#8221;), cash-to-claims ratio, and claims payment requirements prescribed by the DMHC. TNE is defined as net equity less intangibles, less non-allowable assets (which include unsecured amounts due from affiliates), plus subordinated obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the payor and provider contracts with the Company&#8217;s affiliated physician-owned medical groups are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services. Such differing interpretations may not come to light until a substantial period of time has passed following contract implementation. Liabilities for claims disputes are recorded when the loss is probable and can be estimated. Any adjustments to reserves are reflected in current operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standby Letters of Credit</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC and Alpha Care established irrevocable standby letters of credit with a Preferred Bank for a total of $0.3 million and $3.8&#160;million, respectively, for the benefit of certain health plans (see Note 9). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of its business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company&#8217;s financial condition, cash flows, or results of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability Insurance</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its insurance coverage is appropriate based upon the Company&#8217;s claims experience and the nature and risks of the Company&#8217;s business. In addition to the known incidents that have resulted in the assertion of claims, the Company cannot be certain that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against the Company, the Company&#8217;s affiliated professional organizations or the Company&#8217;s affiliated hospitalists in the future where the outcomes of such claims are unfavorable. The Company believes that the ultimate resolution of all pending claims, including liabilities in excess of the Company&#8217;s insurance coverage, will not have a material adverse effect on the Company&#8217;s financial position, results of operations, or cash flows; however, there can be no assurance that future claims will not have such a material adverse effect on the Company&#8217;s business. Contracted physicians are required to obtain their own insurance coverage.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company currently maintains liability insurance policies on a claims-made basis, which are intended to cover malpractice liability and certain other claims, the coverage must be renewed annually, and may&#160;not continue to be available to the Company in future years at acceptable costs, and on favorable terms.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661157716408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Transactions</a></td>
<td class="text">Related-Party Transactions<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022 and 2021, NMM earned approximately $6.3 million and $4.5 million, respectively, in management fees from LMA, which is accounted for under the equity method based on the 25% equity ownership interest held by APC in LMA&#8217;s IPA line of business (see Note 5 &#8212; &#8220;Investments in Other Entities &#8212; Equity Method&#8221;).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022 and 2021, APC paid approximately $0.7 million and $0.5 million, respectively, to PMIOC for provider services, which is accounted for under the equity method based on the 40% equity ownership interest held by APC (see Note 5 &#8212; &#8220;Investments in Other Entities &#8212; Equity Method&#8221;).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022 and 2021, APC paid approximately $0 and $1.6 million, respectively, to DMG for provider services, which is accounted for under the equity method based on the 40% equity ownership interest held by APC. In October 2021,  DMG was consolidated by Apollo. As such, DMG is no longer a related party.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022 and 2021, APC paid approximately $39,000 and $22,000, respectively, to Advanced Diagnostic Surgery Center for services as a provider. Advanced Diagnostic Surgery Center shares common ownership with certain board members of APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022 and 2021, APC paid approximately $5,800 and $33,000, respectively, to Fresenius Medical Care (&#8220;Fresenius&#8221;) and its subsidiaries for services as a provider. During the three months ended March&#160;31, 2022 and 2021, APAACO paid approximately $0.1 million and $0.2 million, respectively, to Fresenius and its subsidiaries for services as a provider. One of the Company&#8217;s board members is an officer of Fresenius and its subsidiaries. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022 and 2021, APC paid approximately $0.1 million and $21,000, respectively, to Fulgent Genetics, Inc. for services as a provider. One of the Company&#8217;s board members is a board member of Fulgent Genetics, Inc.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022 and 2021, APC paid an aggregate of approximately $9.3 million and $7.4 million to shareholders, respectively, which included approximately $1.9 million and $1.7 million, respectively, to shareholders who are also officers of APC. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2022 and 2021, SCHC paid approximately $0.1 million and $0.1 million, respectively, to Numen, LLC (&#8220;Numen&#8221;) for an office lease. Numen is owned by a shareholder of APC. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022 and 2021, NMM paid approximately $0.4 million and $0.4 million, respectively, to One MSO for an office lease, which is accounted for under the equity method based on 50% equity ownership interest held by APC (see Note 5 &#8212; &#8220;Investments in Other Entities &#8212; Equity Method&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022 and 2021, APC paid approximately $3.5 million and $0, respectively, to Arroyo Vista Family Health Center (&#8220;Arroyo Vista&#8221;) for services as a provider. The CEO of Arroyo Vista became a board member with the Company in 2021. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with Health Source MSO Inc., a California corporation (&#8220;HSMSO&#8221;), Aurion Corporation (&#8220;Aurion&#8221;), and AHMC Healthcare Inc. (&#8220;AHMC&#8221;) for services provided to the Company. One of the Company&#8217;s board members is an officer of AHMC, HSMSO, and Aurion. Aurion is also partially owned by one of the Company&#8217;s board members. The following table sets forth fees incurred and income received related to AHMC, HSMSO, and Aurion (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.508%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.305%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AHMC &#8211; Risk pool, capitation, claims payment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,366&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,097&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HSMSO &#8211; Management fees, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aurion &#8211; Management fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receipts, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,211&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,945&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and AHMC have a risk-sharing agreement with certain AHMC hospitals to share the surplus and deficits of each of the hospital pools. During the three months ended March&#160;31, 2022 and 2021, the Company has recognized risk pool revenue under this agreement of $12.0 million and $16.9 million, respectively, of which $66.0 million and $58.4 million remained outstanding as of March&#160;31, 2022 and December&#160;31, 2021, respectively.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022 and 2021, NMM paid approximately $0 and $44,000, respectively, to an ApolloMed board member for consulting services. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, affiliates wholly owned by the Company&#8217;s officers, including Dr. Thomas Lam, ApolloMed&#8217;s Co-CEO and President, are reported in the accompanying consolidated statements of income on a consolidated basis, together with the Company&#8217;s subsidiaries, and therefore, the Company does not separately disclose transactions between such affiliates and the Company&#8217;s subsidiaries as related-party transactions.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For equity method investments and loans receivable from related parties, see Notes 5 and 6, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661157549256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the liability method of accounting for income taxes as set forth in ASC 740</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under the liability method, deferred taxes are determined based on differences between the financial statement and tax bases of assets and liabilities using enacted tax rates.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an interim basis, the Company estimates what its anticipated annual effective tax rate will be and records a quarterly income tax provision in accordance with the estimated annual rate, plus the tax effect of certain discrete items that arise during the quarter. As the fiscal year progresses, the Company refines its estimates based on actual events and financial results during the quarter. This process can result in significant changes to the Company&#8217;s estimated effective tax rate. When this occurs, the income tax provision is adjusted during the quarter in which the estimates are refined so that the year-to-date provision reflects the estimated annual effective tax rate. These changes, along with adjustments to the Company&#8217;s deferred taxes and related valuation allowance, may create fluctuations in the overall effective tax rate from quarter to quarter.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, due to the overall cumulative losses incurred in recent years, the Company maintained a full valuation allowance against its deferred tax assets related to loss entities the Company cannot consolidate under the federal tax consolidation rules, as realization of these assets is uncertain.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective income tax rate for the three months ended March&#160;31, 2022 and March&#160;31, 2021, was 34.0% and 31.9%, respectively. The tax rate for the three months ended March&#160;31, 2022, differed from the U.S. federal statutory rate primarily due to state income taxes, income from flow through entities, non-deductible permanent items, and change in valuation allowance.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company does not have any unrecognized tax benefits related to various federal and state income tax matters. The Company will recognize accrued interest and penalties related to unrecognized tax benefits in income tax expense.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal income tax as well as income tax in California. The Company and its subsidiaries&#8217; state and federal income tax returns are open to audit under the statute of limitations for the years ended December 31, 2017 through December&#160;31, 2021, and for the years ended December 31, 2018 through December&#160;31, 2021, respectively. The Company does not anticipate material changes to the unrecognized tax benefits within the next 12 months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661157554360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings Per Share<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is calculated using the weighted average number of shares of the Company&#8217;s common stock issued and outstanding during a certain period, and is calculated by dividing net income attributable to ApolloMed by the weighted average number of shares of the Company&#8217;s common stock issued and outstanding during such period. Diluted earnings per share is calculated using the weighted average number of shares of common stock and potentially dilutive shares of common stock outstanding during the period, using the as-if converted method for secured convertible notes, preferred stock, and the treasury stock method for options and common stock warrants.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 and December&#160;31, 2021, APC held 10,925,702 shares of ApolloMed&#8217;s common stock, which are treated as treasury shares for accounting purposes and not included in the number of shares of common stock outstanding used to calculate earnings per share.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the earnings per share computations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,681,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,336,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,994,868&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,566,189&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the shares included in the diluted earnings per share computations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,681,218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,336,434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">811,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,994,868&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,566,189&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661157611000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities (VIEs)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Variable Interest Entities (VIEs)</a></td>
<td class="text">Variable Interest Entities (VIEs)A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity&#8217;s economic performance and the obligation to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE.<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows guidance on the consolidation of VIEs that requires companies to utilize a qualitative approach to determine whether it is the primary beneficiary of a VIE. See Note 2 &#8211; &#8220;Basis of Presentation and Summary of Significant Accounting Policies - Variable Interest Entities&#8221; to the accompanying consolidated financial statements for information on how the Company determines VIEs and their treatment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care, and to which the creditors of ApolloMed have no recourse, and liabilities to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the general credit of ApolloMed, as the primary beneficiary of the VIEs. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands). The assets and liabilities of the Company&#8217;s other consolidated VIEs were not considered significant. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount due from affiliate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,567&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,766&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property, and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,656&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans receivable &#8211; related parties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in other entities &#8211; equity method</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in privately held entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total assets</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,140,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiduciary accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion and deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,963&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,674&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661160360728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating and finance leases for corporate offices, physicians&#8217; offices, and certain equipment. These leases have remaining lease terms of four months to eight years, some of which may include options to extend the leases for up to 10 years, and some of which may include options to terminate the leases within one year. As of March&#160;31, 2022 and December&#160;31, 2021, assets recorded under finance leases were $1.5 million and $1.3 million, respectively, and accumulated depreciation associated with finance leases were $0.7 million and $0.6 million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.551%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.09 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.68 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.31 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.42 years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of March&#160;31, 2022, is as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the three months ended March&#160;31, 2022)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,645&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,183&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,558&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company does not have additional operating and finance leases that have not yet commenced.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating and finance leases for corporate offices, physicians&#8217; offices, and certain equipment. These leases have remaining lease terms of four months to eight years, some of which may include options to extend the leases for up to 10 years, and some of which may include options to terminate the leases within one year. As of March&#160;31, 2022 and December&#160;31, 2021, assets recorded under finance leases were $1.5 million and $1.3 million, respectively, and accumulated depreciation associated with finance leases were $0.7 million and $0.6 million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.551%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.09 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.68 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.31 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.42 years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of March&#160;31, 2022, is as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the three months ended March&#160;31, 2022)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,645&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,183&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,558&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company does not have additional operating and finance leases that have not yet commenced.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661154136472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of PresentationThe accompanying consolidated balance sheets at December&#160;31, 2021, have been derived from the Company&#8217;s audited consolidated financial statements, but do not include all annual disclosures required by generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). The accompanying unaudited consolidated financial statements as of March&#160;31, 2022, and for the three months ended March&#160;31, 2022 and 2021, have been prepared in accordance with U.S. GAAP for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, these unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC on February&#160;28, 2022. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made to make the consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated balance sheets as of March&#160;31, 2022 and December&#160;31, 2021, and the consolidated statements of income for the three months ended March&#160;31, 2022 and 2021, include the accounts of (1) ApolloMed, ApolloMed&#8217;s consolidated subsidiaries, NMM, AMM, and APAACO, and its VIEs, AP-AMH, AP-AMH 2, Sun Labs, and DMG; (2) AP-AMH 2&#8217;s consolidated subsidiary, APCMG; (3) AMM&#8217;s consolidated VIEs, SCHC and AMH; (4) NMM&#8217;s VIE, APC; (5) APC&#8217;s consolidated subsidiaries, Universal Care Acquisition Partners, LLC (&#8220;UCAP&#8221;), MPP, AMG Properties, ZLL, and its VIEs, CDSC, APC-LSMA, ICC, and Tag 8; and (6) APC-LSMA&#8217;s consolidated subsidiaries, Alpha Care, Accountable Health Care, and AMG.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred but not reported (&#8220;IBNR&#8221;) claims), determination of full-risk and shared-risk revenue and receivables (including constraints, completion factors and historical margins), income tax-valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entities</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Interest Entities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly owned by the Company in accordance with the consolidation guidance. The evaluation considers all of the Company&#8217;s variable interests, including equity ownership, as well as management services agreements. To fall within the scope of the consolidation guidance, an entity must meet both of the following criteria:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity can be in the form of a partnership, limited liability company, or corporation, among others; and</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company has a variable interest in the legal entity &#8211; i.e., variable interests that are contractual, such as equity ownership, or other financial interests that change with changes in the fair value of the entity&#8217;s net assets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting. If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A legal entity is determined to be a VIE if it has any of the following three characteristics:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The entity does not have sufficient equity to finance its activities without additional subordinated financial support;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s) of voting rights); or</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they lack any of the following:</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entity&#8217;s economic performance, as evidenced by:</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">Substantive participating rights in day-to-day management of the entity&#8217;s activities; or</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Substantive kick-out rights over the party responsible for significant decisions;</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt">The obligation to absorb the entity&#8217;s expected losses; or</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt">The right to receive the entity&#8217;s expected residual returns.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company determines that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and evaluate it for consolidation under the variable interest model.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable interest model</span></div>If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company &#8211; that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE&#8217;s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (economics). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer to Note 16 &#8211; &#8220;Variable Interest Entities (VIEs)&#8221; to the consolidated financial statements for information on the Company&#8217;s consolidated VIEs. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text">Business CombinationsThe Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition-related costs separately from the business combination.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Reportable Segments</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/>Reportable Segments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative healthcare models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in one reportable segment.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.</span></div>The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents, and restricted cash.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investments in Marketable Securities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Marketable Securities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in marketable securities consist of equity securities and certificates of deposit with various financial institutions. The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit are reported at par value, plus accrued interest, with maturity dates from four months to 24 months. As of March&#160;31, 2022 and December&#160;31, 2021, certificates of deposit amounted to approximately $25.0 million and $25.0 million, respectively. Investments in certificates of deposit are classified as Level 1 investments in the fair value hierarchy.<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities are reported at fair value. These securities are classified as Level 1 in the valuation hierarchy, where quoted market prices from reputable third-party brokers are available in an active market and unadjusted. The trading volume of certain equity securities we hold is low, thus resulting in our determination that such equity securities do not have an active market with buyers and sellers ready to trade. Accordingly, we classify such equity securities as Level 2 in the valuation hierarchy, and their valuation is based on weighted average share prices from observable market data.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock', window );">Receivables, Receivables &#8211; Related Parties, and Loan Receivable - Related Party</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables,  Receivables &#8211; Related Parties, and Loan Receivable - Related Party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements, incentive receivables, management fee income, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables &#8211; related parties are comprised of risk pool settlements, management fee income and incentive receivables, and other receivables. Receivables &#8211; related parties are recorded and stated at the amount expected to be collected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s loan receivable &#8211; related party consist of promissory notes from a related party payee that accrues interest per annum. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation and claims receivables relate to each health plan&#8217;s capitation and are received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#8217;s full risk pool receivable that is recorded quarterly based on reports received from the Company&#8217;s hospital partners and management&#8217;s estimate of the Company&#8217;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consist of recoverable claims paid related to the 2021 APAACO performance year to be administered following instructions from CMS for the NGACO program, receivables from GPDC capitation revenue for the 2022 performance year, fee-for-services (&#8220;FFS&#8221;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop-loss insurance premium reimbursements.</span></div>The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (&#8220;CECL&#8221;) model.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risks</a></td>
<td class="text">Concentrations of Credit RisksThe Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The consolidated statements of income present disaggregated revenue by service type.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements of Financial Instruments</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements of Financial Instruments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This hierarchy prioritizes the inputs into three broad levels as follows:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#8217;s own data.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Intangible Assets and Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Long-Lived Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives include network-payor relationships, management contracts, member relationships, subscriber relationships, and developed technology and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized using the accelerated method based on the discounted cash flow rate or using the straight-line method.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses, and are amortized using the straight-line method.</span></div>Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Indefinite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Indefinite-Lived Intangible Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles &#8211; Goodwill and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, at the Company&#8217;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#8217;s three reporting units (1) management services, (2) IPAs, and (3) accountable care organizations. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#8217;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments, and assumptions management believes are appropriate in the circumstances.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy', window );">Investments in Other Entities - Equity Method and Investments in Privately Held Entities</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Other Entities &#8212; Equity Method</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#8217;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#8217;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under income (loss) from equity method investments and also is adjusted by contributions to, and distributions from, the investee. Equity method investments are subject to impairment evaluation. There was no impairment loss recorded related to equity method investments for the years ended March&#160;31, 2022 and 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Privately Held Entities </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The investments in privately held entities that do not report net asset value are subject to qualitative assessment for indicators of impairments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareCostsPolicyPolicyTextBlock', window );">Medical Liabilities</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical Liabilities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC, Alpha Care, Accountable Health Care, and APCMG (&#8220;consolidated IPAs&#8221;) and APAACO are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. These IPAs and APAACO provide integrated care to HMOs, Medicare, and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of income.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimated IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryCashAndPayablePolicyTextBlock', window );">Fiduciary Cash and Payable</a></td>
<td class="text">Fiduciary Cash and PayableThe consolidated IPAs collect cash from health plans on behalf of their sub-IPAs and providers and pass the money through to them.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Swap Agreements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to interest rate risk on its floating-rate debt. The Company has entered into interest rate swap agreements to effectively convert its floating-rate debt to a fixed-rate basis. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#8217;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. Refer to Note 9 for further information on our debt. Interest rate swap agreements are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income and reflected in the accompanying consolidated statements of cash flows as unrealized gain or loss on interest rate swaps.  </span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the interest rate swap agreements was determined using Level 2 inputs. As of March&#160;31, 2022 the fair value of the interest rate swap was $0.5 million and is presented within other assets in the accompanying consolidated balance sheets. As of December&#160;31, 2021, the fair value of the interest rate swap was $1.1&#160;million and is presented within other long-term liabilities in the accompanying consolidated balance sheets.  </span></div><div style="margin-top:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants<br/></span></div>In September 2021, ApolloMed and Clinigence entered into a stock purchase agreement in which ApolloMed purchased shares of common stock and warrants for $3.0&#160;million. The purchased warrants are considered derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income and the accompanying consolidated statements of cash flows. The warrants are classified as a Level 2 instrument as the estimated fair value of the warrants were determined using the Black-Scholes option pricing model and inputs from observable market data. As of March&#160;31, 2022 and December&#160;31, 2021, the fair value of the derivative instrument was $1.1&#160;million and $1.1&#160;million, respectively, and is presented within other assets in the accompanying consolidated balance sheets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Nature of Services and Revenue Streams</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue primarily consists of capitation revenue, risk pool settlements and incentives, GPDC revenue, management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#8217;s billing arrangements and how revenue is recognized for each.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capitation, Net</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#8217; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#8220;Risk Adjustment&#8221; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PMPM managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk sharing. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#8217;s net PMPM transaction price relates specifically to the Company&#8217;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GPDC Capitation Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS contracts with Direct Contracting Entities (&#8220;DCEs&#8221;), which is composed of health care providers operating under a common legal structure and accepts financial accountability for the overall quality and cost of medical care furnished to Medicare FFS beneficiaries aligned to the entity. The combination of the FFS model and the GPDC model changes the distribution of responsibilities, risks, costs, and rewards among CMS, DCEs, and providers. By entering into a contract with CMS, a DCE voluntarily takes on operational, financial, and legal responsibilities and risks that no party has, individually or collectively, under the existing FFS model. Each DCE bears the economic costs, and reaps the economic rewards, of fulfilling its responsibilities and managing its risks as a DCE. APAACO has applied, and been accepted, to participate in the GPDC Model for Performance Year 2022, beginning January 1, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, CMS will pay a total benchmark amount, determined unilaterally by CMS in advance but subject to prospective adjustments throughout the year, for the totality of care provided to the DCE&#8217;s population of aligned beneficiaries over the course of that year. The benchmark is net of a quality withholding applied by CMS. At the end of each performance year, a portion, or all, of the quality withholding can be earned based on APAACO&#8217;s performance. GPDC capitation revenue is recognized based on the estimated transaction price to transfer the service for a distinct increment of the series (i.e. month) and is recognized net of quality incentives/penalties. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Pool Settlements and Incentives</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC enters into full-risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging, and paying for institutional risk and APC is responsible for providing, arranging and paying for professional risk. Under a full-risk pool sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#8217;s risk pools with HMOs after deductions for the affiliated hospital&#8217;s costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#8217;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for historical margin, IBNR completion factors and constraint percentages were used by management in applying the most likely amount methodology.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under capitated arrangements with certain HMOs, APC participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans&#8217; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#8217;s risk share revenue is deemed to be fully constrained until APC is notified of the amount by the health plan. Final settlement of risk pools for prior contract years generally occur in the third or fourth quarter of the following year.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to risk-sharing revenues, the Company also receives incentives under &#8220;pay-for-performance&#8221; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#8217;s incentives under &#8220;pay-for-performance&#8221; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#8217;s performance within the annual measurement period, but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NGACO AIPBP Revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the NGACO Model, CMS aligns beneficiaries to the Company to manage direct care and pay providers based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation-like AIPBP payments from CMS on a monthly basis to pay claims from in-network providers. The Company records such AIPBPs received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided, and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS, while claims from APAACO&#8217;s in-network contracted providers are paid by APAACO. The Company&#8217;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#8217;s risk share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#8217;s efficiency in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#8217;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO AIPBP revenues monthly. Excess AIPBPs over claims paid, plus an estimate for the related IBNR claims (see Note 8), are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there were any excess AIPBPs for the performance year and the excess is refunded to CMS.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company, the risk arrangement for which the Company has been approved by CMS, and as otherwise provided in an NGACO Participation Agreement between APAACO and CMS (the &#8220;Participation Agreement&#8221;). Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within 30 days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within 30 days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within 30 days after the date of a demand letter or settlement report, CMS will assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#8217;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that will likely be recognized in the future and therefore this shared risk pool revenue is considered fully constrained. With the ending of the NGACO Model on December 31, 2021, the Company no longer receives AIPBPs but remains eligible to recognize any shared savings or loss for performance year 2021 upon issuance of the settlement report from CMS. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management Fee Income</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals, and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of gross revenue or fee collections, or amounts fixed on a monthly, quarterly, or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits, or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a significant service of integrating the services selected by the Company&#8217;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#8217;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#8217;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#8217;s performance obligation is satisfied as the Company completes each period&#8217;s obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#8217;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#8217;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management contracts generally have long terms (e.g., 10 years), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fee-for-Service Revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FFS revenue represents revenue earned under contracts in which the professional component of charges for medical services rendered by the Company&#8217;s affiliated physician-owned medical groups are billed and collected from third-party payors, hospitals, and patients. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and is recognized in the period in which the services are rendered to specific patients. All services provided are </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expected to result in cash flows and are therefore reflected as net revenue in the consolidated financial statements. The recognition of net revenue (gross charges, less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#8217;s billing center for medical coding and entering into the Company&#8217;s billing system, and the verification of each patient&#8217;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company&#8217;s billing systems, as well as an estimate of the revenue associated with medical services.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#8217;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#8217;s healthcare plans, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether the patients, to whom services are provided, in the period are insured and the contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of income in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions, and healthcare coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company&#8217;s contract assets are comprised of receivables and receivables &#8211; related parties.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable aging, and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as revenues are recognized. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Liabilities (Deferred Revenue)</span></div>Contract liabilities are recorded when cash payments are received in advance of the Company&#8217;s performance, or in the case of the Company&#8217;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a stock-based compensation program for employees, non-employees, directors, and consultants. The value of share-based awards is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for forfeitures as they occur. From time to time, the Company issues shares of its common stock to its employees, directors, and consultants, which shares may be subject to the Company&#8217;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules. The fair value of options granted are determined using the Black-Scholes option pricing model and include several assumptions, including expected term, expected volatility, expected dividends, and risk-free rates. The expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The expected stock price volatility is determined based on an average of historical volatility. The expected dividend yield is based on the Company&#8217;s expected dividend payouts. The risk-free interest rate is based on the U.S. Constant Maturity curve over the expected term of the option at the time of grant.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basic and Diluted Earnings Per Share</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed by dividing net income attributable to holders of the Company&#8217;s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding, plus the effect of dilutive securities outstanding during the periods presented, using the treasury stock method. Refer to Note 15 for a discussion of shares treated as treasury shares for accounting purposes.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MinorityInterestPolicyPolicyTextBlock', window );">Noncontrolling Interests</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-controlling Interests</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Non-controlling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#8217;s consolidated entities. Net income attributable to non-controlling interests is disclosed in the consolidated statements of income.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_TemporaryEquityPolicyTextBlock', window );">Mezzanine Equity</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mezzanine Equity</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to APC&#8217;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase its shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes non-controlling interests in APC as mezzanine equity in the consolidated financial statements. As of March&#160;31, 2022 and December&#160;31, 2021, APC&#8217;s shares were not redeemable, nor was it probable the shares would become redeemable.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">LeasesThe Company determines if an arrangement is a lease at its inception. The expected term of the lease used for computing the lease liability and right-of-use asset and determining the classification of the lease as operating or financing may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company elected practical expedients for ongoing accounting that is provided by the new standard comprised of the following: (1) the election for classes of underlying asset to not separate non-lease components from lease components, and (2) the election for short-term lease recognition exemption for all leases under a 12-month term. The present value of the lease payments is calculated using a rate implicit in the lease, when readily determinable. However, as most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate to determine the present value of the lease payments for the majority of its leases.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2021, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;)  No. 2021-08, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (&#8220;ASU 2021-08&#8221;). This ASU requires the entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 as if it had originated the contracts. The amendments in this ASU are effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. The Company adopted ASU 2021-08 on January 1, 2022. The adoption of ASU 2021-08 did not have a material impact on the consolidated financial statements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With the exception of the new standards discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#8217;s financial position, results of operations, and cash flows.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements Not Yet Adopted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#8217;s financial position, results of operations, and cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiduciaryCashAndPayablePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiduciary Cash and Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiduciaryCashAndPayablePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MinorityInterestPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minority Interest Policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MinorityInterestPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Receivables and receivables from related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_TemporaryEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_TemporaryEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759068-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for  accruing health care costs for a prepaid health care service provider.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 405<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6491204&amp;loc=d3e4879-115612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 720<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49178521&amp;loc=d3e9162-115647<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661154229864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregated Revenue by Each Payor Type</a></td>
<td class="text">The following table presents disaggregated revenue generated by payor type for the three months ended March&#160;31, 2022 and 2021 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,677&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other third parties</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,258&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,058&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Schedule of Contributions to Revenue and Receivables by Payor</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payors that contributed the following percentages of net revenue:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor A</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor B</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Less than 10% of total net revenues</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payors that contributed to the following percentages of receivables and receivables &#8211; related parties:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,<br/>2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor E</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor F</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Less than 10% of total receivables and receivables &#8212; related parties, net</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Carrying Amounts and Fair Values of Financial Instruments</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of March&#160;31, 2022, are presented below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds*</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,836&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,927&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,270&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,033&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APCMG contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Included in cash and cash equivalents</span></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of December&#160;31, 2021, are presented below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market accounts*</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APCMG contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Included in cash and cash equivalents</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661157593048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Change in Carrying Value of Goodwill</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying value of goodwill for the three months ended March&#160;31, 2022 was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,746)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,379&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661156276760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets, Net</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:46.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net March 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Network relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-21</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87,618)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,998)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Member relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,976)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient management platform</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,777)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade names/trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subscriber relationships </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developed technology </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,736&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108,588)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,148&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare license</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Network relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,865)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,563)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,606)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient management platform</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,682)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tradename/trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,729&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104,922)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,807&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Future Amortization Expense</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the three months ended March 31, 2022)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,558&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,998&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661158023976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Equity Method Investments</a></td>
<td class="text"><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in other entities &#8211; equity method consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:38.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.886%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allocation of Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Funding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Distribution </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LaSalle Medical Associates &#8211; IPA Line of Business</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,034&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,292&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pacific Medical Imaging &amp; Oncology Center, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531 W. College, LLC &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,048&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One MSO, LLC &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tag-6 Medical Investment Group, LLC &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAIPA MSO, LLC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,715&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,433&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,383&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMA&#8217;s summarized balance sheets at March&#160;31, 2022 and December&#160;31, 2021, and summarized statements of income for the three months ended March&#160;31, 2022 and 2021, with respect to its IPA line of business are as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Balance Sheets</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loan receivable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liabilities and Stockholders&#8217; Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; deficit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,790)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,571)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; deficit</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,740&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,834&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Statements of Operations</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,780&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,552)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661157702264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts payable and accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,868&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,583&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subcontractor IPA payable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,918&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to related parties</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,252&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,951&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661157516120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Schedule of Medical Liabilities</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s medical liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,783&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,018)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,360&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,311&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,120)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,713)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,035)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,344)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114,155)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81,057)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,758&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,479&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661155762200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility, Bank Loans, and Lines of Credit (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock', window );">Schedule of Credit Facility</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s debt balance consists of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolver Loan</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real Estate Loans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,635&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,965&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,503)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(780)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,031)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,268)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,101&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,917&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Commitments of Credit Facility</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the future commitments of the Company&#8217;s debt for the years ending </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.836%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the three months ended March 31, 2022) </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,450&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,635&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661156411784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Share-Based Compensation Expense</a></td>
<td class="text">The following table summarizes the stock-based compensation expense recognized under all of the Company&#8217;s stock plans for the three months ended March&#160;31, 2022 and 2021, and associated with the issuance of restricted shares of common stock and vesting of stock options, which are included in general and administrative expenses in the accompanying consolidated statements of income (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.753%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.183%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,055&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,346&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Transactions Under Stock Option Plans</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding stock options consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.917%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding at January&#160;1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813,965&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.94</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591,725&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.33&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.79</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, the Company granted 75,271 stock options to certain ApolloMed employees and Board members. The options granted during the three months ended March&#160;31, 2022 were recognized at fair value, as determined using the Black-Scholes option pricing model as follows: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.637%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00 years - 2.25 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.47% - 75.15%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.02% - 1.06%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market value of common stock</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$20.23 - $22.73</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annual dividend yield</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeiture rate</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Outstanding Warrants</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding warrants consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants outstanding at January&#160;1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.94</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86,235)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants expired/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915,505&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.69</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise&#160;Price&#160;Per Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants<br/>Outstanding</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual&#160;Life</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercisable</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise&#160;Price</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Per Share</span></div></td></tr><tr><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470,827</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.69</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444,678</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.69</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$                  10.00 &#8211; 11.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915,505&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.69</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915,505&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661157634760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Fees Incurred and Revenue Earned from Related Party Transactions</a></td>
<td class="text">The following table sets forth fees incurred and income received related to AHMC, HSMSO, and Aurion (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.508%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.305%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AHMC &#8211; Risk pool, capitation, claims payment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,366&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,097&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HSMSO &#8211; Management fees, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aurion &#8211; Management fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receipts, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,211&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,945&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661156248744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share Computations</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the earnings per share computations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,681,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,336,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,994,868&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,566,189&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of Shares Included in the Diluted Earnings Per Share Computations</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the shares included in the diluted earnings per share computations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,681,218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,336,434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">811,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,994,868&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,566,189&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661157496616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities (VIEs) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock', window );">Schedule of Assets and Liabilities, Variable Interest Entities</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care, and to which the creditors of ApolloMed have no recourse, and liabilities to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the general credit of ApolloMed, as the primary beneficiary of the VIEs. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands). The assets and liabilities of the Company&#8217;s other consolidated VIEs were not considered significant. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount due from affiliate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,567&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,766&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property, and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,656&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans receivable &#8211; related parties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in other entities &#8211; equity method</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in privately held entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total assets</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,140,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiduciary accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion and deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,963&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,674&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5747-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6228884-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfVariableInterestEntitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661155324472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Information Related to Lease Costs</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.551%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.09 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.68 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.31 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.42 years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Operating Lease Payments After Adoption of 842</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of March&#160;31, 2022, is as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the three months ended March&#160;31, 2022)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,645&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,183&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,558&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Finance Lease Payments After Adoption of 842</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of March&#160;31, 2022, is as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the three months ended March&#160;31, 2022)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,645&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,183&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,558&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661148236424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Jul. 31, 1999</div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>plan </div>
<div>clinic</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,383<span></span>
</td>
<td class="nump">$ 41,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_AccessPrimaryCareMedicalGroupMember', window );">Access Primary Care Medical Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_ApolloSunLabsManagementLLCMember', window );">Apollo-Sun Labs Management, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase', window );">Equity interest purchase obligation, period to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent', window );">Equity interest purchase obligation, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DmgMember', window );">DMG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase', window );">Equity interest purchase obligation, period to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ameh_APAMHMedicalCorporationMember', window );">AP-AMH Medical Corporation | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 545,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceReceivableTermOfReceivable', window );">Term of receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceReceivableStatedInterestRate', window );">Stated rate of note of loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate', window );">Interest rate in the event of default</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares purchased by related party | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,015,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement', window );">Fixed term of amended and restated management and administrative services agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | MPP, AMG Properties, and ZLL Asset Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AssetAcquisitionPercentageOfSharesAcquired', window );">Asset acquisition, percentage of shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AssetAcquisitionPercentageOfSharesAcquired', window );">Asset acquisition, percentage of shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | AMG, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Value of shares transferred in acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Apollo Medical Holdings, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.61%<span></span>
</td>
<td class="nump">19.68%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Concourse Diagnostic Surgery Center, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | DMG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | AP-AMH Medical Corporation | Affiliated Entity | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares purchased by related party | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AccountableHealthCareIPAMember', window );">Accountable Health Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfFederallyQualifiedHealthPlans', window );">Number federally qualified health plans | plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember', window );">APC and APC-LSMA | Accountable Health Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember', window );">APC and APC-LSMA | Dr. Jay | Accountable Health Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AmgIncMember', window );">AMG, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfFamilyPracticeClinics', window );">Number of family practice clinics | clinic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ApcLsmaMember', window );">APC LSMA | AMG, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ApcLsmaMember', window );">APC LSMA | Maverick Medical Group, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AssetAcquisitionPercentageOfSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Percentage Of Shares Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AssetAcquisitionPercentageOfSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Equity Interest Purchase Obligation, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Equity Interest Purchase Obligation, Period to Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DescriptionOfBusinessLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DescriptionOfBusinessLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Receivable, Modifications, Subsequent Default, Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceReceivableStatedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Receivable, Stated Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceReceivableStatedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceReceivableTermOfReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Receivable, Term Of Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceReceivableTermOfReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The initial fixed term of amended and restated management and administrative services agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfFamilyPracticeClinics">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Family Practice Clinics</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfFamilyPracticeClinics</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfFederallyQualifiedHealthPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Federally Qualified Health Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfFederallyQualifiedHealthPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AccessPrimaryCareMedicalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AccessPrimaryCareMedicalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_ApolloSunLabsManagementLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_ApolloSunLabsManagementLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DmgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DmgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_APAMHMedicalCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_APAMHMedicalCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AmgIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AmgIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_ApolloMedicalHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_ApolloMedicalHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_ConcourseDiagnosticSurgeryCenterLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_ConcourseDiagnosticSurgeryCenterLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AccountableHealthCareIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AccountableHealthCareIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AccountableHealthCareIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AccountableHealthCareIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_Dr.JayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_Dr.JayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AmgIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AmgIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApcLsmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApcLsmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ameh_MaverickMedicalGroupIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ameh_MaverickMedicalGroupIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661149834856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>segment </div>
<div>unit</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Apr. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Amount deposit accounts exceeded FDIC insured limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 282,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,046,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,024,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentsToAcquireCommonStockAndWarrants', window );">Payments to acquire common stock and warrants</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,847,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,393,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Equity securities, FV-NI, unrealized gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear', window );">Risk pool surplus or deficits, settlement period after risk pool performance year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of main reporting units | unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of indefinite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Equity method investment, other than temporary impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryAccountsPayableCurrent', window );">Fiduciary accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,305,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,534,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,028,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,798,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ameh_AccountsPayableAndAccruedExpensesMember', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Accrued contract liability recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">522,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ameh_ContingentEquitySecuritiesMember', window );">Contingent Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Contingent equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">522,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Contingent Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges: | Interest rate swap | Other Noncurrent Assets | Derivatives designated as hedging instruments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges: | Interest rate swap | Other long-term liabilities | Derivatives designated as hedging instruments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember', window );">Universal Care Acquisition Partners, LLC | Universal Care Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentOwnershipPercentageDisposed', window );">Ownership interest disposed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ameh_PerMemberPerMonthManagedCareContractMember', window );">PMPM Managed Care Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfTiming', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember', window );">Management Fee Income Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfTiming', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ameh_ClinigenceHoldingsIncMember', window );">Clinigence Holdings, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentsToAcquireCommonStockAndWarrants', window );">Payments to acquire common stock and warrants</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ameh_CMSMember', window );">CMS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport', window );">Expected period of payment upon termination of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MarketableSecuritiesCurrentMaturityPeriod', window );">Short-term marketable securities, maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MarketableSecuritiesCurrentMaturityPeriod', window );">Short-term marketable securities, maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentOwnershipPercentageDisposed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Disposed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentOwnershipPercentageDisposed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiduciaryAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiduciaryAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MarketableSecuritiesCurrentMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable Securities, Current, Maturity Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MarketableSecuritiesCurrentMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentsToAcquireCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Common Stock And Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentsToAcquireCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk Pool Surplus Or Deficits, Settlement Period After Performance Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 35<br> -Paragraph 32<br> -URI http://asc.fasb.org/extlink&amp;oid=124268079&amp;loc=d3e32787-111569<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePerformanceObligationDescriptionOfTiming">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePerformanceObligationDescriptionOfTiming</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ameh_AccountsPayableAndAccruedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ameh_AccountsPayableAndAccruedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=ameh_ContingentEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=ameh_ContingentEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ameh_PerMemberPerMonthManagedCareContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ameh_PerMemberPerMonthManagedCareContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_ClinigenceHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_ClinigenceHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_CMSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_CMSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661154415416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 263,258<span></span>
</td>
<td class="nump">$ 176,058<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ameh_CommercialMember', window );">Commercial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">42,140<span></span>
</td>
<td class="nump">32,266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ameh_MedicareMember', window );">Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">133,659<span></span>
</td>
<td class="nump">64,677<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ameh_MedicaidMember', window );">Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">71,663<span></span>
</td>
<td class="nump">69,664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ameh_OtherThirdPartiesMember', window );">Other third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 15,796<span></span>
</td>
<td class="nump">$ 9,451<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_CommercialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_CommercialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_OtherThirdPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_OtherThirdPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661153410136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Revenue | Payor A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Revenue | Payor B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Revenue | Payor C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">10.60%<span></span>
</td>
<td class="nump">16.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Revenue | Payor D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">30.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Receivables and Receivables-Related Parties | Payor D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Receivables and Receivables-Related Parties | Payor E</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Receivables and Receivables-Related Parties | Payor F</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AccountsReceivableAndNetRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AccountsReceivableAndNetRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorFMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorFMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661149602328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Company's Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 96,213<span></span>
</td>
<td class="nump">$ 114,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">25,046<span></span>
</td>
<td class="nump">25,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">17,847<span></span>
</td>
<td class="nump">28,393<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">145,033<span></span>
</td>
<td class="nump">173,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">APCMG contingent consideration</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">2,071<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ameh_ContingentEquitySecuritiesMember', window );">Contingent Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">4,270<span></span>
</td>
<td class="nump">4,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">1,135<span></span>
</td>
<td class="nump">1,145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">96,213<span></span>
</td>
<td class="nump">114,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">25,046<span></span>
</td>
<td class="nump">25,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">13,577<span></span>
</td>
<td class="nump">24,123<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">134,836<span></span>
</td>
<td class="nump">163,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">APCMG contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Contingent Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">4,270<span></span>
</td>
<td class="nump">4,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">5,927<span></span>
</td>
<td class="nump">5,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,071<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">APCMG contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,071<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Contingent Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">1,135<span></span>
</td>
<td class="nump">1,145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">4,270<span></span>
</td>
<td class="nump">4,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">APCMG contingent consideration</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Contingent Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">4,270<span></span>
</td>
<td class="nump">4,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=ameh_ContingentEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=ameh_ContingentEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661148037112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations and Goodwill - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 24, 2022</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">APCMG contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember', window );">Orma Health, Inc., and Provider Growth Solutions LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Value of shares transferred in acquisition</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_AccessPrimaryCareMedicalGroupMember', window );">Access Primary Care Medical Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">APCMG contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_ApolloSunLabsManagementLLCMember', window );">Apollo-Sun Labs Management, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AccessPrimaryCareMedicalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AccessPrimaryCareMedicalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_ApolloSunLabsManagementLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_ApolloSunLabsManagementLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661153824264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations and Goodwill - Summary of Goodwill (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 253,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions</a></td>
<td class="nump">1,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Adjustments</a></td>
<td class="num">(1,746)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 252,379<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e961-128460<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661154335496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net - Schedule of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (108,588)<span></span>
</td>
<td class="num">$ (104,922)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">77,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible Assets, Gross</a></td>
<td class="nump">188,736<span></span>
</td>
<td class="nump">187,729<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net</a></td>
<td class="nump">80,148<span></span>
</td>
<td class="nump">82,807<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite lived assets:</a></td>
<td class="nump">2,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite lived assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember', window );">Network relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">150,679<span></span>
</td>
<td class="nump">150,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(87,618)<span></span>
</td>
<td class="num">(84,865)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 63,061<span></span>
</td>
<td class="nump">$ 65,814<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember', window );">Network relationships | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">11 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember', window );">Network relationships | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_ManagementContractsMember', window );">Management contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">$ 22,832<span></span>
</td>
<td class="nump">$ 22,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(13,998)<span></span>
</td>
<td class="num">(13,563)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 8,834<span></span>
</td>
<td class="nump">$ 9,269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MemberRelationshipsMember', window );">Member relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">12 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">$ 8,997<span></span>
</td>
<td class="nump">$ 8,997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(4,976)<span></span>
</td>
<td class="num">(4,606)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 4,021<span></span>
</td>
<td class="nump">$ 4,391<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_PatientManagementPlatformMember', window );">Patient management platform</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">$ 2,060<span></span>
</td>
<td class="nump">$ 2,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,777)<span></span>
</td>
<td class="num">(1,682)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 283<span></span>
</td>
<td class="nump">$ 378<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trade names/trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">$ 1,011<span></span>
</td>
<td class="nump">$ 1,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(219)<span></span>
</td>
<td class="num">(206)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 792<span></span>
</td>
<td class="nump">$ 805<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Subscriber relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">$ 235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">$ 772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_ManagementContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_ManagementContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MemberRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MemberRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_PatientManagementPlatformMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_PatientManagementPlatformMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661157703224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 3.7<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661156129896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets, Net - Future Amortization Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2022 (excluding the three months ended March 31, 2022)</a></td>
<td class="nump">$ 10,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">11,804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">10,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">9,558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">8,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Thereafter</a></td>
<td class="nump">27,228<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 77,998<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661155349144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities - Equity Method Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,433<span></span>
</td>
<td class="num">$ (677)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates &#8211; IPA Line of Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">531 W. College, LLC &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(182)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember', window );">One MSO, LLC &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember', window );">Tag-6 Medical Investment Group, LLC &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_CAIPAMSOLLCMember', window );">CAIPA MSO, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="nump">$ 11,700<span></span>
</td>
<td class="nump">11,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentsContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Contribution</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentsContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the entity's equity method investment which has been sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSoldCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_CAIPAMSOLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_CAIPAMSOLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661147450712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,433,000<span></span>
</td>
<td class="num">$ (677,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,383,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,715,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | MediPortal LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares', window );">Membership interests purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments', window );">Payments to purchase membership interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest', window );">Membership interests acquired (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants received (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption', window );">Term of option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests', window );">Options to purchase additional membership interests (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet', window );">Number of warrants available to purchase, contingent upon the portal completion date (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementIncMember', window );">Network Medical Management, Inc. | AchievaMed, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears', window );">Percentage of voting common stock, within five years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment', window );">Duration of investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost', window );">Investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments', window );">Related investment balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,258,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,292,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,034,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates | APC and APC-LSMA | Convertible Secured Promissory Note | Dr. Arteaga</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentOwnershipPercentageSold', window );">Ownership percentage sold</a></td>
<td class="nump">21.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates | APC LSMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="num">(700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,725,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,719,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc. | APC LSMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc. | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc. | APC | Ancillary Service Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">531 W. College LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(182,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,048,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">531 W. College LLC | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (200,000)<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember', window );">One MSO, LLC &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,847,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,910,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember', window );">One MSO, LLC &#8211; related party | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCMember', window );">Tag-6 Medical Investment Group, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCMember', window );">Tag-6 Medical Investment Group, LLC | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_CAIPAMSOLLCMember', window );">CAIPA MSO, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,992,000<span></span>
</td>
<td class="nump">$ 11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_CAIPAMSOLLCMember', window );">CAIPA MSO, LLC | Apollo Medical Holdings, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentOwnershipPercentageSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage, Sold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentOwnershipPercentageSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Term Of Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Options Issues, Options To Purchase Additional Interests, If Circumstances Met</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities without Readily Determinable Fair Value, Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the entity's equity method investment which has been sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSoldCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ameh_MediPortalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ameh_MediPortalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_NetworkMedicalManagementIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ameh_AchievaMedInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ameh_AchievaMedInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_Dr.ArteagaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_Dr.ArteagaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApcLsmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApcLsmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ContractTypeAxis=ameh_AncillaryServiceContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ContractTypeAxis=ameh_AncillaryServiceContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_CAIPAMSOLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_CAIPAMSOLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApolloMedicalHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApolloMedicalHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661148167240">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities - Summarized Balance Sheets and Statements of Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 237,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 233,097<span></span>
</td>
<td class="nump">$ 193,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">55,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loan receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">912,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">852,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders&#8217; Deficit</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">160,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders&#8217; deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">479,521<span></span>
</td>
<td class="nump">$ 349,687<span></span>
</td>
<td class="nump">460,490<span></span>
</td>
<td class="nump">$ 330,911<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, mezzanine equity, and stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">912,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">852,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statement of Operations</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">263,258<span></span>
</td>
<td class="nump">176,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">237,047<span></span>
</td>
<td class="nump">154,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,073<span></span>
</td>
<td class="nump">14,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loan receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders&#8217; Deficit</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders&#8217; deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(14,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,571)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, mezzanine equity, and stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statement of Operations</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">67,566<span></span>
</td>
<td class="nump">47,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">61,786<span></span>
</td>
<td class="nump">48,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5,780<span></span>
</td>
<td class="num">$ (1,552)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Company&#8217;s consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#8217;s consolidated VIEs totaling $585.9&#160;million and $567.0&#160;million as of March&#160;31, 2022 and December&#160;31, 2021, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $111.0&#160;million and $91.7&#160;million as of March&#160;31, 2022 and December&#160;31, 2021, respectively. The VIE balances do not include $529.6&#160;million of investment in affiliates and $25.2&#160;million of amounts due from affiliates as of March&#160;31, 2022 and $802.8&#160;million of investment in affiliates and $6.6&#160;million of amounts due to affiliates as of December&#160;31, 2021 as these are eliminated upon consolidation and not presented within the consolidated balance sheets. See Note 16 &#8211; Variable Interest Entities (VIEs) for further detail.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_LasalleMedicalAssociatesIpaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_LasalleMedicalAssociatesIpaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661156037192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Loan Receivable and Loan Receivable &#8211; Related Parties - Additional Information (Details) - Convertible Secured Promissory Note - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember', window );">Pacific6 Enterprises | NMM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember', window );">AHMC | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Note receivable, amount</a></td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceReceivableInterestRateStatedPercentage', window );">Note receivable, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceReceivableInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Receivable, Interest Rate, Stated Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceReceivableInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7A<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953401-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 55<br> -Paragraph 79<br> -URI http://asc.fasb.org/extlink&amp;oid=124267575&amp;loc=SL82922352-210448<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 55<br> -Paragraph 80<br> -URI http://asc.fasb.org/extlink&amp;oid=124267575&amp;loc=SL82922355-210448<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (1)<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (2)<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1404<br> -Paragraph (a)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_Pacific6EnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_Pacific6EnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661148167112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 9,868<span></span>
</td>
<td class="nump">$ 9,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SpecialtyCapitationPayableCurrent', window );">Capitation payable</a></td>
<td class="nump">3,525<span></span>
</td>
<td class="nump">2,697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SubcontractorIPAPayable', window );">Subcontractor IPA payable</a></td>
<td class="nump">1,918<span></span>
</td>
<td class="nump">1,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">900<span></span>
</td>
<td class="nump">878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="nump">2,339<span></span>
</td>
<td class="nump">2,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="nump">20,028<span></span>
</td>
<td class="nump">16,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">9,674<span></span>
</td>
<td class="nump">10,107<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total accounts payable and accrued expenses</a></td>
<td class="nump">$ 48,252<span></span>
</td>
<td class="nump">$ 43,951<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SpecialtyCapitationPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of specialty capitation payable current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SpecialtyCapitationPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SubcontractorIPAPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subcontractor IPA Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SubcontractorIPAPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661148145288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Liabilities - Schedule of Medical Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Medical Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities, beginning of period</a></td>
<td class="nump">$ 55,783<span></span>
</td>
<td class="nump">$ 50,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MedicalCareCostsAbstract', window );"><strong>Components of medical care costs related to claims incurred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current period</a></td>
<td class="nump">153,535<span></span>
</td>
<td class="nump">83,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior periods</a></td>
<td class="num">(175)<span></span>
</td>
<td class="num">(2,018)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total medical care costs</a></td>
<td class="nump">153,360<span></span>
</td>
<td class="nump">81,311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentsForMedicalCareCostsAbstract', window );"><strong>Payments for medical care costs related to claims incurred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current period</a></td>
<td class="num">(70,120)<span></span>
</td>
<td class="num">(41,713)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior periods</a></td>
<td class="num">(44,035)<span></span>
</td>
<td class="num">(39,344)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total paid</a></td>
<td class="num">(114,155)<span></span>
</td>
<td class="num">(81,057)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease', window );">Adjustments</a></td>
<td class="nump">770<span></span>
</td>
<td class="nump">895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities, end of period</a></td>
<td class="nump">$ 95,758<span></span>
</td>
<td class="nump">$ 51,479<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MedicalCareCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medical Care Costs [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MedicalCareCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentsForMedicalCareCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Medical Care Costs [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentsForMedicalCareCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of increase (decrease) in the liability for unpaid claims and claims adjustment expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLossesAndLossAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661155340120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Credit Facility, Bank Loans, and Lines of Credit - Credit Facility (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">$ 188,635<span></span>
</td>
<td class="nump">$ 187,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion of debt</a></td>
<td class="num">(1,503)<span></span>
</td>
<td class="num">(780)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Unamortized financing costs</a></td>
<td class="num">(4,031)<span></span>
</td>
<td class="num">(4,268)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="nump">183,101<span></span>
</td>
<td class="nump">182,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RealEstateLoanMember', window );">Real Estate Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">7,344<span></span>
</td>
<td class="nump">7,396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ameh_ConstructionLoanMember', window );">Construction Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">1,291<span></span>
</td>
<td class="nump">569<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolver Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">$ 180,000<span></span>
</td>
<td class="nump">$ 180,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RealEstateLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RealEstateLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ameh_ConstructionLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ameh_ConstructionLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661159283800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Credit Facility, Bank Loans, and Lines of Credit - Schedule of Maturities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2022 (excluding the three months ended March 31, 2022)</a></td>
<td class="nump">$ 1,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">6,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LongTermDebtMaturityAfterYearFour', window );">2026 and thereafter</a></td>
<td class="nump">180,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Total</a></td>
<td class="nump">$ 188,635<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LongTermDebtMaturityAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Maturity, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LongTermDebtMaturityAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661144143400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility, Bank Loans, and Lines of Credit - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 16, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Aug. 05, 2020</div></th>
<th class="th"><div>Jul. 27, 2020</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>financial_ratio</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 01, 2023</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 10, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,031,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,268,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,073,000<span></span>
</td>
<td class="nump">$ 1,523,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Medical Property Partners LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AssetAcquisitionPercentageOfSharesAcquired', window );">Asset acquisition, percentage of shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | AMG Properties LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AssetAcquisitionPercentageOfSharesAcquired', window );">Asset acquisition, percentage of shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | ZLL Partners LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AssetAcquisitionPercentageOfSharesAcquired', window );">Asset acquisition, percentage of shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_MedicalPropertyPartnersLLCMember', window );">Medical Property Partners LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt, principal sum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum', window );">Debt instrument, covenant, debt coverage ratio, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_MedicalPropertyPartnersLLCMember', window );">Medical Property Partners LLC | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AMGPropertiesLLCMember', window );">AMG Properties LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt, principal sum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum', window );">Debt instrument, covenant, debt coverage ratio, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AMGPropertiesLLCMember', window );">AMG Properties LLC | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ZLLPartnersLLCMember', window );">ZLL Partners LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt, principal sum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum', window );">Debt instrument, covenant, debt coverage ratio, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ZLLPartnersLLCMember', window );">ZLL Partners LLC | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember', window );">Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount', window );">Annual agent fee</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Required annual facility fee</a></td>
<td class="nump">0.175%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Minimum | London Interbank Offered Rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Required annual facility fee</a></td>
<td class="nump">0.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Maximum | London Interbank Offered Rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember', window );">Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentNumberOfKeyFinancialRatios', window );">Number of key financial ratios | financial_ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantLeverageRatioMaximum', window );">Maximum consolidated leverage ratio (not greater than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtCovenantAggregatePurchasePriceMaximum', window );">Debt covenant, aggregate purchase price, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange', window );">Consolidated leverage ratio, annual decrease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum', window );">Debt instrument, covenant, leverage ratio, adjusted maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum', window );">Minimum consolidated interest coverage ratio (not less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Average effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.78%<span></span>
</td>
<td class="nump">2.08%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_ConstructionLoanMember', window );">Construction Loan | Tag-8 Medical Investment Group, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt, principal sum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum', window );">Debt instrument, covenant, cash flow coverage ratio, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_ConstructionLoanMember', window );">Construction Loan | Tag-8 Medical Investment Group, LLC | London Interbank Offered Rate (LIBOR) | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolver Loan | Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Revolving credit facility term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.38%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet', window );">Deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolver Loan | Amended Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="nump">$ 400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolver Loan | Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet', window );">Deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | APC Business Loan Agreement | APC | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Amended Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_BridgeLoanMember', window );">Bridge Loan | Amended Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Term of facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | Alpha Care Medical Group, Inc. | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Term of facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | Amended Credit Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Required annual facility fee</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | Amended Credit Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Required annual facility fee</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AssetAcquisitionPercentageOfSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Percentage Of Shares Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AssetAcquisitionPercentageOfSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtCovenantAggregatePurchasePriceMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Covenant, Aggregate Purchase Price, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtCovenantAggregatePurchasePriceMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Cash Flow Coverage Ratio, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Debt Coverage Ratio, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Leverage Ratio, Adjusted Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Leverage Ratio, Incremental Change</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantLeverageRatioMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Leverage Ratio, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantLeverageRatioMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentNumberOfKeyFinancialRatios">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Key Financial Ratios</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentNumberOfKeyFinancialRatios</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section S45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68176171&amp;loc=SL68176184-208336<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ameh_MedicalPropertyPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ameh_MedicalPropertyPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ameh_AMGPropertiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ameh_AMGPropertiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ameh_ZLLPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ameh_ZLLPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_MedicalPropertyPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_MedicalPropertyPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AMGPropertiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AMGPropertiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ZLLPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ZLLPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ameh_ConstructionLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ameh_ConstructionLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_Tag8MedicalInvestmentGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_Tag8MedicalInvestmentGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ameh_ApcBusinessLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ameh_ApcBusinessLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=ameh_PreferredBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=ameh_PreferredBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_BridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_BridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlphaCareMedicalGroupInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlphaCareMedicalGroupInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661156039608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mezzanine and Stockholders' Equity - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringPeriodSharesMerger', window );">Holdback shares not issued to former shareholders (in shares)</a></td>
<td class="nump">140,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury shares (in shares)</a></td>
<td class="nump">10,925,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,925,702<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury shares (in shares)</a></td>
<td class="nump">10,925,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_CDSCMember', window );">CDSC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends paid</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringPeriodSharesMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringPeriodSharesMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_CDSCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_CDSCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661154087960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Share-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 3,055<span></span>
</td>
<td class="nump">$ 1,346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">780<span></span>
</td>
<td class="nump">589<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ameh_StockAwardsAndUnitsMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 2,275<span></span>
</td>
<td class="nump">$ 757<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ameh_StockAwardsAndUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ameh_StockAwardsAndUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661155486776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 21.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="nump">38,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Purchase price adjustment from Merger</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod', window );">Warrants exercised (in shares)</a></td>
<td class="nump">86,235<span></span>
</td>
<td class="nump">421,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds from warrants exercised</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice', window );">Exercise price of warrants exercised (in dollars per share)</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 9.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice', window );">Exercise price of warrants exercised (in dollars per share)</a></td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="nump">$ 11.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ameh_EmployeesMember', window );">Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period (in shares)</a></td>
<td class="nump">75,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock awards granted (in shares)</a></td>
<td class="nump">76,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance', window );">Contingent on performance (shares)</a></td>
<td class="nump">49,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 50.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Grant date fair value of restricted stock to be recognized straight-line</a></td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Contingent on Performance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Issued During Period Value Stock Options Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ameh_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ameh_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661149414856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">850,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">813,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted (in shares)</a></td>
<td class="nump">75,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(38,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance (in shares)</a></td>
<td class="nump">850,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">813,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares)</a></td>
<td class="nump">591,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 22.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share)</a></td>
<td class="nump">55.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share)</a></td>
<td class="nump">17.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">25.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options exercisable (in dollars per share)</a></td>
<td class="nump">$ 9.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding</a></td>
<td class="text">2 years 11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable</a></td>
<td class="text">1 year 9 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value (in millions)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding</a></td>
<td class="nump">$ 22,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options exercised</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable</a></td>
<td class="nump">$ 20,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Exercise Price [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661153396472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Options, Assumptions Under Black-Scholes (Details) - Board members<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility</a></td>
<td class="nump">71.47%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility</a></td>
<td class="nump">75.15%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate</a></td>
<td class="nump">1.02%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate</a></td>
<td class="nump">1.06%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Annual dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate', window );">Forfeiture rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Market value of common stock (in dollars per share)</a></td>
<td class="nump">$ 20.23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">2 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Market value of common stock (in dollars per share)</a></td>
<td class="nump">$ 22.73<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the forfeiture rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661156355800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Warrant (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SharesWarrantsRollForward', window );"><strong>Shares, Warrants [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">1,001,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfWarrantsGranted', window );">Warrants granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfWarrantsExercised', window );">Warrants exercised (in shares)</a></td>
<td class="num">(86,235)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightCancelledInPeriod', window );">Warrants expired/forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">915,505<span></span>
</td>
<td class="nump">1,001,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_WeightedAverageExercisePriceWarrantsRollForward', window );"><strong>Weighted Average Exercise Price, Warrants [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Warrants outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 10.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod', window );">Warrants granted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod', window );">Warrants exercised (in dollars per share)</a></td>
<td class="nump">10.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod', window );">Warrants expired/forfeited (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Warrants outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">$ 10.49<span></span>
</td>
<td class="nump">$ 10.49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_WeightedaverageremainingcontractualtermyearsAbstract', window );"><strong>Weighted Average Remaining Contractual Term Years [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm', window );">Warrants outstanding</a></td>
<td class="text">8 months 8 days<span></span>
</td>
<td class="text">11 months 8 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AggregateintrinsicvalueAbstract', window );"><strong>Aggregate Intrinsic Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue', window );">Warrants outstanding, beginning balance</a></td>
<td class="nump">$ 63,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue', window );">Warrants granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue', window );">Warrants exercised</a></td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue', window );">Warrants expired/forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue', window );">Warrants outstanding, ending balance</a></td>
<td class="nump">$ 34,800<span></span>
</td>
<td class="nump">$ 63,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AggregateintrinsicvalueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AggregateintrinsicvalueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightCancelledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, cancelled in period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightCancelledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Rights outstanding Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of warrants or rights exercised in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of warrants or rights forfeited in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of warrants or rights granted in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SharesWarrantsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares, Warrants [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SharesWarrantsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_WeightedAverageExercisePriceWarrantsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_WeightedAverageExercisePriceWarrantsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_WeightedaverageremainingcontractualtermyearsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_WeightedaverageremainingcontractualtermyearsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661144120712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 10.49<span></span>
</td>
<td class="nump">$ 10.49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeOneMember', window );">Warrant Exercise Price Range One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise&#160;Price&#160;Per Share (in dollars per share)</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightIssuedInPeriod', window );">Warrants Outstanding (in shares)</a></td>
<td class="nump">470,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term</a></td>
<td class="text">8 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightExercisable', window );">Warrants Exercisable (in shares)</a></td>
<td class="nump">470,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeTwoMember', window );">Warrant Exercise Price Range Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise&#160;Price&#160;Per Share (in dollars per share)</a></td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightIssuedInPeriod', window );">Warrants Outstanding (in shares)</a></td>
<td class="nump">444,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term</a></td>
<td class="text">8 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightExercisable', window );">Warrants Exercisable (in shares)</a></td>
<td class="nump">444,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeThreeMember', window );">Warrant Exercise Price Range Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightIssuedInPeriod', window );">Warrants Outstanding (in shares)</a></td>
<td class="nump">915,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term</a></td>
<td class="text">8 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightExercisable', window );">Warrants Exercisable (in shares)</a></td>
<td class="nump">915,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 10.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeThreeMember', window );">Warrant Exercise Price Range Three | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise&#160;Price&#160;Per Share (in dollars per share)</a></td>
<td class="nump">10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeThreeMember', window );">Warrant Exercise Price Range Three | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise&#160;Price&#160;Per Share (in dollars per share)</a></td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Issued in Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661156205096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding</a></td>
<td class="nump">$ 188,635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | APC</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding</a></td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | Alpha Care Medical Group, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding</a></td>
<td class="nump">$ 3,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlphaCareMedicalGroupInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlphaCareMedicalGroupInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661143993656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty', window );">Recognized risk pool revenue</a></td>
<td class="nump">$ 11,211,000<span></span>
</td>
<td class="nump">$ 12,945,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember', window );">NMM | Board members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentConsultingFees', window );">Consulting services paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember', window );">NMM | LMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from related parties</a></td>
<td class="nump">6,300,000<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | PMIOC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | DMG | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ApcShareholdersMember', window );">APC Shareholders | APC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">9,300,000<span></span>
</td>
<td class="nump">7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AdvanceDiagnosticSurgeryCenterMember', window );">Advance Diagnostic Surgery Center | APC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">39,000<span></span>
</td>
<td class="nump">22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_FreseniusMember', window );">Fresenius | APC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">5,800<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_FreseniusMember', window );">Fresenius | APA ACO Inc | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_FulgentGeneticsIncMember', window );">Fulgent Genetics, Inc. | APC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ShareholdersAndOfficersMember', window );">APC Shareholders and Officers | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">1,900,000<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_NumenLLCMember', window );">Numen LLC | SCHC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_OneMSOInc.Member', window );">One MSO, Inc. | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ArroyoVistaMember', window );">Arroyo Vista | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember', window );">AHMC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty', window );">Recognized risk pool revenue</a></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="nump">$ 16,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilities', window );">Amount outstanding under agreement</a></td>
<td class="nump">$ 66,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LmaMember', window );">LMA | NMM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PmiocMember', window );">PMIOC | APC Shareholders | APC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DmgMember', window );">DMG | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DmgMember', window );">DMG | APC Shareholders | APC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOInc.Member', window );">One MSO, Inc. | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentConsultingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Consulting Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentConsultingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentMadeToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Credit/Duration (Amount paid to related party in relation to providing services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentMadeToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income in future periods and obligations not separately disclosed in the balance sheet (other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ameh_LmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ameh_LmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ameh_PmiocMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ameh_PmiocMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ameh_DmgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ameh_DmgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ApcShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ApcShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AdvanceDiagnosticSurgeryCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AdvanceDiagnosticSurgeryCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_FreseniusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_FreseniusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApaAcoIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApaAcoIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_FulgentGeneticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_FulgentGeneticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ShareholdersAndOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ShareholdersAndOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_NumenLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_NumenLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_SCHCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_SCHCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_OneMSOInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_OneMSOInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ArroyoVistaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ArroyoVistaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PmiocMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PmiocMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DmgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DmgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661153272072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions - Fees Incurred and Income Received (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty', window );">Receipts, net</a></td>
<td class="nump">$ 11,211<span></span>
</td>
<td class="nump">$ 12,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember', window );">AHMC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet', window );">AHMC &#8211; Risk pool, capitation, claims payment</a></td>
<td class="nump">11,366<span></span>
</td>
<td class="nump">13,097<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty', window );">Receipts, net</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="nump">16,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_HSMSOMember', window );">HSMSO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ManagementFeeExpense', window );">Management fees</a></td>
<td class="num">(80)<span></span>
</td>
<td class="num">(77)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AurionMember', window );">Aurion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ManagementFeeExpense', window );">Management fees</a></td>
<td class="num">$ (75)<span></span>
</td>
<td class="num">$ (75)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Insurance Services Revenue, Capitation, And Claims Payment, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementFeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses related to the managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementFeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_HSMSOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_HSMSOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AurionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AurionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661157533416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">31.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661157540408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Treasury shares not included in the calculation of earnings per share (in shares)</a></td>
<td class="nump">10,925,702<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Earnings Per Share [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661154182424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Earnings Per Share Computations (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share &#8211; basic (in dollars per share)</a></td>
<td class="nump">$ 0.32<span></span>
</td>
<td class="nump">$ 0.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share &#8211; diluted (in dollars per share)</a></td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding &#8211; basic (in shares)</a></td>
<td class="nump">44,681,218<span></span>
</td>
<td class="nump">42,336,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of common stock outstanding &#8211; diluted (in shares)</a></td>
<td class="nump">45,994,868<span></span>
</td>
<td class="nump">43,566,189<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661153792008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding &#8211; basic (in shares)</a></td>
<td class="nump">44,681,218<span></span>
</td>
<td class="nump">42,336,434<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of common stock outstanding &#8211; diluted (in shares)</a></td>
<td class="nump">45,994,868<span></span>
</td>
<td class="nump">43,566,189<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Adjustments to weighted average shares of common stock (in shares)</a></td>
<td class="nump">482,337<span></span>
</td>
<td class="nump">318,749<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Adjustments to weighted average shares of common stock (in shares)</a></td>
<td class="nump">101,891<span></span>
</td>
<td class="nump">99,219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Adjustments to weighted average shares of common stock (in shares)</a></td>
<td class="nump">729,422<span></span>
</td>
<td class="nump">811,787<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Earnings Per Share [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661147899944">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Variable Interest Entities (VIEs) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 237,942<span></span>
</td>
<td class="nump">$ 233,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 193,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments in marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">42,893<span></span>
</td>
<td class="nump">53,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">55,280<span></span>
</td>
<td class="nump">10,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Receivables, net &#8211; related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">76,410<span></span>
</td>
<td class="nump">69,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,260<span></span>
</td>
<td class="nump">9,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,631<span></span>
</td>
<td class="nump">18,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">444,416<span></span>
</td>
<td class="nump">398,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">80,148<span></span>
</td>
<td class="nump">82,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">252,379<span></span>
</td>
<td class="nump">253,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44,383<span></span>
</td>
<td class="nump">41,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,770<span></span>
</td>
<td class="nump">15,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,424<span></span>
</td>
<td class="nump">5,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">467,915<span></span>
</td>
<td class="nump">453,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">912,331<span></span>
</td>
<td class="nump">852,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">48,252<span></span>
</td>
<td class="nump">43,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryAccountsPayableCurrent', window );">Fiduciary accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,305<span></span>
</td>
<td class="nump">10,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">95,758<span></span>
</td>
<td class="nump">55,783<span></span>
</td>
<td class="nump">$ 51,479<span></span>
</td>
<td class="nump">$ 50,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">556<span></span>
</td>
<td class="nump">556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,503<span></span>
</td>
<td class="nump">780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">543<span></span>
</td>
<td class="nump">486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,625<span></span>
</td>
<td class="nump">2,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">160,436<span></span>
</td>
<td class="nump">115,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">183,101<span></span>
</td>
<td class="nump">182,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,686<span></span>
</td>
<td class="nump">9,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,172<span></span>
</td>
<td class="nump">973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,558<span></span>
</td>
<td class="nump">13,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,706<span></span>
</td>
<td class="nump">14,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">220,223<span></span>
</td>
<td class="nump">220,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">380,659<span></span>
</td>
<td class="nump">336,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">142,862<span></span>
</td>
<td class="nump">161,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments in marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">38,534<span></span>
</td>
<td class="nump">49,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">23,539<span></span>
</td>
<td class="nump">7,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Receivables, net &#8211; related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">69,948<span></span>
</td>
<td class="nump">62,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income taxes receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,885<span></span>
</td>
<td class="nump">1,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,649<span></span>
</td>
<td class="nump">11,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableRelatedPartiesCurrent', window );">Loan receivable &#8211; related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromAffiliateCurrent', window );">Amount due from affiliate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,150<span></span>
</td>
<td class="nump">6,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">313,567<span></span>
</td>
<td class="nump">305,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Land, property, and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">68,598<span></span>
</td>
<td class="nump">49,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">61,301<span></span>
</td>
<td class="nump">58,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">116,226<span></span>
</td>
<td class="nump">109,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableRelatedPartiesNoncurrent', window );">Loans receivable &#8211; related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">69<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Investment in affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">529,569<span></span>
</td>
<td class="nump">802,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44,383<span></span>
</td>
<td class="nump">41,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue', window );">Investment in privately held entities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">405<span></span>
</td>
<td class="nump">405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,644<span></span>
</td>
<td class="nump">4,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,849<span></span>
</td>
<td class="nump">3,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">827,044<span></span>
</td>
<td class="nump">1,070,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,140,611<span></span>
</td>
<td class="nump">1,376,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,700<span></span>
</td>
<td class="nump">11,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryAccountsPayableCurrent', window );">Fiduciary accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,305<span></span>
</td>
<td class="nump">10,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">61,220<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">481<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">556<span></span>
</td>
<td class="nump">556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,503<span></span>
</td>
<td class="nump">780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">543<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,249<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">86,557<span></span>
</td>
<td class="nump">68,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,063<span></span>
</td>
<td class="nump">7,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,978<span></span>
</td>
<td class="nump">1,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,172<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,651<span></span>
</td>
<td class="nump">3,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,542<span></span>
</td>
<td class="nump">9,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,406<span></span>
</td>
<td class="nump">22,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 110,963<span></span>
</td>
<td class="nump">$ 91,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Company&#8217;s consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#8217;s consolidated VIEs totaling $585.9&#160;million and $567.0&#160;million as of March&#160;31, 2022 and December&#160;31, 2021, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $111.0&#160;million and $91.7&#160;million as of March&#160;31, 2022 and December&#160;31, 2021, respectively. The VIE balances do not include $529.6&#160;million of investment in affiliates and $25.2&#160;million of amounts due from affiliates as of March&#160;31, 2022 and $802.8&#160;million of investment in affiliates and $6.6&#160;million of amounts due to affiliates as of December&#160;31, 2021 as these are eliminated upon consolidation and not presented within the consolidated balance sheets. See Note 16 &#8211; Variable Interest Entities (VIEs) for further detail.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiduciaryAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiduciaryAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership, due within 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=d3e56071-112765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39599-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due within 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due after 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661148168344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease option to extend (up to)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRenewalTerm1', window );">Finance lease option to extend (up to)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable', window );">Operating lease, termination period, if applicable</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable', window );">Finance lease, termination period, if applicable</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Assets recorded under finance leases</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization', window );">Accumulated depreciation associated with finance leases</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term, operating</a></td>
<td class="text">4 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm', window );">Remaining lease term, finance</a></td>
<td class="text">4 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term, operating</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm', window );">Remaining lease term, finance</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Finance Lease, Termination Period, If Applicable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Termination Period, If Applicable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRenewalTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRenewalTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661155256888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 1,574<span></span>
</td>
<td class="nump">$ 1,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceLeaseCostsAbstract', window );"><strong>Finance Lease Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Accumulated depreciation associated with finance leases</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(126)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost, net</a></td>
<td class="nump">$ 1,609<span></span>
</td>
<td class="nump">$ 1,246<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceLeaseCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceLeaseCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661159265816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Other Information Related to Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 1,547<span></span>
</td>
<td class="nump">$ 1,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows from finance leases</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows from finance leases</a></td>
<td class="nump">$ 141<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted Average Remaining Lease Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">6 years 1 month 2 days<span></span>
</td>
<td class="text">6 years 8 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases</a></td>
<td class="text">3 years 3 months 21 days<span></span>
</td>
<td class="text">3 years 5 months 1 day<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LeaseWeightedAverageDiscountRateAbstract', window );"><strong>Weighted Average Discount Rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">6.10%<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases</a></td>
<td class="nump">4.31%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_CashPaidForLeaseLiabilitiesAbstractAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LeaseWeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LeaseWeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LeaseWeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661148137048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future Minimum Payments Under Non-cancelable Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022 (excluding the three months ended March&#160;31, 2022)</a></td>
<td class="nump">$ 2,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">3,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">2,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">2,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">2,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">4,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">18,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">3,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">15,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="nump">2,625<span></span>
</td>
<td class="nump">$ 2,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">12,558<span></span>
</td>
<td class="nump">13,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022 (excluding the three months ended March&#160;31, 2022)</a></td>
<td class="nump">470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">1,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">1,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="nump">543<span></span>
</td>
<td class="nump">486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">$ 1,172<span></span>
</td>
<td class="nump">$ 973<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140661155488456">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsCurrent', window );">Restricted Cash Equivalents, Current</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_RestrictedCashEquivalentsCurrent</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsCurrent', window );">Restricted Cash Equivalents, Current</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_RestrictedCashEquivalentsCurrent</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as current. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>ameh-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ameh="http://www.apollomed.net/20220331"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ameh-20220331.xsd" xlink:type="simple"/>
    <context id="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if80c5db3cf224b5d92f4efbc74830e91_I20220428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2022-04-28</instant>
        </period>
    </context>
    <context id="icdb7399a6abd460491239b97b7522507_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9c0728e5be5f486992e2eeff2682d1eb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i082ebdd9e5cf4b14937116ed41c6d210_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id2b4439fa02d406d9c63972d386e09c1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1b27218f21ed45fc8fe5af87b6180da5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1968744464b94c44b565a81c2bf9632e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id271ccfbc8e049649cd2b13460a8e718_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i45babd110e5c45fe951fced5efef52c3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7b8093adf4ca4e659bfd5cc3d0bf5b91_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6fe7d345269d429594a7165974ccdcb7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i17d738adb8bf4c52a41f5eb43d954b81_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i81200d008433465fa399ae7b4f619096_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4efb856004934021887d5c4fcd6a352c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7dce717fa9914fab879521d726f8cdd8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib7675a417e574dd7bfb341601fa58abc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifd48abaf892342879b0c004889f6395b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0edd9918dcb74ab7b7be0bfe975e98a6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1cc1737bb2ac452c8108152c0b78582e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie565cc08147249b5871999e0d1765ed2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i01c06a901fad47e3a2666a70fe1188df_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9910c7555ace4c2bb115be314dd355b1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3795672568804fb39265965ff8ee0616_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i934f486ebd2244c69aedfbc72f32d753_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i30aca1425f44492ca189ea4600ae924d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4ab27752b93f42388e90627d8c8ba555_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ieb4c95ef672647aca0d3f58bdfd3fd09_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0cce845b4bcb47d4937d16c1ce6294b4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i891990513de04b79b3fbaedbe290deb4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i95ae6859a8584e7eb08ef41e08f26b99_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3e20c02c36c543ab98bbfa086f702db6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8b7e2b312b964191b6e5a99bfa3fad1c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie3da6bad4ba14fb884f02c88f6ad7610_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i48596fff82734547a44b9e4ec2fc95ef_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0f6053bba0574b7c8d8bc3d35aedd364_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaedbc96dc4de4eab8aed3c10bf0e0fb9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id9015851c456402f83746f4b6976dfbb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3b1648f5a7c74820b4705fadeec2d2c1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icd3ffca58ef641c493f6d69c9456f642_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib537036edf0744c69646e8a9929a0638_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7907a63ed1d0470a879fdec321fba0f4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8ea6fe0d59b441beb7ba9b153d330fae_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i109c5e7bd1a14ea599c3a7723e99ade4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0e0d03cf0c84427db63e13d4e462e4e8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5b20ee5e4cb845b183e38f28737aef7a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5879b7991869438bb805be20df7ad0b2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia98bbfcdcddb4e23b97bfb35198297b4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i24aeb633ec154645a1fed86ccb4c65cd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i13156f57748c4cfea02dbb45bd3312df_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibe9ce7d0bb51473c9da95e7918990fd8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5144afd8082f4f17afadb8908f6b4051_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia01bac51df004e83a5b940703fb94049_D19990701-19990731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1999-07-01</startDate>
            <endDate>1999-07-31</endDate>
        </period>
    </context>
    <context id="i080d2011774f4a4f8a04e8046723b130_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i3bec4a71e3844c82b36a7dcc2f0a553b_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i42aa94e36eca45219242d025187b81a7_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic951a78e8e8641ca82615311f26c6e86_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="iad63aacc748841208955dbad50055a32_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic413e1b24cbb43588d69ee94b270c426_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9401c9559d0a4784bee72fa3bb729bdb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i433e9e4dc783427e8e6da7ae18299e15_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ConcourseDiagnosticSurgeryCenterLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1a637dbd41eb4403a231966d0c1d8747_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MaverickMedicalGroupIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iea7256f5bdac481c9e419242402ecfad_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6791450b303a4baaa9c950aac4835c7a_I20190830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-30</instant>
        </period>
    </context>
    <context id="i6618dfdd38574ddd8411e3675f60590e_D20190830-20190830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:Dr.JayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-30</startDate>
            <endDate>2019-08-30</endDate>
        </period>
    </context>
    <context id="ibbbf646a84b242da86cd62eac12d7711_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AmgIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4258726bec994a1db1b081a69de757a8_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i5c160ab74e9f4f3f897f16bcf956f33b_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4452193fa6da4189b503a5f1f57ad4be_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5456a038b204408f8d123aa76b5524e2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib943b580b1c64fc1a7579f4ac67aa99d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iade67c79de8c433297cb64b0aa007e48_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i27d0462359864892b029d29f2dbae1fa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:MPPAMGPropertiesAndZLLAssetAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9e3006cf844c4dcfb98b8464dfdfecaf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iae649481fa4d4190a0f5b74bc999a510_I20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccessPrimaryCareMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="ic4078597aaf8463a99cbfd3e8f573353_I20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="ied48cf0dd52b4ecbacf11485317313d5_D20210801-20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="i47183d9ce9704d30b6eb68894c2e74b3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5067812e23e84e4689a191e85614e031_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic8bb14e9746c41a5b4dc59dfc7318107_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8b1b466c96f147349e71fb4f01795a7f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i06add27710ea4d7785d87fe89373d1fc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib71613c16b2142f097495def3277d766_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i4057678e762644689f10e4ee0607dbed_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:ClinigenceHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if1368e96397d4afb8a5b06c97f9a0e75_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3540b9617bba46ec9221f435473df8d4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i97b7e4411cac4f46bd0609f16888cd7b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i41c5d4e729a642c3a0808ffe69396270_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5c16654928bd4eaca5078b4d6cf0e50d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib5b721f38495479baa1888225f569bae_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic00f4d20ec264fa5b0dec1e5c289db51_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i44447a5bff9d47778021966b6c04440e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i23c400c680394251b215b33cfde92dbc_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib41161b4c97242dbb50361fe75def7b4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iab747f9347d841d7bed8d71175fd16b2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia9221a81959848e0875b822a89e77723_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib4a11153cacb478db352c47209bdd22f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3b9b5a97cba2458e80bbc32a7003a7b5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ide74daf0c2af45c6b4e6486c2b5f07af_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i062a900e196f43a8ad8c043ed3e37741_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7344d9ece6c54bb7a3445b3b4305a208_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8004dd5aaab243ceaebebdd9dfbe5dea_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6526cb352ff14142ad0267923f9b8458_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6cf7e945065b4cbb9be75f83ecca429e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0e0b992a4a41411caa3cf99acedc7773_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i812e1314b74e4b39965703038178723e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i317853952d064c0aae4c8f6086f08c69_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i395def431eb24cc797be851df63b772d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0f97d77f9a334dfaa7f626c14651831b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idedee00e5b814c9ab93ebe0cdd4eefcd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibe65b799ceec4dd4b60d0ed19b877f0c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4f4a833b59b64e6fa2beeccb4539ee17_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iee4f95d0daa5491a9f9b7cf6f20f14f0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1b31a7f7ad9f4eeba82e05b893d8837b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibf6c453b31384c85a91a6dac3bd293f9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i344120b3c93044e5a4e890535a20389f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7191ac8fddae474f98a72365faf35498_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i48154c88054d4bfca4aae23d986f326d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icef23c4f80af41b4a7678b0043957020_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id889a0adfcca4b0483674775e3b7017d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i670c182c37f64d7c81e6e512f5a85911_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1c9680a3ecd2478e8c69cac5c0ca57bc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i626fc76fa8044b489370befcecb36ff4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i54a2dd1d9f194b41bd57c7a175d4260e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icb648af0ac4046e19f5473b63dcc3dac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i64f9c2d2092e49e2a51aeaedde7588ff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaf96d2529f4847d2820cfaff15062529_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9227a3f5dcdb4fe389f9629762b21c04_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i06ded7d511214a6b934ce38ddf56629e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iaaeae6dd376a4544a532f6990d6ef02b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ice1126416af04bd8bb625efbc5740cee_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5f76f479c78d4715a3a1756814601111_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:PerMemberPerMonthManagedCareContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i129c72bde37445abbf565db10f855c61_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:CMSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i37c332bfa67d49cea1f207293667f549_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ameh:AccountsPayableAndAccruedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4043dc9bcd1c428faf9de8df64df4c4c_I20220124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:OrmaHealthIncAndProviderGrowthSolutionsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-24</instant>
        </period>
    </context>
    <context id="ic90a69d35de04dc89bd59af6b50c84d2_D20220124-20220124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:OrmaHealthIncAndProviderGrowthSolutionsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-24</startDate>
            <endDate>2022-01-24</endDate>
        </period>
    </context>
    <context id="i25fa08dfbba0471ab1f73eb7a33ab853_D20210701-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccessPrimaryCareMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="i4326870dc64f4f2f89fd5df3a7f241eb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccessPrimaryCareMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i963385d3851043318a55cac8d1d8e584_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i72e8469da6fd456bb61b083d9a9a2852_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9449f60b9fc845af955a5c89466e5184_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i505d1f1aced648e2ac90c9458f190dd7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib92cc8812a2d47588d05bc790009d105_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0f4cf5ddfa684bd38d0791137d1d848f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i81cd72537a24472dad3429c1494fb9d6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic8569af65a8b4eb9b5df3177f8dd7840_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2b86c52f7f00483faef56f69b319a5ee_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i01b454e0ae7d40d0aa1b524fc4c468b6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i120f957d1af8440481f28a0c928f55b4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id3c1ae4a3ee14160b77a83df27148f53_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1d30ca934a1c4d25a5117a64b30e1ec6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7c57be7d1d9b4186b0c62d58ed16439b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0d873576e5c74d678a79c2181b0def05_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9f881cf7eb4448d49160c4fbe26a606f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic42c656984834bbe802a92fc9c2db0ec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifb3e802a663f4a6b942e4d29cad772ac_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i181ceb45ba734f1e941c3bc5aff82a91_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2fe5dca6b3c94505aeb4f1b8542dce43_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib6f7ecc2ad814ce19177b1caaed8db74_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i82294d54cab940218597a90c5e4ee4f7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic7f4421b21eb4d46abaed6eca504bfe6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iece03f9e8f8a4d22966891f53113f721_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i64402309fd5e4e24ad7105d9ff70a80c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2f11ce9c14364c19887f12faf318e05b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i336efd7ddd3a421f8e5bba9c0816384d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i43360692494245daa938bbb454eea503_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i36852b2625274d7c94f009efe3625131_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iefb065d83e134399924dcb98a8810645_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i20b270836e8e4edfad0aac1201a837a4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i905a801d6f9b4c9ebe17dff9567e4e65_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ief0c35819b504b239cc32ffedc16b209_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib4103b5415884a2cb86152b06ab31f87_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i98dd8ff17e4643278bde170255559ba3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia36eb2cd63f7429d942e17270c0144bf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6b3e371af52a4f9ab3b9ef33b8762eb8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i75681772568f4aed9e00dafa27af9156_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i79f112c0b31c40119270d0df81451392_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibe110e391f1347168555105f65ea038b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id638b192e4b34caeb8ee0fc5e44f48b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i418e308a689d48d4b3de11c2556a4e0f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3f6b860f41b44b04be3fcc1cfe3c2c04_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie6f6ea60415248a6a49fa2d020393b3d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6e7eadc502bc40c6afc071e235c3a98c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i83299a5c90454ecb81deb339e22e4f52_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5bb2d59135f449d3b0e13fa8b28b3809_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5a35e5e78f804b03bb635d5e8df0b4c1_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9ef6f6f7c71f41d68d3add3e70068bc2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib1e3f77f67924bf1b0442138b0c59dba_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic99a2a30fd9144b38c44bd4c90924f6a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i33512e53ca8042e592da50359233581e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id918b0f4941f497f8df9f3953fdf4349_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i224451997ac146958e193c349e0fb137_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i66228b4952d348d9bb6a6f5bd4664a45_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2a5eaf12f18d437286bc9774e4ff6a25_I20150731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-07-31</instant>
        </period>
    </context>
    <context id="ibb7c2acfad5f4d90804dbceb6ca499a1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia67e2b3c33844eafa88eaa05867d7330_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if29bacb1956147fd920ad140828ddf9f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie3512656649a4da789290c7c1a39c58e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie338e6a85a00449c8cb3d0ff9d028af5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id4e2dedbf7694c72b5426585e1f6319e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibf6b4576ffe04e9896a15272126c5839_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6178c9a34de84a89865b60e90b6cf17e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if344fb7586ce4a30a4cbc6d36795b630_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i77422bd33cbc45a1aa372bb8875076a8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if8ed7dfc5ec64dbf909fb3b011b41b8e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i48cf45716cee43579c307972d6f19091_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i168c9d857e684999a379e78e91b03f10_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i127fc1bd4bad4c958f81e1514ab97618_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib5916967379848d7af484250dae5a588_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iea22839056f1415e802909f3740eb6f7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic3691558e51545d9b1a33f630ec3101d_I20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="ib9fc9a6b261b43fa800eedc49ae6e150_I20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="idf10dc5a3be94d50a589bf004e41c88f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ief73fee5943140169a860306e97c01dd_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MediPortalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i0a260d4203424cdc969b85797dd116c6_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MediPortalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i1d2082812210428bb7329995875a8388_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="i519cba15a31640d3bead178989c651a5_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i6f1f415161e146c9982274d3873b0801_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i23ad757dae0649c281c2c43b079538ea_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Pacific6EnterprisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i83913ad0855f49819cfa7c93494153e4_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i26c2e65389c446feb05b2d425a1f08c3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie53154e5f8e44ab2b5b3bc67ed958b95_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia038bf044a5d4b0888c9404c8ef66dce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7ead42b914f74b3a87c5e08a25135c1b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9875be1595584e8793d5a44cabe73104_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia5ff5967c0ad489ca405c9a26138a568_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i04ec29552d16406bb563e4f777751d86_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i93bf4ca5dbf74632b9bcabe542799cf2_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="i6759c2e740754692ab17fe6126840652_I20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-16</instant>
        </period>
    </context>
    <context id="i121db6aa4f234342a066091bbc811f6d_I20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-16</instant>
        </period>
    </context>
    <context id="i2ae5de1ac50140b281d6c8428a5ba873_I20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-16</instant>
        </period>
    </context>
    <context id="i958aafc9bd314ec7a793b41fdf0cc64e_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="if3c3078e4a3a4a97a896b1bc5d0087ef_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="id506af9420ac471bab63d3cba404a645_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="i411a85b04db242d0933b3b997de7b7be_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="i18d5ab7831f740cfbce7f376753f0fba_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="i73d5e3fe56914cf8b95c7c29e9501364_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="i79fd9f0ba878471db847749cc1aa145b_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="iac76cdf5c1e24249bd2cc8b73cea2d4d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iddc202a2a74a429aa384ca0e94f1385f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iab25699159ef422387acd33b3b0c73ae_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia35d32a022eb4f8296d246475815c7be_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i5ceb4bf299aa4fbbb15c38ae65b24964_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6af45110227947abb0e1effa0224037f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i29d27efd274e4640b991eab78aed11b9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8159b237bb57472289fa8745bfaf2c2a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id327c3f30f5442849d60a0720899b6b3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i59ee99254c40475f9b21b9cd872385a5_D20200703-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-03</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="ibb454af8f35b4571bbc0568a6ef8fabc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0c1305632b254a819190bb04db42d4b9_D20200703-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-03</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="if79f0e1f750c4d29acae8c2424f6b5a8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8c965773654f4f76b80d01904268a252_D20200805-20200805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-05</startDate>
            <endDate>2020-08-05</endDate>
        </period>
    </context>
    <context id="if9463aae35c1447dbc10b94c90792330_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id9e05712a8f3404c91c7767902090d7c_D20200805-20200805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-05</startDate>
            <endDate>2020-08-05</endDate>
        </period>
    </context>
    <context id="i28e98c01e378431d9b395cc096cd64f1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i906733a30f24439e91bed1e3615ea7da_D20200727-20200727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-27</startDate>
            <endDate>2020-07-27</endDate>
        </period>
    </context>
    <context id="i3860353465b34dcf83559f00d6e7e4c0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifff506fed9ef409ab5281dde682b04df_D20200727-20200727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-27</startDate>
            <endDate>2020-07-27</endDate>
        </period>
    </context>
    <context id="i039bfa2066b9445ba0c127c9a6b7d4e6_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="ifeba7e1f896c47b0bb477b27fd52fe58_D20230101-20231201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-01</endDate>
        </period>
    </context>
    <context id="i3e730da764a64b29b490afda93124c70_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idcefe512b59843c5a4b809aa58d86dbf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8011f60b0322450ba7087bebdbf48e81_I20190910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-10</instant>
        </period>
    </context>
    <context id="i5a5028538cf949dc976825957bdc20fc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id77595136aad43ce85c81570c5c6ccfd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iaa89643a73ac4d02b199b59ae1e04e17_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic6ec9c984e0f4663b1287c8a1e6f562c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if917b814792a44f39620641ac0df4997_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iba53eb44c7b14a578bb900cac19accbc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3fc704f23ee3440f959bc11b81e7d01f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i59a87528beae42e5905d598caee23304_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1c4a21ba18bf43e2baa22838c457ebc6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib33aa0fdefb44c68985101f13840b075_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ameh:StockAwardsAndUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia57bf156054149e8aed82c44fb4a2e72_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ameh:StockAwardsAndUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id93dea0ce70b4ff2b46f7a49428856fd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2ed7fee6f6304a0998e815c8e5445108_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ameh:EmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3d75852709414d64af680d539dcb36be_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic8fe9de9677f4084b60ffc90c8a538eb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1274ac1b93074e91b7b5207ef70ffa3f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i742b25817ce54efbb408cfa331c5fe5f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i52ed974f00584c72870ff83e96c517c6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3c33bc11247c47b3bf81a50827becf69_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9bc146c68b944c84b6e8aad1dc0a79e5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i17b21603feaa4b6eac83277e537457e2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i481003839719417595b8ccd16571b1b2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7cfeff39834e4f6c84395e2d7dabac69_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i22448a574a694a83ad45e720a7b0491c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i789d3da0a72b4fb89b415c17b6bd2710_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia90b2ff413524e3b90acbbb605243bbb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i297879f201e2401b809e877bc5ca8f1a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iaf372c04e8fd4b7fb0fe8f937ab557bd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i706233a8610b47c986b542c84fc02826_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id61632e270d643278e5a45ab9d986834_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1501307448a04213aad7bd6a8043ca3c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4bee43ded60043dbad50b78762e0cfef_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie54e1b2ff59741a89b0243c59b6ef686_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib152b2b747a74eaeb8147b82a52c9e8c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iaa7033a548444263ac0237b0218a1adb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib5bf970dcad14a8ba4515f1f82038323_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idc43c382a55f4e86bce82fa55ccdec8b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifa663b2f13a34f278cc8242cfbd66f60_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9cb30ce0828947b2b67749be5fbf6bfb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia9fd61dc32854b5794c5219cd64b9c91_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i149029e085754aa781bb4c12925033e9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9a32ef7fa5834e35b4d3446fb2b911d7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i585cd6801b0a4b76917339116f149737_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1e581b13ba1943ada689751040932d87_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7c6d4670d2704e46854a6d362d7ff8dc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8a544d6c34914e8180df76ac79f9061c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia407282c4d7c40f69b845a1980e98f90_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0a710728186e429c9f56a34cae4c7cd8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i119ac7d8ea0849dbb246ad71c51fe403_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic4788b32e9914d0ca0604092d88f6375_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaAcoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia7c1281284034e199a945b4fa25a565f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaAcoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i81646c8d09a94a9aaeadb368f60bd221_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FulgentGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic6a40ab43ad94c908617b8e12ab58ed0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FulgentGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2e92ca4dba96429ca6f565c4a96fae69_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5ef6c81ae0d149dcb8f839d22ecdbf4f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i69208e7b66d34e81be1ece056152eb3d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if7a4db8db1a74901a4e3415b998623f7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iffe651efb930429a8995404b0dc53e6b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie54eef2ca9b5495ea95cad9493906234_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie96af2c696c5435d811fd5623d3302c5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i725a2a08b1e34d65984bdfc031ea6bdb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1c049a48265c4b71906a6728352ec4d1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4608970f45fe4db1a3f4e42e64795259_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifde0ed94454e448ba35d1211452c3daf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ArroyoVistaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i41d101f6c0b44f5aad791956bdabaa9d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ArroyoVistaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i88100c9376d541219eea1723b76e0ce5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5e4fd86eeb0b4ab68d020185faa91a8f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3339dc21c97b4534b86a86264b8aff7b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iac761ad94565453fb1630b4de5935fbb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i66d10132ebde4c69977f0b31055a0271_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i73c05785e9ff4c7cbf5b3cfde9945e78_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if14f6b3f9f9143678ca31fa46792180a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8e487ca262164803a2471112a5aa3b86_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9ac40763eff9488da386a8f3f515dcd2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2437426902314907bb93c3e3a054e882_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idbab252c85d54d69abb776900de44d5a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib88b8cbaf9c044f48d97f4585c10e9b1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8dc8e8d5b2d3450c82e20483d0b1d396_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6cfa814cabb748ff9a56f20f22646f52_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iad0d67abd1ee4eb5a0b58ae347cb78d5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9f93afb80fb24f97b3aa96bd0066452e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6687248226604b5aa14b27933ac85631_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if57d38b69b26462fbe9ef33ebe278bce_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9d3e933fec544494a455857f02039dc6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib066bd91431342b3ac8d11e80261834a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6a6d0c95500f4e4bae253dfa35567e77_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="plan">
        <measure>ameh:plan</measure>
    </unit>
    <unit id="clinic">
        <measure>ameh:clinic</measure>
    </unit>
    <unit id="segment">
        <measure>ameh:segment</measure>
    </unit>
    <unit id="unit">
        <measure>ameh:unit</measure>
    </unit>
    <unit id="financial_ratio">
        <measure>ameh:financial_ratio</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80L2ZyYWc6NjFjM2Y5ZDUwNzQzNGQ3ZGI0YTgyYWZhYTI2OTk5NjMvdGFibGU6ZGU1ZjFlZjFhNzM4NDhlZTg3OGEyNGIwNzgxYzQ5NGIvdGFibGVyYW5nZTpkZTVmMWVmMWE3Mzg0OGVlODc4YTI0YjA3ODFjNDk0Yl8zLTEtMS0xLTcwMDQy_24bdc420-2589-40ad-adb4-183280aaa9e7">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80L2ZyYWc6NjFjM2Y5ZDUwNzQzNGQ3ZGI0YTgyYWZhYTI2OTk5NjMvdGFibGU6ZGU1ZjFlZjFhNzM4NDhlZTg3OGEyNGIwNzgxYzQ5NGIvdGFibGVyYW5nZTpkZTVmMWVmMWE3Mzg0OGVlODc4YTI0YjA3ODFjNDk0Yl80LTEtMS0xLTcwMDQy_6ba248d8-e727-4e56-bb63-e209c5e28b16">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80L2ZyYWc6NjFjM2Y5ZDUwNzQzNGQ3ZGI0YTgyYWZhYTI2OTk5NjMvdGFibGU6ZGU1ZjFlZjFhNzM4NDhlZTg3OGEyNGIwNzgxYzQ5NGIvdGFibGVyYW5nZTpkZTVmMWVmMWE3Mzg0OGVlODc4YTI0YjA3ODFjNDk0Yl81LTEtMS0xLTcwMDQy_8cda3dff-5c4e-4c16-8197-41380dcc7e65">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80L2ZyYWc6NjFjM2Y5ZDUwNzQzNGQ3ZGI0YTgyYWZhYTI2OTk5NjMvdGFibGU6ZGU1ZjFlZjFhNzM4NDhlZTg3OGEyNGIwNzgxYzQ5NGIvdGFibGVyYW5nZTpkZTVmMWVmMWE3Mzg0OGVlODc4YTI0YjA3ODFjNDk0Yl82LTEtMS0xLTcwMDQy_a2e23a05-0455-482b-ba96-fd9648dd123a">0001083446</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80L2ZyYWc6NjFjM2Y5ZDUwNzQzNGQ3ZGI0YTgyYWZhYTI2OTk5NjMvdGFibGU6ZGU1ZjFlZjFhNzM4NDhlZTg3OGEyNGIwNzgxYzQ5NGIvdGFibGVyYW5nZTpkZTVmMWVmMWE3Mzg0OGVlODc4YTI0YjA3ODFjNDk0Yl83LTEtMS0xLTcwMDQy_b97825c6-0e98-4dea-80c8-38dcfec4af48">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGV4dHJlZ2lvbjpmNDkyMmYxMTNlYjQ0YmM5OTg1OGZmZjQ4MjA0YzQ0YV8yMDkz_16fe3c9a-3cef-4260-b47a-11783162e7c0">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGFibGU6NTVhNzk5M2Y0NmNlNGRiYmI0NjllZDM1MDVmZjI2NTQvdGFibGVyYW5nZTo1NWE3OTkzZjQ2Y2U0ZGJiYjQ2OWVkMzUwNWZmMjY1NF8wLTAtMS0xLTcwMDQy_7fd2e898-e4f2-4e79-9b14-a31cc79da5b6">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGV4dHJlZ2lvbjpmNDkyMmYxMTNlYjQ0YmM5OTg1OGZmZjQ4MjA0YzQ0YV8yNzQ4Nzc5MDcxNjA2_aed78149-4c11-4fd5-ba7c-c574fc67e4f9">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGFibGU6MWIzNTc3ZWJlZGVlNGQ0ZDgwM2YyNzcwMGFjZWEyNzEvdGFibGVyYW5nZToxYjM1NzdlYmVkZWU0ZDRkODAzZjI3NzAwYWNlYTI3MV8wLTAtMS0xLTcwMDQy_3731a58e-6830-4393-8236-81d84ad45da5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGV4dHJlZ2lvbjpmNDkyMmYxMTNlYjQ0YmM5OTg1OGZmZjQ4MjA0YzQ0YV8yMDk0_19273c80-614b-417f-afba-1ad6ad81cd27">001-37392</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGV4dHJlZ2lvbjpmNDkyMmYxMTNlYjQ0YmM5OTg1OGZmZjQ4MjA0YzQ0YV8yMDk1_81c01298-3692-4b94-a504-6f0f761004ae">Apollo Medical Holdings, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGFibGU6ZTBlYzk5NmZkMjg4NGFlMzg0Yjk3ZWM2YTZlYWMwNDEvdGFibGVyYW5nZTplMGVjOTk2ZmQyODg0YWUzODRiOTdlYzZhNmVhYzA0MV8wLTAtMS0xLTcwMDQy_33514c8f-c449-44bd-845c-03118d55bf93">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGFibGU6ZTBlYzk5NmZkMjg4NGFlMzg0Yjk3ZWM2YTZlYWMwNDEvdGFibGVyYW5nZTplMGVjOTk2ZmQyODg0YWUzODRiOTdlYzZhNmVhYzA0MV8wLTEtMS0xLTcwMDQy_3630b290-f47f-4257-865a-c6ddc4e2f8a0">95-4472349</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGV4dHJlZ2lvbjpmNDkyMmYxMTNlYjQ0YmM5OTg1OGZmZjQ4MjA0YzQ0YV8yMTAw_bd749aa2-d2da-4b41-8655-be390c1271ee">1668 S. Garfield Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGV4dHJlZ2lvbjpmNDkyMmYxMTNlYjQ0YmM5OTg1OGZmZjQ4MjA0YzQ0YV8yMDk2_23c388a9-6f58-4a97-be5a-251afb637592">2nd Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGV4dHJlZ2lvbjpmNDkyMmYxMTNlYjQ0YmM5OTg1OGZmZjQ4MjA0YzQ0YV8yMDk3_d826bdd1-8f79-4b41-8cff-683411356fe7">Alhambra</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGV4dHJlZ2lvbjpmNDkyMmYxMTNlYjQ0YmM5OTg1OGZmZjQ4MjA0YzQ0YV8yMTAx_4fabff80-2b31-42b0-8347-27f5f4d29aa7">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGV4dHJlZ2lvbjpmNDkyMmYxMTNlYjQ0YmM5OTg1OGZmZjQ4MjA0YzQ0YV8yMDg2_14986ce6-c5f0-4714-a7e5-bcfd8c5e8818">91801</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGV4dHJlZ2lvbjpmNDkyMmYxMTNlYjQ0YmM5OTg1OGZmZjQ4MjA0YzQ0YV8yMDkw_cd32e825-3fcf-49a6-b4fd-8680f3b5daec">626</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGV4dHJlZ2lvbjpmNDkyMmYxMTNlYjQ0YmM5OTg1OGZmZjQ4MjA0YzQ0YV8yMTAy_b8c4c69b-8061-4878-92dd-7cc53336e239">282-0288</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGFibGU6NDI4YWFjNmVmNWEwNDdiMzllNDM0M2ExODJiNjdmYzIvdGFibGVyYW5nZTo0MjhhYWM2ZWY1YTA0N2IzOWU0MzQzYTE4MmI2N2ZjMl8xLTAtMS0xLTcwMDQy_841aac52-39dd-40a2-a16b-2cd892489094">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGFibGU6NDI4YWFjNmVmNWEwNDdiMzllNDM0M2ExODJiNjdmYzIvdGFibGVyYW5nZTo0MjhhYWM2ZWY1YTA0N2IzOWU0MzQzYTE4MmI2N2ZjMl8xLTItMS0xLTcwMDQy_15043a9a-1c75-4da5-8c64-10c11fb82e02">AMEH</dei:TradingSymbol>
    <dei:EntityCurrentReportingStatus
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGV4dHJlZ2lvbjpmNDkyMmYxMTNlYjQ0YmM5OTg1OGZmZjQ4MjA0YzQ0YV8yMDg3_877e5877-20c1-4070-803f-61c63c18e6dc">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGV4dHJlZ2lvbjpmNDkyMmYxMTNlYjQ0YmM5OTg1OGZmZjQ4MjA0YzQ0YV8yMDkx_1ffcb813-7c2c-49af-8e29-dad642f46fa6">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGFibGU6ZWRkN2JkOWY3MjliNDI3YmI5MTA3YzAzYzdjODhiMDYvdGFibGVyYW5nZTplZGQ3YmQ5ZjcyOWI0MjdiYjkxMDdjMDNjN2M4OGIwNl8wLTAtMS0xLTgyNDY3_117b5921-415c-42b5-98af-4ccd0a14eb35">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGFibGU6ZWRkN2JkOWY3MjliNDI3YmI5MTA3YzAzYzdjODhiMDYvdGFibGVyYW5nZTplZGQ3YmQ5ZjcyOWI0MjdiYjkxMDdjMDNjN2M4OGIwNl8xLTMtMS0xLTcwMDQy_ae00dbc9-c8b7-45b4-904a-203d0754603b">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGFibGU6ZWRkN2JkOWY3MjliNDI3YmI5MTA3YzAzYzdjODhiMDYvdGFibGVyYW5nZTplZGQ3YmQ5ZjcyOWI0MjdiYjkxMDdjMDNjN2M4OGIwNl8yLTMtMS0xLTcwMDQy_4cfd7f34-c0d1-4973-899a-5e1402c090a8">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGV4dHJlZ2lvbjpmNDkyMmYxMTNlYjQ0YmM5OTg1OGZmZjQ4MjA0YzQ0YV8yMDky_2ede70f9-c065-4c7e-83d1-1ec35bd4f665">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="if80c5db3cf224b5d92f4efbc74830e91_I20220428"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xL2ZyYWc6ZjQ5MjJmMTEzZWI0NGJjOTk4NThmZmY0ODIwNGM0NGEvdGV4dHJlZ2lvbjpmNDkyMmYxMTNlYjQ0YmM5OTg1OGZmZjQ4MjA0YzQ0YV8xOTg5_b0433f76-ebb0-4e29-b6a3-8eaac91787f3"
      unitRef="shares">56048564</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNS0xLTEtMS03MDA0Mg_d5fd204c-c1af-4689-9d11-79578ade4cae"
      unitRef="usd">237942000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNS0zLTEtMS03MDA0Mg_68b30608-22bf-4134-bee2-1dc4775a17bb"
      unitRef="usd">233097000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNy0xLTEtMS03MDA0Mg_d86457c2-0520-428a-99e8-0d79f90551eb"
      unitRef="usd">42893000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNy0zLTEtMS03MDA0Mg_5a3d7af3-3171-4abe-b9ba-90b45f2f2a5a"
      unitRef="usd">53417000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfOC0xLTEtMS03MDA0Mg_eeeedadc-a18d-4186-b78c-b5c490910eab"
      unitRef="usd">55280000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfOC0zLTEtMS03MDA0Mg_95dddbe4-c42c-4863-8445-3afe7524d486"
      unitRef="usd">10608000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfOS0xLTEtMS03MDA0Mg_3adfdf5e-2285-4371-9690-c41e4e56267e"
      unitRef="usd">76410000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfOS0zLTEtMS03MDA0Mg_393c2af1-60a6-47a6-b870-c0b07e2d5b1e"
      unitRef="usd">69376000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMTAtMS0xLTEtNzAwNDI_beab151e-2e99-4012-9705-374c406f9c91"
      unitRef="usd">13260000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMTAtMy0xLTEtNzAwNDI_b2885ae1-f00c-462a-8437-fb3abe710d44"
      unitRef="usd">9647000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMTEtMS0xLTEtNzAwNDI_a8733a30-4561-4d71-b1e9-ddbc7357d054"
      unitRef="usd">14631000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMTEtMy0xLTEtNzAwNDI_3c5d98dc-4cd9-4279-892c-db44e141a843"
      unitRef="usd">18637000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMTItMS0xLTEtNzAwNDI_f7feb749-34f8-4a7a-b09d-525f423b6b6d"
      unitRef="usd">4000000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMTItMy0xLTEtNzAwNDI_994718aa-da0f-40e0-af7b-9be1d0504f3b"
      unitRef="usd">4000000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMTQtMS0xLTEtNzAwNDI_ac71b2e7-8c92-43a8-ae0d-0046abe586cc"
      unitRef="usd">444416000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMTQtMy0xLTEtNzAwNDI_80604bb3-ed36-4aa7-ae15-c8075059c854"
      unitRef="usd">398782000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMTctMS0xLTEtNzAwNDI_ef3778ab-55e3-4c5b-886c-75a1a4f01b64"
      unitRef="usd">70366000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMTctMy0xLTEtNzAwNDI_190b9250-6445-45fb-aa2d-bf695dd41f69"
      unitRef="usd">53186000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMTgtMS0xLTEtNzAwNDI_a2545590-3c31-4098-b392-1c21b8810af4"
      unitRef="usd">80148000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMTgtMy0xLTEtNzAwNDI_54f9bbf4-ad74-471a-bfde-7b01f73d5ff4"
      unitRef="usd">82807000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMTktMS0xLTEtNzAwNDI_ef5b3901-5e12-4700-a2a1-aed3d46dea78"
      unitRef="usd">252379000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMTktMy0xLTEtNzAwNDI_80c214fc-f0fb-4ec3-add8-0e2eac0ca6a3"
      unitRef="usd">253039000</us-gaap:Goodwill>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMjAtMS0xLTEtNzAwNDI_59b8ed9e-a819-47de-af6e-9032afa6444e"
      unitRef="usd">549000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMjAtMy0xLTEtNzAwNDI_78862984-e9f0-4dee-b745-7a145bb250ac"
      unitRef="usd">569000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:EquityMethodInvestments
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMjItMS0xLTEtNzAwNDI_e0e24c4b-d28c-42cf-93d8-7046c914b865"
      unitRef="usd">44383000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMjItMy0xLTEtNzAwNDI_246c3ed7-04a8-4324-92de-db47a464ea23"
      unitRef="usd">41715000</us-gaap:EquityMethodInvestments>
    <ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMjMtMS0xLTEtNzAwNDI_23c8443c-3c95-4ba7-a59d-ebe39351b572"
      unitRef="usd">896000</ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue>
    <ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMjMtMy0xLTEtNzAwNDI_c707cbd2-e306-4715-bb83-297e7a3cd45f"
      unitRef="usd">896000</ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMjUtMS0xLTEtNzAwNDI_285004e8-8a5a-4607-983e-037e8a78e459"
      unitRef="usd">14770000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMjUtMy0xLTEtNzAwNDI_47283b62-8015-4f36-a178-7c03a8464bdd"
      unitRef="usd">15441000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMjYtMS0xLTEtNzAwNDI_f3bfcdfc-31ee-47d3-a3ad-65bf2299dca5"
      unitRef="usd">4424000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMjYtMy0xLTEtNzAwNDI_3ad8f6b8-ffe8-4995-aff0-96481e3d10b5"
      unitRef="usd">5928000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMjgtMS0xLTEtNzAwNDI_ee8181ba-3f2e-42e8-8995-795089e9cca2"
      unitRef="usd">467915000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMjgtMy0xLTEtNzAwNDI_221b712f-7c57-4ba2-a14a-84832bf79844"
      unitRef="usd">453581000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMzAtMS0xLTEtNzAwNDI_27af7b16-5ca8-4fb0-85e6-327746e1b9d3"
      unitRef="usd">912331000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMzAtMy0xLTEtNzAwNDI_9aa87413-0e81-44b1-a6c9-46b296611732"
      unitRef="usd">852363000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMzYtMS0xLTEtNzAwNDI_204bea25-1e66-4c8e-a02d-c0b02036ef69"
      unitRef="usd">48252000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMzYtMy0xLTEtNzAwNDI_bc6a2f04-9d8a-4f4f-af2b-720e4382f1a6"
      unitRef="usd">43951000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMzctMS0xLTEtNzAwNDI_d1f27251-d9bb-49c0-acd9-c24e6f74c7f6"
      unitRef="usd">6305000</ameh:FiduciaryAccountsPayableCurrent>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMzctMy0xLTEtNzAwNDI_6b90ca90-3284-46e1-8910-5e16a6a631ee"
      unitRef="usd">10534000</ameh:FiduciaryAccountsPayableCurrent>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMzgtMS0xLTEtNzAwNDI_7b93beaf-4ec4-4ae8-9a30-35209003a63b"
      unitRef="usd">95758000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMzgtMy0xLTEtNzAwNDI_7729eb9a-18c8-43d1-8735-7e5339184e6b"
      unitRef="usd">55783000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMzktMS0xLTEtNzAwNDI_752d43de-0370-44e5-a9a4-eb3b20f5c2a6"
      unitRef="usd">4894000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMzktMy0xLTEtNzAwNDI_8a2fddf9-1fe6-4c46-b617-0900caeb9f66"
      unitRef="usd">652000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNDAtMS0xLTEtNzAwNDI_0dcfa439-62c1-47a2-92e6-c319e94074d4"
      unitRef="usd">556000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNDAtMy0xLTEtNzAwNDI_568ba4a0-7772-4002-ab8d-873ef1ecdee0"
      unitRef="usd">556000</us-gaap:DividendsPayableCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNDEtMS0xLTEtNzAwNDI_f4a528dc-4039-40f3-95cb-895ad09aa8fe"
      unitRef="usd">543000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNDEtMy0xLTEtNzAwNDI_246307fa-a8f4-4173-8c5c-11a4c1559e51"
      unitRef="usd">486000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNDItMS0xLTEtNzAwNDI_19f7e593-b7e1-4a6b-9954-4ba20f789d94"
      unitRef="usd">2625000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNDItMy0xLTEtNzAwNDI_495a37d4-5c4a-4cc4-af1a-d28bfa4e5a70"
      unitRef="usd">2629000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNDMtMS0xLTEtNzAwNDI_bced1947-30d4-4ffe-8867-f0da2fe64976"
      unitRef="usd">1503000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNDMtMy0xLTEtNzAwNDI_e8f83085-b6d5-4a16-bf91-79dcb0a53a6d"
      unitRef="usd">780000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNDUtMS0xLTEtNzAwNDI_1392eef8-7f7b-4270-959a-c14316f0262e"
      unitRef="usd">160436000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNDUtMy0xLTEtNzAwNDI_4d27bd27-ee84-4e56-b8aa-03b3690c9a97"
      unitRef="usd">115371000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNDgtMS0xLTEtNzAwNDI_e9c27e7d-1a29-48bf-8622-bd70015d3257"
      unitRef="usd">9686000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNDgtMy0xLTEtNzAwNDI_d3f2728c-8f03-4e4b-bfdd-870a37363ec1"
      unitRef="usd">9127000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNDktMS0xLTEtNzAwNDI_3cce7ae8-1d6f-4523-9c8f-2e749f54ab12"
      unitRef="usd">1172000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNDktMy0xLTEtNzAwNDI_407a96ad-1e4a-4f64-b5c0-9015ec2b8b96"
      unitRef="usd">973000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNTAtMS0xLTEtNzAwNDI_6a6e244a-d98a-493b-bcef-17140e29f9a7"
      unitRef="usd">12558000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNTAtMy0xLTEtNzAwNDI_3eb2b47b-c964-4681-a32f-5cf5dd3e4369"
      unitRef="usd">13198000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNTEtMS0xLTEtNzAwNDI_96cc37fc-2781-4afd-b31e-bf0f4de87e2c"
      unitRef="usd">183101000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNTEtMy0xLTEtNzAwNDI_cd6dfd1e-560e-46a2-8d99-1535524dbf2b"
      unitRef="usd">182917000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNTItMS0xLTEtNzAwNDI_8e2a286f-9cd9-42cf-b4df-5aa7290e0ab6"
      unitRef="usd">13706000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNTItMy0xLTEtNzAwNDI_e3700775-6193-435f-b277-114e5ba54f04"
      unitRef="usd">14777000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNTQtMS0xLTEtNzAwNDI_a4625c1d-eb77-4b35-8d90-82326ec055b2"
      unitRef="usd">220223000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNTQtMy0xLTEtNzAwNDI_bba39928-08ad-4899-8d97-21f4a92e7ccc"
      unitRef="usd">220992000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNTYtMS0xLTEtNzAwNDI_8a508be7-60bb-4369-8ecb-378f3b1c0cb9"
      unitRef="usd">380659000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNTYtMy0xLTEtNzAwNDI_c2c1852f-3a60-4cec-a086-28febf1444cc"
      unitRef="usd">336363000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNTgtMS0xLTEtNzAwNDI_a76608ba-134f-4d41-b5f7-c190084d3601"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNTgtMy0xLTEtNzAwNDI_a685e654-109e-4d77-b8a7-0dde8f2f238c"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjEtMS0xLTEtNzAwNDI_6b0f9323-c9a4-4d37-baa5-2c087b5beee0"
      unitRef="usd">52151000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjEtMy0xLTEtNzAwNDI_1ca081b0-9329-4741-b3f0-cfc03e6c3c21"
      unitRef="usd">55510000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i082ebdd9e5cf4b14937116ed41c6d210_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjQtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjowZDYzMDQ0ZTVjYTc0MzY2YjNmYzYxZmM0YTkzZjQ2Nl8zMA_042d5748-b399-4310-a4b6-38bec05f53f6"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="id2b4439fa02d406d9c63972d386e09c1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjQtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjowZDYzMDQ0ZTVjYTc0MzY2YjNmYzYxZmM0YTkzZjQ2Nl8zMA_ada56805-1057-47fd-a694-ef1fc93ecb56"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i082ebdd9e5cf4b14937116ed41c6d210_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjQtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjowZDYzMDQ0ZTVjYTc0MzY2YjNmYzYxZmM0YTkzZjQ2Nl81NA_5b3d7a6f-af8a-46b5-9901-eb215aa1c7ee"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="id2b4439fa02d406d9c63972d386e09c1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjQtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjowZDYzMDQ0ZTVjYTc0MzY2YjNmYzYxZmM0YTkzZjQ2Nl81NA_632bd2f9-2a47-4077-825c-e381a3e2e3ff"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="id2b4439fa02d406d9c63972d386e09c1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjQtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjowZDYzMDQ0ZTVjYTc0MzY2YjNmYzYxZmM0YTkzZjQ2Nl8xNDc_58b35ea6-9d57-4563-8937-8f827b5fd5a6"
      unitRef="shares">1111111</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i082ebdd9e5cf4b14937116ed41c6d210_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjQtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjowZDYzMDQ0ZTVjYTc0MzY2YjNmYzYxZmM0YTkzZjQ2Nl8xNDc_b803e43f-5e9e-4e6f-bf28-4de331799c23"
      unitRef="shares">1111111</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i082ebdd9e5cf4b14937116ed41c6d210_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjQtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjowZDYzMDQ0ZTVjYTc0MzY2YjNmYzYxZmM0YTkzZjQ2Nl8xNjE_7d53ee6a-66ff-4334-a026-ad1a224da0ed"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="id2b4439fa02d406d9c63972d386e09c1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjQtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjowZDYzMDQ0ZTVjYTc0MzY2YjNmYzYxZmM0YTkzZjQ2Nl8xNjE_8b35a121-d69b-44d0-90a0-dcd95783049c"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i082ebdd9e5cf4b14937116ed41c6d210_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjQtMS0xLTEtNzAwNDI_1654f59b-0564-4473-9aba-8936d6c2ede3"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="id2b4439fa02d406d9c63972d386e09c1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjQtMy0xLTEtNzAwNDI_177a936c-b579-4cbe-8bc5-50b610333a03"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i1b27218f21ed45fc8fe5af87b6180da5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjUtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjo3YmI4MDJiZmFmY2U0NjFmOWMxMzVhZDFhMzE5MjQ5Yl8zMA_53b757f4-1042-4f99-8a27-e9b426e1de6c"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i1968744464b94c44b565a81c2bf9632e_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjUtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjo3YmI4MDJiZmFmY2U0NjFmOWMxMzVhZDFhMzE5MjQ5Yl8zMA_9ab7c11f-51fe-43ba-b4b4-402f2c0709b3"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i1968744464b94c44b565a81c2bf9632e_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjUtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjo3YmI4MDJiZmFmY2U0NjFmOWMxMzVhZDFhMzE5MjQ5Yl81NA_a96e605c-806a-4818-a041-b8361dbd0792"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i1b27218f21ed45fc8fe5af87b6180da5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjUtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjo3YmI4MDJiZmFmY2U0NjFmOWMxMzVhZDFhMzE5MjQ5Yl81NA_cf7580c6-0c51-4f22-a081-e9368fba66af"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i1968744464b94c44b565a81c2bf9632e_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjUtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjo3YmI4MDJiZmFmY2U0NjFmOWMxMzVhZDFhMzE5MjQ5Yl8xNDc_76c1eb9c-09d6-4a52-ae42-e6a08e705c6b"
      unitRef="shares">555555</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i1b27218f21ed45fc8fe5af87b6180da5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjUtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjo3YmI4MDJiZmFmY2U0NjFmOWMxMzVhZDFhMzE5MjQ5Yl8xNDc_f21efd85-c0e6-4614-9d49-b4dd4794a147"
      unitRef="shares">555555</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i1968744464b94c44b565a81c2bf9632e_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjUtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjo3YmI4MDJiZmFmY2U0NjFmOWMxMzVhZDFhMzE5MjQ5Yl8xNjE_5642bac7-9932-4520-9a82-aa7f53e58a91"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i1b27218f21ed45fc8fe5af87b6180da5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjUtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjo3YmI4MDJiZmFmY2U0NjFmOWMxMzVhZDFhMzE5MjQ5Yl8xNjE_74e8cc97-9a91-4ef4-96d5-06b97e262e4d"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i1968744464b94c44b565a81c2bf9632e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjUtMS0xLTEtNzAwNDI_ba157e11-b575-41f7-afe6-b4ac2c37a212"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i1b27218f21ed45fc8fe5af87b6180da5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjUtMy0xLTEtNzAwNDI_4cb6a6bc-67e1-47a9-9c2a-e36f4d4175ce"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjYtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjpmYjFlODBiN2VmOTI0NTBlYjM2YzM0ZmYxYThlYjlhMF8xOA_280ec978-7813-474d-8b38-c39a923f256c"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjYtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjpmYjFlODBiN2VmOTI0NTBlYjM2YzM0ZmYxYThlYjlhMF8xOA_57c786f8-b93a-4df1-8250-170d213f087d"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjYtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjpmYjFlODBiN2VmOTI0NTBlYjM2YzM0ZmYxYThlYjlhMF80Mg_a6df9872-b98b-4374-a0a9-6513ca73b909"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjYtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjpmYjFlODBiN2VmOTI0NTBlYjM2YzM0ZmYxYThlYjlhMF80Mg_e54d90f4-e309-4e07-b6f8-c9bc422b2517"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjYtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjpmYjFlODBiN2VmOTI0NTBlYjM2YzM0ZmYxYThlYjlhMF82NA_192fad18-3f17-4bcc-84d9-ff03f5c27829"
      unitRef="shares">44845059</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjYtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjpmYjFlODBiN2VmOTI0NTBlYjM2YzM0ZmYxYThlYjlhMF82NA_62a70567-a191-4664-b7b0-72ef9d579d10"
      unitRef="shares">44845059</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjYtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjpmYjFlODBiN2VmOTI0NTBlYjM2YzM0ZmYxYThlYjlhMF83MQ_507bba01-b83e-4049-afa2-451edd2dff3b"
      unitRef="shares">44630873</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjYtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjpmYjFlODBiN2VmOTI0NTBlYjM2YzM0ZmYxYThlYjlhMF83MQ_6dc0e33b-35fd-4de4-a27a-f61a640c72e8"
      unitRef="shares">44630873</us-gaap:CommonStockSharesIssued>
    <us-gaap:TreasuryStockCommonShares
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjYtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjpmYjFlODBiN2VmOTI0NTBlYjM2YzM0ZmYxYThlYjlhMF8xMTU_19721132-93c5-402b-a86a-5dfc43d262a3"
      unitRef="shares">10925702</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjYtMC0xLTEtNzAwNDIvdGV4dHJlZ2lvbjpmYjFlODBiN2VmOTI0NTBlYjM2YzM0ZmYxYThlYjlhMF8xMjI_b17585e6-d8a8-4c56-a289-71a6855a3851"
      unitRef="shares">10925702</us-gaap:TreasuryStockCommonShares>
    <us-gaap:CommonStockValue
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjYtMS0xLTEtNzAwNDI_d567eb4e-8264-4aae-8ec2-620ea218d2da"
      unitRef="usd">45000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjYtMy0xLTEtNzAwNDI_52420ca3-5bc5-49a2-b9c3-0c83ea0156c0"
      unitRef="usd">45000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjctMS0xLTEtNzAwNDI_d3c838ad-5a0c-434d-87dc-8aedf96c2b01"
      unitRef="usd">316047000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjctMy0xLTEtNzAwNDI_de4072b5-254f-48c1-bf90-50f65bddca74"
      unitRef="usd">310876000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjgtMS0xLTEtNzAwNDI_d04528bf-eb1a-44bc-961b-9089dc2730cc"
      unitRef="usd">157893000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjgtMy0xLTEtNzAwNDI_967fa890-6300-4172-bb44-1fe82ec46639"
      unitRef="usd">143629000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjktMS0xLTEtNzAwNDI_32a98e36-01e0-457c-a8f3-77d189abe755"
      unitRef="usd">473985000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNjktMy0xLTEtNzAwNDI_78555036-a09b-4f88-a0ec-cecd66bf6b4c"
      unitRef="usd">454550000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNzEtMS0xLTEtNzAwNDI_2fd8d766-6c75-420d-b2a5-f056ad33717f"
      unitRef="usd">5536000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNzEtMy0xLTEtNzAwNDI_6a01499a-84f1-4b37-b2c3-9feb77b87ed3"
      unitRef="usd">5940000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNzMtMS0xLTEtNzAwNDI_020531fb-c16f-4dbd-a459-e928e3449025"
      unitRef="usd">479521000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNzMtMy0xLTEtNzAwNDI_a35693b7-3cf3-4c60-8f52-636f4538a6c7"
      unitRef="usd">460490000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNzUtMS0xLTEtNzAwNDI_3d53c672-a442-4227-b548-905a5fc6ca57"
      unitRef="usd">912331000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNzUtMy0xLTEtNzAwNDI_591009d3-eb13-4916-b332-c7adb604d39b"
      unitRef="usd">852363000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Assets
      contextRef="id271ccfbc8e049649cd2b13460a8e718_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RleHRyZWdpb246NGYzMDBhN2I4OGE3NDUyODk0MGQ5YmRiZTMwYTlkN2RfNDcx_2847496b-6664-4817-9e27-b30871370b09"
      unitRef="usd">585900000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i45babd110e5c45fe951fced5efef52c3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RleHRyZWdpb246NGYzMDBhN2I4OGE3NDUyODk0MGQ5YmRiZTMwYTlkN2RfNDc4_43be6491-9ae9-4468-bec5-dca89efee2b4"
      unitRef="usd">567000000</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="id271ccfbc8e049649cd2b13460a8e718_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RleHRyZWdpb246NGYzMDBhN2I4OGE3NDUyODk0MGQ5YmRiZTMwYTlkN2RfNjYy_f2b62901-bbc6-4378-b175-48fddf573035"
      unitRef="usd">111000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i45babd110e5c45fe951fced5efef52c3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RleHRyZWdpb246NGYzMDBhN2I4OGE3NDUyODk0MGQ5YmRiZTMwYTlkN2RfNjY5_026a3442-463e-4251-9e6d-43e28e59c2ca"
      unitRef="usd">91700000</us-gaap:Liabilities>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="id271ccfbc8e049649cd2b13460a8e718_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RleHRyZWdpb246NGYzMDBhN2I4OGE3NDUyODk0MGQ5YmRiZTMwYTlkN2RfNzM1_11eee145-b062-43b6-a87d-47130fbfb264"
      unitRef="usd">529600000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:DueFromAffiliates
      contextRef="id271ccfbc8e049649cd2b13460a8e718_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RleHRyZWdpb246NGYzMDBhN2I4OGE3NDUyODk0MGQ5YmRiZTMwYTlkN2RfNzcw_82be83c7-cf2c-403a-8205-3dcde59c0f62"
      unitRef="usd">25200000</us-gaap:DueFromAffiliates>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i45babd110e5c45fe951fced5efef52c3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RleHRyZWdpb246NGYzMDBhN2I4OGE3NDUyODk0MGQ5YmRiZTMwYTlkN2RfODE3_16b47868-11ba-4948-b649-00c0c135a73d"
      unitRef="usd">802800000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:DueToAffiliateCurrentAndNoncurrent
      contextRef="i45babd110e5c45fe951fced5efef52c3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RleHRyZWdpb246NGYzMDBhN2I4OGE3NDUyODk0MGQ5YmRiZTMwYTlkN2RfODUy_eeb7f78e-8edd-4896-a252-1147488c6079"
      unitRef="usd">6600000</us-gaap:DueToAffiliateCurrentAndNoncurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b8093adf4ca4e659bfd5cc3d0bf5b91_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMy0xLTEtMS03MDA0Mg_a25d4e33-b57f-4e6a-86d7-7cfdce14ff16"
      unitRef="usd">222060000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6fe7d345269d429594a7165974ccdcb7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMy0zLTEtMS03MDA0Mg_4cfa1af7-81af-45c5-9274-4d3cf2ce32d5"
      unitRef="usd">144740000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17d738adb8bf4c52a41f5eb43d954b81_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfNC0xLTEtMS03MDA0Mg_6f1f292f-17d7-4e97-9a1b-3cf95229ceef"
      unitRef="usd">18075000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81200d008433465fa399ae7b4f619096_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfNC0zLTEtMS03MDA0Mg_d768b041-2489-4f46-b7a6-bb0f1a035f3d"
      unitRef="usd">18010000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4efb856004934021887d5c4fcd6a352c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfNS0xLTEtMS03MDA0Mg_5eda2888-5ba9-4fc6-adc0-34cd21293466"
      unitRef="usd">10473000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7dce717fa9914fab879521d726f8cdd8_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfNS0zLTEtMS03MDA0Mg_5d392982-d4e9-4c18-810d-40e761bdec15"
      unitRef="usd">8550000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib7675a417e574dd7bfb341601fa58abc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfNi0xLTEtMS03MDA0Mg_c19e9449-377d-4e23-b513-c8f5d7023baf"
      unitRef="usd">11095000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd48abaf892342879b0c004889f6395b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfNi0zLTEtMS03MDA0Mg_ede140ed-ecef-494c-b002-c92ac7c608aa"
      unitRef="usd">3086000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0edd9918dcb74ab7b7be0bfe975e98a6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfNy0xLTEtMS03MDA0Mg_8c13b6ee-3c25-4b86-a60b-b6748dafdf27"
      unitRef="usd">1555000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1cc1737bb2ac452c8108152c0b78582e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfNy0zLTEtMS03MDA0Mg_a50d22f4-c226-4a1e-a6c7-661a39710e91"
      unitRef="usd">1672000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfOS0xLTEtMS03MDA0Mg_1ab7e37f-dea4-4b74-947b-5277240e2376"
      unitRef="usd">263258000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfOS0zLTEtMS03MDA0Mg_053be6fd-4712-4c03-b6d1-1fa4749cd998"
      unitRef="usd">176058000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMTItMS0xLTEtNzAwNDI_a989a618-aebb-4fe6-89be-c7c749bb374b"
      unitRef="usd">220730000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMTItMy0xLTEtNzAwNDI_a83effc6-635d-49a8-a889-f7816f2a81fb"
      unitRef="usd">140616000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMTMtMS0xLTEtNzAwNDI_68b88f67-1496-41b5-adf5-2e09a61024d6"
      unitRef="usd">11943000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMTMtMy0xLTEtNzAwNDI_b320de5d-242d-4ffe-b3a2-f62aeae6057c"
      unitRef="usd">9464000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMTQtMS0xLTEtNzAwNDI_a625bad1-c103-404e-b7ab-151c606fda35"
      unitRef="usd">4374000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMTQtMy0xLTEtNzAwNDI_c2af3905-e08b-4c64-84de-91c9af6f925c"
      unitRef="usd">4197000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostsAndExpenses
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMTgtMS0xLTEtNzAwNDI_4be932e9-4abb-4881-8762-eb363e574efe"
      unitRef="usd">237047000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMTgtMy0xLTEtNzAwNDI_8597707a-bb72-4110-881f-31f80f7d390a"
      unitRef="usd">154277000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMjAtMS0xLTEtNzAwNDI_ef200dfb-f117-4d82-9e5f-7d65496d3a3f"
      unitRef="usd">26211000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMjAtMy0xLTEtNzAwNDI_ce97edc9-c190-4bda-a8dd-1e8316932096"
      unitRef="usd">21781000</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMjMtMS0xLTEtNzAwNDI_4ce79814-2213-498b-8d0c-9aae984c0afa"
      unitRef="usd">1433000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMjMtMy0xLTEtNzAwNDI_e76fce9d-8168-443a-a49b-47f95c927934"
      unitRef="usd">-677000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:InterestExpense
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMjUtMS0xLTEtNzAwNDI_4bfa5ba8-da6d-4554-b1a1-546732333201"
      unitRef="usd">1073000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMjUtMy0xLTEtNzAwNDI_776b741d-b2ef-4a61-b2d4-3c79721e9fb4"
      unitRef="usd">1523000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMjYtMS0xLTEtNzAwNDI_130b6f2f-d89a-4a45-91de-d322bb1eae63"
      unitRef="usd">46000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMjYtMy0xLTEtNzAwNDI_4ea9c1a3-1c16-4c4f-9e73-c5770c57c915"
      unitRef="usd">349000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMjctMS0xLTEtNzAwNDI_b89afde0-c0db-488b-983d-f1cfe928430d"
      unitRef="usd">-8962000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMjctMy0xLTEtNzAwNDI_895f31ac-0452-480a-8813-0b4332f60afc"
      unitRef="usd">0</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMjgtMS0xLTEtNzAwNDI_79f1f2e3-bbb9-4a03-b06d-6269b040f968"
      unitRef="usd">613000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMjgtMy0xLTEtNzAwNDI_ba1b5845-b72e-49f8-974a-d71c91dd1295"
      unitRef="usd">1304000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMzAtMS0xLTEtNzAwNDI_3770bb1d-5639-4935-a0ea-c2b3e182ab34"
      unitRef="usd">-7943000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMzAtMy0xLTEtNzAwNDI_9ae90d02-a1b3-4cf3-be9a-3f67e6db5d78"
      unitRef="usd">-547000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMzItMS0xLTEtNzAwNDI_5ba958a4-a848-4064-bc8a-bc149cdd8999"
      unitRef="usd">18268000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMzItMy0xLTEtNzAwNDI_69da2266-a909-43d7-bc31-5e2c6acde580"
      unitRef="usd">21234000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMzQtMS0xLTEtNzAwNDI_f2acb82b-e8bb-4b81-bffb-48fa20e41661"
      unitRef="usd">6195000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMzQtMy0xLTEtNzAwNDI_44a4e9e2-f134-488f-a50b-1603d0c8d619"
      unitRef="usd">6776000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMzYtMS0xLTEtNzAwNDI_89739722-70d8-4f33-94d2-b07e93d7da04"
      unitRef="usd">12073000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMzYtMy0xLTEtNzAwNDI_941d69fa-8138-43ce-8dbf-56a619b5ab4c"
      unitRef="usd">14458000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMzgtMS0xLTEtNzAwNDI_d8f115a8-ff7e-46a8-9caf-40346600252f"
      unitRef="usd">-2191000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfMzgtMy0xLTEtNzAwNDI_75dd10dc-6d40-4047-8733-bb5ea40a2951"
      unitRef="usd">1307000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfNDAtMS0xLTEtNzAwNDI_bd7bb209-13d5-4925-8419-1560c58e2b40"
      unitRef="usd">14264000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfNDAtMy0xLTEtNzAwNDI_9e4ce707-1baa-4097-bc62-be12ef71ab00"
      unitRef="usd">13151000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfNDItMS0xLTEtNzAwNDI_42b9f7ba-bd39-42d6-97c4-6f8dfac7caef"
      unitRef="usdPerShare">0.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfNDItMy0xLTEtNzAwNDI_266e5c9d-a4be-422f-bfcc-4ff568febae2"
      unitRef="usdPerShare">0.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfNDQtMS0xLTEtNzAwNDI_159d3e2a-3d1b-4051-91f9-d40ee297d0c0"
      unitRef="usdPerShare">0.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yNS9mcmFnOjYwYjkwMzU5NDkyODQxYWU5YWEwMGJjMjI3YzI5OTk3L3RhYmxlOmMzMjlmNGNkZmMyYTQxYTc4MDJmMTQzNGNjNmIzMjJlL3RhYmxlcmFuZ2U6YzMyOWY0Y2RmYzJhNDFhNzgwMmYxNDM0Y2M2YjMyMmVfNDQtMy0xLTEtNzAwNDI_c8f45aeb-422a-49d0-b2af-7cfa176ab05d"
      unitRef="usdPerShare">0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="ie565cc08147249b5871999e0d1765ed2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjMtMS0xLTEtNzAwNDI_98f9f37a-7655-45e7-8e57-38dec9bf2d70"
      unitRef="usd">55510000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="i01c06a901fad47e3a2666a70fe1188df_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjMtMy0xLTEtNzAwNDI_bdb204dd-19a6-4375-be2f-6f7e1121ceef"
      unitRef="shares">44630873</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i01c06a901fad47e3a2666a70fe1188df_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjMtNS0xLTEtNzAwNDI_c53218f0-4719-4862-8b71-a97d5d218cb9"
      unitRef="usd">45000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9910c7555ace4c2bb115be314dd355b1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjMtNy0xLTEtNzAwNDI_e1edd93b-2862-4dd7-b6d0-c30cca0b5283"
      unitRef="usd">310876000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3795672568804fb39265965ff8ee0616_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjMtOS0xLTEtNzAwNDI_4366a8b0-ea8e-4787-81f6-95282754e124"
      unitRef="usd">143629000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i934f486ebd2244c69aedfbc72f32d753_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjMtMTEtMS0xLTcwMDQy_2776ed39-b6f4-4377-a613-91f8ccd1bfe8"
      unitRef="usd">5940000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjMtMTMtMS0xLTcwMDQy_338941ff-7302-4eac-a0ce-c2222a4816d0"
      unitRef="usd">460490000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="i30aca1425f44492ca189ea4600ae924d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjQtMS0xLTEtNzAwNDI_ed29e0cf-cf7e-4a3c-936c-81e0530eaf06"
      unitRef="usd">-3129000</us-gaap:TemporaryEquityNetIncome>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i4ab27752b93f42388e90627d8c8ba555_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjQtOS0xLTEtNzAwNDI_e2f3b633-cd46-4100-bf43-a0de9441da51"
      unitRef="usd">14264000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="ieb4c95ef672647aca0d3f58bdfd3fd09_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjQtMTEtMS0xLTcwMDQy_65b1e40c-8f93-4fbb-bba1-cf3de7db6c93"
      unitRef="usd">938000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjQtMTMtMS0xLTcwMDQy_198e4d91-efae-4e21-98e5-17af0c8bc2a9"
      unitRef="usd">15202000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i30aca1425f44492ca189ea4600ae924d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjUtMS0xLTEtNzAwNDI_474074d3-f1e4-48e0-95a6-f760de2ba1d0"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="ieb4c95ef672647aca0d3f58bdfd3fd09_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjUtMTEtMS0xLTcwMDQy_6ee4669e-97e1-4f79-bfc3-7dc0490aa6ce"
      unitRef="usd">200000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjUtMTMtMS0xLTcwMDQy_86160e9b-487a-4cb5-b41a-d3ec8c9f538a"
      unitRef="usd">200000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="ieb4c95ef672647aca0d3f58bdfd3fd09_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfNi0xMS0xLTEtMTAxNjY5_4ae6dfb6-673f-4287-b038-3af3ee271c36"
      unitRef="usd">36000</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfNi0xMy0xLTEtMTAxNjY5_6553e76a-c6f1-4a2c-8b9a-79163d1ee92f"
      unitRef="usd">36000</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i30aca1425f44492ca189ea4600ae924d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfNi0xLTEtMS0xMDE0OTQ_1101a293-21b6-4b59-9203-d1bbb340186c"
      unitRef="usd">230000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i0cce845b4bcb47d4937d16c1ce6294b4_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjYtMy0xLTEtNzAwNDI_1488d490-7061-4d4d-8a7c-043f19381201"
      unitRef="shares">81779</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i891990513de04b79b3fbaedbe290deb4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjYtNy0xLTEtNzAwNDI_43f2cf5c-e9a2-4b5b-86ff-dc6edb4f25b3"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjYtMTMtMS0xLTcwMDQy_8526b648-48d0-4bb2-8162-419355326e43"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants
      contextRef="i0cce845b4bcb47d4937d16c1ce6294b4_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjctMy0xLTEtNzAwNDI_b8ca6519-4d27-473a-ab19-b2de15a7153e"
      unitRef="shares">124735</ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i891990513de04b79b3fbaedbe290deb4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjctNy0xLTEtNzAwNDI_58ea53ee-8d05-4e20-869d-0d15dc404ede"
      unitRef="usd">1573000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjctMTMtMS0xLTcwMDQy_ef398bac-0125-4148-9d3c-6fe4f5dee983"
      unitRef="usd">1573000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i891990513de04b79b3fbaedbe290deb4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjgtNy0xLTEtNzAwNDI_a47d7e9a-a7e8-4990-b4f9-091afc52ed2b"
      unitRef="usd">3055000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjgtMTMtMS0xLTcwMDQy_546d22d3-af2c-466b-8f2b-d503f60eb7dc"
      unitRef="usd">3055000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i0cce845b4bcb47d4937d16c1ce6294b4_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjktMy0xLTEtNzAwNDI_7e800caf-daa3-45f8-a864-a42da4f2e03e"
      unitRef="shares">18756</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i891990513de04b79b3fbaedbe290deb4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjktNy0xLTEtNzAwNDI_3b424891-0579-4876-8196-342e965ba585"
      unitRef="usd">1000000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMjktMTMtMS0xLTcwMDQy_35a8d526-ed71-4f17-87e5-e934bbcc4888"
      unitRef="usd">1000000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="i0cce845b4bcb47d4937d16c1ce6294b4_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMTEtMy0xLTEtMTAxNTA4_afd510bc-3b89-49e7-b481-bf56b0a79414"
      unitRef="shares">11084</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="i891990513de04b79b3fbaedbe290deb4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMTEtNy0xLTEtMTAxNTMw_51a0b90b-8390-4c05-ac92-6de2bf0dc335"
      unitRef="usd">457000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMTItMTMtMS0xLTEwMTcxNg_2ff90a51-bc3e-4169-b456-8d7e3370faf3"
      unitRef="usd">457000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:TemporaryEquityAccretionOfDividends
      contextRef="i30aca1425f44492ca189ea4600ae924d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMzAtMS0xLTEtNzAwNDI_e648a069-c4b9-49e2-8003-d3144eec73a5"
      unitRef="usd">0</us-gaap:TemporaryEquityAccretionOfDividends>
    <ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares
      contextRef="ieb4c95ef672647aca0d3f58bdfd3fd09_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMzAtMTEtMS0xLTcwMDQy_636f3b8d-e877-450c-aad2-8253f22bbefc"
      unitRef="usd">-1178000</ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares>
    <ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMzAtMTMtMS0xLTcwMDQy_7c9e6c09-82e1-4dd2-966f-ba1c82ef5bdf"
      unitRef="usd">-1178000</ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i95ae6859a8584e7eb08ef41e08f26b99_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMzEtMS0xLTEtNzAwNDI_0af3a66f-d0de-41d3-8681-1a169adc534f"
      unitRef="usd">52151000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="i3e20c02c36c543ab98bbfa086f702db6_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMzEtMy0xLTEtNzAwNDI_1a747325-4959-4a47-86b1-d9299c58ff0a"
      unitRef="shares">44845059</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3e20c02c36c543ab98bbfa086f702db6_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMzEtNS0xLTEtNzAwNDI_c7fa45da-4349-4c74-b63a-5ee2103a54f8"
      unitRef="usd">45000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8b7e2b312b964191b6e5a99bfa3fad1c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMzEtNy0xLTEtNzAwNDI_0571df75-ed70-490d-8b29-72e8f6cb2a2d"
      unitRef="usd">316047000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie3da6bad4ba14fb884f02c88f6ad7610_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMzEtOS0xLTEtNzAwNDI_d75c3f5f-d268-4458-9dfa-96dfcd440040"
      unitRef="usd">157893000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i48596fff82734547a44b9e4ec2fc95ef_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMzEtMTEtMS0xLTcwMDQy_ed77f267-c086-4dac-9275-dda855534871"
      unitRef="usd">5536000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOmIxOTI5ZmQwMTA3NTQ5ZGI4NDZjYjNjYjE2MTExMjJjL3RhYmxlcmFuZ2U6YjE5MjlmZDAxMDc1NDlkYjg0NmNiM2NiMTYxMTEyMmNfMzEtMTMtMS0xLTcwMDQy_11a4a447-eea4-48fd-9e33-dd075da78289"
      unitRef="usd">479521000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i0f6053bba0574b7c8d8bc3d35aedd364_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMTgtMS0xLTEtNzAwNDI_42343936-0da7-4ad9-b64e-d8df27cbbf7b"
      unitRef="usd">114237000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="iaedbc96dc4de4eab8aed3c10bf0e0fb9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMTgtMy0xLTEtNzAwNDI_ecbdaa7d-6a79-4d08-a739-ceedf6a55fbb"
      unitRef="shares">42249137</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaedbc96dc4de4eab8aed3c10bf0e0fb9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMTgtNS0xLTEtNzAwNDI_d6af2bdb-5172-4acc-bf0e-22b8bf45f815"
      unitRef="usd">42000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id9015851c456402f83746f4b6976dfbb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMTgtNy0xLTEtNzAwNDI_b24f103b-5402-4652-ba5b-b793632fcfe4"
      unitRef="usd">261011000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3b1648f5a7c74820b4705fadeec2d2c1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMTgtOS0xLTEtNzAwNDI_9676d7d4-668a-4261-99e1-66e3d0e878e7"
      unitRef="usd">69771000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icd3ffca58ef641c493f6d69c9456f642_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMTgtMTEtMS0xLTcwMDQy_eb35d672-f488-4ed3-a3ea-4efa9d936952"
      unitRef="usd">87000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib537036edf0744c69646e8a9929a0638_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMTgtMTMtMS0xLTcwMDQy_dea02b47-829e-4c9c-861f-52ff3ed2a244"
      unitRef="usd">330911000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="i7907a63ed1d0470a879fdec321fba0f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMTktMS0xLTEtNzAwNDI_667d95a9-b078-4ce5-a15a-ed9ea6a6f788"
      unitRef="usd">760000</us-gaap:TemporaryEquityNetIncome>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i8ea6fe0d59b441beb7ba9b153d330fae_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMTktOS0xLTEtNzAwNDI_1d83b8b8-7262-433f-adc1-d21e8f8a7f5b"
      unitRef="usd">13151000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i109c5e7bd1a14ea599c3a7723e99ade4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMTktMTEtMS0xLTcwMDQy_f6d89894-311d-4d85-9cbe-481e469ea39f"
      unitRef="usd">547000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMTktMTMtMS0xLTcwMDQy_1a36683a-ff55-4319-9767-1d894c7718cb"
      unitRef="usd">13698000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i7907a63ed1d0470a879fdec321fba0f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjAtMS0xLTEtNzAwNDI_88fcaf93-4ce8-4582-9c99-1a253fe68e94"
      unitRef="usd">150000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i109c5e7bd1a14ea599c3a7723e99ade4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjAtMTEtMS0xLTcwMDQy_12b6e19f-67d9-4e65-a66d-5a0cb001399b"
      unitRef="usd">75000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjAtMTMtMS0xLTcwMDQy_a0d04efa-a528-4773-90c5-1b82ace82df3"
      unitRef="usd">75000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="i109c5e7bd1a14ea599c3a7723e99ade4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjEtMTEtMS0xLTcwMDQy_87035743-352a-410d-8734-3744dfeb863a"
      unitRef="usd">37000</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjEtMTMtMS0xLTcwMDQy_1443f899-c1d4-4019-adca-812d522fd2b8"
      unitRef="usd">37000</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i0e0d03cf0c84427db63e13d4e462e4e8_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfNy0zLTEtMS03NjkyNQ_82d8a718-f3ae-4320-8887-b1dffbc184e6"
      unitRef="shares">7689</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfNy0xMy0xLTEtNzY5ODA_9fa0c3eb-9276-434e-beda-f4685eeb555a"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants
      contextRef="i0e0d03cf0c84427db63e13d4e462e4e8_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjItMy0xLTEtNzAwNDI_a37eb6d6-6bb4-49fa-bf25-dad7f5c378b7"
      unitRef="shares">421002</ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i0e0d03cf0c84427db63e13d4e462e4e8_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjItNS0xLTEtNzAwNDI_2bb72caa-05e8-4649-b704-398ddebf8e6d"
      unitRef="usd">1000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i5b20ee5e4cb845b183e38f28737aef7a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjItNy0xLTEtNzAwNDI_f0eaaa50-be68-45a9-aab9-1d5880a19034"
      unitRef="usd">4255000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjItMTMtMS0xLTcwMDQy_bd5c3e4b-0eef-4025-bebb-c2a30f458083"
      unitRef="usd">4256000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i0e0d03cf0c84427db63e13d4e462e4e8_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjMtMy0xLTEtNzAwNDI_6261adab-8b86-4933-be08-16fca032c9a5"
      unitRef="shares">34158</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="i5b20ee5e4cb845b183e38f28737aef7a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjMtNy0xLTEtNzAwNDI_437d8da3-7a29-4da8-a97b-d9b491d94d56"
      unitRef="usd">342000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjMtMTMtMS0xLTcwMDQy_9425c4f0-06c5-4813-9d3c-555ea099dece"
      unitRef="usd">342000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5b20ee5e4cb845b183e38f28737aef7a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjQtNy0xLTEtNzAwNDI_84c4fa73-4d2a-4520-bf8b-7d0b9e9cdd7a"
      unitRef="usd">1346000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjQtMTMtMS0xLTcwMDQy_0b4fe3da-3461-43ae-be8b-ea96473cf5f1"
      unitRef="usd">1346000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="i0e0d03cf0c84427db63e13d4e462e4e8_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjUtMy0xLTEtNzAwNDI_26d32c63-9ceb-4071-a58e-afff3a95df79"
      unitRef="shares">5281</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="i5b20ee5e4cb845b183e38f28737aef7a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjUtNy0xLTEtNzAwNDI_da2a33f3-ee8b-4712-92b9-14acbd09def1"
      unitRef="usd">144000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjUtMTMtMS0xLTcwMDQy_fbe169c5-5f50-405b-8158-c7c068b0fd75"
      unitRef="usd">144000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i5879b7991869438bb805be20df7ad0b2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjYtMS0xLTEtNzAwNDI_8a8dab64-a830-4d7d-a681-473ac18fb4af"
      unitRef="usd">114847000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="ia98bbfcdcddb4e23b97bfb35198297b4_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjYtMy0xLTEtNzAwNDI_c5483f6f-8152-466c-89f9-3b4a561fbc94"
      unitRef="shares">42638389</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia98bbfcdcddb4e23b97bfb35198297b4_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjYtNS0xLTEtNzAwNDI_1bf7ce19-3633-45bb-ab04-b8fcd7cf1cab"
      unitRef="usd">43000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i24aeb633ec154645a1fed86ccb4c65cd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjYtNy0xLTEtNzAwNDI_8e667829-171b-4f84-8180-6faeb625260f"
      unitRef="usd">266126000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i13156f57748c4cfea02dbb45bd3312df_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjYtOS0xLTEtNzAwNDI_dd4acb02-a089-4234-9a7c-df497437cab9"
      unitRef="usd">82922000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibe9ce7d0bb51473c9da95e7918990fd8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjYtMTEtMS0xLTcwMDQy_7d955053-6639-40ee-8cb7-c02e271c7828"
      unitRef="usd">596000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5144afd8082f4f17afadb8908f6b4051_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zMS9mcmFnOmVlNWNiZThhNzRhZTRjODA5YTMzZTkyODc2NjlhNjIyL3RhYmxlOjE1ZmE1YmJlYjg5MDRjOTI5N2Q0OTA3ZWRiYWJiNjVmL3RhYmxlcmFuZ2U6MTVmYTViYmViODkwNGM5Mjk3ZDQ5MDdlZGJhYmI2NWZfMjYtMTMtMS0xLTcwMDQy_75444c0b-5ac9-4334-a736-5ea3c1d1e9fb"
      unitRef="usd">349687000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMy0xLTEtMS03MDA0Mg_e221c770-6a81-4d81-b1a5-51bd1d8fdf19"
      unitRef="usd">12073000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMy0zLTEtMS03MDA0Mg_630a6760-814d-4003-9fe7-46016a62e2e8"
      unitRef="usd">14458000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNS0xLTEtMS03MDA0Mg_99cdf237-cc26-4c98-95fa-4b04b944f248"
      unitRef="usd">4374000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNS0zLTEtMS03MDA0Mg_77d860a8-1122-4169-958f-0824168e3d04"
      unitRef="usd">4197000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNy0xLTEtMS03MDA0Mg_47e37e30-9006-4c6e-bd8f-b8afbb9bebe3"
      unitRef="usd">237000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNy0zLTEtMS03MDA0Mg_045f5f17-a7a2-430b-9fd1-6f53b67713a7"
      unitRef="usd">351000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ShareBasedCompensation
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfOC0xLTEtMS03MDA0Mg_20eff41e-66f3-4d14-b724-27137b727b92"
      unitRef="usd">3055000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfOC0zLTEtMS03MDA0Mg_37cd1cce-e9a9-4087-a04a-2efa0ccd451d"
      unitRef="usd">1346000</us-gaap:ShareBasedCompensation>
    <ameh:UnrealizedGainLossFromInvestmentInEquitySecurities
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfOS0xLTEtMS03MDA0Mg_78ee37aa-67ab-4613-8b19-ff7ee181bcfa"
      unitRef="usd">-10556000</ameh:UnrealizedGainLossFromInvestmentInEquitySecurities>
    <ameh:UnrealizedGainLossFromInvestmentInEquitySecurities
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfOS0zLTEtMS03MDA0Mg_7cd868c6-81c3-4a2a-9111-439926aa318e"
      unitRef="usd">9000</ameh:UnrealizedGainLossFromInvestmentInEquitySecurities>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMTAtMS0xLTEtNzAwNDI_97de6064-913f-4692-912c-05c1fdcdddd6"
      unitRef="usd">1433000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMTAtMy0xLTEtNzAwNDI_a577063f-4de7-4801-be9d-e686d1204ef3"
      unitRef="usd">-677000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMTMtMS0xLTEtNzAwNDI_56b14f0e-913b-4775-8c2f-5f8a6f7469be"
      unitRef="usd">1593000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMTMtMy0xLTEtNzAwNDI_b6fda55f-57f0-4461-8c6a-608d35bb2298"
      unitRef="usd">0</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMTQtMS0xLTEtNzAwNDI_78ac2cd4-3497-4e06-b886-b69315036049"
      unitRef="usd">1985000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMTQtMy0xLTEtNzAwNDI_9e011d10-8dfd-4522-8644-24442c2005eb"
      unitRef="usd">-921000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMTctMS0xLTEtNzAwNDI_4972a89d-5d09-4a3a-829c-cb75098ba515"
      unitRef="usd">44673000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMTctMy0xLTEtNzAwNDI_ea33fd5e-e9ce-4244-bfab-c024253913a2"
      unitRef="usd">9390000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMTgtMS0xLTEtNzAwNDI_7dc84ba9-fbae-4ea0-b7d9-699646c08d1e"
      unitRef="usd">6865000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMTgtMy0xLTEtNzAwNDI_d8c78967-8d9e-4d03-8a9a-6e42af778cc4"
      unitRef="usd">17612000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMTktMS0xLTEtNzAwNDI_3f923942-c553-4e3d-a040-2fbed8401c96"
      unitRef="usd">3613000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMTktMy0xLTEtNzAwNDI_3682ee6c-16f0-4fd2-a97b-bdb192ce1fbb"
      unitRef="usd">223000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjAtMS0xLTEtNzAwNDI_125398bb-a4b6-4ea2-8583-0c185987df20"
      unitRef="usd">-4171000</ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
    <ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjAtMy0xLTEtNzAwNDI_18182098-d30e-41cf-9a01-5bf998b20d90"
      unitRef="usd">-7165000</ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
    <ameh:IncreaseDecreaseInOperatingLeaseAssets
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjEtMS0xLTEtNzAwNDI_27f3637d-5033-43f2-9357-201aa3daf8f4"
      unitRef="usd">672000</ameh:IncreaseDecreaseInOperatingLeaseAssets>
    <ameh:IncreaseDecreaseInOperatingLeaseAssets
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjEtMy0xLTEtNzAwNDI_a3ddcbee-2df7-40e0-aa67-5d7520009111"
      unitRef="usd">836000</ameh:IncreaseDecreaseInOperatingLeaseAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjItMS0xLTEtNzAwNDI_075c1722-034e-40b2-afef-fdba3853df74"
      unitRef="usd">-2016000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjItMy0xLTEtNzAwNDI_a215f480-e613-4ff0-a700-c66ee4fff278"
      unitRef="usd">192000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjMtMS0xLTEtNzAwNDI_277aaa79-92c1-446e-b33c-48563a70205e"
      unitRef="usd">3735000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjMtMy0xLTEtNzAwNDI_d5bd89ae-7e93-4b81-858d-2c647705a939"
      unitRef="usd">3915000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjQtMS0xLTEtNzAwNDI_9af6ab85-ef63-4995-a947-66f371661be0"
      unitRef="usd">-4229000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjQtMy0xLTEtNzAwNDI_bd32af6d-ba24-473f-9e12-cdc5cd317f7a"
      unitRef="usd">-2771000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <ameh:IncreaseDecreaseInMedicalLiabilities
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjUtMS0xLTEtNzAwNDI_b037f0ac-c22a-46f1-b752-432cae8ea9d8"
      unitRef="usd">39974000</ameh:IncreaseDecreaseInMedicalLiabilities>
    <ameh:IncreaseDecreaseInMedicalLiabilities
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjUtMy0xLTEtNzAwNDI_0c9035be-4a53-449d-a86d-943e6cb4e037"
      unitRef="usd">1149000</ameh:IncreaseDecreaseInMedicalLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjYtMS0xLTEtNzAwNDI_73fabb02-c952-4860-9b07-830181297244"
      unitRef="usd">4241000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjYtMy0xLTEtNzAwNDI_9830956f-d28f-4cbb-a252-2d3a462c9309"
      unitRef="usd">7835000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjctMS0xLTEtNzAwNDI_552785cb-64be-4071-8f23-cfd57c80527b"
      unitRef="usd">-645000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjctMy0xLTEtNzAwNDI_a96b3567-96de-4942-b6b9-ca0e84102415"
      unitRef="usd">-859000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjktMS0xLTEtNzAwNDI_2a5868b7-1972-4c6b-bcd9-f5f5c5273236"
      unitRef="usd">24038000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMjktMy0xLTEtNzAwNDI_9d13fb71-30a0-47cb-bb62-c6715862cf69"
      unitRef="usd">9952000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMzItMS0xLTEtNzAwNDI_b5d8daa0-cacb-4a33-884b-ea3c8a4f6dea"
      unitRef="usd">999000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMzItMy0xLTEtNzAwNDI_d9a78c26-996b-4466-a62e-eab2ef4f9a65"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMzMtMS0xLTEtNzAwNDI_4f4dce98-2e60-46ec-8e02-c949f9e96331"
      unitRef="usd">19000</us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties>
    <us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMzMtMy0xLTEtNzAwNDI_7089dcdd-be46-4dc9-9806-82e348dce5a4"
      unitRef="usd">16000</us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMzQtMS0xLTEtNzAwNDI_6a8f124a-cc22-48cd-b593-3ebf251ae230"
      unitRef="usd">21000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMzQtMy0xLTEtNzAwNDI_ca587368-d74a-4805-8c4d-1c3044ace4a8"
      unitRef="usd">332000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMzctMS0xLTEtNzAwNDI_caba925f-4665-4f66-969c-ff2fa68663fd"
      unitRef="usd">17489000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMzctMy0xLTEtNzAwNDI_2342e0c6-24e9-4a47-a7ae-249cb9a66286"
      unitRef="usd">98000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMzgtMS0xLTEtNzAwNDI_9faaa3f0-3434-4710-934b-11f79c5fc2a5"
      unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMzgtMy0xLTEtNzAwNDI_fe1f10b6-5a42-49df-a691-0c1dcdfe1d99"
      unitRef="usd">1106000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMzgtMS0xLTEtOTk0NTA_f119ff7b-abfc-47a7-a2f7-ab9710e4b9ec"
      unitRef="usd">200000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMzgtMy0xLTEtOTk0NTA_1c48879d-4bf5-4026-b87c-c476d9af49be"
      unitRef="usd">0</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMzktMS0xLTEtNzAwNDI_ce7bba4c-8c79-435d-a676-c2ab0ed50bbc"
      unitRef="usd">1435000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfMzktMy0xLTEtNzAwNDI_c11e262a-4069-4c9a-bea2-6a414007fa51"
      unitRef="usd">0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNDAtMS0xLTEtNzAwNDI_688e3e82-8c19-4739-a6ad-46c5215acdd4"
      unitRef="usd">-19725000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNDAtMy0xLTEtNzAwNDI_a133a996-b8c3-4e51-abfe-e40bceb8f11e"
      unitRef="usd">692000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfDividends
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNDMtMS0xLTEtNzAwNDI_d830080f-66d7-4d6c-ad3b-373b7b1d5f85"
      unitRef="usd">1178000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNDMtMy0xLTEtNzAwNDI_c5258a20-401e-4f23-8f30-448030b42356"
      unitRef="usd">4000</us-gaap:PaymentsOfDividends>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNDQtMS0xLTEtNzAwNDI_2af353cc-71e1-457c-8222-e6219b4e9479"
      unitRef="usd">52000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNDQtMy0xLTEtNzAwNDI_c57737d1-0ebf-4ae7-a815-a6e417e80d2b"
      unitRef="usd">2434000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNDUtMS0xLTEtNzAwNDI_2017e82c-72df-494d-b0c2-a628a4127804"
      unitRef="usd">141000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNDUtMy0xLTEtNzAwNDI_54577f12-a104-464d-916f-04a9cfa32a77"
      unitRef="usd">27000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNDYtMS0xLTEtNzAwNDI_3b9ba0af-1698-42cb-a365-685d532163a4"
      unitRef="usd">1573000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNDYtMy0xLTEtNzAwNDI_7597e8d4-0473-4b67-b95d-ee0b2bf2e8e9"
      unitRef="usd">4256000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNDctMS0xLTEtNzAwNDI_1bd858ef-6ef5-42ee-aaf1-ae241a1040b8"
      unitRef="usd">230000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNDctMy0xLTEtNzAwNDI_36e5ee1f-6169-4c3e-8d49-bce19e1f5735"
      unitRef="usd">342000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNDgtMS0xLTEtNzAwNDI_91f540aa-f3a3-4376-b0b2-9e469c839f78"
      unitRef="usd">0</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNDgtMy0xLTEtNzAwNDI_b926b244-e83b-49ab-9707-cab9f623bc1e"
      unitRef="usd">225000</us-gaap:PaymentsToMinorityShareholders>
    <ameh:ProceedsFromSaleOfNoncontrollingInterest
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNDktMS0xLTEtNzAwNDI_4a3dcaf1-4adc-4fac-b36c-da2a9535c41f"
      unitRef="usd">38000</ameh:ProceedsFromSaleOfNoncontrollingInterest>
    <ameh:ProceedsFromSaleOfNoncontrollingInterest
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNDktMy0xLTEtNzAwNDI_be6bfdf6-036d-48b7-b843-04648897eb60"
      unitRef="usd">38000</ameh:ProceedsFromSaleOfNoncontrollingInterest>
    <ameh:PaymentsToAcquireNonControllingInterest
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNTAtMS0xLTEtMTAyMzM3_fb1e89c0-df0d-440e-88fe-99eefc942941"
      unitRef="usd">200000</ameh:PaymentsToAcquireNonControllingInterest>
    <ameh:PaymentsToAcquireNonControllingInterest
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNTAtMy0xLTEtMTAyMzM3_0aa98813-60ce-424e-aaf0-4d3bc44e49e7"
      unitRef="usd">0</ameh:PaymentsToAcquireNonControllingInterest>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNTAtMS0xLTEtNzAwNDI_71916b82-efd7-47e1-8b55-9f6d2fa0be1c"
      unitRef="usd">722000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNTAtMy0xLTEtNzAwNDI_1671660e-6e01-4116-8358-341d825984e7"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNTMtMS0xLTEtNzAwNDI_10d8c15b-254f-4d93-bb7f-1ad75dc68997"
      unitRef="usd">532000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNTMtMy0xLTEtNzAwNDI_bd18089a-3030-463d-9969-35668c0258cb"
      unitRef="usd">1262000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNTUtMS0xLTEtNzAwNDI_f661510e-9ebf-4e27-a651-ca7661cb9787"
      unitRef="usd">4845000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNTUtMy0xLTEtNzAwNDI_aa56c456-7c16-46fc-a6df-562ecd7158f2"
      unitRef="usd">11906000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNTctMS0xLTEtNzAwNDI_462cceef-913a-47fa-8a2f-12f23fc09f22"
      unitRef="usd">233097000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib537036edf0744c69646e8a9929a0638_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNTctMy0xLTEtNzAwNDI_04194f90-a169-48cf-b395-f49bbd72a2f0"
      unitRef="usd">193970000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNTktMS0xLTEtNzAwNDI_28acc1a6-a560-40ea-8e9d-39e34f3da808"
      unitRef="usd">237942000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5144afd8082f4f17afadb8908f6b4051_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNTktMy0xLTEtNzAwNDI_a9205a5a-52e8-4446-af43-11f292161f25"
      unitRef="usd">205876000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNjItMS0xLTEtNzAwNDI_d45cb75a-f740-446e-9a6f-c1035871fd24"
      unitRef="usd">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNjItMy0xLTEtNzAwNDI_f0ad76a1-0410-423d-9bb5-401317249ba6"
      unitRef="usd">40000</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNjMtMS0xLTEtNzAwNDI_97935688-2c12-4ecc-8c2a-04ddccd72543"
      unitRef="usd">845000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNjMtMy0xLTEtNzAwNDI_5afdcdb1-f246-4f63-80eb-830cc237ed7d"
      unitRef="usd">1277000</us-gaap:InterestPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNjYtMS0xLTEtNzAwNDI_1227251a-b397-4327-8f71-95bdc1f1b5ab"
      unitRef="usd">398000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNjYtMy0xLTEtNzAwNDI_49fecd73-c006-405c-80d4-a031ee984e49"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:StockIssued1
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNjgtMS0xLTEtMTA0NzY0_abf1e489-1fad-49fc-801c-f4cb7f1a6497"
      unitRef="usd">1000000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjNjMjk3ZGE4ODc1MzQxMzE5ZWUwNGQwMzRkNDBiYWRhL3RhYmxlcmFuZ2U6M2MyOTdkYTg4NzUzNDEzMTllZTA0ZDAzNGQ0MGJhZGFfNjgtMy0xLTEtMTA0NzY0_1735cdd1-0474-4e1b-952d-d800c3410cff"
      unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjdhZTg2ZGEwYTg3YjQ2YTBhZjIwMjk4YjA4NTM1ZjQ0L3RhYmxlcmFuZ2U6N2FlODZkYTBhODdiNDZhMGFmMjAyOThiMDg1MzVmNDRfNS0xLTEtMS03MDA0Mg_8577032a-c1d8-4ae0-8c41-046b7cd36615"
      unitRef="usd">237942000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5144afd8082f4f17afadb8908f6b4051_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjdhZTg2ZGEwYTg3YjQ2YTBhZjIwMjk4YjA4NTM1ZjQ0L3RhYmxlcmFuZ2U6N2FlODZkYTBhODdiNDZhMGFmMjAyOThiMDg1MzVmNDRfNS0zLTEtMS03MDA0Mg_ff71e255-916f-4f1f-be3b-a2aec2c3d1a6"
      unitRef="usd">205876000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjg5M2E5ODM3NTBmMTQxNTliOTNlYzQ2OGFlOWY5NzZjL3RhYmxlcmFuZ2U6ODkzYTk4Mzc1MGYxNDE1OWI5M2VjNDY4YWU5Zjk3NmNfMi0xLTEtMS03MDA0Mg_0ca5442f-c8e8-42db-bfb2-8212d4ba2f91"
      unitRef="usd">233097000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib537036edf0744c69646e8a9929a0638_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjg5M2E5ODM3NTBmMTQxNTliOTNlYzQ2OGFlOWY5NzZjL3RhYmxlcmFuZ2U6ODkzYTk4Mzc1MGYxNDE1OWI5M2VjNDY4YWU5Zjk3NmNfMi0zLTEtMS03MDA0Mg_5adf61a7-b427-4fa6-9475-32a2d7930d04"
      unitRef="usd">193470000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashEquivalentsCurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjg5M2E5ODM3NTBmMTQxNTliOTNlYzQ2OGFlOWY5NzZjL3RhYmxlcmFuZ2U6ODkzYTk4Mzc1MGYxNDE1OWI5M2VjNDY4YWU5Zjk3NmNfMy0xLTEtMS03MDA0Mg_fe60bc25-d9b2-4b58-b248-d3d5dfe64d2d"
      unitRef="usd">0</us-gaap:RestrictedCashEquivalentsCurrent>
    <us-gaap:RestrictedCashEquivalentsCurrent
      contextRef="ib537036edf0744c69646e8a9929a0638_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjg5M2E5ODM3NTBmMTQxNTliOTNlYzQ2OGFlOWY5NzZjL3RhYmxlcmFuZ2U6ODkzYTk4Mzc1MGYxNDE1OWI5M2VjNDY4YWU5Zjk3NmNfMy0zLTEtMS03MDA0Mg_f23feedc-696f-43d6-9c73-e6641dcf3d31"
      unitRef="usd">500000</us-gaap:RestrictedCashEquivalentsCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjg5M2E5ODM3NTBmMTQxNTliOTNlYzQ2OGFlOWY5NzZjL3RhYmxlcmFuZ2U6ODkzYTk4Mzc1MGYxNDE1OWI5M2VjNDY4YWU5Zjk3NmNfNS0xLTEtMS03MDA0Mg_a59391a5-0e38-4ecc-9e6d-299335ff71de"
      unitRef="usd">233097000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib537036edf0744c69646e8a9929a0638_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8zNC9mcmFnOjZmYWIyYTk2Njk3NTQzMTZiODdlZjNmM2QwMmM3ZjRhL3RhYmxlOjg5M2E5ODM3NTBmMTQxNTliOTNlYzQ2OGFlOWY5NzZjL3RhYmxlcmFuZ2U6ODkzYTk4Mzc1MGYxNDE1OWI5M2VjNDY4YWU5Zjk3NmNfNS0zLTEtMS03MDA0Mg_9212058a-3582-4e16-836f-51c1e0e33772"
      unitRef="usd">193970000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMTU4NDU_ef9cdd93-76be-48b3-99bf-581ac52f69d9">Description of Business&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Apollo Medical Holdings, Inc. (&#x201c;ApolloMed&#x201d;) is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high-quality care to patients in a cost-effective manner. ApolloMed was merged with Network Medical Management (&#x201c;NMM&#x201d;) in December 2017 (the &#x201c;2017 Merger&#x201d;). As a result of the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed, and the former NMM shareholders own a majority of the issued and outstanding common stock of ApolloMed and maintain control of the board of directors of ApolloMed. Unless the context dictates otherwise, references in these notes to the financial statements, the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our,&#x201d; and similar words are references to ApolloMed and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (&#x201c;VIEs&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Headquartered in Alhambra, California, ApolloMed&#x2019;s subsidiaries and VIEs include management services organizations (&#x201c;MSOs&#x201d;), affiliated independent practice associations (&#x201c;IPAs&#x201d;), and an accountable care organization (&#x201c;ACO&#x201d;) participating in the GPDC model. NMM and Apollo Medical Management, Inc. (&#x201c;AMM&#x201d;) are the administrative and managerial services companies for the affiliated physician-owned professional corporations that contract with independent physicians to deliver medical services in-office and virtually under the following brands: (i) Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA (&#x201c;APC&#x201d;), (ii) Alpha Care Medical Group, Inc. (&#x201c;Alpha Care&#x201d;), and (iii) Accountable Health Care IPA, a Professional Medical Corporation (&#x201c;Accountable Health Care&#x201d;). These affiliates are supported by ApolloMed Hospitalists, a Medical Corporation (&#x201c;AMH&#x201d;) and Southern California Heart Centers, a Medical Corporation (&#x201c;SCHC&#x201d;). The Company&#x2019;s ACO operates under the APA ACO, Inc. (&#x201c;APAACO&#x201d;) brand and participates in the Centers for Medicare &amp;amp; Medicaid Services (&#x201c;CMS&#x201d;) program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participation in the program&#x2019;s attribution-based risk-sharing model.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company&#x2019;s physician network consists of primary care physicians, specialist physicians, and hospitalists. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;MSOs and Affiliates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AMM, a wholly owned subsidiary of ApolloMed, manages affiliated medical groups, ApolloMed Hospitalists, a Medical Corporation (&#x201c;AMH&#x201d;) and Southern California Heart Centers, a Medical Corporation (&#x201c;SCHC&#x201d;). AMH provides hospitalist, intensivist, and physician advisory services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NMM was formed in 1994 as an MSO for the purposes of providing management services to medical companies and IPAs. The management services primarily include billing, collection, accounting, administration, quality assurance, marketing, compliance, and education. Following the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;IPAs and Affiliates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;APC was incorporated in 1992 for the purpose of arranging healthcare services as an IPA. APC is owned by California-licensed physicians and professional medical corporations, and contracts with various health maintenance organizations (&#x201c;HMOs&#x201d;) and other licensed healthcare service plans, as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (&#x201c;PMPM&#x201d;) that is to be paid to APC. In return, APC arranges for the delivery of healthcare services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering healthcare services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is subject to stop-loss provisions in contracts with HMOs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 1999, APC entered into an amended and restated management and administrative services agreement with NMM (the initial management services agreement was entered into in 1997) for an initial fixed term of 30 years. Under this management arrangement, NMM performs only non-medical administrative services, does not represent that it offers medical services, and does not exercise influence or control over the practice of medicine by APC or its physicians. In accordance with relevant accounting guidance, APC is determined to be a VIE of the Company and is consolidated by NMM.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AP-AMH Medical Corporation (&#x201c;AP-AMH&#x201d;) and AP-AMH 2 Medical Corporation (&#x201c;AP-AMH 2&#x201d;) was formed in May 2019 and July 2021, respectively, as a designated shareholder professional corporation. Dr. Thomas Lam, a shareholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is the sole shareholder of AP-AMH and AP-AMH 2. In accordance with relevant accounting guidance, AP-AMH and AP-AMH 2 is determined to be a VIE of ApolloMed and is consolidated by ApolloMed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, ApolloMed completed the following series of transactions with its affiliates, AP-AMH and APC:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;A $545.0&#160;million loan to AP-AMH, pursuant to a 10-year secured loan agreement (the &#x201c;AP-AMH Loan&#x201d;). The loan bears interest at a rate of 10% per annum simple interest, is not prepayable, (except in certain limited circumstances), requires quarterly payments of interest only in arrears, and is secured by a first priority security interest in all of AP-AMH&#x2019;s assets. To the extent that AP-AMH is unable to make any interest payment when due because it has received dividends on the APC Series A Preferred Stock insufficient to pay in full such interest payment, then the outstanding principal amount of the loan will be increased by the amount of any such accrued but unpaid interest, and any such increased principal amounts will bear interest at the rate of 10.75% per annum simple interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;A $545.0&#160;million private placement, where AP-AMH purchased 1,000,000 shares of APC Series A Preferred Stock which entitle AP-AMH to receive preferential, cumulative dividends that accrue on a daily basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;A $300.0&#160;million private placement, where APC purchased 15,015,015 shares of the Company&#x2019;s common stock and in  connection therewith, the Company granted APC certain registration rights with respect to the purchased shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;ApolloMed licensed to AP-AMH the right to use certain tradenames for specified purposes for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The license fee is payable out of any Series A Preferred Stock dividends received by AP-AMH from APC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Through its subsidiary, NMM, the Company agreed to provide certain administrative services to AP-AMH for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The administrative fee is also payable out of any APC Series A Preferred Stock dividends received by AP-AMH from APC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As part of the series of transactions, in September 2019, APC and AP-AMH entered into a Second Amendment to the Series A Preferred Stock Purchase Agreement clarifying the term excluded assets (&#x201c;Excluded Assets&#x201d;). Excluded Assets means (i) assets received from the sale of shares of the Series A Preferred equal to the Series A Purchase Price, (ii) the assets of the Company that are not Healthcare Services Assets, including the Company&#x2019;s equity interests in Apollo Medical Holdings, Inc., and any entity that is primarily engaged in the business of owning, leasing, developing, or otherwise operating real estate, (iii) any assets acquired with the proceeds of the sale, assignment, or other disposition of any of the assets described in clauses (i) or (ii), and (iv) any proceeds of the assets described in clauses (i), (ii), and (iii). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC&#x2019;s ownership in ApolloMed was 19.61% as of March&#160;31, 2022 and 19.68% as of December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concourse Diagnostic Surgery Center, LLC (&#x201c;CDSC&#x201d;) was formed in March&#160;2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California organized by a group of highly qualified physicians, which utilizes some of the most advanced equipment in the eastern part of Los Angeles County and the San Gabriel Valley. The facility is Medicare-certified and accredited by the Accreditation Association for Ambulatory Healthcare. As of March&#160;31, 2022, APC owned 44.50% of CDSC&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s capital stock. In accordance with relevant accounting guidance, CDSC is determined to be a VIE of APC and is consolidated by APC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC-LSMA Designated Shareholder Medical Corporation (&#x201c;APC-LSMA&#x201d;) was formed in October&#160;2012 as a designated shareholder professional corporation. Dr. Thomas Lam, a stockholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is a nominee shareholder of APC-LSMA. APC makes all investment decisions on behalf of APC-LSMA, funds all investments and receives all distributions from the investments. APC has the obligation to absorb losses and right to receive benefits from all investments made by APC-LSMA. APC-LSMA&#x2019;s sole function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC as the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, including the IPA lines of business of LaSalle Medical Associates (&#x201c;LMA&#x201d;), Pacific Medical Imaging and Oncology Center, Inc. (&#x201c;PMIOC&#x201d;), Diagnostic Medical Group of Southern California (&#x201c;DMG&#x201d;), and AHMC International Cancer Center, a Medical Corporation (&#x201c;ICC&#x201d;). APC-LSMA also holds a 100% ownership interest in Maverick Medical Group, Inc. (&#x201c;MMG&#x201d;), Alpha Care, Accountable Health Care, and AMG, a Professional Medical Corporation (&#x201c;AMG&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Alpha Care, an IPA acquired by the Company in May 2019, has been operating in California since 1993 as a risk-bearing organization engaged in providing professional services under capitation arrangements with its contracted health plans through a provider network consisting of primary care and specialty care physicians. Alpha Care specializes in delivering high-quality healthcare to its enrollees and focuses on Medi-Cal/Medicaid, Commercial, and Medicare and Dual Eligible members in the Riverside and San Bernardino counties of Southern California.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accountable Health Care is a California-based IPA that has served the local community in the greater Los Angeles County area through a network of physicians and healthcare providers for more than 20 years. Accountable Health Care provides quality healthcare services to its members through three federally qualified health plans and multiple product lines, including Medi-Cal, Commercial, and Medicare. In August 2019, APC and APC-LSMA acquired the remaining outstanding shares of Accountable Health Care&#x2019;s capital stock that they did not already own (comprising 75%) for&#160;$7.3 million&#160;in cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AMG is a network of family practice clinics operating out of three main locations in Southern California. AMG provides professional and post-acute care services to Medicare, Medi-Cal/Medicaid, and Commercial patients through its network of doctors and nurse practitioners. In September 2019, APC-LSMA purchased 100% of the shares of capital stock of AMG for $1.2 million in cash and $0.4 million of APC common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;DMG is a professional medical California corporation and a complete outpatient imaging center. APC accounted for its 40% investment in DMG, under the equity method of accounting. In October 2021, DMG entered into an administrative services agreement with a subsidiary of the Company, causing the Company to reevaluate the accounting for the Company&#x2019;s investment in DMG. Based on the reevaluation and in accordance with relevant accounting guidance, DMG is determined to be a VIE of the Company and is consolidated by the Company. In addition, APC-LSMA is obligated to purchase the remaining equity interest within three years from the effective date. The purchase of the remaining equity value is considered a financing obligation with a carrying value of $8.5&#160;million as of March&#160;31, 2022. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, using cash comprised solely of Excluded Assets, APC purchased a 100% interest in each of Medical Property Partners, LLC (&#x201c;MPP&#x201d;), AMG Properties, LLC (&#x201c;AMG Properties&#x201d;), and ZLL Partners, LLC (&#x201c;ZLL&#x201d;) and a 50% interest in each of One MSO, LLC (&#x201c;One MSO&#x201d;), Tag-6 Medical Investment Group, LLC (&#x201c;Tag 6&#x201d;), and Tag-8 Medical Investment Group, LLC (&#x201c;Tag 8&#x201d;). These entities own buildings that are currently leased to tenants, as well as vacant land that is being developed. MPP, AMG Properties, and ZLL are 100% owned subsidiaries of APC and are included in the consolidated financial statements. In April 2021, Tag 8 entered into a loan agreement with MUFG Union Bank N.A. with APC as their guarantor, causing the Company to reevaluate their consolidation of Tag 8. Based on the reevaluation and in accordance with relevant accounting guidance, it was concluded that Tag 8 is a VIE and is consolidated by APC. One MSO and Tag 6 are accounted for as equity method investments, as APC has the ability to exercise significant influence, but not control over the operations of the entity. These purchases are deemed Excluded Assets that are solely for the benefit of APC and its shareholders. As such, any income pertaining to APC&#x2019;s interests in these properties has no impact on the Series A Dividend payable by APC to AP-AMH Medical Corporation, and consequently will not affect net income attributable to ApolloMed.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, AP-AMH 2, a VIE of the Company, purchased an 80% equity interest (on a fully diluted basis) in Access Primary Care Medical Group (&#x201c;APCMG&#x201d;), a primary care physicians&#x2019; group focused on providing high-quality care to senior patients in the northern California cities of Daly City and San Francisco. As a result, APCMG is consolidated by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, Apollo Medical Holdings, Inc. acquired 49% of the aggregate issued and outstanding shares of capital stock of Sun Clinical Laboratories (&#x201c;Sun Labs&#x201d;) for an aggregate purchase price of $4.0 million. Sun Labs is a Clinical Laboratory Improvement Amendments certified full-service lab that operates across the San Gabriel Valley in Southern California. In accordance with relevant accounting guidance, Sun Labs is determined to be a VIE of the Company and is consolidated by the Company (see Note 3). The Company is obligated to purchase the remaining equity interest within three years from the effective date. The purchase of the remaining equity value is considered a financing obligation with a carrying value of at $4.2 million at March&#160;31, 2022. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;NGACO, GPDC / ACO REACH&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APAACO began participating in the NGACO Model of CMS in January 2017. The NGACO Model was a CMS program that allowed provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk-sharing model. With the ending of the NGACO Model on December 31, 2021, APAACO applied, and has been selected by CMS, to participate as a Direct Contracting Entity (&#x201c;DCE&#x201d;) in the standard track of CMS&#x2019;s GPDC Model for Performance Year 2022 (&#x201c;PY22&#x201d;), beginning January 1, 2022. CMS has since redesigned the GPDC Model in response to Administration priorities, including their commitment to advancing health equity, stakeholder feedback, and participant experience, and renamed the GPDC Model to ACO Realizing Equity, Access, and Community Health (&#x201c;ACO REACH&#x201d;) Model. The ACO REACH Model will begin participation on January 1, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <ameh:InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement
      contextRef="ia01bac51df004e83a5b940703fb94049_D19990701-19990731"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfNDY3OQ_0d4de04d-2eac-4071-8b1a-003a23fac774">P30Y</ameh:InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement>
    <us-gaap:NotesReceivableNet
      contextRef="i080d2011774f4a4f8a04e8046723b130_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfNDk0NzgwMjM0MjU1OA_b29533d9-d438-4495-a1c1-c1885a790600"
      unitRef="usd">545000000</us-gaap:NotesReceivableNet>
    <ameh:FinanceReceivableTermOfReceivable
      contextRef="i3bec4a71e3844c82b36a7dcc2f0a553b_D20190901-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMjc0ODc3OTA5NjY1NQ_34b50e6e-e8eb-4e9c-963f-ab5c0faf1d5b">P10Y</ameh:FinanceReceivableTermOfReceivable>
    <ameh:FinanceReceivableStatedInterestRate
      contextRef="i080d2011774f4a4f8a04e8046723b130_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfNDk0NzgwMjM0MjU4NQ_6bd84e6e-d71c-40e2-9d3a-86c970397a18"
      unitRef="number">0.10</ameh:FinanceReceivableStatedInterestRate>
    <ameh:FinanceReceivableModificationsSubsequentDefaultInterestRate
      contextRef="i080d2011774f4a4f8a04e8046723b130_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfNDk0NzgwMjM0MjU5Nw_5262eaf2-98ec-4d2d-8065-3ada8924fca8"
      unitRef="number">0.1075</ameh:FinanceReceivableModificationsSubsequentDefaultInterestRate>
    <us-gaap:NotesReceivableNet
      contextRef="i080d2011774f4a4f8a04e8046723b130_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfNDk0NzgwMjM0MzU1NQ_b29533d9-d438-4495-a1c1-c1885a790600"
      unitRef="usd">545000000</us-gaap:NotesReceivableNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i42aa94e36eca45219242d025187b81a7_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfNDk0NzgwMjM0MzU2OA_092b6d0f-4e1a-44b4-8917-0e5eacb3ddb1"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:NotesReceivableNet
      contextRef="ic951a78e8e8641ca82615311f26c6e86_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfNDk0NzgwMjM0NDQ5NQ_8189b798-902f-4a00-9fc7-6f184fe94b8d"
      unitRef="usd">300000000</us-gaap:NotesReceivableNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="iad63aacc748841208955dbad50055a32_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfNDk0NzgwMjM0NDUyMg_5c7b22f5-b35c-4922-afb7-9c8f21f2e1fa"
      unitRef="shares">15015015</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ic413e1b24cbb43588d69ee94b270c426_I20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfOTI2Nw_80329551-746e-4405-83e2-788c286a5173"
      unitRef="number">0.1961</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i9401c9559d0a4784bee72fa3bb729bdb_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfOTI4Mw_8620c907-8b01-47cb-a93a-170f9e8f6a96"
      unitRef="number">0.1968</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i433e9e4dc783427e8e6da7ae18299e15_I20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfOTc3Mw_5e22f8e4-e57a-4d8f-9588-d9e911475423"
      unitRef="number">0.4450</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i1a637dbd41eb4403a231966d0c1d8747_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMTEwNzM_fd905d08-1e75-4cbe-a056-1553923bd3ef"
      unitRef="number">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ameh:NumberOfFederallyQualifiedHealthPlans
      contextRef="iea7256f5bdac481c9e419242402ecfad_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMTIwNzE_3bb11bc8-70ff-45af-94d3-3444adcd165e"
      unitRef="plan">3</ameh:NumberOfFederallyQualifiedHealthPlans>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i6791450b303a4baaa9c950aac4835c7a_I20190830"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMTIzNDE_2350e3e4-d234-4a66-96e7-91b177ceab0d"
      unitRef="number">0.75</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i6618dfdd38574ddd8411e3675f60590e_D20190830-20190830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMTIzNDk_1f281389-a241-495e-9249-e4e50111feee"
      unitRef="usd">7300000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <ameh:NumberOfFamilyPracticeClinics
      contextRef="ibbbf646a84b242da86cd62eac12d7711_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMTI0MjI_3a1e3119-ffd3-4833-9d55-4d1fa5f6711f"
      unitRef="clinic">3</ameh:NumberOfFamilyPracticeClinics>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i4258726bec994a1db1b081a69de757a8_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMTI2Njk_a8daff77-20a9-4332-8f77-2728327caa37"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i5c160ab74e9f4f3f897f16bcf956f33b_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMTI3MTQ_fac62f3a-2cda-4e7e-ae6f-21a841e90ff0"
      unitRef="usd">1200000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i4452193fa6da4189b503a5f1f57ad4be_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMTI3Mjk_fbb36a7e-72a9-4580-a507-5b0a1f1a0185"
      unitRef="usd">400000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i5456a038b204408f8d123aa76b5524e2_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfNDk0NzgwMjM1MjExOQ_ff481869-4849-42c1-a084-2338a35f8eba"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase
      contextRef="ib943b580b1c64fc1a7579f4ac67aa99d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMjc0ODc3OTA5NjY3Mg_8c9e214c-6afb-4d2e-b107-f84c577e68a6">P3Y</ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase>
    <us-gaap:EquityMethodInvestments
      contextRef="iade67c79de8c433297cb64b0aa007e48_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfNDk0NzgwMjM1MjE2OA_a3e630a4-bde7-4bba-a53d-f9b5ccbf7a0d"
      unitRef="usd">8500000</us-gaap:EquityMethodInvestments>
    <ameh:AssetAcquisitionPercentageOfSharesAcquired
      contextRef="i27d0462359864892b029d29f2dbae1fa_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMTI4MzU_f2c0637e-6989-477f-a16f-a3b4f1eb9310"
      unitRef="number">1</ameh:AssetAcquisitionPercentageOfSharesAcquired>
    <ameh:AssetAcquisitionPercentageOfSharesAcquired
      contextRef="i9e3006cf844c4dcfb98b8464dfdfecaf_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMjc0ODc3OTEwNTE3NQ_0b01cfee-3f7a-4900-b691-f72999619ce9"
      unitRef="number">0.50</ameh:AssetAcquisitionPercentageOfSharesAcquired>
    <ameh:AssetAcquisitionPercentageOfSharesAcquired
      contextRef="i27d0462359864892b029d29f2dbae1fa_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMTMyODU_f2c0637e-6989-477f-a16f-a3b4f1eb9310"
      unitRef="number">1</ameh:AssetAcquisitionPercentageOfSharesAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="iae649481fa4d4190a0f5b74bc999a510_I20210731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMTQyODQ_0411f803-dad6-4b54-90da-1a656df854ee"
      unitRef="number">0.80</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="ic4078597aaf8463a99cbfd3e8f573353_I20210831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMTQ2NTY_e2d15bb5-f846-41fb-b378-79118792df1c"
      unitRef="number">0.49</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ied48cf0dd52b4ecbacf11485317313d5_D20210801-20210831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMTQ4MDA_5afcdaf8-ebe2-4287-a604-3e4be73addf2"
      unitRef="usd">4000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase
      contextRef="ied48cf0dd52b4ecbacf11485317313d5_D20210801-20210831"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfNzE0NjgyNTYxMDM1Mg_b0d46bda-8a6e-4568-94aa-a86c68b7751b">P3Y</ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase>
    <ameh:BusinessCombinationEquityInterestPurchaseObligationNoncurrent
      contextRef="i47183d9ce9704d30b6eb68894c2e74b3_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80MC9mcmFnOjMzNmVhZjIwNWFlNjQ4NGJiMTZmYTRhZGQxZDA3NmI4L3RleHRyZWdpb246MzM2ZWFmMjA1YWU2NDg0YmIxNmZhNGFkZDFkMDc2YjhfMTUzMjM_c0a4b26f-1ad4-4ecc-bf18-da7718ff8bbd"
      unitRef="usd">4200000</ameh:BusinessCombinationEquityInterestPurchaseObligationNoncurrent>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyMzI_14351d27-e74f-408d-90e7-9fadee2b595b">Basis of Presentation and Summary of Significant Accounting Policies&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated balance sheets at December&#160;31, 2021, have been derived from the Company&#x2019;s audited consolidated financial statements, but do not include all annual disclosures required by generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;). The accompanying unaudited consolidated financial statements as of March&#160;31, 2022, and for the three months ended March&#160;31, 2022 and 2021, have been prepared in accordance with U.S. GAAP for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, these unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC on February&#160;28, 2022. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made to make the consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01. Operating results for the three months ended March&#160;31, 2022, are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022, or any future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated balance sheets as of March&#160;31, 2022 and December&#160;31, 2021, and the consolidated statements of income for the three months ended March&#160;31, 2022 and 2021, include the accounts of (1) ApolloMed, ApolloMed&#x2019;s consolidated subsidiaries, NMM, AMM, and APAACO, and its VIEs, AP-AMH, AP-AMH 2, Sun Labs, and DMG; (2) AP-AMH 2&#x2019;s consolidated subsidiary, APCMG; (3) AMM&#x2019;s consolidated VIEs, SCHC and AMH; (4) NMM&#x2019;s VIE, APC; (5) APC&#x2019;s consolidated subsidiaries, Universal Care Acquisition Partners, LLC (&#x201c;UCAP&#x201d;), MPP, AMG Properties, ZLL, and its VIEs, CDSC, APC-LSMA, ICC, and Tag 8; and (6) APC-LSMA&#x2019;s consolidated subsidiaries, Alpha Care, Accountable Health Care, and AMG.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred but not reported (&#x201c;IBNR&#x201d;) claims), determination of full-risk and shared-risk revenue and receivables (including constraints, completion factors and historical margins), income tax-valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly owned by the Company in accordance with the consolidation guidance. The evaluation considers all of the Company&#x2019;s variable interests, including equity ownership, as well as management services agreements. To fall within the scope of the consolidation guidance, an entity must meet both of the following criteria:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity can be in the form of a partnership, limited liability company, or corporation, among others; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The Company has a variable interest in the legal entity &#x2013; i.e., variable interests that are contractual, such as equity ownership, or other financial interests that change with changes in the fair value of the entity&#x2019;s net assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting. If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A legal entity is determined to be a VIE if it has any of the following three characteristics:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;The entity does not have sufficient equity to finance its activities without additional subordinated financial support;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s) of voting rights); or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they lack any of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt"&gt;The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entity&#x2019;s economic performance, as evidenced by:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;i.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt"&gt;Substantive participating rights in day-to-day management of the entity&#x2019;s activities; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;Substantive kick-out rights over the party responsible for significant decisions;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt"&gt;The obligation to absorb the entity&#x2019;s expected losses; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iv.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt"&gt;The right to receive the entity&#x2019;s expected residual returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company determines that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and evaluate it for consolidation under the variable interest model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable interest model&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company &#x2013; that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE&#x2019;s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (economics). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer to Note 16 &#x2013; &#x201c;Variable Interest Entities (VIEs)&#x201d; to the consolidated financial statements for information on the Company&#x2019;s consolidated VIEs. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting.&lt;br/&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition-related costs separately from the business combination.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&lt;br/&gt;Reportable Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative healthcare models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in one reportable segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents, and restricted cash. As of March&#160;31, 2022 and December&#160;31, 2021, the Company&#x2019;s deposit accounts with banks exceeded the FDIC&#x2019;s insured limit by approximately $282.4 million and $285.9 million, respectively. The Company has not experienced any losses to date and performs ongoing evaluations of these financial institutions to limit the Company&#x2019;s concentration of risk exposure.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in marketable securities consist of equity securities and certificates of deposit with various financial institutions. The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificates of deposit are reported at par value, plus accrued interest, with maturity dates from four months to 24 months. As of March&#160;31, 2022 and December&#160;31, 2021, certificates of deposit amounted to approximately $25.0 million and $25.0 million, respectively. Investments in certificates of deposit are classified as Level 1 investments in the fair value hierarchy.&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity securities are reported at fair value. These securities are classified as Level 1 in the valuation hierarchy, where quoted market prices from reputable third-party brokers are available in an active market and unadjusted. The trading volume of certain equity securities we hold is low, thus resulting in our determination that such equity securities do not have an active market with buyers and sellers ready to trade. Accordingly, we classify such equity securities as Level 2 in the valuation hierarchy, and their valuation is based on weighted average share prices from observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Equity securities held by the Company are primarily comprised of common stock of a payor partner that completed its IPO in June 2021 and Clinigence Holdings, Inc. (&#x201c;Clinigence&#x201d;). The common stock of a payor partner were acquired as a result of UCAP selling its 48.9% ownership interest in Universal Care, Inc. (&#x201c;UCI&#x201d;) in April 2020. In September 2021, ApolloMed and Clinigence entered into a stock purchase agreement in which ApolloMed purchased shares of common stock, warrants, and potentially additional common stock if certain metrics are not met (&#x201c;contingent equity securities&#x201d;) for $3.0&#160;million. The common stock is included in investments in marketable securities and the warrants and contingent equity securities are classified as derivatives and included in other assets and prepaid expenses and other current assets, respectively, in the accompanying consolidated balance sheets. See Note 2 &#x2014; &#x201c;Basis of Presentation and Summary of Significant Accounting Policies - Derivative Financial Instruments&#x201d; in the accompanying consolidated financial statements for information on the treatment of the derivative instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of March&#160;31, 2022 and December&#160;31, 2021, the equity securities were approximately $17.8 million and $28.4&#160;million, respectively, in the accompanying consolidated balance sheets. For the three months ended March&#160;31, 2022, the Company recognized unrealized losses of $10.6&#160;million on all equity securities in unrealized loss on investments in the accompanying consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Receivables,  Receivables &#x2013; Related Parties, and Loan Receivable - Related Party&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements, incentive receivables, management fee income, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s receivables &#x2013; related parties are comprised of risk pool settlements, management fee income and incentive receivables, and other receivables. Receivables &#x2013; related parties are recorded and stated at the amount expected to be collected.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s loan receivable &#x2013; related party consist of promissory notes from a related party payee that accrues interest per annum. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitation and claims receivables relate to each health plan&#x2019;s capitation and are received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#x2019;s full risk pool receivable that is recorded quarterly based on reports received from the Company&#x2019;s hospital partners and management&#x2019;s estimate of the Company&#x2019;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consist of recoverable claims paid related to the 2021 APAACO performance year to be administered following instructions from CMS for the NGACO program, receivables from GPDC capitation revenue for the 2022 performance year, fee-for-services (&#x201c;FFS&#x201d;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop-loss insurance premium reimbursements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (&#x201c;CECL&#x201d;) model. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The consolidated statements of income present disaggregated revenue by service type. The following table presents disaggregated revenue generated by payor type for the three months ended March&#160;31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicaid&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other third parties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had major payors that contributed the following percentages of net revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor B&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Less than 10% of total net revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had major payors that contributed to the following percentages of receivables and receivables &#x2013; related parties:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor E&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor F&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Less than 10% of total receivables and receivables &#x2014; related parties, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 820&#x201d;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This hierarchy prioritizes the inputs into three broad levels as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#x2019;s own data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and fair values of the Company&#x2019;s financial instruments as of March&#160;31, 2022, are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds*&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;APCMG contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Included in cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and fair values of the Company&#x2019;s financial instruments as of December&#160;31, 2021, are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market accounts*&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;APCMG contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Included in cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no changes in Level 1, Level 2, or Level 3 classification and no changes in valuation techniques for these assets for the three months ended March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets and Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with finite lives include network-payor relationships, management contracts, member relationships, subscriber relationships, and developed technology and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized using the accelerated method based on the discounted cash flow rate or using the straight-line method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses, and are amortized using the straight-line method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques. The Company determined that there was no impairment of its finite-lived intangible or long-lived assets during the three months ended March&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and Indefinite-Lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 350, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles &#x2013; Goodwill and Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At least annually, at the Company&#x2019;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#x2019;s three reporting units (1) management services, (2) IPAs, and (3) accountable care organizations. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#x2019;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments, and assumptions management believes are appropriate in the circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had no impairment of its goodwill or indefinite-lived intangible assets during the three months ended March&#160;31, 2022 and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Other Entities &#x2014; Equity Method&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#x2019;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#x2019;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under income (loss) from equity method investments and also is adjusted by contributions to, and distributions from, the investee. Equity method investments are subject to impairment evaluation. There was no impairment loss recorded related to equity method investments for the years ended March&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Privately Held Entities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The investments in privately held entities that do not report net asset value are subject to qualitative assessment for indicators of impairments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Medical Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC, Alpha Care, Accountable Health Care, and APCMG (&#x201c;consolidated IPAs&#x201d;) and APAACO are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. These IPAs and APAACO provide integrated care to HMOs, Medicare, and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimated IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fiduciary Cash and Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated IPAs collect cash from health plans on behalf of their sub-IPAs and providers and pass the money through to them. The fiduciary cash balance of $6.3 million and $10.5 million as of March&#160;31, 2022 and December&#160;31, 2021, respectively, is presented within prepaid expenses and other current assets and the related payable is presented as fiduciary payable in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Rate Swap Agreements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is exposed to interest rate risk on its floating-rate debt. The Company has entered into interest rate swap agreements to effectively convert its floating-rate debt to a fixed-rate basis. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#x2019;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. Refer to Note 9 for further information on our debt. Interest rate swap agreements are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income and reflected in the accompanying consolidated statements of cash flows as unrealized gain or loss on interest rate swaps.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the interest rate swap agreements was determined using Level 2 inputs. As of March&#160;31, 2022 the fair value of the interest rate swap was $0.5 million and is presented within other assets in the accompanying consolidated balance sheets. As of December&#160;31, 2021, the fair value of the interest rate swap was $1.1&#160;million and is presented within other long-term liabilities in the accompanying consolidated balance sheets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrants&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In September 2021, ApolloMed and Clinigence entered into a stock purchase agreement in which ApolloMed purchased shares of common stock and warrants for $3.0&#160;million. The purchased warrants are considered derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income and the accompanying consolidated statements of cash flows. The warrants are classified as a Level 2 instrument as the estimated fair value of the warrants were determined using the Black-Scholes option pricing model and inputs from observable market data. As of March&#160;31, 2022 and December&#160;31, 2021, the fair value of the derivative instrument was $1.1&#160;million and $1.1&#160;million, respectively, and is presented within other assets in the accompanying consolidated balance sheets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Contingent Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the common stock and warrants purchased under the stock purchase agreement between ApolloMed and Clinigence, ApolloMed is entitled to additional common stock if Clinigence does not pay NMM management fees exceeding a threshold by the end of December 31, 2022. The contingent equity securities are considered derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income and the accompanying consolidated statements of cash flows. The Company determined the fair value of the contingent equity security using a probability-weighted model, which includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of recognizing management fees and assigned probabilities to each such scenario in determining fair value. As of March&#160;31, 2022 and December&#160;31, 2021, the contingent consideration was valued at $4.3&#160;million, and is presented within prepaid and other current assets in the accompanying consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Nature of Services and Revenue Streams&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue primarily consists of capitation revenue, risk pool settlements and incentives, GPDC revenue, management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#x2019;s billing arrangements and how revenue is recognized for each.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Capitation, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#x2019; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#x201c;Risk Adjustment&#x201d; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PMPM managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk sharing. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#x2019;s net PMPM transaction price relates specifically to the Company&#x2019;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;GPDC Capitation Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CMS contracts with Direct Contracting Entities (&#x201c;DCEs&#x201d;), which is composed of health care providers operating under a common legal structure and accepts financial accountability for the overall quality and cost of medical care furnished to Medicare FFS beneficiaries aligned to the entity. The combination of the FFS model and the GPDC model changes the distribution of responsibilities, risks, costs, and rewards among CMS, DCEs, and providers. By entering into a contract with CMS, a DCE voluntarily takes on operational, financial, and legal responsibilities and risks that no party has, individually or collectively, under the existing FFS model. Each DCE bears the economic costs, and reaps the economic rewards, of fulfilling its responsibilities and managing its risks as a DCE. APAACO has applied, and been accepted, to participate in the GPDC Model for Performance Year 2022, beginning January 1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each performance year, CMS will pay a total benchmark amount, determined unilaterally by CMS in advance but subject to prospective adjustments throughout the year, for the totality of care provided to the DCE&#x2019;s population of aligned beneficiaries over the course of that year. The benchmark is net of a quality withholding applied by CMS. At the end of each performance year, a portion, or all, of the quality withholding can be earned based on APAACO&#x2019;s performance. GPDC capitation revenue is recognized based on the estimated transaction price to transfer the service for a distinct increment of the series (i.e. month) and is recognized net of quality incentives/penalties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk Pool Settlements and Incentives&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC enters into full-risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging, and paying for institutional risk and APC is responsible for providing, arranging and paying for professional risk. Under a full-risk pool sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#x2019;s risk pools with HMOs after deductions for the affiliated hospital&#x2019;s costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#x2019;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for historical margin, IBNR completion factors and constraint percentages were used by management in applying the most likely amount methodology.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under capitated arrangements with certain HMOs, APC participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans&#x2019; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#x2019;s risk share revenue is deemed to be fully constrained until APC is notified of the amount by the health plan. Final settlement of risk pools for prior contract years generally occur in the third or fourth quarter of the following year.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to risk-sharing revenues, the Company also receives incentives under &#x201c;pay-for-performance&#x201d; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#x2019;s incentives under &#x201c;pay-for-performance&#x201d; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#x2019;s performance within the annual measurement period, but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;NGACO AIPBP Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the NGACO Model, CMS aligns beneficiaries to the Company to manage direct care and pay providers based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation-like AIPBP payments from CMS on a monthly basis to pay claims from in-network providers. The Company records such AIPBPs received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided, and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS, while claims from APAACO&#x2019;s in-network contracted providers are paid by APAACO. The Company&#x2019;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#x2019;s risk share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#x2019;s efficiency in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#x2019;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO AIPBP revenues monthly. Excess AIPBPs over claims paid, plus an estimate for the related IBNR claims (see Note 8), are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there were any excess AIPBPs for the performance year and the excess is refunded to CMS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company, the risk arrangement for which the Company has been approved by CMS, and as otherwise provided in an NGACO Participation Agreement between APAACO and CMS (the &#x201c;Participation Agreement&#x201d;). Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within 30 days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within 30 days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within 30 days after the date of a demand letter or settlement report, CMS will assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#x2019;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that will likely be recognized in the future and therefore this shared risk pool revenue is considered fully constrained. With the ending of the NGACO Model on December 31, 2021, the Company no longer receives AIPBPs but remains eligible to recognize any shared savings or loss for performance year 2021 upon issuance of the settlement report from CMS. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Management Fee Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals, and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of gross revenue or fee collections, or amounts fixed on a monthly, quarterly, or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits, or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides a significant service of integrating the services selected by the Company&#x2019;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#x2019;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#x2019;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#x2019;s performance obligation is satisfied as the Company completes each period&#x2019;s obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#x2019;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#x2019;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s management contracts generally have long terms (e.g., 10 years), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fee-for-Service Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;FFS revenue represents revenue earned under contracts in which the professional component of charges for medical services rendered by the Company&#x2019;s affiliated physician-owned medical groups are billed and collected from third-party payors, hospitals, and patients. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and is recognized in the period in which the services are rendered to specific patients. All services provided are &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;expected to result in cash flows and are therefore reflected as net revenue in the consolidated financial statements. The recognition of net revenue (gross charges, less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#x2019;s billing center for medical coding and entering into the Company&#x2019;s billing system, and the verification of each patient&#x2019;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company&#x2019;s billing systems, as well as an estimate of the revenue associated with medical services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#x2019;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#x2019;s healthcare plans, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether the patients, to whom services are provided, in the period are insured and the contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of income in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions, and healthcare coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company&#x2019;s contract assets are comprised of receivables and receivables &#x2013; related parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable aging, and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as revenues are recognized. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Liabilities (Deferred Revenue)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities are recorded when cash payments are received in advance of the Company&#x2019;s performance, or in the case of the Company&#x2019;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred. The Company&#x2019;s contract liability balance was $20.0 million and $16.8 million as of March&#160;31, 2022 and December&#160;31, 2021, respectively, and is presented within accounts payable and accrued expenses in the accompanying consolidated balance sheets. During the three months ended March&#160;31, 2022, $0.5 million of the Company&#x2019;s contract liability accrued in 2021 has been recognized as revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a stock-based compensation program for employees, non-employees, directors, and consultants. The value of share-based awards is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for forfeitures as they occur. From time to time, the Company issues shares of its common stock to its employees, directors, and consultants, which shares may be subject to the Company&#x2019;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules. The fair value of options granted are determined using the Black-Scholes option pricing model and include several assumptions, including expected term, expected volatility, expected dividends, and risk-free rates. The expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The expected stock price volatility is determined based on an average of historical volatility. The expected dividend yield is based on the Company&#x2019;s expected dividend payouts. The risk-free interest rate is based on the U.S. Constant Maturity curve over the expected term of the option at the time of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basic and Diluted Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is computed by dividing net income attributable to holders of the Company&#x2019;s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding, plus the effect of dilutive securities outstanding during the periods presented, using the treasury stock method. Refer to Note 15 for a discussion of shares treated as treasury shares for accounting purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-controlling Interests&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Non-controlling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#x2019;s consolidated entities. Net income attributable to non-controlling interests is disclosed in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Mezzanine Equity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to APC&#x2019;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase its shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes non-controlling interests in APC as mezzanine equity in the consolidated financial statements. As of March&#160;31, 2022 and December&#160;31, 2021, APC&#x2019;s shares were not redeemable, nor was it probable the shares would become redeemable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease at its inception. The expected term of the lease used for computing the lease liability and right-of-use asset and determining the classification of the lease as operating or financing may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company elected practical expedients for ongoing accounting that is provided by the new standard comprised of the following: (1) the election for classes of underlying asset to not separate non-lease components from lease components, and (2) the election for short-term lease recognition exemption for all leases under a 12-month term. The present value of the lease payments is calculated using a rate implicit in the lease, when readily determinable. However, as most of the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate to determine the present value of the lease payments for the majority of its leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2021, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;)  No. 2021-08, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; (&#x201c;ASU 2021-08&#x201d;). This ASU requires the entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 as if it had originated the contracts. The amendments in this ASU are effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. The Company adopted ASU 2021-08 on January 1, 2022. The adoption of ASU 2021-08 did not have a material impact on the consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;With the exception of the new standards discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#x2019;s financial position, results of operations, and cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyMzM_ea8b505d-36cc-444c-85d9-bca56e9c09ec">Basis of PresentationThe accompanying consolidated balance sheets at December&#160;31, 2021, have been derived from the Company&#x2019;s audited consolidated financial statements, but do not include all annual disclosures required by generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;). The accompanying unaudited consolidated financial statements as of March&#160;31, 2022, and for the three months ended March&#160;31, 2022 and 2021, have been prepared in accordance with U.S. GAAP for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, these unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC on February&#160;28, 2022. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made to make the consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyMTk_e71b58c3-27c5-4947-a661-d024afa8275e">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated balance sheets as of March&#160;31, 2022 and December&#160;31, 2021, and the consolidated statements of income for the three months ended March&#160;31, 2022 and 2021, include the accounts of (1) ApolloMed, ApolloMed&#x2019;s consolidated subsidiaries, NMM, AMM, and APAACO, and its VIEs, AP-AMH, AP-AMH 2, Sun Labs, and DMG; (2) AP-AMH 2&#x2019;s consolidated subsidiary, APCMG; (3) AMM&#x2019;s consolidated VIEs, SCHC and AMH; (4) NMM&#x2019;s VIE, APC; (5) APC&#x2019;s consolidated subsidiaries, Universal Care Acquisition Partners, LLC (&#x201c;UCAP&#x201d;), MPP, AMG Properties, ZLL, and its VIEs, CDSC, APC-LSMA, ICC, and Tag 8; and (6) APC-LSMA&#x2019;s consolidated subsidiaries, Alpha Care, Accountable Health Care, and AMG.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyNDI_02035098-9107-4db3-bfee-98fc80609115">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred but not reported (&#x201c;IBNR&#x201d;) claims), determination of full-risk and shared-risk revenue and receivables (including constraints, completion factors and historical margins), income tax-valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationVariableInterestEntityPolicy
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyMjk_a9fa7384-c028-437f-a9a7-b3b80a71ce91">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly owned by the Company in accordance with the consolidation guidance. The evaluation considers all of the Company&#x2019;s variable interests, including equity ownership, as well as management services agreements. To fall within the scope of the consolidation guidance, an entity must meet both of the following criteria:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity can be in the form of a partnership, limited liability company, or corporation, among others; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The Company has a variable interest in the legal entity &#x2013; i.e., variable interests that are contractual, such as equity ownership, or other financial interests that change with changes in the fair value of the entity&#x2019;s net assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting. If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A legal entity is determined to be a VIE if it has any of the following three characteristics:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;The entity does not have sufficient equity to finance its activities without additional subordinated financial support;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s) of voting rights); or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they lack any of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt"&gt;The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entity&#x2019;s economic performance, as evidenced by:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;i.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt"&gt;Substantive participating rights in day-to-day management of the entity&#x2019;s activities; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;Substantive kick-out rights over the party responsible for significant decisions;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt"&gt;The obligation to absorb the entity&#x2019;s expected losses; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iv.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt"&gt;The right to receive the entity&#x2019;s expected residual returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company determines that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and evaluate it for consolidation under the variable interest model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable interest model&lt;/span&gt;&lt;/div&gt;If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company &#x2013; that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE&#x2019;s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (economics). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer to Note 16 &#x2013; &#x201c;Variable Interest Entities (VIEs)&#x201d; to the consolidated financial statements for information on the Company&#x2019;s consolidated VIEs. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting.</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyMjU_35f85a53-2a0d-47c3-855a-07df70b8650b">Business CombinationsThe Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition-related costs separately from the business combination.</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyODQ_9d83f82c-6354-42a4-b35b-b5dea0340706">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&lt;br/&gt;Reportable Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative healthcare models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in one reportable segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNzUxOQ_64bc587f-ae98-4fc0-b0d2-f3051a72982e"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNzUxOQ_ef847346-c50a-44b0-9269-b5a8a6a476e0"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNzc5Ng_64bc587f-ae98-4fc0-b0d2-f3051a72982e"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNzc5Ng_ef847346-c50a-44b0-9269-b5a8a6a476e0"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyMjE_eb791265-d9d1-4ac7-9669-c85ef0f4302a">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.&lt;/span&gt;&lt;/div&gt;The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents, and restricted cash.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashUninsuredAmount
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfODU2MQ_b0564e13-9f04-4829-aedb-7b06244af60b"
      unitRef="usd">282400000</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfODU2OA_15b99fbb-7500-4183-9a8d-034f13d24a76"
      unitRef="usd">285900000</us-gaap:CashUninsuredAmount>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyODU_a3717d42-23d9-4c2f-9f92-34c62b1e2c39">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in marketable securities consist of equity securities and certificates of deposit with various financial institutions. The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificates of deposit are reported at par value, plus accrued interest, with maturity dates from four months to 24 months. As of March&#160;31, 2022 and December&#160;31, 2021, certificates of deposit amounted to approximately $25.0 million and $25.0 million, respectively. Investments in certificates of deposit are classified as Level 1 investments in the fair value hierarchy.&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity securities are reported at fair value. These securities are classified as Level 1 in the valuation hierarchy, where quoted market prices from reputable third-party brokers are available in an active market and unadjusted. The trading volume of certain equity securities we hold is low, thus resulting in our determination that such equity securities do not have an active market with buyers and sellers ready to trade. Accordingly, we classify such equity securities as Level 2 in the valuation hierarchy, and their valuation is based on weighted average share prices from observable market data.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <ameh:MarketableSecuritiesCurrentMaturityPeriod
      contextRef="i5067812e23e84e4689a191e85614e031_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTczMDA_79c380bd-b385-4927-9ea5-84067528041c">P4M</ameh:MarketableSecuritiesCurrentMaturityPeriod>
    <ameh:MarketableSecuritiesCurrentMaturityPeriod
      contextRef="ic8bb14e9746c41a5b4dc59dfc7318107_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfOTMyNg_aa678297-2fa3-4d6c-bada-dbfa685f85d6">P24M</ameh:MarketableSecuritiesCurrentMaturityPeriod>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8b1b466c96f147349e71fb4f01795a7f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfOTQwNA_0197f11f-95d1-4536-8173-789bb374d3c9"
      unitRef="usd">25000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i06add27710ea4d7785d87fe89373d1fc_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfOTQwNA_2cf2d43b-517e-4e19-ac90-f8e12db23c50"
      unitRef="usd">25000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8b1b466c96f147349e71fb4f01795a7f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfOTQxMQ_0fcd92c5-e646-4167-b82f-6490dd78c3de"
      unitRef="usd">25000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ameh:EquityMethodInvestmentOwnershipPercentageDisposed
      contextRef="ib71613c16b2142f097495def3277d766_I20200430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMjc0ODc3OTE0MjIzOA_a5a8a2a8-b4c6-4023-906d-70f59ca7f9a2"
      unitRef="number">0.489</ameh:EquityMethodInvestmentOwnershipPercentageDisposed>
    <ameh:PaymentsToAcquireCommonStockAndWarrants
      contextRef="i4057678e762644689f10e4ee0607dbed_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNDM5ODA0NjU4MjYxNg_f67dc699-6bab-416f-8c09-3d7f75ff3518"
      unitRef="usd">3000000</ameh:PaymentsToAcquireCommonStockAndWarrants>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMTA5OTUxMTcwMDgzOA_694c99ed-a2c4-4916-bc48-9f5bbfabef48"
      unitRef="usd">17800000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMTA5OTUxMTcwMDg0Ng_bbd273cf-b9cf-4a4e-966b-017d3d0703a1"
      unitRef="usd">28400000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMTEwNDQ_7321abb2-b506-4e4a-8f4c-61aa5ad821c2"
      unitRef="usd">10600000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <ameh:ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTczMDc_4b8ecc17-e4dc-4fef-a5fe-633c381b7480">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Receivables,  Receivables &#x2013; Related Parties, and Loan Receivable - Related Party&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements, incentive receivables, management fee income, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s receivables &#x2013; related parties are comprised of risk pool settlements, management fee income and incentive receivables, and other receivables. Receivables &#x2013; related parties are recorded and stated at the amount expected to be collected.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s loan receivable &#x2013; related party consist of promissory notes from a related party payee that accrues interest per annum. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitation and claims receivables relate to each health plan&#x2019;s capitation and are received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#x2019;s full risk pool receivable that is recorded quarterly based on reports received from the Company&#x2019;s hospital partners and management&#x2019;s estimate of the Company&#x2019;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consist of recoverable claims paid related to the 2021 APAACO performance year to be administered following instructions from CMS for the NGACO program, receivables from GPDC capitation revenue for the 2022 performance year, fee-for-services (&#x201c;FFS&#x201d;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop-loss insurance premium reimbursements.&lt;/span&gt;&lt;/div&gt;The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (&#x201c;CECL&#x201d;) model.</ameh:ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock>
    <ameh:RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMTI1MTA_2ace612e-215b-4808-bef6-7b494b42b33a">P18M</ameh:RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTczMDM_d0f8e007-0dfc-42a3-ade6-8046776ca87b">Concentrations of Credit RisksThe Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The consolidated statements of income present disaggregated revenue by service type.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyODg_10e381ae-31bf-42c8-a12d-de1fb4bbebb9">The following table presents disaggregated revenue generated by payor type for the three months ended March&#160;31, 2022 and 2021 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicaid&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other third parties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if1368e96397d4afb8a5b06c97f9a0e75_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjIyNmUzZDE2MTYzODRkODU4ZWY2MGM1MjEzMmZmNzhkL3RhYmxlcmFuZ2U6MjI2ZTNkMTYxNjM4NGQ4NThlZjYwYzUyMTMyZmY3OGRfMy0xLTEtMS03MDA0Mg_9eba0b54-91ae-454d-bab0-086558141c75"
      unitRef="usd">42140000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3540b9617bba46ec9221f435473df8d4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjIyNmUzZDE2MTYzODRkODU4ZWY2MGM1MjEzMmZmNzhkL3RhYmxlcmFuZ2U6MjI2ZTNkMTYxNjM4NGQ4NThlZjYwYzUyMTMyZmY3OGRfMy0zLTEtMS03MDA0Mg_e4569a32-d1d4-40da-a01d-bea04ca93ad2"
      unitRef="usd">32266000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i97b7e4411cac4f46bd0609f16888cd7b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjIyNmUzZDE2MTYzODRkODU4ZWY2MGM1MjEzMmZmNzhkL3RhYmxlcmFuZ2U6MjI2ZTNkMTYxNjM4NGQ4NThlZjYwYzUyMTMyZmY3OGRfNC0xLTEtMS03MDA0Mg_ca200aae-f8a5-4734-85d6-8b9c32486778"
      unitRef="usd">133659000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41c5d4e729a642c3a0808ffe69396270_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjIyNmUzZDE2MTYzODRkODU4ZWY2MGM1MjEzMmZmNzhkL3RhYmxlcmFuZ2U6MjI2ZTNkMTYxNjM4NGQ4NThlZjYwYzUyMTMyZmY3OGRfNC0zLTEtMS03MDA0Mg_cc9eae2b-80e2-4e4d-a1d5-37d4a86995c9"
      unitRef="usd">64677000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c16654928bd4eaca5078b4d6cf0e50d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjIyNmUzZDE2MTYzODRkODU4ZWY2MGM1MjEzMmZmNzhkL3RhYmxlcmFuZ2U6MjI2ZTNkMTYxNjM4NGQ4NThlZjYwYzUyMTMyZmY3OGRfNS0xLTEtMS03MDA0Mg_233bfa59-d55b-4d52-a84a-3a102d77a4e7"
      unitRef="usd">71663000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib5b721f38495479baa1888225f569bae_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjIyNmUzZDE2MTYzODRkODU4ZWY2MGM1MjEzMmZmNzhkL3RhYmxlcmFuZ2U6MjI2ZTNkMTYxNjM4NGQ4NThlZjYwYzUyMTMyZmY3OGRfNS0zLTEtMS03MDA0Mg_2592e166-2102-4a2d-84c2-2744dcf976f4"
      unitRef="usd">69664000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic00f4d20ec264fa5b0dec1e5c289db51_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjIyNmUzZDE2MTYzODRkODU4ZWY2MGM1MjEzMmZmNzhkL3RhYmxlcmFuZ2U6MjI2ZTNkMTYxNjM4NGQ4NThlZjYwYzUyMTMyZmY3OGRfNi0xLTEtMS03MDA0Mg_02539aca-2e88-4d8d-a0db-2b34f220000a"
      unitRef="usd">15796000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i44447a5bff9d47778021966b6c04440e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjIyNmUzZDE2MTYzODRkODU4ZWY2MGM1MjEzMmZmNzhkL3RhYmxlcmFuZ2U6MjI2ZTNkMTYxNjM4NGQ4NThlZjYwYzUyMTMyZmY3OGRfNi0zLTEtMS03MDA0Mg_6ab1d588-7ca5-4663-8006-9114098102d9"
      unitRef="usd">9451000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjIyNmUzZDE2MTYzODRkODU4ZWY2MGM1MjEzMmZmNzhkL3RhYmxlcmFuZ2U6MjI2ZTNkMTYxNjM4NGQ4NThlZjYwYzUyMTMyZmY3OGRfNy0xLTEtMS03MDA0Mg_390d793c-5805-41ed-9699-90b22e6d4d8a"
      unitRef="usd">263258000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjIyNmUzZDE2MTYzODRkODU4ZWY2MGM1MjEzMmZmNzhkL3RhYmxlcmFuZ2U6MjI2ZTNkMTYxNjM4NGQ4NThlZjYwYzUyMTMyZmY3OGRfNy0zLTEtMS03MDA0Mg_48a1abf4-dce5-4baa-be58-f7ba3df36477"
      unitRef="usd">176058000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyMTU_707623c8-8111-42bc-8faa-793cd22d2fe7">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had major payors that contributed the following percentages of net revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor B&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Less than 10% of total net revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had major payors that contributed to the following percentages of receivables and receivables &#x2013; related parties:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor E&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor F&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Less than 10% of total receivables and receivables &#x2014; related parties, net&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i23c400c680394251b215b33cfde92dbc_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjIwMjZjMTg4ZDcyNTQwNGZiNGRmMTM2MTU1NWUzNDdmL3RhYmxlcmFuZ2U6MjAyNmMxODhkNzI1NDA0ZmI0ZGYxMzYxNTU1ZTM0N2ZfMy0zLTEtMS03MDA0Mg_cb482db4-cf60-4214-9691-f8519b268a30"
      unitRef="number">0.128</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib41161b4c97242dbb50361fe75def7b4_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjIwMjZjMTg4ZDcyNTQwNGZiNGRmMTM2MTU1NWUzNDdmL3RhYmxlcmFuZ2U6MjAyNmMxODhkNzI1NDA0ZmI0ZGYxMzYxNTU1ZTM0N2ZfNC0zLTEtMS03MDA0Mg_1a5fafba-6675-4379-a92d-4bbfac24b276"
      unitRef="number">0.105</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iab747f9347d841d7bed8d71175fd16b2_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjIwMjZjMTg4ZDcyNTQwNGZiNGRmMTM2MTU1NWUzNDdmL3RhYmxlcmFuZ2U6MjAyNmMxODhkNzI1NDA0ZmI0ZGYxMzYxNTU1ZTM0N2ZfNS0xLTEtMS03MDA0Mg_224bed85-6c47-4273-85e7-dfb6af7b018b"
      unitRef="number">0.106</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia9221a81959848e0875b822a89e77723_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjIwMjZjMTg4ZDcyNTQwNGZiNGRmMTM2MTU1NWUzNDdmL3RhYmxlcmFuZ2U6MjAyNmMxODhkNzI1NDA0ZmI0ZGYxMzYxNTU1ZTM0N2ZfNS0zLTEtMS03MDA0Mg_3f27212f-4ada-43db-8a79-d095596b31ab"
      unitRef="number">0.169</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib4a11153cacb478db352c47209bdd22f_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjIwMjZjMTg4ZDcyNTQwNGZiNGRmMTM2MTU1NWUzNDdmL3RhYmxlcmFuZ2U6MjAyNmMxODhkNzI1NDA0ZmI0ZGYxMzYxNTU1ZTM0N2ZfNi0xLTEtMS03MDA0Mg_d631d5ce-2ae4-430f-9b57-5820e12b8250"
      unitRef="number">0.304</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3b9b5a97cba2458e80bbc32a7003a7b5_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjU0ZGIzZWQ3NWQ4NzRjMGU5ZDFkNzQ5YWUzYzU5MWZhL3RhYmxlcmFuZ2U6NTRkYjNlZDc1ZDg3NGMwZTlkMWQ3NDlhZTNjNTkxZmFfMy0xLTEtMS03MDA0Mg_2732148b-e719-4bc1-be4c-6b6980a8b19e"
      unitRef="number">0.190</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ide74daf0c2af45c6b4e6486c2b5f07af_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjU0ZGIzZWQ3NWQ4NzRjMGU5ZDFkNzQ5YWUzYzU5MWZhL3RhYmxlcmFuZ2U6NTRkYjNlZDc1ZDg3NGMwZTlkMWQ3NDlhZTNjNTkxZmFfNC0xLTEtMS03MDA0Mg_ebaaf457-56cb-4595-b301-f264990301f5"
      unitRef="number">0.280</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i062a900e196f43a8ad8c043ed3e37741_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjU0ZGIzZWQ3NWQ4NzRjMGU5ZDFkNzQ5YWUzYzU5MWZhL3RhYmxlcmFuZ2U6NTRkYjNlZDc1ZDg3NGMwZTlkMWQ3NDlhZTNjNTkxZmFfNC0zLTEtMS03MDA0Mg_0cd5aac1-051e-469d-a508-38c5d4ad851a"
      unitRef="number">0.450</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7344d9ece6c54bb7a3445b3b4305a208_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjU0ZGIzZWQ3NWQ4NzRjMGU5ZDFkNzQ5YWUzYzU5MWZhL3RhYmxlcmFuZ2U6NTRkYjNlZDc1ZDg3NGMwZTlkMWQ3NDlhZTNjNTkxZmFfNS0xLTEtMS03MDA0Mg_995fc2b7-be3a-4860-8d96-3e212e7e4c77"
      unitRef="number">0.190</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8004dd5aaab243ceaebebdd9dfbe5dea_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjU0ZGIzZWQ3NWQ4NzRjMGU5ZDFkNzQ5YWUzYzU5MWZhL3RhYmxlcmFuZ2U6NTRkYjNlZDc1ZDg3NGMwZTlkMWQ3NDlhZTNjNTkxZmFfNS0zLTEtMS03MDA0Mg_28122850-84ff-457f-a0f4-ca48847cd2a5"
      unitRef="number">0.300</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyNjY_afc2fc4f-df13-46e3-aa15-fae03b45a9c7">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 820&#x201d;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This hierarchy prioritizes the inputs into three broad levels as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#x2019;s own data.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyNzk_a68b8ec0-fb5d-4e7e-b327-2ed016ee75eb">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and fair values of the Company&#x2019;s financial instruments as of March&#160;31, 2022, are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds*&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;APCMG contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Included in cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and fair values of the Company&#x2019;s financial instruments as of December&#160;31, 2021, are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market accounts*&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;APCMG contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Included in cash and cash equivalents&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6526cb352ff14142ad0267923f9b8458_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfMy0xLTEtMS03MDA0Mg_c6a5726e-dce6-4c34-a8a2-56c05a9c2122"
      unitRef="usd">96213000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6cf7e945065b4cbb9be75f83ecca429e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfMy0zLTEtMS03MDA0Mg_073a234b-9d42-46f6-bac0-0675d62b7f4a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0e0b992a4a41411caa3cf99acedc7773_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfMy01LTEtMS03MDA0Mg_68750817-f32a-43ee-ab01-e508c26800b2"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfMy03LTEtMS03MDA0Mg_37c9b085-f77a-4225-a4d3-009aff9c5f28"
      unitRef="usd">96213000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6526cb352ff14142ad0267923f9b8458_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNC0xLTEtMS03MDA0Mg_31c4fd9f-48b1-4684-9605-346d084c46b3"
      unitRef="usd">25046000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6cf7e945065b4cbb9be75f83ecca429e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNC0zLTEtMS03MDA0Mg_8169bb0c-2388-4320-b3ab-de31142d3fc1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0e0b992a4a41411caa3cf99acedc7773_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNC01LTEtMS03MDA0Mg_bed420bc-aa48-4d1d-9942-76e23b88a87e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNC03LTEtMS03MDA0Mg_ecceaf3b-1968-4548-842f-5cb92423c3b4"
      unitRef="usd">25046000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6526cb352ff14142ad0267923f9b8458_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNS0xLTEtMS03MDA0Mg_d631256e-ebe0-425b-b278-a733e916ff5d"
      unitRef="usd">13577000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6cf7e945065b4cbb9be75f83ecca429e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNS0zLTEtMS03MDA0Mg_efb5ef25-f324-47a0-808a-713bab229075"
      unitRef="usd">4270000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i0e0b992a4a41411caa3cf99acedc7773_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNS01LTEtMS03MDA0Mg_8d32f7fd-6fe2-4297-a93d-8ce8e69278e2"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNS03LTEtMS03MDA0Mg_bdce6a6f-7eee-452e-8b80-6efec44fdba5"
      unitRef="usd">17847000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:DerivativeAssets
      contextRef="i812e1314b74e4b39965703038178723e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNi0xLTEtMS03NzUwMQ_48b7fd1b-a40d-4142-a23e-567db24c5ec3"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i317853952d064c0aae4c8f6086f08c69_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNi0zLTEtMS03NzUxMg_c98b4fd5-9a61-4782-875b-926bbfaf511d"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i395def431eb24cc797be851df63b772d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNi01LTEtMS03NzUyMw_9e5df91d-b847-49c3-8356-5a3a03c2a20c"
      unitRef="usd">4270000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i0f97d77f9a334dfaa7f626c14651831b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNi03LTEtMS03NzUzNQ_1bc89bd2-4bbb-4083-95d8-f59b0388bee6"
      unitRef="usd">4270000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="idedee00e5b814c9ab93ebe0cdd4eefcd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNy0xLTEtMS05NjIxOQ_c8bf9e1d-8020-46ac-a6f3-0b0244994b18"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ibe65b799ceec4dd4b60d0ed19b877f0c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNy0zLTEtMS05NjIyOA_4cd3af1e-cb3f-41ad-a922-3e464eb3f806"
      unitRef="usd">1135000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i4f4a833b59b64e6fa2beeccb4539ee17_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNy01LTEtMS05NjIzNw_3010a341-040c-4fe8-8d66-9a84e0d6518e"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="iee4f95d0daa5491a9f9b7cf6f20f14f0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNy03LTEtMS05NjI0Ng_be8c729e-b98d-44d4-bab2-41d09129d51a"
      unitRef="usd">1135000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i1b31a7f7ad9f4eeba82e05b893d8837b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNi0xLTEtMS03MDA0Mg_72e336aa-7989-4e9e-8298-3f7915c04e12"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ibf6c453b31384c85a91a6dac3bd293f9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNi0zLTEtMS03MDA0Mg_2ced4d93-bc10-456a-bf44-a50f8f561eb3"
      unitRef="usd">522000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i344120b3c93044e5a4e890535a20389f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNi01LTEtMS03MDA0Mg_26d92b05-19c6-4eb3-be8f-2257ea78f7cf"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i7191ac8fddae474f98a72365faf35498_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNi03LTEtMS03MDA0Mg_0eff2e00-09df-4ea6-a6b0-20b3907d6697"
      unitRef="usd">522000</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6526cb352ff14142ad0267923f9b8458_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNy0xLTEtMS03MDA0Mg_d1840ad7-df95-4996-ae0b-2929ae6a4408"
      unitRef="usd">134836000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6cf7e945065b4cbb9be75f83ecca429e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNy0zLTEtMS03MDA0Mg_09348989-2ef2-4ba5-8b3c-302e40d9223d"
      unitRef="usd">5927000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0e0b992a4a41411caa3cf99acedc7773_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNy01LTEtMS03MDA0Mg_be225356-bfc7-4cac-ba58-e42b13c69315"
      unitRef="usd">4270000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfNy03LTEtMS03MDA0Mg_3775d625-543d-4eae-8e7f-4988ebab23a0"
      unitRef="usd">145033000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6526cb352ff14142ad0267923f9b8458_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfMTEtMS0xLTEtNzAwNDI_d898fa6d-ce5b-4a74-a0c0-8bf9b72d1ed9"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6cf7e945065b4cbb9be75f83ecca429e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfMTEtMy0xLTEtNzAwNDI_e4c90cc2-2395-463f-8fec-40db5e92e068"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0e0b992a4a41411caa3cf99acedc7773_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfMTEtNS0xLTEtNzAwNDI_1f7ae1a9-1b11-40f8-9ccd-7878e77df237"
      unitRef="usd">1000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfMTEtNy0xLTEtNzAwNDI_ca1fa00e-a599-4eba-aeaf-4cd2c8e8e9c7"
      unitRef="usd">1000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i6526cb352ff14142ad0267923f9b8458_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfMTItMS0xLTEtNzAwNDI_4fde0f77-72f0-4c62-b241-54737d7eed9f"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i6cf7e945065b4cbb9be75f83ecca429e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfMTItMy0xLTEtNzAwNDI_d2934966-f6f7-4f62-9e8e-0fbb6536b57d"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i0e0b992a4a41411caa3cf99acedc7773_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfMTItNS0xLTEtNzAwNDI_2130601b-10a4-4103-a3c5-6f91c02d46c9"
      unitRef="usd">1000000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOjQ4ZmJiMGJlNDQ5ZDQ2ZWM5OTA0NjA5ZWNjN2RhYjdkL3RhYmxlcmFuZ2U6NDhmYmIwYmU0NDlkNDZlYzk5MDQ2MDllY2M3ZGFiN2RfMTItNy0xLTEtNzAwNDI_aa329bc1-8c93-4f9d-871b-d7b12e265d1a"
      unitRef="usd">1000000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i48154c88054d4bfca4aae23d986f326d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfMy0xLTEtMS03MDA0Mg_b6e2ca55-aeaf-474c-b864-bbc7b77fd6e7"
      unitRef="usd">114665000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icef23c4f80af41b4a7678b0043957020_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfMy0zLTEtMS03MDA0Mg_7e2050ae-ec47-418a-bc59-78f220e8cd83"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id889a0adfcca4b0483674775e3b7017d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfMy01LTEtMS03MDA0Mg_a9e85623-0e56-41fa-92a2-113bad5e76b8"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfMy03LTEtMS03MDA0Mg_915f741f-d487-49d8-9307-d6ee75273e31"
      unitRef="usd">114665000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i48154c88054d4bfca4aae23d986f326d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNC0xLTEtMS03NzM1MA_fc0e8594-ccb9-4ecd-8d48-5d609d4a18a1"
      unitRef="usd">25024000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icef23c4f80af41b4a7678b0043957020_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNC0zLTEtMS03NzM2MQ_44cf5fd7-0d07-4ca5-a170-9602e1aa2ba6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id889a0adfcca4b0483674775e3b7017d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNC01LTEtMS03NzM3MQ_78992787-ffa6-4ba9-a907-c8c25d6c684c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNC03LTEtMS03NzM4Mw_f9914edd-4e8d-4739-9da9-8ace94375402"
      unitRef="usd">25024000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i48154c88054d4bfca4aae23d986f326d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNS0xLTEtMS03NzM1MA_1b4e12b5-59a0-4125-a727-cf6630f03533"
      unitRef="usd">24123000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="icef23c4f80af41b4a7678b0043957020_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNS0zLTEtMS03NzM2MQ_b9874591-a13b-46cc-9f32-faf8d1f5356c"
      unitRef="usd">4270000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id889a0adfcca4b0483674775e3b7017d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNS01LTEtMS03NzM3MQ_de08df9c-f956-41e8-b8a3-c1397b69de03"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNS03LTEtMS03NzM4Mw_d8069d2c-9c2d-4bf9-8555-4875623c5a70"
      unitRef="usd">28393000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:DerivativeAssets
      contextRef="i670c182c37f64d7c81e6e512f5a85911_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNC0xLTEtMS03MDA0Mg_a58d65d5-1bf4-490c-a720-a1dc9a818909"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i1c9680a3ecd2478e8c69cac5c0ca57bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNC0zLTEtMS03MDA0Mg_3729a00a-80e6-4e76-b4d8-d45c0b601a89"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i626fc76fa8044b489370befcecb36ff4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNC01LTEtMS03MDA0Mg_32ff068e-d44b-4b8d-9f76-c16975732ab8"
      unitRef="usd">4270000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i54a2dd1d9f194b41bd57c7a175d4260e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNC03LTEtMS03MDA0Mg_c667780f-5cfa-456a-8d44-49e89df59d13"
      unitRef="usd">4270000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="icb648af0ac4046e19f5473b63dcc3dac_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNS0xLTEtMS03MDA0Mg_f04b1641-b0fd-40f5-b285-3de938795684"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i64f9c2d2092e49e2a51aeaedde7588ff_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNS0zLTEtMS03MDA0Mg_411cc620-f99b-4628-99cd-19969482556c"
      unitRef="usd">1145000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="iaf96d2529f4847d2820cfaff15062529_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNS01LTEtMS03MDA0Mg_4eee1207-3035-457d-a2d9-9ea1847422ea"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i9227a3f5dcdb4fe389f9629762b21c04_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNS03LTEtMS03MDA0Mg_2bde0fb7-6450-4a7a-a68a-448922ad041c"
      unitRef="usd">1145000</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i48154c88054d4bfca4aae23d986f326d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNi0xLTEtMS03MDA0Mg_802421aa-b6da-4ad7-9bc5-2f680007af3a"
      unitRef="usd">163812000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icef23c4f80af41b4a7678b0043957020_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNi0zLTEtMS03MDA0Mg_7f54a62d-1e5a-44a5-b484-7e8caba66c80"
      unitRef="usd">5415000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id889a0adfcca4b0483674775e3b7017d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNi01LTEtMS03MDA0Mg_cc3f43ab-868c-4fdb-9b03-96de7364a251"
      unitRef="usd">4270000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfNi03LTEtMS03MDA0Mg_31a7f50a-986c-4a42-9ab2-455bf704c141"
      unitRef="usd">173497000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="i48154c88054d4bfca4aae23d986f326d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfMTEtMS0xLTEtNzc0NTI_ccac5d1c-45d3-4a64-8193-6c6a3da9e656"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="icef23c4f80af41b4a7678b0043957020_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfMTEtMy0xLTEtNzc0NTk_6f9acfef-ecd8-4862-ad3b-5608ac5f1ca5"
      unitRef="usd">1071000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="id889a0adfcca4b0483674775e3b7017d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfMTEtNS0xLTEtNzc0NjY_0fbb1c57-5ba8-4f4d-a186-4d01a6ab319a"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfMTEtNy0xLTEtNzc0NzM_932f795c-3ffa-4013-8d75-3283b66a1dd3"
      unitRef="usd">1071000</us-gaap:DerivativeLiabilities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i48154c88054d4bfca4aae23d986f326d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfMTItMS0xLTEtNzc0NTI_c4bb50a8-89a4-457c-803e-2cda0f50c700"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="icef23c4f80af41b4a7678b0043957020_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfMTItMy0xLTEtNzc0NTk_45f3ea8b-9092-48d3-9882-a03c2781c928"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id889a0adfcca4b0483674775e3b7017d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfMTItNS0xLTEtNzc0NjY_381ce428-e6b9-49d1-af52-8a027e283f2e"
      unitRef="usd">1000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfMTItNy0xLTEtNzc0NzM_ae85c4c8-9a20-4e33-96a4-a0e52cfe9d5e"
      unitRef="usd">1000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i48154c88054d4bfca4aae23d986f326d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfMTMtMS0xLTEtNzc0NTI_46540e52-0f0f-4359-b46c-4456ef5c1cad"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="icef23c4f80af41b4a7678b0043957020_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfMTMtMy0xLTEtNzc0NTk_b2d0c7b5-b7e7-4888-86d4-84f85d610fbb"
      unitRef="usd">1071000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="id889a0adfcca4b0483674775e3b7017d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfMTMtNS0xLTEtNzc0NjY_110a34a6-9874-4f92-8497-eb43cacdc73e"
      unitRef="usd">1000000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RhYmxlOmE5Nzg4OWQ1ZGEwNDRjNWY4MzYwODMxOWFmZGM3M2YzL3RhYmxlcmFuZ2U6YTk3ODg5ZDVkYTA0NGM1ZjgzNjA4MzE5YWZkYzczZjNfMTMtNy0xLTEtNzc0NzM_bc097f7c-3d22-439f-b879-d6c9e2fb369a"
      unitRef="usd">2071000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyNjc_ffb43809-7953-42cf-8940-b9b76bfcfe08">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets and Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with finite lives include network-payor relationships, management contracts, member relationships, subscriber relationships, and developed technology and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized using the accelerated method based on the discounted cash flow rate or using the straight-line method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses, and are amortized using the straight-line method.&lt;/span&gt;&lt;/div&gt;Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMTg4MTM_2304c2d2-4f39-4b0d-a3d0-c5814cb4cf73"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMTg4MTM_535a3427-8ad0-417a-86b1-39fbe2dff4fd"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMTg4MTM_c4a8ef67-11bf-45e9-b7d9-fa3b4cf70169"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMTg4MTM_dbd9b7ea-44bd-457c-9f9c-af5a39f86c3a"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTczMDk_f0716d91-766c-4002-80cd-c386fdc0959f">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and Indefinite-Lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 350, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles &#x2013; Goodwill and Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At least annually, at the Company&#x2019;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#x2019;s three reporting units (1) management services, (2) IPAs, and (3) accountable care organizations. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#x2019;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments, and assumptions management believes are appropriate in the circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:NumberOfReportingUnits
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMTk1NDc_452f1e0d-396f-4587-a340-d9aaeeb07d5b"
      unitRef="unit">3</us-gaap:NumberOfReportingUnits>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMjA4OTc_94276e99-83ca-45c9-ad08-8e0571de1f36"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMjA4OTc_a4fc4233-be79-40d6-8566-8bbf1f087b27"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMjA4OTc_cb1f5c71-6dfc-46e7-ad57-94566948cd7d"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMjA4OTc_f4dfcd35-ba17-4459-9e46-b5b52898c204"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyMjI_ec84fa6b-5945-46f9-b3ba-e45492cc6651">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Other Entities &#x2014; Equity Method&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#x2019;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#x2019;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under income (loss) from equity method investments and also is adjusted by contributions to, and distributions from, the investee. Equity method investments are subject to impairment evaluation. There was no impairment loss recorded related to equity method investments for the years ended March&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Privately Held Entities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The investments in privately held entities that do not report net asset value are subject to qualitative assessment for indicators of impairments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNDM5ODA0NjU2OTU4Ng_0e0e1b7e-33fb-48e4-b225-04a20d94b62a"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNDM5ODA0NjU2OTU4Ng_4ccc062b-5563-491b-bd17-a0277aecb559"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:HealthCareCostsPolicyPolicyTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTczMDQ_61a9c1bf-db5e-4a2a-b9a8-d2e4102233bc">&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Medical Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC, Alpha Care, Accountable Health Care, and APCMG (&#x201c;consolidated IPAs&#x201d;) and APAACO are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. These IPAs and APAACO provide integrated care to HMOs, Medicare, and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimated IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.&lt;/span&gt;&lt;/div&gt;</us-gaap:HealthCareCostsPolicyPolicyTextBlock>
    <ameh:FiduciaryCashAndPayablePolicyTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyNDY_11fd37bc-8ef2-460b-b208-64b7a893e1dc">Fiduciary Cash and PayableThe consolidated IPAs collect cash from health plans on behalf of their sub-IPAs and providers and pass the money through to them.</ameh:FiduciaryCashAndPayablePolicyTextBlock>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMjQzMTE_08460ec5-7f1b-4ba5-a797-8d4b59f36069"
      unitRef="usd">6300000</ameh:FiduciaryAccountsPayableCurrent>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMjQzMTg_e1ce466c-31e1-41b8-bd3a-b05a83a94ca6"
      unitRef="usd">10500000</ameh:FiduciaryAccountsPayableCurrent>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyMzg_e7769d96-ec89-4a31-aa68-7de2ba5cee08">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Rate Swap Agreements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is exposed to interest rate risk on its floating-rate debt. The Company has entered into interest rate swap agreements to effectively convert its floating-rate debt to a fixed-rate basis. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#x2019;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. Refer to Note 9 for further information on our debt. Interest rate swap agreements are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income and reflected in the accompanying consolidated statements of cash flows as unrealized gain or loss on interest rate swaps.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the interest rate swap agreements was determined using Level 2 inputs. As of March&#160;31, 2022 the fair value of the interest rate swap was $0.5 million and is presented within other assets in the accompanying consolidated balance sheets. As of December&#160;31, 2021, the fair value of the interest rate swap was $1.1&#160;million and is presented within other long-term liabilities in the accompanying consolidated balance sheets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrants&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;In September 2021, ApolloMed and Clinigence entered into a stock purchase agreement in which ApolloMed purchased shares of common stock and warrants for $3.0&#160;million. The purchased warrants are considered derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income and the accompanying consolidated statements of cash flows. The warrants are classified as a Level 2 instrument as the estimated fair value of the warrants were determined using the Black-Scholes option pricing model and inputs from observable market data. As of March&#160;31, 2022 and December&#160;31, 2021, the fair value of the derivative instrument was $1.1&#160;million and $1.1&#160;million, respectively, and is presented within other assets in the accompanying consolidated balance sheets.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i06ded7d511214a6b934ce38ddf56629e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMjU0NzI_4d9b0360-928c-4ae3-a3cf-5e65c929cdd4"
      unitRef="usd">500000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="iaaeae6dd376a4544a532f6990d6ef02b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNDM5ODA0NjU4MzQ4Nw_47556160-6fec-4d87-890e-5a7ef454def9"
      unitRef="usd">1100000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <ameh:PaymentsToAcquireCommonStockAndWarrants
      contextRef="ice1126416af04bd8bb625efbc5740cee_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTQ5NzU1ODIxMTY3MA_7468d272-edc4-40b6-9a11-7c783c055e28"
      unitRef="usd">3000000</ameh:PaymentsToAcquireCommonStockAndWarrants>
    <us-gaap:DerivativeAssets
      contextRef="ibe65b799ceec4dd4b60d0ed19b877f0c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMjYyNTg_5c9a8aaf-984b-45d9-9d01-b6f27fd29000"
      unitRef="usd">1100000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="icef23c4f80af41b4a7678b0043957020_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNDk0NzgwMjQzMzc5MA_d50f180f-75b2-464b-a8c2-709598d706fd"
      unitRef="usd">1100000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i54a2dd1d9f194b41bd57c7a175d4260e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNDM5ODA0NjU4MTE2Nw_195e26d9-54d2-4f76-9c9c-a8932abe69f5"
      unitRef="usd">4300000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i0f97d77f9a334dfaa7f626c14651831b_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNDM5ODA0NjU4MTE2Nw_c26602b4-1d13-4652-8cfb-cc25a4942f4f"
      unitRef="usd">4300000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyOTE_5ed25073-c76a-462b-a36d-e323da6a9e08">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Nature of Services and Revenue Streams&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue primarily consists of capitation revenue, risk pool settlements and incentives, GPDC revenue, management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#x2019;s billing arrangements and how revenue is recognized for each.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Capitation, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#x2019; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#x201c;Risk Adjustment&#x201d; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PMPM managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk sharing. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#x2019;s net PMPM transaction price relates specifically to the Company&#x2019;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;GPDC Capitation Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CMS contracts with Direct Contracting Entities (&#x201c;DCEs&#x201d;), which is composed of health care providers operating under a common legal structure and accepts financial accountability for the overall quality and cost of medical care furnished to Medicare FFS beneficiaries aligned to the entity. The combination of the FFS model and the GPDC model changes the distribution of responsibilities, risks, costs, and rewards among CMS, DCEs, and providers. By entering into a contract with CMS, a DCE voluntarily takes on operational, financial, and legal responsibilities and risks that no party has, individually or collectively, under the existing FFS model. Each DCE bears the economic costs, and reaps the economic rewards, of fulfilling its responsibilities and managing its risks as a DCE. APAACO has applied, and been accepted, to participate in the GPDC Model for Performance Year 2022, beginning January 1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each performance year, CMS will pay a total benchmark amount, determined unilaterally by CMS in advance but subject to prospective adjustments throughout the year, for the totality of care provided to the DCE&#x2019;s population of aligned beneficiaries over the course of that year. The benchmark is net of a quality withholding applied by CMS. At the end of each performance year, a portion, or all, of the quality withholding can be earned based on APAACO&#x2019;s performance. GPDC capitation revenue is recognized based on the estimated transaction price to transfer the service for a distinct increment of the series (i.e. month) and is recognized net of quality incentives/penalties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk Pool Settlements and Incentives&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC enters into full-risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging, and paying for institutional risk and APC is responsible for providing, arranging and paying for professional risk. Under a full-risk pool sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#x2019;s risk pools with HMOs after deductions for the affiliated hospital&#x2019;s costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#x2019;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for historical margin, IBNR completion factors and constraint percentages were used by management in applying the most likely amount methodology.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under capitated arrangements with certain HMOs, APC participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans&#x2019; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#x2019;s risk share revenue is deemed to be fully constrained until APC is notified of the amount by the health plan. Final settlement of risk pools for prior contract years generally occur in the third or fourth quarter of the following year.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to risk-sharing revenues, the Company also receives incentives under &#x201c;pay-for-performance&#x201d; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#x2019;s incentives under &#x201c;pay-for-performance&#x201d; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#x2019;s performance within the annual measurement period, but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;NGACO AIPBP Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the NGACO Model, CMS aligns beneficiaries to the Company to manage direct care and pay providers based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation-like AIPBP payments from CMS on a monthly basis to pay claims from in-network providers. The Company records such AIPBPs received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided, and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS, while claims from APAACO&#x2019;s in-network contracted providers are paid by APAACO. The Company&#x2019;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#x2019;s risk share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#x2019;s efficiency in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#x2019;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO AIPBP revenues monthly. Excess AIPBPs over claims paid, plus an estimate for the related IBNR claims (see Note 8), are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there were any excess AIPBPs for the performance year and the excess is refunded to CMS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company, the risk arrangement for which the Company has been approved by CMS, and as otherwise provided in an NGACO Participation Agreement between APAACO and CMS (the &#x201c;Participation Agreement&#x201d;). Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within 30 days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within 30 days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within 30 days after the date of a demand letter or settlement report, CMS will assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#x2019;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that will likely be recognized in the future and therefore this shared risk pool revenue is considered fully constrained. With the ending of the NGACO Model on December 31, 2021, the Company no longer receives AIPBPs but remains eligible to recognize any shared savings or loss for performance year 2021 upon issuance of the settlement report from CMS. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Management Fee Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals, and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of gross revenue or fee collections, or amounts fixed on a monthly, quarterly, or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits, or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides a significant service of integrating the services selected by the Company&#x2019;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#x2019;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#x2019;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#x2019;s performance obligation is satisfied as the Company completes each period&#x2019;s obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#x2019;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#x2019;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s management contracts generally have long terms (e.g., 10 years), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fee-for-Service Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;FFS revenue represents revenue earned under contracts in which the professional component of charges for medical services rendered by the Company&#x2019;s affiliated physician-owned medical groups are billed and collected from third-party payors, hospitals, and patients. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and is recognized in the period in which the services are rendered to specific patients. All services provided are &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;expected to result in cash flows and are therefore reflected as net revenue in the consolidated financial statements. The recognition of net revenue (gross charges, less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#x2019;s billing center for medical coding and entering into the Company&#x2019;s billing system, and the verification of each patient&#x2019;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company&#x2019;s billing systems, as well as an estimate of the revenue associated with medical services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#x2019;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#x2019;s healthcare plans, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether the patients, to whom services are provided, in the period are insured and the contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of income in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions, and healthcare coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company&#x2019;s contract assets are comprised of receivables and receivables &#x2013; related parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable aging, and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as revenues are recognized. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Liabilities (Deferred Revenue)&lt;/span&gt;&lt;/div&gt;Contract liabilities are recorded when cash payments are received in advance of the Company&#x2019;s performance, or in the case of the Company&#x2019;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenuePerformanceObligationDescriptionOfTiming
      contextRef="i5f76f479c78d4715a3a1756814601111_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyOTY_f788ab28-898a-4226-b883-53f4cee3269d">one year</us-gaap:RevenuePerformanceObligationDescriptionOfTiming>
    <ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport
      contextRef="i129c72bde37445abbf565db10f855c61_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMzc3OTM_583456f1-bab8-4046-bf76-72544378ad78">P30D</ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport>
    <ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport
      contextRef="i129c72bde37445abbf565db10f855c61_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMzgwNTM_3feacf27-621e-4416-b6dd-4e56bbc45296">P30D</ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport>
    <ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport
      contextRef="i129c72bde37445abbf565db10f855c61_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfMzgxNzY_3feacf27-621e-4416-b6dd-4e56bbc45296">P30D</ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport>
    <us-gaap:RevenuePerformanceObligationDescriptionOfTiming
      contextRef="i4efb856004934021887d5c4fcd6a352c_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyOTc_b64e4b63-bf1a-4efa-b7ca-121cc155ebff">10 years</us-gaap:RevenuePerformanceObligationDescriptionOfTiming>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNDg2NTM_5373fb6f-c4c7-4850-9719-ffcd31fd03c1"
      unitRef="usd">20000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNDg2NjA_4287d25d-c729-4b07-adcf-bafbfcaa5339"
      unitRef="usd">16800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i37c332bfa67d49cea1f207293667f549_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNDg4MzY_3a6bdee7-e0f6-49a5-a0e5-fe205289e883"
      unitRef="usd">500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyNzg_d693dfa8-5416-40b4-997a-414980a5bcfe">Income Taxes&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTczMTQ_aca72fad-210f-4fd6-8326-ea30e4ab54b9">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a stock-based compensation program for employees, non-employees, directors, and consultants. The value of share-based awards is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for forfeitures as they occur. From time to time, the Company issues shares of its common stock to its employees, directors, and consultants, which shares may be subject to the Company&#x2019;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules. The fair value of options granted are determined using the Black-Scholes option pricing model and include several assumptions, including expected term, expected volatility, expected dividends, and risk-free rates. The expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The expected stock price volatility is determined based on an average of historical volatility. The expected dividend yield is based on the Company&#x2019;s expected dividend payouts. The risk-free interest rate is based on the U.S. Constant Maturity curve over the expected term of the option at the time of grant.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyOTg_c0c1baa3-0abf-421c-9b92-f570c29437d1">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basic and Diluted Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is computed by dividing net income attributable to holders of the Company&#x2019;s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding, plus the effect of dilutive securities outstanding during the periods presented, using the treasury stock method. Refer to Note 15 for a discussion of shares treated as treasury shares for accounting purposes.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <ameh:MinorityInterestPolicyPolicyTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyNDc_4130bd04-4b98-4cfc-b708-f946308a5203">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-controlling Interests&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Non-controlling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#x2019;s consolidated entities. Net income attributable to non-controlling interests is disclosed in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;</ameh:MinorityInterestPolicyPolicyTextBlock>
    <ameh:TemporaryEquityPolicyTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyMzU_fda9136b-4262-4e5e-b546-9a304c0fd31f">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Mezzanine Equity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to APC&#x2019;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase its shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes non-controlling interests in APC as mezzanine equity in the consolidated financial statements. As of March&#160;31, 2022 and December&#160;31, 2021, APC&#x2019;s shares were not redeemable, nor was it probable the shares would become redeemable.&lt;/span&gt;&lt;/div&gt;</ameh:TemporaryEquityPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyOTk_003e2d28-5f46-4651-bf81-94ba5c129515">LeasesThe Company determines if an arrangement is a lease at its inception. The expected term of the lease used for computing the lease liability and right-of-use asset and determining the classification of the lease as operating or financing may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company elected practical expedients for ongoing accounting that is provided by the new standard comprised of the following: (1) the election for classes of underlying asset to not separate non-lease components from lease components, and (2) the election for short-term lease recognition exemption for all leases under a 12-month term. The present value of the lease payments is calculated using a rate implicit in the lease, when readily determinable. However, as most of the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate to determine the present value of the lease payments for the majority of its leases.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF80Ni9mcmFnOjY0NTAxMWI3N2E2ZDQyNTRhMTdjMDcyYzlkOGFmZGUzL3RleHRyZWdpb246NjQ1MDExYjc3YTZkNDI1NGExN2MwNzJjOWQ4YWZkZTNfNTcyMTg_940f70cd-e895-4d5f-b4ef-a355aba807d4">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2021, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;)  No. 2021-08, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; (&#x201c;ASU 2021-08&#x201d;). This ASU requires the entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 as if it had originated the contracts. The amendments in this ASU are effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. The Company adopted ASU 2021-08 on January 1, 2022. The adoption of ASU 2021-08 did not have a material impact on the consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;With the exception of the new standards discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#x2019;s financial position, results of operations, and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;There have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#x2019;s financial position, results of operations, and cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81Mi9mcmFnOjYyZmFmNjU1OTljNzRiMTk5YzE1MzJhYWYyOWEzNmUxL3RleHRyZWdpb246NjJmYWY2NTU5OWM3NGIxOTljMTUzMmFhZjI5YTM2ZTFfMjg3Mg_ba0f4707-956b-4885-a522-cd17738db911">Business Combinations and Goodwill&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Orma Health, Inc., and Provider Growth Solutions LLC (together, &#x201c;Orma Health&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 27, 2022, the Company acquired 100% of the capital stock of Orma Health, Inc., and Provider Growth Solutions, LLC (together, &#x201c;Orma Health&#x201d;) for $1.0 million in cash and $1.0 million in the Company&#x2019;s capital stock. Orma Health&#x2019;s real-time Clinical AI platform ingests data from multiple sources and utilizes advanced risk-stratification models to identify patients for various clinical programs, including remote patient monitoring (&#x201c;RPM&#x201d;), mental health support, chronic disease management, and more. Its clinical platform is also deeply integrated with Orma Health&#x2019;s proprietary RPM ecosystem, which consists of smart health devices and a suite of technology tools to help manage patients&#x2019; health.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;APCMG&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, the Company acquired an 80% equity interest (on a fully diluted basis) in APCMG for an aggregate purchase price of $2.0 million. As part of the transaction, the Company paid $1.0 million in cash and the remaining amount will be paid out in cash as a contingent consideration related to APCMG&#x2019;s financial performance for fiscal year 2022 (&#x201c;APCMG contingent consideration&#x201d;). The APCMG contingent consideration is met if gross revenue and earnings before interest, taxes, and depreciation, and amortization (&#x201c;EBITDA&#x201d;) targets exceed a threshold for fiscal year 2022. The Company determined the fair value of the contingent consideration using a probability-weighted model that includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of gross revenue and EBITDA and assigned probabilities to each such scenario in determining fair value. As of March&#160;31, 2022, the contingent consideration is valued at $1.0 million and was included within other long-term liabilities in the accompanying consolidated balance sheets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sun Labs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, the Company acquired 49% of the aggregate issued and outstanding shares of capital stock of Sun Labs for an aggregate purchase price of $4.0 million. As Sun Labs was concluded to be a VIE and the Company is the primary beneficiary, Sun Labs is consolidated by the Company. The Company is obligated to purchase the remaining equity interest within three years from the effective date. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets. The Company recognized goodwill as a result of consolidating Sun Labs as a VIE. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;DMG&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, DMG entered into an administrative services agreement with a subsidiary of the Company, causing the Company to reevaluate the accounting for the Company&#x2019;s investment in DMG. Based on the reevaluation and in accordance with relevant accounting guidance, DMG is determined to be a VIE and the Company is the primary beneficiary; DMG is consolidated by Apollo.  In addition, APC-LSMA is obligated to purchase the remaining equity interest within three years from the effective date. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets. The Company recognized goodwill as a result of consolidating DMG as a VIE. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisitions were accounted for under the acquisition method of accounting. The fair value of the consideration for the acquired companies were allocated to acquired tangible and intangible assets and liabilities based upon their fair values. The excess of the purchase consideration over the fair value of the net tangible and identifiable intangible assets acquired was recorded as goodwill. The determination of the fair value of assets and liabilities acquired requires the Company to make estimates and use valuation techniques when market value is not readily available. The results of operations from the acquisitions have been included in the Company&#x2019;s financial statements from the date of acquisition. Transaction costs associated with business acquisitions are expensed as they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the time of acquisition, the Company estimates the amount of the identifiable intangible assets based on a valuation and the facts and circumstances available at the time. The Company determines the final value of the identifiable intangible assets as soon as information is available, but not more than one year from the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the carrying value of goodwill for the three months ended March&#160;31, 2022 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,746)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i4043dc9bcd1c428faf9de8df64df4c4c_I20220124"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81Mi9mcmFnOjYyZmFmNjU1OTljNzRiMTk5YzE1MzJhYWYyOWEzNmUxL3RleHRyZWdpb246NjJmYWY2NTU5OWM3NGIxOTljMTUzMmFhZjI5YTM2ZTFfMTA5OTUxMTY0MzU4NQ_c07ab4f0-6f31-40ac-83fd-c600e87d7c72"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ic90a69d35de04dc89bd59af6b50c84d2_D20220124-20220124"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81Mi9mcmFnOjYyZmFmNjU1OTljNzRiMTk5YzE1MzJhYWYyOWEzNmUxL3RleHRyZWdpb246NjJmYWY2NTU5OWM3NGIxOTljMTUzMmFhZjI5YTM2ZTFfMTA5OTUxMTY0MzYwMA_30d02d56-a4d7-47f7-82c8-0d46096f4baa"
      unitRef="usd">1000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="ic90a69d35de04dc89bd59af6b50c84d2_D20220124-20220124"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81Mi9mcmFnOjYyZmFmNjU1OTljNzRiMTk5YzE1MzJhYWYyOWEzNmUxL3RleHRyZWdpb246NjJmYWY2NTU5OWM3NGIxOTljMTUzMmFhZjI5YTM2ZTFfMTA5OTUxMTY0MzYxNQ_660949ff-6ba3-47d9-9e4d-93518082f585"
      unitRef="usd">1000000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="iae649481fa4d4190a0f5b74bc999a510_I20210731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81Mi9mcmFnOjYyZmFmNjU1OTljNzRiMTk5YzE1MzJhYWYyOWEzNmUxL3RleHRyZWdpb246NjJmYWY2NTU5OWM3NGIxOTljMTUzMmFhZjI5YTM2ZTFfOTQ_0411f803-dad6-4b54-90da-1a656df854ee"
      unitRef="number">0.80</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i25fa08dfbba0471ab1f73eb7a33ab853_D20210701-20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81Mi9mcmFnOjYyZmFmNjU1OTljNzRiMTk5YzE1MzJhYWYyOWEzNmUxL3RleHRyZWdpb246NjJmYWY2NTU5OWM3NGIxOTljMTUzMmFhZjI5YTM2ZTFfMTg0_9703afe4-de49-4c57-b0ac-78d493a3d9e4"
      unitRef="usd">2000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i25fa08dfbba0471ab1f73eb7a33ab853_D20210701-20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81Mi9mcmFnOjYyZmFmNjU1OTljNzRiMTk5YzE1MzJhYWYyOWEzNmUxL3RleHRyZWdpb246NjJmYWY2NTU5OWM3NGIxOTljMTUzMmFhZjI5YTM2ZTFfMjMz_a58cb6bf-0d65-4130-8ee3-61233c55cd25"
      unitRef="usd">1000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i4326870dc64f4f2f89fd5df3a7f241eb_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81Mi9mcmFnOjYyZmFmNjU1OTljNzRiMTk5YzE1MzJhYWYyOWEzNmUxL3RleHRyZWdpb246NjJmYWY2NTU5OWM3NGIxOTljMTUzMmFhZjI5YTM2ZTFfODc0_6ad15c8c-752e-484f-b60a-4ee28f3a4eb8"
      unitRef="usd">1000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="ic4078597aaf8463a99cbfd3e8f573353_I20210831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81Mi9mcmFnOjYyZmFmNjU1OTljNzRiMTk5YzE1MzJhYWYyOWEzNmUxL3RleHRyZWdpb246NjJmYWY2NTU5OWM3NGIxOTljMTUzMmFhZjI5YTM2ZTFfMTAzMQ_e2d15bb5-f846-41fb-b378-79118792df1c"
      unitRef="number">0.49</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ied48cf0dd52b4ecbacf11485317313d5_D20210801-20210831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81Mi9mcmFnOjYyZmFmNjU1OTljNzRiMTk5YzE1MzJhYWYyOWEzNmUxL3RleHRyZWdpb246NjJmYWY2NTU5OWM3NGIxOTljMTUzMmFhZjI5YTM2ZTFfMTE0NQ_5afcdaf8-ebe2-4287-a604-3e4be73addf2"
      unitRef="usd">4000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81Mi9mcmFnOjYyZmFmNjU1OTljNzRiMTk5YzE1MzJhYWYyOWEzNmUxL3RleHRyZWdpb246NjJmYWY2NTU5OWM3NGIxOTljMTUzMmFhZjI5YTM2ZTFfMjg3MQ_4f7a43b8-7ca3-48ce-9ffc-211d2f3e91c6">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the carrying value of goodwill for the three months ended March&#160;31, 2022 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,746)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81Mi9mcmFnOjYyZmFmNjU1OTljNzRiMTk5YzE1MzJhYWYyOWEzNmUxL3RhYmxlOjY2MDI4Njk0NjlhODQwMmY4MWZlYWNlMDQyMWJiOGIxL3RhYmxlcmFuZ2U6NjYwMjg2OTQ2OWE4NDAyZjgxZmVhY2UwNDIxYmI4YjFfMC0xLTEtMS03MDA0Mg_24d133a2-872e-484a-869e-0a072edbb398"
      unitRef="usd">253039000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81Mi9mcmFnOjYyZmFmNjU1OTljNzRiMTk5YzE1MzJhYWYyOWEzNmUxL3RhYmxlOjY2MDI4Njk0NjlhODQwMmY4MWZlYWNlMDQyMWJiOGIxL3RhYmxlcmFuZ2U6NjYwMjg2OTQ2OWE4NDAyZjgxZmVhY2UwNDIxYmI4YjFfMS0xLTEtMS03MDA0Mg_082f94e7-1698-430b-a539-46985e0a80af"
      unitRef="usd">1086000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81Mi9mcmFnOjYyZmFmNjU1OTljNzRiMTk5YzE1MzJhYWYyOWEzNmUxL3RhYmxlOjY2MDI4Njk0NjlhODQwMmY4MWZlYWNlMDQyMWJiOGIxL3RhYmxlcmFuZ2U6NjYwMjg2OTQ2OWE4NDAyZjgxZmVhY2UwNDIxYmI4YjFfMi0xLTEtMS05OTIxMA_4cbf4249-306b-4331-b52a-fb519ec8bc59"
      unitRef="usd">-1746000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:Goodwill
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81Mi9mcmFnOjYyZmFmNjU1OTljNzRiMTk5YzE1MzJhYWYyOWEzNmUxL3RhYmxlOjY2MDI4Njk0NjlhODQwMmY4MWZlYWNlMDQyMWJiOGIxL3RhYmxlcmFuZ2U6NjYwMjg2OTQ2OWE4NDAyZjgxZmVhY2UwNDIxYmI4YjFfMi0xLTEtMS03MDA0Mg_4c82f3c9-46ce-4ace-8c6c-e6763e0b68cf"
      unitRef="usd">252379000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RleHRyZWdpb246NDE5YjNiNzliMjFkNGJkMWFjNjY1NDNiOGY4MmM4YzZfNTc4_633bf33c-f351-409a-a2d9-613f52b95c13">Intangible Assets, Net&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2022, the Company&#x2019;s intangible assets, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Useful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite lived assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Network relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11-21&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87,618)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Member relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,976)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient management platform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade names/trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subscriber relationships &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Developed technology &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108,588)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2021, the Company&#x2019;s intangible assets, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Useful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite lived assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare license&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Network relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84,865)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Management contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Member relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,606)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient management platform&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tradename/trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104,922)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in depreciation and amortization on the accompanying consolidated statements of income is amortization expense of $3.7 million and $3.8 million for the three months ended March&#160;31, 2022 and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (excluding the three months ended March 31, 2022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RleHRyZWdpb246NDE5YjNiNzliMjFkNGJkMWFjNjY1NDNiOGY4MmM4YzZfNTcw_3e8cafed-058a-4684-90c2-a226900e778e">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2022, the Company&#x2019;s intangible assets, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Useful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite lived assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Network relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11-21&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87,618)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Member relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,976)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient management platform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade names/trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subscriber relationships &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Developed technology &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108,588)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2021, the Company&#x2019;s intangible assets, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Useful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite lived assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare license&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Network relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84,865)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Management contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Member relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,606)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient management platform&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tradename/trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104,922)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i963385d3851043318a55cac8d1d8e584_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfMi0zLTEtMS03MDA0Mg_93d2112b-ac23-4f20-be29-233cf1001839"
      unitRef="usd">2150000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i963385d3851043318a55cac8d1d8e584_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfMi03LTEtMS03MDA0Mg_2aeb5653-9fb3-4ccd-a934-99ae8a09f4e6"
      unitRef="usd">2150000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i72e8469da6fd456bb61b083d9a9a2852_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfNC0xLTEtMS03MDA0Mi90ZXh0cmVnaW9uOmE5MmIyNTFjMDQ2MTQ2ZGE5YzQ4YmI4NTliNWU3Yjk5XzQ_6bc629cc-7731-4b13-9f60-4cfeecef7f5a">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i9449f60b9fc845af955a5c89466e5184_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfNC0xLTEtMS03MDA0Mi90ZXh0cmVnaW9uOmE5MmIyNTFjMDQ2MTQ2ZGE5YzQ4YmI4NTliNWU3Yjk5Xzc_c2ca6745-fa7f-4fd0-87f9-ad9c640cc7ea">P21Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i505d1f1aced648e2ac90c9458f190dd7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfNC0zLTEtMS03MDA0Mg_48c3eeb4-78a3-4c70-8d95-e905f5761777"
      unitRef="usd">150679000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i505d1f1aced648e2ac90c9458f190dd7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfNC01LTEtMS03MDA0Mg_3ed3d75c-b218-4b0d-ac4a-3e4a86f6426a"
      unitRef="usd">87618000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i505d1f1aced648e2ac90c9458f190dd7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfNC03LTEtMS03MDA0Mg_aad3e5b3-0c51-4a02-b787-5311a6c41061"
      unitRef="usd">63061000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ib92cc8812a2d47588d05bc790009d105_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfNS0xLTEtMS03MDA0Mg_94ada59b-3e6a-40a7-a7d1-6b5577305d9a">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0f4cf5ddfa684bd38d0791137d1d848f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfNS0zLTEtMS03MDA0Mg_838d07d3-a2de-488d-8705-c262f52e79a9"
      unitRef="usd">22832000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0f4cf5ddfa684bd38d0791137d1d848f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfNS01LTEtMS03MDA0Mg_8a0afce8-b2e3-4fed-857b-052f8f835bfb"
      unitRef="usd">13998000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0f4cf5ddfa684bd38d0791137d1d848f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfNS03LTEtMS03MDA0Mg_651f69db-1459-4b1a-b3c7-5c24a301f357"
      unitRef="usd">8834000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i81cd72537a24472dad3429c1494fb9d6_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfNi0xLTEtMS03MDA0Mg_185a9d76-e395-46b1-a956-a56c2b2dead9">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic8569af65a8b4eb9b5df3177f8dd7840_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfNi0zLTEtMS03MDA0Mg_88de681b-70ce-40cd-acb4-07c2e1be5378"
      unitRef="usd">8997000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic8569af65a8b4eb9b5df3177f8dd7840_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfNi01LTEtMS03MDA0Mg_c19e123c-a305-485c-8bb1-2958479b1dc3"
      unitRef="usd">4976000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic8569af65a8b4eb9b5df3177f8dd7840_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfNi03LTEtMS03MDA0Mg_9c2d60b7-e76d-4105-862d-33c6ada118a6"
      unitRef="usd">4021000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i2b86c52f7f00483faef56f69b319a5ee_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfNy0xLTEtMS03MDA0Mg_2f496541-ae0b-4446-9d21-5a41dfd21e64">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i01b454e0ae7d40d0aa1b524fc4c468b6_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfNy0zLTEtMS03MDA0Mg_21a3ef44-c32b-4c9c-96b3-ef06e3c30e0a"
      unitRef="usd">2060000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i01b454e0ae7d40d0aa1b524fc4c468b6_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfNy01LTEtMS03MDA0Mg_4dcbd68a-ffb5-487f-ba30-00c3d9497fcb"
      unitRef="usd">1777000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i01b454e0ae7d40d0aa1b524fc4c468b6_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfNy03LTEtMS03MDA0Mg_6525bd94-d9d8-4087-b7ec-681b9e8a4c1a"
      unitRef="usd">283000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i120f957d1af8440481f28a0c928f55b4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfOC0xLTEtMS03MDA0Mg_94a86f71-fa64-487d-8a2b-87ff86480c5c">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id3c1ae4a3ee14160b77a83df27148f53_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfOC0zLTEtMS03MDA0Mg_5aa86f36-17f9-4cb0-8bdb-551fe8d9a253"
      unitRef="usd">1011000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id3c1ae4a3ee14160b77a83df27148f53_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfOC01LTEtMS03MDA0Mg_3846c7f7-54ae-4aa0-b0b4-f96ffdcd1e5c"
      unitRef="usd">219000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id3c1ae4a3ee14160b77a83df27148f53_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfOC03LTEtMS03MDA0Mg_58584d00-8c85-42b8-9e9c-a0130a5d54dc"
      unitRef="usd">792000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i1d30ca934a1c4d25a5117a64b30e1ec6_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfOS0xLTEtMS05ODQ3NA_dab2f07b-9dd1-4510-a1b0-3af2730ae451">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i7c57be7d1d9b4186b0c62d58ed16439b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfOS01LTEtMS05ODUxOA_f6bb07c3-e66a-444a-8eba-f8cfde1b4e59"
      unitRef="usd">235000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7c57be7d1d9b4186b0c62d58ed16439b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfOS03LTEtMS05ODUyNQ_90050c1c-bd4c-4fa6-936a-7153f362dd30"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7c57be7d1d9b4186b0c62d58ed16439b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfOS05LTEtMS05ODUzMg_a09b39a0-7ead-4a8a-adac-685afdba832b"
      unitRef="usd">235000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i0d873576e5c74d678a79c2181b0def05_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfMTAtMS0xLTEtOTg0ODE_169ebf32-9581-4f03-ae87-96172a3b9ed4">P6Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9f881cf7eb4448d49160c4fbe26a606f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfMTAtNS0xLTEtOTg1MTg_2fc619c3-7b8d-487a-b71b-06d4518155a8"
      unitRef="usd">772000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9f881cf7eb4448d49160c4fbe26a606f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfMTAtNy0xLTEtOTg1MjU_ea73eb44-76d5-41cf-b073-23f08fdac1aa"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9f881cf7eb4448d49160c4fbe26a606f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfMTAtOS0xLTEtOTg1MzI_3cd84aa5-48f0-4cf7-8130-51b32ea4cc3c"
      unitRef="usd">772000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfOS0zLTEtMS03MDA0Mg_4432afd2-0127-428c-82ee-970d63395976"
      unitRef="usd">188736000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfOS01LTEtMS03MDA0Mg_47526db0-7b64-4ae0-84e2-d43195d95a4c"
      unitRef="usd">108588000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjIxY2YwOGY5MGY1YTQyZTM4MWRiNjUxNjQwYjI0ZjBkL3RhYmxlcmFuZ2U6MjFjZjA4ZjkwZjVhNDJlMzgxZGI2NTE2NDBiMjRmMGRfOS03LTEtMS03MDA0Mg_64bc5fe5-8f16-4b14-8307-899ec6e2ccdd"
      unitRef="usd">80148000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ic42c656984834bbe802a92fc9c2db0ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfMi0zLTEtMS04NTk4NA_9afdd26f-a2bf-4a8d-9e29-de014a6f4b07"
      unitRef="usd">2150000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ic42c656984834bbe802a92fc9c2db0ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfMi03LTEtMS04NjAwNg_822c1687-b892-4b23-9f14-717ab25afdd6"
      unitRef="usd">2150000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ifb3e802a663f4a6b942e4d29cad772ac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfMi0xLTEtMS03MDA0Mi90ZXh0cmVnaW9uOjZjYTBmOWMyYWU5ODRjMzc4NjliY2I0ZjZkY2VjZTBmXzQ_36852a3b-2395-49b3-a435-698e3db382fd">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i181ceb45ba734f1e941c3bc5aff82a91_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfMi0xLTEtMS03MDA0Mi90ZXh0cmVnaW9uOjZjYTBmOWMyYWU5ODRjMzc4NjliY2I0ZjZkY2VjZTBmXzc_ed3b46e2-ce25-41d8-8126-692c58284388">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2fe5dca6b3c94505aeb4f1b8542dce43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfMi0zLTEtMS03MDA0Mg_b01568ea-fe53-4b71-9c3e-6011bff5903b"
      unitRef="usd">150679000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2fe5dca6b3c94505aeb4f1b8542dce43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfMi01LTEtMS03MDA0Mg_86249dd2-1891-4a18-a377-9b09d789c5e1"
      unitRef="usd">84865000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2fe5dca6b3c94505aeb4f1b8542dce43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfMi03LTEtMS03MDA0Mg_61bc366f-52f0-44b9-a741-5ce28c357596"
      unitRef="usd">65814000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ib6f7ecc2ad814ce19177b1caaed8db74_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfMy0xLTEtMS03MDA0Mg_cd74f6d4-c8bb-4c8d-a4dc-0675ab900e21">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i82294d54cab940218597a90c5e4ee4f7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfMy0zLTEtMS03MDA0Mg_89ec3c69-5432-4b33-8f93-087b8a324e94"
      unitRef="usd">22832000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i82294d54cab940218597a90c5e4ee4f7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfMy01LTEtMS03MDA0Mg_7d0f86a3-a998-41a6-86ac-3264ed335dee"
      unitRef="usd">13563000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i82294d54cab940218597a90c5e4ee4f7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfMy03LTEtMS03MDA0Mg_01edf471-44c2-4f9f-8387-903c55e130c0"
      unitRef="usd">9269000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ic7f4421b21eb4d46abaed6eca504bfe6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfNC0xLTEtMS03MDA0Mg_b4de7b71-bbe3-4396-8af7-9f60a136d2a6">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iece03f9e8f8a4d22966891f53113f721_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfNC0zLTEtMS03MDA0Mg_0c21e021-421e-4ab6-a19c-b0f15c152452"
      unitRef="usd">8997000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iece03f9e8f8a4d22966891f53113f721_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfNC01LTEtMS03MDA0Mg_199553c4-0fa2-4481-b49d-1b4665ab4cda"
      unitRef="usd">4606000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iece03f9e8f8a4d22966891f53113f721_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfNC03LTEtMS03MDA0Mg_39612351-8f6f-458f-b16e-30d558572719"
      unitRef="usd">4391000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i64402309fd5e4e24ad7105d9ff70a80c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfNS0xLTEtMS03MDA0Mg_69500660-67b9-44c2-a497-8d3e7e7a4562">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2f11ce9c14364c19887f12faf318e05b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfNS0zLTEtMS03MDA0Mg_790699dc-090d-4121-ac89-b58f1b5803ed"
      unitRef="usd">2060000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2f11ce9c14364c19887f12faf318e05b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfNS01LTEtMS03MDA0Mg_7bf62bcf-21b4-42b5-a6d9-74133f7ca033"
      unitRef="usd">1682000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2f11ce9c14364c19887f12faf318e05b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfNS03LTEtMS03MDA0Mg_32b940ef-222e-4698-9bd4-94df8b5fb8a4"
      unitRef="usd">378000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i336efd7ddd3a421f8e5bba9c0816384d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfNi0xLTEtMS03MDA0Mg_c311a7df-d9ac-426b-9fe5-462313ad5e51">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i43360692494245daa938bbb454eea503_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfNi0zLTEtMS03MDA0Mg_7cbde290-b807-4629-a181-15bb1d84fdf9"
      unitRef="usd">1011000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i43360692494245daa938bbb454eea503_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfNi01LTEtMS03MDA0Mg_eea9ab69-9d87-471e-86cb-86cfcdd0ae99"
      unitRef="usd">206000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i43360692494245daa938bbb454eea503_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfNi03LTEtMS03MDA0Mg_f8687bbd-9ff5-4a57-b48b-d79a1ad2cc47"
      unitRef="usd">805000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfNy0zLTEtMS03MDA0Mg_36bc478b-5e2f-4948-90e3-26b4f00ba7ed"
      unitRef="usd">187729000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfNy01LTEtMS03MDA0Mg_da9aa456-4537-4876-89e0-4923dc343c37"
      unitRef="usd">104922000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjhmMTc5N2NlMWI2NTQ0MTViZWJiNGUwOWFhNmQwNjZmL3RhYmxlcmFuZ2U6OGYxNzk3Y2UxYjY1NDQxNWJlYmI0ZTA5YWE2ZDA2NmZfNy03LTEtMS03MDA0Mg_1bd56e5f-f9a2-4fab-87fd-e2f8eb60e7f0"
      unitRef="usd">82807000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RleHRyZWdpb246NDE5YjNiNzliMjFkNGJkMWFjNjY1NDNiOGY4MmM4YzZfMzQw_29ce6738-1d40-4f3b-b91a-baa6297912d6"
      unitRef="usd">3700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RleHRyZWdpb246NDE5YjNiNzliMjFkNGJkMWFjNjY1NDNiOGY4MmM4YzZfMzQ3_0f8cf90e-816d-4b88-b3bc-a70fc3dcdb64"
      unitRef="usd">3800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RleHRyZWdpb246NDE5YjNiNzliMjFkNGJkMWFjNjY1NDNiOGY4MmM4YzZfNTc5_2454d089-e71f-45a2-906a-11194f3a5683">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (excluding the three months ended March 31, 2022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjEwYzMzNzY3ZTNiMjQ4N2ZiYjEyYmNjNjVkYWJiOTNkL3RhYmxlcmFuZ2U6MTBjMzM3NjdlM2IyNDg3ZmJiMTJiY2M2NWRhYmI5M2RfMi0xLTEtMS03MDA0Mg_bf6e8f38-3616-4c75-b267-6d21358ebfe7"
      unitRef="usd">10168000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjEwYzMzNzY3ZTNiMjQ4N2ZiYjEyYmNjNjVkYWJiOTNkL3RhYmxlcmFuZ2U6MTBjMzM3NjdlM2IyNDg3ZmJiMTJiY2M2NWRhYmI5M2RfMy0xLTEtMS03MDA0Mg_8d359f91-24a9-433e-a53d-9bc9730b1d87"
      unitRef="usd">11804000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjEwYzMzNzY3ZTNiMjQ4N2ZiYjEyYmNjNjVkYWJiOTNkL3RhYmxlcmFuZ2U6MTBjMzM3NjdlM2IyNDg3ZmJiMTJiY2M2NWRhYmI5M2RfNC0xLTEtMS03MDA0Mg_45769c7f-ef83-46df-883b-4a39ce47487f"
      unitRef="usd">10735000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjEwYzMzNzY3ZTNiMjQ4N2ZiYjEyYmNjNjVkYWJiOTNkL3RhYmxlcmFuZ2U6MTBjMzM3NjdlM2IyNDg3ZmJiMTJiY2M2NWRhYmI5M2RfNS0xLTEtMS03MDA0Mg_2e76c76e-e857-4d8a-9234-fa191924d29a"
      unitRef="usd">9558000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjEwYzMzNzY3ZTNiMjQ4N2ZiYjEyYmNjNjVkYWJiOTNkL3RhYmxlcmFuZ2U6MTBjMzM3NjdlM2IyNDg3ZmJiMTJiY2M2NWRhYmI5M2RfNi0xLTEtMS03MDA0Mg_679138dd-18b9-4ffb-9c1e-d6f8395170d5"
      unitRef="usd">8505000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <ameh:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjEwYzMzNzY3ZTNiMjQ4N2ZiYjEyYmNjNjVkYWJiOTNkL3RhYmxlcmFuZ2U6MTBjMzM3NjdlM2IyNDg3ZmJiMTJiY2M2NWRhYmI5M2RfNy0xLTEtMS03MDA0Mg_9a8bbd0a-3e31-4d6d-9629-22cfefcd6dca"
      unitRef="usd">27228000</ameh:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF81NS9mcmFnOjQxOWIzYjc5YjIxZDRiZDFhYzY2NTQzYjhmODJjOGM2L3RhYmxlOjEwYzMzNzY3ZTNiMjQ4N2ZiYjEyYmNjNjVkYWJiOTNkL3RhYmxlcmFuZ2U6MTBjMzM3NjdlM2IyNDg3ZmJiMTJiY2M2NWRhYmI5M2RfOS0xLTEtMS03MDA0Mg_b12bf2f4-9f50-4112-9755-e1e9db63342b"
      unitRef="usd">77998000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <ameh:EquityMethodAndOtherEquityInvestmentsTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfOTg4NQ_e61abc74-8dcb-4127-9ad8-49d85fe6202e">Investments in Other Entities&lt;div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; Equity Method&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in other entities &#x2013; equity method consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.886%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Allocation of Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Funding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Distribution &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LaSalle Medical Associates &#x2013; IPA Line of Business&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pacific Medical Imaging &amp;amp; Oncology Center, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531 W. College, LLC &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One MSO, LLC &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tag-6 Medical Investment Group, LLC &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CAIPA MSO, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;LaSalle Medical Associates &#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IPA Line of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LMA was founded by Dr. Albert Arteaga in 1996 and operates as an IPA delivering high-quality care. In September 2021, APC-LSMA sold 21.25% of its interest in LMA back to Dr. Arteaga for $6.4 million, which resulted in  APC-LSMA owning a 25% interest in LMA as of March&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC accounts for its investment in LMA under the equity method as APC has the ability to exercise significant influence, but not control over LMA&#x2019;s operations. For the three months ended March&#160;31, 2022 and 2021, APC recognized income from this investment of $1.3 million and a loss of $0.7 million, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $4.3 million and $3.0 million at March&#160;31, 2022 and December&#160;31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LMA&#x2019;s summarized balance sheets at March&#160;31, 2022 and December&#160;31, 2021, and summarized statements of income for the three months ended March&#160;31, 2022 and 2021, with respect to its IPA line of business are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Balance Sheets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loan receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Liabilities and Stockholders&#x2019; Deficit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,790)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities and stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Statements of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,552)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&lt;br/&gt;Pacific Medical Imaging and Oncology Center, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC-LSMA and PMIOC entered into a share purchase agreement whereby APC-LSMA purchased a 40% ownership interest in PMIOC. Incorporated in California in 2004, PMIOC provides comprehensive diagnostic imaging services using state-of-the-art technology. PMIOC offers high-quality diagnostic services, such as MRI/MRA, PET/CT, CT, nuclear medicine, ultrasound, digital x-rays, bone densitometry, and digital mammography, at its facilities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC and PMIOC have an Ancillary Service Contract together whereby PMIOC provides covered services on behalf of APC to enrollees of the plans of APC. Under the Ancillary Service Contract, APC paid PMIOC fees of approximately $0.7 million and $0.5 million, for the three months ended March&#160;31, 2022 and 2021, respectively. APC accounts for its investment in PMIOC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over PMIOC&#x2019;s operations. For the three months ended March&#160;31, 2022 and 2021, APC recognized income from this investment of approximately $6,700 and a loss from this investment of $15,000, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets had investment balances of $1.7 million and $1.7 million at March&#160;31, 2022 and December&#160;31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;531 W. College LLC &#x2013; Related Party&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC has a 50% ownership in 531 W. College LLC and accounts for its investment in 531 W. College, LLC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over the operations of this joint venture. 531 W. College, LLC owns a former hospital campus in Los Angeles that is now leased to tenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2022 and 2021, APC recognized a loss from this investment of $0.2 million and $0.1 million, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $17.0 million and $17.2 million at March&#160;31, 2022 and December&#160;31, 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;One MSO, LLC &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Related Party&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC has a 50% interest in One MSO. One MSO owns an office building in Monterey Park, California that is leased to tenants, including NMM. For the three months ended March&#160;31, 2022 and 2021, APC recognized income of $0.1 million and $0.1&#160;million in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $2.8 million and $2.9&#160;million at March&#160;31, 2022 and December&#160;31, 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Tag-6 Medical Investment Group, LLC  &#x2014; Related Party&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC has a 50% interest in Tag 6. Tag 6 leases its building to tenants and shares common ownership with certain board members of APC and as such is considered a related party. For the three months ended March&#160;31, 2022, APC recognized income of $66,000 in the accompanying consolidated statements of income. APC did not recognize any income during the three months ended March&#160;31, 2021.  The accompanying consolidated balance sheets include the Tag 6 investment of $6.3 million and $4.8&#160;million at March&#160;31, 2022 and December&#160;31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;CAIPA MSO, LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, ApolloMed purchased 30% interests in CAIPA MSO, LLC for $11.7 million. CAIPA MSO is a New York-based management services organization affiliated with Chinese-American IPA d/b/a Coalition of Asian-American IPA (&#x201c;CAIPA&#x201d;), a leading independent practice association serving the greater New York City area. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ApolloMed accounts for its investment in CAIPA MSO under the equity method of accounting as ApolloMed has the ability to exercise significant influence, but not control over CAIPA MSO&#x2019;s operations. For the three months ended March&#160;31, 2022 and 2021, ApolloMed recognized income from investment of $0.1 million and $0, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $12.1 million and $12.0&#160;million as of March&#160;31, 2022 and December&#160;31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in privately held entities that do not report net asset value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;MediPortal, LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, APC purchased 270,000 membership interests of MediPortal LLC, a New York limited liability company, for $0.4 million or $1.50 per membership interest, which represented an approximately 2.8% ownership interest. In connection with the initial purchase, APC received a five-year warrant to purchase an additional 270,000 membership interests. A five-year option to purchase an additional 380,000 membership interests and a five-year warrant to purchase 480,000 membership interests were contingent upon the portal completion date. However, APC did not exercise the option after completion of the portal. As APC does not have the ability to exercise significant influence, and lacks control over the investee, this investment is accounted for using a measurement alternative, which allows the investment to be measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AchievaMed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, NMM and AchievaMed, Inc., a California corporation (&#x201c;AchievaMed&#x201d;), entered into an agreement in which NMM would purchase 50% of the aggregate shares of capital stock of AchievaMed over a period of time not to exceed five years. As a result of this transaction NMM invested $0.5 million for a 10% interest. The related investment balance of $0.5 million is included in investments in privately held entities in the accompanying consolidated balance sheets as of March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</ameh:EquityMethodAndOtherEquityInvestmentsTextBlock>
    <us-gaap:EquityMethodInvestmentsTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfOTg4Ng_85b30100-0e37-4be6-a1d0-8276455c8e86">&lt;div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in other entities &#x2013; equity method consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.886%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Allocation of Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Funding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Distribution &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LaSalle Medical Associates &#x2013; IPA Line of Business&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pacific Medical Imaging &amp;amp; Oncology Center, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531 W. College, LLC &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One MSO, LLC &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tag-6 Medical Investment Group, LLC &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CAIPA MSO, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LMA&#x2019;s summarized balance sheets at March&#160;31, 2022 and December&#160;31, 2021, and summarized statements of income for the three months ended March&#160;31, 2022 and 2021, with respect to its IPA line of business are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Balance Sheets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loan receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Liabilities and Stockholders&#x2019; Deficit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,790)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities and stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Statements of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,552)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:EquityMethodInvestments
      contextRef="i36852b2625274d7c94f009efe3625131_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfMS0xLTEtMS03MDA0Mg_46399950-b6db-4ad2-902c-cad9b362273e"
      unitRef="usd">3034000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="iefb065d83e134399924dcb98a8810645_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfMS01LTEtMS03MDA0Mg_691a9877-6c41-43a8-b1ec-c4bed1b2285c"
      unitRef="usd">1258000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="iefb065d83e134399924dcb98a8810645_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfMS03LTEtMS03MDA0Mg_cc31df50-9ea7-4a54-b4c0-acbf8262e139"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="iefb065d83e134399924dcb98a8810645_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfMS0xMS0xLTEtNzAwNDI_1bb66c6d-581a-4c12-bb2a-f72b310af3cb"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments
      contextRef="i20b270836e8e4edfad0aac1201a837a4_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfMS0xMy0xLTEtNzAwNDI_169e3945-def6-431b-a857-ddb82e70d3e7"
      unitRef="usd">4292000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i905a801d6f9b4c9ebe17dff9567e4e65_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfMi0xLTEtMS03MDA0Mg_34d1841e-4094-471c-8168-4ed816aacc6a"
      unitRef="usd">1719000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ief0c35819b504b239cc32ffedc16b209_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfMi01LTEtMS03MDA0Mg_650fa4af-774f-4ba2-a2ad-1204e9e426ca"
      unitRef="usd">6000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="ief0c35819b504b239cc32ffedc16b209_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfMi03LTEtMS03MDA0Mg_0f6fc774-20a6-439d-9e12-bcbbf641d2c5"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="ief0c35819b504b239cc32ffedc16b209_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfMi0xMS0xLTEtNzAwNDI_4bec13c1-ff0d-4968-a075-831568ef7c99"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments
      contextRef="ib4103b5415884a2cb86152b06ab31f87_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfMi0xMy0xLTEtNzAwNDI_7c77a69f-7214-4e88-b18b-9622b237c1c1"
      unitRef="usd">1725000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i98dd8ff17e4643278bde170255559ba3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfNC0xLTEtMS03MDA0Mg_8811c218-7a25-4f59-b84d-20339be85ef5"
      unitRef="usd">17230000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia36eb2cd63f7429d942e17270c0144bf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfNC01LTEtMS03MDA0Mg_fb6f4c71-5f1f-4b89-81d9-5f757a10e8da"
      unitRef="usd">-182000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="ia36eb2cd63f7429d942e17270c0144bf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfNC03LTEtMS03MDA0Mg_596e2fff-df04-4b9d-8138-d71abd83ef3b"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="ia36eb2cd63f7429d942e17270c0144bf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfNC0xMS0xLTEtNzAwNDI_b7d76a67-4fe6-40cf-883a-b5e59a0a5ec9"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments
      contextRef="i6b3e371af52a4f9ab3b9ef33b8762eb8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfNC0xMy0xLTEtNzAwNDI_16ff00d1-287a-4dc9-b6cd-f8be615c35dd"
      unitRef="usd">17048000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i75681772568f4aed9e00dafa27af9156_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfNS0xLTEtMS03MDA0Mg_e3ca8ff7-1a22-4fe6-b913-8945646ab19d"
      unitRef="usd">2910000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i79f112c0b31c40119270d0df81451392_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfNS01LTEtMS03MDA0Mg_f8a2816d-ea71-4e4c-b36c-eaae2c8accbc"
      unitRef="usd">137000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i79f112c0b31c40119270d0df81451392_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfNS03LTEtMS03MDA0Mg_ba6a2920-c813-4c74-97bd-f26c88d147f5"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="i79f112c0b31c40119270d0df81451392_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfNS0xMS0xLTEtNzAwNDI_aeef9292-85d2-4b13-867c-8e11f3f7dd5e"
      unitRef="usd">200000</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments
      contextRef="ibe110e391f1347168555105f65ea038b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfNS0xMy0xLTEtNzAwNDI_234bd6bf-7a52-45f2-a55c-59456cd17d15"
      unitRef="usd">2847000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="id638b192e4b34caeb8ee0fc5e44f48b5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfNi0xLTEtMS03MDA0Mg_ebf971fe-22a6-45ce-a0b6-350a25ef0e65"
      unitRef="usd">4830000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i418e308a689d48d4b3de11c2556a4e0f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfNi01LTEtMS03MDA0Mg_2c9ab481-1244-498f-9d1b-0524b3c2b9c8"
      unitRef="usd">66000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i418e308a689d48d4b3de11c2556a4e0f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfNi03LTEtMS03MDA0Mg_0298c33d-e682-48d1-a1af-ec182a4720a0"
      unitRef="usd">1435000</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="i418e308a689d48d4b3de11c2556a4e0f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfNi0xMS0xLTEtNzAwNDI_edac1a2e-c16d-4edf-97c1-c41d7eebf11a"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments
      contextRef="i3f6b860f41b44b04be3fcc1cfe3c2c04_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfNi0xMy0xLTEtNzAwNDI_67a3ffe6-3850-4f15-97b5-c8bae847a364"
      unitRef="usd">6331000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ie6f6ea60415248a6a49fa2d020393b3d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfOC0xLTEtMS03MDA0Mg_30b60572-3392-4690-909b-e409eac1786f"
      unitRef="usd">11992000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i6e7eadc502bc40c6afc071e235c3a98c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfOC01LTEtMS03MDA0Mg_b713dead-4743-4185-b789-303cd575aad0"
      unitRef="usd">148000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i6e7eadc502bc40c6afc071e235c3a98c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfOC03LTEtMS03MDA0Mg_17ffe6bc-7eb9-402c-9e96-d44bae2b8982"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="i6e7eadc502bc40c6afc071e235c3a98c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfOC0xMS0xLTEtNzAwNDI_1bd7d575-f204-4830-a938-ff5af3d13a9c"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments
      contextRef="i83299a5c90454ecb81deb339e22e4f52_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfOC0xMy0xLTEtNzAwNDI_f50538ed-071a-45d1-952a-f55e3e90c6e1"
      unitRef="usd">12140000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfOS0xLTEtMS03MDA0Mg_99395733-30e2-4e16-b916-e394ef46bb19"
      unitRef="usd">41715000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfOS01LTEtMS03MDA0Mg_468465cc-f44a-4d2e-96f7-6993beb07a45"
      unitRef="usd">1433000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfOS03LTEtMS03MDA0Mg_f854bb6b-0558-4fa1-8670-d6a3715914dd"
      unitRef="usd">1435000</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfOS0xMS0xLTEtNzAwNDI_3909cc99-5294-4739-a3b7-0272147944e6"
      unitRef="usd">200000</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOjg1YTdiNDg1MDNhOTQyZmRhYjk4MWZkYzE2OWY5Y2I3L3RhYmxlcmFuZ2U6ODVhN2I0ODUwM2E5NDJmZGFiOTgxZmRjMTY5ZjljYjdfOS0xMy0xLTEtNzAwNDI_743a022b-3cd8-4751-8b62-3a86edb1e72f"
      unitRef="usd">44383000</us-gaap:EquityMethodInvestments>
    <ameh:EquityMethodInvestmentOwnershipPercentageSold
      contextRef="i5bb2d59135f449d3b0e13fa8b28b3809_I20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfMTA1OA_9d237b69-2922-4b91-96ab-65b2a9635c49"
      unitRef="number">0.2125</ameh:EquityMethodInvestmentOwnershipPercentageSold>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="i5a35e5e78f804b03bb635d5e8df0b4c1_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfMTEwOA_b27d7444-a31f-4f5c-912a-7e34c6cb0a9d"
      unitRef="usd">6400000</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i9ef6f6f7c71f41d68d3add3e70068bc2_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfMTE0OQ_987884f0-dd10-4a2d-9d3c-d55b81970749"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ib1e3f77f67924bf1b0442138b0c59dba_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfMTQyMA_e801b70e-d0ac-4727-a162-6810a6666ef2"
      unitRef="usd">1300000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ic99a2a30fd9144b38c44bd4c90924f6a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfMTQzNw_a7fb0b67-de52-4ce2-aeda-7dacf6fd0af8"
      unitRef="usd">-700000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i20b270836e8e4edfad0aac1201a837a4_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfMTc3Nw_9606fbb2-30e9-4b52-9682-e4c10eb63b09"
      unitRef="usd">4300000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i36852b2625274d7c94f009efe3625131_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfMTc4NA_c00a7528-32ad-4d0b-97c2-7921272e285a"
      unitRef="usd">3000000</us-gaap:EquityMethodInvestments>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i33512e53ca8042e592da50359233581e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmM0ZGUyZDlmNDNmZDQ3ZmVhNTRkODAyYWU3Njk4NmI2L3RhYmxlcmFuZ2U6YzRkZTJkOWY0M2ZkNDdmZWE1NGQ4MDJhZTc2OTg2YjZfMy0xLTEtMS03MDA0Mg_3e352781-f0d3-443a-9b12-18a126243def"
      unitRef="usd">10712000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id918b0f4941f497f8df9f3953fdf4349_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmM0ZGUyZDlmNDNmZDQ3ZmVhNTRkODAyYWU3Njk4NmI2L3RhYmxlcmFuZ2U6YzRkZTJkOWY0M2ZkNDdmZWE1NGQ4MDJhZTc2OTg2YjZfMy0zLTEtMS03MDA0Mg_19141062-7738-4f90-9f4b-b6d7a1533f12"
      unitRef="usd">6619000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="i33512e53ca8042e592da50359233581e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmM0ZGUyZDlmNDNmZDQ3ZmVhNTRkODAyYWU3Njk4NmI2L3RhYmxlcmFuZ2U6YzRkZTJkOWY0M2ZkNDdmZWE1NGQ4MDJhZTc2OTg2YjZfNC0xLTEtMS03MDA0Mg_fe9dd453-0844-4b47-bc2b-9b848e158286"
      unitRef="usd">698000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="id918b0f4941f497f8df9f3953fdf4349_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmM0ZGUyZDlmNDNmZDQ3ZmVhNTRkODAyYWU3Njk4NmI2L3RhYmxlcmFuZ2U6YzRkZTJkOWY0M2ZkNDdmZWE1NGQ4MDJhZTc2OTg2YjZfNC0zLTEtMS03MDA0Mg_d25fa41e-707c-43be-a87a-34f9dad2a815"
      unitRef="usd">696000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i33512e53ca8042e592da50359233581e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmM0ZGUyZDlmNDNmZDQ3ZmVhNTRkODAyYWU3Njk4NmI2L3RhYmxlcmFuZ2U6YzRkZTJkOWY0M2ZkNDdmZWE1NGQ4MDJhZTc2OTg2YjZfNS0xLTEtMS03MDA0Mg_d500f209-7706-4e23-8213-af82992efcd6"
      unitRef="usd">6080000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id918b0f4941f497f8df9f3953fdf4349_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmM0ZGUyZDlmNDNmZDQ3ZmVhNTRkODAyYWU3Njk4NmI2L3RhYmxlcmFuZ2U6YzRkZTJkOWY0M2ZkNDdmZWE1NGQ4MDJhZTc2OTg2YjZfNS0zLTEtMS03MDA0Mg_90069473-4e0f-4025-95b5-728997667976"
      unitRef="usd">2269000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="i33512e53ca8042e592da50359233581e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmM0ZGUyZDlmNDNmZDQ3ZmVhNTRkODAyYWU3Njk4NmI2L3RhYmxlcmFuZ2U6YzRkZTJkOWY0M2ZkNDdmZWE1NGQ4MDJhZTc2OTg2YjZfNy0xLTEtMS03MDA0Mg_457290b2-cd4d-43d5-a2ee-676669c65dff"
      unitRef="usd">2250000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="id918b0f4941f497f8df9f3953fdf4349_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmM0ZGUyZDlmNDNmZDQ3ZmVhNTRkODAyYWU3Njk4NmI2L3RhYmxlcmFuZ2U6YzRkZTJkOWY0M2ZkNDdmZWE1NGQ4MDJhZTc2OTg2YjZfNy0zLTEtMS03MDA0Mg_f4af708f-4336-4b75-8f58-4837c636001f"
      unitRef="usd">2250000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:Assets
      contextRef="i33512e53ca8042e592da50359233581e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmM0ZGUyZDlmNDNmZDQ3ZmVhNTRkODAyYWU3Njk4NmI2L3RhYmxlcmFuZ2U6YzRkZTJkOWY0M2ZkNDdmZWE1NGQ4MDJhZTc2OTg2YjZfOS0xLTEtMS03MDA0Mg_65e7d7c8-0c4a-45c7-ae63-aa0aa1688faa"
      unitRef="usd">19740000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id918b0f4941f497f8df9f3953fdf4349_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmM0ZGUyZDlmNDNmZDQ3ZmVhNTRkODAyYWU3Njk4NmI2L3RhYmxlcmFuZ2U6YzRkZTJkOWY0M2ZkNDdmZWE1NGQ4MDJhZTc2OTg2YjZfOS0zLTEtMS03MDA0Mg_725e912b-a260-4cb0-9e0d-814e953b790c"
      unitRef="usd">11834000</us-gaap:Assets>
    <us-gaap:LiabilitiesCurrent
      contextRef="i33512e53ca8042e592da50359233581e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmM0ZGUyZDlmNDNmZDQ3ZmVhNTRkODAyYWU3Njk4NmI2L3RhYmxlcmFuZ2U6YzRkZTJkOWY0M2ZkNDdmZWE1NGQ4MDJhZTc2OTg2YjZfMTItMS0xLTEtNzAwNDI_889dd43d-4d2a-4dfa-b9fe-aa8977a60ac6"
      unitRef="usd">34530000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id918b0f4941f497f8df9f3953fdf4349_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmM0ZGUyZDlmNDNmZDQ3ZmVhNTRkODAyYWU3Njk4NmI2L3RhYmxlcmFuZ2U6YzRkZTJkOWY0M2ZkNDdmZWE1NGQ4MDJhZTc2OTg2YjZfMTItMy0xLTEtNzAwNDI_665ac90a-e320-4919-9484-7c93daeedd39"
      unitRef="usd">32405000</us-gaap:LiabilitiesCurrent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i33512e53ca8042e592da50359233581e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmM0ZGUyZDlmNDNmZDQ3ZmVhNTRkODAyYWU3Njk4NmI2L3RhYmxlcmFuZ2U6YzRkZTJkOWY0M2ZkNDdmZWE1NGQ4MDJhZTc2OTg2YjZfMTMtMS0xLTEtNzAwNDI_4ba1331d-7a9a-4175-bf05-28080ad25890"
      unitRef="usd">-14790000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id918b0f4941f497f8df9f3953fdf4349_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmM0ZGUyZDlmNDNmZDQ3ZmVhNTRkODAyYWU3Njk4NmI2L3RhYmxlcmFuZ2U6YzRkZTJkOWY0M2ZkNDdmZWE1NGQ4MDJhZTc2OTg2YjZfMTMtMy0xLTEtNzAwNDI_d1e604d6-4ca9-4c47-99f4-8b8646c9fb6c"
      unitRef="usd">-20571000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i33512e53ca8042e592da50359233581e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmM0ZGUyZDlmNDNmZDQ3ZmVhNTRkODAyYWU3Njk4NmI2L3RhYmxlcmFuZ2U6YzRkZTJkOWY0M2ZkNDdmZWE1NGQ4MDJhZTc2OTg2YjZfMTUtMS0xLTEtNzAwNDI_4cfd90ea-8963-4142-8610-4ebb0d52f307"
      unitRef="usd">19740000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id918b0f4941f497f8df9f3953fdf4349_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmM0ZGUyZDlmNDNmZDQ3ZmVhNTRkODAyYWU3Njk4NmI2L3RhYmxlcmFuZ2U6YzRkZTJkOWY0M2ZkNDdmZWE1NGQ4MDJhZTc2OTg2YjZfMTUtMy0xLTEtNzAwNDI_520a81e8-d068-4d65-acf1-d57ae0bc12b5"
      unitRef="usd">11834000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i224451997ac146958e193c349e0fb137_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmU3MDk3YTIxY2RiYjRlZDg4MjgwYWVlZjQwM2RhYmVjL3RhYmxlcmFuZ2U6ZTcwOTdhMjFjZGJiNGVkODgyODBhZWVmNDAzZGFiZWNfMy0xLTEtMS03MDA0Mg_cd043e29-09c9-4bbc-a019-ac9877235977"
      unitRef="usd">67566000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66228b4952d348d9bb6a6f5bd4664a45_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmU3MDk3YTIxY2RiYjRlZDg4MjgwYWVlZjQwM2RhYmVjL3RhYmxlcmFuZ2U6ZTcwOTdhMjFjZGJiNGVkODgyODBhZWVmNDAzZGFiZWNfMy0zLTEtMS03MDA0Mg_06c678ee-4ea5-4653-b6b1-fc728bad51ae"
      unitRef="usd">47224000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostsAndExpenses
      contextRef="i224451997ac146958e193c349e0fb137_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmU3MDk3YTIxY2RiYjRlZDg4MjgwYWVlZjQwM2RhYmVjL3RhYmxlcmFuZ2U6ZTcwOTdhMjFjZGJiNGVkODgyODBhZWVmNDAzZGFiZWNfNC0xLTEtMS03MDA0Mg_ed1cd8be-6199-43d1-ae2d-2a32223c7fa1"
      unitRef="usd">61786000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i66228b4952d348d9bb6a6f5bd4664a45_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmU3MDk3YTIxY2RiYjRlZDg4MjgwYWVlZjQwM2RhYmVjL3RhYmxlcmFuZ2U6ZTcwOTdhMjFjZGJiNGVkODgyODBhZWVmNDAzZGFiZWNfNC0zLTEtMS03MDA0Mg_b854b5ae-915b-41da-b1b8-b751c2379b24"
      unitRef="usd">48776000</us-gaap:CostsAndExpenses>
    <us-gaap:ProfitLoss
      contextRef="i224451997ac146958e193c349e0fb137_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmU3MDk3YTIxY2RiYjRlZDg4MjgwYWVlZjQwM2RhYmVjL3RhYmxlcmFuZ2U6ZTcwOTdhMjFjZGJiNGVkODgyODBhZWVmNDAzZGFiZWNfNi0xLTEtMS03MDA0Mg_86816da7-6ee6-45b9-b8ff-f2a995e073d6"
      unitRef="usd">5780000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i66228b4952d348d9bb6a6f5bd4664a45_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RhYmxlOmU3MDk3YTIxY2RiYjRlZDg4MjgwYWVlZjQwM2RhYmVjL3RhYmxlcmFuZ2U6ZTcwOTdhMjFjZGJiNGVkODgyODBhZWVmNDAzZGFiZWNfNi0zLTEtMS03MDA0Mg_719d1638-4d5f-4d9f-bc20-f2e717e24057"
      unitRef="usd">-1552000</us-gaap:ProfitLoss>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i2a5eaf12f18d437286bc9774e4ff6a25_I20150731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfMjUyMw_877450d2-03df-4f09-8bc0-7630ee89e700"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsForFees
      contextRef="ibb7c2acfad5f4d90804dbceb6ca499a1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfMjc4MA_68b0cd74-ce0f-419f-97be-d8a8a4735d5f"
      unitRef="usd">700000</us-gaap:PaymentsForFees>
    <us-gaap:PaymentsForFees
      contextRef="ia67e2b3c33844eafa88eaa05867d7330_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfMjc4Nw_c78ef23b-d779-4c32-85e3-701d02354bc1"
      unitRef="usd">500000</us-gaap:PaymentsForFees>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="if29bacb1956147fd920ad140828ddf9f_D20220101-20220331"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfMzE5OA_a9961f0b-aa12-4712-b919-e9bf1b875f82"
      unitRef="usd">6700</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ie3512656649a4da789290c7c1a39c58e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfMzIzNg_dfd6684e-9e0d-43d6-8e37-d46c9bb5df9a"
      unitRef="usd">-15000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ie338e6a85a00449c8cb3d0ff9d028af5_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfMzUyOQ_417cb309-f953-4f15-aa26-2419cc8b9e86"
      unitRef="usd">1700000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="id4e2dedbf7694c72b5426585e1f6319e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfMzUzNg_b79023aa-dc29-4d73-9c07-f85b2870b154"
      unitRef="usd">1700000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ibf6b4576ffe04e9896a15272126c5839_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfNTI2MA_382c11d0-34c5-445e-9a56-265291e46c0d"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i6178c9a34de84a89865b60e90b6cf17e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfNTY0MA_84bfe9d6-c31e-4b75-9502-9d128bceced5"
      unitRef="usd">-200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="if344fb7586ce4a30a4cbc6d36795b630_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfNTY0Nw_bb13589d-b170-4d9f-8bd1-ad76d9f77ae4"
      unitRef="usd">-100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i6b3e371af52a4f9ab3b9ef33b8762eb8_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfNTk3NA_5bd1aa0f-4832-49c7-9782-285457e5a287"
      unitRef="usd">17000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i98dd8ff17e4643278bde170255559ba3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfNTk4MQ_6ad31f9e-54b9-44fd-8b5b-6665c2377475"
      unitRef="usd">17200000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i77422bd33cbc45a1aa372bb8875076a8_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfMzI5ODUzNDkwNDMzMg_5446e61c-b344-498c-9b3b-5c8d6762208c"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i79f112c0b31c40119270d0df81451392_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfNjUzMQ_85822e3c-2a3f-4e01-b190-c870cdbc1c72"
      unitRef="usd">100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="if8ed7dfc5ec64dbf909fb3b011b41b8e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfNDM5ODA0NjUyMzQ3Ng_b4776b47-b968-4dfe-99f2-d25cd14a4e72"
      unitRef="usd">100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ibe110e391f1347168555105f65ea038b_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfNjgwMA_9c330c39-4f78-4fd7-a88d-21803d99532c"
      unitRef="usd">2800000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i75681772568f4aed9e00dafa27af9156_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfNDM5ODA0NjUyNzc2NQ_bd87ea04-9caf-471e-9aa3-1b148cf6cf4c"
      unitRef="usd">2900000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i48cf45716cee43579c307972d6f19091_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfMjc0ODc3OTA5MDQzOA_01e3ff79-45a3-421e-a5ab-c479447e5b06"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i168c9d857e684999a379e78e91b03f10_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfNzQ3NA_b7c23670-24b4-4e00-975b-b2633e84509c"
      unitRef="usd">66000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i127fc1bd4bad4c958f81e1514ab97618_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfMjc0ODc3OTA5MDM4MQ_8b3ab638-8325-42cd-af80-499158dc97d2"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ib5916967379848d7af484250dae5a588_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfNzYzNQ_8a58ca48-ee86-4696-b463-64584f55b373"
      unitRef="usd">6300000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="iea22839056f1415e802909f3740eb6f7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfNDM5ODA0NjUyNDM1Nw_2ea8515e-2ce8-4d0c-88ad-a452f1eb819e"
      unitRef="usd">4800000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ic3691558e51545d9b1a33f630ec3101d_I20210831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfNzcyNg_f6661cb5-7d04-42e0-a7f9-98375f9ecdbd"
      unitRef="number">0.30</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="ib9fc9a6b261b43fa800eedc49ae6e150_I20210831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfNzc2MQ_814b0b1f-b236-43fa-91b9-5c1634e09d88"
      unitRef="usd">11700000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i6e7eadc502bc40c6afc071e235c3a98c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfODI3OQ_5e252a1d-a793-4a6e-a928-6c445d9946f0"
      unitRef="usd">100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="idf10dc5a3be94d50a589bf004e41c88f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfNDM5ODA0NjUyNDM4Ng_47b91665-8f81-41cb-bb86-11958b9808e1"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i83299a5c90454ecb81deb339e22e4f52_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfODQzMA_ff8d8ae2-c94a-47cc-b2ba-4214100350c6"
      unitRef="usd">12100000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ie6f6ea60415248a6a49fa2d020393b3d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfNDM5ODA0NjUyNDQxMA_9b9114eb-d282-4279-b67d-b5d00b008b46"
      unitRef="usd">12000000</us-gaap:EquityMethodInvestments>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares
      contextRef="ief73fee5943140169a860306e97c01dd_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfODU2MQ_f599f8df-945e-4f97-8e6c-0f17c18644d0"
      unitRef="shares">270000</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares>
    <ameh:PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments
      contextRef="i0a260d4203424cdc969b85797dd116c6_D20180501-20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfODY0Ng_bc2e903e-3514-4e5b-b165-fd24f2f7c41f"
      unitRef="usd">400000</ameh:PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest
      contextRef="ief73fee5943140169a860306e97c01dd_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfODY1Mg_90f57263-6dcc-430e-a1cc-63860315dd11"
      unitRef="usdPerShare">1.50</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage
      contextRef="ief73fee5943140169a860306e97c01dd_I20180531"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfODcxNQ_595dfa48-8634-4704-ad8f-6262c47fe2a5"
      unitRef="number">0.028</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="ief73fee5943140169a860306e97c01dd_I20180531"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfOTg5Nw_10019720-ab3a-4906-afdd-a64e62c4d304">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ief73fee5943140169a860306e97c01dd_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfODgzNg_22077f60-5caa-462c-b632-630daefe7f41"
      unitRef="shares">270000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption
      contextRef="i0a260d4203424cdc969b85797dd116c6_D20180501-20180531"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfOTg5Mg_a77de134-ac7e-4a8a-afde-ebc23886678b">P5Y</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests
      contextRef="i0a260d4203424cdc969b85797dd116c6_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfODkwNA_2fcda45f-b3d2-4431-8bcb-a19e58d022c5"
      unitRef="shares">380000</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="ief73fee5943140169a860306e97c01dd_I20180531"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfOTg4OA_d061885f-a659-4ee3-b0bc-5d2adf389c35">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet
      contextRef="ief73fee5943140169a860306e97c01dd_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfODk2Mg_2aa94333-9942-4ca0-a8f6-ad0b9fdcf1af"
      unitRef="shares">480000</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears
      contextRef="i1d2082812210428bb7329995875a8388_I20190731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfOTU3Mg_2f90a111-1a8b-43e7-bcd1-f53f95da08f7"
      unitRef="number">0.50</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment
      contextRef="i519cba15a31640d3bead178989c651a5_D20190701-20190731"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfOTY2Ng_f62562af-e6c2-4579-b59f-7d80fcd7caad">P5Y</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost
      contextRef="i1d2082812210428bb7329995875a8388_I20190731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfOTcxNQ_a711c9d9-8c2d-45c0-a577-00f729860038"
      unitRef="usd">500000</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage
      contextRef="i1d2082812210428bb7329995875a8388_I20190731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfOTcyNA_d70b2056-bdfa-4c1a-b9f4-227725dfc405"
      unitRef="number">0.10</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments
      contextRef="i6f1f415161e146c9982274d3873b0801_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82MS9mcmFnOjg3ODAxODljMmVjYzQ5ZjA4NTRjYjI2MmMzNWU1ZWIwL3RleHRyZWdpb246ODc4MDE4OWMyZWNjNDlmMDg1NGNiMjYyYzM1ZTVlYjBfOTc3MQ_d199a030-24d0-4454-bf41-7e7e24b69a45"
      unitRef="usd">500000</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments>
    <ameh:LoanReceivableTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82Ny9mcmFnOmFmMTJmMzYxZDIwZDQ2MGNhZTA1NWZkNmNiODc1NmNiL3RleHRyZWdpb246YWYxMmYzNjFkMjBkNDYwY2FlMDU1ZmQ2Y2I4NzU2Y2JfMTI1Mg_94966f37-b895-4e9c-b6bd-9298ec4879dc">Loan Receivable and Loan Receivable &#x2013; Related Parties&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loan receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pacific6&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, NMM received a promissory note from Pacific6 totaling $0.5&#160;million as a result of the sale of the Company&#x2019;s interest in MWN. Interest accrues at a rate of 5% per annum and is payable monthly through the maturity date of December 1, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loan receivable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; related party&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AHMC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, APC entered into a promissory note with AHMC (the &#x201c;AHMC Note&#x201d;) for a principal amount of $4.0&#160;million with a maturity date of April 2022. The contractual interest rate on the AHMC Note is 3.75% per annum. The AHMC Note was entered into using cash strictly related to the Excluded Assets that were generated from the series of transactions with AP-AMH. As of March&#160;31, 2022, the total principal of $4.0&#160;million remains outstanding. One of the Company&#x2019;s board members is an officer of AHMC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the outstanding loan receivable under the CECL model by assessing the party&#x2019;s ability to pay by reviewing their interest payment history quarterly, financial history annually, and reassessing any insolvency risk that is identified. If a failure to pay occurs, the Company assesses the terms of the notes and estimates an expected credit loss based on the remittance schedule of the note.&lt;/span&gt;&lt;/div&gt;</ameh:LoanReceivableTextBlock>
    <us-gaap:NotesReceivableNet
      contextRef="i23ad757dae0649c281c2c43b079538ea_I20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82Ny9mcmFnOmFmMTJmMzYxZDIwZDQ2MGNhZTA1NWZkNmNiODc1NmNiL3RleHRyZWdpb246YWYxMmYzNjFkMjBkNDYwY2FlMDU1ZmQ2Y2I4NzU2Y2JfMTU5_e7a8d70f-8872-4cc5-bfae-0aa80b832a91"
      unitRef="usd">500000</us-gaap:NotesReceivableNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i23ad757dae0649c281c2c43b079538ea_I20201031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82Ny9mcmFnOmFmMTJmMzYxZDIwZDQ2MGNhZTA1NWZkNmNiODc1NmNiL3RleHRyZWdpb246YWYxMmYzNjFkMjBkNDYwY2FlMDU1ZmQ2Y2I4NzU2Y2JfMjUw_4f2110e2-371c-4e60-9521-d2c1dea95f79"
      unitRef="number">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NotesReceivableGross
      contextRef="i83913ad0855f49819cfa7c93494153e4_I20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82Ny9mcmFnOmFmMTJmMzYxZDIwZDQ2MGNhZTA1NWZkNmNiODc1NmNiL3RleHRyZWdpb246YWYxMmYzNjFkMjBkNDYwY2FlMDU1ZmQ2Y2I4NzU2Y2JfNDc4_b23dc8a8-68ef-4c1e-ade5-4cf701c32fee"
      unitRef="usd">4000000</us-gaap:NotesReceivableGross>
    <ameh:FinanceReceivableInterestRateStatedPercentage
      contextRef="i83913ad0855f49819cfa7c93494153e4_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82Ny9mcmFnOmFmMTJmMzYxZDIwZDQ2MGNhZTA1NWZkNmNiODc1NmNiL3RleHRyZWdpb246YWYxMmYzNjFkMjBkNDYwY2FlMDU1ZmQ2Y2I4NzU2Y2JfNTY3_e6781828-d499-4645-9c1d-e0ab7b54b702"
      unitRef="number">0.0375</ameh:FinanceReceivableInterestRateStatedPercentage>
    <us-gaap:NotesReceivableGross
      contextRef="i26c2e65389c446feb05b2d425a1f08c3_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF82Ny9mcmFnOmFmMTJmMzYxZDIwZDQ2MGNhZTA1NWZkNmNiODc1NmNiL3RleHRyZWdpb246YWYxMmYzNjFkMjBkNDYwY2FlMDU1ZmQ2Y2I4NzU2Y2JfNzYx_add9215b-98b8-42c9-92a4-f3b1bc8b1464"
      unitRef="usd">4000000</us-gaap:NotesReceivableGross>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RleHRyZWdpb246N2VkZGE3ZmIxMGQ0NDRiY2FkNDhkODI5MDM5MzNmZGZfMTQy_03c21ad3-e585-4900-9c5f-6b7cbeab91b0">Accounts Payable and Accrued Expenses&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounts payable and accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitation payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subcontractor IPA payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to related parties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RleHRyZWdpb246N2VkZGE3ZmIxMGQ0NDRiY2FkNDhkODI5MDM5MzNmZGZfMTQ1_d56e38d6-5de9-4b2d-b5ea-79fb82bcda81">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounts payable and accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitation payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subcontractor IPA payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to related parties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RhYmxlOjRhZTI3OWMxZmM0ZTRmM2NiNWJlMDMzNDY1MzEyMDI5L3RhYmxlcmFuZ2U6NGFlMjc5YzFmYzRlNGYzY2I1YmUwMzM0NjUzMTIwMjlfMS0xLTEtMS03MDA0Mg_9082eb41-6434-4488-b760-22eaa3c26d69"
      unitRef="usd">9868000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RhYmxlOjRhZTI3OWMxZmM0ZTRmM2NiNWJlMDMzNDY1MzEyMDI5L3RhYmxlcmFuZ2U6NGFlMjc5YzFmYzRlNGYzY2I1YmUwMzM0NjUzMTIwMjlfMS0zLTEtMS03MDA0Mg_d8577e2b-0bc4-4596-a55a-fc84cdf88136"
      unitRef="usd">9583000</us-gaap:AccountsPayableCurrent>
    <ameh:SpecialtyCapitationPayableCurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RhYmxlOjRhZTI3OWMxZmM0ZTRmM2NiNWJlMDMzNDY1MzEyMDI5L3RhYmxlcmFuZ2U6NGFlMjc5YzFmYzRlNGYzY2I1YmUwMzM0NjUzMTIwMjlfMi0xLTEtMS03MDA0Mg_c7a03e14-2010-4e89-b880-9bfed22cab6b"
      unitRef="usd">3525000</ameh:SpecialtyCapitationPayableCurrent>
    <ameh:SpecialtyCapitationPayableCurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RhYmxlOjRhZTI3OWMxZmM0ZTRmM2NiNWJlMDMzNDY1MzEyMDI5L3RhYmxlcmFuZ2U6NGFlMjc5YzFmYzRlNGYzY2I1YmUwMzM0NjUzMTIwMjlfMi0zLTEtMS03MDA0Mg_6fd3badf-6770-463d-9b3d-cd2c6d57c7a2"
      unitRef="usd">2697000</ameh:SpecialtyCapitationPayableCurrent>
    <ameh:SubcontractorIPAPayable
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RhYmxlOjRhZTI3OWMxZmM0ZTRmM2NiNWJlMDMzNDY1MzEyMDI5L3RhYmxlcmFuZ2U6NGFlMjc5YzFmYzRlNGYzY2I1YmUwMzM0NjUzMTIwMjlfMy0xLTEtMS03MDA0Mg_2f9b4fb7-5b21-4579-bba2-1a0b09ede841"
      unitRef="usd">1918000</ameh:SubcontractorIPAPayable>
    <ameh:SubcontractorIPAPayable
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RhYmxlOjRhZTI3OWMxZmM0ZTRmM2NiNWJlMDMzNDY1MzEyMDI5L3RhYmxlcmFuZ2U6NGFlMjc5YzFmYzRlNGYzY2I1YmUwMzM0NjUzMTIwMjlfMy0zLTEtMS03MDA0Mg_b0079efc-9cff-4646-b4bb-c0d264b02077"
      unitRef="usd">1587000</ameh:SubcontractorIPAPayable>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RhYmxlOjRhZTI3OWMxZmM0ZTRmM2NiNWJlMDMzNDY1MzEyMDI5L3RhYmxlcmFuZ2U6NGFlMjc5YzFmYzRlNGYzY2I1YmUwMzM0NjUzMTIwMjlfNC0xLTEtMS03MDA0Mg_502060c1-e267-4feb-8b2e-3fe75dfd5771"
      unitRef="usd">900000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RhYmxlOjRhZTI3OWMxZmM0ZTRmM2NiNWJlMDMzNDY1MzEyMDI5L3RhYmxlcmFuZ2U6NGFlMjc5YzFmYzRlNGYzY2I1YmUwMzM0NjUzMTIwMjlfNC0zLTEtMS03MDA0Mg_2df2cd3d-93c1-4942-b0dc-32df89123dbf"
      unitRef="usd">878000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RhYmxlOjRhZTI3OWMxZmM0ZTRmM2NiNWJlMDMzNDY1MzEyMDI5L3RhYmxlcmFuZ2U6NGFlMjc5YzFmYzRlNGYzY2I1YmUwMzM0NjUzMTIwMjlfNS0xLTEtMS03MDA0Mg_cf6df7d8-33a4-4c63-941a-f14c55f925ca"
      unitRef="usd">2339000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RhYmxlOjRhZTI3OWMxZmM0ZTRmM2NiNWJlMDMzNDY1MzEyMDI5L3RhYmxlcmFuZ2U6NGFlMjc5YzFmYzRlNGYzY2I1YmUwMzM0NjUzMTIwMjlfNS0zLTEtMS03MDA0Mg_3e9ff0f9-6505-4ebc-a3f0-f8aaeb0feb5c"
      unitRef="usd">2301000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RhYmxlOjRhZTI3OWMxZmM0ZTRmM2NiNWJlMDMzNDY1MzEyMDI5L3RhYmxlcmFuZ2U6NGFlMjc5YzFmYzRlNGYzY2I1YmUwMzM0NjUzMTIwMjlfNi0xLTEtMS03MDA0Mg_61c9b61f-4a2f-4d95-8171-851ac2fc83c2"
      unitRef="usd">20028000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RhYmxlOjRhZTI3OWMxZmM0ZTRmM2NiNWJlMDMzNDY1MzEyMDI5L3RhYmxlcmFuZ2U6NGFlMjc5YzFmYzRlNGYzY2I1YmUwMzM0NjUzMTIwMjlfNi0zLTEtMS03MDA0Mg_b565049e-7827-4c14-ae83-d04971d86715"
      unitRef="usd">16798000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RhYmxlOjRhZTI3OWMxZmM0ZTRmM2NiNWJlMDMzNDY1MzEyMDI5L3RhYmxlcmFuZ2U6NGFlMjc5YzFmYzRlNGYzY2I1YmUwMzM0NjUzMTIwMjlfNy0xLTEtMS03MDA0Mg_c660ca6d-fe8e-4507-abe8-bc0cda222de5"
      unitRef="usd">9674000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RhYmxlOjRhZTI3OWMxZmM0ZTRmM2NiNWJlMDMzNDY1MzEyMDI5L3RhYmxlcmFuZ2U6NGFlMjc5YzFmYzRlNGYzY2I1YmUwMzM0NjUzMTIwMjlfNy0zLTEtMS03MDA0Mg_7b0299db-7177-4664-aaf2-17bfd8364c60"
      unitRef="usd">10107000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RhYmxlOjRhZTI3OWMxZmM0ZTRmM2NiNWJlMDMzNDY1MzEyMDI5L3RhYmxlcmFuZ2U6NGFlMjc5YzFmYzRlNGYzY2I1YmUwMzM0NjUzMTIwMjlfOC0xLTEtMS03MDA0Mg_1539671e-5d62-4f4d-80fc-679aef7607e8"
      unitRef="usd">48252000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83My9mcmFnOjdlZGRhN2ZiMTBkNDQ0YmNhZDQ4ZDgyOTAzOTMzZmRmL3RhYmxlOjRhZTI3OWMxZmM0ZTRmM2NiNWJlMDMzNDY1MzEyMDI5L3RhYmxlcmFuZ2U6NGFlMjc5YzFmYzRlNGYzY2I1YmUwMzM0NjUzMTIwMjlfOC0zLTEtMS03MDA0Mg_332f9a64-e7a6-4b79-a9c0-b91c57b3ef39"
      unitRef="usd">43951000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RleHRyZWdpb246NzFiNzZiZTM2MzU3NDhhMjlkOTkyZTNhMjgxNDU0NDRfMTA3_803e2211-e6d2-4d37-9c32-47fadd7abf15">Medical Liabilities&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s medical liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical liabilities, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of medical care costs related to claims incurred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,018)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments for medical care costs related to claims incurred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70,120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41,713)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,035)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,344)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114,155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical liabilities, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock>
    <us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RleHRyZWdpb246NzFiNzZiZTM2MzU3NDhhMjlkOTkyZTNhMjgxNDU0NDRfMTEx_4fed20c2-c8d7-4df8-83a9-41595d6b9a0e">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s medical liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical liabilities, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of medical care costs related to claims incurred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,018)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments for medical care costs related to claims incurred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70,120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41,713)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,035)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,344)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114,155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical liabilities, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfMS0xLTEtMS03MDA0Mg_a945e817-6939-40bd-8bdf-811ca79d0db8"
      unitRef="usd">55783000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ib537036edf0744c69646e8a9929a0638_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfMS0zLTEtMS03MDA0Mg_c66fc493-791e-4f33-8688-39939b2b0073"
      unitRef="usd">50330000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfNS0xLTEtMS03MDA0Mg_af17daf1-4d1f-4292-9d48-e7959b731201"
      unitRef="usd">153535000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfNS0zLTEtMS03MDA0Mg_a87d334b-5b73-4fbc-8714-6c07e445d5a8"
      unitRef="usd">83329000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfNi0xLTEtMS03MDA0Mg_6d05f243-bf4c-4a3f-82e4-27173c55f504"
      unitRef="usd">-175000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfNi0zLTEtMS03MDA0Mg_d570a285-9fe8-427f-8ad7-9a373da64350"
      unitRef="usd">-2018000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfNy0xLTEtMS03MDA0Mg_29bd4027-8059-422d-80b0-e0135d785319"
      unitRef="usd">153360000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfNy0zLTEtMS03MDA0Mg_1cb1aaeb-d2dd-40d7-b2f9-b608717e4b35"
      unitRef="usd">81311000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfOS0xLTEtMS03MDA0Mg_9602af03-7680-442d-b797-655876c1ee81"
      unitRef="usd">70120000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfOS0zLTEtMS03MDA0Mg_9dbd07d9-a3c0-445c-b305-5336773fa012"
      unitRef="usd">41713000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfMTAtMS0xLTEtNzAwNDI_7465df9d-86ce-4e52-8ac8-1a11e74ce159"
      unitRef="usd">44035000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfMTAtMy0xLTEtNzAwNDI_4aedb6a6-09e9-4262-983a-1730b63b9306"
      unitRef="usd">39344000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfMTEtMS0xLTEtNzAwNDI_e4b62b51-0700-4436-aa42-f877625c976a"
      unitRef="usd">114155000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfMTEtMy0xLTEtNzAwNDI_0021335c-f95f-4fe0-bcbe-c2dd8dfd25e8"
      unitRef="usd">81057000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfMTItMS0xLTEtNzAwNDI_2ccb0df8-27df-4825-8145-29d245f8a484"
      unitRef="usd">770000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfMTItMy0xLTEtNzAwNDI_9f7dbcee-7cd8-49df-a4db-f96ebd96d636"
      unitRef="usd">895000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfMTQtMS0xLTEtNzAwNDI_85ed9510-32d9-484b-a870-9787279a4234"
      unitRef="usd">95758000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i5144afd8082f4f17afadb8908f6b4051_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83Ni9mcmFnOjcxYjc2YmUzNjM1NzQ4YTI5ZDk5MmUzYTI4MTQ1NDQ0L3RhYmxlOmNiOTg4YmJlNzY0YTRiMWE5Njc3ZDA5OWEyZjk1OGY4L3RhYmxlcmFuZ2U6Y2I5ODhiYmU3NjRhNGIxYTk2NzdkMDk5YTJmOTU4ZjhfMTQtMy0xLTEtNzAwNDI_3561c904-5ca1-4bd0-bce9-1e3fa0a3849f"
      unitRef="usd">51479000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfMTI0NzE_6c44c364-d8ff-4565-9e2d-d0dd03777645">Credit Facility, Bank Loans, and Lines of Credit&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s debt balance consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revolver Loan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real Estate Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,503)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unamortized financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,031)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of our long-term debt was determined using Level 2 inputs primarily related to comparable market prices. As of March&#160;31, 2022 and December&#160;31, 2021, the carrying value was not materially different from fair value, as the interest rates on the Company&#x2019;s debt approximated rates currently available to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following are the future commitments of the Company&#x2019;s debt for the years ending &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;December 31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (excluding the three months ended March 31, 2022) &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amended Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 16, 2021, the Company entered into an amended and restated credit agreement (the &#x201c;Amended Credit Agreement&#x201d; and the credit facility thereunder, the &#x201c;Amended Credit Facility&#x201d;) with Truist Bank, in its capacity as administrative agent for the lenders, issuing bank, swingline lender and lender, Truist Securities, Inc., JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Preferred Bank, Royal Bank of Canada, and Fifth Third Bank, National Association, in their capacities as joint lead arrangers and/or lenders, and the lenders from time to time party thereto, to, among other things, amend and restate that certain credit agreement, dated September 11, 2019, by and among the Company, Truist Bank, and certain lenders thereto (the credit facility thereunder, the &#x201c;Credit Facility&#x201d;), in its entirety. The Amended Credit Agreement provides for a five-year revolving credit facility to the Company of $400.0 million, which includes a letter of credit sub-facility of up to $25.0 million and a swingline loan sub-facility of $25.0 million. The revolving credit facility will be used to, among other things, refinance certain existing indebtedness of the Company and certain subsidiaries, finance certain future acquisitions and investments, and provide for working capital needs and other general corporate purposes. Under the Amended Credit Agreement, the terms and conditions of the Guaranty and Security Agreement (the &#x201c;Guaranty and Security Agreement&#x201d;) between the Company, NMM and Truist Bank remain in effect.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to pay an annual agent fee of $50,000 and an annual facility fee of 0.175% to 0.350% on the available commitments under the Amended Credit Agreement, regardless of usage, with the applicable fee determined on a quarterly basis based on the Company&#x2019;s leverage ratio. The Company will pay fees for standby letters of credit at an annual rate equal to 1.25% to 2.50%, as determined on a quarterly basis based on the Company&#x2019;s leverage ratio, plus facing fees and standard fees payable to the issuing bank on the respective letter of credit. The Company is also required to pay customary fees between the Company and Truist Bank, the lead arranger of the Amended Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, amounts borrowed under the Amended Credit Agreement bear interest at an annual rate equal to either, at the Company&#x2019;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on LIBOR, adjusted for any reserve requirement in effect, plus a spread of from 1.25% to 2.50%, as determined on a quarterly basis based on the Company&#x2019;s leverage ratio, or (b) a base rate, plus a spread of 0.25% to 1.50%, as determined on a quarterly basis based on the Company&#x2019;s leverage ratio.  As of March&#160;31, 2022, the interest rate on the Credit Agreement was 2.38%. Borrowings under the Amended Credit Agreement may be prepaid at any time without penalty. If LIBOR ceases to be reported under the Amended Credit Agreement, the Company will use the secured overnight financing rate or the Company and the Agent will agree to an alternative rate of interest. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended Credit Agreement requires the Company to comply with two key financial ratios, each calculated on a consolidated basis. The Company must maintain a maximum consolidated total net leverage ratio of not greater than 3.75 to 1.00 as of the last day of each fiscal quarter, provided that for any fiscal quarter during which the Company or certain subsidiaries consummate a permitted acquisition or investment, the aggregate purchase price is greater than $75.0&#160;million, the maximum consolidated total net leverage ratio may temporarily increase by 0.25 to 1.00 to 4.00 to 1.00. The Company must maintain a minimum consolidated interest coverage ratio of not less than 3.25 to 1.00 as of the last day of each fiscal quarter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Guaranty and Security Agreement, the Company and NMM have granted the lenders under the Amended Credit Agreement a security interest in all of their assets, including, without limitation, all stock and other equity issued by their subsidiaries (including NMM) and all rights with respect to the AP-AMH Loan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, certain of the lenders under the Amended Credit Agreement and their affiliates have provided to the Company and its subsidiaries and the associated practices, and may in the future provide, (i) investment banking, commercial banking, cash management, foreign exchange, or other financial services, and (ii) services as a bond trustee and other trust and fiduciary services, for which they have received compensation and may receive compensation in the future.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deferred Financing Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, the Company recorded deferred financing costs of $6.5 million related to its entry into the Credit Facility. In June 2021, the Company recorded additional deferred financing costs of $0.7&#160;million related to its entry into the Amended Credit Facility. Deferred financing costs are recorded as a direct reduction of the carrying amount of the related debt liability using straight-line amortization. The remaining unamortized deferred financing costs related to the Credit Facility and the new costs related to the Amended Credit Facility are amortized over the life of the Amended Credit Facility. At March&#160;31, 2022 and December&#160;31, 2021, the unamortized deferred financing cost was $4.0&#160;million and $4.3&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Real Estate Loans&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 31, 2020, using cash comprised solely of Excluded Assets, APC purchased a 100% interest in MPP, AMG Properties, and ZLL. As a result of this purchase, APC assumed the existing loans held by MPP, AMG Properties, and ZLL. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;MPP&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 3, 2020, MPP entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2021, the principal on the loan was $6.1&#160;million with a variable interest rate of 0.50% less than the independent index, which is the daily Wall Street Journal &#x201c;Prime Rate.&#x201d; If the index is not available, East West Bank may designate a substitute index after notifying MPP. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of March&#160;31, 2022, the balance outstanding was $6.1 million. MPP must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1. &lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AMG Properties&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 5, 2020, AMG Properties entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2021, the principal on the loan was $0.7&#160;million with a variable interest rate of 0.30% less than the independent index, which is the daily Wall Street Journal &#x201c;Prime Rate.&#x201d; If the index is not available, East West Bank may designate a substitute index after notifying AMG Properties. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of March&#160;31, 2022, the balance outstanding was $0.7 million. AMG Properties must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ZLL&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 27, 2020, ZLL entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2021, the principal on the loan was $0.6&#160;million with a variable interest rate of 0.50% less than the independent index, which is the daily Wall Street Journal &#x201c;Prime Rate.&#x201d; If the index is not available, East West Bank may designate a substitute index after notifying ZLL. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of March&#160;31, 2022, the balance outstanding was $0.6 million. ZLL must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Construction Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, Tag 8 entered into a construction loan agreement with MUFG Union Bank N.A. (&#x201c;Construction Loan&#x201d;). Tag 8 is a VIE consolidated by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Construction Loan allows Tag 8 to borrow up to $10.7 million with a maturity date of December 1, 2022 (&#x201c;Construction Loan Term&#x201d;). Interest rate is equal to an index rate determined by the bank. Monthly interest payments began on May 1, 2021, or can become part of the principal and bear interest. If construction is completed and, there are no events of default or substantial deterioration in the financial condition of Tag 8 or APC, guarantor on the loan agreement, at the maturity date of the Construction Loan Term, the loan shall convert to an amortizing loan with an extended maturity date of December 1, 2032 (&#x201c;Permanent Loan Term&#x201d;). Upon conversion to the Permanent Loan Term, monthly principal and interest payments shall be made beginning January 1, 2023. From January 1, 2023 until December 1, 2023, the interest rate will be 2.0% per annum in excess of the LIBOR rate. As of March&#160;31, 2022, the likelihood of the construction being completed by the maturity date was remote. The outstanding balance as of March&#160;31, 2022 was $1.3 million and was recorded as a current portion of long-term debt in the accompanying consolidated balance sheets. Once the loan converts to the Permanent Loan Term, APC, as Tag 8&#x2019;s guarantor, must maintain a Cash Flow Coverage Ratio (defined as consolidated EBITDA minus unfinanced capital expenditures and distributions paid divided by the sum of current portion of long-term debt, plus interest expense) of not less than 1.25 to 1. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Effective Interest Rate&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s average effective interest rate on its total debt during the three months ended March&#160;31, 2022 and 2021, was 1.78% and 2.08%, respectively. Interest expense in the consolidated statements of income included amortization of deferred debt issuance costs for the three months ended March&#160;31, 2022 and 2021, of $0.2 million and $0.3 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lines of Credit&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;APC Business Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September&#160;10, 2019, the APC Business Loan Agreement with Preferred Bank (the &#x201c;APC Business Loan Agreement&#x201d;) was amended to decrease loan availability to $4.1 million. This decrease further limited the purpose of the indebtedness under APC Business Loan Agreement to the issuance of standby letters of credit, and added as a permitted lien the security interest in all of its assets granted by APC in favor of NMM under a Security Agreement dated on or about September 11, 2019, securing APC&#x2019;s obligations to NMM under, and as required pursuant to, the APC management services agreement dated as of July 1, 1999, as amended.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Standby Letters of Credit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $0.3 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Alpha Care established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $3.8 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfMTI0ODE_68d98806-5862-404e-bd29-a79450194639">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s debt balance consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revolver Loan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real Estate Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,503)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unamortized financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,031)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie53154e5f8e44ab2b5b3bc67ed958b95_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOmJjMGU4NDVhY2IzMzQyNDBiMjA3N2MwYTY3NjlhYTZiL3RhYmxlcmFuZ2U6YmMwZTg0NWFjYjMzNDI0MGIyMDc3YzBhNjc2OWFhNmJfMy0xLTEtMS03MDA0Mg_c3597f4a-b8ee-4159-9eb9-65bed7c788b5"
      unitRef="usd">180000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia038bf044a5d4b0888c9404c8ef66dce_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOmJjMGU4NDVhY2IzMzQyNDBiMjA3N2MwYTY3NjlhYTZiL3RhYmxlcmFuZ2U6YmMwZTg0NWFjYjMzNDI0MGIyMDc3YzBhNjc2OWFhNmJfMy0zLTEtMS03MDA0Mg_857b178f-b6ef-4b6f-b499-352194e87242"
      unitRef="usd">180000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7ead42b914f74b3a87c5e08a25135c1b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOmJjMGU4NDVhY2IzMzQyNDBiMjA3N2MwYTY3NjlhYTZiL3RhYmxlcmFuZ2U6YmMwZTg0NWFjYjMzNDI0MGIyMDc3YzBhNjc2OWFhNmJfNC0xLTEtMS03MDA0Mg_42196fea-16b7-4500-aa08-f2dbabae92f7"
      unitRef="usd">7344000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9875be1595584e8793d5a44cabe73104_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOmJjMGU4NDVhY2IzMzQyNDBiMjA3N2MwYTY3NjlhYTZiL3RhYmxlcmFuZ2U6YmMwZTg0NWFjYjMzNDI0MGIyMDc3YzBhNjc2OWFhNmJfNC0zLTEtMS03MDA0Mg_db4ea47b-1abc-4332-8536-7efab1a9a04a"
      unitRef="usd">7396000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia5ff5967c0ad489ca405c9a26138a568_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOmJjMGU4NDVhY2IzMzQyNDBiMjA3N2MwYTY3NjlhYTZiL3RhYmxlcmFuZ2U6YmMwZTg0NWFjYjMzNDI0MGIyMDc3YzBhNjc2OWFhNmJfNS0xLTEtMS03MDA0Mg_a3990329-9e71-46fe-a987-2ae77d57ad33"
      unitRef="usd">1291000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i04ec29552d16406bb563e4f777751d86_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOmJjMGU4NDVhY2IzMzQyNDBiMjA3N2MwYTY3NjlhYTZiL3RhYmxlcmFuZ2U6YmMwZTg0NWFjYjMzNDI0MGIyMDc3YzBhNjc2OWFhNmJfNS0zLTEtMS03MDA0Mg_7bf5de1d-e8a2-4589-a8ce-8de444871af1"
      unitRef="usd">569000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOmJjMGU4NDVhY2IzMzQyNDBiMjA3N2MwYTY3NjlhYTZiL3RhYmxlcmFuZ2U6YmMwZTg0NWFjYjMzNDI0MGIyMDc3YzBhNjc2OWFhNmJfNi0xLTEtMS03MDA0Mg_57c06e59-2b49-4372-b73a-acf779356891"
      unitRef="usd">188635000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOmJjMGU4NDVhY2IzMzQyNDBiMjA3N2MwYTY3NjlhYTZiL3RhYmxlcmFuZ2U6YmMwZTg0NWFjYjMzNDI0MGIyMDc3YzBhNjc2OWFhNmJfNi0zLTEtMS03MDA0Mg_daebb537-b4d2-4594-827b-89b70eb13bd2"
      unitRef="usd">187965000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebtCurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOmJjMGU4NDVhY2IzMzQyNDBiMjA3N2MwYTY3NjlhYTZiL3RhYmxlcmFuZ2U6YmMwZTg0NWFjYjMzNDI0MGIyMDc3YzBhNjc2OWFhNmJfOC0xLTEtMS03MDA0Mg_0d232d47-6822-4aae-9497-793c1efc67ed"
      unitRef="usd">1503000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOmJjMGU4NDVhY2IzMzQyNDBiMjA3N2MwYTY3NjlhYTZiL3RhYmxlcmFuZ2U6YmMwZTg0NWFjYjMzNDI0MGIyMDc3YzBhNjc2OWFhNmJfOC0zLTEtMS03MDA0Mg_84728c1d-18db-415d-ae6b-a3a587401703"
      unitRef="usd">780000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOmJjMGU4NDVhY2IzMzQyNDBiMjA3N2MwYTY3NjlhYTZiL3RhYmxlcmFuZ2U6YmMwZTg0NWFjYjMzNDI0MGIyMDc3YzBhNjc2OWFhNmJfOS0xLTEtMS03MDA0Mg_080ffc3e-6327-4c73-957f-b53e6aa86f33"
      unitRef="usd">4031000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOmJjMGU4NDVhY2IzMzQyNDBiMjA3N2MwYTY3NjlhYTZiL3RhYmxlcmFuZ2U6YmMwZTg0NWFjYjMzNDI0MGIyMDc3YzBhNjc2OWFhNmJfOS0zLTEtMS03MDA0Mg_6d466b16-3677-44ed-bc16-12100e630100"
      unitRef="usd">4268000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOmJjMGU4NDVhY2IzMzQyNDBiMjA3N2MwYTY3NjlhYTZiL3RhYmxlcmFuZ2U6YmMwZTg0NWFjYjMzNDI0MGIyMDc3YzBhNjc2OWFhNmJfMTEtMS0xLTEtNzAwNDI_5bac48ea-8e9b-41d9-bced-b43ca7d88654"
      unitRef="usd">183101000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOmJjMGU4NDVhY2IzMzQyNDBiMjA3N2MwYTY3NjlhYTZiL3RhYmxlcmFuZ2U6YmMwZTg0NWFjYjMzNDI0MGIyMDc3YzBhNjc2OWFhNmJfMTEtMy0xLTEtNzAwNDI_b06eb028-4ddb-4ede-92dd-435976384317"
      unitRef="usd">182917000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfMTI0ODI_329effe6-8d23-4657-8202-7dbed5ff0c49">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following are the future commitments of the Company&#x2019;s debt for the years ending &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;December 31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (excluding the three months ended March 31, 2022) &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOjQ0MjkyYWE0NjQ1NDRjMmZiOGEzYTYzMjJjMzhiYjJjL3RhYmxlcmFuZ2U6NDQyOTJhYTQ2NDU0NGMyZmI4YTNhNjMyMmMzOGJiMmNfMS0xLTEtMS03MDA0Mg_b4a4dfec-ac10-4115-b35b-23b33b176e1d"
      unitRef="usd">1450000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOjQ0MjkyYWE0NjQ1NDRjMmZiOGEzYTYzMjJjMzhiYjJjL3RhYmxlcmFuZ2U6NDQyOTJhYTQ2NDU0NGMyZmI4YTNhNjMyMmMzOGJiMmNfMi0xLTEtMS03MDA0Mg_2a779557-34b1-4948-af5e-451dfce57bf3"
      unitRef="usd">215000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOjQ0MjkyYWE0NjQ1NDRjMmZiOGEzYTYzMjJjMzhiYjJjL3RhYmxlcmFuZ2U6NDQyOTJhYTQ2NDU0NGMyZmI4YTNhNjMyMmMzOGJiMmNfMy0xLTEtMS03MDA0Mg_2e1fe85a-f5fc-4bda-95db-501d545ec773"
      unitRef="usd">222000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOjQ0MjkyYWE0NjQ1NDRjMmZiOGEzYTYzMjJjMzhiYjJjL3RhYmxlcmFuZ2U6NDQyOTJhYTQ2NDU0NGMyZmI4YTNhNjMyMmMzOGJiMmNfNC0xLTEtMS03MDA0Mg_49735f9f-970d-4686-b5be-2066a4764f46"
      unitRef="usd">6748000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <ameh:LongTermDebtMaturityAfterYearFour
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOjQ0MjkyYWE0NjQ1NDRjMmZiOGEzYTYzMjJjMzhiYjJjL3RhYmxlcmFuZ2U6NDQyOTJhYTQ2NDU0NGMyZmI4YTNhNjMyMmMzOGJiMmNfNS0xLTEtMS03MDA0Mg_a0764627-3778-48b2-b2ae-afad431e1814"
      unitRef="usd">180000000</ameh:LongTermDebtMaturityAfterYearFour>
    <us-gaap:LineOfCredit
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RhYmxlOjQ0MjkyYWE0NjQ1NDRjMmZiOGEzYTYzMjJjMzhiYjJjL3RhYmxlcmFuZ2U6NDQyOTJhYTQ2NDU0NGMyZmI4YTNhNjMyMmMzOGJiMmNfNy0xLTEtMS03MDA0Mg_7f8ce824-ee50-4c55-abd8-83cb6b572394"
      unitRef="usd">188635000</us-gaap:LineOfCredit>
    <us-gaap:DebtInstrumentTerm
      contextRef="i93bf4ca5dbf74632b9bcabe542799cf2_D20210616-20210616"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfMjc0ODc3OTA5MTc0OQ_8deeade4-d2fd-4773-a418-49cddbd70a2d">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i6759c2e740754692ab17fe6126840652_I20210616"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUyODMyMg_91940e53-fa45-4c27-bff1-e3e4210083ae"
      unitRef="usd">400000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i121db6aa4f234342a066091bbc811f6d_I20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUyODMzMA_7310b6ba-bfa0-4241-b717-481b7e3e3adf"
      unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i2ae5de1ac50140b281d6c8428a5ba873_I20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUyODMzOA_bfc11724-1611-476e-be4d-ee74ba1c83de"
      unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityCommitmentFeeAmount
      contextRef="i958aafc9bd314ec7a793b41fdf0cc64e_D20210616-20210616"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUyODM1Mw_c432d807-4565-4567-877f-0f315e38015e"
      unitRef="usd">50000</us-gaap:LineOfCreditFacilityCommitmentFeeAmount>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="if3c3078e4a3a4a97a896b1bc5d0087ef_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUyODM2Mw_2c6de9c5-6ebd-4e07-96f7-38e654acceac"
      unitRef="number">0.00175</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="id506af9420ac471bab63d3cba404a645_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUyODM2Nw_24ca66b9-1c52-4aeb-9bb9-7f911dcd3b15"
      unitRef="number">0.00350</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i411a85b04db242d0933b3b997de7b7be_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUyODM3MQ_d6503950-ceb9-4660-beb5-e338c480f615"
      unitRef="number">0.0125</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i18d5ab7831f740cfbce7f376753f0fba_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUyODM3NQ_e0ec9d1a-0689-44bf-91ad-7ae4de23e622"
      unitRef="number">0.0250</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i73d5e3fe56914cf8b95c7c29e9501364_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUyODM3OQ_7897880f-5d3a-45f4-8d7c-e587d756dfbe"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i79fd9f0ba878471db847749cc1aa145b_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUyODM4Mw_ed47bea2-7125-4b78-8af1-9f377b2bec71"
      unitRef="number">0.0250</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="if3c3078e4a3a4a97a896b1bc5d0087ef_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUyODM5NA_a48cbd15-5b68-4e24-9f8b-324f2bbd1579"
      unitRef="number">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="id506af9420ac471bab63d3cba404a645_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUyODM5OA_1c1a7f0a-bf3b-48c1-bc81-be0ca7193ecb"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="iac76cdf5c1e24249bd2cc8b73cea2d4d_I20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUyODQxMA_49f1048e-03b5-4c79-bd0c-070c4eef1881"
      unitRef="number">0.0238</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <ameh:DebtInstrumentNumberOfKeyFinancialRatios
      contextRef="iddc202a2a74a429aa384ca0e94f1385f_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfMjc0ODc3OTA5MTc1Ng_683211c2-4580-4465-8009-25cc1f7150cc"
      unitRef="financial_ratio">2</ameh:DebtInstrumentNumberOfKeyFinancialRatios>
    <ameh:DebtInstrumentCovenantLeverageRatioMaximum
      contextRef="iddc202a2a74a429aa384ca0e94f1385f_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUyODQyMA_415577f5-d2b4-4d5e-a55e-035c77ff87f0"
      unitRef="number">3.75</ameh:DebtInstrumentCovenantLeverageRatioMaximum>
    <ameh:DebtCovenantAggregatePurchasePriceMaximum
      contextRef="iddc202a2a74a429aa384ca0e94f1385f_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfMjc0ODc3OTA5MTc2MQ_a1fbd990-752f-46ed-b94d-f43407ea431a"
      unitRef="usd">75000000</ameh:DebtCovenantAggregatePurchasePriceMaximum>
    <ameh:DebtInstrumentCovenantLeverageRatioIncrementalChange
      contextRef="iddc202a2a74a429aa384ca0e94f1385f_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUyODQ0Nw_7538b3dc-279a-406b-9c17-e52f7fc4b92b"
      unitRef="number">0.25</ameh:DebtInstrumentCovenantLeverageRatioIncrementalChange>
    <ameh:DebtInstrumentCovenantLeverageRatioAdjustedMaximum
      contextRef="iddc202a2a74a429aa384ca0e94f1385f_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUyODQ1OA_156e3c33-af53-4a1c-8166-25d1a582d8c4"
      unitRef="number">4.00</ameh:DebtInstrumentCovenantLeverageRatioAdjustedMaximum>
    <ameh:DebtInstrumentCovenantInterestCoverageRatioMinimum
      contextRef="iab25699159ef422387acd33b3b0c73ae_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUyODQ2NQ_6a8f65e7-d88f-4c9c-9072-791ccbe01696"
      unitRef="number">3.25</ameh:DebtInstrumentCovenantInterestCoverageRatioMinimum>
    <us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet
      contextRef="ia35d32a022eb4f8296d246475815c7be_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNTYyMQ_3b76181c-8b6f-4041-8367-714f9de2f8e0"
      unitRef="usd">6500000</us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet>
    <us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet
      contextRef="i5ceb4bf299aa4fbbb15c38ae65b24964_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNTc0NQ_27e5d989-4415-40de-9854-6b1f7f1b7ed2"
      unitRef="usd">700000</us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNjIwNw_6f769532-a85f-4963-8b21-f71dd100d294"
      unitRef="usd">4000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNjIxNA_8481f5cb-15f1-4091-919e-b6ab15b5616c"
      unitRef="usd">4300000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <ameh:AssetAcquisitionPercentageOfSharesAcquired
      contextRef="i6af45110227947abb0e1effa0224037f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNjMzNw_98f6a572-ba7c-47bf-81bd-71de71ae9024"
      unitRef="number">1</ameh:AssetAcquisitionPercentageOfSharesAcquired>
    <ameh:AssetAcquisitionPercentageOfSharesAcquired
      contextRef="i29d27efd274e4640b991eab78aed11b9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNjMzNw_c86711c1-cc7f-4a03-98a8-a8a69fd0b9f6"
      unitRef="number">1</ameh:AssetAcquisitionPercentageOfSharesAcquired>
    <ameh:AssetAcquisitionPercentageOfSharesAcquired
      contextRef="i8159b237bb57472289fa8745bfaf2c2a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNjMzNw_ccc3f700-5fb9-4ce3-bda1-f420ccad3df2"
      unitRef="number">1</ameh:AssetAcquisitionPercentageOfSharesAcquired>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id327c3f30f5442849d60a0720899b6b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNjY0MA_dec6ee1b-4372-4e89-a474-dade4bacff0d"
      unitRef="usd">6100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i59ee99254c40475f9b21b9cd872385a5_D20200703-20200703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNjY3Ng_57eeba44-2dd8-4d41-a94d-5235b327b4fd"
      unitRef="number">-0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LongTermDebt
      contextRef="ibb454af8f35b4571bbc0568a6ef8fabc_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNzAwNQ_d57152b5-0b6a-4e3a-8d7d-51131811e82c"
      unitRef="usd">6100000</us-gaap:LongTermDebt>
    <ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum
      contextRef="i0c1305632b254a819190bb04db42d4b9_D20200703-20200703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNzE2OA_e3947f4e-4015-41a3-982c-cadf0591d66e"
      unitRef="number">1.25</ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if79f0e1f750c4d29acae8c2424f6b5a8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNzM2MA_62cde236-33c0-4e25-b3e1-ebb8278a14a1"
      unitRef="usd">700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i8c965773654f4f76b80d01904268a252_D20200805-20200805"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNzM5Ng_d6ed87ae-9df2-40ca-8bd7-5ac36acacc59"
      unitRef="number">-0.0030</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LongTermDebt
      contextRef="if9463aae35c1447dbc10b94c90792330_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNzczNg_02c1797a-ffe0-4af0-a6eb-0fd9cbacb8ff"
      unitRef="usd">700000</us-gaap:LongTermDebt>
    <ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum
      contextRef="id9e05712a8f3404c91c7767902090d7c_D20200805-20200805"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNzkxMA_0be8f520-73c0-4c5d-8dcb-7b62c2fb36e5"
      unitRef="number">1.25</ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i28e98c01e378431d9b395cc096cd64f1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfODA3OA_b7da852f-9b23-4a51-9878-6dabedeac187"
      unitRef="usd">600000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i906733a30f24439e91bed1e3615ea7da_D20200727-20200727"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfODExNA_4b32b66e-2611-4087-ace3-a0d1a4d068b7"
      unitRef="number">-0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LongTermDebt
      contextRef="i3860353465b34dcf83559f00d6e7e4c0_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfODQ0Mw_7438b475-53f1-47c3-84cb-546b9bcdbaa6"
      unitRef="usd">600000</us-gaap:LongTermDebt>
    <ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum
      contextRef="ifff506fed9ef409ab5281dde682b04df_D20200727-20200727"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfODYwNg_93239f1a-ff03-4c0f-af54-0c164194d5bc"
      unitRef="number">1.25</ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i039bfa2066b9445ba0c127c9a6b7d4e6_I20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfODg0NQ_9c4c8d13-d8ca-45d6-85de-4b1eea34c208"
      unitRef="usd">10700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ifeba7e1f896c47b0bb477b27fd52fe58_D20230101-20231201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfOTYyNA_46ba6bdb-4d3e-41ec-ac8e-45693ed18863"
      unitRef="number">0.020</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LongTermDebt
      contextRef="i3e730da764a64b29b490afda93124c70_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDM5ODA0NjUzNDkyNQ_e87aa9df-2008-48f4-95ae-49977045659a"
      unitRef="usd">1300000</us-gaap:LongTermDebt>
    <ameh:DebtInstrumentCovenantCashFlowCoverageRatioMinimum
      contextRef="i3e730da764a64b29b490afda93124c70_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfMTAwODU_7747c906-0490-4b12-a361-c3b63e27e74d"
      unitRef="number">1.25</ameh:DebtInstrumentCovenantCashFlowCoverageRatioMinimum>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="iab25699159ef422387acd33b3b0c73ae_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfMTAyMjc_f4436d73-df1e-49f0-b14a-de97248cf406"
      unitRef="number">0.0178</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="idcefe512b59843c5a4b809aa58d86dbf_D20210101-20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfNDk0NzgwMjMzNzQ4NQ_13cd4671-bd93-424e-b04a-0a37b8700ad1"
      unitRef="number">0.0208</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:InterestExpense
      contextRef="iab25699159ef422387acd33b3b0c73ae_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfMTA0MTM_8434879e-9304-451b-856b-76f4af37e06c"
      unitRef="usd">200000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="idcefe512b59843c5a4b809aa58d86dbf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfMTA0MjA_354b6a20-dda7-4de6-bbc9-0ad353386a95"
      unitRef="usd">300000</us-gaap:InterestExpense>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i8011f60b0322450ba7087bebdbf48e81_I20190910"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfMTA2NTk_84a80bbd-1d09-4e14-8141-dd126eaa556f"
      unitRef="usd">4100000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i5a5028538cf949dc976825957bdc20fc_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfMTE3MzA_c30bca32-6f17-4eab-8931-5cd095acbf5b"
      unitRef="usd">300000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityExpirationPeriod
      contextRef="id77595136aad43ce85c81570c5c6ccfd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfMTI0Njk_980e8f1d-ae0e-4630-9ca1-dde25b6041bf">P1Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="iaa89643a73ac4d02b199b59ae1e04e17_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfMTIxNjc_cdd03403-fdcf-414e-9989-343a24007526"
      unitRef="usd">3800000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityExpirationPeriod
      contextRef="ic6ec9c984e0f4663b1287c8a1e6f562c_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF83OS9mcmFnOjBlZGM5YzEwNjUwYTRhNWU4NDI4NzQ5N2U4ZmQwNDIwL3RleHRyZWdpb246MGVkYzljMTA2NTBhNGE1ZTg0Mjg3NDk3ZThmZDA0MjBfMTI0NzA_12331c90-bcde-48af-ac8d-8c48d0cb3c5f">P1Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF84NS9mcmFnOjQzOTVhZWIzZDE2YzRlNzc4ZTFkOGQzNzljZmE2MTJjL3RleHRyZWdpb246NDM5NWFlYjNkMTZjNGU3NzhlMWQ4ZDM3OWNmYTYxMmNfMjAzNw_ca971a15-1696-4d33-b724-9bc6bbafcfa2">Mezzanine and Stockholders&#x2019; Equity&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Mezzanine&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the redemption feature of the APC shares (see Note 2) is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as non-controlling interest in APC as mezzanine or temporary equity. APC&#x2019;s shares were not redeemable, and it was not probable that the shares would become redeemable, as of March&#160;31, 2022 and December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, 140,954 holdback shares have not been issued to certain former NMM shareholders who were NMM shareholders at the time of closing of the 2017 Merger, as they have yet to submit properly completed letters of transmittal to ApolloMed in order to receive their pro rata portion of ApolloMed common stock and warrants as contemplated under the 2017 merger agreement. Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the 2017 Merger. The consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares in connection with the 2017 Merger.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&lt;br/&gt;Treasury Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC owned 10,925,702 shares of ApolloMed&#x2019;s common stock as of March&#160;31, 2022 and December&#160;31, 2021, which are legally issued and outstanding but excluded from shares of common stock outstanding in the consolidated financial statements, as such shares are treated as treasury shares for accounting purposes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Dividends&lt;/span&gt;&lt;/div&gt;During the three months ended March&#160;31, 2022 and 2021, CDSC paid dividends of $1.5 million and $0, respectively.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <ameh:StockIssuedDuringPeriodSharesMerger
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF84NS9mcmFnOjQzOTVhZWIzZDE2YzRlNzc4ZTFkOGQzNzljZmE2MTJjL3RleHRyZWdpb246NDM5NWFlYjNkMTZjNGU3NzhlMWQ4ZDM3OWNmYTYxMmNfNDQ3_b63b476f-4012-4386-b6fb-54bfa613e454"
      unitRef="shares">140954</ameh:StockIssuedDuringPeriodSharesMerger>
    <us-gaap:TreasuryStockCommonShares
      contextRef="if917b814792a44f39620641ac0df4997_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF84NS9mcmFnOjQzOTVhZWIzZDE2YzRlNzc4ZTFkOGQzNzljZmE2MTJjL3RleHRyZWdpb246NDM5NWFlYjNkMTZjNGU3NzhlMWQ4ZDM3OWNmYTYxMmNfMTMwMw_3cc65e5f-f2b0-4e3b-899e-75306bcf66c4"
      unitRef="shares">10925702</us-gaap:TreasuryStockCommonShares>
    <us-gaap:Dividends
      contextRef="iba53eb44c7b14a578bb900cac19accbc_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF84NS9mcmFnOjQzOTVhZWIzZDE2YzRlNzc4ZTFkOGQzNzljZmE2MTJjL3RleHRyZWdpb246NDM5NWFlYjNkMTZjNGU3NzhlMWQ4ZDM3OWNmYTYxMmNfNDM5ODA0NjUxMzQ5MA_10fd688d-291c-4f26-8482-6b6514b866ca"
      unitRef="usd">1500000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i3fc704f23ee3440f959bc11b81e7d01f_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF84NS9mcmFnOjQzOTVhZWIzZDE2YzRlNzc4ZTFkOGQzNzljZmE2MTJjL3RleHRyZWdpb246NDM5NWFlYjNkMTZjNGU3NzhlMWQ4ZDM3OWNmYTYxMmNfNDM5ODA0NjUxMzUzMQ_aabc403e-beac-4d5d-8c84-8ef943eef295"
      unitRef="usd">0</us-gaap:Dividends>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfMjE0NQ_7d6fd655-629a-4506-bf17-044a21477ca8">Stock-Based CompensationThe following table summarizes the stock-based compensation expense recognized under all of the Company&#x2019;s stock plans for the three months ended March&#160;31, 2022 and 2021, and associated with the issuance of restricted shares of common stock and vesting of stock options, which are included in general and administrative expenses in the accompanying consolidated statements of income (in thousands):&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.753%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrecognized compensation expense related to total share-based payments outstanding as of March&#160;31, 2022, was $21.6 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s outstanding stock options consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options outstanding at January&#160;1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;813,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.79&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2022, options were exercised for 38,500 shares of the Company&#x2019;s common stock, resulting in proceeds of $0.7&#160;million. During the three months ended March&#160;31, 2021, no stock options were exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2022, the Company granted 75,271 stock options to certain ApolloMed employees and Board members. The options granted during the three months ended March&#160;31, 2022 were recognized at fair value, as determined using the Black-Scholes option pricing model as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00 years - 2.25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.47% - 75.15%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.02% - 1.06%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Market value of common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$20.23 - $22.73&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Annual dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeiture rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company grants restricted stock to officers and employees which are earned based on service conditions. The grant date fair value of the restricted stock is that day&#x2019;s closing market price of the Company&#x2019;s common stock. During the three months ended March&#160;31, 2022, the Company granted restricted stock totaling 76,828 shares, including 49,124 restricted stock with performance conditions, with a weighted average grant date fair value of $50.76. Restricted stock with performance conditions are recognized to the extent the performance conditions are probable of being achieved. The grant date fair value of restricted stock and restricted stock with performance conditions that are probable of being achieved were $3.9&#160;million and will be recognized on a straight-line basis over the awards&#x2019; vesting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s outstanding warrants consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants outstanding at January&#160;1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86,235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants expired/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants outstanding at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;915,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise&#160;Price&#160;Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual&#160;Life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercisable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise&#160;Price&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470,827&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444,678&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$                  10.00 &#x2013; 11.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;915,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;915,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;During the three months ended March&#160;31, 2022 and 2021, common stock warrants were exercised for 86,235 and 421,002 shares of the Company&#x2019;s common stock, respectively, which resulted in proceeds of approximately $0.9&#160;million and $4.3 million, respectively. The exercise price ranged from $10.00 to $11.00 per share for the exercises during the three months ended March&#160;31, 2022, and $9.00 to $11.00 per share for the exercises during the three months ended March&#160;31, 2021, respectively.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfMjE0Mg_820a10b4-b064-4722-a5c6-a977b8bc1ed7">The following table summarizes the stock-based compensation expense recognized under all of the Company&#x2019;s stock plans for the three months ended March&#160;31, 2022 and 2021, and associated with the issuance of restricted shares of common stock and vesting of stock options, which are included in general and administrative expenses in the accompanying consolidated statements of income (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.753%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i59a87528beae42e5905d598caee23304_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjlhMmY5YTRiNmQ2MjRlNDBiYzI2MWJiYTFmNGI1OThjL3RhYmxlcmFuZ2U6OWEyZjlhNGI2ZDYyNGU0MGJjMjYxYmJhMWY0YjU5OGNfMi0xLTEtMS03MDA0Mg_2a1b9b9b-c4de-4d69-9bd7-3ebc5c94ef8b"
      unitRef="usd">780000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1c4a21ba18bf43e2baa22838c457ebc6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjlhMmY5YTRiNmQ2MjRlNDBiYzI2MWJiYTFmNGI1OThjL3RhYmxlcmFuZ2U6OWEyZjlhNGI2ZDYyNGU0MGJjMjYxYmJhMWY0YjU5OGNfMi0zLTEtMS03MDA0Mg_f111a93a-7971-4845-8bc6-7cee21438cf0"
      unitRef="usd">589000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib33aa0fdefb44c68985101f13840b075_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjlhMmY5YTRiNmQ2MjRlNDBiYzI2MWJiYTFmNGI1OThjL3RhYmxlcmFuZ2U6OWEyZjlhNGI2ZDYyNGU0MGJjMjYxYmJhMWY0YjU5OGNfMy0xLTEtMS03MDA0Mg_ab36b3e9-830f-4d62-83d1-ab0660e6f21d"
      unitRef="usd">2275000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia57bf156054149e8aed82c44fb4a2e72_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjlhMmY5YTRiNmQ2MjRlNDBiYzI2MWJiYTFmNGI1OThjL3RhYmxlcmFuZ2U6OWEyZjlhNGI2ZDYyNGU0MGJjMjYxYmJhMWY0YjU5OGNfMy0zLTEtMS03MDA0Mg_bd230740-6b08-4c9e-b6c6-4e35cd5123a9"
      unitRef="usd">757000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjlhMmY5YTRiNmQ2MjRlNDBiYzI2MWJiYTFmNGI1OThjL3RhYmxlcmFuZ2U6OWEyZjlhNGI2ZDYyNGU0MGJjMjYxYmJhMWY0YjU5OGNfNS0xLTEtMS03MDA0Mg_ab6aafdb-0471-42e6-9597-9b97c537a6da"
      unitRef="usd">3055000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjlhMmY5YTRiNmQ2MjRlNDBiYzI2MWJiYTFmNGI1OThjL3RhYmxlcmFuZ2U6OWEyZjlhNGI2ZDYyNGU0MGJjMjYxYmJhMWY0YjU5OGNfNS0zLTEtMS03MDA0Mg_c9b251d2-5b65-494a-b95b-ac82ab6bc71a"
      unitRef="usd">1346000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfNTI4_97515503-37b8-436b-854a-dfc969a6aa42"
      unitRef="usd">21600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfMjE1Mg_317b1026-3bf1-4385-82d2-29613b4d2092">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s outstanding stock options consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options outstanding at January&#160;1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;813,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.79&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfMS0xLTEtMS03MDA0Mg_b383e628-60b6-4b7f-b01b-e442bd3a70d6"
      unitRef="shares">813965</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfMS0zLTEtMS03MDA0Mg_da8db663-57dc-4667-bfc8-64575b1e6261"
      unitRef="usdPerShare">22.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="id93dea0ce70b4ff2b46f7a49428856fd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfMS01LTEtMS03MDA0Mg_6bc9523b-2b08-4fbe-af73-b239addc566b">P3Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfMS03LTEtMS03MDA0Mg_203c87d3-1544-4734-a3ad-7c45ce6e8c55"
      unitRef="usd">41600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfMi0xLTEtMS03MDA0Mg_53a5c8d8-4469-4ae1-abd8-5cca34e5aedd"
      unitRef="shares">75271</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfMi0zLTEtMS03MDA0Mg_07b9e219-3882-4fb0-8597-b1bc49b93724"
      unitRef="usdPerShare">55.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfMy0xLTEtMS03MDA0Mg_093a3a6e-a5f3-4eb6-b0c4-2b3ca90fc18c"
      unitRef="shares">38500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfMy0zLTEtMS03MDA0Mg_5464c7f9-23b4-411a-9cad-b4535c442025"
      unitRef="usdPerShare">17.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfMy03LTEtMS03MDA0Mg_8c03fd60-9aa3-47f6-84fc-67af75c10c0b"
      unitRef="usd">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfNC0xLTEtMS03MDA0Mg_c14926bf-cc16-4c55-800e-8ea75a7866ac"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfNC0zLTEtMS03MDA0Mg_1d4bdee0-7836-4030-8f39-a839e5edfafd"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfNi0xLTEtMS03MDA0Mg_ff7a8801-9a65-45d9-a448-203ce000a44d"
      unitRef="shares">850736</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfNi0zLTEtMS03MDA0Mg_4aedeb0c-a3ef-4233-ada0-4f83a45538e6"
      unitRef="usdPerShare">25.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfNi01LTEtMS03MDA0Mg_84a9bbe7-3124-4525-b580-10b57a401b7f">P2Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfNi03LTEtMS03MDA0Mg_c87faaaa-4107-44cd-997c-e34dcfbc7693"
      unitRef="usd">22800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfOC0xLTEtMS03MDA0Mg_9ebc742c-6994-4ce4-a95c-796ca8fdaccd"
      unitRef="shares">591725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfOC0zLTEtMS03MDA0Mg_bd8885fa-6afc-475a-b172-4417bb3a68ba"
      unitRef="usdPerShare">9.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfOC01LTEtMS03MDA0Mg_08556ff5-723e-40bd-b5f7-23ab1213d0fa">P1Y9M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOmI0MzRhMjM4NDk4ODQ4MzM5YTAxNWEzN2I0MmFjMDE3L3RhYmxlcmFuZ2U6YjQzNGEyMzg0OTg4NDgzMzlhMDE1YTM3YjQyYWMwMTdfOC03LTEtMS03MDA0Mg_b0902d6d-ae10-45aa-bf6e-78b2735a8405"
      unitRef="usd">20700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfNjY4_093a3a6e-a5f3-4eb6-b0c4-2b3ca90fc18c"
      unitRef="shares">38500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfNzM0_6dc201d2-fc0a-42d3-a487-d1810cdad57a"
      unitRef="usd">700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfMjc0ODc3OTA3Mjc1Mg_8fdea6ea-3548-44a3-b579-bb6dc8bd0d90"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfMjE0Mw_20bf2b8a-6008-4303-8aac-64cde6ba516b">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2022, the Company granted 75,271 stock options to certain ApolloMed employees and Board members. The options granted during the three months ended March&#160;31, 2022 were recognized at fair value, as determined using the Black-Scholes option pricing model as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00 years - 2.25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.47% - 75.15%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.02% - 1.06%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Market value of common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$20.23 - $22.73&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Annual dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeiture rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i2ed7fee6f6304a0998e815c8e5445108_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfNDM5ODA0NjUxNDA0NQ_434845ef-238f-47c2-bad7-319acddd218d"
      unitRef="shares">75271</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i3d75852709414d64af680d539dcb36be_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjhhZDQ4MWQ4NTQ2ZjQ3ODJiNWM5YmNkZjQwOTNkODc1L3RhYmxlcmFuZ2U6OGFkNDgxZDg1NDZmNDc4MmI1YzliY2RmNDA5M2Q4NzVfMS0xLTEtMS03MDA0Mi90ZXh0cmVnaW9uOjVkNTA5YWYyNDJkYTQxN2U5MzY5NDEwMjUyYmFmZjI0XzI3NDg3NzkwNjk0Nzc_80f6af6b-436d-436e-bbcf-0c1a71a5339e">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic8fe9de9677f4084b60ffc90c8a538eb_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjhhZDQ4MWQ4NTQ2ZjQ3ODJiNWM5YmNkZjQwOTNkODc1L3RhYmxlcmFuZ2U6OGFkNDgxZDg1NDZmNDc4MmI1YzliY2RmNDA5M2Q4NzVfMS0xLTEtMS03MDA0Mi90ZXh0cmVnaW9uOjVkNTA5YWYyNDJkYTQxN2U5MzY5NDEwMjUyYmFmZjI0XzI3NDg3NzkwNjk0OTA_69570239-3aaa-47e5-a740-f12d85f25dce">P2Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i1274ac1b93074e91b7b5207ef70ffa3f_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjhhZDQ4MWQ4NTQ2ZjQ3ODJiNWM5YmNkZjQwOTNkODc1L3RhYmxlcmFuZ2U6OGFkNDgxZDg1NDZmNDc4MmI1YzliY2RmNDA5M2Q4NzVfMi0xLTEtMS03MDA0Mi90ZXh0cmVnaW9uOjkzNTk1NmZhMTdjMzRkMThiMzQwNjJmMThiMDljYjMxXzI3NDg3NzkwNjk0NjU_88326c3a-bf10-4de3-92e0-2f7cdab15e5d"
      unitRef="number">0.7147</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i1274ac1b93074e91b7b5207ef70ffa3f_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjhhZDQ4MWQ4NTQ2ZjQ3ODJiNWM5YmNkZjQwOTNkODc1L3RhYmxlcmFuZ2U6OGFkNDgxZDg1NDZmNDc4MmI1YzliY2RmNDA5M2Q4NzVfMi0xLTEtMS03MDA0Mi90ZXh0cmVnaW9uOjkzNTk1NmZhMTdjMzRkMThiMzQwNjJmMThiMDljYjMxXzI3NDg3NzkwNjk0NzQ_3353155b-f4b2-4db5-9218-8449c086f7db"
      unitRef="number">0.7515</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i1274ac1b93074e91b7b5207ef70ffa3f_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjhhZDQ4MWQ4NTQ2ZjQ3ODJiNWM5YmNkZjQwOTNkODc1L3RhYmxlcmFuZ2U6OGFkNDgxZDg1NDZmNDc4MmI1YzliY2RmNDA5M2Q4NzVfMy0xLTEtMS03MDA0Mi90ZXh0cmVnaW9uOjE2MWVhYjE4OTc3ZDQzZWZiMjA0NjZhOTIwNGNiMTMyXzI3NDg3NzkwNjk0NjI_13aff88e-de20-49bf-bda1-dc43d4e0d563"
      unitRef="number">0.0102</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i1274ac1b93074e91b7b5207ef70ffa3f_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjhhZDQ4MWQ4NTQ2ZjQ3ODJiNWM5YmNkZjQwOTNkODc1L3RhYmxlcmFuZ2U6OGFkNDgxZDg1NDZmNDc4MmI1YzliY2RmNDA5M2Q4NzVfMy0xLTEtMS03MDA0Mi90ZXh0cmVnaW9uOjE2MWVhYjE4OTc3ZDQzZWZiMjA0NjZhOTIwNGNiMTMyXzI3NDg3NzkwNjk0NzA_0942eca1-f4ed-4f9d-8589-5d9d67ffca67"
      unitRef="number">0.0106</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharePrice
      contextRef="i742b25817ce54efbb408cfa331c5fe5f_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjhhZDQ4MWQ4NTQ2ZjQ3ODJiNWM5YmNkZjQwOTNkODc1L3RhYmxlcmFuZ2U6OGFkNDgxZDg1NDZmNDc4MmI1YzliY2RmNDA5M2Q4NzVfNC0xLTEtMS03MDA0Mi90ZXh0cmVnaW9uOmIwNTNjODkzNmUxYTRmODJhM2UzM2U0N2M0MmI5NDBkXzI3NDg3NzkwNjk0NjI_ee4527f9-3896-4826-93b3-235efb1b9072"
      unitRef="usdPerShare">20.23</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="i52ed974f00584c72870ff83e96c517c6_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjhhZDQ4MWQ4NTQ2ZjQ3ODJiNWM5YmNkZjQwOTNkODc1L3RhYmxlcmFuZ2U6OGFkNDgxZDg1NDZmNDc4MmI1YzliY2RmNDA5M2Q4NzVfNC0xLTEtMS03MDA0Mi90ZXh0cmVnaW9uOmIwNTNjODkzNmUxYTRmODJhM2UzM2U0N2M0MmI5NDBkXzI3NDg3NzkwNjk0NzA_b777ee8d-d813-46c5-b151-efa01fa20b94"
      unitRef="usdPerShare">22.73</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i1274ac1b93074e91b7b5207ef70ffa3f_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjhhZDQ4MWQ4NTQ2ZjQ3ODJiNWM5YmNkZjQwOTNkODc1L3RhYmxlcmFuZ2U6OGFkNDgxZDg1NDZmNDc4MmI1YzliY2RmNDA5M2Q4NzVfNS0xLTEtMS03MDA0Mg_f27550b9-e256-404e-85dd-bd38d2734bc5"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
      contextRef="i1274ac1b93074e91b7b5207ef70ffa3f_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjhhZDQ4MWQ4NTQ2ZjQ3ODJiNWM5YmNkZjQwOTNkODc1L3RhYmxlcmFuZ2U6OGFkNDgxZDg1NDZmNDc4MmI1YzliY2RmNDA5M2Q4NzVfNi0xLTEtMS03MDA0Mg_cf3a9c3c-a775-4746-8947-f51bb9758266"
      unitRef="number">0</ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i3c33bc11247c47b3bf81a50827becf69_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfMTUxMw_efb657ca-7891-475c-9fdd-d8b54607b04e"
      unitRef="shares">76828</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance
      contextRef="i3c33bc11247c47b3bf81a50827becf69_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfNjA0NzMxMzk1NjA1NA_0ea534ca-9467-46fe-94a5-96e6534a7f74"
      unitRef="shares">49124</ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3c33bc11247c47b3bf81a50827becf69_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfMTU3Mg_e3cbad70-f1c4-453d-9a48-96b9e4e97fae"
      unitRef="usdPerShare">50.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i9bc146c68b944c84b6e8aad1dc0a79e5_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfMTYzMA_2e161314-d3c2-40eb-9985-c51702d88295"
      unitRef="usd">3900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfMjE1MQ_4a2686da-c16c-453c-a98a-2e9e7a77a3de">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s outstanding warrants consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants outstanding at January&#160;1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86,235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants expired/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants outstanding at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;915,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise&#160;Price&#160;Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual&#160;Life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercisable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise&#160;Price&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470,827&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444,678&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$                  10.00 &#x2013; 11.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;915,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;915,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjA4MDJhNDMxN2UzZDRkM2E4MTk2OTE5ZjA0Y2U2YWUwL3RhYmxlcmFuZ2U6MDgwMmE0MzE3ZTNkNGQzYTgxOTY5MTlmMDRjZTZhZTBfMS0xLTEtMS03MDA0Mg_5364ca80-4214-4c39-a169-bb99a06a4d5e"
      unitRef="shares">1001740</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjA4MDJhNDMxN2UzZDRkM2E4MTk2OTE5ZjA0Y2U2YWUwL3RhYmxlcmFuZ2U6MDgwMmE0MzE3ZTNkNGQzYTgxOTY5MTlmMDRjZTZhZTBfMS0zLTEtMS03MDA0Mg_1b5b7eb4-d142-4b74-be5f-a32cb4c1f857"
      unitRef="usdPerShare">10.49</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="id93dea0ce70b4ff2b46f7a49428856fd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjA4MDJhNDMxN2UzZDRkM2E4MTk2OTE5ZjA0Y2U2YWUwL3RhYmxlcmFuZ2U6MDgwMmE0MzE3ZTNkNGQzYTgxOTY5MTlmMDRjZTZhZTBfMS01LTEtMS03MDA0Mg_9f95214f-808c-4842-b993-3d00f7a6e920">P0Y11M8D</ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjA4MDJhNDMxN2UzZDRkM2E4MTk2OTE5ZjA0Y2U2YWUwL3RhYmxlcmFuZ2U6MDgwMmE0MzE3ZTNkNGQzYTgxOTY5MTlmMDRjZTZhZTBfMS03LTEtMS03MDA0Mg_c9364970-61cf-491f-90c2-f4000ffaed1b"
      unitRef="usd">63100000</ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue>
    <ameh:NumberOfWarrantsGranted
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjA4MDJhNDMxN2UzZDRkM2E4MTk2OTE5ZjA0Y2U2YWUwL3RhYmxlcmFuZ2U6MDgwMmE0MzE3ZTNkNGQzYTgxOTY5MTlmMDRjZTZhZTBfMi0xLTEtMS03MDA0Mg_85e532ac-ef73-493c-8599-096b068782e8"
      unitRef="shares">0</ameh:NumberOfWarrantsGranted>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjA4MDJhNDMxN2UzZDRkM2E4MTk2OTE5ZjA0Y2U2YWUwL3RhYmxlcmFuZ2U6MDgwMmE0MzE3ZTNkNGQzYTgxOTY5MTlmMDRjZTZhZTBfMi0zLTEtMS03MDA0Mg_2a2e0c45-9dc1-417a-a7b4-c3ae5aae883e"
      unitRef="usdPerShare">0</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod>
    <ameh:ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjA4MDJhNDMxN2UzZDRkM2E4MTk2OTE5ZjA0Y2U2YWUwL3RhYmxlcmFuZ2U6MDgwMmE0MzE3ZTNkNGQzYTgxOTY5MTlmMDRjZTZhZTBfMi03LTEtMS03MDA0Mg_ffa7fecb-6393-4566-8fad-135890d2d41d"
      unitRef="usd">0</ameh:ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue>
    <ameh:NumberOfWarrantsExercised
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjA4MDJhNDMxN2UzZDRkM2E4MTk2OTE5ZjA0Y2U2YWUwL3RhYmxlcmFuZ2U6MDgwMmE0MzE3ZTNkNGQzYTgxOTY5MTlmMDRjZTZhZTBfMy0xLTEtMS03MDA0Mg_3b6526bc-6b19-42d3-a4e3-bf1902d7cf2f"
      unitRef="shares">86235</ameh:NumberOfWarrantsExercised>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjA4MDJhNDMxN2UzZDRkM2E4MTk2OTE5ZjA0Y2U2YWUwL3RhYmxlcmFuZ2U6MDgwMmE0MzE3ZTNkNGQzYTgxOTY5MTlmMDRjZTZhZTBfMy0zLTEtMS03MDA0Mg_220cd509-6a86-4ce3-bb38-3633fb7caee0"
      unitRef="usdPerShare">10.49</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod>
    <ameh:ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjA4MDJhNDMxN2UzZDRkM2E4MTk2OTE5ZjA0Y2U2YWUwL3RhYmxlcmFuZ2U6MDgwMmE0MzE3ZTNkNGQzYTgxOTY5MTlmMDRjZTZhZTBfMy03LTEtMS03MDA0Mg_59a8a6a3-a70f-493b-94d8-59fb917a1ba2"
      unitRef="usd">3600000</ameh:ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue>
    <ameh:ClassOfWarrantOrRightCancelledInPeriod
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjA4MDJhNDMxN2UzZDRkM2E4MTk2OTE5ZjA0Y2U2YWUwL3RhYmxlcmFuZ2U6MDgwMmE0MzE3ZTNkNGQzYTgxOTY5MTlmMDRjZTZhZTBfNC0xLTEtMS03MDA0Mg_0f46ca48-7c50-4b8c-98bb-fbf99059a68c"
      unitRef="shares">0</ameh:ClassOfWarrantOrRightCancelledInPeriod>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjA4MDJhNDMxN2UzZDRkM2E4MTk2OTE5ZjA0Y2U2YWUwL3RhYmxlcmFuZ2U6MDgwMmE0MzE3ZTNkNGQzYTgxOTY5MTlmMDRjZTZhZTBfNC0zLTEtMS03MDA0Mg_6911beb3-4025-4fce-8b0a-256656b741ba"
      unitRef="usdPerShare">0</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod>
    <ameh:ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjA4MDJhNDMxN2UzZDRkM2E4MTk2OTE5ZjA0Y2U2YWUwL3RhYmxlcmFuZ2U6MDgwMmE0MzE3ZTNkNGQzYTgxOTY5MTlmMDRjZTZhZTBfNC03LTEtMS03MDA0Mg_76fdb2c2-eb29-4c8d-8944-c3548de4d0e8"
      unitRef="usd">0</ameh:ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjA4MDJhNDMxN2UzZDRkM2E4MTk2OTE5ZjA0Y2U2YWUwL3RhYmxlcmFuZ2U6MDgwMmE0MzE3ZTNkNGQzYTgxOTY5MTlmMDRjZTZhZTBfNi0xLTEtMS03MDA0Mg_fdf2d559-aa28-44c0-845b-26e192368390"
      unitRef="shares">915505</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjA4MDJhNDMxN2UzZDRkM2E4MTk2OTE5ZjA0Y2U2YWUwL3RhYmxlcmFuZ2U6MDgwMmE0MzE3ZTNkNGQzYTgxOTY5MTlmMDRjZTZhZTBfNi0zLTEtMS03MDA0Mg_f67b37d6-8c56-4a14-94ca-8ac68950abbf"
      unitRef="usdPerShare">10.49</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjA4MDJhNDMxN2UzZDRkM2E4MTk2OTE5ZjA0Y2U2YWUwL3RhYmxlcmFuZ2U6MDgwMmE0MzE3ZTNkNGQzYTgxOTY5MTlmMDRjZTZhZTBfNi01LTEtMS03MDA0Mg_ab910a15-a63d-4d2f-8516-179dd3e7f2c1">P0Y8M8D</ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjA4MDJhNDMxN2UzZDRkM2E4MTk2OTE5ZjA0Y2U2YWUwL3RhYmxlcmFuZ2U6MDgwMmE0MzE3ZTNkNGQzYTgxOTY5MTlmMDRjZTZhZTBfNi03LTEtMS03MDA0Mg_7833d731-f2bb-4f00-b644-0078fdc89ec2"
      unitRef="usd">34800000</ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i17b21603feaa4b6eac83277e537457e2_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjVhNWUyZmRmMTZiOTRiOWRhZTBkODEwZDkxYzRkNDdiL3RhYmxlcmFuZ2U6NWE1ZTJmZGYxNmI5NGI5ZGFlMGQ4MTBkOTFjNGQ0N2JfMS0wLTEtMS03MDA0Mg_262f1e4f-a485-4887-9394-58edfbb8570c"
      unitRef="usdPerShare">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ameh:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="i481003839719417595b8ccd16571b1b2_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjVhNWUyZmRmMTZiOTRiOWRhZTBkODEwZDkxYzRkNDdiL3RhYmxlcmFuZ2U6NWE1ZTJmZGYxNmI5NGI5ZGFlMGQ4MTBkOTFjNGQ0N2JfMS0yLTEtMS03MDA0Mg_e9b824e8-150d-4247-913c-e2b937f061d4"
      unitRef="shares">470827</ameh:ClassOfWarrantOrRightIssuedInPeriod>
    <ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
      contextRef="i481003839719417595b8ccd16571b1b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjVhNWUyZmRmMTZiOTRiOWRhZTBkODEwZDkxYzRkNDdiL3RhYmxlcmFuZ2U6NWE1ZTJmZGYxNmI5NGI5ZGFlMGQ4MTBkOTFjNGQ0N2JfMS00LTEtMS03MDA0Mg_f3534e48-5802-4733-ad65-69c249e8b148">P0Y8M8D</ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantOrRightExercisable
      contextRef="i17b21603feaa4b6eac83277e537457e2_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjVhNWUyZmRmMTZiOTRiOWRhZTBkODEwZDkxYzRkNDdiL3RhYmxlcmFuZ2U6NWE1ZTJmZGYxNmI5NGI5ZGFlMGQ4MTBkOTFjNGQ0N2JfMS02LTEtMS03MDA0Mg_ec58e0b0-78f7-4e49-829a-20b6f586c8d9"
      unitRef="shares">470827</ameh:ClassOfWarrantOrRightExercisable>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="i17b21603feaa4b6eac83277e537457e2_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjVhNWUyZmRmMTZiOTRiOWRhZTBkODEwZDkxYzRkNDdiL3RhYmxlcmFuZ2U6NWE1ZTJmZGYxNmI5NGI5ZGFlMGQ4MTBkOTFjNGQ0N2JfMS04LTEtMS03MDA0Mg_143ee88b-87de-441d-8e9b-3272112a4706"
      unitRef="usdPerShare">10.00</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i7cfeff39834e4f6c84395e2d7dabac69_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjVhNWUyZmRmMTZiOTRiOWRhZTBkODEwZDkxYzRkNDdiL3RhYmxlcmFuZ2U6NWE1ZTJmZGYxNmI5NGI5ZGFlMGQ4MTBkOTFjNGQ0N2JfMi0wLTEtMS03MDA0Mg_496b6dba-f745-4342-9a64-4253bdb7e002"
      unitRef="usdPerShare">11.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ameh:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="i22448a574a694a83ad45e720a7b0491c_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjVhNWUyZmRmMTZiOTRiOWRhZTBkODEwZDkxYzRkNDdiL3RhYmxlcmFuZ2U6NWE1ZTJmZGYxNmI5NGI5ZGFlMGQ4MTBkOTFjNGQ0N2JfMi0yLTEtMS03MDA0Mg_f9182235-da13-4e7c-86c1-69560c42b418"
      unitRef="shares">444678</ameh:ClassOfWarrantOrRightIssuedInPeriod>
    <ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
      contextRef="i22448a574a694a83ad45e720a7b0491c_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjVhNWUyZmRmMTZiOTRiOWRhZTBkODEwZDkxYzRkNDdiL3RhYmxlcmFuZ2U6NWE1ZTJmZGYxNmI5NGI5ZGFlMGQ4MTBkOTFjNGQ0N2JfMi00LTEtMS03MDA0Mg_97863fcc-10ba-49b9-b3c9-de213bacd1fb">P0Y8M8D</ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantOrRightExercisable
      contextRef="i7cfeff39834e4f6c84395e2d7dabac69_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjVhNWUyZmRmMTZiOTRiOWRhZTBkODEwZDkxYzRkNDdiL3RhYmxlcmFuZ2U6NWE1ZTJmZGYxNmI5NGI5ZGFlMGQ4MTBkOTFjNGQ0N2JfMi02LTEtMS03MDA0Mg_10bcacbe-d2d7-4e63-aeeb-95e5f739ac40"
      unitRef="shares">444678</ameh:ClassOfWarrantOrRightExercisable>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="i7cfeff39834e4f6c84395e2d7dabac69_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjVhNWUyZmRmMTZiOTRiOWRhZTBkODEwZDkxYzRkNDdiL3RhYmxlcmFuZ2U6NWE1ZTJmZGYxNmI5NGI5ZGFlMGQ4MTBkOTFjNGQ0N2JfMi04LTEtMS03MDA0Mg_35467506-9bb7-4d2f-80fa-a7d374bf4aae"
      unitRef="usdPerShare">11.00</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i789d3da0a72b4fb89b415c17b6bd2710_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjVhNWUyZmRmMTZiOTRiOWRhZTBkODEwZDkxYzRkNDdiL3RhYmxlcmFuZ2U6NWE1ZTJmZGYxNmI5NGI5ZGFlMGQ4MTBkOTFjNGQ0N2JfNC0wLTEtMS03MDA0Mi90ZXh0cmVnaW9uOjcwZDYxYzA2ZmMxNDQ0OWM5YTY0MDE5ZmQ2MDBjNGUzXzIz_7730682c-100d-42d1-9b90-b8e715daca8c"
      unitRef="usdPerShare">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ia90b2ff413524e3b90acbbb605243bbb_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjVhNWUyZmRmMTZiOTRiOWRhZTBkODEwZDkxYzRkNDdiL3RhYmxlcmFuZ2U6NWE1ZTJmZGYxNmI5NGI5ZGFlMGQ4MTBkOTFjNGQ0N2JfNC0wLTEtMS03MDA0Mi90ZXh0cmVnaW9uOjcwZDYxYzA2ZmMxNDQ0OWM5YTY0MDE5ZmQ2MDBjNGUzXzI4_9939f2f4-cb00-4a2a-b8ac-6344091b3d5a"
      unitRef="usdPerShare">11.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ameh:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="i297879f201e2401b809e877bc5ca8f1a_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjVhNWUyZmRmMTZiOTRiOWRhZTBkODEwZDkxYzRkNDdiL3RhYmxlcmFuZ2U6NWE1ZTJmZGYxNmI5NGI5ZGFlMGQ4MTBkOTFjNGQ0N2JfNC0yLTEtMS03MDA0Mg_3b332f93-4303-44ff-a88a-b7bec4a9d93a"
      unitRef="shares">915505</ameh:ClassOfWarrantOrRightIssuedInPeriod>
    <ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
      contextRef="i297879f201e2401b809e877bc5ca8f1a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjVhNWUyZmRmMTZiOTRiOWRhZTBkODEwZDkxYzRkNDdiL3RhYmxlcmFuZ2U6NWE1ZTJmZGYxNmI5NGI5ZGFlMGQ4MTBkOTFjNGQ0N2JfNC00LTEtMS03MDA0Mg_3a9b4511-000d-4625-9f5f-587df6d49730">P0Y8M8D</ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantOrRightExercisable
      contextRef="iaf372c04e8fd4b7fb0fe8f937ab557bd_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjVhNWUyZmRmMTZiOTRiOWRhZTBkODEwZDkxYzRkNDdiL3RhYmxlcmFuZ2U6NWE1ZTJmZGYxNmI5NGI5ZGFlMGQ4MTBkOTFjNGQ0N2JfNC02LTEtMS03MDA0Mg_5a823b44-366c-4d71-8e8f-272d6ff4303f"
      unitRef="shares">915505</ameh:ClassOfWarrantOrRightExercisable>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="iaf372c04e8fd4b7fb0fe8f937ab557bd_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RhYmxlOjVhNWUyZmRmMTZiOTRiOWRhZTBkODEwZDkxYzRkNDdiL3RhYmxlcmFuZ2U6NWE1ZTJmZGYxNmI5NGI5ZGFlMGQ4MTBkOTFjNGQ0N2JfNC04LTEtMS03MDA0Mg_21cac797-d30f-488f-820e-a0b16df93af6"
      unitRef="usdPerShare">10.49</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfMTg5Mg_8e76daa7-c8b4-4b45-acd9-50e8eb8bc222"
      unitRef="shares">86235</ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod>
    <ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfMTg5OQ_7726cd7f-fca2-468c-8dfb-b064ba9c1938"
      unitRef="shares">421002</ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod>
    <ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfMTk5OA_30e4819f-2c26-48d0-9fd5-dfa8cc33901f"
      unitRef="usd">900000</ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised>
    <ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfMjAwNQ_8c068a23-eb6a-4eda-8f86-ef7afcaf49d3"
      unitRef="usd">4300000</ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised>
    <ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice
      contextRef="i706233a8610b47c986b542c84fc02826_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfMjA1NA_8277d29e-539d-4c0e-a36a-b1d365b7738f"
      unitRef="usdPerShare">10.00</ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice>
    <ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice
      contextRef="id61632e270d643278e5a45ab9d986834_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfMjA2MA_774110ec-e232-4922-951d-cc9f0212ad65"
      unitRef="usdPerShare">11.00</ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice>
    <ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice
      contextRef="i1501307448a04213aad7bd6a8043ca3c_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfNDk0NzgwMjMyNzg4NA_866f67f4-60ba-4d25-a97e-12aa2b0c047e"
      unitRef="usdPerShare">9.00</ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice>
    <ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice
      contextRef="i4bee43ded60043dbad50b78762e0cfef_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85MS9mcmFnOmZjOTdjMmQ3NTIyZDQ4YWNiZTU5MmZiYTZhMDdhY2M3L3RleHRyZWdpb246ZmM5N2MyZDc1MjJkNDhhY2JlNTkyZmJhNmEwN2FjYzdfNDk0NzgwMjMyNzg5MQ_63529197-1861-46a1-a33f-45eccf38592b"
      unitRef="usdPerShare">11.00</ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85Ny9mcmFnOjUzM2U5NWQyNmFjMzRkZWZiYTllZmU1NDM2NjYzMGJlL3RleHRyZWdpb246NTMzZTk1ZDI2YWMzNGRlZmJhOWVmZTU0MzY2NjMwYmVfMzkxNQ_65ddb0fd-9422-4b3a-9bf3-7e59f28ae73a">Commitments and Contingencies&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Regulatory Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Laws and regulations governing the Medicare program and healthcare generally are complex and subject to interpretation. The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. While no regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and exclusion from the Medicare and Medi-Cal programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As risk-bearing organizations, APC, Alpha Care, and Accountable Health Care are required to comply with the California Department of Managed Healthcare (&#x201c;DMHC&#x201d;) regulations, including maintenance of minimum working capital, tangible net equity (&#x201c;TNE&#x201d;), cash-to-claims ratio, and claims payment requirements prescribed by the DMHC. TNE is defined as net equity less intangibles, less non-allowable assets (which include unsecured amounts due from affiliates), plus subordinated obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Many of the payor and provider contracts with the Company&#x2019;s affiliated physician-owned medical groups are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services. Such differing interpretations may not come to light until a substantial period of time has passed following contract implementation. Liabilities for claims disputes are recorded when the loss is probable and can be estimated. Any adjustments to reserves are reflected in current operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Standby Letters of Credit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC and Alpha Care established irrevocable standby letters of credit with a Preferred Bank for a total of $0.3 million and $3.8&#160;million, respectively, for the benefit of certain health plans (see Note 9). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of its business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company&#x2019;s financial condition, cash flows, or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liability Insurance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that its insurance coverage is appropriate based upon the Company&#x2019;s claims experience and the nature and risks of the Company&#x2019;s business. In addition to the known incidents that have resulted in the assertion of claims, the Company cannot be certain that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against the Company, the Company&#x2019;s affiliated professional organizations or the Company&#x2019;s affiliated hospitalists in the future where the outcomes of such claims are unfavorable. The Company believes that the ultimate resolution of all pending claims, including liabilities in excess of the Company&#x2019;s insurance coverage, will not have a material adverse effect on the Company&#x2019;s financial position, results of operations, or cash flows; however, there can be no assurance that future claims will not have such a material adverse effect on the Company&#x2019;s business. Contracted physicians are required to obtain their own insurance coverage.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although the Company currently maintains liability insurance policies on a claims-made basis, which are intended to cover malpractice liability and certain other claims, the coverage must be renewed annually, and may&#160;not continue to be available to the Company in future years at acceptable costs, and on favorable terms.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LineOfCredit
      contextRef="ie54e1b2ff59741a89b0243c59b6ef686_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85Ny9mcmFnOjUzM2U5NWQyNmFjMzRkZWZiYTllZmU1NDM2NjYzMGJlL3RleHRyZWdpb246NTMzZTk1ZDI2YWMzNGRlZmJhOWVmZTU0MzY2NjMwYmVfMjE0Nw_e698e083-9535-484f-bb1e-9e19f819d9b3"
      unitRef="usd">300000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="ib152b2b747a74eaeb8147b82a52c9e8c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF85Ny9mcmFnOjUzM2U5NWQyNmFjMzRkZWZiYTllZmU1NDM2NjYzMGJlL3RleHRyZWdpb246NTMzZTk1ZDI2YWMzNGRlZmJhOWVmZTU0MzY2NjMwYmVfMjE1NA_56194bd2-7508-4d5f-b0d3-99bbe3f8ea2b"
      unitRef="usd">3800000</us-gaap:LineOfCredit>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzQ2Mzc_4982f485-bb26-481c-b725-4292e821dace">Related-Party Transactions&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2022 and 2021, NMM earned approximately $6.3 million and $4.5 million, respectively, in management fees from LMA, which is accounted for under the equity method based on the 25% equity ownership interest held by APC in LMA&#x2019;s IPA line of business (see Note 5 &#x2014; &#x201c;Investments in Other Entities &#x2014; Equity Method&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2022 and 2021, APC paid approximately $0.7 million and $0.5 million, respectively, to PMIOC for provider services, which is accounted for under the equity method based on the 40% equity ownership interest held by APC (see Note 5 &#x2014; &#x201c;Investments in Other Entities &#x2014; Equity Method&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2022 and 2021, APC paid approximately $0 and $1.6 million, respectively, to DMG for provider services, which is accounted for under the equity method based on the 40% equity ownership interest held by APC. In October 2021,  DMG was consolidated by Apollo. As such, DMG is no longer a related party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2022 and 2021, APC paid approximately $39,000 and $22,000, respectively, to Advanced Diagnostic Surgery Center for services as a provider. Advanced Diagnostic Surgery Center shares common ownership with certain board members of APC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2022 and 2021, APC paid approximately $5,800 and $33,000, respectively, to Fresenius Medical Care (&#x201c;Fresenius&#x201d;) and its subsidiaries for services as a provider. During the three months ended March&#160;31, 2022 and 2021, APAACO paid approximately $0.1 million and $0.2 million, respectively, to Fresenius and its subsidiaries for services as a provider. One of the Company&#x2019;s board members is an officer of Fresenius and its subsidiaries. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2022 and 2021, APC paid approximately $0.1 million and $21,000, respectively, to Fulgent Genetics, Inc. for services as a provider. One of the Company&#x2019;s board members is a board member of Fulgent Genetics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2022 and 2021, APC paid an aggregate of approximately $9.3 million and $7.4 million to shareholders, respectively, which included approximately $1.9 million and $1.7 million, respectively, to shareholders who are also officers of APC. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2022 and 2021, SCHC paid approximately $0.1 million and $0.1 million, respectively, to Numen, LLC (&#x201c;Numen&#x201d;) for an office lease. Numen is owned by a shareholder of APC. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2022 and 2021, NMM paid approximately $0.4 million and $0.4 million, respectively, to One MSO for an office lease, which is accounted for under the equity method based on 50% equity ownership interest held by APC (see Note 5 &#x2014; &#x201c;Investments in Other Entities &#x2014; Equity Method&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2022 and 2021, APC paid approximately $3.5 million and $0, respectively, to Arroyo Vista Family Health Center (&#x201c;Arroyo Vista&#x201d;) for services as a provider. The CEO of Arroyo Vista became a board member with the Company in 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has agreements with Health Source MSO Inc., a California corporation (&#x201c;HSMSO&#x201d;), Aurion Corporation (&#x201c;Aurion&#x201d;), and AHMC Healthcare Inc. (&#x201c;AHMC&#x201d;) for services provided to the Company. One of the Company&#x2019;s board members is an officer of AHMC, HSMSO, and Aurion. Aurion is also partially owned by one of the Company&#x2019;s board members. The following table sets forth fees incurred and income received related to AHMC, HSMSO, and Aurion (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.305%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AHMC &#x2013; Risk pool, capitation, claims payment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;HSMSO &#x2013; Management fees, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aurion &#x2013; Management fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receipts, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and AHMC have a risk-sharing agreement with certain AHMC hospitals to share the surplus and deficits of each of the hospital pools. During the three months ended March&#160;31, 2022 and 2021, the Company has recognized risk pool revenue under this agreement of $12.0 million and $16.9 million, respectively, of which $66.0 million and $58.4 million remained outstanding as of March&#160;31, 2022 and December&#160;31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2022 and 2021, NMM paid approximately $0 and $44,000, respectively, to an ApolloMed board member for consulting services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, affiliates wholly owned by the Company&#x2019;s officers, including Dr. Thomas Lam, ApolloMed&#x2019;s Co-CEO and President, are reported in the accompanying consolidated statements of income on a consolidated basis, together with the Company&#x2019;s subsidiaries, and therefore, the Company does not separately disclose transactions between such affiliates and the Company&#x2019;s subsidiaries as related-party transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For equity method investments and loans receivable from related parties, see Notes 5 and 6, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RevenueFromRelatedParties
      contextRef="iaa7033a548444263ac0237b0218a1adb_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzEwNw_2dd5be30-2702-493e-ab3a-1483911102a5"
      unitRef="usd">6300000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="ib5bf970dcad14a8ba4515f1f82038323_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzExNA_e7ff5d6e-929b-44a6-a40a-e99d60887f24"
      unitRef="usd">4500000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="idc43c382a55f4e86bce82fa55ccdec8b_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzI1MA_00f18be5-54fa-49b4-9536-8fec72c2655a"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ifa663b2f13a34f278cc8242cfbd66f60_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzI1MA_ff446a31-0630-4984-86e7-e2618244fd67"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i9cb30ce0828947b2b67749be5fbf6bfb_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzQwMw_c6599faa-4c38-4761-b5cf-a5b1cc032a8d"
      unitRef="usd">700000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ia9fd61dc32854b5794c5219cd64b9c91_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzQxMA_7cbe5153-7da6-4d70-9893-48a460536154"
      unitRef="usd">500000</ameh:PaymentMadeToRelatedParty>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i149029e085754aa781bb4c12925033e9_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzU0OQ_000eabf0-24ac-4de2-8956-001cc1db5df4"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i9a32ef7fa5834e35b4d3446fb2b911d7_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzU0OQ_a37a9682-b9de-486e-9432-a3e1a875f9b3"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i585cd6801b0a4b76917339116f149737_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzY3Mg_e2d753af-b169-4ef3-b754-3391325ebafb"
      unitRef="usd">0</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i1e581b13ba1943ada689751040932d87_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzY3OQ_60a4fb24-bfed-47f7-8492-a3c26322860f"
      unitRef="usd">1600000</ameh:PaymentMadeToRelatedParty>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i7c6d4670d2704e46854a6d362d7ff8dc_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzgxNg_b798f00c-46c8-4592-b1e4-cf84c351df0b"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i8a544d6c34914e8180df76ac79f9061c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzkzOQ_68128e75-d22d-4302-b9c4-ba5b217d2ab8"
      unitRef="usd">39000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ia407282c4d7c40f69b845a1980e98f90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzk0Ng_02dc2723-d586-4161-ad6e-2e71b449067f"
      unitRef="usd">22000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i0a710728186e429c9f56a34cae4c7cd8_D20220101-20220331"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzEyMDY_9a73d765-e357-46c1-ac23-3ddefb5c28c7"
      unitRef="usd">5800</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i119ac7d8ea0849dbb246ad71c51fe403_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzEyMTM_7c215f37-6103-428d-8b7b-75c00554805c"
      unitRef="usd">33000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ic4788b32e9914d0ca0604092d88f6375_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzE0MjA_4ad78b1d-115b-43cf-a82c-dd88f64cd786"
      unitRef="usd">100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ia7c1281284034e199a945b4fa25a565f_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzE0Mjc_39d6e8c9-3844-4de3-85e8-c0c9b86d39a6"
      unitRef="usd">200000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i81646c8d09a94a9aaeadb368f60bd221_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzE2Njg_cdb8d9ca-bd28-4363-b742-339fc18f8980"
      unitRef="usd">100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ic6a40ab43ad94c908617b8e12ab58ed0_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzE2NzU_4ea3effd-bd2a-4f8b-b955-8ce453d991ca"
      unitRef="usd">21000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i2e92ca4dba96429ca6f565c4a96fae69_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzE5MzI_0eb4fb6b-f050-4ebc-9df1-ae6793660819"
      unitRef="usd">9300000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i5ef6c81ae0d149dcb8f839d22ecdbf4f_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzE5Mzk_962a97bc-5fe1-4f13-a74e-c0a313e38016"
      unitRef="usd">7400000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i69208e7b66d34e81be1ece056152eb3d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzIwMDI_fd0986cc-4561-4aed-8b18-58892ed76a3e"
      unitRef="usd">1900000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="if7a4db8db1a74901a4e3415b998623f7_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzIwMDk_b0954173-5ed3-4a88-b8f6-446359b9029c"
      unitRef="usd">1700000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="iffe651efb930429a8995404b0dc53e6b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzI2MDA_4de03ac2-93ec-4e9e-b788-f68337bca4e2"
      unitRef="usd">100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ie54eef2ca9b5495ea95cad9493906234_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzI2MDc_62749771-6c48-4efc-84f5-77cf7dd04a00"
      unitRef="usd">100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ie96af2c696c5435d811fd5623d3302c5_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzI4MDE_2514ab7c-9dec-4703-9994-a70d4ff2a12c"
      unitRef="usd">400000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i725a2a08b1e34d65984bdfc031ea6bdb_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzI4MDg_5a391a5e-3af1-4014-8e12-b08029844f63"
      unitRef="usd">400000</ameh:PaymentMadeToRelatedParty>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i1c049a48265c4b71906a6728352ec4d1_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzI5NDM_2d96883d-6290-4426-8c80-a4771aa1a67f"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i4608970f45fe4db1a3f4e42e64795259_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzI5NDM_73fa4223-9cfa-4257-80fa-c1709da93d63"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ifde0ed94454e448ba35d1211452c3daf_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzU0OTc1NTgxNDQxMzc_f63cccfc-c647-4995-ad57-45fad02dce09"
      unitRef="usd">3500000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i41d101f6c0b44f5aad791956bdabaa9d_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzU0OTc1NTgxNDQxNDg_0e27f34a-a35a-409b-a867-c59a1881f2d2"
      unitRef="usd">0</ameh:PaymentMadeToRelatedParty>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzQ2NDQ_fad35a60-092f-4d0e-a3fc-cac4af2ab9b6">The following table sets forth fees incurred and income received related to AHMC, HSMSO, and Aurion (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.305%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AHMC &#x2013; Risk pool, capitation, claims payment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;HSMSO &#x2013; Management fees, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aurion &#x2013; Management fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receipts, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet
      contextRef="i88100c9376d541219eea1723b76e0ce5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90YWJsZTozNDc0YTgxMTBiZTg0Njk1YmY2YjBlNTkzOWM2Y2NiOC90YWJsZXJhbmdlOjM0NzRhODExMGJlODQ2OTViZjZiMGU1OTM5YzZjY2I4XzItMS0xLTEtNzAwNDI_584aae52-7727-4aa3-b977-e849bdff9f88"
      unitRef="usd">11366000</ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet>
    <ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet
      contextRef="i5e4fd86eeb0b4ab68d020185faa91a8f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90YWJsZTozNDc0YTgxMTBiZTg0Njk1YmY2YjBlNTkzOWM2Y2NiOC90YWJsZXJhbmdlOjM0NzRhODExMGJlODQ2OTViZjZiMGU1OTM5YzZjY2I4XzItMy0xLTEtNzAwNDI_6da02eef-1dcc-42b9-8e44-2a2335d1fb58"
      unitRef="usd">13097000</ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet>
    <us-gaap:ManagementFeeExpense
      contextRef="i3339dc21c97b4534b86a86264b8aff7b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90YWJsZTozNDc0YTgxMTBiZTg0Njk1YmY2YjBlNTkzOWM2Y2NiOC90YWJsZXJhbmdlOjM0NzRhODExMGJlODQ2OTViZjZiMGU1OTM5YzZjY2I4XzMtMS0xLTEtNzAwNDI_eefdb25d-6510-468a-902b-50741b5bb5b3"
      unitRef="usd">80000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="iac761ad94565453fb1630b4de5935fbb_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90YWJsZTozNDc0YTgxMTBiZTg0Njk1YmY2YjBlNTkzOWM2Y2NiOC90YWJsZXJhbmdlOjM0NzRhODExMGJlODQ2OTViZjZiMGU1OTM5YzZjY2I4XzMtMy0xLTEtNzAwNDI_7464136f-eb0b-430e-9406-758dca816338"
      unitRef="usd">77000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="i66d10132ebde4c69977f0b31055a0271_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90YWJsZTozNDc0YTgxMTBiZTg0Njk1YmY2YjBlNTkzOWM2Y2NiOC90YWJsZXJhbmdlOjM0NzRhODExMGJlODQ2OTViZjZiMGU1OTM5YzZjY2I4XzQtMS0xLTEtNzAwNDI_0dbdd213-2160-4a2e-902a-f8441d3498e4"
      unitRef="usd">75000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="i73c05785e9ff4c7cbf5b3cfde9945e78_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90YWJsZTozNDc0YTgxMTBiZTg0Njk1YmY2YjBlNTkzOWM2Y2NiOC90YWJsZXJhbmdlOjM0NzRhODExMGJlODQ2OTViZjZiMGU1OTM5YzZjY2I4XzQtMy0xLTEtNzAwNDI_43c67f3c-7eb0-4b5f-b426-df74375b4965"
      unitRef="usd">75000</us-gaap:ManagementFeeExpense>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90YWJsZTozNDc0YTgxMTBiZTg0Njk1YmY2YjBlNTkzOWM2Y2NiOC90YWJsZXJhbmdlOjM0NzRhODExMGJlODQ2OTViZjZiMGU1OTM5YzZjY2I4XzYtMS0xLTEtNzAwNDI_c22c27ee-d792-493c-95ee-514fae2de125"
      unitRef="usd">11211000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90YWJsZTozNDc0YTgxMTBiZTg0Njk1YmY2YjBlNTkzOWM2Y2NiOC90YWJsZXJhbmdlOjM0NzRhODExMGJlODQ2OTViZjZiMGU1OTM5YzZjY2I4XzYtMy0xLTEtNzAwNDI_f0e500fd-3506-4217-b2bd-bc532962a2b0"
      unitRef="usd">12945000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i88100c9376d541219eea1723b76e0ce5_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzM3MTU_7aa4b51b-32bf-48de-9107-a3b810eec9fb"
      unitRef="usd">12000000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i5e4fd86eeb0b4ab68d020185faa91a8f_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzM3MjI_4523bfc5-fd17-415a-9f62-03943098d905"
      unitRef="usd">16900000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:DeferredCreditsAndOtherLiabilities
      contextRef="if14f6b3f9f9143678ca31fa46792180a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzM3NjQ_0a041387-34cd-4f90-a4ed-d999cfe89a04"
      unitRef="usd">66000000</us-gaap:DeferredCreditsAndOtherLiabilities>
    <us-gaap:DeferredCreditsAndOtherLiabilities
      contextRef="i8e487ca262164803a2471112a5aa3b86_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzM3NzE_c16f363e-3705-468b-a220-299d2c9e9512"
      unitRef="usd">58400000</us-gaap:DeferredCreditsAndOtherLiabilities>
    <ameh:PaymentConsultingFees
      contextRef="i9ac40763eff9488da386a8f3f515dcd2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzU0OTc1NTgxNDQxNTU_b4aed544-e675-4d3b-8ef3-15fae8b5ee2c"
      unitRef="usd">0</ameh:PaymentConsultingFees>
    <ameh:PaymentConsultingFees
      contextRef="i2437426902314907bb93c3e3a054e882_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDAvZnJhZzo4ZGUwNDJlMmU3MGY0OTVhOGRlZTE4ZmY1NzM1OWJmYy90ZXh0cmVnaW9uOjhkZTA0MmUyZTcwZjQ5NWE4ZGVlMThmZjU3MzU5YmZjXzU0OTc1NTgxNDQxNjk_b9efc95d-5699-4ca3-9b1b-ccaf0c771357"
      unitRef="usd">44000</ameh:PaymentConsultingFees>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDYvZnJhZzoxMmY5NzlmZGQyNzI0OGJjYmU4Mzk1ZmFiZDZjNjI1NC90ZXh0cmVnaW9uOjEyZjk3OWZkZDI3MjQ4YmNiZTgzOTVmYWJkNmM2MjU0XzI0ODE_301c263b-5bd7-434c-b8a4-b2469adb9668">Income Taxes&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the liability method of accounting for income taxes as set forth in ASC 740&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Under the liability method, deferred taxes are determined based on differences between the financial statement and tax bases of assets and liabilities using enacted tax rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an interim basis, the Company estimates what its anticipated annual effective tax rate will be and records a quarterly income tax provision in accordance with the estimated annual rate, plus the tax effect of certain discrete items that arise during the quarter. As the fiscal year progresses, the Company refines its estimates based on actual events and financial results during the quarter. This process can result in significant changes to the Company&#x2019;s estimated effective tax rate. When this occurs, the income tax provision is adjusted during the quarter in which the estimates are refined so that the year-to-date provision reflects the estimated annual effective tax rate. These changes, along with adjustments to the Company&#x2019;s deferred taxes and related valuation allowance, may create fluctuations in the overall effective tax rate from quarter to quarter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, due to the overall cumulative losses incurred in recent years, the Company maintained a full valuation allowance against its deferred tax assets related to loss entities the Company cannot consolidate under the federal tax consolidation rules, as realization of these assets is uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s effective income tax rate for the three months ended March&#160;31, 2022 and March&#160;31, 2021, was 34.0% and 31.9%, respectively. The tax rate for the three months ended March&#160;31, 2022, differed from the U.S. federal statutory rate primarily due to state income taxes, income from flow through entities, non-deductible permanent items, and change in valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, the Company does not have any unrecognized tax benefits related to various federal and state income tax matters. The Company will recognize accrued interest and penalties related to unrecognized tax benefits in income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to U.S. federal income tax as well as income tax in California. The Company and its subsidiaries&#x2019; state and federal income tax returns are open to audit under the statute of limitations for the years ended December 31, 2017 through December&#160;31, 2021, and for the years ended December 31, 2018 through December&#160;31, 2021, respectively. The Company does not anticipate material changes to the unrecognized tax benefits within the next 12 months.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDYvZnJhZzoxMmY5NzlmZGQyNzI0OGJjYmU4Mzk1ZmFiZDZjNjI1NC90ZXh0cmVnaW9uOjEyZjk3OWZkZDI3MjQ4YmNiZTgzOTVmYWJkNmM2MjU0XzEwOTk1MTE2MzAyNzQ_1c3ea04c-69fb-450c-ac8d-aba3e5e805b4"
      unitRef="number">0.340</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDYvZnJhZzoxMmY5NzlmZGQyNzI0OGJjYmU4Mzk1ZmFiZDZjNjI1NC90ZXh0cmVnaW9uOjEyZjk3OWZkZDI3MjQ4YmNiZTgzOTVmYWJkNmM2MjU0XzQzOTgwNDY1MTM1ODg_0b9dfb1a-f151-4715-9e3e-c4a42eb76ea1"
      unitRef="number">0.319</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90ZXh0cmVnaW9uOmIzNDRmMzk1OTc3ZjRjYjk5MzZkOWZlYmU5MzRmMzFkXzExMTQ_7bd4df3f-4596-478c-8009-62fabc55a125">Earnings Per Share&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is calculated using the weighted average number of shares of the Company&#x2019;s common stock issued and outstanding during a certain period, and is calculated by dividing net income attributable to ApolloMed by the weighted average number of shares of the Company&#x2019;s common stock issued and outstanding during such period. Diluted earnings per share is calculated using the weighted average number of shares of common stock and potentially dilutive shares of common stock outstanding during the period, using the as-if converted method for secured convertible notes, preferred stock, and the treasury stock method for options and common stock warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022 and December&#160;31, 2021, APC held 10,925,702 shares of ApolloMed&#x2019;s common stock, which are treated as treasury shares for accounting purposes and not included in the number of shares of common stock outstanding used to calculate earnings per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of the earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,681,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,336,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,994,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,566,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of the shares included in the diluted earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,681,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,336,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;729,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;811,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,994,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,566,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idbab252c85d54d69abb776900de44d5a_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90ZXh0cmVnaW9uOmIzNDRmMzk1OTc3ZjRjYjk5MzZkOWZlYmU5MzRmMzFkXzcyNw_1595fcb1-cf83-4087-beda-21921c0ffbd2"
      unitRef="shares">10925702</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90ZXh0cmVnaW9uOmIzNDRmMzk1OTc3ZjRjYjk5MzZkOWZlYmU5MzRmMzFkXzExMTc_f66d6ad0-ece3-47f6-b8e3-9bebd419c8e5">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of the earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,681,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,336,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,994,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,566,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:EarningsPerShareBasic
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTo0MDc2Zjg1NWYwOGY0ZTMzOWFhNzFjMTY3YjlkMWE5MC90YWJsZXJhbmdlOjQwNzZmODU1ZjA4ZjRlMzM5YWE3MWMxNjdiOWQxYTkwXzEtMi0xLTEtNzAwNDI_fe932702-7148-49d2-9914-21052664fcd6"
      unitRef="usdPerShare">0.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTo0MDc2Zjg1NWYwOGY0ZTMzOWFhNzFjMTY3YjlkMWE5MC90YWJsZXJhbmdlOjQwNzZmODU1ZjA4ZjRlMzM5YWE3MWMxNjdiOWQxYTkwXzEtNC0xLTEtNzAwNDI_8279af8c-32b9-4a4b-bcfa-1ecb922e9737"
      unitRef="usdPerShare">0.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTo0MDc2Zjg1NWYwOGY0ZTMzOWFhNzFjMTY3YjlkMWE5MC90YWJsZXJhbmdlOjQwNzZmODU1ZjA4ZjRlMzM5YWE3MWMxNjdiOWQxYTkwXzItMi0xLTEtNzAwNDI_98938bb9-422e-4565-bb1f-ded162a5d8ec"
      unitRef="usdPerShare">0.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTo0MDc2Zjg1NWYwOGY0ZTMzOWFhNzFjMTY3YjlkMWE5MC90YWJsZXJhbmdlOjQwNzZmODU1ZjA4ZjRlMzM5YWE3MWMxNjdiOWQxYTkwXzItNC0xLTEtNzAwNDI_d8e2291d-4745-4cdd-9460-853823a0e75f"
      unitRef="usdPerShare">0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTo0MDc2Zjg1NWYwOGY0ZTMzOWFhNzFjMTY3YjlkMWE5MC90YWJsZXJhbmdlOjQwNzZmODU1ZjA4ZjRlMzM5YWE3MWMxNjdiOWQxYTkwXzMtMi0xLTEtNzAwNDI_7c11bc6b-4f25-4de8-8a10-bbce31269def"
      unitRef="shares">44681218</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTo0MDc2Zjg1NWYwOGY0ZTMzOWFhNzFjMTY3YjlkMWE5MC90YWJsZXJhbmdlOjQwNzZmODU1ZjA4ZjRlMzM5YWE3MWMxNjdiOWQxYTkwXzMtNC0xLTEtNzAwNDI_bead3588-939c-463c-9541-7cb25826b9bd"
      unitRef="shares">42336434</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTo0MDc2Zjg1NWYwOGY0ZTMzOWFhNzFjMTY3YjlkMWE5MC90YWJsZXJhbmdlOjQwNzZmODU1ZjA4ZjRlMzM5YWE3MWMxNjdiOWQxYTkwXzQtMi0xLTEtNzAwNDI_5dbc0e56-da95-41a3-a1fc-f51e5d66c661"
      unitRef="shares">45994868</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTo0MDc2Zjg1NWYwOGY0ZTMzOWFhNzFjMTY3YjlkMWE5MC90YWJsZXJhbmdlOjQwNzZmODU1ZjA4ZjRlMzM5YWE3MWMxNjdiOWQxYTkwXzQtNC0xLTEtNzAwNDI_2f05a272-c35d-40b9-866d-8305bd52d398"
      unitRef="shares">43566189</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90ZXh0cmVnaW9uOmIzNDRmMzk1OTc3ZjRjYjk5MzZkOWZlYmU5MzRmMzFkXzExMTI_b92ac836-10af-4f8d-8bda-b3f5ae9e7eb9">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of the shares included in the diluted earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,681,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,336,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;729,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;811,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,994,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,566,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTozMTNlYzA0NjJlY2I0NzFiODNhMGFjYTJkYTFjZmY2ZC90YWJsZXJhbmdlOjMxM2VjMDQ2MmVjYjQ3MWI4M2EwYWNhMmRhMWNmZjZkXzEtMi0xLTEtNzAwNDI_fb2a42ed-6cfd-4317-b21b-9f1a1b7f76c9"
      unitRef="shares">44681218</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTozMTNlYzA0NjJlY2I0NzFiODNhMGFjYTJkYTFjZmY2ZC90YWJsZXJhbmdlOjMxM2VjMDQ2MmVjYjQ3MWI4M2EwYWNhMmRhMWNmZjZkXzEtNC0xLTEtNzAwNDI_7a31cb25-d850-47ea-b476-714eabcb594c"
      unitRef="shares">42336434</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ib88b8cbaf9c044f48d97f4585c10e9b1_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTozMTNlYzA0NjJlY2I0NzFiODNhMGFjYTJkYTFjZmY2ZC90YWJsZXJhbmdlOjMxM2VjMDQ2MmVjYjQ3MWI4M2EwYWNhMmRhMWNmZjZkXzMtMi0xLTEtNzAwNDI_676f1f32-e3c5-4018-bd93-264e2939003f"
      unitRef="shares">482337</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i8dc8e8d5b2d3450c82e20483d0b1d396_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTozMTNlYzA0NjJlY2I0NzFiODNhMGFjYTJkYTFjZmY2ZC90YWJsZXJhbmdlOjMxM2VjMDQ2MmVjYjQ3MWI4M2EwYWNhMmRhMWNmZjZkXzMtNC0xLTEtNzAwNDI_e98c44ea-f1c6-4204-a8cc-d7985c0e0d3e"
      unitRef="shares">318749</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i6cfa814cabb748ff9a56f20f22646f52_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTozMTNlYzA0NjJlY2I0NzFiODNhMGFjYTJkYTFjZmY2ZC90YWJsZXJhbmdlOjMxM2VjMDQ2MmVjYjQ3MWI4M2EwYWNhMmRhMWNmZjZkXzQtMi0xLTEtNzAwNDI_abcd7c59-ae3e-4bdf-9800-9c63bb32a8bd"
      unitRef="shares">729422</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="iad0d67abd1ee4eb5a0b58ae347cb78d5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTozMTNlYzA0NjJlY2I0NzFiODNhMGFjYTJkYTFjZmY2ZC90YWJsZXJhbmdlOjMxM2VjMDQ2MmVjYjQ3MWI4M2EwYWNhMmRhMWNmZjZkXzQtNC0xLTEtNzAwNDI_ab566099-e4da-409c-bb47-78975ecf3ce9"
      unitRef="shares">811787</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i9f93afb80fb24f97b3aa96bd0066452e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTozMTNlYzA0NjJlY2I0NzFiODNhMGFjYTJkYTFjZmY2ZC90YWJsZXJhbmdlOjMxM2VjMDQ2MmVjYjQ3MWI4M2EwYWNhMmRhMWNmZjZkXzUtMi0xLTEtOTc1NTk_1f5b7723-8337-4f79-95e3-7180cff98b14"
      unitRef="shares">101891</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i6687248226604b5aa14b27933ac85631_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTozMTNlYzA0NjJlY2I0NzFiODNhMGFjYTJkYTFjZmY2ZC90YWJsZXJhbmdlOjMxM2VjMDQ2MmVjYjQ3MWI4M2EwYWNhMmRhMWNmZjZkXzUtNC0xLTEtOTc1NzA_eb4ce4b6-9e52-4bab-ad24-be5aa92cba87"
      unitRef="shares">99219</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTozMTNlYzA0NjJlY2I0NzFiODNhMGFjYTJkYTFjZmY2ZC90YWJsZXJhbmdlOjMxM2VjMDQ2MmVjYjQ3MWI4M2EwYWNhMmRhMWNmZjZkXzYtMi0xLTEtNzAwNDI_8de74ef8-abc0-4392-872e-1c541498e2b6"
      unitRef="shares">45994868</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMDkvZnJhZzpiMzQ0ZjM5NTk3N2Y0Y2I5OTM2ZDlmZWJlOTM0ZjMxZC90YWJsZTozMTNlYzA0NjJlY2I0NzFiODNhMGFjYTJkYTFjZmY2ZC90YWJsZXJhbmdlOjMxM2VjMDQ2MmVjYjQ3MWI4M2EwYWNhMmRhMWNmZjZkXzYtNC0xLTEtNzAwNDI_7b8364b8-d300-4f9e-940a-463664f9e966"
      unitRef="shares">43566189</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:VariableInterestEntityDisclosureTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90ZXh0cmVnaW9uOmIwOGRkNGMxMTk5ZTRiZWZiMjFhNzEzYmI4OTQ2OTUwXzE5MzM_ac59b76e-f2e5-4274-8678-5a6b2801bdaa">Variable Interest Entities (VIEs)A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity&#x2019;s economic performance and the obligation to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE.&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows guidance on the consolidation of VIEs that requires companies to utilize a qualitative approach to determine whether it is the primary beneficiary of a VIE. See Note 2 &#x2013; &#x201c;Basis of Presentation and Summary of Significant Accounting Policies - Variable Interest Entities&#x201d; to the accompanying consolidated financial statements for information on how the Company determines VIEs and their treatment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care, and to which the creditors of ApolloMed have no recourse, and liabilities to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the general credit of ApolloMed, as the primary beneficiary of the VIEs. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands). The assets and liabilities of the Company&#x2019;s other consolidated VIEs were not considered significant. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables, net &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loan receivable &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount due from affiliate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land, property, and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loans receivable &#x2013; related parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;802,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in other entities &#x2013; equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in privately held entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,140,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fiduciary accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividends payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion and deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <us-gaap:ScheduleOfVariableInterestEntitiesTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90ZXh0cmVnaW9uOmIwOGRkNGMxMTk5ZTRiZWZiMjFhNzEzYmI4OTQ2OTUwXzE5Mzc_6dd867c6-a750-457b-9d3a-95cdbe4c96ad">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care, and to which the creditors of ApolloMed have no recourse, and liabilities to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the general credit of ApolloMed, as the primary beneficiary of the VIEs. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands). The assets and liabilities of the Company&#x2019;s other consolidated VIEs were not considered significant. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables, net &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loan receivable &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount due from affiliate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land, property, and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loans receivable &#x2013; related parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;802,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in other entities &#x2013; equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in privately held entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,140,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fiduciary accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividends payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion and deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfVariableInterestEntitiesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzQtMS0xLTEtNzAwNDI_c77b9d94-70a4-4ff4-a50a-6778f2f87393"
      unitRef="usd">142862000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzQtMy0xLTEtNzAwNDI_0af2ac04-0f94-4030-b32f-e4a39dad686a"
      unitRef="usd">161762000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzUtMS0xLTEtNzAwNDI_80b71372-493e-4a7d-bd42-295755031c03"
      unitRef="usd">38534000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzUtMy0xLTEtNzAwNDI_08248994-8f9c-47b2-935f-f7839ae16a83"
      unitRef="usd">49066000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzYtMS0xLTEtNzAwNDI_c4faeb99-051c-4659-b10d-805544f69e0e"
      unitRef="usd">23539000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzYtMy0xLTEtNzAwNDI_5e419d3d-be57-4716-b9a1-2d1d8ae7d45a"
      unitRef="usd">7251000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzctMS0xLTEtNzAwNDI_73d4ccca-8bdd-49b8-ae72-b02e7033f6dd"
      unitRef="usd">69948000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzctMy0xLTEtNzAwNDI_891ad2d5-9ded-40c9-9d65-3ae05a9707e3"
      unitRef="usd">62180000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:IncomeTaxesReceivable
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzgtMS0xLTEtNzAwNDI_7c0f83c0-0940-4ba5-a87d-12889c6c5dcc"
      unitRef="usd">0</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzgtMy0xLTEtNzAwNDI_c1d6b031-753f-4732-b59f-4fdbb4ade46b"
      unitRef="usd">1342000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzktMS0xLTEtNzAwNDI_9673b796-7f0c-4c22-91d6-97433b8ece10"
      unitRef="usd">1885000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzktMy0xLTEtNzAwNDI_a47dd354-eeb1-4aa1-8adb-40712632892f"
      unitRef="usd">1833000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzEwLTEtMS0xLTcwMDQy_ecd23213-9193-41f5-b80c-6d26bb6a9c8c"
      unitRef="usd">7649000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzEwLTMtMS0xLTcwMDQy_65b65d63-5433-4b3a-bf8b-6a730fa56f0a"
      unitRef="usd">11734000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:NotesReceivableRelatedPartiesCurrent
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzExLTEtMS0xLTcwMDQy_df86a742-2ea7-4f58-826f-eb7654e346bf"
      unitRef="usd">4000000</us-gaap:NotesReceivableRelatedPartiesCurrent>
    <us-gaap:NotesReceivableRelatedPartiesCurrent
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzExLTMtMS0xLTcwMDQy_18a7cd44-b657-465b-8168-7e24ff801e72"
      unitRef="usd">4000000</us-gaap:NotesReceivableRelatedPartiesCurrent>
    <us-gaap:DueFromAffiliateCurrent
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzEyLTEtMS0xLTcwMDQy_999292d0-3c68-4721-a16c-7b984ad38586"
      unitRef="usd">25150000</us-gaap:DueFromAffiliateCurrent>
    <us-gaap:DueFromAffiliateCurrent
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzEyLTMtMS0xLTcwMDQy_03a61f12-3965-485e-aaab-248f68ff983a"
      unitRef="usd">6598000</us-gaap:DueFromAffiliateCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzEzLTEtMS0xLTcwMDQy_f39e1f32-3d22-4150-840d-542144b989e1"
      unitRef="usd">313567000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzEzLTMtMS0xLTcwMDQy_e473164f-8ccf-490c-9cfa-ac835fb0c12e"
      unitRef="usd">305766000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzE2LTEtMS0xLTcwMDQy_1223fdfc-7365-4d17-9c70-a236e527cdc9"
      unitRef="usd">68598000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzE2LTMtMS0xLTcwMDQy_5fa6d36e-135c-412f-9fda-7a5e5b54bfd5"
      unitRef="usd">49547000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzE3LTEtMS0xLTcwMDQy_ab393bd2-cbe8-46c6-8e37-e05ea430f23b"
      unitRef="usd">61301000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzE3LTMtMS0xLTcwMDQy_500db401-712c-41d0-b259-a37417351e31"
      unitRef="usd">58282000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzE4LTEtMS0xLTcwMDQy_138f5fd0-16e5-4686-a4b8-e51411a124b6"
      unitRef="usd">116226000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzE4LTMtMS0xLTcwMDQy_2f3fa9dd-e36d-4fee-8cfe-60a95543a111"
      unitRef="usd">109656000</us-gaap:Goodwill>
    <us-gaap:NotesReceivableRelatedPartiesNoncurrent
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzE5LTEtMS0xLTcwMDQy_504cff17-2e41-4326-8cb1-229de3b33e42"
      unitRef="usd">69000</us-gaap:NotesReceivableRelatedPartiesNoncurrent>
    <us-gaap:NotesReceivableRelatedPartiesNoncurrent
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzE5LTMtMS0xLTcwMDQy_5f0f892d-a953-419c-baee-a508f11c1997"
      unitRef="usd">89000</us-gaap:NotesReceivableRelatedPartiesNoncurrent>
    <us-gaap:OtherLongTermInvestments
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzIwLTEtMS0xLTcwMDQy_8117dfd9-794a-484a-8943-57246eae33d1"
      unitRef="usd">529569000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzIwLTMtMS0xLTcwMDQy_728037b7-ebb7-479c-9d37-6a1daf93625f"
      unitRef="usd">802821000</us-gaap:OtherLongTermInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzIxLTEtMS0xLTcwMDQy_931bceb6-b45c-431b-a9fb-1e431eee4e42"
      unitRef="usd">44383000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzIxLTMtMS0xLTcwMDQy_d7eea0dd-03b8-4716-80d8-0792a095b822"
      unitRef="usd">41715000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzIyLTEtMS0xLTcwMDQy_0fa64e64-3468-45f3-81cd-3ee1c8187bd6"
      unitRef="usd">405000</us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue>
    <us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzIyLTMtMS0xLTcwMDQy_d541aed8-886d-41a0-a661-cfc9a3e0c431"
      unitRef="usd">405000</us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzI0LTEtMS0xLTcwMDQy_cde0e6bc-39ae-4b1e-82d8-a5f089f78732"
      unitRef="usd">4644000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzI0LTMtMS0xLTcwMDQy_9da71950-ed20-4334-893c-37b3aedf32b7"
      unitRef="usd">4953000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzI1LTEtMS0xLTcwMDQy_680dd050-157d-4120-a575-ca99c02bf3fe"
      unitRef="usd">1849000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzI1LTMtMS0xLTcwMDQy_37b3cd5e-5b37-4939-b20b-e169fdb874c8"
      unitRef="usd">3219000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzI3LTEtMS0xLTcwMDQy_898fd194-3787-464d-9184-d40fed889a7c"
      unitRef="usd">827044000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzI3LTMtMS0xLTcwMDQy_abc16aab-6732-41df-ac19-8666893496b8"
      unitRef="usd">1070687000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzI5LTEtMS0xLTcwMDQy_bd376fbb-4350-4695-8e3b-2870df2cde14"
      unitRef="usd">1140611000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzI5LTMtMS0xLTcwMDQy_99bec4b9-43b1-4445-bb59-4a24d19d5d2f"
      unitRef="usd">1376453000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzMyLTEtMS0xLTcwMDQy_5961d1f6-6424-4647-ab07-301cc7d67a50"
      unitRef="usd">14700000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzMyLTMtMS0xLTcwMDQy_c05e3769-5cd4-46db-b85f-a6d9eb8abba1"
      unitRef="usd">11591000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzMzLTEtMS0xLTcwMDQy_3842edf0-5efc-4729-ace4-45fa5f2ed74d"
      unitRef="usd">6305000</ameh:FiduciaryAccountsPayableCurrent>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzMzLTMtMS0xLTcwMDQy_7143eaac-80ac-49d7-98ac-efa97ca49f68"
      unitRef="usd">10534000</ameh:FiduciaryAccountsPayableCurrent>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzM0LTEtMS0xLTcwMDQy_0f6e480c-efeb-4d98-a7ac-73afc2ebcfe2"
      unitRef="usd">61220000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzM0LTMtMS0xLTcwMDQy_3d06acf7-3db2-453f-8a4e-90a0cfd45e91"
      unitRef="usd">44000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:TaxesPayableCurrent
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzM1LTEtMS0xLTcwMDQy_500b2bb8-c24b-41ee-8610-84ebdc69a183"
      unitRef="usd">481000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzM1LTMtMS0xLTcwMDQy_82b2a4bb-e1eb-4d84-903f-6b920f623a86"
      unitRef="usd">0</us-gaap:TaxesPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzM2LTEtMS0xLTcwMDQy_9ab39196-229d-4c6f-bb9b-6609a2dd170d"
      unitRef="usd">556000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzM2LTMtMS0xLTcwMDQy_370e069a-743a-448e-959f-a980984c33d1"
      unitRef="usd">556000</us-gaap:DividendsPayableCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzM4LTEtMS0xLTcwMDQy_f00d88d9-67a4-449a-a10a-13d66f623d31"
      unitRef="usd">1503000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzM4LTMtMS0xLTcwMDQy_ea84ef20-8e71-4447-815f-a49b553a9beb"
      unitRef="usd">780000</us-gaap:LongTermDebtCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzM5LTEtMS0xLTcwMDQy_6838ebe2-ddcc-431a-8599-a8b604060762"
      unitRef="usd">543000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzM5LTMtMS0xLTcwMDQy_674ce8da-fa0e-4374-8e5a-611e3f71ecc4"
      unitRef="usd">110000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzQwLTEtMS0xLTcwMDQy_e0927c3a-b8e7-4074-937d-a20837db3b12"
      unitRef="usd">1249000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzQwLTMtMS0xLTcwMDQy_0c3bcad7-3621-43f2-bfd6-9176c1c2dcd5"
      unitRef="usd">1250000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzQyLTEtMS0xLTcwMDQy_50cf6f9b-b113-44c2-990a-6d7568c27d12"
      unitRef="usd">86557000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzQyLTMtMS0xLTcwMDQy_64a21b4a-391c-42c7-844b-4194d0462841"
      unitRef="usd">68821000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzQ1LTEtMS0xLTcwMDQy_93aa422d-8771-4f7b-844d-8e0abcb6b74f"
      unitRef="usd">7063000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzQ1LTMtMS0xLTcwMDQy_1bdec697-c2e8-4c05-87f4-19a3b798e71a"
      unitRef="usd">7114000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzQ2LTEtMS0xLTcwMDQy_97931584-cdcf-4f58-b4b8-7a642dbfb120"
      unitRef="usd">3978000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzQ2LTMtMS0xLTcwMDQy_80b293ab-d8d7-4de1-b8c6-b80917496458"
      unitRef="usd">1982000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzQ3LTEtMS0xLTcwMDQy_03c888a6-7641-4751-856a-e57b7f9cec18"
      unitRef="usd">1172000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzQ3LTMtMS0xLTcwMDQy_b946a403-b39c-4df1-b5a7-c504fc1bd4fe"
      unitRef="usd">193000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzQ4LTEtMS0xLTcwMDQy_595f9e7d-f544-4b76-90d2-7dee11204c06"
      unitRef="usd">3651000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzQ4LTMtMS0xLTcwMDQy_c11bbd1c-17d2-4170-a4e5-0e6cbd7c73bf"
      unitRef="usd">3950000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzQ5LTEtMS0xLTcwMDQy_ad916381-f5af-4da8-bdcc-b8cd86a579ca"
      unitRef="usd">8542000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzQ5LTMtMS0xLTcwMDQy_b5828126-6063-4be0-b9e9-aacb4344dca1"
      unitRef="usd">9614000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzUxLTEtMS0xLTcwMDQy_2931d20d-7063-4013-90f8-d5111c99881d"
      unitRef="usd">24406000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzUxLTMtMS0xLTcwMDQy_f25cd19c-be93-4854-9457-27462abe71d6"
      unitRef="usd">22853000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="if57d38b69b26462fbe9ef33ebe278bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzUzLTEtMS0xLTcwMDQy_98cbb925-f550-46d0-bf51-b5569c263cc7"
      unitRef="usd">110963000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i9d3e933fec544494a455857f02039dc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTIvZnJhZzpiMDhkZDRjMTE5OWU0YmVmYjIxYTcxM2JiODk0Njk1MC90YWJsZTo4MTllMDdlZDM0YTg0YTdkYmJhMTYzYjAxNDdlYzQ3Ni90YWJsZXJhbmdlOjgxOWUwN2VkMzRhODRhN2RiYmExNjNiMDE0N2VjNDc2XzUzLTMtMS0xLTcwMDQy_b007d2cc-53e3-4a36-86af-3d8561e55d3f"
      unitRef="usd">91674000</us-gaap:Liabilities>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90ZXh0cmVnaW9uOmYxYTYwYTEyYWVmOTRkOGQ5YjU5ZTczZTVkYzI4NjNkXzEwNjA_c5c52838-f1c5-4c7c-87fa-aee4cfc23352">Leases&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating and finance leases for corporate offices, physicians&#x2019; offices, and certain equipment. These leases have remaining lease terms of four months to eight years, some of which may include options to extend the leases for up to 10 years, and some of which may include options to terminate the leases within one year. As of March&#160;31, 2022 and December&#160;31, 2021, assets recorded under finance leases were $1.5 million and $1.3 million, respectively, and accumulated depreciation associated with finance leases were $0.7 million and $0.6 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial term of 12 months or less are not recorded on the balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of lease expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease cost, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Cash Flow Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Lease Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.09 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.68 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.31 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.42 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancellable leases as of March&#160;31, 2022, is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (excluding the three months ended March&#160;31, 2022)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, the Company does not have additional operating and finance leases that have not yet commenced.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90ZXh0cmVnaW9uOmYxYTYwYTEyYWVmOTRkOGQ5YjU5ZTczZTVkYzI4NjNkXzEwNjE_a5dcb41d-c3a6-4ee8-8255-b89bdbbbd30c">Leases&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating and finance leases for corporate offices, physicians&#x2019; offices, and certain equipment. These leases have remaining lease terms of four months to eight years, some of which may include options to extend the leases for up to 10 years, and some of which may include options to terminate the leases within one year. As of March&#160;31, 2022 and December&#160;31, 2021, assets recorded under finance leases were $1.5 million and $1.3 million, respectively, and accumulated depreciation associated with finance leases were $0.7 million and $0.6 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial term of 12 months or less are not recorded on the balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of lease expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease cost, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Cash Flow Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Lease Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.09 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.68 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.31 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.42 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancellable leases as of March&#160;31, 2022, is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (excluding the three months ended March&#160;31, 2022)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, the Company does not have additional operating and finance leases that have not yet commenced.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeFinanceLeaseRemainingLeaseTerm
      contextRef="ib066bd91431342b3ac8d11e80261834a_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90ZXh0cmVnaW9uOmYxYTYwYTEyYWVmOTRkOGQ5YjU5ZTczZTVkYzI4NjNkXzE3Mw_363539f2-1836-4dbe-9336-09f3380256bf">P4M</us-gaap:LesseeFinanceLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="ib066bd91431342b3ac8d11e80261834a_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90ZXh0cmVnaW9uOmYxYTYwYTEyYWVmOTRkOGQ5YjU5ZTczZTVkYzI4NjNkXzE3Mw_9ddeca18-1326-4caf-93eb-3a5ef26e5feb">P4M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeFinanceLeaseRemainingLeaseTerm
      contextRef="i6a6d0c95500f4e4bae253dfa35567e77_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90ZXh0cmVnaW9uOmYxYTYwYTEyYWVmOTRkOGQ5YjU5ZTczZTVkYzI4NjNkXzE3OQ_8c6ce5b7-a2ec-40ab-8cd5-6778960075d9">P8Y</us-gaap:LesseeFinanceLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i6a6d0c95500f4e4bae253dfa35567e77_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90ZXh0cmVnaW9uOmYxYTYwYTEyYWVmOTRkOGQ5YjU5ZTczZTVkYzI4NjNkXzE3OQ_940d87cf-5733-4442-8334-90a5aee5a482">P8Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90ZXh0cmVnaW9uOmYxYTYwYTEyYWVmOTRkOGQ5YjU5ZTczZTVkYzI4NjNkXzI0OA_5c47f118-6c0d-4289-80ff-dcac70d93716">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeFinanceLeaseRenewalTerm1
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90ZXh0cmVnaW9uOmYxYTYwYTEyYWVmOTRkOGQ5YjU5ZTczZTVkYzI4NjNkXzI0OA_a807de5b-043f-4200-b728-7518b786319c">P10Y</us-gaap:LesseeFinanceLeaseRenewalTerm1>
    <ameh:LesseeFinanceLeaseTerminationPeriodIfApplicable
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90ZXh0cmVnaW9uOmYxYTYwYTEyYWVmOTRkOGQ5YjU5ZTczZTVkYzI4NjNkXzMyNw_089381cc-88be-4740-a1cf-beb1725c3925">P1Y</ameh:LesseeFinanceLeaseTerminationPeriodIfApplicable>
    <ameh:LesseeOperatingLeaseTerminationPeriodIfApplicable
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90ZXh0cmVnaW9uOmYxYTYwYTEyYWVmOTRkOGQ5YjU5ZTczZTVkYzI4NjNkXzMyNw_bc82e02f-9e26-4ff0-b69b-807448d82f54">P1Y</ameh:LesseeOperatingLeaseTerminationPeriodIfApplicable>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90ZXh0cmVnaW9uOmYxYTYwYTEyYWVmOTRkOGQ5YjU5ZTczZTVkYzI4NjNkXzM5MA_18636272-d24a-40d0-9023-27460be8f196"
      unitRef="usd">1500000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90ZXh0cmVnaW9uOmYxYTYwYTEyYWVmOTRkOGQ5YjU5ZTczZTVkYzI4NjNkXzM5Nw_dc2ca131-f6d3-415a-a0eb-bc2109a0322d"
      unitRef="usd">1300000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90ZXh0cmVnaW9uOmYxYTYwYTEyYWVmOTRkOGQ5YjU5ZTczZTVkYzI4NjNkXzQ4MA_8b679dad-02e3-4c5b-acf9-f1ece34b7aa1"
      unitRef="usd">700000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="i9c0728e5be5f486992e2eeff2682d1eb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90ZXh0cmVnaW9uOmYxYTYwYTEyYWVmOTRkOGQ5YjU5ZTczZTVkYzI4NjNkXzQ4Nw_a5ec9589-b25f-497f-aff6-b2969fdfc23f"
      unitRef="usd">600000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90ZXh0cmVnaW9uOmYxYTYwYTEyYWVmOTRkOGQ5YjU5ZTczZTVkYzI4NjNkXzEwNjY_9d3df3b1-32c0-4431-8d4c-43ab7933eeb1">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of lease expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease cost, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Cash Flow Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Lease Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.09 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.68 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.31 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.42 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpkNjY4MmY3NDJhNWM0MDZhOTEyNTVhY2MzZDNlNjI2MS90YWJsZXJhbmdlOmQ2NjgyZjc0MmE1YzQwNmE5MTI1NWFjYzNkM2U2MjYxXzMtMS0xLTEtNzAwNDI_a47f6751-0f87-494f-b366-3cb96d6c61dc"
      unitRef="usd">1574000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpkNjY4MmY3NDJhNWM0MDZhOTEyNTVhY2MzZDNlNjI2MS90YWJsZXJhbmdlOmQ2NjgyZjc0MmE1YzQwNmE5MTI1NWFjYzNkM2U2MjYxXzMtMy0xLTEtNzAwNDI_fc82d33f-7595-4d3f-8bc9-389e9d233002"
      unitRef="usd">1252000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpkNjY4MmY3NDJhNWM0MDZhOTEyNTVhY2MzZDNlNjI2MS90YWJsZXJhbmdlOmQ2NjgyZjc0MmE1YzQwNmE5MTI1NWFjYzNkM2U2MjYxXzYtMS0xLTEtNzAwNDI_def93669-0482-495a-88b9-fa056036decf"
      unitRef="usd">141000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpkNjY4MmY3NDJhNWM0MDZhOTEyNTVhY2MzZDNlNjI2MS90YWJsZXJhbmdlOmQ2NjgyZjc0MmE1YzQwNmE5MTI1NWFjYzNkM2U2MjYxXzYtMy0xLTEtNzAwNDI_33dc376c-74bd-416e-8804-2fd3a3901450"
      unitRef="usd">27000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpkNjY4MmY3NDJhNWM0MDZhOTEyNTVhY2MzZDNlNjI2MS90YWJsZXJhbmdlOmQ2NjgyZjc0MmE1YzQwNmE5MTI1NWFjYzNkM2U2MjYxXzctMS0xLTEtNzAwNDI_a780a0e6-ac84-40ce-a6ab-ea803aca8ae4"
      unitRef="usd">20000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpkNjY4MmY3NDJhNWM0MDZhOTEyNTVhY2MzZDNlNjI2MS90YWJsZXJhbmdlOmQ2NjgyZjc0MmE1YzQwNmE5MTI1NWFjYzNkM2U2MjYxXzctMy0xLTEtNzAwNDI_f7922031-979e-4ab8-ba48-a515593ef33f"
      unitRef="usd">3000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:SubleaseIncome
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpkNjY4MmY3NDJhNWM0MDZhOTEyNTVhY2MzZDNlNjI2MS90YWJsZXJhbmdlOmQ2NjgyZjc0MmE1YzQwNmE5MTI1NWFjYzNkM2U2MjYxXzktMS0xLTEtNzAwNDI_bb803478-0a80-4a00-82c5-83367ed9e75e"
      unitRef="usd">126000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpkNjY4MmY3NDJhNWM0MDZhOTEyNTVhY2MzZDNlNjI2MS90YWJsZXJhbmdlOmQ2NjgyZjc0MmE1YzQwNmE5MTI1NWFjYzNkM2U2MjYxXzktMy0xLTEtNzAwNDI_9ec03d72-f306-40f0-be9f-ca2b7f50418b"
      unitRef="usd">36000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpkNjY4MmY3NDJhNWM0MDZhOTEyNTVhY2MzZDNlNjI2MS90YWJsZXJhbmdlOmQ2NjgyZjc0MmE1YzQwNmE5MTI1NWFjYzNkM2U2MjYxXzExLTEtMS0xLTcwMDQy_f74b4298-710d-4cce-b46e-ee00ed1d8487"
      unitRef="usd">1609000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpkNjY4MmY3NDJhNWM0MDZhOTEyNTVhY2MzZDNlNjI2MS90YWJsZXJhbmdlOmQ2NjgyZjc0MmE1YzQwNmE5MTI1NWFjYzNkM2U2MjYxXzExLTMtMS0xLTcwMDQy_2269a779-ac7d-4c91-aabd-591bb4573a07"
      unitRef="usd">1246000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpjYTFkNDk4MDY5NTU0MGI4YmZmNTQwY2ViMmM5Y2VhNS90YWJsZXJhbmdlOmNhMWQ0OTgwNjk1NTQwYjhiZmY1NDBjZWIyYzljZWE1XzYtMS0xLTEtNzAwNDI_48e40ec0-2c11-4f41-b5f7-1bad6205b603"
      unitRef="usd">1547000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpjYTFkNDk4MDY5NTU0MGI4YmZmNTQwY2ViMmM5Y2VhNS90YWJsZXJhbmdlOmNhMWQ0OTgwNjk1NTQwYjhiZmY1NDBjZWIyYzljZWE1XzYtMy0xLTEtNzAwNDI_66bee838-f99d-4653-a953-38dfb5536b61"
      unitRef="usd">1196000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpjYTFkNDk4MDY5NTU0MGI4YmZmNTQwY2ViMmM5Y2VhNS90YWJsZXJhbmdlOmNhMWQ0OTgwNjk1NTQwYjhiZmY1NDBjZWIyYzljZWE1XzctMS0xLTEtNzAwNDI_945d5443-55fa-4d10-a739-19cef706dfd2"
      unitRef="usd">20000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpjYTFkNDk4MDY5NTU0MGI4YmZmNTQwY2ViMmM5Y2VhNS90YWJsZXJhbmdlOmNhMWQ0OTgwNjk1NTQwYjhiZmY1NDBjZWIyYzljZWE1XzctMy0xLTEtNzAwNDI_cd1a4155-8ad1-4a69-8716-7be68ec8f379"
      unitRef="usd">3000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpjYTFkNDk4MDY5NTU0MGI4YmZmNTQwY2ViMmM5Y2VhNS90YWJsZXJhbmdlOmNhMWQ0OTgwNjk1NTQwYjhiZmY1NDBjZWIyYzljZWE1XzgtMS0xLTEtNzAwNDI_fca8d4b6-b46e-4149-8f9f-e9299ca542aa"
      unitRef="usd">141000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="iea275aac57734edca5abe6bccec9cce1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpjYTFkNDk4MDY5NTU0MGI4YmZmNTQwY2ViMmM5Y2VhNS90YWJsZXJhbmdlOmNhMWQ0OTgwNjk1NTQwYjhiZmY1NDBjZWIyYzljZWE1XzgtMy0xLTEtNzAwNDI_320058f0-e538-43e2-b9a0-e045ab4b4dda"
      unitRef="usd">27000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpjYTFkNDk4MDY5NTU0MGI4YmZmNTQwY2ViMmM5Y2VhNS90YWJsZXJhbmdlOmNhMWQ0OTgwNjk1NTQwYjhiZmY1NDBjZWIyYzljZWE1XzMxLTEtMS0xLTcwMDQy_32ec382f-fed7-40fe-b5bd-c0819437bec2">P6Y1M2D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i5144afd8082f4f17afadb8908f6b4051_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpjYTFkNDk4MDY5NTU0MGI4YmZmNTQwY2ViMmM5Y2VhNS90YWJsZXJhbmdlOmNhMWQ0OTgwNjk1NTQwYjhiZmY1NDBjZWIyYzljZWE1XzMxLTMtMS0xLTcwMDQy_eeebcee6-06c9-4d2d-915b-76d744b4963e">P6Y8M4D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpjYTFkNDk4MDY5NTU0MGI4YmZmNTQwY2ViMmM5Y2VhNS90YWJsZXJhbmdlOmNhMWQ0OTgwNjk1NTQwYjhiZmY1NDBjZWIyYzljZWE1XzMyLTEtMS0xLTcwMDQy_4f000613-cc4a-46f8-abe4-64af71b54b6e">P3Y3M21D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i5144afd8082f4f17afadb8908f6b4051_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpjYTFkNDk4MDY5NTU0MGI4YmZmNTQwY2ViMmM5Y2VhNS90YWJsZXJhbmdlOmNhMWQ0OTgwNjk1NTQwYjhiZmY1NDBjZWIyYzljZWE1XzMyLTMtMS0xLTcwMDQy_38520b0f-da97-411c-88db-4a7b949b9d6e">P3Y5M1D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpjYTFkNDk4MDY5NTU0MGI4YmZmNTQwY2ViMmM5Y2VhNS90YWJsZXJhbmdlOmNhMWQ0OTgwNjk1NTQwYjhiZmY1NDBjZWIyYzljZWE1XzM2LTEtMS0xLTcwMDQy_87bfacf1-466b-4482-8674-88963a39f774"
      unitRef="number">0.0610</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i5144afd8082f4f17afadb8908f6b4051_I20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpjYTFkNDk4MDY5NTU0MGI4YmZmNTQwY2ViMmM5Y2VhNS90YWJsZXJhbmdlOmNhMWQ0OTgwNjk1NTQwYjhiZmY1NDBjZWIyYzljZWE1XzM2LTMtMS0xLTcwMDQy_001ba554-903a-43be-a964-889325e02f71"
      unitRef="number">0.0610</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpjYTFkNDk4MDY5NTU0MGI4YmZmNTQwY2ViMmM5Y2VhNS90YWJsZXJhbmdlOmNhMWQ0OTgwNjk1NTQwYjhiZmY1NDBjZWIyYzljZWE1XzM3LTEtMS0xLTcwMDQy_6f99b201-69fb-4642-95ea-b8ca15b7708d"
      unitRef="number">0.0431</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i5144afd8082f4f17afadb8908f6b4051_I20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTpjYTFkNDk4MDY5NTU0MGI4YmZmNTQwY2ViMmM5Y2VhNS90YWJsZXJhbmdlOmNhMWQ0OTgwNjk1NTQwYjhiZmY1NDBjZWIyYzljZWE1XzM3LTMtMS0xLTcwMDQy_1eecc980-81b2-4f77-9d23-ae3ea80806bd"
      unitRef="number">0.0300</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90ZXh0cmVnaW9uOmYxYTYwYTEyYWVmOTRkOGQ5YjU5ZTczZTVkYzI4NjNkXzEwNTY_87bc6776-c8ba-49e1-b6ba-5011e09e0154">&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancellable leases as of March&#160;31, 2022, is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (excluding the three months ended March&#160;31, 2022)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i06b546f053dc4360a3ae3232f6961200_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90ZXh0cmVnaW9uOmYxYTYwYTEyYWVmOTRkOGQ5YjU5ZTczZTVkYzI4NjNkXzEwNTc_5b4833c2-8868-46ae-8725-5f854e35cf3d">&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancellable leases as of March&#160;31, 2022, is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (excluding the three months ended March&#160;31, 2022)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzEtMS0xLTEtNzAwNDI_09b02e7d-3f4b-4885-8918-8b9786bb4ec0"
      unitRef="usd">2645000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzEtMy0xLTEtNzAwNDI_df6d6bcb-29cc-4e75-b989-739fe42190eb"
      unitRef="usd">470000</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzItMS0xLTEtNzAwNDI_6ee04f5a-e546-4944-b7d8-9e0d458697c0"
      unitRef="usd">3303000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzItMy0xLTEtNzAwNDI_e74f20fb-a9d1-42e2-8516-278514b31bd2"
      unitRef="usd">539000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzMtMS0xLTEtNzAwNDI_eb743d73-2240-4620-af48-29d9591a02a7"
      unitRef="usd">2940000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzMtMy0xLTEtNzAwNDI_03383ce7-2b37-4e37-8f29-650f1ba92a49"
      unitRef="usd">473000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzQtMS0xLTEtNzAwNDI_9b805fb0-0d39-477d-913b-ae2197a6fd4d"
      unitRef="usd">2648000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzQtMy0xLTEtNzAwNDI_8ee129ec-f1c5-458e-adcd-c29c80d2003a"
      unitRef="usd">310000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzUtMS0xLTEtNzAwNDI_ef67f28e-5f63-4fb9-b622-4307e562b6f7"
      unitRef="usd">2070000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzUtMy0xLTEtNzAwNDI_d84f4247-676e-4593-ab91-c01a39c0f8ad"
      unitRef="usd">55000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <ameh:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzYtMS0xLTEtNzAwNDI_3eb8cfa1-a177-4417-a43d-9e2ad709704c"
      unitRef="usd">4753000</ameh:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <ameh:FinanceLeaseLiabilityToBePaidAfterYearFour
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzYtMy0xLTEtNzAwNDI_956d43cd-b9ea-4ddb-aa50-860a75b049ab"
      unitRef="usd">0</ameh:FinanceLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzgtMS0xLTEtNzAwNDI_7d3529e0-b3b7-49d3-a0fe-e85610a57e04"
      unitRef="usd">18359000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzgtMy0xLTEtNzAwNDI_3e541a00-d591-44f6-8a9f-b99f727b4641"
      unitRef="usd">1847000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzktMS0xLTEtNzAwNDI_0e94958c-b454-4371-aeee-d919906f239c"
      unitRef="usd">3176000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzktMy0xLTEtNzAwNDI_9ed05ead-6d5c-4c1c-a977-e360c0b60f90"
      unitRef="usd">132000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzEwLTEtMS0xLTcwMDQy_5a307e5b-03a1-4e1d-af05-2b59af9605a7"
      unitRef="usd">15183000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzEwLTMtMS0xLTcwMDQy_f92f7ff7-742f-4819-b11f-ee3dbae14a28"
      unitRef="usd">1715000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzExLTEtMS0xLTcwMDQy_035900d1-d7bd-4a5b-b0bc-85cdd962b6dc"
      unitRef="usd">2625000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzExLTMtMS0xLTcwMDQy_22dff47b-dffb-4a2a-a8dc-05de31120df7"
      unitRef="usd">543000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzEyLTEtMS0xLTcwMDQy_439550b8-0770-4cf9-a376-06a70dd5887f"
      unitRef="usd">12558000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="icdb7399a6abd460491239b97b7522507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8xMTUvZnJhZzpmMWE2MGExMmFlZjk0ZDhkOWI1OWU3M2U1ZGMyODYzZC90YWJsZTo4MmNhM2EzMmIzMmQ0NDgyYjM4YzVlMjFlMTVkY2VhYS90YWJsZXJhbmdlOjgyY2EzYTMyYjMyZDQ0ODJiMzhjNWUyMWUxNWRjZWFhXzEyLTMtMS0xLTcwMDQy_0a98e08c-5e44-4a3e-96c9-395f15b54ac4"
      unitRef="usd">1172000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNTYtMS0xLTEtNzAwNDI_8a508be7-60bb-4369-8ecb-378f3b1c0cb9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNTYtMS0xLTEtNzAwNDI_8a508be7-60bb-4369-8ecb-378f3b1c0cb9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNTYtMy0xLTEtNzAwNDI_c2c1852f-3a60-4cec-a086-28febf1444cc"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNTYtMy0xLTEtNzAwNDI_c2c1852f-3a60-4cec-a086-28febf1444cc"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMzAtMy0xLTEtNzAwNDI_9aa87413-0e81-44b1-a6c9-46b296611732"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMzAtMy0xLTEtNzAwNDI_9aa87413-0e81-44b1-a6c9-46b296611732"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMzAtMS0xLTEtNzAwNDI_27af7b16-5ca8-4fb0-85e6-327746e1b9d3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMzAtMS0xLTEtNzAwNDI_27af7b16-5ca8-4fb0-85e6-327746e1b9d3"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RleHRyZWdpb246NGYzMDBhN2I4OGE3NDUyODk0MGQ5YmRiZTMwYTlkN2RfMTA2MQ_1ec7d3a3-c3b2-4fba-9229-2cf9b363a837" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RleHRyZWdpb246NGYzMDBhN2I4OGE3NDUyODk0MGQ5YmRiZTMwYTlkN2RfMTA2MQ_1ec7d3a3-c3b2-4fba-9229-2cf9b363a837" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Company&#x2019;s consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#x2019;s consolidated VIEs totaling $585.9&#160;million and $567.0&#160;million as of March&#160;31, 2022 and December&#160;31, 2021, respectively, and total liabilities of the Company&#x2019;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $111.0&#160;million and $91.7&#160;million as of March&#160;31, 2022 and December&#160;31, 2021, respectively. The VIE balances do not include $529.6&#160;million of investment in affiliates and $25.2&#160;million of amounts due from affiliates as of March&#160;31, 2022 and $802.8&#160;million of investment in affiliates and $6.6&#160;million of amounts due to affiliates as of December&#160;31, 2021 as these are eliminated upon consolidation and not presented within the consolidated balance sheets. See Note 16 &#x2013; Variable Interest Entities (VIEs) for further detail.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNTYtMS0xLTEtNzAwNDI_8a508be7-60bb-4369-8ecb-378f3b1c0cb9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RleHRyZWdpb246NGYzMDBhN2I4OGE3NDUyODk0MGQ5YmRiZTMwYTlkN2RfMTA2MQ_1ec7d3a3-c3b2-4fba-9229-2cf9b363a837"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfNTYtMy0xLTEtNzAwNDI_c2c1852f-3a60-4cec-a086-28febf1444cc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RleHRyZWdpb246NGYzMDBhN2I4OGE3NDUyODk0MGQ5YmRiZTMwYTlkN2RfMTA2MQ_1ec7d3a3-c3b2-4fba-9229-2cf9b363a837"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMzAtMy0xLTEtNzAwNDI_9aa87413-0e81-44b1-a6c9-46b296611732"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RleHRyZWdpb246NGYzMDBhN2I4OGE3NDUyODk0MGQ5YmRiZTMwYTlkN2RfMTA2MQ_1ec7d3a3-c3b2-4fba-9229-2cf9b363a837"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RhYmxlOmE3MzI0YjE5YTAwOTQwN2Y4MTg0NDJlMGM4ZjZiYThlL3RhYmxlcmFuZ2U6YTczMjRiMTlhMDA5NDA3ZjgxODQ0MmUwYzhmNmJhOGVfMzAtMS0xLTEtNzAwNDI_27af7b16-5ca8-4fb0-85e6-327746e1b9d3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjNjYmUwMzNmMjYxYTRmMWVhNmEwYzkzOWM2ODQ3NTMwL3NlYzozY2JlMDMzZjI2MWE0ZjFlYTZhMGM5MzljNjg0NzUzMF8yMi9mcmFnOjRmMzAwYTdiODhhNzQ1Mjg5NDBkOWJkYmUzMGE5ZDdkL3RleHRyZWdpb246NGYzMDBhN2I4OGE3NDUyODk0MGQ5YmRiZTMwYTlkN2RfMTA2MQ_1ec7d3a3-c3b2-4fba-9229-2cf9b363a837"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>87
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M9KR7//NVY&7.1--N/<5OCC#HSL&4FSZ5CT)<;E0O4W3BS3S/5]OEZ(F6:X:
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M?'M>J^NRR.#N*K-@"C((W< 28BNF%!3&A:DX7<NG+ "XNP*4-E_1 .4^CG5
M1\6J',JB@+MW]QJ'%_=!N8-*=C>V02<(5DF4U0!W[^AM)$YKA7!]2\?9YY#
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M+W=O<FMS:&5E=',O<VAE970T+GAM;*59;5/;.!#^*YI<YZ:=*<22_-H+F8$
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M:0J_2 ')N9#L5_W 1D^S5+!/#_(B[/7H,<V@[X4PM-,3=9E$SDS^IH7B)VN
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M2[?@-.>TH"4WM'3RN)8^T._?8Z&.MIL<B/FTF51H,ZE0?0]B&TRZ6+)"9#9
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MR1;>]AFP0B@/%97489'&L7CQ?/%ODB6[Y6UK1L?4^TQRN&*CT,,V,LO'S]L
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MK*B8- ;Z]Y40W=,7<X/="XUG_P=02P,$%     @ RHFJ5"WE6&GB%P  TD<
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M&;-OH!DC;,2"//V*&<_5)0$CM,?"FBA]>J3NX+H<%0TDK@1]<H13D4@,'I2
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MUOPCN "*TP*\7[903?\+;1#_C,_+_P%02P,$%     @ RHFJ5#@F;474)P
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M8^&>X)G?VY)5@@/P$6@'@&M5T  @*47[P2EZ1PO!Y99*NF1\SD3X66VJNDD
M(HN9?W6GN%59+:?7PS) !0M=J #7U^^F-)&:U2TR].2,#WN47# ,U4:7N'E
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MS1<"P:S0#./W<A!"NPX7M#:@S)K;X)UHLGG1IBP4S;L AZ6J&=DK4.-533L
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M[MYF5Z0]P*M\L1.(X?=1%,9N;OQ\=$B;XP_>)9,S^N#XA/[PI^_M,$ %CQY
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M6FVSPMU>ZJE#-Q&V_X3C3!UM]!U=/\[?$W*EUXVG@R"<(&UP/*2<SU/<N2,
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MXI)N5/:R!'X%VYF+5%3&:KM<PYTV.;4BW72&]'[M$'321F)V=7;Y 3P5O[6
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M20OP?F&,:S[0 >U/>E[_#U!+ P04    " #*B:I4#?0?+T$$  "\"0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6R]5N]OVS80_5<.7C=L0.8?LM,&
MC6/ <5.D0)T::;M^&/:!EDX6$8I422J.__L]4K+L)DV^;4 0B^3=N[O'=R2G
M6V/O7,'LZ:%4VEWT"N^KMX.!2PLNA>N;BC56<F-+X3&TFX&K+(LL.I5JD R'
MKP>ED+HWF\:YE9U-3>V5U+RRY.JR%'9WR<IL+WJCWG[B5FX*'R8&LVDE-OR9
M_==J93$:="B9+%D[:319SB]Z\]';RTFPCP9_2=ZZHV\*E:R-N0N##]E%;Q@2
M8L6I#P@"/_>\8*4"$-+XWF+VNI#!\?A[C_X^UHY:UL+QPJAO,O/%1>^L1QGG
MHE;^UFRON:WG-."E1KGXG[:-[>FD1VGMO"E;9V102MW\BH>6AR.'L^$S#DGK
MD,2\FT QRW?"B]G4FBW98 VT\!%+C=Y(3NJP*9^]Q:J$GY]]-$+3+:<L[\5:
M,0F=T>.YWWXY2T:C<TPIX3FCE;!>LIL./!((,(.T#7;9!$N>"3:FI=&^<'2E
M,\Y^]!\@\2[[9)_]9?(BX%+8/HU')Y0,D^0%O'''QCCBC9_!.Q3MZ._YVGD+
MU?SS O"D YY$X,G_0_-_%JRQLP>[E4AE+M/7]$'3I]2;-=M ]O"$;I;+UA#N
M@BIK2NF<L3O2QC/E&!^\O?$":6[HU;!_"ATK%5O2P=&R0P>1R<D73$X@:/N]
M,&4E]"ZF^N;<D=2>8>WQ0<MO-WWDU$Z(-+4ULA<^ **@ ''Z*U7(5FA=EY$#
MZ:@2NUA6&72H=@AC3;TI8CBT>&VEWU'6 KQ#=64HN!'8N/^$G3V+MF6Q HL[
MFE\O%T_YFJ\6Q#'A+%1B?L+95OJB\?X])!30D^%YG+C!>AR/SO\@G,716^I4
M5D*1*$VM(X6O)OUA1V^$$T_KFL-3Q9;ITQ?$24%&$'H-J([CAD4=F>DR"!2.
M^V^.F6T@#A9;;.H/9=8N['LJ7$'H)YEZT+[G"\L!_^HA535.!)H[Q]YA#ANY
M!01M6+.-IE%/42%L@U"#1JS03L33W;7<K?Z<+Z_[P GK.!W2HCL>3J)W%.(1
M=8\YLQQN,KC7WGF(!KGWZ9-^5I-K(VQ&9=2)"_1 (":'YL%/H!J\- RUCM"\
M8_QE$>TH"JE'VJIQ1MHFYM7B(Q2;L:+U'B!XA+6HN"X;L98J[#1XA=*#M>5[
M7&2MM;2'_<4Z[E9/A<0= P%^KX'$5NU.*)=:@!ZPLU\,.RU46 M]A,N_RR&4
M!+Z,NF>=(IQT=\WV@0J9(0#ZGS.T:@XEYD*JVO(^/9.FM74GQ[SNZ7'-9K$M
MW9[YT"$NQD?Z$J*.(^*'"A<\^$RA..E!HW/QGL[VZL662@^64V@';YJL/IPP
M ;/_L^-]<'2CEFPW\=W@T"GHL^9R[6:[I\F\N9$/YLV[!BK<!$4ISN$Z1/?T
M0%-\*S0#;ZIX/Z^-QVT?/PL\K]@& ZSG!EFV@Q"@>[#-_@502P,$%     @
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M-"?X5'TTD1/2%>6CU605%&?7=UB)DC?PF^![T0@KT"PC2\#.')4#R&T/DKX
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M%7-XKJNCJRG3HC[Z6>KZY"1M/W!&[3BN-_V4^NK>SWIJ$VH$ PT>*#2^*?(
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M=)I2+EM$<CK-Y4V6*W,7+JSXRX6T+ENKSDK+12A=P<E=M]"NVP+UL2.1$+V
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MSV20X\)M+3"6F*7L:'J\R/8XCLTTGA;/6/^[Z4;1*PTKJ>N0?S^88K^G':'
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M5C5NN49!/P>9@,Z72MG]AA7TGY'._@)02P,$%     @ RHFJ5'7S WG:!P
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M2\FT)_(,H]P[_ !R_H[86,P<TM$']QN''VZXD2YE!QV' '_P9R2M/8QPN"X
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M>#[+)KX## ]6M>Y;!UZ7K*K=<",XCEH2P/I*X2+>/Y"!W<>OJW\#4$L#!!0
M   ( ,J)JE3("G>RH@4  +<6   9    >&PO=V]R:W-H965T<R]S:&5E=#(S
M+GAM;.U86V_;-A3^*P=>.Z2 :UN293MI$B!)%ZQ BA9)MSX,>Z E.B(JB1I)
MU?%^_;Y#2;XDJ9'NV2^ZD#S?^<Z5!$^7VGRSF92.'HJ\M&>]S+GJ9#BT228+
M80>ZDB5F%MH4PN'7W ]M9:1(O5"1#\/1:#(LA"I[YZ=^[+,Y/]6URU4I/QNR
M=5$(L[J4N5Z>]8)>-W"K[C/' \/STTK<RSOI_J@^&_P-URBI*F1IE2[)R,59
M[R(XN8QYO5_PIY)+N_5-;,E<ZV_\\R$]ZXV8D,QEXAA!X/5=7LD\9R#0^*?%
M[*U5LN#V=X=^[6V'+7-AY97.OZK496>]68]2N1!U[F[U\G?9VN,))CJW_DG+
M9FV Q4EMG2Y:83 H5-F\Q4/KARV!V>@' F$K$'K>C2+/\KUPXOS4Z"497@TT
M_O"F>FF04R4'Y<X9S"K(N?,;"9/LZ= !BT>&22MWV<B%/Y"+Z*,N76;IMS*5
MZ:[\$!S61,*.R&6X%_"C, .*@CZ%HS#<@Q>M#8L\7K37,/KK8FZ=0>S_WH,Y
M7F../>;XIYWU$CGZDDFZTD4ERA5EPA(JRPBGRGL294H+58HRD90WBU%OE&A3
M:2R1I!<+E4C;IRI;694H4=I??YF%P?3=9HI!$FD<*I'D/[6J4#MNP%KM&C43
MWR5JB:N5]?I1<M(48+. SMI0T<35:?(932LI#-"M+I@&+3.59,C %:DRR>L4
M@Q775R/QX"18N&S'C+KBN6#403'1%\$Q,7@%]F\A+I7+8*$NI<<;T(7GCOP!
M4)= 7L=[F<AB+DTWBJ>P5CH+#\"UR%NJD;WFL>N7TDAZ%0QB%%R>^]X!- Q$
MW4 ?"+:2OJ/DJ\8BD21U4>=@FZ(MH$,B2DWCL5;S-\:9^_/:1H/IKK;18/*\
M-AB<6]WW+NFRR2#2\ (WVWD+VV4".G5.TCKO1;@T4R:E2ABG.&<:]PLP 'U=
METR20[:3G0WB@&XV 0!'!$PY!7".$D<@"+O< 4 NK?6XI78;=\,XICT7N?>
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MOQ("&O@3.-)A="EC KL&#3=>V)X!687R#DD4B!<^-'#PW,]54V].*U)-Z>P
M-=>;$@F:,87:9@<$U>&AV"X!#6;I;)JFN"]!H-[EU1"_+D$-*%L1MZM5BTH
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M*E[NY(CBW'O4VW8H\)%)K EGT1XJ1,F#@4L<%G'> +5NF-L .O-EU[3+67R
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M:_JN16O:3/&S1#]FJ-G:?]@E):IIO@$K9D/[':F'8H11TI3U :P<V\SSYS%
M_OSH3ESEW2VAB_Y 80OT?FA3_^A8'E/1>:M/TQ_!/0V:R1;X7+7/)-I#CBG
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M9N:2G==2S**?A!4F*['Z$*1Y.:JH**YZ%IT>9<I7T8G,[8+&4#@@,;\<^_[
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MZ#BY3'@_E?TG[K!%3'?A)YW/0*XYEZ$19LU$CRGS/G;KKVE@WJ"YZ;B"CO>
M;C 64Q(/?L\0.HCIRC/Z";" E-I'KR=C>9&5+F\^[_CRO''[$5"7RX 4[,)M
M>-=+-X.EJ7GHK5-;;A)7,H,QK0B-@08?L_ =Q3AF05N1\@X5#)+5:M5SN=TD
MHV2HE9I.I\?QX]7B44W(HZ*92'GM898&O-5-*QT4-I)/G?BFN*!P<B9BVA77
M_++0H<07R:!NAGXWC.TQ?CHZ#W.[?H^Q(MT-YUK3.^<7?D<7[!PO56$<U%:+
M/ ?^@2(7=AJC-X)2@XMY:>VR2FTOA3*PSJ9K%A\SIW:TEA1*ZM@H,20MVM+N
M-33QU,HE>-VEIC+1O%OJ\,K9WRR7"/GQM45U9^8I0!4O6H@NZ3/,^7?!%I(%
MLYOJ2W)BBR'50"@\-"K#X%*9Q!GJ[@ TSIAP12ET5!<8!S#X!#.::,?\B4G<
MVW=4/T]W6)Q9-0/NM<%2UG<-D,38FS@Y)1%FU55%R95VV.UVG*58#&%D-#&@
M!X)PY;QG=!;WV\"WI 3+/="[GGR8D8RSE!"-#C'/BRLV>JMYT;W#5@C28#$F
MY+AKY9.&V!+BF#BH'&$6@[2_S@T,ZD=0\CS6#;6;"?89G)Z:^3;03M:LM2[S
MA^4!AD2:.&IALH52C'/^G!-93EPSU_XV[%5^J0<3< "/ 8D\AL6[R^5BT2.K
M>=PW>98NU$^?;&V.=TH@_$,=SSS?8BH)4LR3T.9AV_QX::!/0;!U"#O;#"5Y
M U/EU=5#T/?-3C+FPH? .:+<=)<UD>D%3;(<YP*>366/Z)F'''#Y5NZ$E(85
M%O]U+2(\C>E7DJ(_+F9/BN23[$0J;*K%\D?W^N90BP+?B7#N3+MD:-.'3[$'
M<6%C@;XX["2H4%)5)2?VR+VWFLPQ;@(R472C&9JB([D$-(E=VBI*U_A/TOZ]
MM,0-O.>K(&BB!LA\;]>S=#.U P=:<B1*2]*6PZ=*.'NZFE/\*8W5W1(LWC;6
M/*V=D<1BHBX7FR3E7#PRJK%+6N5$JSPV3%+M.W:FD2[&.M!35OV%8.3:E7E$
M2N_A-*XTSE&A7RVMFC"P(PKV81?+&X!9^\XEUN6I5K]0R^9>&OV1H;VZU1</
M"$5M%[+B5%Q_"%9-H54,:2G:L7&Z?0?HC X?K,ZW>_3,I\Z Q^@<UM=WG5R>
M->JI+0Y#DG7SQ)5WD?SAZ#SM3J;U&2+=%2DQFWJNXTP2X/3MQR1YR4%$U=*"
M'!W<O_%(A'7)#41Y/;GV."8XI/708X[U8$(*T.NZ;+><DD(N#==4PXJ7Q:]&
M_8]\FB-WL%S$FS)0.Z*D&NZYL->+7WJ74."J/]6TB>=/,X?(X3%>W80/$YIB
M!;C+WYK7]L;7P'J91[(KMK%GSUERGM>Q;4+EW*$-^[N/K*.<5ID/U.3/";N?
MR7VFQ]_=P9-L'^-1._^0*9['K+!I@)59% 'NO)[)&F**]KR-@.(E<3,<MP],
M_[93,VF]@26PE X3.^@Z?*:7/#?K2#=:&UI1>LOC#(CKR>1)ZZ:P*[NF")U5
M-4K=+=@-Y!0GS\6:NO68PHU7F/ HL:S!I%57;D$ZY75HAH[* C;<N)]0SLXI
MM 6I]XU%"K 8AWJ8D6/%5#KRF8M#3Z9:1(_%<N]:/CRH!]KM1--&*.K0H<14
MG1.]0I3@37<-,L 6WR>GY5BI8X<XB"&J*U])>*$H)T&PO&AV))>I_A(D6-EP
M#!C!TY"X5VKD8F?855*>(E)'M>UZ"^5<A@3=^_//X"N;2'WP?B]N#VP71+NA
M5<$Q>#D3A_2(T638465828YXJ#MG(C'C1NVETS[MR--;Y9O84==IZ76X9_<!
M7A91XG5'G$<@!J&JZ,U,[S<'OK\?8';_S[(WDJD"<*)^XU%/2:;:;U@RN4#3
M08U'#&%A[EATSO+/$89DGDE3+$E@QZ&TCCC=/]5T\1V*(R"1\"%AMHPXI. Z
MOCM*BQ&CO4D;A![4%J9)<%6H-_VMV=$8A:#B^?7(.RH5K7N^@3@HYS85U3^;
M\,&U5HC58=/T8B6(B&Q]L&^5:SGTU H@G5I5YVEF/0++%#2K67F_.!=^85SW
M84@L"IM+#WGJ9*BY[I)]>.1D/14S \72'1F?)R047;<%HH!9)!ZPB%0_CU=?
M6NI'HIC;!L_U!(DF3#?*PK++(\C88\JB?N%YET#7C*>S1G_)> N7UD6Y#?$^
M%S6 %NP303MAGE)3,XM]7/'RY['3,[D45!-^L.>1HN]:UT2+CWY[[FE!BF<L
M7CQ^S*C77"^I_Y8_((#.KF;D#/=MT27A75H_6/2:0I]B,ELCR<3<2BNRHL6Z
M<%#C<K%0G,2!M:>OE"_[OO-C*EY8.,2 &O<*[L*H&3X3!66*L<H3;?.'>_VF
M^^WOE' 7[F')='IADNN8Y<@VP=2DXD_9"[$6OGN4:)U:MBW4K>;;=&C?,#G\
MD;'0"<?L>A^ZTQ:KF#HR:9+*M69WW%V#N[/2*;+>5^XR*.DO77L\HR:6G-V<
M"I,2>8MY3=H"1:N&8K]I=2#K): _:6A)4@-#27>Z3*IZFG&',S0DHM^.6/.!
M.,BAU$Q7/"\PN2O94'R"HL$5?@E<(SCUJE*5_I0B,38'M0*R2[J:NAMYQ!BU
M*(MC\:PK65/I1.C514)M>#]@.&W6:Z05O2@H IOEL>&"SR[&"&'2<>N(&)B<
MNYC.65/CSA+@#K&%9RP1&&_IN!$[]9.G*^5)LNHZR7R6?G\:LN-H*IY)=O:$
M:GU*%24N>6;!/EYT%:&,IHJ9A:@8I[$PBI)IJ=4"[2;;-CJ,7!H(4'&;$2->
M?PW.TV\T[T5H^>18V^>+V/;YXH%KZX@S_9Q_F+^PYR->S]X*3^!\%#[]?&D$
M_:ST/FCY$B=]84NTFLU8>$[4%;Z\$CZJ7>FNG:;KC[3 HZSB#5F8\R4XBC/&
MB[\PXSMV>?.7*Q%?HMF W*F'H_I*U7IQI<I<)*G9F(XW1^B%LDDVHT>%3<=!
MKC&(:3.% U>Y0M/ZIN!GB%J?%F>MZR04;C4_$9L2V4[N/IF;R:/0KIO"_JW!
M9R<!LL!*0O6'[1G&C2IFHHN+=TPN_ K;<8-[N:YGS&WI%H#H8;$[5:5P44@G
MVPTM]BGKDA7U4U\N/4L--95KC7?HUMWM';VY&2U6^LV(L@1/ZZ676;[4#DK<
M7W]T&8.RY!D<@U28G1#OM?#59HBWY*)BN?YA;MN0WVBS3.=%7RIT8U6,^Q0D
MN,*;BSOL@T0.:&"DIYR5=8I]0$_Q1!#RDJK!O.=>:)3)BQZ;%-MH6I%W=P03
M?T].$#H? 4PL^HS<O#7 QY&'1SCS?XQQN;F5T=5NXJCPH(K3K8[]9),C*0%4
M4JHLH4W,LC2OZ]&0'N/3+R*??G&4T5)?B]/79'I>:0EX>:!'_Q\;*J$:C.5Q
MIXV<K]0\9;-WY5]0#S+YHK:[JME3(V;,^W(?_9V8TEN&/&J]1=GE<@7RP<@\
M.;?1FS163.97MD+Y5XY%I]?;<[F6Y9'@A1T2I=0P.^ZY]*%++O^#_Z^#9-.R
M0WFOC2G>$HN7^#S^F[K$*-M?TA:9&?:=]D[D&TK1S8-'^#%XTN0*&6Z:F36G
M;@(['5K@9AT6<&#*ZE.]J#5JK2?,]*M\%_O6X"F"]>@^I#7,\JWBL%L!^QHJ
MZZF?W)712/^A#75(+>:O($;(7V-OC].;%9Q;1-;.#'KN7:R=&E7T44OHO/(]
MCKR5%QD0S+2('^\:I Z.@MB7Y&?C.\2T.^+IFJYU9VL05Y4,J+=Z#+&'!R70
ME,6N*5VQBJ<TNW.MO[7:D[%QCV./IF,Z8<=&!/Y0OVS,TQ0[#=MY1L4^OCH:
M7]>>[<O #/-XX=_D/=37!XNK&NK2^U'&PU)N/D8ED+*S]^ARHT8:0WOGKO5,
M<2[X$LH8A>>(O(XRV4\BD_WD*&<$G@BF,.[4-V5%:NH;O>#V&@ CQCG+</_\
ML!D_9!?J8J"8?=+2J'60_$#"OGIV5<42V:Q5"B@ 0WOP"HF$#TGBPWU 'D'^
M62:B>/%!9&+)B[CUZ,PF"E>G>+ T.KOZYLQ6_<#B(D/X4\!(&2%1D:GJ!8+
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MMY7Y(K<_XRX>1S"7E7:_L.W.QM$ \E8;6>^,B4$MFN[+[W=Y.##(@A<,V,Z
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MENK:IFYBY,:U*DMIJ/%QPY(Z353V .VOI#2/$^N@[UWG_P!02P,$%     @
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M;PLW+?$QQY05P.\K*<UN80WTS\/S_P!02P,$%     @ RHFJ5%;DNG[G @
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M!9!0=5C U1/57J.&XWO[ID]F@2%.:QGD._SS'C]^ S^!&]F82L-54V#QKWU
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MPY4$C9MY<)U,E[G3]PI_<=R;$QE<)FNEGMWF8SD/8A<0"BRL0V"TO. *A7!
M%,8_!\R@<^D,3^4C^JW/G7)9,X,K)?[FI:WFP3B $C>L$?9![3_@(1\?8*&$
M\5_8M[HY*1>-L:H^&%,$-9?MREX/=3@Q&,=G#-*#0>KC;AWY*&^898N95GO0
M3IO0G.!3]=84')>N*8]6TU].=G:QTEAR"[>LX(+;MQ"63#[#G6+2A,!D"7=D
M8$!MX*#9>V)K@:8_BRRY=R!1<7"U;%VE9UQE\$E)6QEX+TLL?[2/*.PN]O08
M^S*]"/B)Z2O(DA#2.$TOX&5=+3*/EYW!N\&UA1MN"J%,HQ&^7*^-U<2;KQ?
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M(=?PQ/8GU7>P?F)DZ[K&6AKJ0>ZSHJ:/RAK0_D9*LY]8@O%OQ/(K4$L#!!0
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MPZGX%0LY?KE$+*0X*P*/[,!5SD0#QL IF$<1EK=A#.[2<E7)1C\L$8<X9N_
MMP"GX..!Y RF$3L?<V&.5#H.JZZORJZ=CJ[G^?X,N-8)<"Q[]MMF"7[X]EV+
MED4?+;;4XMC=6I9Z+3_G<1\MUWHM&Y2]&A$[0(K:O/.^IT7V;#9K$;_1BZ\@
MK0?D5*9D,4Q#T1"'+?IN]?J6*.SCH+O^6JSGXF,1N'7T.G7T.H4^MT?T?FA$
M[U_WXA/<<92POS7=N'4W;M&-U]'-77I$C O$<R9CGO #HD!<B?6!&/C^FZEC
MVS\!]#G'_!$DB!](U#9C92=!T8G<A(Z7GN=.W?/QL3D/+:WLB>W7K9Z-P*M'
MX&E', ]#Z9<UQ7)+ PL1DV"%(AR*U7U#29YIO.37??A#3D90=Q,8)H,CL:*X
MV">%PREJ<_52KV)JG5G6=QI;)K4M$ZVB!1&[?H1HB49.8<IVB';8-'DUL2(C
ML=KG=5H;,-4:L(:/95AR\N0/L*T<WV;#])4-=J<-L]J&F3ZV,A+'Y'23I^ >
M;AE8P52D2=*L$W!_O]"XV;;4+F4-&5MV8SNT_W=T+0PZO)DAO&S%-]MYLP!;
M5+J>H:-S=FT%/UM/O^N2:_C),UE.PX/(+P'9QGA?6'8",D0QB608/OW<:J&^
M)Q<\(DB9SG,*>+:>>+VL3DD:YL*=*6_=8;W7_G0Z_:DP:?M:RY:K&]T(%0?M
M8- UH2!GZRGW=@%P8^BI1P H,MIZ-+[1IFV_1N;4[PP"Q4S; ,WUZ7QU6^_!
M"T(S4JWR?\!\M\,QAAQ%X%H:_*A+E11#G4$9ZBB&.GK^S1.2IUR6$S&!:5L:
M72EH.M7W_$Y6.8U\4,_+CX@FLF.*0H2/<!NW1>&U08EM&</04?1T]$S;\&(>
MQ=PB:5A*RD_I&9.5>L6V*8EQ%"L=/2OK3:^P4BP6L58 .J)R$JNC@U83]7J%
MB1-?:Z*"IJ.'YGR]^-J%H4#J# I21X'4T>.MQ\)XG22ZEM6],!0-'3T-?\F3
MK>"?Z+HL2&M*1V#[* (Q+IR:02I@^ _H+%JOJV[\9@;I6\5?AXD*B8X)B;I<
MT56<<P?EG*LXY^HY]QY_$3[C%7*@V&HB<0U3L=K%8BH<FM2Y<'$?1HDHOQF7
MI#\BP! ]8E&8 ;BGJ&C5=DY@L,(UT\I5_'3UZ"N7V6J]/@'SU8VH%XG8U^6&
M>5+8_^?]/9@SACB8R_28%0=$NHX;%;8[Z*0IUKF&2K@P'RKSB]0E%+X7$]58
M'YK\_\[0A2BI#&AV%??</MS[('RPVGPHZJD3\!'N3X,Z=5!Y3EG)5XWD=,F&
M4WU#G9$*H.Z@ '450%T#0/__Y-T:NO"-<Z>8Z^J96^U9JYL3X?M0IU(QTIT-
MZ6E/0=2SM+;_#N.\Z=%&Z2D3!-BU_,M=HE+^HA+M.,)2O/4,>67IS^*XH8[J
M6Q)'.-TSDX\]Q4!OT$-%3S'/TV=P'QY21-D!9W5IU5: &)38L[/ _JXMT'L(
M3G6![C4.%PU,+29F(8IIDE-1%RXQW*>$<1R"34[W2)XX(CE$$W(\Q45OT,-&
M3['-TY\5]IPDO1+/._.U4/$4 CT# @M?Z\\0/(4H;SJH&Q6X/'URU].->B6>
MB<V^XINOYUO%DJ^JPL6]#:+R]& N,B-4T7##2?A)9Y/BFV\/.1F^(IROS_+>
MJABHNGE6#%B:<L57:/3U<)J'H2R59&D,;A&,^:%X9J$;O:*5[PWJYL;S$'WN
M5KEYA^0!;AP_@L\YC/$."]\>RC'))W),N%A^MJV'JH.F@]T.URJ@^7H6R<B7
MR:'X/+W?K.8RTK_>VXI7_F10;RN4^:;S/O/)_95!Q\0W 48!SS=6LR_=O*1G
MX&?X^)\<'BBR!8.6OX'"5:!/Q[[FV<15\/K$;^)V<2)0) L,]:HYN0X4=()!
M:]! $2C0YTN*OSN88 &&C,J7?D($RL?S$@F=#^IO*N4]H! H5 7F,O,)!CU<
MVGA6.VAE&"C,!/JTJ,_JOS;H,-?M@:)1\*8/9J^#EB>SG<^: D6AP$RA:EY7
M\"B2E_#3\^?^IJF>*.Y,!N7.1'%GHN=.OU32H$0SU^/&VU3RA;\5I'LLMND8
M[80J>:0] K1\AZZ\X"0K7K#:$LY)4GP5^[L@HVP@?M\1PI\NY#M;]9N,E_\"
M4$L#!!0    ( ,J)JE0+P#^;?P@  &8K   9    >&PO=V]R:W-H965T<R]S
M:&5E=#,X+GAM;+U:;6_;.!+^*X3O!3T@C27JQ4XN"9#:"39 TP8-NOMA<1\8
MB;:)2J*7I.-D<3_^AI(BVI8\5O8*]T,C2YSA,R]\9DCI8BW5#[W@W)"7/"OT
MY6!AS/)\.-3)@N=,G\HE+^#)3*J<&?BIYD.]5)REI5">#:GGQ<.<B6)P=5'>
M>U!7%W)E,E'P!T7T*L^9>OW$,[F^'/B#MQO?Q'QA[(WAU<62S?DC-]^7#PI^
M#1LMJ<AYH84LB.*SR\&U?WX[\JQ .>)7P==ZXYI84YZD_&%_W*67 \\BXAE/
MC%7!X,\SG_ LLYH QQ^UTD$SIQ7<O'[3?EL:#\8\,<TG,OM-I&9Q.1@/2,IG
M;)69;W+]"Z\-BJR^1&:Z_)^LZ['>@"0K;61>"P."7!357_92.V)#@/I[!&@M
M0'<$ KI'(*@%@KXSA+5 V%<@J@6B'0$_W",0UP)QZ?O*6:6GI\RPJPLEUT39
MT:#-7I3A*J7!P:*PF?5H%#P5(&>N/C$M-)$S\J"XYH5A5;R+E#Q6N6:?/8IY
M(68B884AUTDB5X41Q9P\R$PD@FORD5RGJ;"2+"-W197O5L^'*3=,9/I?%T,#
M8.V4PZ0&]JD"1O< \\F]+,Q"DYLBY6F'_ 27#Q#Y(3BI\11]\]0GBBI\Y,M3
M$G@GA'K4__XX)1_^WF76!-=RSQ1H\4LMM-:B^1S6JED5PG0HG/97B,"ZP;5,
M>=)'RRVNY7JI&A=YB,N#)CF#4E^PS^5U"GX]G(*_?P99<F=XKO^#S!PV,X?E
MS.&>F;^L\B>N;.X#ARM6SE6'29/_OEUVA;_2&Y5Z+:T_7_D7P^<.*%$#)>H)
M1?&E5(8]9;PGEJ@OEKC!$J-8KG/K>&#NI=3"0%DH Z$)?TDXAV5&;J=W$R(*
MO5+P(Q-Y9T9/JDGB#5QT3$//_FOP55G;-3(ZVQZY9<FHL62$6@++Y@=_\V6R
M4L!>D$7__-N8^OZ_2<*5*;/-\)(<:X.[;!FU?$PC+XS;IG0.+*WNMF3<6#)&
M+7E@KU4J& D!^6,E%">)S'.@7Z@>R8^2S-=,*5@ZNHN'QRT?!Q[BX;,&UQF*
MZP:@F-<-[W9Y[ZR=H:-Q.&I[KSV0CH.S8"]*WW,%T'L?SA-R^^O'+W<G9%5
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MY$TR"ZI@(O(?+-/K0= -4 9+NLWU7.P^0I50V_*E(E?N%^VJM5& TJW2HJC
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M>QH4 ?;[59J:[V^*)T?K)X7/_@-02P,$%     @ RHFJ5 *E%#J* P  , T
M !D   !X;"]W;W)K<VAE971S+W-H965T-#(N>&ULM5?1CMHX%/T5*^I*K30E
M<0@,4P'23.A,9S6C167;?:CZ8!)#K#HVM9VA_?N]-IDDJX(!;><%8L?GWN-[
M3TZ<\5:J;[J@U* ?)1=Z$A3&;-Z%H<X*6A+=DQLJX,Y*JI(8&*IUJ#>*DMR!
M2A[&430,2\)$,!V[N;F:CF5E.!-TKI"NRI*HGS>4R^TDP,'SQ$>V+HR="*?C
M#5G3!36?-G,%H[")DK.2"LVD0(JN)L$U?G>+1Q;@5GQF=*L[U\AN92GE-SNX
MSR=!9!E13C-C0Q#X>Z(IY=Q& A[?ZZ!!D],"N]?/T6_=YF$S2Z)I*OD_+#?%
M)!@%**<K4G'S46X_T'I# QLODUR[7[2MUT8!RBIM9%F#@4')Q.Z?_*@+T0'@
MY  @K@'QJ8!^#>B?"DAJ0'(J8% #!J<"AC5@Z&J_*Y:K](P8,ATKN47*KH9H
M]L*URZ&AP$Q892V,@KL,<&9Z4VF8T1JELEPR06R[-2(B1W=2YEO&.7J+KO.<
MV1N$HWNQ4[-5Q>L9-81Q_0:6?%K,T.M7;] KQ 3ZNY"5AAAZ'!K@:#.%6<WG
M9L<G/L#G3R)Z*$XN4!S%\1YXZH=?5^L>ZF,'QWO@LR/9*^Z%O_?#'XEJX/O(
MW_KA,YH=RAY"6YO>QDUO8Q>O?ZRWU]GWBFG70O3E >;0O:&E_NK)T6]R]%V.
MY%#!Y^GC'<JD,$RLJ3#V4K.<*B>1?27<Q1NZ>-;WGJ8XBJ)Q^-0MU)%%_Z&:
M-%03+]6_0+?H R7<%!>@XZQWX70^5_+)$D9W$,\4:"%YM7L*'AY23X4&3=K!
MBW5AV.08>K=V+PQ55!LP:LBA:+[OP?.'@/KVHN@/#YG+ALRE-U+:50 RB@B]
MHNH J<LS&CUJ"(R\!#X37E$D5T@7!*K2I6#=B;1]V,=H= :CJX;1E?\IR3*K
M@+EB]O6-4J"%'FG.,G!4D%VU\90=1ZV51R^F--QY8>#_K;79D1BC8UK#K<?A
M^+>I;5;'ZC8W/MA<W'H@]IO@G/R$PY8!I<GGJJ!EW8R]-,ZQ-]SZ&_8;W/E>
M7 <\D4CK>'C@)[*1G,NWBTJ@![+4Z)$(.*7:$ET<,57<.AX>OIS86RO#?B\[
M1>SID1C)U3&QM\:&_<YVCMA3_*N3);\V-^R<'>VW!)QAU@Q>?IRN !;U+J'5
M:G<\WPV,W+CCY%(:.)RZRP(^::BR"^#^2DKS/+ GU.8C:?HO4$L#!!0    (
M ,J)JE0E_515: (  -8%   9    >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM
M;(5436_;, S]*X*Q0PNLM6,G<5<X!IIV7X<"1;-NAV$'Q69BK;*82G+=_?M1
MLN-F6Y)=;(GB>X^D1&8MZD=3 5CV4DME9D%E[>8R#$U10<W-.6Y T<D*=<TM
M;?4Z-!L-O/2@6H9Q%$W#F@L5Y)FWW>D\P\9*H>!.,]/4-=>_YB"QG06C8&NX
M%^O*.D.89QN^A@78A\V=IETXL)2B!F4$*J9A-0NN1I?SU/E[AZ\"6K.S9BZ3
M)>*CVWPN9T'D @()A74,G'[/< U2.B(*XZGG# 9)!]Q=;]D_^-PIER4W<(WR
MFRAM-0LN E;"BC?2WF/["?I\)HZO0&G\E[6];Q2PHC$6ZQY,$=1"=7_^TM=A
M!Q"/#@#B'A#[N#LA'^4-MSS/-+9,.V]B<PN?JD=3<$*Y2UE83:>"<#:?-X8L
MQK!KK)="<5<JP[@JV4?$LA52LC.VZ&Z,X>K5>G(#E@MI3MD;)A3[4F%C"&:R
MT%)8CCPL^A#F70CQ@1 2=HO*5H:]5R64?^)#2F?(*=[F-(^/$MYR?<Z2T5L6
M1W'\L+AA)V].C] F0ZD23YL<H!U2_WZ/]*5'T7)=_CC"/!Z8QYYY?.@28"V4
M$FI-#TQR5<"^(G844T_A6NTYCR=)E+S+PN<]TI-!>G)4^JIX:H01_MKWJ7;H
MR8[J*+J8[M><#IK3XYKE3WK8U-EVK^3T'\FS43H^H)D.FNE137I;_ZEONJ>^
M<9+^7=]PI]=JT&L_40PKL%&V:[O!.@RMJZY77]V[B4?OE.[=, DK@D;G*>6L
MNRG2;2QN?.<NT=(<\,N*!B]HYT#G*T2[W3B!893GOP%02P,$%     @ RHFJ
M5&(O7E%%!@  VB,  !D   !X;"]W;W)K<VAE971S+W-H965T-#0N>&ULO9I?
M;]LV$,"_"F'TH06:2OPKJ4@,I,FZ!4B&H&FWAV$/C$W;0B71D^@D'?;A1\F*
M:$D45;NI7Q)+OCL>[\C?46>=/LK\:[$20H&G-,F*L\E*J?5[SRMF*Y'RXIU<
MBTQ_LY!YRI6^S)=>L<X%GU=*:>(AWV=>RN-L,CVM[MWFTU.Y44F<B=L<%)LT
MY?FW#R*1CV<3.'F^\2E>KE1YPYN>KOE2W GU97V;ZRNOL3*/4Y$5L<Q +A9G
MDW/X_H)5"I7$'[%X+'8^@W(J]U)^+2^NYF<3O_1()&*F2A-<_WL0%R))2DO:
MCW]JHY-FS%)Q]_.S]8_5Y/5D[GDA+F3R9SQ7J[-). %SL>";1'V2C[^)>D*T
MM#>325']!8^UK#\!LTVA9%HK:P_2.-O^YT]U('84M!V[ JH54%>!#2C@6@%7
M$]UZ5DWKDBL^/<WE(\A+:6VM_%#%IM+6LXFS,HUW*M??QEI/3:\RQ;-E?)\(
M<%X40A5OP>]Z\9R .[U@YAM]6RY 3PB\OA2*QTGQ1DM^N;L$KU^] :] G('/
M*[DI>#8O3CVEW2L'\6:U*Q^VKJ !5S"XD9E:%>"7;"[F%OT+MSY$#@.>CDL3
M'/0<G _(:?&&Y^\ AF\!\A&R.>16OQ2S1ATZW,%-KG!E#P_8^QAGL1(GUWK=
MSRTY^>M:RX,K)=+B;\=HI!F-5*.1@='.9[--NDFXTH.=IS)7\;^\W'FVQ&XM
ML<I2"8Z'Z0GT0QJ&I][#;KRL<B0J@_M@<94VKE*GJY^EXHG-KZT:W1DO"*(H
MM(_&FM&8,PU7>G4MMJE(?BP503-BX)R?99/^FLO"NL>"WI1A& :8=3)A$PL"
M%-E#$S:.AOLZJFEB<S/LC1_ZD'37BT4*A7Y@=S)JG(S<JR7G<UT+=9UTI ;Z
M!J#^D98#W($V'(GS\YA@.R:O!GIOA2[L!1%!ZMMC")%Q 3E=N(YG93'/EN!\
MF0NA*[MRQM- #KHI]X+Q-*B#;M;M$<^+VM1WQM,@#+H9IO=)>>#11Z.DPFRQ
MBM?.@!I<03>O7J9L0 ,KZ*9572ST8+$9C(]Q"UJ(1'T61!TDC,NUW3;H@FYV
M[5/O8!],)V' 8)=?5CD2,CK@K$$8'&'84,6K]79++,,^@UW'+&(TA,3N%S(P
M1/[^JQC\!V[T&DPWJ>M,9N"'X!'6,S*D0V[2?2G$8I. ZW@A;!$?T880?!,\
MMZWYBX-4V[,P6$7XL,SPI[',&(PB<HS,&&8B-S/',N/61J[,N%4A'<^,X3-B
M3F,W/-,/S&4!!3/]_)+K)UNG80-B%!PC'8:@R$W0L72XM>TQK=-QB&I[%@:M
MR(W6P\H7Z@,5H1"C#G='Q=H/AH:[V,W=?8I7;:I5E"#>?2S:^FJ7HPP/.&L
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MXGM\I$AEC;$/KD(D>*J5=I.H(MI<QK$K*JR%&Y@-:CY9&5L+8M.N8[>Q*,H
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M&>>7*\$#D68OF-\74NJGFRQ >0HW^1=02P,$%     @ RHFJ5%L:+3 8"0
M;C4  !D   !X;"]W;W)K<VAE971S+W-H965T-#@N>&ULO9M;;^.V$H#_"N%S
M6FR!)#9)W;S-!G#N/DB:8-.>/A3G@9$96UA=7(E.&F!__!E=;-HK:JAN4N<A
ML17.<(:<^3BDI..7+/]2+*14Y*\D3HM/@X52RX_#81$N9"**HVPI4_C/4Y8G
M0L'7?#XLEKD4LTHHB8=L-/*&B8C2P<EQ=>T^/SG.5BJ.4GF?DV*5)")_/95Q
M]O)I0 ?K"Y^C^4*5%X8GQTLQEP]2_;:\S^';<*-E%B4R+:(L);E\^C28T(_3
MP"L%JA;_C>1+L?69E*X\9MF7\LMT]FDP*BV2L0Q5J4+ GV=Y)N.XU 1V_-DH
M'6SZ+ 6W/Z^U7U;.@S./HI!G6?Q[-%.+3X-@0&;R2:QB]3E[N9:-0VZI+\SB
MHOI-7IJVHP$)5X7*DD88+$BBM/XK_FH&8DL ])@%6"/ OA5P.@1X(\"_%> =
M DXCX/0UR6T$W+XF>8V UU? ;P3\O@)!(Q#T%1@W N,J'.KYJR;_7"AQ<IQG
M+R0O6X.V\D,5094TS'F4EL'^H'+X;P1RZF2:/LM"0?2J@D0IN5,+F9.+5$4J
MD@4Y))/9+"JC4L1DFM:Y5<;HAW.I1!07/T&3WQ[.R8=__W0\5&!/J748-GV?
MUGVSCKXIN<U2M2B@OYF<&>0O<'F.R ]A'#:#P=:#<<I0A0]R>43XZ("P$:,&
M>\YP\?^L8A"GI3@=&\3/<?%;\;J6#DR#89/.UYTS9A"_["]N<OT*%S^7(2I^
MC8M/5G-4?-I_X%TD#O@F*7BECW?% 2PILU4L2?9$+OY<1>J5W$JUR&9D.UW^
MN $Q,E4R*?Z'=.IL.G6J3IVN(8P*E4>/JS*_3--?2WN5=+F$/9_ @@8_Q\-G
M0Z_NIE<7[76:AEDBR8<X*R"9G_(L(;+V.*D]CK3')JMJ[>Z65=3A?-NL.OK<
MEO6'GN]WFN]MS/<LYN_@*ZOP)=?X^O%? :/TYUV/3%YX+2\<AP=M-ZZ\EAL.
M]:G;Z8>_\<-'_9C<GY&O$&2SZ#[+%<#VYN8,B:E@HS;87R"/-YV.45]N9?(H
M\V(1+6%*E,RAGX(L5WFX@*)D1C[ /!4+ 9=-2\;YN#45S.\.<SK2Z]P(M>I>
MO-;>JFQC#$1$VU2348WNG7E'DH]NK;[T[X^5"&&J\F:H9ED<BQP&$ *[&C;C
MJ#7=!-MY>.1V6,>T=0RU[NXE;8R#WD,8/2A_C;WC:MA1,/H!"2RJN4PYJNE7
MF2=E++^(/!>I,MJ":W#)JX3AQ*S1P*8XL7]9E9.W94\!Y7\HH7BW1GFCN7>8
M:YQ3G.?K$<J6'>O(N45!CP'2<*8XG>\J(W933NB"TI1]UH%KHYH'R,!I %.<
MP(;)%,]0XHI'P.>6 P<DA*(S2N>0#F2UA%H8UARRK*D-:^DREE6%/!-*6IWQ
MV^L.YHS&/@UP9Z0J]YC5@A*"7;<BA=0M^7< Y(=2[2N9A(M(/@MH45_")ER3
MGX[WM]XPS7:&L[TGI\XL:NCH:(2"BFFN,YSK]QL[RJ%XSLJ *:,C@<B /5WX
MY0#V>6H!X?$$N#"E7&,QWHUKM5BSGN&0/E_E]=8.[-4UG]$F7)$=($SSGN&T
MUE%#1)*M.NSAK<79119GIOG.<+Y_EC$D\78)3!Y%+-+0%%P7K(UTU R-=(83
M^48\B!AR:IW,DZ+(P@@L0\=80YIY>\Q9S5N&\]:VW6%M-G:-I,8BP['XULU.
MHWYGM\/<H'N.-3@97C._TSZFZ66G3F5CUM['L':9S4?<Z?2$:Q9S'*+=T5HN
M.K#-$>FL_'MX\W [@4MG&;B>JZA<9A]DN"KKWGN8F0CD\E?R2P;+Z%=RGA^1
M2:ZDF ML?Z_YS.G^@IYKR/*_7U"3(HM-DWEJT<7H$7,Q]O.MXPX<LY9</.5M
MPGK8_H=KQ'(<L=9H*:,$\U%3E+M[G'%-5VXI@3<SOBYQ37EK4<)<RS+/-78Y
MCEW;@&.=:,[R/1X[< U1;H/HV_#.V_2D?#?,Z\,LWJ;GH8_D@Z/IZ=A.*<+H
M*0HWTS--Q+PL'7\4R?)G<@<.QMG\E9S),IBLA;NC>>CLD8>.YJ%C*3IM9YZL
M;Q'@:-@YMIKR;5'2J-^VR>N>^:W37YR$[U0!..TJE/K,;5< QH9TW.V))JV#
MUZO?$</]8.]HZCI[K&D=#5<'AVLOV$\M2AS;GL[1'';P>O>[9P+K7>/8V>-A
M@*L1ZN((??,=C5$[O_WV_8QVJT/D/H"K2>SB6_IWXD#3RVYZ&]:RJQX-=SW1
M<'=QN'\_!^!W&D;EN?<K[ GRYRB4Y3Y!Y2)46(SH-<#=XPT^5S/>Q1E_*6$*
MER(RSU@;R*8)NS2TP\X9W*T[@9:37T[)[T<PT% ?PK8$OP/E:A:[>V2QJUGL
MONU\P>U]ON!JWKK_[/F"VSY?.*0!ZYY;S6)W+^<+KJ%"]D=.8,!*NT2&.H1W
MQZFG >_A@&_'J771\C1^O3T6PIYFI=?W8 #;)EJ46$^#/0U([Y\MDKWVB<$A
M,]',:U?3AQ3!F:=AZ^&PO8,9NGVX.Z@"9!WA>7.DNQ2Y>L5&2E/3V^.Y@K?U
MW -^)&##F]>^3X8]+N)IKGHX5]\<&6WN4NX; L/0#G- 0]JS0?I]'AD)VL_C
M!$[;D2NO#74VIH@G&NH>#G5[A%O!Z&OJ^J/]Q;FO>>SCY7 _,%J46,'H:U#[
M.&-_%?-#3Y>T^L[059ZME@>6JLG7 /;W6*'Z&IJ^[13B;=GMMY]2\[QV<OOM
M&K;K 2H-8M_V)-N[Y+7??E+-,QT"7OGM1]_JF_==GFBV^SC;>\28/;&WGCSS
M]QAI&L,^CN&>B8TKL2>VAJF/P_1L,KV?;'"*/7NGD1GL$9F!1F: T\Y6&C3B
MGCWY HW% ,?B6[D1M ]ZJ6%;<=FTZV.[1FW0]R&#-X$C:)>\E%''0 Y32SHV
MW*:]-K;$3F<"3?H )_UNO)<\6<*&*MM@YSJ+9U$Z+ZJ#&2PN-:"#/5;*@:9I
M\ YWX*XM2G@G:(9;[UXD,I]7+^X4)"R?5JF?.-]<W;P<-*E>B?GF^BG]>$X-
MUR_HQ\OZU1^MOGX3Z5;D\R@M2"R?H*O14;DBY?7+/?47E2VK-S\>,Z6RI/JX
MD&(F\[(!_/\IR]3Z2]G!YA6KD_\#4$L#!!0    ( ,J)JE0RQ^S=[ 8  $4;
M   9    >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;+59;6_;-A#^*X07%"V0
MVB+UZC8)T,0)%J#MBJ;K/@S[0$MT1%02/9%.VO[Z'2E9LB6:<='NBRV)=\?G
MCL?G3M39HZB_R)PQA;Z6127/)[E2ZU>SF4QS5E(Y%6M6P<A*U"55<%O?S^2Z
M9C0S2F4Q(YX7S4K*J\G%F7GVH;XX$QM5\(I]J)'<E"6MOUVR0CR>3_!D^^ C
MO\^5?C"[.%O3>W;'U)_K#S7<S3HK&2]9);FH4,U6YY,W^-6-3[2"D?C,V:/<
MN4;:E:407_3-;78^\30B5K!4:1,4_A[8%2L*;0EP_-L:G71S:L7=ZZWU&^,\
M.+.DDEV)XB^>J?Q\DDQ0QE9T4ZB/XO%WUCH4:GNI**3Y18^MK#=!Z48J4;;*
M@*#D5?-/O[:!.$:!M IDH  3VQ7\5L$?*@0'%()6(3A6(6P5PF,5HE8A,K%O
M@F4BO:"*7IS5XA'56AJLZ0NS7$8; LPKG5EWJH91#GKJXK9Z8%)!JBB)>(7^
M4#FKT76EN.),HI?HSF0<_\XR=$D+6J4,W>G))*)5ANX45:Q1%BMT6Z6B9.CY
M@BG*"_D"U/^\6Z#G)R_0B3;^*1<;"6KR;*8 N@8P2UN85PU,<@"FC]Z)2N42
MH&4LV]>?@<N=WV3K]Q5Q&GQ'ZRGR\2DB'B$6/(OCU;%%_=JMOF"I4_WF>'7/
M$0R_2P+?V/,/V'LC):RHPU#0&0J,H>" H2LJ<Y,8J;Y@_V[X RUT>MA6O#$5
M&5.: !\NB!_/ UB-A]U(VL1\;Q[OB]V,Q?#<#V*O$]MS*.P<"IT.?60I Q^6
M!9.GJ&+*YD=C(=R9.0Q)X@W<&$MA+_(2.[RH@Q<YX;T55//[%J,-732:-_"\
M(;@GA/:PQ1VVV(GMDU"T0-226D;[TJW]-_['YDT\ CK'D YXX,]8+ F)'_EV
MCY+.H\2Y3=YRNN1%PXP-^XGT2RZ*C-7RV6\)P?%KM& KGG+EV$OS;K:Y>R]M
MZAJV#BKZ66T1F8_S*O("/QI$Q"*&0S_&]HA@KR\?GA.E+0:9+08MRWOC3(OG
M(1DLX**5V]W.?C"/DL&NO[;9 _?G@P2_L=D#$L&'_-\IG_B(+-]9HU-4LN_?
M:05RA@#5MU.3+-(2J&;<&B=\7*);Y%R9CDGO%W'F>E?9=6'_8\UJJAM!5XW
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MC)>84NU)<?QKG%KMFEIXVG[U_MT$KX+9(H&7C/XFJ=S/K,@"*<Y01>4]._S
M34"^]I<P*LPO.#2VT )))23+&[$BR$E1_Z-CDX@3@3,Y(W ;@?M9@=<(/!-H
M36;"6B&)YE/.#H!K:^5--TQNC%I%0PJ]C1O)U2Q1.CE?) FK"BG &KV@+<4
M%2E0@[S"*?AV5*=%8 &^@HTZ/VFEYED&/J>Y7&&)"!572OVX68'+BRMP 4@!
M'O:L$DHBIK94$6@..VEH;VM:]PSM3\2O@>=\ 2YTW0'Y<ER^PDDK=][+;96W
M-GENFSS7^//.^&OB%V\)0%2 /XNMD%R=S[\C2WCM$IY98O+1_I3U6D,YJST$
MQH.^ML_S. JBJ?U\FID!(S_R6J-W<),6;C(*MT0ED<A<QQ&\VH=_LK+GNWX'
MKV_D!G$XC.>W>/XHWJ;:)JPP6\$XN%LOQBC]'H 3.]TD#ACYT1G*H*4,1BG7
MG&58Z+*(*,@P'KP606_A&,(.7-\F"J-AMK!E"T?95A4&DJER39%4=[M$7))A
MP+"_?YX7=PB'C* SC!BUB-'X&6QV&%""MH22<X!1?VT(W>X&]ZV<((S/9#%N
M$>./[K IC0G+=6TT%V8(,>YO<A!..H1](P<Z\,P9=.#;,P!'&1^85,</=:J-
M*6RHP<=-91\LV[!77B:1Z[L=^"$S+_:[1\ ^><_TQX0J^SM2"$!QIG3P.E3A
M\_I]KCN2E>:)VS*I'DS3W*MO&LRU@9K/&).O'?UJME])\_]02P,$%     @
MRHFJ5+ZF%2EO P  6 L  !D   !X;"]W;W)K<VAE971S+W-H965T-3(N>&UL
MK99?;]LV$,"_"B'TH07:2!0E2PYL XG380,6P$C:[6'8 RV=;;84Z9%TW'[[
MD;0B.Q:M=6T1(!:I^_.[XU%WD[U4G_4&P* O#1=Z&FV,V5['L:XVT%!]);<@
M[)N55 TU=JG6L=XJH+57:GB<)LDH;B@3T6SB]Q9J-I$[PYF A4)ZUS14?;T%
M+O?3"$?/&P]LO3%N(YY-MG0-CV ^;A?*KN+.2LT:$)I)@12LIM$-OI[CS"EX
MB3\8[/7),W*A+*7\[!:_U=,H<43 H3+.!+4_3S 'SITER_%/:S3J?#K%T^=G
MZ[_XX&TP2ZIA+OF?K#:;:51&J(85W7'S(/>_0AM0[NQ5DFO_'^U;V21"U4X;
MV;3*EJ!AXO!+O[2).%&P=L(*::N0GBMD%Q1(JT!\H <R']8=-70V47*/E).V
MUMR#SXW7MM$PX8[QT2C[EED],[N'FE64H]\973+.# .-WJ%'6RWUC@.2*Q22
M>'T'AC*NWUC9CX]WZ/6K-^@58@)]V,B=IJ+6D]A8.N<CKEJ2VP-)>H&$H'LI
MS$:C]Z*&^J5^;*/J0DN?0[M-!PW>4W6%"'Z+TB1- SSS;U?' SBDRS3Q]LC_
MR/1?#Y)S9.MQ3U7]]X"3K'.2>2?9?SCA1R=OT1+63 @FUNXXMZ"8K$/'<[ \
M\I;=[7^:Y7E1DDG\=)JT@%1"2-))O<#..^Q\,#=SV6RE &&T0VS:("JJ %52
MVUT%G!JHD9&HXI0UVA9;M5,*ZNN!K(TZ]Z/!K,V=)6$&<G/0ST^BQCFQ?V?)
MZ8N5A*3C<'**CJX8I%M8*-6R!>]5T?/Z#A?G: &A-,%E&*WLT,I!M _2V'/J
MGU>(L@RED(R2,\Z^6(D)QF'.<<<Y'JRO!?W:^.JR?>_GE1=.CA_9Y <+K#7P
MXGR*!*?GZ0G)9;C ))P@?-('\(]56:O_TG.6].Y 2(Z,299=($R/A.DW%-N6
MLG "T\ MP!G.>WP!P1(G>7&![_A]QV20[Z;^9/NUK[,@(.GY+8K>\?:%RG%^
M@>S8%/!W= 40]7 _P/U/_3@O\O(<.= 1<%:<?_3BDQFE ;7VHYNV]V\GS*&G
M=[O=>'CCAZ*S_5LW-OK9YVCF,'/:CFT;G48<5M9D<E78-*K#&'=8&+GUD]!2
M&CM7^<>-'7U!.0'[?B6E>5XX!]TP/?L74$L#!!0    ( ,J)JE3('F'+*P,
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M*-JF8J+XRG8>,ZYT'V.'2]UJ@C &>G_.N7J9F&:F:EY'_P%02P,$%     @
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M4;L >W^M%'U,7!?J_D-F?P%02P,$%     @ RHFJ5 =W-JWJ"0  63T  !D
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M$:%EO3"IFJB797Y1E[559AZPU,/A-VYWW/F6KS,Q5=YK/K&KU.^YC;8N93Q
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M;#$$@,  1^!V71'KWO%''L7\H0C%IB@,#G=-'4JQ^CP N 5X'?S2ST=D=@"
M"WK9-PV 4P'.J2-"]BYH.,!Q,5\"P *\:-P/1!VT]V,RVF3J8U67%PZNQVUY
M8^I>;FW7E[DQ;P#G@EYN[P3 J@!GS3'1^Z72M1>]V)68 $ 5&.[PB#PO-PW
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MYKA LL57F.F3!1<%4GHKEJY<"8PR"RJH&WA>QRT08<YH8&U3,1KPM:*$X:D
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MNKJPHIR7Y4;QE9T@<Z[T/+++7']C8&$<]/F"<[7;F OJKY;1;U!+ P04
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MA9F@WZ\Y5Q\/9H'B7Y'9'U!+ P04    " #*B:I4MQ'/654#  "U"P  &0
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M4):F/+^L:*Y&[2[0\Y52]GGC'/23^O0_4$L#!!0    ( ,J)JE0WM$8) P0
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M%CL"*R3?1*Y7BGS)8X@;Y*?M\I2U*/"1HXHHMB/JCK5J_,;E#0GI%6$!8TV
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M)2C, OU^QKG:#$R ^NYL_ ]02P,$%     @ RHFJ5-C$9QEK @  J 8  !D
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M064#:'\MI7F>V/;6_YR2/U!+ P04    " #*B:I4QZYF>O8%   V(@  &0
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M1?NI>OB'&AK$37U9533=7_30VXKD!&7;IJW60V&M8)V7_?_IMZ$C]@K$D:<
M&0J040',/ 7H4(#.+<"& FQN 3X4X',+B*& Z/J^[ZRNIZ_3-KV\J*L'5!MK
M79OYT U75UIW<%Z:F?6YK?757)=K+[^F=9[>%@J]+UM5JZ9%[\HV;W/5H&=?
MW[]K?D'/KE6;YH7^] +]^?D:/3O]!9VBO$1?5M6V2<M%<W'>:B6FOO-LN.O;
M_J[$<]</:7V&*'Z.2$0(4/PZ7/Q:9;OB&"C^;O[=H>(W\^\>'18_U[V_&P*R
M&P+2U4<]];W=UK4J6Y0VC6J;0(5T5R'M*F2^"M-FA?3 H,Q\4']O\_NTT'<
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MNX-0EQI,R&1O7 >I@!VG//;UI.4+#@.F%^L5>#51_%_XWV"S -A@[3V--W?
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M7R3X3/[HKNAG@V[4TR38->1I%IQRDIR)P_N:N>4Y<^NE$GY&G"+IN@_AW 1
M,]&2TS@B9_&1&@2@>E^"'AM' -QEYJ(>,'-*5"NDBGRMX6LFPW:CJ[73XVFD
M3/=M="]K8=KH(6]76EX;7G5GZ+-2Z/>J50B+W3'@]$MO9BHNMW4'HD7W_ML9
MY-J=[[UXMU;U7?>*I)G:NCOZ][5VO^Y>P[SJWE8<_R[ERW=Z@W2OZ#U.7^G>
MW#RWM^C?^]0#>Y?KG:%02WV[Z,Q H^Y?I>R_M-6F>_7OMFK;:MU]7*ETH6IC
MH*\O*]TSPQ=S@]T+K9?_ 5!+ P04    " #*B:I4-E,"-EP#  !<#   &0
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M)7E*56&83,PDM$C&089QE?BJ3$P_2!R1>R5M:LB-3"!Y'Q^BB%H)W2FYHJV
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M !)OM%;F;9USR^=3K3:@732QN0^?&X\F-T*Z9;RRFD8%X>S\"U(.#+R';[9
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MN\^D*Z@UF/-2MO_!KEL;>"!OI.)5%ZP=5)3M/_%SUXB# !@Y E 7@$X-"+N
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MV._[]B>*U^W6:<65WHBUAX7>*Q-A%NC?-YRKEQ.S&^MWW\O_ %!+ P04
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M37!UNZ9$C\=K#%!U?JOM%=K][INUO9% NP0[7BJ%Q\!M^OF.2W\!4$L#!!0
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MYW'0#A5V<65%>-EL?$S2L MIOEXNA] VJ:'V*K>_6-C^VN+3?U!+ P04
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MZAT$>@?J'01ZQ^1G$P*] _4. KT#]0X"O0/U#@*],^J="?3.J'<FT#NCWIE
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M0/KX!M+'-4@??('2"(JH'(54CF(J1T&5HZC*45CE**YR%%@YBJP"15:!(JM
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M;W!S+V%P<"YX;6Q02P$"% ,4    " #*B:I4<[D*W>X    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #*B:I4
MF5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( ,J)JE0PRM<&3 4  )\5   8              "
M@0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #*B:I4
MK'GK[),*  #C+   &               @(&/#0  >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ RHFJ5 NVLFP5!@  2Q@  !@
M     ("!6!@  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M ,J)JE3\G[[TZP4  'X8   8              " @:,>  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    " #*B:I4P(3UJG '   ()0  &
M            @('$)   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ RHFJ5-D*,I0^"0  W"@  !@              ("!:BP  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( ,J)JE0MY5AIXA<  -)'
M   8              " @=XU  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    " #*B:I4."9M1=0G  ""AP  &               @('V30
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ RHFJ5'_Z+=6V
M"   J!<  !@              ("! '8  'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    ( ,J)JE0MXH<]CP0  .4*   9              "
M@>Q^  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ RHFJ
M5)?DSY27"P  WB,  !D              ("!LH,  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    " #*B:I4#?0?+T$$  "\"0  &0
M        @(& CP  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   ( ,J)JE3++TMLUP(  $@&   9              " @?B3  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ RHFJ5$X4K<0- P  T 8
M !D              ("!!I<  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    " #*B:I4&S)AD<L0  ",-@  &0              @(%*F@
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( ,J)JE2Y")UX
MF@0  -T*   9              " @4RK  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ RHFJ5-8,!(' !@  4A(  !D
M ("!';   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " #*
MB:I4=?,#>=H'  "Q$@  &0              @($4MP  >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( ,J)JE0K;[1%8P<  #<8   9
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M970R,RYX;6Q02P$"% ,4    " #*B:I4RU<7(\P]   \U@  &0
M    @('JW@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M ,J)JE1C4'&-@@4  (P/   9              " @>T< 0!X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @ RHFJ5#B:NE21 @  B 4  !D
M             ("!IB(! 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    " #*B:I4_O]#&W$$  #'"@  &0              @(%N)0$ >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( ,J)JE3)>S^PJ00
M "H*   9              " @18J 0!X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @ RHFJ5%;DNG[G @  -P8  !D              ("!
M]BX! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " #*B:I4
M B1$AQX#  #1!@  &0              @($4,@$ >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    ( ,J)JE0-%&'=<P,  *@'   9
M      " @6DU 0!X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @ RHFJ5*L(&J[:!0  MP\  !D              ("!$SD! 'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " #*B:I4EI*G&L@"  #V!0
M&0              @($D/P$ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+
M 0(4 Q0    ( ,J)JE3*0V-;_P(  %((   9              " @2-" 0!X
M;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ RHFJ5*5KF^MJ
M!@  N X  !D              ("!644! 'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6Q02P$"% ,4    " #*B:I487F/9'L$  !<#0  &0
M@('Z2P$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( ,J)
MJE1[X_;IT@<  -4H   9              " @:Q0 0!X;"]W;W)K<VAE971S
M+W-H965T,S<N>&UL4$L! A0#%     @ RHFJ5 O /YM_"   9BL  !D
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M=#0R+GAM;%!+ 0(4 Q0    ( ,J)JE0E_515: (  -8%   9
M  " @3=S 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @
MRHFJ5&(O7E%%!@  VB,  !D              ("!UG4! 'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6Q02P$"% ,4    " #*B:I4H#CM D\"   X!0  &0
M            @(%2? $ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4
M Q0    ( ,J)JE2/#JK\D@(  +H&   9              " @=A^ 0!X;"]W
M;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ RHFJ5(S<79^)!0
MD1L  !D              ("!H8$! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX
M;6Q02P$"% ,4    " #*B:I46QHM,!@)  !N-0  &0              @(%A
MAP$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( ,J)JE0R
MQ^S=[ 8  $4;   9              " @;"0 0!X;"]W;W)K<VAE971S+W-H
M965T-#DN>&UL4$L! A0#%     @ RHFJ5,=3U3K0 @  M@<  !D
M     ("!TY<! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,J)JE0'=S:MZ@D  %D]   9              "
M@>"G 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ RHFJ
M5!)TJC#K @  P0@  !D              ("! ;(! 'AL+W=O<FMS:&5E=',O
M<VAE970U-BYX;6Q02P$"% ,4    " #*B:I4@6F:>[P"  "5"   &0
M        @($CM0$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0
M   ( ,J)JE2(*9E87 0  "X0   9              " @1:X 0!X;"]W;W)K
M<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ RHFJ5&-@:%1/!   (1$
M !D              ("!J;P! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q0
M2P$"% ,4    " #*B:I4MQ'/654#  "U"P  &0              @($OP0$
M>&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( ,J)JE0WM$8)
M P0  / /   9              " @;O$ 0!X;"]W;W)K<VAE971S+W-H965T
M-C$N>&UL4$L! A0#%     @ RHFJ5(;:]0#X P  1Q,  !D
M ("!]<@! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    " #*
MB:I4V,1G&6L"  "H!@  &0              @($DS0$ >&PO=V]R:W-H965T
M<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( ,J)JE3'KF9Z]@4  #8B   9
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M970V."YX;6Q02P$"% ,4    " #*B:I4,T*N_#4#  #]"@  &0
M    @('XX $ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    (
M ,J)JE2/<)NP@PL  -PZ   9              " @63D 0!X;"]W;W)K<VAE
M971S+W-H965T-S N>&UL4$L! A0#%     @ RHFJ5#93 C9< P  7 P  !D
M             ("!'O ! 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"
M% ,4    " #*B:I47A/? >8"   0"   &0              @(&Q\P$ >&PO
M=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( ,J)JE0&P-3 0@,
M -X*   9              " @<[V 0!X;"]W;W)K<VAE971S+W-H965T-S,N
M>&UL4$L! A0#%     @ RHFJ5&WW$;[R P  B0\  !D              ("!
M1_H! 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q02P$"% ,4    " #*B:I4
MV&GVT><!  #O!   &0              @(%P_@$ >&PO=V]R:W-H965T<R]S
M:&5E=#<U+GAM;%!+ 0(4 Q0    ( ,J)JE2'TZN1&P,  "X2   -
M      "  8X  @!X;"]S='EL97,N>&UL4$L! A0#%     @ RHFJ5)>*NQS
M    $P(   L              ( !U ," %]R96QS+RYR96QS4$L! A0#%
M  @ RHFJ5)%-^8'4!0  \3$   \              ( !O00" 'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( ,J)JE1G_%)"3 (  &@L   :
M  "  ;X* @!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M ,J)JE2&IF-(# (  &$K   3              "  4(- @!;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@    !3 %, O!8  '\/ @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>350</ContextCount>
  <ElementCount>464</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>149</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2110103 - Disclosure - Business Combinations and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BusinessCombinationsandGoodwill</Role>
      <ShortName>Business Combinations and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2114104 - Disclosure - Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNet</Role>
      <ShortName>Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2119105 - Disclosure - Investments in Other Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntities</Role>
      <ShortName>Investments in Other Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2124106 - Disclosure - Loan Receivable and Loan Receivable ??? Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties</Role>
      <ShortName>Loan Receivable and Loan Receivable ??? Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2126107 - Disclosure - Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/AccountsPayableandAccruedExpenses</Role>
      <ShortName>Accounts Payable and Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2129108 - Disclosure - Medical Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MedicalLiabilities</Role>
      <ShortName>Medical Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2132109 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit</Role>
      <ShortName>Credit Facility, Bank Loans, and Lines of Credit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2137110 - Disclosure - Mezzanine and Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MezzanineandStockholdersEquity</Role>
      <ShortName>Mezzanine and Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2139111 - Disclosure - Stock Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensation</Role>
      <ShortName>Stock Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2147112 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2149113 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RelatedPartyTransactions</Role>
      <ShortName>Related-Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2153114 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2155115 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2160116 - Disclosure - Variable Interest Entities (VIEs)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/VariableInterestEntitiesVIEs</Role>
      <ShortName>Variable Interest Entities (VIEs)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2163117 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Business Combinations and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables</Role>
      <ShortName>Business Combinations and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/BusinessCombinationsandGoodwill</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2315303 - Disclosure - Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNetTables</Role>
      <ShortName>Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/IntangibleAssetsNet</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2320304 - Disclosure - Investments in Other Entities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesTables</Role>
      <ShortName>Investments in Other Entities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/InvestmentsinOtherEntities</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2327305 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/AccountsPayableandAccruedExpenses</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2330306 - Disclosure - Medical Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MedicalLiabilitiesTables</Role>
      <ShortName>Medical Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/MedicalLiabilities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2333307 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables</Role>
      <ShortName>Credit Facility, Bank Loans, and Lines of Credit (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2340308 - Disclosure - Stock Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationTables</Role>
      <ShortName>Stock Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/StockBasedCompensation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2350309 - Disclosure - Related-Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related-Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/RelatedPartyTransactions</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2356310 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/EarningsPerShare</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2361311 - Disclosure - Variable Interest Entities (VIEs) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables</Role>
      <ShortName>Variable Interest Entities (VIEs) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/VariableInterestEntitiesVIEs</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2364312 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/Leases</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Description of Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails</Role>
      <ShortName>Description of Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Company's Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Company's Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Business Combinations and Goodwill - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails</Role>
      <ShortName>Business Combinations and Goodwill - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Business Combinations and Goodwill - Summary of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails</Role>
      <ShortName>Business Combinations and Goodwill - Summary of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets, Net - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - Intangible Assets, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails</Role>
      <ShortName>Intangible Assets, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2418410 - Disclosure - Intangible Assets, Net - Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails</Role>
      <ShortName>Intangible Assets, Net - Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - Investments in Other Entities - Equity Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails</Role>
      <ShortName>Investments in Other Entities - Equity Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2422412 - Disclosure - Investments in Other Entities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails</Role>
      <ShortName>Investments in Other Entities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2423413 - Disclosure - Investments in Other Entities - Summarized Balance Sheets and Statements of Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails</Role>
      <ShortName>Investments in Other Entities - Summarized Balance Sheets and Statements of Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2425414 - Disclosure - Loan Receivable and Loan Receivable ??? Related Parties - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails</Role>
      <ShortName>Loan Receivable and Loan Receivable ??? Related Parties - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails</Role>
      <ShortName>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Medical Liabilities - Schedule of Medical Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails</Role>
      <ShortName>Medical Liabilities - Schedule of Medical Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2434417 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Credit Facility (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails</Role>
      <ShortName>Credit Facility, Bank Loans, and Lines of Credit - Credit Facility (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2435418 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Schedule of Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails</Role>
      <ShortName>Credit Facility, Bank Loans, and Lines of Credit - Schedule of Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails</Role>
      <ShortName>Credit Facility, Bank Loans, and Lines of Credit - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2438420 - Disclosure - Mezzanine and Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Mezzanine and Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2441421 - Disclosure - Stock Based Compensation - Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails</Role>
      <ShortName>Stock Based Compensation - Share-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2442422 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2443423 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2444424 - Disclosure - Stock-Based Compensation - Options, Assumptions Under Black-Scholes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails</Role>
      <ShortName>Stock-Based Compensation - Options, Assumptions Under Black-Scholes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2445425 - Disclosure - Stock-Based Compensation - Summary of Warrant (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Warrant (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2446426 - Disclosure - Stock-Based Compensation - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails</Role>
      <ShortName>Stock-Based Compensation - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2448427 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2451428 - Disclosure - Related-Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related-Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2452429 - Disclosure - Related-Party Transactions - Fees Incurred and Income Received (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails</Role>
      <ShortName>Related-Party Transactions - Fees Incurred and Income Received (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2454430 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2457431 - Disclosure - Earnings Per Share - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails</Role>
      <ShortName>Earnings Per Share - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2458432 - Disclosure - Earnings Per Share - Earnings Per Share Computations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails</Role>
      <ShortName>Earnings Per Share - Earnings Per Share Computations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2459433 - Disclosure - Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails</Role>
      <ShortName>Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2462434 - Disclosure - Variable Interest Entities (VIEs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails</Role>
      <ShortName>Variable Interest Entities (VIEs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2465435 - Disclosure - Leases - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesAdditionalinformationDetails</Role>
      <ShortName>Leases - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2466436 - Disclosure - Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2467437 - Disclosure - Leases - Other Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails</Role>
      <ShortName>Leases - Other Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2468438 - Disclosure - Leases - Future Minimum Payments Under Non-cancelable Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails</Role>
      <ShortName>Leases - Future Minimum Payments Under Non-cancelable Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="ameh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - ameh-20220331.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - ameh-20220331.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="ameh-20220331.htm">ameh-20220331.htm</File>
    <File>ameh-20220331.xsd</File>
    <File>ameh-20220331_cal.xml</File>
    <File>ameh-20220331_def.xml</File>
    <File>ameh-20220331_lab.xml</File>
    <File>ameh-20220331_pre.xml</File>
    <File>ex3112022033110-q.htm</File>
    <File>ex3122022033110-q.htm</File>
    <File>ex3132022033110-q.htm</File>
    <File>ex322022033110-q.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1000">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>92
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ameh-20220331.htm": {
   "axisCustom": 1,
   "axisStandard": 37,
   "contextCount": 350,
   "dts": {
    "calculationLink": {
     "local": [
      "ameh-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ameh-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ameh-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ameh-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ameh-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ameh-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 774,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 5
   },
   "keyCustom": 86,
   "keyStandard": 378,
   "memberCustom": 84,
   "memberStandard": 47,
   "nsprefix": "ameh",
   "nsuri": "http://www.apollomed.net/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Document and Entity Information",
     "role": "http://www.apollomed.net/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114104 - Disclosure - Intangible Assets, Net",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNet",
     "shortName": "Intangible Assets, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ameh:EquityMethodAndOtherEquityInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119105 - Disclosure - Investments in Other Entities",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntities",
     "shortName": "Investments in Other Entities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ameh:EquityMethodAndOtherEquityInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ameh:LoanReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124106 - Disclosure - Loan Receivable and Loan Receivable \u2013 Related Parties",
     "role": "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties",
     "shortName": "Loan Receivable and Loan Receivable \u2013 Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ameh:LoanReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126107 - Disclosure - Accounts Payable and Accrued Expenses",
     "role": "http://www.apollomed.net/role/AccountsPayableandAccruedExpenses",
     "shortName": "Accounts Payable and Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129108 - Disclosure - Medical Liabilities",
     "role": "http://www.apollomed.net/role/MedicalLiabilities",
     "shortName": "Medical Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132109 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit",
     "shortName": "Credit Facility, Bank Loans, and Lines of Credit",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137110 - Disclosure - Mezzanine and Stockholders' Equity",
     "role": "http://www.apollomed.net/role/MezzanineandStockholdersEquity",
     "shortName": "Mezzanine and Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139111 - Disclosure - Stock Based Compensation",
     "role": "http://www.apollomed.net/role/StockBasedCompensation",
     "shortName": "Stock Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147112 - Disclosure - Commitments and Contingencies",
     "role": "http://www.apollomed.net/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149113 - Disclosure - Related-Party Transactions",
     "role": "http://www.apollomed.net/role/RelatedPartyTransactions",
     "shortName": "Related-Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "icdb7399a6abd460491239b97b7522507_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "icdb7399a6abd460491239b97b7522507_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2153114 - Disclosure - Income Taxes",
     "role": "http://www.apollomed.net/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2155115 - Disclosure - Earnings Per Share",
     "role": "http://www.apollomed.net/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2160116 - Disclosure - Variable Interest Entities (VIEs)",
     "role": "http://www.apollomed.net/role/VariableInterestEntitiesVIEs",
     "shortName": "Variable Interest Entities (VIEs)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2163117 - Disclosure - Leases",
     "role": "http://www.apollomed.net/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Business Combinations and Goodwill (Tables)",
     "role": "http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables",
     "shortName": "Business Combinations and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315303 - Disclosure - Intangible Assets, Net (Tables)",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNetTables",
     "shortName": "Intangible Assets, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320304 - Disclosure - Investments in Other Entities (Tables)",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesTables",
     "shortName": "Investments in Other Entities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327305 - Disclosure - Accounts Payable and Accrued Expenses (Tables)",
     "role": "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables",
     "shortName": "Accounts Payable and Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "icdb7399a6abd460491239b97b7522507_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "icdb7399a6abd460491239b97b7522507_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330306 - Disclosure - Medical Liabilities (Tables)",
     "role": "http://www.apollomed.net/role/MedicalLiabilitiesTables",
     "shortName": "Medical Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333307 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit (Tables)",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables",
     "shortName": "Credit Facility, Bank Loans, and Lines of Credit (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340308 - Disclosure - Stock Based Compensation (Tables)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationTables",
     "shortName": "Stock Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2350309 - Disclosure - Related-Party Transactions (Tables)",
     "role": "http://www.apollomed.net/role/RelatedPartyTransactionsTables",
     "shortName": "Related-Party Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2356310 - Disclosure - Earnings Per Share (Tables)",
     "role": "http://www.apollomed.net/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2361311 - Disclosure - Variable Interest Entities (VIEs) (Tables)",
     "role": "http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables",
     "shortName": "Variable Interest Entities (VIEs) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2364312 - Disclosure - Leases (Tables)",
     "role": "http://www.apollomed.net/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "icdb7399a6abd460491239b97b7522507_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Description of Business - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
     "shortName": "Description of Business - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "ied48cf0dd52b4ecbacf11485317313d5_D20210801-20210831",
      "decimals": null,
      "lang": "en-US",
      "name": "ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "if1368e96397d4afb8a5b06c97f9a0e75_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF INCOME",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
     "shortName": "CONSOLIDATED STATEMENTS OF INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i23c400c680394251b215b33cfde92dbc_D20210101-20210331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i23c400c680394251b215b33cfde92dbc_D20210101-20210331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "icdb7399a6abd460491239b97b7522507_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Company's Financial Instruments (Details)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Company's Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "icdb7399a6abd460491239b97b7522507_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "icdb7399a6abd460491239b97b7522507_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Business Combinations and Goodwill - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
     "shortName": "Business Combinations and Goodwill - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i4043dc9bcd1c428faf9de8df64df4c4c_I20220124",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i9c0728e5be5f486992e2eeff2682d1eb_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Business Combinations and Goodwill - Summary of Goodwill (Details)",
     "role": "http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails",
     "shortName": "Business Combinations and Goodwill - Summary of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "icdb7399a6abd460491239b97b7522507_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details)",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
     "shortName": "Intangible Assets, Net - Schedule of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "icdb7399a6abd460491239b97b7522507_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - Intangible Assets, Net - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails",
     "shortName": "Intangible Assets, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "icdb7399a6abd460491239b97b7522507_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418410 - Disclosure - Intangible Assets, Net - Future Amortization Expense (Details)",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails",
     "shortName": "Intangible Assets, Net - Future Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "icdb7399a6abd460491239b97b7522507_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i9c0728e5be5f486992e2eeff2682d1eb_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - Investments in Other Entities - Equity Method Investments (Details)",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails",
     "shortName": "Investments in Other Entities - Equity Method Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ameh:EquityMethodInvestmentsContribution",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentSoldCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422412 - Disclosure - Investments in Other Entities - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
     "shortName": "Investments in Other Entities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "ief73fee5943140169a860306e97c01dd_I20180531",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "icdb7399a6abd460491239b97b7522507_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423413 - Disclosure - Investments in Other Entities - Summarized Balance Sheets and Statements of Income (Details)",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails",
     "shortName": "Investments in Other Entities - Summarized Balance Sheets and Statements of Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i33512e53ca8042e592da50359233581e_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i0f6053bba0574b7c8d8bc3d35aedd364_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i0f6053bba0574b7c8d8bc3d35aedd364_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i23ad757dae0649c281c2c43b079538ea_I20201031",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425414 - Disclosure - Loan Receivable and Loan Receivable \u2013 Related Parties - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
     "shortName": "Loan Receivable and Loan Receivable \u2013 Related Parties - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i23ad757dae0649c281c2c43b079538ea_I20201031",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "icdb7399a6abd460491239b97b7522507_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)",
     "role": "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails",
     "shortName": "Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "icdb7399a6abd460491239b97b7522507_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i9c0728e5be5f486992e2eeff2682d1eb_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Medical Liabilities - Schedule of Medical Liabilities (Details)",
     "role": "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails",
     "shortName": "Medical Liabilities - Schedule of Medical Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "icdb7399a6abd460491239b97b7522507_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434417 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Credit Facility (Details)",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails",
     "shortName": "Credit Facility, Bank Loans, and Lines of Credit - Credit Facility (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "icdb7399a6abd460491239b97b7522507_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "icdb7399a6abd460491239b97b7522507_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435418 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Schedule of Maturities (Details)",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails",
     "shortName": "Credit Facility, Bank Loans, and Lines of Credit - Schedule of Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "icdb7399a6abd460491239b97b7522507_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "icdb7399a6abd460491239b97b7522507_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
     "shortName": "Credit Facility, Bank Loans, and Lines of Credit - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ameh:AssetAcquisitionPercentageOfSharesAcquired",
       "ameh:AssetAcquisitionPercentageOfSharesAcquired",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i8159b237bb57472289fa8745bfaf2c2a_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ameh:AssetAcquisitionPercentageOfSharesAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ameh:StockIssuedDuringPeriodSharesMerger",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438420 - Disclosure - Mezzanine and Stockholders' Equity - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
     "shortName": "Mezzanine and Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ameh:StockIssuedDuringPeriodSharesMerger",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441421 - Disclosure - Stock Based Compensation - Share-Based Compensation Expense (Details)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails",
     "shortName": "Stock Based Compensation - Share-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "icdb7399a6abd460491239b97b7522507_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442422 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "icdb7399a6abd460491239b97b7522507_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "icdb7399a6abd460491239b97b7522507_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443423 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i1274ac1b93074e91b7b5207ef70ffa3f_D20220101-20220331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444424 - Disclosure - Stock-Based Compensation - Options, Assumptions Under Black-Scholes (Details)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails",
     "shortName": "Stock-Based Compensation - Options, Assumptions Under Black-Scholes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i1274ac1b93074e91b7b5207ef70ffa3f_D20220101-20220331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i9c0728e5be5f486992e2eeff2682d1eb_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445425 - Disclosure - Stock-Based Compensation - Summary of Warrant (Details)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails",
     "shortName": "Stock-Based Compensation - Summary of Warrant (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ameh:NumberOfWarrantsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "icdb7399a6abd460491239b97b7522507_I20220331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446426 - Disclosure - Stock-Based Compensation - Warrants (Details)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails",
     "shortName": "Stock-Based Compensation - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i17b21603feaa4b6eac83277e537457e2_I20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "icdb7399a6abd460491239b97b7522507_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCredit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448427 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "ie54e1b2ff59741a89b0243c59b6ef686_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LineOfCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451428 - Disclosure - Related-Party Transactions - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related-Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i9ac40763eff9488da386a8f3f515dcd2_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ameh:PaymentConsultingFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452429 - Disclosure - Related-Party Transactions - Fees Incurred and Income Received (Details)",
     "role": "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails",
     "shortName": "Related-Party Transactions - Fees Incurred and Income Received (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i88100c9376d541219eea1723b76e0ce5_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454430 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "idbab252c85d54d69abb776900de44d5a_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457431 - Disclosure - Earnings Per Share - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
     "shortName": "Earnings Per Share - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "idbab252c85d54d69abb776900de44d5a_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareBasic",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458432 - Disclosure - Earnings Per Share - Earnings Per Share Computations (Details)",
     "role": "http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails",
     "shortName": "Earnings Per Share - Earnings Per Share Computations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459433 - Disclosure - Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details)",
     "role": "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails",
     "shortName": "Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "ib88b8cbaf9c044f48d97f4585c10e9b1_D20220101-20220331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of Business",
     "role": "http://www.apollomed.net/role/DescriptionofBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "icdb7399a6abd460491239b97b7522507_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462434 - Disclosure - Variable Interest Entities (VIEs) (Details)",
     "role": "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails",
     "shortName": "Variable Interest Entities (VIEs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "if57d38b69b26462fbe9ef33ebe278bce_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "icdb7399a6abd460491239b97b7522507_I20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465435 - Disclosure - Leases - Additional information (Details)",
     "role": "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
     "shortName": "Leases - Additional information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "icdb7399a6abd460491239b97b7522507_I20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466436 - Disclosure - Leases - Components of Lease Expense (Details)",
     "role": "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails",
     "shortName": "Leases - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2467437 - Disclosure - Leases - Other Information Related to Leases (Details)",
     "role": "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails",
     "shortName": "Leases - Other Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "icdb7399a6abd460491239b97b7522507_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2468438 - Disclosure - Leases - Future Minimum Payments Under Non-cancelable Leases (Details)",
     "role": "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
     "shortName": "Leases - Future Minimum Payments Under Non-cancelable Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "icdb7399a6abd460491239b97b7522507_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110103 - Disclosure - Business Combinations and Goodwill",
     "role": "http://www.apollomed.net/role/BusinessCombinationsandGoodwill",
     "shortName": "Business Combinations and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "i06b546f053dc4360a3ae3232f6961200_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "ib537036edf0744c69646e8a9929a0638_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashEquivalentsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - ameh-20220331.htm",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - ameh-20220331.htm",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220331.htm",
      "contextRef": "ib537036edf0744c69646e8a9929a0638_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashEquivalentsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 149,
   "tag": {
    "ameh_AHMCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AHMC [Member]",
        "terseLabel": "AHMC",
        "verboseLabel": "AHMC"
       }
      }
     },
     "localname": "AHMCMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AMGPropertiesLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AMG Properties LLC",
        "label": "AMG Properties LLC [Member]",
        "terseLabel": "AMG Properties LLC"
       }
      }
     },
     "localname": "AMGPropertiesLLCMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_APAMHMedicalCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AP-AMH Medical Corporation [Member]",
        "label": "AP-AMH Medical Corporation [Member]",
        "terseLabel": "AP-AMH Medical Corporation"
       }
      }
     },
     "localname": "APAMHMedicalCorporationMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_APCAndAPCLSMAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "APC And APC-LSMA [Member]",
        "label": "APC And APC-LSMA [Member]",
        "terseLabel": "APC and APC-LSMA"
       }
      }
     },
     "localname": "APCAndAPCLSMAMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AccessPrimaryCareMedicalGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Access Primary Care Medical Group",
        "label": "Access Primary Care Medical Group [Member]",
        "terseLabel": "Access Primary Care Medical Group"
       }
      }
     },
     "localname": "AccessPrimaryCareMedicalGroupMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AccountableHealthCareIPAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accountable Health Care IPA [Member]",
        "verboseLabel": "Accountable Health Care"
       }
      }
     },
     "localname": "AccountableHealthCareIPAMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AccountsPayableAndAccruedExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable And Accrued Expenses [Member]",
        "terseLabel": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedExpensesMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AccountsReceivableAndNetRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable And Net Revenue [Line Items]",
        "terseLabel": "Accounts Receivable And Net Revenue [Line Items]"
       }
      }
     },
     "localname": "AccountsReceivableAndNetRevenueLineItems",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_AccountsReceivableAndNetRevenueTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable And Net Revenue [Table]",
        "terseLabel": "Accounts Receivable And Net Revenue [Table]"
       }
      }
     },
     "localname": "AccountsReceivableAndNetRevenueTable",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_AchievaMedInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AchievaMed, Inc. [Member]",
        "label": "AchievaMed, Inc. [Member]",
        "terseLabel": "AchievaMed, Inc."
       }
      }
     },
     "localname": "AchievaMedInc.Member",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AdvanceDiagnosticSurgeryCenterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advance Diagnostic Surgery Center [Member]",
        "terseLabel": "Advance Diagnostic Surgery Center"
       }
      }
     },
     "localname": "AdvanceDiagnosticSurgeryCenterMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AggregateintrinsicvalueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value [Abstract]"
       }
      }
     },
     "localname": "AggregateintrinsicvalueAbstract",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_AlliedPacificOfCaliforniaIPAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allied Pacific Of California IPA",
        "label": "Allied Pacific Of California IPA [Member]",
        "verboseLabel": "APC"
       }
      }
     },
     "localname": "AlliedPacificOfCaliforniaIPAMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AlphaCareMedicalGroupInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alpha Care Medical Group, Inc. [Member]",
        "label": "Alpha Care Medical Group, Inc. [Member]",
        "terseLabel": "Alpha Care Medical Group, Inc."
       }
      }
     },
     "localname": "AlphaCareMedicalGroupInc.Member",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AmendedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Credit Agreement",
        "label": "Amended Credit Agreement [Member]",
        "terseLabel": "Amended Credit Agreement"
       }
      }
     },
     "localname": "AmendedCreditAgreementMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AmgIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AMG, Inc [Member]",
        "terseLabel": "AMG, Inc"
       }
      }
     },
     "localname": "AmgIncMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AncillaryServiceContractMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ancillary Service Contract [Member]",
        "terseLabel": "Ancillary Service Contract"
       }
      }
     },
     "localname": "AncillaryServiceContractMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApaAcoIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "APA ACO Inc [Member]",
        "terseLabel": "APA ACO Inc"
       }
      }
     },
     "localname": "ApaAcoIncMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApcBusinessLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "APC Business Loan Agreement [Member]",
        "terseLabel": "APC Business Loan Agreement"
       }
      }
     },
     "localname": "ApcBusinessLoanAgreementMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApcLsmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "APC LSMA [Member]",
        "terseLabel": "APC LSMA"
       }
      }
     },
     "localname": "ApcLsmaMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApcShareholdersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "APC Shareholders [Member]",
        "terseLabel": "APC Shareholders"
       }
      }
     },
     "localname": "ApcShareholdersMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApolloMedicalHoldingsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Apollo Medical Holdings, Inc [Member]",
        "terseLabel": "Apollo Medical Holdings, Inc"
       }
      }
     },
     "localname": "ApolloMedicalHoldingsIncMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApolloSunLabsManagementLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Apollo-Sun Labs Management, LLC",
        "label": "Apollo-Sun Labs Management, LLC [Member]",
        "terseLabel": "Apollo-Sun Labs Management, LLC"
       }
      }
     },
     "localname": "ApolloSunLabsManagementLLCMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ArroyoVistaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arroyo Vista",
        "label": "Arroyo Vista [Member]",
        "terseLabel": "Arroyo Vista"
       }
      }
     },
     "localname": "ArroyoVistaMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AssetAcquisitionPercentageOfSharesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Percentage Of Shares Acquired",
        "label": "Asset Acquisition, Percentage Of Shares Acquired",
        "terseLabel": "Asset acquisition, percentage of shares acquired"
       }
      }
     },
     "localname": "AssetAcquisitionPercentageOfSharesAcquired",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_AurionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "xxx_Aurion Member",
        "label": "Aurion [Member]",
        "verboseLabel": "Aurion"
       }
      }
     },
     "localname": "AurionMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Equity Interest Purchase Obligation, Noncurrent",
        "label": "Business Combination, Equity Interest Purchase Obligation, Noncurrent",
        "terseLabel": "Equity interest purchase obligation, noncurrent"
       }
      }
     },
     "localname": "BusinessCombinationEquityInterestPurchaseObligationNoncurrent",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Equity Interest Purchase Obligation, Period to Purchase",
        "label": "Business Combination, Equity Interest Purchase Obligation, Period to Purchase",
        "terseLabel": "Equity interest purchase obligation, period to purchase"
       }
      }
     },
     "localname": "BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_CAIPAMSOLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CAIPA MSO, LLC",
        "label": "CAIPA MSO, LLC [Member]",
        "terseLabel": "CAIPA MSO, LLC"
       }
      }
     },
     "localname": "CAIPAMSOLLCMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CDSCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CDSC",
        "label": "CDSC [Member]",
        "terseLabel": "CDSC"
       }
      }
     },
     "localname": "CDSCMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CMSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CMS [Member]",
        "label": "CMS [Member]",
        "terseLabel": "CMS"
       }
      }
     },
     "localname": "CMSMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CashPaidForLeaseLiabilitiesAbstractAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid For Lease Liabilities [Abstract]",
        "verboseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashPaidForLeaseLiabilitiesAbstractAbstract",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ClassOfWarrantOrRightCancelledInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right, cancelled in period",
        "label": "Class Of Warrant Or Right Cancelled In Period",
        "negatedLabel": "Warrants expired/forfeited (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightCancelledInPeriod",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ClassOfWarrantOrRightExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Exercisable",
        "label": "Class Of Warrant Or Right Exercisable",
        "terseLabel": "Warrants Exercisable (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisable",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ClassOfWarrantOrRightIssuedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Issued in Period",
        "label": "Class Of Warrant Or Right Issued In Period",
        "verboseLabel": "Warrants Outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuedInPeriod",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term",
        "label": "Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Rights outstanding Weighted Average Remaining Contractual Term",
        "label": "Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Term",
        "verboseLabel": "Warrants outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of warrants or rights exercised in period.",
        "label": "Class Of Warrants Or Right, Exercises In Period, Aggregate Intrinsic Value",
        "verboseLabel": "Warrants exercised"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of warrants or rights forfeited in period.",
        "label": "Class Of Warrants Or Right, Forfeitures In Period, Aggregate Intrinsic Value",
        "verboseLabel": "Warrants expired/forfeited"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of warrants or rights granted in period.",
        "label": "Class Of Warrants Or Right, Grant In Period, Aggregate Intrinsic Value",
        "verboseLabel": "Warrants granted"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of warrants or rights outstanding.",
        "label": "Class Of Warrants Or Right, Outstanding, Aggregate Intrinsic Value",
        "periodEndLabel": "Warrants outstanding, ending balance",
        "periodStartLabel": "Warrants outstanding, beginning balance"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants",
        "label": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants",
        "periodEndLabel": "Warrants outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Warrants outstanding, beginning balance (in dollars per share)",
        "terseLabel": "Weighted Average Exercise\u00a0Price Per Share (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails",
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share of warrants or rights exercised during the period.",
        "label": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Exercised In Period",
        "verboseLabel": "Warrants exercised (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share of warrants or rights forfeited during the period.",
        "label": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Forfeited In Period",
        "verboseLabel": "Warrants expired/forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share of warrants or rights granted during the period.",
        "label": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Grant In Period",
        "verboseLabel": "Warrants granted (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_ClinigenceHoldingsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinigence Holdings, Inc.",
        "label": "Clinigence Holdings, Inc. [Member]",
        "terseLabel": "Clinigence Holdings, Inc."
       }
      }
     },
     "localname": "ClinigenceHoldingsIncMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CommercialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ameh:CommercialMember",
        "label": "Commercial [Member]",
        "terseLabel": "Commercial"
       }
      }
     },
     "localname": "CommercialMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ConcourseDiagnosticSurgeryCenterLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concourse Diagnostic Surgery Center, LLC [Member]",
        "terseLabel": "Concourse Diagnostic Surgery Center, LLC"
       }
      }
     },
     "localname": "ConcourseDiagnosticSurgeryCenterLlcMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ConstructionLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Construction Loan",
        "label": "Construction Loan [Member]",
        "terseLabel": "Construction Loan"
       }
      }
     },
     "localname": "ConstructionLoanMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ContingentEquitySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Equity Securities",
        "label": "Contingent Equity Securities [Member]",
        "terseLabel": "Contingent Equity Securities"
       }
      }
     },
     "localname": "ContingentEquitySecuritiesMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ContractTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract Type [Axis]",
        "terseLabel": "Contract Type [Axis]"
       }
      }
     },
     "localname": "ContractTypeAxis",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract Type [Domain]",
        "terseLabel": "Contract Type [Domain]"
       }
      }
     },
     "localname": "ContractTypeDomain",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Agreement [Member]",
        "label": "Credit Agreement [Member]",
        "terseLabel": "Credit Agreement"
       }
      }
     },
     "localname": "CreditAgreementMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_DebtCovenantAggregatePurchasePriceMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Covenant, Aggregate Purchase Price, Maximum",
        "label": "Debt Covenant, Aggregate Purchase Price, Maximum",
        "terseLabel": "Debt covenant, aggregate purchase price, maximum"
       }
      }
     },
     "localname": "DebtCovenantAggregatePurchasePriceMaximum",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Cash Flow Coverage Ratio, Minimum",
        "label": "Debt Instrument, Covenant, Cash Flow Coverage Ratio, Minimum",
        "terseLabel": "Debt instrument, covenant, cash flow coverage ratio, minimum"
       }
      }
     },
     "localname": "DebtInstrumentCovenantCashFlowCoverageRatioMinimum",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Debt Coverage Ratio, Minimum",
        "label": "Debt Instrument, Covenant, Debt Coverage Ratio, Minimum",
        "terseLabel": "Debt instrument, covenant, debt coverage ratio, minimum"
       }
      }
     },
     "localname": "DebtInstrumentCovenantDebtCoverageRatioMinimum",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum",
        "label": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum",
        "terseLabel": "Minimum consolidated interest coverage ratio (not less than)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantInterestCoverageRatioMinimum",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Leverage Ratio, Adjusted Maximum",
        "label": "Debt Instrument, Covenant, Leverage Ratio, Adjusted Maximum",
        "terseLabel": "Debt instrument, covenant, leverage ratio, adjusted maximum"
       }
      }
     },
     "localname": "DebtInstrumentCovenantLeverageRatioAdjustedMaximum",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Leverage Ratio, Incremental Change",
        "label": "Debt Instrument, Covenant, Leverage Ratio, Incremental Change",
        "terseLabel": "Consolidated leverage ratio, annual decrease"
       }
      }
     },
     "localname": "DebtInstrumentCovenantLeverageRatioIncrementalChange",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentCovenantLeverageRatioMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Leverage Ratio, Maximum",
        "label": "Debt Instrument, Covenant, Leverage Ratio, Maximum",
        "terseLabel": "Maximum consolidated leverage ratio (not greater than)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantLeverageRatioMaximum",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentNumberOfKeyFinancialRatios": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Number Of Key Financial Ratios",
        "label": "Debt Instrument, Number Of Key Financial Ratios",
        "terseLabel": "Number of key financial ratios"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfKeyFinancialRatios",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_DescriptionOfBusinessLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description Of Business [Line Items]",
        "terseLabel": "Description Of Business [Line Items]"
       }
      }
     },
     "localname": "DescriptionOfBusinessLineItems",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_DescriptionOfBusinessTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description Of Business [Table]",
        "terseLabel": "Description Of Business [Table]"
       }
      }
     },
     "localname": "DescriptionOfBusinessTable",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_DmgMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DMG [Member]",
        "terseLabel": "DMG"
       }
      }
     },
     "localname": "DmgMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_Dr.ArteagaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dr. Arteaga [Member]",
        "label": "Dr. Arteaga [Member]",
        "verboseLabel": "Dr. Arteaga"
       }
      }
     },
     "localname": "Dr.ArteagaMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_Dr.JayMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dr. Jay [Member]",
        "label": "Dr. Jay [Member]",
        "terseLabel": "Dr. Jay"
       }
      }
     },
     "localname": "Dr.JayMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_EarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Earnings Per Share [Table]",
        "label": "Earnings Per Share [Line Items]",
        "terseLabel": "Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareLineItems",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_EarningsPerShareTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share [Table]",
        "label": "Earnings Per Share [Table]",
        "terseLabel": "Earnings Per Share [Table]"
       }
      }
     },
     "localname": "EarningsPerShareTable",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_EmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees",
        "label": "Employees [Member]",
        "terseLabel": "Employees"
       }
      }
     },
     "localname": "EmployeesMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_EquityMethodAndOtherEquityInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method And Other Equity Investments [Text Block]",
        "label": "Equity Method And Other Equity Investments [Text Block]",
        "verboseLabel": "Investments in Other Entities"
       }
      }
     },
     "localname": "EquityMethodAndOtherEquityInvestmentsTextBlock",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_EquityMethodInvestmentOwnershipPercentageDisposed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Ownership Percentage Disposed",
        "label": "Equity Method Investment, Ownership Percentage Disposed",
        "terseLabel": "Ownership interest disposed"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentageDisposed",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_EquityMethodInvestmentOwnershipPercentageSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Ownership Percentage, Sold",
        "label": "Equity Method Investment, Ownership Percentage, Sold",
        "terseLabel": "Ownership percentage sold"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentageSold",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_EquityMethodInvestmentsContribution": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investments, Contribution",
        "label": "Equity Method Investments, Contribution",
        "terseLabel": "Funding"
       }
      }
     },
     "localname": "EquityMethodInvestmentsContribution",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquityMethodInvestmentsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investments [Roll Forward]",
        "label": "Equity Method Investments [Roll Forward]",
        "terseLabel": "Equity Method Investments [Roll Forward]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsRollForward",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Term Of Option",
        "label": "Equity Securities Without Readily Determinable Fair Value Investment, Options Issued, Term Of Option",
        "terseLabel": "Term of option"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments",
        "terseLabel": "Related investment balance"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost",
        "terseLabel": "Investment amount"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment",
        "terseLabel": "Duration of investment"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest",
        "terseLabel": "Membership interests acquired (in dollars per share)"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests",
        "terseLabel": "Options to purchase additional membership interests (in shares)"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Options Issues, Options To Purchase Additional Interests, If Circumstances Met",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Options Issues, Options To Purchase Additional Interests, If Circumstances Met",
        "terseLabel": "Number of warrants available to purchase, contingent upon the portal completion date (in shares)"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years",
        "terseLabel": "Percentage of voting common stock, within five years"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares",
        "terseLabel": "Membership interests purchased (in shares)"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities without Readily Determinable Fair Value, Ownership Percentage",
        "label": "Equity Securities Without Readily Determinable Fair Value, Ownership Percentage",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_FiduciaryAccountsPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.",
        "label": "Fiduciary Accounts Payable Current",
        "terseLabel": "Fiduciary accounts payable"
       }
      }
     },
     "localname": "FiduciaryAccountsPayableCurrent",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_FiduciaryCashAndPayablePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiduciary Cash and Payable",
        "label": "Fiduciary Cash and Payable [Policy Text Block]",
        "terseLabel": "Fiduciary Cash and Payable"
       }
      }
     },
     "localname": "FiduciaryCashAndPayablePolicyTextBlock",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_FinanceLeaseCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease Costs",
        "label": "Finance Lease Costs [Abstract]",
        "terseLabel": "Finance Lease Cost [Abstract]"
       }
      }
     },
     "localname": "FinanceLeaseCostsAbstract",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_FinanceLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Liability, To Be Paid, After Year Four",
        "label": "Finance Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_FinanceReceivableInterestRateStatedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Receivable, Interest Rate, Stated Percentage",
        "label": "Finance Receivable, Interest Rate, Stated Percentage",
        "terseLabel": "Note receivable, interest rate"
       }
      }
     },
     "localname": "FinanceReceivableInterestRateStatedPercentage",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Receivable, Modifications, Subsequent Default, Interest Rate",
        "label": "Finance Receivable, Modifications, Subsequent Default, Interest Rate",
        "terseLabel": "Interest rate in the event of default"
       }
      }
     },
     "localname": "FinanceReceivableModificationsSubsequentDefaultInterestRate",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_FinanceReceivableStatedInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Receivable, Stated Interest Rate",
        "label": "Finance Receivable, Stated Interest Rate",
        "terseLabel": "Stated rate of note of loan receivable"
       }
      }
     },
     "localname": "FinanceReceivableStatedInterestRate",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_FinanceReceivableTermOfReceivable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Receivable, Term Of Receivable",
        "label": "Finance Receivable, Term Of Receivable",
        "terseLabel": "Term of receivable"
       }
      }
     },
     "localname": "FinanceReceivableTermOfReceivable",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_FiveThreeOneW.CollegeLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Five Three One W. College LLC [Member]",
        "terseLabel": "531 W. College LLC",
        "verboseLabel": "531 W. College, LLC \u2013 related party"
       }
      }
     },
     "localname": "FiveThreeOneW.CollegeLLCMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_FreseniusMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fresenius",
        "label": "Fresenius [Member]",
        "terseLabel": "Fresenius"
       }
      }
     },
     "localname": "FreseniusMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_FulgentGeneticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fulgent Genetics, Inc.",
        "label": "Fulgent Genetics, Inc. [Member]",
        "terseLabel": "Fulgent Genetics, Inc."
       }
      }
     },
     "localname": "FulgentGeneticsIncMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_HSMSOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "xxx_HSMSO Member",
        "label": "HSMSO [Member]",
        "verboseLabel": "HSMSO"
       }
      }
     },
     "localname": "HSMSOMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_HealthCareCapitationRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ameh_HealthCareCapitationRevenueMember",
        "label": "Health Care Capitation Revenue [Member]",
        "verboseLabel": "Capitation, net"
       }
      }
     },
     "localname": "HealthCareCapitationRevenueMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_IncreaseDecreaseInMedicalLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of medical liabilities.",
        "label": "Increase (Decrease) In Medical Liabilities",
        "verboseLabel": "Medical liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInMedicalLiabilities",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_IncreaseDecreaseInOperatingLeaseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents increase in operating lease assets.",
        "label": "Increase (Decrease) In Operating Lease Assets",
        "verboseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseAssets",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the value of prepaid expenses and other current assets.",
        "label": "Increase (Decrease) In Prepaid Expenses And Other Current Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The initial fixed term of amended and restated management and administrative services agreement.",
        "label": "Initial Fixed Term Of Amended And Restated Management And Administrative Services Agreement",
        "terseLabel": "Fixed term of amended and restated management and administrative services agreement"
       }
      }
     },
     "localname": "InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insurance Services Revenue, Capitation, And Claims Payment, Net",
        "label": "Insurance Services Revenue, Capitation, And Claims Payment, Net",
        "terseLabel": "AHMC \u2013 Risk pool, capitation, claims payment"
       }
      }
     },
     "localname": "InsuranceServicesRevenueCapitationAndClaimsPaymentNet",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of Investment in privately held entity that does not report net asset value per share .",
        "label": "Investment In Privately Held Entity That Does Not Report Net Asset Value",
        "verboseLabel": "Investments in privately held entities"
       }
      }
     },
     "localname": "InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_LasalleMedicalAssociatesIpaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LaSalle Medical Associates IPA [Member]",
        "terseLabel": "LaSalle Medical Associates \u2013 IPA Line of Business",
        "verboseLabel": "LaSalle Medical Associates"
       }
      }
     },
     "localname": "LasalleMedicalAssociatesIpaMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_LeaseWeightedAverageDiscountRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Weighted Average Discount Rate [Abstract]",
        "verboseLabel": "Weighted Average Discount Rate"
       }
      }
     },
     "localname": "LeaseWeightedAverageDiscountRateAbstract",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_LeaseWeightedAverageRemainingLeaseTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Weighted Average Remaining Lease Term [Abstract]",
        "verboseLabel": "Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "LeaseWeightedAverageRemainingLeaseTermAbstract",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Finance Lease, Termination Period, If Applicable",
        "label": "Lessee, Finance Lease, Termination Period, If Applicable",
        "terseLabel": "Finance lease, termination period, if applicable"
       }
      }
     },
     "localname": "LesseeFinanceLeaseTerminationPeriodIfApplicable",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Termination Period, If Applicable",
        "label": "Lessee, Operating Lease, Termination Period, If Applicable",
        "terseLabel": "Operating lease, termination period, if applicable"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTerminationPeriodIfApplicable",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_LmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LMA [Member]",
        "terseLabel": "LMA"
       }
      }
     },
     "localname": "LmaMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_LoanReceivableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Receivable",
        "label": "Loan Receivable [Text Block]",
        "verboseLabel": "Loan Receivable and Loan Receivable \u2013 Related Parties"
       }
      }
     },
     "localname": "LoanReceivableTextBlock",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_LongTermDebtMaturityAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt, Maturity, After Year Four",
        "label": "Long-Term Debt, Maturity, After Year Four",
        "terseLabel": "2026 and thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturityAfterYearFour",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MPP, AMG Properties, and ZLL Asset Acquisition",
        "label": "MPP, AMG Properties, and ZLL Asset Acquisition [Member]",
        "terseLabel": "MPP, AMG Properties, and ZLL Asset Acquisition"
       }
      }
     },
     "localname": "MPPAMGPropertiesAndZLLAssetAcquisitionMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ManagementContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Management Contracts",
        "label": "Management Contracts [Member]",
        "verboseLabel": "Management contracts"
       }
      }
     },
     "localname": "ManagementContractsMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MarketableSecuritiesCurrentMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities, Current, Maturity Period",
        "label": "Marketable Securities, Current, Maturity Period",
        "terseLabel": "Short-term marketable securities, maturity period"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrentMaturityPeriod",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_MaverickMedicalGroupIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maverick Medical Group, Inc [Member]",
        "terseLabel": "Maverick Medical Group, Inc"
       }
      }
     },
     "localname": "MaverickMedicalGroupIncMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MediPortalLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MediPortal LLC [Member]",
        "terseLabel": "MediPortal LLC"
       }
      }
     },
     "localname": "MediPortalLLCMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MedicaidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ameh:MedicaidMember",
        "label": "Medicaid [Member]",
        "terseLabel": "Medicaid"
       }
      }
     },
     "localname": "MedicaidMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MedicalCareCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Care Costs [Abstract]",
        "label": "Medical Care Costs [Abstract]",
        "terseLabel": "Components of medical care costs related to claims incurred:"
       }
      }
     },
     "localname": "MedicalCareCostsAbstract",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_MedicalPropertyPartnersLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Property Partners LLC",
        "label": "Medical Property Partners LLC [Member]",
        "terseLabel": "Medical Property Partners LLC"
       }
      }
     },
     "localname": "MedicalPropertyPartnersLLCMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ameh:MedicareMember",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MemberRelationshipsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member Relationships",
        "label": "Member Relationships [Member]",
        "terseLabel": "Member relationships"
       }
      }
     },
     "localname": "MemberRelationshipsMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MezzanineEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MEZZANINE EQUITY [Abstract]",
        "verboseLabel": "Mezzanine equity"
       }
      }
     },
     "localname": "MezzanineEquityAbstract",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_MezzanineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mezzanine [Member]",
        "terseLabel": "Mezzanine"
       }
      }
     },
     "localname": "MezzanineMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MinorityInterestPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minority Interest Policy.",
        "label": "Minority Interest Policy [Policy Text Block]",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "MinorityInterestPolicyPolicyTextBlock",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity",
        "label": "Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity",
        "terseLabel": "Net (loss) income"
       }
      }
     },
     "localname": "NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_NetworkMedicalManagementIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Network Medical Management, Inc. [Member]",
        "terseLabel": "Network Medical Management, Inc."
       }
      }
     },
     "localname": "NetworkMedicalManagementIncMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_NetworkMedicalManagementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Network Medical Management [Member]",
        "terseLabel": "NMM"
       }
      }
     },
     "localname": "NetworkMedicalManagementMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_NetworkRelationshipsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Network Relationships",
        "label": "Network Relationships [Member]",
        "terseLabel": "Network relationships"
       }
      }
     },
     "localname": "NetworkRelationshipsMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders And Stock Repurchased During Period, Value, Release Of Hold Back Shares",
        "label": "Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders And Stock Repurchased During Period, Value, Release Of Hold Back Shares",
        "terseLabel": "Dividends"
       }
      }
     },
     "localname": "NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_NumberOfFamilyPracticeClinics": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Family Practice Clinics",
        "label": "Number Of Family Practice Clinics",
        "terseLabel": "Number of family practice clinics"
       }
      }
     },
     "localname": "NumberOfFamilyPracticeClinics",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_NumberOfFederallyQualifiedHealthPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Federally Qualified Health Plans",
        "label": "Number Of Federally Qualified Health Plans",
        "terseLabel": "Number federally qualified health plans"
       }
      }
     },
     "localname": "NumberOfFederallyQualifiedHealthPlans",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_NumberOfWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercised",
        "label": "Number Of Warrants Exercised",
        "negatedLabel": "Warrants exercised (in shares)"
       }
      }
     },
     "localname": "NumberOfWarrantsExercised",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_NumberOfWarrantsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Warrants Granted",
        "label": "Number Of Warrants Granted",
        "verboseLabel": "Warrants granted (in shares)"
       }
      }
     },
     "localname": "NumberOfWarrantsGranted",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_NumenLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Numen LLC [Member]",
        "terseLabel": "Numen LLC"
       }
      }
     },
     "localname": "NumenLLCMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_OneMSOInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One MSO, Inc. [Member]",
        "label": "One MSO, Inc. [Member]",
        "terseLabel": "One MSO, Inc."
       }
      }
     },
     "localname": "OneMSOInc.Member",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_OneMSOLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One MSO, LLC",
        "label": "One MSO, LLC [Member]",
        "terseLabel": "One MSO, LLC \u2013 related party"
       }
      }
     },
     "localname": "OneMSOLLCMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC",
        "label": "One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC [Member]",
        "terseLabel": "One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC"
       }
      }
     },
     "localname": "OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Orma Health, Inc., and Provider Growth Solutions LLC",
        "label": "Orma Health, Inc., and Provider Growth Solutions LLC [Member]",
        "terseLabel": "Orma Health, Inc., and Provider Growth Solutions LLC"
       }
      }
     },
     "localname": "OrmaHealthIncAndProviderGrowthSolutionsLLCMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_OtherThirdPartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ameh:OtherThirdPartiesMember",
        "label": "Other Third Parties [Member]",
        "terseLabel": "Other third parties"
       }
      }
     },
     "localname": "OtherThirdPartiesMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_Pacific6EnterprisesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pacific6 Enterprises [Member]",
        "label": "Pacific6 Enterprises [Member]",
        "terseLabel": "Pacific6 Enterprises"
       }
      }
     },
     "localname": "Pacific6EnterprisesMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PacificMedicalImagingAndOncologyCenterIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pacific Medical Imaging and Oncology Center, Inc [Member]",
        "terseLabel": "Pacific Medical Imaging &amp; Oncology Center, Inc."
       }
      }
     },
     "localname": "PacificMedicalImagingAndOncologyCenterIncMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PatientManagementPlatformMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patient Management Platform",
        "label": "Patient Management Platform [Member]",
        "terseLabel": "Patient management platform"
       }
      }
     },
     "localname": "PatientManagementPlatformMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PaymentConsultingFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Consulting Fees",
        "label": "Payment Consulting Fees",
        "terseLabel": "Consulting services paid"
       }
      }
     },
     "localname": "PaymentConsultingFees",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PaymentMadeToRelatedParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit/Duration (Amount paid to related party in relation to providing services",
        "label": "Payment Made To Related Party",
        "terseLabel": "Payments to related parties"
       }
      }
     },
     "localname": "PaymentMadeToRelatedParty",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PaymentsForMedicalCareCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Medical Care Costs [Abstract]",
        "label": "Payments For Medical Care Costs [Abstract]",
        "terseLabel": "Payments for medical care costs related to claims incurred:"
       }
      }
     },
     "localname": "PaymentsForMedicalCareCostsAbstract",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_PaymentsToAcquireCommonStockAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Common Stock And Warrants",
        "label": "Payments To Acquire Common Stock And Warrants",
        "terseLabel": "Payments to acquire common stock and warrants"
       }
      }
     },
     "localname": "PaymentsToAcquireCommonStockAndWarrants",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments",
        "label": "Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments",
        "terseLabel": "Payments to purchase membership interests"
       }
      }
     },
     "localname": "PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PaymentsToAcquireNonControllingInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to Acquire Non-controlling Interest",
        "label": "Payments to Acquire Non-controlling Interest",
        "negatedLabel": "Purchase of non-controlling interest"
       }
      }
     },
     "localname": "PaymentsToAcquireNonControllingInterest",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PayorAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payor A [Member]",
        "label": "Payor A [Member]",
        "terseLabel": "Payor A"
       }
      }
     },
     "localname": "PayorAMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payor B [Member]",
        "label": "Payor B [Member]",
        "terseLabel": "Payor B"
       }
      }
     },
     "localname": "PayorBMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payor C [Member]",
        "label": "Payor C [Member]",
        "terseLabel": "Payor C"
       }
      }
     },
     "localname": "PayorCMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payor D [Member]",
        "terseLabel": "Payor D"
       }
      }
     },
     "localname": "PayorDMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payor E",
        "label": "Payor E [Member]",
        "terseLabel": "Payor E"
       }
      }
     },
     "localname": "PayorEMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorFMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payor F [Member]",
        "label": "Payor F [Member]",
        "terseLabel": "Payor F"
       }
      }
     },
     "localname": "PayorFMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PerMemberPerMonthManagedCareContractMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per-Member-Per-Month Managed Care Contract [Member]",
        "label": "Per-Member-Per-Month Managed Care Contract [Member]",
        "terseLabel": "PMPM Managed Care Contract"
       }
      }
     },
     "localname": "PerMemberPerMonthManagedCareContractMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PmiocMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PMIOC [Member]",
        "terseLabel": "PMIOC"
       }
      }
     },
     "localname": "PmiocMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PreferredBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Bank [Member]",
        "terseLabel": "Preferred Bank"
       }
      }
     },
     "localname": "PreferredBankMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ProceedsFromSaleOfNoncontrollingInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Sale of Noncontrolling Interest",
        "label": "Proceeds from Sale of Noncontrolling Interest",
        "terseLabel": "Proceeds from sale of non-controlling interest"
       }
      }
     },
     "localname": "ProceedsFromSaleOfNoncontrollingInterest",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Receivables and receivables from related parties.",
        "label": "Receivables And Related parties Receivables Policy Text Block [Policy Text Block]",
        "verboseLabel": "Receivables, Receivables \u2013 Related Parties, and Loan Receivable - Related Party"
       }
      }
     },
     "localname": "ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract",
        "label": "Reconciliation Of Cash Cash Equivalents And Restricted Cash [Abstract]",
        "verboseLabel": "Reconciliation of cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report",
        "terseLabel": "Expected period of payment upon termination of agreement"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk Pool Surplus Or Deficits, Settlement Period After Performance Year",
        "label": "Risk Pool Surplus Or Deficits, Settlement Period After Performance Year",
        "terseLabel": "Risk pool surplus or deficits, settlement period after risk pool performance year"
       }
      }
     },
     "localname": "RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_SCHCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SCHC [Member]",
        "label": "SCHC [Member]",
        "terseLabel": "SCHC"
       }
      }
     },
     "localname": "SCHCMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Contingent on Performance",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Contingent on Performance",
        "terseLabel": "Contingent on performance (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the forfeiture rate.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate",
        "verboseLabel": "Forfeiture rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value (in millions)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Exercise Price [Abstract]",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Exercise Price [Abstract]",
        "verboseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period",
        "label": "Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period",
        "terseLabel": "Warrants exercised (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price",
        "label": "Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price",
        "terseLabel": "Exercise price of warrants exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_ShareholdersAndOfficersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders And Officers [Member]",
        "terseLabel": "APC Shareholders and Officers"
       }
      }
     },
     "localname": "ShareholdersAndOfficersMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_SharesWarrantsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares, Warrants [Roll Forward]",
        "label": "Shares, Warrants [Roll Forward]",
        "terseLabel": "Shares, Warrants [Roll Forward]"
       }
      }
     },
     "localname": "SharesWarrantsRollForward",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_SpecialtyCapitationPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of specialty capitation payable current.",
        "label": "Specialty Capitation Payable Current",
        "verboseLabel": "Capitation payable"
       }
      }
     },
     "localname": "SpecialtyCapitationPayableCurrent",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_StockAwardsAndUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Awards And Units",
        "label": "Stock Awards And Units [Member]",
        "terseLabel": "Restricted stock awards"
       }
      }
     },
     "localname": "StockAwardsAndUnitsMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_StockIssuedDuringPeriodSharesMerger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to merger.",
        "label": "Stock Issued During Period, Shares, Merger",
        "terseLabel": "Holdback shares not issued to former shareholders (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesMerger",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents number of share issued exercise of option and warrants during the period",
        "label": "Stock issued during the period shares of exercise of option and warrants",
        "verboseLabel": "Shares issued for exercise of options and warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents value of stock issued during the period",
        "label": "Stock issued during the period value of exercise of option and warrants",
        "verboseLabel": "Shares issued for exercise of options and warrants"
       }
      }
     },
     "localname": "StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_SubcontractorIPAPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subcontractor IPA Payable",
        "label": "Subcontractor IPA Payable",
        "verboseLabel": "Subcontractor IPA payable"
       }
      }
     },
     "localname": "SubcontractorIPAPayable",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_Tag6MedicalInvestmentGroupLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tag-6 Medical Investment Group, LLC",
        "label": "Tag-6 Medical Investment Group, LLC [Member]",
        "terseLabel": "Tag-6 Medical Investment Group, LLC"
       }
      }
     },
     "localname": "Tag6MedicalInvestmentGroupLLCMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tag-6 Medical Investment Group, LLC - Related Party",
        "label": "Tag-6 Medical Investment Group, LLC - Related Party [Member]",
        "terseLabel": "Tag-6 Medical Investment Group, LLC \u2013 related party"
       }
      }
     },
     "localname": "Tag6MedicalInvestmentGroupLLCRelatedPartyMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_Tag8MedicalInvestmentGroupLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tag-8 Medical Investment Group, LLC",
        "label": "Tag-8 Medical Investment Group, LLC [Member]",
        "terseLabel": "Tag-8 Medical Investment Group, LLC"
       }
      }
     },
     "localname": "Tag8MedicalInvestmentGroupLLCMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_TemporaryEquityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity [Policy Text Block]",
        "label": "Temporary Equity [Policy Text Block]",
        "terseLabel": "Mezzanine Equity"
       }
      }
     },
     "localname": "TemporaryEquityPolicyTextBlock",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_UniversalCareAcquisitionPartnersLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Universal Care Acquisition Partners, LLC [Member]",
        "terseLabel": "Universal Care Acquisition Partners, LLC"
       }
      }
     },
     "localname": "UniversalCareAcquisitionPartnersLlcMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_UniversalCareIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Universal Care Inc [Member]",
        "terseLabel": "Universal Care Inc"
       }
      }
     },
     "localname": "UniversalCareIncMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_UnrealizedGainLossFromInvestmentInEquitySecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrealized (Gain) Loss from Investment in Equity Securities",
        "label": "Unrealized (Gain) Loss from Investment in Equity Securities",
        "negatedLabel": "Unrealized loss (gain) from investment in equity securities"
       }
      }
     },
     "localname": "UnrealizedGainLossFromInvestmentInEquitySecurities",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_WarrantExercisePriceRangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Exercise Price Range One [Member]",
        "verboseLabel": "Warrant Exercise Price Range One"
       }
      }
     },
     "localname": "WarrantExercisePriceRangeOneMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_WarrantExercisePriceRangeThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Exercise Price Range Three [Member]",
        "verboseLabel": "Warrant Exercise Price Range Three"
       }
      }
     },
     "localname": "WarrantExercisePriceRangeThreeMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_WarrantExercisePriceRangeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Exercise Price Range Two [Member]",
        "verboseLabel": "Warrant Exercise Price Range Two"
       }
      }
     },
     "localname": "WarrantExercisePriceRangeTwoMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Issued During Period Value Stock Options Exercised",
        "label": "Warrant Issued During Period Value Stock Options Exercised",
        "terseLabel": "Proceeds from warrants exercised"
       }
      }
     },
     "localname": "WarrantIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_WeightedAverageExercisePriceWarrantsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants [Roll Forward]",
        "label": "Weighted Average Exercise Price, Warrants [Roll Forward]",
        "terseLabel": "Weighted Average Exercise Price, Warrants [Roll Forward]"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsRollForward",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_WeightedaverageremainingcontractualtermyearsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Term Years [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term Years [Abstract]"
       }
      }
     },
     "localname": "WeightedaverageremainingcontractualtermyearsAbstract",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ZLLPartnersLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ZLL Partners LLC",
        "label": "ZLL Partners LLC [Member]",
        "terseLabel": "ZLL Partners LLC"
       }
      }
     },
     "localname": "ZLLPartnersLLCMember",
     "nsuri": "http://www.apollomed.net/20220331",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r397",
      "r576",
      "r577",
      "r580",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r133",
      "r286",
      "r291",
      "r297",
      "r486",
      "r487",
      "r494",
      "r495",
      "r583",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r133",
      "r286",
      "r291",
      "r297",
      "r486",
      "r487",
      "r494",
      "r495",
      "r583",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r68",
      "r70",
      "r130",
      "r131",
      "r303",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Board members"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r210",
      "r378",
      "r383",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r302",
      "r340",
      "r400",
      "r403",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r620",
      "r686",
      "r689",
      "r707",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails",
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r302",
      "r340",
      "r400",
      "r403",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r620",
      "r686",
      "r689",
      "r707",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails",
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r210",
      "r378",
      "r383",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r208",
      "r378",
      "r381",
      "r621",
      "r685",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r208",
      "r378",
      "r381",
      "r621",
      "r685",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r302",
      "r340",
      "r389",
      "r400",
      "r403",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r620",
      "r686",
      "r689",
      "r707",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails",
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r302",
      "r340",
      "r389",
      "r400",
      "r403",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r620",
      "r686",
      "r689",
      "r707",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails",
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r69",
      "r70",
      "r130",
      "r131",
      "r303",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r143",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r143",
      "r148",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r143",
      "r148",
      "r280",
      "r401",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r211",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued expenses",
        "totalLabel": "Total accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r44",
      "r587"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "verboseLabel": "Receivables and Receivables-Related Parties"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r5",
      "r33",
      "r212",
      "r213"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Receivables, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r59",
      "r129",
      "r577",
      "r580"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.",
        "label": "Accounts Receivable, Related Parties, Current",
        "terseLabel": "Receivables, net \u2013 related parties",
        "verboseLabel": "Receivables, net \u2013 related party"
       }
      }
     },
     "localname": "AccountsReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r25",
      "r640",
      "r663"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "verboseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r50"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "verboseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r34",
      "r436",
      "r587"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r433",
      "r434",
      "r435",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "verboseLabel": "Additional Paid-in\u00a0Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r405",
      "r430",
      "r438"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r85",
      "r111",
      "r322",
      "r549"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance cost"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r111",
      "r256",
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Treasury shares not included in the calculation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r126",
      "r190",
      "r200",
      "r206",
      "r229",
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r486",
      "r494",
      "r538",
      "r585",
      "r587",
      "r638",
      "r662"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r63",
      "r126",
      "r229",
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r486",
      "r494",
      "r538",
      "r585",
      "r587"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r126",
      "r229",
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r486",
      "r494",
      "r538",
      "r585"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Non-current assets",
        "verboseLabel": "Non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r216",
      "r218",
      "r241",
      "r644"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Marketable securities \u2013 certificates of deposit"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r407",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r512",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BridgeLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing which is expected to be replaced by a medium to long-term loan. The loan \"bridges\" the gap in time when otherwise no financing would be in place.",
        "label": "Bridge Loan [Member]",
        "terseLabel": "Bridge Loan"
       }
      }
     },
     "localname": "BridgeLoanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r399",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r399",
      "r402",
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Interest acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r471",
      "r472",
      "r474"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r471",
      "r472"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Value of shares transferred in acquisition"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r470",
      "r473",
      "r476"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "APCMG contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Combinations and Goodwill"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r3",
      "r134",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "verboseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r41",
      "r113"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r15",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r105",
      "r113",
      "r119"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of period",
        "totalLabel": "Cash, cash equivalents, restricted cash total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r105",
      "r539"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash flow hedges:"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "verboseLabel": "Supplemental disclosures of non-cash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashUninsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, Uninsured Amount",
        "terseLabel": "Amount deposit accounts exceeded FDIC insured limit"
       }
      }
     },
     "localname": "CashUninsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of Deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r123",
      "r126",
      "r151",
      "r152",
      "r153",
      "r155",
      "r157",
      "r166",
      "r167",
      "r168",
      "r229",
      "r286",
      "r291",
      "r292",
      "r293",
      "r297",
      "r298",
      "r338",
      "r339",
      "r343",
      "r347",
      "r538",
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise\u00a0Price\u00a0Per Share (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "verboseLabel": "Number of warrants received (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Warrants outstanding, ending balance (in shares)",
        "periodStartLabel": "Warrants outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r364",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r55",
      "r279",
      "r648",
      "r669"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies (Note 12)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r281",
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r135",
      "r136",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common\u00a0Stock\u00a0Outstanding"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r30",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r30",
      "r587"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value per share; 100,000,000 shares authorized, 44,845,059 and 44,630,873 shares issued and outstanding, excluding 10,925,702 and 10,925,702 treasury shares, as of March\u00a031, 2022 and December\u00a031, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r176",
      "r177",
      "r210",
      "r536",
      "r537",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r176",
      "r177",
      "r210",
      "r536",
      "r537",
      "r696",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r176",
      "r177",
      "r210",
      "r536",
      "r537",
      "r696",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r172",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risks"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r176",
      "r177",
      "r210",
      "r536",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r176",
      "r177",
      "r210",
      "r536",
      "r537",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r120",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.",
        "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]",
        "verboseLabel": "Investments in Other Entities - Equity Method and Investments in Privately Held Entities"
       }
      }
     },
     "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "auth_ref": [
      "r493",
      "r497",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "terseLabel": "Variable Interest Entities"
       }
      }
     },
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r366",
      "r367",
      "r379"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "verboseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r380"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Accrued contract liability recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r81",
      "r82"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.",
        "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization",
        "terseLabel": "Cost of services, excluding depreciation and amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.",
        "label": "Cost, Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "terseLabel": "Expenses",
        "totalLabel": "Total expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r175",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Subscriber relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r122",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r316",
      "r323",
      "r324",
      "r326",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Credit Facility, Bank Loans, and Lines of Credit"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r125",
      "r133",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r312",
      "r313",
      "r314",
      "r315",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r330",
      "r331",
      "r332",
      "r333",
      "r550",
      "r639",
      "r641",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r26",
      "r327",
      "r641",
      "r661"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Total debt"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r299",
      "r330",
      "r331",
      "r548",
      "r550",
      "r551"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt, principal sum"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r52",
      "r319",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Average effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r52",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate on loan receivable"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r53",
      "r125",
      "r133",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r312",
      "r313",
      "r314",
      "r315",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r330",
      "r331",
      "r332",
      "r333",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r53",
      "r125",
      "r133",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r312",
      "r313",
      "r314",
      "r315",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r325",
      "r330",
      "r331",
      "r332",
      "r333",
      "r355",
      "r358",
      "r359",
      "r360",
      "r547",
      "r548",
      "r550",
      "r551",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Revolving credit facility term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r312",
      "r328",
      "r330",
      "r331",
      "r549"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Less: Unamortized financing costs",
        "terseLabel": "Unamortized financing costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet": {
     "auth_ref": [
      "r552"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Line of Credit Arrangements, Net",
        "terseLabel": "Deferred financing costs"
       }
      }
     },
     "localname": "DebtIssuanceCostsLineOfCreditArrangementsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCreditsAndOtherLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income in future periods and obligations not separately disclosed in the balance sheet (other liabilities).",
        "label": "Deferred Credits and Other Liabilities",
        "terseLabel": "Amount outstanding under agreement"
       }
      }
     },
     "localname": "DeferredCreditsAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r442",
      "r443"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability",
        "verboseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "verboseLabel": "Deferred tax"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r111",
      "r187"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r66",
      "r67",
      "r70",
      "r535"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Derivative assets"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsCurrent": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Current",
        "terseLabel": "Contingent equity securities"
       }
      }
     },
     "localname": "DerivativeAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r65",
      "r70",
      "r71",
      "r514",
      "r602"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "verboseLabel": "Derivative asset, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r65",
      "r70",
      "r71",
      "r514",
      "r602"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Derivative liability, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r70",
      "r513",
      "r515",
      "r517",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r510",
      "r513",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r66",
      "r67",
      "r70",
      "r535"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Interest rate swaps"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r132",
      "r507",
      "r508",
      "r510",
      "r511",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Derivatives designated as hedging instruments:"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed technology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r378",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "verboseLabel": "Schedule of Disaggregated Revenue by Each Payor Type"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r361",
      "r657"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "verboseLabel": "Dividends paid"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrent": {
     "auth_ref": [
      "r11",
      "r50"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Dividends Payable, Current",
        "terseLabel": "Dividend payable",
        "verboseLabel": "Dividends payable"
       }
      }
     },
     "localname": "DividendsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueFromAffiliateCurrent": {
     "auth_ref": [
      "r59",
      "r577",
      "r579",
      "r584"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership, due within 1 year (or 1 business cycle).",
        "label": "Due from Affiliate, Current",
        "terseLabel": "Amount due from affiliate"
       }
      }
     },
     "localname": "DueFromAffiliateCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueFromAffiliates": {
     "auth_ref": [
      "r577",
      "r579",
      "r672"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership.",
        "label": "Due from Affiliates",
        "terseLabel": "Due from affiliates"
       }
      }
     },
     "localname": "DueFromAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToAffiliateCurrentAndNoncurrent": {
     "auth_ref": [
      "r577",
      "r584",
      "r647",
      "r671",
      "r698"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership.",
        "label": "Due to Affiliate",
        "terseLabel": "Due to affiliate"
       }
      }
     },
     "localname": "DueToAffiliateCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r44",
      "r129",
      "r289",
      "r291",
      "r292",
      "r296",
      "r297",
      "r298",
      "r577"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "verboseLabel": "Due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r84",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r149",
      "r151",
      "r155",
      "r156",
      "r157",
      "r162",
      "r163",
      "r524",
      "r525",
      "r652",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Earnings per share \u2013 basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r84",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r151",
      "r155",
      "r156",
      "r157",
      "r162",
      "r163",
      "r524",
      "r525",
      "r652",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Earnings per share \u2013 diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r158",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "verboseLabel": "Basic and Diluted Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r158",
      "r160",
      "r161",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r431"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options",
        "verboseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails",
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r75",
      "r76",
      "r77",
      "r135",
      "r136",
      "r137",
      "r139",
      "r145",
      "r147",
      "r165",
      "r231",
      "r354",
      "r361",
      "r433",
      "r434",
      "r435",
      "r452",
      "r453",
      "r523",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r690",
      "r691",
      "r692",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": {
     "auth_ref": [
      "r2",
      "r126",
      "r229",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Axis]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": {
     "auth_ref": [
      "r2",
      "r126",
      "r229",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Domain]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": {
     "auth_ref": [
      "r225"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.",
        "label": "Equity Method Investment, Other than Temporary Impairment",
        "terseLabel": "Equity method investment, other than temporary impairment"
       }
      }
     },
     "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership interest"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentSoldCarryingAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the entity's equity method investment which has been sold.",
        "label": "Equity Method Investment, Amount Sold",
        "negatedTerseLabel": "Distribution",
        "terseLabel": "Distribution"
       }
      }
     },
     "localname": "EquityMethodInvestmentSoldCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r42",
      "r191",
      "r226"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Investments in other entities \u2013 equity method",
        "verboseLabel": "Investments in other entities \u2013 equity method"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]",
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.",
        "label": "Equity Method Investments [Table Text Block]",
        "verboseLabel": "Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r533"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue": {
     "auth_ref": [
      "r533"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) and investment in equity security without readily determinable fair value.",
        "label": "Equity Securities, FV-NI and without Readily Determinable Fair Value",
        "verboseLabel": "Investment in privately held entities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r224",
      "r677"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Equity securities, FV-NI, unrealized gain (loss)"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r526",
      "r527",
      "r528",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r526",
      "r527",
      "r528",
      "r530",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "verboseLabel": "Schedule of Carrying Amounts and Fair Values of Financial Instruments"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r314",
      "r330",
      "r331",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r527",
      "r592",
      "r593",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r314",
      "r390",
      "r391",
      "r396",
      "r398",
      "r527",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r314",
      "r330",
      "r331",
      "r390",
      "r391",
      "r396",
      "r398",
      "r527",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r314",
      "r330",
      "r331",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r527",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r314",
      "r330",
      "r331",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r592",
      "r593",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r532",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r555",
      "r563",
      "r572"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r557",
      "r566"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Operating cash flows from finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r554",
      "r571"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r554"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "netLabel": "Less: current portion",
        "terseLabel": "Finance lease liabilities",
        "verboseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Finance Lease Payments After Adoption of 842"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r554"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long-term lease liabilities",
        "verboseLabel": "Finance lease liabilities, net of current portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r571"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r571"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r571"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r571"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r571"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r571"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.",
        "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022 (excluding the three months ended March\u00a031, 2022)"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r571"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r556",
      "r566"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Payment of finance lease obligations",
        "verboseLabel": "Financing cash flows from finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r553"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Assets recorded under finance leases"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": {
     "auth_ref": [
      "r555",
      "r563"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization",
        "terseLabel": "Accumulated depreciation associated with finance leases"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r555",
      "r563",
      "r572"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Accumulated depreciation associated with finance leases"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r569",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "verboseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r568",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r233",
      "r234",
      "r235",
      "r236",
      "r238",
      "r242",
      "r243",
      "r244",
      "r245",
      "r325",
      "r352",
      "r522",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis": {
     "auth_ref": [
      "r479",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by financial support arrangement provided to a nonconsolidated legal entity that is required to comply with or operate in accordance with requirements that are similar to those included in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds.",
        "label": "Financial Support to Nonconsolidated Legal Entity [Axis]",
        "terseLabel": "Financial Support to Nonconsolidated Legal Entity [Axis]"
       }
      }
     },
     "localname": "FinancialSupportToNonconsolidatedLegalEntityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain": {
     "auth_ref": [
      "r479",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial support arrangement provided to a nonconsolidated legal entity that is required to comply with or operate in accordance with requirements that are similar to those included in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds.",
        "label": "Financial Support to Nonconsolidated Legal Entity [Domain]",
        "terseLabel": "Financial Support to Nonconsolidated Legal Entity [Domain]"
       }
      }
     },
     "localname": "FinancialSupportToNonconsolidatedLegalEntityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r263"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "2022 (excluding the three months ended March 31, 2022)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r257",
      "r259",
      "r263",
      "r267",
      "r622",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r263",
      "r623"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Amortized intangible assets, Gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r257",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r263",
      "r622"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r246",
      "r248",
      "r587",
      "r637"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r252",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "verboseLabel": "Goodwill and Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r111",
      "r247",
      "r250",
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Impairment of goodwill"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillPurchaseAccountingAdjustments": {
     "auth_ref": [
      "r251",
      "r462"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Purchase Accounting Adjustments",
        "terseLabel": "Adjustments"
       }
      }
     },
     "localname": "GoodwillPurchaseAccountingAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HealthCareCostsPolicyPolicyTextBlock": {
     "auth_ref": [
      "r703",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for  accruing health care costs for a prepaid health care service provider.",
        "label": "Health Care Costs, Policy [Policy Text Block]",
        "verboseLabel": "Medical Liabilities"
       }
      }
     },
     "localname": "HealthCareCostsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_HealthCareOtherMember": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service provided for maintenance, diagnosis and treatment of physical and mental health, classified as other.",
        "label": "Health Care, Other [Member]",
        "terseLabel": "Risk pool settlements and incentives"
       }
      }
     },
     "localname": "HealthCareOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HealthCarePatientServiceMember": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service provided to patient for maintenance, diagnosis and treatment of physical and mental health. Excludes service to resident in health care facility.",
        "label": "Health Care, Patient Service [Member]",
        "terseLabel": "Fee-for-service, net"
       }
      }
     },
     "localname": "HealthCarePatientServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r510",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r111",
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-lived",
        "terseLabel": "Impairment of finite-lived intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r111",
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "terseLabel": "Impairment of indefinite-lived intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r111",
      "r272",
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r271",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "verboseLabel": "Intangible Assets and Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r79",
      "r190",
      "r199",
      "r202",
      "r205",
      "r207",
      "r636",
      "r650",
      "r654",
      "r678"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r80",
      "r111",
      "r188",
      "r226",
      "r649",
      "r674"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "(Income) loss from equity method investments",
        "netLabel": "Income (loss) from equity method investments",
        "terseLabel": "Income (loss) from equity method investments",
        "verboseLabel": "Allocation of Income (Loss)"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Statement of Operations"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r127",
      "r446",
      "r447",
      "r450",
      "r454",
      "r456",
      "r458",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r128",
      "r146",
      "r147",
      "r189",
      "r444",
      "r455",
      "r457",
      "r679"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r74",
      "r440",
      "r441",
      "r447",
      "r448",
      "r449",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r107",
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r60",
      "r646",
      "r673"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Current",
        "terseLabel": "Income taxes receivable"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "verboseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedParties": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.",
        "label": "Increase (Decrease) in Due from Related Parties",
        "negatedLabel": "Receivables, net \u2013 related parties"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities, net of business combinations:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r110",
      "r566"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayable": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Increase (Decrease) in Other Accounts Payable",
        "verboseLabel": "Fiduciary accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedLabel": "Other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r258",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-lived Intangible Assets [Line Items]",
        "terseLabel": "Indefinite-lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r266"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Indefinite lived assets:"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r258",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets, Net"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Intangible Assets, Gross"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r255",
      "r261"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Intangible Assets, Net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r78",
      "r186",
      "r546",
      "r549",
      "r653"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r102",
      "r106",
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest rate swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r90",
      "r185"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "terseLabel": "Investments in affiliates"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r570",
      "r572"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost, net"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Information Related to Lease Costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term, finance"
       }
      }
     },
     "localname": "LesseeFinanceLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeFinanceLeaseRenewalTerm1": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Renewal Term",
        "terseLabel": "Finance lease option to extend (up to)"
       }
      }
     },
     "localname": "LesseeFinanceLeaseRenewalTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Operating Lease Payments After Adoption of 842"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r571"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r571"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r571"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r571"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r571"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r571"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022 (excluding the three months ended March\u00a031, 2022)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r571"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term, operating"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease option to extend (up to)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r48",
      "r126",
      "r201",
      "r229",
      "r286",
      "r287",
      "r288",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r487",
      "r494",
      "r495",
      "r538",
      "r585",
      "r586"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r38",
      "r126",
      "r229",
      "r538",
      "r587",
      "r643",
      "r667"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, mezzanine equity, and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Deficit",
        "verboseLabel": "Liabilities, mezzanine equity, and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r51",
      "r126",
      "r229",
      "r286",
      "r287",
      "r288",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r487",
      "r494",
      "r495",
      "r538",
      "r585",
      "r586",
      "r587"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "terseLabel": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r26",
      "r27",
      "r126",
      "r229",
      "r286",
      "r287",
      "r288",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r487",
      "r494",
      "r495",
      "r538",
      "r585",
      "r586"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities",
        "verboseLabel": "Non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r680",
      "r683"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.",
        "label": "Liability for Claims and Claims Adjustment Expense",
        "periodEndLabel": "Medical liabilities, end of period",
        "periodStartLabel": "Medical liabilities, beginning of period",
        "terseLabel": "Medical liabilities"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock": {
     "auth_ref": [
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments.",
        "label": "Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]",
        "terseLabel": "Medical Liabilities"
       }
      }
     },
     "localname": "LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": {
     "auth_ref": [
      "r682"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year",
        "negatedLabel": "Current period"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": {
     "auth_ref": [
      "r682"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years",
        "negatedLabel": "Prior periods"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": {
     "auth_ref": [
      "r681"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims",
        "totalLabel": "Total medical care costs"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]",
        "terseLabel": "Medical Liabilities [Roll Forward]"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease": {
     "auth_ref": [
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of increase (decrease) in the liability for unpaid claims and claims adjustment expense.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease)",
        "terseLabel": "Adjustments"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r26",
      "r641",
      "r661"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "totalLabel": "Total",
        "verboseLabel": "Amount outstanding"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r46",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeeAmount": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Commitment Fee Amount",
        "terseLabel": "Annual agent fee"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Required annual facility fee"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Line of Credit Facility, Expiration Period",
        "terseLabel": "Term of facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective interest rate at the end of the reporting period.",
        "label": "Line of Credit Facility, Interest Rate at Period End",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r46",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum loan availability"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r46",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "London Interbank Offered Rate (LIBOR)"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r26",
      "r313",
      "r329",
      "r330",
      "r331",
      "r641",
      "r664"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "verboseLabel": "Long-term debt, net of current portion and deferred financing costs"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedTerseLabel": "Less: Current portion of debt",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r133",
      "r284",
      "r318"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r133",
      "r284",
      "r318"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r133",
      "r284",
      "r318"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "2022 (excluding the three months ended March 31, 2022)"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net of current portion and deferred financing costs",
        "verboseLabel": "Long-term debt, net of current portion and deferred financing costs"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r53",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ManagementFeeExpense": {
     "auth_ref": [
      "r578"
     ],
     "calculation": {
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses related to the managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).",
        "label": "Management Fee Expense",
        "negatedLabel": "Management fees"
       }
      }
     },
     "localname": "ManagementFeeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ManagementServiceMember": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractually stipulated right to receive compensation for operating and managing business.",
        "label": "Management Service [Member]",
        "terseLabel": "Management fee income",
        "verboseLabel": "Management Fee Income Contract"
       }
      }
     },
     "localname": "ManagementServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r7",
      "r49"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "verboseLabel": "Investments in marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "verboseLabel": "Investments in Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r62",
      "r126",
      "r229",
      "r286",
      "r291",
      "r292",
      "r293",
      "r297",
      "r298",
      "r538",
      "r642",
      "r666"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r361",
      "r484",
      "r485"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "negatedTerseLabel": "Purchase of non-controlling interest"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Ownership interest"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r169",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r105",
      "r109",
      "r112"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r72",
      "r73",
      "r77",
      "r83",
      "r112",
      "r126",
      "r138",
      "r140",
      "r141",
      "r142",
      "r143",
      "r146",
      "r147",
      "r154",
      "r190",
      "r199",
      "r202",
      "r205",
      "r207",
      "r229",
      "r286",
      "r287",
      "r288",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r525",
      "r538",
      "r651",
      "r675"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income attributable to Apollo Medical Holdings, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r72",
      "r73",
      "r77",
      "r146",
      "r147",
      "r490",
      "r504"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "verboseLabel": "Net (loss) income attributable to non-controlling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recent Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest": {
     "auth_ref": [
      "r362",
      "r484",
      "r492"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest.",
        "label": "Noncontrolling Interest, Increase from Sale of Parent Equity Interest",
        "verboseLabel": "Sale of non-controlling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r361",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "verboseLabel": "Non-controlling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other expense"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesAndLoansReceivableNetCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r31",
      "r212",
      "r213",
      "r645"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.",
        "label": "Financing Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Loan receivable \u2013 related party",
        "verboseLabel": "Loan receivable"
       }
      }
     },
     "localname": "NotesAndLoansReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesAndLoansReceivableNetNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.",
        "label": "Financing Receivable, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Loans receivable"
       }
      }
     },
     "localname": "NotesAndLoansReceivableNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableGross": {
     "auth_ref": [
      "r214",
      "r232",
      "r235",
      "r237",
      "r239",
      "r240",
      "r720",
      "r721",
      "r722"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of financing receivable.",
        "label": "Financing Receivable, before Allowance for Credit Loss",
        "terseLabel": "Note receivable, amount"
       }
      }
     },
     "localname": "NotesReceivableGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date(s) within one year of the balance sheet date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.",
        "label": "Notes Receivable [Member]",
        "terseLabel": "Convertible Secured Promissory Note"
       }
      }
     },
     "localname": "NotesReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesReceivableNet": {
     "auth_ref": [
      "r33",
      "r212",
      "r237"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.",
        "label": "Financing Receivable, after Allowance for Credit Loss",
        "terseLabel": "Amount of loan"
       }
      }
     },
     "localname": "NotesReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r59",
      "r129",
      "r577"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due within 1 year (or 1 business cycle).",
        "label": "Notes Receivable, Related Parties, Current",
        "terseLabel": "Loan receivable \u2013 related party"
       }
      }
     },
     "localname": "NotesReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableRelatedPartiesNoncurrent": {
     "auth_ref": [
      "r17",
      "r32",
      "r129",
      "r577"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due after 1 year (or 1 business cycle).",
        "label": "Notes Receivable, Related Parties, Noncurrent",
        "terseLabel": "Loans receivable \u2013 related party"
       }
      }
     },
     "localname": "NotesReceivableRelatedPartiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of main reporting units"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r190",
      "r199",
      "r202",
      "r205",
      "r207"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r564",
      "r572"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "verboseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r554"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r554"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Less: current portion",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r554"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term lease liabilities",
        "verboseLabel": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r558",
      "r566"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "verboseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r553"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r569",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "verboseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r568",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermInvestments": {
     "auth_ref": [
      "r42",
      "r670"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term investments classified as other.",
        "label": "Other Long-term Investments",
        "terseLabel": "Investment in affiliates"
       }
      }
     },
     "localname": "OtherLongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other Noncurrent Assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "verboseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables",
        "verboseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForFees": {
     "auth_ref": [
      "r108"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for fees classified as other.",
        "label": "Payments for Other Fees",
        "terseLabel": "Fees paid"
       }
      }
     },
     "localname": "PaymentsForFees",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": {
     "auth_ref": [
      "r108",
      "r682"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid",
        "negatedTotalLabel": "Total paid"
       }
      }
     },
     "localname": "PaymentsForLossesAndLossAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of shares"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "negatedTerseLabel": "Dividends paid"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r95",
      "r475"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Payments to acquire business"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Payments for business acquisition, net of cash acquired and shares issued"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "negatedLabel": "Contribution to investment - equity method"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r217"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.",
        "label": "Payments to Noncontrolling Interests",
        "negatedTerseLabel": "Distribution to non-controlling interest"
       }
      }
     },
     "localname": "PaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r29",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r29",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r29",
      "r587"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r8",
      "r39",
      "r40"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties": {
     "auth_ref": [
      "r93",
      "r576"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with collection, whether partial or full, of long-term loans to a related party. Alternate caption: Proceeds from Advances to Affiliates.",
        "label": "Proceeds from Collection of Long-term Loans to Related Parties",
        "terseLabel": "Proceeds from repayment of loans receivable \u2013 related parties"
       }
      }
     },
     "localname": "ProceedsFromCollectionOfLongtermLoansToRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": {
     "auth_ref": [
      "r94",
      "r104"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.",
        "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital",
        "terseLabel": "Distribution from investment - equity method"
       }
      }
     },
     "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Borrowings on loans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sale of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from the exercise of stock options and warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r72",
      "r73",
      "r77",
      "r103",
      "r126",
      "r138",
      "r146",
      "r147",
      "r190",
      "r199",
      "r202",
      "r205",
      "r207",
      "r229",
      "r286",
      "r287",
      "r288",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r483",
      "r489",
      "r491",
      "r504",
      "r505",
      "r525",
      "r538",
      "r654"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r64",
      "r273",
      "r563"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "terseLabel": "Land, property, and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r19",
      "r20",
      "r273",
      "r587",
      "r656",
      "r668"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Land, property, and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RealEstateLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan to finance the purchase of real estate, including but not limited to, land or building.",
        "label": "Real Estate Loan [Member]",
        "terseLabel": "Real Estate Loan"
       }
      }
     },
     "localname": "RealEstateLoanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]",
        "terseLabel": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r397",
      "r576",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r397",
      "r576",
      "r577",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.",
        "label": "Related Party Transaction, Other Revenues from Transactions with Related Party",
        "totalLabel": "Receipts, net",
        "verboseLabel": "Recognized risk pool revenue"
       }
      }
     },
     "localname": "RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r397",
      "r576",
      "r580",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r574",
      "r575",
      "r577",
      "r581",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "verboseLabel": "Related-Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Repayment of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r4",
      "r15",
      "r119"
     ],
     "calculation": {
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashEquivalentsCurrent": {
     "auth_ref": [
      "r4",
      "r15",
      "r119",
      "r700",
      "r701"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as current. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash Equivalents, Current",
        "terseLabel": "Restricted cash - current"
       }
      }
     },
     "localname": "RestrictedCashEquivalentsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted stock awards"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r35",
      "r361",
      "r436",
      "r587",
      "r665",
      "r693",
      "r694"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r135",
      "r136",
      "r137",
      "r139",
      "r145",
      "r147",
      "r231",
      "r433",
      "r434",
      "r435",
      "r452",
      "r453",
      "r523",
      "r690",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "verboseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r183",
      "r184",
      "r198",
      "r203",
      "r204",
      "r208",
      "r209",
      "r210",
      "r377",
      "r378",
      "r621"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r121",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r88",
      "r289",
      "r291",
      "r292",
      "r296",
      "r297",
      "r298",
      "r699"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from Related Parties",
        "terseLabel": "Revenue from related parties"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuePerformanceObligationDescriptionOfTiming": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service.",
        "label": "Revenue, Performance Obligation, Description of Timing",
        "terseLabel": "Contract term"
       }
      }
     },
     "localname": "RevenuePerformanceObligationDescriptionOfTiming",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolver Loan",
        "verboseLabel": "Revolver Loan"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r567",
      "r572"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Fixed asset obtained in exchange for finance lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]",
        "terseLabel": "Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]"
       }
      }
     },
     "localname": "RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r176",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "verboseLabel": "Net Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share Computations"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r405",
      "r429",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Share-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r2",
      "r126",
      "r228",
      "r229",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r257",
      "r262",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r257",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets, Net"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r252",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Change in Carrying Value of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r266",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.",
        "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]",
        "terseLabel": "Schedule of Medical Liabilities"
       }
      }
     },
     "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Schedule of Line of Credit Facilities [Table Text Block]",
        "terseLabel": "Schedule of Credit Facility"
       }
      }
     },
     "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Future Commitments of Credit Facility"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r578",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "verboseLabel": "Schedule of Fees Incurred and Revenue Earned from Related Party Transactions"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.",
        "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]",
        "verboseLabel": "Schedule of Contributions to Revenue and Receivables by Payor"
       }
      }
     },
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r407",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails",
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r410",
      "r418",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Transactions Under Stock Option Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r57",
      "r123",
      "r166",
      "r167",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r347",
      "r352",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r364",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Outstanding Warrants"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r486",
      "r487",
      "r494",
      "r495",
      "r496",
      "r498",
      "r500",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": {
     "auth_ref": [
      "r496",
      "r498",
      "r500",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table Text Block]",
        "verboseLabel": "Schedule of Assets and Liabilities, Variable Interest Entities"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "verboseLabel": "Schedule of Shares Included in the Diluted Earnings Per Share Computations"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "verboseLabel": "Schedule of Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "verboseLabel": "Reportable Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Preferred Stock"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Service"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Annual dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "verboseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails",
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r420"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Options forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options, grants in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r432"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r412",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding, ending balance (in shares)",
        "verboseLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "verboseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Options outstanding, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "verboseLabel": "Options exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r404",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r407",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]",
        "terseLabel": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]",
        "terseLabel": "Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Market value of common stock (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Grant date fair value of restricted stock to be recognized straight-line"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r426",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r432"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Equity, ending balance (in shares)",
        "periodStartLabel": "Equity, beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StandbyLettersOfCreditMember": {
     "auth_ref": [
      "r282",
      "r283",
      "r480",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation.",
        "label": "Standby Letters of Credit [Member]",
        "terseLabel": "Standby Letters of Credit"
       }
      }
     },
     "localname": "StandbyLettersOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r28",
      "r29",
      "r30",
      "r123",
      "r126",
      "r151",
      "r152",
      "r153",
      "r155",
      "r157",
      "r166",
      "r167",
      "r168",
      "r229",
      "r286",
      "r291",
      "r292",
      "r293",
      "r297",
      "r298",
      "r338",
      "r339",
      "r343",
      "r347",
      "r354",
      "r538",
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r58",
      "r75",
      "r76",
      "r77",
      "r135",
      "r136",
      "r137",
      "r139",
      "r145",
      "r147",
      "r165",
      "r231",
      "r354",
      "r361",
      "r433",
      "r434",
      "r435",
      "r452",
      "r453",
      "r523",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r690",
      "r691",
      "r692",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r165",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r116",
      "r117",
      "r118"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Common stock issued in business combination"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r29",
      "r30",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "verboseLabel": "Issuance of shares for business acquisition (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r29",
      "r30",
      "r354",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Number of shares purchased by related party"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "auth_ref": [
      "r29",
      "r30",
      "r354",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "negatedLabel": "Cancellation of restricted stock awards (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r354",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Shares issued for vesting of restricted stock awards (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r29",
      "r30",
      "r354",
      "r361",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Options exercised (in shares)",
        "terseLabel": "Shares issued for exercise of options and warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r58",
      "r354",
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "verboseLabel": "Issuance of shares for business acquisition"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": {
     "auth_ref": [
      "r29",
      "r30",
      "r354",
      "r361"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures",
        "negatedTerseLabel": "Cancellation of restricted stock awards"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r29",
      "r30",
      "r354",
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Shares issued for vesting of restricted stock awards"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r29",
      "r30",
      "r361",
      "r406",
      "r419"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r58",
      "r354",
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Purchase price adjustment from Merger"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r29",
      "r30",
      "r354",
      "r361"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedTerseLabel": "Share buy back"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r30",
      "r36",
      "r37",
      "r126",
      "r215",
      "r229",
      "r538",
      "r587"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders' equity, parent"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r76",
      "r126",
      "r135",
      "r136",
      "r137",
      "r139",
      "r145",
      "r229",
      "r231",
      "r361",
      "r433",
      "r434",
      "r435",
      "r452",
      "r453",
      "r481",
      "r482",
      "r503",
      "r523",
      "r538",
      "r540",
      "r541",
      "r545",
      "r691",
      "r692",
      "r724"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Equity, ending balance",
        "periodStartLabel": "Equity, beginning balance",
        "terseLabel": "Stockholders\u2019 deficit",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r124",
      "r339",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r353",
      "r361",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Mezzanine and Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r565",
      "r572"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplementary disclosures of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r681"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.",
        "label": "Current Year Claims and Claims Adjustment Expense",
        "terseLabel": "Current period"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r681"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.",
        "label": "Prior Year Claims and Claims Adjustment Expense",
        "terseLabel": "Prior periods"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityAccretionOfDividends": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of accretion of temporary equity during the period due to unpaid dividends.",
        "label": "Temporary Equity, Accretion of Dividends",
        "negatedTerseLabel": "Dividends"
       }
      }
     },
     "localname": "TemporaryEquityAccretionOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r56",
      "r126",
      "r229",
      "r538"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "periodEndLabel": "Temporary equity, carrying amount, ending balance",
        "periodStartLabel": "Temporary equity, carrying amount, beginning balance",
        "terseLabel": "Non-controlling interest in Allied Physicians of California, a Professional Medical Corporation"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityNetIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of net income or loss attributable to temporary equity interest.",
        "label": "Temporary Equity, Net Income",
        "terseLabel": "Net income"
       }
      }
     },
     "localname": "TemporaryEquityNetIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trademarks and Trade Names [Member]",
        "terseLabel": "Trade names/trademarks"
       }
      }
     },
     "localname": "TrademarksAndTradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Trademarks"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r325",
      "r352",
      "r522",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "terseLabel": "Treasury shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r30",
      "r354",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedLabel": "Purchase of treasury shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredParValueMethod": {
     "auth_ref": [
      "r354",
      "r361",
      "r363"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the par value method.",
        "label": "Treasury Stock, Value, Acquired, Par Value Method",
        "negatedLabel": "Purchase of treasury shares"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredParValueMethod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Derivatives",
        "negatedTerseLabel": "Unrealized gain on interest rate swaps"
       }
      }
     },
     "localname": "UnrealizedGainLossOnDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Unrealized loss on investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r170",
      "r171",
      "r173",
      "r174",
      "r178",
      "r179",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "verboseLabel": "Variable Interest Entities (VIEs)"
       }
      }
     },
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEs"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Not Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Not Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "auth_ref": [
      "r486",
      "r487",
      "r494",
      "r495",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Term of warrant"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r157"
     ],
     "calculation": {
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Adjustments to weighted average shares of common stock (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r150",
      "r157"
     ],
     "calculation": {
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted average shares of common stock outstanding \u2013 diluted (in shares)",
        "verboseLabel": "Weighted average shares of common stock outstanding \u2013 diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r149",
      "r157"
     ],
     "calculation": {
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Weighted average shares of common stock outstanding \u2013 basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=SL94080555-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=124268079&loc=d3e32787-111569"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "79",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82922352-210448"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "80",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82922355-210448"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123408193&loc=d3e12803-110250"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569655-111683"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4616395-111683"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2AA",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759068-111685"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498348-110258"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=68176171&loc=SL68176184-208336"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=d3e56071-112765"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(7))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(cc)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/subtopic&trid=2560295"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04.12(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413209&loc=SL6242269-115581"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491204&loc=d3e4879-115612"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "720",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=49178521&loc=d3e9162-115647"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r709": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r710": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r711": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r712": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r713": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r714": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r715": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r716": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r717": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r718": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r719": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r720": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1404"
  },
  "r721": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(1)"
  },
  "r722": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(2)"
  },
  "r723": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>93
<FILENAME>0001628280-22-013661-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-013661-xbrl.zip
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M)JFEL<4X!SY!*E1+V<7('I-#%:DN-DTL 4PWO.1[5OA$"HD<.[5H)#B=0L;
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M7P.LJ4X_&PV/CWZLT#\CKT=I8WR(+0&<L%9+*B9F3.#9Y1!,4PT@%*6"N;F
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MA[94&&DV<HNWJQRF2D$ZR"(U.&D]LR I3+&&4&C?X 7]S4=W+H:4>8^/LK8
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M!&#V$FHUVQ**#D:77$!#"UJ,MPV[V>4WE0(P,@2'28(-QI,,.C%H)$J4VK6
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M9)=ND]JV4I>4I^"3D*2=!RUSB#J8E$2P*5LHLHTN\ :3>C/</2JLTQHY;%<
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MWRQX!PM8L>CD5R>#RX<"SC686DEKB1D-<]1I Y\;YOA:FUV1M>G!11&/S&@
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M:.8L8 Y0!(X#0TI8@S(EM,/Q^%W(FUM6S9S6V%*7Q0XJ2UVFI<XW;6)8!HW
M)#GB1#*466$1(9I;(H3R@L2D[P=3A"IDL)P^"E6ZPY/U3Y@'GVK785G(--\3
MDJ@@O5 ,&>D)XCHU2"G!\Z)<.,A,.<4WMF@MI54=O34VY=7T3ZA,>:6F/-M
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M>>I9".!QUH#WQ?]N 7B%JB7Z0O[)+ZT8:1BTOOD8(];M=G(Z2^]:DUA$,J:
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M:SASE[_W=@>;2?RR6]T\#QB,;S\\UL/$@MX90-0!?*C7;9_!)0F\.X2UJ6=
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M_%K-'%FYSCZ!'2PK]?])A?/!?_/=D;^-9C^H\LR]#FW<]KS:(PYR#;3TAI*
MLG"[RJ&PBU-MBSK9T=6N)5T_5V/F+D]]Z\3JISNW??NLZD7/]]/<SZ=[L#M$
M':7)L&+:!6XU]ZE0)CAA+7/8!&$4^;R3[V@03-!M*QKGF!>W-[;C:4L8PC^M
MX?'V: !J[?N[DY: ,4T$_M\=ZA_/(YNZ>3")1QY]/SKY"M_S431WOI[!/7\<
M_?-1'/VS^[WQ]L^3QLD>.SK?$_N'7]EE-G7CO''2[C3?-K]^ZC3.C@[A,X>6
M-W;^[#0._SJ'UT^:G3VXYL_Y;.KSQMG^/T?XB'[H')W_>=S<>7/<//_RO=$Y
M^M'<:<#K#7ITTCAK=/X.DTSJQ@%FC9UZW@J>"L<]8\@(&1"(6*,L=1))&YSU
MA(= 4J 1E-9P^N 3F \JB%K8RS(/+U9XM79XE08O'>."ILIQJH3B6A* +<FM
M==;('*_(!*](A5=EQZOS&;SB-FBB@T09_$1<6($4E1QQQ^(&L&?4Q<PBSFOR
MX<6$5HM7:T!G;SA2_PSH[(?6X&MRVNNUQPG3^59ZOFW6ZD9?OO7-#QZ_.,^S
MP%DBG8PMF4QF@!H*JCD)PAO.G!+<9!4O?%8XV]R>XX5I(($J&E"4-/!")9'2
MQ,1"'4I0JJ*& \YF-2R754#[T6CADY?B>18FGA&*L<,XXXSQ5 0=2P=X:7A(
MB<(JK:C4,S/Q62KE9)H9S$%\/%.(!YXB(S7\,#@0C9D(,<\IFCAYVMH[+X%)
M/>_ 8$-W]9></R7!^TB?P*+O19T>U$WH6> J]\%D(L68*\8!.+-,.F%YL"[5
M3%!;4:=GA:L'<]1)>*=IEF5(&!UQU:9(.XL1X]910D'J:0JXBFM</FW/L.5'
MU"H3+Z+FSOI8D%PK17C0)I/ F8F3- V9=2ZKJ-,S,_%9ZB0<4U1E%#D>SVA:
MDJ&,8(<X]C(E!F:9B(VM;!DM1JH8U%K'H-YXC\!0X\>_M:Q?N*]:.:0YJAJ9
M2J$YD5Y([IPTP3 .MD2"%IDV%7%Z7JC:FB-.EBBO.%>(R7B4S].X*TD8LED0
M3F+*C(XQ)U+#JHHYK:6)!\?!DG7(%&6< FTRV(*CE&4JI$P)4Q&G9V;BL\3)
M.T^ )#GDK0_Q;)U%!F.*K*+:2IOB3.N-+5;#V=.V\7D)Q.EYAYSV\W-F5:3I
M!C0%.W/@@68Q\8%K(^'_/#;!*RF\RG1:$:9GA:;SR5N9)<RDX$$P2P7B)DN1
M3K%!)I4\<SJX0"40)G!#'\R7JD!3&2V<6$LDD\; ZLD%M1G!&8%_L9&9R*BO
M^-(SL_!9OJ0%=I0&CBRE*>*:>!1[8J T)9HI2;!7)%IX*J\K;U$2"R\M7YHY
M@W[''AXE/"7Q+ 996G5X*'TN-6<NVHWT?W+LZ&4OJ3@U@J<!"^8L9RG63'M&
M&0VI2F-&3$6:G].2NC^_/4O $_),!IA/S8$T2XX4EP8)*B7EV%,FXXF'E-6H
MN*[ 3TD6U8HVW\_&O:92:&V%E(Q[9[70QJ<&UCBKX >I:/,SL_%9V@SH#0(-
M>3U BKC%#'QB1Q ).M9/MDZI#&BS3&NX[#9>6J94$>>*.*\?<5Y\4G__U/?U
M,%;%]S].?7=PP[F01VJF^,CW6 .U>]YY(MN]05X.?9PG,JB!)HY)!3"3T[Z/
M93XG5?]T)S:X/<]?J)))'L?-BP+:#V][/9?W!"O$=$'\=J9$!+^W?=Y_N.OJ
M4Y*J&.'2SHT>[LVU3=0J4SHE&=+>&,2#3U&FC$=66F"$QC#)33SHCFN2E?RX
M0Y5=4A*WK[+YDMG\;'OQC(%*VQ2E3( OJ#18?Y8I%&1&TD!U1H*)A\5Q+255
MODF5;W(3SKP==Z;)^97KM+JMP;"?%RC^N4_PLJ-M2Z=:8U%$*+TBB-U"#A6F
M+@]3&W,\*LU,EH54(L)5BC@Q FD7!*(>1WZ%*7=IGJ2K>'6Z:2WM>>DTJK+G
MQ[3G&8YD&,7. SVBG )'"L$CPS1%(:7::Y]B(>W&EJKQE)?;G-> (3WO$-5.
M%89Z>FZTT"4='/3:;EH\E1>Z,H3]:S[RE%)AM"/(PEJ(..8^UMDPB AB4YP&
MIV,S1%YC\L$(6\6=RFCDCQ-WJHS\48U\AD99J@-36""/,X.X33G*N/-($:MT
M2(.BPD8C)^JZ5I@E,?)G1Z/*-^#G<F4UL67.D%GB1O^UR2>E2458R@A+JP@/
M]0!+[?852>4/BH&O/P5<B9\7R=\X1C:HV-WRV-V7.1>.&Z\8C:5^=$P>R#*"
M,IE2Y U+62Q'X@/8/&6RAGG)^5WEQ)7(B:LL>&46/..?94))B:5&QDB*."$8
M@14'Q$C(<) .?#>]L44$KU%9<@LN+<TI/]]]%I2W8KVE8KV+&^SNY85'DM#O
M=9)>D1W>ZU;L]Y'8[T4^?B&&=[U!M7PN;_D\J<\18!]B,?A@4"!$(NXRBI07
M 4F7"JY2QS0+\=!DC1)2[M6SXK\EX;^5#:_:AF>W*+R2(#B%+%$8<>,TTIES
MB/B,D13\6ZSBP6=2DUG);;BTE*=BP!4#?@$,>*H WSCN^Y >QF4YHONR-.Z&
M9#RB2J-ZBVG+V/GZI0V<X=?"!_/_';6&9TG'#X][L7_;-S\8YOW<JJ3\QW')
M+EE<K(*QFXNCD4MC[U(8%<%;'L&;3\WGUDN5$8XH)0QQE1F4.6R1TMJKC%NL
M0XQQUCBK,O.?CU'_\KA.V@">%GZ[IWE7%GPW"YYQT;Q, [AI#F4DS1#G#%PT
MK@SB,BAA%96*\8VM=,$.Q:\E,=UGQXS*-^#G<N4RCS<\ \HY]'W N9\Z/&L8
M);S+"K0"7EE,?'48;.GKS\<%>2Y!"Z,SY'3J$!>"(T,T02!2"5)D#"07&21>
MT+GN]BM0%> OI>DN/<)?F>XJ37>&.DJ9&LF)0X;&SBHZ)?";XXA9J20E7@7#
M\UX M+RFNP8<YWF'U<8<I^JJ\K@,9^) %T[V1 P5)-X)$H_FV QAV*2!!N0R
MI0$2N4"*.(\<H]08$D^WLXTM_N#*/U4PK(QVN@(Z4]GI<NQTAKIPKY4EFB%B
M28JXY0$I+QF*HL/PPZK839=Q56Y#70/V\IPC-!^[?0_#./<NB?N"":##0[<!
M7X#3MP0V<\V.P:4\WNI6-^X<['>KK<"50*J=HSX&&$]P'B.+77Y@R2"5,8<"
ML<$KFG&&76Q0KM+YOE%E\0:K0$Y)B,^=+#FT?GB'SGV_5QGQ78UX]LR2$H$1
M;1'F@H(18QW/+#&$#6<1H;$.=@,X4$8)?5UE;%:1G:I9;HG".OF<-WO=WM4\
M]XM@> 6.=P#'^2/94@42J&?(&!//9<<6/SAU**6I,ICCH-)L8RLE5:K36IKK
M\H^C_,1<*V]EB;8\6X-4$R,R+I"1U".N0H:4Y!HY2:PBSA&J1-R[8KBJ0?H4
M!U-*V ?K60RRM.JP%-;[#$K2%K6)>M,G56I)UP]?$@<N1S2P6EE7O[*>SY_;
M9E)B8XA#(F7 DA432&.OD:6&>9)1;6)"L5Q8K+\L*<4512[=:8#*K5V:P<Y0
M8:6]P@Y3!)28(6X#N+5>:<1"*GWJC' 2W%JQH,I86<RUM*2GXL 5!WZ4R&_^
M=ZOK?'?X"I'LM%SGML>'9XT'WN63TW[O6VL0%Q+X<QPA3H;Z1]7-ZFD.SL;V
M\:WN""9O_Z*JU.^YJ(KK#J-H=G\,^QKLL]75_;.]H>\,8$&.H^SWVNU\29YD
M)E7<>EE+]7Q'46&T$IGF2&<\0QRG'!F;:?A!8HMYERFE-K9(5J-IR7O,5PR[
M)$'H"@N>"Q;,T/94.4UIFB*M,/C9S$F  4:0\-2FVCHO,IS75J*L"F$_<_K^
M#.]16J$^E(27.OK\ON+6I>#6L$Z.PU._^ZX/K6HM7.):.-_O+%!M348-\EDL
MEF\R@DP(,0LU:(H])VE*-K;2&E&BW$MA18M+18LK,UZM&<^>RN&:>^4I"H3Q
MF$(>D!;8(#!0YK#-7$I4-&,I2WZ KK3DIS2,M@I(ET$=UH0++ZZ7W_35L?+'
MY;[@?< :69757NXZ.7_*/%.2*4DIDMAEB ?&D.*.(H.E5\Q)IW$LO$$7%LTI
MU4)9\=V2\-W*=%=DNK/)%IRX5 6-,L+ =)GU*',F()%J(+<&Q,@MF"ZO<5'R
M'9S2DIKR<]SR$]R*W9:'W<XM%A?L=ER-?!SFU<-AOV5&0VW:/AGV$I@1-+4K
M!Y<5VW(OB0V7)!/9#R^W6>M38CKL53NGJUZ#Y\_QN2P0(G2&0I >\11^4U8'
MQ#'C:8HQ%31VEJH1-=^4IBPICQ5Q+@EQKFS[:6U[MB:E<(Y@9U'J. :+YA)E
MDL4CN\)KCC55@A3G^A[<<K6BUR6EU\^"85<DNU0D>W'B\F4(>8Y=UT\!UGM)
MP[LXV.2/7CL^U:"6P&JP^1 ,6;C@ELG]R&?F7P]ZQ)_"XY,^VU.&T*_0B8HJ
M+(LJ-'?F#RH:)XVA6"'"G$!<48$R3N!/D6(K,D\-QWDHCJ9/FT!Y80S+] <J
M2%I32%JMAU-!TE(A:79WP,>&:E@B8K0&[T7%G.Z4(N,)]4$2;7"$)%8CXL']
M<E<.2:6EK&7T8!A,O>N-(KDLL0OSL%&65B'6VH?9U?UN]$R24P^:?ZS[/LGK
M-Y+7B=&#EGT47^7I8H,K9@7E#'J^]_V#*.GE>BMTEAE,5&OR=;]'?;H@ ;@B
M ;<@ ?.'/#DU*DBCD7&Q@ IU*5+2<I2&S 5MI=4^;&SA339?1[E4$<QRN"05
M\I0!>1[HE%3(LQKDF7$_:)IZ895#FAL/R$,#,L%:Q$,0:1:\T9[FR/.TSD>U
M=U(*OZ Z4/JRO0?7:H^&WE7^PXM9Q5?M/^P4&E6MXW=:Q^>/PQ*A'/-4(^:(
M01P+@A0)"CF.O:=*.FSQ<UC'*P^BPI['\B J[+DG]LSX$#8+7&AOHON@$5<.
M(T-U0-(&362J#18NQQY<;NPI*=W\+4] @7]=Z]O6O^''Y!,=W?_2ZN91^ID2
MV=;'S,,G2E,_//:)MK;7@>\^BUGHW=X0[AYYI.[F*>E?^KJ=G.K^,.F%9'CL
M!Q[@0(]<"ZPQ0D">,J7C'Z'5U5W;@LL'0W@A[P1UF6HS.R'C87!:U P_[0U:
M4<M>]7U;#UO?_.OO+3<\G@#2U <+OOT*7WY$&Q@$H,.U'YF;[2L%&5F:+U)/
M,?W9U>F9_AF'GR,<L\8#7 ::$LT#\3K5V"JF;)IQ*1C^#$@Z^=#QA0M[JK]X
M9/I>?T4ZP!._TNWO^FRP\=M5K025G!'$=7,X5N#Q[%-Y,6=;_S9]N.N"!UFL
M_OG4/+[^+SZ$7'^__^[=?M+8W=G;KK]+_MA_M[/7?'M02_::V]?K;EE&O[W?
M/-A_M[=3/]S=20X.X9_&;O/P(-E_ T_TZ5.]N=?<3>K-^-[^]G_BP^U^.,C]
M0_DZV?WKX][A48F><;&)_++73 [_V/]X ,\!<MG]O^W=]X?)P1_U#[L)/'C]
MU_(_P<=F_>/.'LCH^K%>71YBT"E/9+R O'R+%P;<UJ<#_VKRR^O).M3JYE^;
M?^CU54L5\\5F\XDIWAZ;N\HV)2;1XL?QDO$7C\%@,P>#F16_>(^J3<6N?QMO
MDFO?N^FV:A,K>:^[WOP>X]G2QRHW4WG?\3SV6+--2N\GK6I>UV6LS\FVLDTA
MQ*WNNCB$SVZ(X-\FN-WO?;_N8PO"$V-R6:;,Q(8_/]?@2?N<I>W^=]0:GA6.
MW#A.G+_>O'H6-7]M<B"JN+K5+?ZMO]^^]H#JW::VNO39*]<'/]3PHBMT:QRQ
M>;;JL1A!Z$,AY+:7JF>J!-N]3J<W1H>#8<]^+7[='PT'0]V-#[(DC;@P%_I,
M9ZH.@XT!"]W.#>:];CDTP=5M?=H:PAN/;CS/?E9O6KLJS2M<T-PNCWMM\"('
M8_]_B@]<F:5K4B&R1T+!J=VEVQS-O/7T/]UF2KY]<9M5<6D'9M=DXNJ=WJB[
M+!-^,CIQ[YR;TF]__J[;NFOCT=OD3]T=Z?Y90FI)S"RX]1[1K>L<K>,QM[L]
M_/H<@!.IL!9GA$O*E1&9)$HICQV1J?".?MZ+&\2$_NS<VZ'OG/;ZH'7%(K:M
M^_VX@U6@QE[7MD=Q\M[W^G% MZG\\3P.SYTW)CO/G;_;S7^:K4^'Q\?-\P_'
MGPX_G.SOU,71(=SG,.Y$6]H\:1\W3_;.+G>>]W[L'^Z)3YV_OC<.ZS"&O\2G
MMWN\N?/IY"B.^V27-@YW?S1._CR9VWD^V15QU_K33OU'8\>2YD[[ZU$<5Z?9
M:E#X[_#H!WSVK-%IAL9)8R[K165!!28U C$+Q(67*/-"(I;!#"L3J)-X8TN(
MFB /WGN^DVFM^J3O;7,I;ZK\\W"@?$:8D><Q#F:3VXC%J5:8!.VX]$S3_\_>
MNS:U>2QKH']%1>US:JTJQFONEV07502<A'4,.#%)*OF2FJN1+22V+G;PKS\]
M\^J&)&PP,D@PJU:PI/<V[_3T,T_W=/=(*:W"*1*B=4BK8>/HY,=%W&CXV)QY
M>CNU?^2 D^U1^ZO%-'Y',0\!$6,EXDP)Y")-2"8%DJ,D#^R=/<YW)<.[^OX%
M<;=)]2LOJKSHG@"WS(OF;?V&&GT-&:ITYXZX=[) =[Q@E.B$$0=^B[B6%&FG
M"+)&!1'@D'<&<._>&]Y4O*MXMSEO?0>\,X9@KX00UD?NJ7.$"!<9 :[ A'#D
MH?&NVGYK!,,%$AA)#,$PAVC&09"P0DX&C#S#WEOL!-5L9X^1S #OO7=01<2*
MB)OSUG= 1*:,D(H*J37FR3%#I3!2I*1CQ)+(BHC;BXBGBU4D&)![[3"*5D?@
MB%HA39)$!J"0*L$CH7F/&,YV)345$2LB/DM$-(PG,)VB"Y1R[J6Q,23G%4V,
M!B581<3M143X/%XC\!^/#W^Y^ILJ)6.NJ>-DXME3J)"5A.7<6.U]("Y%O;,G
M=@U_5NL#%1 K(,X T6-%=01#661@-(9&FCN"2DT#B:X"XC8#XO%U0&1,&TY2
M0HIAL)JC]<AB'Y&G\#_+-0$3>F>/2[S+S79 X@.59'F\F)BE;9\>?C>G1X6R
MNVSHQ+#UEG *2,:YH?!9FVAA.&,;#>7AZS=T6@@-F59(KGBU/KQ:+FL2 S41
M^X1\V;?),H\,DQ[LVH@%P]$F+'?VV"Y98= ^T+Y-WZ14^Q-7Z1(O3+_?M/+5
M54Q53%5,54R/;I)QZZA2@CK#$J=,ZVBPI"IHKYT50MQZCQGX<WY]-X>OL<GV
MNV&!_E36LT[6L^C(CS0Q)QE#/G"). P?Y!)G8*F%:#@GP98=[9[H-C45!J9A
M[8Y[(V*2"@2MP++!@26A74CP;\!F V"@:OK=[)M%![44CD2.P:))AB&>G$/.
M60+V#@M1!2>]83M[ACWNSO!5S[]MF.:ZMI2KT_UV@,""4Y88'7DP!,5D(^*1
M$@2_"$2431@HGZ?6P'PO=D'Z&X0#3SX;\?6H[\_M(.8RA=WK*>&ECN%GT\%O
MD7KSM%%M#;[8ZR[8XW:WUR_+2DW7'T;?CR">'_N]BU]C ,C*35I(N4OM?V)
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MR>=0$Z)TW<#V:2+(&OQF%4&>$8(L!*LI;Z+TV !DQ+Q1%8"'D3(A9XF'GY*
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MEVB=D([PA&.F=0YQI032GB8DDK8R*>!Y+F9:)\Q]:%WU*#UI6G</?4[M?V)
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M:/O7T*1X<S<)3XY[(4=F-:[A-R,W@,$*?7P8DQUUAA5G5N",./GXMZ"21IL
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M<UE!#+;1-+JAEFFQ .8*&C6%)_/(+RM&>63G 3?.8.WTQO7 +C(=N9KTY5N
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M^783H#K=^_C^X]Z;#_P]7+/_YJ_3_>?O^_O/88QO]BBXIV3_G[=?]W?#T6J
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M]__ \__YB^]__?OCWO.WXOWN,_#Q_A+OP!=\]_6MV/OG_>&R/PCW_O3NX_X
M_$CR?O<#VW^^=_K^S>#37K[7[N#P_9O]C_MO/GUY?_1L7?L0JA@E7#L4%3&(
M.T^0B]PCZ:31V&I'#-C,Q&QO2/.0N^,/7K],[CZF:CZH..'3+DYXP;X0HN+!
M)NRI35QXZ7B47$M/G4A8V2Y.^-/VA36- :*S>944$M([Q(41R#%8F40E-P;#
MCTD\>DSU]^\+79RPR]@[#S*PI-9@'(F1B3.K;= ><Q8#BTPIOLRT0&@'&3\.
M,I8/>[$/F16#("Q(1%R:@*S &C&=6TO T@EB'SWFHH.,;S:.[K+3_*QSFB]
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M/O;@PX?>2:YMPM9SS&4D)N7F/4ZRX#T+MC/X-^7,O8:=A+DCDA/D< JY.:9
MCFJ!6(B&:66$U+R+^S\ Q94\Y< QQ89&V'.H%<1&&T.(2FB=4F<T;(#V+KOK
MN<6(EQ2C9$P^<*<:&>,#(L9(PS45Y<"=;!&^216!G>[>L.[:9&2@@IK$-5>!
M:HK!B$R)""SSG[M-=T,.VQNUC3$2BA5BF FP]55 X+$99*(EL("<TFB[3?<!
M**ZA5%F61/#!\129-J#)U"A)'24>=U&V3=#>94^=NMREU"DDN<"(6V61E1I\
M=JYA/6W G&S@IOL0F&*K?M-V+5_L-Y.&WFO^D^N]_+W!W1MC%2BBUC&AW"8
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M.^4#\P\%UN#^<9!/Q^&O1_'D<!1ZSD[@EPR+\'D :PRV\OQQV5_28'1:T5C
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M5 EKO5"*\1B\%=9%Z<!>\P;^(66!2;/ I%O@6UY@SZV.22I$B$N(BVB04\&
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M@TWNO$C1I6A^-\!L9UF=MGIU?*D.;1004;]G.R?;F;VS:,<(S)5R:C<9C8:
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MP/Z$Q?8;O_G9G>)UC#[9H8SA1 W CK7Z"?DZ%MQAZ]RRX*SML<6PY3D8?V#
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M:HG57%@(Z0L]QZ,U)=];(@>W2@^YD2DHM$3#[S=<6_C4@\>'KJ[+FI9O@@#
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MY &=Z]!UPW\.#I\/ZRI^.0BF]Z,U5.;($._]B;4>1#AVSE9H0"=^.)LOO?N
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MR@/_[ &"USHMTTQYY.P.>%:MW^ \ W83HTQ.,/W4K<PNVG#.#<L,-OC<1>;
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M&+88 ^QU %KQRW7Q\%!>BO(PG2ZQ.Q<*_J1! SJ[V /F[*;:0<YJ%&I]"!5
M3=V5B>-;CM<]"U-6>+W-O3"T1^/C^:[?)]J@[BZ'*8\J%^0*)3(U?*9;-=\$
MZQTVR/>)FD)*+.A?WV-K4/?P.-/KAHK!^:9(O[ZI'PU7#"Y=5^?45E7C-T :
ML:F[Z8S6&1;M [*=4+Y;AO,/_X3LY/Z+5W^\NA:IL+4(Q:8+KYO.@4-%0QH/
MAU?U<F>]F\7^TP7W0A]'3-#Y:/<ZJ#2WQTR=6I<0"K?J+)N59ROE#AH0LN5=
MS-0:1[?.'4]6ND,ZI=T9>9W8:TVF@X=N4')PG_0Z;KKJSEX%16M^SO. -G\S
M!/>0T \3O[Q<D)D)/^K.J[;I&E^;P.WHY:I;.0N[L@8LC0GPR]#F$#_9&D$+
MI-![\0R #<Z+@)=5]074O*T%7^I=R^AW!3!?>VLP;>.45F>7T/;PH/!:2K"V
MS_ZP,I<^8H%C;>$?*^P,@D'JNC$>^$(+IXS"+;*VJ&7=*M3Z<(17<"^JX5 :
M4Z?!:W_.^R!+[*>X]FW#6O79GZ##:%_?E(ATVXU"K\2):R -^/>]P9/6SG6%
MI?=-__!PJ0!XWB6>,7PTUAT9Z"6(6XNQL1%J>*+[ZGJKT!M.%?]H]Z,*)#^^
MC61[L]=NR973:WS#%L( K[-P;SN!=PDID."IQ 04,LG4>N/5<EXMP?G?@ !L
M^<D-/U2S_6TIK\,[6/@R1L\G* R<8[,*]E,ML4>\D8\1 6S*]9[T W(JL*/U
M/'2B8ZFO02ZBZ8O>3K/64'BZ6-%M/0Q5[0JX]P18\,HY6=57&Q1((P\K@H"X
M 9\$[57NUBK2JKMSW4AOZ)+:PHJTHSBMWJ.P>3X"*BX;_0A&%58#M[Z&<@3&
M(@+>(+@;7,]:#UDA@',P!PM2ME5];7C5/5#WPR[VV9EJ-\<KTY!PG<UK"<"7
MMWN MI)IGK^I)<G8%EFO"4EZ+V2](F^;(W6IH+\H]@;//J%6\HH>(U1>5\"9
M'PYPQ+S5^3<(<2C,;G7"'3RLK+^/32S*1T/?!]?HVMAMMU/F-3'V98C= FY[
M'!Y5:YT0DI^#15SCD&H]T"2!,;,($]>=*=5@^![:IE;,_N-H2( J=V<#%,97
M)1EWR4)(%F;W.EEX;?*OWP!5JCS32B0TT322C,6<%:7.A5&%2E*^.5EX3?)O
MI=]E*H4RA18)IWD:LSC+3%$R!OQ$)LW6KL;V^1C7  ZQ?+-C6D[]E5D[[T[[
MC:&]-6^'9ZQ%#@#?435I,D:@")SE!0_WX%$([:GV2X:-/]LV ILOMP<$#W&@
MT_"DSKU5N3OC8E2UL(DC-%N<4GY59T)!%/97.2D=T!4)*>V8'\*[?:QMPU<#
M^GMO\+S3,_HJW*$;[,)=4IZN!K>9(Z,&&#"N)+%#J+EA "VLZ,C:YEC&U(1I
M7*OUONT!'_ (J+"E+CHWPZU;8UGZGWB[HJ: K+_EW;+9%!V\%\9Y2!>Z*T^K
MSVU_KX=Z[0DB1GA\_.BJPKPX8;)(A-)I06G&A3!9GBD11Z;,,IE?59B'E/D^
M@/"WGG#D75Q;GO?LTSEV2'*5>2_-&_2<'%3S%89S7AK/O?_66AS/73DW=^5\
M#>;P;]R=#@^>/=KR-[6T1^[R%ROX._@LTY='!R=9F=(L-S$17)2$1C0G K@,
MBR2SNKHHN2J 8S]:*?7#D&!32:RP=UF;'\!: OHC6+&K!Z1)SV&D<XA&RCE2
MQ[<5R17G$*6^+;,H_2#1W;/3$WKXV$H5+U^)MZYQAN",>)#W[FS\]&?C],*.
M]20U]D(Q24'R)-:$TMB>C5PI0G66"R%IEK#\)F?CYB=A1:P-'XWK2%?+%QHH
MAPS8B>0O(Y*?#C\?WYE(.G4-ND_9O<1:JP7B#N:K0MJR%%SR9E"-P(UO^HCY
MP,URZ@)IGHR4^^0)O KK123WH22GDNM*..CX6)/">.;3&@"'="IC?N',N.8Q
M<WWJ*UXJ+'D.R (?Q/<VT]N]-WN#IQHP>>T*C:,Y9H0NT0"$-#:"#9J'8V_/
M%A?; L$=_*,]C6$.H?\\?M,?2KQ=NJQ"VYGRN3&791_,"#-SL1:7IO?KV4JB
M!$A_[Y-N6WJ%WS,'H\,0)_:ZMEN(^7WP1WIQW(;,N\T4Z9THC@+SWO71]'9R
MSPJ'T*%/'P <CX_'/N$:1.6*E M4>8(A,MC'3^-?_VCE7=H!]\9>:07V \U-
M"!<U/V_%I'MT5!NHE!8.N]Y=BWLH9?M5\/^N13H@+#/DQ5U);H<T8@.R(82V
MK8<GN<>J+*<.>A"@_"',9U_0BO1Y1LH&JA8^[Z2ELJOI*/X;+37TI;).M;4^
MWH06FR2[ O+[V3F$_)[6"+\* ND3GPQ#+#&NCO]6$Q'LNH)KHJYX'%!=>[R)
M6$= Y3OW]D&LHVIU(5NHNA8(9 7^L3?X)\0L?/!Y53O 5=%O]A!WS>WIS'.(
M-$E"'^L$I,(<38^JGYEPD]O@3N-6(3*O'QJ M[LH-7CS'6E:,=5"<O#G*,H[
M:&I3GFL-E7BSR3W,XQ^L8X%%\BTK3.@!(N4)VB5U6M;[>'6N&\IV1]5L?CGL
MT,<LH,X+Z]D\,'WN@G!-ML0:6.3&](*@8E[M5\-V65_SJ#7L?("PAY@5SL!'
MJL+A[5+)5F!K84Y/$93FL]D2BLG ]')L+76!DOW2Z1S.0ZLF %:N,78J5YWK
M31KL;=[)O@^;:C7WR5:*TJ5HPJ-AS(%GIB'$::.F'3#']=MP"CDPS\ ,*K<'
MD&8.F2O0M@LWPM:(88;N5W850#TL&I"%6^4A\GH%5AQ>P;+X)6WEWK@\&VE0
M&RVHZ&(.&;+555K-1K638?5T.YC(.C_5)2!N0')MO%V[8XO#V^%6=!5V,!\\
MWT'-P\BKNG3 BV'@!&[%..'Y-:UFR_JML\/WT*SH&*_N(%4];'R L?B^]J>>
M&J23NW=<FBN'N"GS= SESC3!"A]/!C);+LZ7_8"Z^W0#KD![#P7(;>/0[7ZK
M7G =7QK\#,3W&N8L)YC3FEQ\W? W<&XY4 UD:Y'E0JTW0EL\ K7P>5$&VJ]J
M-KS-.QWK=$WN90=<XQH#7R%,PLJ(>_%JF@+'6[4&[%ZT/FV_>>8.C^,[6[:?
M[Y/6T,K*YQ?LJ.H'MB []_"X/.D@%M'$62N%;4HS*X)>NH)AC1C+'HV5HQKK
MH%MJE$?K[NG<.YZ4-& :'"+-Z4BWKRAB[2/>P2M]Q/8$V")TKV82 N&LQS*:
M?IQ9&>[#0U:.=3/FX#-Z9Q.7Q>G-;AFW6M9XVS3":(L;Z 8DZV@]U&7MVD^@
MIXM'@+G*!'\A=+"Z&-7IGISZX$ %GF-+6M2<86'OH-.$JR=23;$1!.L^.KH:
M?V \(-AAUE80!ZV3I-Q][GQR-PQL]S!R[['&M&M_4ZU!S-;C;!\_C>'$RL\Y
M<(7=P[.V3AU=H_+1(P9OR,N<9U^[*L1+M1%EED<192FU[DU9%BJ3U$B5\S1+
MY(XJ\TZH,N6)R*FF(D^),#$G=MDY$87D)$YB*>,LT\*8!X_CR!6 ]0.R ""R
M!G^ J%\&:S3 G^QYLU^SZN@F!ELM.FTRW'D(TF_200'DUU$CW)[ &8C><MI<
MB%#0-*I\H:&[L"'.Y0+(5]-XMHMAFFZ5[JX_78X0Z]#U_UN\5_ASU_L9(X3:
M$39@Y?,GYU=8E2>M?]^R=?QT6OBQM<P^S?*L'_F6WN:W=/.M;X\U2[[#S/T%
M[+=ZNK3OD/ CSQ+5)Y;O$-9WZL*1-'#J4P* ASS=U"Z@;@2SP15HL<'4$04R
MNY@B>ZM[EO6XE^<>!3I"UEE7UC?V3H8OY>KW4%H)%=3AWD%W.<9M(Z #-J]G
M@5%MB&,US%-M\QT.S06< !^IQJ9M>+B\0[I"7[6AAT['B^KTT6G7$S43 9K@
MU= )?'$'3_QJ>&)^K^&)U\(->[#!-+4&3BERPU+[%<9+662<)8HSD2FEBTWP
MQ&OAAKWWE#JS5E4J-1<%+3+*8YUPR;.,V;=3O45]8ZZ4#NW3].XR1#",BXWY
M_L$U.+V)-MG_\QJ+.W[ 'L=OIR=EDZQI.A2'^&#=Z0_T4/M!#UUPTBODH6L-
ML%Y1/7)JLPNT[Q=*XF]KWB;4,.=X0[1QZ'4AE7TK9O0"M)!WXX[#$'L%LD^?
MW\ 7^"]N<"I#ZRRG'#J7C)RI0)/6I5&]ZCG59667LTE<0B<*"&W5U.88I7 #
M;\H5H)=$Y1AEYLT-ZI'WG@T$?,7URIM7S?5BKZ:'=O57"."\=QP6I>&)6=>"
MK5/Q,9HZD >,Q9<&MT:$;.U^<<+#V]^XX8)56&)]H1'&T$G,>3.QJ?CJ\K'W
M+8+M- QO'!5=D]^V!\R,YA-75(BIN5;'FYKMW2>TL9]DF_7 KMM(7]B/S:!@
M=N3"(5@6Z1JB^*!)B]@(V5-JJN40?&T41JBWQ<1=?SM6##/<UX8ROU7UO#Z\
MTW:7^K$D="!\W09X0Y@![B@@T_0T&;=P"#.'C+EB'J-56GYX7MOC@.%4=>T-
M<AG+/H?#J/+K&-KV87:#-[74JR4R3J?BP%MP@\X<&KZ9^RC>:Z*88"!W4DU7
M1S#K"&&MEU8:^0!!-E9@UI&RM@#,]6@B@%8WZ,!:T -S]!@K*F\4XG1='E^M
MC*#3,E*?CZJ9TE7-#^RIN:56B*'!%);!!F!U7/!TAOU_ ,-0\V+51G<UFE@C
M@$_U;%DAK]2IQM0D"HK+4D*,'=MIU4@H(%7$3K:88:NC 0BQ\>ET_ZIAD[H2
MEZW.'M>&$$Q=1['26RED]I!=([P3TH/(L<,7]8#KNC*$#/3C 96C>K'_@)]*
MCT92HQ4H,%>S<S1_D,G8&@JCF2N.@.&%4JRV;U9A$U?86O0!FT7MT=_;M;<+
M.E];F<>MOWKY6;<9*M%*:R= %Z ,J\ 5WWYT\-/J\;H*4#37>B^#)DU+Z8EN
M]+1J17+=_0A&HI6F&:)UX.J<!VUO3"=0-;7G&M,RUE"""A5@#$->6A>W#M&=
MV9H.P*WAMQS;]?N_I5",*W75,U_3:5<6#-^VL" %AC--/X6:9VL"@RGL,PS^
M$@4F?6<8M439UVC[SH">-P@>%3C$NQ(70@SP'<0=@5B[8^VN/]AUG#A\MU=
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M/+/+^9-HW$/K8GC2,@0/!G&XA[#<MM?5"H!4CJ=KI'L4+!V.GT%[#9J 2;#
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MX5#8B=N_3?C\PRZAC3HF37-M5*&42CE-8E/J3 C.9%3&>5I2M7.J?[S.Z=>
MGY[(-(YYH0Q1C$MK&^2",&BL07.[/RE7F<YB:_I'NX3V][ROJ3U,UB5+**,)
MS13G+"V%$#2C6O,LVA5P;^/16O&JI5 Z81$1953 @6*$QV5,8JL78U52HPP#
MLSN*MRE8OCO+=^U5?X?#O-&KWIW@VYS@ON-L]X=QD3/"5&E/<!%K4N92P!]&
M*A5QS1A<CKN,]3TZNMMU<G=N\ZU/:=]M-F5>%D(H:[@::[CRK"""EH*H@O&8
MJT1*6D SN%42A?N;DMY*UL%OVD4OVO7LO.4"_31JF,FH2""<H#-#RYRQ1">P
M6$E>)BK6-XY>[MK,?V==O5I;F^;":F.KG#.=&&+OU9*P2*<DR04U421X 9G&
MN"R&17)7=3MW=Z1^VF[(.^7Z<RG7V[BG=Z5==TG?'ZII^[ZKLJXK0*((S5+K
MNY9%3DJF(ZMSDU3)E*8R+:#?/!VRY [2OCLENU.ROYB2W0(+]E=M//_=M&H_
MUA +E>5V$XEA4,5BN"!E812QUFRI11[IPD0/'I?)L(R^NDIM:S3KFM[S_6S@
M/>A%_V(*!P7[8M@S=CZW!P*MD &?J@%OF26#V12;S',I77]ZZ#,/+>AA8<&&
ML2.W_P>X^@H:TH^F]G-Z,*JZ3]&?SJ%'(GSBOVZA*J)<9#0W469O:9KF$4^Y
M3I,T,3G47D01IM&3D$9/HK2G,[*^SFA;7"]-7X/<3%OD]U-;C/7__'WY[A]U
M+A*:'SY]9K]S.#K\/!X=O'_^X?#/?W\X^.<YC-QJ@<.1U0ST8') CS^_,P>?
M7U^<)$SJO$A+$BMJ[2:3"B)8S(G@/$]8P>($>MRD>ZL'?6#%=QQ$ZS:;KWE2
M9)S+K"A2JI7D&1?:NLQ22V;_Z//H[S;_&VU^>A*94AH6:5+&N2)4E"41J9"$
M%Y&1]F@JD0,6:V\5BU5OOEU;U".+L[G6@XG=Y[-JH*>@@@[X7)ZYZ\ W;$Y0
M5F!3]P9=BOPK(#=?I"NZ O)&GFFU'.N9N<)_>[Y<+.>Z+4O/G'([@COAR([G
MC_%,?OC%Y.30FB G"<VHBDI&=!%#19RU"EB4<Q+',;,J@V=Y:4TM;8_2N5WU
MQ7RI'VRZ+?$>VYKKTNWY^BO-7G7:CFV"E^%B-A#08<K*^W@\NZAJN7?_ALL3
MX%DH^O"/T*H\B/_@X0CNV]G2CE95CW[K2O]&P\(N"UHDM?WDK""[/&-^7NG?
MPE]^5Z/J?,PO?QM-<9+XI=_]L[Q1!79*SP+"?7"__OUBI!9G8/3O1<[P]XD;
M_V;_ZSW\5<^J<[\K\[VXW/SK:"_>^+NK'AO'>WERL\=>DV^Z14IH6P&+Q:9N
M:,OIHF-R^Z4((PD?ITZDOG9YOD,/\2]K2C<9*376/\A5Q@ONH0ZNZI77XB#<
MB%]5>O"3!E=^SO"(M::*E#&><Z%H'E%K6J=,L$(469)DD:/C6W5U;A6"7C5>
M_M83/K)R-W]I;1^P=8\11?SS1T]@#'9DGX_3=T>'ULQY30^3=Z/C]\\NCR>'
M]CW_^?_9>_>F-I)D??BK=/">_<5NA(JI^\5S@@C&V%XF+.$+'@?\0]05A(7$
MT<48/OV;U9*X2 (C$""@O3L@I%9U=57F4T]F967^V/G^=W-KN_%CTGM2W_[K
ML'Y69XW#T*K3S=/&QC[;/?J[6=_^N[E#Z[3Q/5^_*>KTRW3!J?T]EV34"2PJ
M)HE$W"N!')4*R4 )$SJZ%$N?=(W(%WC&8:F1"!2,71O3_>H#P9X&H!IP_^V3
MV/H9Z^4J66'3PK!I.J&^#DR89,!2YM8@SEA$%NQJ9)PWBN$<L9VQB=0T?H%U
M/)8=F_B=L.E5G.U\&FS*7&G[I%-!TJ(@:4:R42Z4-%XE%)-FB,N0D-;,(6Z9
M\9$KKE4JZ9)B]XYMK>C2O) D*KJTA)"4G0H5*"T,E*:S,-&HI%<RHJB%0CQH
MBPQE'&2.&&)HKAYN<]YU(>YMPE4T:5Y,DA5-6CY,>M\95&ZEQ4'2M%M)*D.8
M#@$1G1/#I>20\22B(($W&4$4#B)GCA;W/P)4T:2Y]'/[(':C3?W8K<C20P$3
M_#BX 94R$/F)P.OU/",5-"T<FJ:]2L9JYP*VB$5&@"W)@$Q.!$"I3S%Y^-L#
M6Z*J1ND2TJ5Y]D@?]+CA(^RJWC!Z:E4M<5JB(=!V^K95S"LJOPTM?<D[JG<:
M@VK5J9*Q/\G:LC5MB3M"7:*)(Y,$1IP0BHP2 D4237"2,4[=RII2-6,6M;;,
MI2P/&&Z>_\[BW&P/2D)S)4YLI!*<#F'[N--KYFO>#(N0_8P7\5S_NAJ+-WHL
M?/$5ZV"I&?2O_\IT]%/Y3@XK:/??,%DN2$\1OL?(U3BZRS]S_TN%8]Y%4/%$
M);$\D0AH@+UAQDO-E6!X3Y*5\9<.SMG L=V/R &O_X%*:O_&MD[L:6_ECZO1
M>LTVFIB)ZP;Q:C >5>>#MO:_KOO'VJP'N2&"<B2"*"]-;X@>KU>C*4'YG<</
M1BOG1*P.M6[ZYP,%^9:FP;O_&S3[I_78/^B$]7;8ZH---GQOL_TS]OKE.88E
MB>&E]7,HWF=;&^N_MC9:A_6C?PYWSCZ+W<-UWMC^<KB3VSF"'GS_1G:_;YY,
MQO!N;7A>WWC'H2_P'D#P1NNHOK%/&A\R/.^< ER3W>U_6CN'?Z6M[7W>^+P7
M00&<5QSIX%U.@*V0L4$C;H(6*4H8V#A<0 %QP);*"YKG1F P;N%[CENKC5 \
M"IV\IJ!(FDY&_5X:[7P$I9R'XAVTV&_&WK7I]<8AX)?1;CA%O[__U?Y:SU5Y
MI3.>:YNLB9:E),!$T8XD>G-<\I-J5=GBFR90W*:_A9X50_$NAC+_F-'TEW6M
MTJZA=NWO:>$8#!M&..:CR"[FRFX!(TV5Y$)X';6<E%;.<(@.,ZFBXA*NP2QP
MHR+FSHK(]#PQ]<NP(EQW)NT*)G1*3(@C3"C^W_^G*2%_%G$HSD>E6)4GT9J]
M''G?21-Q]G>+I)\.X7[TV'IC5@FE=PFM9WJ5/D1H/5WETMRIV9L_8_K6K<YP
M6XS'&R LWNG*6P^ 667JKL^XH.>__?&*56+H*YXK@E<UE\]DL@A9U?IVG7VM
MAU;&)Z3R28C2 LK' F^1<'F. ;FW<#[[05Z'1=./SGNG8G-XAOO?'SN]WM2Y
MD]<D>^\'Y2F]2MH6K-+ V+I--RCE[37+U]4C7K,.YKWH&)V/]JMM ;&NQY"[
M5*SW>IV<A^(2V]_\M%Y\A"]F6/IKT(-7O:D*$PO9+WN)FSIS/_^+V=!A4@OJ
MJ*2"*AZ4-SF?HHDI,GB+L%M7U[W&A?$L=G+NZN 8[>3LDYWMT&QL[)/Z1N-@
M:_OSZ>X1?';X@]>_[_[8.7M'M[[OB!VZR::R"FW ,]!-O+4!ST;?B<;&WT>[
M']XWM[;W?T$;A_7M';A_"^X=4GUZ)X=+9HP1&#D9<GAWR$D$J$?>!N-@_JAB
ML!JR&F;W/GHRKX(L2PFOQ=M5\X_-JT;.%PJ;,3DL1= L$L:S%E(>O#/::DVP
MY.)WZ99FI&C+ED2V(]YW.T<5FCX\FDYFOI2&6*.50M)S@CBS&CD2 4VYBX$X
M2K7PN>X*O7^$^EQ*\SP26U:<\?5PQH6!W]1&\R6L>PMW')N^5W$O-7_%@,YB
MMW,.>;B"O-M WF1:2N\9"3D*R$2K<@D,CASW&%GOD@:; .;7K*R5%B;]LZ*0
M%86L*.02HNC-)OC73BN\M=UN3D<Z3&OU6S2M".3MS/&Q2=XX6S]I;&SN$>>D
M]#(@H8E%W!.*G*,6)44=(]@FYMVCP>DR86F%>Q7N7105QXXJK)F,.O(8D@W8
M6M 53*QFRO+;AI!7-O)C0-SI!,1)$YGA @8T23"2B4,V'^@.P6D:%0XLI^+B
M-6JFBT,L(\"]\-.49;38)^N;J>G/-X\VC^Q^#OOZ?_;H^,]BJYW[L7]:O"UW
M_6IY3WNU.G9Y;4D&+*S&),ADP%0RT46B0DI&2 5H)D6U7[(LZ#5]X)OQ0#0G
M$7%L>*[+ZG.:;HU@%8+?L AY:;.'3Y%[UQ!;XO*L#Q%?\>IA(2;L&=!^XP3F
MCC+C/:,IQ>")=!2;A]H/J !A'D"8<OD+G"RW"2G%$^+.4F2I#0C631Y-Y%3F
M8];399I?#AA4BKLHQ5V8+[O2Y5OI\J0O&R>9/.@Q3)/-EHD)R,3L@?'.)<E)
MH%XLS/FRQ!I=+>_+C!*5K_:)3(%)7RUWT1/F"4H)!\0-F $6*X$T(T+JF)0W
MB]OZ6F*X>/6J[3C!S E.A-;<4N^T)((Z+*UC).E;9[2H#/K'T.()=Z2"%=]*
M P2>$K#H8RZW1;3+R9(HP+3RQ)/2HJ?W3N%6996<2P,%(\7WU>)MI]6*^[%6
M?/SX]CQ4O<RH$4-Q;+O]TRKUY+6N1AV"3HFHR"5G5&D7(E&8"OAGG&65JW%)
MD&E&#FZM"?&4:*0L%8@G89#3/*"\D!@7M8@)K!&B:I3A)4HNN<2Q,R\<%_X]
M!S!8)J.C/DB6%*<F&$X!&*C"'A/.7;J%-=*#!X97E=?Q$;!ATNN8G$S<*X)$
MRK4?G39(DV#@3R64)3CJD+<A]/0.ZKU*FRT+)KQ,_7U<]:U<CD^AR),N1V%D
MI& 4H) P6!_.!%!DIE%0Q+H<V)?8PN.]EE&CJU5^F5&B<CD^D4DPZ7)T*BAI
MI0)S($K$L2_K\ECD1!3&8BNB7WBT_3+"Q:M7;>E89+!&)$$M3\8ZY@RL%<QI
M)6ETNG(Y+I,63T5 IH1Q -35RB(>/%CVT@>4M(N2",]$"*5ECWE5C/1Q57"K
M'8OZUZU%.QM?Q3:($E(3I2C\2MS&8"((N4V6*IL,$;)R-BX+)DWG@8C,6YV2
M0L12.F07SA"&M.%"<FD=,0!)M&;(O7V-2[R3604^/ 0LF 1*[[%CQ'-,B $#
M)."0-.&",$.KN,9E (0I#Z.V5!,94+2*(!ZY1XY)#W_:2+VVWKN<RH"I%PP'
ME>HN2G4K-^/C:O.DF]%9::FA&'D-BSK/^>:-<F!Q4.FU#H2K5$4V5@O\'3<3
M%[["W][/6,'"7*Q_TI]H8TP&@ %I$8#VN\SXI?)(1T(22RH$$7-YUVG2?_M]
MQ"6&@Y>INO-$+L(\X\@,281Q1:060A LDA318J9=Y49<)N6=<"-2QEV0+B%E
M!2BO2!19(3P2V6;W@:A 1+;9-5\FDOX:(A>W[3Z2%X>ESQ6B^ !/=EQ%,MX!
MJ8($. )F$;ECW-OH=(PX>1$Y3UR[ZM#TTB#5]*'IZ))1)$5$:3Y7)7Q$%CN)
MF,"6BIAPE")G?-!5(&,5XC ?+'"B(\/:2FT"UP' (<0<-BN$M!P HG(N+@,@
M3#H7J3?6<4T0H9PC;G1")A"'L* P@YXZX_7*FKSWJ>DE1H-*<Q>EN7?S+59+
M_+TT>NKH-#7:,Q90E!IL$1T(LL0F%#W1U')%L<7Y%!5G]SY%M<1*72WQRPP4
M513C$YD#DU['&*PGED;D\P9C3N"'C/($>4Z"BF M$&*K*,97H-HL2:<E3IPX
MSAWF+K+D/?$I @GTN,KCN%1:/.%^E"H7<8Y@QFN!$4]$Y#U%@;QV-FH.GTH.
M)+[&<D'XI='AUQ#$^'8]5_(:AS%6 8O7IF21248K,2=@=P+!L-PD2P,&Q#$,
M:$;E4UP2^-F:/AW-L)-8*(H8,V!P2(.1P<:AR+&)0"^4E@D,#E(S]T\CN\0[
MF%5 PT,<KH@JVN %ILYS[*5-'BL2*1.>6;!S*Z?B,B#"I%/1*0*6H06#0G&&
MP&H4R"EM$,/,!Z&$M2&[(.Y_I&*)X:!2W46I;A6Q^+C:/.E0)"K;%LXC%9U!
M/->D--%(%,!0M)$Z;32M(A:K!7XY%OC*I?C(UL!TW9R@\B*/$LUY%#3#R!JF
M44K")A8(3*M_#7#QZE5;,VJ,%=Y@+GCT3I,0'=B(D=+(DZ"52W&9M'C"I9@$
M%DP#)@(:6\1%(,B(7/U*B,BB :2..1<CK1&^3,<0[QO2>,=:5\-.O&'0Z] 9
MN%9\;?6N;C, +P;8#% 4JJ-P422NI3$TTCP85&H:2'25LW)9@&WZ=+4QS C%
M&&(X4L0C*4]72Y3K8,7$I7/$K*SQ7#9F4>$1MU>19=D-??PBJ16 OB8 Q=()
M+A,PC. YD]@R&QEE-$DC"<7XH;RZ%:XN#%<G7;Y<:BZ%]RAQGA/IT(B,3 K!
MZLA<=%A9+H919^RUP>J]'J1"P1EC4 %A%7F[!!@XZ2A/6G#G9 Z>%QKQ9$D^
MPHM1D)8!G32$E\G$%AAY.Y?:5.RR@M9G#JWSI$)8.,FL4B$\D(D^N8/ ##;>
M&X,$+2N[,H,L<PIAF@O#*,-YE/=-A? , ;0"N]<%=G-@G0\.M,18:5W@$G-#
M*#/.**<$I0)79:^6"NXFRUYQ9F%V'&(^ &U4 FBCDQ0QJV4,CD1%T\H:YS6F
M'\5V7A3LE7LQ?_0MM N_0_/GVKCWC<$1J(1?^U]X<]S7(]O=;[91OW/\1EQ%
MI<-!K]],IP^GA66+;YI]N)V_62]IULN/]JMMP5B-DTJL]WH=W[1]N.=H5[L8
MS\<CPT;9O1QP_A'>+3JI^&O0@U>]WKE\E+,P>]3+YA]SV&\>Y/IZ<6)[ #P@
MO3$4[K38Z*X6ZRT'(E>L=_O1[MNBV2Z(,;*P[5!TCF.WG 3X%O0W#T.(K2:(
M* AR<0!MH_\;P*/U3PMONW&UV&P77^-Q/QY!DT7>L:D5ZY_>HH]?X=8]8'7%
MM0 ," C?F<!@X1P-8.0QD3@W@3D<"4M6.ZH=T]@,=X6P8?@R!O-;6/!;)^W8
M[1TTCS_%KH>_[7[,K/,<>!%]GLC;BO_]<KK[/1P[R@%%/:]OO./0%WBO<=C8
M:!W5 8T;'QI-Z//ISEF=[&[_T]HY_"O5M]?)UOJ>"90I)PVB)F?*=88@ RL@
MDL)1:R03GAO@B61U1KW ?V7U:/9[($+]V(6!SK*4A2YC9M'O#*5M)&:P^A7_
M,\=R+"P3442ED\;<8>8<=":(J$/"CGM2FAX@"D/38THFD%A,4--U"[5\=>+R
M[@3$Q5$5%.<<C(E<J2D)CX G6:0BXUYZAVU.K"Q7^92P% !P+7A1*TX.FOZ@
M 'D9M'*F()"9"\SHG+0STM@Y<</$).%_RBN2. E2!P:++XL*8ZF=OR9,AMY.
M1&9 QVN&C7=XZ_.>T4IKGC *@6#$+0T(X-JC((33Q"BL2MB8A1F38 %+#<!(
MW7;]P9"(,5A$\G2M%L]OR05!+JSW&4=Z)>0-X?$\8];HF?-ZW"WZ![&(I<@5
M1Z7,Y;'(+1S [_RA=<URK04HC;] ^)J]6-:I:R8@365KJ36(;1]KA1OTBW:G
M7ZI%M],J.K!FYUN5;$K]V1LM[3 %O=7B?6=X\_Y!-\;B"+YRT"MBR1%FS$/)
M#,[7=E!<WX$NG)6JF[<,B]3M'$%;S2M/"G,Z#]P#16=)J225H=PEXC#GE##M
ML!<F./L[3],4W"]P._/U8?WGT_KZ7M28.(4C"MAZL*FH0I: 324UP5;"OYCH
MRAI9G3:HQEA?2HXM6C )\\J#!TN<6H93,+FX$],>?@;N#0;Y2-*.EG\R7OYG
MR,/]*CI6@C%3,,X:)WM6)8>=5# >.5.CCQ39&( $!.MA%09Q27IE#:].YVF\
M( &P AQ'>/-G;)W6,BR6> ?(>02HG<E8%@>P()JA3"?8Z\.O<F9*SEE.X6JQ
M?>-WG&U9P,:B=Q!CB<*^-0BQO-$X2^$EO!I=/;>@4@R<"&LFHXXY]X.%Q[<>
M5@-B-5/VND/_MZ2GE2!>(XB>@2 :B64"DS$'HADP7D :34[8$\$^P!$,!H=S
M(-KO$&J>Z692"^JHI((J'I0W0((PT,_(X"W"R#5QB]5TWW.Z>6-]SV-LE: :
M,9K/10;L<J(5BH R$*IHI%K8E36V.KVG<3'=_6L9SD;TI1OCRD?D*E*M7F6D
M^399.IKM04FMKG#4$2_D=%5E9]QQI]?,U[PIL0=:^_.D&?H'8S_UI2^./(KX
MXBO6 :H-^M=_Y1+_S19*[ X9<1,H7;O_ALER#^0I^#"C$R-VZ>=!=]R;8S"I
MD.M&^P/9!+U_8ULG]K2W\L=5T@^,?V)0KQN/D7TP&DFJSI]_[7]=%UJ=T:>)
MJ1PJF/5<*<>M=<9S;9,U,6<)$<9J[0C0GV+TG1C6L\Y*'"C1.GE+-/?!6R=B
MD$HX6!B2"&GEFOMPAD-TF$D550X!TY@%;E3$W%D1F9[Y=,MG_5RV-WJ#(^AG
M:29,+,1WT,'\V:4&9[&!TMJZDU%STNP?C+4\FUK99,N>S];( >Q&#N#"=F-1
MNE-;K<Y)K_AWR5HZ QBQT/O/F^=FK [[ 4M+9V@7OBF-TGS5RMI?HQG[6L[8
M;9Y,E"I6;E1<X%BY00)/T[+'O?AF_.+/<2!*LUWVJ?S2GU=5-BOWQ,9(V=WA
MQQ=ZOXJ'NC\ZKC*Z\^CCU?*CB?V<X6>*KA(NKOT8KY)K/[NI64)6#;G^JS<U
M>_-G@EU_TWMUEM^JV=\<"9HC7.F&Q$.CE>MIMH_5S.WC$C@*P(QRV<BX<6WZ
MH5<P&F-TOCP@Y,J /'8V_-D4:%E1=;W7FT+3NP2WC("U7%".^T5I\4[M.M]"
M^A81?KC 3HZ$9X(_$SY<61XL$<'S;.,)-6W4!,K7OY$E$7\BOOG6]@Y*(N?S
MB^Q*_PGV<?LZ';MW=LKG']OU,D.W&!.$1I&+OF(.+PP-5F &O^$33>)M0[>R
M/*VW0_[U[D*8UOOC#>)_;&L07T$@UU$=[W[X=KJ[T3IJ;#2.=J$?NT?0M^TO
M/Z"MTYWOWUCC\ =O'&W2R4"NG;,O/W:W__ZQ]7T'U^GNC\9&.-K]_HXT/GSF
M]8V_#W:W/=W:WJ<[A[MI',1U.0]>9((J35#"@2'.F47&$8J(MH1*REF(.0\>
MKBER[SQXRY=*MP*H%PI0P1#M<.*&$_BAD@[))&8$2R%QQLUM3[M7 /78 '4V
MF<@+3&:")45*L7P^*2?J3-PA)X.R1#"6",UI@B4Q2X1/"TH37-Y;#5VORXPZ
M7V*OWVWZO,.7F6&5,OBAB=/%@&=H>COH=N-+.</S2%#3F,X)G*()@0N&L,YE
MA1Q7R'GJ@!!IKB,1FFH)4&.J#* O6$,7Q1PJ#5V ADZ2@4!%LIQ$I+#RB#,7
MD=7*(@:\(-A K<XE2Z6Y=^6O)<KN]2(<1U^BC\">72OV:D4[]G_CDZTJFRR(
M)ZR/0F,OQK\1^^=@5)DM"T*JZ91=06"<*#9@MF")>*0,:4H8LDG3G'LM^9"Y
M1 WKEURS]-7K\:+81*7'CZ3'DXS#8"P-5PSE4G$YC[A 1CB!%-7&*"D5_,A%
MTJE\1NZ'Q:4"7]25CUU6:2E)TL<.W+-[KN'WX$BOPE);%$=J=/JQM]X.>?@K
M@'U8@)W>@.)"48,=13[P "9=$,C2&)$$<)7&2Q%2*@%6+%/*YLKMLJ1$J5+F
MQU3F2;:4N$T*:R!*C('5XY1 .N6T<IHI+YG$F"RA,B\D#NHQ(KF6/]9L0;%3
MBV-W2Q*EN+*VW>G;5F%OB$B\]P*P=-N"MP]&F/6(+V9M6Y@SKQ2>:@%;U (V
M(].^%%$%Y37"/F>$%EXA&R5#UF)KB=0Z6;NR1DQ-+54%D071T0J!7B@"+<P-
M62'0HA%HDD(K*J(AU($5+#'BWF%D(@Y($QYAPIPRV)>%B36;SOFS=!Q:+ &'
MOB%3X!+QZ-OV\@&X](@8+PNX_>90S\?F,$M/,V?-:X?B:[_C?QQT6G!!;W08
MMMB(J>F;_5N<':L.HSQ;=_G(H5.T+@2B.H;RJJ*\%V5878*4RDNXZ)#N[<W^
M9*YTK7.@)<LI16BNNY,L<B9%L+*T4<I*;+U<66.\)M@+C(ZHX.B%PM&BK*P*
MCAX8CB9RF4LIK#?8HL@HF%R&&&2XYDAYPX*-,01F<F:=&L>+JH&S1&=,GC<)
MG,7^PP3[?TWQ$_,4F[D[?;HFT^/ER1CF6]LL<P#"&'[J='-WUOO#JEYY3W:[
MT^BT1^E3X4'V-T=Y:BNP6QS8U:>X%W>6P(P&I*P![D640"YA@:C&&MM A39X
M98WPFC+W*56S?,[M2O$70%0JQ7\^BC_!<@*)$O,@$??6P ^ND#&)(^VTY-*;
MY*3/!:IJ0I'E4/PE]BF_P#1 573&94_B, /BO.3R=T/VJJN=W6D,EGO1?5I?
MY7H[3"^\U2*ZN$7TVS1[]BD8'"W21C)@SYPB+7-!CN@<#H(FAM6"XT.6JMKC
M/0-(*OQ[M?CW ,[1"O\>'O\FC A!L87%2J. I49@30AD?2(H"&4C=IY0)Q8<
MG?)491^7H\SC'8,DOEY)V+UU7HKH96:6YDP_1+)F)>^6L/I),DLKJ1XEL[2Y
M>R[EHV8(K?A$N92WRRSU]4Z9I?[=19;Z,K?R(E,J+\(!\#R&]);IN:L1NSQB
M,_-WW\_%M<!HLX=S<3UI)ZLTZ3D%S\_8'E0Q<J\L*(52S@4Q1EE/N#1"1V*8
M!X,KXN0(4[^K\S@CL5DI1[F6W]N\AP-=^-[L'[P%X>X<Q>Z[7Z.-GWQ6 /X?
MMNVOUV"3?6/UC1]L9WOSUP[]TMPY_-+:W=CG]</]DYWO_[1V#S^?U&F^]I_#
M29L,;*Z3K>UP4#]\?[C[X>]FX\,_8,?MGVYM_'6P^_T?L/'6SW8_O&_N?F_,
MRN#L ^8L4H.P\;DFF_/(8F+ +C-:*<J$46IE3:J:D/=.BU8%TU6X]4BX)26E
MVG$C:&!<!^.<M#()%[B4W'+QNWJD%6XM&6Y-'G3"TDNE8T0\6H&X% PYZ0A*
M7L'$VR"(!9K.50U6L"7"K6JW=&7MW:_CV.Y=1R5?>*#-4W*OMYU>/[N]QQ-0
M =2B &I&.N@8B _:121A"G-F(H)LI %1RRBES*MD"1 K4E-ZF?+-5N%RR\Y$
M*BU^0"V>I!E."^Z$C<@0X1 GP2)'G$9.">(I4\91#C1#UY1:)BVN8M^>:^S;
M\IVF7EEKQ/ZX:N^_6YU>;^YPSBIPX]4&;BR<Q'[J=E*S_Q'$L%KX%K;P-:?H
MJY::R& 5DC%*Q(4SR.F44*+6&!&Q8CD#N0#V6D6J58#WT@%OGN,Q"R#\UYR3
MJ:#O0:!O*H<2,8'(7"XNB 0_3,J%G#! 7U1$1<JQR%&Z-2&F:UH^+#5:8'Q:
M[G@6VV9[4,9V+4O$6MGBFV8?;N=O04W+NN:?K&^FIB_J,>0A*#:/+'1_OSR$
ML=7.G=L_+=Z6\1RU8K/M5V\3QU9V:6E\INN?WJ*/7^OKY3-]JF]NO2W*YXD!
MF'F_4]BB=V"[L3@>=/V![<7"[G=C&<)7G!S 9>ZT.&]B?$V ;UV+:X I+G8G
MR9P5T29"$]&!,T6U=-XHQ2-/25HJ<A0N$< -KB :G<2Q8:AM/?8/.F&S_3/V
M^KFC6R?MV.T=-(\_Q6X.OK'[\1S)$'V>4-:*__URNOL]'#O*Y=:&Y_6-=QSZ
M N\U#AL;K:/ZQCYI?&@TH<^G.V=ULKO]3VOG\*]4/_QV6C_9TS"X @>*, L
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M1J<K#\:#".(/UEC?$R!UUN;]*\THXL8K9)2FB&H!9#0*"W8MF+1J=89S]:[
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M#L#PN>94 -^/P@I=[0 ^#';MG &_US# WG*-8M02<9@&Y+AD2'*A>1+",<4
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MP\H(IJ,MV2K WN^.I#2@/[T+U6O<=I?EJ4GHXR/D-[$7E=5@N22DM<I[+%X
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MITO%G2LX?1HXG=H99#3!XLA15%8B[I1!%N88.4.\4([%Q S *:L9<>^MP26
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M;48VA(!%HIPAE[A'W+*$-(T<4444RQF7!.; >-0TV_E/=3;Q)4#  IC.DT-
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MK*P1C6L@<TN4$WA!$0<5,+U08+*8:9<P@)((W&&MM3=@YWH=DY3!Q]N6JJN
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M<]D:-9)^D\:7_IJODQ.7QCU?-J=!+X>+0\PD467TYG#[L#T\&XZN4"SN?!'
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M+"A&PMUL$HV=)2YV8VJ7[)713)FC:#M 9J<=(.\J'KR8($MC]#-0[P#;X$P
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M#%%.$ZX,Z/(\,2,IEIQ8CT/*15AW=HZ.-K#LW\M"RG_7-UR+J3DF(ZRS>7[
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M\:0=0B=^IT/,RM =#NH!^[#>Y;++Y)NSPTJPF/<QWHQD.>OV.^'8C *'QXE
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M[V.,-+J?W+T::72#X)U@R 69)\\]H^2I.6YFZ+P!%=PHC"3Q"7%#$C+84Y2
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M)*Y18TU4E1^V@NJ*J$I3W[_S@^V>YB6-R>Z.Y/9,VP _@-P^B]WM X8CU\2
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M(+1$G$B";-[&HE$1QSE(GH+UFM*%([Y@J=X(W[,+4VALMNVW;@_PS#<^C?J
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MK'+4^98]4W^/W0AJ^J#9V.[Z]>7A\I6?"FQ>^,#7JM2#%'[[EA,>#>/#JDL
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M!ZW7 ]PA;HQ -F3749%LR/[>$9N<)_SZ$/=[4S). HQODAX[6/E%KN1JB!'
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M:NTMYW<M<0,P51;^;N6T(Y<3U>3<*'XZ2M,T*<\Q3\TV\(40VF58J4T)5FK
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M_PO 5520!]&TIZ?]GO6'!:9$&'L8Y0@H'^$9_49[F!%K> V8P4-M(96-3X#
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MEQJ=7O<;RIF*0<;=L+9^K'P#9EP=:Q-ZN]X.7CZ,\CFRDS .6@>#I+(<8!0
MU1)L$6%!RJQ@A9PQFC0%KE)X3VT<J2C=62C M8S>4T9GJ$ZTFL=$,=)1%6%X
M"FF274.Y<4(P:UQT:V^5?O!N26T >8!?:-=V?1RG2*^]-AZ1-(R[OLBF/-WF
MK<'GE\!G/A6!U$SG(4$A^*(6G45:&(,LC!SF6&(E*>A9O$KYDFMK2$7I02VJ
M2Q75&9X@%?=1!PO3!4<05<6!,0B+)"&1)46B]SEK"*F<5\4_AMDT-DU%5#9N
M9W0"\]J7W_-L;'='MFAMSI\T$]G/Z;K*%.&T-VCG<][T8P=._AY_.VN'X>%D
MQE^ZL&S&&WQQB76#7F<TO/Z22V_F8<+&?OFN[6Z ;V^8+,#C*3)Q<CF3S.G2
MY^$T"<*I_1:1ZT=[C&R"UK^QG3-[/EC[QY67/&EWT4RG7M<?)[;_#<X>]R15
MT_=_^W^N#W==T*;B8V8\2VD7BF.% Q<\*,XQLT '+/ #%:1)DK.UZZ[#,6(9
M(B56<J##!MH)WSAVP3+&1<[W4 1V3\>]R'$ 0].QIX/X9O+';Q/[5[M;='!Q
MT6]77S%WQLQL+F9 >?BBG]9QV5=C_CM^\OCP>G%H1L;*8XJL:\&N/8S7R;7'
M;KHM\&=NY"_=]N9C@EW_T%]N+%F7]&X-ND7'N$^.A')2C(?Y^JQQ"];U,1)4
M*5]%R_;]88.19B&&F43?(5W%J^VMS>CCB8O]RQU&KG38:_/\FRWX]5!M]E58
MT%93Z&N>)-?6\&4QZ ]G<\INQ(8JSRQR.BH$A(0CPU1 EF(-_SKF",W6<%J7
MY7C)LKR:2E^U+*]6EF>T8>R9\S8HQ(!/@C:<*'(I2&2(DIYX&GP0A2R+"MK-
MJYBX[BK1JV+2NKNT\ 7F>KZI/(>_(7?=E<3/-?JO*IJT3J&S$L1?D.L+^R23
M<<@1PA#GGB)CL$4R*"&UIRID]J9E4X@J)?FOZ5M%Z5LMP*L6X-D-#&XI<=PB
M9HA'G'J%-"\BM@P/&+!8<[+V5NJFIE4*U7HVG.U9T+;*,+>G,$;N7*JF5J<;
MOJ>;4-4=C/^XXDW<;'3C,#L9^QF_XYR!.,04X=?02,6.>;;%^M[@%VOKO0H7
MA56X(-<5NE:R\,\':!MF+:<T(*VRAV-2+B_\\#5BZ[R33O&T]E8UL:S=C%ZP
M#*_""[F6X57)\ QY)PZZ4AJ%/(T:<8\%2'/BB!C+G#+9=]EF&2;DP7GEZJPN
MOQZH/2$60_MCRC#/ZVW=E4=KC_N]S*JS9W]<,B[LQ!J;EHE-"T*ZE6%$:(Y\
M\ GXA=#(<:>1LI+3X)(C%.=:[4;I"MD5:L-@1?E%+<R/*LRS.6&PHZ P.!1T
M4(B'2)#37L('-D1Q([DHROD:32LDS'5 U%A KK-[U*:-)PF4JO6CE< 6F\]H
MR[S6VDJD)">(*T&0%M*B*)13R?CH20%;1#T8MFH;1W6%>:6A5)>%N9;7>\KK
M#,UPADO+,4..&0\T(P'-$%8A+S!/GKC 4P1Y-56R2+XV:\8-GNI+I1FO0CM:
ML0=[3316 ESS*5V$$<E$%5""%09QIR0R.%"D0HRPL&#NL<S&#BFJY$11&SLJ
M2C1J<7YD<9XM#$B(<X%X1!0(,2<*(\NC0#A*[X+RBKE4V"ZKZ,?^:LP=N\/#
MV+^4+Z[. /.8C"-W_F4;;(U-J\"F^>0P-A@BF29 -6P"'<EJY'*:&*=]T-(*
M9;Q=>ZN;@M<VC1<LQTNC&K4</Y(<S]HZA*::4(DDE@Q4AHB1,]$@:[WCC//@
M<_%ATY15]-UXF-_U<_"2K9"G;55)V*60M^X]?:A?/7RO(."M1NY5(/?G'W,,
MC!I& L4!J0*Y,6'(X*11$(00;XS6)*R]I;S)<94RH=<4K*(4K);A1Y#A&?:5
MJ/"!&%";8 @1UX(CPX5"5 $:6Q<5"1)DF#:UJ.!F4V7HU^K"WIZTD8]-W!XA
M8<%<[-LE]G9KHH([!A:.LY,QZ.30&^4$@(O2DRU<"*K$:XMUX'_N*][WZX,7
MLPBN@,C62]\2E[Z?\X[9VCMGJ$!)"(RX#!BY)+*GA9#&4\F\5T7*VJ996NC7
MO83CB0EN#78UV#T>XZ_!;KE@-VMEQ5@%ZCT2+ +/MTPB+6U"+&@A210BL+3V
MUI"F5,LRLSX*UEW-X3V7K7O!+Y-<T.5$8MY%6)03E<3R1**5%GO#C)>:*\'P
M 2$YC?/%5>.W'B=G+K@TOC'Y=)TP?"9AN'I&"<-_:;B?1H4A:KV4T_G/_[N2
MU?XJE&/I!)<)"Q8\9Q);9B.CC"9I)-P8'VP6O)5@@BX([ R*Q\$@QJN^.H,]
M>,(_.SU__.2(_7F"V'#?+=KZ?>M'Z^1]Y^O1,?X*"+[[99L LK(6_4R^_MXZ
MW]W<__D5$/OK?PZQ/_FK:[^8T>Y);M?^V?[>UOG^E[].=O<^'N_^_D'L'WT6
M7_?\SZ][?QWO_]SF@,3'__FY=;9SM''@A1=4,XT2\0)QKWP.2;;(QLA]\I0Q
M0<M5%; IAHV\\'DI 'U<R '+W''A@(9B4-U!?<#))+/6B+ .GF;I[H_B=,5>
M[;A>=O9^Y:.Z=6!%\(X36.J8E8C'J)&F0B"GC0O.N<"PGQU5:8P$U9!$9PPG
M#ENK,36*>)@=(20Z.ZIE3R\L17'E^V7465B>X/;I=+6AG($2:XGW,!E@+33.
M&F6T<RF90!3EUY5!N/T%KSZ') JZ,;$D1<Y5"H9"FY1S\/ H"X^R&Z#W,C\X
M&@V&[73^5#M^A['QKG<"3SYO'-I!HS=U",]9=-+E&+1!)K?0"_W3'IP2&[V4
MVC[[B9\>G@_:O@VM*.K(J]\N#N6;>* ^MMUMQ/^.VJ<GL'"O-^"I@^E=#^WW
MV.C'$SCGPA$]^X -LO?Y3?#@L)0P,PAGA''JF/4Z$!)AX"31C-O+YHK;4.'C
MI '%MYS\X@J9A_[U;\*H?P9\<!"[KP\Y6.OL@$DFF$D40>\"< 07$2A0$F&3
M&(->%[*8]RL<L:OK<SUFMX^9":!^6J(1813&S(.Z9%ATB%D106&((N7:AZDW
MZC=.8*0.;\7LQK!WHU!**P-H'T)@G'CDSD8*RW>R3 BIHE*U4"YQ@'<_'&@O
M?11.(4NC1QQ;A[0/ DFEM)&@,8M@;A;*AXY8+93W'3/#<=#*)R04RXEV.44:
MZ HRV K@UL)R3=?>%NMTXSS:_JU"V6P,>B=Y26Z<';;]8>/$GC?:7=\9!?CQ
M-+.<099;&/((*_+P\,J2/CJ]3:9]<(H98Z5U@4O,#:',.*.<$I0*?.\9THUG
MMG/MU,AO_.KFQ3;>W3@0'J@D ;"6'@?$J39(XY10\-8K' Q31-XLRP\=J:OH
M.QTG4@_4E8$"Y4 %0%V$0=^ @<(8.44U4H)HI[1DQ/BUMQ>% J]=3 OI+GGR
MG20X\V(8(J#?EX3XK#T\!(*](DT:/@X7S(Z]<4N@97_"\WIA.VV<GG;:/ILQ
M:\B_-&-:YSMG!U@;T"Z]1UH#;>:*8P1::D(N.E!+A6>&BI490RX-X54HK@?Q
M7H/HO*814Z#0,9/IE$#LI0'"A17G.FB:!%][V^O&0JYO$_[UQD:AXA;EYDHC
M)R/-1AZ\ A FA=6N'()/"^,X'(#*[//F1&B,NB'V9W7UL]B/C?^YQW;8?5:.
M2]MAXJ:\"A\S@]E-GP=Q([?Y;MMC\O7-+=':.""P:DBJ* J46^#Q 0,=I*QP
M8L,NZD0,K/UD7<SM;#5.VIW.)/'Q?8;<> R+%BQCH 5R+8VAD68G*RHU#22Z
M:W9 ZR%?QI #G 1/035G!"490 T@PB*+03=WGA)L+&:4ACSD\XX;DR%O @H,
M3J//&V^=\Y)'6.]')Z,.<(2<!OL48*)=VCD!-WKY;_@],X;G@!@;%^^R<9+S
M3_PL7J6>58MGU0<.0**=5";8@##-N^0>6*KUR:!$8#UAW"F;8Y'P^GP)ERH#
M23T3[CD3 %^LB-X(4"(=%:"E&)6034G"5R--"GD#+^69,!_8L!A?UJ]U"JCL
M_L9&9]!K%KK29)<C^^,#[>HW!MF/HT"^R0Y%/]I.(PZ&A7H%NM9ANQ\:I[9?
MIL,I]3(+( D(VQMU,XYF\\F579/RCL^PH_ZX4"5!_$'U; _;T!M%+#YP5$+'
MYN'<<QW0)(J.Z/:&%S04("+WL[.=8E49'$9@J>MS6WPKW>N%=WC7&PSWLOKR
MNK=Y]P],8"$Q1Q"C'B/.@6?HP#WBS#IE&(N@><[N:D;'N'!""J<\+ZK'IV"(
M((80C@6U<YOWSV%JYSU.#](/>EDA^FF\QQA_G,8N_%L0'YMMH9U.[VS0^%L[
MS^3>")X9!G]_<Q=9%F7,1IYV%^Y.A><8O&3'G@[BF\D?OX7VX+1CS]^TNT53
MBXM^N^K9DWV 9CS&BMXL#U^X!ZWCTD5H'-TP?O+M->*57M=J^:7G];K@YI?N
M>O,QP5;25G&W]MP2/W)K4(N9._5YU'7?.^S'V&B5J+_5S1!?6"J*.N_W*.]^
MGZB?6TN1/H^NRPO474I.+:4V[,OI,[)H6LV&Q_$;PN.6T6WW[/Z5/O():NTN
M<+U]VM5[-D5E+N-US\"VNZ:K>\:A'(M>\<5$:OR2:G#WE'Q98W@ND1N_IDJ4
MD1NGQ] ZWCK99SN;_S[<^=+"K<VOA[N@4NSL_76X3Z$-FSN=G=R.3S.1&R<?
M*+3C_.N1QZV3+;+_\\,9O)-H[6V3G2_OC_9_[AS#,VE^Y__\G$1M; UW?FZ<
M[6QN'UBNDLP)NW'2"G'#$W),2L2\,S)(+TG(VZ5-\?"XC>IEU*QAZ87"4K14
M"6N]4(KQ&+P5UD7IX)V]@0]2P!*9P!*I8>G)8>G\*BPEKVE@+"$EC$ \P%_:
M>8.8-M$$RAC&-,,2%14LA+(J7GR'>L,WA,&MC#'?]9DU99XM'7,]8:Y$7K5'
MR,VVA+$=WP+E\]\04N33?:HMC4O;7W/&S%L&^M6G>5JZ*G'3EN65?<IZK;['
M6KT_IT*$F RH# 9AKBFH$,)F3SH#$PH+B9F$,4JP5O,'I^1?>9*V>^1B>]FR
MN'3^7,OBBF1QAC<S $^FI$>*NX XD1%D$7-$4V"6&4RXP&MOZ;R#R8VB6*'Z
M/<^<(6QGXWX<#/.6_%Q=GP<PA%=1]F.E#&$R,ELE6ZN1Z%Y(Y.<-BTICBZ-$
MUFN../8197=$%*W&S'JK;>1Y:ZE"ZGM=I^<YT8A:8!\HL+,F-V4R9A)DE(F(
M6Z>1LUPC*X@0AN5L@[D83X7D]8G,;:LQJ%7"9/84>/)I[.R98^IZ)_&7<MD_
M7S3]VU/RGTG7E\7>:P2]%X(>SU$>YX#:<*41!HX#"(HQTM2+'$ N50PF*I'+
MJM)YI^Z_UW3G)0CHTOE.+: /$] 9BF.BQRPHBA+#$G22'"0:34+>4J>2P)QH
M!Q2G(O+Y]+N)K\K];KPQ6!7PN9PW?KI96%1^ON]<?-6)E'^I#ZJ](CTE8ZS=
M7U:P4&W-USY*.:,B-1HIDM/-P"Q&CLN(8L0X!A(TUSEY?%-BLR2%O%*IXQ_H
MMU<CWJM%O*53\!KQ5H1X,QGD*97&*F60]2HCGB'(6A>0,,0Y+A2SN$ \RA]<
M[.TQ$>]J OER8V]![IG;TLH7%SZG($:A] H" Z41SR:(41IUGR#&&36/LN6H
M>=4Q5D_F)4S]>//=%YVYTIO7#:X;7#>X;G#=X+K!=8-_J<%7*6Y=E&BF*)%^
M+D6)%E;@^-7*'7>HQ+'PNEMSW3R/[#:[P\/8;[2[I=T@OUTQZ6/(*:PFJ?WL
MX-4EN*EUPWOJAK^LL;V<!#<%8-5);NHD-U5.<E.Q\NK/HI&/70/^*>;6I]'I
M:2?F ENVTWAG!X>-][#:-[8OF,%=I'4)_JB/?X^J25&E[_&R9&'Q7EXQ_4]M
M>YRA]22G:QU,ZFF$1KM,57H"['C4+T3F(I#Z4JC4FY<N, _U;"HWM6D1ZU;I
M^7"11,SGF9$*-2CU>R=SJ7L?E-KF96[RO\P]_!4G%?O3GF=<&;R*#?VC_;WW
MQSN;Q[RUN2]V]C[CUN_;?/_DZ\G.WH>S??I7NW72$O#OX<[<AO[.8>O+![R[
M]^TLEYDOSC\Z;'\]V2<[F_\\^OIE^WP?VOKURQ99E!6 Z\AQ]!A13PCBB1/D
M1%*(.!LDQ<))S(K$8OR>P<C/P2>^AJ87"DTK3BQ60]-*H&DF#$!*%V-1.]V8
M@+@4#%D#'TR'Y(1@TDF2H8F89;D:/4D"A1O2I3QO8GBU.LXO!0S6&966E2]A
M#%F[W3_&VMEYC4_WPJ?YU F&BR X9TB(9!$/!".KF$'$^)@4EB$%NHS4"2O/
MI_3KVO.KE]U'29U0R^[#97>&6_A +"="(&T#J#U6&J05D4C!Z.GH=6+*+"&+
MPA)%][49G$I!6!&O>+YQSE7A%7_VVS ZI[9SH0O5D'0/2/HV1R>2MSIP)\L(
M,DXX0%(R"45#C8&%A5-KEY*?L7IVF%IF'X5/U#+[8)F=S>,(,"ITPB@*IA%G
MD2)G+'S%' :..QZ"O7\>QZ>T3U34;[5N\.H;/+/Y3TD=VO02AO6IFU$WN&YP
MW>"ZP76#ZP8_*H'1+XV_O*(X@KI0;AU#4,<0U#$$M_E-/VTVP,73ZTOQ!3!L
M UIEO\7&QWABV]V\E5&8X1I[L7_RTAVC*R-+E;[':X@DV+W%/WQ)[UU9L_\X
M@=15.[\/3C%C<JF-P"7FAE!FG%%."4H%5@?;%UMR-WDB3K!F##53I"D.9IPA
M5WP4X57\FS#JGT?;KTW^=S#YM^9S/C(:/=,TH12#RMF)(W+"P4S%FAC.E(N>
MKKV5ZQ<I'R<IQ!JYVY<R_Y>!VL]>A@3AW*:@,0P&3T399(/3!NLD'<>"%#)$
M:AFJ@@S-9!&,,3I8%B7"TAO$ PW($.&0DD%Q[KB1+&89DOH.,O0:JF^\OYO/
MR\/>^GF)_Z\OH9?WQ&OA7['PG\\MH#S!I)&$(>^Y15PFC:R+'$E <T6<X$Z"
M\+-U1I:X@*Z R3]["?KU!;26H,>5H)GEDVE!L<,)!6N @A+BD=;!(6Z5,QQ
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M%V%*M$K.BK59I:*RO)"33"6Y%M9["NL,^Z TI,250_!/+BI,+;(Z>(1%B(S
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M&2\U5X+A T+5VLW%J8K>N780WOZ?Z__C[;5%KL8=R&FQN_S;:6]0],:;?NQ
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MR1"W :AW/F@7L%G2CS; X+M>MX3$XIR/<3#J#(M3QNI>KSMH# Y[HTYHN-@
M><A^J9D3'8VZ)5LZ:P\/"\@==>T([A4S9>\6:YC-7]+T68,A_% 6]\L/R]<
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MQC1K>FO)RE.OZ<W-O*5VK>@NX?*"U]R I.?-IM<6*>;\%QH^\/V0QTGHXT_
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MX-;Q,(J!W#A62:!9/0G\^X >SZ.JSBX W,"9$PQZGO<X+  II/(PB!#3^N
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M[R(=T X*"1$ M=_4]&;ZVN+(2G78_T^.*S$O8!P84P*2@%+3ACWZ0# S& 0
M7!@D]T-A)OOTDG"?T*(;P%H'6 5=I[\)^<I?)YM8<)(P#*$V!",!Y [L^)]L
M' 0>"%D<"T<@DM*(MA[@(;0:< F3(]XG8 9"V/?4&-X+'UR'%[ .&(XSL0<#
M0DWX93R<1"Z KL\PXCJ6\O[Y\RV@JSOJ)6$D/ER8!<Y1*(28#6I$X/.)U(O4
MC(&NA'^*ZY?C@97N#ESA8]!K^)U9;:.O2$,/K5KB2)3 <!T79^1E* 0S0>K.
M,B9E!\@QKEVQ\+!!PIAAXBCC870(POH=9NTLP2MTV$"&D<&214)QR?]]4R_
M$ G@&].R=&,5$"#$L%IZYQF<T=F9$'0I>.AV9Z9<P0A&R446Q53)0C"(\;R2
MQ2QZ/8+TO#$+./<$T)R5OHL 9M0*<+G60 QA?V1PB!;S2I]]M(O8T0]!A^6K
MZ+_!7WW!D!#DWT]XE"O)V';[TAR**! ^U23_6.J@"CEPAK9_3SY/<3S"7\;G
M  (]0 (<&YKQJ>-.A'!'TC[/KY.#44PD&J $BIE,F+ !R"M]0H5I]20HR-%N
M:@[Y!_&E'/VF$*^(A3J3\43ZJ@@"Y9^;)KR8&\\F0)(BL;:(@D(BQ0S(ZX">
M$'@<<B'0H@??)?!][IVFGC[%'; _C-=0J ^5,\!@68*AC#!XC(<%#J#3?P 0
M1/I-(34W/6$V0_-^$F;"M(YZ&QV]E:MW05T2JA\%/@"(=224&#@%5)56*<+@
MF%8^4N]6;D]I.>.1OP5W'%X1VQ3BG2E@\<4*3OZ:"$HNBE[)ES,[2N"#\RR)
M" _L,'9I40T& Q!O5!L;_']$\%XB]:0(#L^-HZ:;^3B>P/"FK&+Y(D!<JBUG
M4A@XG/=ET"^"M0F'-M]P%K3+EY^<#%.L7OQR3;?RY0AU=$4)J>4?76=O<)$&
MKNW*E4J5BS(B/?'MJ'.MZ-8\LU;/_;"0#VOCI7JUZ:UGB<RNY$+J;=8+0L![
M6L=\=F??LW86TCH#X(_#1 35+@-;3*2H1T)XIS1'A&1XZ+ABJ0O&<B&%EH]V
M&-H(:8) S2+XN(NQ!402"(%?$I H7S=S;0YYJD'X+!K:8:9HA5;%-B(6"<MI
M  \I\B]OQIYY2QJGA2]+#XN)2%/0 _V0ML*LAL[P\3E^97A%A)@+2[/$I:V#
M^20F5M4+0IC3<U[X<FJ*0(H1\Y#A."4S7R464+J(9V(5FEH,UB#W8E13V_NX
MO=]<O+V_1@2P4?^M]$D!VXI'KMS/KN.3Y^EN8)>\FVH;V(9)U078+6Z^HQL.
M0&9TQ+8GU4V]/NU>?66D3&1= K3=8C <'@'J] EYZ+<0E[8NNP[Y@(?8E@[;
MLNL4=;KW@)[8/ W6.!ZL:!2G(7!%Z)*;_#,4EOO]^O+'<M_ZQ'V;NIW3MBQ^
M)+4.\X4&?UTX=K#A*.HYTRJ=T77HPG)R@IC/87$1QC=M&:8M['3.;S48&(P,
MG\K1P<>1R%-;NE^Y[<5#\@!OTXB:F.3*G\E=:^@]6R6D%9^B-[GIW3%@>L"N
M9#3O:^#A:^"=7_B.+K?;_0FRGJ)@.$ZW:(EP_QZ0)QM-YNF@[?#H4X(!+K7T
MCSZXWUXPIG_#^D9[W8^T%F8N-.[(,Q@;>+I$+.0C?#X-(:0;YK35)_9EY0(K
MN8B\Q1!-! HFQ"S]$"YJZ1J"K;%;^9+LO<\C!U8]N2/IV;0]AY($72#?!#5.
MW <QIME//].+-M4'_'.U#?-&63$CVR^?442TN8$B\_<":+LV%1VTS$,7W55D
MQ]P@D8RRS!./!<9KJMP_SBYTUO5S\Q,WX:)$^ &H<J3]0Q!WGNXC8\0+Q?>^
M$."9F1QTN6AV-)Z%8<PY=.K9'EFB:<Y,/Q6D 6HDV?33!67?K[K(X-6AE:D^
M7]>;[<T*NB\MDM[06[2JK=_M'BJZXV ;FU=TS\]1K''DHEJ%:J=<K%4*!1\L
M)5*(R?S-4M?OK43M754W=YZ@G2W:-'U1F<T#.TTU;XKE/@]5;V@-PZC\X7(E
M=%42NJ:I->KKWL2B#KJO61WRV9RQA7;38=X*8[6UAK7N]0HEOO_G,+E4[VBU
M9O7+HI4:&R[!CM.RK6EM>F^:3JIL! W5O7BET=&,M:\&*Y\5=.!<JIN:8:C[
M<5X7&G"C6&R2D+5 NP7&A^Q@&6WI'YWI4->@?V4Y*"8=N>&0.Q4BJ9=VTF@S
M$'=G4JR82@\\,DO";&JF>4!W(!\HE^I:9^WZD+NS) [@1O@*FC[B_I^"[2.N
M0IC*YSF.E;315F&2DK.H8ZD8R0[0H)!\<F2&S(G9:52I]MN163 GAF:TVE6N
M9U9J[;\,_/M32C_M\]YFT=#JKBTG+:W36$/YU>*_>P8UZ_MA4-DJE#]?CWW?
M-</7'.$QH.L=WADRFP&[U=MX#SKA8WT"E!O.C&9#:S4V=#E7I\*>UR0EST<C
MSZVZUJYM6+3U]>5Y^27B&Q\V671T;]5CC*T7762VP[QK<6@]Y'TW9I]M9S8\
M4,DC?[/776:'Q-#]><6S*?,96IGC*FU3[S1?X01(76];374"9+,3(-4_]' ,
M\=4;_A!X,""ZBT*=(:AR.K?1KFV0>J$BDFOJ"[K,XJPKJLRQ[4FV-*N^QUW)
M8X#D)U<$'=F6EZ&9G3T>A=IJ56M3-QLE%S<1!7SI_LKSX=4J26"[K36M==/'
MUJ+$H03^CS9X?LFCZ#T[2T(J/H-7?LHK3(YQI]+0&C5KGQMA!VT0"%'[X<L*
M.WAK4G9W(=T[>V0&PDE=JUG&/I,N5%"C,N;-\A22%7>-%]<:/8(0R'HT*#=T
M&&U+,VH;>A=K$:(BVT+30';D-X&V*ECHLU*WTN4;57BW&VU=B?)13C :N?)$
MTX)B8+0%EM[W.^%V2!?]8E^%RY?4!IC: -OI!EAWA%5NYFU\';3W2W<KGN1%
M/E>Y@]M\R[862SETTVOM^9?<[-+J:]_KL"X)5 1AJ;I:1Q8D,(T]'O\]DB6@
M?F1Q3M/<,)M0X=3*,M4X,IQJ:JUZ6R'5*TM54Q27&W+PV]%I/S+@VBPUZ!C/
M*VTO;GX0:0%;39L_+J?M0.+E+\^$*'6\_/7H2CV^Q^+<KK-">%2>9,A*\92Y
M^-+\&0@A>?K?[S[[:^)S9C2+A3=D>'>Z?!$,VAZ)T%%:P%A45Q7$R8KIL!/L
M0M8<ZLHW9BF8%A^2*W_:R4"<%9D(:P"DEH=B1/.[DT=+)K*WMZ+*S5V8N%',
M/MK^3XWJ>L98SWH,;445>/A__9'K8\4VVC^!H>.PT_"UAY\((XI61PD67!+O
M3J9'<I_/ LL'15&"L;8>?33",#HR078FKLF1?VCI &^S6X;3VD%_O;X*PGL@
M]!G5)Q(S^*9WX='5C\]?V \?\UB*/^>EE\2O-\$$5@;\-X;JSVS?[MNR8+@[
M0-H,W3!M^XW*^$'S;A0%CDM_:;(LD1O.D.S?@>M3Q6Z8"%;<NZ<B,'[_'5 M
MHUB!/I?BMYQ".(9T7-CNGR _&A5AO0M"D-_@]%. 7,DG")+_?X/P)_L(GW.&
M&KSA><#R\#Y8-';\QAF*3_:8OKA@2G*(6#(;7AT%6!*2;C2)ARX5=")Q+PJ[
MJ.;D .396*IH1O UUB>%R&N"&11<Q;I@/5'=5'REH&):UIL<3:81)&"9_.(%
M<B&/)^M405UM=['<FU*+\".M,BGJ/MIL 'I\BAM/6+$Z\!XH_68&4TZD:$X=
MJ\B@0Y8K2Z$/ZS36:[5BM6%1?DW6J8Y(GV/ 1ZIO+3X5);W3['/P<S(6Y=@;
MA3+F @H*"(&WB<Z^./6**%6\>%Z/T(SUN*ACO$B60Y[6\4P%CO]R195AY'0/
M!#>M0E8D U6SD"_ (".W[]HA(=9L=W*SL%"O.9*%P;/[$+6T A5RCACW"/I-
M4Z**XQ[SJ305U4NGT8,.\!!^=X)P'(2H@>,$_A5Q+"U.R!HO$1(MJY GR[0'
M?M_-2I?BLR^)C=5#Q3PE'D\*4A;RD4V5H1G83-R)5ZM 5H$SC OU*N14,"Z:
MD@(JQ3X:>Q-91NXQ8#]Y5J47^$-5TX&_W*;UTG,2<14NRCL=B40?CG[IV9$;
M+2'CJY:]K,R>L67H5F.US=WU]I.-%:MF'?9@V]O<-E_73UZ6;;.W4RT/'%0Y
M9C>DQYEV;G4L3;VQPF#FI#>A3I]:^AR= S#AV %F.;^=R<5Y/HFAPOD.B\Z_
M$79/>:C[(</([?<]OB<R/'_N>7NIO)6*M9\5%V*/P]# \Q5K]PKRLI]<Z4H1
M& \#H(_H,TMO-=!L@J6H5DG:EA#>@);UEVES!7==IW0VK4,-LWVQ\K[".;,J
MT/-+R.V8_$;24O-E6KH;(I90%\V67K.>*F,98_U+?6&P&UG7\TBAR (FA6*Q
M&WOPD21V/>@L#2$\J20/NCCF#L60*0,Z"P4N\W"K$RBXP=@RZL>W(.:LDQ6O
MD'&TF2"\)H*M=/&"B/1<8F%[BD-3RS3F#QT&23@=%LA#"11H%<GF%/]G%_ G
M,P3)W8C]/;%#X(<W83<<3W9BC.%S$$*3VNG?132P+Z(\T)GKPP\C"@:_0LRA
MQ#M6G])M@<_9:<2SJ=.(AQ\^OO +D7@1A2_&M$+NH%W41YT6I)HYN$EQ6'!:
ML\AM6M\)Y%>&Y,.)V!JC?J>U06<7<FOMZ;9:]NF"I"X=14UOB>VZU8:R8)=,
M9Y\6?01/?.2CPMAV'QQ)!\.!?7G9A8R8.G883NB0""77IS^G R(83&^$G[ D
MPJ:XT8:,.:6 MSPI*Y52A+8QRHHMD\(YVH44*4Q^#N&S#10?Q&CN"PO(0T3(
M/X\6EM@/= <\G>9"RFY=K]2A+RJR4<%#7R5>%<YI$P/-E8O4D[@!S=CC M=9
M(WNA@FO0O.LB;>FZ\8P9F5M'.UR!V/&-LZM?6#\)GSO'(RB4QKP( \6Z\P@]
M@W_3:O\N?M1K[=^U@N'J 7CETL!_C;D?\=2^G3+1"H89H*'K.\&(I[NA_2E4
M%S=M2/2F&6!ZA+P>$P$Y3;58>S9B,32G-E/A!RO?I)V:V18D9AO;3KM6_OG7
ML2Z^'2V=5,4-ON]^\;0IR4Y-DR:(8T=#VL,,7=PE!ZD&^4!QFKEA76/=ZS/<
M9'8P P=WZG%YR#44%./J^AI:77UAUZ(X,.V&HR#^O\M+';J!=Z!IXF6V4=H;
M:C;^W2<M'Q2WRL5G;="2$7P4K,YZ+M%H_>5_28G/?L&.LIU\S"6(V)![?4PX
M63;060@HI:OW9^;JA:_GZFVH^"56],5WU!V%T]<%'??D>G%GW[/V3!HC26-&
M'TJ_R7,7*;]A)M>.4NVR[*$GU,TSB# YS,9#])'\,'RN%X1A\)AF AD%S=5E
M(Q<1XQ\7YS-Y$I.BRWAH"GK4^DG6EB-C ?-7XNK%"L\Q\P?$JWOU56-75U]@
MY?G;%;L"67. ]U_"(!F++-=,D>!YGAUZ>_;U+,T1G; N.'/L:Q!14ABFRJ99
MGC#>]/6/W:_=3/5@>7V2K/R$S(4L)U+S[M65%&N1V8=_8T>$!A0M2%/5[$+V
M'0%&?B4&-J.L)TH5M@<#T#_2(BKYBT$9D3A-P1*P,% KXB%EE.%;2P:IL_-G
M6N1)D 0],/[,R0AZ("3"&(<!CNR?6*IS NKX@&8XS#$!U]:F[0307HQO@](C
M>9.QM%+2WPJQ'Q 2<%SHRS.(B4_M\1CD7U0%G24#1<-2+-">G?K,Q$[<MS3Z
M$>[<("ZALP\]2(R,AG;(AX'7%[F8(HZ5CKDPJNOA)')!BGQV6W@C_RC U8GK
MOMW^[,6*X\8)$A@^SQ^XB)R!DV2CH9ADJ8Q+Y0$W*K"16VPD;3[P*EF/<^C<
M<P4O:9<B!W:<R?0%+.#XK0(\\AQ855+GC(YN-5M;ST8#)[/]"I>X&'K'V'1
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ML+KKV]Y$CN5S-H6SE(#4YD:2'9I\'W.!JE%>;5N"#A;D@%=OGA3?_%M68GL
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M4AS*V@_*=W7*5V"?NV=WWV\J".O?I\![KO@4XAKDZLD3&0B?TA*G?13F)YA
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MNU)(-NK-NA$Q5T5B(;F/4 "V*5N(N(-<6(3Y1Q1\ 4, /!!=2"<*1Z*!>:D
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M(Q=!71!<EIN6'3IICS(5D_596W9Z8H!-J%/A(8&M.CDQP2Z9X*?SU^@]FLU
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M0H#;42"-2OA@2ZRVBL-'''\-Z1<>SP1K>D)F&E^6"L(&\G<9D3#.'E7/PHL
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M9%".E)SQX$,*@%%SPPJSDIDN;-F,:1N"Z!^.((UDT(P3;^?X.8SSLZ^?<;I
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M2%%PGD3H%/7?"^^04E<>D&0[BZY-DML:H-^N7\>,6:5@G0%6%.E6YC--2)&
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MQG#J^^G5CU,83@#-H1G4:Q+H,2\DC=827"@GT@;\*J,9GI2PP<A$16ACBG8
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M<X+D.[8AN_4Q3U_OE479HL7*!W]>#.[)Y]%B UNN'":+'HT60%&1B&8E\P@
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M%SMW&O]C-$K?^X/!)8MG-EDTD+,'0T0RN-*DD*XA&<(DBT(;84QJLYNLQW/
MO*B@@#6\V#D ?-OA^&:XT,#\@'SU(P[.2D^8Y5)Z5F<?8E3$J](1)C!-G!*6
M9 O*F82\IFT:1^Z"^H YMC=EKF'BSDUJ-P0OIU]A_/FK'WZ&DS)U97Q^N<A>
M4!)?D@ $'##T*'W95!,CR>7 I* "5*?VU?=T^;?!>L"L:ZRX-5S;+>[\NI_.
M8A\!+00R^>#/R^W*XH*NIT&$I'(D-H C,MI$$"]ZE)Z[:#VP&+J52]WQH .D
M1'7YKE'^S@'FES#N?_-3W 5?(Q__[@=G<)PO?SC;+GO F3.EI8,TKE1@%I":
M4\(2-<*%Y%-NDTC3!=T!,J>9<M8P:.>(]!T@W_9]Z ]P3^P%Z3R@@4>XD;Y$
MSH$$A]Z@BT89EUR2KM/PSMHLND#X\S+I?DI:PZ:=B[E6V(VKCE[DK"/)DB+'
ML^;$&^WP#ZYTEDX8:-.+>Q7)3\&.>PA]#0MV#B2O EJ>EE(PT$I1(E1&L]P(
M6M),'8F4*BVLQ'U0[84,AVNUU%3!FNR]G0/#'^$;#,_@RLW'<1CTORS2ZJ\4
MO7[NGZ!0>@!"1:T#23:B=4V1SY8G!*V0T#J&'!NU;MD2Z %3J:7*UE!LM]K!
M!=B/4&181+$.]:L?IQ"GD.: 48CXTTF>S\Z:7\\=YT6&R5^GH^'K_K!<__KY
M*B]O\N9AT9YE.AB*QRU3-!&IT1OP3&5"M7169S".=KQ1W3OV V3M4V#!&M;O
M'!1_,1I.QPC^'_WIUQ=GD^GH!,87=N&%NQJSE")Z8AR: U)K0;QRB>C O8:8
MP/!&TW$ZH#M ,C93SAH&[1P^OQ7DQ1L51RBM?T'J92HR*^.AHX/2AT(6>93*
MX.P,I\8*!6VRJ+?#^;.R:C>%K>'7;BG5W>0R[W"2+#4NHQ!RC)G@.P'$471B
M8_8\"1YY4-T.U"T>6I$F?C!XZ/.OE;3757<]*X)(T[_%0<G"_NV7Z?@,+G^(
M%(4?TU?SH_*W7R;SFK)=^CI_],,O\Q$@+F>CM2OS+8,@DMM T._%+<.#CUYI
MFV.GV$*GCLX7CWV0?D#-%#K:5;"5NW;/0"P[ 72 4;TA^Q4 ^V_&?D\5K"IQ
M!_DU5*<U "F+2%) 3%(8W,TLXT0FDUE"\]C*3GGOCT.-MS1?KZO%;<1667OO
M4%(G9R<+("$8$:TP968@VJ?*,N(L-Z7<1N= =8BJD\'727_7'KW?ONOW%OZH
MAN0JST=\YW]< 1*9S-PFM"6BQS]80" !CQ_#?!1)>VM\115>??035.&])5?Y
M+7Q13GD8GY89WQ?CSY*W691Q.MJ47CTBH;,HA"0Q2L.%]4X)7TV3ZQ <K!FT
ML[@KSQ_Z"*=GX_C53^#HRQCFLWU7("[[L7< 6=]>Z@IO_];4[IH<[4L-M<VN
MSF!]<-HS3TG*H00%8B NXQ89-$V26D3/.MVO/ 6NW&*R/1!5MI%^[2Z++_"G
M_2\PC'!S/&+ 988LT5JU928,T')[XR@1SCH9'>#6VG'PX.:'[-DB:*.340.!
M5I\W^>[3 H573$E&,[%:>[1DN"7!EX"@*;$E)BWUW9JB7'SDX2GQ7L*JO'U_
M&(_269P>CS_!^%L_SG<C[KR6PEOBN M$VC*=(TM/,LW,69D3$[':3KT.P<%:
M?#N+NV(SFRMX2D_6!:+)@M9=0%6W\#;"V;]%M[NF;JJ]DIC;; %KP$5E>=1<
MX(:F$)SSDEB3RCQ4[8VA/ *M-\=PS[J_Q4+;D^JWD6YMB^P#C.=G3_EB-)Q^
MG<]K2&5:Q_*N;W$X,9VEY$81YDW"\RW[>4,+[7ET5-NH3>YTDG=_YGZ/^DH:
M&K47;X.FF)=S.A9K7\"B+"<>;40<B1,98B0^E5%=I;XN4F>X:Y.^L0'04Z9$
M35FWFEP[]T*9IE*5/<Z:4F.KBT6JT+3!W<U()GQ0G5I=/I&)T_LP^.XOX(J=
MYM:->.T"Y=!'4&^ECEN&%=]'EHU'4&OG+,\V$&85PSW%(3@%J \:A5',Y:#K
MN7"/:P1U+:UN(\+:]ME?P_XW!.,'Q6*X,C[A@Q]/"\JW@XN9RC$Y)0(EBF51
M.J$:XBE31(&#J*)U+L5.YEGG1S[L:.JMM#)J+M**)EF"?N\M?/&#5WC^3,]G
M7(Y9"!.S19N0:2*3Y,0%;7&U-AM 2X&*VV+F$XB_?AE]>XX?/7N+_TN6+\G\
MRYGJUSST(,_B785;L8MG@3)'L;0I.^#H<!1W4_;5)^_W_-U9!:.*\JNX8=_
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MI5>X3V= MUHJ&8EU%C=5GD  ];BOMAF-O&?6W&$]/2K2;*.31A.T7P]&WQ<
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M(]O(O_Z @.75T6J.S>+$S 9\UM21(''3E")X8G/2Q$7\)),LY;Q;*X.[GO0
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MFC3=7[0-?<WO(&Z"V0$P=DES#M=T^T7^=-IRA K6E3A"?@WCQ'4XT;H2E%9
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M=?C=KY,IW"L7:RSC#B?D%H1GAD[I4#("*HR5S$Z!*\J"-$(JQ@*/2G2Q_BV
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M'NM%Z[2M)%OG"EZM2"VOHZ/_G%W49UN+VVR5BW2&2:[ <,PU+/* T4K(2L;
MLXT^#0M$'A_G16ZN[237>O7^GI=_SN;_NL;V&T[Q?'53?@<=QZ0D,R"C)X=<
M"@7..0'>)]3"!@Q^V'NA)X=ZB:IM*[_62W;5\ _C\B/]XY4OYX6W+J@ PFE#
M>U/MJAZ-IC"Z:.:\(S3#'M&L?_()1I7C)=@ZYW<7S+7A#H&S.;P<H-AC!)(-
MI+Y-?R-$UGK;W02K).Y=3""4J&]-!0.GBZ4O7BMI>.V9\JPTN"6$/( "=Y!4
M<V]W&B<7%SC_]B'/OTYBOH%WO=DS=,87U%!$KBUO0H10G^7$$H521BFIAU&I
M/#[.@;W<L3J8]1%@PYBS9J"_/S%9&2PYTZA928 YD!<?A*1H*GEPQDIEM2I\
MO8/]B+*8>T.?X%$Z3KP-+U'N ;FY6A@ I7GMW!J(PQ?+C5#')J6.D&7C<K=U
M2"IEC)4]3CE-D @ 1>(,P<7HDG6%$9R7I=9'"MKZ:'47$;8^<&MD]7XV7^+%
M[0U>\38$)RU(S*SR]4?PRB!%S3PJPTPT;%@9TH8//^RMYRA)SQJ*J7G^-GZ:
MY*](L"@2_MLU(.FX#)(C:%6GF+DBRY09I&9TLB=16RT,\XXV?/H+5=QH077H
M(O JQMK,8/'[;)D7;V<XK91-OTZF2+[;]/R/'//D:_4%?OIV^_UW3U\I<@EE
M,)!3K8VMU^LNE A9<QVBE<F;/M3>8U"?H,]U<&4VK)6XP7X?T<U2&X!I%W]M
M9T/;A.JP#MSA=3OKI)@.N]=&; 8C<S%;"$[1_NRM ^>9A2R\9C%2H+G.'O3B
MC&6+6_@\;647?72PD940;H%='[NJ9&.3*>!++3++-D! *VBJOGCD/#O9IQ_9
M1CB'?V@\7E.SUF+NT&[K;E/+CW-:!QA7G#O5\&__LC)[[J3+@B8KC34T=ZX!
M)<$5W FC=9 *^QC$<(PG[+ET4E3#G@6;D%XOFR&(.GLIZYB.XZ/TTN(CQC)"
M!5W\D0?(8I)%.@KHT-8L=W2,HD5:)-F9Z+CR2>4^,=*AC.()7^1X-K&+Y%NG
MLGZ>_^W5?)GQ_'O9%M;B24M'JU<$ID@%0;-:^!&1)R4XR\-**]8_^1BNPSA1
MSUK)::O#<*B>Q1\N/W_&^>1_<OH)+RI!WX=/.2\7.$T?EB2BU7\R*U?=V[JT
M,MX'0-\.QZ-%LM[XN)AHO2%G4:'2E1T\,<]D8-KY:&Q^I/'Q/E .U@_9Y4!K
M(P5(F)!63 A 4Q. RCJ:,P:Q7FKU8OHA?X]":Q^JQ:NP6%WZGH5H' H6:3TK
M!HK4!YYLG.8NO$4NG'^TFGY$LO >CF?-Z;2+53Q(_NTO[@Z1UVM<?'HU3?7_
MZJR_XL6*H6QYTT-W12MUABAHOHIB!%^3W\$D0"\T1*92-(*EI/H$78/@'=Y4
MQNAPG0^_N0*Z^,LTTTDD;Z+B?'TYGU?B1(79!6TXQ.CK+8L@ : V$+U.'C&Y
MQ/JTZ]@(YT5;P7@!-ZQ374]/WF:+?L_+&VPQ2.F\H3U/UCE:S.0*DF>I<LDA
M!.-E&E2,L_>=TB94+]H&FHF[88WKO:PA;5.K)/5&@#KG(*0.P*VAH#!R13//
M&;11(@B;$\\=$[6/07O11M%6\ W+MN[/]<R0(?(L!5" B5=M6;Q=]3)&Z2C$
M%(4_]FQZK-?XHG6\AP@[7.R^G6"87*PBLE<U])K%?WV:7=!G+Z[<X>]333QZ
M40N%M8^5'2DBU(8/@$9(GA7SR/NT5!J*\&1#ARXJZN NWL%YLTLQPZ*(PM)D
MR:25LQR"-;G6%'NO)6=&]Z%Y?8CE\.;11V_;C6,?H7<P@X<3?3.-%Y?UJ=W[
MJR8"KY;D]8;+Y>I^<_;[;%JY84FR](GGW[MDTKX7E40/' O-0M:DI<F5_M8%
M8W500G9B"&Z"_T3-[0C*[1#B/"6J,R^%],XB1=I6@.*511NS ;1)!HO:*=DG
MQGT*V8F:55.%= B$KM+0WQ/3W^<LDM,QDAH%UI(,81F@YI:\\(A%Q!R#ZI,U
MW0+H9'V@%@KHL)'\D;_FZ67^E<1R\WRJ\O6_OEPL">[\EW]?[XW5UZ?_I8_X
M[S-.VYV51D+)S$%]1P4$T@&SA3,AE4*CN]C,'F /;T]-%/T@S=972QV<J-HC
MI&Z%O_S[2YX2JC.=/!,^<3"1(D1E:UD[S1K0T98KK;-6];&:=22G81*CY-MA
M(WD_GY7)\NULL3B+T2NN68(@G:)M$@-X'@ND:*))R0NG;1=-WV(X#1WO*=,.
M[L/ $CU1F Y96BC)TF1-*N"ECB #<FN2SVF]N^2/WA1EC$O102G';HIR,[7-
M$[J*Q1:SBTFJ%4(WW)ZKXBZA8S9<U1(A.N04CY(6"#,@G,RA).F#2EU,;V>H
MS[S,=B=SF1U2;1V\E)T 7Q>C#8'<M1QW#]#'J=?M; YCC&^$+I^+&3+C/-,&
MS*IA.Q<>G"@&"K?,<%N0L7S:YO=$9? +L+X=5'CX_BR%_%81L3[/J@>!M;&F
MPW1]LE6\T!:-&T;P]8SZLQQ,6[LU;ME%U >J2JX7][?W]GAUDW_[BSM%VC7E
M>:>S>)G-/Z^:U8ZH2&XW>(MJY$ZB6*M$3J5@D8;LBB%M/28(EV+FJ+21(G-Q
MU@Y&PR?]#TL\;F,;7=!I46@[=8;7QWD(R',$,G95A"S<89\:Y*$(&S_]_#TO
M:<X4U*L@(5+<3_'<BL=*9-!)!VTRRO(H#7^S=Y^$Y0BU)3TLXXF'H+L*O4,M
M\L\Y+-],%Q077]%U7ET1_D&K<94.2N\I1J,_X'D^,\IY7[GKF,X%E):B/F01
M%&&AH7#+1>;Z5)L-QWBB9M-)2?T?E/]]7O-_Z*S7(7C0J%=,T.0KH% 09:Y9
MQ!R2[%.\M G-B9K(:,&WYMR]HE3(MY >-=LH:MFU=Z!9HEW09#);JSDD;YUV
M,B4TPYX [C3LB=E"9[EW3<T/I>6XRO/%E'QE>0=34)%TI 5,=(9JP;C@(48,
M?6[^]P1\J.3]0;::0RCMN>3R1['%N.PU1BXAE9!I<=$75^^]LHY).FME[$2;
M\;(IP#I:54M.L%VT>RAZIR&8_N($:ZS;(3Q/^RCF4$83K&(AHP5;F5&5# J<
MBA&"0 H8LL^<]V+A. 5.L.:VLHL^#L8)9ES22;D$EM52$,TTH$\)O&>*69F<
M-'V>'CYG3K"=-#6($VP7,1^7$TQ(98.2# B6 &6CKR2O%#FDQ$K00BG?QR!>
M$B?8X5R93IKK4K7[@")G"**_2,)&:/%I0JA]5' 8DK!@) JA$T3+$JB$ NB_
MLY!1*&:8"6P]-?3"C*(=25ACF]A%\JVO^*_;_YE?:O;JRWRRR(OK(]*B])HY
M!]IE\K<P)YJD$A"RM\*DXJ5?NZ7:DBK<.L2SH W;2?BSYI)K3H3_G[_=\/$K
M))_8F0 RL$JF$!C03Q)XTB6G&+Q2?) ";S_S96ML3]DT7'*;^AUKAIZG8"&F
M^J9>>@?!6O),/6TLW'I.V\DC^^X+;<K>WV,;*^N&:?@'_1^'X#C1+NT[J6!;
M>^]]Y-=X&=_#X[30T@4#1:<(%*Q2)"EK>6"V##,6B^ZQURS/18\[=&EOHL9=
MQ-;:\=G62?7Z@-#(8C+60<$*2$@#F&N'%*]$<#*@Q6$MP!\?YX@]:'<2_I >
MM'M(KKGW\W1+:_+17:%3 XRJCVF*YH!.6$@E!?+;C4QB8,O$9]0<O)UR&TMP
MZZIM6XCZ>D[&N/R54%^0#'["Z;]6+D6M?YQ,\V)6KO[!_7\VHO9TU'@MRDW;
M37BMPI07%P+%+ZEPJYB3SH9H4\HY&"YDX&>C1AY+:#$ES_'^)[_]?M5N(WK&
M4@'F*DL5+QJ"M!ZJO;N(D:/KDRA]%%;;NL$;XLQ7GZOS?,:"EM%*#L90_*.0
M#F'/?::M%HMW0<3H^A1\/8;J&.0=K>SB\8+ $=+O<(?P=C8]_YCGGRO&&U*D
M4@O#)08*9AUM]HG3UARXI5. (\\L<=1]V@YM '-*=C!6UATRN/=-\[^F^+DR
M$_U/3C]/%JO0^OT\?YY<?J:P>O5/%XO+6J^VH@2H]= T:QN31; JUTXI4EY9
MK^!&).MITQ_6<'CDWK$S\%,RJT/JL ?!U)U549]%72\,4QV'HC)(D0T% ,Q
MP!B@=N")VBG]('3JL G=XCDE@VD@\0[5I9OF>Y6WD]+*D*(DBXRK-VL9?'22
M(@<O+&,^:=^+3G,+I$-5B':T@2;2?BZ%G_?GL4HM^:@+"[* E/4-I:[$LXIE
M0#+C)*QW/O9A:7B(Y5AY\D8Z7J<#&B?K'@10]Z/$J]S%$$Q=JQ0VH3I.G<)8
MC3UJ "/$?2A3*$[9'-#2QNAKJLDG""NZUQ)8R5S8.^W\7J@)/%&5< @+V$7*
M76I1OLXNOE)<?1_<=;:19<-LS@6B2+4?:-3@%6? C&,Y,G32]WF"\BBLPSN5
MXS7WD"^PD=@[)3>6UX[N]PK@+!G+SB&87$GD"Z-P)]3H1[B$+A=-?^\66*RC
M.2W78+2\.X67=S%=V_P05%W=@\VXCN,@C-?;$X8P0N@]R/<WHPLY1Q2(D#$I
M4,YE<)HIR"XE+[USR7<BLCZ@*3SA*!S*$G:1=1=G 2]^6=3GM?7:Z88:)VMA
MG?"@*)0&%>BP0F<2>%0FAZ22ZM:LZR&:(^2;&FCJ@7,P4LRM;_9?SU9YTE5)
M[AU(6;JD*U6JD=7 @T8(HF@Z\Z+.C,MLXQIA\);;_,V?_Z)UV4INS^L.OS6-
M5(MA#WBCOS]UE.)<F:AU;6+K(W-6BVSK%Z:R8''HQ7Y'TJC[UR&WV5(G0G*$
MFW9?0YN/UPY",A:$B%8*7FI=P@&NJM[VN=.O^?RS1!&5#I$!AAK3&\T@H&)
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M@_3<Y"1LU.L,9"/T=V_HPQV8HX0_:R&YQ@?C-27-36XM%QFRH /?)T<GM/2
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ME!6.#I5B3+#DH)EA;;:>&NDE*K>I])JOW=_^?@ULDN] "L&+@%9""CF DJR
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MUA_BIYPN+_+U['[ZMIKK5=B-##5G: D:5K9.\LM\KF_\HG/!T7FK31^>O4=
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M$"?L(-+GC1!^3*^NC48:MW]X .B?D^6G/_+%2AZ+3Y,O'V>_W"/5&0"U>9^
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MP@;D* \GC*?@'OXVIZ$MK:>W^RNL=7/>C8BO:%^_TP07&]*J&)WV<PIYN=>
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MV$43@7=(3U\]'_HM+S_-TEU83!H7DB\4R];'&[$^(/K_R[NVW49N)/J^_T*
M]\O+ K,Q# 3([@PFV6>A2!83 ;8UD.WL>K]^BRU;Z6@DN661\DSG18 ,N/NP
MZHBL&ZN2M\R(0$:/5]SS3L6Z^P'-A 8MQ-TA,+V!]4?V_?KW?RW)VJU#9%:/
M#Y\1\O+FZ0H?B+O+N[JO7<-RO:G72*!3=($(:Y%\["+)'*8-C 577 @"5=IM
MA]V4*&_!/"LN=5=:AP#W1_*IX(&LXY\0[O%S[5#QL?S[?F,^+R(/.=4Z9^[J
MD&N9$_/:94*H?=0$TV&?Q.A16#,A33O1=PAGCU(Q(U,I\FRXK]NB,['VL^-U
M:)5BH6@KDI-U7$P_DV07SEQX<+:HN\6R1WBX\"BB2 P<S^0T(V>QMJ0AVQDJ
MSN@[5=S-5.MG";A?7'N!)D935,W&>Z1]IXZKCE$SB $M:&WHLZ.>9Q"S/DF$
M'<(0/RTA+F_&I9O;Q>6@,29:#4^Y=A"H&)&.%TZ A?"!RTX6XF%,\[IDT4CV
M/>X</Q?H?8*GNGBR3NDOZT?,7T->J&2M$,JR'$$S39XO\Q CDSX#@LS9NDY[
M_720E^=-*]T>J)QLK9C639VOE_DQ+6']M /X!9NS8(I5FA$,77M,U,[$A;1,
MOQDI%7J..]52!YK#O?*B[U[QS:79(4?QLN2GZ]5Z,UE[.V+[CVZ7+T.6C4@F
MHZG]\G1A6GGR4J373$408)/6R?7Q"DY!^=W3IKMJ.I@B0P'P+K-C5(YV+:*R
M%>3=5,/(<45^KM263%_4G7H/[ $S&U*<*^@.>8VKY>_+C'=Y%]8PWUJ5S*0;
M^FSJ1/Z2M@P,CTH%G>E Z%,0MQ_0;#C00N =TAHOF98KC-OB;V\\%[9ZRHK+
M.C)4,&_KA L;4\JQ #G4?4Z,K\',1O_G"KI#,N-Z>0=W"8< Y_;<VA;L%N63
MKS6 W-9"/O*XH-1+A1P((YB019\VD<=0S88-S43?/>GP%;I2$^^Y3L&4=;*)
M\98%S@VI,3D?D6/L=)GS.*[94*.A^#MD'O:XO:+F/"![!EG7T*@E9TA(R6@+
MDT6AL\7T=3!F&'8X4\P=4@XC1'MB[=&@,"4",[YZ,KS.-0XJ,I7! M"*4?2Y
MC'44UFRCEV=JH$=(8F3>C-(F8"2M*$HFM?1$6CK%? 9!RY<<-(<,H8\[L1_/
MN^X/YRKMB$'Y1HEW"&1?$:\)2-Y>,1X+ !\6Z&E3E(2'*ZCE?(56C('09E\*
M(MG LM.%J^/ YL2,ECKHL%7LM7U'#!9>VRRLH.--U$XF<1B=1[NER_4*6=0N
M]KFF\0JP.5&DI0XZ1"8/V, C@%X9P75&5G,N9 8[168PDD&L!((04)*(E_1"
MYDF3MGKH5IZ];_T+67P=Z!48-TEM@BM1D#5>5!1DC,=L79\Z_L.89D6--I+O
M$=+<"RJ:Z%P4M(5E"8Q<*55;VP#913Q;0"<R= IJSIT)Y\N[0VQS!&I1;Y"
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M"@]DR)__7#\B'>A__]O_ 5!+ P04    " #*B:I4]\4PTVEN 0!)*0\ %0
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MB!8=ZIQ0#G;U SL* OH"=J]KE 25EC/0Z*E8=*LI4/-<Z^HPFV2XB7";>3*
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M#N# U-[*NT&M3X61OGA:L+MS7$>B]W/XNB)E*UPZ6=GL2>/1LI5F>[QL=^<
MO;;>9&6U$ZZ3U^^%>I-T.>8DC$2LHR<]CT*$N+*^XY!#G :Z_ K#$:<.>VV=
M$&%ZQOB O;9.38&9NS\DK .3^>5>6ZW\5=60JM0(<UJVN2]XXW7;.B7$=+IM
M=4!DU6VKZSD]=RJ7JXQGB[6N=K5M?_OVAZ[7(?@[I::.=E^OFMV-MZ30O4ET
MF8\JV+TYO!.QYS,6$\A#3_<#8 $D$?-A% 9$$BEBGQ@9JTZEFIH]^U5[$^OB
MI6DW"Y9Y55"J4JGU_927P=:+S5:?:!33'F)]6_]^M6YFVG!O=>SY&WH+=D<?
ML%4(M!H!S0=@1R<]>:U6FH[KM*:9\Q-AIT"[W==U(MFXV[\NP3S:)7;Z\)[Q
M+4U+J;]GJ\?;=;G*GT31;FJ\?!;?Q'(M/@N6/RRS?P@^9WXH9( Q#/P00Y3X
M F(B AC)*$Q\Q,+80U:A+U;#3XV^F]1CP!HM-GMQ+[H322.T91R,W7R8<>]P
M* ]]+-\"^UU)#EK19YM]Z!===*\2'WR^#+A]<$TOW-S&W=B),&Y(3B]XCJ)U
M^CVE3V;!DF6+!2E>OHCB6\9$.W(3P$$3D<H )3#BF$/$ @E3WX\A$V& ",51
M$%LD%G2.-3DB:Z4%C;B;OI,VV03=\!ILJ;H#;7#C[QQ>KGO;F4'2G4G0_8@1
M$PF,=-G/(S"[I9_M\\NZS):B+)651;-EG;N]Y-49_0W[[W569M6OS+)A^CUT
M0N]T*SC8D;PJ85O)#G:$=YHP<QUN3M=:2Q%&76O[P7.XUO9\RG6?U^Z3JP8P
MH4 DX@BF*9$0A7IKG!(!"0IB0N,$AX%18]D+XTQMC=U\7_M?DGF/ETNXVO'3
M%6B-14060/6FFS,P#,(KAV.]"H&<4?@<4YR[O'\VS;M%_OTO@C]DRX?&,F0D
MCGG@(8@]%$'D<PF5L<VKNJ7"#VDL?:O8UY.C3(T.JFKP4DD)'I68HORC?;[,
M,9*&VP'7XC.TUZ^AT0*"1L(A$OV[,'">.7,\TNBY,V>5/94]<_[B'FYWW?Y'
M;)N3?LQY73= UT#ZLJ:E^.^U6*[>"$G6BU5[EJ\/M.:>#GU/8P8C%'L0(9I
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M1"L%BLUMSUO]P(M2T,(0N6Y.#4R7T69J8%JL)DDK AI-P%T!WFPF::M-X]&
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MT NS*VJFG0=CH,)I)P9\I>IIYU4_7T*MXYX>]7+/["#71SMUN^$YB7U?$);
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M)S)*@C2ULY>=X#E2\=$A$#6SOYR@-##]G2SDJ4O2U"T:9DW9H $.32^BX]2
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M=*-_4$]^_$B6Y$%P71:Q37YN<R*5J4'#@, D3+$R0_P8$JY(F;(@(0++1.+
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MSWJE-HS?@'W6>VZ=&H)6_RU4O:B/WTHU!)23+56#'A"GU-X^//)RU30;LTZ
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M6@<36DXC$I;.@WIY5^T%JJ$/ &-0"MI;+Z)P]?YZGL)H>^Q%(??WV<L77UN
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M/#EN ]L0G@;6SZF^'JZ!-[ =4EL6P2^=((4W$>S$H-^&@:=)C=L<L%/<HT:
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M[*I47_6[)5^T6PXBF<2J$# 55$(L%8$4Y<C-D,&99H)J%31K]3F!J7WC#7_
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M4&629EJG&3=ZUC1R_[SFJ[7G\?<XW(=\9L]E&.Z+:V4 RYT0-T#HK^7"1:V
MX/9JJ:^:93'V6Y+*!#'[0L!420XQH@9R12CDFDML<DZ$2-NWY.>%^C=_1S82
MC/R&Z*:QY;_CZ^&W24YPP<>(!?;?_/3BA)5)MD/U6;.I]D?MY/W?M6&JSX(,
MV$'5BWR<\;09->(*:^KY-'MDZ[8R*,M%AAF%::&LU9-J-W4Z(5!F1J-,*YZ$
M3;:_1'!R[I%+:]A-\@G;52ZBZ[<=](G9P'I\.^/*'7XUS![JXWY;^O@BTZNV
MO$AT5#7G"\%S_>1]7TRO9EY]^\A+]6:Y>J>M?GM7<N%:796[N:';K(?<6/V"
M<0$-$ZY=2(H@-VD"<R*+%%-6I)GG6/M0TM,[-:K3]Q\M]\ L5X _N%A]!<J%
MG#\I:\)8.]<-"WNP<CVM]#93S8D)YCLY_SND$W+ 2GD<.0V$_L!*JX;=L>VZ
MY(.:<;#'>:_)*[$P=?=8#GC>B-V7PZ4\[,L<<7^$LOJ@UW\L5[^_UZJ4?/Z>
M+WACG[5AS41B9F_*H!;*=<2PM@_CM(!:(TEQD6EI4N^$EFY:4[-]/KQ_'Z!*
M+N#HH3WZ0V=@A=$R"EI.P8[5OL^K_2#I5 X7'C&>/O"3Y4 %>-X2Y_O4J?>W
M\I]/954ZEZMM)XYXP67.W3@A4;0>#R\0I#C-"3-&%RAH'.)I,E/[UFLNP1Z;
MD3/.SH#JY^A<#]7 'WX$2L$^33<(O7HR9TB-ZK]TB_O<:[EP]745DF[$XK:Y
MR(\OUCVJ7*^]Y:)Z]>/@+RY_9I9B9 3*,J@,32%&2+C*? D%SH7@&B52L! ]
M$<7%U-3(?D'=07<KL"_(C0OE'OZYJ: +5#9Q"^<9@Q]Z.8:.J ^U$M$%C%%(
M#E*I&,;)BY0D1H%UKO8P[F%QRK1I=*AKCZT.+-V;7RK=ZFWY]/!4D]LO=9P)
MF:8F2P4D.',)PXF&0K(,)I2DA694T,1K($8\"U-3HWML J4?5UJ6S7$8KZJE
M^]G^^Q_E^EO;%58W0:# #)Z(E?)3G</B/[#>;)EOPD W30P;+@VT$C2EX#=@
M?W7VI>A/9<8CV*N^C&!C5&49#]-S37G%DZZU.9LTQ_=Z_6VIFHZQ=3WGNW*A
MWZ[U0S4KC%)9S@U46&0NI81#GBL)=6IRPPKKEA9!3?3]24]-+>[;-&V2;\,\
MV.,>_.;X![4 T?;DQ44)-2+[A'I$R_%*E*^P%7T!&\A O$C^A:Q"7UC.FX+>
M3PA3;$J7LWIZVH^[I]7*/O&3?G3:<O'U\YJOGZJ9<!,_<D-@S@H&L9099"C#
M4*8XSZ1*!=9><;5+A*:FM!I>0<LLV'(+&G;]--1%=+OU49^8#:Q]8N'R5C6^
M6)Q0+)66?_VZ_/Y?]A&U3ODG=C_"YL=:D5Q\^"AJPU?$C9+POCZF3G2U6OY8
M_EI6:[Z9V\Q-P0M-8)'F+I&ZD)#9_X/4_LZP)(04_B7B1X^?VN??, AJ#D/*
M/X]@\SA NPJ,H4/G>SC$S#4\!B2@[^-5P(S4UM'K10FL=CTG=G>!Z]%=(]:T
MGN/XL(SU[%4CEY"\X>7J5SY_<I[BTT.3N.DZ=TGK+/ZZ=&,4W8"_3]9WW#0K
M3:E0*J<9Y&EFE1]*).0)36&:%:(H)$J)0($-%$=C?GH)4QMVP?<MOR/E_8>O
MO*?'.,G5'-KCO#[[WXD/:OG!'@ W8/N&[#!P+7%UCQUQ7V[IIE$$$,[^OT<=
M0/2R]%8*$,]!9 <'8[0;3Z7?+N3R07_A?[IGWRVM:[!XLM[ _:->-:.!9QEG
MN3"I=H.BD*N&M-Y\87]E7!**L-::AG5Q\"8]-0-_R[E+U+6L@S7_TW6>#VSJ
M&X"]WTXR#*)#>_];,!NN@66[UM=NXH_]WNT+7_-\XWK+2=U1D!'>NR$8KW[[
M-_B3'[>'0S L1WT<PI\0$6<X[@SQQLJR"W"^73SO)S'3G"*140Q%FB402U%
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M]:MTM_RN%]96>Z>;_M.?W+OU=B&;%J26]#=GM\T$I5SFF$.4666..4.0Y81
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MU# -MER#ENVF*<E/->>!P54_]#V=HKXQ'=I7\H%S@+K7()SZ]:^\*(_K=H6
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M1S0]A/-4I5G&(.>%L)Y];B!5DD-AU00R F5I'C2XX!21J:D(QR-T3-:=LV^
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MOWTL4\48%AHF66%W7$K=,26R&W"694(@HADN@L8]78?E&+5Y Z#HM\==A\W
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MA>X$[09*IREXX1'C68%NNNP9@(ZW]""$MX\/K8.6<0:-S08P3ZL^!!H0P3/
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MK<<N[.OSXR,K7^[UU^)A4>A"L,6ZJ8QI=H"?E_/"AMI6+#>C2&28P 2D!!&
M"*6 H)0 (91@A"8T@4Y!_KX#3\V]U(ANDTAWA(^VTD>M^,W:[K/A\9D0A^W@
M0# /S$N30=ACRSD0TB-M20,B[K=I[0%;YZ;6YWGC;7I[:+FW*>YS?X_5X/:Y
M-&_9IF^0Y Q1#'!"4X"X,G0/-009SQ66<2($9QY.N=UG3V_S6TOGP2)[4#D0
M<5_U!V;:6JP^GKD] #QXLB\0(_KF&E"".N=.J=U)9'LWC,=4I^3<HZ*3%_3;
M[^Z?-+0'##.FF,YBE@"M4FFKI=LF#F:O2U &A4Y@)K&G1^[T0--CH>U1FV"K
M[Y&>+_]817:"=H+*YE8%SWWM&:#=MK/7@S<PAQT=4+8RAMNY=F,0=,-Z9JA1
M]ZG=ZAYN3R]<W<,.:4/2WK/'8O[RV>9V%D*],9<78C6+8Y8SHCFPP:8 B9@"
MKK &<9+F*$6IY*E[#[3.H::V\]R&3>I*W.BID3<2M< >ZW<WQ@X633#D!J:'
M!C2SLZDEC5I1HS>!0?.P@H*!-Y)9M'WS?$'T,Y.<<.FTF[J?,)XAY:3)GF7E
M=D</.JU[=7U5PIANMJ?";\7Z^_)Y_44Q:09ZJPQU/18+NWE\SXJR*J5T_\?"
M\-GWXNFS,F^0>;T>U$P2'6<Q3P'EF=D04D.^!",%<IJD9H^H(*72F7?#R#0U
M@MZ(:'/:&QD]Z"701#F0]_CP#\SR33O"K491HU+4Z!3M*A59K>HB?C?1=M(^
MO^*D>2P>XT_>6&6[CR;QCT$FT6]-"@MWY^(5:*CQ5KFPV.PMAX$?W<]%<:+S
MY9OE8E7(:LNS7%3E=[4J2R7C&5,4ITQ+0+)8 )0H#KA,(" *QC@6.B:9T\:D
MS^!36PGW!(W66TG]/!=>^+OY,X9"=> %[G07WGV8OSG [.W[Z(-74(^(EP"C
M^DGZ0'/H/>GUC)X!D8JO[Q:K=5FMY6]86;X4BX?;1WN,-"-I+!FA.<ASP@&2
M@@".: QP3#.49W&2)]B'O+H&FQI9?5NNV3R21F+/@,8N0-W8*!1, [//A^7B
M =@5-[("WT2_E,N.VC#^<8H.*(0-3^P:<-RH1 ?5CX(17>[IQQ&_+)?RCV(^
M_[*<S]\ORS]8*6=2$YC@& .=L]C8-;9$!Q<QB#'&DD%"&<E\J.'$&%-CA%;$
MZ'<K9-1(Z9E/>PI+-U:X$J&!R< 7'&\ZZ% _* N<&F?4C[]#T<-OONO2?I_Z
M>V-N&"FK4YNJTOJ]_G55)[::K0S"&M$4R,2V/;5%SPDV^YE$"0EUC)E*O&KQ
M=(PUM4^_SNR-2B4LF#)Z7AA((UTKT.OXM0MH-SX(!-_ O-!(V1[#5H*"I09&
MU#I/_B9BVDRA#2M[?GRN>P^95:M<%_^J;-UP#.( 6% FZ1IO5$9Q4/R065QN
MZ<<P]:>T<<]L*_;.,DA5*A,!$+)-%1*: &8K 7(B<ZG3!%)"9FMKEKOQR]F1
MO-AE,][06PU6B>O'(N?!=..0(! -S"!M-8VM9W>GA'<X=K@(15!N.#_:J,QP
M4>E#7KA\0Y\^*^I?_V*+8J%J]^ZF2KW02&)BN*!RH");](?H&(%<&(N#":)R
MXA-M>F88GU=]I!XKK:"1JB3U:1MR!DJ'X[\ \ S,!!_?_=__>_OI[M.[Z-W_
M_^O=M_\)6K_?!8/N/B%G[AVQ2TBW]/L]0BY<V^,S?E_(9U&P\J6)0E]]9B_V
M*.;-<UFJQ7J69 JS#'.0IXFR,5H)H!(IP*7F%&8Q@CESCA6X,-C4-A ;<2/6
MR!L]U0)[?-R7 ';XR /"-OC&H46L%35J9(T:80,BYW'0'A#!D4[0:Q]@%2%X
M]BV\B:2QJ^J=V-(L/"^V<,^RC+AZ62YDU?MZL2P?C9FZC3H6+\+>6.AHOEP\
MJ#)47SU'A#O)^-(SQB-E1VWVR-GUGK[MI=G\W<J\=>K#DK79&MC\3TD&04)B
M#!!4.6 0$9 KGNI<B90RKR*MIP:9&BE;&:-:R,A*Z=LN^@2,;MNN:\$9F'H/
M<1F@!G,7 H$[/I\8:.3>SN=5/>[BW'%MKPZ69L=2B'\T]=I_*9?/3W<+T;RL
M,4R4E(0!*(0QR%*E $$( 6C=+41CIBEQ-L@ZAYK:E]\*&[7= RIQ;R(CL%>/
MQBYT7;9<H3 ;>N-U'J[0C1:<(+G0K['K"6/V;'30Y*!OH\L=US4R*Y1MP/-U
MO13_^+Z<F_M7]09PACCF"<<"(,:0,0 T!A1)";1&.C>_0!RF/M[72P-.TPD[
MWTI]$ST>^&%NJB98JQU5JBXY^7][^6F<9\3-E@B)\\ TLB-JA>2[;M1Z=PB[
M!,4@K;_.#OHJ/;TN07"N6=?%^WH8(0>1*<L?:L$6YB=U82;[[Y(]V$84Q?)C
ML2@>GQ]G2MEZ E@!":FV%4!S0"C, !$P2\W_%$?NKB+_\2=GKM1BV8[;J^6\
MD*SN9]]4MA*-!E$5'!C]M%BNH[F-"EU_9XN_>-@S/2;*P<@9%OZ!*<L*'VVE
MM\&UM?S6^&GP;U6(*AUNHD:+88'W\%@-.P$C.;&&F @_R[0_C)WF:H_'CF?#
M]M=YS["]XC%].Y77?<]M?LB;9V.Q/:IR4[6Z=?KB-,ESVU$,"GN\F"4"$)6E
MP.Q]19XPL_2DCIT'?8:=WG%C*_6N\>O;?-P!;C=S-C2$ Z\/&^QL4EK4"KQ7
M#__2:46/#N/N$ 5N+.XP\,C]Q-VA.&XC[G%O#[.WJHC\IBV&A&,FD1 @I5C:
M,JW0NM<1P$K2.$]U$E/W.HF[3YZ:J5K7@7[C8?SLX>1@3_;5?F F:!3O4S9K
M_TUQ-^SZ(C&2R>:,B)\==DKK3@MK[X;Q;*=3<NY912<OZ&?O?%7ECT*TW3]3
MGF6,0PQRE#. %*> $ZI KB3/82*8E$Y-K4\^?6J$TPCG9[#LX^5FF?1&86#B
M:>0:X)#NI,9!+8K]$48U'4XJ=V@CG+ZHYS?ZG97J9[92\LWRT?:[K^CWMBS-
M9*JJ/-;/+]MKFI)9MS:GX_[)7KEZ]Z<J1;%2J[O%9U462_F;LI'92M[6^Z?V
M]Y]+(_*,Q$Q1B2&@S+9-Q%D,>(P4@*E B"N6F)_[[6[&56!Z^Z1&BT@U8LKH
MIV(1R>5\SLJ5+>X2K:SVCAZW5WHM'+ENLE,]-)E:I0"W6D6[JD>[NMNF)[L7
M-OI'%0"V.5H%P4VT 2$R[TD-PTW4 A$U2&RNBBHL K+WJ\QAV.5A7!7&77]>
M97J.%KC7D:)/'>HF%.Z+$JKX8:/A;A?RDUHW35<^% MUMU:/JUFF%6%*80#-
MSAH@&2M@MMX:0!E+EL4,8^*^U78==6I6\29F=BMX9"2/C.C;)D-6^J@2WZO(
ML^M$..SEAX!WX!4B&+*>M:(]D>JN(^WZL!%K3'OJMU]_VO?F:]KP5CF1;]5*
ME$5%@757B!3RF&.> X9%#%#&C.$=(PZR/!80(\T)SOT;[IX<:VI<TS:%;5)\
M=\3UZ\3A K.;^1H(O(&9Y K<>C;-[41D@/:XI\=[A4:XG8J?;GG;?<MUE>-V
M'FN(RIA6Q>I>?S;O5NN4W78^C%.2I3C1(,$V$H:D&# F(<BP3'..L4@Y]]O&
M^PLQO:UX):W-:-F5MXHI:YO6+"\VK>E7=,YCZMRX:MCI&)C"-@7H=LG+3L/I
M"?I]D(:6_1$<I"2=AQBO4IC.'Z9SY>EZ/*D?;[YCY<)\NBNSPZPVH]MO+*$I
ME5@1H!*B &(* ::( !#!!.5Q&I,L\Z/'LV--CP5;4:UOJ79(^7':>5C=J"L(
M5 ,SU#%& ['013""DLWYT4;EE(M*'U+'Y1MZN(;>S-G*,,]OS+JMUJO[LJY8
M\[Q>K<U:9*O@M7VK[Q;KLEBL"E%5KYB1#"N6Y1)0205 4BG *"0 9IC'.&&*
MY7KV5+FUOJY9N79P&/65Q>>3.91HN*^G52-:;A6XB;AZ*!9V&B/.YK9,D(?W
MJ/=<Z8QP3+D "<'(;+!)"DB200 3PA-)J-9)TLS5NX6<U$RU\HP]3ZKZ<\Q)
M<G#YC0'[P&M*I8)M'K.!_;ZL*YO=1/>[$[!1)=KH4E<P&F,N/ *)QIB3D8*.
MMD#_J$I%F2W('YN/HXQ*J]C>9Q*J:L&U&'8Z;'L_?#P'[K7Z[SETKW[8E<T'
MW_UIS\+4:E,_B3&ED,@TD DT^PQ-D<U%$H!DFMEH*YFRV,>]>W:DJ3EWMXWT
M5"-ISS:#1Y"Z[3&" #7P>K#%J!4R:&4J9RB&Z3EX--KKM!T\I_39SH-G;^CI
M@ZCR(#^J]?>EO%O\4*NU7<U.=>U)D11:)0)PG>4 $9P#DL,$8$AXC&B>J<RK
ME(KSR)/CCDW_G397T=,_X0RYH[]B"""']E_4[8]JH:.MU$-U-^J-55CWAO/H
MX[H[?$$Y<G]X/Z!/XDFY%$K)U7LC_U<V5_?ZDU'/9KLLY^:>AS;O;J8HS[F2
M N2)YL:H@1KP3.4@3S,29R)3'#J=67N-.C62:N6N>RJOC.1VS[!8+L".\)X$
MYC<-#IOF(< =F+CV<?W:X+HO]B9U=PA8?1)I!H!WK"2;(#![9N!XPM6=G>/Z
ML!$S=SSUV\_J\;VY!\-?C-H\%[19KS_;5.S5_?J[*K]]9XLFG-,F11HA[:)D
MXSFUK?EH )M!LSC A" 04Z8!RLW6E\9IY3/'MD@SIS!Q7BI&%W]J:\Y6S&BY
ML)D#K:#13U4*P<JG:L?X+X/#@C7I*1YXY7/)(;B00M!8_3LP1!4.54F7;8+!
M_GNT@\:D7Q^/A7G2K]%(*_R47R<_N^'59K/3 !E?JO$LF5=#?,\D>CTI>F9J
MVD,&_O)!K:TQ<*_?E$H6ZR996 G%C;D3@UC;DP F;&FRG *<RTQI1%F6^R57
M=PPV-;NED35JA+4[C5I<SY3'+GS=7'FA4!O:%#@'V!#9V@Z0A,W.ZQIPW%PZ
M!]6/,M]<[O'CCU6YGC7UJYJ7.8]9(E6, 4,),=LF(@%)& ,L(W$NB8I1XD06
M1T^>&C-XU;P[Q@GEN8:,&O,%D]1L*C,&*,09D##--"0R(RAQ"^.\"JF1VOM<
MAU4W05ZE_\!LV):Q#,=]9[7M(CISTP[)F7\=$MSQ4T=AL[/*M-1U_H(^^;1_
M^]B6',JLY9(@ 2"!&" M,>"9;<&G&62QQ##/G=I\'SQW:AQE)?/)<]T"E"14
MJ20G0*0VRCROB,K\,S;4A#%"N5*Q1R.R?A"-0T[]07+P"O53?&!6LD*%KE%U
MK&AW/N[V\A$S;H]DW,^I/?[U-5FSF[",*J]N4V>OV>VMWCZK_U&L_/;'<B9%
MG"5,< "ELF4YB08DSR6(<Z&@1BS-D5-7BI[C3XVUS-N"^N3/N@/NMN,:$,:!
M/_ VSW8;IM5DW.X4Z5PO(ZZBSZR0-Y'5(#(JA,Z^]<9N@(Q<=QE>(4O7&Z#3
MF;O^C^EA/KU[?)HO7Y1:-:L?1(I0GC.S9<$0(,0SP*72 %%!H18QH5GJ;$,=
M/'QJE+01S\-0.,3+P5JX H6!&64C69]JGX=(>!R'7('(2(<5EU\-/T/JC,:=
MUM3A/>.95&>DW;.KSEW3MZW/0K6^*[./2[A0S&S<,#>6D^30[..( !G+1)9(
MII/,LX7/]N%>'#16NQ[?ACL[6"528 )3"#"6"""E<D"U-3433F(!,Z6(9^)P
M7[1&VM<U34"W*117@.=H,?8$9&AS<+EX &:9?(RL@ YG&#WZ$!TK'KCGT,X
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M W_P/;%R_O@=D3C! 2LE_OJP_/%?Y@G5Y_]/9/\*ZK]6W_RE9X_RZ3LJV#*
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ML4%0F@A;KSJU7=(YSU$L("1^'HCN :?GCMBNO75[RWDCL7?J\06D,<T5)9H
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M0I6R#&(D->1YFD.>DBQ6QA+B2>YU&=]7DJE1Q.X&O%NCM56@KX'CNT"^ELZ
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MVY>$WW )1S2]3\::-2M7]["Y8R_%FLVM7C>@<<J.4SQ\H!48B/%#2_M&6\-
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M!8\@PT1 FJ<HC@C)$^R7)N4T[=18OA(6\NJ,*';$!:J6US,AR@UZ-T()#^C
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M,6"$W\YD;QC3=ZQR=Q3?B<]?6:KIMDH$N%W(3]LT@*8BD;Q??+$%)6VPH/G
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M&0^?INL93)+*2CHG2%#"(.TL$Z>S)B8$!=*RQ.G^$+C[U'X0:#C_N9<81X;
MIZ4OUZ,^7IR&Q6S">,I&<HF4ZA(592!6\8P"$4$K[X&*_0]";CVRG_(;3FCN
M+L F_,+#\V61T^80K_"!PC]?39C2'&3RZ-4Z7D[S/+':>J)8SCH*]&>2'\@S
M?)B"?KAH/G,Y@'B;@,F;.7X:BF/Z!5[YM=^R-3&,"2X4)]Z!(I)'3IRDCE :
MI4\QTI!@()@\3$$_F#2?OQQ O$W I)P&+P\Q5#Y9+"\F.O& /B_*1+NPD8G7
M 6-FDT%K;V-R0QF16P_N=QNK^;3E[L)L @L?3_UL]LOY:CK'X'ABP7AF62"
M6$;R.4>O6!F2 K.::@4J#V4I;CVX'Q::3U3N+LPFL/#Z%)8GN/W]>;GX8_WY
M<'%ZYN<7$\\ABA(B"Y$[\Q9)2#(3D%*QB/X2NDX#8>)! OIAH_D4Y?[";0(C
M'S_#;'9)O14Q!QD9B<J@M<N&$<M\(DI%HY).09BASC9N/K<?(IK/2.XLRB:
M@(2?EELAB_BWCY]1;JNC\W6I.2EAUH3SY(6TAC@%4.Z&) RP="8T9YMRS"8Y
M-A PGJ*C'U :SEH.+.J1@7-P"O-4KJ7^.O,GDZP,NLW,$1U,)A+ $V^H(C8;
MS1(5TLO]]Y5;C^P'AX:SF+L+L)%;WK].5]'/_B_XY:_XD]6$:H8@54"850(%
MD1.R("*AW#BOE=-6[Y_)>N3A_=#0<$)S"*$VA8M-$<.&B92I-0SC:28D[H>J
M7%0W8(BV!N'M1&!Q?]?BT<?WPT;#^<YA!-N&HX%L+/WLS3S!U_\-%Q,3 +@W
MGO! #8I$)Q*HE;CA&2%3U%JKP7R+VX_NAXKVLYU["'3L0_!-RNW:XEU5/'&@
M1CA/@#'<"V.ITU:6EU,=[AQDE<+^SL1C3^^'BX;3FX.(=3!H_.GG>W)\BS_8
MN;C\\.C]QZ.W;UX=?'K]ZI>#MP?O#U]__.WUZT\?;U/>K[+\\0\;IJR\)[%[
MUI2?K\B)]V>3[L)4V2>.\J_3N9_'*6X6BTW%V!6J8H2D,I5$F22)Y%03)S0O
MC1"XU XQD)\Z;LY^%3J-;Q_:+;"?8;9>7?ZD6V>$LFT;@?_^'.IVM2;WGO')
MAUD!O*%1,R!4&K2%RAN,IE@@7J8 $O=&%9ZZ:S4 KQT=XU2M5T/%I:T90.@C
M;D#WJ#^<^=7J*'>!^<'7Z6KB+!K%(#$6Y]*C_94,>;",* :! T?G*C\5S@R
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MF3@O(V$.I-1:**:K=WAYD+)FRJY>Y,!Y?^4,!K8__7Q/XF_Q!]VONM^4O_H
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M-8P>&L@SW(XVRFG]='Z.3&U3*(OYZA?(BR5LWO?)?X75ZZ\H/U3?=.Z7%UV
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M14G1=\THM^-*)C&F+*13)$>PI6=:Z9XF)+%&HZ_*6+*^4G[Z2;J:3#K7AMT
M*AI_A^U*,.X>$!WE1T8C<?! #=IR'Q5'83E# L\470@E960,9+QS;>>1TI>^
M3VPR.SPTL.KI8,3]=,/4W7PW\G3X $_)!Z0;(VP*#,TTLDB\98D$H%K[0&,T
MO!^N^CVPR?QN'5A5T$ ;&^6-]5+&&I:8YRAW@34X85ABD6C/@,BH(O$!)9:]
M#D;G8+6OY)\]2M.X97PCA@-[J*:!8*"_X"9*)!:TB"3)DC-TWA('#E\)GYU4
M6416IVB^/XTCU_"], HKZ:Z!8ZW"5OE_.3S^@JY"U_3N<H)K=YM\GF[_X,8[
M-V-?[U>6;0=EOOZ*4=3\!#Z@H7Z=,Y3#'"U,8,H30:4G4@=%K!>.>!ER$"*9
M6MTY7Y;/<3,VU8[3&@;+][Z4)M;;"-0SHA)#5SQ0],(E:DA3;D$;*YFLDWG<
MB^QQ<T1M OU9JMQS4"M*8+EN +VX'&7BLDO,1MQ2E23!@B/14J&#E#[R.KFD
M^NBMEFIJ%+W/464K(ZO/S\YFG2C][%*4;^9YL3S=*/-2J)0+ !4R 49U"4S+
M7I(H<1FD,ZJ4T5<:O]Z/P'$S5-7P6$,]#01TM_IX3--$NYP=QJ1EAA@&&)G'
M4GA)"2X;&PRN&Q1:%73=(63DV<(UE/W@=)C=)-\$<#:)LD([1I:3*'04H!+A
M7&"@:*DKW75QJ7$G:4S&,5:G[O\.(2,7];\(<':7? / N11+R>;CR^M;M?/T
M0"KBU7059XO5^1*N9*<CE9E)06RPI8>&3R5EYHD!GK(3N//S.DC;E_)QD^Q5
M/;474V@3O7H^3$\^HQA_WS;D/0IK/YV77-IE_/_K8GGSUM%U6Z)8BG%U*<!U
M'(V\,VCN0\J$>YV8,#'Q6*<9Q<XDC[L1ORRV[EY4?!$U-V"2NZLAY6 "$IN
M29"-"23YTER:.D:LUIQHGKGG1E"JZXQRN4G%N+OXJ*C;61ECGVU?CF&:;N<4
M/Q#!WXO9KR2676*&:2"9TC(3!!VBP(PB1C%5QFTCJW<JI1\Y\-Z'BG$/)0??
MH%]6*TWLS-O$T%T&UX=^N;S 5?L7/SN'"3C-(H^*6+"9R&1PH29?;B1%#R+3
M%&V=(+<7>>/LN"\,E@=\R&'UUL"V^FAZ<CL:9!*D2UE&B5%@MB@Q'8E+21+&
MA7'4B^1,G78ZWZ)LG.UW7 @.JJT&T+=? AUE1\%)26@&68XM(_'9<)+ Y:1-
M=(;K:B:R[EG(X'4MXYO.E]'S8,?3?_KYGG[>X@^Z7W6_*7_U ?(/Y=_?/[RY
M]?G^;#&;+4XA_32']>;S7\$J+J=GY7,6^;*9X&VJ5]/3L]DW/<B'/^CG:\+N
MDKS]O'LPVHU(^+J&>8+TXWXK_VAYXN?3?W1$'B[FJ\5LFC:+8)Z.;S!PE+?1
MC)]=^9[7'J>W/F61/:$& I&J#"HPX G(K*B*C&I=YY;+(.3O?=&M] ."H[QM
MXHMD3'BT&,U'2XPL+04B4AX,2H7CXDS"!9J@3F!\GY9QDS(OCZ][5]GVT\Y@
MN_.+&+*#E*;E)WYVXR3A%:S]=#:<D7OR(14-8'_FFC*.0O@83;FG:\KP<4[+
MK(/ B0!+0Q0B*%>GL=NHQK%S=&ZH\>A*C9\VLVV4,XXIBXN.X1K,S! 4$RYI
M7.9":BD=[U>U\/@S_ADLWW/ <RN7,Y#H1PQ.$DPG;^'$SU[/U]/UQ<'7*5IN
MF3G+*9&D=-D(T/EU.N-NH)T.)NF8Q%.AQ@KB3R>++S_C1W?+Z.^RO"2;EQVD
M'GCHB#F6H92X&$:B(X-A0_6KQ:F?SB>2.>XCX)J0OHPG%T!L.1_7/'+IP(F8
MGLJ']$/"S2>. X.]5;880'YCGQ8<S&;3TBT[3O,TEG!Y-L7]?S[U;XX/WL%I
M@.4D9Z^8U+2L!%YJ8S*Q,I;^#(8:GJQ,HM]V\NUGC0>$W16XJ"?-\0?/;<?F
M%;/X&_C9^O,A2O*:&52OCLHHDG+I3@DL$L]<)AE9R48Z%%V_R<-//V></.B
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M13PR.C94;Q>.$$Z5&]DD8?2')A7W 8M@)HPY977T.MC]H7'SB>/8C+U5MAA
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MF\K$-5?_S)>)HO+?EGD2;3)",PF\%I\HG1""$ :,RRF2PR$C;W,V=R)O_'E
M_4.P'UV- ( _OHV0S'ZCO;2<:&-XL$$#8YD"<!D%.(5UCH1B419T.K8Q>[OI
M&?^3>XN7JJ.T,0),_6,^3W],+R]O-\S::8TVEX+9@DR6!%,KTT-(%OAZYI"5
MUC9*T]]-3S=,/=^7AAZU,0),/7;^OYXE\E1O?("?_XR75W5^ZY;SB3,%0XP:
M4$L*EP(WX+5T4%S6WB;:0JQ-=\]3J.Z&S^?_!'$VS8X Q7MNPFOQP\?/./N8
MOY#=)\'?RF02M*+]&#)DGSF%^EAM?^*0? E<22:S;I/T?3BMW1#[?!\SSJ3%
MH2]L7DW359P2_?>J*S8OU!.394BZ1' A>U#1)2#V2IT\Z:/#S&.XYQONN9)Y
M8J%N<'KF+QA]"GL$!NZVVOZF@U!M@KO]Y=JJ3[+@WBI/[%A?0+G*DQ$,>&)6
M^I PW9^8TWM+E/W4=4/=\W_:Z%U3@TX)[<C5MJ[P^R0HCYD\8!!687W$R1 \
MA>D^6FU]\DGY-LWMNE+8#8?/_\6CB<9&90FO7=D)CRA+,1&*8K2ABA& UGCZ
M(K0IRDN;0V/$75/2+>OW^3YF]**!$2)HZQ(HR;/1FH'4A6(>*UG-AO<0&=-&
M.D4&NW5_]1\(ZH:GY_\$T8<^1@"K]_E;GEWE.^]W;\/E]--U55I>QL7T:_WV
M;?DX_4(RG.0L=32FCOF+%+HPVCI.).)1T]XQ,928VS2P.Y#0;C!\_L\0+?4W
M=.BYX>U]KL6157*[F*RU_7&5TS5_)'/Z[;)@7(^07#]0ORV;Q+#?OLYG=<['
MY?0_>"V4V[?LZSOVB>,F6$8>!=<L@3*E=DG5!9A1WIE2VX!U3# X.^W=$/]\
M7T6> R1&8-"W?>W^/5U]?GFU7,V_Y,6-VWQSCQ"+4C(B6$\>CS)& FJ?P 2!
M)L>4K6AS!=Z%NFY ?OY/,;UK:A0Q]Z-<W6S?."?Q_B>G26&R<)LL1)\U>>&J
M"I"".2S>"F:=U+E-Z<=A=';#Y/-_?FFHO=YLX__[]P=*(.9_7__1^D_JOWJ?
MR_]3___;^]<_?#Y^G5]>$E?I;[.\NO[\%[B<+N?EW9W/PUG:2'W^N-1_FB[Q
MTZ=%OCYXYF4CHO#]9XR?Z8R9+];]1?,*IY?+'R6QG'[Y>OFD,W$^XOY^*\#[
MHMW0^ #2XQ%F_G.59XGVZ8D5:P]HN@C+]8:82*F8=[684_%<FT8Q0*LL\(!2
M)%.L<FT2[O?3=/*5P@_R?KN5]W6_"!8C;6&E(,EL0>7:E41E 88K9IQ47(1&
M%U2/4#5LWY:>T/'@)J$O-0P\1OP7_._Y8GMH+->]DC!S9[FQ8*0FZHM+X&2Q
M($JT*'-R170"4:?1X0_7'[@?>6]ZG?<FY($A4B=@ORT_\+!I?<1IXTAF#-A8
M:C-UY8'HEL2)=A&SM*ST-V1^+QG#S0L_5:_SOH4\].5/K=W+BSJ1==MN7VBC
MC=$0!3F<RL<$B-S1!G(YEF!C*.XI;VKG)P^G])XT->]+;$/K_)><R#5<Y WI
M0A:,S"!HD@4H%VIBET 0QFHK6?0B8B>-__BYP_2Y::3O$T0V#FU/TW:0%*O-
M U*!F!2%K2&2")@7]5DW.RY]9IP?H.WMYP[3A*:IMH\2V=#:WB3$31?I'2[N
MM'+.*(V(9)_0RMK3Q$= X118<I^%T=R;E#JI?<\"PW20::3_/H0X@COJ/9[Q
M[16634FI4#PHD0102!4 @U_W6,W>)JY"HP&Z3U$V\/2:OB.*)@H9 < V]+\B
M">ZZT;S)'*]/]_1?^HA_3C3#(G3R4$I]&8TD2<>L HPF&A53BK9-:O41Q(XR
ML#T2+;L?M)NI[B]Y#;V6U#1<K2=LK^8;&=(_?Y]CGGZK]F$9OJ^O4 >ZBSZ"
MPN$OI$\5:_M;:69UPI@03*F#Q1R=^4AG/1C'BS69>8-M*C/[OY7^883#K8 O
M9NG7O/KAI M:*&0F@K-$F](H 5.NQ6K(&=,E*Z8ZN8Q=5AOME?,AJM\Y)J,W
M&8_@P*>=6KN&+=:*J:TK7GQ_D6?Q,VWRZT&BDGQ@K2P#+^IE&DJ2EBL);. Y
M>>=,TFTFC#U%V8 ]G?L'PL/7Y/ZT,DJ4;;G9-O"/04J!=2?6TNS@-/A<OQ@2
M7DI.B' NE/U(V;!6K%\</ FR$Y0R I#5QIO+S1:DS;B=(%J2M'4BJ5F[U,8@
M>)XR&#H#M"JAN-0F[W8G.6.#TRD:G_<M_E&D83VT[=L;8FU"R=* "+:.U:98
M*4A?&YV'8J4NUODVY7;[*!KV2J4IEGI1PJ!PVO,T&546.90(@G/R/7TJ@$5E
ML-$99^HD4MVIRWS+=_TVN?W-?*8>)#W:Q_TH#"8, 2P+=?:,]V0]C0;#HRK)
MYB!\IS'U?Z''_8/TVNEQ_Q A#_T8M+XRN=B^8F4;'!<9D',&*@D$IU0!YX/D
MC Y=YKL]\][]U#$^ZA^DH7D?XAJ%GE]L#[W"@\!"3.OL0#%>\UG(FV*2S*1P
M1B-CW?7\8KR/^:?I^1AQC4+/+S>$2Q^XP'H1+XT$9>LYZ&4$:X.OO3]CO#^"
MYC$]OQSO,_YI>CY&7*/0\T_;&=\LI*R3A)AK]SE#V S1)D!69(A:NG*_A/TQ
M/?\TWN?ZT_1\C+A&H>>?MP>.L 1/6?M),W)5:MZ"QR @(<,26/3N?H.6Q_3\
M\P%Z[KV>IJ6>CQ'7*/3\ZI9P3T>+ 6T262,5 \6C-8<]"IF,-!CN=V1\3,^O
M#M!S[TW 6NKY&'&-X%IQQQULK:99!R-<%Q=KMVX1E $*71EX6;MU2R]$8C$6
MVZP<=!]1 PZ/&^)=Y"A=C!%6ZQ*MZWU&48FQNDA@RI(E-$Z!]XE!\#998P2Z
MTF@6X7ZBQG9S?:3BGP+4D5H8 Z VMOH!2ULWRGK.(UE<EV0MMY(: N=89>6"
MXCX9U:8N[0G"1@:L8P%P'U@]:F-H9^<)L_[F)GTM)<G),T]@2_1 [H$"5"&"
M]$D7905+K%M@TW7% :=<-COKVHE\#$;J_G:XG5K')R5GGD4I($VNXW@HQO/*
M6S#11/16!.O.E 1PAZKQIID<"8*G3L!C-?+7S _%Q>)[39I=3R=>TK^[::](
M'_ER_N4KSK[7R2DXJZ5CKV?+U>)J/4MOJ'31DPD>0?9HOT)OGTS*>5(1%47#
MJD[+B3I!"-E!1(NIJ$BG^W-))MU^\HW$KYOTD>'9=C-9%\_@>F;WV]G[.F)M
M475%EFD^6VQ_7*O_^@PT9#^,EH7D4H6#9*:"YP*TBSE$'DUIU&>Q-Q9&F\EZ
M".[NV_UA%#P"%^2&\1??;[[]YS0OB*C/W]_0T7JYCBIS,>3K*X18/!U])GM
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MU8]F1@"Q RS_;4A7W>42>02="@.5JI_"A0(K>"HZERAEFP>08Z@=2X;%F#S
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M_FE ;*JNT<)PQQZKJ4=2%^T 72U;,8Z#URJ",3KZ$+F5[ISM=':0./(TH)9
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MU@SZ:K)__O-KGA$7$YT\$SYQ,)$B=V7K]$Z2$J"CHT%:9ZUJ@[C[E SKR+6
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ME@RB\QV@C?0W,F1N=ZN1*(1.$"U+H!(*H']G(:-0S# 3Z+_F"!S#4=E*ZX^
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MDA^%ZU-;/]NW]AK77]^>+?^Q=7MT*0?A$]EU9,6!0D9^L0X<A'%<(L9:(GX
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MSTPSW(6K74TS9#)*[S6X& 4H.A 0O(D0/=U+P@8=V7-*])2G&>XDLB>G&>[
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MAV8/L/P4Y^5!BE0IH9F."#9=^D,(CDD&B&0+^4S.N>_SL.R13^^OI+#?DW(
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M$WV\XS&V-I\V=)$:)^@B-0F"B@RB\0X=P3>R-HT7IQUDLC6:=-D',=.*WJD
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M%'KONU1S]3A\HY.H3N8%>E\8T.T90#'O(20I(<<< Q%C2SAAU7EI;CR]TF6
M,X7 F3,.1"0;1DE+//!,@,C>DV?$([,#7YB^L-(IZ;I=@''?NAN3W3T$?6G)
M^?E;C)M9M9N,JE4./>V"O!Z903G) :5(8+A)/@?D_.$\I;$.S2-:)GP7/ZZ@
M'UZ7AW&].]Q<%>E$X;7QG)QF70L$A:8+WE0Y&Y8S.B65:S,R9QLU$ZNC R7\
M+&#V8'<'D/E4W_N%'[_E\_K-]^5R3U=)V.@X8UI%X$S0::KA%V\C ^=5=$ES
M&7AI IWGJ.H)0OO(_&'M^5@"Z !,;^<+)&6,9Y\NOG]?KLX_+_]8+N)RL5Z>
MS=-F.$#^@F>_DM:^.GV)\V*=LR#KX!L5G(; Z_-Z(9FRP6H6VCP#W)72"=MQ
M-+WSFDKLQ!!Y=9B5XR(XX4#FVJC+6$=6*&+M/,)"(?L[NS:6UNZT3JL*VV+G
M *#N(<@.H/KL14"*W@M7FRY97BNM,4,0T@$JXEI4$NE6^#>[B5LC8I=[>A?Q
M3 BUE.>SAX>R"!F3$!IB4IR<[EQGPX@Z5"H8'[+T@3]7*K3.\3^^+/_\3_KT
M!E3_2]4?X?+'#9*V+#IA9Z$FM^FA?)T8$O?.B,DF(_/UF45BY! Q,CE+J'4D
M(?F@$HOE.4TS# _37V('BVPY O^FSE:_.CN;U]8)<5[FD50:GLW+<K68X[L/
MKZXT6[;D@)"G 26IVK8TD&M#W@P$9JP7R3K]\+'_4XT^7UQK.B#L+\!E.VY.
M7Z3UZNS[5WQ-W/N=KKJ(9_^U6EY\?[>(_W&]FVBET$:#,2[3>9$>?'T#5HL4
M/7,VHAXV<."%A:9QOL8$QGA\G%IE/'-__G93IA&CT#'G"*Q(,O1U%H"Z;LBF
M8(S/D13LH=F-WW8J8F_3&ZZ),=&&S1TX.)7P:[MYQDTT)28$'PQA/M60F541
M#&(RJ(-&.>B5S,X.S5TJ^LQD["G@Y4C<'O'>&3NY?]7ZZ0.NSG]\7N%BC;%^
M<Z_L_9/?&B<]/XS4D?+O3RUVDUD-1FK#?0"D*P64C1PP>P23M"<8&5EDFSCK
M2Y0=JE.>^OZV^A;2N4893MX_>?YU>(HBNRMY,-:J@%H%AVTZK.U Y+0AE5%Q
M]% AM1+5">JKC7$PJM:Z^F);W;6-[&-I,!]91E$D:"4V+P9XK8/C$&U*/NG@
MY+"N"MUIL$_Q:TX79W17/\OVV[/A:^N+)#3HQ.LH$^*)<T9 XCH;I9U/TK0)
M!>](:>>Z;!=$/0H&MQ3:"2JTL4LK]UJGK?([>E'EBP#.)?)4^VL4@QL .\""
M!IP(R3 TF9^H4??RZ?KEQ[W?;'QMP9+D3#&0WMO:,4" 5\08+Q4ZYV)0#^>T
M'TTO;B&W<^6X"[9V5XZ'BF_B?A^W&_SU?UW,SW_\GL^_+M.[Q9]YO?'H'__7
MG/\@);=),KC"E*^91\U3 :4,@HLL@,U>"\=#=CBHIFI0>Y!#*)VX#6-[$"TG
MD.C$R'UJ'U<1;LYTU$8@9"<962D,(<@@(1HNT;#D'KUD/0";S],R72NCXV%A
MV40P4V<(?ON&5WD-QH0327C(J#(QHS;P$Q;)!A:A,&]XBL-RAS>?G X58PIH
M>3"WII;QAV_S9;RBVV?C=23'R1I%.M?7HIHZ+%BR7'ARBN/ 86EW/CI=)ZM6
M<MZ78U-+^LVW+U=4ZYHD2$0UTPY!<6X@^!A !Z&DC"$X/RS;>_/):<J 6DIY
M/VY-+>/:3/K3^SL):1<][5XDX*6&7QG1C5AJU+=$*5P1,0YK]OWPR]/D:EM*
M_"#>=9"4'69=;VR;F(IPJ39C1,>K;6/!\TQ_6(,\Q"R#:-/$;CB-$S?T/IK/
MTEAZG>'RZHPRPZ2G\P-9U:9!3&?P,3NHL^XTYI!\'M17]2#\]5!XWTKJSX!K
M#Q%,?:N]^AXWW<V_+L]('.OK<0E(YXT)"PQ-98A/X$/28)-![XHD!V[@X/)M
MG^\'%_L(;#DJ]R:7?_H3%S&_F>.7Q7)]/H^?+E9?\NK':^)D7EW?UEQ+:6P
M(CZ1*5XT^>O<UY:C 9U0Q<=A0\:'K#;M[30J.L;F[=1@>;L1QOSB&N@^9)V9
M"L0*1Y=RT03T5!)HGUCF(DD;[2!<//CPM)T!QX3 (1R;7-H79U^(7?^5%YFP
MNR;K_7K$2< D:W*6])PF-T I<![K! JIL\R1_F]8+..I%:9MX3>J_,?@X=1
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M,U^9QQR% 2;KV!MEZZ@2TL]:!FF-UTH^6S9P@+%^EXR)[ZW#Q?K0#M^;QQT
MY,"LPB\_MG]@<_I*ULYG%VLE? '%8SU]QH(+PHJ0,I?HFL"MX::ZRW8><E?V
M(OQNS\$?Q/@K#6%,8L6:# R=)SX["2Y:"YIK$XO15I0V ;>7*)M6G78#H4'0
MWE.>'>#SUV_?SY8_<OYTOHQ_?__]_+:=%S/!!1L"1%E[E# =(9!2 !TR2TP&
MNK_:-(AYDJ0>$;FOY!\:A:.(H8M([\=,#OL\UE!AW<QUGT<;G#.:C.7B#&U#
M,3*6Z8]@O#>&+!MCV]S96\F9-E_5%$F'LW_JFL2GRUQBCE9G9R%S^D.A)6M:
M:0.<>R&<+BCS@^J )D5GHR>61C;#1N1B!S?4;HDQCC[GB.07D9D RL@"P25#
M:/<V^N2#YVW"O^/G+X]=1+83+@[*7NXBI"[NM*W;>RHA]BK]SXO+47*S.D33
M*LQ0='UF5G\*VI1:5,Z=*72F8YOQ?GL2W)$7VA"7(PNN7QWY9,K6>"4D&@23
M-0<E&1F51A&0$(-D(HGLV]CV+;+KQ[F.F^K)4035;5>]O^)J7HV9=PM"/)FG
MF\<69/'^]=VO>^7*G_W>.-GOX22/E,]^O_J"B_F_-K36L5C+LWFZ[C_[X<X^
MWI>W\P4NXAS/;E(4M[-GG$)OBR\@7"&XN/I$(8A,OF.Q-M36HJE-,&D4\@_5
M@EN%]F-;ASF?43M5#%CE-!D@R@%&'H'[.OG:9R]3FX3%8!*GC74<'XT/%64;
M679<?O2<QMF_4<Z K[97F T;Z(P#U!1343$*T#$74%%J\(BU$X7*04B/2K1I
MXM&%VKSMH/&4$&\/6PK1YV 2:"<$'>G@R2[6 J06SL?HZ5>MVYV\2.3/H#IW
M0>33'5'&E>>)*L\#BC*'?+:]^FQ91CD.6K5$2[BL<WL)2HJP!"[K ED(%3 Q
MYWD;<^I4].<FE$N^7,;,4@TB,%"6?#E?&(-BM O:.)T:-:P=2.#/H#=W0>(>
M>G-G.4X8&UJOSF>WC,SI>A.;%+@A!>]3,H %)2BO _BD$$R)5I)%+;0=Y"C2
M(G=P2'][B,'GJ.AE=.:(XEZ.S/L.\7.5HU31L"2*(('7T>TIDN40LH52LO?<
M^1+#H">(>R-HRBJ5\>3[ F#V8'8'X>CMSON'U?P;KG[\DA>YS$E_KWY<):>M
M3?58)9"YSB[Q2H(/=."$,2D4DZ4:!J61HC%/T=D7U/9!QJ 8RRABZA:$MV%\
MKVL=!=D&B>BC[7!7'X,;B,X4%H2U/+1I-? "8;W,]AO_5FPAF0Z ]FJ]SG=,
M4.2!3$WA 5,])EI8<%HRB'1*F"XBRM+&S+]/Q[3&U:@B?EB"N3^_NR@FN*3_
M]<6J,O)F&[F8* 17P&JP1S&E ;U$D-[R& WR[-NHHZWD3%QJ>8"$MX+E$&9W
M@9G7N/Y:)U'2_ZL/3?[$LXW;>_X:5ZL?\\67O^+919X5F83,)M3! (6,@<PA
M:$D2+\G+E$KA/#?!T"#R>L#404!8MI9)%U#['5=_S^=5>=_6IEZQ;4:G4-?:
M>=";N96&TYFTOC;.Y8DN?H4RM^G*\ Q1$]?RC@ZKL?C?!9A>Q5C;PZT_YICI
MA-"F_LCGU[MAD6=1+(-<R)=01@9PQ7C2Z\HI;[1PO-&5]PQ5T[:6&1].HTF@
M4SS=&4)ZYZ"0D<!+R X\DL)5W#D(9"A DIYEM&A#HX%% PF<MFW,,5!VN%RZ
M -R=Z8>W>YM96Y(3WH-F/H%26D*@<P1H,K<I.BE5&WAM)6<0F/3I@.EPGG<0
M%;B:GGQ-_OJ.UC6:V)&* 69K"[G,,G@9&&@A!#DW,?-&U6=/TS0(0N9T(#02
M]SO T8=5_H[S=#4YGOR-S=;N<6Q&S+"H8P+$RP>M$9RI'2Z#BO07Z5.C(40#
MB!N$+'LZR!I;'EW<<G\LS_.+=[=A.I,]*"!J2P>';Q2PM:"*-#%%FUAJTV1H
M"'6#8.9.!V:C2Z0#5?;F(M>'^Z]*F9_-Z\S<JVT4;Y.IQ(M8IVZH7(W"J(!G
M9S#%(+#1(-4G"!J$)7\Z6!J#[QW Y[Z.=9XIH02"T!QK)P<#WF0+R2EK8TGH
M[!'BY<-BFNQTL+(_DT=[?G0H0OY8+N(#CB!&U"@4E-H$5?'$P&='VC)QC94C
M4;5YA_D413T$+4?,KQS(\@Z4RX?5\GM>G?_X<(:TB46J$?WOM;:0/(>9E@HY
M"X+L.6Y 6<W!\41;<Z*629/?T.A9U7-4]9!..53NCVSKD830 :#>D3 67^9D
MNUVQ*I]?=B^:+[[\UW*9_C$_.YN5S 7YHP&X*Q(4E@Q8QP\JY[C'I)20;?32
M$.IZT%$C VQTH70 M!NZC8^6\:@A11] >>$J3QQX'R4WF:%-;1YU[P28QJF3
MD0&S%W,[ ,6S[N,MCV;*^U*$LI>ORLD*0 @H)9@8I90)@RMM%-!  GO(DXP,
MJ1:BZ0!QFS#8;\O%E\]Y]>W=XL]\V4EC/1,NB!BC Z:E!T64 VKR(5@ITB>7
M+.HVG;^>HJB'=,G(F!J%^1V Z+*)[N_Y_.LRW=T&D\:%Y N$4KM@Q=I&-SH#
MFGLR"IUDCC7J1;B=H![2)2-#: S6=X.@V\J9MW_^,2=/XF]SVM?%^<>,:7[V
MXTVF!;_-%U7_OL7YZK)2*Z**P7HZ'"9K4$60JT&*%KPMUGN>)3&W(<CVH;F'
MY$H3'#878!=IE_?D[9*T%E]^R[C.'VMKH/?E+^M+YV06F$^QMGUD-M#)$RF"
M4S;1GI0+BC9F<YLB@V?)ZB'1,O;M.9H8.E" =]*1=XS)P))FKBIPJT,=:<W
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M #?;"-9#",0]$5T4=.9<\L=HUK!;<;8_><R-(8X.M. 3VWA]-:1::;):F0W
MI:FM=I2"D-% M,$S73S9=&T>03Y/U[ 0.?M90;:/=/K58'=FHEL=!,\Q@'6!
MU\'HNO;_*L!3E-)8D5&TL?E>)&T8XDX_*S.NC#H W;:9;T_PC=N"5MD"5DA5
M:WYK6*F^>,[,:\>]48V2],-I[.K=P"'IZD9BZ11P+^0S"^-9I)(!523[4RL'
MO@0Z5XHS%[+5NK1Q*G:G==KD="O4#)D3.9X(>P?IMLPE[8V71+:%E,*#*O2'
MSY*LW"A99CQ:B>U;.?6?@NX!H(>*[P3@>9VQM*AL$DE!B37NI!2=OZ00#-(5
MA.@E,VT2>@,)G#;1W D8]Q'6J6!PDY.409GD7"+=SR4H7N??)$Q UG8HA1F1
M&N7L!I,X;3JY)QSN++ 30>(F%12CSB9(!E:Z^@;<2D!!2E\7Y40@]I7<)A0X
ME,)ID\8=X7!G<4V=*MZZJ>T)R6*,8B)E"+H^HM6FMD?A'M GABRH:!]VIQG0
M#K;GU'!C7+7D_PEHMYF14A94AJP%7O.*I8[=3J2&I#$64S38:.C?2Y1-FP#N
M1)OM))X.$AY;]_-DCC F[X2+&6*JY68.-;E,I9XJIXT/TF5SQ!NUSS3OE$ <
M17"]*L&9PR!CK25+&SM51 NA-O:QIM92T#:"YL=#W[2)W2E1MI,@>M5Q-TE#
MH871,8+QTH'*EH&/S@!'RXI +)$=$51])'2G!-<^<CF@5?)Y.X3=21(:)[C)
MN4 4M<&\B0D<I[^F'$MFRAIMRO% UDT:=TJ<[2F=SH<9[?/@>_;@'+5^X3[C
MD[]Q?[CEFU?N1-B58.H?@?[)__=__6]02P,$%     @ RHFJ5#57UTN>"
MS"P  !4   !E>#,Q,3(P,C(P,S,Q,3 M<2YH=&WM6EM3&SD6?M]?H3&U&:CR
M_0+8$*H<XU1<18 ASB;SM"6WU+86=:M'4MMX?OV<([5OV$Z<8@8<:GDP[I9T
M="Z?SODDZ_R7RYM.__?;+AG92)+;S^^N>AV2*Y1*7VJ=4NFR?TD^]#]>D7JQ
M7"%]36,CK% QE:52]SI'<B-KDU:I-)E,BI-:4>EAJ7]70E'UDE3*\"*S+'=Q
MCF_@DU-V\:_S7PH%<JF"-.*Q)8'FU')&4B/B(?G"N+DGA4+6JZ.2J1;#D275
M<K5*OBA]+\;4MUMA);^8R3DO^>?SDIOD?*#8].*<B3$1[&U.'->#1C,LEVN\
M5J_7JX-3'IPVFM6@5AV$E? D_&\%E"Q!=S_&V*GD;W.1B LCCO.WZM7B22.Q
M9Q/![*A5*9?_G7-=+\Y#%5N83\-X_]6+61-F^8,M4"F&<<N9E/-#9\V!DDJW
M#LKN[PQ;"B&-A)RV?NV+B!MRS2?D3D4T_C5O( P%P[4(?4<C_N2@$ZCG'B=>
MY1.0(T7,9R94JJAT]^N'WKM>G]0JQ<JJQIMU#<"Y7)^Y-R)F\-2J'2?_O/;U
MC=J_.:@<E\]F>K^$_SK=NW[O?:_3[O=NKLG->W)[U[ON]&[;5Z3[M=OYW._]
MIPNOH4?W;JM_(ZJ'@"VK$C_MFK^?'QPG=3#N]O/=I\_MZS[IW_QTNG_J=EQ(
M:N4JAJ7_H4L^M>_>M:^[GPHW7Z^ZOY-VIX\MU7*YNI-UU57K_I<:*\+I"R&_
MER?]$8@QY(I&>?*Q>%G,DX!K5(G8$;5O#AJG9SO;E5#&(.$6) _]@MY@Z<JB
M+U1/7FS55XK/L^(WS;[JJ4JSV$ W],B(CCG1?"SX!*J7'0E#_DBI!OS+*;Q/
ME+9$Q>2]TA&IE N_$162=J*D5.0C9R*@DGQ0$B6;/.G%01'BUWRE\:ON7?S>
M40-1@_A$4W(?JXGD;,CS/HQ9\)@"%6(%# 5FH"(F-)Z2-+8ZY6 !<!9'7R"J
ME$3PI 5$-*0!O-)$1<(2JWR_M0XQ#[@Q5$^Q2T3O.<R[)-/ .P;*P)32<1^8
M SL$0@/7@6XQ# =-&-=D,A+!B)@4/Q;C)USS3 @:$ DC@10AOYH(.P(#3<(#
MIR#*34 UQ<#,,0QC9#!==L,K1F7MYT$E)Z&((>X(H46<\P!)Z [->JE=Q"'D
M'(HL';X',F4@$["T%-0\X%!@GDH "HAB1+>4"YAF"#&/IH:5P!S]SV./5$('
MP*8" +GIC-,GH&9$0JDF9@9<S8?"6-@[6$+QI=<;M,POX<_,E%G3]A5#L+YW
M$.ROQ.O-P6FU<G)F,I!E= ,3B0I# 8^'YL@%LT>HY@XV  ,QD!S#2SA@=2"%
M&>$([!9!'L5<BL],F$ JD\(XS+!:28^?1*N ,WAMR"' A7' G\=$]R$8T7C(
M21N2UUTJH4>E1@N5QB'W6E0:S#_Y1X%L-/:X1?D$,]P2G#V\4)>=)PI7)@IA
M(K3S,<BA!]*#)S"R>F._@7M(C_8&N8UBLX*.N.0&7 41=.7P^_#*8Z4.:&IV
M'X(E<\ !*ME,O@BK5(, 2&-C85QRA%X\=G*0F"_2ZG)JUEQ2A[VL"B_PD\_2
M-C8*2+&@BU%2,'=,8M*!$4Q0+=  X;F"*Q8Q2DH-UF^W6HTK]BZ5*L-!(0NI
M&P<EP%)%D$J*%0#,<DHL> ",\*QBF0S!MP''CI"D83QG3TC*>X_MP3YANU9?
MQ_;.B6T-XKNGQ)V1#JMC+!@"F!H54\S]U #XD:8BJJEF,X0!Y@4=""GL%+G!
MIFEQO3DP.ISYI;+2=8GFNA+SD!F4I#H!G!O'98) :>84<(1WR&.@*!+@#BT\
MP76$78#,>TC#>A,)9/G7#.I@GT#M$W9W3&7JLAI&G(<A4$XQAEB9#=1Q3D5V
MR-+^<3.;=!B&@9!AC>>L Y7:[1KL4D?HO#='0AY^?UM%!C.J[Y8E]YX ?1P$
M<8)7"D.V3S#,<JN/\#I2<,.?$4'7LA&./Y!1D0NH($@UXF&I\&Z0&BECX3T>
MJ((L@Z=%V>D2.=PR) 1@0ZY[U#M3'#9EW)U5X#%&G,[U.O):C:B9LQ3,DFXA
M<.;*A_-'EMJG1(I[+K.#BT?]\T]VT1/!O^^[O<;KV>VYTT\V6SCY13K#[+H,
MWD5F0_C] '%9H\5S[2A08ZNTF7,%]P)$1I&PEO-OU(Z! C:"[4R ?D[((4 <
M4K7!4@#_D:#/UB7_(Q6@OEN#:1RX(XZC_V_JGI4CM"50/G"6  #BWAIWZ8'@
M )>LSL\W5Q-.[[%P>PKH2K<CK^X\=G9$]4,@S/9!_F1C0P:D# 8:/D^ 6P&;
M45X8 J@#9IKW[,$ =3!I!)@!+SECLL*S\3#OM3.#/=QUM8$ A!K22QZ@P%U2
M!#"Y(_4,=7E?/T4\5G+,L8C&=)C],J"S/,JC1*HIA];)2/G,25<P#1C\6QA&
M<9??\U=_Q=QP<>&;P_;S'L":XH\N;<#&T!U;M_RARYBO7>.8#1PH:U74*B^&
MT(%1,K7;AVS[_7OKG1#_.=(S 0D@IC" #'-?H"&,;U$YH5.3^^>NHBPE"D<#
MSJW;ML]]H&&O7X!02IH8WII].8-ZGT@Z;8G8!<0-.LMD98Y#O<;(&X"#9DYQ
M_O'-F<K-9O&T44.M+:AJV6SBS*"B,ZADV7K;<;'9J&YM+1<K6]N^);5V4CQN
M-O]VL8UJL5S?36S).<([ ]QM$AJ_S=5R"X2X[-2J)@^DLCF-/W*Z]_?S+TX'
MQDM(CJLT*;/_YS?M(YV22CGOKJ,]S;KL7M4^&??FH [UQGTNW359,7-'H):)
M(V^O*/"/"LYVN[+LZ4A8 FKBR3V9Z?<-HY%Y;+5XAW+SC->MG$,V &1+F<E*
M S+2I<)3W;0<7BBX'57HC 0/2?>!!RD2!'+C=[R.E=]JV$@P=\GT^T3I10TY
MO/5GV< *UTPY>D0*YLNYY KYS\FB2OZ>K[MQ?/$74$L#!!0    ( ,J)JE24
MZQID>@@  &8L   5    97@S,3(R,#(R,#,S,3$P+7$N:'1M[5IK4QLY%OV^
MOT)C:C-0Y5?[ ;$A5!GC5%R5  O.9N;3EMQ2VUK4K1Y);>/Y]7NOU'YA\T@Q
M0QQJ^6#<K=>]ND?G'LDZ^>7\LCOX_:I'QC:6Y.KKV>=^EQ1*E<JW>K=2.1^<
MDT^#+Y])HUP-R$#3Q @K5$)EI=*[*)#"V-JT7:E,I]/RM%Y6>E097%>PJT9%
M*F5XF5E6.#W!-_#)*3O]Q\DOI1(Y5V$6\\224'-J.2.9$<F(?&/<W))2*:_5
M5>E,B]'8DEJU5B/?E+X5$^K+K;"2G\[[.:GXYY.*&^1DJ-CL](2)"1'L0T&T
M#IM!BQ_6&\TH:#1Y8TCYX>'14=BJT8@UAM7_!&!D!:K[-L;.)/]0B$52&G,<
MO]VHE8^:J3V>"F;'[:!:_6?!53T]B51B83P-[?U7W\U&9Y;?V1*58I2TG4L%
MWW1>'"JI='NOZOZ.L:04T5C(6?O7@8BY(1=\2JY53)-?BP;"4#)<B\A7-.)/
M#C:!>>YQZDT^@GZD2/C<A:"&1I/>;Y_Z9_T!J0?EVKK)VXT-87:Y/G9O1,+@
MJ5T_3/]^\QM;S7^W%QQ6CW?9[NW3WNU=#_H?^]W.H']Y02X_DJOK_D6W?]7Y
M# 'I=;\.^O_NP6NHT;M^T+N8ZA% TJK4#[OA[>L[=]0 YZZ^7M]\[5P,R.#R
MI[/]IM=U(:E7:QB6P:<>N>E<GW4N>C>ER]\^]WXGG>X 2VK5ZL/K9=6[VKIW
M_\V,%='L!ZV7?I&< 6LSE9 ;$1=)R#5:0^R8VG=[S?</+Z7[+J64,:#HDN21
M7TE;G%Q;;:7:T0^CB: \]^OU1U^?J:!5;N(T],F83CC1?"+X%/*='0M#_LBH
M!NC+&;Q/E;8$PO11Z9@$U=*_B(I()U52*O*%,Q%223XIB3V;(NDG81GBUWJC
M\:OM7/S.J(&H07SB&;E-U%1R-N)%'\8\>$R!"8D"30,C4)$0FLQ(EEB=<?
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M YM%P*/(I7C/A FD,BGT0X;52GK\)%H%G,%C0XX!+HP#_CPF>E\#D#\C3CI
M7O>IA!:5&BU4&L?<>U%I,'_G;P7JSMCC%NT39+@5.'MXH2][#Q2N#13"0!CG
M8Y!#"Y0'3U!D]<9A _>8GAP,<AO%9@4GXHH;F"K(H"N'?PZO/%;J@*9F_RY8
M,H<<H)*-Y(NP2C48 !J;"./($5KQV-E!8;ZDU55JUEQ2A[VL"B_QD\]H&U\*
MH%CPQ2@IF#N.,.G0"":H%AB \%K!%8L8+:4&Z[=;K<85>T>ERG!PR )U8Z<$
M5*H(4DFQ D!8SHFE#H >7E6LBB&X&G)L""0-_3E[ BD?/+:'AX3M6GT3VWL3
MVP;$]Z?$O9$.JV,B& *8&A53Y'YJ /PH4Q'55+,YP@#S@@Z%%':&VF#;L+C>
M'!@=SOQ266NZ(G-=B?F:!92D.@&<&Z=E@D!IYAQP@G?$8Y H$N .;WB"ZPB;
M@)CWD(;U)A)@^=<,ZN"00.T)NS>A,G6LAAGG80B24TP@5V:+=%Q(D3U8VM]N
M5Y,.P] 1&-9XS3I4J=WMP3YUA"Y:<Q3DX9]OJ\AP+O7=LN1^)L ?!T$<X)7"
MD!T2##-N]1G>1 IN^#,AZ-YLA>-W,"IJ 14$J48\K!3>+58C92P\QZ-3L&7P
MM"@[72+'.[J$ &S@ND>M,\=A4\;=604>8\3IPJ\3[]68FH5*099T"X$S5S[<
M?&34/B-2/'"9'5P\:I]_\A0]$?R'OMMKO)[=GCO]9/.%DU_2&;+K*GB7S(;P
M^P[ALB&+%]Y1D,96:;/0"NX!F(PB82WGWZ@=0P5J!-\S ?XY(\< <:!J@Z4
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M:\5F=U@9<SKAE(";>-I.YO[]OV#?H]0\X\=0;D*V0^0;8N&9O-V>OCZ.+2(
MMN AN5[HG5N_&3UX_X_O_,$RN+SA_,FC2K]8IB57G5^F-"KYCUO=9[:7_P-0
M2P,$%     @ RHFJ5&$1I^I8!0  VRD  !0   !E>#,R,C R,C S,S$Q,"UQ
M+FAT;>V:ZW/:.!# O]]?L25S?<S@%X\0'LT,,<Z$F00H.-?VTXUBRT%7VW)E
M$4+_^EO+D)  O:;7N] [\X&QO:O5[FJE_<&X\Z(WM-V/(P>F,@IA='ERWK>A
MI!G&^ZIM&#VW!V?NQ3G4=-,"5Y X99+QF(2&X0Q*4)I*F;0,8SZ?Z_.JSL6U
MX8Z-S%3-"#E/J>Y+OW3<R9[@-R7^\2^=%YH&/>[-(AI+\ 0EDOHP2UE\#>]]
MFGX"35MJV3Q9"'8]E5 Q*Q5XS\4G=D-RN60RI,<K.QTCO^\8:I+.%?<7QQV?
MW0#SWY:85R&-H%$GC<-&I18<5H[(84"O@FKUR#2;-""_6^BD@>KYF%0N0OJV
M%+%8F])L_E:MHC?JB6S/F2^G+<LT?RTIU>-.P&.)\PD<GU_F9C:,27HK-1*R
MZ[BE0BKE0U=BCX=<M Y,]6EG$BT@$0L7K5<NBV@* SJ',8](_*J<XC)H*14L
MR!53]H6B3^B>NIWG+C?03LABN@K!JF1..Q_.^B=]%ZJ5A_YN]]3#U%+15D]8
M[.-=JWJ8_/.^U[;Z_O+ .C3;W^[W,Z78=L9N_[1O=]W^< ##4QB-^P.[/^J>
M@_/!L2_=_F\./D8-9SR![J"WIG#:'W3Q$J^6"D^.=DLM[F&.1I?CR65WX(([
MW/#U9XK#.H)+?:+;.DP<6ZVW5:V;^D\=4Q>+LC<<N0X6YG]DF5:+TS0/LPWI
MGCDPZ8Y/N@-GH@T_G#L?H6N[F:1BFKL/QHB(:VP)DB=H%N==B^Z/62I9L-B7
MD[)?!G>*9E(X)U$9+O2>7@:/BLS',B0SD<X(>B4YK!4P];+6K@JX##B4^#S)
M6O.Z^DHI2R0/0$XI3(BX(C%-M>%M2!?0]60FR1)91CF12NG=C A<_G !8YIP
M@2HQG'(1@65J[S+];L+#D,,%]9E'0CCCH8] D):A'WLZ!%PH,Y]S,T QPSY<
M$.%-\Z90M<HY(P2S$"?Q>)2$#/,Y9W*J1@KZ><8$S5@AS>:[C_8U>0-HWJJ_
M]M_<Q42]F4#200O.K3<E\35=!68UJ[4\/9'R J]C_SY0%J.O$5&V/5PG@FOC
MXU-(9]X4O5#!!X1EJ4@$33-_RIF<A"'@.%QO#!\%"3J8EI7-@,4D]K+G:-%7
M *8F1:U9F(?#$RK4I.E?)O-;-NNRG/>SSZ]MP[K:89)<A70EO>+"IT)#7T.2
MI+2UNFC[+$U"LFBQ6,VH!K67MJZXE#S*S+5OLEV"65MF0B4E%R_AK]G4C^K5
MC/\DGGS27TV\1$-=H:$A_4U93:]:C9U24[=VRKYFM=K0F\W*#S=;1V^;NX>N
MFS54(O)D8+K3A,1O2]72:D!"_*S\6I7D%JSMQ^:CI.?Y_O>K3V%]#S?ARX/Z
M41ON*G"9@!\2&Y;M,P5V019XW.;GY-\+;?FS8)]6[>5!K=%.U?=:ZWL0YC>6
MJ9E%6_K>U(0TV#Q#GFW)'YVDNR-:GIH*;1)TDX?,AY5_3PSWK@[V"P150K:4
MQH[VLFP)&>>M-9S*MHWP3(MK<\V>,AH@HB"N2'9#81@$##%/T<$(\8#YZK^1
MO:'S[8&\'@F&?),@JFR$\N;1WRIW&]E0#?SK>-#8=T@_$;A22',3%A5\7O#Y
MU_G\^W]^/OU'>H'4!5(72%T@]0JIUQI5P=0%4S](R+;:V%?4W,W,>^_Z_Y>2
M;00\G\1P0M(I+SBYX.1GY^3[_\<+4"Y N0#E I17H/R@5Q6H7*#R0_S<6AW[
M2IS];&X604[,IW?=^R<DY@WGGT[,C]X$3'C^*F1+T)!D++[Q;N!]<:L&;]X/
M(5=8X3.Y>\@37NYZ\)V_]JA>P#S^$U!+ 0(4 Q0    ( ,J)JE0\(]>G1=X"
M 'B.'P 1              "  0    !A;65H+3(P,C(P,S,Q+FAT;5!+ 0(4
M Q0    ( ,J)JE1+$-3R-AT  ()3 0 1              "  73> @!A;65H
M+3(P,C(P,S,Q+GAS9%!+ 0(4 Q0    ( ,J)JE25GPPZVC    KV 0 5
M          "  =G[ @!A;65H+3(P,C(P,S,Q7V-A;"YX;6Q02P$"% ,4
M" #*B:I4:]N-M[>E  "8! < %0              @ 'F+ , 86UE:"TR,#(R
M,#,S,5]D968N>&UL4$L! A0#%     @ RHFJ5/?%,--I;@$ 22D/ !4
M         ( !T-(# &%M96@M,C R,C S,S%?;&%B+GAM;%!+ 0(4 Q0    (
M ,J)JE2$+M*?_.@  !-E"@ 5              "  6Q!!0!A;65H+3(P,C(P
M,S,Q7W!R92YX;6Q02P$"% ,4    " #*B:I4-5?72YX(  #,+   %0
M        @ &;*@8 97@S,3$R,#(R,#,S,3$P+7$N:'1M4$L! A0#%     @
MRHFJ5)3K&F1Z"   9BP  !4              ( !;#,& &5X,S$R,C R,C S
M,S$Q,"UQ+FAT;5!+ 0(4 Q0    ( ,J)JE3\&)$H: @  ,$K   5
M      "  1D\!@!E>#,Q,S(P,C(P,S,Q,3 M<2YH=&U02P$"% ,4    " #*
MB:I481&GZE@%  #;*0  %               @ &T1 8 97@S,C(P,C(P,S,Q
>,3 M<2YH=&U02P4&      H "@"5 @  /DH&

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
